15705495,20050328,review,xref,"Animals,Ethers,Female,Male,Mice,Propylene Glycols,Public Health,Rats,Risk Assessment,Solvents,Toxicity Tests","pharmacokinetics,toxicity","D011409 Q000633 NY,D004987 Q000493 NN,D012997 Q000633 NY,D004987 Q000633 NY,D011409 Q000493 NN,D012997 Q000493 NN","8114,8252,8254,8909","127789678,128468424,128945327,129060975",New toxicity data for the propylene glycol ethers - a commitment to public health and safety.,"Propylene glycol ethers are a class of solvents used in a wide array of industrial, commercial and consumer applications, such as in paints, cleaners and inks. A robust toxicity database exists for the propylene glycol ethers that provide strong product safety support. Standard toxicity studies conducted under good laboratory practices indicate a lack of genotoxic, developmental and reproductive hazards. Recent testing efforts have primarily focused in two areas: (1) examination of the chronic toxicity/onco",Toxicology letters,P J Spencer," Toxicology and Environmental Research and Consulting, The Dow Chemical Company, 1803 Building, Midland, MI 48674, USA. pjspencer@dow.com",2005 Mar;156(1):181-8,10.1016/j.toxlet.2003.09.023
18158714,20070101,article,"xref,mesh","Administration, Inhalation,Animals,Cyclosporine,Dogs,Drug Evaluation, Preclinical,Female,Immunosuppressive Agents,Male,Propylene Glycol,Rats,Rats, Sprague-Dawley","administration &amp; dosage,pharmacokinetics,toxicity","D007166 Q000008 NN,D019946 Q000633 NY,D016572 Q000008 NN,D016572 Q000493 NN,D007166 Q000493 NN,D019946 Q000008 NN,D016572 Q000633 NY,D019946 Q000493 NN,D007166 Q000633 NY","1030,2909,8252,62280,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",129060975,Preclinical safety evaluation of inhaled cyclosporine in propylene glycol.,"Cyclosporine inhalation solution has the potential to improve outcomes following lung transplantation by delivering high concentrations of an immunosuppressant directly to the allograft while minimizing systemic drug exposure and associated toxicity. The objective of these studies was to evaluate the potential toxicity of aerosolized cyclosporine formulated in propylene glycol when given by inhalation route to rats and dogs for 28 days. Sprague-Dawley rats received total inhaled doses of 0 (air), 0 (vehicle",Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,"Tao Wang, Sarah Noonberg, Ronald Steigerwalt, Maryellen Lynch, Rosemary A Kovelesky, Carlos A Rodríguez, Katherine Sprugel, Nancy Turner"," Novartis Pharmaceuticals, Safety Profiling and Assessment, Emeryville, California 94608, USA. tao.wang@novartis.com",2007 Jan;20(4):417-28,10.1089/jam.2007.0626
20131984,20100201,article,"xref,mesh","Administration, Inhalation,Aerosols,Animals,Chemistry, Pharmaceutical,Ethanol,Hexoses,Inflammation,Lung,Propylene Glycol,Rats,Rats, Sprague-Dawley,Solvents","chemically induced,drug effects,pathology,pharmacology","D008168 Q000187 NN,D000431 Q000494 NY,D008168 Q000473 NN,D000336 Q000494 NY,D007249 Q000139 NN,D019946 Q000494 NY,D006601 Q000494 NY","702,1030,8252,347521,5385498,6433271,9920342,13798887,23725020,70693544","128482492,129060975,135808686","Evaluation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols.","BACKGROUND: Aerosol therapy is an expanding technique allowing administration of drugs acting locally in the bronchial tree and lungs or acting systemically after absorption through the respiratory tract. However, the choice of solvents and adjuvants is a critical step in the formulation process of new drugs. Pulmonary tolerance of ethanol, propylene glycol and sorbitan ester was evaluated in a rat model of intratracheal administration using a Microsprayer in a 4-day toxicity study. METHODS: Four groups of ",Journal of aerosol medicine and pulmonary drug delivery,"Jérôme Montharu, Sandrine Le Guellec, Birgit Kittel, Yvon Rabemampianina, Joël Guillemain, Francis Gauthier, Patrice Diot, Michèle de Monte"," INSERM U618, IFR135, Faculté de Médecine, CHRU Bretonneau, Tours, France.",2010 Feb;23(1):41-6,10.1089/jamp.2008.0740
2883293,19870301,article,mesh,"Cytotoxicity, Immunologic,Drug Compounding,Humans,Killer Cells, Natural,Luminescent Measurements,Neutrophils,Propylene Glycol,Propylene Glycols","drug effects,immunology,pharmacology","D003602 Q000187 NN,D007694 Q000187 NY,D009504 Q000187 NY,D011409 Q000494 NY,D007694 Q000276 NN",1030,NULL,Detrimental effect of propylene glycol on natural killer cell and neutrophil function.,Propylene glycol (PG) in a concentration of 0.5-1.0% inhibits natural cytotoxicity and neutrophil chemiluminescence. This is the first reported effect of PG on defence mechanisms in man. PG is frequently used as a vehicle in high concentrations by the pharmaceutical industry and it would be wise to consider its potential immunosuppressive effects in the evaluation of drug formulations. ,The Journal of pharmacy and pharmacology,"D W Denning, A D Webster",NULL,1987 Mar;39(3):236-8,10.1111/j.2042-7158.1987.tb06258.x
15996585,20050801,article,"xref,mesh","Administration, Cutaneous,Aminolevulinic Acid,Animals,Chemistry, Pharmaceutical,Glycerides,In Vitro Techniques,Male,Mice,Mice, Hairless,Propylene Glycol,Protoporphyrins,Rats,Skin,Skin Absorption","administration &amp; dosage,biosynthesis,chemistry,drug effects,metabolism,pharmacokinetics,pharmacology","D012867 Q000378 NY,D000622 Q000493 NY,D005989 Q000494 NY,D005989 Q000737 NN,D000622 Q000008 NN,D005989 Q000008 NN,D000622 Q000494 NN,D011524 Q000096 NY,D000622 Q000737 NN,D012869 Q000187 NY,D019946 Q000737 NY","137,1030,4971,8252,33022,71484,123608,5283468,5364833,9548816,12178130,20056951","129060975,129204988,129901017",Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin.,"Photodynamic therapy (PDT), a potential therapy for cancer treatment, utilizes exogenously applied or endogenously formed photosensitizers, further activated by light in an appropriate wavelength and dose to induce cell death through free radical formation. 5-Aminolevulinic acid (5-ALA) is a pro-drug which can be converted to the effective photosensitizer, protoporphyrin IX (PpIX). However, the use of 5-ALA in PDT is limited by the low penetration capacity of this highly hydrophilic molecule into appropriat",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Regilene Steluti, Fernanda Scarmato De Rosa, John Collett, Antônio Cláudio Tedesco, Maria Vitória Lopes Badra Bentley"," Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.",2005 Aug;60(3):439-44,10.1016/j.ejpb.2005.01.011
18700847,20091201,article,"xref,mesh","Animal Feed,Animal Nutritional Physiological Phenomena,Animals,Antioxidants,Calendula,DNA Damage,Diet,Lipid Peroxidation,Plant Extracts,Propylene Glycol,Swine,Vitamin E","analysis,chemistry,drug effects,growth &amp; development,pharmacology,veterinary","D010936 Q000737 NN,D000821 Q000032 NN,D004032 Q000662 NN,D014810 Q000494 NY,D015227 Q000187 NN,D004249 Q000187 NN,D010936 Q000494 NY,D013552 Q000254 NY,D000975 Q000737 NN,D014810 Q000737 NN,D020838 Q000737 NY,D000975 Q000494 NY,D019946 Q000737 NY","1030,8252,10964,14985,124886,9882223,135433642","129060975,129192846,129627858,135790204",The comparison of in vivo antigenotoxic and antioxidative capacity of two propylene glycol extracts of Calendula officinalis (marigold) and vitamin E in young growing pigs.,The objective of the study was to evaluate the protective effect of Calendula officinalis propylene glycol extracts against oxidative DNA damage and lipid peroxidation induced by high polyunsaturated fatty acid (PUFA) intake in young growing pigs. Forty young growing pigs were assigned to five treatment groups: control; oil (linseed oil supplementation); C. officinalis 1 and 2 groups (linseed oil plus 3 ml/day of C. officinalis propylene glycol extracts); and vitamin E group (linseed oil plus 100 mg/kg of v,Journal of animal physiology and animal nutrition,"T Frankic, K Salobir, J Salobir"," Biotechnical Faculty, Department of Animal Science, University of Ljubljana, Domzale, Slovenia.",2009 Dec;93(6):688-94,10.1111/j.1439-0396.2008.00855.x
18656538,20081101,article,"xref,mesh","Cell Line, Tumor,Chemistry, Pharmaceutical,Cyclosporine,Dialysis,Diffusion,Drug Compounding,Electric Impedance,Humans,Immunosuppressive Agents,Kinetics,Liposomes,Lung,Permeability,Pharmaceutical Solutions,Phosphatidylcholines,Propylene Glycol","blood,chemistry,metabolism","D007166 Q000097 NN,D010713 Q000737 NY,D008168 Q000378 NY,D016572 Q000737 NN,D016572 Q000378 NY,D007166 Q000378 NY,D007166 Q000737 NN,D016572 Q000097 NN,D019946 Q000737 NY","1030,2909,8252,62280,453626,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",129060975,Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo.,"Aerolized cyclosporine A (CsA) has been successfully used for prevention of organ rejection in lung transplant recipients. Various formulations of CsA are available and so far no direct comparison of their pharmacokinetics has been performed. Since clinical studies are elaborate, we sought a way to predict the kinetic behaviour of a propylene glycol solution of CsA (CsA-PG) and a liposomal formulation (L-CsA). The permeability across the human bronchial cell line Calu-3 revealed low permeability for CsA wit",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Beatrice Trammer, Annette Amann, Eleonore Haltner-Ukomadu, Sascha Tillmanns, Manfred Keller, Petra Högger"," Universität Würzburg, Würzburg, Germany.",2008 Nov;70(3):758-64,10.1016/j.ejpb.2008.07.001
20433889,20100701,article,"xref,mesh","Animals,CHO Cells,Cell Survival,Cells, Cultured,Comet Assay,Cricetinae,Cricetulus,Cryopreservation,Cryoprotective Agents,DNA,DNA Damage,Dimethyl Sulfoxide,Ethylene Glycols,Female,Humans,Indicators and Reagents,Micronucleus Tests,Mutagenicity Tests,Mutagens,Oocyte Donation,Preservation, Biological,Propylene Glycol,Rats,Rats, Sprague-Dawley","drug effects,genetics,toxicity","D004121 Q000633 NY,D002470 Q000187 NN,D019946 Q000633 NY,D005026 Q000633 NY,D004247 Q000235 NN,D003451 Q000633 NY","679,1030,8252,44135672","128141778,129060975","Assessment of the genotoxicity of three cryoprotectants used for human oocyte vitrification: dimethyl sulfoxide, ethylene glycol and propylene glycol.","Vitrification requires high concentrations of cryoprotectants that may induce long-term toxic effects on cells. The aim of this study was to evaluate the possible genotoxicity of three cryoprotectants extensively used for oocyte vitrification: dimethyl sulfoxide (DMSO), ethylene glycol (EG) and propylene glycol (PROH). For this purpose, a Chinese Hamster Ovary cell line (CHO), commonly used in genetic toxicology, was selected as an in vitro biological model to assess both the induction of DNA strand-breaks ",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,"M Aye, C Di Giorgio, M De Mo, A Botta, J Perrin, B Courbiere"," Laboratoire de Biogénotoxicologie et Mutagenèse Environnementale, Fédération de Recherche CNRS 3098 ECCOREV, Université de la Méditerranée, Facultés de Médecine et Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France.",2010 Jul;48(7):1905-12,10.1016/j.fct.2010.04.032
30965726,20170906,article,NULL,NULL,NULL,NULL,NULL,NULL,"Acid-Labile Surfactants Based on Poly(ethylene glycol), Carbon Dioxide and Propylene Oxide: Miniemulsion Polymerization and Degradation Studies.","Partially degradable, nonionic AB and ABA type di- and triblock copolymers based on poly(propylene carbonate) and poly(ethylene glycol) blocks were synthesized via immortal copolymerization of carbon dioxide and propylene oxide, using mPEG or PEG as a macroinitiator, and (R,R)-(salcy)-CoOBzF₅ as a catalyst in a solvent-free one-pot procedure. The amphiphilic surfactants were prepared with molecular weights (M(n)) between 2800 and 10,000 g·mol(-)¹ with narrow molecular weight distributions (1.03⁻1.09). The c",Polymers,"Markus Scharfenberg, Sarah Wald, Frederik R Wurm, Holger Frey"," Institute of Organic Chemistry, Duesbergweg 10-14, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. mscharfe@uni-mainz.de. Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany. wald@mpip-mainz.mpg.de. Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany. wurm@mpip-mainz.mpg.de. Institute of Organic Chemistry, Duesbergweg 10-14, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. hfrey@uni-mainz.de.",2017 Sep;9(9):?,NULL
10506120,19991001,article,mesh,"Adenine,Animals,Carbon Radioisotopes,Cell Line,Cytosine,DNA Adducts,DNA Repair,Epoxy Compounds,Humans,Lung,Lymphocytes,Male,Nasal Mucosa,Phosphorus Radioisotopes,Rats,Rats, Inbred F344,Uracil","chemistry,drug effects,metabolism,pharmacology","D008168 Q000187 NN,D004852 Q000494 NY,D008214 Q000378 NN,D003596 Q000378 NY,D000225 Q000378 NY,D004852 Q000737 NN,D009297 Q000378 NN,D009297 Q000187 NN,D008214 Q000187 NN,D014498 Q000378 NY,D008168 Q000378 NN","190,597,1174,6378,56841445",NULL,32P-postlabelling of propylene oxide 1- and N(6)-substituted adenine and 3-substituted cytosine/uracil: formation and persistence in vitro and in vivo.,"Propylene oxide, a widely used monofunctional alkylating agent, has been shown to be genotoxic in in vitro test systems and induces tumors in the nasal tissues of experimental animals. Propylene oxide, like related alkylating agents, forms several different adducts with DNA bases, but predominantly at the 7-position of guanine. We have previously described the in vitro and in vivo formation and stability of this major adduct. The aim of the present study was to perform a similar investigation of other adduc",Carcinogenesis,"K Plna, R Nilsson, M Koskinen, D Segerbäck"," Center for Nutrition and Toxicology, Department of Biosciences, Karolinska Institute, Novum, S-141 57 Huddinge, Sweden. kamila.plna@cnt.ki.se",1999 Oct;20(10):2025-32,10.1093/carcin/20.10.2025
17341482,20070601,article,"xref,mesh","Alkenes,Animals,Antimetabolites,Bromodeoxyuridine,Cell Proliferation,DNA,DNA Adducts,Endpoint Determination,Erythrocytes,Female,Gas Chromatography-Mass Spectrometry,Globins,Hemoglobins,Hydrolysis,Hypoxanthine Phosphoribosyltransferase,Inhalation Exposure,Male,Micronucleus Tests,Mutagens,Nasal Mucosa,Rats,Rats, Inbred F344,Spectrometry, Mass, Electrospray Ionization","administration &amp; dosage,drug effects,genetics,isolation &amp; purification,metabolism,pathology,toxicity","D006454 Q000378 NN,D000475 Q000633 NY,D018736 Q000187 NN,D005914 Q000302 NN,D000475 Q000008 NN,D005914 Q000378 NN,D004912 Q000378 NN,D049109 Q000187 NN,D007041 Q000378 NN,D004247 Q000235 NN,D006454 Q000187 NN,D009297 Q000473 NN,D004247 Q000302 NN,D004912 Q000187 NN","6035,6378,8252,6918942,44135672,54046434,54571567,136121739","127983601,128524583,129060975,129969871,136216744",Evaluation of effects from repeated inhalation exposure of F344 rats to high concentrations of propylene.,"Chronic exposure to propylene does not result in any increased incidence of tumors, yet does increase N7-hydroxypropylguanine (N7-HPGua) adducts in tissue DNA. To investigate any potential for genotoxicity (mutagenicity or clastogenicity), male F344 rats were exposed via inhalation to up to 10,000 ppm propylene for 1, 3, or 20 days (6 h/day, 5 days/week). The endpoints examined included gene (Hprt, splenocytes) and chromosomal (bone marrow micronucleus [MN]) mutations, hemoglobin (hydroxypropylvaline, HPVal",Toxicological sciences : an official journal of the Society of Toxicology,"Lynn H Pottenger, Linda A Malley, Matthew S Bogdanffy, E Maria Donner, Patricia B Upton, Yutai Li, Vernon E Walker, Jack R Harkema, Marcy I Banton, James A Swenberg"," Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, MI 48674, USA. lpottenger@dow.com",2007 Jun;97(2):336-47,10.1093/toxsci/kfm038
7503374,19950101,article,mesh,"Administration, Topical,Animals,Anti-Inflammatory Agents, Non-Steroidal,Cell Division,Chinchilla,Cholesteatoma, Middle Ear,Connective Tissue,Disease Models, Animal,Epidermis,Epithelium,Female,Hyaluronic Acid,Hyperplasia,Inflammation,Male,Propylene Glycol,Propylene Glycols,Tympanic Membrane,Wound Healing","administration &amp; dosage,adverse effects,chemically induced,drug effects,pathology,prevention &amp; control,therapeutic use","D018424 Q000517 NY,D011409 Q000009 NN,D002455 Q000187 NN,D018424 Q000139 NN,D004817 Q000473 NN,D003238 Q000187 NN,D014432 Q000473 NN,D004817 Q000187 NN,D003238 Q000473 NN,D004848 Q000473 NN,D000894 Q000009 NN,D006820 Q000008 NN,D006820 Q000627 NY,D014432 Q000187 NN,D004848 Q000187 NN","1030,3084049",NULL,Effect of topical hyaluronic acid on experimental cholesteatoma.,PURPOSE: Inflammation and connective tissue hyperplasia are believed to be important etiological factors in cholesteatoma pathogenesis. Previous work has shown that topically applied hyaluronic acid can reduce connective tissue proliferation in healing wounds and accelerate healing of tympanic membrane perforations. This study was undertaken to determine whether the antiproliferative effect of hyaluronic acid may inhibit propylene glycol-induced cholesteatoma in an animal model. MATERIALS AND METHODS: A 60%,American journal of otolaryngology,"S J White, C G Wright, K S Robinson, W L Meyerhoff"," Department of Otolaryngology, University of Texas Southwestern Medical Center, Dallas 75235-9035, USA.",1995 Jan;16(5):312-8,10.1016/0196-0709(95)90059-4
16471857,20060216,article,"xref,mesh","Alkenes,Catalysis,Epoxy Compounds,Gases,Gold,Models, Chemical,Oxidation-Reduction,Quantum Theory","chemical synthesis,chemistry","D000475 Q000737 NY,D006046 Q000737 NY,D004852 Q000737 NN,D005740 Q000737 NN,D004852 Q000138 NY","6378,8252,160438","127523511,127983601,129060975",Partial oxidation of propylene to propylene oxide over a neutral gold trimer in the gas phase: a density functional theory study.,"We report a B3LYP study of a novel mechanism for propylene epoxidation using H(2) and O(2) on a neutral Au(3) cluster, including full thermodynamics and pre-exponential factors. A side-on O(2) adsorption on Au(3) is followed by dissociative addition of H(2) across one of the Au-O bonds (DeltaE(act) = 2.2 kcal/mol), forming a hydroperoxy intermediate (OOH) and a lone H atom situated on the Au(3) cluster. The more electrophilic O atom (proximal to the Au) of the Au-OOH group attacks the C=C of an approaching ",The journal of physical chemistry. B,"Ajay M Joshi, W Nicholas Delgass, Kendall T Thomson"," School of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907, USA.",2006 Feb;110(6):2572-81,10.1021/jp054809f
18463477,20080501,article,"xref,mesh","Acanthamoeba Keratitis,Acanthamoeba castellanii,Animals,Contact Lens Solutions,Humans,Microscopy, Electron, Transmission,Propylene Glycol","drug effects,growth &amp; development,isolation &amp; purification,parasitology,pharmacology,ultrastructure","D048248 Q000254 NY,D015823 Q000469 NN,D019946 Q000494 NY,D048248 Q000648 NN,D018639 Q000494 NY,D048248 Q000187 NY,D048248 Q000302 NN","1030,8252",129060975,Encystment of Acanthamoeba during incubation in multipurpose contact lens disinfectant solutions and experimental formulations.,OBJECTIVES: Acanthamoeba keratitis (AK) is most commonly found in contact lens wearers with poor lens care hygiene. Recent reports have indicated an increase in cases of AK in the United States associated with the use of Complete MoisturePlus multipurpose solution. This association may not appear explainable by differences in Acanthamoeba kill rates among multipurpose solutions. In this study the physiologic response of Acanthamoeba trophozoites to incubation in various contact lens solutions was investigat,Eye & contact lens,"Simon Kilvington, Wayne Heaselgrave, John M Lally, Kate Ambrus, Hayes Powell"," Department of Infection, Immunity & Inflammation, University of Leicester, Leicester, United Kingdom. sk46@le.ac.uk",2008 May;34(3):133-9,10.1097/icl.0b013e3181772c95
30606596,20190301,article,NULL,NULL,NULL,NULL,NULL,NULL,Formation of porous biodegradable scaffolds based on poly(propylene carbonate) using gas foaming technology.,"Polyester-based scaffolds have been employed in tissue engineering due to their biocompatibility, biodegradability, microstructure, and affordability. However, the acidic degradation byproducts of most common polyesters have the potential to cause inflammation and/or necrosis. In this study, we introduce a porous scaffold with benign degradation byproducts fabricated by gas-foaming based on poly(propylene carbonate) (PPC) blended with starch and bioglass particles. The pore sizes ranged from 100 to 500 μm. ","Materials science & engineering. C, Materials for biological applications","Iman Manavitehrani, Thi Y L Le, Sean Daly, Yiwei Wang, Peter K Maitz, Aaron Schindeler, Fariba Dehghani"," School of Chemical and Biomolecular Engineering, the University of Sydney, Sydney, 2006, Australia. Electronic address: i.manavitehrani@sydney.edu.au. School of Chemical and Biomolecular Engineering, the University of Sydney, Sydney, 2006, Australia. School of Chemical and Biomolecular Engineering, the University of Sydney, Sydney, 2006, Australia. Burns Research Group, ANZAC Research Institute, University of Sydney, Concord, NSW 2139, Australia. Burns Research Group, ANZAC Research Institute, University o",2019 Mar;96(?):824-830,NULL
1376439,19920701,review,mesh,"Animals,Epoxy Compounds,Humans,Mutagenicity Tests,Mutagens,Trichloroepoxypropane",toxicity,"D004852 Q000633 NY,D014239 Q000633 NY,D009153 Q000633 NY","6378,18321",NULL,Genetic toxicology of propylene oxide and trichloropropylene oxide--a review.,"Aliphatic epoxides are a group of compounds extensively used in industry and as laboratory reagents, and can be produced as metabolic intermediates. An important aliphatic epoxide is propylene oxide, extensively used in the production of propylene glycol and polyols used in the manufacture of polyurethane polymers. The widespread human exposure to propylene oxide is of great health concern. In this review an attempt has been made to evaluate and update the genotoxic effects of propylene oxide and trichlorop",Mutation research,A K Giri," Division of Toxicology, Central Drug Research Institute, Lucknow, India.",1992 Jul;277(1):1-9,10.1016/0165-1110(92)90023-3
3916988,19851001,article,mesh,"Adult,Alkylation,DNA,Environmental Exposure,Epoxy Compounds,Ethers, Cyclic,Hemoglobins,Humans,Middle Aged","adverse effects,biosynthesis,drug effects,metabolism","D006454 Q000378 NN,D006454 Q000187 NY,D004852 Q000009 NY,D004988 Q000009 NY,D004247 Q000096 NY","6378,44135672",NULL,Unscheduled DNA synthesis correlated to alkylation of hemoglobin in individuals occupationally exposed to propylene oxide.,"Exposure to propylene oxide was determined previously by the degree of alkylation of hemoglobin measured on the histidine residue as N-3-(2-hydroxypropyl) histidine, using blood samples from 8 propylene oxide-exposed employees and 13 unexposed referents. Mononuclear leukocytes isolated from the same blood samples were used to quantify DNA repair proficiency following an in vitro challenge with the carcinogen, N-acetoxy-2-acetylamino-fluorene. Decreases in the DNA repair proficiency index correlated signific",Cell biology and toxicology,"R W Pero, S Osterman-Golkar, B Högstedt"," Wallenberg Laboratory, Molecular Ecogenetics, University of Lund, Sweden.",1985 Oct;1(4):309-14,10.1007/bf00118195
12927974,20030901,article,"xref,mesh","Bacillus subtilis,Cadaver,Cells, Cultured,Collagen,Collagenases,Disinfection,Glycerol,Humans,Inflammation,Peracetic Acid,Phagocytes,Propylene Glycol,Skin,Skin Transplantation,Tissue Preservation,Tumor Necrosis Factor-alpha","biosynthesis,drug effects,etiology,metabolism,methods,microbiology,pathology,physiology","D004203 Q000379 NY,D014409 Q000096 NN,D012867 Q000473 NN,D001412 Q000187 NN,D017364 Q000378 NN,D007249 Q000209 NN,D010586 Q000378 NN,D014021 Q000379 NY,D012867 Q000382 NY,D012867 Q000187 NN,D016038 Q000502 NY","753,1030,6585,8252,23674263","128375819,128902940,129060975",Assessment of the biological properties of human split skin allografts disinfected with peracetic acid and preserved in glycerol.,"Skin allografts derived from cadaveric human donors are widely used in the treatment of serious burn injuries and other conditions, such as ulcers. In order to render these allografts safe for clinical use, and to enable them to be preserved and banked for long periods, effective methods of decontamination and preservation are required. These methods must not adversely affect graft properties essential for clinical performance. We have investigated the application of a peracetic acid (PAA) disinfection prot",Burns : journal of the International Society for Burn Injuries,"R J Lomas, J E Cruse-Sawyer, C Simpson, E Ingham, R Bojar, J N Kearney"," Tissue Services R&D, National Blood Service, Sheffield Blood Centre, Longley Lane, S5 7JN, Sheffield, UK. richard.lomas@nbs.nhs.uk",2003 Sep;29(6):515-25,10.1016/s0305-4179(03)00137-2
3265859,19880101,article,mesh,"Animals,Cholesteatoma,Ear Diseases,Ear, Middle,Propylene Glycols,Rats,Rats, Inbred Lew","chemically induced,pathology,toxicity,ultrastructure","D002781 Q000473 NY,D002781 Q000139 NN,D004427 Q000473 NN,D004432 Q000648 YN,D011409 Q000633 NY,D004427 Q000139 NN",NULL,NULL,Experimental induction of middle ear cholesteatoma in rats.,"We induced cholesteatoma in two groups of rats by instilling different concentrations of propylene glycol into the middle ear cavity. Fifteen rats were exposed to 50% propylene glycol (group I), while pure propylene glycol was applied to six others (group II). The group I rats were killed 1 month after instillation. Seven of the 15 showed cholesteatoma in the middle ear with accumulation of keratin debris. The group II rats were killed 3 months after instillation. All six animals showed inflammation in the ",American journal of otolaryngology,"C C Huang, G S Shi, Z X Yi"," Department of Otolaryngology, College of Physicians and Surgeons, Columbia University, New York, NY 10032.",1988 Jan;9(4):165-72,10.1016/s0196-0709(88)80024-3
7688081,19930801,article,mesh,"Animals,Bone Marrow,Chromosome Aberrations,Epoxy Compounds,Ethylene Oxide,Female,Mice,Micronuclei, Chromosome-Defective,Radiation Dosage,Sister Chromatid Exchange","drug effects,radiation effects,toxicity,ultrastructure","D001853 Q000648 NN,D048629 Q000187 NY,D004852 Q000633 NY,D005027 Q000633 NY,D001853 Q000528 NN,D012854 Q000187 NY,D001853 Q000187 NY","6354,6378",NULL,Genotoxic effects of ethylene oxide and propylene oxide in mouse bone marrow cells.,"Ethylene oxide and propylene oxide are high-volume reactive alkylating agents used primarily as intermediates in the chemical industry. Studies were undertaken to investigate the ability of these alkylating agents to induce chromosomal aberrations, micronuclei and sister-chromatid exchanges in mouse bone marrow cells. The mice were exposed to these chemicals by intraperitoneal injection. The data show that both compounds are effective in inducing chromosomal alterations. Our studies confirm the findings rep",Mutation research,"Z Farooqi, M Törnqvist, L Ehrenberg, A T Natarajan"," Department of Radiation Genetics and Chemical Mutagenesis, State University of Leiden, The Netherlands.",1993 Aug;288(2):223-8,10.1016/0027-5107(93)90088-w
8013473,19940101,article,mesh,"Bacteriophage M13,Chi-Square Distribution,Cytosine,DNA Damage,DNA Glycosylases,DNA Repair,DNA, Single-Stranded,DNA, Viral,Deoxyuridine,Dose-Response Relationship, Drug,Endodeoxyribonucleases,Epoxy Compounds,Escherichia coli,Escherichia coli Proteins,Lac Operon,Mutagenesis,Mutagens,N-Glycosyl Hydrolases,Point Mutation,SOS Response (Genetics),Templates, Genetic,Uracil-DNA Glycosidase","analogs &amp; derivatives,genetics,metabolism,toxicity","D003857 Q000031 NN,D003596 Q000378 NY,D009153 Q000378 NY,D004706 Q000378 NN,D017104 Q000235 NN,D004279 Q000378 NN,D004852 Q000633 NY,D003857 Q000378 NN,D004926 Q000235 NN,D004277 Q000378 NN,D009699 Q000378 NN,D004852 Q000378 NN,D009153 Q000633 NN","597,6378,13712,124412",NULL,Propylene oxide mutagenesis at template cytosine residues.,"Propylene oxide (PO) is a widely used industrial reagent which is mutagenic and carcinogenic. We have recently shown that a variety of aliphatic epoxides, including propylene oxide, can react with DNA to form hydroxyalkyl adducts at N-3 of cytosine which rapidly undergo hydrolytic deamination to produce uracil adducts. These 3-hydroxyalkyl uracil adducts are stable in DNA and are postulated to be an important class of potentially mutagenic lesions. Mutagenesis at cytosine residues due to PO modification of ",Environmental and molecular mutagenesis,"E T Snow, J Singh, K L Koenig, J J Solomon"," Nelson Institute of Environmental Medicine, New York University Medical Center, Tuxedo 10987.",1994 Jan;23(4):274-80,10.1002/em.2850230403
9118964,19970101,article,mesh,"Animals,Aziridines,DNA Repair,Drosophila,Epoxy Compounds,Ethylene Oxide,Female,Germ Cells,Germ-Line Mutation,Male,Methyl Methanesulfonate,Mice,Mutagens","drug effects,genetics,toxicity","D004330 Q000235 NY,D008741 Q000633 NY,D005854 Q000187 NY,D004852 Q000633 NY,D005027 Q000633 NY,D018095 Q000235 NN,D001388 Q000633 NY,D009153 Q000633 NY,D018095 Q000187 NY","4156,6354,6377,6378",NULL,"The response of germ cells to ethylene oxide, propylene oxide, propylene imine and methyl methanesulfonate is a matter of cell stage-related DNA repair.","We describe the consequences of a defect for nucleotide excision repair (NER) in oocytes for alkylation-induced mutagenesis in different germ-cell stages of Drosophila males. Mutant frequencies induced in NER+ condition (cross NER+female female x NER+male) were compared with those fixed in a NER- background (cross NER-female female x NER+male), using the X-linked recessive lethal assay (SLRL) for the measurement of forward mutations in 700 loci. In successive male germ-cell stages exposed to a low dose of 2",Environmental and molecular mutagenesis,"E W Vogel, M J Nivard"," Department of Radiation Genetics and Chemical Mutagenesis, Leiden University, The Netherlands. vogel@rullf2.MedFac.LeidenUniv.nl",1997 Jan;29(2):124-35,10.1002/(sici)1098-2280(1997)29:2&lt;124::aid-em3&gt;3.0.co;2-e
9851292,19981002,article,mesh,"Administration, Inhalation,Alkylation,Animals,Carcinogens,DNA Adducts,Epoxy Compounds,Guanine,Isotope Labeling,Male,Phosphorus Radioisotopes,Rats,Rats, Inbred F344,Tissue Distribution","analysis,metabolism,toxicity","D006147 Q000032 NY,D018736 Q000032 NY,D002273 Q000633 NY,D004852 Q000633 NY,D006147 Q000378 NN","764,6378,92077,56841445",NULL,Tissue distribution of DNA adducts in male Fischer rats exposed to 500 ppm of propylene oxide: quantitative analysis of 7-(2-hydroxypropyl)guanine by 32P-postlabelling.,"7-(2-Hydroxypropyl)guanine (7-HPG) constitutes the major adduct from alkylation of DNA by the genotoxic carcinogen, propylene oxide. The levels of 7-HPG in DNA of various organs provides a relevant measure of tissue dose. 7-Alkylguanines can induce mutation through abasic sites formed from spontaneous depurination of the adduct. In the current study the formation of 7-HPG was investigated in male Fisher 344 rats exposed to 500 ppm of propylene oxide by inhalation for 6 h/day, 5 days/week, for up to 20 days.",Chemico-biological interactions,"D Segerbäck, K Plná, T Faller, P E Kreuzer, K Hakansson, J G Filser, R Nilsson"," Center for Nutrition and Toxicology, Department of Biosciences, Karolinska Institute, Novum, Huddinge, Sweden. dan.segerback@cnt.ki.se",1998 Oct;115(3):229-46,10.1016/s0009-2797(98)00076-3
15312998,20040827,article,"xref,mesh","Administration, Cutaneous,Animals,Antineoplastic Agents, Phytogenic,Antispermatogenic Agents,Chromatography, High Pressure Liquid,Diterpenes,Emulsions,Epoxy Compounds,Immunosuppressive Agents,In Vitro Techniques,Irritants,Male,Mice,Oleic Acid,Permeability,Phenanthrenes,Propylene Glycol,Skin Absorption","administration &amp; dosage,adverse effects,pharmacology","D004224 Q000009 NN,D007509 Q000494 NN,D010616 Q000008 NY,D004224 Q000008 NY,D000972 Q000009 NN,D000988 Q000008 NY,D007166 Q000009 NN,D007166 Q000008 NY,D000988 Q000009 NN,D000972 Q000008 NY,D010616 Q000009 NN","965,1030,8252,16666,107985,160438,445639,5460221","127523511,128732144,129060975",A study of microemulsion systems for transdermal delivery of triptolide.,"Triptolide possesses immunosuppressive, anti-fertility and anti-cancer activities. Due to its severe toxicity, microemulsions with controlled, sustained and prolonged delivery of triptolide via a transdermal route are expected to reduce its adverse side effects. The purpose of the present study was to investigate the microemulsions for transdermal delivery of triptolide. The pseudo-ternary phase diagrams were developed and various microemulsion formulations were prepared using oleic acid as an oil, Tween 80",Journal of controlled release : official journal of the Controlled Release Society,"Huabing Chen, Xueling Chang, Ting Weng, Xiaozhi Zhao, Zhonghong Gao, Yajiang Yang, Huibi Xu, Xiangliang Yang"," Institute of Materia Medica, College of Life Science and Technology, Huazhong University of Science and Technology, 430074 Wuhan, China.",2004 Aug;98(3):427-36,10.1016/j.jconrel.2004.06.001
15483188,20050101,article,"xref,mesh","Administration, Inhalation,Animals,Dose-Response Relationship, Drug,Epoxy Compounds,Glutathione,Male,Nasal Mucosa,Nose Neoplasms,Rats,Rats, Inbred F344,Solubility,Sulfhydryl Compounds,Time Factors,Tissue Distribution","blood,chemically induced,drug effects,metabolism,pharmacokinetics,toxicity","D004852 Q000097 NY,D009297 Q000378 NY,D013438 Q000493 NY,D009669 Q000139 NY,D009297 Q000187 NN,D004852 Q000633 NN,D009669 Q000378 NN,D005978 Q000378 NY","6378,8252,124886,160438","127523511,127983601,129060975,129192846",Propylene oxide in blood and soluble nonprotein thiols in nasal mucosa and other tissues of male Fischer 344/N rats exposed to propylene oxide vapors--relevance of glutathione depletion for propylene oxide-induced rat nasal tumors.,"High concentrations of propylene oxide (PO) induced inflammation in the respiratory nasal mucosa (RNM) of rodents. Concentrations > or =300 ppm caused nasal tumors. In order to investigate if glutathione depletion could be relevant for these effects, we determined in PO exposed male Fischer 344/N rats PO in blood and soluble nonprotein SH-groups (NPSH) in RNM and other tissues. Rats were exposed once (6 h) to PO concentrations between 0 and 750 ppm, and repeatedly for up to 20 days (6 h, 5 days/week) to con",Toxicological sciences : an official journal of the Society of Toxicology,"Moung S Lee, Thomas H Faller, Paul E Kreuzer, Winfried Kessler, György A Csanády, Christian Pütz, Melva N Ríos-Blanco, Lynn H Pottenger, Dan Segerbäck, Siv Osterman-Golkar, James A Swenberg, Johannes G Filser"," Institute of Toxicology, GSF National Research Center for Environment and Health, D-85764 Neuherberg, Germany.",2005 Jan;83(1):177-89,10.1093/toxsci/kfi006
15744162,20050301,article,"xref,mesh","Animals,Cell Movement,Cholesteatoma, Middle Ear,Cytokines,Ear, Middle,Growth Substances,Inflammation,Latex,Membranes, Artificial,Propylene Glycol,Rats,Rats, Wistar,Tympanic Membrane Perforation","etiology,metabolism,pathology","D016207 Q000378 NN,D018424 Q000209 NY,D006133 Q000378 NN,D018424 Q000473 NN,D004432 Q000473 NN","1030,8252",129060975,A new experimental model of acquired cholesteatoma.,"OBJECTIVE: Cholesteatoma is a recurrent disease that is difficult control by otologists. This study aims to develop an experimental model of cholesteatoma that is easy to reproduce, using latex to induce the inflammatory reaction and propylene glycol as the foreign body in the middle ear. STUDY DESIGN: We used a new experimental model in which an intentional perforation was performed on the tympanic membrane of rats, followed by the introduction of a latex biomembrane. METHODS: A control group was submitted",The Laryngoscope,"Eduardo T Massuda, José Antonio Oliveira"," Faculty of Medicine of the University of São Paulo, Ophthalmology, Otorhinolaryngology & Head and Neck Surgery, São Paulo, Brazil.",2005 Mar;115(3):481-5,10.1097/01.mlg.0000157826.15756.67
25152525,20150125,article,mesh,"1-Propanol,Bioreactors,Carbon,Fermentation,Kinetics,Mycelium,Propionates,Propylene Glycol,Streptomyces,Tacrolimus,Time Factors","chemistry,drug effects,growth &amp; development,metabolism,microbiology,pharmacology","D011422 Q000494 NY,D013302 Q000254 NN,D002244 Q000378 NY,D019946 Q000494 NY,D013302 Q000187 NN,D025282 Q000254 NN,D016559 Q000378 NY,D000433 Q000494 NY,D019149 Q000382 NN,D005285 Q000187 NN,D016559 Q000737 NN,D013302 Q000378 NY,D025282 Q000378 NN","1030,1031,1032,5372,11189,445643,5282315,6473866,6536850,13682636,23663619,23689528,71668407,134694629",NULL,Use of three-carbon chain compounds as biosynthesis precursors to enhance tacrolimus production in Streptomyces tsukubaensis.,"Tacrolimus, a 23-membered polyketide macrolide, is isolated as a metabolite from the whole fermentation broth of Streptomyces species. This potent immunosuppressive calcineurin inhibitor has been widely used in various fields of medicine, including transplantology, dermatology and pharmacotherapy of autoimmune diseases. The current study was focused on optimisation of tacrolimus biosynthesis by Streptomyces tsukubaensis through the use of culture media supplements. Enrichment of the fermentation medium with",New biotechnology,"Wanda Gajzlerska, Justyna Kurkowiak, Jadwiga Turło"," Medical University of Warsaw, Department of Drug Technology & Pharmaceutical Biotechnology, Banacha 1a, Warszawa 02-097, Poland. Electronic address: wanda.gajzlerska@interia.pl. Medical University of Warsaw, Department of Physical Chemistry, Banacha 1a, Warszawa 02-097, Poland. Medical University of Warsaw, Department of Drug Technology & Pharmaceutical Biotechnology, Banacha 1a, Warszawa 02-097, Poland.",2015 Jan;32(1):32-9,10.1016/j.nbt.2014.07.006
28678965,20170703,article,mesh,"Animals,Anti-Infective Agents,Calcium Hydroxide,Drug Carriers,Drug Evaluation, Preclinical,Ethanol,Inflammation,Male,Materials Testing,Pharmaceutical Vehicles,Plant Extracts,Plant Leaves,Propylene Glycol,Psidium,Rats, Wistar,Reproducibility of Results,Subcutaneous Tissue,Time Factors,Water","chemistry,drug effects,drug therapy,pathology,pharmacology","D014677 Q000494 NN,D000890 Q000494 NN,D007249 Q000188 NN,D002126 Q000494 NY,D014677 Q000737 NN,D000431 Q000494 NN,D040521 Q000187 NY,D010936 Q000494 NY,D014867 Q000737 NN,D040521 Q000473 NN,D019946 Q000494 NN,D031647 Q000737 NY,D007249 Q000473 NN,D018515 Q000737 NN","702,962,1030",NULL,Calcium hydroxide associated with a new vehicle: Psidium cattleianum leaf extracts. Tissue response evaluation.,"The aim of this study was to evaluate edemogenic activity and subcutaneous inflammatory reaction induced by Psidium cattleianum leaf extracts associated with Ca(OH)2. Thirty male Wistar rats, split equally into three groups [aqueous extract + Ca(OH)2; ethanolic extract + Ca(OH)2; and propylene glycol + Ca(OH)2], were assessed every 3 h or 6 h (five animals in each period). Under general anesthesia, 0.2 mL of 1% Evans blue per 100 g of body weight was injected into the penile vein and each combination to be ",Brazilian oral research,"Diego Valentim, Carlos Roberto Emerenciano Bueno, Vanessa Abreu Sanches Marques, Ana Maria Veiga Vasques, Marina Tolomei Sandoval Cury, Luciano Tavares Angelo Cintra, Eloi Dezan"," Centro Universitário do Distrito Federal - UDF, School of Dentistry, Department of Endodontics, Brasilia, DF, Brazil. Universidade Estadual Paulista - UNESP, Araçatuba School of Dentistry, Department of Endodontics, Araçatuba, SP, Brazil. Universidade Estadual Paulista - UNESP, Araçatuba School of Dentistry, Department of Endodontics, Araçatuba, SP, Brazil. Universidade Estadual Paulista - UNESP, Araçatuba School of Dentistry, Department of Endodontics, Araçatuba, SP, Brazil. Universidade Estadual Paulista",2017 Jul;31(?):e43,10.1590/1807-3107bor-2017.vol31.0043
7461754,19800801,article,mesh,"Animals,Anti-Inflammatory Agents,Dexamethasone,Drug Evaluation, Preclinical,Inflammation,Phenylbutazone,Propylene Glycol,Propylene Glycols,Rats","drug therapy,therapeutic use","D003907 Q000627 NN,D007249 Q000188 NN,D010653 Q000627 NN,D011409 Q000627 NY","1030,4781,5743",NULL,"Anti-inflammatory activity of propane 1,2-diol (propylene glycol) in rat.",NULL,Indian journal of experimental biology,"V K Pandse, M M Mahawar, V S Acharya",NULL,1980 Aug;18(8):909-11,NULL
8197707,19940401,article,mesh,"Animals,Erythrocytes,Female,Heinz Bodies,Male,Mink,Oxidants,Propylene Glycol,Propylene Glycols","blood,drug effects,toxicity,ultrastructure","D016877 Q000633 NY,D004912 Q000648 NN,D008907 Q000097 NY,D011409 Q000633 NN,D004912 Q000187 NN,D006366 Q000187 NN",1030,NULL,Hematologic response of adult brown mink to oxidative stress.,"We evaluated the response of mink to oral administration of the oxidant compound propylene glycol (PG) to better understand the relative susceptibility of mink red blood cells (RBC) to oxidant injury. Feeding a diet containing 12% PG to 6 mink for 1 w resulted in a 17% decrease in hematocrit, a 21% decrease in RBC count and a 4.8-fold increase in reticulocyte count. A marked increase in Heinz body and eccentrocyte numbers was consistent with oxidative injury to RBC. Because of high food intake, mink ingeste",Veterinary and human toxicology,"D J Weiss, V Perman, W Wustenberg, T J Bucci"," Department of Veterinary PathoBiology, College of Veterinary Medicine, University of Minnesota, St Paul.",1994 Apr;36(2):109-11,NULL
8692227,19960705,article,mesh,"Animals,Benzene,Cytochrome P-450 CYP2E1,Cytochrome P-450 Enzyme Inhibitors,Cytochrome P-450 Enzyme System,DNA,DNA Damage,Male,Mice,Oxidoreductases, N-Demethylating,Propylene Glycol,Propylene Glycols","antagonists &amp; inhibitors,drug effects,metabolism,pharmacology,physiology,toxicity","D010089 Q000502 NY,D004247 Q000187 NY,D010089 Q000037 NN,D003577 Q000502 NY,D001554 Q000633 NY,D011409 Q000494 NN,D001554 Q000378 NN","241,1030,44135672",NULL,Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: reduction by CYP2E1 inhibition.,"The myelotoxic and genotoxic effects of benzene have been related to oxidative DNA damage after metabolism by CYP2E1. Single cell gel electrophoresis (alkaline comet assay) detects DNA damage and may thus be a convenient method for the study of benzene genotoxicity. Benzene exposure to NMRI mice as a single oral gavage at 40, 200 or 450 mg/kg resulted in dose-related DNA damage indicated by an increased comet tail length of peripheral blood lymphocytes and bone marrow nucleated cells sampled 6 h after expos",Mutation research,"J Tuo, S Loft, M S Thomsen, H E Poulsen"," Department of Pharmacology, Panum Institute 118-5, University of Copenhagen, Denmark.",1996 Jul;368(?):213-9,NULL
9062860,19970201,article,mesh,"Adult,Anti-Infective Agents, Local,Anti-Inflammatory Agents, Non-Steroidal,Carbonates,Dose-Response Relationship, Drug,Double-Blind Method,Drug Eruptions,Drug Interactions,Ethanol,Female,Histamine,Humans,Multivariate Analysis,Olive Oil,Pharmaceutical Vehicles,Plant Oils,Polysorbates,Propylene Glycol,Propylene Glycols,Skin Tests,Sodium Chloride,Solutions,Solvents,Triclosan","administration &amp; dosage,antagonists &amp; inhibitors,chemistry,drug therapy,pharmacology","D014677 Q000494 NN,D014260 Q000737 NN,D012996 Q000737 NN,D012997 Q000494 NN,D010938 Q000494 NN,D000894 Q000008 NN,D000431 Q000494 NN,D014260 Q000037 NY,D000891 Q000008 NN,D000894 Q000037 NY,D003875 Q000188 NY,D000894 Q000737 NN,D000891 Q000737 NN,D000891 Q000037 NY,D014260 Q000008 NN,D012997 Q000737 NY,D011409 Q000494 NN,D011136 Q000494 NN,D002254 Q000494 NN","702,774,1030,5234,5564,5818,10340,120160,151402,443314,443315,5281955,6364656,25201573,86289060,86289077",NULL,Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study.,"The anti-inflammatory properties of triclosan have been revealed in several recent studies, including an effect on histamine-induced inflammation. In other studies, the nature of the solvent has been shown to be of importance for the plaque inhibiting as well as the antibacterial potential of triclosan. This study was aimed at examining whether the nature of the solvent also may influence the anti-inflammatory capacity of triclosan and further to study a possible dose/ response relationship. The study was p",Journal of clinical periodontology,"A B Skaare, V Kjaerheim, P Barkvoll, G Rölla"," Department of, Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo, Norway.",1997 Feb;24(2):124-8,10.1111/j.1600-051x.1997.tb00478.x
12660494,20030101,article,"xref,mesh","Animals,Blotting, Western,Calcitriol,Cells, Cultured,Drug Delivery Systems,Ethanol,Immunohistochemistry,In Situ Hybridization,Injections, Intraperitoneal,Injections, Subcutaneous,Kidney,Kidney Glomerulus,Kidney Tubules, Proximal,Loop of Henle,Male,Microscopy, Immunoelectron,Osteopontin,Propylene Glycol,Rats,Rats, Sprague-Dawley,Sialoglycoproteins","administration &amp; dosage,biosynthesis,chemistry,cytology,drug effects,immunology,metabolism,methods,pharmacology,ultrastructure","D012795 Q000378 NN,D012795 Q000096 NY,D007678 Q000187 NN,D008138 Q000648 NN,D008138 Q000187 NN,D007668 Q000648 NN,D002117 Q000008 NN,D008138 Q000166 NN,D007668 Q000187 NY,D016503 Q000379 NN,D000431 Q000494 NN,D017403 Q000379 NN,D000431 Q000008 NN,D007687 Q000187 NN,D007668 Q000737 NN,D019946 Q000008 NN,D002117 Q000494 NY,D012795 Q000276 NN,D015153 Q000379 NN,D007687 Q000648 NN,D008138 Q000737 NN,D007687 Q000737 NN,D016253 Q000379 NN,D019946 Q000494 NN,D007678 Q000737 NN,D007678 Q000648 NN,D007150 Q000379 NN","702,1030,2524,8252,134070,5280453,5283740,5371993,6437079,9953732,13019066,53846421,73946427,129631814","127975875,127975892,128482492,129060975","1,25-Dihydroxyvitamin D3 stimulates osteopontin expression in rat kidney.","Osteopontin (OPN) is a secreted phosphoprotein expressed constitutively in the descending thin limb (DTL) and papillary surface epithelium (PSE) of the kidney. Although its function is not fully established, a role for OPN in the regulation of calcium-mediated or calcium-dependent processes has been proposed. The aim of this study was to examine the effects of 1,25-dihydroxyvitamin D(3) (vitD), a hormone involved in the regulation of calcium homeostasis, on renal OPN expression. Four groups of rats were stu",Nephron. Physiology,"Ki-Hwan Han, Ju-Young Jung, Jung-Ho Cha, Hyang Kim, Kirsten M Madsen, Jin Kim"," Department of Anatomy and Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.",2003 Jan;93(3):p76-86,10.1159/000069556
14514233,20030801,article,"xref,mesh","Amelogenin,Animals,Anti-Infective Agents, Local,Cattle,Colony Count, Microbial,Dental Enamel Proteins,Humans,Pharmaceutical Vehicles,Porphyromonas gingivalis,Propylene Glycol","chemistry,drug effects,pharmacology","D014677 Q000494 NN,D003746 Q000494 NY,D016966 Q000187 NY,D019946 Q000494 NY,D000891 Q000494 NY,D003746 Q000737 NY","1030,8252",129060975,Effects of enamel matrix derivative on Porphyromonas gingivalis.,BACKGROUND: Enamel matrix derivative (EMD) is used during periodontal surgery for the regeneration of periodontal tissue. It consists of the amelogenin fraction of porcine enamel matrix (AMEL) suspended in a vehicle of propylene glycol alginate (PGA). EMD-treated sites appear to heal with less inflammation. It has been suggested that antimicrobial properties of EMD might account for improved healing in vivo. The objectives of this study were: 1) to determine the antibacterial effects of EMD on the periodont,Journal of periodontology,"Seth A Newman, Salvatore A Coscia, Ravi Jotwani, Vincent J Iacono, Christopher W Cutler"," Department of Periodontics, School of Dental Medicine, Stony Brook University, Stony Brook, NY 11794-8703, USA.",2003 Aug;74(8):1191-5,10.1902/jop.2003.74.8.1191
17121190,20061001,article,"xref,mesh","Adhesives,Administration, Cutaneous,Algorithms,Animals,Anti-Inflammatory Agents, Non-Steroidal,Benzopyrans,Biological Transport,Body Temperature,Diffusion,Gels,Hypromellose Derivatives,Laurates,Male,Methylcellulose,Permeability,Poloxamer,Propionates,Propylene Glycols,Rats,Rats, Sprague-Dawley,Reproducibility of Results,Skin,Skin Absorption,Solubility,Surface Tension,Technology, Pharmaceutical,Temperature,Viscosity","administration &amp; dosage,analogs &amp; derivatives,chemistry,metabolism,methods,pharmacokinetics","D011422 Q000493 NY,D012867 Q000378 NY,D000894 Q000493 NN,D020442 Q000737 NN,D000894 Q000008 NN,D011422 Q000008 NN,D011409 Q000737 NN,D001578 Q000493 NY,D001578 Q000737 NN,D007848 Q000737 NN,D011409 Q000493 NN,D008747 Q000737 NN,D001578 Q000008 NN,D011422 Q000737 NN,D008747 Q000031 NN,D013678 Q000379 NN,D007848 Q000493 NN,D000269 Q000737 NN,D005782 Q000737 NY","3893,4888,8252,14870,10154203,51063134","127515881,128946789,129060975,129320693",Enhanced transdermal delivery of pranoprofen from the bioadhesive gels.,"Percutaneous delivery of NSAIDs has advantages of avoiding hepatic first pass effect and delivering the drug for extended period of time at a sustained, concentrated level at the inflammation site that mainly acts at the joint and the related regions. To develop the new topical formulations of pranoprofen that have suitable bioadhesion, the gel was formulated using hydroxypropyl methylcellulose (HPMC) and poloxamer 407. The effects of temperature on drug release was performed at 32 degrees C, 37 degrees C a",Archives of pharmacal research,"Sang-Chul Shin, Cheong-Weon Cho"," College of Pharmacy, Chonnam National University, Gwangju 500-757, Korea.",2006 Oct;29(10):928-33,10.1007/bf02973916
21264854,20110601,article,"xref,mesh","Animals,Calorimetry, Differential Scanning,Cell Line, Tumor,Cell Survival,Dose-Response Relationship, Drug,Drug Carriers,Drug Stability,Humans,Immunosuppressive Agents,Insulin-Secreting Cells,Islets of Langerhans,Mice,Micelles,Microscopy, Electron, Transmission,Molecular Structure,Particle Size,Polyethylene Glycols,Polypropylenes,Rats,Sirolimus,Solubility,Surface Properties,Surface-Active Agents,Tissue Distribution","administration &amp; dosage,chemical synthesis,chemistry,cytology,drug effects,pharmacokinetics,toxicity","D013501 Q000737 NN,D002470 Q000187 NN,D007515 Q000166 NN,D011092 Q000737 NN,D020123 Q000008 NY,D011126 Q000138 NY,D007515 Q000187 NN,D020123 Q000737 NN,D007166 Q000493 NY,D050417 Q000187 NN,D011092 Q000138 NY,D007166 Q000633 NN,D004337 Q000138 NY,D011126 Q000737 NN,D013501 Q000138 NY,D050417 Q000166 NN,D020123 Q000633 NN,D020123 Q000493 NY,D007166 Q000737 NN,D007166 Q000008 NY,D004337 Q000737 NN","7861,5284616,91454826,91534498","129698520,248184126,248766214",Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution.,"Our objective was to synthesize an amphiphilic diblock copolymer for micellar delivery of rapamycin. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) (PEG-b-PBC) with different hydrophobic core lengths were synthesized from methoxy poly(ethylene glycol) and 2-methyl-2-benzoxycarbonyl-propylene carbonate through ring-opening polymerization using 1,8-diazabicycloundec-7-ene as a catalyst. The critical micelle concentration of PEG-b-PBC was around 10(-8) M and depends on the hyd",Journal of pharmaceutical sciences,"Wenli Lu, Feng Li, Ram I Mahato"," Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38103, USA.",2011 Jun;100(6):2418-29,10.1002/jps.22467
22317828,20130301,article,mesh,"Animals,Anisoles,Benzaldehydes,Benzenesulfonates,Body Weight,Drug Therapy, Combination,Erythrocyte Count,Erythrocytes,Flavoring Agents,Food Coloring Agents,Hemoglobins,Liver,Liver Function Tests,Male,Naphthalenesulfonates,Oxidative Stress,Propylene Glycol,Rats,Rats, Sprague-Dawley,Tartrazine,Weight Loss","drug effects,metabolism,toxicity","D005505 Q000633 NY,D001835 Q000187 NN,D005421 Q000633 NY,D000840 Q000633 NN,D018384 Q000187 NN,D019946 Q000633 NN,D013645 Q000633 NN,D008099 Q000378 NN,D001547 Q000633 NN,D009282 Q000633 NN,D001557 Q000633 NN,D008099 Q000187 NN,D004912 Q000187 NN","1030,1183,17559,17560,18099,19700,29622,123671,164825,637563,5353682,5473480,5483632,6321394,9933195,54598756,54601732,101116159,118705701",NULL,Toxic effects of some synthetic food colorants and/or flavor additives on male rats.,"The objective of the present work was to evaluate the broadest toxic effect of some synthetic additives of colorants and/or flavors on different body organs and metabolic aspects in rats. A number of chemical food color and flavor additives are routinely added during processing to improve the aesthetic appearance of the dietary items. However, many of them are toxic after prolonged use. In this experiment, a total of 100 male albino rats of Spargue Dawley strain were divided into 10 groups: G(1) was fed bas",Toxicology and industrial health,"Hanan Mohamed Fathy Abd El-Wahab, Gehan Salah El-Deen Moram"," Biochemistry and Nutrition Department, Women's College for Art Science and Education, Ain Shams University, Egypt. mf_nana@hotmail.com",2013 Mar;29(2):224-32,10.1177/0748233711433935
24184533,20140201,article,mesh,"Animals,Calorimetry, Differential Scanning,Cell Death,Cell Line,Dendrimers,Drug Delivery Systems,Freeze Drying,Light,Magnetic Resonance Spectroscopy,Polypropylenes,Scattering, Radiation,Solubility,Solutions,Spectrophotometry, Ultraviolet,Sulfonamides","chemical synthesis,chemistry,drug effects,pharmacology","D011126 Q000138 NN,D013449 Q000737 NN,D011126 Q000737 NY,D016923 Q000187 NN,D050091 Q000138 NN,D013449 Q000494 NY,D050091 Q000737 NY",4495,NULL,Drug delivery investigations of quaternised poly(propylene imine) dendrimer using nimesulide as a model drug.,"This study describes the demonstration of quaternized poly(propylene imine) dendrimer of generation-3, QPPI (G3) as a drug carrier for poorly soluble drug nimesulide (NMD, an anti-inflammatory drug). QPPI (G3) was prepared by treating the surface amine groups of poly(propylene imine) dendrimer with glycidyltrimethyl ammonium chloride and it was characterized with FTIR, (1)H and (13)C NMR and MALDI-TOF mass spectral techniques. The drug carrying potential of QPPI (G3) was assessed by analyzing drug solubilit","Colloids and surfaces. B, Biointerfaces","E Murugan, D P Geetha Rani, V Yogaraj"," Department of Physical Chemistry, School of Chemical Sciences, University of Madras, Maraimalai Campus, Guindy, Chennai 600 025, TamilNadu, India. Electronic address: dr.e.murugan@gmail.com. Department of Physical Chemistry, School of Chemical Sciences, University of Madras, Maraimalai Campus, Guindy, Chennai 600 025, TamilNadu, India. Department of Physical Chemistry, School of Chemical Sciences, University of Madras, Maraimalai Campus, Guindy, Chennai 600 025, TamilNadu, India.",2014 Feb;114(?):121-9,10.1016/j.colsurfb.2013.10.002
29108729,20180301,article,mesh,"Administration, Cutaneous,Animals,Anti-Inflammatory Agents,Celecoxib,Chemistry, Pharmaceutical,Drug Carriers,Drug Delivery Systems,Drug Liberation,Edema,Glycerides,Inflammation,Liquid Crystals,Male,Oleic Acid,Permeability,Propylene Glycol,Rats,Rats, Wistar,Skin,Skin Absorption,Solubility,Water","chemistry,drug effects,drug therapy,metabolism,methods,pharmacology,physiology","D012867 Q000378 NY,D007249 Q000188 NN,D010539 Q000187 NN,D000893 Q000737 NN,D012869 Q000502 NN,D012995 Q000187 NN,D002626 Q000379 NN,D000068579 Q000494 NN,D019301 Q000737 NN,D004487 Q000188 NN,D016503 Q000379 NN,D019946 Q000737 NN,D005989 Q000737 NY,D012869 Q000187 NN,D065546 Q000187 NN,D014867 Q000737 NN,D050866 Q000737 NY,D000893 Q000494 NN,D004337 Q000737 NN,D000068579 Q000737 NY","962,965,1030,2662,33022,445639,5283468,5364833,5460221,12178130,20056951",NULL,"Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies.","Celecoxib (CXB) is a widely used anti-inflammatory drug that also acts as a chemopreventive agent against several types of cancer, including skin cancer. As the long-term oral administration of CXB has been associated with severe side effects, the skin delivery of this drug represents a promising alternative for the treatment of skin inflammatory conditions and chemoprevention of skin cancer. We prepared and characterized liquid crystalline systems based on glyceryl monooleate and water containing penetrati",Journal of pharmaceutical sciences,"Mariane de Cássia Lima Dante, Livia Neves Borgheti-Cardoso, Marcia Carvalho de Abreu Fantini, Fabíola Silva Garcia Praça, Wanessa Silva Garcia Medina, Maria Bernadete Riemma Pierre, Marilisa Guimarães Lara"," School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, 14040-903 Ribeirão Preto, São Paulo, Brazil. School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, 14040-903 Ribeirão Preto, São Paulo, Brazil; Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC) and Barcelona Institute for Global Health (ISGlobal), Rosselló 149-153, 08036 Barcelona, Spain. Institute of Physics, University of São Paulo, Rua do Matão 1371, 0",2018 Mar;107(3):870-878,10.1016/j.xphs.2017.10.039
29698819,20180710,article,mesh,"Administration, Cutaneous,Animals,Cyclosporine,Drug Carriers,Drug Compounding,Emulsions,Ethylene Glycols,Humans,Immunosuppressive Agents,Kinetics,Models, Biological,Oleic Acid,Polysorbates,Propylene Glycols,Rheology,Skin,Skin Absorption,Surface-Active Agents,Sus scrofa,Technology, Pharmaceutical,Viscosity,Vitamin E","administration &amp; dosage,chemistry,metabolism,methods","D012867 Q000378 NY,D011136 Q000737 NN,D007166 Q000378 NN,D004337 Q000737 NY,D019301 Q000737 NN,D011409 Q000737 NN,D005026 Q000737 NN,D016572 Q000737 NN,D014810 Q000737 NN,D016572 Q000378 NN,D007166 Q000737 NN,D016572 Q000008 NY,D013501 Q000737 NY,D013678 Q000379 NN,D007166 Q000008 NY","965,2909,8146,10442,14985,62280,71406,443314,443315,445639,5280754,5281955,5284373,5458585,5460221,6364656,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,86289060,86289077,122172945,123134263,123134270,132274082",NULL,Development of microemulsions of suitable viscosity for cyclosporine skin delivery.,"Psoriasis is a widespread chronic disease affecting 2-4% of the population in Western countries. Its mild-to-moderate form, representing approximately 80% of the total cases, is treated by topical application, with corticosteroid being the standard treatment. However, in case of psoriasis, no single treatment works for every patient and optimizing topical therapy is a key aspect. A possible alternative is represented by cyclosporine, an immunosuppressant cyclic peptide administered orally in the treatment o",International journal of pharmaceutics,"Marta Benigni, Silvia Pescina, Maria Aurora Grimaudo, Cristina Padula, Patrizia Santi, Sara Nicoli"," Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Food and Drug Department, Parco Area delle Scienze 27/A, 43124 Parma, Italy. Electronic address: sara.nicoli@unipr.it.",2018 Jul;545(?):197-205,10.1016/j.ijpharm.2018.04.049
614417,19770401,article,mesh,"Animals,Edema,Female,Inflammation,Male,Mice,Propylene Glycols","chemically induced,drug therapy","D004487 Q000188 NN,D004487 Q000139 NY,D007249 Q000139 NY",NULL,NULL,"Propane 1, 2-diol (propylene glycol): a new phlogistic agent in mice.",NULL,Journal of postgraduate medicine,"K M Mogre, S R Amladi, P D Soman, U K Sheth",NULL,1977 Apr;23(2):73-6,NULL
1655079,19910101,article,mesh,"Animals,Antibody Formation,Antineoplastic Agents,Carcinoma, Hepatocellular,Cell Survival,Cytotoxicity, Immunologic,Dose-Response Relationship, Drug,Epoxy Compounds,Ethylene Oxide,Immunosuppression,Immunosuppressive Agents,Killer Cells, Natural,Leukemia L1210,Liver Neoplasms,Lymphocytes,Mice","drug effects,drug therapy,methods,pharmacology","D003602 Q000187 NN,D007166 Q000494 NY,D000970 Q000494 NY,D004852 Q000494 NY,D006528 Q000188 NN,D002470 Q000187 NN,D008113 Q000188 NN,D007939 Q000188 NN,D005027 Q000494 NY,D000917 Q000187 NN,D007165 Q000379 NY,D007694 Q000187 NN,D008214 Q000187 NN","6354,6378",NULL,Block copolymers of ethylene oxide and propylene oxide (pluronics) as immunomodulators and antitumour agents.,"Block copolymers of ethylene oxide and propylene oxide (pluronics) are nontoxic water-soluble membranotropic surfactants available as polymers with various compositions, molecular masses, number, and arrangement of blocks. In vivo experiments are reported which demonstrate that these polymers and their functional derivatives stimulate the production of anti-sheep-erythrocyte antibodies in mice. The introduction of reactive (hydroperoxide) groups into the polymers by chemical modification or by solubilizatio",Biomedical science,"I N Topchieva, V N Erokhin, S V Osipova, M M Khrutskaya, T A Kupriyanova, S N Bykovskaya"," Department of Chemistry, Moscow State University.",1991 Jan;2(1):38-44,NULL
1944340,19910101,article,mesh,"Cell Survival,Epoxy Compounds,Ethylene Oxide,Humans,Mutagenicity Tests,Mutagens,Saccharomyces cerevisiae,Salmonella typhimurium,Sister Chromatid Exchange","drug effects,toxicity","D012441 Q000187 NN,D004852 Q000633 NY,D005027 Q000633 NY,D012486 Q000187 NN,D009153 Q000633 NY","6354,6378",NULL,Genotoxic effects of ethylene oxide and propylene oxide: a comparative study.,"The two alkylating agents ethylene oxide (EO) and propylene oxide (PO) were compared for genotoxic effectiveness in various test systems. The study was undertaken partly to shed light on the difference between the compounds found after chronic exposure of monkeys (Lynch et al., 1984) where EO but not PO was able to induce SCE and chromosomal aberrations. In the present study EO was found to be 5-10 times more effective than PO with respect to gene conversion and reverse mutation in Saccharomyces cerevisiae ",Mutation research,"E Agurell, H Cederberg, L Ehrenberg, K Lindahl-Kiessling, U Rannug, M Törnqvist"," Department of Genetic and Cellular Toxicology, Stockholm University, Sweden.",1991 Jan;250(?):229-37,10.1016/0027-5107(91)90180-v
2147390,19901101,article,mesh,"Animals,Azepines,Cyclosporins,Guinea Pigs,Humans,Hypersensitivity, Delayed,In Vitro Techniques,Leukocyte Count,Male,Pharmaceutical Vehicles,Propylene Glycols,Skin,Skin Absorption,T-Lymphocytes, Cytotoxic,T-Lymphocytes, Regulatory,Time Factors","drug effects,immunology,pharmacokinetics,prevention &amp; control","D006968 Q000517 NN,D003524 Q000493 NY,D013602 Q000276 NN,D050378 Q000276 NN,D012869 Q000187 NY,D012867 Q000276 NN",42981,NULL,Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity.,"No clinically successful topical cyclosporin A (CyA) formulation has been produced, mainly due to the apparent lack of drug penetration. This study has produced the first in vitro kinetic data on CyA penetration across human cadaver stratum corneum and has shown that addition of the penetration enhancers (PE) Azone and propylene glycol to the CyA vehicle significantly enhanced drug permeation across the skin barrier. Using flow-through permeability cells with 5% w/v CyA (Sandimmun) alone (CyA) or with PE (C",The British journal of dermatology,"J I Duncan, S N Payne, A J Winfield, A D Ormerod, A W Thomson"," Department of Pathology, University of Aberdeen, Foresterhill, Scotland, U.K.",1990 Nov;123(5):631-40,10.1111/j.1365-2133.1990.tb01480.x
7768198,19950201,article,mesh,"Animals,Cell Death,Cells, Cultured,Cricetinae,Dose-Response Relationship, Drug,L-Lactate Dehydrogenase,Polyethylenes,Polypropylenes,Rats,Toxicity Tests","drug effects,pharmacokinetics,toxicity","D007770 Q000493 NN,D016923 Q000187 NY,D011095 Q000633 NY,D011126 Q000633 NY",16212863,NULL,Cytotoxicity of ethylene oxide/propylene oxide copolymers in cultured mammalian cells.,"Cytotoxicity was measured in vitro for 8 ethylene oxide/propylene oxide copolymers (EO/PO copolymers) using lactate dehydrogenase release from cultured mammalian cells as the endpoint. Three cell types were used in these assays: Chinese hamster ovary cell line (AS52), rat lung epithelial cell line (LEC), and freshly isolated rat alveolar macrophages (RAM). A range of cytotoxicity was seen with toxic effects observed from 20 to > 20,000 micrograms/ml. The same relative order of toxicities were observed for a",Drug and chemical toxicology,"L D Kier, L M Wagner, T V Wilson, A P Li, R D Short, G L Kennedy"," Monsanto Company, Environmental Health Laboratory, St. Louis, MO 63110, USA.",1995 Feb;18(1):29-41,10.3109/01480549509017856
9546267,19980401,article,mesh,"Animals,Anti-Inflammatory Agents,Cell Movement,Cholesteatoma, Middle Ear,Ear, Middle,Epithelium,Fibrosis,Glucocorticoids,Granulation Tissue,Hyperplasia,Inflammation,Injections,Irritants,Keratins,Otitis Media,Prednisolone,Propylene Glycol,Rats,Rats, Wistar,Temporal Bone,Tympanic Membrane","administration &amp; dosage,adverse effects,chemically induced,drug effects,pathology,prevention &amp; control,therapeutic use","D011239 Q000627 NY,D018424 Q000517 NY,D013701 Q000473 NN,D007509 Q000009 NN,D007633 Q000187 NN,D005938 Q000627 NY,D018424 Q000139 NN,D010033 Q000473 NN,D014432 Q000473 NN,D011239 Q000008 NN,D000893 Q000008 NN,D006097 Q000473 NN,D005938 Q000008 NN,D004848 Q000473 NN,D013701 Q000187 NN,D018424 Q000473 NN,D006097 Q000187 NN,D019946 Q000009 NN,D010033 Q000139 NN,D014432 Q000187 NN,D004848 Q000187 NN,D000893 Q000627 NY","1030,5755",NULL,Effect of intratympanic steroid application on the development of experimental cholesteatoma.,"By introducing certain irritants into the middle ear it is possible to produce cholesteatoma. Propylene glycol, the main agent used for this purpose, produces a long-standing inflammation that causes hyperplasia and migration of the epithelium through an intact tympanic membrane. In the present investigation topical prednisolone was used in order to inhibit the production of cholesteatoma. The results indicate that there is a marked decrease in inflammation and hence experimental cholesteatoma production wh",The Laryngoscope,"L Sennaroglu, A Ozkul, G Gedikoglu, E Turan"," Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey.",1998 Apr;108(?):543-7,10.1097/00005537-199804000-00015
9641618,19980701,article,mesh,"Animals,Biocompatible Materials,Biodegradation, Environmental,Bone Regeneration,Calcium Phosphates,Composite Resins,Fumarates,Guided Tissue Regeneration,Inflammation,Male,Materials Testing,Polypropylenes,Rats,Rats, Inbred Lew","adverse effects,chemically induced,metabolism","D002130 Q000009 NN,D002130 Q000378 NY,D005650 Q000009 NN,D011126 Q000378 NY,D007249 Q000139 NN,D005650 Q000378 NY,D003188 Q000378 NY,D011126 Q000009 NN,D001672 Q000009 NN,D003188 Q000009 NN,D001672 Q000378 NY",NULL,NULL,In vivo degradation of a poly(propylene fumarate)/beta-tricalcium phosphate injectable composite scaffold.,This study was designed to investigate the in vivo biodegration and biocompatibility of a poly(propylene fumarate) (PPF)-based orthopedic biomaterial. The effects of varying the PPF to N-vinyl pyrrolidinone ratio and PPF to beta-tricalcium phosphate content were studied. The composite mechanical properties and local tissue interactions were analyzed over 12 weeks. An initial increase in both compressive modulus and strength was seen for composite formulations that incorporated beta-tricalcium phosphate. The,Journal of biomedical materials research,"S J Peter, S T Miller, G Zhu, A W Yasko, A G Mikos"," Institute of Biosciences and Bioengineering and Department of Chemical Engineering, Rice University, Houston, Texas 77005-1892, USA.",1998 Jul;41(1):1-7,10.1002/(sici)1097-4636(199807)41:1&lt;1::aid-jbm1&gt;3.0.co;2-n
9748619,19980920,article,mesh,"Administration, Inhalation,Animals,Chromosome Aberrations,Crosses, Genetic,DNA Repair,Dose-Response Relationship, Drug,Drosophila,Epoxy Compounds,Ethylene Oxide,Female,Genes, Lethal,Genes, Recessive,Germ Cells,Germ-Line Mutation,Male,Methyl Methanesulfonate,Mutagens","administration &amp; dosage,drug effects,physiology,toxicity","D005027 Q000008 NN,D008741 Q000633 NN,D004260 Q000502 NY,D005854 Q000187 NY,D004852 Q000008 NN,D009153 Q000008 NN,D004852 Q000633 NY,D005027 Q000633 NY,D009153 Q000633 NY","4156,6354,6378",NULL,"Genotoxic effects of inhaled ethylene oxide, propylene oxide and butylene oxide on germ cells: sensitivity of genetic endpoints in relation to dose and repair status.","We report here results on forward mutation induction (recessive lethal mutations, RL) in Drosophila spermatozoa and spermatids by the three 1,2-alkyl-epoxides ethylene oxide (EO), propylene oxide (PO) and butylene oxide (BO), at doses ranging from 47 to 24,000 ppm h for EO, 375 to 48,000 ppm h for PO, and 24,000 to 91,200 ppm h for BO. The results indicate for EO mutation induction at doses 500-fold below the LD50. In crosses of mutagenized NER+ males with NER+ females, the 500-fold increase in EO dose from",Mutation research,"E W Vogel, M J Nivard"," Medical Genetics Centre South-West Netherlands (MGC), Department of Radiation Genetics and Chemical Mutagenesis, Leiden University Medical Centre, Wassenaarseweg 72, 2300 RA, Leiden, Netherlands.",1998 Sep;405(2):259-71,10.1016/s0027-5107(98)00143-2
9814436,19980101,article,mesh,"Carcinogens,Cell Survival,Cells, Cultured,DNA Damage,DNA Repair,Dose-Response Relationship, Drug,Electrophoresis, Gel, Pulsed-Field,Epichlorohydrin,Epoxy Compounds,Fibroblasts,Humans",pharmacology,"D004852 Q000494 NY,D002273 Q000494 NY,D004811 Q000494 NY","6378,7835",NULL,Rejoining of DNA strand breaks induced by propylene oxide and epichlorohydrin in human diploid fibroblasts.,"The repair kinetics of DNA single- and double-strand breaks (SSBs, DSBs) induced with two carcinogenic epoxides, propylene oxide (PO) and epichlorohydrin (ECH), was studied in human diploid fibroblasts. The methods used were: alkaline DNA unwinding (ADU), the comet assay, and pulsed field gel electrophoresis (PFGE). About 70% of SSBs, measured by ADU, were rejoined after the treatment with 5 mMh and 10 mMh of PO within 20 hr, and the half-life was estimated to be approximately 15 hr. On the other hand, effe",Environmental and molecular mutagenesis,"M Chovanec, M Näslund, I Spivak, M Dusinská, B Cedervall, A Kolman"," Department of Molecular Genetics, Cancer Research Institute, Bratislava, Slovak Republic.",1998 Jan;32(3):223-8,10.1002/(sici)1098-2280(1998)32:3&lt;223::aid-em4&gt;3.0.co;2-9|10.1002/(sici)1098-2280(1998)32:3&lt;223::aid-em4&gt;3.3.co;2-0
9890471,19990101,article,mesh,"Adolescent,Child,Female,Humans,Inflammatory Bowel Diseases,Male,Radionuclide Imaging,Radiopharmaceuticals,Retrospective Studies,Sensitivity and Specificity,Technetium Tc 99m Exametazime",diagnostic imaging,D015212 Q000000981 NY,"450484,56841051,129626367",NULL,Clinical applications of technetium Tc 99m hexamethyl propylene amine oxime leukocyte scan in children with inflammatory bowel disease.,"BACKGROUND: Labeled leukocyte imaging is a helpful diagnostic tool in the detection of inflammation and sepsis. The technetium Tc 99m hexamethyl propylene amine oxime (99mTc HMPAO)-labeled leukocyte scan has been found to be more sensitive than the Indium-111 labeled leukocyte scan in detecting inflammatory bowel disease, with reported sensitivities of 95% to 100%. Experience with the 99mTc HMPAO-labeled leukocyte scan was examined and its clinical applications evaluated in the immediate treatment of patien",Journal of pediatric gastroenterology and nutrition,"M A Del Rosario, J F Fitzgerald, A R Siddiqui, S K Chong, J M Croffie, S K Gupta"," Division of Gastroenterology, James Whitcomb Riley Hospital for Children, Indiana University Medical Center, Indianapolis 46202, USA.",1999 Jan;28(1):63-70,10.1097/00005176-199901000-00015
10095198,19990101,article,mesh,"Animals,Chinchilla,Cholesteatoma, Middle Ear,Ear, Middle,Electric Impedance,Pharmaceutical Vehicles,Propylene Glycol,Temporal Bone","chemically induced,pathology,toxicity","D013701 Q000473 NN,D018424 Q000139 NN,D019946 Q000633 NN,D004432 Q000473 NY,D018424 Q000473 NY",1030,NULL,Pathogenesis of experimental aural cholesteatoma in the chinchilla.,"Histopathological observation of celloidin serial sections of the chinchilla middle ear after treatment with propylene glycol disclosed the development of severe inflammation of the middle ear mucosa and tympanic membrane, papillary proliferation of the epidermis of the tympanic membrane and external auditory meatus, and retraction and adhesion of the tympanic membrane. The findings for the tympanic membrane, impedance testing and histopathological examination suggested that there were two types of acquired",ORL; journal for oto-rhino-laryngology and its related specialties,"S Imamura, I Nozawa, M Imamura, Y Murakami"," Department of Otolaryngology, Yamanashi Medical University, Yamanashi, Japan. imamuras@res.yamanashi-med.ac.jp",1999 Jan;61(2):84-91,10.1159/000027647
10190577,19990212,article,mesh,"Cell Cycle,Cell Death,Cell Line,DNA,DNA Fragmentation,DNA Replication,Diploidy,Epichlorohydrin,Epoxy Compounds,Ethylene Oxide,Fibroblasts,Glutathione,Humans,Male","biosynthesis,cytology,drug effects,metabolism,pharmacology","D004247 Q000096 NN,D005347 Q000166 NY,D004852 Q000494 NY,D004247 Q000187 NN,D002453 Q000187 NY,D005347 Q000378 NN,D053938 Q000187 NN,D016923 Q000187 NN,D004261 Q000187 NY,D004811 Q000494 NY,D005347 Q000187 NN,D005027 Q000494 NY,D005978 Q000378 NN","6354,6378,7835,124886,44135672",NULL,"Effects of three epoxides--ethylene oxide, propylene oxide and epichlorohydrin--on cell cycle progression and cell death in human diploid fibroblasts.","Ethylene oxide (EtO), propylene oxide (PO), and epichlorohydrin (ECH) strongly influenced the G1/S progression in human diploid fibroblasts, VH-10. However, these epoxides did not affect substantially the G2/M progression. It was found that G1 arrest is induced by these epoxides 6-18 h after the treatment at doses above 5, 3, and 0.5 mMh for EtO, PO, and ECH, respectively. An inhibitory effect on DNA synthesis was also demonstrated at the same doses within the same time interval. On the contrary, the epoxid",Chemico-biological interactions,"P Mlejnek, A Kolman"," Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno. mlejnek@ibp.cz",1999 Feb;117(3):219-39,10.1016/s0009-2797(98)00109-4
10357132,19990701,article,mesh,"Animals,Biocompatible Materials,Cell Count,Cell Survival,Coloring Agents,Exudates and Transudates,Female,Hydrogels,Implants, Experimental,Macrophages,Materials Testing,Microscopy, Electron, Scanning,Oxazines,Polyethylene Glycols,Polypropylenes,Rats,Rats, Sprague-Dawley,Tetrazolium Salts,Thiazoles,Thymidine,Time Factors,Xanthenes","chemical synthesis,cytology,drug effects,enzymology,metabolism,toxicity","D011092 Q000138 NN,D002470 Q000187 NN,D011126 Q000138 NN,D001672 Q000633 NY,D020100 Q000633 NY,D005122 Q000166 NN,D011092 Q000633 NY,D008264 Q000187 NN,D013936 Q000378 NN,D020100 Q000138 NN,D011126 Q000633 NY,D001672 Q000138 NN,D005122 Q000201 NN","5789,11077,64965,64966",NULL,In vitro cytotoxicity and in vivo biocompatibility of poly(propylene fumarate-co-ethylene glycol) hydrogels.,"The in vitro cytotoxicity and in vivo biocompatibility of poly(propylene fumarate-co-ethylene glycol) [P(PF-co-EG)] hydrogels were assessed in order to investigate the influence of poly(ethylene glycol) molecular weight and copolymer composition. These materials have application as injectable cardiovascular implants; cytotoxicity due to leachable products, as well as inflammation caused by the biomaterial itself, may ultimately affect the biocompatibility of the implant. We utilized a 7-day in vitro cytotox",Journal of biomedical materials research,"L J Suggs, M S Shive, C A Garcia, J M Anderson, A G Mikos"," Institute of Biosciences and Bioengineering and Department of Chemical Engineering, Rice University, Houston, Texas 77251-1892, USA.",1999 Jul;46(1):22-32,10.1002/(sici)1097-4636(199907)46:1&lt;22::aid-jbm3&gt;3.0.co;2-r
10993433,20000901,article,mesh,"Adult,Aged,Blood Sedimentation,C-Reactive Protein,Cell Separation,Crohn Disease,Data Interpretation, Statistical,Female,Humans,Immunoenzyme Techniques,Leukocyte Elastase,Leukocytes,Male,Middle Aged,Neutrophils,Radionuclide Imaging,Radiopharmaceuticals,Technetium Tc 99m Exametazime","analysis,blood,diagnosis,diagnostic imaging,enzymology","D003424 Q000097 NN,D007962 Q000000981 NY,D009504 Q000201 NY,D003424 Q000000981 NN,D002097 Q000032 NN,D003424 Q000175 NY,D003424 Q000201 NN,D019272 Q000097 NY","450484,56841051,129626367",NULL,Polymorphonuclear leukocyte-elastase in Crohn's disease: correlation with 99mtechnetium hexamethyl propylene amine oxime leukocyte scintigraphy.,"In Crohn's disease (CD), labeled leukocyte scintigraphy results are highly correlated with radioendoscopic findings and the degree of histologic inflammation. We evaluated the correlation between leukocyte activity measured by two complementary methods. polymorphonuclear leukocyte (PMN)-elastase concentration and leukocyte scintigraphy. In 20 patients with CD, labeled leukocytes, 99m technetium hexamethyl propylene amine oxime (99mTc-HMPAO) scintigraphy, and PMN-elastase concentration were evaluated on the ",Journal of clinical gastroenterology,"R Dhôte, P Dhôte-Burger, T Thevenot, J Y Devaux, E Beades, B Richard, B Christoforov"," Service de Médecine Interne, Hôpital Cochin, Paris, France. robin.dhote@cch.ap-hop-paris.fr",2000 Sep;31(2):152-5,10.1097/00004836-200009000-00013
11287031,20010401,article,"xref,mesh","Animals,Cell Death,Cell Survival,Cryopreservation,Cryoprotective Agents,Culture Media,Dimethyl Sulfoxide,Female,Organ Preservation,Ovarian Follicle,Ovary,Propylene Glycols,Sheep,Time Factors","cytology,drug effects,methods,pharmacology","D010053 Q000166 YN,D009926 Q000379 NY,D004121 Q000494 NN,D015925 Q000379 NY,D006080 Q000166 NY,D003451 Q000494 NY,D006080 Q000187 NN,D011409 Q000494 NN","679,8252","128141778,129060975",Follicular viability and morphology of sheep ovaries after exposure to cryoprotectant and cryopreservation with different freezing protocols.,"OBJECTIVE: To test the toxicity of cryoprotectant in sheep ovarian tissue and to determine optimal conditions for freezing hemiovary cortex. DESIGN: Small follicles (<60 microm in diameter) were isolated enzymatically for viability testing. Dead and live follicles were identified by using trypan blue staining, and follicle morphology was examined histologically. SETTING: Centre hospitalo-universitaire de Biologie de la Reproduction, Hôpital Edouard Herriot, Lyon, France. ANIMAL(S): Lambs 5 to 6 months of ag",Fertility and sterility,"B Demirci, J Lornage, B Salle, L Frappart, M Franck, J F Guerin"," Laboratoire de Zootechnie, Ecole Nationale Vétérinaire de Lyon, Marcy l'Etoile, France. b.demirci@vet-lyon.fr",2001 Apr;75(4):754-62,10.1016/s0015-0282(00)01787-8
11337167,20010521,article,"xref,mesh","Algorithms,Caprylates,Dermatologic Agents,Diffusion,Emulsions,Excipients,Guanine,Humans,Immunosuppressive Agents,In Vitro Techniques,Myristates,Ointment Bases,Ointments,Propylene Glycols,Skin Absorption,Solubility","administration &amp; dosage,analogs &amp; derivatives,chemistry,pharmacokinetics","D006147 Q000031 NN,D006147 Q000493 NN,D003879 Q000493 NN,D007166 Q000493 NN,D003879 Q000737 NN,D003879 Q000008 NY,D006147 Q000008 NY,D007166 Q000737 NN,D007166 Q000008 NY,D006147 Q000737 NN","753,764,8042,8252,60817,135398634,135413525","127472665,127763543,128902940,129060975,129439837",Evaluation of creams and ointments as suitable formulations for peldesine.,"In-vitro studies were conducted to study the efficacy of mixed and self-emulsifying creams and hydrophobic ointment formulations in delivering peldesine (BCX-34) into and across cryopreserved human cadaver skin (HCS). Oil-in-water cream formulations, containing 1% w/w of radiolabeled C(14) BCX-34 and propylene glycol (PG), glycerin (GLY), isopropyl myristate (IPM), oleic acid (OA) and capric-caprylic esters (CE) were prepared. Petrolatum and lanolin based ointments were also prepared with PG. Sections of th",International journal of pharmaceutics,"T X Viegas, L L Van Winkle, P A Lehman, S F Franz, T J Franz"," BioCryst Pharmaceuticals, Inc., 2190 Parkway Lake Drive, Birmingham, AL 35244, USA. tviegas@biocryst.com",2001 May;219(?):73-80,10.1016/s0378-5173(01)00632-9
11774313,20020305,article,mesh,"Animals,Bone Substitutes,Connective Tissue,Cross-Linking Reagents,Fumarates,Inflammation,Models, Animal,Photochemistry,Polypropylenes,Rabbits,Skull,Tissue Engineering","adverse effects,chemistry,cytology,drug effects,methods,pharmacology,standards,therapeutic use","D003238 Q000187 NN,D012886 Q000187 NN,D023822 Q000379 NY,D018786 Q000494 NY,D023822 Q000009 NN,D011126 Q000627 NY,D011126 Q000494 NN,D005650 Q000627 NY,D018786 Q000737 NY,D023822 Q000592 NN,D018786 Q000627 NN,D005650 Q000494 NN,D012886 Q000166 NN",NULL,NULL,Soft and hard tissue response to photocrosslinked poly(propylene fumarate) scaffolds in a rabbit model.,"The treatment of large cranial defects may be greatly improved by the development of precisely formed bone tissue engineering scaffolds. Such scaffolds could be constructed by using UV laser stereolithography to photocrosslink a linear, biodegradable polymer into a three-dimensional implant. We have previously presented a method to photocrosslink the biodegradable polyester, poly(propylene fumarate) (PPF). To ensure the safety and effectiveness of this technique, the soft and hard tissue response to photocr",Journal of biomedical materials research,"John P Fisher, Johan W M Vehof, David Dean, Jan Paul C M van der Waerden, Theresa A Holland, Antonios G Mikos, John A Jansen"," Department of Bioengineering, Rice University, Houston, Texas, USA.",2002 Mar;59(3):547-56,10.1002/jbm.1268
11895884,20020301,article,"xref,mesh","Adult,Air Pollutants, Occupational,Carcinogens,Chromatography, High Pressure Liquid,DNA Adducts,Epoxy Compounds,Female,Hemoglobins,Humans,Male,Nose Neoplasms,Occupational Exposure,Pilot Projects,Sister Chromatid Exchange","adverse effects,analysis,blood,chemically induced,genetics,metabolism,standards","D004852 Q000378 NY,D009669 Q000139 NN,D002273 Q000009 NN,D012854 Q000235 NY,D006454 Q000032 NY,D009669 Q000235 NN,D016273 Q000592 NY,D018736 Q000097 NY,D004852 Q000009 NN,D002273 Q000378 NY,D000395 Q000378 NY,D000395 Q000009 NN","6378,160438,91038077","127523511,127983601,245142481",Analysis of DNA and hemoglobin adducts and sister chromatid exchanges in a human population occupationally exposed to propylene oxide: a pilot study.,"Propylene oxide (PO), a simple alkylating agent used in the chemical industry, is weakly genotoxic and induces nasal cavity tumors in rodents on inhalation at high air concentrations. DNA adducts, hemoglobin adducts, and sister chromatid exchanges (SCE) were analyzed as biomarkers of exposure in a group of eight PO-exposed workers and eight nonexposed subjects. 1-2-Hydroxypropyladenine (1-HP-adenine) in DNA of WBCs was analyzed using a hypersensitive (32)P-postlabeling assay. HP-valine in hemoglobin was mea","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","Kamila Czene, Siv Osterman-Golkar, Xiao Yun, Gang Li, Fulin Zhao, Hermes Licea Pérez, Ming Li, A T Natarajan, Dan Segerbäck"," Department of Biosciences, Karolinska Institute, Novum, S-141 57 Huddinge, Sweden.",2002 Mar;11(3):315-8,NULL
12376143,20021005,article,"xref,mesh","Animals,DNA Adducts,Epoxy Compounds,Hemoglobins,Inhalation Exposure,Rats,Rats, Inbred F344,Valine","administration &amp; dosage,analogs &amp; derivatives,chemistry","D004852 Q000008 NY,D006454 Q000737 NY,D014633 Q000737 NY,D014633 Q000031 NY","6287,6378,130204,160438,21121256","127523511,127983601,128458032,128525917",Exposure-dependent accumulation of N-(2-hydroxypropyl)valine in hemoglobin of F344 rats exposed to propylene oxide by the inhalation route.,"The detection of hemoglobin adducts by mass spectrometry is a very sensitive and specific measurement of the extent of covalent binding of electrophilic chemicals. The exposure-dependent accumulation of N-(2-hydroxypropyl)valine (N-HPVal) in globin of rats exposed to propylene oxide (PO) (0, 5, 25, 50, 300 or 500 ppm) by the inhalation route was measured to assess the utility of Hb adducts as biomarkers of exposure. Analysis of N-HPVal by gas-chromatography tandem mass spectrometry showed a linear exposure-","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","Melva N Ríos-Blanco, Asoka Ranasinghe, Patricia Upton, Moung S Lee, Johannes G Filser, James A Swenberg"," Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, USA.",2002 Oct;778(?):383-91,10.1016/s1570-0232(02)00115-0
12464351,20021201,review,"xref,mesh","Carcinogens,Cohort Studies,DNA,Disinfectants,Environmental Pollutants,Epichlorohydrin,Epoxy Compounds,Ethylene Oxide,Hemoglobins,Humans,Mutagenicity Tests,Mutagens,Mutation,Neoplasms,Occupational Exposure,Polymorphism, Genetic,Risk Assessment,Smoking","chemically induced,chemistry,drug effects,epidemiology,metabolism,mortality,toxicity","D009369 Q000139 NY,D006454 Q000378 NN,D009369 Q000401 NN,D006454 Q000737 NN,D002273 Q000633 NN,D004247 Q000187 NN,D004202 Q000633 NN,D004247 Q000378 NN,D004852 Q000633 NY,D004811 Q000633 NY,D005027 Q000633 NY,D009153 Q000633 NY,D009369 Q000453 NN,D004785 Q000633 NN","6354,6378,7835,160438,44135672","127523511,127557587,127983601,128141679","Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001).","Ethylene oxide (EtO), propylene oxide (PO) and epichlorohydrin (ECH) are important industrial chemicals widely used as intermediates for various synthetic products. EtO and PO are also environmental pollutants. In this review we summarize data published during the period 1990-2001 concerning both the genotoxic and carcinogenic effects of these epoxides in humans. The use of DNA and hemoglobin adducts as biomarkers of exposure and the role of polymorphism, as well as confounding factors, are discussed. We ha",Mutation research,"Ada Kolman, Miroslav Chovanec, Siv Osterman-Golkar"," Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91, Stockholm, Sweden. ada.kolman@molbio.su.se",2002 Dec;512(?):173-94,10.1016/s1383-5742(02)00067-4
12857943,20031001,article,"xref,mesh","Administration, Inhalation,Animals,Bromodeoxyuridine,Carcinogens,Cell Division,Dose-Response Relationship, Drug,Epoxy Compounds,Goblet Cells,Liver,Male,Rats,Rats, Inbred F344","administration &amp; dosage,drug effects,metabolism,pathology,toxicity","D008099 Q000473 NN,D002455 Q000187 NN,D004852 Q000008 NN,D020397 Q000378 NN,D002273 Q000633 NY,D004852 Q000633 NY,D008099 Q000378 NN,D001973 Q000378 NN,D002273 Q000008 NN,D020397 Q000187 NY,D020397 Q000473 NN,D008099 Q000187 NN","6035,6378,160438,6918942","127523511,127983601,136216744",Effects of propylene oxide exposure on rat nasal respiratory cell proliferation.,"Long-term exposure of rodents to propylene oxide (PO) induced inflammation, respiratory cell hyperplasia, and nasal tumors at concentrations >/= 300 ppm, suggesting a possible role for cytotoxicity and compensatory cell proliferation in PO carcinogenesis. In this study, the effects of PO exposure on histopathology and cell proliferation in nasal and hepatic tissues were studied in male F344 rats exposed by inhalation for 3 or 20 days (0, 5, 25, 50, 300, and 500 ppm). Histopathology revealed an increase in m",Toxicological sciences : an official journal of the Society of Toxicology,"Melva N Ríos-Blanco, Shuji Yamaguchi, Mukta Dhawan-Robl, Winfried Kessler, Robert Schoonhoven, Johannes G Filser, James A Swenberg"," Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.",2003 Oct;75(2):279-88,10.1093/toxsci/kfg187
12943923,20030828,article,"xref,mesh","Animals,Biotransformation,DNA Repair,Drosophila,Epoxy Compounds,Ethylene Oxide,Female,Genes, Lethal,Genes, Recessive,Guanine,Male,Mutagens,Spermatozoa,X Chromosome","analogs &amp; derivatives,cytology,drug effects,genetics,pharmacokinetics,pharmacology","D004330 Q000235 NY,D004852 Q000494 NY,D013094 Q000187 NN,D004852 Q000493 NN,D006147 Q000493 NY,D004260 Q000235 NN,D013094 Q000166 NN,D006147 Q000031 NY,D005027 Q000493 NN,D004330 Q000187 NN,D005027 Q000494 NY,D009153 Q000494 NY","764,6354,6378,160438,135398634","127523511,127983601,128141679,129439837",Mutagenic activity of ethylene oxide and propylene oxide under XPG proficient and deficient conditions in relation to N-7-(2-hydroxyalkyl)guanine levels in Drosophila.,"Ethylene oxide (EO) and propylene oxide (PO) are direct acting mutagens with high Swain-Scott s-values, which indicate that they react preferentially with ring nitrogens in the DNA. We have previously described that in the X-linked recessive lethal (RL) assay in Drosophila postmeiotic male germ cells EO is, per unit exposure dose, 5-10 times more mutagenic than PO. Furthermore, at the higher dose range of EO tested, 62.5-1000 ppm, up to 20-fold enhanced mutation rates were measured in the absence of materna",Mutation research,"Madeleine J M Nivard, Kamila Czene, Dan Segerbäck, Ekkehart W Vogel"," Sylvius Laboratories, Department of Toxicogenetics, Medical Genetics Centre South-West Netherlands, Leiden University Medical Centre, Wassenaarseweg 72, 2300 RA Leiden, The Netherlands. m.j.m.nivard@lumc.nl",2003 Aug;529(?):95-107,10.1016/s0027-5107(03)00111-8
14648624,20040130,article,xref,NULL,NULL,NULL,8252,129060975,Density functional investigation of reaction of borohydride cation BH2+ with propylene.,"The reactions of BH2+ with propylene (CH2=CHCH3) to form both the adducts BC3H8+ and the H2-elimination products BC3H6+ + H2 have been investigated at the density functional B3LYP/6-311G(d,p) level of theory. It is shown that the electrophilic attacks of BH2+ towards two olefinic carbons of H2C=CHCH3 and two subsequent 1,3-H-shifts may form four low-lying BC3H8+ isomers (with the relative energies in parentheses in kcal/mol): 1 BH2+.CH2CHCH3 (0.0), 1' BH2+.CH3CHCH2 (6.3), 3 BHCH2CH2CH3+ (4.3), and 4 BHCH(CH",Journal of computational chemistry,"Zheng-Wang Qu, Hui Zhu, Ze-Sheng Li, Xing-Kang Zhang, Qi-Yuan Zhang"," State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Center of Molecular Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100080, PR China. qzwzhh@hotmail.com",2004 Jan;25(2):258-64,10.1002/jcc.10229
17084575,20070219,article,"xref,mesh","Algorithms,Antimalarials,Artemisinins,Chromatography, High Pressure Liquid,Drug Stability,Ethanol,Polyethylene Glycols,Propylene Glycol,Reproducibility of Results,Sesquiterpenes,Solvents,Spectrophotometry, Ultraviolet",analysis,"D000962 Q000032 NY,D012717 Q000032 NY,D037621 Q000032 NY","702,1030,6342,8252,65664,105031,156252,5464098,6917864,9821433,16394563,23697153,44410736,49769200,53486426,57253359,60196289,71300409,91746179,126963478,129317578","128482492,129060975,129571406,136206684",Stability of artesunate in pharmaceutical solvents.,"Stability of artesunate (ART) was established in three pharmaceutical solvents. The chromatographic conditions developed for this study were acetonitrile:potassium phosphate buffer 10 mM (40:60, v:v; pH 2.9) at 0.7 mL min(-1) with UV detection at 220 nm using a short X-Terra RP C18 column (50 mm x 3 mm, 3.5 microm). This isocratic condition led to the separation between ART and its main degradation products (i.e. alpha-DHA and beta-DHA) with analysis time of less than 4 min. The retention factors are 1.49, ",Journal of pharmaceutical and biomedical analysis,"Karen Gaudin, Marie-Hélène Langlois, Anne Barbaud, Chantal Boyer, Pascal Millet, Fawaz Fawaz, Jean-Pierre Dubost"," Laboratoire de Chimie Analytique UFR Pharmacie, EA 3677, Bases Thérapeutiques des Inflammations et Infections, Université Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. karen.gaudin@u-bordeaux2.fr",2007 Feb;43(3):1019-24,10.1016/j.jpba.2006.09.039
17109414,20070401,article,"xref,mesh","Caspase 3,Caspase 7,Cell Death,Cell Line, Tumor,DNA,Gene Transfer Techniques,Humans,Materials Testing,Methacrylates,Micelles,Polyethylene Glycols,Polymers,Propylene Glycols","chemical synthesis,chemistry,metabolism","D011409 Q000737 NY,D011092 Q000138 NN,D008689 Q000138 NN,D011092 Q000737 NY,D011108 Q000737 NY,D053179 Q000378 NN,D011108 Q000138 NN,D053148 Q000378 NN,D011409 Q000138 NN,D004247 Q000737 NN,D008689 Q000737 NY","174,8252,32881,44135672,54133229","128558036,128762144,129060975",Investigation of in vitro biocompatibility of novel pentablock copolymers for gene delivery.,"Novel pentablock copolymers of poly(diethylaminoethylmethacrylate) (PDEAEM), poly(ethylene oxide) (PEO), and poly(propylene oxide) (PPO), (PDEAEM-b-PEO-b-PPO-b-PEO-b-PDEAEM), were synthesized as vectors for gene delivery, and were tested for their biocompatibility on SKOV3 (human ovarian carcinoma) and A431 (human epidermoid cancer) cell lines under different in vitro conditions using various assays to elucidate the mechanism of cell death. These copolymers form micelles in aqueous solutions and can be tune",Journal of biomedical materials research. Part A,"Ankit Agarwal, Robert Unfer, Surya K Mallapragada"," Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA.",2007 Apr;81(1):24-39,10.1002/jbm.a.30920
17258836,20070312,article,"xref,mesh","Animals,Antioxidants,Biological Availability,Chitosan,Cyclosporine,Dose-Response Relationship, Drug,Drug Evaluation, Preclinical,Ellagic Acid,Ethanolamines,Gels,Glycerol,Immunosuppressive Agents,Kidney,Kinetics,Lactic Acid,Male,Nanoparticles,Polyglycolic Acid,Polymers,Propylene Glycol,Rats,Rats, Sprague-Dawley,Solvents,Temperature,Water","adverse effects,chemistry,drug effects,pathology,pharmacology,toxicity","D000975 Q000009 NN,D016572 Q000633 NN,D019344 Q000737 NN,D048271 Q000737 NN,D007668 Q000473 NN,D004983 Q000737 NN,D007668 Q000187 NY,D004610 Q000494 NY,D012997 Q000737 NN,D019946 Q000737 NN,D007166 Q000633 NN,D011100 Q000737 NN,D014867 Q000737 NN,D005990 Q000737 NN,D000975 Q000494 NY,D011108 Q000737 NN,D053758 Q000737 NY,D004610 Q000009 NN","612,753,962,1030,2909,7618,8252,61430,61503,62280,62358,62633,71391,71853,91435,101814,107689,159752,5280754,5281855,5284373,5458585,6435893,9855081,21896651,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127400142,127998497,128902940,129060975",Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.,"Ellagic acid (EA) is a potent antioxidant marketed as a nutritional supplement. Its pharmacological activity has been reported in wide variety of disease models; however its use has been limited owing to its poor biopharmaceutical properties, thereby poor bioavailability. The objective of the current study was to develop chitosan-glycerol phosphate (C-GP) in situ gelling system for sustained delivery of ellagic acid (EA) via subcutaneous route. EA was incorporated in the system employing propylene glycol (P",Journal of controlled release : official journal of the Controlled Release Society,"G Sharma, J L Italia, K Sonaje, K Tikoo, M N V Ravi Kumar"," Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Mohali, Punjab, 1600 62, India.",2007 Mar;118(1):27-37,10.1016/j.jconrel.2006.11.026
17383165,20070501,article,"xref,mesh","Administration, Oral,Animals,Biological Availability,Calcitriol,Excipients,Fasting,Female,Immunosuppressive Agents,Injections, Intravenous,Molecular Structure,Polyethylene Glycols,Postprandial Period,Propylene Glycol,Swine,Swine, Miniature,Triglycerides","administration &amp; dosage,analogs &amp; derivatives,blood,chemistry,pharmacokinetics","D014280 Q000737 NN,D002117 Q000737 NN,D007166 Q000008 NN,D011092 Q000737 NN,D002117 Q000493 NN,D007166 Q000097 NN,D019946 Q000737 NN,D002117 Q000031 NY,D007166 Q000493 NN,D005079 Q000737 NN","1030,2524,8252,134070,5280453,5283740,5288149,5371993,6435810,6437079,9953732,13019066,20055510,57200020,73946427,99121954,129631814","127975892,129060975,136117265",Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state.,"The bioavailability of seocalcitol from two lipid-based formulations and a propylene glycol (PG) solution was studied in minipigs in the fasted and fed state. The lipid-based formulations were a medium chain triglyceride (MCT) solution and a self-microemulsifying drug delivery system (MC-SMEDDS) having a composition of 25% MCT, 48% cremophor RH 40, 27% akoline MCM. An IV solution was administered in order to determine the absolute bioavailability. In the fasted state the absolute bioavailability of seocalci",European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,"Mette Grove, Anette Müllertz, Gitte P Pedersen, Jeanet L Nielsen"," Pharmaceutical Formulation, LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark.",2007 May;31(1):8-15,10.1016/j.ejps.2007.01.007
17531411,20070801,article,"xref,mesh","Administration, Oral,Aerosols,Anti-Infective Agents,Bornanes,Chemistry, Pharmaceutical,Drug Carriers,Drug Compounding,Drug Stability,Emulsions,Ethylene Glycols,Glycerides,Models, Chemical,Oils,Phase Transition,Polyethylene Glycols,Propylene Glycol,Solubility,Solvents,Surface-Active Agents,Technology, Pharmaceutical,Temperature,Time Factors,Viscosity","administration &amp; dosage,chemistry","D011092 Q000737 NN,D000890 Q000008 NN,D005026 Q000737 NN,D005989 Q000737 NN,D019946 Q000737 NN,D001892 Q000737 NY,D009821 Q000737 NY,D012997 Q000737 NY,D013501 Q000737 NY,D000890 Q000737 NY","1030,8146,8252,72144,11777299,76967262","129060975,129155567",Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.,"Xibornol is a lipophilic drug mainly used in Italy and Spain in spray dosage forms for the local treatment of infection and inflammation of the throat. Its poor water solubility makes difficult the development of aqueous formulations of the drug, thus giving rise to a limited number of stable and pharmaceutically accepted preparations. In fact, xibornol is actually marketed only as spray aqueous suspension. The aim of this work was to evaluate the possibility of developing a stable liquid formulation of the",International journal of pharmaceutics,"M Cirri, P Mura, P Corvi Mora"," Dip. Scienze Farmaceutiche, Polo Scientifico di Sesto Fiorentino, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy. marzia.cirri@unifi.it",2007 Aug;340(?):84-91,10.1016/j.ijpharm.2007.03.021
17661214,20070101,review,"xref,mesh","Animals,Carcinogens,DNA,DNA Adducts,Epoxy Compounds,Ethylene Oxide,Humans,Molecular Epidemiology,Mutagens,Mutation,Nose Neoplasms,Occupational Exposure","chemically induced,drug effects,metabolism,toxicity","D009669 Q000139 NN,D004247 Q000187 NN,D004247 Q000378 NN,D002273 Q000633 NY,D004852 Q000633 NY,D005027 Q000633 NN,D009153 Q000633 NY","6354,6378,124886,160438,44135672","127523511,127983601,128141679,129192846",Propylene oxide: genotoxicity profile of a rodent nasal carcinogen.,"Propylene oxide (PO) is a DNA-reactive genotoxic agent; that is, it reacts with DNA to produce lesions in the genetic material. PO also induces tumors in rodents, although only at high concentrations and at portals of entry. This review of PO's genotoxicity profile is organized according to endpoints measured, that is, nonmutational or mutational endpoints, and as to whether the results were from in vitro or in vivo studies. In addition to results of experimental studies, PO's genotoxicity for humans is ass",Critical reviews in toxicology,"Richard J Albertini, Lisa M Sweeney"," Department of Pathology, University of Vermont, Burlington, Vermont 05401, USA. Ralbert315@aol.com",2007 Jan;37(6):489-520,10.1080/10408440701382959
19545197,20090101,review,"xref,mesh","Animals,Carcinogens,Environmental Exposure,Epoxy Compounds,Humans,Reference Values,Risk Assessment,Threshold Limit Values","adverse effects,analysis,metabolism,standards,toxicity","D004781 Q000032 NY,D002273 Q000378 NN,D002273 Q000633 NN,D004852 Q000032 NY,D004781 Q000009 NN,D002273 Q000032 NY,D004781 Q000592 NN,D004852 Q000633 NN,D004852 Q000378 NN","6378,160438","127523511,127983601",Derivation of inhalation toxicity reference values for propylene oxide using mode of action analysis: example of a threshold carcinogen.,"Propylene oxide (PO) is an important industrial chemical used primarily in the synthesis of other compounds. Inhalation carcinogenesis studies in rodents, with no-observed-adverse-effect levels (NOAELs) of 100 and 200 ppm, have revealed that chronic, high exposure to PO can induce tumors at the site of contact. Despite these characteristics, there is no evidence that typical environmental or occupational exposures to PO constitute a health risk for humans. The nongenotoxic effects of PO (glutathione depleti",Critical reviews in toxicology,"Lisa M Sweeney, Christopher R Kirman, Richard J Albertini, Yu-Mei Tan, Harvey J Clewell, Johannes G Filser, György Csanády, Lynn H Pottenger, Marcy I Banton, Cynthia J Graham, Larry S Andrews, Raymond J Papciak, Michael L Gargas"," The Sapphire Group, Inc., 2661 Commons Blvd., Second Floor, Dayton, OH 45431, USA. LMS29@case.edu",2009 Jan;39(6):462-86,10.1080/10408440902837959
19616607,20091028,article,"xref,mesh","Adult,Aged,Aged, 80 and over,Cartilage,Cell Survival,Cells, Cultured,Chondrocytes,Comet Assay,Dose-Response Relationship, Drug,Ethanolamines,Female,Glucose,Humans,Lymphocytes,Male,Middle Aged,Mutagens,Polyethylene Glycols,Propylene Glycols,Tissue Engineering,Tissue Scaffolds,Young Adult","adverse effects,drug effects,growth &amp; development,toxicity","D019902 Q000187 NN,D005947 Q000633 NN,D054457 Q000009 NY,D011092 Q000633 NN,D002356 Q000254 NY,D004983 Q000633 NN,D002470 Q000187 NY,D009153 Q000633 NY,D008214 Q000187 NN,D011409 Q000633 NN","4939,5793,7618,8252,24749,61430,62633,65047,101814,107526,159752,439494,10954115,87517085","127623992,127796650,127998497,129060975,129621433,129888650",Cytotoxic and genotoxic effects of matrices for cartilage tissue engineering.,"Customizing auricles with biodegradable polyurethane colonized with autologous chondrocytes as an approach for tissue engineering cartilage transplants has been suggested for the reconstruction of the external ear to repair auricular deformities. Dextrose, triethanolamine and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (PEG-PPG-PEG) are matrices of an open-pored polyurethane three-dimensional scaffold. After release from the polymer, these compounds can be absorbed into th",Toxicology letters,"Amelie S Lotz, Joachim B Havla, Elmar Richter, Katrin Frölich, Rainer Staudenmaier, Rudolf Hagen, Norbert H Kleinsasser"," Department of Toxicology, Walther-Straub-Institute, Ludwig-Maximilian-University Munich, Nussbaumstr. 26, D-80336 Munich, Germany.",2009 Oct;190(2):128-33,10.1016/j.toxlet.2009.06.880
20172606,20100501,article,"xref,mesh","Animals,Bone Cements,Calcium Phosphates,Cell Death,Chromatography, Gel,Compressive Strength,Elastic Modulus,Endothelial Cells,Femur Head,Fumarates,Ginsenosides,Injections,Magnetic Resonance Spectroscopy,Mice,Microscopy, Electron, Scanning,NIH 3T3 Cells,Neovascularization, Physiologic,Osteonecrosis,Polypropylenes,Surface Properties,Umbilical Veins,X-Ray Diffraction","cytology,drug effects,drug therapy,metabolism,pathology,pharmacology,therapeutic use,toxicity","D042783 Q000166 NN,D018919 Q000187 YN,D019245 Q000187 NN,D042783 Q000378 NN,D055119 Q000187 NN,D001843 Q000494 NN,D005270 Q000473 NY,D001843 Q000633 NN,D005270 Q000187 NN,D001843 Q000627 NY,D002130 Q000494 NN,D016923 Q000187 NN,D042783 Q000187 NN,D014471 Q000166 NN,D010020 Q000188 NY,D011126 Q000627 NY,D011126 Q000494 NN,D036145 Q000494 NN,D005650 Q000627 NY,D013499 Q000187 NN,D005650 Q000494 NN,D002130 Q000627 NY","441923,3086007,13386145",135879654,A poly(propylene fumarate)--calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis.,"Osteonecrosis of the femoral head commonly occurs when the blood supply to bone was disrupted. The general treatment for early stages of necrosis in the femoral head is core decompression. However, the long-term outcome of this operation is usually compromised due to collapse of the necrotic bone. In this study, poly(propylene fumarate) (PPF) and calcium phosphate cement (CPC) were combined to provide appropriate mechanical strength after core-decompressed femoral heads and offer the properties of osteocond",Biomaterials,"Chih-Hung Chang, Tai-Chieh Liao, Yuan-Ming Hsu, Hsu-Wei Fang, Chia-Chun Chen, Feng-Huei Lin"," Division of Orthopaedics, Department of Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan, ROC.",2010 May;31(14):4048-55,10.1016/j.biomaterials.2010.01.124
20722996,20100101,article,"xref,mesh","Administration, Cutaneous,Animals,Anti-Inflammatory Agents, Non-Steroidal,Disease Models, Animal,Emulsions,Excipients,Gels,Inflammation,Ketorolac Tromethamine,Male,Myristates,Plant Oils,Polyethylene Glycols,Propylene Glycol,Rats,Skin Absorption,Stomach Ulcer","administration &amp; dosage,chemically induced,chemistry,drug therapy,pharmacokinetics,physiopathology,toxicity","D007249 Q000188 NN,D000894 Q000493 NN,D011092 Q000737 NN,D010938 Q000737 NN,D000894 Q000633 NN,D007249 Q000503 NN,D009226 Q000737 NN,D019946 Q000737 NN,D020911 Q000008 NY,D013276 Q000139 NN,D020911 Q000493 NN,D005079 Q000737 NY,D000894 Q000008 NY,D020911 Q000633 NN","1030,3826,8042,8252,11005,84003,181818,5364713,53796455","127472665,127839161,128885449,129060975,129315957,135957297","Ketorolac trometamol topical formulations: release behaviour, physical characterization, skin permeation, efficacy and gastric safety.","OBJECTIVES: The objective of this study was to improve systemic delivery of the highly analgesic ketorolac trometamol (ketorolac tromethamine) via the transdermal route, through cost-effective topical formulations, to avoid most of the problems associated with ketorolac trometamol therapy. METHODS: In-vitro release behaviour of the drug from different microemulsion and emulgel formulations was evaluated. E2 emulgel (based on isopropyl myristate as penetration enhancer) and E7 emulgel (based on Brij 92 as pe",The Journal of pharmacy and pharmacology,"Doaa Ahmed El-Setouhy, Sahar Mohy Ahmed El-Ashmony"," Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt. doaaahmed@hotmail.com",2010 Jan;62(1):25-34,10.1211/jpp.62.01.0002
21070888,20110601,article,"xref,mesh","Biological Assay,Cell Death,Cell Survival,Dendrimers,Dextrans,Flow Cytometry,Folic Acid,Galactose,HeLa Cells,Hemolysis,Humans,Ligands,Neoplasms,Organ Specificity,Paclitaxel,Polypropylenes","chemical synthesis,chemistry,drug effects,pathology,pharmacology","D005690 Q000737 NY,D003911 Q000737 NY,D005492 Q000737 NY,D009928 Q000187 NN,D002470 Q000187 NN,D009369 Q000473 NY,D011126 Q000737 NY,D016923 Q000187 NN,D050091 Q000138 NN,D017239 Q000494 NN,D006461 Q000187 NN,D050091 Q000737 NY","4666,6036,6037,22986,36314,184492,439357,3037556,4125253,5460037,23678413,53782703,135398658","127796659,128866026,129621445",Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison.,"The present investigation was aimed at developing and comparing the cancer-targeting potential of ligand-anchored dendrimers. Folate-, dextran-, and galactose-anchored poly(propylene imine) dendrimers were synthesized and characterized. Dendritic formulations were evaluated for ex vivo cytotoxicity on HeLa and SiHa cell lines. Flow cytometry studies were performed on the HeLa cell line. An ex vivo MTT assay on HeLa cells indicated IC(50) values of 0.05, 0.2, 0.8, and 0.08 μM for folate, dextran, and galacto","Nanomedicine : nanotechnology, biology, and medicine","Prashant Kesharwani, Rakesh K Tekade, Virendra Gajbhiye, Keerti Jain, Narendra K Jain"," Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, India.",2011 Jun;7(3):295-304,10.1016/j.nano.2010.10.010
21476863,20110801,article,"xref,mesh","Administration, Inhalation,Administration, Intranasal,Aerosols,Animals,Cyclosporine,Dogs,Dose-Response Relationship, Drug,Female,Immunosuppressive Agents,Male,Propylene Glycol,Sialorrhea","administration &amp; dosage,chemically induced,chemistry,pharmacokinetics,toxicity","D007166 Q000008 NN,D019946 Q000633 NY,D016572 Q000008 NN,D016572 Q000493 NN,D019946 Q000737 NN,D007166 Q000493 NN,D016572 Q000633 NY,D012798 Q000139 NN,D007166 Q000633 NY","1030,2909,8252,62280,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",129060975,Safety and toxicology of cyclosporine in propylene glycol after 9-month aerosol exposure to beagle dogs.,"BACKGROUND: Cyclosporine inhalation solution (CIS) delivered via nebulization is under evaluation for the prevention of chronic rejection post-lung transplant. A 300-patient randomized, controlled clinical trial (CYCLIST) is expected to be completed late in 2011. In support of this trial, a chronic inhalation toxicology study in dogs has been completed. METHODS: To mimic the clinical setting, animals (four/sex/dose plus two/sex/dose in the control and high dose recovery groups) were exposed to aerosolized C",Journal of aerosol medicine and pulmonary drug delivery,"Ralph Niven, Maryellen Lynch, Ronald Moutvic, Seth Gibbs, Crystal Briscoe, Howard Raff"," APT Pharmaceuticals, Burlingame, California. rniven@aptbio.com",2011 Aug;24(4):205-12,10.1089/jamp.2010.0863
22605555,20120801,article,xref,"Carbohydrates,Cell Survival,Comet Assay,DNA Damage,Dendrimers,Humans,Leukocytes, Mononuclear,Polypropylenes","adverse effects,chemistry,drug effects","D002470 Q000187 NN,D011126 Q000009 NY,D002241 Q000737 NN,D050091 Q000009 NY,D011126 Q000737 NY,D004249 Q000187 NN,D007963 Q000187 NN,D050091 Q000737 NY","8252,192826","129060975,136228527",Genotoxicity of poly(propylene imine) dendrimers.,"Dendrimers are highly branched macromolecules with the potential in biomedical applications. Due to positively charged surfaces, several dendrimers reveal toxicity. Coating peripheral cationic groups with carbohydrate residues can reduce it. In this study, the cytotoxicity and genotoxicity of three types of 4th generation poly(propylene imine) dendrimers were investigated. Peripheral blood mononuclear cells (PBMCs) were treated with uncoated (PPI-g4) dendrimers, and dendrimers in which approximately 40% or ",Biopolymers,"Barbara Ziemba, Gabriela Matuszko, Dietmar Appelhans, Brigitte Voit, Maria Bryszewska, Barbara Klajnert"," Department of General Biophysics, University of Lodz, Lodz, Poland. barzie@biol.uni.lodz.pl",2012 Aug;97(8):642-8,10.1002/bip.22056
22619090,20121001,article,"xref,mesh","Animals,Cell Death,Chromatography, Gel,Delayed-Action Preparations,Gels,HeLa Cells,Humans,Magnetic Resonance Spectroscopy,Mice,Neoplasms,Paclitaxel,Phase Transition,Polyesters,Polyethylene Glycols,Propylene Glycol,Rheology,Spectroscopy, Fourier Transform Infrared,Temperature,Urethane","administration &amp; dosage,chemical synthesis,chemistry,drug effects,pathology,toxicity","D019946 Q000138 NN,D011092 Q000138 NN,D011091 Q000737 NY,D011092 Q000737 NY,D011091 Q000138 NN,D009369 Q000473 NY,D016923 Q000187 NN,D044367 Q000187 NN,D014520 Q000737 NY,D012212 Q000187 NN,D014520 Q000138 NN,D017239 Q000633 NY,D017239 Q000008 NN,D019946 Q000737 NY","1030,4666,5641,8252,36314,184492",129060975,Sustained delivery of paclitaxel using thermogelling poly(PEG/PPG/PCL urethane)s for enhanced toxicity against cancer cells.,"A multiblock poly(ether ester urethane)s comprising poly(ε-caprolactone), poly(ethylene glycol), and poly(propylene glycol) segments was synthesized. The aqueous copolymer solution exhibited thermogelling behavior at a critical gelation concentration of 3 wt %. The chemical structure and molecular characteristic of the copolymers were studied by gel permeation chromatography, NMR, and fourier transform infrared spectroscopy (FTIR). Rheological characterizations on the thermogel were carried out. Drug releas",Journal of biomedical materials research. Part A,"Xian Jun Loh, Benjamin Jia Han Yee, Fu Siong Chia"," Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Cambridge, United Kingdom. XianJun_Loh@scholars.a-star.edu.sg",2012 Oct;100(10):2686-94,10.1002/jbm.a.34198
22705640,20120901,article,"xref,mesh","Administration, Cutaneous,Animals,Cholesterol,Dermatitis, Atopic,Disease Models, Animal,Drug Delivery Systems,Ethanol,Immunosuppressive Agents,Liposomes,Male,Mast Cells,Mice,Mice, Inbred BALB C,Particle Size,Propylene Glycol,Rats,Rats, Wistar,Skin Absorption,Tacrolimus,Time Factors","administration &amp; dosage,chemistry,drug therapy,metabolism,pharmacokinetics,pharmacology","D007166 Q000494 NY,D007166 Q000008 NN,D016559 Q000008 NN,D016559 Q000493 NN,D019946 Q000737 NN,D007166 Q000493 NN,D003876 Q000188 NY,D002784 Q000737 NN,D000431 Q000737 NN,D016559 Q000494 NY,D008407 Q000378 NN","304,702,1030,5372,5997,6264,8252,445643,453626,5282315,5283629,6473866,6536850,71668407,90726579,134694629","128121087,128482492,128519904,129060975,242963342",Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation.,"The purpose of this work was to prepare and characterize a novel ethosomal carrier for tacrolimus, an immunosuppressant treating atopic dermatitis (AD), and to investigate inhibition action upon allergic reactions of mice aiming at improving pharmacological effect for tacrolimus in that commercial tacrolimus ointment (Protopic®) with poor penetration capability exhibited weak impact on AD compared with common glucocorticoid. Results indicated that the ethosomes showed lower vesicle size and higher encapsula",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Guiling Li, Yating Fan, Chao Fan, Xinru Li, Xiaoning Wang, Mei Li, Yan Liu"," Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.",2012 Sep;82(1):49-57,10.1016/j.ejpb.2012.05.011
23299087,20130225,article,mesh,"Animals,Anti-Inflammatory Agents, Non-Steroidal,Dermatitis, Contact,Diclofenac,Drug Carriers,Drug Compounding,Ethanol,In Vitro Techniques,Lipid Bilayers,Liposomes,Mice,Microscopy, Electron, Transmission,Nanoparticles,Propylene Glycol,Skin,Skin Absorption,Surface Properties,X-Ray Diffraction","administration &amp; dosage,chemistry,drug effects,drug therapy,metabolism,pathology,pharmacokinetics,therapeutic use","D000894 Q000493 NN,D004337 Q000737 NY,D003877 Q000188 NY,D004008 Q000493 NN,D008051 Q000737 NY,D004008 Q000627 NN,D019946 Q000737 NN,D000894 Q000627 NN,D004008 Q000008 NY,D012867 Q000378 NN,D012867 Q000473 NN,D003877 Q000473 NN,D000431 Q000737 NN,D000894 Q000008 NY,D053758 Q000737 NY,D012867 Q000187 NN","702,1030,3033,152165,453626,5018304,23667642",NULL,"Inhibition of skin inflammation in mice by diclofenac in vesicular carriers: liposomes, ethosomes and PEVs.","Diclofenac-loaded phospholipid vesicles, namely conventional liposomes, ethosomes and PEVs (penetration enhancer-containing vesicles) were developed and their efficacy in TPA (phorbol ester) induced skin inflammation was examined. Vesicles were made from a cheap and unpurified mixture of phospholipids and diclofenac sodium; Transcutol P and propylene glycol were added to obtain PEVs, and ethanol to produce ethosomes. The structure and lamellar organization of the vesicle bilayer were investigated by transmi",International journal of pharmaceutics,"Carla Caddeo, Octavio Diez Sales, Donatella Valenti, Amparo Ruiz Saurí, Anna Maria Fadda, Maria Manconi"," Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.",2013 Feb;443(?):128-36,10.1016/j.ijpharm.2012.12.041
23826859,20140901,article,mesh,"Administration, Cutaneous,Animals,Anti-Inflammatory Agents,Celecoxib,Chemistry, Pharmaceutical,Edema,Glycerides,Male,Mice,Oleic Acid,Permeability,Propylene Glycol,Pyrazoles,Rabbits,Skin,Skin Absorption,Sulfonamides,Swine","administration &amp; dosage,chemistry,drug therapy,metabolism,methods,physiology","D011720 Q000737 NY,D012867 Q000378 NY,D013449 Q000008 NY,D000893 Q000737 NN,D012869 Q000502 NN,D002626 Q000379 NN,D019301 Q000737 NN,D004487 Q000188 NN,D005989 Q000737 NN,D019946 Q000737 NN,D000893 Q000008 NN,D011720 Q000008 NY,D013449 Q000737 NY","965,1030,2662,33022,445639,5283468,5364833,5460221,12178130,20056951",NULL,In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib.,"OBJECTIVE: We investigated the potential effects of oleic acid (OA) and glycerol monooleate (GMO) on the skin delivery of CXB. METHODS: The influence of both OA and GMO (5.0% or 10.0%) on the in vitro skin permeability of CXB (2.0%) was evaluated using propylene glycol (PG) as a vehicle. Also the in vitro potential cytotoxicity and genotoxicity and in vivo assays (skin irritation in rabbits and topical anti-inflammatory activity by in mice) were conducted. RESULTS: As expected, the amount of CXB that permea",Drug development and industrial pharmacy,"Oliesia Gonzalez Quiñones, Hilton Antonio Mata dos Santos, Daniel Mabundu Kibwila, Alvaro Leitão, Alexandre dos Santos Pyrrho, Marcelo de Pádula, Elaine Cruz Rosas, Marilisa Guimarães Lara, Maria Bernadete Riemma Pierre"," School of Pharmacy, Federal University of Rio de Janeiro , Rio de Janeiro, RJ , Brazil .",2014 Sep;40(9):1180-9,10.3109/03639045.2013.809731
23830940,20130915,article,mesh,"Administration, Cutaneous,Animals,Anti-Inflammatory Agents,Carrageenan,Chemistry, Pharmaceutical,Curcumin,Delayed-Action Preparations,Disease Models, Animal,Drug Stability,Edema,Female,Inflammation,Kinetics,Lipids,Liposomes,Male,Particle Size,Propylene Glycol,Rats, Sprague-Dawley,Skin,Skin Absorption,Solubility,Technology, Pharmaceutical","administration &amp; dosage,chemically induced,chemistry,metabolism,methods,prevention &amp; control","D012867 Q000378 NY,D003474 Q000737 NN,D003474 Q000378 NN,D000893 Q000737 NN,D000893 Q000378 NN,D007249 Q000139 NN,D007249 Q000517 NN,D003474 Q000008 NY,D000893 Q000008 NY,D008055 Q000737 NY,D019946 Q000737 NN,D004487 Q000139 NN,D013678 Q000379 NN,D004487 Q000517 NN","1030,453626,969516,11966249",NULL,Selection of high efficient transdermal lipid vesicle for curcumin skin delivery.,"Curcumin shows effective anti-inflammatory activities but is seldom used in clinic because of its poor solubility in water and vulnerablity to sunshine ultraviolet effect. Novel lipid vesicles have been developed as carriers for skin delivery. In this paper, lipid vesicles-propylene glycol liposomes (PGL), Ethosomes and traditional liposomes, were prepared as curcumin carriers respectively. Their morphology, particle size and encapsulation efficiency and drug release behavior in vitro were evaluated. Transd",International journal of pharmaceutics,"Ying-Zheng Zhao, Cui-Tao Lu, Yi Zhang, Jian Xiao, Ya-Ping Zhao, Ji-Lai Tian, Yan-Yan Xu, Zhi-Guo Feng, Chong-Yong Xu"," Wenzhou Medical University, Wenzhou City, Zhejiang Province 325035, China.",2013 Sep;454(1):302-9,10.1016/j.ijpharm.2013.06.052
24269869,20140201,article,mesh,"Cartilage, Articular,Cell Survival,Chondrocytes,Cryopreservation,Cryoprotective Agents,Dimethyl Sulfoxide,Ethylene Glycol,Formamides,Glycerol,Humans,Primary Cell Culture,Propylene Glycol,Vitrification","cytology,drug effects,pharmacology","D002470 Q000187 NN,D002358 Q000187 NN,D004121 Q000494 NN,D019902 Q000166 NN,D019902 Q000187 NY,D019855 Q000494 NN,D002358 Q000166 NN,D003451 Q000494 NY,D019946 Q000494 NN,D005559 Q000494 NN,D005990 Q000494 NN","174,679,713,753,1030",NULL,Dose-injury relationships for cryoprotective agent injury to human chondrocytes.,Vitrification of articular cartilage (AC) could enhance tissue availability but requires high concentrations of cyroprotective agents (CPAs). This study investigated relative injuries caused by commonly used CPAs. We hypothesized that the in situ chondrocyte dose-injury relationships of five commonly used CPAs are nonlinear and that relative injuries could be determined by comparing cell death after exposure at increasing concentrations. Human AC samples were used from four patients undergoing total knee ar,Cryobiology,"M D Fahmy, K A Almansoori, L Laouar, V Prasad, L E McGann, J A W Elliott, N M Jomha"," Division of Orthopaedic Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada. Division of Orthopaedic Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada. Division of Orthopaedic Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada. Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, Canada. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. Department of Chemi",2014 Feb;68(1):50-6,10.1016/j.cryobiol.2013.11.006
25173234,20141001,article,mesh,"Alkylating Agents,DNA Adducts,DNA Repair,DNA Replication,Epoxy Compounds,Escherichia coli,Ethylene Oxide,Guanine","analogs &amp; derivatives,drug effects,genetics,metabolism,toxicity","D006147 Q000031 NN,D004926 Q000378 NN,D004926 Q000235 NN,D004926 Q000187 NN,D005027 Q000633 NN,D004852 Q000633 NN,D000477 Q000633 NN","764,6354,6378",NULL,Ethylene oxide and propylene oxide derived N7-alkylguanine adducts are bypassed accurately in vivo.,"Adducts formed at the nucleophilic N7 position of guanine are the most abundant lesions produced by alkylating agents such as ethylene oxide (EO) and propylene oxide (PO). In order to investigate the intrinsic mutagenic potential of N7-alkylguanine adducts, we prepared single-stranded DNA probes containing a single well-defined N7-alkylguanine adduct under conditions that minimize the presence of depurinated molecules. Following introduction of these probes into Escherichia coli cells, the effect of the N7-",DNA repair,"Gaëlle Philippin, Jean Cadet, Didier Gasparutto, Gerard Mazon, Robert P Fuchs"," Cancer Research Center of Marseille, CNRS, UMR7258 Genome Instability and Carcinogenesis (equipe labellisée Ligue Contre le Cancer) Inserm, U1068, Paoli-Calmettes Institute, Aix-Marseille Univ, F-13009 Marseille, France. Lésions des Acides Nucléiques, INAC/SCIB - UMR-E3 CEA/UJF, CEA Grenoble 17 avenue des Martyrs, F-38054 Grenoble Cedex 9, France. Lésions des Acides Nucléiques, INAC/SCIB - UMR-E3 CEA/UJF, CEA Grenoble 17 avenue des Martyrs, F-38054 Grenoble Cedex 9, France. Cancer Research Center of Marsei",2014 Oct;22(?):133-6,10.1016/j.dnarep.2014.08.001
26637209,20150101,article,mesh,"Animals,Animals, Genetically Modified,Caenorhabditis elegans,Electronic Nicotine Delivery Systems,Green Fluorescent Proteins,Humans,Menthol,Microscopy, Confocal,Models, Animal,Nicotine,Oxidative Stress,Propylene Glycol,Tobacco,Volatilization","administration &amp; dosage,chemistry,drug effects,genetics,metabolism,methods,pharmacology,physiology","D009538 Q000494 NN,D049452 Q000235 NN,D017173 Q000187 NY,D017173 Q000235 NN,D009538 Q000008 NN,D008610 Q000494 NN,D019946 Q000494 NY,D066300 Q000379 NY,D018384 Q000187 NY,D017173 Q000502 NN,D019946 Q000008 NN,D014026 Q000737 NN,D049452 Q000378 NN,D008610 Q000008 NN","1030,1254,16666,89594,2735102,57351368",NULL,A C. elegans model of electronic cigarette use: Physiological effects of e-liquids in nematodes.,"BACKGROUND: Electronic cigarettes (e-cigs) have recently become very popular particularly among the younger generation. These nicotine delivery devices are viewed as a preferable alternative to more conventional forms of tobacco use and are thought to reduce the risk of chronic obstructive pulmonary disease, the third leading cause of death worldwide. However, there is very little data available on the consequences of e-cig use, though recently nicotine-independent inflammatory responses have been reported.",BMC pharmacology & toxicology,"Daniel Panitz, Harsha Swamy, Keith Nehrke"," Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel. danielp2345@hotmail.com. Department of Medicine and Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, USA. danielp2345@hotmail.com. Department Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, USA. harsha_swamy@urmc.rochester.edu. Department of Medicine and Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, USA. keith_nehrke@urmc.roches",2015 Jan;16(?):32,10.1186/s40360-015-0030-0
26671548,20160301,article,mesh,"Cell Line,Cell Survival,Dendrimers,Dose-Response Relationship, Drug,Endocytosis,Humans,Keratinocytes,Microscopy, Confocal,Molecular Structure,Nanoparticles,Oxidative Stress,Polypropylenes,Structure-Activity Relationship,Time Factors","chemistry,drug effects,metabolism,pathology,toxicity","D053758 Q000378 NN,D002470 Q000187 NN,D015603 Q000473 NN,D015603 Q000378 NN,D050091 Q000633 NY,D053758 Q000737 NN,D015603 Q000187 NY,D018384 Q000187 NY,D050091 Q000378 NN,D050091 Q000737 NN,D011126 Q000737 NN,D011126 Q000633 NY,D011126 Q000378 NN,D053758 Q000633 NY",NULL,NULL,"Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles.","The in vitro cytotoxic and intracellular oxidative stress responses to exposure to poly(propylene imine) (PPI) dendritic nanoparticles of increasing generation (number of repeated branching cycles) (G0-G4) were assessed in an immortal non-cancerous human keratinocyte cell line (HaCaT). Confocal fluorescence microscopy with organelle staining was used to explore the uptake and intracellular trafficking mechanisms. A generation- and dose-dependent cytotoxic response was observed, increasing according to gener",Journal of applied toxicology : JAT,"Humza Khalid, Sourav Prasanna Mukherjee, Luke O'Neill, Hugh J Byrne"," FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. Institute of Environmental Medicine (IMM), Karolinska Institute, Stockholm, Sweden. FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland.",2016 Mar;36(3):464-73,10.1002/jat.3267
27275951,20160901,article,mesh,"Alkenes,Animals,Biomarkers,Cell Death,Cell Differentiation,Cell Movement,Cell Proliferation,Cells, Cultured,Diglycerides,Hydrophobic and Hydrophilic Interactions,Mice, Inbred C57BL,Mice, Transgenic,Polyesters,Polymers,Proton Magnetic Resonance Spectroscopy,Retina,Spectroscopy, Fourier Transform Infrared,Stem Cells,Temperature,Wound Healing","chemical synthesis,chemistry,cytology,drug effects,metabolism,pharmacology","D004075 Q000737 NN,D013234 Q000166 NY,D002465 Q000187 NN,D000475 Q000737 NN,D011091 Q000138 NN,D000475 Q000494 NY,D016923 Q000187 NN,D011091 Q000737 NN,D002454 Q000187 NY,D049109 Q000187 NN,D011108 Q000138 NN,D004075 Q000494 NY,D012160 Q000166 NY,D013234 Q000187 NN,D000475 Q000138 NN,D011091 Q000494 NY,D011108 Q000494 NY,D015415 Q000378 NN,D011108 Q000737 NN,D013234 Q000378 NN,D014945 Q000187 NN,D004075 Q000138 NN",8252,NULL,"Poly(1,3-propylene sebacate) and Poly(sebacoyl diglyceride): A Pair of Potential Polymers for the Proliferation and Differentiation of Retinal Progenitor Cells.","Using suitable polymers as a carrier for growing and delivering retinal progenitor cells (RPCs) is a promising therapeutic strategy in retinal cell-replacement therapy. Herein recently developed polymer, poly(sebacoyl diglyceride) (PSeD), is selected and its nonhydroxylized counterpart poly(1,3-propylene sebacate) (PPS) is designed to evaluate their potentials for RPC growth and future RPC application. The structures and mechanical properties of the polymers are characterized. The cytocompatibility and effe",Macromolecular bioscience,"Ni Ni, Jing Ji, Shuo Chen, Dandan Zhang, Zi Wang, Bingqiao Shen, Chunyu Guo, Yi Zhang, Shaofei Wang, Xianqun Fan, Zhengwei You, Min Luo, Ping Gu"," Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200011, China. Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200011, China. State Key Laboratory for Modification of Chemical Fibersand Polymer Materials, College of Materials Science and Engineering, Donghua University, 2999 North Renmin Road, Shanghai, 201620, China. Department of Ophthalmology, Shanghai Nin",2016 Sep;16(9):1334-47,10.1002/mabi.201600058
27664893,20161001,article,mesh,"Abdominal Wall,Absorbable Implants,Animals,Biocompatible Materials,Biomechanical Phenomena,Guided Tissue Regeneration,Male,Nanofibers,Polyesters,Propylene Glycol,Random Allocation,Rats,Surgical Mesh,Tissue Scaffolds","instrumentation,methods,pathology,surgery","D048091 Q000379 NN,D034861 Q000473 NN,D034861 Q000601 NY,D048091 Q000295 NY","1030,123633",NULL,Strength and histology of a nanofiber scaffold in rats.,"Full-thickness soft tissue defects from congenital absence or traumatic loss are difficult to surgically manage. Healing requires cell migration, organization of an extracellular matrix, inflammation, and wound coverage. PLCL (70:30 lactide:caprolactone, Purac), poly(propylene glycol) nanofibrous scaffolds enhance cell infiltration in vitro. This study compares strength and tissue ingrowth of aligned and unaligned nanofibrous scaffolds to absorbable and permanent meshes. We hypothesize that PLCL nanofibrous",The Journal of surgical research,"Laura M Fluke, Ryan D Restrepo, Shyam Patel, Benjamin D Hoagland, Lori M Krevetski, Jacob T Stephenson"," Naval Medical Center Portsmouth, Portsmouth, Virginia. Electronic address: laura.m.fluke.mil@mail.mil. Naval Medical Center Portsmouth, Portsmouth, Virginia; Uniformed Services University of the Health Sciences, Bethesda, Maryland. NanoNerve, Inc, Berkeley, California. Naval Medical Center Portsmouth, Portsmouth, Virginia; Uniformed Services University of the Health Sciences, Bethesda, Maryland. Naval Medical Center Portsmouth, Portsmouth, Virginia. Naval Medical Center Portsmouth, Portsmouth, Virginia; Un",2016 Oct;205(2):432-439,10.1016/j.jss.2016.06.057
27845181,20170201,article,mesh,"Animals,Anti-Inflammatory Agents, Non-Steroidal,Chromatography, High Pressure Liquid,Cluster Analysis,Crystallization,Diclofenac,Dimethyl Sulfoxide,Epidermis,Inflammation,Light,Multivariate Analysis,Pain,Principal Component Analysis,Propylene Glycol,Skin,Spectroscopy, Fourier Transform Infrared,Swine,Thermodynamics","chemistry,drug effects","D004008 Q000737 NY,D004817 Q000187 NY,D004121 Q000737 NN,D012867 Q000187 NY,D019946 Q000737 NN,D000894 Q000737 NN","679,1030,3033,152165,5018304,23667642",NULL,The application of ATR-FTIR spectroscopy and multivariate data analysis to study drug crystallisation in the stratum corneum.,"Drug permeation through the intercellular lipids, which pack around and between corneocytes, may be enhanced by increasing the thermodynamic activity of the active in a formulation. However, this may also result in unwanted drug crystallisation on and in the skin. In this work, we explore the combination of ATR-FTIR spectroscopy and multivariate data analysis to study drug crystallisation in the skin. Ex vivo permeation studies of saturated solutions of diclofenac sodium (DF Na) in two vehicles, propylene g",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Choon Fu Goh, Duncan Q M Craig, Jonathan Hadgraft, Majella E Lane"," School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia; Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom. Electronic address: gohchoonfu@hotmail.com. Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom. Electronic address: duncan.craig@ucl.ac.uk. Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom. Electro",2017 Feb;111(?):16-25,10.1016/j.ejpb.2016.10.025
30724099,20190206,article,NULL,NULL,NULL,NULL,NULL,NULL,Fourth generation e-cigarette vaping induces transient lung inflammation and gas exchanges disturbances: results from two randomized clinical trials.,"BACKGROUND: When heated by an electronic cigarette, propylene glycol and glycerol produce a nicotine-carrying-aerosol. This hygroscopic/hyperosmolar aerosol can deposit deep within the lung. Whether these deposits trigger local inflammation and disturb pulmonary gas exchanges is not known. AIMS: To assess the acute effects of high-wattage electronic cigarette vaping with or without nicotine on lung inflammation biomarkers, transcutaneous gas tensions, and pulmonary function tests in young and healthy tobacc",American journal of physiology. Lung cellular and molecular physiology,"Martin Chaumont, Philippe van de Borne, Alfred Bernard, Alain Van Muylem, Guillaume Deprez, Julien Ullmo, Eliza Starczewska, Rachid Briki, Quentin de Hemptinne, Wael Zaher, Nadia Debbas"," Cardiology, Hôpital Erasme, Belgium. Cardiologie, Erasme Hospital, Belgium. Chest Department, Erasme University Hospital, Université libre de Bruxelles, Belgium. Department of Clinical Chemistry, Hôpital Erasme, Belgium. Cardiology, Hôpital Erasme, Belgium. Cardiology, Hôpital Erasme, Belgium. Cardiology, Hôpital Saint-Pierre, Belgium. Cardiology, Hôpital Saint-Pierre, Belgium. Cardiology, Hôpital Saint-Pierre, Belgium. Cardiology, Hôpital Saint-Pierre, Belgium.",2019 Feb;?(?):?,NULL
30765332,20180911,article,NULL,NULL,NULL,NULL,NULL,NULL,The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation.,"BACKGROUND & AIMS: Food additives, such as emulsifiers, stabilizers, or bulking agents, are present in the Western diet and their consumption is increasing. However, little is known about their potential effects on intestinal homeostasis. In this study we examined the effect of some of these food additives on gut inflammation. METHODS: Mice were given drinking water containing maltodextrin (MDX), propylene glycol, or animal gelatin, and then challenged with dextran sulfate sodium or indomethacin. In paralle",Cellular and molecular gastroenterology and hepatology,"Federica Laudisi, Davide Di Fusco, Vincenzo Dinallo, Carmine Stolfi, Antonio Di Grazia, Irene Marafini, Alfredo Colantoni, Angela Ortenzi, Claudia Alteri, Francesca Guerrieri, Maria Mavilio, Francesca Ceccherini-Silberstein, Massimo Federici, Thomas Thornton MacDonald, Ivan Monteleone, Giovanni Monteleone"," Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Department of Systems Medicine, University of Rom",2018 Sep;7(2):457-473,NULL
8359802,19930901,article,mesh,"Adenosine Triphosphate,Animals,Chlorides,Endocytosis,Ethinyl Estradiol,Gluconates,Hydrogen-Ion Concentration,Kinetics,Liver,Male,Organelles,Potassium Chloride,Rats,Rats, Sprague-Dawley,Time Factors","drug effects,metabolism,pharmacology,ultrastructure","D002712 Q000494 NN,D008099 Q000187 NY,D000255 Q000378 NN,D015388 Q000378 NN,D004705 Q000187 NY,D000255 Q000494 NN,D011189 Q000494 NN,D004997 Q000494 NY,D008099 Q000378 NN,D015388 Q000187 NN,D008099 Q000648 NN,D005942 Q000494 NN","312,4873,5957,5991,10692,15126,124341,5461108,14475285,18666496,71366967,91746205,129660564,131854750",NULL,Ethinyl estradiol decreases acidification of rat liver endocytic vesicles.,"Treatment with ethinyl estradiol is known to impair bile formation, bile acid transport and Na,K-ATPase activity, to alter receptor-mediated endocytosis and transcytosis of IgA and asialoorosomucoid and to affect membrane lipid composition and fluidity. Because appropriate sorting and trafficking of asialoorosomucoid requires adequate acidification of endocytic vesicles by a lipid-sensitive electrogenic proton pump, we examined the effects of 5 days of treatment with ethinyl estradiol (5 mg/kg body wt, subc","Hepatology (Baltimore, Md.)","R W Van Dyke, K V Root"," Department of Medicine, University of Michigan School of Medicine, Ann Arbor 48109-0682.",1993 Sep;18(3):604-13,10.1002/hep.1840180320|10.1016/0270-9139(93)90362-q
15225206,20040101,article,"xref,mesh","Dermis,Disinfectants,Ethylene Oxide,Extracellular Matrix,Glycerol,Humans,In Vitro Techniques,Peracetic Acid,Skin Transplantation,Sterilization,Tissue Donors","drug effects,methods,pharmacology","D010463 Q000494 NY,D016038 Q000379 NN,D005027 Q000494 NN,D013242 Q000379 NY,D004202 Q000494 NY,D020405 Q000187 NY,D005990 Q000494 NN,D005109 Q000187 NY","753,6354,6585,8252,23674263","128141679,128375819,128902940,129060975",Use of peracetic acid to sterilize human donor skin for production of acellular dermal matrices for clinical use.,"We previously reported methods for sterilizing human skin for clinical use. In a comparison of gamma-irradiation, glycerol, and ethylene oxide, sterilization with ethylene oxide after treatment with glycerol provided the most satisfactory dermis in terms of structure and its ability to produce reconstructed skin with many of the characteristics of normal skin. However, the use of ethylene oxide is becoming less common in the United Kingdom due to concerns about its possible genotoxicity. The aim of this stu",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,"Qizhi Huang, Rebecca A Dawson, David E Pegg, John N Kearney, Sheila Macneil"," Medical Cryobiology Unit, Department of Biology, the University of York, York, United Kingdom. qizhi.huang@NBS.NHS.UK",2004 Jan;12(3):276-87,10.1111/j.1067-1927.2004.012312.x
15848052,20050501,article,"xref,mesh","Administration, Cutaneous,Administration, Topical,Animals,Chemistry, Pharmaceutical,Chromatography, High Pressure Liquid,Cyclosporine,Diffusion,Excipients,Glycerides,Immunosuppressive Agents,In Vitro Techniques,Lipids,Male,Skin Absorption,Solubility,Swine","administration &amp; dosage,chemistry,drug effects,pharmacokinetics,pharmacology","D005989 Q000494 NY,D007166 Q000493 NY,D016572 Q000493 NY,D008055 Q000737 NN,D016572 Q000008 NY,D007166 Q000008 NY,D012869 Q000187 NY","2909,8252,33022,62280,5280754,5283468,5284373,5364833,5458585,6435893,9855081,12178130,20056951,24883466,25246316,49867938,57317596,71306795,71463825,73896891,122172945,123134263,123134270,132274082","129060975,129204988,136314073",Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer.,"Topical delivery of cyclosporin A (CysA) is of great interest for the treatment of autoimmune skin disorders, but it is frequently ineffective due to poor drug penetration in the skin. The present study was aimed at investigating whether the presence of monoolein (a lipidic penetration enhancer) in a preparation of propylene glycol can improve CysA delivery to the skin. CysA was incorporated in a propylene glycol preparation containing 5-70% (w/w) of monoolein. The topical (to the skin) and transdermal (acr",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Luciana B Lopes, John H Collett, M Vitória L B Bentley"," Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.",2005 May;60(1):25-30,10.1016/j.ejpb.2004.12.003
16978761,20061110,article,xref,"Cytochrome P-450 CYP2E1,DNA, Bacterial,Dose-Response Relationship, Drug,Mutagenicity Tests,Mutagens,Plasmids,Salmonella typhimurium,Species Specificity,Substrate Specificity,Transfection,Xenobiotics","classification,drug effects,enzymology,genetics,metabolism,methods,toxicity","D015262 Q000145 NN,D012486 Q000201 NY,D012486 Q000235 NN,D019392 Q000235 NN,D009152 Q000379 NN,D019392 Q000378 NY,D010957 Q000235 NN,D009153 Q000145 NN,D012486 Q000187 NN,D009153 Q000633 NY,D015262 Q000633 NY","178,1539,5641,5921,6378,6575,6579,6656,7850,7855,7904,8252,8821,11937,13591,31373","127618454,127697393,127750840,127983601,128103209,128278985,128306526,128718804,128854081,129060975,129371915,129557820,129608820,129735795,129740424,129776823",Mutagenicity of cytochrome P450 2E1 substrates in the Ames test with the metabolic competent S. typhimurium strain YG7108pin3ERb5.,"Poor metabolic competence of in vitro systems was proposed to be one of their major shortcomings accounting for false negative results in genotoxicity testing. For several ""low molecular weight cancer suspects"" this was specifically attributed to the lack of cytochrome P450 2E1 (CYP2E1) in conventional in vitro metabolising systems. One promising attempt to overcome this problem is the transfection of ""methyltransferase-deficient""S. typhimurium strains with the plasmid pin3ERb5. This plasmid contains DNA en",Toxicology,"Birgit Emmert, Jürgen Bünger, Kristian Keuch, Michael Müller, Steffen Emmert, Ernst Hallier, Götz A Westphal"," Department of Occupational and Social Health, Georg-August-University Göttingen, Waldweg 37, Göttingen, Germany. baut@gwdg.de",2006 Nov;228(1):66-76,10.1016/j.tox.2006.08.013
18302615,20080401,article,"xref,mesh","Alginates,Alveolar Bone Loss,Animals,Bone Morphogenetic Proteins,Bone Regeneration,Cementogenesis,Cytokines,Dental Enamel Proteins,Gels,Growth Substances,Inflammation Mediators,Macrophages,Male,Periodontal Ligament,Periodontitis,Random Allocation,Rats,Rats, Sprague-Dawley,Wound Healing","administration &amp; dosage,biosynthesis,drug effects,drug therapy,immunology,metabolism,pharmacology,physiology","D019485 Q000096 NN,D003746 Q000008 NN,D010518 Q000276 NN,D003746 Q000494 NY,D008264 Q000378 NN,D001861 Q000187 NY,D016207 Q000096 NN,D010513 Q000187 NN,D000464 Q000494 NN,D016301 Q000188 NY,D018836 Q000378 NN,D006133 Q000096 NN,D025021 Q000187 NN,D008264 Q000502 NY,D014945 Q000187 NN,D010518 Q000188 NY,D000464 Q000008 NN","8029,8252,131752735","129060975,129813428",The role of macrophages in the periodontal regeneration using Emdogain gel.,"BACKGROUND AND OBJECTIVE: Emdogain gel is clinically used as a periodontal regenerative material. However, the mechanism of the regeneration has not been completely elucidated. Although many studies have focused on the regenerative effect of Emdogain on connective tissue attachment and alveolar bone, the role of macrophages and the expression of growth factors remains unclear in the regeneration stimulated by Emdogain gel in vivo. The aim of this study was to investigate the effect of Emdogain gel on the ex",Journal of periodontal research,"N Fujishiro, H Anan, T Hamachi, K Maeda"," Section of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukoka, Japan.",2008 Apr;43(2):143-55,10.1111/j.1600-0765.2007.01004.x
22954101,20121001,article,"xref,mesh","Cell Line, Tumor,Disulfides,HeLa Cells,Humans,Melanoma, Experimental,Micelles,Oxidation-Reduction,Particle Size,Polyethylene Glycols,Polymerization,Polymers,Prodrugs,Sulfides,Thioguanine,Water",chemistry,"D011092 Q000737 NN,D004220 Q000737 NN,D011355 Q000737 NY,D013440 Q000737 NN,D014867 Q000737 NN,D013866 Q000737 NY,D011108 Q000737 NN","962,5862,14072,2723601,91669166","128572009,129654227,129742316",Reduction-sensitive tioguanine prodrug micelles.,"Colloidal drug and prodrug conjugates have unique targeting characteristics for tumor vasculature from the blood and for the lymphatics draining a tissue injection site. Tioguanine and tioguanine-generating prodrugs have been investigated as anticancer and immunosuppressive agents, including use in cancer immunotherapy. Recently we developed block copolymers of poly(ethylene glycol)-bl-poly(propylene sulfide) that self-assemble in aqueous solutions to form micellar structures. Since the polymers carry a fre",Molecular pharmaceutics,"André J van der Vlies, Urara Hasegawa, Jeffrey A Hubbell"," Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.",2012 Oct;9(10):2812-8,10.1021/mp3001183
23469862,20130401,article,mesh,"Adult,Anti-Inflammatory Agents, Non-Steroidal,Basophils,Cell Survival,Drug Hypersensitivity,Female,Humans,Indomethacin,Male,Middle Aged,Skin Tests,Tetraspanin 30","administration &amp; dosage,adverse effects,diagnosis,drug effects,immunology,methods","D001491 Q000187 NY,D002470 Q000276 NN,D002470 Q000187 NN,D004342 Q000175 NY,D007213 Q000008 NY,D012882 Q000379 NY,D060149 Q000276 NN,D007213 Q000009 NN,D004342 Q000276 NN,D000894 Q000009 NY,D007213 Q000276 NN,D001491 Q000276 NN,D000894 Q000276 NN","3715,23675763",NULL,Basophil activation test with indomethacin to assess hypersensitivity to non-steroidal anti-inflammatory drugs: a preliminary study.,BACKGROUND: The basophil activation test has been investigated for diagnosing hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs). This has not yet been done in relation to indomethacin. OBJECTIVE: First seek to establish the viable concentrations of indomethacin and the diluent propylene glycol (PPG) in relation to basophils then test this in patients with hypersensitivity to NSAIDs. MATERIALS & METHODS: The ideal concentrations of PPG and indomethacin were assessed by incubating them with b,Inflammation & allergy drug targets,"Zamir Calamita, Roseli Nunes da Silveira Antunes, Andrea Bronhara Pelá Calamita, Wilson Baleotti Júnior, Débora de Aguiar Cavaretto, Josianne Thomazini Fukazawa, Odilon Marques de Almeida Filho"," Division of Allergy and Clinical Immunology of Marilia Medical School (FAMEMA), Av. Vicente Ferreira, 648, Marilia, São Paulo, Brazil. calamita@unimedmarilia.com.br",2013 Apr;12(2):147-51,10.2174/1871528111312020008
1752128,19911001,article,mesh,"Adenine,Animals,Biological Transport, Active,Cell Death,Cells, Cultured,Cryoprotective Agents,Dimethyl Sulfoxide,Drug Evaluation, Preclinical,Endothelium, Vascular,Ethylene Glycols,Glycerol,Propylene Glycol,Propylene Glycols,Solutions","cytology,drug effects,metabolism,toxicity","D004730 Q000166 NN,D004730 Q000187 NY,D001693 Q000187 NN,D016923 Q000187 NN,D005026 Q000633 NN,D004730 Q000378 NN,D004121 Q000633 NN,D000225 Q000378 NN,D011409 Q000633 NN,D005990 Q000633 NN,D003451 Q000633 NY","190,679,753,1030",NULL,Effects of four cryoprotectants in combination with two vehicle solutions on cultured vascular endothelial cells.,"The necessary first step in successful organ cryopreservation will be the maintenance of endothelial cell integrity during perfusion of high concentrations of cryoprotective agents (CPAs). In this report we compare the effects of incubation on cultured porcine endothelial cells at 10 degrees C for 1 h with the CPAs glycerol, dimethyl sulfoxide (Me2SO), ethanediol (EG), and propane-1,2-diol (PG) in the vehicle solutions RPS-2 (high potassium, high glucose) and HP-5NP (low potassium, high sodium), both with a",Cryobiology,"G A Pollock, L Hamlyn, S H Maguire, P A Stewart-Richardson, I R Hardie"," Department of Surgery, University of Queensland, Australia.",1991 Oct;28(5):413-21,10.1016/0011-2240(91)90049-t
2426822,19860101,article,mesh,"Cells, Cultured,Epoxy Compounds,Ethers, Cyclic,Ethylene Oxide,Gases,Humans,Hydrocarbons, Brominated,In Vitro Techniques,Lymphocytes,Mutagenicity Tests,Sister Chromatid Exchange,Vehicle Emissions","drug effects,methods,toxicity","D009152 Q000379 NY,D001335 Q000633 NY,D004852 Q000633 NY,D005027 Q000633 NY,D006842 Q000633 NY,D008214 Q000187 NN,D012854 Q000187 NY,D004988 Q000633 NY","6323,6354,6378",NULL,Detection of sister chromatid exchanges induced by volatile genotoxicants.,"To test the recently developed method of exposing cells to volatile compounds, phytohemagglutinin-stimulated human peripheral lymphocyte cultures were exposed to gaseous methyl bromide, ethylene oxide, and propylene oxide, as well as diesel exhaust. The cultures were placed in sterile dialysis tubing and inserted into enclosed flasks containing additional culture medium. The test compounds (in gaseous state) were diluted with air and bubbled through the flasks for various lengths of time. The cells were the","Teratogenesis, carcinogenesis, and mutagenesis","J D Tucker, J Xu, J Stewart, P C Baciu, T M Ong",NULL,1986 Jan;6(1):15-21,10.1002/tcm.1770060103
11932959,20020301,article,"xref,mesh","Animals,Antifungal Agents,Area Under Curve,Biological Availability,Chromatography, High Pressure Liquid,Cyclosporine,Drug Interactions,Immunosuppressive Agents,Intestinal Absorption,Ketoconazole,Male,Pharmaceutical Vehicles,Rats,Spectrophotometry, Ultraviolet","drug effects,pharmacokinetics,pharmacology","D000935 Q000494 NY,D007166 Q000493 NY,D016572 Q000493 NY,D007654 Q000494 NY,D007408 Q000187 NY","2909,3823,8252,47576,62280,456201,5280754,5284373,5458585,5702077,6435893,9855081,16757695,24883466,25246316,49867938,57317596,71306795,71463825,73896891,122172945,123134263,123134270,132274082","129060975,129708236,136314073",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption.,"The current work evaluated the effect of the CYP3A inhibitor ketoconazole on the oral absorption and first-pass metabolism of cyclosporine administered as the SangCyA formulation. Groups of 6 male Sprague-Dawley rats were administered SangCyA (5 and 15 mg/kg) by oral gavage alone and with ketoconazole (30 mg/kg). Blood cyclosporine levels were measured over 6 h, encompassing the cyclosporine absorption window. A significant vehicle effect on SangCyA absorption was observed. Comparing a 15 mg/kg dose, cyclos",Biopharmaceutics & drug disposition,"Susan Wong, Harrison T Wong, Vincent J Wacher"," AvMax Inc., South San Francisco, CA 94080, USA.",2002 Mar;23(2):53-7,10.1002/bdd.295
16116600,20060201,article,mesh,"Abdominal Wall,Animals,Biocompatible Materials,Foreign-Body Reaction,Inflammation,Materials Testing,Polypropylenes,Polytetrafluoroethylene,Porosity,Rats,Reconstructive Surgical Procedures,Wound Healing","chemically induced,drug effects,pharmacology,surgery,therapeutic use","D011126 Q000627 NN,D011138 Q000627 NN,D014945 Q000187 NY,D034861 Q000601 NN,D011138 Q000494 NY,D011126 Q000494 NN,D007249 Q000139 NY",NULL,NULL,Macroporous condensed poly(tetrafluoroethylene). I. In vivo inflammatory response and healing characteristics.,"This study was designed to determine whether the novel spatial geometry of macroporous condensed poly(tetrafluoroethylene) (cPTFE) favorably affects the in vivo repair process. Specifically, the macroporous surface geometry and the reduced material thickness contribute to better healing characteristics. For this purpose, three other materials used for abdominal wall repair were selected, expanded poly(tetrafluoroethylene) (ePTFE), low-weight poly(propylene) (lwPP), and high-weight poly(propylene) (hwPP). Sa",Journal of biomedical materials research. Part A,"Gabriela Voskerician, Peter H Gingras, James M Anderson"," Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA. gxv4@case.edu",2006 Feb;76(2):234-42,10.1002/jbm.a.30481
17129399,20061130,article,"xref,mesh","Analysis of Variance,Animals,Chemical and Drug Induced Liver Injury,Cisplatin,Drug Interactions,Male,Nitric Oxide,Oxidative Stress,Protective Agents,Rats,Rats, Sprague-Dawley,Silymarin","adverse effects,drug effects,metabolism,pharmacology","D002945 Q000494 NY,D009569 Q000378 NN,D020011 Q000494 NY,D018384 Q000187 NY,D012838 Q000494 NY,D002945 Q000009 NN","602,5213,5960,8252,84691,124886,145068,441203,1548994,6610285,7073228,44147684","127638306,129046631,129060975,129192846",Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats.,"Cisplatin (CDDP) is a widely used anticancer drug, but at high dose, it can produce undesirable side effects such as hepatotoxicity. Because silymrin has been used to treat liver disorders, the protective effect of silymarin on CDDP-induced hepatotoxicity was evaluated in rats. Hepatotoxicity was determined by changes in serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST], nitric oxide [NO] levels, albumin and calcium levels, and superoxide dismutase [SOD], glutathione peroxidase [GSHP",Journal of biochemistry and molecular biology,"Heba Hosny Mansour, Hafez Farouk Hafez, Nadia Mohamed Fahmy"," Health Radiation Research Department, National Center for Radiation Research and Technology, Cairo, Egypt. Hebahosny@hotmail.com",2006 Nov;39(6):656-61,10.5483/bmbrep.2006.39.6.656
18041725,20080901,article,xref,"Animals,Biocompatible Materials,Cell Adhesion,Cell Death,Cell Line,Cell Survival,Cross-Linking Reagents,Fibroblasts,Fluorescence,Microscopy, Confocal,Nanocomposites,Nanotubes, Carbon,Polymers,Rats","cytology,drug effects,pharmacology","D005347 Q000166 NY,D002470 Q000187 NN,D001672 Q000494 NY,D002448 Q000187 NN,D016923 Q000187 NN,D011108 Q000494 NY,D005347 Q000187 NY,D003432 Q000494 NN","7366,53983024","128350288,129847855",In vitro cytotoxicity of single-walled carbon nanotube/biodegradable polymer nanocomposites.,"Injectable nanocomposites made of biodegradable poly(propylene fumarate) and the crosslinking agent propylene fumarate-diacrylate as well as each of three forms of single-walled carbon nanotubes (SWNTs) were evaluated for their in vitro cytotoxicity. Unreacted components, crosslinked networks, and degradation products of the nanocomposites were investigated for their effects on cell viability using a fibroblast cell line in vitro. The results did not reveal any in vitro cytotoxicity for purified SWNTs, SWNT",Journal of biomedical materials research. Part A,"Xinfeng Shi, Balaji Sitharaman, Quynh P Pham, Patrick P Spicer, Jared L Hudson, Lon J Wilson, James M Tour, Robert M Raphael, Antonios G Mikos"," Department of Bioengineering, Rice University, MS-142, Houston, Texas 77251-1892, USA.",2008 Sep;86(3):813-23,10.1002/jbm.a.31671
19332089,20090720,article,"xref,mesh","Animals,Collagen Type I,Drug Delivery Systems,Extracellular Matrix,Immunosuppressive Agents,Micelles,Microscopy, Electron, Transmission,Poloxamer,Polyethylene Glycols,Polymers,Protein Binding,Rats,Sirolimus,Sulfates,Sulfides,Ultracentrifugation","administration &amp; dosage,chemical synthesis,chemistry,metabolism,methods","D011092 Q000138 NN,D007166 Q000008 NN,D011092 Q000737 NN,D013431 Q000138 NN,D005109 Q000378 NN,D013440 Q000138 NN,D020123 Q000737 NN,D020123 Q000008 NN,D013431 Q000737 NN,D024042 Q000378 NY,D013440 Q000737 NN,D011108 Q000138 NN,D013431 Q000378 NY,D020442 Q000737 NY,D020442 Q000378 NY,D016503 Q000379 NY,D007166 Q000737 NN,D011108 Q000737 NN,D020442 Q000138 NN","14072,5284616,10154203,91534498","128572009,248766214",Extracellular matrix binding mixed micelles for drug delivery applications.,"We present the formation of collagen-binding mixed micelles and their potential suitability to deliver therapeutic drugs to the vessel wall. We modified poly(ethylene oxide)-bl-poly(propylene oxide)-bl-poly(ethylene oxide) (Pluronic F-127) to display sulfate groups on the terminus of the PEO block to act as a heparin mimics and bind to collagen in the extracellular matrix. This functionalized macroamphiphile was incorporated into a mixed micelle with poly(propylene sulfide)-bl-poly(ethylene oxide), a macroa",Journal of controlled release : official journal of the Controlled Release Society,"Conlin P O'Neil, André J van der Vlies, Diana Velluto, Christine Wandrey, Davide Demurtas, Jacques Dubochet, Jeffrey A Hubbell"," Institute for Bioengineering and Institute for Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Station 15, CH-1015 Lausanne, Switzerland.",2009 Jul;137(2):146-51,10.1016/j.jconrel.2009.03.013
19671444,20091101,article,xref,"Administration, Cutaneous,Analgesics,Animals,Anti-Inflammatory Agents,Chemistry, Pharmaceutical,Disease Models, Animal,Drugs, Chinese Herbal,Edema,Excipients,Female,Inflammation,Male,Mice,Pain,Permeability,Skin Absorption","administration &amp; dosage,chemistry,drug therapy,methods,pharmacokinetics,pharmacology","D007249 Q000188 NN,D000893 Q000493 NN,D002626 Q000379 NN,D004487 Q000188 NN,D000893 Q000008 NY,D010146 Q000188 NN,D004365 Q000493 NN,D000700 Q000494 NN,D000700 Q000008 NY,D000700 Q000493 NN,D004365 Q000008 NY,D005079 Q000737 NY,D000893 Q000494 NN,D004365 Q000494 NN",8252,129060975,Effects of penetration enhancers on Shuangwu traumatic formula: In vitro percutaneous absorption and in vivo pharmacodynamic evaluation of an herb medicine.,"The purposes of this study were to improve the transdermal permeation of the Shangwu traumatic formula by chemical penetration enhancers and to investigate the pharmacodynamic changes of the formula caused by incorporated enhancers. The effects of different enhancers on the transdermal absorption of piperine, the representative component of formula, were investigated by in vitro permeation studies. The tests showed an increasing enhancement effect in the following order: Azone/N-methylpyrrolidone (NMP) > ol",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Shengying Gu, Jing Gao, Xuemei Hou, Baoyue Ding, Wei Zhang, Shen Gao, Xueying Ding"," Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, PR China.",2009 Nov;73(3):385-90,10.1016/j.ejpb.2009.08.001
22285587,20120830,article,"xref,mesh","Alkenes,Butadienes,Comet Assay,Epoxy Compounds,HL-60 Cells,Hemiterpenes,Humans,Leukocytes, Mononuclear,Mutagens,Pentanes","drug effects,toxicity","D010420 Q000633 NN,D007963 Q000187 NY,D045782 Q000633 NN,D004852 Q000633 NY,D018922 Q000187 NY,D002070 Q000633 NN,D009153 Q000633 NY,D000475 Q000633 NN","6557,7845,11254,160438,54277882,57271697,123446892","127523511,128353953,129159778,129170463,129894555,136237359,324157522",Genotoxicity of alkene epoxides in human peripheral blood mononuclear cells and HL60 leukaemia cells evaluated with the comet assay.,"Volatile organic compounds (VOCs) exert their carcinogenic activity through the production of epoxide metabolites. Because of their high reactivity some epoxides are also produced in the chemical industry for the synthesis of other compounds. Therefore, human exposure to VOCs epoxides does occur and may be an important human health concern. In this study, the in vitro genotoxic potential of epoxides originating from 1,3-butadiene (3,4-epoxy-1-butene: EB; 1,2:3,4-diepoxybutane: DEB), isoprene (3,4-epoxy-2-me",Mutation research,"Roberto Fabiani, Patrizia Rosignoli, Angelo De Bartolomeo, Raffaela Fuccelli, Guido Morozzi"," Dipartimento di Specialità Medico-Chirurgiche e Sanità Pubblica, Università di Perugia, via del Giochetto, Perugia, Italy. fabirob@unipg.it",2012 Aug;747(1):1-6,10.1016/j.mrgentox.2012.01.004
22607120,20130201,article,mesh,"Animals,Antioxidants,Chromatography, High Pressure Liquid,Lipids,Skin Absorption,Swine","administration &amp; dosage,chemistry,pharmacokinetics","D000975 Q000008 NN,D008055 Q000737 NY,D000975 Q000493 NY",NULL,NULL,Quantification of skin penetration of antioxidants of varying lipophilicity.,"Antioxidants play a vital role in protecting the skin from environmental distress. As the skin is constantly exposed to harmful UV radiation, endogenous antioxidants present in the superficial layers of the skin neutralize reactive oxygen species. Over time, antioxidants become depleted and loss their protective effect on the skin. Therefore, supplementing skin with topical antioxidant can help replenish this loss and fight the oxidative stress. The objective of this study was to deliver antioxidants topica",International journal of cosmetic science,"M J Abla, A K Banga"," College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA.",2013 Feb;35(1):19-26,10.1111/j.1468-2494.2012.00728.x
22889714,20120928,article,"xref,mesh","Acrylic Resins,Animals,Carbocyanines,Cell Line,Cell Survival,Drug Carriers,Fluorescent Dyes,L-Lactate Dehydrogenase,Macrophages,Mice,Micelles,Oxazines,Reactive Oxygen Species,Sulfides","administration &amp; dosage,chemistry,drug effects,metabolism","D010078 Q000737 NN,D004337 Q000008 NN,D000180 Q000737 NY,D002470 Q000187 NN,D008264 Q000378 NN,D005456 Q000737 NN,D017382 Q000378 NN,D002232 Q000737 NN,D004337 Q000737 NY,D005456 Q000008 NN,D017382 Q000737 NY,D007770 Q000378 NN,D010078 Q000008 NN,D013440 Q000737 NY,D002232 Q000008 NN,D000180 Q000008 NN,D013440 Q000008 NN","14072,65182,65388,2762625,3080911,3080912,5706734,6449810,9962797,58283676,129893797","128572009,129765304,247202070",Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release.,"A new micelle drug carrier that consists of a diblock polymer of propylene sulfide (PS) and N,N-dimethylacrylamide (poly(PS₇₄-b-DMA₃₁₀)) has been synthesized and characterized for site-specific release of hydrophobic drugs to sites of inflammation. Propylene sulfide was first polymerized using a thioacyl group transfer (TAGT) method with the RAFT chain transfer agent (CTA) 4-cyano-4-(ethylsulfanylthiocarbonylsulfanyl) pentanoic acid (CEP), and the resultant poly(PS₇₄-CEP) macro-CTA was used to polymerize a ",Journal of controlled release : official journal of the Controlled Release Society,"Mukesh K Gupta, Travis A Meyer, Christopher E Nelson, Craig L Duvall"," Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.",2012 Sep;162(3):591-8,10.1016/j.jconrel.2012.07.042
23376503,20130310,article,mesh,"2-Hydroxypropyl-beta-cyclodextrin,Administration, Oral,Animals,Caco-2 Cells,Chemistry, Pharmaceutical,Drug Delivery Systems,Drug Stability,Flavonoids,Humans,Male,Permeability,Plant Extracts,Rats,Rats, Sprague-Dawley,Rhizome,Solubility,Zingiberaceae,beta-Cyclodextrins","chemistry,pharmacokinetics","D010936 Q000737 NY,D047392 Q000737 NY,D005419 Q000737 NY,D005419 Q000493 NN,D027343 Q000737 NN",14049689,NULL,Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-β-cyclodextrin.,"The Kaempferia parviflora (KP) plant contains several methoxyflavones including 5,7-dimethoxyflavone (DMF), 5,7,4'-trimethoxyflavone (TMF), and 3,5,7,3',4'-pentamethoxyflavone (PMF). Ethanolic extracts of KP have shown various pharmacological effects and have been used as an aphrodisiac, a antimicrobial agent and for the treatment of inflammation, and peptic ulcers. Given its poor water solubility and low oral bioavailability (1-4%), there are limitations to the utilization of KP. Accordingly, self-microemu",International journal of pharmaceutics,"Catheleeya Mekjaruskul, Yu-Tsai Yang, Marina G D Leed, Matthew P Sadgrove, Michael Jay, Bungorn Sripanidkulchai"," Center for Research and Development of Herbal Health Products, Khon Kaen University, Khon Kaen 40002, Thailand.",2013 Mar;445(?):1-11,10.1016/j.ijpharm.2013.01.052
28192250,20170501,article,mesh,"Animals,Animals, Newborn,Anti-Infective Agents, Local,Antioxidants,Cell Survival,Drug Stability,Fibroblasts,Gallic Acid,Humans,In Vitro Techniques,Keratinocytes,Liposomes,Particle Size,Phospholipids,Skin Diseases,Skin Diseases, Bacterial,Stilbenes,Swine,Viscosity","administration &amp; dosage,chemistry,drug effects,microbiology,pharmacology,prevention &amp; control","D000891 Q000008 NY,D005707 Q000737 NN,D017192 Q000517 NY,D015603 Q000187 NN,D012871 Q000517 NY,D000975 Q000008 NY,D017192 Q000382 NN,D013267 Q000494 NN,D000975 Q000494 NN,D005347 Q000187 NN,D000891 Q000737 NN,D005707 Q000494 NN,D000975 Q000737 NN,D013267 Q000737 NN,D013267 Q000008 NY,D000891 Q000494 NN,D005707 Q000008 NY","370,445154,453626,1548910,25113755",NULL,Bifunctional viscous nanovesicles co-loaded with resveratrol and gallic acid for skin protection against microbial and oxidative injuries.,"Resveratrol and gallic acid were co-loaded in phospholipid vesicles aiming at protecting the skin from external injuries, such as oxidative stress and microbial infections. Liposomes were prepared using biocompatible phospholipids dispersed in water. To improve vesicle stability and applicability, the phospholipids and the phenols were dispersed in water/propylene glycol or water/glycerol, thus obtaining PEVs and glycerosomes, respectively. The vesicles were characterized by size, morphology, physical stabi",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Justina Vitonyte, Maria Letizia Manca, Carla Caddeo, Donatella Valenti, Josè Esteban Peris, Iris Usach, Amparo Nacher, Maria Matos, Gemma Gutiérrez, Germano Orrù, Xavier Fernàndez-Busquets, Anna Maria Fadda, Maria Manconi"," Dept. of Clinical Pharmacy, Lithuanian University of Health Sciences, Sukileliu pr. 13, Kaunas, Lithuania. Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. Electronic address: caddeoc@unica.it. Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. Dept. of Pharmacy and Pharmaceutical Technology,",2017 May;114(?):278-287,10.1016/j.ejpb.2017.02.004
28719877,20171001,article,mesh,"DNA Damage,Escherichia coli,Flame Retardants,Gene Knockout Techniques,Genomics,Oxidative Stress,Propylene Glycol,Propylene Glycols,Toxicity Tests","drug effects,genetics,toxicity","D011409 Q000633 NY,D004926 Q000235 NN,D004926 Q000187 NY,D005411 Q000633 NY","1030,18692",NULL,"Functional genomic assessment of 2, 2-bis (bromomethyl)-1, 3-propanediol induced cytotoxicity in a single-gene knockout library of E. coli.","Functional gene fingerprinting of chemicals could be used to understand the direct gene-chemical interaction in the process of toxification from a genome-wide scale. 2, 2-bis (bromomethyl)-1, 3-propanediol (BMP) is a brominated flame retardant with widespread production but with very limited toxicological data. Here the cytotoxicity of BMP was assessed by Escherichia coli (E. coli) functional genome-wide knockout mutants screening and the underlying molecular mechanism was investigated. The median inhibitio",Chemosphere,"Miao Guan, Xiaowei Zhang"," State Key Laboratory of Pollution Control & Resource Reuse, School of the Environment, Nanjing University, Nanjing, 210023, PR China. State Key Laboratory of Pollution Control & Resource Reuse, School of the Environment, Nanjing University, Nanjing, 210023, PR China; Research Center for Environmental Toxicology & Safety of Chemicals, Nanjing University, PR China; Jiangsu Key Laboratory of Environmental Safety and Health Risk of Chemicals, Nanjing, 210023, PR China. Electronic address: zhangxw@nju.edu.cn.",2017 Oct;185(?):582-588,10.1016/j.chemosphere.2017.07.031
29991814,20180101,article,NULL,NULL,NULL,NULL,NULL,NULL,"Differential Effects of E-Cigarette on Microvascular Endothelial Function, Arterial Stiffness and Oxidative Stress: A Randomized Crossover Trial.","Propylene glycol and glycerol are electronic cigarettes vehicles allowing liquid vaporization and nicotine transport. The respective effects of these different constituents on the cardiovascular system are unknown. We assessed the differential effects of vehicles (propylene glycol and glycerol) and nicotine on microcirculatory function, arterial stiffness, hemodynamic parameters and oxidative stress. Twenty-five tobacco smokers were exposed to vaping with and without nicotine, and sham vaping, in a randomiz",Scientific reports,"Martin Chaumont, Benjamin de Becker, Wael Zaher, Antoine Culié, Guillaume Deprez, Christian Mélot, Florence Reyé, Pierre Van Antwerpen, Cédric Delporte, Nadia Debbas, Karim Zouaoui Boudjeltia, Philippe van de Borne"," Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. martin.chaumont@ulb.ac.be. Institute for Translational Research in Cardiovascular and Respiratory Sciences, Université Libre de Bruxelles, Brussels, Belgium. martin.chaumont@ulb.ac.be. Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. Institute for Translational Research in Cardiovascular and Respiratory Sciences, Université Libre de Bruxelles, Brusse",2018 Jan;8(1):10378,10.1038/s41598-018-28723-0
7845605,19940926,article,"xref,mesh","Animals,Anticonvulsants,Antiparkinson Agents,Benzazepines,Catalepsy,Dopamine D2 Receptor Antagonists,Dyskinesia, Drug-Induced,Haloperidol,Male,Phenylcarbamates,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Dopamine D1","antagonists &amp; inhibitors,chemically induced,pharmacology,prevention &amp; control","D002375 Q000139 NN,D001552 Q000494 NN,D000978 Q000494 NY,D004409 Q000517 NN,D006220 Q000494 NN,D011409 Q000494 NY,D017447 Q000037 NN,D000927 Q000494 NY","3331,3559,5018,3036864","53790451,81065503,87350372,376229544","Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.","The potency of felbamate, an anti-convulsive drug, to influence dopamine D1 (SCH 23390) and D2 (haloperidol) receptor-mediated catalepsy (akinesia and bradykinesia) was studied in rats. In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia. Bradykinesia in the open field was never influenced. The results demonstrate that felbamate has similar anti-parkinsonian potential as glycine site antagonists blocking the N-methyl-D-aspartate (NMDA) receptor complex. ",Neuroscience letters,B D Kretschmer," Department of Neuropharmacology, University of Tübingen, Germany.",1994 Sep;179(?):115-8,10.1016/0304-3940(94)90948-2
30565857,20181122,article,NULL,NULL,NULL,NULL,NULL,NULL,Synthetic polymer coatings diminish chronic inflammation risk in large ECM-based materials.,"Degradable materials that can support cell infiltration and remodeling are the basis of tissue engineered approaches to vascular repair. In addition, to replace or close a large area of the vasculature, a patch material or scaffold must also withstand high pressure over time. Extracellular matrix-based (ECM-based) scaffolds offer a biological substrate with environmental cues that can support the formation of appropriate vascular tissue. However, scaffolds made from pure natural materials can degrade rapidl",Journal of biomedical materials research. Part A,"Laura G Bracaglia, Shira Winston, Douglas A Powell, John P Fisher"," Fischell Department of Bioengineering, University of Maryland, College Park, Maryland. Center for Engineering Complex Tissues, University of Maryland, College Park, Maryland. Fischell Department of Bioengineering, University of Maryland, College Park, Maryland. Center for Engineering Complex Tissues, University of Maryland, College Park, Maryland. Department of Laboratory Animal Resources, University of Maryland, College Park, Maryland. Fischell Department of Bioengineering, University of Maryland, College",2018 Nov;?(?):?,NULL
30977360,20190412,article,NULL,NULL,NULL,NULL,NULL,NULL,Hydroxyl Radicals in E-cigarette Vapor and E-vapor Oxidative Potentials under Different Vaping Patterns.,"Available studies, while limited in number, suggest that e-cigarette vaping induces oxidative stress, with one potential mechanism being the direct formation of reactive oxygen species (ROS) in e-vapor. In the present studies, we measured the formation of hydroxyl radical (•OH), the most destructive ROS, in e-vapor under a range of relevant vaping patterns (i.e., power settings, solvent concentrations, flavorings). Study results show that increased power output and puff volume correspond with the formation ",Chemical research in toxicology,"Yeongkwon Son, Vladimir Mishin, Jeffrey D Laskin, Gediminas Mainelis, Olivia A Wackowski, Cristine Delnevo, Stephan Schwander, Andrey Khlystov, Vera Samburova, Qingyu Meng",NULL,2019 Apr;?(?):?,NULL
31004848,20190406,article,NULL,NULL,NULL,NULL,NULL,NULL,"An LC-MS/MS method to profile urinary mercapturic acids, metabolites of electrophilic intermediates of occupational and environmental toxicants.","INTRODUCTION: Mercapturic acids are urinary metabolites of occupational and environmental toxicants. The aim of this work was to develop and validate an analytical assay for the determination of several urinary mercapturic acids to be used as biomarkers of exposure. METHOD: An isotope dilution tandem mass spectrometric method, coupled with reversed-phase liquid chromatography, was developed for the analysis of mercapturic acids derived from several compounds, including those of benzene, toluene, 1,3-butadie","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","Gianfranco Frigerio, Rosa Mercadante, Elisa Polledri, Pasquale Missineo, Laura Campo, Silvia Fustinoni"," EPIGET - Epidemiology, Epigenetics, and Toxicology Lab, Department of Clinical Sciences and Community Health, University of Milan and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via S. Barnaba, 8, 20122 Milan, Italy. Electronic address: gianfranco.frigerio@unimi.it. EPIGET - Epidemiology, Epigenetics, and Toxicology Lab, Department of Clinical Sciences and Community Health, University of Milan and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via S. Barnaba, 8, 20122 Milan, Ital",2019 Apr;1117(?):66-76,NULL
146628,19780101,article,mesh,"Acne Vulgaris,Administration, Topical,Adolescent,Adult,Anti-Infective Agents, Local,Clinical Trials as Topic,Double-Blind Method,Drug Therapy, Combination,Ethylene Glycols,Humans,Male,Ointments,Triclosan","administration &amp; dosage,drug therapy,therapeutic use","D000891 Q000627 NY,D005026 Q000627 NN,D014260 Q000627 NN,D014260 Q000008 NN,D000152 Q000188 NY",5564,NULL,The effectiveness of topical antibacterials in acne: a double-blind clinical study.,"In a double-blind study, three groups of patients with mild to moderate acne were treated for eight weeks with topical acne creams containing the antibacterials triclosan or triclosan plus propylene phenoxetol. The formula without antibacterials served as the control. Total-face lesion counts, evaluation of the overall degree of inflammation of the lesions, and patient self-assessment showed the added efficacy of the antibacterials when incorporated into the control. ",The Journal of international medical research,"E Franz, S Weidner-Strahl",NULL,1978 Jan;6(1):72-7,10.1177/030006057800600113
320608,19770101,article,mesh,"Animals,Cannabidiol,Cannabinoids,Cannabinol,Dose-Response Relationship, Drug,Dronabinol,Hemagglutination,Hemolytic Plaque Technique,Immunity,Immunosuppressive Agents,Male,Mice,Organ Size,Spleen,T-Lymphocytes","cytology,drug effects,immunology,pharmacology","D002185 Q000494 NY,D013154 Q000187 NN,D007109 Q000187 NY,D009929 Q000187 NN,D013154 Q000166 NN,D006384 Q000187 NN,D013154 Q000276 NN,D002186 Q000494 NY,D002187 Q000494 NY,D013759 Q000494 NY,D013601 Q000187 NN","2543,16078,644019,9852188",NULL,"delta1-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice.","delta1-tetrahydrocannabinol (THC) elicited a dose-dependent (1, 5, 10 mg/kg) depression of the immune response, of immature mice, stimulated with sheep red blood cells. The impairment of humoral immunity was specific for THC but not for cannabidiol at 25 mg/kg or cannabinol at 25 mg/kg. The mice were given four daily doses (i.p.) of either drug or vehicle (Tween 80-propylene glycol in 1% saline) or a single injection (i.p.) of sheep red blood cells in addition to four daily doses (i.p.) of drug or vehicle. ",Pharmacology,"S Zimmerman, A M Zimmerman, I L Cameron, H L Laurence",NULL,1977 Jan;15(1):10-23,10.1159/000136658
1376441,19920701,review,mesh,"Animals,DNA Damage,Epidemiologic Methods,Feasibility Studies,Humans,Mutagens",toxicity,D009153 Q000633 NY,NULL,NULL,DNA adduct formation by 12 chemicals with populations potentially suitable for molecular epidemiological studies.,"DNA adduct formation, route of absorption, metabolism and chemistry of 12 hazardous chemicals are reviewed. Methods for adduct detection are also reviewed and approaches to sensitivity and specificity are identified. The selection of these 12 chemicals from the Environmental Protection Agency list of genotoxic chemicals was based on the availability of information and on the availability of populations potentially suitable for molecular epidemiological study. The 12 chemicals include ethylene oxide, styrene",Mutation research,"M Uziel, N B Munro, D S Katz, T Vo-Dinh, E A Zeighami, M D Waters, J D Griffith"," Health and Safety Research Division, Oak Ridge National Laboratory, TN 37831-6101.",1992 Jul;277(1):35-90,10.1016/0165-1110(92)90025-5
1585949,19920101,article,mesh,"Acrylonitrile,Air Pollution,Carcinogens,Environmental Exposure,Humans,Maximum Allowable Concentration,Neoplasms,Occupational Exposure,Public Policy,State Government,United States,United States Environmental Protection Agency,United States Occupational Safety and Health Administration","adverse effects,analysis,chemically induced,legislation &amp; jurisprudence,prevention &amp; control","D016273 Q000009 NN,D009369 Q000139 NN,D000397 Q000032 NN,D009369 Q000517 NN,D004781 Q000009 NN,D000397 Q000009 NN,D000397 Q000331 NY",7855,NULL,The role of threshold limit values in U.S. air pollution policy.,"This paper analyzes the role of threshold limit values (TLVs) in national air pollution policy during the 1980s, a period in which the Environmental Protection Agency (EPA) sought to delegate to individual states the authority to evaluate and regulate airborne toxic substances. We focus on 20 carcinogens and 11 substances with non-genotoxic health effects that were regulated by local air toxics programs using TLVs. Data from EPA's National Air Toxics Information Clearinghouse indicate that maximum TLV-based",American journal of industrial medicine,"J C Robinson, D G Paxman"," Center for Occupational and Environmental Health, School of Public Health, University of California, Berkeley 94720.",1992 Jan;21(3):383-96,10.1002/ajim.4700210311
2244420,19900101,article,mesh,"Chronic Disease,Diatrizoate,Drug Combinations,Fatty Acids,Fibrin Tissue Adhesive,Humans,Pancreas Transplantation,Pancreatic Diseases,Pancreatic Ducts,Pancreatic Neoplasms,Pancreatitis,Postoperative Complications,Propylene Glycols,Proteins,Zein","administration &amp; dosage,drug effects,pharmacology,therapy","D011183 Q000628 NN,D010183 Q000187 NY,D011506 Q000008 NY,D015718 Q000008 NY,D010182 Q000628 NY,D015718 Q000494 NN,D011506 Q000494 NN,D010195 Q000628 NN,D010190 Q000628 NN",NULL,NULL,[Development and critical evaluation of pancreatic duct occlusion].,"The three original aims of pancreatic duct occlusion (PDO) were first the reduction of early complications after Whipple's operation in chronic pancreatitis and carcinoma as well as segmental pancreas transplantation, second to finish the inflammation in cases of chronic pancreatitis and third to protect the B-cell function in remained or transplanted pancreas. We have compared PDO by Tissucol and Ethibloc with non-occluded pancreases up to 3 years after Whipple's operation in patients with chronic pancreat",Zentralblatt fur Chirurgie,"D Lorenz, H Waclawiczek"," Klinik für Chirurgie, Ernst-Moritz-Arndt-Universität Greifswald.",1990 Jan;115(18):1141-53,NULL
2328306,19900401,article,mesh,"Animals,Creatinine,Cyclosporins,Drug Interactions,Female,Immunosuppressive Agents,Lovastatin,Rats,Rats, Zucker,T-Lymphocytes","blood,drug effects,pharmacokinetics,pharmacology,toxicity","D003404 Q000097 NN,D003524 Q000633 NN,D008148 Q000494 NY,D003524 Q000493 NN,D013601 Q000187 NN,D003524 Q000494 NY","588,53232",NULL,"Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat.","The combined use of lovastatin, a hypolipidemic agent effective in the reduction of cholesterol levels, and the lipophilic immunosuppressant, cyclosporine, was studied in the obese rat model. Pharmacokinetics, immunosuppressive activity, lipid levels, and creatinine clearances were compared between groups administered drug-free vehicle, lovastatin or cyclosporine alone, or concomitant cyclosporine and lovastatin. All groups were pre-treated with either oral lovastatin 2.5 mg kg-1 day-1 or propylene glycol v",Biopharmaceutics & drug disposition,"K L Berens, K Vadiei, L J Brunner, K M Wasan, D R Luke"," Department of Pharmaceutics, University of Houston, Texas Medical Center 77030.",1990 Apr;11(3):197-206,10.1002/bdd.2510110304
2414892,19850901,article,mesh,"Angiography,Diatrizoate,Drug Combinations,Embolization, Therapeutic,Ethanol,Fatty Acids,Humans,Kidney Neoplasms,Palliative Care,Propylene Glycols,Proteins,Zein","blood supply,methods,therapy","D004621 Q000379 NY,D007680 Q000628 NY,D007680 Q000098 NN",702,NULL,[Clinical observations in vascular occlusion of kidney tumors by absolute alcohol].,"The results of the occlusion of renal tumors by two different materials-Ethibloc (n = 26) and absolute alcohol (n = 72) are being compared. The kidneys were occluded under equal clinical conditions. The clinical symptoms following embolisation are fewer in the group of alcohol embolized patients than in the group with Ethibloc. On the capillary level, the histological reaction to alcohol corresponds to a histotoxic alteration. This reaction goes beyond the reactive inflammation of the tissue observed after ",Der Urologe. Ausg. A,"J Timmermann, W Straube, W Schlake",NULL,1985 Sep;24(5):260-3,NULL
2416228,19850101,article,mesh,"Animals,Chinchilla,Cholesteatoma,Disease Models, Animal,Drug Combinations,Ear Diseases,Ear, Middle,Epidermis,Epithelium,Granulation Tissue,Hydrocortisone,Keratins,Metaplasia,Neomycin,Osteogenesis,Polymyxin B,Temporal Bone,Time Factors","chemically induced,pathology","D002781 Q000473 NY,D013701 Q000473 NN,D002781 Q000139 NN,D004817 Q000473 NN,D004432 Q000473 YN,D004848 Q000473 NN,D008679 Q000473 NN,D004427 Q000139 NN,D004427 Q000473 NY","4868,5754,62403,65344,197162,229860,291576,5702091,5702092,5702105,6419968,9833652,24978553,44134844,45073487,45356929,49800004,56842110,71299257,71463900,118855445,123134032,124080932,134692135",NULL,Middle ear cholesteatoma: an animal model.,"Topical otic preparations now in clinical use contain a variety of antibiotics and solvents that may produce severe inflammation if they reach the middle ear cavity. This report describes the response of the chinchilla middle ear to direct application of one such preparation that appears to act as a nonspecific irritant. Cortisporin otic suspension (containing neomycin, polymyxin B, hydrocortisone, and propylene glycol) was introduced into the bullae of 32 chinchillas that were kept alive for four days to f",American journal of otolaryngology,"C G Wright, W L Meyerhoff, D K Burns",NULL,1985 Jan;6(5):327-41,10.1016/s0196-0709(85)80010-7
2434323,19870101,article,mesh,"Air Pollutants,Biotransformation,Cloning, Molecular,DNA Damage,DNA, Bacterial,Gases,Microsomes, Liver,Mutagenicity Tests,Mutagens,Plants, Toxic,SOS Response (Genetics),Salmonella typhimurium,Smoke,Tobacco,Vehicle Emissions","drug effects,metabolism,toxicity","D008862 Q000378 NN,D004269 Q000187 NN,D000393 Q000633 NY,D012486 Q000187 NN,D001335 Q000633 NN",NULL,NULL,Application of SOS umu-test for the detection of genotoxic volatile chemicals and air pollutants.,"The SOS umu-test has been used for the detection of DNA-damaging agents. In this system the plasmid pSK1002 carrying a fused gene umuC-lacZ was introduced into Salmonella typhimurium TA1535. The SOS function induced by genotoxic agents is detected by a colorimetric measurement of beta-galactosidase activity encoded by the lacZ gene, which is regulated by the Umu operon. This system was used with modifications to study the SOS function inducibility of volatile chemicals (propylene oxide, methyl bromide, and ",Environmental mutagenesis,"T M Ong, J Stewart, Y F Wen, W Z Whong",NULL,1987 Jan;9(2):171-6,10.1002/em.2860090207
2680146,19891101,article,mesh,"4-Aminobenzoic Acid,Aniline Compounds,Animals,Benzhydryl Compounds,Biotransformation,Cytochrome P-450 CYP1A1,Cytochrome P-450 Enzyme System,In Vitro Techniques,Methylenebis(chloroaniline),Microsomes, Liver,Mixed Function Oxygenases,Mutagenicity Tests,Mutagens,Oxidoreductases,Phenylenediamines,Propylene Glycols,Rats,Rats, Inbred Strains,Salmonella typhimurium,Structure-Activity Relationship,para-Aminobenzoates","drug effects,enzymology,metabolism,pharmacology","D010088 Q000378 NN,D011409 Q000494 NY,D008753 Q000494 NY,D010655 Q000494 NY,D001711 Q000187 NN,D001559 Q000494 NY,D008862 Q000201 NY,D012486 Q000187 NN,D000814 Q000494 NY,D003577 Q000378 NN,D010129 Q000494 NN,D006899 Q000378 NN","978,7543,86262,92343,93312,23663628,23663633",NULL,"Genotoxicity and effects on rat liver drug-metabolizing enzymes by possible substitutes for 4,4'-methylene bis(2-chloroaniline).","The mutagenic properties of Ethacure 300, Cyanacure and Polacure 740M, all possible substitutes for the industrial carcinogen, 4,4'-methylene bis(2-chloroaniline), have been determined in Salmonella typhimurium strains TA100, TA98, TA1535 and TA1537. These data have been compared with the effects of these chemicals on ethoxyresorufin O-deethylase (EROD) activity and aldrin epoxidase (AE) activity in rat liver. Ethacure 300 was clearly positive in both TA100 and TA98 bacterial strains, while Cyanacure was po",Carcinogenesis,"K Wu, A M Bonin, C L Leslie, R S Baker, N H Stacey"," National Institute of Occupational Health and Safety, University of Sydney, NSW, Australia.",1989 Nov;10(11):2119-22,10.1093/carcin/10.11.2119
2971521,19880101,review,mesh,"Administration, Topical,Drug Eruptions,Humans,Pharmaceutical Vehicles,Risk Factors,Skin Neoplasms","chemically induced,etiology","D012878 Q000139 NN,D003875 Q000209 NY",NULL,NULL,Adverse reactions of externally applied drugs and inert substances.,"The lack of a first-pass effect for locally-applied substances is often not considered. This is especially true for such central nervous system agents as salicylic acid, hexachlorophene or caffeine which have a relatively low toxicity when applied orally. Manifestation of dermal irritation, such as a beginning rash or inflammation, are often tolerated because the beneficial effects of some topically applied substances outweight the damage (Dithranol, 5-Fluorouracil). This applies to some anti-phlogistics as",Dermatosen in Beruf und Umwelt. Occupation and environment,A Zesch," Institute for Drugs, Federal Health Office, Berlin, Fed. Rep. of Germany.",1988 Jan;36(4):128-33,NULL
3081798,19860301,article,mesh,"Animals,Benzo(a)pyrene,Biotransformation,Cell Line,Cricetinae,DNA Replication,Fibroblasts,Humans,Indoles,Lithium,Lithium Carbonate,Lung,Male,Mazindol,Microsomes, Liver,Mutagenicity Tests,Propylene Glycols","drug effects,metabolism,pharmacology","D008094 Q000378 NN,D004261 Q000187 NN,D007211 Q000494 NY,D001564 Q000494 NN,D008454 Q000494 NY,D008862 Q000378 NN,D011409 Q000494 NY,D008094 Q000494 NY,D008454 Q000378 NN,D005347 Q000187 NY,D001564 Q000378 NN,D011409 Q000378 NN","2336,3169,4020,11125,65859,3028194,11564465,21917306,23678576",NULL,"Results of genotoxicity testing of mazindol (degonan), lithium carbonicum (contemnol) and dropropizine (ditustat) in Chinese hamster V79 and human EUE cells.","We studied inhibition of DNA synthesis, alkaline elution of DNA, cytotoxicity and occurrence of induced 6-thioguanine resistant mutants in mammalian cells, treated with mazindol, lithium carbonicum, and dropropizine, respectively, in the presence and in the absence of microsomal fraction S9. Among the above-mentioned clinically used drugs only dropropizine showed neither mutagenic nor clastogenic effects. Lithium carbonicum manifested a weak and mazindol a medium genotoxic response which was in both cases r",Mutation research,"D Slamenová, E Budayová, A Gábelová, A Morávková, L Pániková",NULL,1986 Mar;169(3):171-7,NULL
3088234,19860401,article,mesh,"Acrylates,Adhesiveness,Animals,Calcium Hydroxide,Ceramics,Composite Resins,Dental Cavity Preparation,Dental Pulp,Female,Ferrets,Male,Methacrylates,Minerals,Propylene Glycols,Pulpitis,Time Factors","adverse effects,analysis,anatomy &amp; histology,chemically induced,drug effects,pathology,pharmacology","D008903 Q000494 NN,D011671 Q000473 NN,D002126 Q000494 NN,D003782 Q000187 NY,D003188 Q000494 NN,D003782 Q000033 NN,D008689 Q000032 NN,D011409 Q000494 NY,D011409 Q000032 NN,D002516 Q000494 NN,D003188 Q000009 NN,D008689 Q000494 NY,D011671 Q000139 NN,D002516 Q000032 NN,D000179 Q000494 NY",135095,NULL,Pulpal response to an experimental adhesion promoter.,"The pulpal response to an experimental adhesion promoter (PTP) used in conjunction with a composite resin material, Biogloss, is described, in lined and unlined cavities. Dycal was the lining and negative control material. Standardised Class V cavities were prepared in ferret canine teeth and the pulpal responses studied after 1, 2 and 4 weeks and 6 months post-operatively. Pre-treatment of cavities with PTP causes a reduction in pulpal inflammation at 7 and 14 days compared with Biogloss. There was no obvi",Journal of oral pathology,"C G Plant, R S Tobias, R M Browne",NULL,1986 Apr;15(4):196-200,NULL
3381484,19880401,article,mesh,"Administration, Inhalation,Administration, Oral,Administration, Topical,Animals,Eye Diseases,Female,Irritants,Lethal Dose 50,Male,Propylene Glycols,Rabbits,Rats,Rats, Inbred Strains,Skin Diseases","chemically induced,toxicity","D011409 Q000633 NY,D005128 Q000139 NN,D012871 Q000139 NN",15286,NULL,The acute toxicity and primary irritancy of 1-propoxy-2-propanol.,"1-Propoxy-2-propanol, a widely used industrial chemical, was found to have acute peroral LD50 values in the rat of 4.92 ml/kg (males) and 2.83 ml/kg (females), with the signs of systemic toxicity being principally related to narcosis. Acute percutaneous LD50 values in the rabbit (24-hr occluded) were 4.29 ml/kg (males) and 4.92 ml/kg (females); signs of systemic toxicity were related to narcosis, and local effects were severe inflammation and corrosion. There were signs of sensory irritation of the eye duri",Veterinary and human toxicology,"B Ballantyne, R C Myers, P E Losco"," Applied Toxicology Department, Union Carbide Corporation, Danbury, Connecticut 06817.",1988 Apr;30(2):126-9,NULL
3474462,19870801,article,mesh,"Acetates,Alkylating Agents,Animals,Epoxy Compounds,Formates,Formic Acid Esters,Hydrolysis,Male,Methyl Methanesulfonate,Nasal Mucosa,Nose Neoplasms,Propiolactone,Rats,Rats, Inbred Strains","chemically induced,drug effects,toxicity","D008741 Q000633 NN,D011420 Q000633 NN,D009669 Q000139 NY,D005561 Q000633 NN,D000085 Q000633 NN,D004852 Q000633 NN,D000477 Q000633 NY,D009297 Q000187 NY","2365,4156,6378,6593,10928",NULL,Inhalation carcinogenesis of various alkylating agents.,"A series of earlier studies showed that inhalation exposures of rats to three water-reactive electrophilic compounds produced brisk yields of nasal cancer even when the animals were exposed for only 30 days (6 hr/day X 5 day/wk). In addition, carcinogenic potencies of the compounds appeared to relate to their chemical reactivities as measured by hydrolysis rates. For a further study of this phenomenon, inhalation exposures were conducted with five additional water-reactive compounds: beta-propiolactone [(BP",Journal of the National Cancer Institute,"A R Sellakumar, C A Snyder, R E Albert",NULL,1987 Aug;79(2):285-9,NULL
3619640,19870101,article,mesh,"Acrylamide,Acrylamides,Alkylating Agents,Amino Acids,Animals,Carcinogens,Epoxy Compounds,Ethylene Oxide,Female,Gas Chromatography-Mass Spectrometry,Guanine,Hemoglobins,Methylation,Rats,Rats, Inbred Strains","analogs &amp; derivatives,analysis,toxicity,urine","D002273 Q000032 NN,D000178 Q000633 NN,D004852 Q000032 NN,D005027 Q000032 NN,D002273 Q000633 NY,D000477 Q000032 NN,D006147 Q000031 NY,D006147 Q000652 NN,D006454 Q000032 NY,D000178 Q000032 NN,D005027 Q000633 NN,D004852 Q000633 NN,D000477 Q000633 NY,D000596 Q000032 NN","764,6354,6378,6579,11361,24828",NULL,Estimation of exposure to alkylating carcinogens by the GC-MS determination of adducts to hemoglobin and nucleic acid bases in urine.,"Many carcinogens and mutagens are electrophilic in nature and will react with nucleophilic sites in protein and nucleic acid. Determination of the extent of formation of these adducts of genotoxic agents with protein provides a practical method of monitoring human exposure and of determining the possible risk associated with the exposure. Proteins are predominantly attacked on the cysteine, histidine and N-terminal amino acids. Hemoglobin is the most suitable protein for dose monitoring due to its ready ava",Archives of toxicology,"E Bailey, P B Farmer, D E Shuker",NULL,1987 Jan;60(?):187-91,10.1007/bf00296978
3798446,19870101,article,mesh,"Antibody-Dependent Cell Cytotoxicity,Carbamazepine,DNA, Single-Stranded,Humans,Hydrogen-Ion Concentration,In Vitro Techniques,Killer Cells, Natural,Monocytes,Phenytoin","drug effects,toxicity","D000920 Q000187 NN,D009000 Q000187 NN,D007694 Q000187 NY,D004277 Q000187 NY,D002220 Q000633 NY,D010672 Q000633 NY","1775,2554,158856,657302,9795547,13241308,21935075,23679632,54721898,129734996",NULL,Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro.,"Human peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers and exposed in vitro to phenytoin or carbamazepine, two widely used antiepileptic drugs (AED). This study investigated the effects of these drugs on natural killer (NK) cell activity and antibody-dependent cell-mediated cytotoxicity (ADCC), which are both thought to protect against developing neoplasms. Also, the genotoxicity of phenytoin on human PBMC was investigated by gravity-flow alkaline elution. Concentrations of ph",Toxicology and applied pharmacology,"N C Margaretten, J R Hincks, R P Warren, R A Coulombe",NULL,1987 Jan;87(1):10-7,10.1016/0041-008x(87)90079-2
4420689,19740101,article,mesh,"Administration, Topical,Anti-Infective Agents, Local,Anti-Inflammatory Agents,Chronic Disease,Deodorants,Drug Combinations,Hexachlorophene,Humans,Inflammation,Mouth Mucosa,Postoperative Complications,Propylene Glycols,Salicylates,Samarium","drug therapy,surgery,therapeutic use","D000891 Q000627 NY,D012493 Q000627 NY,D012459 Q000627 NY,D006582 Q000627 NY,D007249 Q000188 NY,D003836 Q000627 NN,D009061 Q000601 YN,D011183 Q000188 NN,D000893 Q000627 NY","3598,23951",NULL,Phlogosol therapy in inflammations of the oral mucosa.,NULL,Therapia Hungarica (English edition),G Balogh,NULL,1974 Jan;22(2):83-9,NULL
4604483,19740101,review,mesh,"Administration, Topical,Croton Oil,Drug Hypersensitivity,Eczema,Fluocinolone Acetonide,Humans,Inflammation,Pharmaceutical Vehicles,Propylene Glycols,Psoriasis,Radiation Injuries,Skin Diseases,Steroids, Fluorinated,Ultraviolet Rays,Vasoconstrictor Agents","administration &amp; dosage,adverse effects,chemically induced,drug therapy,pharmacology,therapeutic use","D004485 Q000627 NN,D011832 Q000188 NN,D013259 Q000627 NN,D005446 Q000009 NN,D007249 Q000139 NN,D005446 Q000627 NY,D011565 Q000188 NN,D005446 Q000008 NN,D014662 Q000627 NN,D012871 Q000188 NY,D003436 Q000494 NN","899,6215",NULL,Fluocinonide in FAPG base: a review of its therapeutic efficacy in inflammatory dermatoses.,NULL,Drugs,"R N Brogden, T M Speight, G S Avery",NULL,1974 Jan;7(5):337-43,10.2165/00003495-197407050-00004
4976666,19690401,article,mesh,"Animals,Antibody Formation,Chlorphenesin,Erythrocytes,Hemocyanins,Immunodiffusion,Immunoglobulin G,Immunosuppressive Agents,Mice,Muscles,Penicillin G,Propylene Glycols,Rabbits,Rats,Sheep,Spleen,Tuberculin Test","administration &amp; dosage,analysis,drug effects,immunology,pharmacology","D002743 Q000494 NN,D004912 Q000276 NN,D007074 Q000032 NN,D011409 Q000494 NY,D013154 Q000276 NN,D009132 Q000494 NY,D002743 Q000008 NN,D000917 Q000187 NY","5904,7697,517573,23664709,23668834,44134885,54607813",NULL,The effect of chlorphenesin on the immune response.,NULL,"Journal of immunology (Baltimore, Md. : 1950)","F M Berger, G M Fukui, E G Goldenbaum, M DeAngelo, G C Chandlee",NULL,1969 Apr;102(4):1024-31,NULL
5291641,19710501,article,mesh,"Acetates,Betamethasone,Croton Oil,Erythema,Esters,Evaluation Studies as Topic,Fatty Alcohols,Flumethasone,Fluocinolone Acetonide,Humans,Male,Occlusive Dressings,Ointments,Pharmaceutical Vehicles,Pregnanes,Propylene Glycols,Triamcinolone Acetonide,Valerates","chemically induced,drug therapy,therapeutic use","D005443 Q000627 NN,D011278 Q000627 NN,D014222 Q000627 NN,D004890 Q000188 NY,D005446 Q000627 NY,D004890 Q000139 NN,D014631 Q000627 NN,D001623 Q000627 NN","899,6215,6436,9782,16490,545800,633097",NULL,The croton oil inflammation suppression assay as a measure of topical corticosteroid potency.,NULL,Acta dermato-venereologica. Supplementum,"E Ortega, C Rodriguez, K H Burdick, V A Place, L Gonzales",NULL,1971 May;52(67):95-7,NULL
5657827,19680501,article,mesh,"Abscess,Adrenal Glands,Animals,Anti-Inflammatory Agents,Carrageenan,Granuloma,Hydrocortisone,Inflammation,Male,Propylene Glycols,Rats","chemically induced,drug effects,drug therapy,therapeutic use","D000038 Q000188 NY,D006099 Q000139 NN,D000038 Q000139 NN,D007249 Q000139 NN,D000311 Q000187 NN,D006854 Q000627 NN,D006099 Q000188 NY,D011409 Q000627 NY,D000893 Q000627 NY","5754,229860,11966249",NULL,Anti-inflammatory activity of alkoxyglycerols in rats.,NULL,Archives internationales de pharmacodynamie et de therapie,"R G Burford, C W Gowdey",NULL,1968 May;173(1):56-70,NULL
6061942,19671201,article,mesh,"Adult,Bone Marrow,Bone Marrow Cells,Bone Marrow Examination,Endotoxins,Etiocholanolone,Female,Fever,Heme,Humans,Inflammation,Leukocyte Count,Leukocytes,Male,Porphyrins,Propylene Glycols","administration &amp; dosage,adverse effects,biosynthesis,blood,chemically induced,drug effects,etiology,pharmacology","D005043 Q000009 NN,D007962 Q000187 NN,D005043 Q000494 NY,D005334 Q000139 NN,D005334 Q000097 NN,D011166 Q000096 NN,D005043 Q000097 NN,D006418 Q000096 NN,D005043 Q000008 NN,D007249 Q000209 NN,D011409 Q000494 NN,D001853 Q000187 NN,D004731 Q000494 NN","4973,5880,26945,444097,444098,644347,6420080,25203933,53356659,53356674,53629486",NULL,The biological properties of etiocholanolone. Combined clinical staff conference at the National Institutes of Health.,NULL,Annals of internal medicine,NULL,NULL,1967 Dec;67(6):1268-95,NULL
7078574,19820401,article,mesh,"Adult,Cells, Cultured,DNA Repair,DNA Replication,Environmental Exposure,Epoxy Compounds,Ethers, Cyclic,Ethylene Oxide,Humans,Lymphocytes,Middle Aged,Mutagens,Occupational Medicine","drug effects,metabolism,pharmacology,ultrastructure","D004852 Q000494 NY,D004988 Q000494 NY,D008214 Q000378 NY,D008214 Q000648 NN,D005027 Q000494 NY,D004261 Q000187 YN,D004260 Q000187 YN","6354,6378",NULL,A reduced capacity for unscheduled DNA synthesis in lymphocytes from individuals exposed to propylene oxide and ethylene oxide.,NULL,Mutation research,"R W Pero, T Bryngelsson, B Widegren, B Högstedt, H Welinder",NULL,1982 Apr;104(?):193-200,10.1016/0165-7992(82)90144-0
7513639,19940101,review,mesh,"Acetates,Amines,Animals,Anticonvulsants,Cyclohexanecarboxylic Acids,Drugs, Investigational,Epilepsy,Humans,Ion Channels,Mice,Phenylcarbamates,Propylene Glycols,Rats,Receptors, GABA-A,Receptors, N-Methyl-D-Aspartate,Receptors, Neurotransmitter,Triazines,Valproic Acid,gamma-Aminobutyric Acid","drug effects,drug therapy,pharmacology,therapeutic use","D014227 Q000627 NN,D000085 Q000494 NN,D014635 Q000627 NN,D004827 Q000188 NY,D014227 Q000494 NN,D015507 Q000627 NN,D011963 Q000187 NN,D007473 Q000187 NY,D000927 Q000627 NN,D017981 Q000187 NY,D015507 Q000494 NN,D000085 Q000627 NN,D016194 Q000187 NN,D000927 Q000494 NY,D011409 Q000494 NN,D011409 Q000627 NN,D014635 Q000494 NN","119,3121,3331,3446,3878,86480,147515,3549980,16760703,23663956",NULL,Mechanisms of action of currently prescribed and newly developed antiepileptic drugs.,"Clinically available antiepileptic drugs (AEDs) decrease membrane excitability by interacting with neurotransmitter receptors or ion channels. AEDs developed before 1980 appear to act on sodium (Na) channels, gamma-aminobutyric acid A (GABAA) receptors, or calcium (Ca) channels. Benzodiazepines and barbiturates enhance GABAA-receptor-mediated inhibition. Phenytoin, carbamazepine and, possibly, valproate (VPA) decrease high-frequency repetitive firing of action potentials by enhancing Na channel inactivation",Epilepsia,"R L Macdonald, K M Kelly"," Department of Neurology, University of Michigan Medical School, Ann Arbor.",1994 Jan;?(?):S41-50,10.1111/j.1528-1157.1994.tb05955.x
7608159,19950707,article,mesh,"Base Sequence,Carbon-Oxygen Lyases,DNA,DNA Repair,DNA-(Apurinic or Apyrimidinic Site) Lyase,Endonucleases,Ethylene Glycols,Exonucleases,Furans,Humans,Kinetics,Molecular Sequence Data,Nuclear Proteins,Oligodeoxyribonucleotides,Propylene Glycols,Substrate Specificity,Thionucleotides","chemistry,metabolism","D005092 Q000378 NN,D009687 Q000378 NY,D009838 Q000378 NY,D004247 Q000378 NY,D013873 Q000378 NN,D009838 Q000737 NN,D004720 Q000378 NY,D004247 Q000737 NN","8028,44135672",NULL,Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA.,"The major apurinic/apyrimidinic (AP) endonuclease of human cells, the Ape protein, incises DNA adjacent to abasic sites to initiate DNA repair and counteract the cytotoxic and mutagenic effects of AP sites. Here we address the determinants of Ape AP endonuclease activity using duplex DNA substrates that contain synthetic analogs of AP sites: tetrahydrofuranyl (F), propanediol (P), ethanediol (E), or 2-(aminobutyl)-1,3-propanediol (Q). The last of these, a branched abasic structure, was a poor substrate for ",The Journal of biological chemistry,"D M Wilson, M Takeshita, A P Grollman, B Demple"," Harvard University School of Public Health, Department of Molecular and Cellular Toxicology, Boston, Massachusetts 02115, USA.",1995 Jul;270(27):16002-7,10.1074/jbc.270.27.16002
7679188,19930301,article,mesh,"Alkylating Agents,Animals,Cells, Cultured,Chromosome Aberrations,Epoxy Compounds,Lymphocytes,Male,Mice,Mice, Inbred C57BL,Mutagens,Trichloroepoxypropane","drug effects,toxicity","D014239 Q000633 NN,D004852 Q000633 NY,D000477 Q000633 NY,D009153 Q000633 NY,D008214 Q000187 NN","18321,119125",NULL,Chromosomal aberrations in mouse lymphocytes exposed in vivo and in vitro to aliphatic epoxides.,"Mouse lymphocytes in vivo or in vitro were exposed for 24 h to 4 aliphatic epoxides, glycidyl 1-naphthyl ether, glycidyl 4-nitrophenyl ether, 1-naphthyl-propylene oxide and trichloropropylene oxide (TCPO), and tested for the induction of chromosomal aberrations (CA). These epoxides were among the most genotoxic aliphatic epoxides in our previous studies. With the exception of TCPO, the test epoxides caused significant increases in CA in vivo compared to a negative control. There were concentration related i",Mutation research,"L Das, S K Das, E H Chu, J E Sinsheimer"," Department of Human Genetics, University of Michigan, Ann Arbor 48109.",1993 Mar;299(1):19-24,10.1016/0165-1218(93)90114-s
7683266,19930401,article,mesh,"Airway Resistance,Animals,Antitussive Agents,Bronchoconstriction,Capsaicin,Codeine,Guinea Pigs,Male,Propylene Glycols,Substance P,Tobacco Smoke Pollution","adverse effects,antagonists &amp; inhibitors,drug effects,pharmacology,toxicity","D013373 Q000037 NN,D000996 Q000494 NY,D000403 Q000187 NY,D011409 Q000494 NY,D013373 Q000633 NN,D014028 Q000009 NY,D002211 Q000037 NN,D016084 Q000187 NY,D003061 Q000494 NN,D002211 Q000633 NN","3169,36511,65859,1548943,5284371,5324288,5359227,5362471,6321303,9953630",NULL,Effectiveness of levodropropizine against cigarette smoke-induced airway hyperreactivity: possible mechanism.,"We verified the possible effect of the new antitussive drug levodropropizine on airway hyperreactivity and lung inflammation induced by cigarette smoke exposure in anaesthetized guinea-pigs. Levodropropizine, administered by aerosol at 25 mg/ml for 30 s completely prevented smoke induced airway hyperreactivity. The protective effect was early in onset (3 min) and lasted up to 30 min. The same dose of codeine, administered in the form of an aerosol, decreased the increase in airway responsiveness induced by ",European journal of pharmacology,"L Daffonchio, A Hernandez, G Melillo, G Clavenna, C Omini"," Institute of Pharmacological Sciences, University of Milan, Italy.",1993 Apr;228(?):257-61,10.1016/0926-6917(93)90058-x
7690900,19930901,article,mesh,"Adenine,Azides,DNA Repair,Escherichia coli,Gene Expression,Molecular Structure,Mutagenicity Tests,Mutagens,Propylene Glycols,SOS Response (Genetics)","analogs &amp; derivatives,drug effects,genetics,toxicity","D015870 Q000187 NN,D011409 Q000633 NY,D001386 Q000633 NY,D004926 Q000187 NN,D000225 Q000031 NY,D004926 Q000235 NY,D009153 Q000633 NY,D000225 Q000633 NN","190,108212,128890",NULL,"Mutagenicity of 3-azido-1,2-propanediol and 9-(3-azido-2-hydroxypropyl)-adenine in repair deficient strains of Escherichia coli.","The mutagenicity of two non-aromatic organic azido compounds, 3-azido-1,2-propanediol (AG) and 9-(3-azido-2-hydroxypropyl)-adenine (AHPA), was studied in E. coli repair deficient strains uvrA6, uvrA6 + umuC36, uvrA6+ umuC122::Tn5, polA1, tagA1+ alkA1, ada and dam3. The mutagenicity of both agents was markedly enhanced by defects of UvrABC excinuclease (uvrA6) and was independent of umuC function of the SOS error-prone pathway. Neither azido compound promoted umuDC operon expression. The mutagenicity of AG i",Mutation research,"P Grúz, M Jurícek, P Zák, J Velemínský"," Department of Genetics, Academy of Sciences of the Czech Republic, Prague.",1993 Sep;303(1):1-9,10.1016/0165-7992(93)90002-d
7866813,19950101,article,mesh,"Adolescent,Adult,Colitis, Ulcerative,Colon,Enema,Female,Humans,Inflammation,Leukocytes,Male,Middle Aged,Organotechnetium Compounds,Oximes,Pneumoradiography,Predictive Value of Tests,Radionuclide Imaging,Sensitivity and Specificity,Technetium Tc 99m Exametazime",diagnostic imaging,"D003106 Q000000981 NY,D007249 Q000000981 NN,D003093 Q000000981 NY","450484,56841051,129626367",NULL,Air enema radiology compared with leukocyte scintigraphy for imaging inflammation in active ulcerative colitis.,OBJECTIVE: To compare air enema radiology with a leukocyte scintigraphy technique using technetium-99m-hexamethyl propylene amine oxime-labelled leukocytes for imaging colonic inflammation in ulcerative colitis. DESIGN: Prospective study in a University hospital. One radiologist and one nuclear physician independently graded the degree of inflammation in six colon segments per patient using radiographs and leukocyte scans. PATIENTS: Twenty consecutive patients with symptoms of active ulcerative colitis requ,European journal of gastroenterology & hepatology,"S Almer, G Bodemar, E Lindström, A M Peters, M Ström"," Department of Internal Medicine, Faculty of Health Sciences, Linköping University, Sweden.",1995 Jan;7(1):59-64,NULL
7880120,19950101,article,mesh,"Aged,Arthritis, Rheumatoid,Cell Movement,Female,Humans,Kinetics,Lymphocytes,Male,Middle Aged,Organotechnetium Compounds,Oximes,Radionuclide Imaging,Synovial Membrane,Synovitis,Technetium Tc 99m Exametazime,Time Factors","complications,diagnostic imaging,etiology,pathology,physiology","D001172 Q000473 NN,D013585 Q000209 NN,D013585 Q000000981 NY,D001172 Q000000981 NY,D008214 Q000502 NN,D013583 Q000473 NN,D008214 Q000000981 NY,D001172 Q000150 NN,D013585 Q000473 NN","450484,56841051,129626367",NULL,Radiolabelled lymphocyte migration in rheumatoid synovitis.,"OBJECTIVES: To study the ability of technetium-99m hexamethyl propylene amineoxime (HMPAO) labelled lymphocyte scintigraphy to quantify synovial inflammation, and to analyse the kinetics of lymphocyte retention in the joints of patients with rheumatoid arthritis (RA). METHODS: After isolation of the lymphocytes, the cells were radiolabelled in vitro with 250 MBq 99mTc-HMPAO. The scans were performed 30 minutes, three hours and 20 hours after injection. RESULTS: An increase of the scintigram signal obtained ",Annals of the rheumatic diseases,"C Jorgensen, I Couret, C Bologna, M Rossi, J Sany"," Service d'Immuno-Rhumatologie, Centre Gui-de-Chauliac, Montpellier, France.",1995 Jan;54(1):39-44,10.1136/ard.54.1.39
8179486,19940101,article,mesh,"Chloroprene,Gas Chromatography-Mass Spectrometry,Mutagenicity Tests,Salmonella typhimurium","analogs &amp; derivatives,drug effects,metabolism,toxicity","D002737 Q000633 NY,D002737 Q000031 NN,D002737 Q000378 NN,D012486 Q000187 NY",31369,NULL,"Bacterial mutagenicity of 2-chloro-1,3-butadiene (chloroprene) caused by decomposition products.","Since the literature on genotoxicity of 2-chloro-1,3-butadiene (chloroprene) is controversial, the mutagenicity of this compound was reinvestigated with respect to its chemical stability. Because of the volatility of chloroprene, Ames tests with S. typhimurium TA 100 were carried out with gas-tight preincubation. Propylene oxide, a volatile direct mutagen, served as a positive control. Benzo[a]pyrene was used as a control for an indirect mutagen. Using this experimental regimen, freshly distilled chloropren",Archives of toxicology,"G A Westphal, M Blaszkewicz, M Leutbecher, A Müller, E Hallier, H M Bolt"," Institut für Arbeitsphysiologie, Universität Dortmund, Germany.",1994 Jan;68(2):79-84,10.1007/s002040050038
8232598,19930801,article,mesh,"Animals,Antitussive Agents,Bronchial Hyperreactivity,Bronchitis,Bronchoalveolar Lavage Fluid,Disease Models, Animal,Guinea Pigs,Histamine,Leukocytes,Male,Methacholine Chloride,Parainfluenza Virus 3, Human,Paramyxoviridae Infections,Premedication,Propylene Glycols,Specific Pathogen-Free Organisms","administration &amp; dosage,cytology,metabolism,microbiology,pharmacology,prevention &amp; control,therapeutic use","D016535 Q000382 NN,D000996 Q000008 NN,D000996 Q000627 NY,D001992 Q000166 NN,D001991 Q000382 NN,D011409 Q000008 NN,D007962 Q000378 NN,D016210 Q000494 NN,D018184 Q000517 NY,D016535 Q000517 NY,D001991 Q000517 NY,D006632 Q000494 NN,D011409 Q000627 NY","774,1993,3169,5818,6114,65859,120160,25201573",NULL,Virus-induced airway inflammation and hyperresponsiveness in the guinea-pig is inhibited by levodropropizine.,"Intratracheal Parainfluenza type 3 (PI-3) virus inoculation of guinea pigs leads to a non-specific airway hyperresponsiveness in vivo and in vitro which coincides with a significant increase in the number of inflammatory cells in the broncho-alveolar lavage fluid (90% increase, 4 days after inoculation). The activity of the bronchoalveolar cells, as measured by the chemiluminescence production of infected animals is significantly diminished (34.2%, 4 days after inoculation) after renewed stimulation with PI",Naunyn-Schmiedeberg's archives of pharmacology,"G Folkerts, H J van der Linde, C Omini, F P Nijkamp"," Department of Pharmacology, Faculty of Pharmacy, Utrecht University, The Netherlands.",1993 Aug;348(2):213-9,10.1007/bf00164801
8600623,19960127,article,mesh,"Animals,Cell Death,Cells, Cultured,Dogs,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Liver Transplantation,Male,Propylene Glycols,Rats,Sphingosine,Spleen,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,drug effects,pathology,pharmacokinetics,prevention &amp; control","D013154 Q000187 NN,D016923 Q000187 NN,D013110 Q000031 NN,D011409 Q000493 NN,D013154 Q000473 NN,D011409 Q000008 NY,D007166 Q000008 NY,D006084 Q000517 NY","107969,107970,5280335",NULL,"A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation.","A new compound with an immunosuppressive property was purified from culture filtrates of Isaria sinclairii and was chemically modified to FTY720. Rat spleen cells incubated with FTY720 demonstrated features characteristic of apoptosis--such as the absence of surface microvilli, chromatin condensation, and the formation of apoptotic bodies--by electron microscopy, and genemic DNA fragmentation by agarose gel electrophoresis. When FTY720 was administered in liver-allografted rats at a dose of 0.5 mg/kg from d",Transplantation,"S Suzuki, S Enosawa, T Kakefuda, T Shinomiya, M Amari, S Naoe, Y Hoshino, K Chiba"," Department of Experimental Surgery and Bioengineering, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan.",1996 Jan;61(2):200-5,10.1097/00007890-199601270-00006
8623225,19960401,article,mesh,"Animals,Cyclosporine,Drug Synergism,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Interleukin-2,Major Histocompatibility Complex,Male,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Rats, Inbred Strains,Skin Transplantation,Sphingosine,Spleen,T-Lymphocytes,Transplantation, Homologous","analogs &amp; derivatives,biosynthesis,drug effects,immunology,therapeutic use","D007376 Q000096 NN,D016572 Q000627 NY,D013601 Q000276 NN,D016038 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D011409 Q000627 NY,D013601 Q000187 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats.",NULL,Transplantation proceedings,"K Chiba, Y Hoshino, C Suzuki, Y Masubuchi, Y Yanagawa, M Ohtsuki, S Sasaki, T Fujita"," Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd, Saitama, Japan.",1996 Apr;28(2):1056-9,NULL
8623226,19960401,article,mesh,"Animals,Cyclosporine,Dose-Response Relationship, Drug,Drug Synergism,Drug Therapy, Combination,Fingolimod Hydrochloride,Flow Cytometry,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred Strains,Sphingosine,Time Factors,Transplantation, Heterotopic,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D016572 Q000627 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D008214 Q000276 NN,D008214 Q000187 NN,D016027 Q000276 NY,D011409 Q000627 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A.",NULL,Transplantation proceedings,"Y Hoshino, C Suzuki, M Ohtsuki, Y Masubuchi, Y Amano, K Chiba"," Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd, Saitama, Japan.",1996 Apr;28(2):1060-1,NULL
8623227,19960401,article,mesh,"Animals,Blood Urea Nitrogen,Creatinine,Cyclosporine,Dogs,Drug Synergism,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,blood,drug effects,immunology,physiology,therapeutic use","D016030 Q000502 NN,D016572 Q000627 NY,D003404 Q000097 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D016030 Q000276 NY,D011409 Q000627 NY","588,2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.",NULL,Transplantation proceedings,"T Kawaguchi, Y Hoshino, F Rahman, Y Amano, H Higashi, H Kataoka, M Ohtsuki, K Teshima, K Chiba, T Kakefuda, S Suzuki"," Research Laboratories of Yoshitomi Pharmaceutical Industries, Ltd., Saitama, Japan.",1996 Apr;28(2):1062-3,NULL
8658701,19960601,article,mesh,"Animals,Cyclosporine,Dogs,Dose-Response Relationship, Drug,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Liver Transplantation,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D016572 Q000627 NN,D016031 Q000502 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D016027 Q000502 NN,D016027 Q000276 NY,D011409 Q000627 NY,D016031 Q000276 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720.",NULL,Transplantation proceedings,"S Suzuki, S Enosawa, T Kakefuda, H Amemiya, Y Hoshino, K Chiba"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1996 Jun;28(3):1375-6,NULL
8685935,19960701,article,"xref,mesh","Animals,Anticonvulsants,Apoptosis,Brain Ischemia,Cell Death,Cell Nucleus,Cell Survival,Cytoplasm,Disease Models, Animal,Gerbillinae,Glycine,Hippocampus,Injections, Intravenous,Neurons,Neuroprotective Agents,Phenylcarbamates,Propylene Glycols,Receptors, N-Methyl-D-Aspartate","administration &amp; dosage,drug effects,metabolism,pathology,prevention &amp; control,therapeutic use,ultrastructure","D009474 Q000187 NY,D017209 Q000187 NY,D018696 Q000008 NN,D002467 Q000648 NN,D000927 Q000627 NN,D011409 Q000008 NN,D006624 Q000187 NY,D000927 Q000008 NN,D002545 Q000517 NY,D016194 Q000378 NN,D005998 Q000378 NN,D003593 Q000648 NN,D011409 Q000627 NY,D018696 Q000627 NY,D002545 Q000473 NN","750,3331,22316,161644,3018095,4684308,9813116","87350372,376229544",Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia.,"BACKGROUND AND PURPOSE: Felbamate, a novel anticonvulsant that binds to the glycine site of the N-methyl-D-aspartate receptor, has been shown to have neuroprotective properties in vitro and in vivo. In a rat pup model of hypoxia-ischemia, felbamate selectively reduced delayed death in hippocampal granule cells. The present study explores its neuroprotective potential in a gerbil model of global ischemia, in which good evidence exists that ischemia triggers apoptosis of CA1. METHODS: Gerbils were subjected t",Stroke,"C G Wasterlain, L M Adams, J K Wichmann, R D Sofia"," Department of Neurology, VA Medical Center at Sepulveda, California 91343-2099, USA.",1996 Jul;27(7):1236-40,10.1161/01.str.27.7.1236
8730239,19960401,review,mesh,"Acute-Phase Proteins,Colitis, Ulcerative,Crohn Disease,Humans,Indium Radioisotopes,Leukocytes,Organotechnetium Compounds,Oximes,Severity of Illness Index,Technetium Tc 99m Exametazime,Tomography, Emission-Computed, Single-Photon","analysis,diagnostic imaging,methods,physiopathology","D003093 Q000503 NN,D000209 Q000032 NN,D007962 Q000000981 NY,D003424 Q000503 NN,D003424 Q000000981 NY,D015899 Q000379 NY,D003093 Q000000981 NY","450484,56841051,129626367",NULL,Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy.,"Inflammatory bowel disease (IBD) symptoms may be due not only to the effects of bowel inflammation, but also can result from many non-inflammatory consequences of the disease. Clinical scores and health questionnaire ratings produce a global assessment which is useful in the overall evaluation of the impact of the illness on the patient, and the effect of treatment. However many studies have failed to recognize the need to separately assess changes in the degree of bowel inflammation, in addition to a globa",Alimentary pharmacology & therapeutics,"M J Weldon, C Lowe, A E Joseph, J D Maxwell"," Department of Cellular and Molecular Sciences, St George's Hospital and Medical School, London, UK.",1996 Apr;10(2):123-32,10.1046/j.1365-2036.1996.728120000.x
8741290,19960601,review,mesh,"Animals,Apoptosis,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Immunosuppressive Agents,Propylene Glycols,Signal Transduction,Sphingosine","metabolism,physiology","D013110 Q000502 NY,D013110 Q000378 NN","107969,107970,5280335,6438394",NULL,"[""Sphingosine pathway"": a novel apoptosis inducing pathway].",NULL,Seikagaku. The Journal of Japanese Biochemical Society,"Y Kozutsumi, S Nakamura, T Kawasaki"," Department of Biological Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University.",1996 Jun;68(6):444-52,NULL
8769151,19960801,article,mesh,"Animals,Apoptosis,Cell Line,Creatinine,Cyclosporine,Dogs,Fingolimod Hydrochloride,Graft Survival,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocytes,Lymphoma,Male,Mice,Mice, Mutant Strains,Neoplasm Transplantation,Propylene Glycols,Sphingosine,Time Factors,Transplantation, Homologous,Tumor Cells, Cultured","analogs &amp; derivatives,blood,drug effects,immunology,pharmacology,physiology,toxicity","D006085 Q000187 NN,D008214 Q000276 NY,D007166 Q000494 NY,D016030 Q000502 NN,D017209 Q000187 NY,D003404 Q000097 NN,D006085 Q000276 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000633 NN,D016572 Q000494 NN,D014184 Q000276 NN,D016030 Q000276 NY,D008214 Q000187 NN,D011409 Q000633 NN","588,2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720.,NULL,Transplantation proceedings,"S Suzuki, X K Li, T Shinomiya, S Enosawa, T Kakefuda, M Mitsusada, H Amemiya, S Takahara, M Amari, S Naoe, Y Hoshino, K Chiba"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1996 Aug;28(4):2049-50,NULL
8821739,19951224,article,"xref,mesh","Animals,Anticonvulsants,Binding Sites,Calcium,Cell Death,Cells, Cultured,Cerebral Cortex,Excitatory Amino Acid Agonists,Excitatory Amino Acid Antagonists,Glycine,Kainic Acid,Kynurenic Acid,N-Methylaspartate,Neurons,Neuroprotective Agents,Neurotoxins,Phenylcarbamates,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, N-Methyl-D-Aspartate,Strychnine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,metabolism,pharmacology,physiology","D016202 Q000494 NN,D009474 Q000187 NY,D018691 Q000494 NN,D001665 Q000502 NN,D018690 Q000494 NN,D007736 Q000031 NN,D013331 Q000378 NN,D009474 Q000166 NN,D016923 Q000187 NN,D016194 Q000819 NN,D011409 Q000494 NY,D018696 Q000494 NY,D002478 Q000187 NN,D016194 Q000037 NN,D007608 Q000494 NN,D009498 Q000494 NN,D000927 Q000494 NY,D002118 Q000378 NN,D002540 Q000166 NY,D007736 Q000494 NN,D005998 Q000037 NN","750,1779,3331,3845,10255,22316,22880,161644,441071,3018095,4684308,5460341,6337033,9813116,23616203","53789803,87350372,376229544",Excitoprotective effect of felbamate in cultured cortical neurons.,"The effect of felbamate on excitatory amino acid-induced biochemical changes was investigated in cultured cortical neurons. Felbamate inhibited NMDA- and glutamate-induced neuronal injury in a dose-dependent manner, but it did not rescue cells from kainate-induced neurotoxicity. The neuroprotective effect was accompanied by a decrease in NMDA- and glutamate-induced neuronal calcium (Ca2+) influx. Exogenous addition of glycine failed to modulate the effect of felbamate on NMDA-induced neurotoxicity or Ca2+ i",Brain research,"A G Kanthasamy, R R Matsumoto, P G Gunasekar, D D Trunong"," Department of Neurology, University of California Irvine 92717, USA.",1995 Dec;705(?):97-104,10.1016/0006-8993(95)01147-1
8886861,19960901,article,mesh,"Animals,Apoptosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Subsets,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,pharmacology,physiology","D016131 Q000187 NN,D007166 Q000494 NY,D017209 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D013601 Q000187 NY,D013601 Q000502 NN","107969,107970,5280335",NULL,"Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720.","A novel immunosuppressant, FTY720, induces a rapid and marked decrease of peripheral lymphocytes, and prolong allograft survival in rats. Its mechanism of action is mediated by apoptotic cell death. In this study, we determined the time-related changes in the numbers of total lymphocytes, and the ratios of lymphocyte subpopulations in peripheral blood and lymphomyeloid organs in rats after the single oral administration of FTY720 (10 mg/kg), comparing with the effects of cyclophosphamide (80 mg/kg, ip). Tot",Immunopharmacology,"S Enosawa, S Suzuki, T Kakefuda, X K Li, H Amemiya"," Department of Experimental Surgery and Bioengineering, National Children's medical Research Center, Tokyo, Japan.",1996 Sep;34(?):171-9,10.1016/0162-3109(96)00132-4
8893458,19960901,article,mesh,"Animals,Dose-Response Relationship, Immunologic,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Lymphocyte Activation,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology","D006085 Q000187 NN,D008214 Q000276 NY,D007166 Q000494 NY,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D008213 Q000187 NN,D014184 Q000276 NN,D016027 Q000276 NY","107969,107970,5280335",NULL,"Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats.",NULL,Transplant immunology,"S Suzuki, S Enosawa, T Kakefuda, X K Li, M Mitsusada, S Takahara, H Amemiya"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1996 Sep;4(3):252-5,10.1016/s0966-3274(96)80026-8
8893839,19961025,article,"mesh,assay","Acyltransferases,Alkylation,Animals,Ascomycota,Eicosanoic Acids,Fatty Acids, Monounsaturated,Fatty Acids, Unsaturated,Immunosuppressive Agents,Interleukin-2,Mice,Propylene Glycols,Rats,Serine C-Palmitoyltransferase,Skin,Spleen","biosynthesis,chemical synthesis,chemistry,drug effects,metabolism","D011409 Q000737 NY,D005229 Q000737 NY,D005231 Q000737 NN,D007376 Q000096 NN,D013154 Q000187 NN,D004537 Q000737 NN,D000217 Q000378 NN,D007166 Q000138 NY,D012867 Q000187 NN","130997,162274,5284373,6438394,6439267,6439504,6441222,9860720,10045763,10266875,10476304,10499723,10539234,10571288,10572438,10633304,10643106,10663185,10666807,10712432,10715135,10761630,10810970,10834317,10845836,10849886,71340608",NULL,"Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.","Several immunosuppressants, ISP-I [(2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoeicos++ +-6-enoic acid, myriocin = thermozymocidin] and mycestericins A-G, were isolated from culture broths of Isaria sinclairii and Mycelia sterilia, respectively. In order to investigate structure-activity relationships, extensive modifications of ISP-I were conducted, and it was established that the fundamental structure possessing the immunosuppressive activity is a symmetrical 2-alkyl-2-aminopropane-1,3-dio",Journal of medicinal chemistry,"T Fujita, R Hirose, M Yoneta, S Sasaki, K Inoue, M Kiuchi, S Hirase, K Chiba, H Sakamoto, M Arita"," Faculty of Pharmaceutical Sciences, Kyoto University, Japan.",1996 Oct;39(22):4451-9,10.1021/jm960391l
8919045,19960901,article,mesh,"Animals,Chemexfoliation,Collagen,Female,Fluorescent Antibody Technique, Indirect,Immunochemistry,Irritants,Mice,Mice, Hairless,Regeneration,Skin Aging,Sodium Dodecyl Sulfate,Stimulation, Chemical,Tretinoin,Ultraviolet Rays","biosynthesis,drug effects,methods,pharmacology,physiology","D012967 Q000494 NN,D015595 Q000502 NY,D002615 Q000379 NY,D012038 Q000187 NN,D003094 Q000096 NY,D014212 Q000494 NY,D007509 Q000494 NY","444795,3423265,6419707,21909502",NULL,"Peeling agents and irritants, unlike tretinoin, do not stimulate collagen synthesis in the photoaged hairless mouse.","Tretinoin has been shown to stimulate the synthesis of collagen in photo-aged human and hairless mouse skin. It has been suggested that this partial reversal of photodamage by tretinoin is a consequence of low-grade inflammation. The purpose of this study was to compare the effect of tretinoin with a number of irritants and peeling agents on collagen synthesis. Hairless mice were irradiated thrice weekly for 10 weeks with UVB. In the 10-week postirradiation period, the mice were treated topically five times",Archives of dermatological research,"L H Kligman, A N Sapadin, E Schwartz"," University of Pennsylvania, School of Medicine, Department of Dermatology, Philadelphia 19104, USA.",1996 Sep;288(10):615-20,10.1007/bf02505265|10.1007/s004030050112
8943268,19961213,article,mesh,"DNA Repair,DNA-(Apurinic or Apyrimidinic Site) Lyase,Deoxyribonuclease (Pyrimidine Dimer),Deoxyribonuclease IV (Phage T4-Induced),Endodeoxyribonucleases,Furans,Kinetics,Lyases,Mutagenesis,Propylene Glycols,Protein Conformation,Pyrrolidines,Structure-Activity Relationship,Viral Proteins","antagonists &amp; inhibitors,chemistry,genetics,metabolism","D011759 Q000378 NN,D008190 Q000037 NN,D005663 Q000378 NN,D004706 Q000235 NN,D011409 Q000378 NN,D004706 Q000737 NY","8028,31268,212848",NULL,Structural determinants for specific recognition by T4 endonuclease V.,"DNA glycosylases catalyze the scission of the N-glycosyl bond linking either a damaged or mismatched base to the DNA sugar phosphate backbone. T4 endonuclease V is a glycosylase/apurinic (AP) lyase that is specific for UV light-induced cis-syn pyrimidine dimers. As a proposed transition state analog/inhibitor for glycosylases, a phosphoramidite derivative containing a pyrrolidine residue has been synthesized. The binding of endonuclease V to this duplex was analyzed by gel mobility shift assays and resulted",The Journal of biological chemistry,"A K McCullough, O Schärer, G L Verdine, R S Lloyd"," Sealy Center for Molecular Science and Department of Human Biological Chemistry & Genetics, University of Texas Medical Branch, Galveston, Texas 77555-1071, USA.",1996 Dec;271(50):32147-52,10.1074/jbc.271.50.32147
8968330,19961201,article,"xref,mesh","Animals,Electric Stimulation,Evoked Potentials,Hippocampus,In Vitro Techniques,Kainic Acid,Male,Phenylcarbamates,Propylene Glycols,Rats,Rats, Wistar,Receptors, N-Methyl-D-Aspartate,Synaptic Transmission,alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","drug effects,pharmacology,physiology","D009435 Q000187 NY,D005071 Q000187 NN,D006624 Q000502 NN,D018350 Q000494 NN,D006624 Q000187 NY,D011409 Q000494 NY,D016194 Q000187 NN,D007608 Q000494 NN","1221,3331,10255","87350372,376229544",Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices.,"The antiepileptic drug felbamate (FBM) is known to block N-methyl-D-aspartate receptor-mediated responses and to decrease voltage-sensitive Na+ and Ca+2 channels. The present work was aimed at investigating the actions of FBM on synaptic potentials in the hippocampus, a region frequently involved in epileptic discharges. In rat hippocampal slices, application of FBM (100-1300 microM, 10 min) elicited a concentration-dependent, fully reversible decrease in amplitude of electrically evoked population spikes r",The Journal of pharmacology and experimental therapeutics,"A M Pugliese, M B Passani, G Pepeu, R Corradetti"," Dipartimento di Farmacologia Preclinica e Clinica Mario Aiazzi-Mancini, Università di Firenze, Italy.",1996 Dec;279(3):1100-8,NULL
9010264,19970101,article,mesh,"Administration, Oral,Animals,Antibodies, Monoclonal,Apoptosis,CD3 Complex,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Leukocyte Common Antigens,Male,Mice,Mice, Inbred MRL lpr,Propylene Glycols,Sphingosine,T-Lymphocytes,Thymus Gland,fas Receptor","administration &amp; dosage,analogs &amp; derivatives,analysis,drug effects,immunology,pharmacology,ultrastructure","D007166 Q000494 NY,D017209 Q000187 NY,D013950 Q000187 NN,D011409 Q000008 NN,D011409 Q000494 NY,D017252 Q000032 NN,D013110 Q000031 NN,D013601 Q000648 NN,D013601 Q000187 NY,D000911 Q000494 NN,D019014 Q000276 NN,D017493 Q000032 NN","107969,107970,5280335",NULL,The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720.,"The in vitro treatment of lpr thymocytes with FTY720 resulted in a dose-dependent reduction in cell viability due to apoptosis. In order to study the effect of FTY720 in vivo, lpr mice received an oral daily dose of 1 mg/kg FTY720 for 14 days, beginning at 16 weeks of age which was when the animals were developing massive lymphoadenopathy. Compared with untreated lpr mice, FTY720-treated lpr mice had significantly prolonged lives. At 24 weeks of age, treated mice demonstrated markedly reduced weights of the",Clinical and experimental immunology,"S Suzuki, X K Li, T Shinomiya, S Enosawa, H Amemiya, M Amari, S Naoe"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1997 Jan;107(1):103-11,10.1046/j.1365-2249.1997.d01-885.x
9014815,19961201,article,mesh,"Apoptosis,Fingolimod Hydrochloride,Gene Expression,Genes, bcl-2,Humans,Immunosuppressive Agents,Intracellular Fluid,Jurkat Cells,Leukocytes, Mononuclear,Propylene Glycols,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-bcl-2,Sphingosine,Transfection,bcl-2-Associated X Protein","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology,physiology","D007166 Q000494 NY,D007424 Q000378 NN,D017209 Q000187 NY,D011518 Q000378 NN,D017209 Q000235 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007963 Q000187 NN,D007963 Q000502 NY","107969,107970,5280335",NULL,"A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes.",FTY720 is a unique immunosuppressive drug produced by modification of a metabolite from Isaria sinclairii. In vitro treatment of human mononuclear cells with FTY720 resulted in a dose-dependent reduction of cell viability. These treated cells demonstrated characteristic DNA ladder formation on agarose gel electrophoresis. Jurkat cells transfected with human bcl-2 gene were resistant to FTY720; their neo type was susceptible to the drug. A rapid acceleration of cell death in human mononuclear cells was seen ,Immunology,"S Suzuki, X K Li, S Enosawa, T Shinomiya"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Centre, Tokyo, Japan.",1996 Dec;89(4):518-23,10.1046/j.1365-2567.1996.d01-777.x
9084702,19970101,article,mesh,"Adolescent,Adult,Brain Neoplasms,Child,Child, Preschool,Diatrizoate,Drug Combinations,Facial Neoplasms,Fatty Acids,Female,Humans,Inflammation,Injections, Subcutaneous,Lymphangioma, Cystic,Male,Neck,Propylene Glycols,Prospective Studies,Sclerosing Solutions,Zein","administration &amp; dosage,adverse effects,chemically induced,drug therapy,pathology,therapeutic use","D011409 Q000009 NN,D018191 Q000473 NN,D009333 Q000473 YN,D012597 Q000627 NN,D005153 Q000188 NY,D005227 Q000009 NN,D015028 Q000627 NN,D012597 Q000009 NN,D007249 Q000139 NN,D001932 Q000188 NY,D015028 Q000009 NN,D003973 Q000009 NN,D015028 Q000008 NY,D005227 Q000627 NN,D005227 Q000008 NY,D012597 Q000008 NY,D003973 Q000008 NY,D003973 Q000627 NN,D011409 Q000627 NN,D018191 Q000188 NY,D011409 Q000008 NY",NULL,NULL,[Evaluation of the treatment of cystic lymphangioma by percutaneous injection of Ethibloc in 20 patients].,"BACKGROUND: Surgical treatment of cystic lymphangioma (CL) is so often followed by local and general complications that non invasive treatment must be considered. POPULATION AND METHODS: Between 1987 and 1993, 20 patients with a superficial macrocystic lymphangioma were treated by percutaneous injection of Ethibloc in order to reduce the volume of the CL, with a minimum follow-up of 1 year. Fourteen CL were cervico-facial and six were located in the upper half of the body. The size of the lesion was determi",Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,"V Martinot, S Descamps, P Février, P Patenotre, J M Brevière, F Piette, P Pellerin"," Service de chirurgie plastique, hôpital Roger-Salengro, Lille, France.",1997 Jan;4(1):8-14,10.1016/s0929-693x(97)84296-0
9114984,19970401,article,mesh,"Acetylcysteine,Adult,Animals,Anticonvulsants,Humans,Magnetic Resonance Spectroscopy,Male,Mass Spectrometry,Phenylcarbamates,Propylene Glycols,Rats,Rats, Sprague-Dawley","pharmacokinetics,urine","D011409 Q000493 NY,D000927 Q000493 NY,D000111 Q000652 NY","3331,12035,12114682,23678798",NULL,Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration.,"3-Carbamoyl-2-phenylpropionaldehyde has recently been proposed [Thompson et al. (1996) Chem. Res. Toxicol. 9, 1225-1229] as a potential reactive metabolite of the anti-epileptic drug felbamate. This aldehyde was found to undergo rapid elimination to generate 2-phenylpropenal and reversible cyclization to generate 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one at physiological pH. 2-Phenylpropenal, an alpha,beta-unsaturated aldehyde commonly termed atropaldehyde, is a potent electrophile and undergoes rapid c",Chemical research in toxicology,"C D Thompson, P H Gulden, T L Macdonald"," Chemistry Department, University of Virginia, Charlottesville 22901, USA.",1997 Apr;10(4):457-62,10.1021/tx960205e
9123298,19970101,article,mesh,"Cells, Cultured,E-Selectin,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Propylene Glycols,Sphingosine,Tumor Necrosis Factor-alpha,Umbilical Veins,Vascular Cell Adhesion Molecule-1","analogs &amp; derivatives,biosynthesis,drug effects,pharmacology,physiology","D019010 Q000096 NN,D007166 Q000494 NY,D019040 Q000096 NN,D014409 Q000494 NY,D004730 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D004730 Q000502 NY,D018799 Q000096 NY","107969,107970,5280335",NULL,"FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecular ICAM-1 in TNF-alpha treated human umbilical vein endothelial cells.",NULL,Transplantation proceedings,"X K Li, S Enosawa, T Kakefuda, H Amemiya, S Suzuki"," Department of Experimental Surgery & Bioengineering, National Children Medical Research Center, Tokyo, Japan.",1997 Jan;29(?):1265-6,10.1016/s0041-1345(96)00491-5
9123299,19970101,article,mesh,"Administration, Oral,Animals,Apoptosis,Cells, Cultured,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Jurkat Cells,Kinetics,Lymphocytes,Male,Mice,Mice, Inbred Strains,Mice, Mutant Strains,Propylene Glycols,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-bcl-2,Sphingosine,T-Lymphocytes,bcl-2-Associated X Protein,fas Receptor","administration &amp; dosage,analogs &amp; derivatives,biosynthesis,cytology,drug effects,pharmacology,physiology","D007166 Q000494 NY,D007166 Q000008 NN,D017209 Q000187 NY,D011409 Q000008 NN,D011409 Q000494 NY,D019253 Q000096 NY,D013110 Q000031 NN,D019014 Q000096 NY,D008214 Q000502 NY,D013601 Q000166 NN,D011518 Q000096 NY,D008214 Q000166 NN,D013601 Q000502 NN,D008214 Q000187 NN,D013601 Q000187 NN","107969,107970,5280335",NULL,"Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with Fas, Bcl-2 and Bax expression.",NULL,Transplantation proceedings,"X K Li, T Shinomiya, S Enosawa, T Kakefuda, H Amemiya, S Suzuki"," Department of Experimental Surgery & Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1997 Jan;29(?):1267-8,10.1016/s0041-1345(96)00490-3
9142166,19970101,article,mesh,"Acrylates,Administration, Topical,Animals,DNA Damage,Erythrocytes, Abnormal,Female,Mice,Mice, Transgenic,Micronucleus Tests,Propylene Glycols","administration &amp; dosage,toxicity","D011409 Q000633 NY,D011409 Q000008 NN,D000179 Q000008 NN,D000179 Q000633 NY","8821,4128060",NULL,Absence of systemic in vivo genotoxicity after dermal exposure to ethyl acrylate and tripropylene glycol diacrylate in Tg.AC (v-Ha-ras) mice.,"Acrylates may be polymerized to stable surface coatings (paints, lacquers, inks, etc.) by alkylation via the Michaelis-type addition reaction. Thus, acrylates have an inherent potential as electrophiles to be genotoxic, limited in their biological activity by their physicochemical properties. To evaluate their systemic genotoxicity, ethyl acrylate (EA), tripropylene glycol diacrylate (TPGDA), or Lacquer A, an ultraviolet radiation curable lacquer containing TPGDA as the active ingredient, were applied derma",Environmental and molecular mutagenesis,"R R Tice, L A Nylander-French, J E French"," Integrated Laboratory Systems, Research Triangle Park, NC 27709, USA. tice@niehs.nih.gov",1997 Jan;29(3):240-9,10.1002/(sici)1098-2280(1997)29:3&lt;240::aid-em3&gt;3.0.co;2-g|10.1002/(sici)1098-2280(1997)29:3&lt;240::aid-em3&gt;3.3.co;2-#
9154878,19970501,article,mesh,"Acute Disease,Administration, Inhalation,Adult,Aerosols,Bronchoalveolar Lavage Fluid,Cyclosporine,Dose-Response Relationship, Drug,Female,Forced Expiratory Flow Rates,Forced Expiratory Volume,Graft Rejection,Humans,Immunosuppressive Agents,Interleukin-6,Lung,Lung Transplantation,Male,Middle Aged,RNA, Messenger,Vital Capacity","administration &amp; dosage,adverse effects,analysis,chemistry,drug therapy,genetics,pathology","D007166 Q000032 NN,D012333 Q000032 NN,D006084 Q000188 NY,D016572 Q000032 NN,D008168 Q000473 NN,D008168 Q000737 NN,D016572 Q000009 NN,D001992 Q000737 NN,D015850 Q000235 NN,D006084 Q000473 NN,D016572 Q000008 NY,D007166 Q000009 NN,D007166 Q000008 NY","2909,62280,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Dose-related reversal of acute lung rejection by aerosolized cyclosporine.,"This study evaluated the effectiveness of aerosolized cyclosporine as rescue therapy for refractory acute rejection in lung-transplant patients that is unresponsive to conventional therapy. Over 2 yr, nine allograft recipients with histologic evidence of persistent acute rejection and worsening pulmonary function were enrolled. Twenty-two patients with similar degrees of unremitting rejection served as historical controls. Aerosolization of cyclosporin A (300 mg in 4.8 ml propylene glycol) using an AeroTech",American journal of respiratory and critical care medicine,"A T Iacono, G C Smaldone, R J Keenan, P Diot, J H Dauber, A Zeevi, G J Burckart, B P Griffith"," Department of Medicine, University of Pittsburgh, Pennsylvania, USA.",1997 May;155(5):1690-8,10.1164/ajrccm.155.5.9154878
9287398,19970101,article,mesh,"Animals,Cyclosporine,Fingolimod Hydrochloride,Graft Rejection,Graft vs Host Reaction,Immunosuppressive Agents,Intestine, Small,Lymphocyte Count,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine","analogs &amp; derivatives,drug effects,prevention &amp; control,therapeutic use,transplantation","D016572 Q000627 NN,D013110 Q000031 NN,D007421 Q000637 NY,D007166 Q000627 NY,D006087 Q000187 NY,D011409 Q000627 NY,D018655 Q000187 NN,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation.","In the present study, we examined the immunosuppressive effect of a new drug, FTY720, on small bowel transplantation (SBT) in rats. Grafts from (LEW x BN) F1-to-LEW rats treated with FTY720 at 0.5 mg/kg from day 0 to 14 post-SBT survived significantly longer than untreated grafts. In addition, the administration of FTY720 combined with cyclosporin (CyA; 5 mg/kg per day) had a synergistic effect on allograft survival. The graft-versus-host reaction (GVHR) that occurred in the LEW-to-F1 rats was markedly redu",Transplant international : official journal of the European Society for Organ Transplantation,"M Mitsusada, S Suzuki, E Kobayashi, S Enosawa, T Kakefuda, M Miyata"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1997 Jan;10(5):343-9,10.1007/s001470050068|10.1111/j.1432-2277.1997.tb00927.x
9358414,19970101,article,mesh,"Animals,Cerumen,Dioctyl Sulfosuccinic Acid,Dog Diseases,Dogs,Drug Combinations,Drug Therapy, Combination,Ear, Middle,Ethanolamines,Evoked Potentials, Auditory, Brain Stem,Female,Glycerol,Guinea Pigs,Hearing Loss, Conductive,Injections,Male,Otitis Media,Peroxides,Propylene Glycol,Random Allocation,Squalene,Surface-Active Agents,Urea,Vestibulocochlear Nerve","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,methods,pathology,physiology,physiopathology,therapeutic use,veterinary","D014508 Q000008 NN,D010545 Q000009 NN,D013185 Q000009 NN,D004283 Q000139 NN,D004432 Q000503 NN,D014508 Q000031 NN,D000159 Q000502 NN,D005990 Q000627 NN,D010033 Q000662 NY,D002571 Q000502 NN,D005990 Q000009 NN,D004143 Q000627 NN,D013501 Q000009 NY,D006314 Q000503 NN,D013501 Q000008 NN,D010545 Q000008 NN,D004983 Q000009 NN,D013185 Q000008 NN,D002571 Q000187 NY,D014508 Q000009 NN,D019946 Q000627 NN,D004283 Q000503 NN,D019946 Q000008 NN,D005990 Q000008 NN,D013501 Q000627 NN,D014508 Q000627 NN,D006314 Q000662 NN","753,1030,1176,11339,15426,31294,31407,517065,638072,21867904,21924627,23673837,23675755,53249634,87085892",NULL,"The effects of four, commercial ceruminolytic agents on the middle ear.","Four, commercially available ceruminolytic agents and physiological saline were screened for ototoxic and inflammatory reactions on the middle ear mucosae of guinea pigs (n = 38) and dogs (n = 24). Each solution was injected transtympanically in anesthetized animals. The effects were assessed by brain stem auditory evoked response (BAER) tests to evaluate hearing function and by histological examination of the middle ear structures. Varying degrees of hearing loss and inflammation were observed in some guin",Journal of the American Animal Hospital Association,"P D Mansfield, J E Steiss, T R Boosinger, A E Marshall"," Department of Small Animal Surgery, College of Veterinary Medicine, Auburn University, Alabama 36849-5523, USA.",1997 Jan;33(6):479-86,10.5326/15473317-33-6-479
9365631,19971101,article,mesh,"Abdomen,Animals,Drug Administration Schedule,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Intraoperative Period,Kidney Function Tests,Liver Function Tests,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Regression Analysis,Sphingosine,Tacrolimus,Transplantation, Heterotopic,Transplantation, Homologous,Weight Gain","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,therapeutic use","D007166 Q000008 NN,D015430 Q000187 NN,D016559 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D016027 Q000276 NY,D011409 Q000627 NY,D016559 Q000627 NY","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation.,NULL,Transplantation proceedings,"M Xu, E A Antoniou, S C Afford, S Suzuki, J Pirenne, P McMaster, M D'Silva"," Liver & Hepatobiliary Unit, Queen Elizabeth Hospital and Medical Center, Birmingham, United Kingdom.",1997 Nov;29(7):2964-6,10.1016/s0041-1345(97)00747-1
9378500,19970801,article,mesh,"Apoptosis,Calcium,DNA Fragmentation,Estrenes,Fingolimod Hydrochloride,HL-60 Cells,Humans,Immunosuppressive Agents,Lymphocytes,Pertussis Toxin,Phosphodiesterase Inhibitors,Propylene Glycols,Pyrrolidinones,Sphingosine,Type C Phospholipases,Virulence Factors, Bordetella","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,physiology","D007166 Q000494 NY,D002118 Q000378 NY,D010738 Q000502 NN,D017209 Q000187 NY,D011760 Q000494 NN,D010726 Q000494 NN,D004963 Q000494 NN,D008214 Q000378 NN,D053938 Q000187 NN,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D010566 Q000494 NN,D008214 Q000276 NN","5631,104794,107969,107970,5280335,5460341,6337033,11957723,21117951",NULL,"An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60.","We previously reported that FTY720 is an efficient inducer of apoptosis in lymphocytes and cultured cell lines. In the present study, HL-60 human promyerocytoma cells also induced apoptosis through in vitro treatment with the drug, demonstrating extensive DNA fragmentation 6 hr after incubation. The major target of FTY720 was the common signalling pathway of apoptosis, since a rapid (< 1 min) increase in the intracellular Ca2+ concentration ([Ca2+]i) was found in the cells treated with the drug. Calcium che",Immunology,"T Shinomiya, X K Li, H Amemiya, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Centre, Tokyo, Japan.",1997 Aug;91(4):594-600,10.1046/j.1365-2567.1997.d01-2281.x
9381559,19970101,article,mesh,"Cell Survival,Cells, Cultured,Cockayne Syndrome,DNA Damage,DNA Repair,Dose-Response Relationship, Drug,Dose-Response Relationship, Radiation,Epoxy Compounds,Fibroblasts,Gamma Rays,Humans,Mutagens,Time Factors,Xeroderma Pigmentosum","drug effects,metabolism,pathology,pharmacology,radiation effects","D014983 Q000473 NY,D004260 Q000528 NY,D005347 Q000528 NN,D003057 Q000378 NY,D002470 Q000187 NN,D005347 Q000378 NN,D002470 Q000528 NN,D003057 Q000473 NY,D004852 Q000494 NN,D004260 Q000187 NY,D005347 Q000187 NN,D014983 Q000378 NY,D009153 Q000494 NY",NULL,NULL,[Decreased survivability and a DNA repair defect in the cells of patients with xeroderma pigmentosum and Cockayne syndrome under the action of radiation and chemical mutagens].,"The action of ionizing radiation and chemical mutagens--epoxides (ethylene oxide, propylene oxide, epichlorohydrin)--upon survival and repair processes in xeroderma pigmentosum (XP2SP) and Cockayne syndrome (CS1SP) patients' cells was studied, compared to healthy donor's cells VH-10 and C5RO. Ionizing radiation was demonstrated to enhance significantly higher survival decrease of XP2SP and CS1SP fibroblasts, compared to healthy donor's cells, according to the cloning efficiency criterion. In contrast to thi",Tsitologiia,"I M Spivak, N M Pleskach, V M Mikhel'son, D Bootsma, A Kolman",NULL,1997 Jan;39(6):420-34,NULL
9385384,19971031,article,xref,"Adenoma,Administration, Inhalation,Animals,Carcinogenicity Tests,Carcinogens,Databases, Factual,Female,Government Programs,Inflammation,Male,Mice,Nasal Cavity,Neuroblastoma,Nose Diseases,Nose Neoplasms,Rats","chemically induced,drug effects,toxicity","D000236 Q000139 NY,D009296 Q000187 NY,D007249 Q000139 NN,D002273 Q000633 NY,D009668 Q000139 NN,D009669 Q000139 NY,D009447 Q000139 NY","4915,6378,6896,7280,7281,7834,7839,8445,10555,21852,31275","53788566,53788677,53789496,53789721,53789864,53789891,53790978,56459442,57309828,92729745,121147436",An update of the National Toxicology Program database on nasal carcinogens.,"Nearly 500 long-term rodent carcinogenicity studies carried out by the National Cancer Institute and the National Toxicology Program were examined, and 12 chemicals were identified that produced nasal tumors: allyl glycidol ether, p-cresidine, 1,2-dibromo-3-chloropropane, 1,2-dibromoethane, 2,3-dibromo-1-propanol, dimethylvinyl chloride, 1,4-dioxane, 1,2-epoxybutane, iodinated glycerol, procarbazine, propylene oxide, and 2,6-xylidine. All 12 of these chemicals produced nasal tumors in rats, and 5 also produ",Mutation research,"J K Haseman, J R Hailey"," Statistics and Biomathematics Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. haseman@fred.niehs.nih.goo",1997 Oct;380(?):3-11,10.1016/s0027-5107(97)00121-8
9392303,19971127,article,mesh,"Animals,Epitopes,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Histocompatibility Antigens Class I,Immune Tolerance,Immunization, Passive,Immunosuppressive Agents,Interleukin-2,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred BN,Rats, Inbred WF,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D015395 Q000627 NY,D007108 Q000187 NN,D015395 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D014184 Q000276 NN,D006084 Q000517 NN,D016027 Q000276 NY,D011409 Q000627 NY,D007376 Q000494 NN","107969,107970,5280335",NULL,Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720.,"BACKGROUND: The combination of FTY 720, a novel immunosuppressant, and allochimeric class I MHC proteins bearing donor-type amino acid (aa) epitope substitutions for host-type sequences induces tolerance of Wistar Furth (WF; RT1.Au) heart allografts in ACI (RT1.Aa) recipients. METHODS: Allochimeric alpha(1h)l58-80-RT1.Aa proteins were produced by substituting the allogeneic nucleotide sequence encoding 10 aa residues unique to the alpha1 helical (alpha1h) region of RT1.Al Lewis (Asp58, Arg62, Glu63, Gln65, ",Transplantation,"S C Chueh, L Tian, M Wang, M E Wang, S M Stepkowski, B D Kahan"," Department of Surgery, The University of Texas Medical School at Houston, 77030, USA.",1997 Nov;64(10):1407-14,10.1097/00007890-199711270-00006
9495465,19980201,article,mesh,"Animals,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Survival,Hindlimb,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,pharmacology,transplantation","D007166 Q000494 NY,D006614 Q000637 NY,D011409 Q000494 NY,D013110 Q000031 NN,D006085 Q000187 NY","107969,107970,5280335",NULL,"A new immunosuppressant, FTY720, prolongs limb allograft survival in rats.","A new immunosuppressant, FTY720, was applied to limb allotransplants and its effectiveness was investigated. Using inbred rats, for which the major histocompatibility complexes were completely mismatched, 31 limb transplantations were performed and FTY720 was administered at a dose of 1.5 or 3 mg per kilogram per day for 10 days postoperatively. Rejection was monitored by the appearance of the skin of the grafted hind limb, soft radiograph, microangiography, and histology. In animals receiving no immunosupp",Annals of plastic surgery,"K Muramatsu, K Doi, M Shigetomi, K Kido, S Kawai"," Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Ube, Japan.",1998 Feb;40(2):160-5,NULL
9547869,19980101,article,mesh,"Animals,Female,Granuloma,Hazardous Substances,Male,Mouth Neoplasms,Oropharynx,Pharyngitis,Rats,Rats, Inbred F344,Sex Factors","chemically induced,drug effects,genetics,pathology,toxicity","D010612 Q000139 NN,D010612 Q000235 NY,D011916 Q000235 NY,D009960 Q000187 NN,D009960 Q000473 NY,D015386 Q000633 NN,D010612 Q000473 NN,D009062 Q000235 NN,D006099 Q000473 NN",NULL,NULL,Pathology of the oropharyngeal cavity in six strains of rats: predisposition of Fischer 344 rats for inflammatory and degenerative changes.,"The sagittolongitudinal histopathological evaluation of the oropharyngeal cavity in 6 strains of rats revealed a clear predisposition of the Fischer 344 strain for degenerative and inflammatory lesions in this region. A degeneration and calcification predominantly of the laryngeal cartilage is evident in 72%, granulomas of the seromucinous glands in 38%, and an inflammation with bacterial colonies or plant material in the basal part of the laryngotracheal junction in 26% of the Fischer 344 rats. The inciden",Toxicologic pathology,"P G Germann, D Ockert, M Heinrichs"," Institute of Pathology and Toxicology, Hamburg, Germany.",1998 Jan;26(2):283-9,10.1177/019262339802600215
9561675,19980101,article,mesh,"Animals,Cyclosporine,Dogs,Drug Evaluation, Preclinical,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Graft vs Host Disease,Immunosuppressive Agents,Kidney Transplantation,Leukocyte Count,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,prevention &amp; control,therapeutic use","D016572 Q000627 NY,D013110 Q000031 NN,D006086 Q000517 NY,D007166 Q000627 NY,D011409 Q000627 NY,D007958 Q000187 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation.,"FTY720 induces apoptosis, specifically in lymphocytes, and prolongs allograft survival in rats and dogs. The purpose of this study was to define an effective range of FTY720 doses that could be combined with a suboptimal dose (10 mg/kg) of cyclosporin for canine kidney allograft recipients. The combination significantly prolonged allograft survival in all groups receiving FTY720 at a dose of 0.1, 0.3, 1.0, or 3.0 mg/kg. None of the recipients died due to notable side effects of the drug. In peripheral blood",Transplant international : official journal of the European Society for Organ Transplantation,"S Suzuki, T Kakefuda, H Amemiya, K Chiba, Y Hoshino, T Kawaguchi, H Kataoka, F Rahman"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan. ssuzuki@nch.go.jp",1998 Jan;11(2):95-101,10.1007/s001470050111|10.1111/j.1432-2277.1998.tb00783.x
9565092,19980415,article,mesh,"Animals,Antibodies, Monoclonal,Cyclosporine,Drug Synergism,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Humans,Immunosuppressive Agents,Lymphocyte Activation,Lymphocytes,Male,Phytohemagglutinins,Polyenes,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred BUF,Rats, Inbred WF,Sirolimus,Sphingosine,Stimulation, Chemical","analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control","D006085 Q000187 NN,D007166 Q000494 NY,D010835 Q000494 NN,D011090 Q000494 NN,D016027 Q000276 NN,D013110 Q000031 NN,D008213 Q000187 NN,D016572 Q000494 NN,D008214 Q000276 NN,D000911 Q000494 NN,D011409 Q000494 NN,D006084 Q000517 NN,D008214 Q000187 NN","2909,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.,"BACKGROUND: We examined the ability of FTY720, a novel immunosuppressant that prolongs the survival of allografts in experimental animal models, to potentiate the immunosuppressive effects of cyclosporine (CsA) and/or sirolimus (SRL) in vitro and in vivo. METHODS: FTY720 alone (10-5000 ng/ml) or in combination with other drugs was added to human peripheral blood lymphocytes (PBLs) undergoing stimulation in vitro with phytohemagglutinin (PHA) or OKT3 monoclonal antibody. The combination index (CI) values wer",Transplantation,"M E Wang, N Tejpal, X Qu, J Yu, M Okamoto, S M Stepkowski, B D Kahan"," Department of Surgery, University of Texas Medical School, Houston 77030, USA.",1998 Apr;65(7):899-905,10.1097/00007890-199804150-00007
9590253,19980515,article,mesh,"Animals,CD11 Antigens,Cell Line,Cell Movement,Cyclosporine,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Interleukin-2,Lymphocyte Count,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred F344,Skin Transplantation,Sphingosine,Tacrolimus","analogs &amp; derivatives,analysis,biosynthesis,drug effects,immunology,pharmacology,physiology","D006085 Q000187 NN,D007166 Q000494 NY,D007376 Q000096 NN,D002465 Q000187 NN,D016559 Q000494 NN,D018655 Q000187 NY,D018845 Q000032 NN,D016038 Q000276 NN,D008214 Q000187 NY,D008214 Q000502 NN,D011409 Q000494 NY,D013110 Q000031 NN,D016572 Q000494 NN","2909,5372,62280,107969,107970,445643,5280335,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,122172945,123134263,123134270,132274082,134694629",NULL,"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.","FTY720, given i.v. or orally at 0.03 mg/kg or more, significantly prolonged skin allograft survival in a dose-dependent manner and showed more potent immunosuppressive activity than cyclosporin A (CsA) or tacrolimus (FK506) in MHC-incompatible rat strains of WKAH donors and F344 recipients. However, unlike CsA or FK506, FTY720 up to 1000 nM did not affect IL-2 production in allogeneic MLC. Within 3 to 24 h after a single oral administration of FTY720 at 0.1 to 1 mg/kg, the number of lymphocytes in the rats ","Journal of immunology (Baltimore, Md. : 1950)","K Chiba, Y Yanagawa, Y Masubuchi, H Kataoka, T Kawaguchi, M Ohtsuki, Y Hoshino"," Research Laboratories, Yoshitomi Pharmaceutical Industries, Limited, Iruma, Saitama, Japan. chiba@yoshitomi.co.jp",1998 May;160(10):5037-44,NULL
9605152,19980601,article,mesh,"Animals,CD3 Complex,Cell Movement,Cyclosporine,Cytokines,Fingolimod Hydrochloride,Graft Survival,Histocompatibility,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Lymphocyte Culture Test, Mixed,Major Histocompatibility Complex,Male,Polymerase Chain Reaction,Propylene Glycols,RNA, Messenger,Rats,Rats, Inbred F344,Rats, Inbred Strains,Skin Transplantation,Sphingosine,T-Lymphocytes,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,biosynthesis,drug effects,genetics,immunology,metabolism,pharmacology","D007166 Q000494 NY,D007376 Q000096 NN,D002465 Q000187 NN,D008285 Q000235 NN,D016207 Q000096 NY,D007371 Q000187 NN,D002465 Q000276 NY,D016038 Q000276 NY,D007376 Q000235 NN,D006648 Q000235 NN,D017252 Q000235 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007371 Q000096 NN,D012333 Q000378 NN,D012333 Q000187 NN,D006085 Q000187 NY,D016572 Q000494 NN,D017252 Q000187 NN,D013601 Q000276 NY,D007371 Q000235 NN,D012333 Q000096 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo.","FTY720, a novel immunosuppressant, prolonged the survival of WKAH skin allografts transplanted into MHC-incompatible F344 rats. In this allograft model, the median survival time of the control group was 7 days, whereas those of the groups given FTY720 orally at 0.1 mg/kg and cyclosporin A (CsA) at 10 mg/kg were 10.5 and 11 days, respectively. In contrast, FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) synergistically prolonged allograft survival with a median survival time exceeding 70 days. To elucidate t","Journal of immunology (Baltimore, Md. : 1950)","Y Yanagawa, K Sugahara, H Kataoka, T Kawaguchi, Y Masubuchi, K Chiba"," Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Saitama, Japan.",1998 Jun;160(11):5493-9,NULL
9615042,19980101,article,mesh,"Aerosols,Aged,Aged, 80 and over,Anti-Infective Agents, Local,Biopsy,Combined Modality Therapy,Diabetes Complications,Drug Combinations,Female,Humans,Male,Middle Aged,Poloxalene,Polymers,Propylene Glycols,Quinoxalines,Soft Tissue Infections,Surgical Procedures, Operative,Surgical Wound Infection","complications,methods,pathology,prevention &amp; control,surgery,therapeutic use","D013530 Q000517 NY,D011810 Q000627 NN,D011060 Q000627 NN,D018461 Q000473 NN,D018461 Q000601 NN,D000891 Q000627 NN,D013514 Q000379 NY,D011108 Q000627 NN,D011409 Q000627 NN,D018461 Q000150 NN","28467,32881",NULL,[The comprehensive prevention of suppurative wound infection in the postoperative period in diabetic patients].,"The strict acceptance of the radicalism principles while the purulent inflammation origin eliminate, an accurate sanation and early placement of suture on the operation wound, its adequate and active drainage in combination with expedient local with the help of foamy aerosol ""Dioxizol"" and stable compensation of hyperglycemia, correction of the homeostasis disorders are necessary in the treatment of diabetes mellitus patients with local purulent-necrotic disease of the soft tissues. ",Klinichna khirurhiia,"N N Veligotskiĭ, A K Florikian, G S Bashura, V V Dubenko",NULL,1998 Jan;?(1):17-9,NULL
9623716,19980401,article,mesh,"Animals,Brain,Digitoxin,Fingolimod Hydrochloride,Flow Cytometry,Fluorescent Dyes,Immunosuppressive Agents,In Vitro Techniques,Neurons,Propylene Glycols,Rats,Rats, Wistar,Spectrometry, Fluorescence,Sphingosine,Thymus Gland","analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D009474 Q000187 NY,D013950 Q000166 NN,D011409 Q000494 NY,D013110 Q000031 NN,D001921 Q000187 NY,D013950 Q000187 NY,D009474 Q000378 NN,D004074 Q000494 NN,D001921 Q000166 NN","3061,107969,107970,441207,5280335",NULL,"Cytotoxic actions of FTY720, a novel immunosuppressant, on thymocytes and brain neurons dissociated from the rat.","Effects of FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol HCl), a novel immunosuppressant, were examined on neurons and thymocytes respectively dissociated from rat brains and thymus glands using a flow cytometer to see if FTY720 exerts cytotoxic actions not only on spleen cells as previously reported but also on the other cells. FTY720 at a concentration of 10 microM deteriorated almost all of the thymocytes, while it was not the case for brain neurons. FTY720 increased the intracellular concen",Japanese journal of pharmacology,"Y Oyama, L Chikahisa, K Kanemaru, M Nakata, S Noguchi, T Nagano, E Okazaki, A Hirata"," Laboratory of Cellular Signalling, Faculty of Integrated Arts and Sciences, The University of Tokushima, Japan.",1998 Apr;76(4):377-85,10.1254/jjp.76.377
9636420,19980601,article,mesh,"Animals,Blood Transfusion,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppression,Immunosuppressive Agents,Myocardial Contraction,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,physiology,therapeutic use","D013110 Q000031 NN,D007166 Q000627 NY,D007165 Q000379 NN,D006085 Q000187 NY,D006085 Q000276 NN,D016027 Q000502 NN,D016027 Q000276 NY,D011409 Q000627 NY,D009200 Q000187 NN","107969,107970,5280335",NULL,Donor-specific blood transfusion does not enhance the effect of FTY720 in rat cardiac allotransplantation.,NULL,Transplantation proceedings,"E A Antoniou, M Drayson, A J Howie, P McMaster, M D'Silva"," Transplant Microsurgery Laboratory, Queen Elizabeth Hospital and Medical Centre, Edgbaston, Birmingham, UK.",1998 Jun;30(4):1042-3,10.1016/s0041-1345(98)00142-0
9636421,19980601,article,mesh,"Animals,Diabetes Mellitus, Type 1,Fingolimod Hydrochloride,Immunosuppressive Agents,Islets of Langerhans,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Thymectomy","analogs &amp; derivatives,prevention &amp; control,radiation effects,therapeutic use","D013110 Q000031 NN,D003922 Q000517 NY,D007166 Q000627 NY,D007515 Q000528 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720.,NULL,Transplantation proceedings,"K Suzuki, H Yan, X K Li, H Amemiya, S Suzuki, K Hiromitsu"," Department of Research Surgery, National Children Medical Research Center, Tokyo, Japan.",1998 Jun;30(4):1044-5,10.1016/s0041-1345(98)00143-2
9636422,19980601,article,mesh,"Acute Disease,Animals,Blood Cell Count,Cyclosporine,Dogs,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,blood,drug effects,immunology,physiology,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D016030 Q000502 NN,D001772 Q000187 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006084 Q000097 NN,D016030 Q000276 NY,D006084 Q000276 NN,D011409 Q000627 NY,D018655 Q000187 NN,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,An effect of FTY720 on acute rejection in canine renal transplantation.,NULL,Transplantation proceedings,"K Yuzawa, M Otsuka, H Taniguchi, Y Takada, N Sakurayama, Y Jinzenji, S Suzuki, K Fukao"," Department of Surgery, University of Tsukuba, Ibaraki-ken, Japan.",1998 Jun;30(4):1046,10.1016/s0041-1345(98)00144-4
9636432,19980601,article,mesh,"Animals,Combined Modality Therapy,Duodenum,Fingolimod Hydrochloride,Graft Survival,Immunosuppression,Immunosuppressive Agents,Lymphocyte Transfusion,Male,Pancreas Transplantation,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Spleen,Thymus Gland,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,therapeutic use,transplantation","D006085 Q000187 NN,D006085 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D016035 Q000276 NY,D004386 Q000637 NY,D007165 Q000379 NY,D014184 Q000276 NY,D017710 Q000379 YN,D011409 Q000627 NY","107969,107970,5280335",NULL,Beneficial immunosuppressive effect of FTY720 combined with intrathymic injection of splenic cells on rat pancreaticoduodenal allograft.,NULL,Transplantation proceedings,"K Suzuki, T Kazui, A Kawabe, X K Li, H Amemiya, S Suzuki"," First Department of Surgery, Hamamatsu University School of Medicine, Japan.",1998 Jun;30(4):1067-8,10.1016/s0041-1345(98)00154-7
9665039,19980101,article,mesh,"Animals,Apoptosis,B-Lymphocytes,Cricetinae,Fingolimod Hydrochloride,Graft Survival,Humans,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Inbred Lew,Skin Transplantation,Sphingosine,T-Lymphocytes,Transplantation Immunology,Transplantation, Heterologous","analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D014183 Q000276 NY,D017209 Q000187 NN,D013601 Q000276 NN,D014181 Q000187 NY,D016038 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D001402 Q000276 NN","107969,107970,5280335",NULL,Effect of FTY720 on immunoregulation in concordant xenotransplantation.,"The present study was designed to analyze the immunosuppressive activity of FTY720 in concordant xenotransplantation. When T and B lymphocytes of human peripheral blood were incubated with FTY720, the number of viable cells decreased in a dose-dependent manner at doses higher than 4 x 10(-5) M. DNA fragmentation was observed at doses higher than 1 x 10(-5) M in T cell-rich fractions and at doses higher than 4 x 10(-5) M in B cell-rich fractions. These data demonstrate that FTY720 is cytotoxic to B lymphocyt",Transplant international : official journal of the European Society for Organ Transplantation,"Y Fukuda, H Ohdan, Y Miyata, S Shintaku, K Dohi"," Second Department of Surgery, Hiroshima University, School of Medicine, Japan.",1998 Jan;?(?):S461-4,10.1007/s001470050521|10.1111/j.1432-2277.1998.tb01182.x
9704394,19980101,article,mesh,"Animals,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Kidney,Leukocyte Count,Liver,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Tacrolimus,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,drug effects,physiopathology,therapeutic use","D006085 Q000187 NN,D007668 Q000187 NN,D016559 Q000008 NN,D007668 Q000503 NN,D011409 Q000008 NN,D008099 Q000503 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY,D016559 Q000627 NY,D008099 Q000187 NN","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation.,"FTY720 is a recently discovered compound that is derived from the fungus Isaria sinclairii. Using a DA donor-to-LEW recipient rat combination, we assessed the efficacy of peritransplant FTY720 alone or in combination with post-transplant tacrolimus on the survival of cardiac allografts. Peritransplant FTY720 given orally at a dose of 5 mg/kg on days-1 and 0 prolonged graft survival from 5 to 13 days (P < 0.05). Combining peritransplant FTY720 with post-transplant tacrolimus resulted in a further prolongatio",Transplant international : official journal of the European Society for Organ Transplantation,"M Xu, J Pirenne, E A Antoniou, S C Afford, M D'Silva, P McMaster"," Liver Transplant and Hepatobiliary Unit, Queen Elizabeth Hospital and Medical Center, Edgbaston, Birmingham, UK.",1998 Jan;11(4):288-94,10.1007/s001470050144|10.1111/j.1432-2277.1998.tb00973.x
9710310,19980101,article,mesh,"Animals,Blood Glucose,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Islets of Langerhans Transplantation,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,therapeutic use","D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D001786 Q000378 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,"Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts.","A newly developed immunosuppressant, FTY720, has a unique mechanism that is quite different from those of conventional immunosuppressants, and is presumed to be mediated through decreases in the number of peripheral lymphocytes, especially helper T cells. This study was performed to ascertain whether this innovative drug could prolong islet allograft survival. The donors were inbred Lewis rats and the recipients were ACI rats rendered hyperglycemic with intravenous streptozotocin. In the study group, FTY720",Cell transplantation,"T Yamasaki, K Inoue, H Hayashi, Y Gu, H Setoyama, J Ida, W Cui, Y Kawakami, M Kogire, M Imamura"," Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan.",1998 Jan;7(4):403-6,10.1016/s0963-6897(98)00021-9
9721436,19980701,review,mesh,"Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Activation,Propylene Glycols,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,drug effects,pharmacokinetics,pharmacology,therapeutic use","D007166 Q000493 NN,D013110 Q000031 NN,D007166 Q000627 NY,D008213 Q000187 NN,D011409 Q000493 NN,D011409 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN","107969,107970,5280335",NULL,"Preclinical evaluation of a new immunosuppressive agent, FTY720.","FTY720 is a synthetic analog of a fungal metabolite that shows potent immunosuppressive activity in vitro and in vivo with little apparent toxicity. The drug displays marked synergistic effects in vivo with CsA and/or rapamycin. Therefore, this drug may improve the therapeutic window of agents that target cytokine synthesis or signal transduction. Because of these promising findings, the agent is likely to be tested in humans as an adjunct to clinical immunosuppressive regimens. ",Clinical biochemistry,"P Troncoso, B D Kahan"," Department of Surgery, University of Texas Medical School, Houston 77030, USA.",1998 Jul;31(5):369-73,10.1016/s0009-9120(98)00043-5
9723444,19980801,review,mesh,"Animals,Dogs,Fingolimod Hydrochloride,Graft Survival,Haplorhini,Immunosuppressive Agents,Mice,Molecular Structure,Organ Transplantation,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,drug effects,pharmacokinetics,pharmacology,therapeutic use","D006085 Q000187 NN,D007166 Q000494 NY,D011409 Q000493 NY,D007166 Q000627 NN,D007166 Q000493 NY,D011409 Q000494 NY,D013110 Q000031 NN,D011409 Q000627 NN","107969,107970,5280335",NULL,FTY720: a new immunosuppressive agent with novel mechanism(s) of action.,NULL,Transplantation proceedings,B D Kahan," University of Texas Medical School, Houston 77030, USA.",1998 Aug;30(5):2210-3,10.1016/s0041-1345(98)00593-4
9723445,19980801,article,mesh,"Animals,Cyclosporine,Drug Synergism,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Male,Polyenes,Propylene Glycols,Rats,Rats, Inbred BUF,Rats, Inbred WF,Sirolimus,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,prevention &amp; control,therapeutic use","D016572 Q000627 NY,D011090 Q000627 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D016027 Q000276 NY,D011409 Q000627 NY,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.,NULL,Transplantation proceedings,"S M Stepkowski, M Wang, X Qu, J Yu, M Okamoto, N Tejpal, B D Kahan"," Department of Surgery, University of Texas Medical School, Houston 77030, USA.",1998 Aug;30(5):2214-6,10.1016/s0041-1345(98)00594-6
9723446,19980801,article,mesh,"Animals,DNA Primers,Fingolimod Hydrochloride,Graft Survival,Granzymes,Heart Transplantation,Immunosuppressive Agents,Membrane Glycoproteins,Perforin,Polymerase Chain Reaction,Pore Forming Cytotoxic Proteins,Propylene Glycols,RNA, Messenger,Rats,Rats, Inbred BN,Rats, Inbred Lew,Serine Endopeptidases,Sphingosine,T-Lymphocytes, Cytotoxic,Transcription, Genetic,Transplantation, Homologous","analogs &amp; derivatives,drug effects,genetics,immunology,pharmacology,physiology,therapeutic use","D006085 Q000187 NN,D012333 Q000235 NN,D013602 Q000276 NN,D006085 Q000502 NY,D016027 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D016027 Q000502 NY,D011409 Q000494 NN,D014158 Q000187 NY,D008562 Q000235 NY,D011409 Q000627 NY,D007166 Q000494 NN,D012697 Q000235 NY","107969,107970,5280335",NULL,"FTY720 inhibits the mRNA expression of intragraft cytotoxic molecules, leading to cardiac allograft survival.",NULL,Transplantation proceedings,"H Nakajima, E Sun, N Mizuta, I Fujiwara, T Oka"," Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.",1998 Aug;30(5):2217-20,10.1016/s0041-1345(98)00595-8
9723447,19980801,article,mesh,"Animals,Drug Administration Schedule,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Tacrolimus,Time Factors,Transplantation, Heterotopic","analogs &amp; derivatives,drug effects,drug therapy,immunology,therapeutic use","D006084 Q000188 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D016027 Q000276 NY,D011409 Q000627 NY,D016559 Q000627 NY","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation.,NULL,Transplantation proceedings,"M Xu, J Pirenne, S Antoniou, B Gunson, M D'Silva, P McMaster"," Liver Unit, Queen Elizabeth Hospital, University of Birmingham, Edgbaston, UK.",1998 Aug;30(5):2221-2,10.1016/s0041-1345(98)00596-x
9723502,19980801,article,mesh,"Animals,Apoptosis,Caspase 1,Caspase 2,Caspases,Cell Nucleus,Cysteine Endopeptidases,Dose-Response Relationship, Drug,Enzyme Activation,Fingolimod Hydrochloride,Immunosuppressive Agents,Kinetics,Lymphoma,Mice,Propylene Glycols,Proteins,Sphingosine,Tumor Cells, Cultured","analogs &amp; derivatives,drug effects,enzymology,immunology,metabolism,pathology,pharmacology,physiology","D007166 Q000494 NY,D017209 Q000187 NN,D008223 Q000473 NN,D008223 Q000276 NY,D008223 Q000201 NN,D002467 Q000473 NN,D017209 Q000502 NY,D011409 Q000494 NY,D013110 Q000031 NN,D011506 Q000378 NN,D003546 Q000378 NY,D002467 Q000187 NN","107969,107970,5280335,100953062",NULL,Caspase requirement for the apoptotic death of WR19L-induced by FTY720.,NULL,Transplantation proceedings,"T Matsuda, H Nakajima, I Fujiwara, N Mizuta, T Oka"," Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.",1998 Aug;30(5):2355-7,10.1016/s0041-1345(98)00652-6
9749865,19980101,article,mesh,"Adult,Aged,Aqueous Humor,Cytokines,Enzyme-Linked Immunosorbent Assay,Female,Fingolimod Hydrochloride,Glucocorticoids,Humans,Hydrocortisone,Immunosuppressive Agents,Male,Middle Aged,Ophthalmic Solutions,Propylene Glycols,Sphingosine,T-Lymphocytes,Tacrolimus,Uveitis","administration &amp; dosage,analogs &amp; derivatives,biosynthesis,cytology,drug effects,drug therapy,immunology,therapeutic use","D001082 Q000166 NN,D016207 Q000187 NN,D007166 Q000008 NN,D005938 Q000627 NN,D016559 Q000627 NN,D016207 Q000096 NY,D007166 Q000627 NN,D016559 Q000008 NN,D011409 Q000008 NN,D014605 Q000188 NN,D006854 Q000627 NN,D013110 Q000031 NN,D006854 Q000008 NN,D005938 Q000008 NN,D013601 Q000276 NY,D014605 Q000276 NY,D011409 Q000627 NN,D013601 Q000187 NN","5372,5754,107969,107970,229860,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,Cytokine production by T cells infiltrating in the eye of uveitis patients.,"The capacity of T cells to produce cytokines was investigated using T-cell clones (TCCs) established from infiltrating cells in the aqueous humor (AH) or peripheral blood mononuclear cells (PBMC) of patients with Vogt-Koyanagi-Harada (VKH) disease or sarcoidosis. The cytokines produced and tested in the study were interleukin (IL)-1alpha, IL-6, IL-8, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, and granulocyte monocyte colony stimulating factor (GM-CSF). All TCCs (n = 9) from AH of VKH patient",Japanese journal of ophthalmology,"M Sakaguchi, S Sugita, K Sagawa, K Itoh, M Mochizuki"," Department of Ophthalmology, Kurume University School of Medicine, Fukuoka, Japan.",1998 Jan;42(4):262-8,10.1016/s0021-5155(98)00016-1
9767438,19980801,article,mesh,"Animals,Apoptosis,Enterotoxins,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Receptors, Antigen, T-Cell,Skin Transplantation,Sphingosine,Staphylococcus aureus,Superantigens,T-Lymphocytes,Thymus Gland","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,physiology","D007166 Q000494 NY,D018089 Q000494 NY,D017209 Q000187 NY,D013950 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013950 Q000276 NN,D011948 Q000378 NN,D013601 Q000187 NY,D013601 Q000502 NN,D004768 Q000494 NY","107969,107970,5280335",NULL,"A novel immunosuppressant, FTY720, increases the efficiency of a superantigen-induced peripheral T-cell deletion whilst inhibiting negative selection in the thymus.","A novel immunosuppressant, FTY720, was generated by chemical modification of ISP-I, an immunosuppressive compound purified from culture filtrates of Isaria sinclairii. FTY720 directly induces apoptotic cell death in lymphocytes, which is believed to be the mechanism by which this drug exerts its immunosuppressive effect. We examined the effect of FTY720 treatment on antigen-induced apoptotic cell death in peripheral T cells and thymocytes. A superantigen, staphylococcus enterotoxin B (SEB), induces T-cell a",Immunology,"C Shimizu, X Li, M Kimura, K Hashimoto, K Sugaya, M Kubo, S Suzuki, T Nakayama"," Research Institute for Biological Sciences, Science University of Tokyo, Chiba 278, Japan.",1998 Aug;94(4):503-12,10.1046/j.1365-2567.1998.00545.x
9838506,19981101,article,mesh,"Animals,Apoptosis,Diabetes Mellitus, Experimental,Duodenum,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Male,Pancreas Transplantation,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,blood,drug effects,immunology,pathology,physiology,surgery,therapeutic use,transplantation","D006085 Q000187 NN,D004386 Q000637 NN,D003921 Q000097 NN,D016035 Q000473 NN,D006085 Q000502 NY,D013110 Q000031 NN,D007166 Q000627 NY,D016035 Q000276 NY,D003921 Q000601 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,Immunosuppressive effect of FTY 720 on rat pancreas allograft.,NULL,Transplantation proceedings,"K Suzuki, T Kazui, A Kawabe, X K Li, N Funeshima, H Amemiya, S Suzuki"," First Department of Surgery, Hamamatsu University School of Medicine, Japan.",1998 Nov;30(7):3417-8,10.1016/s0041-1345(98)01084-7
9838514,19981101,article,mesh,"Animals,Diabetes Mellitus, Type 1,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Islets of Langerhans,Lymphopenia,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Thymectomy","analogs &amp; derivatives,drug effects,immunology,pathology,prevention &amp; control,therapeutic use","D003922 Q000276 NN,D003922 Q000473 NN,D007515 Q000187 NN,D013110 Q000031 NN,D003922 Q000517 NY,D007166 Q000627 NY,D011409 Q000627 NY,D007515 Q000473 NN","107969,107970,5280335",NULL,Immunosuppressive effect of FTY 720 on autoimmune diabetes models.,NULL,Transplantation proceedings,"H Yan, K Suzuki, X K Li, H Amemiya, S Suzuki, K Hiromitsu"," Department of Research Surgery, National Children Medical Research Center, Tokyo, Japan.",1998 Nov;30(7):3436-7,10.1016/s0041-1345(98)01092-6
9862987,19990115,article,mesh,"Cyclopentanes,DNA Footprinting,DNA Repair,DNA-Formamidopyrimidine Glycosylase,Escherichia coli,Escherichia coli Proteins,Furans,Hydroxyl Radical,Lactococcus lactis,Lyases,N-Glycosyl Hydrolases,Propylene Glycols,Protein Binding,Purines,Pyrimidines,Substrate Specificity","chemistry,enzymology,metabolism","D013294 Q000201 NN,D003517 Q000378 NN,D008190 Q000378 NN,D009699 Q000378 NY,D011743 Q000737 NN,D011687 Q000737 NN,D004926 Q000201 NN,D005663 Q000378 NN,D011409 Q000378 NN","7298,8028,9253,10442",NULL,AP site structural determinants for Fpg specific recognition.,"The binding of Escherichia coli and Lactococcus lactis Fapy-DNA glyosylase (Fpg) proteins to DNA containing either cyclic or non-cyclic abasic (AP) site analogs was investigated by electrophoretic mobility shift assay (EMSA) and by footprinting experiments. We showed that the reduced AP site is the best substrate analog for the E.coli and L.lactis enzymes ( K Dapp = 0.26 and 0.5 nM, respectively) as compared with the other analogs tested in this study ( K Dapp >2.8 nM). The 1,3-propanediol (Pr) residue-cont",Nucleic acids research,"B Castaing, J L Fourrey, N Hervouet, M Thomas, S Boiteux, C Zelwer"," Centre de Biophysique Moléculaire, UPR 4301 affiliated to the University of Orleans, CNRS, rue Charles Sadron, 45071 Orleans Cedex 2, France. castaing@cnrs-orleans.fr",1999 Jan;27(2):608-15,10.1093/nar/27.2.608
9865334,19981201,article,mesh,"Administration, Oral,Animals,B-Lymphocytes,Cricetinae,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Humans,Immunosuppressive Agents,Liver Transplantation,Lymphocyte Depletion,Mesocricetus,Propylene Glycols,Rats,Rats, Inbred Lew,Skin Transplantation,Sphingosine,T-Lymphocytes,Transplantation, Heterologous","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,pharmacology,therapeutic use","D014183 Q000276 NY,D007166 Q000008 NN,D013601 Q000276 NN,D016038 Q000276 NY,D001402 Q000187 NN,D011409 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D001402 Q000276 NN,D006085 Q000187 NY,D011409 Q000494 NN,D016027 Q000276 NY,D011409 Q000627 NY,D007166 Q000494 NN,D013601 Q000187 NN,D016031 Q000276 NY","107969,107970,5280335",NULL,Prolongation of concordant xenograft survival by treatment with FTY720.,NULL,Transplantation proceedings,"Y Miyata, H Ohdan, T Noriyuki, S Shintaku, S Shibata, H Yamamoto, X H Fan, Y Fudaba, S Yoshioka, T Asahara, Y Fukuda, K Dohi"," Second Department of Surgery, Hiroshima University, School of Medicine, Japan.",1998 Dec;30(8):4163-5,10.1016/s0041-1345(98)01379-7
9893050,19981201,article,mesh,"Animals,Antigens, CD,Cell Movement,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Integrin alpha1,L-Selectin,Lymph Nodes,Lymphocyte Count,Lymphocyte Function-Associated Antigen-1,Male,Peyer's Patches,Propylene Glycols,Rats,Rats, Inbred F344,Receptors, Lymphocyte Homing,Sphingosine,Stimulation, Chemical,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology","D007166 Q000494 NY,D002465 Q000187 NN,D016201 Q000502 NY,D008198 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D015703 Q000276 NN,D010581 Q000276 NY,D013601 Q000276 NY,D018655 Q000187 NN,D016169 Q000276 NN,D013601 Q000187 NN,D019041 Q000276 NY","107969,107970,5280335",NULL,"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.","FTY720, a novel immunosuppressant, sequesters circulating mature lymphocytes, especially T cells, within lymph nodes and Peyer's patches by accelerating lymphocyte homing, and thereby causes lymphocyte depletion in the blood. The FTY720-induced acceleration of lymphocyte homing appears to be mediated by lymphocyte homing receptors including CD62L, CD49d/beta7, and CD11a/CD18. In this study, expressions of CD62L, CD49d and CD11a on T cells in the peripheral blood, lymph nodes and Peyer's patches were analyse",Immunology,"Y Yanagawa, Y Masubuchi, K Chiba"," Research Laboratories, Yoshitomi Pharmaceutical Industries Ltd, Iruma, Saitama, Japan.",1998 Dec;95(4):591-4,10.1046/j.1365-2567.1998.00639.x
9921811,19990115,article,mesh,"Acute Disease,Animals,Cyclosporine,Dose-Response Relationship, Drug,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Kidney Transplantation,Macaca fascicularis,Propylene Glycols,Sphingosine,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,blood,prevention &amp; control,therapeutic use","D007166 Q000008 NN,D016572 Q000627 NY,D007166 Q000097 NN,D016572 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY,D016572 Q000097 NN,D006084 Q000517 NY,D011409 Q000097 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine.,"BACKGROUND: In rodent transplant models, FTY720 exerts a synergistic affect with cyclosporine (CsA) to prolong allograft survival. The present experiments sought to test this combination in subhuman primates. METHODS: Cynomolgus monkeys were transplanted with kidney allografts that were incompatible in mixed lymphocyte culture reactions. The animals were treated with daily intramuscular injections of CsA using doses selected to maintain whole blood trough concentrations at therapeutic values between 40 and ",Transplantation,"P Troncoso, S M Stepkowski, M E Wang, X Qu, S C Chueh, J Clark, B D Kahan"," Department of Surgery, The University of Texas Medical School at Houston, 77030, USA.",1999 Jan;67(1):145-51,10.1097/00007890-199901150-00024
9925439,19980106,article,"mesh,assay","Animals,Ethanolamines,Fingolimod Hydrochloride,Host vs Graft Reaction,Immunosuppressive Agents,Propylene Glycols,Rats,Sphingosine,Structure-Activity Relationship,T-Lymphocytes","analogs &amp; derivatives,chemical synthesis,drug effects,immunology,pharmacology","D006789 Q000187 NN,D013601 Q000276 NN,D011409 Q000138 NY,D013110 Q000031 NN,D004983 Q000138 NY,D004983 Q000494 NN,D007166 Q000138 NY,D011409 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335,5284373,6857804,9796114,10064205,10380521,10493971,10519824,10542927,10567802,10616805,10782040,22618699",NULL,"Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720.",Desymmerization of symmetric FTY720 by substitution of different alkyl groups for one of the prochiral hydroxymethyl groups was performed. The size of the alkyl groups and the absolute configuration at quaternary carbon were important on immunosuppressive activity. ,Bioorganic & medicinal chemistry letters,"M Kiuchi, K Adachi, T Kohara, K Teshima, Y Masubuchi, T Mishina, T Fujita"," Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Saitama, Japan.",1998 Jan;8(1):101-6,10.1016/s0960-894x(97)10188-3
10083381,19990101,article,mesh,"Acute Disease,Animals,B-Lymphocytes,Cyclosporine,Dogs,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug therapy,immunology,pathology,physiology,therapeutic use","D016572 Q000627 NN,D006084 Q000188 NY,D016030 Q000502 NN,D013601 Q000276 NN,D016030 Q000473 NN,D013110 Q000031 NN,D007166 Q000627 NY,D001402 Q000276 NN,D006084 Q000473 NN,D016030 Q000276 NY,D006084 Q000276 NN,D011409 Q000627 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Rescue effect of FTY720 on acute renal rejection in dogs.,NULL,Transplantation proceedings,"K Yuzawa, M Otsuka, H Taniguchi, Y Takada, N Sakurayama, Y Jinzenji, S Suzuki, K Fukao"," Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Japan.",1999 Jan;31(?):872,10.1016/s0041-1345(98)01811-9
10083517,19990101,article,mesh,"Animals,Apoptosis,Drug Administration Schedule,Drug Monitoring,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Kidney Transplantation,Leukocyte Count,Lymphocyte Count,Male,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Spleen,Transplantation, Homologous,Transplantation, Isogeneic","analogs &amp; derivatives,drug effects,genetics,immunology,therapeutic use","D006085 Q000187 NN,D017209 Q000187 NN,D013154 Q000187 NN,D007376 Q000235 NN,D006085 Q000276 NY,D013110 Q000031 NN,D013154 Q000276 NN,D007166 Q000627 NY,D016030 Q000276 NY,D007371 Q000235 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Immunosuppressive action of FTY720 for renal allograft a rat model.,NULL,Transplantation proceedings,"S Kunikata, T Nagano, T Nishioka, T Akiyama, T Kurita"," Department of Urology, Kinki University School of Medicine, Osaka, Japan.",1999 Jan;31(?):1157-9,10.1016/s0041-1345(98)01944-7
10083526,19990101,article,mesh,"Animals,Cyclosporine,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Liver Transplantation,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred Lew,Sphingosine,Tacrolimus,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D016572 Q000627 NN,D016559 Q000627 NN,D006085 Q000502 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D016027 Q000276 NY,D011409 Q000627 NY,D016031 Q000276 NY","2909,5372,62280,107969,107970,445643,5280335,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,122172945,123134263,123134270,132274082,134694629",NULL,"Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats.",NULL,Transplantation proceedings,"K Yamashita, M Nomura, T Omura, M Takehara, T Suzuki, T Shimamura, A Kishida, H Furukawa, M Murakami, T Uede, S Todo"," First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.",1999 Jan;31(?):1178-9,10.1016/s0041-1345(98)01953-8
10083540,19990101,article,mesh,"Analysis of Variance,Animals,Dogs,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Kidney Function Tests,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D006085 Q000187 NN,D016030 Q000502 NN,D006085 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D016030 Q000276 NY,D011409 Q000627 NY,D018655 Q000187 NN","107969,107970,5280335",NULL,"Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model.",NULL,Transplantation proceedings,"T Suzuki, T Shimamura, M B Jin, R Yokota, M Fukai, J Iida, M Taniguchi, S Magata, H Horiuchi, K Yamashita, M Nomura, T Omura, A Kishida, H Furukawa, S Todo"," Hokkaido University School of Medicine, Sapporo, Japan.",1999 Jan;31(?):1208-9,10.1016/s0041-1345(98)01967-8
10083547,19990101,article,mesh,"Animals,Drug Synergism,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Skin Transplantation,Sphingosine,Tacrolimus,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D016038 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D016027 Q000276 NY,D011409 Q000627 NY,D016559 Q000627 NY","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,"FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models.",NULL,Transplantation proceedings,"Y Hoshino, Y Yanagawa, M Ohtsuki, S Nakayama, T Hashimoto, K Chiba"," Tokyo Laboratories, Yoshitomi Pharmaceutical Industries, Saitama, Japan.",1999 Jan;31(?):1224-6,10.1016/s0041-1345(98)01973-3
10083548,19990101,article,mesh,"Animals,CD8-Positive T-Lymphocytes,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Activation,Male,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Strains,Receptors, Interleukin-2,Skin Transplantation,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes,Transplantation, Homologous,Transplantation, Isogeneic","analogs &amp; derivatives,analysis,drug effects,immunology,pathology,therapeutic use","D018414 Q000276 NN,D016038 Q000276 NY,D016038 Q000473 NN,D015375 Q000032 NN,D013110 Q000031 NN,D007166 Q000627 NY,D013601 Q000276 NY,D013601 Q000473 NN,D016176 Q000276 NN,D011409 Q000627 NY,D013601 Q000187 NN","107969,107970,5280335",NULL,"FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts.",NULL,Transplantation proceedings,"Y Yanagawa, Y Hoshino, H Kataoka, T Kawaguchi, M Ohtsuki, K Sugahara, K Chiba"," Tokyo Laboratories, Yoshitomi Pharmaceutical Industries, Saitama, Japan.",1999 Jan;31(?):1227-9,10.1016/s0041-1345(98)01974-5
10083549,19990101,article,mesh,"Animals,Cyclosporine,Female,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Lymph Nodes,Lymphocyte Count,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Receptors, Lymphocyte Homing,Skin Transplantation,Sphingosine,Spleen,Tacrolimus","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology,therapeutic use","D006085 Q000187 NN,D008214 Q000276 NY,D016572 Q000627 NN,D016559 Q000627 NN,D016038 Q000276 NY,D008198 Q000276 NN,D006085 Q000276 NY,D013110 Q000031 NN,D013154 Q000276 NN,D007166 Q000627 NY,D016201 Q000502 NN,D011409 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN,D018655 Q000187 NN","2909,5372,62280,107969,107970,445643,5280335,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,122172945,123134263,123134270,132274082,134694629",NULL,"FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing.",NULL,Transplantation proceedings,"K Chiba, Y Yanagawa, H Kataoka, T Kawaguchi, M Ohtsuki, Y Hoshino"," Tokyo Laboratories, Yoshitomi Pharmaceutical Industries, Saitama, Japan.",1999 Jan;31(?):1230-3,10.1016/s0041-1345(98)01975-7
10092785,19990315,article,mesh,"Apoptosis,Calcium-Calmodulin-Dependent Protein Kinases,Enzyme Activation,Fingolimod Hydrochloride,Glycogen Synthase Kinase 3,Humans,Immunosuppressive Agents,JNK Mitogen-Activated Protein Kinases,Jurkat Cells,Mitogen-Activated Protein Kinases,Oligopeptides,Propylene Glycols,Signal Transduction,Sphingosine,T-Lymphocytes,p38 Mitogen-Activated Protein Kinases","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,enzymology,immunology,metabolism,pharmacology,physiology","D007166 Q000494 NY,D013601 Q000201 NY,D017209 Q000187 NY,D013601 Q000276 NN,D015398 Q000276 NN,D017871 Q000502 NY,D004789 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000037 NN,D004789 Q000276 NN,D017209 Q000276 NN,D011409 Q000037 NN,D009842 Q000494 NN,D017871 Q000378 NY,D015398 Q000187 NN,D013601 Q000187 NN","107969,107970,5280335,9847059",NULL,Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway.,"FTY720 is a novel immunosuppressive drug derived from a metabolite from Isaria sinclairii that is known to induce apoptosis of rat splenic T cells. In this study, we examined the intracellular signaling pathway triggered by FTY720. Treatment of human Jurkat T lymphocytes with FTY720-induced apoptosis characterized by DNA fragmentation. The same treatment induced activation of protein kinases such as c-Jun NH2-terminal kinase (JNK), p38/CSBP (CSAID-binding protein), and a novel 36-kDa myelin basic protein (M","Journal of immunology (Baltimore, Md. : 1950)","S Matsuda, A Minowa, S Suzuki, S Koyasu"," Department of Immunology, Keio University School of Medicine, Tokyo, Japan.",1999 Mar;162(6):3321-6,NULL
10363553,19990501,article,mesh,"Anastomosis, Surgical,Animals,Disease Models, Animal,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Knee Joint,Male,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred F344,Sphingosine,Statistics, Nonparametric,Transplantation, Homologous,Treatment Outcome","analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control,surgery","D007166 Q000494 NY,D007719 Q000601 NY,D011409 Q000494 NY,D013110 Q000031 NN,D014184 Q000276 NN,D006084 Q000276 NN,D007719 Q000187 NY,D006084 Q000517 NY","107969,107970,5280335",NULL,"Effect of a new immunosuppressant, FTY720, on joint allografts.","The immunosuppressive effects of a new agent, FTY720, on joint allografts were studied histologically in a rat model. Favorable results without side effects were obtained at a dose of 3.0 mg/kg/day. The authors believe that this agent is one of the most useful immunosuppressants in the reported experimental model. ",Journal of reconstructive microsurgery,"H Watanabe, Y Hamada, T Toshima, K Nagasawa, Y Sakano"," Department of Orthopaedic Surgery, Yamanashi Medical College, Nakakomagun, Yamanashi-Ken, Japan.",1999 May;15(4):295-8,10.1055/s-2007-1000104
10399041,19990512,article,mesh,"Animals,Anti-Bacterial Agents,Dose-Response Relationship, Drug,Drug Implants,Fish Diseases,Hydrocortisone,Immunosuppressive Agents,Infection,Oncorhynchus mykiss,Oomycetes,Propylene Glycols,Spores,Testosterone,Water","administration &amp; dosage,analysis,blood,drug effects,drug therapy,microbiology,pharmacology,physiology,therapeutic use,veterinary","D013170 Q000187 NN,D013739 Q000008 NN,D007166 Q000008 NN,D007166 Q000627 NN,D006854 Q000097 NN,D000900 Q000494 NN,D009868 Q000502 YN,D000900 Q000627 NY,D007239 Q000382 NN,D006854 Q000627 NN,D007239 Q000662 NY,D011409 Q000032 NN,D009868 Q000187 YN,D000900 Q000032 NN,D006854 Q000008 NN,D005393 Q000188 NY,D005393 Q000382 NN,D011409 Q000494 NN,D007239 Q000188 NN,D013739 Q000627 NN,D011409 Q000627 NY,D014867 Q000032 NN","962,2450,5754,6013,119207,229860,12304591",NULL,A Saprolegnia parasitica challenge system for rainbow trout: assessment of Pyceze as an anti-fungal agent for both fish and ova.,"A reproducible Saprolegnia parasitica spore delivery system was developed and demonstrated to be effective in providing a sustained spore challenge for up to 10 d. Treatment of rainbow trout with slow-release intraperitoneal implants containing cortisol resulted in chronically elevated blood cortisol levels and rendered the fish susceptible to infection by S. parasitica when exposed to the spore challenge. Sham-implanted fish were not susceptible to infection. Bronopol (2-bromo-2-nitro-propane-1,3-diol), fo",Diseases of aquatic organisms,"T G Pottinger, J G Day"," NERC Institute of Freshwater Ecology, Windermere Laboratory, Cumbria, United Kingdom. t.pottinger@ife.ac.uk",1999 May;36(2):129-41,10.3354/dao036129
10428648,19990401,article,mesh,"Animals,Cell Movement,Female,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Lymphocyte Activation,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Propylene Glycols,Skin Transplantation,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,pharmacology,physiology","D006085 Q000187 NN,D007166 Q000494 NY,D002465 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D008213 Q000187 NN,D013601 Q000502 NN,D013601 Q000187 NN","107969,107970,5280335",NULL,Analysis of the mode of action of a novel immunosuppressant FTY720 in mice.,"Accelerated lymphocyte homing and apoptosis have been suggested to contribute to potent immunosuppressive effects of FTY720, however, its main mechanism of action remains to be fully elucidated. Here, we examined the mode of action of FTY720 in mice. FTY720, when given at a single dose of 1 mg/kg, markedly decreased the number of peripheral blood lymphocytes (PBL) but moderately increased the lymphocyte numbers in lymph nodes (LN) and Peyer's patches (PP) in normal mice, as previously observed in rats. Howe",Immunopharmacology,"Z J Luo, T Tanaka, F Kimura, M Miyasaka"," Department of Bioregulation, Biomedical Research Center, Osaka University Medical School, Suita, Japan.",1999 Apr;41(3):199-207,10.1016/s0162-3109(99)00004-1
10487276,19990801,review,mesh,"Acute Disease,Adult,Age Factors,Antibodies, Monoclonal,Child,Cohort Studies,Cyclosporine,Drug Monitoring,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Humans,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Protein-Tyrosine Kinases,Recombinant Fusion Proteins,Sirolimus,Sphingosine,Time Factors,Tyrphostins","administration &amp; dosage,adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,prevention &amp; control,therapeutic use,therapy","D020123 Q000009 NN,D016572 Q000627 NN,D007166 Q000008 NN,D020032 Q000627 NN,D011505 Q000037 NN,D000911 Q000627 NN,D020123 Q000008 NN,D016572 Q000008 NN,D016572 Q000009 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006084 Q000628 NN,D020123 Q000627 NY,D011409 Q000627 NN,D007166 Q000009 NN,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5284616,5328779,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,The potential role of rapamycin in pediatric transplantation as observed from adult studies.,"Although pediatric patient and renal graft survival rates have shown marked improvements during the past decade, the persistent toxicities of immunosuppressive drugs and chronic allograft attrition remain major obstacles in transplant therapy. Results in adult patients suggest that complete steroid withdrawal is possible in the majority of recipients under treatment with a cyclosporin A-rapamycin (CsA RAPA) regimen. Furthermore, preliminary studies suggest that a marked reduction in the dose of CsA may be p",Pediatric transplantation,B D Kahan," Department of Surgery, The University of Texas Medical School at Houston, 77030, USA. bkahan@orgtx71.med.uth.tmc.edu",1999 Aug;3(3):175-80,10.1034/j.1399-3046.1999.00036.x
10491378,19990921,article,mesh,"Animals,Coronary Artery Disease,Cyclosporine,Disease Progression,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Male,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Mice, Inbred DBA,Postoperative Complications,Propylene Glycols,Sphingosine,T-Lymphocytes, Cytotoxic","analogs &amp; derivatives,biosynthesis,drug effects,immunology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D007376 Q000096 NN,D013602 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D007371 Q000096 NN,D006085 Q000187 NY,D011183 Q000517 NN,D003324 Q000517 NY,D011409 Q000627 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.","Background-Effective immunosuppression is a critical determinant of organ and patient survival in cardiac transplantation. The present study was designed to determine the potency of FTY720, a new synthesized immunosuppressant, and examine its clinical potential as an immunosuppressant. Methods and Results-Hearts of DBA/2 mice were transplanted heterotopically in C57BL/6 mice. Recipients were treated with oral FTY720 in doses of 0.3, 1, 3, or 10 mg. kg(-1). d(-1) or with 40 mg. kg(-1). d(-1) of cyclosporin A",Circulation,"M W Hwang, A Matsumori, Y Furukawa, K Ono, M Okada, A Iwasaki, M Hara, S Sasayama"," Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.",1999 Sep;100(12):1322-9,10.1161/01.cir.100.12.1322
10565994,19990101,article,mesh,"Animals,Drugs, Investigational,Fingolimod Hydrochloride,Graft Rejection,Graft vs Host Disease,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,pharmacokinetics,pharmacology,prevention &amp; control,therapeutic use","D011409 Q000009 NN,D015507 Q000627 NY,D015507 Q000493 NN,D006086 Q000188 NN,D007166 Q000493 NN,D013110 Q000031 NN,D015507 Q000009 NN,D015507 Q000494 NN,D006086 Q000517 NY,D007166 Q000627 NY,D011409 Q000493 NN,D011409 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D006084 Q000517 NY","107969,107970,5280335",NULL,FTY 720.,NULL,Drugs in R&D,NULL,NULL,1999 Jan;1(1):78-80,10.2165/00126839-199901010-00026
10576553,19990101,article,mesh,"Animals,Body Weight,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver,Organ Size,Propylene Glycols,Rats,Sphingosine,Spleen,Thyroid Gland,Thyroiditis, Autoimmune,Thyrotropin","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,drug therapy,pathology,therapeutic use","D013972 Q000097 NN,D008099 Q000473 NN,D007166 Q000008 NN,D001835 Q000187 NN,D009929 Q000187 NN,D013961 Q000473 NN,D011409 Q000008 NN,D013110 Q000031 NN,D013967 Q000188 NY,D007166 Q000627 NY,D013967 Q000473 NN,D013154 Q000473 NN,D013967 Q000097 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,"Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720.","While autoimmune disease needs to be continuously treated via long term, administration of immunosuppressants conventional immunotherapy using drugs such as cyclosporin and tacrolimus may cause adverse effects. Recently, a novel agent, FTY720, which was structurally modified from a natural product, has been shown to have a moderate and different immunosuppressive effect from conventional drugs. In this study, we examined the effect of FTY720 on experimental autoimmune thyroiditis (EAT), which was induced in",Life sciences,"Y Hozumi, E Kobayashi, M Miyata, A Fujimura"," Department of Surgery, Omiya Medical Center, Jichi Medical School, Japan.",1999 Jan;65(17):1739-45,10.1016/s0024-3205(99)00426-9
10578288,19991101,review,mesh,"Animals,Apoptosis,Dogs,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Humans,Immunosuppressive Agents,Kidney Transplantation,Liver Transplantation,Propylene Glycols,Rats,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D016030 Q000276 NN,D017209 Q000187 NN,D016031 Q000276 NN,D016027 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,FTY720: mechanisms of action and its effect on organ transplantation (review).,NULL,Transplantation proceedings,S Suzuki," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1999 Nov;31(7):2779-82,10.1016/s0041-1345(99)00564-3
10578289,19991101,article,mesh,"Animals,Dogs,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Sphingosine,Time Factors","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D018655 Q000187 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D016030 Q000276 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,A short-course therapy with FTY720 prolongs allograft survival after canine kidney transplantation.,NULL,Transplantation proceedings,"T Omura, T Suzuki, T Shimamura, M B Jin, R Yokota, M Fukai, J Iida, M Taniguchi, S Magata, H Horiuchi, K Yamashita, M Nomura, A Kishida, M Matsushita, H Furukawa, S Todo"," First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.",1999 Nov;31(7):2783-4,10.1016/s0041-1345(99)00565-5
10578290,19991101,article,mesh,"Animals,Apoptosis,Cytokines,Fingolimod Hydrochloride,Gene Expression Regulation,Graft Rejection,Graft Survival,Immunosuppressive Agents,In Situ Nick-End Labeling,Liver Transplantation,Propylene Glycols,RNA, Messenger,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Tacrolimus,Transcription, Genetic,Transplantation, Homologous","analogs &amp; derivatives,analysis,drug effects,genetics,immunology,pathology,prevention &amp; control,therapeutic use","D012333 Q000032 NN,D016031 Q000473 NN,D017209 Q000187 NN,D005786 Q000276 NN,D013110 Q000031 NN,D016207 Q000235 NN,D007166 Q000627 NY,D014158 Q000276 NN,D006085 Q000187 NY,D006085 Q000276 NN,D005786 Q000187 NN,D006084 Q000517 NN,D014158 Q000187 NN,D011409 Q000627 NY,D016559 Q000627 NY,D016031 Q000276 NY","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,Combination effect of tacrolimus and FTY720 in liver transplantation in rats.,NULL,Transplantation proceedings,"A Tamura, X K Li, N Funeshima, S Enosawa, H Amemiya, S Suzuki"," National Children's Medical Research Center, Tokyo, Japan.",1999 Nov;31(7):2785-6,10.1016/s0041-1345(99)00566-7
10578291,19991101,article,mesh,"Abatacept,Animals,Antigens, CD,Antigens, Differentiation,CTLA-4 Antigen,Combined Modality Therapy,Fingolimod Hydrochloride,Genetic Therapy,Graft Survival,Heart Transplantation,Humans,Immunoconjugates,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Recombinant Fusion Proteins,Sphingosine,Transfection,Transplantation, Homologous","analogs &amp; derivatives,genetics,immunology,therapeutic use","D000943 Q000235 NN,D000943 Q000627 NY,D013110 Q000031 NN,D011993 Q000627 NN,D007166 Q000627 NY,D016027 Q000276 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,Prolonged graft survival induced by CTLA4IG-gene transfection combined with FTY720 administration in rat heart grafting.,NULL,Transplantation proceedings,"Y Kita, X K Li, N Funeshima, S Enosawa, A Tamura, S Hayashi, K Suzuki, T Kazui, H Amemiya, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",1999 Nov;31(7):2787-8,10.1016/s0041-1345(99)00567-9
10578306,19991101,article,mesh,"Animals,Antibodies, Heterophile,Combined Modality Therapy,Cricetinae,Fingolimod Hydrochloride,Graft Survival,Guanidines,Heart Transplantation,Immunosuppression,Immunosuppressive Agents,Lymphocyte Culture Test, Mixed,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Spleen,Splenectomy,Transplantation, Heterologous","analogs &amp; derivatives,blood,drug effects,immunology,methods,pathology,therapeutic use","D014183 Q000276 NY,D006146 Q000627 NN,D013110 Q000031 NN,D013154 Q000276 NN,D016027 Q000473 NN,D007166 Q000627 NY,D007165 Q000379 NN,D000910 Q000097 NN,D006085 Q000187 NY,D006085 Q000276 NN,D016027 Q000276 NY,D011409 Q000627 NY,D014183 Q000473 NN","55361,55362,91272,107969,107970,5280335",NULL,"Prolongation of concordant xenograft survival by a newly developed drug, FTY720.",NULL,Transplantation proceedings,"I Fujiwara, H Nakajima, T Matsuda, N Mizuta, H Yamagishi, T Oka"," Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.",1999 Nov;31(7):2831-3,10.1016/s0041-1345(99)00582-5
10608298,19990901,article,mesh,"Animals,B-Lymphocytes,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Immunosuppressive Agents,In Vitro Techniques,Lymphocyte Activation,Lymphocyte Count,Lymphocyte Depletion,Macaca fascicularis,Papio,Propylene Glycols,Species Specificity,Sphingosine,T-Lymphocytes,Transplantation Immunology,Transplantation, Heterologous,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,blood,cytology,drug effects,immunology,methods,pharmacology","D007166 Q000494 NY,D007166 Q000008 NN,D013601 Q000276 NN,D007166 Q000097 NN,D001402 Q000166 NN,D001402 Q000187 NY,D011409 Q000008 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013601 Q000166 NN,D008213 Q000187 NN,D001402 Q000276 NN,D013601 Q000187 NY,D008212 Q000379 NY,D011409 Q000097 NN","107969,107970,5280335",NULL,"A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.","OBJECTIVE: FTY720, a new immunosuppressant active in transplantation models, modulates lymphocyte re-circulation, leading to peripheral lymphopenia and increased lymphocytes in lymph nodes and Peyer's patches. Here, we investigated the susceptibility of baboons to FTY720 as an introductory study to transplantation protocols. METHODS: FTY720 was administered orally to Chacma baboons at 0.3 or 0.1 mg/kg/day for 3 days or at 0.03 mg/kg/day for 10 days. Haematological parameters, lymphocyte phenotype (CD3, CD4,",Transplant immunology,"V Quesniaux, L Fullard, H Arendse, G Davison, N Markgraaff, R Auer, F Ehrhart, G Kraus, H J Schuurman"," Novartis Pharma Transplantation Research, Basel, Switzerland. valerie.quesniaux@pharma.Novartis.com",1999 Sep;7(3):149-57,10.1016/s0966-3274(99)80034-3
10617602,20000107,article,mesh,"Animals,Apoptosis,Brain,Ceramides,Fatty Acids,Mice,Molecular Mimicry,Nerve Tissue,Neuroblastoma,Palmitic Acids,Propanolamines,Propylene Glycols,Protein Kinase C,Rats,Signal Transduction,Sphingolipids,Stearic Acids,Tumor Cells, Cultured","antagonists &amp; inhibitors,drug effects,enzymology,metabolism,pharmacology","D009417 Q000187 NN,D013229 Q000494 NN,D002518 Q000494 NY,D011409 Q000494 NY,D013107 Q000378 NN,D005227 Q000494 NY,D010169 Q000494 NN,D011493 Q000037 NN,D001921 Q000201 NN,D011412 Q000494 NN",NULL,NULL,N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells.,"A novel structural analog of ceramide was synthesized by N-acylation of serinol (2-amino-1,3-propanediol) and studied for its effects on glycolipid biosynthesis and cell differentiation of neuroblastoma cells. Incubation with N-palmitoylated serinol (C16-serinol) increased the concentration of endogenous ceramide by 50-80% and caused apoptosis in rapidly dividing low density cells but not in confluent cells. Cell death was not suppressed by simultaneous incubation with phorbol ester, known to antagonize cer",The Journal of biological chemistry,"E Bieberich, T Kawaguchi, R K Yu"," Department of Biochemistry, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia 23298-0614, USA. ebieberi@hsc.vcu.edu",2000 Jan;275(1):177-81,10.1074/jbc.275.1.177
10644416,20000101,article,mesh,"Animals,Antibodies,Arrestin,Autoimmune Diseases,Blood Cell Count,Body Weight,Chi-Square Distribution,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Retinitis,Sphingosine,Statistics, Nonparametric,T-Lymphocytes,Uveitis","analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,therapeutic use","D014605 Q000188 NY,D000906 Q000097 NN,D001835 Q000187 NN,D013601 Q000276 NN,D007166 Q000097 NN,D014605 Q000276 NN,D001327 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D012173 Q000188 NY,D012173 Q000276 NN,D011409 Q000627 NY,D011409 Q000097 NN,D001327 Q000188 NY","107969,107970,5280335",NULL,"Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.","The immunosuppressive properties of FTY720, a novel immunosuppressant obtained by structural modification of ISP-I isolated from the fermentation broth of Isaria sinclairii, were studied in experimental autoimmune uveoretinitis (EAU) in rats. Lewis rats were immunized with S-antigen and treated with FTY720 (0. 03, 0.06, 0.1 mg kg(-1)day(-1)) or distilled water for 16 days after the immunization. FTY720 suppressed the incidence and intensity of EAU in a dose-dependent manner as demonstrated by clinical and h",Experimental eye research,"S Kurose, E Ikeda, M Tokiwa, N Hikita, M Mochizuki"," Department of Ophthalmology, Kurume University School of Medicine, Fukuoka, Japan.",2000 Jan;70(1):7-15,10.1006/exer.1999.0777
10660758,20000101,article,mesh,"Animals,Apoptosis,CD2 Antigens,Drug Combinations,Fingolimod Hydrochloride,Graft Survival,Granzymes,Immunosuppressive Agents,In Situ Nick-End Labeling,Interferon-gamma,Interleukin-2,Liver,Liver Transplantation,Lymphocytes,Male,Propylene Glycols,RNA, Messenger,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Serine Endopeptidases,Sphingosine,Tacrolimus","analogs &amp; derivatives,drug effects,genetics,metabolism,pathology,physiology,therapeutic use","D006085 Q000187 NN,D008099 Q000473 NN,D008214 Q000473 NN,D008214 Q000378 NN,D007376 Q000235 NN,D008214 Q000502 NN,D018801 Q000378 NN,D013110 Q000031 NN,D008099 Q000378 NN,D007166 Q000627 NY,D012333 Q000378 NN,D007371 Q000235 NN,D011409 Q000627 NY,D016559 Q000627 NY,D012697 Q000235 NN","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation.,"BACKGROUND: FTY720 (FTY) exerts its effects through a reduction of peripheral lymphocytes. This unique mechanism allows for a possible combination effect with other immunosuppressants. We investigated therapy with FTY combined with tacrolimus (FK) in rat liver transplantation. METHODS: Different doses of FK, FTY, or both were orally administered to the recipients for 15 days. Expression of cytokine mRNAs using RT-PCR and appearance of lymphocyte apoptosis by immunohistologic staining were studied in the all",Surgery,"A Tamura, X K Li, N Funeshima, S Enosawa, H Amemiya, M Kitajima, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",2000 Jan;127(1):47-54,10.1067/msy.2000.100884
10664606,20000201,article,mesh,"Cell Movement,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Activation,Lymphocyte Subsets,Organ Transplantation,Propylene Glycols,Protective Agents,Sphingosine,Transplantation, Homologous","adverse effects,analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D011409 Q000009 NN,D002465 Q000187 NN,D020011 Q000494 NN,D011409 Q000494 NY,D013110 Q000031 NN,D008213 Q000187 NN,D016131 Q000187 NY,D007166 Q000009 NN,D016131 Q000276 NN","107969,107970,5280335",NULL,FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.,NULL,Trends in pharmacological sciences,"V Brinkmann, D Pinschewer, K Chiba, L Feng"," Transplantation Research, Novartis Pharma AG, Transplantation Research, WSJ-386.1.25, CH-4002 Basel, Switzerland. volker.brinkmann@pharma.novartis.com",2000 Feb;21(2):49-52,10.1016/s0165-6147(99)01419-4
10670633,20000127,article,mesh,"Animals,Bilirubin,Cyclosporine,Dogs,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Liver Transplantation,Propylene Glycols,Sphingosine,Survival Rate,Tacrolimus,Time Factors","analogs &amp; derivatives,blood,drug effects,immunology,mortality,physiology,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D016031 Q000401 NN,D001663 Q000097 NN,D016559 Q000627 NN,D016031 Q000502 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006084 Q000517 NN,D011409 Q000627 NY,D016031 Q000276 NY","2909,5372,62280,107969,107970,445643,5280335,5280352,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,122172945,123134263,123134270,129320333,132274082,134694629",NULL,"Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs.","BACKGROUND: The immunosuppressive effect and other properties of a novel immunosuppressant, FTY720, have been studied mostly in the experimental transplantation of various extrahepatic organs. In this experiment, we evaluated the antirejection potency and adverse effects of this agent on liver grafts using a canine liver transplantation model. METHODS: Forty-eight orthotopic liver transplantations were performed by the standard technique under a veno-venous bypass. Liver recipients were divided into two stu",Transplantation,"H Furukawa, T Suzuki, M B Jin, K Yamashita, M Taniguchi, S Magata, H Ishikawa, K Ogata, H Masuko, T Shimamura, M Fukai, T Hayashi, M Fujita, K Nagashima, T Omura, A Kishida, S Todo"," First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.",2000 Jan;69(2):235-41,10.1097/00007890-200001270-00008
10678498,19991201,article,mesh,"Animals,Cyclosporine,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Leukocytes, Mononuclear,Liver,Male,Neutrophil Activation,Peroxidase,Propylene Glycols,Rats,Rats, Wistar,Reperfusion Injury,Sphingosine,Transaminases,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,blood,blood supply,drug effects,enzymology,immunology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D009195 Q000378 NN,D000637 Q000097 NN,D008099 Q000187 NY,D008099 Q000201 NN,D014409 Q000378 NN,D008099 Q000098 NN,D016572 Q000494 NY,D007963 Q000473 NN,D008099 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007963 Q000187 NN,D015427 Q000276 NY,D018375 Q000187 NN,D007958 Q000187 NN,D015427 Q000201 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,11973707,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Effect of pretreatment with FTY720 and cyclosporin on ischaemia-reperfusion injury of the liver in rats.,"The effect of pretreatment with FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride) or cyclosporin, or both, on neutrophil-mediated injury has been examined by use of a rat model of transient clamping of hepatic flow. Pretreatment with FTY720 alone or with cyclosporin induced a marked reduction of circulatory lymphocytes, whereas the use of these drugs in combination was very effective at suppressing the elevation of the number of peripheral polymorphonuclear neutrophils (PMN) after re",The Journal of pharmacy and pharmacology,"K Mizuta, M Ohmori, F Miyashita, Y Kitoh, A Fujimura, M Mori, T Kanno, K Hashizume, E Kobayashi"," Department of Clinical Pharmacology, Centre for Molecular Medicine, Jichi Medical School, Kawachi-gun, Tochigi, Japan.",1999 Dec;51(12):1423-8,10.1211/0022357991777065
10688258,20000201,review,mesh,"Animals,Clinical Trials as Topic,Drug Combinations,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunity, Cellular,Immunosuppressive Agents,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,pharmacology,toxicity","D007166 Q000494 NY,D006084 Q000188 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000633 NN,D005229 Q000494 NN,D007111 Q000187 NN,D005229 Q000633 NN","107969,107970,5280335,6438394",NULL,The FTY720 story.,"The chemical 2-amino-2[2-(4-octylphenyl)ethyl]-1,3,propane diol is one of a class of small-molecule immunosuppressive agents. Better known as FTY720, this compound was chemically synthesized in an effort to minimize the toxic in vivo properties of a structurally related and highly potent immunosuppressive agent, myriocin. FTY720's mechanism of action, although not fully characterized, appears to be unique among immunosuppressants. Whereas the most well known biochemical characteristic of myriocin is its abi",Therapeutic drug monitoring,K L Napoli," Department of Surgery, The University of Texas Medical School at Houston, 77030, USA.",2000 Feb;22(1):47-51,10.1097/00007691-200002000-00010
10689105,20000401,article,mesh,"Animals,Arthritis, Experimental,Collagen,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Prednisolone,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Sprague-Dawley,Ribonucleosides,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D011239 Q000627 NN,D012263 Q000627 NN,D013110 Q000031 NN,D003094 Q000276 NY,D007166 Q000627 NY,D001169 Q000188 NY,D011409 Q000627 NY","5755,104762,107969,107970,5280335,46926304",NULL,"Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats.","The anti-arthritic effect of FTY720, 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride, a novel immunosuppressant which induces peripheral lymphocyte homing to peripheral lymph nodes, was compared with those of anti-rheumatic compounds, mizoribine and prednisolone in rat adjuvant-induced arthritis (AA) and collagen-induced arthritis (CIA). FTY720 at doses of 0.03-0.3 mg/kg, mizoribine at 3-30 mg/kg, and prednisolone at 1-10 mg/kg were orally administered to rats for 21 days from the day of in",International journal of immunopharmacology,"M Matsuura, T Imayoshi, T Okumoto"," Pharmacology, Drug Development Laboratories, Yoshitomi Pharmaceutical Industries Ltd, Koiwai 955, Yoshitomi-cho, Chikujo-gun, Fukuoka, Japan.matsuura_mamoru@yoshitomi.co.jp",2000 Apr;22(4):323-31,10.1016/s0192-0561(99)00088-0
10710126,20000301,article,mesh,"Analysis of Variance,Animals,Autoimmune Diseases,Body Weight,Fingolimod Hydrochloride,Immunosuppressive Agents,Injections, Intraperitoneal,Lymphocyte Count,Lymphocytes,Male,Myocarditis,Organ Size,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Tacrolimus","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,pathology,prevention &amp; control,therapeutic use","D007166 Q000008 NN,D009205 Q000473 NN,D001835 Q000187 NN,D009929 Q000187 NN,D016559 Q000008 NN,D009205 Q000517 NY,D011409 Q000008 NN,D013110 Q000031 NN,D009205 Q000276 NN,D007166 Q000627 NY,D008214 Q000187 NN,D011409 Q000627 NY,D016559 Q000627 NY,D001327 Q000473 NN,D001327 Q000517 NY","5372,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,134694629",NULL,FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes.,"FTY720 is a new immunosuppressant agent and selectively decreases the number of circulating lymphocytes. In this study, we compared the effects of FTY720 with those of tacrolimus on experimental autoimmune myocarditis (EAM) in rats. A significant decrease in circulating lymphocyte counts was noted after a single administration of FTY720 in normal rats. At day 0, 7-week-old male Lewis rats were immunized with purified porcine cardiac myosin emulsified in complete Freund's adjuvant. FTY720 or tacrolimus was a",Journal of cardiovascular pharmacology,"H Kitabayashi, M Isobe, N Watanabe, J Suzuki, Y Yazaki, M Sekiguchi"," First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.",2000 Mar;35(3):410-6,10.1097/00005344-200003000-00010
10714494,20000221,article,mesh,"Animals,Antibodies,Antibody Formation,Antibody Specificity,Cross Reactions,Enzyme-Linked Immunosorbent Assay,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Immunosuppressive Agents,Propanolamines,Propylene Glycols,Rabbits,Sphingosine","analogs &amp; derivatives,chemical synthesis,chemistry,immunology","D011412 Q000737 NN,D011412 Q000138 NN,D011409 Q000276 NY,D005229 Q000276 NY,D011409 Q000737 NN,D005229 Q000737 NN,D013110 Q000031 NN,D007166 Q000138 NN,D007166 Q000276 NY,D011412 Q000276 NY,D000906 Q000276 NY,D011409 Q000138 NN,D007166 Q000737 NN,D005229 Q000138 NN","107969,107970,5280335,6438394",NULL,"Antibody against a novel, myriocin (ISP-I)-based immunosuppressant, FTY720.","An antibody was prepared by immunizing rabbits with an ovalbumin conjugate of 2-amino-2-(2-(4-(4-mercaptobutyl)phenyl)ethyl)propane-1,3-diol HCl (AMPD-4), which contains the essential structure of the novel immunosuppressant FTY720. As the antibody reacted to not only AMPD-4, but also FTY720, it should be useful for immunoassay of FTY720 in body fluids, tissues and cells. ",Bioorganic & medicinal chemistry letters,"T Fujita, N Matsumoto, S Uchida, T Kohno, T Shimizu, R Hirose, K Yanada, W Kurio, K Watabe"," Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan. fujita@pharm.setsunan.ac.jp",2000 Feb;10(4):337-9,10.1016/s0960-894x(99)00695-2
10715413,20000301,article,mesh,"Animals,Fingolimod Hydrochloride,Graft Rejection,Heart Transplantation,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Inbred BUF,Rats, Inbred WF,Sphingosine,T-Lymphocytes, Cytotoxic,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,prevention &amp; control,therapeutic use","D013602 Q000187 NN,D013110 Q000031 NN,D007166 Q000627 NY,D013602 Q000276 NY,D006084 Q000276 NN,D016027 Q000276 NY,D011409 Q000627 NY,D006084 Q000517 NY","107969,107970,5280335",NULL,FTY720 blocks allograft rejection by homing of lymphocytes in vivo.,NULL,Transplantation proceedings,"K Yuzawa, S M Stephkowski, M Wang, B D Kahan"," Division of Immunology. Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas, USA.",2000 Mar;32(2):269,10.1016/s0041-1345(99)00953-7
10726478,19991201,review,mesh,"Animals,Antigens, Surface,Apoptosis,Fas Ligand Protein,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Ligands,Membrane Glycoproteins,Organ Transplantation,Propylene Glycols,Sphingosine,Transfection,fas Receptor","analogs &amp; derivatives,genetics,prevention &amp; control,therapeutic use","D000954 Q000235 NN,D019014 Q000235 NN,D008562 Q000235 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006084 Q000517 NN,D011409 Q000627 NN","107969,107970,5280335",NULL,[Immunomodulation after organ grafting by novel immunosuppressive drug and gene transfection].,NULL,Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,"S Suzuki, X K Li, T Okuyama, A Tamura, N Funeshima, S Enosawa, M Ohba, H Amemiya",NULL,1999 Dec;22(6):422-7,NULL
10736091,20000301,article,mesh,"Animals,Antigens, CD,Antigens, Differentiation, T-Lymphocyte,Apoptosis,Concanavalin A,Cycloheximide,Dose-Response Relationship, Immunologic,Fingolimod Hydrochloride,HL-60 Cells,Humans,Immunosuppressive Agents,K562 Cells,Lectins, C-Type,Leukocyte Count,Lymphocyte Activation,Male,Mice,Mice, Inbred BALB C,Propylene Glycols,Protein Synthesis Inhibitors,Sphingosine,T-Lymphocyte Subsets","analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology","D016176 Q000276 NY,D017209 Q000276 NY,D017209 Q000187 NN,D003513 Q000494 NN,D015703 Q000096 NY,D000945 Q000276 NN,D000945 Q000096 NY,D003208 Q000494 NY,D013110 Q000031 NN,D008213 Q000187 NN,D011500 Q000494 NN,D015703 Q000276 NN,D016176 Q000378 NY,D011409 Q000494 NN,D007166 Q000494 NN,D008213 Q000276 NY","6197,107969,107970,5280335",NULL,Apoptotic cells actively inhibit the expression of CD69 on Con A activated T lymphocytes.,"Although apoptosis is commonly viewed as a silent cell death without damage to adjacent tissues, the effect of apoptosis on immunity has been unclear. We have investigated the influence of apoptotic cells on T-cell activation. The K562 or HL-60 human leukemia cell lines that had been induced apoptosis by FTY720 or cycloheximide (CHX) were added into the culture of mouse spleen cells stimulated with Con A. Six to 20 h later, the expression of CD69, an early T-cell activation antigen, was detected using flowc",Scandinavian journal of immunology,"E Sun, L Zhang, Y Zeng, Q Ge, M Zhao, W Gao"," Hemopurification and Renal Transplantation Center, Zhujiang Hospital, Guangzhou, China.",2000 Mar;51(3):231-6,10.1046/j.1365-3083.2000.00666.x
10771694,20000401,review,mesh,"Acute Disease,Animals,Autoimmune Diseases,Cyclosporine,Drug Design,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug therapy,pharmacology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D007166 Q000494 YN,D007166 Q000627 YN,D013110 Q000031 NN,D001327 Q000188 NN,D011409 Q000494 YN,D006084 Q000517 NN,D011409 Q000627 YN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,[Immunosuppressive agent FTY720].,NULL,"Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme","T Kobayakawa, K Chiba"," YOSHITOMI Pharmaceutical Industries, Ltd., Osaka, Japan. kobayakawa@yoshitomi.co.jp",2000 Apr;45(?):1188-92,NULL
10812142,20000501,article,mesh,"Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppression,Immunosuppressive Agents,Propylene Glycols,Sirolimus,Sphingosine,Transplantation","analogs &amp; derivatives,methods,therapeutic use,trends","D014180 Q000379 NN,D007165 Q000639 NY,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NN,D020123 Q000627 NN","107969,107970,5280335,5284616",NULL,New immunosuppressive agents.,NULL,Transplantation proceedings,"S M Katz, J C Hong, B D Kahan"," Department of Surgery, Division of Immunology and Organ Transplantation, The University of Texas Medical School, Houston, TX 77030, USA.",2000 May;32(3):620-1,10.1016/s0041-1345(00)00920-9
10820254,20000601,article,mesh,"Animals,Antibodies, Viral,Autoimmune Diseases,Cell Movement,Cytotoxicity, Immunologic,Diabetes Mellitus, Experimental,Edema,Fingolimod Hydrochloride,Hypersensitivity, Delayed,Immunologic Memory,Immunosuppressive Agents,Lymphocyte Activation,Lymphocyte Count,Lymphocytic choriomeningitis virus,Lymphopenia,Mice,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Sphingosine,T-Lymphocytes, Cytotoxic","analogs &amp; derivatives,biosynthesis,blood,drug effects,immunology,pathology,pharmacology,prevention &amp; control,virology","D004487 Q000097 NN,D004487 Q000276 NN,D007166 Q000494 NY,D003921 Q000473 NN,D003921 Q000276 NN,D002465 Q000187 NY,D008231 Q000276 NN,D003602 Q000187 NY,D013602 Q000473 NN,D001327 Q000276 NN,D011409 Q000494 NY,D006968 Q000821 NN,D008231 Q000097 NN,D013110 Q000031 NN,D004487 Q000473 NN,D008231 Q000473 NN,D008217 Q000276 NN,D003921 Q000517 NN,D006968 Q000473 NN,D007156 Q000187 NY,D013602 Q000276 NY,D006968 Q000276 NN,D000914 Q000096 NN,D001327 Q000517 NN,D001327 Q000473 NN,D008213 Q000187 NY,D013602 Q000187 NY","107969,107970,5280335",NULL,"FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.","FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) prolongs survival of solid organ allografts in animal models. Mechanisms of FTY720 immunomodulation were studied in mice infected with lymphocytic choriomeningitis virus (LCMV) to assess T cell responses or with vesicular stomatitis virus to evaluate Ab responses. Oral FTY720 (0.3 mg/kg/day) did not affect LCMV replication and specific CTL and B cells were induced and expanded normally. Moreover, the anti-viral humoral immune response","Journal of immunology (Baltimore, Md. : 1950)","D D Pinschewer, A F Ochsenbein, B Odermatt, V Brinkmann, H Hengartner, R M Zinkernagel"," Institute of Experimental Immunology and Laboratory for Special Techniques, Department of Pathology, University Hospital, Zurich, Switzerland.",2000 Jun;164(11):5761-70,10.4049/jimmunol.164.11.5761
10820391,20000501,article,mesh,"Animals,Cell Movement,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,Thymus Gland","analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D016176 Q000276 NY,D007166 Q000494 NY,D013950 Q000166 NN,D002465 Q000187 NY,D002465 Q000276 NY,D016176 Q000166 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013950 Q000276 NY","107969,107970,5280335",NULL,Immunosuppressant FTY720 inhibits thymocyte emigration.,"One major role of the thymus is to provide the peripheral immune system with mature T cells, but the mechanisms involving the cellular export are not fully understood. In this study, we examined the ability of a novel immunosuppressive reagent, FTY720, to inhibit T cell export from the thymus. Daily administration of FTY720 at a dose of 1 mg / kg resulted in a marked decrease in the number of peripheral blood T lymphocytes. In the thymus, long-term daily administration of FTY720 caused a three- to fourfold ",European journal of immunology,"H Yagi, R Kamba, K Chiba, H Soga, K Yaguchi, M Nakamura, T Itoh"," Division of Immunology and Embryology, Department of Cell Biology, Tohoku University School of Medicine, Sendai, Japan.",2000 May;30(5):1435-44,10.1002/(sici)1521-4141(200005)30:5&lt;1435::aid-immu1435&gt;3.0.co;2-o|10.1002/(sici)1521-4141(200005)30:5&lt;1435::aid-immu1435&gt;3.3.co;2-f
10822091,20000601,article,mesh,"Administration, Oral,Animals,Annexin A5,Apoptosis,B-Lymphocytes,Cell Separation,Dose-Response Relationship, Drug,Down-Regulation,Fingolimod Hydrochloride,Fluorescein-5-isothiocyanate,Granulocytes,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Monocytes,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,cytology,drug effects,pharmacology","D007166 Q000494 NY,D009000 Q000187 NN,D001402 Q000187 NN,D006098 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013601 Q000166 NN,D013601 Q000187 NY","18730,107969,107970,5280335",NULL,Evidence that FTY720 induces T cell apoptosis in vivo.,"The immunosuppressant FTY720 induces a drastic decrease in blood lymphocytes, especially T cells; a decrease which is assumed to be the immunosuppressive mechanism of this drug. FTY720 causes cell death in vitro in lymphocytes and leukemia cells. However, the deletion mechanism of blood lymphocytes in vivo remains unclear. We investigated whether administration of FTY720 induced lymphocyte apoptosis in blood circulation. A marked decrease in the number of blood lymphocytes was observed within an hour after ",Immunopharmacology,"Y Nagahara, S Enosawa, M Ikekita, S Suzuki, T Shinomiya"," Division of Research Promotion, National Children's Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8509, Japan.",2000 Jun;48(1):75-85,10.1016/s0162-3109(00)00181-8
10852286,20000601,article,mesh,"Adolescent,Adult,Age of Onset,Child,Female,HLA-B27 Antigen,Humans,Ileum,Inflammatory Bowel Diseases,Leukocytes,Male,Predictive Value of Tests,Radionuclide Imaging,Radiopharmaceuticals,Rheumatic Diseases,Spinal Diseases,Technetium Tc 99m Exametazime","analysis,diagnostic imaging,immunology","D015796 Q000032 NY,D007962 Q000000981 NY,D013122 Q000000981 NY,D015212 Q000000981 NY,D012216 Q000000981 NY,D007082 Q000000981 NN,D007082 Q000276 NN","450484,56841051,129626367",NULL,Evidence of subclinical intestinal inflammation by 99m technetium leukocyte scintigraphy in patients with HLA-B27 positive juvenile onset active spondyloarthropathy.,OBJECTIVE: The concept that gut inflammation is implicated in the pathogenesis of spondyloarthropathies (SpA) has long been considered. Subclinical intestinal inflammation has been reported in adult patients with SpA by histological examination of intestinal biopsies. We assessed the presence of gut inflammation by abdominal 99mTc-hexamethyl propylene amine oxime (99mTc-HMPAO) labeled leukocyte scintigraphy in a group of children and adolescents with HLA-B27 positive SpA without gastrointestinal (GI) sympto,The Journal of rheumatology,"P Lionetti, A Pupi, M Veltroni, C Fonda, M C Cavicchi, C Azzari, F Falcini"," Department of Pediatrics, University of Florence, Italy. lionetti@unifi.it",2000 Jun;27(6):1538-41,NULL
10910272,20000627,article,mesh,"Animals,Carotid Arteries,Carotid Artery Diseases,Cyclosporine,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Count,Magnetic Resonance Imaging,Male,Muscle, Smooth, Vascular,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,blood,pathology,prevention &amp; control,transplantation","D002339 Q000473 NN,D009131 Q000473 NN,D002340 Q000517 NY,D013110 Q000031 NN,D016572 Q000008 NY,D002339 Q000637 NY,D016572 Q000097 NN,D011409 Q000008 NY,D007166 Q000008 NY,D011409 Q000097 NN","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Prevention of graft vessel disease by combined FTY720/cyclosporine. A treatment in a rat carotid artery transplantation model.,"BACKGROUND: Graft vessel disease (GVD) is an important problem often responsible for late graft loss. The effects of FTY720, an immunomodulator with a novel mechanism of action were investigated in combination with cyclosporine A (CsA) in a carotid artery allograft model. METHODS: A segment of the carotid artery of Lewis rats was replaced by a DA allograft. Seven groups of eight rats were treated for 8 weeks with vehicle (P), CsA 0.3 (C0.3), 1 (C1) or 3 (C3) mg x kg(-1).day(-1) or a combination of CsA 1 wit",Transplantation,"Z Nikolova, A Hof, M Rudin, Y Baumlin, G Kraus, R P Hof"," Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.",2000 Jun;69(12):2525-30,10.1097/00007890-200006270-00010
10936327,20000801,article,mesh,"Animals,Cyclosporine,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Islets of Langerhans Transplantation,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Swine,Transplantation, Heterologous","analogs &amp; derivatives,immunology,prevention &amp; control,therapeutic use","D014183 Q000276 NY,D016572 Q000627 NY,D013110 Q000031 NN,D016381 Q000276 NY,D007166 Q000627 NY,D011409 Q000627 NY,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,FTY720 in combination with CsA inhibits islet xenograft rejection: a study in the pig-to-rat model.,NULL,Transplantation proceedings,"J Zhang, Z Song, M Wijkström, S Bari, B Sundberg, S Nava, C G Groth, O Korsgren, L Wennberg"," Department of Transplantation Surgery, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden. zhangjiang43@hotmail.com",2000 Aug;32(5):1017,10.1016/s0041-1345(00)01091-5
10956203,20000727,article,"mesh,assay","Animals,Drug Evaluation, Preclinical,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Inhibitory Concentration 50,Lymph Nodes,Organ Size,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Skin Transplantation,Sphingosine,Stereoisomerism,Structure-Activity Relationship,T-Lymphocytes","analogs &amp; derivatives,chemical synthesis,chemistry,cytology,drug effects,pharmacology,prevention &amp; control","D011409 Q000138 NY,D011409 Q000737 NN,D008198 Q000187 NN,D013110 Q000031 NN,D013601 Q000166 NN,D007166 Q000138 NY,D007166 Q000737 NN,D011409 Q000494 NN,D006084 Q000517 NN,D007166 Q000494 NN,D013601 Q000187 NN","107969,107970,5280335,5284373,10064205,10494965,10519824,10519976,10520125,10591879,10591887,10616805,10687399,10710924,10781919,10782040,10830706,10854293,19974416,21258640,21849154,21849271,21849363,21849371,21849460,21849489,21849498,22439347,22618699,22618799,22618920,45261202,45261229,45261248,45261249,45261259,45261273,45261277,45261290,45261292,45264761,45264783,45264850,45264940,70691839,73355883",NULL,"Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.","A series of 2-substituted 2-aminopropane-1,3-diols was synthesized and evaluated for their lymphocyte-decreasing effect and immunosuppressive effect on rat skin allograft. A phenyl ring was introduced into the alkyl chain of the lead compound 3, which is an immunosuppressive agent structurally simplified from myriocin (1, ISP-I) via compound 2. The potency of the various compounds was dependent upon the position of the phenyl ring within the alkyl side chain. The most suitable length between the quaternary ",Journal of medicinal chemistry,"M Kiuchi, K Adachi, T Kohara, M Minoguchi, T Hanano, Y Aoki, T Mishina, M Arita, N Nakao, M Ohtsuki, Y Hoshino, K Teshima, K Chiba, S Sasaki, T Fujita"," Drug Discovery Laboratories, Welfide Corporation, Iruma-shi, Saitama, Japan. kiuchi@welfide.co.jp",2000 Jul;43(15):2946-61,10.1021/jm000173z
10975841,20000915,article,mesh,"Apoptosis,Caspase 3,Caspases,Cell Nucleus,Cytochrome c Group,Cytosol,Enzyme Activation,Fingolimod Hydrochloride,HL-60 Cells,Humans,Immunosuppressive Agents,Intracellular Membranes,Jurkat Cells,Membrane Potentials,Mitochondria,Permeability,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,drug effects,enzymology,genetics,immunology,metabolism,pharmacology,physiology,secretion","D007425 Q000187 NN,D019253 Q000235 NN,D007425 Q000201 NY,D007166 Q000494 NY,D008928 Q000187 NN,D019253 Q000502 NN,D017209 Q000187 NY,D008564 Q000276 NN,D010539 Q000187 NN,D003574 Q000557 NY,D019253 Q000096 NN,D004789 Q000187 NN,D008928 Q000201 NY,D011409 Q000494 NY,D013110 Q000031 NN,D004789 Q000276 NN,D007425 Q000557 NN,D017209 Q000276 NN,D008564 Q000187 NN,D003600 Q000187 NN,D002467 Q000187 NN,D020169 Q000378 NN,D008928 Q000557 NN,D003574 Q000037 NN","107969,107970,5280335",NULL,Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria.,"FTY720 has immunosuppressive activity in experimental organ transplantation and shows a prompt and protracted decrease of blood T lymphocytes upon oral administration. The blood lymphocyte decrease in vivo was mainly a result of FTY720-induced apoptosis. However, this apoptotic mechanism is not well understood. We examined the mechanism of FTY720-induced apoptosis in lymphoma. Western blotting and fluorescent caspase-specific substrate revealed that caspase-3 is involved in FTY720-induced apoptosis, whereas","Journal of immunology (Baltimore, Md. : 1950)","Y Nagahara, M Ikekita, T Shinomiya"," Division of Research Promotion, National Children's Medical Research Center, Tokyo, Japan. Chiba, Japan.",2000 Sep;165(6):3250-9,10.4049/jimmunol.165.6.3250
10988354,20000801,article,mesh,"Animals,CD8-Positive T-Lymphocytes,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Lymphocyte Count,Male,Propylene Glycols,Rats,Rats, Inbred F344,Skin Transplantation,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D016038 Q000276 NY,D011409 Q000494 NY,D013110 Q000031 NN,D006085 Q000187 NY,D018414 Q000187 NN,D018655 Q000187 NN","107969,107970,5280335",NULL,The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival.,"FTY720, a potent immunosuppressant, dramatically decreases the number of peripheral blood lymphocytes within a few hours after administration. The current study assessed the significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival (WKAH donor to F344 recipient). The median survival time of allografts was 7 days in the control recipients. FTY720 (1 mg/kg/day) significantly prolonged allograft survival when administered from days 0 and 3, but faile",International journal of immunopharmacology,"Y Yanagawa, Y Hoshino, K Chiba"," Tokyo Laboratories, Yoshitomi Pharmaceutical Industries Ltd., 3-7-25 Koyata, Iruma, 358-0026, Saitama, Japan.",2000 Aug;22(8):597-602,10.1016/s0192-0561(00)00022-9
10995936,20000901,article,mesh,"Animals,Blood Transfusion,Combined Modality Therapy,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppression,Immunosuppressive Agents,Intestine, Small,Male,Propylene Glycols,Rats,Rats, Inbred Strains,Sphingosine,Survival Rate,T-Lymphocytes,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,physiology,therapeutic use,transplantation","D006085 Q000187 NN,D013601 Q000276 NN,D006085 Q000502 NY,D013110 Q000031 NN,D007421 Q000637 NY,D007166 Q000627 NY,D007165 Q000379 NY,D014184 Q000276 NY,D016027 Q000276 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,Tolerance induction with FTY720 and donor-specific blood transfusion: discrepancy between heart transplantation and intestinal transplantation.,NULL,Transplantation proceedings,"T Koshiba, P Ji, K Tanaka, P McMaster, B Van Damme, M Waer, J Pirenne"," Abdominal Transplant Surgery Anatomopathology and Experimental Transplant Laboratory, KU, Leuven, Belgium.",2000 Sep;32(6):1255-7,10.1016/s0041-1345(00)01213-6
11005317,20000601,article,mesh,"Animals,Body Weight,Drug Therapy, Combination,Everolimus,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Lymphocyte Count,Male,Myocardium,Propylene Glycols,Rats,Rats, Inbred Lew,Sirolimus,Sphingosine,Transplantation, Heterotopic","analogs &amp; derivatives,drug effects,immunology,pathology,therapeutic use","D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D009206 Q000473 NN,D020123 Q000031 NY,D016027 Q000276 NY,D011409 Q000627 NY,D020123 Q000627 NN","107969,107970,5280335,5284616,6442177",NULL,The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD.,"OBJECTIVE: The new immunomodulator 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720) lowers the peripheral lymphocyte count (PLC) by inducing migration of circulating lymphocytes to secondary lymphoid organs. This effect is dose-dependent at low (up to 0.1 mg/kg per day) doses in rats. We investigated the correlation between PLC and the later rejection, when FTY720 was combined with RAD. METHODS: Heterotopic cardiac grafting was performed using the DA-Lewis strain combination. FTY720",Transplant immunology,"Z Nikolova, A Hof, Y Baumlin, R P Hof"," Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.",2000 Jun;8(2):115-24,10.1016/s0966-3274(00)00016-2
11028757,20000801,article,mesh,"Animals,Arthritis, Experimental,Cyclosporine,Edema,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Lymphocytes,Male,Monocytes,Mycobacterium tuberculosis,Neutrophils,Osteolysis,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Tacrolimus","administration &amp; dosage,analogs &amp; derivatives,blood,immunology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D016559 Q000627 NN,D001169 Q000097 NN,D016572 Q000008 NN,D011409 Q000008 NN,D001169 Q000276 NN,D013110 Q000031 NN,D010014 Q000517 NN,D009169 Q000276 NN,D007166 Q000627 NY,D001169 Q000517 NY,D011409 Q000627 NY,D004487 Q000517 NN","2909,5372,62280,107969,107970,445643,5280335,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,122172945,123134263,123134270,132274082,134694629",NULL,"Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats.","OBJECTIVE AND DESIGN: Anti-arthritic effect of FTY720, a novel immunosuppressant, was compared with those of immunosuppressants cyclosporin A and tacrolimus in adjuvant-induced arthritis in rats. MATERIAL: Male LEW rats. TREATMENT: FTY720 (0.03-0.3 mg/kg), cyclosporin A (1-10 mg/kg) or tacrolimus (0.3-3 mg/kg) were orally administered to rats for 21 days beginning on the day (day 0) of adjuvant inoculation. In addition, the anti-arthritic effect of FTY720 (0.3 mg/kg) and cyclosporin A (10 mg/kg) were evalua",Inflammation research : official journal of the European Histamine Research Society ... [et al.],"M Matsuura, T Imayoshi, K Chiba, T Okumoto"," Drug Development Laboratories, Welfide Corporation, Chikujo-gun, Fukuoka, Japan. matsuura_mamoru@welfide.co.jp",2000 Aug;49(8):404-10,10.1007/s000110050608
11091096,20000901,article,NULL,NULL,NULL,NULL,NULL,NULL,Effects of selenium deficiency on the formation and detoxification of endogenous electrophiles in rats.,"Selenium deficiency could be expected to lead to enhanced lipid peroxidation through loss of selenium-dependent glutathione peroxidase activity. Such a relation has, however, been difficult to verify. In the present study, the influence of selenium deficiency in rats on in vivo doses of some endogenously occurring low-molecular mass aldehydes and epoxides was determined. In vivo doses were measured by mass-spectrometric analysis according the N-alkyl Edman method of reaction products (adducts) with N-termin",The Journal of nutritional biochemistry,"A Kautiainen, M Törnqvist, U Olsson"," Department of Environmental Chemistry, Wallenberg Laboratory, Stockholm University, Stockholm, Sweden.",2000 Sep;11(9):425-30,10.1016/s0955-2863(00)00099-1
11111172,20000101,article,mesh,"Animals,Blood Cell Count,Blood Cells,CD4-CD8 Ratio,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Flow Cytometry,Graft Rejection,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Monocytes,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Wistar,Receptors, Interleukin-2,Sphingosine,Spleen,Transplantation, Homologous","analogs &amp; derivatives,drug effects,metabolism,pathology,therapeutic use","D009000 Q000473 NN,D009000 Q000378 NN,D015375 Q000378 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D013154 Q000473 NN,D011409 Q000627 NY,D001773 Q000187 NN","107969,107970,5280335",NULL,"Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats.","FTY720 was developed by chemical modification of ISP-1 which was purified from culture filtrates of an ascomycete, Isaria sinclairii. We evaluated the effect of FTY720 on allograft survival using a rat renal transplantation model in which Wistar King Aptekman Hokkaido rats (WKAH, RT1(K)) served as the organ donor and Lewis rats (LEW, RT1(l)) as the recipient. WKAH renal allografts were acutely rejected by the untreated LEW recipients at a mean graft survival +/- SD of 7.2 +/- 0.4 days (n = 5). Consecutive o",European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,"H Ueda, S Takahara, H Azuma, M Kusaka, S Suzuki, Y Katsuoka"," Department of Urology, Osaka Medical College, Osaka, Japan.",2000 Jan;32(5):279-83,10.1159/000008776
11112021,20000101,article,mesh,"Apoptosis,Dose-Response Relationship, Drug,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Lymphocytes,Placebos,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,immunology,pharmacology","D008214 Q000276 NY,D007166 Q000494 NY,D011409 Q000009 NN,D007166 Q000008 NN,D017209 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D016030 Q000276 NY,D008214 Q000187 NN","107969,107970,5280335",NULL,FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.,The novel immunosuppressive compound FTY 720A posseses a mode of action which is different from all other immunosuppressive drugs. The most prominent feature is a reversible decrease in peripheral lymphocyte counts observed in animal experiments. We investigated in the first human trial (phase 1) whether FTY 720A induces apoptosis of peripheral blood mononuclear cells (PBMC) in stable renal allograft recipients. Monitoring of lymphocyte counts revealed a significant and dose-dependent decrease within 6 h po,Transplant international : official journal of the European Society for Organ Transplantation,"T Böhler, J Waiser, M Schütz, M Friedrich, R Schötschel, S Reinhold, R Schmouder, K Budde, H H Neumayer"," Department of Nephrology, Humboldt-University Berlin, Germany. torsten.boehler@charite.de",2000 Jan;?(?):S311-3,10.1111/j.1432-2277.2000.tb02048.x
11119867,20001101,article,mesh,"Animals,Bone Marrow Cells,Dendritic Cells,Female,Fingolimod Hydrochloride,H-Y Antigen,Immunization,Immunologic Memory,Immunosuppressive Agents,Isoantibodies,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Recombination, Genetic,Skin Transplantation,Sphingosine,Transplantation, Isogeneic","analogs &amp; derivatives,drug effects,immunology,pharmacology","D007518 Q000276 NN,D007166 Q000494 NY,D016038 Q000276 NY,D001854 Q000276 NY,D014185 Q000276 NN,D006182 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D003713 Q000276 NY,D007156 Q000187 NY","107969,107970,5280335",NULL,"New immunosuppressive reagent, FTY 720, spares immunologic memory.",NULL,Transplantation proceedings,"G Lei, H Amemiya, S Suzuki, T Goto, T Kokubo, M Miyamoto, H Kimura"," Department of Research Surgery, National Children's MRC , Tokyo, Japan.",2000 Nov;32(7):1628,10.1016/s0041-1345(00)01443-3
11119868,20001101,article,mesh,"Animals,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred WKY,Sphingosine,Survival Rate,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D006084 Q000188 NY,D006085 Q000276 NY,D013110 Q000031 NN,D016027 Q000473 NN,D007166 Q000627 NY,D006084 Q000473 NN,D006084 Q000517 NN,D016027 Q000276 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,Rescuing acute rejection of rat cardiac allografts with FTY720.,NULL,Transplantation proceedings,"S C Chueh, C C Tsai, B Chiu, Y C Li, M K Lai"," Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan.",2000 Nov;32(7):1629-30,10.1016/s0041-1345(00)01442-1
11120049,20001101,article,mesh,"Abatacept,Animals,Antigens, CD,Antigens, Differentiation,CTLA-4 Antigen,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunoconjugates,Immunosuppressive Agents,Intraoperative Period,Lymphocyte Culture Test, Mixed,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Time Factors","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D007166 Q000008 NN,D000943 Q000008 NN,D000943 Q000627 NY,D006085 Q000276 NY,D011409 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D016027 Q000276 NY,D011409 Q000627 NY","107969,107970,5280335",NULL,Perioperative administration of FTY720 and CTLA4IG in rat heart transplantation.,NULL,Transplantation proceedings,"M Ohba, X K Li, Y Kita, A Tamura, S Enosawa, S Sasakuri, S Ogoshi, H Amemiya, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",2000 Nov;32(7):2024-5,10.1016/s0041-1345(00)01541-4
11137062,20001215,review,mesh,"Animals,Binding Sites,DNA,DNA Adducts,Environmental Monitoring,Epoxy Compounds,Humans,Mutagens,Structure-Activity Relationship","chemistry,metabolism,pharmacokinetics","D018736 Q000378 NY,D004852 Q000493 NY,D004247 Q000378 NY,D009153 Q000493 NN,D004247 Q000737 NN",44135672,NULL,Specific DNA adducts induced by some mono-substituted epoxides in vitro and in vivo.,"Alkyl epoxides are important intermediates in the chemical industry. They are also formed in vivo during the detoxification of alkenes. Alkyl epoxides have shown genotoxicity in many toxicology assays which has been associated with their covalent binding to DNA. Here aspects of the formation and properties of DNA adducts, induced by some industrially important alkenes and mono-substituted epoxides are discussed. These include propylene oxide, epichlorohydrin, allyl glycidyl ether and the epoxy metabolites o",Chemico-biological interactions,"M Koskinen, K Plná"," Department of Biosciences at Novum, Center for Nutrition and Toxicology, Karolinska Institute, S-141 57, Huddinge, Sweden. mikko.koskinen@cnt.ki.se",2000 Dec;129(3):209-29,10.1016/s0009-2797(00)00206-4
11147698,20001101,article,mesh,"Administration, Oral,Animals,B-Lymphocytes,Cyclosporine,Dose-Response Relationship, Drug,Drug Tolerance,Everolimus,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Count,Lymphocyte Depletion,Macaca fascicularis,Propylene Glycols,Sirolimus,Sphingosine,T-Lymphocytes,Transplantation Immunology","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,immunology,methods,pharmacology","D007166 Q000494 NY,D007166 Q000008 NN,D007166 Q000097 NN,D001402 Q000276 NY,D001402 Q000187 NY,D020123 Q000008 NN,D016572 Q000008 NN,D011409 Q000008 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013601 Q000187 NY,D008212 Q000379 NY,D013601 Q000276 NY,D011409 Q000097 NN,D020123 Q000031 NN","2909,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,"The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.","OBJECTIVE: FTY720 is a new immunosuppressant active in transplantation models, which modulates lymphocyte recirculation, leading to transient peripheral lymphopenia and increased lymphocytes in lymph nodes and Peyer's patches. Here, we investigated the susceptibility of cynomolgus monkeys to FTY720 given orally either alone or in combination with two other immunosuppressants, Cyclosporin Neoral or RAD, as an introductory study to transplantation protocols. METHODS: Each of the three phases of the study comp",Transplant immunology,"V F Quesniaux, K Menninger, A Kunkler, C Vedrine, M Bernhard, R Hedinger, G Kraus, H J Schuurman"," Transplantation Research Department, Novartis Pharma, Basel, Switzerland. quesniaux@cnrs-orleans.fr",2000 Nov;8(3):177-87,10.1016/s0966-3274(00)00025-3
11165091,20010201,article,"xref,mesh","Anti-Bacterial Agents,Chemical Phenomena,Chemistry, Physical,Chromatography, High Pressure Liquid,Sirolimus,Solubility,Solvents",chemistry,"D020123 Q000737 NY,D000900 Q000737 NY","243,244,702,8252,5284616,91454826,91534498","128482492,129060975,129617188,129638713,248184126,248766214",Solubilization of rapamycin.,"The solubilization of rapamycin, a poorly water soluble investigational immunosuppressive drug, by facilitated hydrotropy is presented. Partially water-miscible aromatic solutes (such as benzyl alcohol, benzoate, or benzoic acid) can be solubilized by water-miscible cosolvents, such as ethanol and propylene glycol. Once solubilized, the partially miscible aromatic solute becomes a solubilizing agent. This technique yielded a dramatic (>1000-fold) increase in the aqueous solubility of rapamycin. ",International journal of pharmaceutics,"P Simamora, J M Alvarez, S H Yalkowsky"," Pharmaceutical Research and Development, Schering-Plough HealthCare Products, Inc., 3030 Jackson Avenue, Memphis, TN 38151, USA. pahala.simamora@spcorp.com",2001 Feb;213(?):25-9,10.1016/s0378-5173(00)00617-7
11181042,20010223,article,"xref,mesh","Antineoplastic Agents, Phytogenic,Apoptosis,Caspase 3,Caspase 6,Caspases,Cell Death,Cell Survival,Cysteine Proteinase Inhibitors,DNA Fragmentation,Dose-Response Relationship, Drug,Enzyme Activation,Etoposide,Fingolimod Hydrochloride,Focal Adhesion Kinase 1,Focal Adhesion Protein-Tyrosine Kinases,Glioma,Humans,Immunosuppressive Agents,Oligopeptides,Phosphatidylinositol 3-Kinases,Phosphorylation,Propylene Glycols,Protein Tyrosine Phosphatases,Protein-Serine-Threonine Kinases,Protein-Tyrosine Kinases,Proto-Onc","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology","D015853 Q000494 NN,D007166 Q000494 NY,D017209 Q000187 NY,D019869 Q000378 NN,D014638 Q000494 NN,D005910 Q000188 NN,D002470 Q000187 NN,D014407 Q000166 NN,D011518 Q000378 NN,D053938 Q000187 NN,D020169 Q000187 NN,D016923 Q000187 NN,D004789 Q000187 NN,D011409 Q000494 NY,D017027 Q000037 NN,D013110 Q000031 NN,D005047 Q000494 NN,D009842 Q000494 NN,D020169 Q000378 NN,D010766 Q000187 NN,D000972 Q000494 NN,D011505 Q000378 NN,D005910 Q000473 NY,D014407 Q000187 NN,D014443 Q000378 NN","5862,6057,8252,26218,31270,36462,61671,107969,107970,284997,417214,439525,5280335,9830615,16760394,54376315","128394615,128865459,129060975,129431592,129645792,129742316,135867281","FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells.","FTY720, a metabolite from Isaria sinclairii, has been developed to be a potent immunosuppressive drug with induction of apoptosis in T cells and several cell lines. We investigated whether FTY720 induces apoptosis in human glioma cell lines, since they are relatively resistant to multiple apoptotic stimuli. In human glioma cells including T98G, FTY720 induced apoptosiswith ED50 between 1 to 10 microg/ml, while etoposidedid not induce apoptosis at the same doses. Among the caspase family proteases, mainly ca",Biochemical and biophysical research communications,"Y Sonoda, D Yamamoto, S Sakurai, M Hasegawa, E Aizu-Yokota, T Momoi, T Kasahara"," Department of Biochemistry and Immunology, Kyoritsu College of Pharmacy, Shibakoen 1-5-30, Minato-ku, Tokyo 105, Japan.",2001 Feb;281(2):282-8,10.1006/bbrc.2001.4352
11207666,20010201,article,"xref,mesh","Animals,Apoptosis,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Liver,Liver Transplantation,Lymphocytes,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,immunology,pathology,prevention &amp; control","D008214 Q000276 NY,D008099 Q000473 NN,D011409 Q000276 NN,D008214 Q000473 NN,D008099 Q000276 NN,D013110 Q000031 NN,D017209 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY,D006084 Q000276 NY,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720.,"The action mechanism of FTY720, a novel immunosuppressant, is completely different from conventional immunosuppressants. The drug, which triggers apoptosis in murine and human lymphocytes, has a potent immunosuppressive activity to prevent allograft rejection without any severe side-effect. The present study was designed to determine whether FTY720 induces apoptotic cell death in activated lymphocytes infiltrated into liver grafts with ongoing rejection. FTY720 was orally administered at 5 mg/kg to the reci",Clinical and experimental immunology,"X K Li, A Tamura, M Fujino, L Guo, T Kakefuda, N Funeshima, S Enosawa, M Amari, S Naoe, H Amemiya, S Suzuki"," Department of Experimental Surgery & Bioengineering, National Children's Medical Research Centre, Tokyo, Japan.",2001 Feb;123(2):331-9,10.1046/j.1365-2249.2001.01434.x
11220404,20010101,review,"xref,mesh","Animals,Child,Child, Preschool,Cyclosporine,Drug Interactions,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Liver Transplantation,Mycophenolic Acid,Propylene Glycols,Sirolimus,Sphingosine,Tacrolimus","analogs &amp; derivatives,drug therapy,metabolism,pharmacokinetics,therapeutic use","D006084 Q000188 NY,D016572 Q000627 NY,D009173 Q000031 NY,D009173 Q000627 NY,D016559 Q000493 NN,D006084 Q000378 NN,D016572 Q000493 NN,D007166 Q000493 NN,D013110 Q000031 NN,D009173 Q000493 NN,D007166 Q000627 NY,D011409 Q000493 NN,D011409 Q000627 NN,D020123 Q000493 NN,D020123 Q000627 NN,D016559 Q000627 NY","2909,4271,4272,5372,8252,31270,62280,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6473866,6536850,9855081,23665584,24883466,25246316,49867938,57123750,57317596,71306795,71463825,71668407,73896891,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129645792,135979775,136314073,242963342,248766214",Immunosuppressive drugs in paediatric liver transplantation.,"Orthotopic liver transplantation is established treatment for children with acute and chronic liver failure. Despite advances in pre- and postoperative management, innovative surgical techniques and new immunosuppressive drugs, acute and chronic rejection remains a problem. In addition, well established adverse effects of commonly used immunosuppressive drugs are no longer accept able. More potent, but less toxic, immunosuppressive agents have been developed and some novel compounds are now entering routine",Paediatric drugs,"I D van Mourik, D A Kelly"," Liver Unit, The Birmingham Children's Hospital NHS Trust, England. Tracey.Ellis@bhamchildrens.wmids.nhs.uk",2001 Jan;3(1):43-60,10.2165/00128072-200103010-00004
11224744,20010301,review,"xref,mesh","Adrenal Cortex Hormones,Alkylating Agents,Calcineurin Inhibitors,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Purines,Pyrimidines,Sirolimus,Sphingosine,Vitamin D","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,therapeutic use","D011687 Q000037 NN,D020123 Q000037 NN,D000477 Q000627 NN,D014807 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011743 Q000037 NN,D014807 Q000031 NN,D011409 Q000627 NN,D000305 Q000627 NN,D011743 Q000096 NN,D011687 Q000096 NN","1044,8252,9260,31270,107969,107970,5280335,5284616,91454826,91534498","127700914,128365023,128394615,129060975,129645792,248184126,248766214",New immunosuppressive drugs: an update.,"An increasing number of immunosuppressive drugs became available for clinical use over the past few decades. These include substances with recently recognized immunosuppressive properties, which needed careful evaluation in various trials before they could be approved for use in different diseases. The effectiveness of other agents was already established, but knowledge about their modes of action or the mechanisms that lead to side effects was acquired much later. This understanding also contributed to the",Current opinion in urology,E Pohanka," Department of Nephrology and Dialysis, Clinic of Internal Medicine III, University of Vienna, Medical School, Vienna, Austria. pohanka@nephro.imed3.akh-wien.ac.at",2001 Mar;11(2):143-51,10.1097/00042307-200103000-00004
11266942,20010101,article,"xref,mesh","B-Lymphocytes,Cell Movement,Fingolimod Hydrochloride,Graft Survival,Humans,Immunosuppression,Immunosuppressive Agents,Propylene Glycols,Sphingosine,T-Lymphocytes,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology","D007166 Q000494 NY,D013601 Q000276 NN,D002465 Q000187 NY,D001402 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D001402 Q000276 NN,D013601 Q000187 NY,D006085 Q000187 NY,D006085 Q000276 NN,D002465 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression.,NULL,Transplantation proceedings,"V Brinkmann, S Chen, L Feng, D Pinschewer, Z Nikolova, R Hof"," Transplantation Research, Novartis Pharma AG, Basel, Switzerland. volker.brinkmann@pharma.novartis.com",2001 Jan;33(?):530-1,10.1016/s0041-1345(00)02126-6
11266948,20010101,article,"xref,mesh","Animals,Chronic Disease,Fingolimod Hydrochloride,Graft Rejection,Heart Transplantation,Immunosuppressive Agents,Male,Models, Animal,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Sphingosine,Transplantation, Heterotopic,Transplantation, Homologous","analogs &amp; derivatives,pathology,prevention &amp; control,therapeutic use","D013110 Q000031 NN,D007166 Q000627 NY,D016027 Q000473 NY,D011409 Q000627 NY,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 prevents chronic rejection of rat heterotopic cardiac allografts.,NULL,Transplantation proceedings,"S C Chueh, J R Chen, J Chen, M K Lai"," Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan.",2001 Jan;33(?):542-3,10.1016/s0041-1345(00)02132-1
11267010,20010101,article,"xref,mesh","Animals,Diabetes Mellitus, Experimental,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Islets of Langerhans,Islets of Langerhans Transplantation,Mice,Mice, Inbred BALB C,Mice, Inbred CBA,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Transplantation, Heterologous","analogs &amp; derivatives,drug effects,pharmacology,physiology,therapy","D007166 Q000494 NY,D003921 Q000628 NN,D016381 Q000502 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007515 Q000187 NY,D006085 Q000187 NY,D007515 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model.",NULL,Transplantation proceedings,"F Fu, S Hu, S Li, J DeLeo, J Hoover, S Wang, P Lake, V Shi"," Novartis Pharmaceuticals Corp, Transplantation Research Department, Summit, New Jersey, USA.",2001 Jan;33(?):672-3,10.1016/s0041-1345(00)02195-3
11267102,20010101,article,"xref,mesh","Animals,Biomarkers,Creatinine,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Male,Propylene Glycols,Rats,Rats, Sprague-Dawley,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,blood,blood supply,prevention &amp; control,therapeutic use","D003404 Q000097 NN,D015427 Q000517 NY,D013110 Q000031 NN,D007166 Q000627 NY,D007668 Q000098 NY,D011409 Q000627 NY,D015415 Q000097 NN","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792",FTY 720 prevents ischemic reperfusion damage in rat kidneys.,NULL,Transplantation proceedings,"P Troncoso, M Ortíz, L Martínez, B D Kahan"," Department of Urology and Renal Transplantation, Pontificia Universidad Católica de Chile, Santiago, Chile.",2001 Jan;33(?):857-9,10.1016/s0041-1345(00)02349-6
11316070,20010201,article,"xref,mesh","Adjuvants, Immunologic,Animals,Body Weight,Cyclosporine,Dose-Response Relationship, Drug,Drug Evaluation, Preclinical,Drug Synergism,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Histocompatibility Antigens,Immunosuppressive Agents,Lymphocyte Count,Male,Models, Animal,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Skin Transplantation,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,immunology,pharmacology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D007166 Q000494 NY,D007166 Q000008 NN,D001835 Q000187 NN,D007166 Q000627 NN,D016038 Q000276 NY,D007166 Q000097 NN,D006649 Q000276 NN,D016572 Q000494 NY,D016572 Q000008 NN,D011409 Q000008 NN,D011409 Q000494 NY,D000276 Q000494 NY,D013110 Q000031 NN,D000276 Q000627 NN,D000276 Q000008 NN,D006085 Q000187 NY,D006084 Q000517 NN,D011409 Q000627 NN,D016027 Q000276 NY,D016572 Q000097 NN,D000276 Q000097 NN,D011409 Q000097 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models.,"OBJECTIVE: The immunomodulator, FTY720, lowers the peripheral lymphocyte count (PLC) by inducing migration of circulating lymphocytes to secondary lymphoid organs. We investigated the efficacy of mono- vs. combined-FTY720/CsA therapy on graft survival (GS) and on lowering the PLC in a solid organ and a skin graft model, using strains with strong MHC disparity. METHODS: Heterotopic cardiac or tail skin grafting was performed using the DA (RT1a) to Lewis (RT1(1)) rat strain combination. FTY720 was administere",Transplant immunology,"Z Nikolova, A Hof, Y Baumlin, R P Hof"," Novartis Pharma Research, Nocartis Pharma AG, Basel, Switzerland.",2001 Feb;8(4):267-77,10.1016/s0966-3274(01)00031-4
11336992,20010509,article,xref,"Animals,DNA Adducts,DNA Damage,DNA Repair,DNA-Binding Proteins,Drosophila,Endonucleases,Female,Humans,Male,Mice,Mutagens,Mutation,Nuclear Proteins,Phenotype,Species Specificity,Spermatozoa,Transcription Factors","drug effects,genetics,toxicity","D004330 Q000235 NY,D013094 Q000187 NN,D018736 Q000187 NN,D004268 Q000235 NY,D018736 Q000235 NN,D009153 Q000633 NN","4033,4156,6354,8252,9033,13369","128034383,128141679,128569758,128733350,129060975,129488546",Phenotypes of Drosophila homologs of human XPF and XPG to chemically-induced DNA modifications.,"DmXPF (mei9) and DmXPG (mus201) mutants are Drosophila homologs of the mammalian XPF and XPG genes, respectively. For Drosophila germ cells, causal correlations exist between the magnitude of a potentiating effect of a deficiency in these functions, measured as the M(NER-)/M(NER+) mutability ratio, and the type of DNA modification. M(NER-)/M(NER+) mutability ratios may vary with time interval between DNA adduct formation and repair, mutagen dose and depend also on the genetic endpoint measured. For forward ",Mutation research,"E W Vogel, M J Nivard"," Department of Radiation Genetics & Chemical Mutagenesis, MGC Sylvius Laboratories, Leiden University Medical Centre, Wassenaarseweg 72, 2300 RA Leiden, The Netherlands. e.w.vogel@lumc.nl",2001 May;476(?):149-65,10.1016/s0027-5107(01)00121-x
11344387,20010401,article,"xref,mesh","Abatacept,Animals,Antigens, CD,Antigens, Differentiation,CTLA-4 Antigen,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunoconjugates,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Recombinant Fusion Proteins,Sphingosine,Transfection","analogs &amp; derivatives,blood,genetics,immunology,therapeutic use","D011993 Q000097 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000235 NY,D000943 Q000097 NN,D016027 Q000276 NY,D011409 Q000627 NY,D011993 Q000235 NY,D000943 Q000235 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Long-term graft acceptance in rat heart transplantation by CTLA4Ig gene transfection combined with FTY720 treatment.,"CTLA4Ig strongly adheres to B7 molecules on antigen-presenting cells to block intracellular signal transduction via CD28 on helper T cells, which eventually inhibits immune responses. We have demonstrated that the administration to recipient animals of adenoviral vectors containing CTLA4Ig gene (adCTLA4Ig) prolonged graft survival, although the gene expression diminished in a time-dependent manner and the grafts were finally rejected. In addition, recipient animals treated with FTY720, a new immunosuppressa",World journal of surgery,"M Ohba, X K Li, Y Kita, S Enosawa, N Funeshima, H Nagai, H Zhang, T Okuyama, S Ogoshi, S Sasaguri, H Amemiya, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8509, Japan.",2001 Apr;25(4):?,10.1007/s002680020071
11344393,20010401,article,xref,"Animals,Diatrizoate,Drug Combinations,Fatty Acids,Male,Microcirculation,Necrosis,Pancreas,Pancreatic Ducts,Pancreatitis,Propylene Glycols,Rats,Rats, Inbred Lew,Sclerosing Solutions,Zein","blood supply,drug effects,drug therapy,pathology,pharmacology,surgery,therapeutic use","D003973 Q000494 NY,D010195 Q000473 NY,D010179 Q000098 NY,D012597 Q000627 NN,D015028 Q000494 NY,D015028 Q000627 NN,D010195 Q000188 NN,D011409 Q000494 NY,D012597 Q000494 NY,D010179 Q000473 NN,D005227 Q000627 NN,D005227 Q000494 NY,D010195 Q000601 NY,D003973 Q000627 NN,D011409 Q000627 NN,D008833 Q000187 NN","300,2140,6675,8252","127875057,129060975,129854680,135750992","Temporary pancreatic duct occlusion by ethibloc: cause of microcirculatory shutdown, acute inflammation, and pancreas necrosis.","Temporary obliteration of the pancreatic duct has been suggested to be beneficial in chronic pancreatitis, segmental pancreatic transplantation, and following Roux-Y pancreaticojejunostomy. Little is known, however, as to whether obliteration of the duct alters exocrine pancreatic physiology. Therefore we studied in male inbred Lewis rats the immediate effects of Ethibloc-induced duct obliteration (Ethibloc: Ethicon, Norderstedt, Germany) on pancreatic microcirculation, inflammation, and tissue injury (n = ",World journal of surgery,"T Plusczyk, S Westermann, B Bersal, M Menger, G Feifel"," Department of General Surgery, University of Saarland, Kirrbergerstrasse, 66421 Homburg/Saar, Germany.",2001 Apr;25(4):432-7,10.1007/s002680020041
11345389,20010501,article,"xref,mesh","Acute Disease,Animals,Cardiovirus Infections,Disease Models, Animal,Drug Evaluation, Preclinical,Encephalomyocarditis virus,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-gamma,Interleukin-12,Interleukin-2,Male,Mice,Mice, Inbred DBA,Myocarditis,Nitric Oxide,Proportional Hazards Models,Propylene Glycols,Severity of Illness Index,Sphingosine,Survival Analysis,Treatment Outcome,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,analysis,complications,diagnosis,drug therapy,immunology,mortality,pharmacology,therapeutic use,virology","D009205 Q000188 NY,D009205 Q000821 NY,D009205 Q000175 NN,D009205 Q000401 NN,D007376 Q000032 NN,D007371 Q000032 NN,D009569 Q000032 NN,D013110 Q000031 NN,D018188 Q000150 NY,D009205 Q000276 NN,D018664 Q000032 NN,D007166 Q000627 NY,D011409 Q000494 NN,D014409 Q000032 NN,D011409 Q000627 NY,D007166 Q000494 NN","8252,31270,107969,107970,145068,5280335","128394615,129060975,129645792","Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis.","OBJECTIVES: This study examines the efficacy of FTY720 (FTY), a new immunosuppressor, in the treatment of acute viral myocarditis in a murine model. BACKGROUND: Immunosuppressive agents have no proven therapeutic efficacy in experimental or clinical myocarditis. METHODS: Encephalomyocarditis virus was inoculated i.p. in DBA/2 mice on day 0. Postinoculation treatment consisted of FTY 10 mg/kg/day p.o. (FTY group), or cyclosporine A (CsA) 40 mg/kg/day p.o. (CsA group) or distilled water p.o. only (control gro",Journal of the American College of Cardiology,"T Miyamoto, A Matsumori, M W Hwang, R Nishio, H Ito, S Sasayama"," Department of Cardiovascular Medicine, Kyoto University, Japan.",2001 May;37(6):1713-8,10.1016/s0735-1097(01)01204-9
11356940,20010601,article,"xref,mesh","Animals,Cyclosporine,Dose-Response Relationship, Drug,Drug Synergism,Everolimus,Fibrosarcoma,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Histocompatibility,Immunity, Cellular,Immunosuppression,Immunosuppressive Agents,Mice,Mice, Inbred Strains,Mice, Nude,Models, Immunological,Neoplasm Transplantation,Propylene Glycols,Sirolimus,Sphingosine,T-Lymphocytes,Transplantation, Homologous,Tumor Cells, Cultured","analogs &amp; derivatives,drug effects,immunology,methods,pharmacology","D006085 Q000187 NN,D009368 Q000276 NN,D007111 Q000276 NY,D013601 Q000276 NN,D006085 Q000276 NY,D013110 Q000031 NN,D020123 Q000494 NN,D006648 Q000276 NN,D016572 Q000494 NN,D007165 Q000379 NY,D005354 Q000276 NY,D011409 Q000494 NN,D006084 Q000276 NN,D007111 Q000187 NN,D007166 Q000494 NN,D013601 Q000187 NN,D020123 Q000031 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,24883466,25246316,49867938,57317596,71306795,71463825,73896891,90696889,91534498,122172945,123134263,123134270,132274082","128394615,129060975,129645792,136314073,242749350,248766214",A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor.,"We describe a high-capacity in vivo assay to measure drug-mediated transplant immunosuppression using a mouse model of Sa1 tumor rejection. Sa1 grew poorly and was rejected by 14 days in immunocompetent allogeneic recipient mice. In nude (nu/nu) mice, Sa1 grew more rapidly and was not rejected, confirming the T cell dependence of this response. In immunocompetent animals, administration of immunosuppressive agents resulted in increased tumor growth relative to vehicle-treated animals. Treatment with immunos",The Journal of pharmacology and experimental therapeutics,"D Hammond-McKibben, P Lake, J Zhang, N Tart-Risher, R Hugo, M Weetall"," Transplantation Research, Novartis Pharmaceuticals, Summit, New Jersey, USA.",2001 Jun;297(3):1144-51,NULL
11377496,20010501,article,"xref,mesh","Animals,Carotid Arteries,Cyclosporine,Drug Therapy, Combination,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Lymphocyte Count,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Time Factors,Transplantation, Homologous,Tunica Intima","analogs &amp; derivatives,immunology,physiology,therapeutic use,transplantation","D017539 Q000637 NY,D016572 Q000627 NY,D002339 Q000502 NN,D013110 Q000031 NN,D007166 Q000627 NY,D002339 Q000637 NY,D014184 Q000276 NY,D011409 Q000627 NY,D017539 Q000502 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Neointima suppression in rat carotid allografts by FTY720 combined with a small fixed cyclosporine dose is related to a diminution of the peripheral lymphocyte count.,NULL,Transplantation proceedings,"Z Nikolova, R P Hof"," Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.",2001 May;33(3):2184-5,10.1016/s0041-1345(01)01935-2
11377564,20010501,article,"xref,mesh","ABO Blood-Group System,Animals,B-Lymphocytes,Cyclosporine,Drug Therapy, Combination,Everolimus,Fingolimod Hydrochloride,Graft Survival,Histocompatibility Testing,Immunophenotyping,Immunosuppressive Agents,Kidney Transplantation,Macaca fascicularis,Major Histocompatibility Complex,Propylene Glycols,Sirolimus,Sphingosine,T-Lymphocytes,Time Factors","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D013601 Q000276 NN,D006085 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D001402 Q000276 NN,D016030 Q000276 NY,D000017 Q000276 NN,D011409 Q000627 NY,D020123 Q000627 NN,D020123 Q000031 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,24883466,25246316,49867938,71306795,71463825,73896891,90696889,91534498,122172945,123134263,123134270,132274082","128394615,129060975,129645792,242749350,248766214",FTY-720 is efficacious in monkey kidney transplantation.,NULL,Transplantation proceedings,"V Quesniaux, K Menninger, M Audet, L Gaschen, H J Schuurman"," Department of Transplantation, Preclinical Research, Novartis Pharma AG, Basel, Switzerland.",2001 May;33(3):2374-5,10.1016/s0041-1345(01)02026-7
11406149,20010801,article,"xref,mesh","Animals,Biomarkers,CD4 Antigens,CD4-Positive T-Lymphocytes,CD8 Antigens,Concanavalin A,Cyclosporine,Everolimus,Fingolimod Hydrochloride,Flow Cytometry,Guanidines,Immunosuppressive Agents,Mitogens,Propylene Glycols,Rats,Rats, Inbred Lew,Sirolimus,Sphingosine,Tacrolimus","analogs &amp; derivatives,biosynthesis,drug effects,immunology,methods,pharmacology","D007166 Q000494 NY,D015496 Q000276 NN,D016559 Q000494 NN,D015496 Q000187 NY,D003208 Q000494 NN,D005434 Q000379 NN,D013110 Q000031 NN,D020123 Q000494 NN,D016827 Q000096 NY,D016572 Q000494 NN,D006146 Q000494 NN,D011409 Q000494 NN,D008934 Q000494 NN,D020123 Q000031 NN,D015704 Q000096 NY","2909,5372,8252,31270,55361,55362,62280,91272,107969,107970,445643,5280335,5280754,5282315,5284373,5284616,5458585,6435893,6442177,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90696889,90726579,91454826,91534498,122172945,123134263,123134270,132274082,134694629","128151681,128394615,129060975,129645792,242749350,242963342,248184126,248766214",Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs.,"The aim of this study was to develop a new quantitative method for measuring in vitro the effects of T-cell immunosuppressive drugs by flow cytometry. Rat whole blood samples were stimulated with the T-cell mitogen succinylated concanavalin A in the presence or absence of different drugs. After 3 days, the expression of CD25 and CD8alpha in mitogen-stimulated CD4(+) cells increased 10- to 20-fold as measured by flow cytometry. Drug efficacy and potency was calculated based on dose-response curves of the dru",Journal of immunological methods,"J Diaz-Romero, G Vogt, G Weckbecker"," Department of Transplantation, Preclinical Research, Building 386/628, Novartis Pharma AG, Lichstrasse 35, CH-4002 Basel, Switzerland.",2001 Aug;254(?):1-12,10.1016/s0022-1759(01)00363-5
11429058,20010601,article,"xref,mesh","Antineoplastic Agents,Apoptosis,Blotting, Western,Bromodeoxyuridine,Cell Cycle,Cell Division,DNA Fragmentation,Down-Regulation,Enzyme Activation,Fingolimod Hydrochloride,HL-60 Cells,Humans,Immunosuppressive Agents,Jurkat Cells,Okadaic Acid,Phosphoprotein Phosphatases,Phosphorylation,Precipitin Tests,Propylene Glycols,Retinoblastoma Protein,Signal Transduction,Sphingosine,Time Factors","analogs &amp; derivatives,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D000970 Q000494 NY,D019319 Q000494 NN,D002455 Q000187 NN,D010749 Q000378 NN,D016160 Q000378 NN,D053938 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D001973 Q000378 NN,D002453 Q000187 YN","4584,6035,8252,31270,107969,107970,446512,5280335,5353844,5468826,6102351,6426933,6476659,6917781,6918942,11953808,42628599,45356271,57059112,90479758,118701651,122172941,131839562,134688093","128394615,129060975,129645792,135870608,136216744",Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720.,"A novel reagent, FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), has been shown to induce a significant decrease of lymphocytes and lymphoma cells and is expected to be a potent immunosuppressant and anti-tumor drug. The decrease in lymphocytes and lymphoma cells is mainly the result of FTY720-induced apoptosis. FTY720 directly affects mitochondria and induces cell death. Moreover, FTY720 activates protein phosphatase (PP) 2A and affects anti-apoptotic intracellular signal transdu",Japanese journal of cancer research : Gann,"Y Nagahara, Y Matsuoka, K Saito, M Ikekita, S Higuchi, T Shinomiya"," Division of Research Promotion, National Children's Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8509, Japan.",2001 Jun;92(6):680-7,10.1111/j.1349-7006.2001.tb01148.x
11468555,20010715,article,"xref,mesh","Animals,Cyclosporine,Dose-Response Relationship, Drug,Drug Combinations,Female,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Lymphocyte Count,Mice,Mice, Inbred BALB C,Mice, Inbred C3H,Propylene Glycols,Sphingosine,Transplantation, Heterotopic,Transplantation, Homologous","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D016572 Q000494 NY,D011409 Q000494 NY,D013110 Q000031 NN,D006085 Q000187 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model.,"BACKGROUND: FTY720 lowers the peripheral lymphocyte count (PLC) by accelerating the migration of circulating lymphocytes to secondary lymphoid organs. We investigated the efficacy of combined FTY720+cyclosporine (CsA) treatment versus monotherapy on prolonging graft survival and on lowering the PLC. METHODS: BALB/c hearts were heterotopically grafted in C3H mice. FTY720 was administered alone or in combination with CsA. PLC and body weight were determined on day 7, day 28, or the day of rejection. RESULTS: ",Transplantation,"Z Nikolova, A Hof, Y Baumlin, R P Hof"," Novartis Pharma Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.",2001 Jul;72(1):168-71,10.1097/00007890-200107150-00033
11513883,20010817,article,"xref,mesh","Acetylcysteine,Apoptosis,Calpain,Caspase 8,Caspase 9,Caspase Inhibitors,Caspases,Cyclosporine,Cysteine Endopeptidases,Cysteine Proteinase Inhibitors,Eukaryotic Initiation Factor-4G,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Jurkat Cells,Leupeptins,Multienzyme Complexes,Peptide Fragments,Peptide Initiation Factors,Propylene Glycols,Proteasome Endopeptidase Complex,Sphingosine,T-Lymphocytes,fas Receptor","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,immunology,metabolism,pharmacology","D013601 Q000378 NN,D007166 Q000494 NY,D019014 Q000378 NN,D017209 Q000187 NN,D007976 Q000494 NN,D013601 Q000276 NN,D002154 Q000037 NN,D000111 Q000494 NN,D010446 Q000378 NY,D010448 Q000378 NY,D009097 Q000037 NY,D013110 Q000031 NN,D015853 Q000494 NY,D013601 Q000166 NN,D016572 Q000494 NN,D020169 Q000378 NN,D011409 Q000494 NN,D013601 Q000187 NN,D000111 Q000031 NY","2909,5862,8252,12035,31270,62280,107969,107970,425562,462382,5280335,5280754,5284373,5458585,6435893,6610292,9855081,12114682,23678798,24883466,25246316,49867938,53863337,57317596,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128022692,128394615,128977994,129060975,129645792,129742316,135909161,136314073",Proteasome inhibitors and immunosuppressive drugs promote the cleavage of eIF4GI and eIF4GII by caspase-8-independent mechanisms in Jurkat T cell lines.,"Previously, we have shown that translation eukaryotic initiation factor (eIF) 4GI is cleaved during anti-Fas-mediated apoptosis. Here, we have investigated the effects of the proteasome inhibitors, MG132 and lactacystin, and the immunosuppressants, 2-amino-2[2-(4-octylphenyl)ethyl]-1,3,propane diol (FTY720) and cyclosporin A, on the integrity of eIF4GI and eIF4GII in T cells. Using wild-type Jurkat T cells, we show that the proteasome inhibitors MG132 and lactacystin promote the cleavage of eIF4G, activate ",FEBS letters,"S J Morley, V M Pain"," Biochemistry Laboratory, School of Biological Sciences, University of Sussex, Falmer, Brighton, BN1 9QG, UK. s.j.morley@sussex.ac.uk",2001 Aug;503(?):206-12,10.1016/s0014-5793(01)02735-1
11571432,20010915,review,"xref,mesh","Animals,Autoimmune Diseases,Cell Movement,Chemokines,Clinical Trials as Topic,Cyclosporine,Diabetes Mellitus, Type 1,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Humans,Immunologic Memory,Immunosuppressive Agents,Inflammation,Islets of Langerhans Transplantation,Lymphocyte Activation,Lymphocytes,Models, Animal,Propylene Glycols,Safety,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,physiology,prevention &amp; control,therapy","D006085 Q000187 NN,D007249 Q000188 NN,D007166 Q000494 NY,D018925 Q000276 NN,D003922 Q000276 NN,D002465 Q000187 NN,D008214 Q000187 NY,D008214 Q000502 NN,D011409 Q000494 NY,D007156 Q000187 NN,D013110 Q000031 NN,D002465 Q000276 NN,D001327 Q000188 NN,D008213 Q000187 NN,D007249 Q000276 NN,D016572 Q000494 NN,D008214 Q000276 NN,D003922 Q000628 NN,D006084 Q000517 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",FTY720: altered lymphocyte traffic results in allograft protection.,NULL,Transplantation,"V Brinkmann, D D Pinschewer, L Feng, S Chen"," Novartis Pharma AG, Transplantation Research, WSJ-386.1.01, CH-4002 Basel, Switzerland.",2001 Sep;72(5):764-9,10.1097/00007890-200109150-00002
11575705,20010301,review,"xref,mesh","Antibodies, Monoclonal,Antimetabolites,Calcineurin Inhibitors,Cyclosporine,Cytokines,Drug Design,Fingolimod Hydrochloride,Graft Rejection,Guanidines,Humans,Immunosuppressive Agents,Lymphocyte Activation,Molecular Structure,Organ Transplantation,Propylene Glycols,Signal Transduction,Sirolimus,Sphingosine,T-Lymphocytes,Tacrolimus,Triterpenes","analogs &amp; derivatives,chemistry,drug effects,immunology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D016207 Q000276 NN,D016559 Q000627 NN,D006146 Q000627 NN,D020123 Q000737 NN,D011409 Q000737 NN,D000911 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D008213 Q000187 NN,D016572 Q000737 NN,D014315 Q000627 NN,D016559 Q000737 NN,D000963 Q000627 NN,D015398 Q000187 NN,D011409 Q000627 NN,D020123 Q000627 NN,D006084 Q000517 NY,D013601 Q000187 NN,D000963 Q000737 NN","2909,5372,8252,31270,55361,55362,62280,91272,107969,107970,445643,5280335,5280754,5282315,5284373,5284616,5458585,6435893,6473866,6536850,9855081,11643509,24883466,25246316,44315262,49867938,71306795,71463825,71668407,73896891,90726579,91534498,101187915,118701650,122172945,123134263,123134270,132274082,134694629","128151681,128394615,129060975,129645792,242963342,248766214",Treatment of transplant rejection: are the traditional immunosuppressants good enough?,"Due to the improvement in the understanding of the anti-allogenic immune response, the success of transplantation medicine has increased rapidly over the last two decades. The knowledge that the T-lymphocyte played an integral role in transplant rejection, brought cyclosporine A and FK-506 to the fore as therapeutic immunosuppressants. However, the current mainstays in transplant rejection are not without their problems and many drug companies are exploring the possibilities of improving the available thera","Current opinion in investigational drugs (London, England : 2000)",F J Dumont," Department  Immunology & Rheumatology, Merck Research Laboratories, Rahway, NJ 07065, USA. francis_dumont@merck.com",2001 Mar;2(3):357-63,NULL
11577586,20010901,article,"xref,mesh","Cyclosporine,Drug Interactions,Drug Therapy, Combination,Everolimus,Fingolimod Hydrochloride,Hyperlipidemias,Immunosuppressive Agents,Kidney,Neoplasms,Propylene Glycols,Sirolimus,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,therapeutic use","D020123 Q000009 NN,D007668 Q000187 NN,D006949 Q000139 NN,D016572 Q000009 NN,D009369 Q000188 NN,D013110 Q000031 NN,D007166 Q000627 NY,D020123 Q000627 NY,D011409 Q000627 NN,D007166 Q000009 NN,D020123 Q000031 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,24883466,25246316,49867938,71306795,71463825,73896891,90696889,90726579,91454826,91534498,122172945,123134263,123134270,132274082","128394615,129060975,129645792,242749350,242963342,248184126,248766214",[mTOR and FTY 720 inhibitors].,"SIROLIMUS: The leading member of the mTOR inhibitor family, sirolimus or rapamycin, has dose-dependent side effects that can generally be well controlled. Sirolimus can be combined with tacrolimus at therapeutic doses; likewise for the sirolimus-cyclosporine combination at moderate dosage. Effective plasma concentrations of sirolimus vary from 5 to 20 ng/ml depending on the combination of immunosuppressant agents used. Sirolimus has been shown to inhibit metastatic diffusion of renal adenocarcinoma in the m","Presse medicale (Paris, France : 1983)",D Morel," Hôpital Pellegrin, Bordeaux.",2001 Sep;30(?):35-7,NULL
11577590,20010901,article,"xref,mesh","Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,Chicago,Fingolimod Hydrochloride,Humans,Immunoglobulins, Intravenous,Immunosuppression,Immunosuppressive Agents,Organ Transplantation,Propylene Glycols,Review Literature as Topic,Sphingosine","analogs &amp; derivatives,methods,therapeutic use","D000911 Q000627 NN,D000912 Q000627 NN,D013110 Q000031 NN,D016756 Q000627 NY,D007166 Q000627 NY,D007165 Q000379 NN,D011409 Q000627 NN","8252,31270,107969,107970,5280335,91534498","128394615,129060975,129645792,248766214",[What is new on transplantation in 2001?].,"IMMUNOSUPPRESSIVE THERAPY: Intravenous immunoglobulins have demonstrated their value for highly immunized cross-match positive transplantation candidates. Graft rejection during the first two post-transplantation weeks can be avoided with CMPATH-1H, humanized anti-CD52 monoclonal antibody, which produces major and persistent T- and B-cell as well as monocyte depletion. FTY 720 is well tolerated and has demonstrated its efficacy in preventing acute rejection. Sirolimus would have an antiatheromatous effect. ","Presse medicale (Paris, France : 1983)",E Thervet," Hôpital Saint-Louis, AP-HP, Paris.",2001 Sep;30(?):5-7,NULL
11606032,20011001,article,"xref,mesh","Apoptosis,Caspase Inhibitors,Caspases,Chromatin,DNA Fragmentation,Enzyme Activation,Enzyme Inhibitors,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunohistochemistry,Immunosuppressive Agents,Indicators and Reagents,Jurkat Cells,Mitochondria,Propylene Glycols,Proteins,Sphingosine","analogs &amp; derivatives,drug effects,enzymology,metabolism,pharmacology","D007166 Q000494 NY,D008928 Q000187 NN,D017209 Q000187 NY,D053938 Q000187 NN,D004789 Q000187 NN,D008928 Q000201 NY,D011409 Q000494 NY,D013110 Q000031 NN,D011506 Q000378 NN,D002843 Q000378 NN,D020169 Q000378 NY,D004791 Q000494 NN","8252,31270,107969,107970,5280335,6323481","128394615,129060975,129645792,245283296",Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat.,"FTY720, a novel immunosuppressive drug originally derived from a metabolite from Isaria sinclairii, is known to induce apoptosis in lymphocytes. In this study, we investigated the involvement of caspases and mitochondria in FTY720-mediated apoptosis using Jurkat cells, a human T cell line. Our results indicated that FTY720-induced activation of caspases 2, 3, 6, 8, 9 and 10, whereas caspases 1 and 5 were not activated. We also observed in the FTY720-treated cells a loss of mitochondrial membrane potential, ",International immunopharmacology,"M Fujino, X K Li, L Guo, T Amano, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",2001 Oct;1(11):2011-21,10.1016/s1567-5769(01)00130-8
11686830,20011101,article,"xref,mesh","Adult,Alginates,Anti-Infective Agents, Local,Bacteria,Biofilms,Bone Substitutes,Chlorhexidine,Dental Enamel Proteins,Dental Plaque,Fluorescent Dyes,Humans,Microscopy, Fluorescence,Periodontitis,Pharmaceutical Vehicles,Sodium Chloride,Statistics as Topic,Statistics, Nonparametric,Time Factors","administration &amp; dosage,analogs &amp; derivatives,drug effects,microbiology,pharmacology,physiopathology","D003746 Q000008 NN,D018441 Q000187 NN,D003746 Q000494 NY,D002710 Q000008 NN,D003773 Q000503 NN,D002710 Q000494 NN,D018786 Q000494 NY,D003773 Q000382 NY,D000891 Q000008 NN,D018786 Q000008 NN,D000891 Q000494 NY,D010518 Q000382 NN,D002710 Q000031 NY,D001419 Q000187 NY","2713,5234,5967,8252,29089,9552079,9552081,9562059,9571016,9939931,12303048,53486446,60148207,131752735","127956537,129060975",Effect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality.,BACKGROUND: A common clinical observation following surgical periodontal therapy with an enamel matrix derivative (Emdogain) is the improved healing of the soft tissues and the limited inflammation of the operated areas. These clinical observations are empirical and difficult to explain. One of the factors influencing the early wound healing might be a potential antimicrobial effect of Emdogain. AIM: To investigate the effect of Emdogain on the vitality of ex vivo supragingival dental plaque and to compare ,Journal of clinical periodontology,"A Sculean, T M Auschill, N Donos, M Brecx, N B Arweiler"," Department of Periodontology and Conservative Dentistry, University of Saarland, Homburg, Germany. anton.sculean@gmx.de",2001 Nov;28(11):1074-8,10.1034/j.1600-051x.2001.281113.x
11748287,20011217,article,mesh,"Animals,B-Lymphocytes,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cell Movement,Chemokine CCL19,Chemokine CCL21,Chemokines, CC,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Receptors, CCR7,Receptors, Chemokine,Sphingosine","analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D002465 Q000187 NN,D011409 Q000276 NN,D018414 Q000276 NY,D002465 Q000276 NY,D001402 Q000276 NY,D001402 Q000166 NN,D013110 Q000031 NN,D015496 Q000276 NY,D018414 Q000166 NN,D015496 Q000166 NN,D019707 Q000276 NY,D007166 Q000276 NN,D011409 Q000494 NN,D007166 Q000494 NN,D019742 Q000276 NN","107969,107970,5280335",NULL,CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720.,"Cognate interaction of chemokine receptor CCR7 on lymphocytes with its ligands CCL19 and CCL21 expressed on high endothelial venules (HEVs) is essential for effective migration of T and B cells across HEVs into secondary lymphoid organs. Plt mice, which lack expression of CCL19 and CCL21-ser, both ligands for CCR7 on HEVs, as well as CCR7-deficient mice, have a defective cell migration and reduced homing of lymphocytes. FTY720, a novel immunosuppressant, causes a reduction of lymphocytes in peripheral blood",The Journal of experimental medicine,"G Henning, L Ohl, T Junt, P Reiterer, V Brinkmann, H Nakano, W Hohenberger, M Lipp, R Förster"," Section of Experimental Surgery and Immunology, University Clinic for Surgery and Nikolaus-Fiebiger-Zentrum, 91054 Erlangen, Germany.",2001 Dec;194(12):1875-81,10.1084/jem.194.12.1875
11750317,20010101,article,"xref,mesh","Animals,Cell Movement,Chemokines,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Leukopenia,Lymphocytes,Lymphopenia,Mice,Phosphatidylinositol 3-Kinases,Propylene Glycols,Sphingosine,Transplantation Immunology","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,immunology,metabolism,physiology,prevention &amp; control,therapeutic use","D011409 Q000009 NN,D002465 Q000187 NN,D019869 Q000378 NN,D008231 Q000139 NN,D018925 Q000276 NY,D013110 Q000031 NN,D008214 Q000502 NY,D007166 Q000627 NY,D007970 Q000139 NN,D007166 Q000009 NN,D008214 Q000187 NN,D011409 Q000627 NY,D006084 Q000517 NY,D002465 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines.",NULL,Transplantation proceedings,"S Chen, K B Bacon, G Garcia, R Liao, Z K Pan, S K Sullivan, H Nakano, A Matsuzawa, V Brinkmann, L Feng"," Department of Immunology, The Scripps Research Institute, La Jolla, California, USA.",2001 Jan;33(?):3057-63,10.1016/s0041-1345(01)02306-5
11750323,20010101,article,"xref,mesh","Apoptosis,CD4-Positive T-Lymphocytes,Cell Division,Cell Movement,Cells, Cultured,Chemotaxis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Culture Test, Mixed,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology","D007166 Q000494 NY,D002465 Q000187 NN,D002455 Q000187 NN,D017209 Q000187 NN,D015496 Q000276 NN,D002633 Q000187 NY,D015496 Q000187 NN,D011409 Q000494 NY,D002633 Q000502 NN,D013110 Q000031 NN,D013601 Q000276 NY,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects.",NULL,Transplantation proceedings,"V Brinkmann, C Wilt, C Kristofic, Z Nikolova, R P Hof, S Chen, R Albert, S Cottens"," Transplantation Research, Novartis Pharma AG, Basel, Switzerland",2001 Jan;33(?):3078-80,10.1016/s0041-1345(01)02312-0
11750324,20010101,article,"xref,mesh","Animals,Chemokines,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Models, Animal,Propylene Glycols,Receptors, CCR4,Receptors, Chemokine,Sphingosine,Transplantation Immunology,Up-Regulation","agonists,analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D019707 Q000819 NN,D018925 Q000276 NN,D015854 Q000187 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY,D019707 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: a new dimension in transplantation.,NULL,Transplantation proceedings,B D Kahan," Division of Immunology and Organ Transplantation, University of Texas-Houston, Houston, Texas, USA.",2001 Jan;33(?):3081-3,10.1016/s0041-1345(01)02313-2
11750325,20010101,article,"xref,mesh","Apoptosis,Fingolimod Hydrochloride,Genes, bcl-2,Humans,Immunosuppressive Agents,Jurkat Cells,Mitochondria,Propylene Glycols,Sphingosine,T-Lymphocytes,Transfection","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology","D007166 Q000494 NY,D008928 Q000187 NN,D017209 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D008928 Q000502 NY,D013601 Q000276 NY,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",T-cell apoptosis triggered by FTY720 via mitochondrial pathway.,NULL,Transplantation proceedings,"M Fujino, X K Li, L Guo, Y Kitazawa, N Funeshima, S Fukuda, H Kimura, T Miyashita, T Okuyama, T Amano, S Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",2001 Jan;33(?):3084-5,10.1016/s0041-1345(01)02314-4
11805722,20020201,article,"xref,mesh","Animals,Drug Interactions,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Organ Transplantation,Propylene Glycols,Rats,Sirolimus,Sphingosine","analogs &amp; derivatives,pharmacokinetics,pharmacology,prevention &amp; control,therapeutic use,toxicity","D011409 Q000493 NY,D007166 Q000493 NY,D013110 Q000031 NN,D020123 Q000494 NN,D007166 Q000633 NN,D007166 Q000627 NY,D020123 Q000633 NN,D020123 Q000493 NY,D011409 Q000494 NN,D006084 Q000517 NN,D020123 Q000627 NY,D011409 Q000633 NN,D011409 Q000627 NY,D007166 Q000494 NN","8252,31270,107969,107970,5280335,5284616,91534498","128394615,129060975,129645792,248766214",Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.,"Expanding the cytokine paradigm beyond the use of calcineurin inhibitors as baseline therapy provides new strategies in immunosuppression. Drugs such as FTY720 alter the sensitivity of lymphocytes to homing chemokines, and agents such as sirolimus (SRL) disrupt downstream cytokine signal transduction. Confirming studies in rodents and nonhuman primates, administration of either FTY720 or both of these drugs afford synergistic interactions with cyclosporine to renal transplant patients to rapidly and dramati",Therapeutic drug monitoring,Barry D Kahan," University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA. Barry.D.Kahan@uth.tmc.edu",2002 Feb;24(1):47-52,10.1097/00007691-200202000-00009
11821753,20020127,article,"xref,mesh","Animals,Dogs,Fingolimod Hydrochloride,Graft Rejection,Hematopoietic Stem Cell Transplantation,Immunosuppressive Agents,Propylene Glycols,Sphingosine,T-Lymphocytes,Whole-Body Irradiation","analogs &amp; derivatives,blood,immunology,therapeutic use","D013601 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY,D011409 Q000097 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation?","BACKGROUND: Stable mixed donor/host hematopoietic chimerism was almost uniformly achieved in dogs given 200 cGy total body irradiation (TBI) before, and a short course of immunosuppression after, transplantation of marrow from dog leukocyte antigen-identical littermates, but was transient when the TBI dose was decreased to 100 cGy. Here, we examined whether stable engraftment could be achieved in five dogs given FTY720 (days -5 and -4), followed by 100 cGy TBI, dog leukocyte antigen-identical marrow grafts,",Transplantation,"Chang-Qing Xun, Marie-Térèse Little, Eustacia Zellmer, Cong Yu, Jan M Zaucha, George E Sale, Barry Storer, Rainer Storb"," Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA 98109-1024, USA.",2002 Jan;73(2):310-3,10.1097/00007890-200201270-00031
11823485,20020215,article,"xref,mesh","Animals,Antibodies, Monoclonal,Cell Movement,Cells, Cultured,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Isoantigens,Kinetics,L-Selectin,Lymph Nodes,Lymphocyte Activation,Lymphoid Tissue,Mice,Mice, Knockout,Propylene Glycols,Sphingosine,Spleen,T-Lymphocytes,Transplantation Tolerance","analogs &amp; derivatives,genetics,immunology,pathology,pharmacology,physiology","D008198 Q000276 NN,D016027 Q000276 NN,D013110 Q000031 NN,D019041 Q000276 NN,D013154 Q000276 NN,D016027 Q000473 NN,D019041 Q000502 NY,D019041 Q000235 NN,D013154 Q000473 NN,D000911 Q000494 NN,D013601 Q000276 NY,D011409 Q000494 NN,D007166 Q000494 NN,D008221 Q000276 NN,D008198 Q000473 NN,D007519 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance.,"Maneuvers that interfere with signals 1, 2, 3, or Ag processing can result in indefinite allograft survival. However, they are not applicable to all tissues, strains, or species, suggesting that there are additional levels of immune regulation. We hypothesized that secondary lymphoid organs are important for interactions among lymphocytes, alloantigen, and immunosuppressants that lead to tolerance. To explore this, cardiac allografts were performed with a tolerogenic immunosuppressive regimen. Concurrent ad","Journal of immunology (Baltimore, Md. : 1950)","Yalai Bai, Jianhua Liu, Yinong Wang, Shaun Honig, Lihui Qin, Peter Boros, Jonathan S Bromberg"," Carl C. Icahn Institute for Gene Therapy and Molecular Medicine and Recanati/Miller Transplant Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.",2002 Feb;168(4):1579-89,10.4049/jimmunol.168.4.1579
11861801,20020301,article,"xref,mesh","Antibodies,Antineoplastic Agents, Phytogenic,Apoptosis,Blotting, Western,Caspases,DNA Fragmentation,Enzyme Activation,Enzyme Activators,Etoposide,Fingolimod Hydrochloride,Gene Expression Regulation, Neoplastic,Genes, bcl-2,Humans,Immunosuppressive Agents,Indicators and Reagents,Jurkat Cells,Propylene Glycols,Sphingosine,fas Receptor","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D007166 Q000494 NY,D017209 Q000187 NY,D019254 Q000187 NN,D015972 Q000187 NN,D000972 Q000494 NY,D053938 Q000187 NN,D020536 Q000494 NN,D004789 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D020169 Q000378 NN,D005047 Q000494 NY,D000906 Q000494 NY,D019014 Q000276 NY","8252,10442,31270,36462,107969,107970,284997,439525,5280335","128394615,129060975,129645792,129828206,135867281","Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells).","2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY720), a synthetic product derived from a metabolite of Isaria sinclairii, has been demonstrated to have a potent immunosuppressive activity that induces apoptotic cell death in T cells and several other cell lines. In this study, using the human T-lymphoma cell line, Jurkat cells, we investigated the apoptotic signal transduction mediated by FTY720, in particular comparing its role on the cleavage of caspases, with that mediated by etopos",The Journal of pharmacology and experimental therapeutics,"Masayuki Fujino, Xiao-Kang Li, Yusuke Kitazawa, Lei Guo, Mikiko Kawasaki, Naoko Funeshima, Takashi Amano, Seiichi Suzuki"," Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan.",2002 Mar;300(3):939-45,10.1124/jpet.300.3.939
11888913,20020301,article,"xref,mesh","Actins,Animals,Apoptosis,Cell Adhesion,Cell Movement,Cytoskeleton,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Integrins,Mammary Neoplasms, Experimental,Mice,Mice, Inbred BALB C,Microscopy, Electron,Neoplasm Metastasis,Propylene Glycols,Sphingosine,Tumor Cells, Cultured","adverse effects,analogs &amp; derivatives,analysis,drug effects,drug therapy,metabolism,pathology,pharmacology,prevention &amp; control,therapeutic use,ultrastructure","D008325 Q000473 NN,D011409 Q000009 NN,D002465 Q000187 NN,D017209 Q000187 NN,D009362 Q000517 NY,D002448 Q000187 NN,D008325 Q000188 NY,D011409 Q000494 NY,D013110 Q000031 NN,D016023 Q000032 NN,D007166 Q000627 NY,D000199 Q000378 NN,D008325 Q000648 NN,D003599 Q000187 NN","8252,31270,107969,107970,5280335,44258291","128394615,129060975,129645792,243214637","Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.","FTY720 is a unique immunosuppressive agent that exerts its activity by inducing apoptosis in lymphocytes. We conducted the present study to investigate the effects of FTY720 on cancer growth and metastasis, as well as its mechanism of action. In vitro treatment with FTY720 induced dramatic cancer cell apoptosis in a mouse breast cancer cell line, JygMC(A). Electron microscopy revealed distinct changes on the cell surface with decreased filopodias and microvilli in cancer cells treated with FTY720 at 2 micro",Cancer research,"Haruhito Azuma, Shiro Takahara, Naotsugu Ichimaru, Jing Ding Wang, Yuko Itoh, Yoshinori Otsuki, Junji Morimoto, Ryosuke Fukui, Masaaki Hoshiga, Tadashi Ishihara, Norio Nonomura, Seiichi Suzuki, Akihiko Okuyama, Yoji Katsuoka"," Department of Urology, Osaka Medical College, Takatsuki, Osaka, 569-8686, Japan.",2002 Mar;62(5):1410-9,NULL
11912269,20020401,article,"xref,mesh","Adult,Amylases,Dose-Response Relationship, Drug,Double-Blind Method,Electrocardiography,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Kidney,Kidney Function Tests,Kidney Transplantation,Lipase,Lung,Lymphocyte Count,Male,Middle Aged,Propylene Glycols,Respiratory Function Tests,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,blood,drug effects,pharmacokinetics,physiopathology,therapeutic use","D000681 Q000097 NN,D008168 Q000187 NN,D011409 Q000009 NN,D007166 Q000008 NN,D008049 Q000097 NN,D007668 Q000187 NN,D007668 Q000503 NN,D011409 Q000008 NN,D007166 Q000493 NN,D013110 Q000031 NN,D008168 Q000503 NN,D007166 Q000627 NY,D011409 Q000493 NN,D006339 Q000187 NN,D007166 Q000009 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335,54603431","128394615,129060975,129645792","First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.","FTY720 is a novel immunomodulator to be developed for use in organ transplantation. The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics in stable renal transplant patients-the first human use of FTY720. This study used a randomized, double-blind, placebo-controlled design that explored single oral doses of FTY720 from 0.25 to 3.5 mg in 20 stable renal transplant patients on a cyclosporine-based regimen. Safety assessments and blood samples were taken",Journal of the American Society of Nephrology : JASN,"Klemens Budde, Robert L Schmouder, Reinhard Brunkhorst, Bjorn Nashan, Peter W Lücker, Thomas Mayer, Somesh Choudhury, Andrej Skerjanec, Gerolf Kraus, Hans H Neumayer"," Department of Nephrology, University Hospital Charité, Schumannstrasse 20/21, 10117 Berlin, Germany. klemens.budde@charite.de",2002 Apr;13(4):1073-83,NULL
11923495,20020412,article,"xref,mesh","Animals,B-Lymphocytes,Binding, Competitive,CHO Cells,Calcium,Cricetinae,Cyclic AMP,Fingolimod Hydrochloride,Guanosine 5'-O-(3-Thiotriphosphate),Humans,Immunosuppressive Agents,Ligands,Lymph Nodes,Lymphocyte Count,Lymphopenia,Lysophospholipids,Mice,Organophosphates,Organophosphonates,Phosphorylation,Propylene Glycols,Rats,Receptors, Cell Surface,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine,Spleen,Stereoisomerism,T-Lymphocytes","agonists,analogs &amp; derivatives,chemical synthesis,chemically induced,chemistry,cytology,drug effects,metabolism,pharmacology,physiology","D010755 Q000737 NN,D063065 Q000138 NN,D013601 Q000502 NY,D013154 Q000187 NN,D011956 Q000378 NN,D007166 Q000378 NN,D001402 Q000187 NN,D008231 Q000139 NN,D063065 Q000494 NY,D000242 Q000378 NN,D008198 Q000187 NN,D013110 Q000494 NY,D011409 Q000378 NY,D013154 Q000166 NN,D013110 Q000031 NY,D011956 Q000819 NY,D013110 Q000378 NN,D008198 Q000166 NN,D063065 Q000737 NN,D001402 Q000502 NY,D002118 Q000378 NN,D010755 Q000494 NY,D063065 Q000378 NN,D011409 Q000494 NN,D010755 Q000378 NN,D007166 Q000494 NN,D013601 Q000187 NN","1764,6076,6802,8252,31270,37792,105065,107969,107970,5280335,5283560,5460341,6337033,7059571,9908268,71458556,135398635","128394615,128771931,129060975,129645792,135650261,136111139,178103238,244413598",Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.,"Blood lymphocyte numbers, essential for the development of efficient immune responses, are maintained by recirculation through secondary lymphoid organs. We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720. Both species were high-affinity agonists of at least four of the five S1P receptors. These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in","Science (New York, N.Y.)","Suzanne Mandala, Richard Hajdu, James Bergstrom, Elizabeth Quackenbush, Jenny Xie, James Milligan, Rosemary Thornton, Gan-Ju Shei, Deborah Card, CarolAnn Keohane, Mark Rosenbach, Jeffrey Hale, Christopher L Lynch, Kathleen Rupprecht, William Parsons, Hugh Rosen"," Department of Immunology and Rheumatology, Merck Research Laboratories, Post Office Box 2000, Rahway, NJ 07065, USA.",2002 Apr;296(5566):346-9,10.1126/science.1070238
11950011,20020401,article,"xref,mesh","Administration, Oral,Animals,Antibodies, Antinuclear,Antigen-Antibody Complex,Apoptosis,Bone Marrow Cells,Cells, Cultured,DNA,Disease Models, Animal,Female,Fingolimod Hydrochloride,Flow Cytometry,Immunoglobulin G,Immunosuppressive Agents,Interleukin-2,Kidney Glomerulus,Longevity,Lupus Erythematosus, Systemic,Lymphoid Tissue,Methylprednisolone,Mice,Mice, Inbred BALB C,Mice, Inbred MRL lpr,Propylene Glycols,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,metabolism,methods,pathology,therapeutic use","D013601 Q000378 NN,D017209 Q000187 NN,D007678 Q000187 NN,D007678 Q000473 NN,D008136 Q000187 NN,D000974 Q000097 NN,D007074 Q000276 NN,D001854 Q000187 NN,D008221 Q000473 NN,D007376 Q000378 NN,D000936 Q000276 NN,D007678 Q000276 NN,D011409 Q000008 NN,D008221 Q000378 NN,D005434 Q000379 NN,D013110 Q000031 NN,D007166 Q000627 NY,D008180 Q000188 NY,D008221 Q000187 NN,D008775 Q000627 NN,D004247 Q000276 NN,D013601 Q000473 NN,D001854 Q000473 NN,D008775 Q000008 NN,D011409 Q000627 NY,D013601 Q000187 NN,D008180 Q000276 NN","4939,6741,8252,31270,104919,107969,107970,5280335,24883465,44135672","128394615,129060975,129645792,129888650,134409758,135750811",Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.,"OBJECTIVE To examine the effects of a novel immunosuppressant, FTY720, on hematolymphoid cells and the clinical course of MRL-lpr/lpr (MRL/lpr) mice genetically predisposed to systemic lupus erythematosus (SLE). METHODS: Apoptosis of hematolymphoid cells was determined in vitro by FACScan after staining with propidium iodide or merocyanine 540. From 4 months of age, 15 female MRL/lpr mice received oral administration of 2 mg/kg each of FTY720, methylprednisolone (mPSL), or vehicle, 3 times per week. Therape",The Journal of rheumatology,"Hitoaki Okazaki, Daisuke Hirata, Takeshi Kamimura, Hidetomo Sato, Masahiro Iwamoto, Taku Yoshio, Junichi Masuyama, Akio Fujimura, Eiji Kobayashi, Shogo Kano, Seiji Minota"," Department of Medicine, Jichi Medical School, Tochigi, Japan.",2002 Apr;29(4):707-16,NULL
11961052,20020501,article,"xref,mesh","Administration, Oral,Animals,Biological Transport,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Injections, Intravenous,Macaca fascicularis,Male,Models, Animal,Propylene Glycols,Sex Factors,Sphingosine","analogs &amp; derivatives,pharmacokinetics","D011409 Q000493 NY,D007166 Q000493 NY,D013110 Q000031 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.","The pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720), a novel immunosuppressive agent, were examined in cynomolgus monkeys (three males and three females). After single doses of 0.1 mg/kg p.o. or i.v. bolus and 1 mg/kg p.o. were administered to the animals, the concentrations of FTY720, and the numbers of lymphocytes, CD20+CD2-B cells, and CD2+CD20-T cells in blood were measured over 23 days. A linear three-compartment model characte",The Journal of pharmacology and experimental therapeutics,"Hongshan Li, Guy M L Meno-Tetang, Kenji Chiba, Noriyuki Arima, Peter Heining, William J Jusko"," Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York, Buffalo, New York 14260, USA.",2002 May;301(2):519-26,10.1124/jpet.301.2.519
12016517,20020101,article,xref,"Administration, Cutaneous,Adolescent,Adult,Bone Cysts, Aneurysmal,Child,Child, Preschool,Diatrizoate,Drug Combinations,Fatty Acids,Female,Foot Bones,Humans,Humerus,Injections,Leg,Magnetic Resonance Imaging,Male,Pelvic Bones,Propylene Glycols,Radiography,Time,Zein","administration &amp; dosage,diagnostic imaging,drug therapy,pathology,therapeutic use","D010384 Q000000981 NY,D005529 Q000000981 NY,D017824 Q000188 NY,D003973 Q000627 NY,D006811 Q000473 NY,D006811 Q000000981 NY,D005529 Q000473 NY,D015028 Q000627 NY,D015028 Q000008 NY,D007866 Q000000981 NY,D005227 Q000627 NY,D010384 Q000473 NY,D005227 Q000008 NY,D003973 Q000008 NY,D007866 Q000473 NY,D011409 Q000627 NY,D011409 Q000008 NY","2140,8252","129060975,129854680",Aneurysmal bone cysts: treatment with direct percutaneous Ethibloc injection: long-term results.,PURPOSE: To assess the efficacy and long-term results of Ethibloc treatment in aneurysmal bone cysts (ABC). METHODS: Thirteen patients with ABC were treated with direct percutaneous Ethibloc injection. Four patients had only one injection and the other nine patients from two to four injections. No severe complications were observed; in two patients a local leakage of Ethibloc from the cyst into the soft tissues occurred but it was temporary and the consequent inflammation self-healed without residua and seq,Cardiovascular and interventional radiology,"Piergiorgio Falappa, Fausto M Fassari, Arturo Fanelli, Elisabetta Genovese, Elio Ascani, Marco Crostelli, Vittorio Salsano, Antonello Montanaro, Antonio Di Lazzaro, Fabrizio Serra"," Department of Radiology, Hospital IDI IRCCS, Via Monti di Creta, 104, I-00167 Rome, Italy. piergiorgio@falappa.net",2002 Jan;25(4):282-90,10.1007/s00270-001-0062-2
12023620,20020515,article,"xref,mesh","Animals,Autoimmune Diseases,Blood Glucose,Diabetes Mellitus,Diabetes Mellitus, Experimental,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Insulin,Islets of Langerhans,Islets of Langerhans Transplantation,Male,Mice,Mice, Inbred BALB C,Mice, Inbred CBA,Mice, Inbred NOD,Propylene Glycols,Sphingosine,Time Factors","analogs &amp; derivatives,analysis,drug effects,metabolism,pharmacology,secretion,surgery","D007328 Q000557 NN,D007166 Q000494 NY,D003920 Q000601 NY,D007515 Q000187 NN,D001327 Q000601 NY,D011409 Q000494 NY,D013110 Q000031 NN,D003921 Q000601 NY,D003921 Q000378 NN,D007515 Q000557 NN,D003920 Q000378 NN,D001786 Q000032 NN","5793,8252,29327,31270,107969,107970,5280335,70678557,118984375","128394615,129060975,129621433,129645792,135758261",Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.,"BACKGROUND: Toxicity of current immunosuppressive agents to islet grafts is one of the major obstacles to clinical islet transplantation (Tx). This study was designed to assess the efficacy of FTY720, a novel immunomodulator with a unique mechanism of action, on islet graft survival and function in streptozotocin (STZ)- and autoimmune-induced diabetic recipients. METHODS: Islet allograft from BALB/C mice or islet isografts were transplanted into STZ-induced diabetic CBA mice and autoimmune nonobese diabetic",Transplantation,"Fumin Fu, Shiling Hu, Jeffrey Deleo, Shu Li, Christine Hopf, Jennifer Hoover, Shuya Wang, Volker Brinkmann, Philip Lake, Victor C Shi"," Novartis Institute for Biomedical Research, Summit, New Jersey; Novartis Pharma AG, Basel, Switzerland.",2002 May;73(9):1425-30,10.1097/00007890-200205150-00011
12034170,20020501,article,"xref,mesh","Animals,Blood Transfusion,Cyclosporine,Fingolimod Hydrochloride,Graft Rejection,Heart Transplantation,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred Strains,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,immunology,pathology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D016572 Q000494 NY,D011409 Q000494 NY,D013110 Q000031 NN,D016027 Q000473 NN,D006084 Q000473 NN,D014184 Q000473 NN,D014184 Q000276 NY,D016027 Q000276 NY,D006084 Q000517 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy.,NULL,Transplantation proceedings,"T Koshiba, B Van Damme, Y Lu, Y Yan, O Rutgeerts, L Overbergh, K Tanaka, M Waer, C Mathieu, J Pirenne"," Abdominal Transplant Surgery, Leuven, Belgium.",2002 May;34(3):748-9,10.1016/s0041-1345(01)02901-3
12034266,20020501,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Intestine, Small,Lymphocytes,Propylene Glycols,Rats,Rats, Inbred BN,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology,transplantation","D006085 Q000187 NN,D008214 Q000276 NY,D007166 Q000494 NY,D006085 Q000276 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007421 Q000637 NY,D014184 Q000276 NY,D008214 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Donor pretreatment with FTY720 increases graft lymphocytes but does not affect graft survival following rat small bowel transplantation.,NULL,Transplantation proceedings,"T Sakagawa, H Kiyochi, K Honda, N Kobayashi"," First Department of Surgery, Ehime University, Ehime, Japan. sakagawa@pop.m.ehime-u.ac.jp",2002 May;34(3):973-4,10.1016/s0041-1345(02)02722-7
12057704,20020601,article,"xref,mesh","Abatacept,Animals,Antigens, CD,Antigens, Differentiation,Bronchiolitis Obliterans,CTLA-4 Antigen,Disease Models, Animal,Fingolimod Hydrochloride,Immunoconjugates,Immunoglobulin G,Immunosuppressive Agents,Lung Transplantation,Mice,Postoperative Complications,Propylene Glycols,Respiratory Mucosa,Sphingosine,Trachea","analogs &amp; derivatives,prevention &amp; control,therapeutic use,transplantation","D000943 Q000627 NY,D013110 Q000031 NN,D007074 Q000627 NN,D001989 Q000517 NY,D007166 Q000627 NY,D020545 Q000637 NN,D011409 Q000627 NY,D014132 Q000637 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model.,BACKGROUND: Mouse heterotopic tracheal transplantation offers a reproducible model of obliterative bronchiolitis after lung transplantation. CTLA4IgG inhibits signaling of the CD28/B7 pathway and induces antigen-specific T-cell unresponsiveness. FTY720 induces T-cell apoptosis and sequestration of circulating mature lymphocytes. We previously found that CTLA4IgG could prevent the development of obliterative airway disease but could not preserve the respiratory epithelium of grafted tracheae. We evaluated wh,The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,"Katsuhito Konishi, Manabu Inobe, Akira Yamada, Masaaki Murakami, Satoru Todo, Toshimitsu Uede"," Division of Molecular Immunology, Institute for Genetic Medicine and First Department of Surgery, Hokkaido University, Sapporo, Japan. kinishik@med.hokudai.ac.jp",2002 Jun;21(6):692-700,10.1016/s1053-2498(01)00775-6
12061845,20020201,article,"xref,mesh","Butylene Glycols,Cell Adhesion,Cell Division,Cell Line,Cell Survival,Cryopreservation,Cryoprotective Agents,Culture Media,Dimethyl Sulfoxide,Electric Conductivity,Endothelium, Vascular,Ethylene Glycol,Humans,Permeability,Propylene Glycol","chemistry,cytology,drug effects,metabolism,methods,toxicity","D015925 Q000379 NN,D002455 Q000187 NN,D004730 Q000166 NN,D002470 Q000187 NN,D003470 Q000737 NN,D003470 Q000633 NN,D004730 Q000187 NN,D002448 Q000187 NN,D002072 Q000633 NN,D019946 Q000633 NN,D003451 Q000737 YN,D004730 Q000378 NN,D019855 Q000633 NN,D003451 Q000633 YN,D004121 Q000633 NN","174,187,262,679,1030,8252,12220,259994","127759454,128140457,128141778,128558036,128814285,128870188,129060975","Vitrification media: toxicity, permeability, and dielectric properties.","The aim of this study was to select a cryoprotectant for use in attempts to preserve tissues and organs by vitrification. The first step was to select a cell line with which to compare the toxicity of a range of commonly used cryoprotectants. An immortal vascular endothelial cell (ECV304) was exposed to vitrifying concentrations of four cryoprotectants: dimethyl sulfoxide (Me(2)SO; 45% w/w); 2,3 butanediol (BD; 32%); 1,2-propanediol (PD; 45%); and ethanediol (ED; 45%). Three times of exposure (1, 3, and 9 m",Cryobiology,"Monica C Wusteman, David E Pegg, Martin P Robinson, Li-Hong Wang, Paul Fitch"," Medical Cryobiology Unit, Department of Biology, University of York, York YO10 5YW, UK. mcw3@york.ac.uk",2002 Feb;44(1):24-37,10.1016/s0011-2240(02)00002-0
12175531,20020726,article,"xref,mesh","Apoptosis,Cell Movement,Cyclosporine,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine,Transforming Growth Factor beta,Tumor Cells, Cultured","analogs &amp; derivatives,drug effects,pharmacology,physiology,toxicity","D016212 Q000502 NN,D007166 Q000494 NY,D002465 Q000187 NN,D017209 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D016572 Q000633 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,56842206,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792","A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine.","Cyclosporine A (CsA), the most frequently used immunosuppressive drug, has been reported to induce cancer by a cell-autonomous mechanism. Herein, we report that FTY720, a novel immunosuppressant, prevents CsA-induced alterations in both morphology and cell motility at a low concentration (0.1 microM) and induces the CsA-treated cancer cells to undergo apoptosis at a higher concentration (more than 5 microM). The inhibitory activity of FTY720 is unrelated to the decrease of TGF-beta. We believe that a combin",Cancer letters,"Toshiyuki Tanaka, Shiro Takahara, Motoaki Hatori, Kazuhiro Suzuki, Jing Wang, Naotsugu Ichimaru, Seiichi Suzuki, Kunio Morozumi, Akihiko Okuyama, Hidetoshi Yamanaka"," Department of Urology, Gunma University School of Medicine, Maebashi, Gunma, Japan.",2002 Jul;181(2):165-71,10.1016/s0304-3835(01)00799-6
12176429,20020801,article,"xref,mesh","Adenoviridae,Animals,Fingolimod Hydrochloride,Genetic Vectors,Graft Survival,Immunosuppression,Immunosuppressive Agents,Lung Transplantation,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Transfection,Transplantation, Homologous","analogs &amp; derivatives,drug effects,genetics,immunology,methods,therapeutic use","D006085 Q000187 NN,D014162 Q000379 NN,D006085 Q000276 NY,D013110 Q000031 NN,D000256 Q000235 NN,D007166 Q000627 NY,D007165 Q000379 NY,D011409 Q000627 NY,D016040 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts.,NULL,Transplantation proceedings,"Yusuke Kita, H Nogimura, M Ida, Y Kageyama, S Ohi, Y Ito, K Matsushita, T Takahashi, K Suzuki, T Kazui, S Hayashi, X Li, S Suzuki"," Department of Thoracic Surgery, Haibara General Hospital, 2887-1 Hosoe, Haibara-cho, Haibara-gun, Shizuoka-pref, 421-0493 Japan.",2002 Aug;34(5):1437-40,10.1016/s0041-1345(02)02918-4
12176443,20020801,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver,Liver Circulation,Lymphocyte Count,Peroxidase,Propylene Glycols,Rats,Rats, Inbred Lew,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,blood supply,drug effects,metabolism,pharmacology,physiology,prevention &amp; control","D009195 Q000378 NN,D008099 Q000098 NN,D008099 Q000502 NN,D011409 Q000494 NY,D015427 Q000517 NY,D013110 Q000031 NN,D008102 Q000187 NY,D007166 Q000494 NN,D008099 Q000187 NN","8252,31270,107969,107970,5280335,11973707","128394615,129060975,129645792",FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury.,NULL,Transplantation proceedings,"D Anselmo, F F Amersi, X-D Shen, F Gao, M Katori, B Ke, C Lassman, A J Coito, V Brinkmann, R W Busuttil, J W Kupiec-Weglinski, D G Farmer"," Dumont-UCLA Transplant Center, Department of Surgery, UCLA School of Medicine, 10833 LeConte Avenue, Los Angeles, CA 90095, USA.",2002 Aug;34(5):1467-8,10.1016/s0041-1345(02)02933-0
12183155,20021001,review,"xref,mesh","Animals,Autoimmune Diseases,Bone Marrow Transplantation,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Islets of Langerhans Transplantation,Lymph Nodes,Peyer's Patches,Propylene Glycols,Receptors, Cell Surface,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D016381 Q000276 NN,D011956 Q000187 NY,D008198 Q000276 NN,D013110 Q000031 NN,D010581 Q000276 NN,D007166 Q000627 NY,D011409 Q000494 NN,D011409 Q000627 NY,D016026 Q000276 NN,D001327 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.,The novel immunomodulator FTY720 is remarkably effective in models of transplantation and autoimmunity. Recent data show that phosphorylated FTY720 is an agonist at four sphingosine 1-phosphate receptors. Stimulation of sphingosine 1-phosphate receptors leads to sequestration of lymphocytes in secondary lymphatic tissues and thus away from inflammatory lesions and graft sites. ,Current opinion in immunology,"Volker Brinkmann, Kevin R Lynch"," Novartis Pharma AG Transplantation Research WSJ-386.101, CH-4002 Basel, Switzerland. volker.brinkmann@pharma.novartis.com",2002 Oct;14(5):569-75,10.1016/s0952-7915(02)00374-6
12270383,20020901,article,"xref,mesh","Antigens, CD,Dose-Response Relationship, Drug,Double-Blind Method,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes","adverse effects,analogs &amp; derivatives,blood,drug effects,immunology,physiology","D016176 Q000276 NY,D016030 Q000502 NN,D015703 Q000097 NN,D016176 Q000187 NN,D013110 Q000031 NN,D016030 Q000276 NY,D007166 Q000009 NY,D013601 Q000187 NN,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.,NULL,Transplantation proceedings,"T Boehler, M Schuetz, K Budde, H Neumayer, J Waiser"," Department of Nephrology, Charité, Campus Charité-Mitte, Humboldt-University, Berlin, Germany. torsten.boehler@charite.de",2002 Sep;34(6):2242-3,10.1016/s0041-1345(02)03220-7
12352874,20020915,article,"xref,mesh","Administration, Oral,Animals,Blood Pressure,Creatinine,Fingolimod Hydrochloride,Heart Rate,Hemodynamics,Immunosuppressive Agents,Kidney,Liver,Liver Circulation,Portal System,Propylene Glycols,Rats,Renal Circulation,Sodium,Sphingosine,Urea,Vascular Resistance","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,metabolism,pathology,pharmacology,physiology,urine","D008102 Q000187 NN,D003404 Q000378 NN,D007166 Q000494 NY,D011168 Q000502 NN,D008099 Q000473 NN,D007166 Q000008 NN,D007668 Q000187 NN,D007668 Q000473 NN,D006339 Q000502 NN,D014508 Q000097 NN,D006439 Q000187 NY,D011409 Q000008 NN,D011409 Q000494 NY,D014655 Q000187 NN,D013110 Q000031 NN,D012964 Q000652 NN,D014655 Q000502 NN,D001794 Q000187 NN,D006339 Q000187 NN,D008102 Q000502 NY,D006439 Q000502 NN,D012079 Q000502 NY,D012079 Q000187 NN,D008099 Q000187 NN","588,1176,8252,31270,107969,107970,5280335,5360545","127719861,128394615,129060975,129645792,129735276",Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat.,"BACKGROUND: FTY720 is a novel immunomodulator that may provide an opportunity for a reduction in calcineurin inhibitor dosage in transplant recipients with renal/hepatic side effects. However, the effects of FTY720 on renal or hepatic hemodynamics are unknown. The aim of this study was to establish the hemodynamic and renal actions of FTY720 at therapeutically relevant dosages. METHODS: The effects of acute and repeat oral administration of FTY720 on systemic, renal, and hepatic hemodynamics were investigat",Transplantation,"Michael N Tawadrous, Ayako Mabuchi, Arthur Zimmermann, Antony M Wheatley"," Microcirculation Research Laboratory, Department of Physiology, University of Otago.",2002 Sep;74(5):602-10,10.1097/00007890-200209150-00004|10.1097/01.tp.0000021368.09132.d6
12361804,20021001,article,"xref,mesh","Antioxidants,Fluoresceins,Kinetics,Luminescent Measurements,Oxidation-Reduction,Photochemistry,Singlet Oxygen,Sodium Chloride,Solvents,Spectrophotometry",chemistry,D005452 Q000737 NY,"5234,64944,159832,14598431,18183689,129630296","129467723,129889442","Photosensitized oxidation of 2',7'-dichlorofluorescin: singlet oxygen does not contribute to the formation of fluorescent oxidation product 2',7'-dichlorofluorescein.","2',7'-Dichlorofluorescin (DCFH) is often employed to assess oxidative stress in cells by monitoring the appearance of 2',7'-dichlorofluorescein (DCF), its highly fluorescent oxidation product. We have investigated the photosensitized oxidation of DCFH in solution and elucidated the role played by singlet molecular oxygen (1O(2)) in this reaction. We used rose bengal (RB), protoporphyrin, and DCF as photosensitizers. Irradiation (550 nm) of RB (20 microM) in 50 mM phosphate (pH 7.4) in the presence of DCFH (",Free radical biology & medicine,"P Bilski, A G Belanger, C F Chignell"," Laboratory of Pharmacology and Chemistry, NIEHS/NIH, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA. Bilski@niehs.nih.gov",2002 Oct;33(7):938-46,10.1016/s0891-5849(02)00982-6
12389077,20021001,article,mesh,"Adult,Cerebrovascular Circulation,Cerebrovascular Disorders,Cognition Disorders,Cyclosporine,Female,Frontal Lobe,Heart Transplantation,Humans,Immunosuppressive Agents,Liver Transplantation,Male,Middle Aged,Postoperative Complications,Radiopharmaceuticals,Technetium Tc 99m Exametazime,Tomography, Emission-Computed, Single-Photon","adverse effects,blood supply,diagnostic imaging,epidemiology,physiology,physiopathology,psychology,therapeutic use","D016572 Q000627 NN,D002561 Q000453 NY,D016027 Q000523 NN,D005625 Q000098 NY,D007166 Q000627 NN,D016031 Q000009 NN,D005625 Q000000981 NN,D003072 Q000453 NN,D011183 Q000503 NN,D016027 Q000009 NY,D011183 Q000523 NN,D002560 Q000502 NY","2909,62280,450484,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,56841051,71306795,71463825,73896891,122172945,123134263,123134270,129626367,132274082",NULL,Frontal cerebral blood flow is impaired in patients with heart transplantation.,"Patients with cardiovascular disease have cognitive function disturbances that are still evident after heart transplantation (HT). The aim of this study was to evaluate cerebral function in transplant patients and to assess whether cyclosporine therapy was responsible for cerebral abnormalities 1 year after transplantation. Six HT patients, eight liver transplant (LT) patients, and ten age-matched healthy controls underwent regional cerebral blood flow (rCBF) assessment by the (99m)Tc-hexamethyl-propylene-a",Transplant international : official journal of the European Society for Organ Transplantation,"Patrizia Burra, Marco Senzolo, Gilberto Pizzolato, Vincenzo Tursi, Ugolino Livi, Franca Chierichetti, Mauro Dam"," Gastroenterology Section, Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, Italy. burra@unipd.it",2002 Oct;15(?):459-62,10.1007/s00147-002-0448-3|10.1111/j.1432-2277.2002.tb00200.x
12392290,20021001,article,"xref,mesh","Animals,Cell Movement,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Liver,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Reperfusion Injury,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D008099 Q000187 NY,D002465 Q000187 NN,D013601 Q000276 NN,D008099 Q000276 NN,D015427 Q000276 NN,D011409 Q000494 NY,D015427 Q000517 NY,D013110 Q000031 NN,D002465 Q000276 NN,D013601 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration.,"Ischemia and reperfusion (IR) injury remains a significant problem in clinical liver transplantation. We investigated the effects of lymphocyte depletion with FTY720 in models of warm hepatic IR. Using 60-min partial warm hepatic IR, three groups of rats were studied: Sham--laparotomy alone; Control--water p.o. x 3 d before ischemia; Treatment--FTY720 p.o. x 3 d before ischemia. Animals were sacrificed for analysis at 6 h and 24 h post reperfusion. The effect of FTY720 pretreatment on survival was also stud",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Dean M Anselmo, Farin F Amersi, Xiu-Da Shen, Feng Gao, Masamichi Katori, Charles Lassman, Bibo Ke, Ana J Coito, Jeffrey Ma, Volker Brinkmann, Ronald W Busuttil, Jerzy W Kupiec-Weglinski, Douglas G Farmer"," Dumont-UCLA Transplant Center, UCLA School of Medicine, Los Angeles, CA 90095-7054, USA.",2002 Oct;2(9):843-9,10.1034/j.1600-6143.2002.20906.x
12394836,20021015,article,"xref,mesh","Administration, Oral,Animals,B-Lymphocytes,Cyclosporine,Drug Combinations,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Macaca fascicularis,Male,Phenotype,Propylene Glycols,Sirolimus,Sphingosine,T-Lymphocytes,Transplantation, Homologous","administration &amp; dosage,adverse effects,analogs &amp; derivatives,physiology,therapeutic use","D020123 Q000009 NN,D011409 Q000009 NN,D007166 Q000008 NN,D016572 Q000627 NY,D020123 Q000008 NN,D016572 Q000008 NN,D011409 Q000008 NN,D016572 Q000009 NN,D013110 Q000031 NN,D001402 Q000502 NN,D007166 Q000627 NY,D013601 Q000502 NN,D020123 Q000031 NY,D007166 Q000009 NN,D011409 Q000627 NY","588,1176,2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,91454826,91534498,122172945,123134263,123134270,132274082","127719861,128394615,129060975,129645792,129735276,248184126,248766214","Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.","BACKGROUND: FTY720 is a novel immunomodulator with a unique mechanism of action, i.e. chemokine-dependent lymphocyte homing into secondary lymphoid organs associated with profound lymphocyte depletion in blood. We investigated its efficacy, either FTY720 alone or together with cyclosporine or the rapamycin derivative rapamycin derivative (RAD), in cynomolgus monkey kidney allotransplantation. METHODS: Life-supporting allotransplantation was performed in bilaterally nephrectomized hosts. Compounds were given",Transplantation,"Henk-Jan Schuurman, Klaus Menninger, Maxime Audet, Adrien Kunkler, Claudine Maurer, Corinne Vedrine, Mario Bernhard, Lorrie Gaschen, Volker Brinkmann, Valerie Quesniaux"," Transplantation Research, Novartis Pharma AG, Basel, Switzerland. Presently, Immerge BioTherapeutics, Charlestown, MA 02129, USA. henk.schuurman@immergebt.com",2002 Oct;74(7):951-60,10.1097/00007890-200210150-00009
12429567,20021201,article,"xref,mesh","Animals,Apoptosis,B-Lymphocytes,Cell Survival,Cytochrome c Group,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Jurkat Cells,Mitochondria,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Rats,Sphingosine,T-Lymphocytes,Transfection,Tumor Cells, Cultured","analogs &amp; derivatives,cytology,drug effects,genetics,metabolism,pharmacology,physiology,secretion","D019253 Q000235 NN,D007166 Q000494 NY,D008928 Q000187 NN,D017209 Q000187 NY,D002470 Q000187 NN,D001402 Q000166 NN,D001402 Q000187 NN,D011409 Q000494 NY,D003574 Q000557 NN,D013110 Q000031 NN,D013601 Q000166 NN,D019253 Q000502 NY,D013601 Q000187 NY,D008928 Q000378 NN,D019169 Q000187 NN,D014407 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.","1. A novel immunosuppressant FTY720 caused a significant decrease in peripheral T lymphocytes, but not in B lymphocytes upon oral administration. This decrease was mainly a result of FTY720-induced apoptosis. In this study, we confirmed FTY720-induced T cell selective apoptosis using lymphoma cell lines in vitro. 2. Viability loss, DNA fragmentation, Annexin V binding, and caspases activation (caspase-3, -8, and -9) were observed in Jurkat cells (T lymphoma cells), but not significantly in BALL-1 cells (B l",British journal of pharmacology,"Yukitoshi Nagahara, Masahiko Ikekita, Takahisa Shinomiya"," Division of Radio Isotopes and Biosafety Research, National Research Institute for Child Health and Development, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8567, Japan.",2002 Dec;137(7):953-62,10.1038/sj.bjp.0704970
12431509,20021101,article,"xref,mesh","Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppression,Immunosuppressive Agents,Multicenter Studies as Topic,Propylene Glycols,Sirolimus,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,drug effects,methods,therapeutic use","D014181 Q000187 YN,D013110 Q000031 NN,D007166 Q000627 NY,D007165 Q000379 NY,D020123 Q000627 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335,5284616,91534498","128394615,129060975,129645792,248766214",Sirolimus and FTY720: new approaches to transplant immunosuppression.,NULL,Transplantation proceedings,B D Kahan," Division of Immunology and Organ Transplantation, University of Texas-Houston, USA.",2002 Nov;34(7):2520-2,10.1016/s0041-1345(02)03472-3
12431647,20021101,article,"xref,mesh","Animals,Disease Models, Animal,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Mycophenolic Acid,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D009173 Q000627 NY,D006085 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D016027 Q000276 NY,D011409 Q000627 NY","4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129645792",Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.,NULL,Transplantation proceedings,"Y Matsumoto, R P Hof"," Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.",2002 Nov;34(7):2891-2,10.1016/s0041-1345(02)03549-2
12451233,20021127,article,"xref,mesh","Animals,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Leukocyte Count,Male,Mycophenolic Acid,Myocardium,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,drug effects,pathology,therapeutic use","D006085 Q000187 NN,D009173 Q000627 NY,D013110 Q000031 NN,D007166 Q000627 NY,D009206 Q000473 NN,D009173 Q000008 NN,D011409 Q000008 NY","4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129645792",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model.,"BACKGROUND: Mycophenolate sodium (MPS), which is in clinical development as an enteric-coated tablet (Myfortic), has not yet been characterized as a combination partner of FTY720. We therefore report here the effects of MPS and FTY720 mono and combination therapy in a rat heart allograft model. METHODS: Heterotopic heart allotransplantation was performed in the DA-to-Lewis-strain combinations. Groups of six rats were treated with placebo, MPS monotherapy, FTY720 monotherapy, and their combination. To circum",Transplantation,"Yuji Matsumoto, Akiko Hof, Yves Baumlin, Robert P Hof"," Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.",2002 Nov;74(10):1372-6,10.1097/00007890-200211270-00004|10.1097/01.tp.0000034924.41318.85
12499880,20021227,article,"xref,mesh","Animals,Body Weight,Cyclophosphamide,Diabetes Mellitus, Type 1,Female,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Islets of Langerhans Transplantation,Mice,Mice, Inbred NOD,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemically induced,drug therapy,pharmacology,prevention &amp; control","D007166 Q000494 NY,D003922 Q000139 NN,D006084 Q000188 NN,D011409 Q000494 NY,D013110 Q000031 NN,D003922 Q000517 NY,D003922 Q000188 NY","2907,8252,22420,31270,107969,107970,5280335","128394615,129060975,129645792",Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice.,"BACKGROUND: FTY720 prevents allograft rejection with remarkable potency without inducing generalized immunosuppression. We determined the effect of FTY720 on development of autoimmune diabetes in nonobese diabetic (NOD) mice. METHODS: NOD mice were given FTY720 (0.5 mg/kg, orally) five times per week starting from 4 weeks of age. RESULTS: Daily FTY720 prevented development of diabetes in 15 of 16 treated mice, whereas 70% of untreated NOD mice became diabetic by 35 weeks of age. Withdrawal of FTY720 at 35 w",Transplantation,"Takashi Maki, Rita Gottschalk, Anthony P Monaco"," Transplant Center, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. tmaki@caregroup.harvard.edu.",2002 Dec;74(12):1684-6,10.1097/00007890-200212270-00006|10.1097/01.tp.0000038969.72218.0f
12521294,20021231,article,"xref,mesh","Animals,Apoptosis,Caspase 3,Caspase Inhibitors,Caspases,Cell Membrane,Cell Nucleus,Dose-Response Relationship, Drug,Enzyme Inhibitors,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Jurkat Cells,Lymphoma,Mice,Propylene Glycols,Sphingolipids,Sphingosine,Tumor Cells, Cultured,fas Receptor","analogs &amp; derivatives,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D002462 Q000187 NY,D017209 Q000187 NY,D019014 Q000235 NN,D014407 Q000473 NN,D014407 Q000378 NN,D011409 Q000494 NY,D013110 Q000031 NN,D019014 Q000494 NY,D002467 Q000187 NY,D008223 Q000188 NN,D008223 Q000378 NN,D020169 Q000378 NN,D019014 Q000276 NN,D004791 Q000494 NN,D002467 Q000378 NN,D013107 Q000494 NN,D002462 Q000378 NN,D014407 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Different mechanisms for membrane and nuclear damages in apoptosis induced by an immunosuppressant, FTY720.","A novel immunosuppressant, FTY720, that was purified from cultures of Isaria sinclairii has been shown to cause apoptosis of lymphocytes, but its biochemical and molecular mechanisms are largely unknown. In this study, we investigated the signal transduction of FTY720-induced apoptosis in comparison with the Fas-induced apoptosis. Although FTY720 induced nuclear and membrane damages in a dose-dependent manner, nuclear damage, but not membrane damage, was suppressed by the caspase-3 inhibitor, DEVD-FMK. It b",Molecules and cells,"Hiroo Nakajima, Yun-Sik Lee, Tetsuro Matsuda, Naruhiko Mizuta, Junji Magae"," Department of Endocrine, Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan.",2002 Dec;14(3):332-8,NULL
12531459,20030102,article,"xref,mesh","Acetates,Amines,Animals,Anticonvulsants,Carbamates,Carbamazepine,Cell Death,Cells, Cultured,Chlordiazepoxide,Cyclohexanecarboxylic Acids,Dose-Response Relationship, Drug,Ethosuximide,Glucose,Hippocampus,Hypoxia,Ischemia,Midazolam,Neurons,Neuroprotective Agents,Nipecotic Acids,Phenobarbital,Phenylcarbamates,Phenylenediamines,Phenytoin,Piracetam,Propylene Glycols,Rats,Rats, Wistar,Triazines,Valproic Acid,gamma-Aminobutyric Acid","administration &amp; dosage,analogs &amp; derivatives,cytology,deficiency,drug effects,drug therapy,metabolism,pharmacology","D009557 Q000494 NN,D000085 Q000494 NN,D009474 Q000187 NY,D010634 Q000494 NN,D007511 Q000188 NN,D010655 Q000494 NN,D018696 Q000008 NN,D002707 Q000494 NN,D014227 Q000494 NN,D000860 Q000378 NN,D005947 Q000172 NY,D009474 Q000378 NY,D016923 Q000187 NN,D002219 Q000494 NN,D006624 Q000187 NY,D000927 Q000008 NN,D007511 Q000378 NN,D010889 Q000494 NN,D018696 Q000494 NY,D006624 Q000166 NN,D000860 Q000188 NY,D005013 Q000494 NN,D006624 Q000378 NY,D010889 Q000031 NY,D000927 Q000494 NY,D011409 Q000494 NN,D010672 Q000494 NN","119,1775,2554,2712,3121,3291,3331,3446,3878,4192,4763,4843,5793,8252,9916,24749,34312,43032,59708,60648,86480,91274,107526,121892,147515,158856,441341,657302,3549980,5284583,5384200,9795547,10954115,13241308,16760703,21935075,23663956,23674889,23679632,54721898,87517085,129734996","127433480,127564392,127676405,127692443,127718929,127838758,127977224,128033308,128093761,128093762,128706830,128891680,128896436,128988737,129060975,129364554,129593872,129621433",Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation.,"Some anticonvulsants show neuroprotective effects, and may be of use in reducing neuronal death resulting from stroke or traumatic brain injury. Here I report that a broad range of anticonvulsants protect cells in hippocampal slice cultures from death induced by oxygen/glucose deprivation (OGD). Hippocampal slice cultures were submitted to 1 h OGD and the resulting cell death was quantified 24 h later using a novel automated fluorescent scanning method. The classical anticonvulsants phenobarbital, phenytoin",Neuroscience letters,Jens C Rekling," H. Lundbeck A/S, Biological Research, Department 828, Ottiliavej 9, DK-2500 Valby, Denmark. jre@lundbeck.com",2003 Jan;335(3):167-70,10.1016/s0304-3940(02)01193-x
12581966,20030201,article,"xref,mesh","Animals,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Cell Survival,Cells, Cultured,Fingolimod Hydrochloride,Immunoglobulin G,Immunosuppressive Agents,Islets of Langerhans,Propylene Glycols,Rats,Sirolimus,Sphingosine","analogs &amp; derivatives,cytology,drug effects,pharmacology","D007166 Q000494 NY,D002470 Q000187 NN,D007515 Q000166 NY,D013110 Q000031 NN,D020123 Q000494 NN,D000911 Q000494 NN,D007074 Q000494 NN,D011409 Q000494 NN","8252,31270,107969,107970,5280335,5284616,91454826,91534498","128394615,129060975,129645792,248184126,248766214",[Effects of three different immunosuppressive drugs on SD rat islet cell viability].,"OBJECTIVE: To investigate the effect of immunosuppressive drugs on the viability of pancreatic islet cells cultured in vitro, and to explore their effects on the outcome of islet transplantation. METHODS: Pancreatic islet cells from SD rats were cultured in vitro, and the changes in their viability determined by MTT assay after incubation with immunosuppressive drugs at different concentrations. RESULTS: The viability of the islet cells was reduced after exposure to rapamycin at higher concentrations (>or= ",Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA,"De-ming Zhao, Hua Zhang, Hong Chen, De-hong Cai"," Department of Endocrinology, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, China.",2003 Feb;23(2):151-2,NULL
12591486,20030201,article,"xref,mesh","Abatacept,Animals,Combined Modality Therapy,Fingolimod Hydrochloride,Immunoconjugates,Immunosuppressive Agents,Male,Models, Animal,Postoperative Period,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Recombinant Proteins,Sphingosine,Time Factors,Trachea,Transfection,Transplantation, Heterotopic,Transplantation, Homologous","analogs &amp; derivatives,genetics,immunology,methods,pathology,therapeutic use,transplantation","D014184 Q000379 NN,D011994 Q000627 NN,D007166 Q000627 NN,D018796 Q000235 NY,D013110 Q000031 NN,D014132 Q000637 NY,D014162 Q000379 NY,D014132 Q000473 NN,D018796 Q000627 NN,D014184 Q000473 NN,D014184 Q000276 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",CTLA4Ig-gene transfection with FTY720 administration markedly inhibits the obliterative airway disease in heterotopically transplanted rat tracheas.,NULL,Transplantation proceedings,"Y Kita, X-K Li, H Nogimura, M Ida, Y Kageyama, S Ohi, K Suzuki, T Kazui, S Suzuki"," Department of Thoracic Surgery, Haibara General Hospital, Shizuoka, Japan.",2003 Feb;35(1):458-60,10.1016/s0041-1345(02)03977-5
12591534,20030201,article,"xref,mesh","Animals,Drug Administration Schedule,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Microsurgery,Propylene Glycols,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,pharmacology","D006085 Q000187 NN,D016027 Q000379 NN,D007166 Q000494 NY,D008866 Q000379 NN,D006085 Q000276 NY,D011409 Q000494 NY,D013110 Q000031 NN,D014184 Q000276 NN,D016027 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Pretreatment with FTY720 alone induced long-term survival of mouse heart allograft.,NULL,Transplantation proceedings,"L Zhang, T Zhu, E W Sun, S Q Shen, Z L Min, Z K Chen"," Department of Kidney Transplantation, Zhujiang Hospital, The First Military Medical University, Guangzhou, China. zc104@yahoo.com",2003 Feb;35(1):567-8,10.1016/s0041-1345(02)03928-3
12618517,20030301,article,"xref,mesh","ATP-Binding Cassette, Sub-Family B, Member 1,Animals,Apoptosis,Arachidonate 5-Lipoxygenase,Chemokine CCL19,Chemokines, CC,Chemotaxis, Leukocyte,Cysteine,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukotrienes,Lymph Nodes,Lysophospholipids,Mice,Mice, Inbred C57BL,Multidrug Resistance-Associated Proteins,Phosphorylation,Propylene Glycols,Receptors, Cell Surface,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology,secretion","D015289 Q000557 NN,D001094 Q000502 NN,D007166 Q000494 NY,D002634 Q000187 NY,D019742 Q000502 NN,D013601 Q000276 NN,D003545 Q000557 NN,D003545 Q000502 NY,D013110 Q000031 NY,D008198 Q000276 NY,D013601 Q000187 NY,D011409 Q000494 NN,D015289 Q000502 NY,D027425 Q000502 NY,D020168 Q000502 NY","231,594,5862,8252,25150,31270,92851,105065,107969,107970,5280335,5283560,19900077,53395091","128394615,129060975,129645792,129742316,129872283,136051445,136111139",FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.,"FTY720 is a sphingosine-derived immunosuppressant. Phosphorylated FTY720 promotes T cell homing from spleen and peripheral blood to LNs by acting as an agonist for sphingosine-1-phosphate (S1P) receptors. Here we demonstrate that FTY720 enhances the activity of the sphingosine transporter Abcb1 (Mdr1) and the leukotriene C(4) transporter Abcc1 (Mrp1). Both transporters must be active for FTY720-mediated T cell migration and LN homing. Migration and homing driven by FTY720, phosphorylated FTY720, or S1P also",The Journal of clinical investigation,"Shaun M Honig, Shuang Fu, Xia Mao, Adam Yopp, Michael D Gunn, Gwendalyn J Randolph, Jonathan S Bromberg"," Carl C. Icahn Center For Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.",2003 Mar;111(5):627-37,10.1172/jci16200|10.1172/jci200316200
12618520,20030301,article,"xref,mesh","Animals,Bone Marrow Transplantation,Cell Movement,Female,Fingolimod Hydrochloride,Graft vs Host Disease,Graft vs Tumor Effect,Immunosuppressive Agents,Lymphocyte Activation,Lymphocytes,Male,Mice,Mice, Inbred Strains,Propylene Glycols,Sphingosine,T-Lymphocytes, Cytotoxic","analogs &amp; derivatives,drug effects,drug therapy,immunology,mortality,pathology,pharmacology,physiology","D007166 Q000494 NY,D002465 Q000187 NN,D006086 Q000473 NN,D006086 Q000401 NN,D006086 Q000188 NY,D020350 Q000187 NY,D008214 Q000187 NY,D008214 Q000502 NN,D013602 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D008213 Q000187 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.,"Graft-versus-host disease (GvHD) mediated by donor T cells recognizing host alloantigens is associated with beneficial graft-versus-tumor effects in recipients of allogeneic hematopoietic cell transplants. Since leukemias and lymphomas reside largely within the lymphohematopoietic system, we have proposed that the desired graft-versus-leukemia or graft-versus-lymphoma effect can be separated from the complication of GvHD by confinement of the graft-versus-host alloresponse to the lymphohematopoietic tissues",The Journal of clinical investigation,"Yong-Mi Kim, Teviah Sachs, Wannee Asavaroengchai, Roderick Bronson, Megan Sykes"," Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA.",2003 Mar;111(5):659-69,10.1172/jci16950|10.1172/jci200316950
12646631,20030401,article,"xref,mesh","Animals,Antigens,Bromodeoxyuridine,CD4-Positive T-Lymphocytes,Cell Division,Cell Movement,Epitopes, T-Lymphocyte,Fingolimod Hydrochloride,Flow Cytometry,Fluoresceins,Fluorescent Dyes,Growth Inhibitors,Immunosuppressive Agents,Injections, Subcutaneous,Interphase,Lymph Nodes,Lymphocyte Activation,Lymphocyte Culture Test, Mixed,Lymphocyte Depletion,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Mice, Transgenic,Ovalbumin,Propylene Glycols,Receptors, Cell Surface,Receptors, G-Protein-Coupled,Receptors, Lysophospho","administration &amp; dosage,agonists,blood,cytology,drug effects,immunology,metabolism,pharmacology,transplantation","D018417 Q000276 NN,D000941 Q000494 NY,D015496 Q000637 NN,D005452 Q000378 NN,D002465 Q000187 NN,D006131 Q000008 NN,D002455 Q000187 NN,D010047 Q000494 NY,D007166 Q000008 NN,D010047 Q000008 NN,D002465 Q000276 NY,D018984 Q000276 NN,D007166 Q000097 NN,D013110 Q000378 NY,D008213 Q000187 YN,D015496 Q000187 NN,D005456 Q000378 NN,D008198 Q000187 NN,D008198 Q000276 NN,D000941 Q000008 NN,D011409 Q000008 NN,D011956 Q000819 NY,D018417 Q000187 NN,D007399 Q000276 NY,D013388 Q000378 NN,D015496 Q000276 NY,D007399 Q000187 NN","6035,8252,31270,105065,107969,107970,5280335,5289086,6918942,21707526","128394615,129060975,129645792,136111139,136216744,244249447",Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.,"FTY720 (2-amino-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride) is an immunosuppressive agent that inhibits allograft rejection. We recently demonstrated that FTY-phosphate, the active metabolite of FTY720, acts as a full agonist for sphingosine-1-phosphate (S1P) receptors. Furthermore, activation of S1P receptors with their natural ligand, S1P, as well as pharmacological ligands leads to lymphopenia, probably due to sequestration of lymphocytes in secondary lymphoid organs. In the present study we","Journal of immunology (Baltimore, Md. : 1950)","Jenny H Xie, Naomi Nomura, Sam L Koprak, Elizabeth J Quackenbush, Michael J Forrest, Hugh Rosen"," Department of Pharmacology, Merck Research Laboratories, Rahway NJ 07065, USA. jenny_xie@merck.com",2003 Apr;170(7):3662-70,10.4049/jimmunol.170.7.3662
12649354,20030401,article,"xref,mesh","Animals,Apoptosis,Central Nervous System,Central Nervous System Diseases,Cytokines,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,cytology,drug effects,drug therapy,metabolism,prevention &amp; control,therapeutic use","D002493 Q000188 NN,D016207 Q000378 NN,D013110 Q000031 NN,D007166 Q000627 NY,D004681 Q000517 NN,D002490 Q000187 NN,D002490 Q000166 NN,D011409 Q000627 NY,D013601 Q000187 NN,D004681 Q000188 NY","8252,31270,107969,107970,5280335,21707526","128394615,129060975,129645792,244249447",Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.,"Experimental autoimmune encephalomyelitis (EAE) is a T-cell-dependent autoimmune disease that reproduces the inflammatory demyelinating pathology of multiple sclerosis (MS). We investigated the efficacy and mechanism of immunosuppression against EAE by administering 2-amino-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride (FTY720) in Lewis rats immunized with myelin basic protein together with complete Freund's adjuvant. FTY720 treatment almost completely protected the rats against disease. The prote",The Journal of pharmacology and experimental therapeutics,"Masayuki Fujino, Naoko Funeshima, Yusuke Kitazawa, Hiromitsu Kimura, Hiroshi Amemiya, Seiichi Suzuki, Xiao-Kang Li"," Laboratory of Transplantation Immunology, Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan.",2003 Apr;305(1):70-7,10.1124/jpet.102.045658
12698078,20030415,article,"xref,mesh","Animals,Chronic Disease,Complement C3,Coronary Vessels,Cyclosporine,Drug Therapy, Combination,Endothelium, Vascular,Fingolimod Hydrochloride,Graft Rejection,Heart Transplantation,Immunoglobulin G,Immunohistochemistry,Immunosuppressive Agents,Lymphocyte Subsets,Lymphocytes,Male,Monocytes,Myocardium,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,pathology,physiology,therapeutic use","D016131 Q000187 NN,D006084 Q000188 NY,D003331 Q000187 NN,D016572 Q000627 NY,D003331 Q000378 NN,D009000 Q000473 NN,D003331 Q000473 NN,D007074 Q000378 NN,D006084 Q000378 NN,D008214 Q000187 NY,D013110 Q000031 NN,D008214 Q000502 NY,D004730 Q000378 NN,D007166 Q000627 NY,D003176 Q000378 NN,D006084 Q000473 NN,D009206 Q000473 NN,D009206 Q000378 NN,D011409 Q000627 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792","FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.","BACKGROUND: Chronic rejection remains the leading cause of failure after transplantation (Tx). FTY720, a new immunosuppressant altering lymphocyte trafficking, is effective against acute rejection, but its activity against chronic rejection is not known. METHODS: A valid model of chronic rejection was produced. Heart transplantation (HTx) was performed using fully mismatched RA (RT1p) and PVG (RT1c) rats. Administration of donor-specific blood transfusion 12 days before HTx prolongs graft survival, but feat",Transplantation,"Takaaki Koshiba, Boudewijn Van Damme, Omer Rutgeerts, Mark Waer, Jacques Pirenne"," Abdominal Transplant Surgery Department, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.",2003 Apr;75(7):945-52,10.1097/01.tp.0000058469.38572.10
12709439,20030718,article,"xref,mesh","Amino Acid Transport Systems,Base Sequence,DNA, Fungal,Fingolimod Hydrochloride,Gene Expression,Genes, Fungal,Genes, Regulator,Humans,Immunosuppressive Agents,Models, Biological,Mutation,Plasmids,Propylene Glycols,Saccharomyces cerevisiae,Saccharomyces cerevisiae Proteins,Sphingosine,T-Lymphocytes,Ubiquitin","analogs &amp; derivatives,drug effects,genetics,growth &amp; development,immunology,metabolism,pharmacology","D007166 Q000494 NY,D015870 Q000187 NN,D013601 Q000276 NN,D012441 Q000235 NN,D026905 Q000378 NN,D004271 Q000235 NN,D026905 Q000235 NN,D012441 Q000378 NY,D029701 Q000235 NN,D011409 Q000494 NY,D013110 Q000031 NN,D029701 Q000378 NY,D025801 Q000378 NY,D012441 Q000254 NN,D010957 Q000235 NN,D013601 Q000187 NN,D012441 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Ubiquitin pathway proteins influence the mechanism of action of the novel immunosuppressive drug FTY720 in Saccharomyces cerevisiae.,"FTY720 is an immunosuppressive drug in clinical development for transplant graft protection in humans. This agent is of particular interest because, unlike currently available regimes, it acts to sequester lymphocytes without causing cytotoxicity or blocking differentiation and growth potential. In an effort to elucidate the mechanism of action of FTY720, and identify its downstream effectors, we have screened genomic libraries and spontaneous mutants of the model system Saccharomyces cerevisiae for resista",The Journal of biological chemistry,"Carole A Welsch, Shinji Hagiwara, Jean Francois Goetschy, N Rao Movva"," Transplantation Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.",2003 Jul;278(29):26976-82,10.1074/jbc.m213144200
12711631,20030401,article,"xref,mesh","Blood Cells,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,In Vitro Techniques,Leukemia,Phosphorylation,Propylene Glycols,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-akt,Ribosomal Protein S6 Kinases, 70-kDa,Sphingosine,U937 Cells","analogs &amp; derivatives,blood,diagnosis,drug effects,metabolism,pathology,pharmacology","D020298 Q000378 NY,D020298 Q000187 NN,D038762 Q000378 NN,D001773 Q000473 NY,D007938 Q000097 NY,D011409 Q000494 NY,D013110 Q000031 NN,D017346 Q000378 NY,D007938 Q000175 NY","8252,31270,107969,107970,5280335,57059112","128394615,129060975,129645792,135870608",A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.,"1. Our previous studies revealed that the immunosuppressive agent, FTY720, mainly induces mitochondria-involved apoptosis in some types of cancer cells, since Bcl-2 overexpression prevents the FTY720-induction of apoptotic stimuli. Furthermore, FTY720 induces G0/G1 cell cycle arrest. The present study further examines the correlation between intracellular signaling kinases with FTY720-induced mitochondria-involved apoptosis. 2. Human T cell leukemia Jurkat was exposed to FTY720. Dephosphorylation of Akt occ",British journal of pharmacology,"Yumiko Matsuoka, Yukitoshi Nagahara, Masahiko Ikekita, Takahisa Shinomiya"," Division of Radio Isotopes and Biosafety Research, National Research Institute for Child Health and Development, 3-35-31 Taishido, Setagaya-ku, Tokyo 154-8567, Japan.",2003 Apr;138(7):1303-12,10.1038/sj.bjp.0705182
12717240,20030427,article,"xref,mesh","Animals,Blood Cell Count,Cyclosporine,Diabetes Mellitus, Experimental,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Immunosuppression,Immunosuppressive Agents,Islets of Langerhans Transplantation,Isoantibodies,Mice,Mice, Nude,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Swine,Transplantation, Heterologous","analogs &amp; derivatives,analysis,immunology,prevention &amp; control,surgery,therapeutic use","D016572 Q000627 NY,D016381 Q000276 YN,D014183 Q000276 YN,D013110 Q000031 NN,D003921 Q000601 NN,D007166 Q000627 NY,D007518 Q000032 NN,D011409 Q000627 NY,D006084 Q000517 NY","2909,5793,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129621433,129645792",Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.,"BACKGROUND: Our aim was to evaluate the effect of FTY720 in discordant islet xenotransplantation. METHODS: Fetal porcine islet-like cell clusters (ICCs) were transplanted into normoglycemic rats that were either left untreated or treated with FTY720 only, with FTY720 plus cyclosporine A (CsA) or with CsA only. Twelve or 24 days after transplantation, graft morphology was evaluated immunohistochemically. Furthermore, adult porcine islets (APIs) were transplanted into diabetic rats immunosuppressed with FTY72",Transplantation,"A Maeda, M Goto, J Zhang, W Bennet, C G Groth, O Korsgren, L Wennberg"," Department of Transplantation Surgery, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.",2003 Apr;75(8):1409-14,10.1097/01.tp.0000061770.39569.7f
12723592,20030301,article,"xref,mesh","Animals,Apoptosis,Caspase 3,Caspase Inhibitors,Caspases,Cell Cycle,Cell Cycle Proteins,Cell Differentiation,Cell Line,Enzyme Activation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Isoenzymes,Lymphoma,Mice,Oligopeptides,Proliferating Cell Nuclear Antigen,Propylene Glycols,Retinoblastoma Protein,Sphingosine,T-Lymphocytes,Transcription Factors,Transfection,fas Receptor","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology,physiology","D013601 Q000378 NN,D007166 Q000494 NY,D018797 Q000378 NN,D019014 Q000378 NN,D018809 Q000378 NN,D008223 Q000235 NN,D017209 Q000187 NY,D014157 Q000037 NN,D016160 Q000037 NN,D007527 Q000378 NN,D016160 Q000378 NN,D007527 Q000037 NN,D004789 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D018797 Q000037 NY,D002453 Q000187 NN,D009842 Q000494 NN,D008223 Q000378 NN,D020169 Q000378 NY,D002454 Q000187 NN,D002453 Q000502 NN,D014157 Q000378 NN","8252,31270,107969,107970,5280335,9847059","128394615,129060975,129645792,129926176","Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720.","The immunosuppressant, FTY720 causes apoptosis of lymphocytes, reduces numbers of lymphocytes in peripheral blood, and prevents infiltration of lymphocytes into allografts, which may be one of the mechanisms involved in its effects. Here we compared caspase activation and expression of cell-cycle regulators during apoptosis caused by FTY720, and Fas-stimulation in a mouse lymphoma transfected with human Fas antigen. FTY720 activated caspases-3, -8, and -9 as rapidly as did Fas-mediated apoptosis. The activa","Bioscience, biotechnology, and biochemistry","Yun-Sik Lee, Hiroo Nakajima, Mie Tsuruga, Junji Magae"," National Institute of Bioscience and Human Technology, 1-1 Higashi, Tsukuba 305-8566, Japan.",2003 Mar;67(3):467-74,10.1271/bbb.67.467
12738247,20030401,article,"xref,mesh","Animals,Diabetes Mellitus, Type 1,Female,Fingolimod Hydrochloride,Glucose,Immunohistochemistry,Immunosuppressive Agents,Insulin,Islets of Langerhans,Lymphocyte Count,Male,Mice,Mice, Inbred C57BL,Mice, Inbred NOD,Propylene Glycols,Random Allocation,Sphingosine","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,prevention &amp; control","D007166 Q000494 NY,D003922 Q000276 NN,D007515 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D003922 Q000517 NY,D005947 Q000378 NN,D007515 Q000378 NN,D007515 Q000276 NN,D007328 Q000378 NN","5793,8252,24749,31270,107526,107969,107970,5280335,10954115,70678557,87517085,118984375","128394615,129060975,129621433,129645792",The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.,"FTY720 is a novel immune regulatory drug derived from the fungal sphingosine analog ISP-1 (myriocin). FTY720 causes a redistribution of lymphocytes from circulation to secondary lymphoid tissues. Type 1 diabetes is an autoimmune disorder caused by cellular-mediated destruction of insulin-producing pancreatic beta cells in the islets of Langerhans. Indeed, local infiltration of islets by mononuclear cells is the hallmark of Type 1 diabetes. Based on both FTY720's action and the involvement of cellular infilt","Clinical immunology (Orlando, Fla.)","Zandong Yang, Meng Chen, Lawrence B Fialkow, Justin D Ellett, Runpei Wu, Volker Brinkmann, Jerry L Nadler, Kevin R Lynch"," Department of Internal Medicine, P.O. Box 801413, University of Virginia, Charlottesville, VA 22908, USA. zy4g@virginia.edu",2003 Apr;107(1):30-5,10.1016/s1521-6616(02)00054-2
12771800,20030601,article,"xref,mesh","Animals,Apoptosis,Blotting, Western,Cell Division,Cell Line,Cell Survival,DNA Fragmentation,DNA, Neoplasm,Drug Screening Assays, Antitumor,Enzyme Activation,Fibroblasts,Fingolimod Hydrochloride,Hepatocyte Growth Factor,Humans,Immunosuppressive Agents,Male,Mice,Mice, Inbred BALB C,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Mitogen-Activated Protein Kinases,Neoplasm Transplantation,Phosphorylation,Propylene Glycols,Sphingosine,Tumor Cells, Cultured,Urinary Bladder Neoplasms","analogs &amp; derivatives,cytology,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,therapeutic use","D001749 Q000473 NY,D017228 Q000494 NN,D007166 Q000494 NY,D002455 Q000187 NN,D017209 Q000187 NY,D002470 Q000187 NN,D007166 Q000627 NN,D053938 Q000187 NN,D014407 Q000473 NN,D020928 Q000378 NN,D004789 Q000187 NN,D011409 Q000494 NY,D005347 Q000166 NN,D013110 Q000031 NN,D004273 Q000187 NN,D001749 Q000235 NN,D019950 Q000378 NN,D005347 Q000187 NN,D010766 Q000187 NN,D011409 Q000627 NN,D001749 Q000188 NN,D014407 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment.,"PURPOSE: FTY720 is a unique immunosuppressant that induces apoptosis in activated lymphocytes but not in other hematopoietic cells. We examined whether FTY720 has anticancer effects on human bladder cancer cells by inducing apoptosis and we investigated its molecular pathway. MATERIALS AND METHODS: We used the 3 human bladder cancer cell lines T24, UMUC3 and HT1197, and the human fibroblast derived cell line CRL-2096 (American Type Tissue Collection, Rockville, Maryland) in this study. The difference in dru",The Journal of urology,"Haruhito Azuma, Shigero Takahara, Shigeo Horie, Satoru Muto, Yoshinori Otsuki, Yoji Katsuoka"," Department of Urology, Osaka Medical College, Takatsuki, Japan.",2003 Jun;169(6):2372-7,10.1097/01.ju.0000064938.32318.91
12792499,20030515,article,"xref,mesh","Animals,Cell Movement,Fingolimod Hydrochloride,Immunosuppressive Agents,Intestine, Small,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pathology,pharmacology,physiology,transplantation","D007166 Q000494 NY,D002465 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007421 Q000637 NY,D013601 Q000187 NY,D013601 Q000502 NN,D016176 Q000276 NN,D007421 Q000473 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.,"BACKGROUND: Effective immunosuppression is a critical determinant of graft survival in small-bowel transplantation (SBTx). The present study was designed to determine the potency of FTY720, a newly synthesized immunosuppressant, in rat SBTx and examine the phenotype of graft-infiltrating cells to evaluate its effect on intestinal allografts. MATERIALS AND METHODS: A segment of intestine of Dark Agouti rats was transplanted heterotopically into Lewis rats. The recipients were treated with or without oral FTY",Transplantation,"Takuya Kimura, Toshimichi Hasegawa, Hiroshi Nakai, Tatsuo Azuma, Noriaki Usui, Takashi Sasaki, Akira Okada"," Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Japan.",2003 May;75(9):1469-74,10.1097/01.tp.0000058816.13525.92
12814476,20030701,article,"xref,mesh","Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Subsets,Lymphopenia,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacokinetics,prevention &amp; control","D016131 Q000187 NN,D011409 Q000493 NY,D007166 Q000493 NY,D013110 Q000031 NN,D008231 Q000378 NN,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.,"FTY720, a new and potent immunosuppressant, causes in animal models a rapid, reversible reduction of all subsets of peripheral blood lymphocytes, inducing their migration to secondary lymphoid organs. In this human phase I trial, the pharmacodynamics of single oral doses of FTY720 were evaluated. A randomized, double-blind, placebo-controlled, time-lagged study of six different single ascending oral doses of FTY720 ranging from 0.25 to 3.5 mg was conducted in stable renal transplant patients receiving a cyc",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Klemens Budde, Robert L Schmouder, Bjorn Nashan, Reinhard Brunkhorst, Peter W Lücker, Thomas Mayer, Laurence Brookman, Jerry Nedelman, Andrej Skerjanec, Torsten Böhler, Hans-Hellmut Neumayer"," Department of Nephrology, Charité University Hospital, Berlin, Germany.",2003 Jul;3(7):846-54,10.1034/j.1600-6143.2003.00130.x
12819868,20030601,article,"xref,mesh","Animals,Antibodies, Anti-Idiotypic,Antibody Formation,Blood Transfusion,Fingolimod Hydrochloride,Heart Transplantation,Histocompatibility,Immunoglobulin G,Immunoglobulin M,Immunosuppressive Agents,Intestines,Lymphocyte Culture Test, Mixed,Lymphocyte Subsets,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred Strains,Sphingosine,Tissue Donors,Transplantation Conditioning,Transplantation Tolerance,Transplantation, Heterotopic,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,pharmacology,transplantation","D016131 Q000187 NN,D007166 Q000494 NY,D007075 Q000276 NN,D007074 Q000276 NN,D007422 Q000637 NY,D019172 Q000379 NN,D011409 Q000494 NY,D013110 Q000031 NN,D000888 Q000276 NN,D008214 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The effect of FTY 720 on engraftment in a model of spontaneous allograft acceptance.,"Further development in organ transplantation requires the utilization of new immunosuppressive drugs that-in addition to being effective against rejection-do not block tolerance. We previously reported that FTY 720, a drug that alters lymphocyte trafficking, has marked anti-rejection properties. We now investigate how FTY 720 influences tolerance in a model of graft acceptance by donor-specific blood transfusion (DSBT). Two different transplant models--heart transplantation (Htx) and intestinal transplantat",Transplant international : official journal of the European Society for Organ Transplantation,"Takaaki Koshiba, Boudewijn Van Damme, Ping Ji, Hassan Sefrioui, Omer Rutgeerts, Mark Waer, Jacques Pirenne"," Abdominal Transplant Department, University Hospital of Leuven, Herestraat 49, 3000 Leuven, Belgium.",2003 Jun;16(6):383-90,10.1007/s00147-002-0523-9|10.1111/j.1432-2277.2003.tb00318.x
12826223,20030601,article,"xref,mesh","Analysis of Variance,Animals,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Kidney Transplantation,Male,Oligonucleotides, Antisense,Propylene Glycols,Rats,Rats, Sprague-Dawley,Renal Circulation,Reperfusion Injury,Sphingosine,Thionucleotides,Transplantation, Isogeneic","analogs &amp; derivatives,drug effects,genetics,immunology,physiology,prevention &amp; control,therapeutic use","D015427 Q000517 NY,D013110 Q000031 NN,D018799 Q000235 NY,D013873 Q000627 NN,D007166 Q000627 NY,D016030 Q000276 NY,D012079 Q000502 NY,D011409 Q000627 NY,D012079 Q000187 NN,D016376 Q000627 NY","588,8252,31270,107969,107970,5280335","127719861,129060975,129645792",Prevention of renal ischemic reperfusion injury using FTY 720 and ICAM-1 antisense oligonucleotides.,"BACKGROUND: Renal damage secondary to ischemia-reperfusion injuries (I-R) is frequent in organ transplantation and adversely affects the graft survival. An important component of this damage is caused by initial adhesion of neutrophils and lymphocytes to endothelial cells. FTY 720, which induces lymphopenia, has previously been shown to display protective effects in models of I-R. The purpose of the present study was to evaluate the combination of FTY 720 and intracellular adhesion molecule and ICAM-1 antis",Transplantation proceedings,"A M Ortiz, P Troncoso, B D Kahan"," Unidad de Trasplante Renal, Pontificia Universidad Catolica de Chile, Santiago, Chile.",2003 Jun;35(4):1571-4,10.1016/s0041-1345(03)00374-9
12831371,20030701,review,"xref,mesh","Animals,Clinical Trials, Phase I as Topic,Clinical Trials, Phase II as Topic,Dogs,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Infection,Mice,Primates,Propylene Glycols,Rats,Reperfusion Injury,Sphingosine,Transplantation Immunology,Transplantation, Heterologous","adverse effects,analogs &amp; derivatives,immunology,pharmacokinetics,pharmacology,prevention &amp; control,therapeutic use","D007239 Q000276 NN,D011409 Q000009 NN,D007166 Q000493 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000493 NN,D014183 Q000276 NN,D011409 Q000494 NN,D015427 Q000517 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D006084 Q000517 NY","8252,31270,107969,107970,5280335,57024517","128394615,129060975,129645792,135812730",FTY720: A new kid on the block for transplant immunosuppression.,"FTY720, a synthetic analogue of myriocin (ISP-1), is derived from culture filtrates of the fungus Isaria sinclairii. As a sphingosine analogue, FTY720 appears to undergo phosphorylation and thereby interact with specific G-protein-linked receptors. In vivo, FTY720 causes emigration of lymphocytes from peripheral blood to secondary lymphoid structures. Thus, the drug is the archetype of a new class of agents that alter cellular homing patterns: the adhesion-migration paradigm. Since FTY720 seems to spare non",Expert opinion on biological therapy,"Fazil Tuncay Aki, Barry D Kahan"," The University of Texas Medical School at Houston, Department of Surgery, Suite 6.240, 6431 Fannin, Houston, TX 77030, USA.",2003 Jul;3(4):665-81,10.1517/14712598.3.4.665
12926052,20030101,article,"xref,mesh","Animals,Antineoplastic Agents,Apoptosis,Cell Division,Enzyme Activation,Female,Fingolimod Hydrochloride,Hepatocyte Growth Factor,Immunosuppressive Agents,Male,Mammary Neoplasms, Experimental,Mice,Mice, Inbred BALB C,Mice, Nude,Mitogen-Activated Protein Kinases,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Sphingosine,bcl-X Protein","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,enzymology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D000970 Q000494 NY,D008325 Q000473 NN,D011409 Q000009 NN,D002455 Q000187 NN,D017209 Q000187 NY,D020928 Q000037 NY,D020928 Q000378 NN,D008325 Q000188 NY,D004789 Q000187 NN,D011409 Q000494 NY,D008325 Q000201 NN,D013110 Q000031 NN,D019253 Q000378 NY,D000970 Q000009 NN,D008325 Q000378 NN,D007166 Q000009 NN,D017228 Q000037 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity.,"BACKGROUND: FTY720 is a unique immunosuppressant that induces apoptosis in activated lymphocytes, but not in other hematopoietic cells. We conducted the present study to investigate its anticancer effect and molecular pathway in inducing apoptosis using murine breast cancer models. MATERIALS AND METHODS: The difference in drug susceptibility to FTY720 between cancer cells and non-cancer cells was examined by MTT assay and cell growth assay. FTY720-induced apoptosis was determined by electron microscopy and ",Anticancer research,"Haruhito Azuma, Shigeo Horie, Satoru Muto, Yoshinori Otsuki, Kenji Matsumoto, Junji Morimoto, Rieko Gotoh, Akihiko Okuyama, Seiichi Suzuki, Yoji Katsuoka, Shiro Takahara"," Department of Urology, Osaka Medical College, Takatsuki, Osaka, 569-8686, Japan.",2003 Jan;23(4):3183-93,NULL
12941420,20030801,review,"xref,mesh","Animals,Binding, Competitive,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Ligands,Lymphocytes,Lysophospholipids,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingolipids,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,immunology,metabolism,physiology,therapeutic use","D007166 Q000627 NN,D043562 Q000502 NY,D043562 Q000037 NN,D013110 Q000378 NY,D043562 Q000819 NN,D013110 Q000031 NY,D013107 Q000378 NN,D008214 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000096 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm.,"New insights have been gained into the therapeutic relevance of the sphingosine 1-phosphate (S1P) pathway, on the basis of reverse pharmacological approaches to defining the mechanism of action of the immunosuppressive agent FTY720. Natural and synthetic sphingosine 1-phosphate receptor agonists can make picomolar interactions with their cognate G-protein-coupled receptors, and provide chemical approaches to defining the contribution of distinct receptor subtypes to pathology, physiology and treatment. The ",Current opinion in chemical biology,"Hugh Rosen, Jiayu Liao"," Department of Immunology and Committee for Advanced Human Therapeutics, The Scripps Research Institute, ICND-118 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. hrosen@scripps.edu",2003 Aug;7(4):461-8,10.1016/s1367-5931(03)00085-1
12954648,20031121,article,"xref,mesh","Adherens Junctions,Animals,Capillary Permeability,Cell Survival,Cells, Cultured,Drug Antagonism,Endothelial Cells,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Mitogen-Activated Protein Kinases,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-akt,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine,Umbilical Veins,Vascular Endothelial Growth Factor A","administration &amp; dosage,adverse effects,agonists,analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology,physiology","D017853 Q000378 NN,D042783 Q000378 NN,D002199 Q000187 NY,D007166 Q000008 NN,D002470 Q000187 NN,D011518 Q000378 NN,D007166 Q000378 NN,D020928 Q000378 NN,D011409 Q000378 NY,D043562 Q000819 NN,D011409 Q000008 NN,D011409 Q000494 NY,D042783 Q000187 NN,D014471 Q000166 NN,D013110 Q000031 NN,D022005 Q000378 NN,D042461 Q000009 NY,D007166 Q000494 NN,D043562 Q000502 NN","8252,31270,107969,107970,5280335,71458556","128394615,129060975,129645792,178103238",Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.,"FTY720, a potent immunosuppressive agent, is phosphorylated in vivo into FTY720-P, a high affinity agonist for sphingosine 1-phosphate (S1P) receptors. The effects of FTY720 on vascular cells, a major target of S1P action, have not been addressed. We now report the metabolic activation of FTY720 by sphingosine kinase-2 and potent activation of vascular endothelial cell functions in vitro and in vivo by phosphorylated FTY720 (FTY720-P). Incubation of endothelial cells with FTY720 resulted in phosphorylation ",The Journal of biological chemistry,"Teresa Sanchez, Tatiana Estrada-Hernandez, Ji-Hye Paik, Ming-Tao Wu, Krishnan Venkataraman, Volker Brinkmann, Kevin Claffey, Timothy Hla"," Center for Vascular Biology, Department of Cell Biology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3501, USA.",2003 Nov;278(47):47281-90,10.1074/jbc.m306896200
12956930,20030901,article,"xref,mesh","Animals,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Lymphocyte Count,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Myocardium,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pathology,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D013110 Q000031 NN,D007166 Q000627 NY,D009206 Q000473 NN,D016027 Q000276 NY,D011409 Q000627 NY,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation.","AIM: FTY720 is a new synthetic immunosuppressive agent which has a unique mechanism of action and induces long-term graft acceptance in rat and dog allotransplantation as prophylactic administration. The present study investigated whether FTY720 was able to rescue ongoing acute rejection of solid organ transplants in a mouse heterotopic cardiac transplantation model. METHODS: BALB/c hearts were heterotopically grafted in C57BL/6 mice. FTY720, at the doses of 0.5, 1, and 5 mg.kg-1.d-1 or vehicle was administ",Acta pharmacologica Sinica,"Ming-Hui Wang, Vitaliy Milekhin, Hua Zhang, Hong-Zheng Huang"," Department of Nephrology, Essen University Hospital, Essen (45122), Germany. wangminghui01@hotmail.com",2003 Sep;24(9):847-52,NULL
12957632,20030901,article,"xref,mesh","Administration, Topical,Animals,Diterpenes,Drug Delivery Systems,Emulsions,Epoxy Compounds,Lipids,Male,Nanotechnology,Phenanthrenes,Rats,Rats, Wistar,Skin","administration &amp; dosage,drug effects,metabolism,methods,pharmacokinetics","D008055 Q000493 NN,D004224 Q000493 NN,D004655 Q000493 NN,D004655 Q000008 NY,D010616 Q000008 NY,D010616 Q000493 NN,D012867 Q000378 NN,D008055 Q000008 NY,D016503 Q000379 NY,D004224 Q000008 NY,D036103 Q000379 NY,D012867 Q000187 NN","8042,8252,107985,160438","127472665,127523511,129060975",Solid lipid nanoparticle and microemulsion for topical delivery of triptolide.,"Triptolide (TP) has been shown to have anti-inflammatory, immunosuppressive, anti-fertility and anti-neoplastic activities. However, its clinical use is restricted to some content due to its poor water solubility and some toxic effects. In order to find innovative ways for administering TP and alleviating its disadvantages, the controlled release delivery systems such as solid lipid nanoparticle (SLN) and microemulsion have been developed. In the present paper we describe the preparation and some characteri",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,"Zhinan Mei, Huabing Chen, Ting Weng, Yajiang Yang, Xiangliang Yang"," Pharmaceutical Institute, Huazhong University of Science and Technology, Wuhan, PR China.",2003 Sep;56(2):189-96,10.1016/s0939-6411(03)00067-5
13129923,20031128,article,"xref,mesh","Animals,Blotting, Northern,Cell Line,Cloning, Molecular,DNA, Complementary,Endothelial Cells,Fingolimod Hydrochloride,Genetic Variation,Genome, Human,Humans,Immunosuppressive Agents,Kinetics,Mice,Mice, Inbred BALB C,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Isoforms,Protein Structure, Tertiary,Rats,Rats, Wistar,Sphingosine,Tissue Distribution","analogs &amp; derivatives,chemistry,metabolism,pharmacokinetics,pharmacology","D007166 Q000494 NY,D042783 Q000378 NN,D011409 Q000493 NY,D013110 Q000031 NN,D018076 Q000378 NN,D017853 Q000378 NY,D017853 Q000737 NN","8252,31270,69676,105065,107969,107970,5280335","128394615,129060975,129308074,129645792,135836815,136111139",Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.,"The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biological effects of the compound. So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented. We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2. Similarly, murine SPHK",The Journal of biological chemistry,"Andreas Billich, Frederic Bornancin, Piroska Dévay, Diana Mechtcheriakova, Nicole Urtz, Thomas Baumruker"," Novartis Research Institute, Brunnerstrasse 59, A-1235 Vienna, Austria. andreas.billich@pharma.novartis.com",2003 Nov;278(48):47408-15,10.1074/jbc.m307687200
14557756,20031015,article,"xref,mesh","Adult,Cyclosporine,Dose-Response Relationship, Drug,Double-Blind Method,Drug Administration Schedule,Drug Therapy, Combination,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Middle Aged,Placebos,Prednisone,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,pharmacokinetics,therapeutic use","D016572 Q000627 NN,D011409 Q000009 NN,D011409 Q000493 NY,D007166 Q000493 NY,D013110 Q000031 NN,D011241 Q000627 NN,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","2909,5865,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792,129717275","Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.","BACKGROUND: FTY720, a novel immunomodulator, displays potent immunosuppressive activity in a variety of preclinical transplant models. This study examined the safety, pharmacodynamics, and pharmacokinetics of multiple doses of FTY720 in stable renal transplant patients. METHODS: This randomized, multicenter, double-blind, placebo-controlled, phase I study included adults who had been maintained on a regimen of cyclosporine A (CsA) microemulsion and prednisone (or its equivalent) for at least 1 year after re",Transplantation,"Barry D Kahan, Janet L Karlix, Ronald M Ferguson, Alan B Leichtman, Shamkant Mulgaonkar, Thomas A Gonwa, Andrej Skerjanec, Robert L Schmouder, Lawrence Chodoff"," Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA. barry.d.kahan@uth.tmc.edu.",2003 Oct;76(7):1079-84,10.1097/01.tp.0000084822.01372.ac
14569608,20030101,review,"xref,mesh","Antibodies, Monoclonal,Azathioprine,Calcineurin Inhibitors,Cyclosporine,Fingolimod Hydrochloride,Glucocorticoids,Humans,Immunosuppressive Agents,Kidney Transplantation,Mycophenolic Acid,Propylene Glycols,Receptors, Interleukin-2,Sirolimus,Sphingosine,Tacrolimus","analogs &amp; derivatives,biosynthesis,metabolism,methods,pharmacology,therapeutic use","D000911 Q000378 NN,D016559 Q000494 NN,D009173 Q000031 NY,D016030 Q000379 NY,D013110 Q000031 NN,D020123 Q000494 NN,D001379 Q000627 NN,D007166 Q000627 NY,D016572 Q000494 NN,D011409 Q000494 NN,D005938 Q000378 NN,D015375 Q000096 NN,D009173 Q000627 NN","2265,2909,4271,4272,5372,8252,31270,62280,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6473866,6536850,9855081,11529527,23665584,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129645792,242963342,248766214",Renal transplantation: basic concepts and evolution of therapy.,"Within the last 5 years, dramatic changes in the area of renal transplantation have occurred. There have been shifts in the dominant types of rejection, and in the types and utilization of immunosuppressants. Hyperacute rejection is now rarely seen, and acute cellular rejection within the first 6 to 12 months has been reduced to about 10%. However, humoral/antibody-mediated rejection has become a more prevalent problem. In the area of immunosuppressants, the ability to reduce acute cellular rejection to abo",Journal of clinical apheresis,William E Braun," Department of Nephrology and Hypertension, Consultant Organ Transplantation, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. braunw@ccf.org",2003 Jan;18(3):141-52,10.1002/jca.10070
14578745,20031027,article,"xref,mesh","Acute Disease,Animals,Dogs,Fingolimod Hydrochloride,Graft vs Host Disease,Hematopoietic Stem Cell Transplantation,Histocompatibility,Immunosuppressive Agents,Lymphocyte Count,Propylene Glycols,Recurrence,Severity of Illness Index,Sphingosine","adverse effects,analogs &amp; derivatives,mortality,pathology,pharmacology,physiopathology","D007166 Q000494 NY,D011409 Q000009 NN,D006086 Q000503 NY,D006086 Q000473 NN,D006086 Q000401 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000009 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.,"BACKGROUND: Acute graft-versus-host disease (GVHD) remains a significant impediment to successful hematopoietic stem-cell transplantation (HSCT). Here, we examined the effectiveness of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720), an immunosuppressant that retraffics activated lymphocytes to secondary lymphoid organs, for the treatment of acute GVHD in an established dog leukocyte antigen-nonidentical unrelated canine HSCT model. METHODS: Dogs were given HSCT after conditioning ",Transplantation,"Richard S Lee, Christian S Kuhr, George E Sale, Eustacia Zellmer, William J Hogan, Rainer Storb, Marie-Térèse Little"," Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.",2003 Oct;76(8):1155-8,10.1097/01.tp.0000083891.14089.b8
14596200,20030101,review,"xref,mesh","Antigens, CD,Antigens, Differentiation,CTLA-4 Antigen,Comorbidity,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunoglobulins, Intravenous,Immunosuppression,Immunosuppressive Agents,Organ Transplantation,Propylene Glycols,Sphingosine,Transplantation Immunology","adverse effects,analogs &amp; derivatives,chemistry,drug effects,immunology,methods,prevention &amp; control,therapeutic use,trends","D000943 Q000627 NN,D011409 Q000276 NN,D016756 Q000276 NN,D016756 Q000627 NN,D000943 Q000276 NN,D013110 Q000031 NN,D014181 Q000187 NN,D007166 Q000627 NY,D014181 Q000276 NY,D007165 Q000379 NY,D007166 Q000276 NN,D007165 Q000639 NN,D007166 Q000737 NN,D006084 Q000517 NN,D006084 Q000276 NN,D011409 Q000627 NN,D007165 Q000009 NN,D016377 Q000009 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",New paradigms in immunosuppression.,"With the decrease in donor quality and the increase in recipient co-morbidities, transplantation immunosuppression is changing. New paradigms in transplantation include co-stimulation, lymphocyte retrafficking, and inhibiting antibody production. With these new paradigms come new immunosuppressive agents. While these new agents show great promise, their use in day-to-day clinical transplantation remains to be seen. ",CANNT journal = Journal ACITN,"Robert Huizinga, Therese Voyer"," Isotechnika Inc., Edmonton, Alberta. robert.huizinga@isotechnika.com",2003 Jan;13(3):66-8,NULL
14596938,20031106,article,"xref,mesh","Animals,Biotransformation,Cell Line,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Octoxynol,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Sphingosine,Transfection","genetics,metabolism,pharmacokinetics,pharmacology","D011409 Q000493 NY,D017853 Q000235 NN,D007166 Q000493 NY,D017830 Q000494 NN,D013110 Q000378 NN,D017853 Q000378 NY,D011409 Q000494 NN,D007166 Q000494 NN","5590,8252,31270,107969,107970,5280335","128394615,129060975,129645792",The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.,"The potent immunosuppressive drug FTY720, a sphingosine analog, induces redistribution of lymphocytes from circulation to secondary lymphoid tissues. FTY720 is phosphorylated in vivo and functions as an agonist for four G-protein-coupled sphingosine-1-phosphate receptors. The identity of the kinase that phosphorylates FTY720 is still not known. Here we report that although both sphingosine kinase type 1 (SphK1) and type 2 (SphK2) can phosphorylate FTY720 with low efficiency, SphK2 is much more effective tha",FEBS letters,"Steven W Paugh, Shawn G Payne, Suzanne E Barbour, Sheldon Milstien, Sarah Spiegel"," Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.",2003 Nov;554(?):189-93,10.1016/s0014-5793(03)01168-2
14634137,20031201,article,"xref,mesh","Animals,Anti-Inflammatory Agents, Non-Steroidal,Asthma,Bronchial Hyperreactivity,Bystander Effect,Cell Movement,Disease Models, Animal,Epitopes, T-Lymphocyte,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Lung,Mice,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine,Th1 Cells,Th2 Cells","administration &amp; dosage,agonists,biosynthesis,drug effects,drug therapy,immunology,metabolism,pathology,prevention &amp; control,transplantation","D007249 Q000378 NN,D008168 Q000187 NN,D008168 Q000276 NN,D043562 Q000819 NY,D002465 Q000187 NN,D018417 Q000378 NN,D018418 Q000637 NY,D018984 Q000276 NN,D013110 Q000378 NY,D001249 Q000188 NN,D007249 Q000517 NN,D018417 Q000637 NY,D008168 Q000473 NY,D018417 Q000187 NN,D001249 Q000276 NN,D002465 Q000276 NN,D007249 Q000276 NN,D018418 Q000378 NN,D001249 Q000473 NN,D024201 Q000187 NN,D000894 Q000008 NY,D018418 Q000187 NN,D016535 Q000517 NN,D011409 Q000008 NY,D007166 Q000008 NY,D008168 Q000378 NN,D016535 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.,"The sphingosine 1-phosphate receptor agonist FTY720 is a novel immunomodulator that sequesters lymphocytes in secondary lymphoid organs and thereby prevents their migration to sites of inflammation. However, there is currently no information available on whether this drug affects Th1 or Th2 cell-mediated lung-inflammatory responses. The effect of FTY720 was therefore investigated in a murine airway inflammation model using OVA-specific, in vitro differentiated, and adoptively transferred Th1 and Th2 cells. ","Journal of immunology (Baltimore, Md. : 1950)","Elzbieta Sawicka, Claudia Zuany-Amorim, Corinne Manlius, Alexandre Trifilieff, Volker Brinkmann, David M Kemeny, Christoph Walker"," Novartis Horsham Research Centre, Horsham, U.K.",2003 Dec;171(11):6206-14,10.4049/jimmunol.171.11.6206
14657695,20031127,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Corneal Transplantation,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred C3H,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D015496 Q000276 NN,D007166 Q000627 NN,D016039 Q000276 NY,D015496 Q000187 NN,D006085 Q000276 NY,D013110 Q000031 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice.,"BACKGROUND: The novel immunomodulator, FTY720, mainly acts through sequestering of lymphocytes to secondary lymphatic tissue, thereby suppressing their infiltration into grafted organs. This study aimed to investigate its influence on corneal-graft survival. METHODS: Sixteen BALB/c mice (H-2d) received corneal transplants from C3H (H-2k) mice. Eight mice were treated with FTY720 (10 mg/kg per day) orally from day -1 to day 11, and all animals received 0.1% dexamethasone eye drops for the same time. In addit",Transplantation,"Er-Ping Zhang, Anja Müller, Ralf Ignatius, Friedrich Hoffmann"," Department of Ophthalmology, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany.",2003 Nov;76(10):1511-3,10.1097/01.tp.0000086344.04487.4f
14703955,20031001,article,"xref,mesh","Apoptosis,Cells, Cultured,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocytes,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D017209 Q000187 NN,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine.","FTY is a novel immunomodulator currently undergoing clinical investigation and has the potential of improving immunosuppressive therapy after organ transplantation. Previous experimental studies in animals have shown that FTY has a unique mechanism of action. We have studied the pharmacodynamic effects of FTY in stable renal allograft recipients taking part in a phase I clinical trial. As in various animal models including non-human primates, a single oral dose of FTY (0.25 - 3.5 mg) significantly reduced p",International journal of clinical pharmacology and therapeutics,"T Böhler, J Waiser, M Schütz, B Schumann, H H Neumayer, K Budde"," Department of Internal Medicine, Nephrology, Charité, Campus Mitte, Humboldt University, Berlin, Germany. torsten.boehler@charite.de",2003 Oct;41(10):482-7,NULL
14710781,20031201,review,"xref,mesh","Abatacept,Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,Antilymphocyte Serum,Area Under Curve,Cyclosporine,Drug Therapy, Combination,Drug Utilization,Everolimus,Fingolimod Hydrochloride,Graft Survival,Humans,Immunoconjugates,Immunoglobulin G,Immunosuppressive Agents,Muromonab-CD3,Mycophenolic Acid,Propylene Glycols,Recombinant Fusion Proteins,Sirolimus,Sphingosine,Tacrolimus","administration &amp; dosage,adverse effects,analogs &amp; derivatives,blood,drug effects,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D007166 Q000008 NN,D016559 Q000627 NN,D009173 Q000031 NY,D000911 Q000627 NN,D020123 Q000008 NN,D016572 Q000008 NN,D000912 Q000627 NN,D013110 Q000031 NN,D007074 Q000627 NN,D007166 Q000627 NY,D018796 Q000627 NN,D020123 Q000031 NY,D007166 Q000009 NY,D009173 Q000627 NN,D000961 Q000627 NN,D016853 Q000627 NN,D011409 Q000627 NN,D016572 Q000097 NN,D020123 Q000627 NN,D009173 Q000009 NN","2909,4271,4272,5372,8252,31270,62280,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6442177,6473866,6536850,9855081,23665584,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90696889,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129645792,242749350,242963342,248766214","Current immunosuppressive agents: efficacy, side effects, and utilization.","Advances in immunosuppressive therapy over the past decade have led to dramatic improvements in graft survival. With the development of new agents, the focus of the transplant community is to establish regimens that maintain excellent graft survival rates but with fewer toxicities including infection, nephrotoxicity, malignancy, and cosmetic effects. Examples include the use of steroid-free protocols and calcineurin avoidance regimens, which are currently being studied by NAPRTCS. The ultimate goal of trans",Pediatric clinics of North America,"Jodi M Smith, Thomas Lajos Nemeth, Ruth A McDonald"," Division of Nephrology, Children's Hospital and Regional Medical Center, 4800 Sand Point Way, NE 5G-1, Seattle, WA 98105-0371, USA. jodi.smith@seattlechildrens.org",2003 Dec;50(6):1283-300,10.1016/s0031-3955(03)00121-4
14715694,20040301,article,"xref,mesh","Animals,Chemotaxis,Dose-Response Relationship, Drug,Down-Regulation,Drug Design,Endocytosis,Fingolimod Hydrochloride,Gene Targeting,Humans,Immunosuppressive Agents,Jurkat Cells,Lymphocyte Subsets,Lymphopenia,Lysophospholipids,Mice,Propylene Glycols,Protein Isoforms,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Recombinant Fusion Proteins,Signal Transduction,Sphingosine,Transduction, Genetic,Transfection","analogs &amp; derivatives,chemically induced,cytology,drug effects,genetics,metabolism,pharmacology","D020033 Q000187 NN,D007166 Q000494 NY,D011993 Q000187 NN,D002633 Q000187 NN,D043562 Q000235 NN,D015536 Q000187 NN,D008231 Q000139 NN,D013110 Q000494 NY,D011409 Q000494 NY,D008246 Q000494 NY,D013110 Q000031 NN,D016131 Q000378 NN,D016131 Q000187 NY,D019169 Q000187 NN,D015398 Q000187 NN,D016131 Q000166 NN,D043562 Q000187 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.,FTY720 is an immunosuppressant that reduces circulating levels of naïve lymphocytes by increasing their localization and sequestration in secondary lymphoid organs. It is considered to be an agonist for sphingosine 1-phosphate (S1P) G protein-coupled receptors (GPCRs) after phosphorylation at micromolar concentrations. We now describe its nonagonist and noncompetitive inhibitory activity at low nanomolar concentrations for types 1 and 5 S1P-GPCRs and of moderate potency for type 2 S1P-GPCRs. FTY720 blocks S,FASEB journal : official publication of the Federation of American Societies for Experimental Biology,"Markus H Gräler, Edward J Goetzl"," University of California, Room UB-8B, UC Box 0711, 533 Parnassus Ave., San Francisco, CA 94143-0711, USA. graeler@itsa.ucsf.edu",2004 Mar;18(3):551-3,10.1096/fj.03-0910fje
14726122,20040211,article,"xref,mesh","Chemistry, Pharmaceutical,Immunosuppressive Agents,Ointments,Propane,Solvents,Tacrolimus,Thermodynamics","administration &amp; dosage,analogs &amp; derivatives,chemistry","D007166 Q000008 NN,D007166 Q000737 NY,D016559 Q000008 NN,D012997 Q000737 NN,D011407 Q000031 NY,D011407 Q000737 NN,D016559 Q000737 NY","5372,6334,7924,445643,5282315,6473866,6536850,18183689,71668407,90726579,134694629","127458310,129889442,242963342",In vitro release of Tacrolimus from Tacrolimus ointment and its speculated mechanism.,"The in vitro release profiles and the bleeding phenomenon of Tacrolimus and propylene carbonate (PC) as a dispersing solvent for Tacrolimus drug substance in Tacrolimus ointment were investigated when changing concentrations of Tacrolimus and PC in the ointment were used, respectively. The bleeding test result indicated that Tacrolimus was in equilibrium between inside and outside of PC droplets in intact ointment base. A cumulative release amount of Tacrolimus from ointment, plotted against the square root",International journal of pharmaceutics,"H Yoshida, S Tamura, T Toyoda, K Kado, N Ohnishi, R Ibuki"," Pharmaceutical Science Laboratories, Fujisawa Pharmaceuticals Co., Ltd, 1-6, 2-chome Kashima Yodogawa-ku, Osaka 532-8514, Japan. hiromitsu_yoshida@po.fujisawa.co.jp",2004 Feb;270(?):55-64,10.1016/j.ijpharm.2003.10.013
14732717,20040402,article,"xref,mesh,assay","Animals,CHO Cells,Calcium,Cell Movement,Cricetinae,Fingolimod Hydrochloride,Guanosine 5'-O-(3-Thiotriphosphate),Heart Rate,Immunosuppressive Agents,Lymphatic System,Lymphocytes,Lymphopenia,Mice,Mice, Inbred C57BL,Mice, Mutant Strains,Phosphorylation,Propylene Glycols,Protein Kinases,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,chemically induced,cytology,drug effects,immunology,metabolism,pharmacology,physiology","D011494 Q000378 NN,D002465 Q000187 NN,D008208 Q000166 NN,D043562 Q000502 NY,D002465 Q000276 NY,D008214 Q000166 NY,D008231 Q000139 NN,D043562 Q000819 NN,D013110 Q000031 NN,D016244 Q000494 NN,D002118 Q000378 NN,D011409 Q000494 NN,D010766 Q000187 NN,D015398 Q000187 NN,D007166 Q000494 NN,D015398 Q000502 NN,D006339 Q000502 NY","1764,6802,8252,31270,37792,107969,107970,4077460,5280335,5283560,5460341,6337033,9908268,10904818,135398635","128394615,128771931,129060975,129645792,135649899,135650261,135650290,135651038,135651563","Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.","Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors. Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clinical immunosuppression preventing transplant rejection but is associated with transient bradycardia. Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P(1) knock-out and",The Journal of biological chemistry,"M Germana Sanna, Jiayu Liao, Euijung Jo, Christopher Alfonso, Min-Young Ahn, Melissa S Peterson, Bill Webb, Sophie Lefebvre, Jerold Chun, Nathanael Gray, Hugh Rosen"," Department of Immunology, The Center for Mass Spectrometry, The Scripps Research Institute, La Jolla, California 92037, USA.",2004 Apr;279(14):13839-48,10.1074/jbc.m311743200
14766378,20040101,review,"xref,mesh","Adrenal Cortex Hormones,Animals,Antimetabolites,Calcineurin Inhibitors,Cyclosporine,Fingolimod Hydrochloride,Humans,Immunosuppression,Immunosuppressive Agents,Immunotherapy,Muromonab-CD3,Propylene Glycols,Sphingosine","analogs &amp; derivatives,pharmacology","D007166 Q000494 NY,D000305 Q000494 NY,D016853 Q000494 NN,D000963 Q000494 NY,D013110 Q000031 NN,D016572 Q000494 NN,D011409 Q000494 NN","1044,2909,4271,5793,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,91454826,122172945,123134263,123134270,132274082","128365023,128394615,129060975,129178479,129621433,129645792,248184126",Pharmacologic immunosuppression.,"Clinical organ transplantation only became a viable treatment option after the advent of effective pharmacologic immunosuppression. Azathioprine and steroids were among the first drugs available for pharmacologic immunosuppression allowed for the first long-term successes in kidney and liver transplantation, though survivors experienced significant adverse effects of the immunosuppression. Azathioprine is an antimetabolite which inhibits the de novo and salvage pathways of purine synthesis. This results in ",Frontiers in bioscience : a journal and virtual library,"Neal R Barshes, Sarah E Goodpastor, John A Goss"," Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 6550 Fannin. Suite 1628, Houston, TX 77030, USA.",2004 Jan;9(?):411-20,10.2741/1249
14767029,20040301,article,"xref,mesh","Cell Culture Techniques,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Propylene Glycols,Receptors, Chemokine,Receptors, Leukocyte-Adhesion,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D013601 Q000378 NY,D007166 Q000494 NY,D016030 Q000276 NN,D011409 Q000494 NY,D016028 Q000378 NY,D013110 Q000031 NN,D019707 Q000378 NY,D013601 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.,"BACKGROUND: FTY720 (FTY), a novel immunomodulator with the potential to improve immunosuppressive therapy after organ transplantation, is currently under clinical investigation. Previous experimental animal studies have shown that FTY has a unique mechanism of action associated with altered lymphocyte recirculation. METHODS: Participating in a phase I clinical trial, we studied the pharmacodynamic effects of FTY in stable renal allograft recipients. We analysed the effect of FTY on surface marker expression","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Torsten Böhler, Johannes Waiser, Manuela Schuetz, Hans H Neumayer, Klemens Budde"," Department of Nephrology, Charité, Campus Mitte, Humboldt-University, Berlin, Germany. boehler@charite.de",2004 Mar;19(3):702-13,10.1093/ndt/gfg599
14871428,20040301,article,"xref,mesh","Animals,Cell Movement,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Kidney Tubular Necrosis, Acute,Lymphocyte Subsets,Male,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,cytology,drug effects,drug therapy,immunology,pharmacology","D006085 Q000187 NN,D007166 Q000494 NY,D002465 Q000187 NN,D002465 Q000276 NY,D007683 Q000188 NN,D016131 Q000166 NY,D015427 Q000276 NN,D011409 Q000494 NY,D013110 Q000031 NN,D006085 Q000276 NN,D016030 Q000276 NY,D007683 Q000276 NN,D015427 Q000188 NY,D016131 Q000276 NN","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792",FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury.,"BACKGROUND: A novel immunomodulator, FTY720, modulates lymphocyte migration to injured tissues via enhanced lymphocyte sequestration to secondary lymphoid organs. We tested whether or not single-dose FTY720 (0.5 mg/kg) pretreatment rescues renal grafts from post-transplant preservation/reperfusion injury. METHODS: Rat renal grafts were cold-preserved in University of Wisconsin (UW) solution for 4 hours and then transplanted into syngeneic or allogeneic recipients that received a single dose of FTY720 24 hou",Kidney international,"Duska Dragun, Torsten Böhler, Melina Nieminen-Kelhä, Johannes Waiser, Wolfgang Schneider, Hermann Haller, Friedrich C Luft, Klemens Budde, Hans-Hellmut Neumayer"," Department of Nephrology, Medical Faculty of the Charité Campus Mitte, Berlin, Germany. duska.dragun@charite.de",2004 Mar;65(3):1076-83,10.1111/j.1523-1755.2004.00478.x
14979997,20040101,article,"xref,mesh","Administration, Topical,Anti-Inflammatory Agents,Chromatography, High Pressure Liquid,Circular Dichroism,Dermatitis, Contact,Drug Stability,Drug Storage,Hydrogen-Ion Concentration,Pharmaceutical Vehicles,Psoriasis,Sodium Chloride,Spectrometry, Mass, Electrospray Ionization,Substance P,Temperature","analogs &amp; derivatives,chemistry,drug therapy,therapeutic use","D012965 Q000737 NN,D013373 Q000627 NN,D011565 Q000188 NN,D013373 Q000737 NY,D000893 Q000627 NN,D000893 Q000737 NY,D013373 Q000031 NY,D003877 Q000188 NN","702,5234,8042,8123,8252,13387,36511,151211,16131028,90790712","127472665,127480562,128482492,128546424,129060975,129223097,243410798","Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis.","Substance P is readily expressed in skin inflammatory disorders such as psoriasis and contact dermatitis. Spantide II is a peptide (MW 1668.76) that specifically binds to neurokinin-1 receptor (NKR-1) and blocks inflammation associated with substance P. The anti-inflammatory property of Spantide II makes it a suitable candidate to be studied as a topical formulation for the treatment of dermal inflammatory disorders. The objective of this study was to investigate the influence of pH, temperature, salt conce",The Journal of pharmacy and pharmacology,"Loice Kikwai, R J Babu, Narayanasamy Kanikkannan, Mandip Singh"," Division of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A and M University, Tallahassee, Florida, USA.",2004 Jan;56(1):19-25,10.1111/j.2042-7158.2004.tb02573.x|10.1211/0022357022539
14988150,20040615,article,"xref,mesh","Antigens, CD,Antigens, CD34,Bone Marrow Cells,Cell Separation,Cells, Cultured,Chemokines,Endothelial Cells,Fingolimod Hydrochloride,Hematopoietic Stem Cell Mobilization,Hematopoietic Stem Cells,Humans,Immunosuppressive Agents,Integrin alpha4beta1,Integrin alpha5beta1,Propylene Glycols,Receptors, CXCR4,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine","analogs &amp; derivatives,analysis,antagonists &amp; inhibitors,cytology,drug effects,pharmacology,physiology","D042783 Q000166 NN,D019718 Q000187 NN,D001854 Q000502 NY,D018952 Q000032 NN,D018925 Q000502 NN,D019718 Q000502 NY,D011409 Q000494 NY,D013110 Q000031 NN,D006412 Q000502 NY,D039041 Q000502 NN,D042783 Q000502 NN,D039081 Q000502 NN,D015703 Q000032 NN,D006412 Q000187 NN,D007166 Q000494 NN,D001854 Q000166 NN,D043562 Q000037 NY,D006412 Q000166 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells.,"The novel immunosuppressant FTY720 activates sphingosine 1-phosphate receptors (S1PRs) that affect responsiveness of lymphocytes to chemokines such as stromal cell-derived factor 1 (SDF-1), resulting in increased lymphocyte homing to secondary lymphoid organs. Since SDF-1 and its receptor CXCR4 are also involved in bone marrow (BM) homing of hematopoietic stem and progenitor cells (HPCs), we analyzed expression of S1PRs and the influence of FTY720 on SDF-1/CXCR4-mediated effects in human HPCs. By reverse tr",Blood,"Takafumi Kimura, Andreas M Boehmler, Gabriele Seitz, Selim Kuçi, Tina Wiesner, Volker Brinkmann, Lothar Kanz, Robert Möhle"," Department of Medicine II, University of Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.",2004 Jun;103(12):4478-86,10.1182/blood-2003-03-0875
14999299,20031001,article,"xref,mesh","Aldehydes,Alkadienes,Animals,Body Weight,Carcinogens,DNA Adducts,Estrous Cycle,Intubation, Gastrointestinal,Mice,Mice, Inbred Strains,Mutagens,Organ Size,Oxidative Stress,Rats,Rats, Inbred F344,Reproduction","administration &amp; dosage,drug effects,physiology,toxicity","D001835 Q000187 NN,D012098 Q000187 NN,D009929 Q000187 NN,D000466 Q000008 NN,D002273 Q000633 NY,D030762 Q000187 NN,D018384 Q000502 NN,D000447 Q000008 NN,D002273 Q000008 NN,D000447 Q000633 NY,D000466 Q000633 NY,D009153 Q000633 NN","7847,8901,10964,124886,637564","53790456,127488395,128056944,129192846,129627858","NTP toxicology and carcinogensis Studies of 2,4-hexadienal (89% trans,trans isomer, CAS No. 142-83-6; 11% cis,trans isomer) (Gavage Studies).","2,4-Hexadienal, a colorless to yellow liquid with a pungent ""green"" or citrus odor, is used as a food additive for flavor enhancement, as a fragrance agent, as a starting material or intermediate in synthetic reactions in the chemical and pharmaceutical industries, as a fumigant, and as a corrosion inhibitor for steel. 2,4-Hexadienal was nominated for study by the National Cancer Institute because of the potential for carcinogenicity based on its alpha,beta-unsaturated aldehyde structure and the potential l",National Toxicology Program technical report series,National Toxicology Program,NULL,2003 Oct;?(509):1-290,NULL
15020292,20040601,article,"xref,mesh","Animals,Bronchoalveolar Lavage Fluid,Capillary Permeability,Disease Models, Animal,Endothelial Cells,Endotoxins,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Kidney Diseases,Lipopolysaccharides,Lung,Lysophospholipids,Male,Mice,Mice, Inbred C57BL,Neutrophils,Organ Size,Perfusion,Peroxidase,Pneumonia,Propylene Glycols,Respiratory Distress Syndrome, Adult,Sphingosine,Time Factors","adverse effects,analogs &amp; derivatives,blood supply,chemically induced,cytology,drug effects,drug therapy,etiology,injuries,metabolism,microbiology,pharmacokinetics,pharmacology,prevention &amp; control","D009195 Q000378 NN,D012128 Q000517 NY,D011014 Q000517 NY,D007668 Q000187 NN,D001992 Q000166 NN,D007668 Q000293 NN,D002199 Q000187 NN,D009929 Q000187 NN,D008246 Q000493 NN,D012128 Q000139 NY,D013110 Q000494 NY,D007674 Q000382 NN,D008168 Q000382 NN,D008246 Q000494 NY,D042783 Q000187 NN,D013110 Q000031 NN,D008168 Q000098 NY,D013110 Q000493 NN,D004731 Q000009 NY,D008168 Q000166 NN,D007674 Q000188 NN,D007674 Q000209 NN,D009504 Q000378 NN,D011409 Q000494 NN,D007166 Q000494 NN,D011014 Q000139 NY,D007668 Q000382 NN","8252,31270,107969,107970,5280335,5283560,11973707","128394615,129060975,129645792",Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury.,"Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of",American journal of respiratory and critical care medicine,"Xinqi Peng, Paul M Hassoun, Saad Sammani, Bryan J McVerry, Melissa J Burne, Hamid Rabb, David Pearse, Rubin M Tuder, Joe G N Garcia"," Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",2004 Jun;169(11):1245-51,10.1164/rccm.200309-1258oc
15041402,20040301,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Models, Molecular,Molecular Conformation,Propylene Glycols,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,chemistry,drug effects,immunology,pharmacology,therapeutic use","D007166 Q000494 NY,D011409 Q000737 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000627 NY,D008214 Q000276 NN,D007166 Q000737 NN,D008214 Q000187 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335,57024517","128394615,129060975,129645792,135812730",FTY720: from bench to bedside.,"FTY720, a synthetic myriocin analogue derived from culture filtrates of Isaria sinclairii, is a novel immunosuppressant that in experimental animals and nonhuman primates produces lymphocytopenia and prolongs allograft survival in dose-dependent fashion. FTY720 exerts synergistic interactions not only with calcineurin antagonists, but also with proliferation signal inhibitors. These interactions offer the possibility of reducing exposure to and mitigating toxicity of existing drugs. The mechanism of drug ac",Transplantation proceedings,B D Kahan," University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA. barry.d.kahan@uth.tmc.edu",2004 Mar;36(?):531S-543S,10.1016/j.transproceed.2004.01.092
15041403,20040301,review,"xref,mesh","Animals,Drug Therapy, Combination,Fingolimod Hydrochloride,Half-Life,Heart Rate,Humans,Immunosuppressive Agents,Models, Animal,Propylene Glycols,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,drug effects,pharmacokinetics,therapeutic use","D007166 Q000493 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000493 NN,D006339 Q000187 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: early clinical experience.,"FTY720 is the first in a new class of immunomodulators--sphingosine 1-phosphate receptor (S1P-R) agonists. It is highly effective in prolonging allograft survival in preclinical models of transplantation. Furthermore, FTY720 acts synergistically with calcineurin inhibitors and proliferation inhibitors in these models, suggesting that use of FTY720 in combination with classical immunosuppressants may be a promising new option for transplant patients. Phase I studies conducted in stable renal transplant patie",Transplantation proceedings,"D Dragun, L Fritsche, T Boehler, H Peters, K Budde, H H Neumayer"," University Hospital Charité, Department of Nephrology, Campus Mitte, Berlin, Germany.",2004 Mar;36(?):544S-548S,10.1016/j.transproceed.2003.12.048
15041404,20040301,review,"xref,mesh","Clinical Trials as Topic,Female,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Propylene Glycols,Sphingosine,Transplantation Immunology","analogs &amp; derivatives,drug effects,immunology,prevention &amp; control,therapeutic use","D016030 Q000276 NN,D014181 Q000187 NY,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY,D006084 Q000517 NY","4271,8252,31270,107969,107970,5280335,90696889","128394615,129060975,129178479,129645792,242749350",FTY720 immunomodulation: optimism for improved transplant regimens.,"FTY720, a sphingosine 1-phosphate receptor (S1P-R) agonist, is the first in a new class of immunomodulators. FTY720 has been shown to be highly effective for preventing graft rejection in preclinical models of cardiac, renal, and hepatic transplantation. To date, phase I single and multiple dosing studies conducted in stable renal transplant patients have revealed a favorable efficacy and tolerability profile. Following these preliminary clinical evaluations, phase II studies have determined optimal dosing ",Transplantation proceedings,R Ferguson," Division of Transplantation, Ohio State University, Columbus 43210, USA. ferguson.7@osu.edu",2004 Mar;36(?):549S-553S,10.1016/j.transproceed.2004.01.061
15043683,20040301,article,"xref,mesh","Adjuvants, Immunologic,Animals,Blood Glucose,Diabetes Mellitus, Type 1,Fingolimod Hydrochloride,Immunity, Innate,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Inbred BB,Sphingosine,Survival Analysis","analogs &amp; derivatives,drug effects,metabolism,prevention &amp; control,therapeutic use","D000276 Q000627 NY,D001786 Q000187 NN,D013110 Q000031 NN,D003922 Q000517 NY,D007166 Q000627 NY,D001786 Q000378 NN,D011409 Q000627 NY","5793,8252,31270,107969,107970,5280335","128394615,129060975,129621433,129645792",The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat.,BACKGROUND: Autoimmune diabetes of the diabetes-resistant biobreeding (DRBB) rat shares similarities with diabetes in humans and has stages of diabetes that can be controlled and compared. FTY720 is an immunomodulator that has been efficacious in transplant and autoimmune models without inducing an immunosuppressed state. We determined the stages of diabetes that are affected by FTY720 in the DRBB rat. METHODS: Autoimmune diabetes was induced with RT6.1 T-cell-depleting antibody and polyIC starting at 4 wee,Pediatric diabetes,"Jadranka Popovic, Karen L Kover, Wayne V Moore"," Children's Mercy Hospital, University of Missouri Kansas City School of Medicine, Kansas City, MO 64108, USA. jpopovic@cmh.edu",2004 Mar;5(1):3-9,10.1111/j.1399-543x.2004.00036.x
15056396,20040501,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Mast Cells,Mice,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophosphatidic Acid,Receptors, Lysophospholipid,Sphingosine,T-Lymphocytes","immunology,pharmacology,physiology","D013601 Q000276 NN,D011409 Q000494 NN,D008246 Q000276 NY,D007166 Q000494 NN,D043562 Q000502 NN,D008407 Q000276 NY,D013110 Q000502 NN","3988,8252,31270,107969,107970,5280335","128394615,129060975,129622673,129645792",Immunoregulatory lysophospholipids: new stars in the mast cell constellation.,NULL,Current allergy and asthma reports,Edward J Goetzl," Department of Medicine, University of California Medical Center, San Francisco, 94143-0711, USA. egoetzl@itsa.ucsf.edu",2004 May;4(3):175-7,10.1007/s11882-004-0019-z
15077021,20040327,article,"xref,mesh","Animals,Antibodies, Monoclonal,Diabetes Mellitus, Experimental,Everolimus,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Islets of Langerhans,Islets of Langerhans Transplantation,Macaca fascicularis,Propylene Glycols,Recombinant Fusion Proteins,Sirolimus,Sphingosine","analogs &amp; derivatives,cytology,drug effects,immunology,pathology,prevention &amp; control,surgery,therapeutic use","D007515 Q000166 NN,D003921 Q000473 NN,D016381 Q000473 NN,D007515 Q000187 NN,D013110 Q000031 NN,D016381 Q000276 NY,D007166 Q000627 NY,D003921 Q000601 NY,D000911 Q000627 NY,D006085 Q000187 NY,D020123 Q000627 NY,D011409 Q000627 NY,D006084 Q000517 NY,D020123 Q000031 NN","5793,6322,8252,31270,107969,107970,5280335,5284616,6442177,90696889,91534498","128394615,128793026,129060975,129621433,129645792,242749350,248766214","Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720.","OBJECTIVE: In a preclinical, nonhuman primate islet allotransplant model, the authors evaluated a novel immunosuppressive combination of basiliximab for induction and of RAD and FTY720 for maintenance. METHODS: Five ABO-compatible and mixed lymphocyte reactivity-mismatched streptozotocin-induced diabetic juvenile cynomolgus monkeys underwent transplantation intraportally with 48-hr cultured 10,000 islet equivalents per kilogram. Induction immunosuppression was with intravenous basiliximab (10 mg on postoper",Transplantation,"Martin Wijkstrom, Norma S Kenyon, Nicole Kirchhof, Norman M Kenyon, Claudy Mullon, Philip Lake, Sylvain Cottens, Camillo Ricordi, Bernhard J Hering"," Diabetes Institute for Immunology and Transplantation, Department of Surgery, University of Minnesota, Minneapolis, 55455, USA.",2004 Mar;77(6):827-35,10.1097/01.tp.0000116390.76425.20
15089811,20040501,article,"xref,mesh","Administration, Oral,Adult,Area Under Curve,Circadian Rhythm,Cross-Over Studies,Dietary Fats,Fasting,Fingolimod Hydrochloride,Food,Heart Rate,Humans,Immunosuppressive Agents,Intestinal Absorption,Lymphocyte Count,Male,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,pharmacokinetics,pharmacology","D011409 Q000493 NY,D007166 Q000008 NN,D007166 Q000493 NY,D011409 Q000008 NN,D005215 Q000097 NN,D013110 Q000031 NN,D006339 Q000187 NN,D004041 Q000494 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.","AIMS: FTY720 is a sphingosine-1-phosphate receptor agonist that redirects lymphocytes from the circulation to lymph nodes without impairing lymphocyte function. It is being developed as an immunomodulator for the prevention of acute rejection after organ transplantation. This study was performed to provide guidance on administration with respect to meals and to measure pharmacologic responses in healthy subjects. METHODS: In this randomized, two-period, crossover study, 14 healthy subjects received placebo ",British journal of clinical pharmacology,"John M Kovarik, Robert Schmouder, Denise Barilla, Yibin Wang, Gerolf Kraus"," Novartis Pharmaceuticals, Basel, Switzerland. john.kovarik@pharma.novartis.com",2004 May;57(5):586-91,10.1111/j.1365-2125.2003.02065.x
15102874,20040501,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Area Under Curve,Capsules,Dose-Response Relationship, Drug,Double-Blind Method,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Half-Life,Humans,Immunosuppressive Agents,Lymphocyte Count,Lymphocytes,Male,Propylene Glycols,Sphingosine,Time Factors","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,methods,pharmacokinetics,physiology","D011409 Q000493 NY,D007166 Q000008 NN,D007166 Q000097 NN,D008214 Q000187 NY,D008214 Q000502 NN,D007166 Q000493 NN,D013110 Q000031 NN,D018655 Q000379 NN,D008214 Q000097 NN,D011409 Q000008 NY,D011409 Q000097 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.","FTY720 is a sphingosine-1-phosphate receptor agonist being developed as an immunomodulator for acute rejection prophylaxis after organ transplantation. This study was performed to characterize the pharmacokinetics of and lymphocyte response to multiple-dose FTY720. In this randomized, double-blind study, three groups of 20 healthy subjects each received either placebo, 1.25 mg/day FTY720, or 5 mg/day FTY720 for 7 consecutive days. FTY720 blood concentrations and lymphocyte counts were assessed over the week",Journal of clinical pharmacology,"John M Kovarik, Robert Schmouder, Denise Barilla, Gilles-Jacques Riviere, Yibin Wang, Thomas Hunt"," Novartis Pharma AG, Building WSJ 27.4093, 4002 Basel, Switzerland.",2004 May;44(5):532-7,10.1177/0091270004264165
15138297,20040101,article,"xref,mesh","Adult,Area Under Curve,Cross-Over Studies,Cyclosporine,Drug Interactions,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Lymphocyte Count,Male,Middle Aged,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine","adverse effects,agonists,analogs &amp; derivatives,drug effects,pharmacokinetics,pharmacology","D011409 Q000009 NN,D011409 Q000493 NY,D007166 Q000493 NY,D043562 Q000819 NN,D016572 Q000009 NN,D013110 Q000031 NN,D016572 Q000493 NY,D016572 Q000494 NN,D006339 Q000187 NN,D011409 Q000494 NN,D007166 Q000009 NN,D007166 Q000494 NN","2909,8252,31270,62280,105065,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792,136111139",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.,"BACKGROUND: FTY720 is a sphingosine-1-phosphate receptor agonist intended for use in immunoprophylaxis regimens to prevent acute rejection after organ transplantation. OBJECTIVE: To evaluate the potential for a pharmacokinetic drug interaction between the immunomodulator FTY720 and cyclosporine to support the use of this drug combination in organ transplantation. METHODS: In this open-label, randomized crossover study, 12 subjects with psoriasis received a single dose of FTY720 1 mg alone and on day 5 of an",The Annals of pharmacotherapy,"John M Kovarik, Robert L Schmouder, Denise Barilla, Monika Büche, Marisel Rouilly, Stephane Berthier, Yibin Wang, Claudia Van Saders, Thomas Mayer, Alice B Gottlieb"," Novartis Pharma, Basel, Switzerland. John.Kovarik@pharma.novartis.com",2004 Jan;38(?):1153-8,10.1345/aph.1e035
15147419,20040601,article,"xref,mesh","Animals,Antibodies, Monoclonal,Biopsy,CD4 Antigens,Creatinine,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Male,Models, Animal,Polymerase Chain Reaction,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,T-Lymphocytes,Transplantation Tolerance,Uremia","analogs &amp; derivatives,drug effects,etiology,immunology,metabolism,pathology,therapeutic use","D013601 Q000378 NN,D003404 Q000378 NN,D015704 Q000276 NY,D013601 Q000276 NN,D023001 Q000187 NN,D013110 Q000031 NN,D007166 Q000627 NY,D014511 Q000209 NN,D000911 Q000627 NY,D016030 Q000276 NY,D013601 Q000473 NN,D011409 Q000627 NY","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792",FTY720 prevents anti-CD4 mAb-induced tolerance but cannot reverse established tolerance in a rat kidney transplantation model.,"FTY720 is highly effective in various models of transplantation and autoimmunity. In order to find drugs that act synergistically with a tolerance-inducing nondepleting anti-CD4 mAb we studied this combination in a strong DA to LEW kidney transplantation model. Rats were treated with 0.3 mg/kg of FTY720 for 14 days and anti-CD4 mAb RIB5/2, alone or in combination. After kidney transplantation serum creatinine and blood lymphocyte counts were monitored. Immunohistology, ELISPOT and TaqMan trade mark -PCR ana",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Grit Schroeder, Kirsten Risch, Katja Kotsch, Anja Siepert, Josef Brock, Peter Nickel, Petra Reinke, Thomas Ritter, Hans-Dieter Volk, Manfred Lehmann"," Institute of Medical Biochemistry and Molecular Biology, University of Rostock, Germany. grit.schroeder@med.uni-rostock.de",2004 Jun;4(6):863-71,10.1111/j.1600-6143.2004.00442.x
15149705,20040621,article,"xref,mesh,assay","Animals,CHO Cells,Cricetinae,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Injections, Intravenous,Male,Mice,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,agonists,analogs &amp; derivatives,chemistry,metabolism","D011409 Q000737 NY,D007166 Q000008 NN,D049349 Q000819 NY,D007166 Q000378 NN,D007155 Q000737 NY,D013110 Q000031 NN,D007155 Q000008 NY,D007166 Q000737 NN,D007155 Q000378 NN,D011409 Q000378 NN,D011409 Q000008 NY,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560,9885762,9908268,10125714,10149595,10150171,10172338,10172545,10271422,10309022,10384596,44341276,44341291,44341399,44341457,44341466","128394615,129060975,129645792,136111139",Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.,Alteration in lymphocyte trafficking and prevention of graft rejection in rodents observed on exposure to FTY720 (1) or its corresponding phosphate ester 2 can be induced by the systemic administration of potent sphingosine-1-phosphate receptor agonists exemplified by 19. The similar S1P receptor profiles of 2 and 19 coupled with their comparable potency in vivo supports a connection between S1P receptor agonism and immunosuppressive efficacy. ,Bioorganic & medicinal chemistry letters,"Jeffrey J Hale, William Neway, Sander G Mills, Richard Hajdu, Carol Ann Keohane, Mark Rosenbach, James Milligan, Gan-Ju Shei, Gary Chrebet, James Bergstrom, Deborah Card, Gloria C Koo, Sam L Koprak, Jesse J Jackson, Hugh Rosen, Suzanne Mandala"," Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. jeffrey_hale@merck.com",2004 Jun;14(12):3351-5,10.1016/j.bmcl.2004.02.106
15153030,20040528,article,"xref,mesh","Catalysis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Iron,Molecular Structure,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemical synthesis,chemistry","D011409 Q000138 NY,D013110 Q000031 NN,D007166 Q000138 NY,D007501 Q000737 NY","8252,16607,31270,62406,68294,107969,107970,5280335,10313045","127608890,128218145,128390838,128394615,129060975,129645792",Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720.,"A chemo- and regioselective cross-coupling reaction of the functionalized aryl triflate 5 with octylmagnesium bromide catalyzed by cheap, nontoxic, and environmentally benign Fe(acac)(3) sets the basis for a practical and scaleable synthesis of the octylbenzene derivative 6, which serves as a key building block for the preparation of FTY720 (1). This 2-amino-1,3-propanediol derivative shows highly promising immunosuppressive properties and is currently in human clinical phase III trials. ",The Journal of organic chemistry,"Günter Seidel, Daniel Laurich, Alois Fürstner"," Max-Planck-Institut für Kohlenforschung, D-45470 Mülheim/Ruhr, Germany fuerstner@mpi-muelheim.mpg.de",2004 May;69(11):3950-2,10.1021/jo049885d
15158755,20040601,review,"xref,mesh","Animals,Cell Movement,Fingolimod Hydrochloride,GTP-Binding Proteins,Immunosuppressive Agents,Lysophospholipids,Mice,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacology,physiology","D002465 Q000187 NN,D013110 Q000378 NY,D043562 Q000187 NN,D013110 Q000031 NN,D008246 Q000378 NY,D019204 Q000378 NN,D011409 Q000494 NN,D007166 Q000494 NN,D043562 Q000378 NY,D002465 Q000502 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy.,"Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that has recently been shown to bind cell surface S1P receptors (previously called endothelial differentiation gene (Edg) receptors), which are members of the G-protein-coupled family of receptors. Signaling via S1P is a complex process, as cells usually express a number of these receptors on their surfaces. Many of the S1P receptors share common G-proteins, invoking the question of how these receptors are specific in their actions. This review descr",Biochimica et biophysica acta,"Tarek A Taha, Kelly M Argraves, Lina M Obeid"," Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.",2004 Jun;1682(?):48-55,10.1016/j.bbalip.2004.01.006
15165029,20040101,article,"xref,mesh","Calcium Signaling,Cells, Cultured,Endothelium, Vascular,Fingolimod Hydrochloride,GTP-Binding Protein alpha Subunits, Gi-Go,Humans,Immunosuppressive Agents,Isomerism,Lysophospholipids,Mitogen-Activated Protein Kinases,Molecular Structure,Organogenesis,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Structure-Activity Relationship,Umbilical Veins","agonists,analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology","D017853 Q000378 NN,D049349 Q000378 NY,D049349 Q000819 NY,D013110 Q000378 NY,D020928 Q000378 NN,D011409 Q000378 NY,D013110 Q000031 NY,D014471 Q000166 NN,D008246 Q000378 NY,D007166 Q000378 NY,D038081 Q000187 NN,D011409 Q000494 NN,D020013 Q000187 NN,D014471 Q000378 NN,D007166 Q000494 NN,D004730 Q000378 NY","4285,8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792,129839329",Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.,"Sphingosine 1-phosphate (S1P) is a pleiotropic lysophospholipid mediator involved in many cellular responses, including transient calcium mobilization, activation of MAP kinase signaling, inhibition of adenylyl cyclase and increased cell migration. S1P has been shown to be an effective activator of vascular endothelial cells via the interaction with cell surface G protein-coupled receptors (GPCRs), namely S1P-R (formerly EDG-R). The potent immunomodulator, FTY720, is phosphorylated by sphingosine kinase (SK",Prostaglandins & other lipid mediators,"Jeannene Butler, Diana Lana, Oliver Round, Kenneth LaMontagne"," Novartis Institute for Biomedical Research, Inc., One Health Plaza, Room 2223, Bldg 436, East Hanover, NJ 07936, USA.",2004 Jan;73(?):29-45,10.1016/j.prostaglandins.2003.11.003
15165113,20040101,article,"xref,mesh","Apoptosis,Cell Division,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,HL-60 Cells,Humans,Immunosuppressive Agents,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Phosphorylation,Propylene Glycols,Signal Transduction,Sphingosine,U937 Cells","analogs &amp; derivatives,drug effects,metabolism,pharmacology","D002455 Q000187 NN,D017209 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D048052 Q000378 NY,D048049 Q000378 NN,D019950 Q000378 NY,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937.,"The effects of a novel immunosuppressive agent FTY720 on proliferation inhibition and apoptosis of acute leukemia cell lines HL-60 and U937, and the role of extracelluar regulated protein kinase (ERK) in the course of proliferation inhibition and apoptosis induced by FTY720 were studied. The proliferation inhibition rate of HL-60 and U937 cells by various concentrations of FTY720 was detected by MTT assay. Cell apoptosis was detected by DNA fragment analysis and flow cytometry. The phosphorylated ERK1/2 pro",Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,"Dengju Li, Yaozhen Zhang, Xiangrong Hu, Wenjing Cao, Wei Huang"," Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030.",2004 Jan;24(1):45-7,10.1007/bf02830703
15167585,20040515,review,"xref,mesh","Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine,Transplants","analogs &amp; derivatives,drug therapy,therapeutic use","D006084 Q000188 NY,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY: not just a homely drug.,NULL,Transplantation,Sir Roy Calne," Addenbrooke's Hospital, Douglas House Annex, Cambridge, England.",2004 May;77(9):1327,10.1097/00007890-200405150-00003
15167602,20040515,article,"xref,mesh","Apoptosis,Biomarkers,CD11a Antigen,CD3 Complex,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppression,Immunosuppressive Agents,Integrin alpha4,Kidney Transplantation,L-Selectin,Lymphopenia,Propylene Glycols,Receptors, CCR5,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,metabolism,methods","D013601 Q000378 NN,D006084 Q000188 NY,D013601 Q000276 NN,D017252 Q000378 NN,D039441 Q000378 NN,D008231 Q000139 NY,D019713 Q000378 NN,D040881 Q000378 NN,D013110 Q000031 NN,D007165 Q000379 NN,D017209 Q000276 NN,D019041 Q000378 NN,D016030 Q000276 NY,D006084 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.,"BACKGROUND: The sphingolipid FTY720 (FTY), a novel immune modulator, induces lymphopenia and prevents allograft rejection. This study was designed to study the effect of FTY on lymphocyte subpopulations and apoptosis in stable renal allograft recipients. METHODS: Stable renal allograft recipients received a single oral dose of 0.25 to 3.5 mg of FTY (n= 13) or placebo (n= 3). Whole blood was drawn immediately before and at 4, 8, 12, 24, 72, and 96 hr after administration. The number of lymphocyte subpopulati",Transplantation,"Torsten Böhler, Johannes Waiser, Manuela Schütz, Duska Dragun, Hans-H Neumayer, Klemens Budde"," Department of Nephrology, Charité, Campus Charité-Mitte, Humboldt-University, Berlin, Germany. torsten.boehler@charite.de",2004 May;77(9):1424-32,10.1097/01.tp.0000120539.94629.6a
15190065,20040827,article,"xref,mesh","Amino Acids,Biological Transport,Cell Division,Cell Membrane,Cytoskeleton,DNA, Complementary,Down-Regulation,Escherichia coli,Fingolimod Hydrochloride,Genotype,Immunoblotting,Immunosuppressive Agents,Mutation,Oligonucleotide Array Sequence Analysis,Phosphotransferases (Alcohol Group Acceptor),Plasmids,Polymerase Chain Reaction,Propylene Glycols,RNA,Reverse Transcriptase Polymerase Chain Reaction,Saccharomyces cerevisiae,Saccharomyces cerevisiae Proteins,Sphingolipids,Sphingosine,Transcription, Genetic,Up-Re","analogs &amp; derivatives,chemistry,genetics,metabolism,pharmacology","D011409 Q000737 NY,D013107 Q000737 NY,D012313 Q000378 NN,D012441 Q000235 NN,D013110 Q000737 NY,D004926 Q000378 NN,D010957 Q000378 NN,D012441 Q000378 NY,D013110 Q000031 NY,D003599 Q000378 NN,D000596 Q000737 NN,D029701 Q000737 NN,D018076 Q000378 NN,D017853 Q000737 NN,D013110 Q000494 NN,D007166 Q000494 NN,D002462 Q000378 NN","4285,8252,31270,107969,107970,122121,5280335,5282309,6438166,11963529","128394615,129060975,129645792,129839329,136039819","Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine.","Sphingolipids are signaling molecules that influence diverse cellular functions from control of the cell cycle to degradation of plasma membrane proteins. The synthetic sphingolipid-like compound FTY720 is an immunomodulating agent in clinical trials for transplant graft maintenance. In this report, we compare the effects of the natural yeast sphingolipid phytosphingosine with FTY720 in Saccharomyces cerevisiae. We show that the multicopy suppressor genes that induce growth resistance to FTY720 also confer ",The Journal of biological chemistry,"Carole A Welsch, Lukas W A Roth, Jean François Goetschy, N Rao Movva"," Novartis Institute for Biomedical Research, Autoimmunity, and Transplantation, Novartis Pharma AG, CH-4002 Basel, Switzerland.",2004 Aug;279(35):36720-31,10.1074/jbc.m406179200
15194292,20040501,article,"xref,mesh","Analysis of Variance,Animals,Creatinine,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver,Mice,Necrosis,Propylene Glycols,Reperfusion Injury,Sphingosine,Urea","analogs &amp; derivatives,blood,blood supply,drug effects,pathology,prevention &amp; control,therapeutic use,urine","D008099 Q000473 NN,D007166 Q000627 NN,D003404 Q000097 NN,D014508 Q000652 NN,D015427 Q000517 NY,D013110 Q000031 NN,D008099 Q000098 NY,D011409 Q000627 NY,D008099 Q000187 NN","588,1176,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792,129735276",FTY720 impairs necrosis development after ischemia-reperfusion injury.,"Ischemia-reperfusion (IR) injury is a common early feature that contributes to graft damage by impairing resident cell function. Our previous results showed that IR injury impaired renal function, by causing extensive tubular necrosis and increasing MHC class II and ICAM-1 molecule expression by mesangial cells (MC). MCs are likely candidates to come into close contact with immune cells such as monocytes or lymphocytes. It has been suggested that under inflammatory circumstances, there is increased MC expre",Transplantation proceedings,"C M S Oliveira, R C Borra, M Franco, N Schor, H T Silva, J O M Pestana, V Bueno"," Nephrology Division, Department of Medicine, Paulista Medical School, UNIFESP, Sao Paulo, Brazil.",2004 May;36(4):854-6,10.1016/j.transproceed.2004.03.045
15194353,20040501,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Survival,Histocompatibility Testing,Immunosuppression,Immunosuppressive Agents,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Skin Transplantation,Sphingosine,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,methods,therapeutic use","D016038 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D007165 Q000379 NN,D006085 Q000187 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.,"FTY720 has shown potent immunomodulatory activity in a variety of animal organ transplant models. However, the in vivo immunosuppressive mechanism of FTY720 is still not fully understood. It has been suggested that the marked decrease in the number of peripheral blood lymphocytes during FTY720 administration could be responsible for its immunosuppressive effects. Our aims were: (1) to study the effects of FTY720 treatment on skin graft survival using a fully mismatched strain combination and (2) to evaluate",Transplantation proceedings,"R S M Lima, M F Nogueira-Martins, H T Silva, J O M Pestana, V Bueno"," Nephrology Division, Department of Medicine, Paulista School of Medicine, UNIFESP, Sao Paulo, Brazil.",2004 May;36(4):1015-7,10.1016/j.transproceed.2004.03.052
15196057,20040701,review,"xref,mesh","Animals,Cell Proliferation,Clinical Trials as Topic,Endothelium, Vascular,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Inflammation,Lymphocytes,Lysophospholipids,Models, Biological,Models, Chemical,Phosphorylation,Propylene Glycols,Protein Binding,Rats,Receptors, G-Protein-Coupled,Receptors, Lysosphingolipid,Sphingosine,Thymus Gland","analogs &amp; derivatives,chemistry,cytology,metabolism,pharmacology","D007166 Q000494 NY,D049349 Q000378 NY,D013950 Q000166 NN,D008214 Q000378 NY,D011409 Q000737 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D043562 Q000378 NN,D008246 Q000378 NN,D004730 Q000378 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.,"The novel immunomodulator FTY720 is effective in experimental models of transplantation and autoimmunity, and is currently undergoing Phase III clinical trials for prevention of kidney graft rejection. In contrast to conventional immunosuppressants, FTY720 does not impair T- and B-cell activation, proliferation and effector function, but interferes with cell traffic between lymphoid organs and blood. The molecular basis for the mode of action of the drug has only recently been established. FTY720, after pho",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Volker Brinkmann, Jason G Cyster, Timothy Hla"," Transplantation and Immunology, Novartis Institutes for BioMedical Research, Basel, Switzerland. volker.brinkmann@pharma.novartis.com",2004 Jul;4(7):1019-25,10.1111/j.1600-6143.2004.00476.x
15199193,20040701,review,"xref,mesh","Animals,Clinical Trials as Topic,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Sphingosine,T-Lymphocytes","blood,drug effects,immunology,physiology,prevention &amp; control,therapeutic use","D007166 Q000627 NY,D006084 Q000097 NN,D016030 Q000276 NY,D011409 Q000627 NY,D006084 Q000517 NY,D013601 Q000187 NN,D013110 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720--the first compound of a new promising class of immunosuppressive drugs.,NULL,"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Ulrich Kunzendorf, Ekkehard Ziegler, Dieter Kabelitz"," Division of Nephrology and Hypertension, University Hospital of Schleswig-Holstein, Campus Kiel, Germany. kunzendorf@nephro.uni-kiel.de",2004 Jul;19(7):1677-81,10.1093/ndt/gfh295
15205237,20040701,article,"xref,mesh","Animals,Antigens, CD,Corneal Transplantation,Female,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Lymphocyte Count,Lymphocytes,Mycophenolic Acid,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Sphingosine,Weight Loss","analogs &amp; derivatives,drug effects,immunology,prevention &amp; control,therapeutic use","D011409 Q000276 NN,D009173 Q000276 NN,D009173 Q000031 NY,D008214 Q000187 NY,D013110 Q000031 NN,D007166 Q000627 NY,D015703 Q000276 NN,D008214 Q000276 NN,D007166 Q000276 NN,D009173 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY,D015431 Q000276 NN,D006084 Q000517 NY","4271,4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129178479,129645792",FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations.,"BACKGROUND: FTY720 is a potent immunomodulator with unique effects on lymphocyte homing and has recently proved to be safe and effective in renal transplantation in man. The authors investigated the potency of FTY720 in inhibiting allograft rejection in the rat model of orthotopic allogeneic penetrating keratoplasty. METHODS: Penetrating keratoplasties were performed using Fisher rats as donors and Lewis rats as recipients or donors: group 1 (n = 10), allogeneic control; group 2 (n = 10), Lewis/Lewis syngen",The British journal of ophthalmology,"K Mayer, F Birnbaum, T Reinhard, A Reis, S Braunstein, F Claas, R Sundmacher"," Eye Hospital, Heinrich-Heine University, Moorenstr 5, 40225 Dusseldorf, Germany. Klaus.mayer@uni-duesseldorf.de",2004 Jul;88(7):915-9,10.1136/bjo.2003.034017
15213767,20040601,article,xref,"Administration, Oral,Animals,Atrophy,Dose-Response Relationship, Drug,Female,Humans,Inflammation,Kidney Diseases,Liver,Male,Mice,Neoplasms,Nose,Propylene Glycols,Rats,Rats, Inbred F344,Risk Assessment,Salivary Glands,Sex Factors,Water Supply","chemically induced,pathology,toxicity,veterinary","D007674 Q000662 NN,D008099 Q000473 NN,D011409 Q000633 NY,D012469 Q000473 NN,D009369 Q000139 NN,D009369 Q000662 NN,D007674 Q000139 NY,D009666 Q000473 NN",8252,129060975,NTP toxicology and carcinogensis studies of dipropylene glycol (CAS No. 25265-71-8) in F344/N rats and B6C3F1 mice (drinking water studies).,"BACKGROUND: Dipropylene glycol is found in antifreeze, air fresheners, cosmetic products, solvents, and plastics. We studied the effects of dipropylene glycol on male and female rats and mice to identify potential or cancer-related hazards to humans. METHODS: We gave groups of 50 male and female mice drinking water containing dipropylene glycol at concentrations of 10,000, 20,000, or 40,000 parts per million (corresponding to 1%, 2%, or 4%) for two years. Male and female rats received concentrations of 2,50",National Toxicology Program technical report series,NULL,NULL,2004 Jun;?(511):6-260,NULL
15221804,20040701,article,"xref,mesh","Acute Disease,Animals,Blood-Brain Barrier,Brain,Contrast Media,Dextrans,Encephalomyelitis, Autoimmune, Experimental,Female,Ferrosoferric Oxide,Fingolimod Hydrochloride,Heterocyclic Compounds,Immunohistochemistry,Immunosuppressive Agents,Iron,Macrophages,Magnetic Resonance Imaging,Magnetite Nanoparticles,Organometallic Compounds,Oxides,Propylene Glycols,Rats,Rats, Inbred Lew,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Recurrence,Sphingosine","agonists,diagnosis,drug therapy,metabolism,pathology,therapeutic use","D004681 Q000378 NN,D004681 Q000175 NY,D001921 Q000473 NY,D043562 Q000819 NN,D001921 Q000378 NN,D007166 Q000627 NY,D008264 Q000473 NY,D011409 Q000627 NY,D004681 Q000473 NN,D004681 Q000188 NY","8252,14789,31270,107969,107970,122152,158536,4125253,5280335,5460037,10313045,49868115,71300392,71300410,71300448,71464587","128394615,129060975,129645792",Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.,"PURPOSE: To examine the efficacy of FTY720 as a new agent to reduce inflammatory activity in an animal model of multiple sclerosis (MS) by in vivo macrophage tracking. MATERIAL AND METHODS: FTY720 was used for treatment of rats in a model of chronic relapsing experimental autoimmune encephalomyelitis (EAE) at an oral dose of 0.3 mg/kg/day. Magnetic resonance imaging (MRI) based on in vivo tracking of macrophages labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, immunohistological s",Journal of magnetic resonance imaging : JMRI,"Martin Rausch, Peter Hiestand, Carolyn A Foster, Diana R Baumann, Catherine Cannet, Markus Rudin"," Novartis Institute for Biomedical Research, Basel, Switzerland. martin.rausch@pharma.novartis.com",2004 Jul;20(1):16-24,10.1002/jmri.20057
15223899,20040627,article,"xref,mesh","Adolescent,Adult,Aged,Cadaver,Cyclosporine,Dose-Response Relationship, Drug,Drug Therapy, Combination,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Middle Aged,Propylene Glycols,Safety,Sphingosine,Tissue Donors,Treatment Outcome","adverse effects,analogs &amp; derivatives,immunology,pharmacokinetics,therapeutic use","D016572 Q000627 NN,D011409 Q000009 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000493 NN,D016030 Q000276 NY,D007166 Q000009 NN,D011409 Q000627 NY","2909,4271,8252,31270,62280,105065,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129178479,129645792,136111139","FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.","BACKGROUND: FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation. METHODS: This phase 2a, multicenter, open-label, dose-finding study compared FTY720 (0.25, 0.5, 1.0, or 2.5 mg) with mycophenolate mofetil (MMF), in combination with cyclosporine and corticosteroids.",Transplantation,"Helio Tedesco-Silva, Georges Mourad, Barry D Kahan, Josep Grinyo Boira, Willem Weimar, Shamkant Mulgaonkar, Björn Nashan, Soren Madsen, Bernard Charpentier, Pascale Pellet, Yves Vanrenterghem"," Hospital do Rim e Hipertensao, Borges Lagoa 960, Sao Paulo, SP 04038-002, Brazil. heliotedesco@hrim.com.br",2004 Jun;77(12):1826-33,10.1097/01.tp.0000121761.02129.a6
15223918,20040627,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Intestine, Small,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Sphingosine,Survival Analysis,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,immunology,pharmacology,transplantation","D007166 Q000494 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007421 Q000637 NY,D014184 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 on rat small bowel transplantation.,NULL,Transplantation,"Jun Fujishiro, Seiichiro Inoue, Hisashi Shimizu, Hiroyuki Yoshino, Takashi Murakami, Eiji Kobayashi",NULL,2004 Jun;77(12):1910-1,10.1097/01.tp.0000129804.11210.c3
15240672,20040715,article,"xref,mesh","Animals,Arachidonate 5-Lipoxygenase,Cell Movement,Fingolimod Hydrochloride,Immunosuppressive Agents,Ligands,Mice,Propylene Glycols,Receptors, CCR2,Receptors, CCR5,Receptors, CCR7,Receptors, CXCR4,Receptors, Chemokine,Receptors, G-Protein-Coupled,Receptors, Leukotriene,Receptors, Lysophospholipid,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,pharmacology,physiology","D002465 Q000502 NY,D001094 Q000502 NN,D013601 Q000502 NY,D002465 Q000187 NN,D018077 Q000502 NN,D019718 Q000502 NY,D019707 Q000187 NN,D019713 Q000502 NY,D013110 Q000031 NN,D019707 Q000502 NY,D011409 Q000494 NN,D007166 Q000494 NN,D043562 Q000502 NN,D013601 Q000187 NN","231,8252,31270,107969,107970,5280335","128394615,129060975,129645792,129872283","FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments.","FTY720 stimulates CCR7-driven T cell homing to peripheral lymph nodes (LN) by direct activation of sphingosine 1-phosphate receptors, along with the participation of multidrug transporters, 5-lipoxygenase, and G protein-coupled receptors for chemokines. In this study, we demonstrate that FTY720 also directly stimulates in vitro T cell chemotaxis to CCR2-CCL2, but not to a variety of other chemokines, including CCR5-CCL3/4/5 and CXCR4-CXCL12. FTY720 influences CCR2-CCL2-driven migration through activation of","Journal of immunology (Baltimore, Md. : 1950)","Adam C Yopp, Shuang Fu, Shaun M Honig, Gwendalyn J Randolph, Yaozhong Ding, Nancy R Krieger, Jonathan S Bromberg"," Carl C. Icahn Center for Gene Therapy and Molecular Medicine, and. Recanti/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.",2004 Jul;173(2):855-65,10.4049/jimmunol.173.2.855
15244075,20040601,article,"xref,mesh","Cordyceps,Depression, Chemical,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation Mediators,Ligands,Lymphocyte Count,Lymphocytes,Lysophospholipids,Phosphorylation,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Sphingosine","agonists,analogs &amp; derivatives,chemical synthesis,chemistry,immunology,isolation &amp; purification,pharmacology,physiology","D007166 Q000494 NY,D032661 Q000737 NY,D043562 Q000819 NY,D008246 Q000494 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000138 NN,D005229 Q000302 NN,D008214 Q000276 NN,D008246 Q000502 NN,D011409 Q000138 NN,D007166 Q000302 NN,D013110 Q000494 NN,D043562 Q000502 NN,D013110 Q000502 NN","8252,31270,107969,107970,121989,5280335,5283560,6438394,57317596","128394615,129060975,129645792,129976789,136314073",['Vegetable wasps and plant worms' and G-protein-coupled receptors].,"Following the discovery of an immunosuppressive substance isolated from one of the entomopathogenic fungi 'vegetable wasps and plant worms', FTY720, whose immunosuppressive action is more potent than that of cyclosporin, was developed. In contrast to classical immunosuppressants such as cyclosporin, FTY720 does not affect the growth, maturation and activation of lymphocytes, but causes a reduction in the number of circulating lymphocytes as a result of enhanced homing of lymphocytes to the secondary lymphoi",Journal of UOEH,Hiroyuki Takeya," Department of Biochemistry, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan. takeya@grape.med.tottori-u.ac.jp",2004 Jun;26(2):227-38,10.7888/juoeh.26.227
15264459,20040601,review,"xref,mesh","Drug Approval,Drug Interactions,Drug Monitoring,Everolimus,Fingolimod Hydrochloride,Forecasting,Graft Survival,Humans,Immunosuppression,Immunosuppressive Agents,Mycophenolic Acid,Organ Transplantation,Propylene Glycols,Safety,Sirolimus,Sphingosine,Transplantation Immunology,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug effects,immunology,methods,pharmacology,therapeutic use,trends","D006085 Q000187 NN,D009173 Q000627 NY,D007165 Q000639 NY,D009173 Q000494 NN,D013110 Q000031 NN,D020123 Q000494 NN,D007166 Q000627 NY,D007165 Q000379 NN,D006085 Q000276 NN,D011409 Q000494 NN,D020123 Q000627 NY,D011409 Q000627 NY,D007166 Q000494 NN,D016377 Q000009 NN,D020123 Q000031 NN","588,4272,8252,31270,107969,107970,446541,5280335,5281078,5284616,6441022,6442177,23665584,90696889,91534498","127719861,128094727,128394615,129060975,129645792,242749350,248766214",Future immunosuppressive agents in solid-organ transplantation.,"OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of mycophenolate sodium, everolimus, and FTY720. STUDY SELECTION AND DATA EXTRACTION: Clinical trials and abstracts evaluating mycophenolate sodium, everolimus, and FTY720 in solid-organ transplantation were considered for evaluation. English-language studies and published abstracts were selected for inclusion. DATA SYNTHESIS: Mycophenolate sodium has recently been approved by the Food and Drug Adminstration for marketing in the U","Progress in transplantation (Aliso Viejo, Calif.)","Steven Gabardi, Jeffrey Cerio"," Brigham and Women's Hospital, Boston, MA, USA.",2004 Jun;14(2):148-56,10.7182/prtr.14.2.58517260818257h8
15265669,20040801,article,"xref,mesh","Animals,Antineoplastic Agents,Disease Models, Animal,Dose-Response Relationship, Drug,Drug Interactions,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Granulocyte-Macrophage Colony-Stimulating Factor,Immunosuppressive Agents,Interferon-gamma,Lymphocytes,Lymphopenia,Mice,Mice, Inbred Strains,Mitoxantrone,Molecular Sequence Data,Myelin Proteins,Myelin Proteolipid Protein,Nitric Oxide Synthase,Nitric Oxide Synthase Type II,Peptide Fragments,Propylene Glyc","agonists,analogs &amp; derivatives,biosynthesis,blood,chemically induced,drug effects,drug therapy,etiology,genetics,immunology,metabolism,methods,pharmacology,physiology,therapeutic use","D016178 Q000378 NN,D043562 Q000819 NY,D019001 Q000235 NN,D007371 Q000378 NN,D004681 Q000378 NN,D008231 Q000188 NN,D020133 Q000379 NN,D004681 Q000097 NN,D004681 Q000139 NN,D008214 Q000502 NN,D005786 Q000276 NN,D019001 Q000378 NN,D013110 Q000031 NN,D000970 Q000627 NN,D009185 Q000235 NN,D007166 Q000627 NY,D008942 Q000627 NN,D008231 Q000209 NN,D016178 Q000235 NN,D009185 Q000378 NN,D007371 Q000235 NN,D011409 Q000494 NN,D012333 Q000096 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN,D004681 Q000188 NY","4212,8252,31270,51082,51151,105065,107969,107970,5280335,5458171,16199055,54607525,102601612","128394615,128397534,129060975,129645792,136111139",Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.,"FTY720 is a prodrug for FTY-phosphate, an agonist at four of the five known receptors for sphingosine-1-phosphate (S1P). We show that administration of either FTY720 or FTY-P to SJL mice with established relapsing-remitting experimental autoimmune encephalitis (EAE) results in a rapid and sustained improvement in their clinical status, and a reversal of changes in expression of mRNAs encoding some myelin proteins and inflammatory mediators. EAE produced by adoptively transferring lymph node cells from immun",Journal of neuroimmunology,"Michael Webb, Chui-Se Tham, Fen-Fen Lin, Karen Lariosa-Willingham, Naichen Yu, Jeffrey Hale, Suzanne Mandala, Jerold Chun, Tadimeti S Rao"," Molecular Neuroscience Laboratory, Merck Research Laboratories, 3535 General Atomics Court, San Diego, CA 92121, USA. xhua@san.rr.com",2004 Aug;153(?):108-21,10.1016/j.jneuroim.2004.04.015
15290910,20040501,article,"xref,mesh","Animals,Apoptosis,CD4-CD8 Ratio,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Colitis,Disease Models, Animal,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Interferon-gamma,Interleukin-10,Lymphocytes,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Tissue Distribution","analogs &amp; derivatives,biosynthesis,deficiency,drug effects,drug therapy,immunology,pathology,pharmacology","D007166 Q000494 NY,D003092 Q000276 NN,D017209 Q000187 NN,D007371 Q000187 NN,D015496 Q000187 NN,D008214 Q000187 NY,D003092 Q000188 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007371 Q000096 NN,D018414 Q000187 NN,D016753 Q000172 NN,D014018 Q000187 NN,D003092 Q000473 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.,"BACKGROUND: FTY720 is a novel reagent that possesses potent immunosuppressive activity. The immunosuppression induced by FTY720 is mediated by completely different mechanisms from those of conventional immunosuppressants, that is, by altering the tissue distribution of lymphocytes rather than inhibiting activation. In this study, we examined the efficacy of FTY720 in the treatment of chronic colitis in an interleukin-10 gene-deficient (IL-0-/-) mouse model. METHODS: FTY720 was administered orally for 4 week",Inflammatory bowel diseases,"Tsunekazu Mizushima, Toshinori Ito, Daisuke Kishi, Yasuyuki Kai, Hiroshi Tamagawa, Riichiro Nezu, Hiroshi Kiyono, Hikaru Matsuda"," Department of Surgery (E1), Osaka University Graduate School of Medicine, Japan.",2004 May;10(3):182-92,10.1097/00054725-200405000-00002
15297371,20041201,article,"xref,mesh","Apoptosis,Carcinoma, Hepatocellular,Cell Cycle Proteins,Cyclin D1,Cyclin-Dependent Kinase Inhibitor p27,Down-Regulation,Enzyme Inhibitors,Fingolimod Hydrochloride,G1 Phase,Glycogen Synthase Kinase 3,Glycogen Synthase Kinase 3 beta,Humans,Immunosuppressive Agents,Liver Neoplasms,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Phosphatidylinositol 3-Kinases,Phosphorylation,Propylene Glycols,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-akt,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,metabolism,pathology,pharmacology","D011518 Q000378 NY,D007166 Q000494 NY,D018797 Q000378 NN,D048052 Q000037 NN,D017209 Q000187 NY,D006528 Q000473 NN,D019938 Q000378 NN,D019869 Q000378 NY,D025521 Q000378 NN,D006528 Q000378 NY,D011409 Q000494 NY,D013110 Q000031 NN,D019950 Q000378 NN,D017346 Q000378 NY,D016159 Q000378 NN,D019950 Q000037 NN,D038362 Q000378 NN,D008113 Q000473 NN,D004791 Q000494 NN,D010766 Q000187 NN,D008113 Q000378 NY,D016193 Q000187 NN,D048052 Q000378 NN","8252,31270,107969,107970,5280335,71581456","129060975,129645792,135897353",FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.,"Our aim was to study the anticancer effect of the novel immunomodulator FTY720 in vitro and in vivo by investigation of cell cycle entry, cell cycle regulation, cell survival and apoptosis pathways. Three hepatoma cell lines with different p53 statuses (HepG2, Huh-7 and Hep3B) and one non-tumorigenic immortalized liver cell line (MIHA) were used for an in vitro study. The in vivo effects of FTY720 were evaluated in a nude mouse tumor model. Cell cycle distribution and cell cycle regulator proteins p27(Kip1)",Carcinogenesis,"Terence K Lee, Kwan Man, Joanna W Ho, Chris K Sun, Kevin T Ng, Xiang Hong Wang, Yong Chuan Wong, Irene O Ng, Ray Xu, Sheung Tat Fan"," Centre for the Study of Liver Disease and Department of Surgery, University of Hong Kong, Pokfulam, Hong Kong, China.",2004 Dec;25(12):2397-405,10.1093/carcin/bgh250
15307827,20040901,article,"xref,mesh","Alanine Transaminase,Animals,Aspartate Aminotransferases,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Liver,Liver Transplantation,MAP Kinase Signaling System,Male,Propylene Glycols,Protein-Serine-Threonine Kinases,Protein-Tyrosine Kinases,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-akt,Rats,Rats, Inbred Lew,Signal Transduction,Sphingosine,Transcription Factors,Transplantation, Homologous","analogs &amp; derivatives,anatomy &amp; histology,blood,drug effects,immunology,metabolism,physiology,therapeutic use","D006085 Q000187 NN,D001219 Q000097 NN,D011518 Q000502 NY,D011505 Q000502 NN,D006085 Q000502 NY,D013110 Q000031 NN,D007166 Q000627 NY,D017346 Q000502 NY,D006085 Q000276 NN,D020935 Q000187 NN,D008099 Q000033 NY,D000410 Q000097 NN,D020935 Q000502 NN,D011409 Q000627 NY,D014157 Q000378 NN,D016031 Q000276 NY","602,5960,8252,31270,107969,107970,5280335","127638306,128394615,129046631,129060975,129645792",Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway.,"To investigate the protective mechanism of FTY720 in small-for-size liver grafts, we applied a rat orthotopic liver transplantation model using 40% of liver grafts. FTY720 was administered (1 mg/kg, i.v.) at 20 min before graft harvesting in the donor, immediately before total hepatectomy and immediately after graft reperfusion in the recipient. The 7-day graft survival rates in the FTY720 group were significantly improved compared with the control group [100% (6/6) vs. 40% (4/10), p = 0.034]. FTY720 signif",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Yi Zhao, Kwan Man, Chung Mau Lo, Kevin T Ng, Xian Liang Li, Chris K Sun, Terence K Lee, Xian Wei Dai, Sheung Tat Fan"," Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China.",2004 Sep;4(9):1399-407,10.1111/j.1600-6143.2004.00527.x
15319278,20041215,article,"xref,mesh","Animals,Antibodies,Antibody Formation,B-Lymphocytes,Fingolimod Hydrochloride,Flow Cytometry,Germinal Center,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,blood,drug effects,immunology,pharmacology","D000906 Q000097 NN,D013601 Q000276 NN,D001402 Q000276 NY,D001402 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D000917 Q000276 NN,D018858 Q000187 NN,D007166 Q000494 NN,D018858 Q000276 NY,D000917 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 suppresses humoral immunity by inhibiting germinal center reaction.,"FTY720 is a novel immunosuppressant that is highly effective in inhibiting rejection of allografts and autoimmunity in various animal models. It has been shown that the sphingosine 1 phosphate (S1P) receptors are the direct molecular targets of FTY720. However, the mechanisms responsible for inhibiting specific immune responses by FTY720 are not well resolved. In particular, there is no available information on whether or how this compound affects humoral immunity. We have investigated the effect of FTY720 ",Blood,"Shuhua Han, Xuejun Zhang, Gangdou Wang, Hui Guan, Gabriela Garcia, Ping Li, Lili Feng, Biao Zheng"," Department of Immunology, Baylor College of Medicine, M929, 1 Baylor Plaza, Houston, TX 77030, USA.",2004 Dec;104(13):4129-33,10.1182/blood-2004-06-2075
15327424,20040901,article,"xref,mesh","Animals,Chronic Disease,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,In Situ Nick-End Labeling,Kidney Transplantation,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred F344,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,pharmacology","D006084 Q000188 NY,D007166 Q000494 NY,D008214 Q000473 NN,D011409 Q000494 NY,D013110 Q000031 NN,D006084 Q000473 NN,D008214 Q000276 NN,D008214 Q000187 NN,D006084 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration.,"BACKGROUND: Lymphocytic infiltration is obvious throughout early and late stages of chronic allograft nephropathy. Early infiltrating lymphocytes are involved in initial insults to kidney allografts, but the contribution of late infiltration to long-term allograft attrition is still controversial. Early application of FTY720 reduced the number of graft infiltrating lymphocytes, and inhibited acute rejection. The present study investigated the potential of FTY720 to reduce the number of infiltrating lymphocy",Kidney international,"Minghui Wang, Shanying Liu, Nengtai Ouyang, Erwei Song, Jens Lutz, Uwe Heemann"," Department of Nephrology TU-Klinikum rechts der Isar, Munich, Germany.",2004 Sep;66(3):1248-56,10.1111/j.1523-1755.2004.00878.x
15336258,20040915,article,"xref,mesh","Animals,CHO Cells,Cricetinae,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Molecular Conformation,Organophosphates,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemical synthesis","D011409 Q000138 NY,D013110 Q000031 NN,D010755 Q000138 NY,D007166 Q000138 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720.","The novel immunosuppressive agent FTY720 (1) is phosphorylated in vivo in a variety of species yielding an active metabolite that is an agonist of four of the five known G-protein-coupled sphingosine-1-phosphate (S1P) receptors. A synthesis amenable to producing gram quantities of the stereoisomeric phosphate esters, a determination of their absolute stereochemistry via an enantioselective synthesis and their characterization as S1P receptor agonists and antagonists is reported. ",Bioorganic & medicinal chemistry,"Jeffrey J Hale, Lin Yan, William E Neway, Richard Hajdu, James D Bergstrom, James A Milligan, Gan-Ju Shei, Gary L Chrebet, Rosemary A Thornton, Deborah Card, Mark Rosenbach,  HughRosen, Suzanne Mandala"," Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. jeffrey_hale@merck.com",2004 Sep;12(18):4803-7,10.1016/j.bmc.2004.07.020
15340225,20040901,article,"xref,mesh","Animals,Dermatitis, Atopic,Disease Models, Animal,Epidermis,Fingolimod Hydrochloride,Immunoglobulin E,Immunosuppressive Agents,Male,Mice,Mice, Inbred Strains,Propylene Glycols,Specific Pathogen-Free Organisms,Sphingosine,Time Factors","analogs &amp; derivatives,blood,drug effects,immunology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D007073 Q000097 NN,D004817 Q000276 NN,D004817 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D003876 Q000276 NN,D003876 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice.","Oral administration of a novel immunomodulator, FTY720 (0.1 mg/kg, once a week), completely prevented the spontaneous development of dermatitis in NC/Nga mice. It also strongly suppressed hyper IgE production in serum, as well as hypertrophy of the epidermis and the degranulation of granulocytes in the skin, all of which were observed in mice in which the dermatitis had become established. These results strongly suggest that FTY720 is a promising candidate for treatment of human atopic dermatitis. ",Biological & pharmaceutical bulletin,"Takeyuki Kohno, Takumi Tsuji, Kaori Hirayama, Kazuhito Watabe, Akiko Matsumoto, Tomoko Kohno, Tetsuro Fujita"," Department of Environmental Health Sciences, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan. kohno@pharm.setsunan.ac.jp",2004 Sep;27(9):1392-6,10.1248/bpb.27.1392
15381198,20041101,article,"xref,mesh","Adjuvants, Immunologic,Animals,Cell Movement,Cyclosporine,Drug Synergism,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Intestine, Small,Lymph Nodes,Lymphocyte Count,Lymphocytes,Male,Premedication,Preoperative Care,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Sphingosine,Tissue Donors","analogs &amp; derivatives,drug effects,immunology,pathology,pharmacology,prevention &amp; control,transplantation","D006085 Q000187 NN,D007166 Q000494 NY,D002465 Q000187 NN,D016572 Q000494 NY,D008198 Q000276 NN,D011409 Q000494 NY,D000276 Q000494 NY,D013110 Q000031 NN,D007421 Q000637 NY,D007421 Q000276 NN,D008214 Q000276 NN,D007421 Q000473 NN,D008214 Q000187 NN,D006084 Q000517 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.,"BACKGROUND: Severe rejection of small bowel transplantation (SBTx) has been ascribed to abundant lymphoid tissues in the small intestine without well-established evidence. However, the role of donor lymphocytes in rejection is still unclear. The novel immunosuppressant, FTY720, is reported to transfer peripheral blood lymphocytes (PBLs) to lymphoid tissues such as mesenteric lymph nodes (MLNs) and Peyer patches (PP). In the present study, the number of donor lymphocytes in the graft was increased by FTY720,",Transplant immunology,"Taichi Sakagawa, Hidenori Kiyochi, Kazuo Honda, Nobuaki Kobayashi"," First Department of Surgery, Ehime University School of Medicine, Shitsukawa Shigenobu-cho, Onsen-gun, 791-0295, Japan. sakagawa@pop.m.ehime-u.ac.jp",2004 Nov;13(3):161-8,10.1016/j.trim.2004.06.004
15458436,20041001,article,"xref,mesh","Animals,Blood Pressure,Blood Urea Nitrogen,Body Weight,Creatinine,Extracellular Matrix,Fibrosis,Fingolimod Hydrochloride,Glomerulosclerosis, Focal Segmental,Heart Rate,Immunosuppressive Agents,Isoantibodies,Lymphocyte Count,Lymphocytes,Male,Propylene Glycols,Proteinuria,Rats,Rats, Wistar,Sphingosine","analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,pathology,pharmacology","D007166 Q000494 NY,D005109 Q000187 NN,D003404 Q000097 NN,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D005923 Q000188 NY,D011507 Q000473 NN,D005923 Q000276 NY,D011507 Q000276 NN,D011507 Q000188 NN,D005923 Q000473 NN,D005109 Q000473 NN","588,5196,8252,31270,107969,107970,5280335","127719861,127788218,128394615,129060975,129645792",Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.,"BACKGROUND: Progression is a hallmark of chronic renal disease and histologically characterized by fibrosis and inflammation of the tubulointerstitial compartment. To define the role of lymphocytes in this process, the novel lymphocyte-specific inhibitor FTY720 was administered to rats with anti-thy 1-induced chronic progressive glomerulosclerosis. In this model, the initial and short-term inflammatory glomerular injury progresses self-perpetuatedly toward tubulointerstitial fibrosis by not primarily immune",Kidney international,"Harm Peters, Sebastian Martini, Yingrui Wang, Fuijo Shimizu, Hiroshi Kawachi, Stephanie Krämer, Hans-H Neumayer"," Department of Nephrology and Center of Cardiovascular Research, Charité, University Medicine Berlin, Charité Campus Mitte, Humboldt University, Berlin, Germany. Harm.Peters@charite.de",2004 Oct;66(4):1434-43,10.1111/j.1523-1755.2004.00906.x
15459201,20041210,article,"xref,mesh","Animals,Base Sequence,DNA,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocytes,Lymphopenia,Lysophospholipids,Mice,Mice, Knockout,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Prodrugs,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,chemically induced,deficiency,drug effects,enzymology,etiology,genetics,metabolism,physiology,toxicity","D017853 Q000172 NY,D011409 Q000633 NY,D008231 Q000201 NN,D007166 Q000378 NN,D017853 Q000235 NN,D008231 Q000139 NN,D008231 Q000209 NY,D011355 Q000633 NN,D008214 Q000502 NN,D013110 Q000031 NY,D013110 Q000378 NN,D017853 Q000502 NN,D007166 Q000633 NN,D004247 Q000235 NN,D011355 Q000378 NN,D008246 Q000378 NN,D008214 Q000187 NN,D011409 Q000378 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560,44135672","128394615,129060975,129645792",Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.,"Sphingosine-1-phosphate (S1P), a lipid signaling molecule that regulates many cellular functions, is synthesized from sphingosine and ATP by the action of sphingosine kinase. Two such kinases have been identified, SPHK1 and SPHK2. To begin to investigate the physiological functions of sphingosine kinase and S1P signaling, we generated mice deficient in SPHK1. Sphk1 null mice were viable, fertile, and without any obvious abnormalities. Total SPHK activity in most Sphk1-/-tissues was substantially, but not co",The Journal of biological chemistry,"Maria L Allende, Teiji Sasaki, Hiromichi Kawai, Ana Olivera, Yide Mi, Gerhild van Echten-Deckert, Richard Hajdu, Mark Rosenbach, Carol Ann Keohane, Suzanne Mandala, Sarah Spiegel, Richard L Proia"," Genetics of Development and Disease Branch, NIDDK and NIAMS, National Institutes of Health, Bethesda, Maryland 20892, USA.",2004 Dec;279(50):52487-92,10.1074/jbc.m406512200
15501305,20041001,article,"xref,mesh","Analgesics, Non-Narcotic,Animals,Anti-Inflammatory Agents, Non-Steroidal,Asteraceae,Carrageenan,Indomethacin,Inflammation,Lactones,Magnolia,Male,Molecular Structure,Rats,Rats, Sprague-Dawley,Sesquiterpenes","chemistry,drug therapy,etiology,isolation &amp; purification,pharmacology","D007249 Q000188 NN,D012717 Q000494 NY,D007783 Q000737 NN,D000894 Q000494 NY,D012717 Q000302 NY,D018712 Q000302 NY,D012717 Q000737 NN,D000894 Q000737 NN,D007213 Q000494 NN,D000894 Q000302 NY,D031566 Q000737 NY,D007783 Q000302 NN,D019659 Q000737 NY,D007249 Q000209 NN,D007783 Q000494 NN,D018712 Q000737 NN,D018712 Q000494 NY","3715,4692,8252,108068,927704,5320420,5353864,5420804,5420805,5702252,6473881,7251185,11966249,11972532,23631982,23675763,73759808,91873711,123134657,124463365","129060975,136279940",Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot.,"Sesquiterpene lactones possess a variety of biological activities, including anti-inflammatory activity. Two plants native to the southeastern United States, Magnolia grandiflora (L.) and Smallanthus uvedalius (L.) [syn Polymnia uvedalius (L.)], are novel sources of the sesquiterpene lactones parthenolide and enhydrin, respectively. In this study, the anti-inflammatory and anti-hyperalgesic effects of these isolated lactones from these two plant sources were evaluated in the rat carrageenan inflammation mod","Pharmacology, biochemistry, and behavior","M W Feltenstein, W Schühly, J E Warnick, N H Fischer, K J Sufka"," Department of Psychology, University of Mississippi, University, MS 38677, USA.",2004 Oct;79(2):299-302,10.1016/j.pbb.2004.08.008
15561279,20041001,article,"xref,mesh","Animals,Antigens, CD,Atrophy,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocytes,Lymphoid Tissue,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine,Spleen,Thymus Gland","analogs &amp; derivatives,analysis,drug effects,immunology,pathology,pharmacology","D008214 Q000276 NY,D007166 Q000494 NY,D013950 Q000187 NN,D008214 Q000473 NN,D013154 Q000187 NN,D013154 Q000276 NY,D011409 Q000494 NY,D013950 Q000473 NN,D013110 Q000031 NN,D008221 Q000276 NY,D015703 Q000032 NN,D013154 Q000473 NN,D013950 Q000276 NY,D008221 Q000187 NN,D008214 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effects of FTY720 on rat lymphoid organs.,"INTRODUCTION: In this study, we examined the in vivo effect of FTY720 on rat thymus and spleen. MATERIALS AND METHODS: Inbred male Lewis (RT-I(l)) rats, 5-weeks-old, received FTY720 (0.1, 1, or 10 mg/kg) by intramuscular injection into 1 of 4 limbs daily for 7 days. The rats were humanely killed at 1, 3, 5, or 7 days after starting administration of FTY720. The thymus and spleen were obtained for hematoxylin and eosin (HE) as well as immunoperoxidase staining using the antibodies OX8 (CD8), W3/25 (CD4), and",Transplantation proceedings,"K Takai, S Takahara, N Isoyama, M Tsuchida, M Matsumura, Y Kishi, K Uchiyama, K Naito"," Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan. takai@yamaguchi-u.ac.jp",2004 Oct;36(8):2453-6,10.1016/j.transproceed.2004.08.001
15573862,20041101,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Propylene Glycols,Sphingosine","analogs &amp; derivatives,pharmacology,physiology,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D008246 Q000502 NN,D011409 Q000494 NN,D011409 Q000627 NY,D013110 Q000502 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792","Editorial overview: Tie me up, tie me down: immunosuppressive therapies for the 21st century.",NULL,"Current opinion in investigational drugs (London, England : 2000)",Mariano J Elices,NULL,2004 Nov;5(11):1137-40,NULL
15592714,20041101,article,"xref,mesh","Animals,Blood Cell Count,Coronary Vessels,Cyclosporine,Dogs,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Intestines,Kidney,Liver Transplantation,Lung,Propylene Glycols,Sphingosine,Survival Analysis,Tacrolimus","analogs &amp; derivatives,blood,drug effects,pathology,pharmacokinetics,physiopathology,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D016559 Q000627 NN,D007166 Q000097 NN,D007422 Q000473 NN,D008168 Q000473 NN,D003331 Q000473 NN,D007668 Q000473 NN,D007668 Q000503 NN,D007166 Q000493 NN,D013110 Q000031 NN,D007166 Q000627 NY,D011409 Q000493 NN,D006084 Q000473 NN,D011409 Q000627 NY,D011409 Q000097 NN","2909,5372,8252,31270,62280,107969,107970,445643,5280335,5280754,5282315,5284373,5458585,6435893,6473866,6536850,9855081,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90726579,122172945,123134263,123134270,132274082,134694629","128394615,129060975,129645792,242963342","A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.","Three different types of treatment were conducted to clarify the properties of a novel immunomodulator, FTY720, in canine kidney allograft models. Survival, biochemical and hematological tests, pharmacokinetics, and histopathology of grafts and extra-renal organs were analyzed. Accompanying a remarkable reduction in circulating lymphocytes, single-drug treatment of FTY720, ranging from 0.05 to 10 mg/kg, exhibited significant prolongation of graft survival without a dose-dependent effect. Short-course induct",Transplant international : official journal of the European Society for Organ Transplantation,"Tomomi Suzuki, Maeng Bong Jin, Tsuyoshi Shimamura, Kenichiro Yamashita, Masahiko Taniguchi, Masaru Nomura, Ryouichi Yokota, Moto Fukai, Shinichiro Magata, Hiroyuki Horiuchi, Miri Fujita, Kazuro Nagashima, Hiroyuki Furukawa, Satoru Todo"," The First Department of Surgery, Hokkaido University School of Medicine, N-15, W-7, Kita-ku, 060-8638 Sapporo, Japan. t-suzu@med.hokudai.ac.jp",2004 Nov;17(10):574-84,10.1007/s00147-004-0767-7|10.1111/j.1432-2277.2004.tb00389.x
15598332,20041201,review,"xref,mesh","Abatacept,Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,CD40 Ligand,Child,Fingolimod Hydrochloride,Guanidines,Humans,Immunoconjugates,Immunosuppressive Agents,Isoxazoles,Lymphocyte Depletion,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,immunology,therapeutic use","D023201 Q000276 NN,D013601 Q000276 NN,D006146 Q000627 NN,D000911 Q000627 NN,D000912 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D018796 Q000627 NN,D011409 Q000627 NN,D007555 Q000627 NN","3899,8252,9254,31270,55361,55362,91272,107969,107970,5280335","128151681,128394615,129060975,129476173,129645792",Novel immunosuppressants.,"Advances in maintenance immunosuppression over the past decade has resulted in dramatic improvements in short- and long-term outcomes in organ transplantation as well as a decreased incidence of acute rejection. However, immunosuppressive drugs need to be given long term, lack specificity, and are accompanied by adverse metabolic derangements, toxicities, the risk of infection and cancer, and a myriad of other side effects. Further, they fail to prevent and control chronic rejection. This review will outlin",Pediatric transplantation,"Nancy R Krieger, Sukru Emre"," Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.",2004 Dec;8(6):594-9,10.1111/j.1399-3046.2004.00237.x
15598563,20050117,article,"xref,mesh","Animals,Cell Line,Cell Movement,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Mice,Models, Chemical,Molecular Structure,Propylene Glycols,Protein Binding,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,Stereoisomerism","analogs &amp; derivatives,chemical synthesis,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D002465 Q000187 NN,D011409 Q000138 NY,D007166 Q000378 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000138 NY,D008214 Q000187 NN,D011409 Q000378 NN,D049349 Q000378 NN","7904,8252,31270,107969,107970,5280335,14122294","128394615,129060975,129645792,129740424,246464401",Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.,"A practical asymmetric synthesis of both enantiomers of the immunosuppressive FTY720-phosphate (2) was accomplished, and the enantiomers were pharmacologically evaluated. Several lipases showed considerable activity and enantioselectivity for O-acylation of N-acetyl FTY720 (3) or N-benzyloxycarbonyl FTY720 (7) in combination with vinyl acetate or benzyl vinyl carbonate as the acyl donors. The synthesis using the lipase-catalyzed acylation as the key step produced the enantiomerically pure (>99.5% ee) enanti",Bioorganic & medicinal chemistry,"Masatoshi Kiuchi, Kunitomo Adachi, Ayumi Tomatsu, Masao Chino, Shuzo Takeda, Yoshihito Tanaka, Yasuhiro Maeda, Noriko Sato, Naoko Mitsutomi, Kunio Sugahara, Kenji Chiba"," Research Laboratory III (Immunology), Mitsubishi Pharma Corporation, Kamoshida-cho 1000, Aoba-ku, Yokohama 227-0033, Japan. kiuchi.masatoshi@ms.m-pharma.co.jp",2005 Jan;13(2):425-32,10.1016/j.bmc.2004.10.008
15627289,20041231,review,"xref,mesh","Animals,Autoimmune Diseases,Clinical Trials as Topic,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Organ Transplantation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Transplantation Immunology","agonists,analogs &amp; derivatives,drug effects,drug therapy,therapeutic use","D049349 Q000819 NN,D007107 Q000187 NN,D004730 Q000187 NN,D013110 Q000031 NN,D001327 Q000188 NN,D007166 Q000627 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: mechanism of action and potential benefit in organ transplantation.,"FTY720 is a novel immunomodulator that has proven effective in animal models of transplantation and autoimmunity, has achieved promising results in Phase I and Phase II studies of renal transplantation in humans, and is currently undergoing phase III studies. FTY720 acts as a high-affinity agonist at the sphingosine 1-phosphate receptor-1 (S1P1), where it internalises the receptor and causes alterations to the normal circulation of lymphocytes between the blood and lymphoid tissue. Unlike conventional immun",Yonsei medical journal,Volker Brinkmann," Novartis Institutes for Biomedical Research, Auto Immunity and Transplantation, WSJ-386.101, CH-4002 Basel, Switzerland. volker.brinkmann@pharma.novartis.com",2004 Dec;45(6):991-7,10.3349/ymj.2004.45.6.991
15635240,20050101,article,"xref,mesh","Benzylamines,Catalysis,Dihydroxyacetone,Fingolimod Hydrochloride,Hydrogenation,Immunosuppressive Agents,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemical synthesis,chemistry,metabolism","D011409 Q000138 NY,D001596 Q000737 NN,D007166 Q000378 NN,D001596 Q000378 NN,D004098 Q000737 NN,D013110 Q000031 NN,D004098 Q000378 NN,D007166 Q000138 NY,D011409 Q000378 NN","670,7504,8252,31270,107969,107970,2724127,2734685,5280335,6327445,12998568,17918559,73115753","128078808,128168570,128394615,129060975,129195613,129578881,129645792,136076275,248356899",A convenient synthesis of immunosuppressive agent FTY720 using the petasis reaction.,"A convenient synthesis of immunosuppressive agent FTY720 (1) using the Petasis reaction was developed. 4-Octylbenzaldehyde (9) was converted into 1-ethenyl-4-octylbenzene (11) by two-step synthesis. Hydroboration of 11 using catecholborane and hydrolysis gave (E)-2-(4-octylphenyl)vinylboronic acid (4). The Petasis reaction of 4, dihydroxyacetone (3), and benzylamine following catalytic hydrogenation afforded FTY720 (1). ",Chemical & pharmaceutical bulletin,"Shigeo Sugiyama, Satoshi Arai, Matsuri Kiriyama, Keitaro Ishii"," Meiji Pharmaceutical University, Tokyo, Japan.",2005 Jan;53(1):100-2,10.1248/cpb.53.100
15636610,20050101,article,"xref,mesh","Animals,Apoptosis,Blotting, Western,Chemokine CXCL2,Chemokines, CXC,DNA Primers,Down-Regulation,Endothelin-1,Epidermal Growth Factor,Extracellular Signal-Regulated MAP Kinases,Fibrosis,Fingolimod Hydrochloride,Gene Expression Regulation,HSP70 Heat-Shock Proteins,Heme Oxygenase (Decyclizing),Heme Oxygenase-1,Hepatocytes,Immunosuppressive Agents,In Situ Nick-End Labeling,Inflammation,Intercellular Signaling Peptides and Proteins,Interleukin-10,Liver,MAP Kinase Signaling System,Male,Microscopy, Electron,Nitric","analogs &amp; derivatives,biosynthesis,chemistry,cytology,drug effects,drug therapy,injuries,metabolism,pathology,pharmacology","D007166 Q000494 NY,D008099 Q000187 NY,D008099 Q000293 NN,D018840 Q000378 NN,D005355 Q000188 NN,D048490 Q000378 NN,D006419 Q000096 NN,D004815 Q000378 NN,D011409 Q000494 NY,D022781 Q000166 NN,D019001 Q000378 NN,D013110 Q000031 NN,D036341 Q000378 NN,D008099 Q000378 NN,D005355 Q000473 NY,D019743 Q000378 NN,D048049 Q000378 NN,D011506 Q000378 NN,D015427 Q000188 NY,D019332 Q000378 NN,D048051 Q000378 NN,D017931 Q000737 NN,D016753 Q000096 NN","8252,31270,107969,107970,5280335,16133807,16168476,16212950,44284481,56841751,56842074","128394615,129060975,129645792",FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers.,"Hepatic ischemia-reperfusion injury is an inevitable consequence during liver surgery. The outcome is particularly poor in cirrhotic livers, which are more prone to hepatic ischemia-reperfusion injury. We aim to study whether FTY720 could attenuate hepatic ischemia-reperfusion injury both in normal and in cirrhotic livers. We applied a 70% liver-ischemia (60 min) model in rats with normal or cirrhotic livers. FTY720 was given 20 min before ischemia and 10 min before reperfusion (1 mg/kg, i.v.). Liver tissue",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Kwan Man, Kevin T Ng, Terence K Lee, Chung Mau Lo, Chris K Sun, Xian Liang Li, Yi Zhao, Joanna W Ho, Sheung Tat Fan"," Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China. kwanman@hkucc.hku.hk",2005 Jan;5(1):40-9,10.1111/j.1600-6143.2004.00642.x
15641148,20050128,article,"xref,mesh","Acute Disease,Alanine Transaminase,Animals,Apoptosis,Aspartate Aminotransferases,Cell Division,Concanavalin A,Fingolimod Hydrochloride,Hepatocytes,Immunosuppressive Agents,Interferon-gamma,Interleukin-4,Lipopolysaccharides,Liver Diseases,Male,Mice,Mycobacterium bovis,Propylene Glycols,Rats,Rats, Wistar,Sphingosine,Spleen","analogs &amp; derivatives,blood,cytology,drug therapy,immunology,pharmacology","D008107 Q000188 NY,D007166 Q000494 NY,D015847 Q000097 NN,D022781 Q000276 NN,D001219 Q000097 NN,D013154 Q000166 NN,D011409 Q000494 NY,D013110 Q000031 NN,D013154 Q000276 NN,D017209 Q000276 NN,D008107 Q000276 NY,D000410 Q000097 NN,D007371 Q000097 NN,D002455 Q000276 NN","602,5960,8252,31270,107969,107970,5280335","127638306,128394615,129046631,129060975,129645792","Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice.","AIM: To investigate the protective effect against two immune liver injury models in mice by 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride and its possible mechanisms in Con A-induced liver damage. METHODS: Liver tissue or hepatocyte injury was monitored biochemically by measuring alanine aminotransferase (sALT) and aspartate aminotransferase (sAST) activity. Hematoxylin and eosin (HE) staining was used for histopathological examination. To evaluate the role of IFN-gamma and IL-4 in the ",World journal of gastroenterology,"Jing-Hua He, Hui-Na Zhang, Zhi-Bin Lin"," Department of Pharmacology, Basic Medical School, Peking University Health Science Center, Beijing 100083, China.",2005 Jan;11(4):573-6,10.3748/wjg.v11.i4.573
15642767,20050118,article,"xref,mesh","Animals,Bradycardia,Chemotaxis, Leukocyte,Chronic Disease,Cyclosporine,Drug Evaluation, Preclinical,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Guinea Pigs,Heart Rate,Heart Transplantation,Immunosuppressive Agents,Male,Molecular Structure,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Rats, Inbred Strains,Rats, Wistar,Skin Transplantation,Sphingosine,Sulfhydryl Compounds,Transplantation, Heterotopic,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,chemistry,drug effects,drug therapy,immunology,pharmacology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D006084 Q000188 NY,D016038 Q000276 NY,D016572 Q000008 NN,D013110 Q000031 NN,D001919 Q000517 NN,D007166 Q000627 NY,D006085 Q000187 NY,D014184 Q000276 NN,D002634 Q000187 NN,D006339 Q000187 NN,D007166 Q000737 NN,D011409 Q000494 NN,D006084 Q000517 NN,D013438 Q000627 NY,D011409 Q000627 NN,D013438 Q000494 NN,D016027 Q000276 NY,D007166 Q000494 NN,D013438 Q000737 NN,D013438 Q000008 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,11155873,11155874,24883466,25246316,49867938,57317596,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792,136314073,354702203","KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.","BACKGROUND: A novel immunomodulator, KRP-203, the molecular structure of which has some similarity to FTY720, has been developed for use in organ transplantation. The present study was designed to investigate the potency and safety of KRP-203 on allograft survival against both acute and chronic rejection in rat skin and heart transplantation. METHODS AND RESULTS: KRP-203 significantly prolonged skin or heart allograft survival of a minor histocompatibility complex (mHC)-disparate (LEW to F344) rat combinati",Circulation,"Hisashi Shimizu, Masafumi Takahashi, Takashi Kaneko, Takashi Murakami, Yoji Hakamata, Shinji Kudou, Tetsuya Kishi, Kazunori Fukuchi, Satoru Iwanami, Kazuhiko Kuriyama, Tokutaro Yasue, Shin Enosawa, Koshi Matsumoto, Izumi Takeyoshi, Yasuo Morishita, Eiji Kobayashi"," Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan.",2005 Jan;111(2):222-9,10.1161/01.cir.0000152101.41037.ab
15657952,20050201,article,"xref,mesh","Actins,CD18 Antigens,CD40 Antigens,Chemokines,Chemotaxis,Dendritic Cells,Fingolimod Hydrochloride,Gene Expression,Humans,Immunosuppressive Agents,Interferon-gamma,Interleukin-10,Interleukin-4,Propylene Glycols,Sphingosine,T-Lymphocytes,Time Factors","analogs &amp; derivatives,drug effects,genetics,immunology,metabolism,pharmacology,physiology","D013601 Q000378 NN,D007166 Q000494 NY,D019013 Q000276 NN,D003713 Q000187 NY,D007371 Q000378 NN,D015847 Q000378 NN,D018821 Q000235 NN,D018821 Q000276 NY,D003713 Q000276 NN,D011409 Q000494 NY,D002633 Q000502 NN,D013110 Q000031 NN,D015870 Q000187 NY,D000199 Q000378 NN,D016753 Q000378 NN,D018925 Q000378 NN,D003713 Q000378 NN,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.,"The potent immunomodulator FTY720 elicits immunosuppression via acting on sphingosine 1-phosphate receptors (S1PR), thereby leading to an entrapment of lymphocytes in the secondary lymphoid tissue. To elucidate the potential in vitro effects of this drug on human monocyte-derived DC, we used low nanomolar therapeutic concentrations of FTY720 and phosphorylated FTY720 (FTY720-P) and investigated their influence on DC surface marker expression, protein levels of S1PR and DC effector functions: antigen uptake,",European journal of immunology,"Hansgeorg Müller, Susanne Hofer, Nicole Kaneider, Hannes Neuwirt, Birgit Mosheimer, Gert Mayer, Günther Konwalinka, Christine Heufler, Martin Tiefenthaler"," Department of Nephrology, Innsbruck Medical School, Innsbruck, Austria.",2005 Feb;35(2):533-45,10.1002/eji.200425556
15669207,20041001,review,"xref,mesh","Adrenal Cortex Hormones,Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Monoclonal, Murine-Derived,Antibodies, Neoplasm,Azathioprine,Cyclosporine,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Mycophenolic Acid,Propylene Glycols,Risk Factors,Rituximab,Sirolimus,Sphingosine,Tacrolimus","adverse effects,analogs &amp; derivatives,drug therapy,etiology,immunology,methods,pharmacology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D006084 Q000188 NY,D007166 Q000494 NY,D016559 Q000494 NN,D016559 Q000627 NN,D009173 Q000031 NY,D016030 Q000009 YN,D000911 Q000627 NN,D006084 Q000209 NN,D000912 Q000627 NN,D009173 Q000494 NN,D013110 Q000031 NN,D000912 Q000494 NN,D020123 Q000494 NN,D001379 Q000627 NN,D007166 Q000627 NY,D016572 Q000494 NN,D016030 Q000276 YN,D000911 Q000494 NN,D011409 Q000494 NN,D009173 Q000627 NN,D016030 Q000379 YN,D001379 Q000494 NN,D011409 Q000627 NN,D000305 Q000627 NN,D020123 Q000627 NN,D000305 Q000494 NN","2265,2909,4271,4272,5372,8252,31270,62280,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6473866,6536850,9855081,11529527,23665584,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129645792,242963342,248766214",[Immunossupresive drugs in renal transplantation].,"Modem immunosupressive agents have greatly reduced incidence and severity of acute renal allograft rejection. One-year graft survival rate of 95% can be easily achieved with optimal immunosuppressive regimens. However, long-term kidney transplant survival has improved poorly. At present, chronic allograft nephropathy (CAN) and recipients death (mainly due to circulatory complications, neoplasms and infections) are most common reasons of graft loss in the second and subsequent years after transplantation. Mo",Polskie Archiwum Medycyny Wewnetrznej,"Teresa Baczkowska, Magdalena Durlik", Klinika Medycyny Transplantacyjnej i Nefrologii Instytutu Transplantologii AM w Warszawie.,2004 Oct;?(?):99-120,NULL
15680492,20050415,article,"xref,mesh","Adrenomedullin,Animals,Autoimmune Diseases,Blood Chemical Analysis,Fingolimod Hydrochloride,Glomerulonephritis,Humans,Immunosuppressive Agents,Kidney,Male,Mercuric Chloride,Peptides,Propylene Glycols,Proteinuria,Radioimmunoassay,Random Allocation,Rats,Sphingosine,Statistics as Topic,Urine","analogs &amp; derivatives,chemically induced,chemistry,drug therapy,immunology,metabolism,pathology,physiopathology,therapeutic use","D007668 Q000378 NN,D011507 Q000188 NY,D007668 Q000473 NN,D007166 Q000378 NN,D005921 Q000503 NN,D005921 Q000188 NY,D010455 Q000378 NY,D001327 Q000276 NN,D005921 Q000276 NY,D013110 Q000031 NN,D001327 Q000139 NN,D014556 Q000737 NN,D007166 Q000627 NY,D005921 Q000139 NN,D011409 Q000378 NN,D011409 Q000627 NY,D001327 Q000503 NN,D001327 Q000188 NY","588,5997,8252,24085,31270,107969,107970,5280335,56841671","53789101,99300584,127719861,128121087,128394615,129060975,129645792,283537481",A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis.,"FTY720 has been originally developed as a new immunosuppressive agent, which prolongs graft survival in organ transplantation. Adrenomedullin (AM) participates in the regulation of sodium homeostasis and has renoprotective effects. The possible involvement of renal AM in the pathophysiology of glomerulonephritis (GN) and the effect of FTY720 has been evaluated in rats. HgCl2 (1 mg/kg body weight) was inoculated subcutaneously 3 times/week for a total of 2 weeks. FTY720 (3 or 10 mg/kg) was inoculated subcuta",Regulatory peptides,"Yi Shi, Fumiki Yoshihara, Hajime Nakahama, Naotsugu Ichimaru, Koji Yazawa, Masaharu Sada, Rieko Goto, Yuhei Kawano, Toshiki Moriyama, Shiro Takahara, Akihiko Okuyama, Kenji Kangawa"," Department of Urology, Osaka University School of Medicine, Japan.",2005 Apr;127(?):233-8,10.1016/j.regpep.2004.12.013
15699759,20050215,article,"xref,mesh","Animals,Corneal Transplantation,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Lymph Nodes,Mice,Mice, Inbred BALB C,Propylene Glycols,Rats,Rats, Sprague-Dawley,Sphingosine,Transplantation, Heterologous","analogs &amp; derivatives,immunology,prevention &amp; control,therapeutic use","D014183 Q000276 NY,D016039 Q000276 NY,D008198 Q000276 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006084 Q000517 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 in corneal concordant xenotransplantation.,"BACKGROUND: : Currently, there are no effective treatments for the control of corneal xenograft rejection. We evaluated the efficacy and mode of action of a novel immunosuppressant, FTY720, in a model of corneal xenograft transplantation. METHODS: : Rat-to-mouse corneal xenografts were performed and the effects of treatment with daily intraperitoneal injections of FTY720 (0.5 or 3.0 mg/kg/day) or saline from 2 days pretransplantation were assessed clinically. Immunohistochemical studies of the grafts and fl",Transplantation,"Klára Sedláková, Elizabeth Muckersie, Marie Robertson, Martin Filipec, John V Forrester"," Department of Ophthalmology, University of Aberdeen, Aberdeen, UK.",2005 Feb;79(3):297-303,10.1097/01.tp.0000151005.37985.de
15707407,20050301,article,"xref,mesh","Animals,Depression, Chemical,Fingolimod Hydrochloride,G Protein-Coupled Inwardly-Rectifying Potassium Channels,Heart Atria,Heart Rate,Immunosuppressive Agents,Mice,Myocytes, Cardiac,Patch-Clamp Techniques,Potassium Channels, Inwardly Rectifying,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D006325 Q000187 NN,D006339 Q000187 NY,D024661 Q000187 NY,D011409 Q000494 NY,D032383 Q000378 NN,D013110 Q000031 NN,D024661 Q000235 NN,D024661 Q000378 NN,D032383 Q000187 NN","187,8252,31270,107969,107970,5280335","128394615,128814285,129060975,129645792,135650261",The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.,"Sphingosine-1-phosphate (S1P) is an endogenous agonist for a family of five G protein-coupled receptors (S1P(1-5)) involved in cell proliferation, cardiovascular development and lymphocyte trafficking. The sphingolipid drug FTY720 displays structural similarity to S1P and efficacy as an immunosuppressant in models of autoimmune disease and in solid organ transplantation. While FTY720 is well-tolerated in humans, it produces a transient reduction of heart rate (HR). As S1P activates the cardiac G protein-gat",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Lev Koyrakh, Maria I Roman, Volker Brinkmann, Kevin Wickman"," Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.",2005 Mar;5(3):529-36,10.1111/j.1600-6143.2005.00754.x
15729178,20050227,article,"xref,mesh","Cell Adhesion,Cell Movement,Cytoskeleton,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Phosphatidylinositol 3-Kinases,Propylene Glycols,Proteomics,Sphingosine,Ubiquitin-Conjugating Enzymes","analogs &amp; derivatives,analysis,drug effects,pharmacology,physiology","D007166 Q000494 NY,D002465 Q000187 NN,D002448 Q000187 NN,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D044763 Q000032 NN,D003599 Q000187 NN,D019869 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Novel mediators of FTY720 in human lymphocytes.,"FTY720 (FTY), a novel immunosuppressive drug, can be distinguished from other immunosuppressive drugs by a completely different mechanism of action. FTY induces altered lymphocyte trafficking, leading to peripheral blood lymphopenia and to increased lymphocyte counts in lymph nodes. FTY mediates its immune-modulating effects by binding to sphingosine 1-phosphate receptors expressed on lymphocytes. In an attempt to identify mediators of the FTY-induced signal transduction, we used a proteomic approach. FTY-t",Transplantation,"Torsten Böhler, Klemens Budde, Hans-H Neumayer, Johannes Waiser"," Department of Internal Medicine-Nephrology, Charité Campus Mitte, Humboldt-University Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany. torsten.boehler@charite.de",2005 Feb;79(4):492-5,10.1097/01.tp.0000151773.43266.17
15745421,20050101,article,"xref,mesh","Administration, Topical,Animals,Female,Mice,Mice, Hairless,Radionuclide Imaging,Skin,Skin Diseases,Ultraviolet Rays,gamma-Tocopherol","diagnostic imaging,pharmacology,prevention &amp; control,radiation effects","D024504 Q000494 NY,D012871 Q000517 NY,D012867 Q000528 NY,D012871 Q000000981 NY","86472,92729","129075776,129874402,129875982","Topical application of a novel, water-soluble gamma-tocopherol derivative prevents UV-induced skin damage in mice.","We investigated whether the topical application of a novel, water-soluble gamma-tocopherol (gamma-Toc) derivative, gamma-tocopherol-N,N-dimethylglycinate hydrochloride (gamma-TDMG), could protect against UV-induced skin damage in hairless mice. Topical pre- or post-application of a 5% (93 mM) gamma-TDMG solution in water/propylene glycol/ethanol (2:1:2) significantly prevented sunburn cell formation, lipid peroxidation and edema/inflammation that were induced by exposure to a single dose of UV irradiation o",Photochemistry and photobiology,"Shingo Yasuoka, Jiro Takata, Yoshiharu Karube, Eiko Katoh, Toshi Tsuzuki, Junko Kizu, Masao Tsuchiya, Shizuko Kobayashi"," Kyoritsu University of Pharmacy, Tokyo, Japan.",2005 Jan;81(4):908-13,10.1562/2004-09-02-ra-300|10.1562/2004-09-02-ra-300r2.1
15771568,20050101,review,"xref,mesh","Adaptation, Physiological,Animals,Antigen-Presenting Cells,Cell Movement,Chemokines,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Activation,Lymphocytes,Lymphoid Tissue,Lysophospholipids,Models, Immunological,Plasma Cells,Propylene Glycols,Receptors, Chemokine,Sphingosine","analogs &amp; derivatives,cytology,drug effects,immunology,metabolism,pharmacology","D008221 Q000166 NN,D000938 Q000276 NN,D002465 Q000187 NN,D000938 Q000166 NN,D013110 Q000378 NY,D008221 Q000378 NY,D013110 Q000031 NY,D008221 Q000276 NY,D008246 Q000378 NY,D010950 Q000276 NN,D008214 Q000166 NN,D019707 Q000378 NN,D008214 Q000276 NN,D018925 Q000378 NY,D011409 Q000494 NN,D010950 Q000166 NN,D008214 Q000187 NN,D007166 Q000494 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139","Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs.","Secondary lymphoid organs serve as hubs for the adaptive immune system, bringing together antigen, antigen-presenting cells, and lymphocytes. Two families of G protein-coupled receptors play essential roles in lymphocyte migration through these organs: chemokine receptors and sphingosine-1-phosphate (S1P) receptors. Chemokines expressed by lymphoid stromal cells guide lymphocyte and dendritic cell movements during antigen surveillance and the initiation of adaptive immune responses. S1P receptor-1 is requir",Annual review of immunology,Jason G Cyster," Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, California 94143-0414, USA. cyster@itsa.ucsf.edu",2005 Jan;23(?):127-59,10.1146/annurev.immunol.23.021704.115628
15772896,20050301,review,"xref,mesh","Administration, Oral,Animals,Clinical Trials as Topic,Drug Evaluation, Preclinical,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Meta-Analysis as Topic,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,chemistry,immunology,methods,prevention &amp; control,therapeutic use","D007166 Q000008 NN,D013110 Q000008 NN,D004353 Q000379 NN,D011409 Q000737 NN,D013110 Q000031 NY,D011409 Q000008 NN,D013110 Q000737 NN,D007166 Q000627 NY,D007166 Q000737 NN,D006084 Q000517 NN,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Fingolimod. Mitsubishi Pharma/Novartis.,"Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist. ",IDrugs : the investigational drugs journal,Francis J Dumont, Francisj_dumont@yahoo.com,2005 Mar;8(3):236-53,NULL
15782091,20050401,article,"xref,mesh","Animals,Body Weight,Fingolimod Hydrochloride,Hydroxyproline,Immunosuppressive Agents,Interferon-gamma,Male,Organ Size,Pancreas,Pancreatitis, Chronic,Peroxidase,Propylene Glycols,RNA, Messenger,Rats,Rats, Wistar,Sphingosine,T-Lymphocytes,Transforming Growth Factor beta,Transforming Growth Factor beta1","analogs &amp; derivatives,analysis,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology,physiology","D012333 Q000032 NN,D007166 Q000494 NY,D009195 Q000378 NN,D050500 Q000276 NY,D006909 Q000378 NN,D011409 Q000494 NY,D010179 Q000187 NN,D013110 Q000031 NN,D010179 Q000473 NN,D050500 Q000473 NN,D010179 Q000502 NN,D013601 Q000276 NY,D007371 Q000235 NN,D016212 Q000235 NN,D013601 Q000187 NN,D050500 Q000188 NY","825,5810,8252,31270,69248,107969,107970,269023,440015,5280335,6971054,11973707,56842206,90726579","127843891,128394615,129060975,129645792,242963342","FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration.","OBJECTIVES: FTY720, a novel synthetic immunosuppressant, decreases peripheral blood lymphocytes by accelerating their homing to the peripheral and mesenteric lymph nodes and Peyer's patches. We previously reported that tacrolimus, another immunosuppressant, attenuates chronic pancreatitis by suppressing T-cell infiltration in male Wistar Bonn/Kobori rats but also may cause toxicity. To assess the effects of FTY720 on the development of pancreatic inflammation and fibrosis in the same model, the agent dissol",Pancreas,"Tetsu Okamoto, Tamaki Yamada, Atsushi Kuno, Kumiko Ogawa, Mingxi Tang, Hitoshi Sano, Hirotaka Ohara, Haruhisa Nakao, Hiromi Kataoka, Tomoyuki Shirai, Makoto Itoh"," Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.",2005 Apr;30(3):e64-70,10.1097/01.mpa.0000157386.15898.3a
15786373,20050101,review,"xref,mesh","Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,Calcineurin Inhibitors,Clinical Trials as Topic,Cyclosporins,Drugs, Investigational,Everolimus,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Isoxazoles,Kidney Transplantation,Mycophenolic Acid,Propylene Glycols,Sirolimus,Sphingosine,Tacrolimus,Treatment Outcome","analogs &amp; derivatives,prevention &amp; control,therapeutic use","D003524 Q000627 NN,D016559 Q000627 NN,D009173 Q000031 NY,D015507 Q000627 NN,D000911 Q000627 NN,D000912 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D020123 Q000031 NY,D009173 Q000627 NN,D011409 Q000627 NN,D007555 Q000627 NN,D020123 Q000627 NN,D006084 Q000517 NY","3899,4271,4272,5372,8252,9254,31270,107969,107970,445643,446541,5280335,5281078,5282315,5284616,6441022,6442177,6473866,6536850,23665584,71668407,90696889,90726579,91454826,91534498,134694629","128094727,128394615,129060975,129178479,129476173,129645792,242749350,242963342,248184126,248766214",[New immunodepressant drugs for the prevention and control of kidney transplant rejection].,"The increasing number of kidney transplantations performed yearly in Italy should prompt nephrologists to improve their knowledge in these patients that fall ""by default"" in the nephrologists' province. In taking on of this task in addition to a skilled clinical and organizational capacity, it demands experience and an updated knowledge of the immunosuppressive drug machinery currently available. Calcineurin inhibitors (cyclosporine and tacrolimus) are well-defined milestones, currently used. Less well know",Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia,G P Segoloni," Cattedra di Nefrologia dell'Universita' di Torino - SCU Nefrologia, Dialisi e Trapianto Azienda Ospedaliera S. Giovanni Battista, Molinette, Torino - Italy. giuseppe.segoloni@unito.it",2005 Jan;22(1):3-15,NULL
15802614,20050429,article,"xref,mesh","Cells, Cultured,Enzyme Activation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Nitric Oxide,Nitric Oxide Synthase,Nitric Oxide Synthase Type III,Phosphorylation,Propylene Glycols,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins,Proto-Oncogene Proteins c-akt,Receptors, Lysosphingolipid,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization,Sphingosine,Vasodilation","analogs &amp; derivatives,drug effects,pharmacology,physiology","D007166 Q000494 NY,D009569 Q000502 NN,D014664 Q000187 NY,D011409 Q000494 NY,D019001 Q000502 NY,D017346 Q000502 NN,D013110 Q000031 NN,D049349 Q000502 NY,D011518 Q000502 NN","4782,8252,31270,105065,107969,107970,145068,5280335","128394615,129060975,129266124,129645792,136111139",Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.,"The novel immunomodulator FTY720 is effective in experimental models of transplantation and autoimmunity, and is currently undergoing Phase III clinical trials for prevention of kidney graft rejection. FTY720 is a structural analogue of sphingosine-1-phosphate (S1P) and activates several of the S1P receptors. We show that FTY720 induces endothelium-dependent arterial vasodilation in phenylephrine precontracted mouse aortae. Vasodilation did not occur in thoracic aortic rings from eNOS-deficient mice, implic",Circulation research,"Markus Tölle, Bodo Levkau, Petra Keul, Volker Brinkmann, Günter Giebing, Gilbert Schönfelder, Michael Schäfers, Karin von Wnuck Lipinski, Joachim Jankowski, Vera Jankowski, Jerold Chun, Walter Zidek, Markus Van der Giet"," Med. Klinik IV, Charite-Campus Benjamin Franklin, Berlin, Germany.",2005 Apr;96(8):913-20,10.1161/01.res.0000164321.91452.00
15802820,20050401,article,"xref,mesh","Animals,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Myasthenia Gravis, Autoimmune, Experimental,Propylene Glycols,Specific Pathogen-Free Organisms,Sphingosine,Time Factors","analogs &amp; derivatives,pharmacology,prevention &amp; control","D007166 Q000494 NY,D020720 Q000517 NY,D011409 Q000494 NY,D013110 Q000031 NN","187,8252,31270,107969,107970,5280335","128394615,128814285,129060975,129645792","A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice.","Prophylactic oral administration of a novel immunomodulator (immunosuppressant), FTY720 (1 mg/kg, three times a week), completely prevented the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL/6 mice. EAMG has been used as an animal model for human myasthenia gravis, and was established by immunizing the mice with acetylcholine receptor (AChR) from Torpedo californica. FTY720 also suppressed the production of both anti-Torpedo californica AChR antibody and anti-mouse AChR autoantibod",Biological & pharmaceutical bulletin,"Takeyuki Kohno, Takumi Tsuji, Kaori Hirayama, Rumi Iwatsuki, Michitaka Hirose, Kazuhito Watabe, Hiroaki Yoshikawa, Tomoko Kohno, Akiko Matsumoto, Tetsuro Fujita, Masatoshi Hayashi"," Department of Environmental Health Sciences, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan. kohno@pharm.setsunan.ac.jp",2005 Apr;28(4):736-9,10.1248/bpb.28.736
15808561,20050101,article,"xref,mesh","Animals,Azathioprine,Cyclosporine,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Mycophenolic Acid,Propylene Glycols,Rats,Rats, Inbred Lew,Rats, Inbred Strains,Receptors, Lysosphingolipid,Skin Transplantation,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D016572 Q000627 NN,D049349 Q000037 NY,D007166 Q000627 NN,D016038 Q000276 NY,D006085 Q000276 NY,D013110 Q000031 NN,D001379 Q000627 NN,D009173 Q000031 NN,D009173 Q000627 NN,D011409 Q000627 NY","356,2265,2909,4271,4272,8252,31270,62280,107969,107970,446541,5280335,5280754,5281078,5284373,5458585,6435893,6441022,9855081,11529527,23665584,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127461190,128094727,128394615,129060975,129178479,129645792","Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate.","FTY720, a new class of immunomodulator, induces lymphopenia by sequestration of circulating lymphocytes into secondary lymphoid tissues. FTY720 at 0.1 to 1 mg/kg significantly prolonged the allograft survival in a dose-dependent manner and showed a marked synergistic effect in combination with cyclosporine (CsA) in rat skin and cardiac allograft models. In addition, the canine renal allograft survival was significantly prolonged by combination therapy with FTY720 at 0.03 to 1 mg/kg and CsA at 10 mg/kg as co",Transplantation proceedings,"K Chiba, Y Hoshino, M Ohtsuki, H Kataoka, Y Maeda, H Matsuyuki, K Sugahara, M Kiuchi, R Hirose, K Adachi"," Research Laboratory III (Immunology), Mitsubishi Pharma Corporation, Yokohama, Japan. chiba.kenji@mk.m-pharma.co.jp",2005 Jan;37(1):102-6,10.1016/j.transproceed.2004.12.286
15808562,20050101,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Survival,Graft vs Host Reaction,Host vs Graft Reaction,Immunosuppressive Agents,Lymphocyte Transfusion,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,immunology,therapeutic use","D006085 Q000187 NN,D006789 Q000187 NN,D049349 Q000037 NY,D006789 Q000276 NY,D006085 Q000276 NY,D013110 Q000031 NN,D007166 Q000627 NY,D006087 Q000187 NN,D006087 Q000276 NY,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice.",NULL,Transplantation proceedings,"H Kataoka, M Ohtsuki, K Shimano, S Mochizuki, K Oshita, M Murata, K Sugahara, N Sato, Y Hoshino, K Chiba"," Research Laboratory III (Immunology), Mitsubishi Pharma Corporation, Yokohama, Japan.",2005 Jan;37(1):107-9,10.1016/j.transproceed.2004.12.287
15808564,20050101,article,"xref,mesh","Animals,Diuresis,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,pathology,pharmacology","D007668 Q000187 NN,D007668 Q000473 NY,D004231 Q000187 NN,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Prolonged administration of FTY720 does not cause renal toxicity in mice.,"Prevention of allograft rejection without renal toxicity caused by calcineurin-inhibitor immunosuppression is a major goal for transplantation. FTY720 is a synthetic drug that modulates immune responses of transplantation in many animal models. FTY720 modulating mechanisms relate to lymphocyte migration to peripheral lymph nodes instead of inflammatory sites. The drug has no effect on T-cell proliferation or cytokine production, and therefore prevents generalized immunosuppression. However, it is still to b",Transplantation proceedings,"V R Galvão, M Ginoza, M Franco, E A Burdmann, V Bueno"," Sâo José do Rio Preto Medicine School, São Paulo, Brazil. valquiriabueno@hotmail.com",2005 Jan;37(1):112-3,10.1016/j.transproceed.2004.12.300
15808565,20050101,article,"xref,mesh","Animals,Antibodies, Monoclonal,CD40 Ligand,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Histocompatibility Testing,Immunosuppressive Agents,Intestine, Small,Major Histocompatibility Complex,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pathology,prevention &amp; control,therapeutic use,transplantation","D006085 Q000187 NN,D023201 Q000276 NN,D007166 Q000627 NN,D007421 Q000187 NN,D000911 Q000627 NN,D006085 Q000276 NY,D013110 Q000031 NN,D007421 Q000637 NY,D007421 Q000276 NN,D007421 Q000473 NN,D014184 Q000276 NY,D011409 Q000627 NY,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Control of intestinal allograft rejection by FTY720 and costimulation blockade.,"INTRODUCTION: The clinical application of small bowel transplantation (SBTx) is hampered by its pronounced immunogenicity. In this study we examined the effects of the novel immunosuppressant FTY720 and costimulation blockade by an anti-CD40L mAb (MR-1) in a stringent mouse model of SBTx. METHODS: SBTx was performed in mice with a full MHC mismatch (donors: C3H=H-2(k); recipients: C57BL/6=H-2(b)). Recipients were divided into four groups: 1, untreated group; 2, MR1 monotherapy (500 microg IV on days 0, 2, 4",Transplantation proceedings,"S Yan, J I Rodriguez-Barbosa, O Pabst, J H Beckmann, V Brinkmann, R Förster, M W Hoffmann"," Medical School of Hannover, Hannover, Germany.",2005 Jan;37(1):114-5,10.1016/j.transproceed.2004.12.089
15808648,20050101,article,"xref,mesh","Animals,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Reperfusion Injury,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pathology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D007668 Q000187 NN,D007668 Q000473 NN,D007668 Q000276 NY,D011409 Q000494 NY,D015427 Q000517 NY,D013110 Q000031 NN,D013601 Q000276 NY,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury.,"Ischemia/reperfusion (I/R) injury, a common early feature in renal transplantation, results from both free radical species generation and local inflammatory responses that attract different types of cells. The interaction with infiltrating leukocytes could promote damage and death of resident renal cells contributing to worsening of renal function. It has been shown that depletion of host T cells protects against kidney damage after I/R injury, although the mechanism is not fully understood. FTY720, a synth",Transplantation proceedings,"M Suleiman, P M Cury, J O M Pestana, E A Burdmann, V Bueno"," UNESP, São Paulo, Brazil.",2005 Jan;37(1):373-4,10.1016/j.transproceed.2004.12.280
15814275,20050301,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Fingolimod Hydrochloride,Graft Survival,Granulocytes,Immunosuppressive Agents,Kidney Transplantation,Leukocytes,Male,Preoperative Care,Propylene Glycols,Rats,Receptors, Interleukin-2,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,metabolism,therapeutic use","D018414 Q000276 NN,D011409 Q000276 NN,D015496 Q000276 NN,D015375 Q000378 NN,D013110 Q000031 NN,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D007962 Q000276 NN,D011409 Q000627 NY,D006098 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Preoperative administration of FTY720 prolonged renal allograft survival.,"BACKGROUND: FTY729 is an immunomodulator obtained by chemical modification of Myriocin(ISI-1) which exists in the culture filtrate of an ascomycete, Isaria sinclairii. It has been reported that postoperative administration of FTY720 prolonged survival of various kinds of transplanted organs. In the present study, we evaluated the effect of 2-day preoperative administration of FTY 720 on graft survival. MATERIALS AND METHODS: We used a rat renal transplantation model in which Wistar King Aptekman Hokkaido (W",Transplant immunology,"Haruhiko Ueda, Shiro Takahara, Susumu Itoh, Hayahito Nomi, Nobuhisa Shibahara, Yoji Katsuoka"," Department of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. uro002@poh.osaka-med.ac.jp",2005 Mar;14(1):1-8,10.1016/j.trim.2005.01.002
15870184,20050815,article,"xref,mesh","Adoptive Transfer,Animals,Chemotaxis, Leukocyte,Fingolimod Hydrochloride,Immunosuppressive Agents,Integrins,Lymph Nodes,Lymphatic Vessels,Lymphocyte Count,Lymphocytes,Lysophospholipids,Mice,Mice, Knockout,Microscopy, Video,Peyer's Patches,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,deficiency,drug effects,immunology,metabolism,pharmacology,physiology","D007166 Q000494 NY,D002634 Q000187 NY,D013601 Q000502 NY,D011409 Q000276 NN,D002634 Q000502 NN,D013110 Q000031 NY,D008246 Q000276 NN,D011409 Q000494 NY,D013110 Q000172 NN,D013110 Q000276 NN,D008246 Q000172 NN,D008246 Q000502 NY,D007166 Q000276 NN,D016023 Q000378 NN,D013601 Q000187 NN,D013110 Q000502 NN","8252,31270,107969,107970,5280335,5283560,44258291","128394615,129060975,129645792,243214637",The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.,"Sphingosine-1-phosphate (S1P) and its receptor S1P1 control T-cell egress from thymus and secondary lymphoid organs (SLOs). To further define the role of S1P1 in lymphocyte trafficking, we performed adoptive transfer experiments and intravital microscopy (IVM) using both S1P1-/- lymphocytes and recipient wild-type (WT) mice treated with FTY720, an immunosuppressant that downmodulates S1P receptors. S1P1 deficiency and FTY720 caused rapid disappearance of T cells from blood, prolonged retention in SLOs, and ",Blood,"Cornelia Halin, M Lucila Scimone, Roberto Bonasio, Jean-Marc Gauguet, Thorsten R Mempel, Elizabeth Quackenbush, Richard L Proia, Suzanne Mandala, Ulrich H von Andrian"," The CBR Institute for Biomedical Research, 200 Longwood Ave, Boston, MA 02115, USA.",2005 Aug;106(4):1314-22,10.1182/blood-2004-09-3687
15880042,20050515,article,"xref,mesh","Administration, Oral,Animals,Diabetes Mellitus, Type 1,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred NOD,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology,prevention &amp; control,therapeutic use","D003922 Q000276 NN,D007166 Q000627 NN,D011409 Q000008 NN,D013110 Q000031 NN,D003922 Q000517 NY,D003922 Q000188 NY,D011409 Q000627 NY","5793,8252,31270,107969,107970,5280335,91534498","128394615,129060975,129621433,129645792,248766214",Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.,"BACKGROUND: Treatment of nonobese diabetic (NOD) mice with FTY720 before the development of insulitis prevents the onset of diabetes. In this study, the authors investigated whether FTY720 treatment of NOD mice with established insulitis prevents the development of diabetes. METHODS: FTY720 (1 mg/kg) was administered continuously to euglycemic NOD mice starting at 14 or 23 weeks of age. A group of untreated, age-matched NOD mice served as controls. Mice with more than 300 mg/dL blood glucose on three consec",Transplantation,"Takashi Maki, Rita Gottschalk, Norihiko Ogawa, Anthony P Monaco"," The Transplant Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard Institute of Medicine, Boston, MA 02215, USA. tmaki@bidmc.harvard.edu",2005 May;79(9):1051-5,10.1097/01.tp.0000161220.87548.ee
15894589,20050801,article,"xref,mesh","Animals,Antigens, CD,B-Lymphocytes,Cell Movement,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Germinal Center,Immunosuppressive Agents,Injections, Intraperitoneal,Lipopolysaccharides,Lymphocyte Activation,Lymphoid Tissue,Macrophages,Mice,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,cytology,drug effects,metabolism,physiology","D008221 Q000166 NN,D049349 Q000037 NY,D008264 Q000378 NN,D002465 Q000187 NY,D005786 Q000502 NN,D001402 Q000166 NN,D018858 Q000378 NY,D008221 Q000378 NN,D008070 Q000008 NN,D013110 Q000031 NN,D008213 Q000187 NN,D015703 Q000096 NN,D008264 Q000166 NN,D001402 Q000502 NY,D005786 Q000187 NN,D018858 Q000166 NN,D011409 Q000008 NY,D007166 Q000008 NY,D008213 Q000502 NN,D049349 Q000378 NN,D002465 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement.,"FTY720 is an immunosuppressive agent that modulates lymphocyte trafficking. It is phosphorylated in vivo to FTY720-phosphate (FTY-P) and binds to a family of G protein-coupled receptors recognizing sphingosine 1-phosphate (S1P) as the natural ligand. It has previously been reported that FTY-P blocks egress of lymphocytes from the thymus and lymph nodes, resulting in peripheral blood lymphopenia. We now report that FTY-P also causes displacement of marginal zone (MZ) B cells to the splenic follicles, an effe",Journal of leukocyte biology,"Kalpit A Vora, Elizabeth Nichols, Gene Porter, Yan Cui, Carol Ann Keohane, Richard Hajdu, Jeffery Hale, William Neway, Dennis Zaller, Suzanne Mandala"," Department of Immunology, Merck Research Laboratories, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, USA. Kalpit_vora@merck.com",2005 Aug;78(2):471-80,10.1189/jlb.0904487
15906328,20050601,article,"xref,mesh","Animals,Blood-Brain Barrier,Brain,Contrast Media,Dextrans,Encephalomyelitis, Autoimmune, Experimental,Ferrosoferric Oxide,Fingolimod Hydrochloride,Heterocyclic Compounds,Immunohistochemistry,Immunosuppressive Agents,Iron,Macrophages,Magnetic Resonance Imaging,Magnetite Nanoparticles,Organometallic Compounds,Oxides,Propylene Glycols,Rats,Receptors, G-Protein-Coupled,Receptors, Lysophospholipid,Recurrence,Sphingosine","agonists,diagnosis,drug therapy,metabolism,pathology,therapeutic use","D004681 Q000378 NN,D004681 Q000175 NY,D001921 Q000473 NY,D043562 Q000819 NN,D001921 Q000378 NN,D007166 Q000627 NY,D008264 Q000473 NY,D011409 Q000627 NY,D004681 Q000473 NN,D004681 Q000188 NY","8252,14789,31270,107969,107970,4125253,5280335,5460037,10313045,49868115","128394615,129060975,129645792",Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis.,NULL,Journal of magnetic resonance imaging : JMRI,"Martin Bendszus, Guido Stoll",NULL,2005 Jun;21(6):?,10.1002/jmri.20299
15917949,20050501,article,"xref,mesh","Adolescent,Adult,Aged,Cyclosporine,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocyte Count,Lymphocytes,Lymphopenia,Male,Middle Aged,Mycophenolic Acid,Propylene Glycols,Sphingosine,Time Factors","administration &amp; dosage,analogs &amp; derivatives,blood,chemically induced,drug effects,immunology,metabolism,pharmacokinetics","D011409 Q000493 NY,D007166 Q000008 NN,D009173 Q000031 NY,D007166 Q000097 NN,D008214 Q000378 NY,D008231 Q000139 NN,D007166 Q000493 NY,D016572 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D016572 Q000493 NY,D009173 Q000493 NN,D016030 Q000276 NY,D009173 Q000008 NN,D008214 Q000187 NN,D011409 Q000097 NN","2909,4271,4272,8252,31270,62280,107969,107970,446541,5280335,5280754,5281078,5284373,5458585,6435893,6441022,9855081,23665584,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128094727,128394615,129060975,129178479,129645792",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.,"FTY720 is a new and effective immunosuppressive agent, which produces peripheral blood lymphopenia through a lymphocyte homing effect. We investigated the relationship between the dose of FTY720 or blood concentration (pharmacokinetics, PK) and peripheral lymphopenia (pharmacodynamics, PD) in 23 kidney transplant recipients randomized to receive FTY720 (0.25-2.5 mg/day) or mofetil mycophenolate (2 mg/day) in combination with cyclosporine and steroids. FTY720 dose, blood concentrations and lymphocyte counts ",Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,"S I Park, C R Felipe, P G Machado, R Garcia, A Skerjanec, R Schmouder, H Tedesco-Silva, J O Medina-Pestana"," Divisão de Nefrologia, Hospital do Rim e Hipertensão, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil. parksung@hotmail.com",2005 May;38(5):683-94,10.1590/s0100-879x2005000500005
15932724,20050316,article,"xref,mesh","Cell Separation,Cell Survival,Cells, Cultured,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Islets of Langerhans,Propylene Glycols,Sirolimus,Sphingosine,Tacrolimus","analogs &amp; derivatives,cytology,drug effects,pharmacology","D007166 Q000494 NY,D002470 Q000187 NN,D016559 Q000494 NN,D007515 Q000166 NY,D011409 Q000494 NY,D013110 Q000031 NN,D020123 Q000494 NY","5372,8252,31270,107969,107970,445643,5280335,5282315,5284616,6473866,6536850,71668407,90726579,91454826,91534498,134694629","128394615,129060975,129645792,242963342,248184126,248766214",[Study of the effects of immunosuppressive agents on human islet cells in vitro].,OBJECTIVE: To investigate the effects of immunosuppressive agents on insulin secretion of human islet cells in vitro. METHODS: Human islet cells were isolated by the solution of the liberase and purified by Ficoll's density gradient centrifugation and then were exposed to various concentrations of four immunosuppressive agents for 24 hr respectively. Glucose-stimulated insulin secretion during subsequent static incubation was measured using the human insulin ELISA kit. RESULTS: Glucose-stimulated insulin se,Zhonghua yi xue za zhi,"Jin-Quan Cai, Jian-Ming Tan, Wei-Ping Dong, Yu-Fei Wang, Jian-Bo Wang"," Institute of Organ Transplantation, Fuzhou General Hospital, Fuzhou 350025, China.",2005 Mar;85(10):654-6,NULL
15940045,20050615,article,"xref,mesh","Adolescent,Adult,Aged,Biopsy,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Infection,Kidney Transplantation,Middle Aged,Mycophenolic Acid,Postoperative Complications,Propylene Glycols,Safety,Sphingosine,Time Factors,Treatment Outcome","analogs &amp; derivatives,blood,classification,epidemiology,immunology,pathology,therapeutic use,toxicity","D007239 Q000453 NN,D007166 Q000627 NN,D011183 Q000453 NN,D009173 Q000031 NY,D007166 Q000097 NN,D011183 Q000145 NN,D013110 Q000031 NN,D007166 Q000633 NN,D006084 Q000473 NN,D016030 Q000276 NY,D009173 Q000627 NN,D011409 Q000633 NN,D011409 Q000627 NY,D006084 Q000453 NN,D011409 Q000097 NN","4271,4272,8252,31270,105065,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129178479,129645792,136111139","FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.","BACKGROUND: FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation. METHODS: This phase 2a, multicenter, open-label, dose-finding study compared FTY720 (0.25, 0.5, 1.0, or 2.5 mg) with mycophenolate mofetil (MMF), in combination with cyclosporine and corticosteroids.",Transplantation,"Helio Tedesco-Silva, Georges Mourad, Barry D Kahan, Josep Grinyo Boira, Willem Weimar, Shamkant Mulgaonkar, Björn Nashan, Soren Madsen, Bernard Charpentier, Pascale Pellet, Yves Vanrenterghem"," Hospital do Rim e Hipertensao, Sao Paulo 04038-002, Brazil. heliotedesco@hrim.com.br",2005 Jun;79(11):1553-60,10.1097/01.tp.0000121761.02129.a6
15946263,20050701,article,xref,"Animals,Calcification, Physiologic,Calcium Hydroxide,Dogs,Extravasation of Diagnostic and Therapeutic Materials,Inflammation,Root Canal Filling Materials,Statistics, Nonparametric,Tooth Apex,Wound Healing","administration &amp; dosage,adverse effects,drug effects,growth &amp; development,pharmacology,prevention &amp; control","D014945 Q000187 NY,D007249 Q000517 NN,D019227 Q000187 NY,D002126 Q000008 NY,D012387 Q000494 NY,D012387 Q000009 NN,D002113 Q000187 NY,D019227 Q000254 NN,D002126 Q000009 NN",7858,129755920,The effect of the renewal of calcium hydroxide paste on the apexification and periapical healing of teeth with incomplete root formation.,"AIM: To evaluate the influence of renewing calcium hydroxide paste on apexification and periapical healing of teeth in dogs with incomplete root formation and previously contaminated canals. METHODOLOGY: Forty premolars from four 6-month-old dogs were used. After access to the root canals and complete removal of the pulp, the canal systems remained exposed to the oral environment for 2 weeks. Canal preparation was then carried out using Hedströem files, under irrigation with 1% sodium hypochlorite, 1 mm sho",International endodontic journal,"M C S Felippe, W T Felippe, M M Marques, J H Antoniazzi"," Discipline of Endodontics, Faculty of Dentistry, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil. mcsfelippe@hotmail.com",2005 Jul;38(7):436-42,10.1111/j.1365-2591.2005.00959.x
15951022,20051201,review,"xref,mesh","Animals,Autoimmune Diseases,Calcineurin Inhibitors,Clinical Trials as Topic,Disease Models, Animal,Drug Synergism,Fingolimod Hydrochloride,Graft vs Host Disease,Humans,Immunosuppressive Agents,Lymph Nodes,Lymphocytes,Peyer's Patches,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Spleen,T-Lymphocytes,Thymus Gland","agonists,analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D013601 Q000276 NN,D049349 Q000819 NY,D008198 Q000276 NN,D008214 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013950 Q000276 NN,D010581 Q000276 NN,D013154 Q000276 NN,D008214 Q000276 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335,57317596,90726579","128394615,129060975,129645792,136314073,242963342","FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.","FTY720 is the first of a new immunomodulator class: sphingosine 1-phosphate (S1P) receptor agonist. In 1994, an immunosuppressive natural product, ISP-I (myriocin), was isolated from the culture broth of Isaria sinclairii, a type of vegetative wasp. The chemical modification of ISP-I yielded a new compound, FTY720, which has more potent immunosuppressive activity and less toxicity than ISP-I does. FTY720 has been shown to be highly effective in experimental allotransplantation models and autoimmune disease ",Pharmacology & therapeutics,Kenji Chiba," Research Laboratory III (Immunology), Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Japan. Chiba.Kenji@mk.m-pharm.co.jp",2005 Dec;108(3):308-19,10.1016/j.pharmthera.2005.05.002
15970369,20050915,article,"xref,mesh","Animals,Cyclophosphamide,Cyclosporine,Drug Synergism,Everolimus,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Macaca fascicularis,Male,Methotrexate,Mycophenolic Acid,Organ Transplantation,Papio,Propylene Glycols,Sirolimus,Sphingosine","analogs &amp; derivatives,pharmacology,toxicity,veterinary","D008727 Q000494 NN,D003520 Q000494 NN,D016377 Q000662 NN,D003520 Q000633 NY,D009173 Q000494 NN,D013110 Q000031 NN,D020123 Q000494 NN,D016572 Q000494 NN,D011409 Q000494 NN,D007166 Q000494 NN,D008727 Q000633 NY,D020123 Q000031 NN,D007166 Q000633 NY","2907,2909,4112,4272,8252,22420,31270,62280,107969,107970,126941,165528,446541,5280335,5280754,5281078,5284373,5284616,5458585,6435893,6441022,6442177,9855081,11329481,23665584,23678981,24883466,24906323,25246316,49867938,71306795,71463825,73896891,90696889,91534498,122172945,123134263,123134270,132274082","128094727,128394615,129060975,129645792,242749350,248766214",Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.,"Transplantation in nonhuman primates, in particular using solid organs from porcine donors, requires an efficacious induction immunosuppression. Besides biologicals, the low molecular weight drugs used include cyclophosphamide (CyP) and methotrexate (MTX). As these compounds generally have a narrow therapeutic window, we performed tolerability studies in baboons and cynomolgus monkeys, with/without maintenance immunosuppressants such as cyclosporine A, everolimus, mycophenolate sodium and FTY720. In both sp",Toxicology,"Henk-Jan Schuurman, Harold T Smith, Emanuele Cozzi"," Imutran Ltd. (A Novartis Pharma AG Company), Cambridge CB2 2YP, UK. henkjan.schuurman@numico-research.nl",2005 Sep;213(?):1-12,10.1016/j.tox.2005.03.017
15973172,20050627,article,"xref,mesh","Animals,Antibodies, Monoclonal,Fingolimod Hydrochloride,Flow Cytometry,Graft Rejection,Graft Survival,Immunosuppressive Agents,Intestine, Small,Lymphocytes,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,therapeutic use,transplantation","D006085 Q000187 NN,D007421 Q000187 NN,D000911 Q000276 NN,D000911 Q000627 NN,D013110 Q000031 NN,D007421 Q000637 NY,D007166 Q000627 NY,D006085 Q000276 NN,D008214 Q000276 NN,D014184 Q000276 NY,D006084 Q000276 NN,D008214 Q000187 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Protection of mouse small bowel allografts by FTY720 and costimulation blockade.,"BACKGROUND: The clinical application of small bowel transplantation (SBTx) is hampered by its pronounced immunogenicity. We aimed to test the hypothesis that prolonged sequestration of lymphocytes in secondary lymphoid organs may enhance the alloprotective effect of costimulation blockade. METHODS: For this purpose, recipients of intestinal allografts were treated with MR1, FTY720, combined FTY720 plus MR1, or were left untreated. Grafts were examined 6 and 14 days after transplantation by applying a histol",Transplantation,"Sheng Yan, Jose-Ignacio Rodriguez-Barbosa, Oliver Pabst, Jan H Beckmann, Volker Brinkmann, Reinhold Förster, Matthias W Hoffmann"," Department of Surgery, The 1st Affiliated Hospital of Zhejiang University, Zhejiang, China.",2005 Jun;79(12):1703-10,10.1097/01.tp.0000164501.65352.39
15982878,20050801,article,"xref,mesh,assay","Animals,Benzimidazoles,Binding Sites,Bradycardia,CHO Cells,Cricetinae,Fingolimod Hydrochloride,Immunosuppressive Agents,Lethal Dose 50,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Structure-Activity Relationship","agonists,analogs &amp; derivatives,chemical synthesis,drug therapy,metabolism,pharmacology","D008246 Q000494 NN,D001919 Q000188 NN,D049349 Q000819 NY,D008246 Q000138 NY,D011409 Q000138 NY,D013110 Q000031 NY,D013110 Q000138 NN,D001562 Q000138 NY,D001562 Q000494 NN,D007166 Q000138 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560,9908268,10019486,44398011,44398057,44398093,44398124,44398169,44398171,45263213,45263215,45265686","128394615,129060975,129645792,136111139",Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.,"The novel immunosuppressant FTY720 has been demonstrated to elicit immunomodulating effects via interaction with the G-protein coupled receptor S1P(1). FTY720 induced agonism at the S1P(3) receptor, however, has been shown to result in mild bradycardia, a minor side-effect of initial FTY720 therapy. This report describes the synthesis of several potent 4(5)-phenylimidazole-based S1P(1) receptor agonists that are accompanied by poor agonist activity at S1P(3). For instance, compound 20 displayed an EC(50)=4.",Bioorganic & medicinal chemistry letters,"Jeremy J Clemens, Michael D Davis, Kevin R Lynch, Timothy L Macdonald"," Department of Chemistry, University of Virginia, Charlottesville, VA, USA. clemens@chem.ucla.edu",2005 Aug;15(15):3568-72,10.1016/j.bmcl.2005.05.097
16034547,20050101,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Lymphatic Diseases,Lymphocyte Count,Lymphocytes,Lymphoid Tissue,Lymphopenia,Male,Mice,Propylene Glycols,Skin Transplantation,Sphingosine,Splenectomy,T-Lymphocytopenia, Idiopathic CD4-Positive","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,etiology,immunology,pharmacology","D007166 Q000494 NY,D011409 Q000009 NN,D018344 Q000139 NN,D008221 Q000187 NY,D018344 Q000209 NN,D016038 Q000276 NN,D008231 Q000139 NN,D008231 Q000209 NY,D008214 Q000187 NY,D011409 Q000494 NY,D013110 Q000031 NN,D007166 Q000009 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs.","PURPOSE: FTY720 is a novel immunosuppressive agent that is thought to reduce the number of peripheral blood lymphocytes (PBL) by directing them toward secondary lymphoid organs such as the lymph nodes and Peyer's patches. We studied the effects of FTY720 on aly/aly mice that do not have either lymph nodes or Peyer's patches, as well as on splenectomized aly/aly mice. METHODS: FTY720 was orally administered by gavage (1 mg/kg) to aly/aly mice as well as to aly/+ mice with and without a splenectomy on 14 cons",Surgery today,"Kiminobu Sugito, Tsugumichi Koshinaga, Mikiya Inoue, Taro Ikeda, Noritsugu Hagiwara, Masahiro Fukuzawa"," Division of Pediatric Surgery, Department of Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan.",2005 Jan;35(8):662-7,10.1007/s00595-005-3011-x
16093248,20051104,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Flow Cytometry,Homozygote,Immunosuppressive Agents,Lymphocytes,Lymphopenia,Lysophospholipids,Mice,Mice, Inbred C57BL,Mice, Knockout,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Prodrugs,Propylene Glycols,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine","analogs &amp; derivatives,chemically induced,drug effects,enzymology,genetics,metabolism,physiology,toxicity","D008214 Q000201 NY,D011409 Q000633 NY,D007166 Q000378 NN,D017853 Q000235 NN,D011355 Q000633 NN,D008214 Q000187 NY,D013110 Q000378 NN,D013110 Q000031 NN,D017853 Q000502 NY,D011355 Q000378 NN,D008246 Q000378 NN,D010766 Q000187 NN,D008231 Q000139 YN,D008231 Q000201 YN,D011409 Q000378 NN,D007166 Q000633 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.,"Immunotherapeutic drugs that mimic sphingosine 1-phosphate (S1P) disrupt lymphocyte trafficking and cause T helper and T effector cells to be retained in secondary lymphoid tissue and away from sites of inflammation. The prototypical therapeutic agent, 2-alkyl-2-amino-1,3-propanediol (FTY720), stimulates S1P signaling pathways only after it is phosphorylated by one or more unknown kinases. We generated sphingosine kinase 2 (SPHK2) null mice to demonstrate that this kinase is responsible for FTY720 phosphory",The Journal of biological chemistry,"Yugesh Kharel, Sangderk Lee, Ashley H Snyder, Stacey L Sheasley-O'neill, Margaret A Morris, Yulius Setiady, Ran Zhu, Molly A Zigler, Tracy L Burcin, Klaus Ley, Kenneth S K Tung, Victor H Engelhard, Timothy L Macdonald, Sonia Pearson-White, Kevin R Lynch"," Department of Pharmacology, University of Virginia, Charlottesville, Virginia 22908, USA.",2005 Nov;280(44):36865-72,10.1074/jbc.m506293200
16103102,20050815,article,"xref,mesh","Antineoplastic Agents,Apoptosis,Bone Marrow Cells,Caspases,Cell Growth Processes,Coculture Techniques,Drug Resistance, Neoplasm,Fingolimod Hydrochloride,Immunosuppressive Agents,Insulin-Like Growth Factor I,Interleukin-6,Membrane Potentials,Mitochondria,Multiple Myeloma,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Signal Transduction,Sphingosine,Stromal Cells,bcl-2-Associated X Protein","analogs &amp; derivatives,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology,physiology","D000970 Q000494 NY,D008928 Q000187 NN,D019253 Q000378 NN,D017209 Q000187 NY,D048708 Q000502 NN,D007334 Q000494 NN,D009101 Q000473 NN,D017209 Q000502 NN,D009101 Q000188 NY,D011409 Q000494 NY,D017154 Q000166 NN,D008928 Q000502 NN,D013110 Q000031 NN,D008564 Q000187 NN,D015850 Q000494 NN,D020169 Q000378 NN,D015398 Q000187 NN,D007166 Q000494 NN,D001854 Q000166 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.,"The novel immunomodulator FTY720 down-modulates sphingosine-1-phosphate receptor 1 on lymphocytes at low nanomolar concentrations, thereby inhibiting sphingosine-1-phosphate receptor 1-dependent egress of lymphocytes from lymph nodes into efferent lymphatics and blood. At high micromolar concentration, FTY720 has been shown to induce growth inhibition and/or apoptosis in human cancer cells in vitro. In this study, we investigated the biological effects of FTY720 on multiple myeloma cells. We found that FTY7",Cancer research,"Hiroshi Yasui, Teru Hideshima, Noopur Raje, Aldo M Roccaro, Norihiko Shiraishi, Shaji Kumar, Makoto Hamasaki, Kenji Ishitsuka, Yu-Tzu Tai, Klaus Podar, Laurence Catley, Constantine S Mitsiades, Paul G Richardson, Rainer Albert, Volker Brinkmann, Dharminder Chauhan, Kenneth C Anderson"," Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.",2005 Aug;65(16):7478-84,10.1158/0008-5472.can-05-0850
16118221,20051007,article,"xref,mesh","Aldehyde-Lyases,Animals,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Mice,Propylene Glycols,Sphingosine,Tissue Distribution","analogs &amp; derivatives,analysis,antagonists &amp; inhibitors,drug effects,metabolism,pharmacology","D008246 Q000032 NN,D007166 Q000494 NY,D013110 Q000032 NN,D011409 Q000494 NY,D013110 Q000378 NN,D013110 Q000031 NN,D000446 Q000378 NY,D000446 Q000037 NY,D005786 Q000187 NN,D008246 Q000378 NN,D008214 Q000187 NN","8252,31270,105065,107969,107970,5280335,5283560,57024517","128394615,129060975,129645792,135812730,136111139",The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.,"FTY720 is a novel immunomodulatory agent that inhibits lymphocyte trafficking and prevents allograft rejection. FTY720 is phosphorylated in vivo, and the phosphorylated drug acts as agonist for a family of G protein-coupled receptors that recognize sphingosine 1-phosphate. Evidence suggests that FTY720-phosphate-induced activation of S1P1 is responsible for its mechanism of action. FTY720 was rationally designed by modification of myriocin, a naturally occurring sphingoid base analog that causes immunosuppr",The Journal of biological chemistry,"Padmavathi Bandhuvula, Yuen Yee Tam, Babak Oskouian, Julie D Saba"," Children's Hospital Oakland Research Institute, Oakland, California 94609-1673, USA.",2005 Oct;280(40):33697-700,10.1074/jbc.c500294200
16129068,20050801,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,physiology","D013601 Q000502 NY,D013601 Q000276 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000502 NY,D049349 Q000502 NY,D011409 Q000494 NN,D008246 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013601 Q000187 NN,D013110 Q000502 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",[Effects of sphingosine 1-phosphate on functions of T cell - review].,"Sphingosine 1-phosphate (S1P), a bioactive lipid produced by metabolism of sphingolipid, plays an important roles in the regulation of various biological responses. T cell expresses the S1P receptors, including S1P1, S1P2, S1P3, S1P4 and S1P5. Activation of S1P signal regulates multiple immunological functions of T cell, including proliferation, apoptosis, differentiation, migration and cytokine excretion. FTY720, a sphingosine analog, suppresses the S1P signal resulting in redistribution of lymphocytes fro",Zhongguo shi yan xue ye xue za zhi,"Wen-Rong Huang, Li-Sheng Wang, Wan-Ming DA"," Department of Hematology, PLA General Hospital, Beijing 100853, China.",2005 Aug;13(4):718-22,NULL
16144412,20050914,article,"xref,mesh","Alkenes,Amination,Aniline Compounds,Catalysis,Crystallography, X-Ray,Models, Molecular,Molecular Structure,Organometallic Compounds,Platinum,Sulfonamides","chemical synthesis,chemistry","D010984 Q000737 NY,D000475 Q000737 NY,D000814 Q000737 NY,D000475 Q000138 NN,D009942 Q000737 NY,D013449 Q000737 NY","6115,6269,8079,8252,8870,23939,68330,6452955,13000444,13129031,69911550","128055920,128512369,128889888,129060975,129473051",Platinum-based catalysts for the hydroamination of olefins with sulfonamides and weakly basic anilines.,"Electrophilic Pt(II) complexes catalyze efficient hydroaminations of olefins by sulfonamides and weakly basic anilines. Catalysts include the structurally characterized complex (COD)Pt(OTf)2 (1) and the known dimer [PtCl2(C2H4)]2, activated by AgBF4. Experiments with substituted anilines establish an empirical pKa cutoff (conjugate acid pKa < 1) for the participation of nitrogen-containing substrates in this catalysis. Arylsulfonamides (conjugate acid pKa approximately -6) with various para substituents hyd",Journal of the American Chemical Society,"Dmitry Karshtedt, Alexis T Bell, T Don Tilley"," Department of Chemistry and Chemical Engineering, University of California, Berkeley, Berkeley, California 94720, USA.",2005 Sep;127(36):12640-6,10.1021/ja052836d
16150998,20050909,article,"xref,mesh","Aldehyde-Lyases,Animals,Cell Movement,Chemotaxis, Leukocyte,Diet,Enzyme Inhibitors,Fingolimod Hydrochloride,Food Coloring Agents,Imidazoles,Immunosuppressive Agents,Lymphoid Tissue,Lysophospholipids,Mice,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,blood,immunology,metabolism,pharmacology,physiology","D013110 Q000097 NN,D005505 Q000494 NN,D005505 Q000008 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000097 NN,D008246 Q000378 NY,D000446 Q000037 NY,D013601 Q000502 NN,D013601 Q000276 NY,D007093 Q000008 NN,D011409 Q000494 NN,D004791 Q000494 NN,D000446 Q000378 NN,D007093 Q000494 NY,D007166 Q000494 NN,D008221 Q000276 NN,D049349 Q000378 NN","8252,31270,107969,107970,108037,180624,5280335,5283560","128394615,129060975,129645792",Immunology. Dietary factors and immunological consequences.,NULL,"Science (New York, N.Y.)",Timothy Hla," Center for Vascular Biology, Department of Cell Biology, University of Connecticut Health Center, Farmington, CT 06030, USA. hla@nso2.uchc.edu",2005 Sep;309(5741):1682-3,10.1126/science.1118340
16170036,20050901,article,"xref,mesh","Animals,Antineoplastic Agents, Hormonal,Apoptosis,Carcinoma, Hepatocellular,Cell Proliferation,Endothelium, Vascular,Fingolimod Hydrochloride,Flow Cytometry,G1 Phase,Humans,Liver Neoplasms,Male,Mice,Mice, Inbred BALB C,Mice, Nude,Microcirculation,Neovascularization, Pathologic,Propylene Glycols,Sphingosine,Transplantation, Heterologous,Umbilical Veins,Wounds and Injuries","analogs &amp; derivatives,blood supply,cytology,drug effects,drug therapy,immunology,pharmacology,prevention &amp; control,therapeutic use","D017209 Q000187 NN,D004730 Q000166 NN,D014471 Q000187 NN,D006528 Q000188 NY,D008113 Q000098 NY,D004730 Q000187 NN,D006528 Q000276 NN,D008113 Q000188 NY,D049109 Q000187 NN,D008113 Q000276 NN,D014471 Q000166 NN,D013110 Q000031 NN,D006528 Q000098 NY,D018931 Q000494 NY,D009389 Q000517 NY,D016193 Q000187 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma.","In this study, we aimed to evaluate the potential anticancer and antiangiogenic effects of FTY720 on hepatocellular carcinoma. In vitro, chemosensitivity was tested on hepatoma cells, nontumorigenic, immortalized hepatocyte cells, as well as human umbilical vein endothelial cells (HUVEC). Moreover, effect of FTY720 on cell cycle and apoptosis was analyzed. In addition, a number of angiogenesis-associated assays were carried out. The in vivo effect of the drug on hepatocellular carcinoma tumor growth on nude",Molecular cancer therapeutics,"Joanna W Y Ho, Kwan Man, Chris K Sun, Terence K Lee, Ronnie T P Poon, Sheung Tat Fan"," Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Queen Mary Hospital, China.",2005 Sep;4(9):1430-8,10.1158/1535-7163.mct-05-0021
16176922,20050101,article,"xref,mesh","Acrylates,Administration, Topical,Animals,Carcinogenicity Tests,Dose-Response Relationship, Drug,Epidermis,Female,Genes, ras,Hyperplasia,Inflammation,Liver,Male,Mice,Mice, Transgenic,Necrosis,Papilloma,Precancerous Conditions,Propylene Glycols,Rats,Rats, Inbred F344,Sex Factors,Skin,Skin Neoplasms,Stomach Neoplasms,Time Factors","administration &amp; dosage,chemically induced,drug effects,genetics,pathology,toxicity","D010212 Q000235 NN,D012878 Q000139 NY,D008099 Q000473 NN,D011230 Q000139 NY,D013274 Q000473 NN,D011409 Q000633 NY,D004817 Q000473 NN,D012878 Q000473 NN,D004817 Q000187 NN,D011409 Q000008 NN,D011230 Q000235 NN,D013274 Q000139 NY,D012867 Q000473 NN,D010212 Q000473 NN,D012878 Q000235 NN,D010212 Q000139 NY,D013274 Q000235 NN,D011230 Q000473 NN,D000179 Q000008 NN,D008099 Q000187 NN,D012867 Q000187 NN,D000179 Q000633 NY","8252,19042,27423,88240,25019176","127706156,128120594,128685403,129060975","Topical application of representative multifunctional acrylates produced proliferative and inflammatory lesions in F344/N rats and B6C3F1 mice, and squamous cell neoplasms in Tg.AC mice.","Widespread human exposure to multifunctional acrylates is of concern, due to their inherent reactivity and irritating properties. Trimethylolpropane triacrylate (TMPTA) and pentaerythritol triacrylate (PETA) are industrially important representatives of multifunctional acrylates. The current studies characterized the toxicity of 3-month topical administration of technical grade TMPTA and PETA in F344/N rats and B6C3F1 mice, and evaluated the carcinogenic potential of TMPTA and PETA in hemizygous Tg.AC (v-Ha",Toxicologic pathology,"Adriana M Doi, James R Hailey, Milton Hejtmancik, John D Toft, Molly Vallant, Rajendra S Chhabra"," National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.",2005 Jan;33(6):631-40,10.1080/01926230500295615
16212624,20051101,article,"xref,mesh","Animals,Apoptosis,B-Lymphocytes,Cell Adhesion Molecules,Cell Differentiation,DNA Primers,Dendritic Cells,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Depletion,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Oxadiazoles,Polymerase Chain Reaction,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes,Thiophenes","agonists,analogs &amp; derivatives,cytology,drug effects,genetics,immunology,pharmacology,physiology","D007166 Q000494 NY,D003713 Q000187 NN,D013601 Q000276 NN,D049349 Q000819 NY,D010069 Q000494 NN,D049349 Q000235 NN,D001402 Q000187 NN,D003713 Q000502 NY,D003713 Q000166 NN,D011409 Q000494 NY,D013110 Q000031 NN,D001402 Q000276 NN,D013876 Q000494 NN,D013601 Q000187 NN,D015815 Q000502 NN","8252,31270,105065,107969,107970,4077460,5280335,10523409","128394615,129060975,129645792,136111139",The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo.,"The pro-drug FTY720 is undergoing phase III clinical trials for prevention of allograft rejection. After phosphorylation, FTY720 targets the G protein-coupled-sphingosine-1-phosphate receptor 1 (S1PR1) on lymphocytes, thereby inhibiting their egress from lymphoid organs and their recirculation to inflammatory sites. Potential effects on dendritic cell (DC) trafficking have not been evaluated. Here, we demonstrate the expression of all five S1PR subtypes (S1PR1-5) by murine DCs. Administration of FTY720 to C",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"Yuk Yuen Lan, An De Creus, Bridget L Colvin, Masanori Abe, Volker Brinkmann, P Toby H Coates, Angus W Thomson"," Thomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.",2005 Nov;5(11):2649-59,10.1111/j.1600-6143.2005.01085.x
16223773,20060215,article,"xref,mesh","Animals,Cell Movement,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Kinetics,Lymphocytes,Mice,Mice, Knockout,Phosphates,Phosphotransferases (Alcohol Group Acceptor),Polymerase Chain Reaction,Propylene Glycols,RNA, Messenger,Sphingosine","analogs &amp; derivatives,deficiency,drug effects,enzymology,genetics,immunology,metabolism,pharmacology,physiology","D008214 Q000201 NN,D012333 Q000235 NN,D007166 Q000494 NY,D002465 Q000187 NN,D010710 Q000378 NN,D017853 Q000235 NN,D008214 Q000502 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008214 Q000276 NN,D017853 Q000378 NY,D017853 Q000172 NN,D013110 Q000494 NN,D008214 Q000187 NN","1061,8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.,"FTY720, a potent immunomodulatory drug in phase 2/3 clinical trials, induces rapid and reversible sequestration of lymphocytes into secondary lymphoid organs, thereby preventing their migration to sites of inflammation. As prerequisite for its function, phosphorylation of FTY720 to yield a potent agonist of the sphingosine-1-phosphate receptor S1P(1) is required in vivo, catalyzed by an as-yet-unknown kinase. Here, we report on the generation of sphingosine kinase 2 (SPHK2) knockout mice and demonstrate tha",Blood,"Barbara Zemann, Bernd Kinzel, Matthias Müller, Roland Reuschel, Diana Mechtcheriakova, Nicole Urtz, Frédéric Bornancin, Thomas Baumruker, Andreas Billich"," Novartis Institutes for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna, Austria.",2006 Feb;107(4):1454-8,10.1182/blood-2005-07-2628
16236505,20060101,article,"xref,mesh,assay","Calcium,Cell Line,Cells, Cultured,Dose-Response Relationship, Drug,Endothelium, Vascular,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Lysophospholipids,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Models, Chemical,Oxadiazoles,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Binding,Receptors, Lysosphingolipid,Recombinant Proteins,Sphingosine,Substrate Specificity,Time Factors","agonists,analogs &amp; derivatives,chemistry,cytology,metabolism,pharmacology","D007166 Q000494 NY,D010069 Q000494 NY,D049349 Q000819 NN,D004730 Q000166 NN,D010069 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D004730 Q000378 NN,D019950 Q000378 NN,D002118 Q000378 NN,D017853 Q000737 NN,D011994 Q000737 NN,D008246 Q000737 NN,D048052 Q000378 NN,D013110 Q000494 NN","8252,27814,31270,107969,107970,5280335,5460341,6337033,6857804,10523409,10904818,11678855,44405969,44405979,44406004,44406009,44406062,44406063,44406749","128394615,129060975,129645792,129884218",NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.,"Fluorescently labeled chiral analogs of the immunomodulatory drug FTY720 and its corresponding phosphates with variable aliphatic spacers between the aromatic ring and the NBD label have been synthesized. Determining the influence of the spacer on the in vitro phosphorylation rate by SPHK1 and 2 resulted in the identification of NBD-(R)-AAL 1c,d which are phosphorylated with an efficiency comparable to that of the unlabeled FTY720 analog (R)-AAL. Furthermore, the NBD-(R)-AAL phosphates 10c,d were proven to ",Bioorganic & medicinal chemistry letters,"Peter Ettmayer, Thomas Baumruker, Danilo Guerini, Diana Mechtcheriakova, Peter Nussbaumer, Markus B Streiff, Andreas Billich"," Novartis Institutes for BioMedical Research, Brunnerstrasse 59, A-1230 Vienna, Austria. peter.ettmayer@vie.boehringer-ingelheim.com",2006 Jan;16(1):84-7,10.1016/j.bmcl.2005.09.038
16239360,20051101,article,"xref,mesh","Adult,Aged,Cyclosporine,Dose-Response Relationship, Drug,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Middle Aged,Models, Biological,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,blood,pharmacokinetics","D011409 Q000493 NY,D007166 Q000008 NN,D013110 Q000008 NN,D007166 Q000493 NY,D013110 Q000031 NY,D011409 Q000008 NN,D016572 Q000493 NN,D013110 Q000493 NN,D016572 Q000097 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792","FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.","The pharmacokinetics, safety, and preliminary efficacy of FTY720, a novel immunomodulator, were examined in de novo renal transplant patients. Both noncompartmental and population methods were used to estimate pharmacokinetic estimates in the patients. The steady-state plasma concentrations of FTY720 increased in accordance with maintenance dose level, indicating linearity in clearance and volume of distribution over the 0.25- to 2.5-mg dose range. The pharmacokinetics of FTY720 in de novo renal transplant ",Journal of clinical pharmacology,"Andrej Skerjanec, Helio Tedesco, Hans-H Neumayer, Edward Cole, Klemens Budde, Chyi-Hung Hsu, Robert Schmouder"," Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA. andrej.skerjanec@novartis.com",2005 Nov;45(11):1268-78,10.1177/0091270005279799
16285007,20051201,article,"xref,mesh","Animals,Cell Movement,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymph Nodes,Lymphoid Tissue,Lymphopenia,Male,Mice,Mice, Inbred C57BL,Models, Biological,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,chemically induced,cytology,drug effects,immunology,pathology,pharmacology","D008221 Q000166 NN,D007166 Q000494 NY,D002465 Q000187 NY,D008231 Q000276 NN,D008231 Q000139 NY,D008198 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002465 Q000276 NN,D008231 Q000473 NN,D013601 Q000166 NN,D013601 Q000187 NY,D008198 Q000187 NY,D008198 Q000166 NN,D008221 Q000187 NN,D013110 Q000494 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.,"FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is an orally available immunomodulatory agent that induces severe peripheral blood lymphopenia. Most studies of these lymphopenic effects have been limited to short-term exposure to FTY720. FTY720 alters the ability of lymphocytes to respond to sphingosine-1-phosphate (S1P) through S1P receptors, particularly S1P1. FTY720 affects different leukocyte populations and their trafficking through major lymphoid organs. We show the dynamics ",European journal of immunology,"Margaret A Morris, David R Gibb, Franck Picard, Volker Brinkmann, Marty Straume, Klaus Ley"," Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22908, USA.",2005 Dec;35(12):3570-80,10.1002/eji.200526218
16299553,20060101,article,"xref,mesh","Animals,Cells, Cultured,Collagen Type IV,Connective Tissue Growth Factor,Fibrosis,Fingolimod Hydrochloride,Glomerular Mesangium,Immediate-Early Proteins,Immunosuppressive Agents,Intercellular Signaling Peptides and Proteins,MAP Kinase Signaling System,Male,Phosphorylation,Propylene Glycols,Rats,Rats, Sprague-Dawley,Signal Transduction,Smad Proteins,Smad1 Protein,Smad2 Protein,Smad3 Protein,Sphingosine,Transforming Growth Factor beta,Up-Regulation","analogs &amp; derivatives,biosynthesis,cytology,drug effects,metabolism,pharmacology,physiology","D051785 Q000502 NY,D016212 Q000502 NN,D007166 Q000494 NY,D051898 Q000378 NN,D051785 Q000378 NN,D007166 Q000378 NN,D005920 Q000187 NY,D051900 Q000378 NN,D017874 Q000096 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D005920 Q000378 NN,D024141 Q000096 NY,D005920 Q000166 NN,D020935 Q000502 NN,D013110 Q000494 NN,D011409 Q000378 NN,D036341 Q000096 NY,D051899 Q000378 NN","5361,8252,31270,107969,107970,5280335,56842206","127850182,128394615,129060975,129645792",The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.,"1.--The immunomodulating agent FTY720 is a substrate for the sphingosine kinase and the phosphorylated form is able to bind to sphingosine 1-phosphate (S1P) receptors. In this study, we show that exposure of renal mesangial cells to phospho-FTY720 leads to a rapid and transient activation of several protein kinase cascades, including the mitogen- and stress-activated protein kinases. The nonphosphorylated FTY720 also increased MAPK phosphorylation, but with a reduced potency and a more delayed time course. ",British journal of pharmacology,"Cuiyan Xin, Shuyu Ren, Wolfgang Eberhardt, Josef Pfeilschifter, Andrea Huwiler"," Pharmazentrum frankfurt Izafes, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.",2006 Jan;147(2):164-74,10.1038/sj.bjp.0706452
16301618,20051201,article,"xref,mesh","Animals,Cell Communication,Endothelial Cells,Endothelium, Lymphatic,Endothelium, Vascular,Female,Fingolimod Hydrochloride,Fluorescent Antibody Technique,Immunosuppressive Agents,Lymph Nodes,Lymphocytes,Macrophages,Mesentery,Mice,Mice, Inbred C57BL,Microscopy, Electron, Transmission,Microscopy, Immunoelectron,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Tight Junctions","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,ultrastructure","D008214 Q000276 NY,D004729 Q000648 NN,D007166 Q000494 NY,D008214 Q000378 NN,D008264 Q000378 NN,D004729 Q000187 NN,D004730 Q000648 NN,D004730 Q000187 NN,D008198 Q000187 NN,D008264 Q000276 NY,D019108 Q000276 NN,D008198 Q000276 NY,D011409 Q000494 NY,D042783 Q000187 NN,D013110 Q000031 NN,D042783 Q000276 NN,D008264 Q000187 NN,D049349 Q000187 NN,D042783 Q000648 NN,D008643 Q000276 NN,D002450 Q000276 NN,D049349 Q000276 NY,D008214 Q000187 NN,D019108 Q000648 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.","The sphingosine-1-phosphate (S1P) receptor agonist, phosphorylated FTY720 (FTY-P), causes lymphopenia, lymphocyte sequestration in mesenteric lymph nodes (MLNs), and immunosuppression. Using multiple techniques to analyze MLN cells harvested from mice treated with S1P receptor agonists, we saw a redistribution of lymphocytes out of nodal sinuses and an expansion of follicles. Although changes in circulating monocytes were not observed with overnight exposure to FTY720, we saw a significant increase in S1P r","Journal of immunology (Baltimore, Md. : 1950)","Irwin I Singer, Min Tian, L Alexandra Wickham, Jeffrey Lin, Scaria S Matheravidathu, Michael J Forrest, Suzanne Mandala, Elizabeth J Quackenbush"," Immunology and Rheumatology, Merck and Co., Inc., Merck Research Laboratories, Rahway, NJ 07065, USA. Irwin_Singer@Merck.com",2005 Dec;175(11):7151-61,10.4049/jimmunol.175.11.7151
16314802,20051115,article,"xref,mesh","Angiotensin II,Animals,Chronic Disease,Cyclosporine,Extracellular Matrix Proteins,Fibrosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Kidney Diseases,Lymphocytes,Macrophages,Male,Osteopontin,Propylene Glycols,RNA, Messenger,Rats,Rats, Sprague-Dawley,Sialoglycoproteins,Sphingosine,T-Lymphocytes,Transforming Growth Factor beta,Transforming Growth Factor beta1","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,genetics,metabolism,pathology,pharmacology,prevention &amp; control","D007674 Q000473 NN,D007166 Q000494 NY,D007674 Q000378 NN,D016572 Q000009 NY,D007674 Q000517 NY,D007668 Q000473 NN,D012795 Q000235 NN,D000804 Q000378 NN,D011409 Q000494 NY,D008264 Q000473 NN,D013110 Q000031 NN,D016212 Q000378 NN,D012333 Q000378 NN,D007674 Q000139 NY,D013601 Q000473 NN,D007166 Q000009 NY,D016212 Q000235 NN,D016326 Q000378 NN,D008214 Q000187 NN","2909,8252,25476,31270,62280,107969,107970,172198,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,56842206,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129645792",Effect of FTY720 on chronic cyclosporine nephropathy in rats.,"BACKGROUND: Long-term treatment with cyclosporine A (CsA) causes tubulointerstitial inflammation and fibrosis in the kidney. To define the role of lymphocytes in this process, the novel lymphocyte-specific inhibitor FTY720 was administered to rats with experimental model of chronic CsA nephropathy. METHODS: Sprague-Dawley rats were treated daily for 4 weeks with CsA (7.5 mg/kg), or both CsA and FTY720 (0.125 mg/kg). The effects of FTY720 on CsA-induced renal injury were evaluated using renal function tests ",Transplantation,"Jin Young Kim, Sun Woo Lim, Can Li, Jung Shim Kim, Kyung Ohk Ahn, Hyun Joo Yang, Bum Soon Choi, Yong Soo Kim, Jin Kim, Byung Kee Bang, Chul Woo Yang"," Xenotransplantation Center, Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, and Department of Internal Medicine, The Affiliated Hospital, YanBian University Medical College, JiLin, China.",2005 Nov;80(9):1323-30,10.1097/01.tp.0000189709.21474.33
16322309,20051201,article,"xref,mesh","Animals,Antigens, CD34,Carcinoma, Hepatocellular,Disease Models, Animal,Down-Regulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Liver Neoplasms, Experimental,Mice,Mice, Nude,Microcirculation,Neovascularization, Pathologic,Propylene Glycols,Sphingosine,Tumor Cells, Cultured,Vascular Endothelial Growth Factor A,Wound Healing,rac GTP-Binding Proteins","analogs &amp; derivatives,chemistry,drug therapy,metabolism,pathology,prevention &amp; control,secondary,therapeutic use","D006528 Q000556 NN,D006528 Q000188 NY,D020744 Q000737 NN,D008114 Q000188 NY,D042461 Q000378 NN,D009389 Q000517 NN,D013110 Q000031 NN,D020744 Q000378 NN,D007166 Q000627 NY,D008114 Q000378 NN,D008114 Q000473 NN,D018952 Q000378 NN,D006528 Q000378 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.,"PURPOSE: Recurrence after resection and metastasis are common in hepatocellular carcinoma and are associated with poor prognosis. Therefore, effective treatment is urgently needed for improvement of patients' survival. Previously, we reported that FTY720 has an antimetastatic effect on hepatocellular carcinoma cell line through down-regulation of Rac signaling pathway. This study aims to investigate the in vivo antimetastatic potential of FTY720 in an orthotopic nude mice model using metastatic human hepato",Clinical cancer research : an official journal of the American Association for Cancer Research,"Terence K Lee, Kwan Man, Joanna W Ho, Xiang Hong Wang, Ronnie T P Poon, Yang Xu, Kevin T Ng, Alan C Chu, Chris K Sun, Irene O Ng, Hui Chuan Sun, Zao You Tang, Ray Xu, Sheung Tat Fan"," Centre for the Study of Liver Disease, Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China.",2005 Dec;11(23):8458-66,10.1158/1078-0432.ccr-05-0447
16339533,20051215,article,"xref,mesh","Animals,Cell Proliferation,Chemotaxis, Leukocyte,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Lymph Nodes,Lymphocyte Activation,Lymphocyte Count,Mice,Mice, Inbred C57BL,Organ Specificity,Ovalbumin,Propylene Glycols,Receptors, Interleukin-2,Receptors, Lysosphingolipid,Respiratory System,Sphingosine,T-Lymphocytes, Regulatory","agonists,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pathology,pharmacology,physiology","D007249 Q000188 NN,D049349 Q000819 NY,D007249 Q000139 NN,D008213 Q000276 NN,D050378 Q000502 NN,D049109 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008213 Q000187 NN,D050378 Q000187 NY,D002634 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D012137 Q000473 NN","8252,31270,107969,107970,5280335,5289086","128394615,129060975,129645792",The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.,"The sphingosine 1-phosphate (S1P) receptor agonist FTY720 is well known for its immunomodulatory activity, sequestering lymphocytes from blood and spleen into secondary lymphoid organs and thereby preventing their migration to sites of inflammation. Because inflammation is critically dependent on a balance between Ag-specific Th/effector cells and T-regulatory cells, we investigated the effect of FTY720 on T-regulatory cell trafficking and functional activity. An increased number of CD4+/CD25+ T cells was f","Journal of immunology (Baltimore, Md. : 1950)","Elzbieta Sawicka, Gerald Dubois, Gabor Jarai, Matthew Edwards, Matthew Thomas, Andy Nicholls, Rainer Albert, Catherine Newson, Volker Brinkmann, Christoph Walker"," Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom.",2005 Dec;175(12):7973-80,10.4049/jimmunol.175.12.7973
16365393,20060101,article,"xref,mesh","Adoptive Transfer,Animals,Apoptosis,CD4-Positive T-Lymphocytes,Chemotaxis, Leukocyte,Chronic Disease,Cytokines,Disease Models, Animal,Fingolimod Hydrochloride,Flow Cytometry,Graft Rejection,Heart Transplantation,Immunohistochemistry,Immunologic Memory,Immunosuppressive Agents,Lymphocyte Activation,Mice,Mice, Transgenic,Propylene Glycols,Receptors, Antigen, T-Cell,Skin Transplantation,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,genetics,immunology,pharmacology,prevention &amp; control,secretion","D007166 Q000494 NY,D016207 Q000187 NN,D017209 Q000187 NN,D015496 Q000187 NN,D016038 Q000276 NN,D008213 Q000276 NN,D011409 Q000494 NY,D016027 Q000276 NN,D007156 Q000187 NN,D013110 Q000031 NN,D015496 Q000276 NY,D008213 Q000187 NN,D017209 Q000276 NN,D002634 Q000276 NN,D002634 Q000187 NN,D011948 Q000235 NN,D016207 Q000557 NN,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection.,"FTY720 is a high-affinity agonist at the sphingosine 1-phosphate receptor 1 that prevents lymphocyte egress from lymphoid tissue and prolongs allograft survival in several animal models of solid organ transplantation. In this study we used a recently developed adoptive transfer model of TCR transgenic T cells to track allospecific CD4+ T cell expansion and trafficking characteristics, cytokine secretion profiles, and surface phenotype in vivo in the setting of FTY720 administration. We report that FTY720 ad","Journal of immunology (Baltimore, Md. : 1950)","Antje Habicht, Michael R Clarkson, Jun Yang, Joel Henderson, Volker Brinkmann, Stacey Fernandes, Mollie Jurewicz, Xueli Yuan, Mohamed H Sayegh"," Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital, Boston, MA 02115, USA.",2006 Jan;176(1):36-42,10.4049/jimmunol.176.1.36
16376813,20051201,article,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Integrin alpha2,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,immunology,prevention &amp; control,therapeutic use","D039421 Q000276 NN,D007166 Q000627 NN,D000911 Q000009 NN,D007249 Q000517 NN,D000911 Q000627 NN,D013110 Q000031 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Multiple sclerosis poses tough drug development challenges.,NULL,Drug discovery today,Kathryn Senior,NULL,2005 Dec;10(?):1583-4,10.1016/s1359-6446(05)03658-5
16378736,20060301,article,"xref,mesh","Animals,CHO Cells,Cell Death,Cell Survival,Cells, Cultured,Cricetinae,Cricetulus,Ethidium,Hemolysis,Humans,Molecular Weight,Mutagens,Polyethylene Glycols,Polymers,Propylene Glycols,Titrimetry","chemistry,drug effects,toxicity","D011409 Q000737 NY,D016923 Q000187 NY,D002470 Q000187 NN,D011092 Q000737 NY,D011092 Q000633 NY,D006461 Q000187 NY,D011108 Q000633 NY,D009153 Q000633 NY,D011108 Q000737 NN,D011409 Q000633 NN","3624,8252,14710,64966","127899424,129060975,129071090","Cytotoxicity, haematotoxicity and genotoxicity of high molecular mass arborescent polyoxyethylene polymers with polyglycidol-block-containing shells.","We have examined the impact on biological systems of some newly synthesised polyoxyethylene polymers using in vitro assays. Toxicity was tested by the 3-[4,5-dimethylthiazole-2-yl]-2,5 diphenyltetrazolium bromide (MTT) assay, haemolysis was assessed, and an ethidium bromide (EB) assay was used to study interactions between the polymers and DNA. All the assay data showed that the polymers are biocompatible. No differences were found between generations (i.e. macromolecule sizes). The results encourage contin",Cell biology international,"Barbara Klajnert, Wojciech Walach, Maria Bryszewska, Andrzej Dworak, Dzmitry Shcharbin"," Department of General Biophysics, University of Lodz, 12/16 Banacha St., 90-237 Lodz, Poland.",2006 Mar;30(3):248-52,10.1016/j.cellbi.2005.10.026
16386642,20051101,article,"xref,mesh","Animals,Antibody Formation,Female,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Models, Animal,Propylene Glycols,Skin Transplantation,Sphingosine,Thymectomy,Time Factors,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D016038 Q000276 NY,D011409 Q000494 NY,D013110 Q000031 NN,D006084 Q000517 NN,D014184 Q000276 NY,D000917 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 inhibits TH1-mediated allogeneic humoral immune response.,"Phosphorylated FTY720 is an analog of Sphingosine 1 Phosphate (S1P) with immunosuppressive activity that negatively regulates the expression of S1P-Receptor 1. It also inhibits the migration of CD4 and CD8 single-positive T cells from the thymus to the periphery, sequesters peripheral blood lymphocytes in lymph nodes and Peyer's patches, and delays the exit of effector T cells toward the graft. The aim of our work was to study the effect of FTY720 on the kinetics of skin allograft rejection in a fully misma",Transplantation proceedings,"G Peñuelas-Rivas, R Domínguez-Perles, V Brinkmann, M L Del Rio, A Muñoz-Luna, P Ramírez-Romero, P Parrilla-Paricio, J I Rodríguez-Barbosa"," Unit of Transplantation Research, Experimental Surgery, Arrixaca University Hospital, Murcia, Spain.",2005 Nov;37(9):4124-6,10.1016/j.transproceed.2005.09.184
16387148,20051201,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Gene Expression Regulation,Graft Survival,Immunoglobulins,Immunosuppressive Agents,Intestinal Mucosa,Jejunum,Mucoproteins,Propylene Glycols,Rats,Rats, Inbred BN,Sphingosine,Transplantation, Homologous,Transplantation, Isogeneic","analogs &amp; derivatives,drug effects,genetics,pathology,physiology,therapeutic use,transplantation","D006085 Q000187 NN,D009088 Q000235 NY,D007583 Q000637 NY,D013110 Q000031 NY,D014185 Q000473 NN,D014184 Q000502 NY,D007166 Q000627 NY,D014184 Q000473 NN,D007413 Q000502 NY,D013110 Q000627 NN,D011409 Q000627 NY,D007136 Q000235 NY,D014185 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.,"AIM: Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) mediates the homing of lymphocytes to gut-associated tissues (GALT). We performed a semiquantitative analysis of MAdCAM-1 expression during small bowel graft rejection in rat treated with FTY720. METHODS: Orthotopic small bowel transplantations (SBT) were performed from BN rats to LEW rats. Isografted animals served as controls. Three groups of SBT animals were studied on days 3, 5, 7 after operations (Isograft, untreated allograft, allograft with F",Transplantation proceedings,"K Sugito, T Koshinaga, M Inoue, T Ikeda, N Hagiwara, M Fukuzawa"," Nihon University, Pediatric Surgery, Tokyo, Japan. ksugito@hotmail.com",2005 Dec;37(10):4472-4,10.1016/j.transproceed.2005.10.114
16393960,20060115,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Female,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunologic Memory,Immunosuppressive Agents,Isoantibodies,Lymphoid Tissue,Male,Mice,Mice, Congenic,Mice, Inbred C3H,Mice, Inbred C57BL,Mice, Knockout,Mice, Transgenic,Propylene Glycols,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,biosynthesis,drug effects,immunology,pathology,pharmacology","D006085 Q000187 NN,D018414 Q000276 NN,D015496 Q000187 NN,D006085 Q000276 NY,D013110 Q000031 NN,D007518 Q000096 NN,D015496 Q000276 NY,D008221 Q000276 NY,D016027 Q000473 NN,D008221 Q000187 NN,D011409 Q000494 NN,D013110 Q000494 NN,D016027 Q000276 NY,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival.,"Memory T cells specific for donor Ags present a unique challenge in transplantation. In addition to expressing robust immune responses to a transplanted organ, memory T cells may be resistant to the effects of immunosuppressive therapies used to prolong graft survival. In this study, we explore the possibility of controlling deleterious donor-reactive memory CD4 T cells through lymphoid sequestration. We showed that sphingosine 1-phosphate receptor-1 agonist FTY720 induces relocation of circulating memory C","Journal of immunology (Baltimore, Md. : 1950)","Qiwei Zhang, Yifa Chen, Robert L Fairchild, Peter S Heeger, Anna Valujskikh"," Department of Immunology, The Cleveland Clinic Foundation, Cleveland OH 44195, USA.",2006 Jan;176(2):770-7,10.4049/jimmunol.176.2.770
16394548,20060101,article,xref,"Administration, Intranasal,Aerosols,Algorithms,Analgesics, Non-Narcotic,Animals,Bupleurum,Chemistry, Pharmaceutical,Cilia,Escherichia coli,Excipients,Female,Fever,Male,Nasal Mucosa,Oils, Volatile,Pyrogens,Rabbits,Rats,Rats, Sprague-Dawley,Solubility,Solvents,Turpentine","administration &amp; dosage,chemically induced,chemistry,drug effects,pathology,pharmacology,prevention &amp; control,toxicity","D002923 Q000187 NN,D018712 Q000633 NN,D009822 Q000494 NY,D005334 Q000139 NN,D009297 Q000187 NN,D029972 Q000737 NY,D009297 Q000473 NN,D009822 Q000633 NN,D018712 Q000008 NY,D009822 Q000008 NY,D018712 Q000494 NY,D005334 Q000517 NN","3283,8252","129060975,129181549",Preparation of bupleurum nasal spray and evaluation on its safety and efficacy.,"Radix Bupleuri is widely used in traditional medicine for the treatment of fever, pain, and inflammation associated with influenza or the common cold. The essential oil extracted from the herb is generally claimed to play the major role in the efficacious treatment of fever. The purpose of the present study was to formulate an intranasal delivery system for the essential oil in an aqueous solution used in the form of nasal spray. From 450 g Radix Bupleuri was extracted the essential oil in the amount of abo",Chemical & pharmaceutical bulletin,"Yueling Xie, Wei Lu, Shilei Cao, Xinguo Jiang, Ming Yin, Wenlu Tang"," Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, PR China.",2006 Jan;54(1):48-53,10.1248/cpb.54.48
16468955,20060301,article,"xref,mesh","Adiponectin,Animals,Disease Models, Animal,Drug Therapy, Combination,Fatty Liver,Fingolimod Hydrochloride,Follow-Up Studies,Graft Rejection,Graft Survival,Immunosuppressive Agents,Liver Transplantation,Male,Propylene Glycols,Rats,Rats, Zucker,Sphingosine,Treatment Outcome","analogs &amp; derivatives,blood,drug effects,drug therapy,pathology,pharmacokinetics,surgery,therapeutic use","D006084 Q000188 NY,D052242 Q000493 NN,D005234 Q000601 NY,D052242 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D006084 Q000097 NN,D006084 Q000473 NN,D006085 Q000187 NY,D005234 Q000473 NN,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival.,"Owing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomod",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"K Man, Y Zhao, A Xu, C M Lo, K S L Lam, K T Ng, J W Y Ho, C K Sun, T K Lee, X L Li, S T Fan"," Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China. kwanman@hkucc.hku.hk",2006 Mar;6(3):467-76,10.1111/j.1600-6143.2005.01201.x
16497020,20060303,article,"xref,mesh","Azides,Fingolimod Hydrochloride,Immunosuppressive Agents,Photochemistry,Propanolamines,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemical synthesis,chemistry","D001386 Q000737 NY,D011409 Q000737 NY,D011412 Q000138 NN,D001386 Q000138 NN,D007166 Q000737 NY,D011412 Q000737 NY,D013110 Q000031 NY,D013110 Q000737 NN,D007166 Q000138 NN","6115,8252,10393,31270,107969,107970,5280335,11508523","128394615,128889888,129060975,129645792,129774317,243549384",A photoreactive analogue of the immunosuppressant FTY720.,"An azido group was incorporated into the immunomodulatory agent FTY720, accomplishing the first synthesis of a photoactivatable analogue of this ligand (2) in 9 steps from 2-(4-hydroxyphenyl)ethanol and in 34% overall yield. The key steps are formation of a primary amine at a quaternary center of aniline derivative 13 followed by selective diazotization of the arylamine. ",The Journal of organic chemistry,"Chaode Sun, Robert Bittman"," Department of Chemistry and Biochemistry, Queens College of The City University of New York, Flushing, New York 11367-1597, USA.",2006 Mar;71(5):2200-2,10.1021/jo0526237
16523968,20060201,review,"xref,mesh","Antibodies, Monoclonal,Azathioprine,Cyclophosphamide,Cyclosporine,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Diseases,Kidney Transplantation,Mycophenolic Acid,Propylene Glycols,Recombinant Fusion Proteins,Ribonucleosides,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,pharmacology,prevention &amp; control","D007166 Q000494 NY,D007166 Q000008 NN,D000911 Q000008 NN,D000911 Q000009 NN,D003520 Q000494 NN,D011993 Q000008 NN,D012263 Q000009 NN,D001379 Q000009 NN,D016572 Q000008 NN,D016572 Q000009 NN,D007674 Q000188 NY,D009173 Q000494 NN,D013110 Q000031 NN,D003520 Q000009 NN,D011993 Q000009 NN,D012263 Q000008 NN,D012263 Q000494 NN,D016572 Q000494 NN,D009173 Q000008 NN,D000911 Q000494 NN,D001379 Q000008 NN,D009173 Q000031 NN,D001379 Q000494 NN,D003520 Q000008 NN,D007166 Q000009 NN,D011993 Q000494 NN,D006084 Q000517 NY","2265,2907,2909,4271,4272,8252,22420,31270,62280,104762,107969,107970,121989,446541,5280335,5280754,5281078,5284373,5458585,6435893,6438394,6441022,9855081,11529527,23665584,24883466,25246316,46926304,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128094727,128394615,129060975,129178479,129645792,129976789",[Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].,NULL,Nihon rinsho. Japanese journal of clinical medicine,"Masaharu Nishikido, Hiroshi Kanekake, Takashi Harada"," Division of Nephro Urology, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences.",2006 Feb;?(?):634-8,NULL
16549044,20060201,review,"xref,mesh","Animals,Cell Movement,Chemokines,Down-Regulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymph,Lymphocytes,Molecular Structure,Propylene Glycols,Receptors, Chemokine,Receptors, Lysosphingolipid,Sphingosine,Stereoisomerism,Structure-Activity Relationship,Thymus Gland","analogs &amp; derivatives,chemistry,drug effects,immunology,pharmacology","D008214 Q000276 NY,D002465 Q000187 NN,D015536 Q000187 NN,D002465 Q000276 NY,D011409 Q000737 NN,D018925 Q000276 NY,D015536 Q000276 NN,D013110 Q000737 NN,D013110 Q000031 NN,D008214 Q000737 NN,D019707 Q000276 NY,D013950 Q000276 NY,D011409 Q000494 NN,D049349 Q000276 NY,D013110 Q000494 NN,D007166 Q000494 NN,D008196 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.,"Circulation of mature lymphocytes between blood and secondary lymphoid tissues plays a central role in the immune system. Homing of lymphocytes from blood into secondary lymphoid tissues beyond high endothelial venules is highly dependent on the interaction between the chemokines CCL19, CCL21, CXCL12, and CXCL13, and their receptors CCR7, CXCR4 and CXCR5. However, the molecular mechanism(s) of lymphocyte egress from secondary lymphoid tissues to lymph remained unclear. We have found a new class of immunomod",Cellular & molecular immunology,"Kenji Chiba, Hirofumi Matsuyuki, Yasuhiro Maeda, Kunio Sugahara"," Research Laboratory III (Immunology), Pharmaceutical Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Yokohama, Japan. Chiba.Kenji@mk.m-pharma.co.jp",2006 Feb;3(1):11-9,NULL
16563863,20060601,review,"xref,mesh","Animals,Asthma,Capillary Permeability,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Lung,Lysophospholipids,Mast Cells,Muscle, Smooth, Vascular,Propylene Glycols,Receptors, Lysosphingolipid,Respiratory Mucosa,Signal Transduction,Sphingosine,T-Lymphocytes,Vasoconstriction","analogs &amp; derivatives,blood supply,drug effects,drug therapy,metabolism,pharmacokinetics,pharmacology,therapeutic use","D013601 Q000378 NN,D007249 Q000378 NN,D020545 Q000187 NN,D007249 Q000188 NN,D007166 Q000627 NN,D004730 Q000187 NY,D008246 Q000493 NN,D013110 Q000031 NY,D008246 Q000494 NY,D020545 Q000378 NN,D004730 Q000378 NN,D049349 Q000187 NN,D009131 Q000187 NY,D009131 Q000378 NN,D001249 Q000378 NN,D013110 Q000493 NN,D008168 Q000098 NN,D011409 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN,D008168 Q000187 NY,D013601 Q000187 NN,D008407 Q000378 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Pulmonary and vascular pharmacology of sphingosine 1-phosphate.,"Dysregulation of vasomotor tone, endothelial barrier function and immune cell trafficking are central to the pathology of many lung diseases, including acute lung injury, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma. There is increasing evidence that the serum sphingolipid sphingosine 1-phosphate and its G-protein-coupled receptors are pivotal not only in the regulation of lymphocyte migration, but also in the maintenance of vascular homeostasis and the preservation ",Current opinion in pharmacology,"Volker Brinkmann, Thomas Baumruker"," Autoimmunity & Transplantation, Novartis Institutes for BioMedical Research, WSJ-386.101, Lichtstrasse 35, CH-4002 Basel, Switzerland. volker.brinkmann@novartis.com",2006 Jun;6(3):244-50,10.1016/j.coph.2005.12.004
16571654,20060701,article,"xref,mesh","Animals,Benzoxazines,Binding, Competitive,CHO Cells,Cell Line,Cricetinae,Cricetulus,Cyclohexanes,Cyclohexanols,Endocytosis,Enzyme Activation,Fingolimod Hydrochloride,Guanosine 5'-O-(3-Thiotriphosphate),Humans,Immunosuppressive Agents,Mice,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Morpholines,Naphthalenes,Phenols,Piperidines,Propylene Glycols,Proto-Oncogene Proteins c-akt,Pyrazoles,Radioligand Assay,Receptor, Cannabinoid, CB1,Receptor, Cannabinoid, CB2,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,metabolism,pharmacology","D010636 Q000378 NN,D003510 Q000494 NN,D011720 Q000378 NN,D004705 Q000187 NN,D043884 Q000378 NY,D011720 Q000494 NN,D009025 Q000378 NN,D007166 Q000378 NN,D010880 Q000494 NN,D009025 Q000494 NN,D013110 Q000494 NY,D004789 Q000187 NN,D043885 Q000378 NN,D013110 Q000031 NY,D043884 Q000819 NN,D011409 Q000494 NY,D013110 Q000378 NN,D009281 Q000494 NN,D019950 Q000378 NN,D009281 Q000378 NN,D003510 Q000378 NN,D001667 Q000187 NN,D051057 Q000378 NN,D010636 Q000494 NN,D048052 Q000378 NN,D011409 Q000378 NN,D007166 Q000494 NN","1764,5689,6802,7966,8252,31270,37792,104849,104850,104895,107969,107970,4412255,5280335,5311501,54358654,90792447,135398635","128348432,128394615,128771931,129060975,129383166,129645792,129823212,243422089","Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.","Sphingosine-1-phosphate (S1P) and cannabinoid receptors are G-protein-coupled receptors that mediate the effects of S1P and endocannabinoids, respectively. Cannabinoid receptors also mediate the effects of Delta9-tetrahydrocannabinol, the primary psychoactive ingredient in marijuana, whereas S1P receptors contribute to the immunosuppressant effects of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720). FTY720 is a sphingosine analog that can prevent renal graft rejections and suppress a variety of ",Molecular pharmacology,"Steven W Paugh, Michael P Cassidy, Hengjun He, Sheldon Milstien, Laura J Sim-Selley, Sarah Spiegel, Dana E Selley"," Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, 1112 East Clay Street, Box 980524, Richmond, VA 23298, USA.",2006 Jul;70(1):41-50,10.1124/mol.105.020552
16572112,20060501,article,"xref,mesh","Animals,Cytosol,Diabetes Mellitus, Experimental,Diabetic Nephropathies,Enzyme Activation,Extracellular Signal-Regulated MAP Kinases,Fibronectins,Flavonoids,Free Radical Scavengers,Gene Expression,Glucose,Glycation End Products, Advanced,Kidney Glomerulus,Male,Mesangial Cells,Oxidative Stress,Polyenes,Polyunsaturated Alkamides,Proto-Oncogene Proteins c-jun,Rats,Rats, Wistar,Superoxide Dismutase,Superoxides,Transforming Growth Factor beta,ras Proteins","analysis,antagonists &amp; inhibitors,chemistry,complications,drug effects,enzymology,etiology,genetics,metabolism,pathology,pharmacology,toxicity","D005353 Q000235 NY,D007678 Q000378 NY,D048049 Q000037 NN,D017127 Q000633 NN,D050527 Q000737 NN,D003928 Q000378 NY,D005947 Q000494 NN,D007678 Q000473 NN,D003928 Q000235 NN,D003600 Q000378 NN,D018384 Q000187 NN,D011090 Q000494 NN,D018631 Q000037 NN,D005353 Q000032 NN,D003921 Q000150 NN,D013481 Q000378 NY,D050527 Q000187 NN,D018631 Q000378 NY,D013482 Q000494 NN,D003600 Q000201 NN,D016212 Q000378 NN,D003928 Q000209 NN,D016166 Q000494 NN,D016755 Q000378 NN,D005419 Q000494 NN,D050527 Q000378 NN,D016212 Q000032 NN","2094,4010,4713,5793,12877,24749,107526,5359597,6438330,9882223,10954115,11981008,53230011,56842206,71684620,87517085,135401907,135433642","53786806,53787607,53787922,53789116,53789751,53790080,128799971,129621433,135790204",Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries.,"Although previous studies have demonstrated that diabetic nephropathy is attributable to early extracellular matrix accumulation in glomerular mesangial cells, the molecular mechanism by which high glucose induces matrix protein deposition remains not fully elucidated. Rat mesangial cells pretreated with or without inhibitors were cultured in high-glucose or advanced glycation end product (AGE) conditions. Streptozotocin-induced diabetic rats were given superoxide dismutase (SOD)-conjugated propylene glycol",Kidney international,"C-L Lin, F-S Wang, Y-R Kuo, Y-T Huang, H-C Huang, Y-C Sun, Y-H Kuo"," Department of Nephrology, Chiayi Chang Gung Memorial Hospital & Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan. linchunliang@adm.cgmh.org.tw",2006 May;69(9):1593-600,10.1038/sj.ki.5000329
16574986,20060801,article,"xref,mesh","Animals,CD4 Antigens,Colitis,Female,Fingolimod Hydrochloride,Hyaluronan Receptors,Immunologic Memory,Immunosuppressive Agents,Inflammation Mediators,L-Selectin,Mice,Mice, Inbred BALB C,Mice, SCID,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,metabolism,prevention &amp; control","D018960 Q000276 NY,D007166 Q000008 NN,D018836 Q000276 NN,D007156 Q000276 YN,D015704 Q000276 NY,D013110 Q000008 NN,D013110 Q000031 NY,D003092 Q000276 NY,D007156 Q000187 YN,D003092 Q000517 NY,D019041 Q000378 NY,D011409 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.,"FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer",American journal of physiology. Gastrointestinal and liver physiology,"R Fujii, T Kanai, Y Nemoto, S Makita, S Oshima, R Okamoto, K Tsuchiya, T Totsuka, M Watanabe"," Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.",2006 Aug;291(2):G267-74,10.1152/ajpgi.00496.2005
16579750,20060401,article,"xref,mesh","Animals,Cats,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Neutrophils,Phosphorylation,Propylene Glycols,Reactive Oxygen Species,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacology,physiology","D007166 Q000494 NY,D009504 Q000502 NY,D009504 Q000187 NN,D017382 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN","3624,4939,8252,31270,107969,107970,5280335","128394615,129060975,129071090,129645792,129888650","In vitro evaluation of the effect of a novel immunosuppressive agent, FTY720, on the function of feline neutrophils.","OBJECTIVE: To use in vitro assays to evaluate the effects of a novel immunosuppressive agent, FTY720, on biological functions (migration, phagocytosis, and production of reactive-oxygen species [ROS]) of feline peripheral neutrophils and determine the cytotoxic effects of FTY720 on feline peripheral neutrophils. SAMPLE POPULATION: Peripheral neutrophils obtained from 8 healthy cats. PROCEDURE: Peripheral neutrophils were isolated from blood samples obtained from the 8 cats and exposed to the phosphorylated ",American journal of veterinary research,"Yi-Je Chen, Andrew E Kyles, Clare R Gregory"," Comparative Transplantation Laboratory, Department of Surgical and Radiological Sciences and Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis, CA 95616-8745, USA.",2006 Apr;67(4):588-92,10.2460/ajvr.67.4.588
16635748,20060401,article,"xref,mesh","Animals,Apoptosis,Atrophy,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,DNA Fragmentation,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,In Situ Nick-End Labeling,Male,Propylene Glycols,Rats,Rats, Inbred Lew,Receptors, Antigen, T-Cell, alpha-beta,Sphingosine,T-Lymphocyte Subsets,Thymus Gland","administration &amp; dosage,analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D007166 Q000494 NY,D016176 Q000187 NY,D018414 Q000276 NN,D016693 Q000276 NN,D007166 Q000008 NN,D017209 Q000187 NY,D015496 Q000276 NN,D013950 Q000166 NN,D015496 Q000187 NY,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D016176 Q000166 NN,D011409 Q000494 NY,D018414 Q000187 NY,D018414 Q000166 NN,D013950 Q000187 NY,D016176 Q000276 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Evidence that FTY720 induces rat thymocyte apoptosis.,"FTY720, a novel immunomodulator with the potential to improve immunosuppressive therapy after organ transplantation, is currently under clinical investigation. FTY720 drastically decreases blood lymphocytes, especially T cells, accelerating lymphocyte homing to secondary lymphoid organs. However, its immunosuppressive effects remain unknown. We investigated these effects in rat thymocytes. Rats were intramuscularly injected with 10mg/kg/day FTY720 or saline for 7days. Thymuses were removed on days 0, 1, 3, ",Transplant immunology,"Naohito Isoyama, Kimio Takai, Masahiro Tsuchida, Masafumi Matsumura, Katsusuke Naito"," Department of Urology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.",2006 Apr;15(4):265-71,10.1016/j.trim.2006.02.004
16635750,20060401,article,"xref,mesh","B-Lymphocytes,Fingolimod Hydrochloride,Granulocytes,Humans,Immunosuppressive Agents,Kidney Transplantation,Killer Cells, Natural,Leukocytes, Mononuclear,Monocytes,Mycophenolic Acid,Propylene Glycols,Receptors, CCR5,Receptors, CCR7,Receptors, CXCR3,Receptors, Chemokine,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,pharmacology,therapeutic use","D007166 Q000494 NY,D009000 Q000187 NN,D007694 Q000187 NY,D007166 Q000008 NN,D013601 Q000276 NN,D013110 Q000008 NN,D006098 Q000187 NN,D001402 Q000187 NY,D013110 Q000031 NY,D011409 Q000008 NN,D009000 Q000276 NN,D001402 Q000276 NN,D013601 Q000187 NY,D009173 Q000031 NN,D009173 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NY,D007694 Q000276 NN,D019713 Q000276 NN,D019707 Q000276 NN,D006098 Q000276 NN","4271,4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129178479,129645792","FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.","FTY720 alters lymphocyte recirculation and homing by interfering with S1P receptors on lymphocytes, possibly in combination with chemokine receptors, and induces a decrease in PBL counts. In fresh, whole blood samples of 14 kidney transplant patients, we analyzed by flow cytometry the effect of FTY on the number of NK cells, monocytes, naïve (CCR7+) T cells, memory (CCR5+) T cells and B cells. Patients treated with 0.5, 2.5 or 5mg FTY/day showed a strong decrease in T and B cell numbers. NK cells and monocy",Transplant immunology,"Leonard M B Vaessen, Nicole M van Besouw, Wendy M Mol, Jan N M Ijzermans, Willem Weimar"," Department of Internal Medicine-Transplantation, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Room Ee559, P.O. Box 1738, NL-3000 DR Rotterdam, The Netherlands.",2006 Apr;15(4):281-8,10.1016/j.trim.2006.02.002
16647442,20060401,article,"xref,mesh","Animals,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Injections, Intraperitoneal,Ischemia,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Renal Circulation,Reperfusion Injury,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,physiopathology,prevention &amp; control,therapeutic use","D007166 Q000008 NN,D007166 Q000627 NN,D007511 Q000503 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D015427 Q000517 NY,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice.,"BACKGROUND: Organ dysfunction followed by single-organ or even multiorgan failure due to ischemia-reperfusion injury (I/RI) is a common problem in liver and heart transplantation. Various approaches had been attempted to prevent this I/RI. One is the administration of FTY720, a synthetic structural analogue of sphingosine, which induces T-lymphocyte homing with consecutive lymphopenia. The purpose of this study was to evaluate the effect of intraoperative FTY720 administration following controlled bilateral",Transplantation proceedings,"C P Kaudel, U Schmiddem, M Frink, S Bergmann, H-C Pape, C Krettek, J Klempnauer, M Winkler"," Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, Germany. kaudel.philipp@mh-hannover.de",2006 Apr;38(3):679-81,10.1016/j.transproceed.2006.01.033
16700726,20060601,article,"xref,mesh","Animals,Colon,Electromyography,Gastrointestinal Motility,Inflammatory Bowel Diseases,Irritable Bowel Syndrome,Male,Mice,Pain Threshold,Paroxetine,Serotonin Plasma Membrane Transport Proteins,Serotonin Uptake Inhibitors","drug effects,metabolism,pharmacology,physiology,physiopathology","D050486 Q000378 NY,D003106 Q000378 NY,D017288 Q000502 NY,D015212 Q000503 NN,D017367 Q000494 NN,D005769 Q000502 NY,D003106 Q000187 NN,D017374 Q000494 NN,D017288 Q000187 NN,D005769 Q000187 NN,D043183 Q000503 NN,D050486 Q000187 NN","5202,43815,62878,5282487,6435921,9800501,9843029","127407860,129095671",Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse.,"Serotonin-selective reuptake transporter (SERT) expression is decreased in animal models of intestinal inflammation and in individuals with inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS), and it is possible that resultant changes in intestinal serotonin signalling contribute to the manifestation of clinical features associated with these disorders. The objective of this investigation was to determine whether inhibition of SERT function leads to changes in gut motility and sensitivity. Mi",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,"M D Coates, A C Johnson, B Greenwood-Van Meerveld, G M Mawe"," Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington, VT 05405, USA.",2006 Jun;18(6):464-71,10.1111/j.1365-2982.2006.00792.x
16708400,20060601,article,"xref,mesh","Animals,Brain,CD11a Antigen,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cell Movement,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver,Lung,Male,Mice,Mice, Inbred C57BL,Mice, Transgenic,Microscopy, Confocal,Pertussis Toxin,Propylene Glycols,Receptors, CCR7,Receptors, Chemokine,Skin,Specific Pathogen-Free Organisms,Sphingosine","analogs &amp; derivatives,immunology,pharmacology","D008168 Q000276 NN,D037342 Q000494 NN,D018414 Q000276 NY,D002465 Q000276 NY,D008099 Q000276 NN,D013110 Q000031 NN,D015496 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001921 Q000276 NN,D019707 Q000276 NN,D040881 Q000276 NN,D012867 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway.,"Only activated and effector memory T cells are thought to access non-lymphoid tissues. In contrast, naive T cells are thought to circulate only between the blood, lymph and secondary lymphoid organs. We examined the phenotype of endogenous T cells in various non-lymphoid organs and showed that a subset of cells exhibited an apparently naive phenotype and were functionally inactive. FTY720 treatment selectively depleted this population from the non-lymphoid tissues. In addition, RAG-deficient TCR transgenic ",European journal of immunology,"Stephen Cose, Clair Brammer, Kamal M Khanna, David Masopust, Leo Lefrançois"," Department of Immunology, University of Connecticut Health Center, Farmington, 06030, USA.",2006 Jun;36(6):1423-33,10.1002/eji.200535539
16751263,20060901,article,"xref,mesh","Administration, Oral,Animals,Computer Simulation,Dogs,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Injections, Intravenous,Male,Models, Biological,Propylene Glycols,Rats,Rats, Wistar,Sphingosine,Tissue Distribution","administration &amp; dosage,analogs &amp; derivatives,blood,pharmacokinetics","D013110 Q000097 NN,D011409 Q000493 NY,D007166 Q000008 NN,D007166 Q000097 NN,D013110 Q000008 NN,D007166 Q000493 NY,D013110 Q000031 NY,D011409 Q000008 NN,D013110 Q000493 NN,D011409 Q000097 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.","FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis and prevention of solid organ transplant rejection. A physiologically based pharmacokinetic model was developed to predict the concentration of FTY720 in various organs of the body. Single oral and intravenous doses of FTY720 were administered to male Wistar rats, with blood and tissue sampling over 360 h analyzed by liquid chromatography/tandem m",Drug metabolism and disposition: the biological fate of chemicals,"Guy M L Meno-Tetang, Hongshan Li, Suzette Mis, Nancy Pyszczynski, Peter Heining, Philip Lowe, William J Jusko"," Novartis Pharma AG, Basel, Switzerland.",2006 Sep;34(9):1480-7,10.1124/dmd.105.009001
16759708,20061001,review,"xref,mesh","Animals,Cyclooxygenase 2,Cytokines,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Lipopolysaccharides,Phospholipases A,Propylene Glycols,Prostaglandins,Sphingolipids,Sphingosine","analogs &amp; derivatives,immunology,metabolism,pharmacology","D011453 Q000378 NN,D008070 Q000494 NN,D013107 Q000276 NN,D051546 Q000378 NN,D016207 Q000378 NN,D013107 Q000378 NY,D007249 Q000378 NY,D013110 Q000031 NN,D010741 Q000378 NN,D007249 Q000276 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Bioactive sphingolipids in the modulation of the inflammatory response.,"Inflammation is viewed as a protective response against insults to the organism. It involves the recruitment of many cell types and the production of various inflammatory mediators in attempts to contain and reverse the insult. However, inflammation can lead to irreversible tissue destruction by itself and, therefore, can represent a disease state that causes significant morbidity and mortality. Understanding the molecular mechanisms controlling the inflammatory response is essential to formulate therapeuti",Pharmacology & therapeutics,"Mazen El Alwani, Bill Xingjun Wu, Lina M Obeid, Yusuf A Hannun"," Department of Medicine, Division of General Internal Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.",2006 Oct;112(1):171-83,10.1016/j.pharmthera.2006.04.004
16771816,20060801,article,"xref,mesh","Adult,Biopsy,Cyclosporine,Dose-Response Relationship, Drug,Drug Therapy, Combination,Drug-Related Side Effects and Adverse Reactions,Female,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney,Kidney Transplantation,Lung,Male,Middle Aged,Propylene Glycols,Sphingosine,Time Factors","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,immunology,pharmacology,physiology","D007166 Q000494 NY,D008168 Q000187 NN,D011409 Q000009 NN,D013110 Q000009 NN,D008168 Q000502 NN,D007668 Q000187 NN,D013110 Q000008 NN,D016572 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D016572 Q000009 NN,D007668 Q000502 NN,D016030 Q000276 NY,D016572 Q000008 NY,D006084 Q000276 NN,D013110 Q000494 NN,D011409 Q000008 NY,D007166 Q000008 NY","2909,4271,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128394615,129060975,129178479,129645792",FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.,FTY720 is a novel immunomodulator being investigated for rejection prophylaxis in renal transplantation when combined with full-dose cyclosporine (CsA; FDC). This 1-year phase II study compared FTY720 plus FDC (Neoral) with FTY720 plus reduced-dose CsA (RDC) and mycophenolate mofetil (MMF) plus FDC in de novo renal transplant patients. Patients were randomized 2:2:2:1 to FTY720 5 mg plus RDC (n = 72); FTY720 2.5 mg plus RDC (n = 74); FTY720 2.5 mg plus FDC (n = 76); or MMF plus FDC (n = 39) for 12 months. C,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"S Mulgaonkar, H Tedesco, F Oppenheimer, R Walker, U Kunzendorf, G Russ, A Knoflach, Y Patel, R Ferguson, FTYA121 study group"," Saint Barnabas Medical Center, Livingston, New Jersey, USA. smulgaonkar@sbhcs.com",2006 Aug;6(8):1848-57,10.1111/j.1600-6143.2006.01404.x
16830220,20060101,review,"xref,mesh","Animals,Autoimmune Diseases,B-Lymphocytes,Cell Movement,Dendritic Cells,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Lymphatic System,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","adverse effects,analogs &amp; derivatives,biosynthesis,drug effects,drug therapy,immunology,metabolism,prevention &amp; control,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D003713 Q000187 NN,D007166 Q000627 NN,D001402 Q000276 NY,D001402 Q000187 NN,D013110 Q000031 NY,D008208 Q000378 NN,D002465 Q000276 NN,D008246 Q000096 NN,D001327 Q000188 NN,D013110 Q000276 NN,D003713 Q000276 NY,D013601 Q000276 NY,D006084 Q000517 NN,D008246 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NN,D049349 Q000276 NY,D013110 Q000096 NN,D007166 Q000009 NN,D013601 Q000187 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.,"Sphingosine 1-phosphate (S1P) has been shown to be a bioactive lipid mediator intimately involved in mediating a variety of immunological processes. In particular, S1P regulates lymphocyte cell trafficking between the lymphatic system and the blood. The lysophospholipid signals mainly through five related G protein-coupled receptor subtypes, termed S1P(1) to S1P(5). S1P(1) seems to play an essential role in cell trafficking, as this receptor subtype promotes the egress of T and B cells from secondary lympha",Archivum immunologiae et therapiae experimentalis,"Henrik von Wenckstern, Karsten Zimmermann, Burkhard Kleuser"," Institute of Pharmacy, Pharmacology and Toxicology, Freie Universität Berlin, D-14195, Berlin, Germany.",2006 Jan;54(4):239-51,10.1007/s00005-006-0028-9
16842223,20060701,review,xref,"Antioxidants,Caffeic Acids,Combinatorial Chemistry Techniques,Indazoles,Molecular Structure,Peptide Library,Propylene Glycols,Quinones","chemical synthesis,chemistry","D011409 Q000737 NN,D002109 Q000737 NN,D007191 Q000737 NN,D000975 Q000737 NY,D000975 Q000138 NY,D011809 Q000737 NN",8252,129060975,Combinatorial library synthesis of antioxidant compounds.,"Since oxidative cellular damage contributes to the development of cancers, heart disease and ageing, the synthesis of antioxidative agents which are able to either prevent or mitigate oxidative stress to cells is an important area of investigation. Combinatorial chemistry has had a profound impact on the discovery and optimisation of potential lead compounds, especially in the medicinal field. This review details recent examples of combinatorial chemistry dealing with the synthesis of novel antioxidants wit",Combinatorial chemistry & high throughput screening,Stifun Mittoo," School of Chemistry, University of Southampton, Southampton, SO17 1BJ, UK. sm15@soton.ac.uk",2006 Jul;9(6):421-3,10.2174/138620706777698490
16855074,20060801,article,"xref,mesh","Adolescent,Adult,Arrhythmias, Cardiac,Blood Pressure,Dose-Response Relationship, Drug,Double-Blind Method,Electrocardiography, Ambulatory,Exercise Test,Female,Fingolimod Hydrochloride,Heart Conduction System,Heart Rate,Humans,Immunosuppressive Agents,Male,Propylene Glycols,Reference Values,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,pharmacology","D007166 Q000494 NY,D006329 Q000187 NY,D011409 Q000009 NN,D013110 Q000009 NN,D006339 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D015716 Q000187 NN,D001794 Q000187 NN,D001145 Q000139 NN,D013110 Q000494 NN,D007166 Q000009 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.,"The purpose of this double-blind, placebo-controlled study was to measure the effects of FTY720, a novel immunomodulator, on heart rate and rhythm in healthy volunteers. Subjects (n = 66) were randomized to FTY720 1.25 mg or 5 mg or placebo administered once daily for 7 days. Continuous telemetry revealed an acute, dose-dependent decrease in mean heart rate (10-bpm decrease vs placebo) following the first dose of FTY720, with a nadir generally 4 hours postdose. Although a persistent FTY720-related decrease ",Journal of clinical pharmacology,"Robert Schmouder, Denise Serra, Yibin Wang, John M Kovarik, John DiMarco, Thomas L Hunt, Marie-Claude Bastien"," Exploratory Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA.",2006 Aug;46(8):895-904,10.1177/0091270006289853
16963799,20060101,article,"xref,mesh","Animals,Antineoplastic Agents,Cisplatin,Creatinine,Free Radical Scavengers,Kidney,Kidney Diseases,Kidney Function Tests,Lipid Peroxidation,Male,Oxidative Stress,Quercetin,Rats,Rats, Wistar,Time Factors","blood,chemically induced,drug effects,metabolism,pathology,pharmacology,prevention &amp; control,therapeutic use,toxicity,urine","D002945 Q000633 NY,D000970 Q000633 NY,D007674 Q000378 NN,D007668 Q000378 NN,D007674 Q000517 NY,D007674 Q000139 NN,D007668 Q000473 NN,D016166 Q000494 NY,D007668 Q000187 NY,D003404 Q000097 NN,D007674 Q000652 NN,D011794 Q000494 NY,D015227 Q000187 NN,D018384 Q000187 NY,D007674 Q000097 NN,D011794 Q000627 NN,D016166 Q000627 NN","588,8252,84691,441203,5280343","127719861,129060975,129116523",Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys.,"Quercetin, a typical bioflavonoid ubiquitously present in fruits and vegetables, is considered to be helpful for human health. Cisplatin (cDDP) is one of the most active cytotoxic agents in the treatment of a wide range of solid tumors. The aim of this study was to investigate the possible effect of quercetin, a bioflavonoid with antioxidant potential, on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Gavage administrations of water, propylene glycol and quercetin (50 mg/kg) were made 24 a",Pharmacological reports : PR,"Estela B Behling, Milena C Sendão, Heloísa D C Francescato, Lusânia M G Antunes, Roberto S Costa, Maria de Lourdes P Bianchi"," Departamento de Alimentos e Nutrição, Faculdade de Ciencias Farmaceuticas de Araraquara, UNESP, Rod. Araraquara/Jaú, km 01, 14801-902, Araraquara, SP, Brazil.",2006 Jan;58(4):526-32,NULL
16968402,20061001,article,"xref,mesh","Acute Disease,Animals,Body Weight,Cytokines,Fingolimod Hydrochloride,Graft vs Host Disease,Immunosuppressive Agents,Intestine, Small,Liver,Lymphocyte Count,Male,Propylene Glycols,Rats,Rats, Inbred WF,Skin,Sphingosine,T-Lymphocyte Subsets,Transplantation Chimera","analogs &amp; derivatives,biosynthesis,drug effects,drug therapy,immunology,pathology,therapeutic use,transplantation","D016176 Q000187 NY,D006086 Q000276 NN,D008099 Q000473 NN,D006086 Q000473 NN,D016207 Q000096 NN,D006086 Q000188 NY,D013110 Q000031 NY,D007421 Q000637 NY,D012867 Q000473 NN,D007166 Q000627 NY,D007421 Q000276 NN,D007421 Q000473 NN,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation.,"In small bowel transplantation (SBTx), graft-versus-host disease (GVHD) is mediated by donor-derived T cells recognizing host major histocompatibility complex (MHC) alloantigens, and represents an important immunological event influencing life in experimental and clinical situations. We evaluated the possibility that a new sphingosine 1-phosphate receptor agonist, FTY720, could diminish GVHD in a rat SBTx model through traffic alteration of donor-derived T cells in target organs. Heterotopic SBTx was perfor",Clinical and experimental immunology,"J Song, T Ito, C Matsuda, G Miao, M Tanemura, T Nishida, M Nozawa, H Matsuda, Y Sawa"," Department of Surgery (E1), Osaka University Graduate School of Medicine, Osaka, Japan.",2006 Oct;146(1):85-92,10.1111/j.1365-2249.2006.03175.x
16969482,20061001,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Cell Transplantation,Colitis,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammatory Bowel Diseases,L-Selectin,Male,Mice,Mice, Inbred BALB C,Mice, SCID,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Spleen","analogs &amp; derivatives,biosynthesis,metabolism,pharmacology,physiology,prevention &amp; control,therapy","D007166 Q000494 NY,D015496 Q000378 NN,D015212 Q000628 NN,D015212 Q000517 NN,D013110 Q000031 NY,D011409 Q000494 NY,D019041 Q000096 NN,D003092 Q000517 NY,D049349 Q000502 NY,D013154 Q000378 NN,D013110 Q000494 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.,"To evaluate the therapeutic effects of the new synthetic sphingosine-1-phosphate (S1P) receptor modulator, FTY720, we investigated how FTY720 affects the development of dextran sulfate sodium (DSS)-induced colitis and CD4+CD62L+ T cell transfer colitis. BALB/c mice were fed a chow containing 3.5% (wt/wt) DSS to induce colitis. The CD4+CD62L+ T cell transfer colitis was induced by an intraperitoneal injection of CD4+CD62L+ spleen T cells into recipient CB17 SCID mice. The FTY720 was administered by lavage at",Oncology reports,"Yasuyuki Deguchi, Akira Andoh, Yuki Yagi, Shigeki Bamba, Osamu Inatomi, Tomoyuki Tsujikawa, Yoshihide Fujiyama"," Department of Internal Medicine, Shiga University of Medical Science, Otsu 520-2192, Japan.",2006 Oct;16(4):699-703,NULL
16971715,20060914,article,"xref,mesh","Animals,Autoantigens,Cell Movement,Central Nervous System,Down-Regulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymph Nodes,Lysophospholipids,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocytes","adverse effects,agonists,analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pharmacology,physiology,therapeutic use","D013110 Q000009 NN,D011409 Q000009 NN,D002465 Q000187 NN,D002490 Q000276 NN,D008198 Q000276 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000819 NN,D007166 Q000627 NY,D013601 Q000187 NY,D013601 Q000502 NN,D020529 Q000188 NY,D011409 Q000494 NN,D008246 Q000378 NN,D009103 Q000276 NN,D013110 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D013110 Q000819 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.,NULL,The New England journal of medicine,"Steffen Massberg, Ulrich H von Andrian"," Harvard Medical School and at the CBR Institute for Biomedical Research, Boston, USA.",2006 Sep;355(11):1088-91,10.1056/nejmp068159
16971719,20060914,article,"xref,mesh","Adolescent,Adult,Brain,Brain Diseases,Double-Blind Method,Female,Fingolimod Hydrochloride,Gadolinium,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Respiratory Tract Infections,Sphingosine,Statistics, Nonparametric","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,pathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D001927 Q000139 NN,D020529 Q000473 NN,D001921 Q000473 NN,D007166 Q000627 NY,D012141 Q000139 NN,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","602,8252,23982,31270,107969,107970,5280335","128394615,129046631,129060975,129645792",Oral fingolimod (FTY720) for relapsing multiple sclerosis.,"BACKGROUND: Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis. METHODS: We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) and clinical evaluations (core study, months 0 to 6). The primary end point was the total number of gadolinium-enhanced lesions recorded on T(1)-weighted MRI at mont",The New England journal of medicine,"Ludwig Kappos, Jack Antel, Giancarlo Comi, Xavier Montalban, Paul O'Connor, Chris H Polman, Tomas Haas, Alexander A Korn, Goeril Karlsson, Ernst W Radue, FTY720 D2201 Study Group"," Department of Neurology, University Hospital, Basel, Switzerland. lkappos@uhbs.ch",2006 Sep;355(11):1124-40,10.1056/nejmoa052643
16986722,20060801,review,"xref,mesh","Animals,Biological Transport,Cell Membrane,Drug Design,Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lysophospholipids,Membrane Proteins,Neovascularization, Physiologic,Phosphoric Monoester Hydrolases,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Saccharomyces cerevisiae Proteins,Signal Transduction,Sphingosine","analogs &amp; derivatives,chemistry,metabolism,physiology","D008565 Q000502 NN,D013110 Q000031 NY,D029701 Q000502 NN,D013110 Q000737 NN,D013110 Q000378 NN,D017853 Q000502 NN,D008246 Q000502 NY,D010744 Q000502 NN,D008246 Q000378 NN,D008246 Q000737 NN,D002462 Q000378 NN,D049349 Q000502 NN,D013110 Q000502 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139","[Multifunctional sphingolipid, sphingosine (long-chain base) 1-phosphate: physiological role, metabolism, and intracellular dynamics].",NULL,Seikagaku. The Journal of Japanese Biochemical Society,Akio Kihara," Laboratory of Biomembrane and Biofunctional Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.",2006 Aug;78(8):725-37,NULL
17008548,20070201,article,"xref,mesh","Animals,Cell Degranulation,Cell Line,Cysteine,Cytosol,Eicosanoids,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukotrienes,Mast Cells,Phospholipases A,Phospholipases A2,Propylene Glycols,Prostaglandin D2,Rats,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,pharmacology,secretion","D015289 Q000557 NN,D007166 Q000494 NY,D003545 Q000557 NN,D015230 Q000557 NN,D013110 Q000031 NY,D011409 Q000494 NY,D015550 Q000187 NN,D010741 Q000037 NY,D015777 Q000037 NN,D013110 Q000494 NN,D049349 Q000819 YN","231,594,753,5862,8252,25150,31270,92851,105065,107969,107970,448457,5280335,53395091","128394615,128902940,129060975,129645792,129742316,129872283,136111139",The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.,"FTY720 is a potent immunomodulator drug that inhibits the egress of lymphocytes from secondary lymphoid tissues and thymus. FTY720 is phosphorylated in vivo by sphingosine kinase 2 to FTY720-phosphate, which acts as a potent sphingosine-1-phosphate (S1P) receptor agonist. However, in contrast to S1P, FTY720 has no effect on mast-cell degranulation, yet significantly reduces antigen-induced secretion of PGD2 and cysteinyl-leukotriene. Unexpectedly, this effect of FTY720 was independent of its phosphorylation",Blood,"Shawn G Payne, Carole A Oskeritzian, Rachael Griffiths, Preeti Subramanian, Suzanne E Barbour, Charles E Chalfant, Sheldon Milstien, Sarah Spiegel"," Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0614, USA.",2007 Feb;109(3):1077-85,10.1182/blood-2006-03-011437
17062723,20070101,article,"xref,mesh","Air Pollutants,Animals,Biomarkers,Calibration,Computer Simulation,DNA Adducts,Dose-Response Relationship, Drug,Epoxy Compounds,Evaluation Studies as Topic,Glutathione,Hemoglobins,Humans,Inhalation Exposure,Male,Models, Biological,Nose,Nose Neoplasms,Rats,Rats, Inbred F344,Reproducibility of Results,Risk Assessment,Sensitivity and Specificity,Time Factors,Tissue Distribution","blood,chemically induced,drug effects,metabolism,pharmacokinetics,toxicity","D000393 Q000633 NN,D006454 Q000378 NN,D009666 Q000378 NY,D018736 Q000378 NN,D009666 Q000187 NN,D009669 Q000139 NY,D004852 Q000097 NN,D004852 Q000493 NY,D005978 Q000378 NN,D004852 Q000633 NN,D015415 Q000378 NN,D000393 Q000097 NN,D000393 Q000493 NY","6378,124886,160438","53789864,127523511,127983601,129192846",A physiological toxicokinetic model for inhaled propylene oxide in rat and human with special emphasis on the nose.,"Chronic exposure to high concentrations of PO induced inflammation in the respiratory nasal mucosa (RNM) of rodents and, for concentrations >or= 300 ppm, caused nasal tumors. Considering the nose to be the most relevant target organ for PO-induced tumorigenicity, we developed a physiological toxicokinetic model for PO in rats and humans. It includes compartments for arterial, venous, and pulmonary blood, liver, muscle, fat, richly perfused tissues, lung, and nose. It simulates inhalation of PO, its distribu",Toxicological sciences : an official journal of the Society of Toxicology,"György A Csanády, Johannes G Filser"," Institute of Toxicology, GSF National Research Center for Environment and Health, D-85764 Neuherberg, Germany.",2007 Jan;95(1):37-62,10.1093/toxsci/kfl140
17100697,20060101,review,"xref,mesh","Clinical Trials as Topic,Fingolimod Hydrochloride,Graft Survival,Humans,Immunosuppressive Agents,Kidney Transplantation,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,therapeutic use","D006085 Q000187 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 (fingolimod) in renal transplantation.,"FTY720 (Fingolimod) is a novel immunomodulator with a mode of action that is completely different from classical immunosuppressants. FTY is a structural and functional analogue of the natural serum lipid, sphingosine, and is the first in a new class of drugs called sphingosine 1-phosphate receptor (S1P-R) modulators. This review discusses the recent findings on the mechanism of action, preclinical models and outlines the results of the ongoing clinical development program. FTY is highly effective in prolong",Clinical transplantation,"Klemens Budde, Manuela Schütz, Petra Glander, Harm Peters, Johannes Waiser, Lutz Liefeldt, Hans-H Neumayer, Torsten Böhler"," Department of Nephrology, Charité Universitatsmedizin Berlin, Berlin, Germany. klemens.budde@charite.de",2006 Jan;?(?):17-24,10.1111/j.1399-0012.2006.00596.x
17100731,20060101,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Organ Transplantation,Prognosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,metabolism,prevention &amp; control,therapeutic use","D013601 Q000378 NN,D006084 Q000378 NN,D013110 Q000031 NN,D049349 Q000187 NY,D007166 Q000627 NY,D013601 Q000276 NY,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NN,D006084 Q000517 NY,D049349 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.,"In this review, we summarize how FTY720 came from the lab bench to the bedside by examining its structural similarities to natural occurring sphingosine analogues, the mechanism of action, and clinical applicability to not only transplantation but also autoimmune, oncological, and neurobiological fields. FTY720, a sphingosine 1-phosphate (S1P) analogue, promotes the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. The mechanism of sequestration is thre",Clinical transplantation,"Adam C Yopp, Levi G Ledgerwood, Jordi C Ochando, Jonathan S Bromberg"," Department of Gene and Cell Medicine, The Mount Sinai School of Medicine, New York, NY 10029-6574, USA.",2006 Jan;20(6):788-95,10.1111/j.1399-0012.2006.00570.x
17112899,20061101,article,"xref,mesh","Animals,Apoptosis,Fas Ligand Protein,Fingolimod Hydrochloride,Immunosuppressive Agents,Intestinal Mucosa,Intestine, Small,Models, Animal,Peyer's Patches,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Sphingosine,Transplantation, Homologous,Transplantation, Isogeneic","analogs &amp; derivatives,analysis,drug effects,immunology,pathology,therapeutic use,transplantation","D007413 Q000473 NY,D017209 Q000187 NY,D007413 Q000187 NN,D010581 Q000473 NN,D010581 Q000187 NN,D013110 Q000031 NY,D014185 Q000473 NN,D007421 Q000637 NY,D007166 Q000627 NY,D010581 Q000276 NY,D007421 Q000473 NN,D014184 Q000473 NN,D013110 Q000627 NN,D053222 Q000032 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes in gut-associated lymphoid tissues.,"AIM: We investigated the extent of apoptosis in crypt cells and Peyer's patches (PPs) during small bowel allograft rejection in rats to examine the effect of FTY720 during rejection. METHODS: Orthotopic small bowel transplantations (SBTs) were performed from BN to LEW rats. Isografted animals served as controls. Three groups of SBT animals were studied on days 3, 5, and 7 after operation: isograft, untreated allograft, allograft with FTY720. FTY720 was orally administered by gavage (1 mg/kg/d) to allograft ",Transplantation proceedings,"K Sugito, T Koshinaga, M Inoue, T Ikeda, N Hagiwara, T Kusafuka, M Fukuzawa"," Nihon University, Pediatric Surgery, Tokyo, Japan. ksugito@hotmail.com",2006 Nov;38(9):3058-60,10.1016/j.transproceed.2006.08.147
17144774,20061101,article,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Practice Patterns, Physicians',Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use,trends","D007166 Q000627 NN,D002986 Q000639 NY,D013110 Q000031 NY,D010818 Q000639 NY,D000911 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.,NULL,Expert review of neurotherapeutics,Robert Weissert,NULL,2006 Nov;6(11):1587-90,10.1586/14737175.6.11.1587
17158351,20070301,article,"xref,mesh","Animals,Apolipoproteins E,Atherosclerosis,Cell Movement,Cells, Cultured,Cholesterol, Dietary,Cytokines,Disease Models, Animal,Fingolimod Hydrochloride,Gene Expression Regulation,Immunohistochemistry,Lysophospholipids,Mice,Mice, Inbred C57BL,Muscle, Smooth, Vascular,Probability,Propylene Glycols,RNA, Messenger,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Statistics, Nonparametric","administration &amp; dosage,analogs &amp; derivatives,analysis,cytology,deficiency,drug effects,genetics,metabolism,pharmacology,physiopathology,prevention &amp; control","D012333 Q000032 NN,D002465 Q000187 NN,D001057 Q000172 NY,D016207 Q000378 NN,D002791 Q000008 NN,D013110 Q000031 NY,D011409 Q000494 NY,D016207 Q000235 NN,D050197 Q000517 NY,D050197 Q000503 NN,D009131 Q000166 NN,D009131 Q000187 NN,D013110 Q000494 NN","5997,8252,31270,105065,107969,107970,5280335,5283560","128121087,128394615,129060975,129645792,136111139",The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.,"OBJECTIVE: The sphingosine-1-phosphate (S1P) analogue FTY720 is a potent immunosuppressive agent currently in Phase III clinical trials for kidney transplantation. FTY720 traps lymphocytes in secondary lymphoid organs thereby preventing their migration to inflammatory sites. Previously, we have identified FTY720 as a potent activator of eNOS. As both inhibition of immune responses and stimulation of eNOS may attenuate atherosclerosis, we administered FTY720 to apolipoprotein E-/- mice fed a high-cholesterol","Arteriosclerosis, thrombosis, and vascular biology","Petra Keul, Markus Tölle, Susann Lucke, Karin von Wnuck Lipinski, Gerd Heusch, Mirjam Schuchardt, Markus van der Giet, Bodo Levkau"," Institute of Pathophysiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.",2007 Mar;27(3):607-13,10.1161/01.atv.0000254679.42583.88
17161343,20061220,article,"xref,mesh","Animals,Antigens, CD,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cell Count,Cell Movement,Female,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Kidney,Liver,Lung,Lymph Nodes,Lymphocyte Depletion,Lymphoid Tissue,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Spleen,T-Lymphocyte Subsets,T-Lymphocytes","analogs &amp; derivatives,analysis,cytology,drug effects,immunology,pharmacology","D008221 Q000166 NN,D008168 Q000187 NN,D007668 Q000166 NN,D018414 Q000276 NN,D002465 Q000187 NN,D015496 Q000276 NN,D007668 Q000187 NN,D013601 Q000276 NN,D013154 Q000187 NN,D008221 Q000187 NY,D015496 Q000187 NN,D008198 Q000187 NN,D013154 Q000166 NN,D013110 Q000031 NY,D016176 Q000166 NN,D011409 Q000494 NY,D016176 Q000187 NN,D013601 Q000166 NN,D018414 Q000166 NN,D015496 Q000166 NN,D008099 Q000166 NN,D013601 Q000187 NY,D015703 Q000032 NN,D018414 Q000187 NN,D008198 Q000166 NN,D008168 Q000166 NN,D016176 Q000276 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.,"The sphingosine-1-phosphate receptor agonist FTY720 induces lymphopenia by inhibiting lymphocyte egress from thymus and lymph nodes. The immediate effect of the drug on T cells in blood and lymphoid tissues is well documented, however effects on peripheral T cell sub-populations have not been studied. We therefore analyzed the changes in T cell subset compositions in liver, lung, kidney, spleen, lymph nodes and blood induced by FTY720-treatment using 9-parameter flow cytometry. In untreated mice, naive T ce",International immunopharmacology,"Matthias Hofmann, Volker Brinkmann, Hans-Günter Zerwes"," Novartis Institutes for BioMedical Research, Transplantation Research, Autoimmunity/Transplantation Disease Area, Novartis Pharma AG, Basel, Switzerland. matthias.hofmann@novartis.com <matthias.hofmann@novartis.com>",2006 Dec;6(?):1902-10,10.1016/j.intimp.2006.07.030
17161344,20061220,article,"xref,mesh","Animals,Body Weight,Cell Count,Creatinine,Cyclosporine,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Survival,Histocompatibility Antigens Class II,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Kidney,Lymph Nodes,Lymphocyte Count,Lymphocytes,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Potassium,Propylene Glycols,Skin Transplantation,Sodium,Sphingosine,Spleen,Transplantation, Homologous","analogs &amp; derivatives,blood,cytology,drug effects,immunology,metabolism,pharmacology,physiology,therapeutic use","D000949 Q000378 NN,D001835 Q000187 NN,D016572 Q000627 NY,D013154 Q000187 NN,D007166 Q000627 NN,D008214 Q000378 NN,D007668 Q000187 NY,D008198 Q000187 NN,D003404 Q000097 NN,D013154 Q000166 NN,D013110 Q000031 NY,D007668 Q000502 NN,D012964 Q000378 NN,D011188 Q000097 NN,D008214 Q000166 NN,D006085 Q000187 NY,D006085 Q000276 NN,D016572 Q000494 NN,D008198 Q000166 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN,D012964 Q000097 NN,D018799 Q000378 NN","588,2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5360545,5458585,5462222,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,129060975,129645792",FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.,"Acute and chronic nephrotoxicity caused by CsA continuous administration impair kidney allograft survival. Several clinical and experimental protocols have shown benefits to the kidney after decreasing CsA dose, withdrawing the drug or delaying its introduction after transplantation. FTY720 is a new compound that has immunosuppressive characteristics and increase allograft survival in animal models without causing the side effects of calcineurin inhibitors (CNIs). FTY720 described mechanism of action that c",International immunopharmacology,"Francieli Ruiz Silva, Lea Bueno Lucas Silva, Patricia Maluf Cury, Emmanuel Almeida Burdmann, Valquiria Bueno"," UNESP, Ibilce, São Jose do Rio Preto, SP, Brazil.",2006 Dec;6(?):1911-8,10.1016/j.intimp.2006.07.014
17161821,20070101,article,"xref,mesh","B-Lymphocytes,CD11a Antigen,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Integrin alpha4,Kidney Transplantation,L-Selectin,Propylene Glycols,Receptors, CXCR4,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","agonists,analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D049349 Q000819 NN,D039441 Q000276 NN,D013601 Q000276 NN,D019718 Q000276 NN,D001402 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D019041 Q000276 NN,D001402 Q000276 NN,D013601 Q000187 NY,D016030 Q000276 NY,D013110 Q000494 NN,D040881 Q000276 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.,"FTY720, a sphingosine-1-phosphate receptor agonist, is the archeotype of a new class of immune modulators, which redirects lymphocytes from the peripheral blood into secondary lymphatic tissue. Previously, it was shown that FTY720 differentially decreases peripheral T-cells, expressing specific chemokine and adhesion receptors. Here, we investigated the effect of single doses FTY720 on peripheral B-cells expressing CD62L, CD11a, CD49d and CXCR4 in stable human renal allograft recipients. Peripheral blood ly",International immunopharmacology,"Torsten Böhler, Manuela Schütz, Klemens Budde, Hans-H Neumayer, Johannes Waiser"," Department of Internal Medicine-Nephrology, Charité Campus Mitte, Humboldt-University, Berlin, Germany. Boehlert@toulouse.inserm.fr",2007 Jan;7(1):88-95,10.1016/j.intimp.2006.08.018
17166789,20070101,article,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Brain,Canada,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interleukin-18,Multiple Sclerosis,Natalizumab,Propylene Glycols,Randomized Controlled Trials as Topic,Sex Factors,Sphingosine","adverse effects,analogs &amp; derivatives,deficiency,epidemiology,pathology,therapeutic use,therapy","D002170 Q000453 NN,D011409 Q000009 NN,D013110 Q000009 NN,D009103 Q000453 NN,D009103 Q000473 NN,D007166 Q000627 NN,D000911 Q000009 NN,D020382 Q000172 NN,D000911 Q000627 NN,D001921 Q000473 NN,D013110 Q000031 NN,D009103 Q000628 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D004681 Q000473 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Multiple sclerosis: new insights and therapeutic progress.,NULL,The Lancet. Neurology,David Miller," Institute of Neurology, University College London, London, UK. d.miller@ion.ucl.ac.uk",2007 Jan;6(1):5-6,10.1016/s1474-4422(06)70660-3
17168766,20060101,article,"xref,mesh","Amidohydrolases,Animals,Antineoplastic Agents,Apoptosis,Cell Movement,Cell Proliferation,Ceramidases,Ceramides,Enzyme Inhibitors,Fingolimod Hydrochloride,Humans,Lipid Metabolism,Lysophospholipids,Neoplasms,Neovascularization, Pathologic,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,blood supply,drug effects,drug therapy,metabolism,pathology,pharmacology,therapeutic use","D017853 Q000378 NN,D000970 Q000494 NY,D002465 Q000187 NN,D009369 Q000473 NN,D017209 Q000187 NN,D002518 Q000378 NY,D000581 Q000037 NN,D004791 Q000627 NN,D009369 Q000098 NN,D000581 Q000378 NN,D049109 Q000187 NN,D013110 Q000031 NY,D013110 Q000378 NN,D000970 Q000627 NN,D008246 Q000378 NY,D049349 Q000187 NN,D004791 Q000494 NY,D009389 Q000188 NN,D011409 Q000494 NN,D017853 Q000037 NN,D015398 Q000187 NN,D013110 Q000494 NN,D050356 Q000187 NY,D009369 Q000378 NY","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,135836815,136111139",Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.,"In recent years sphingolipids have emerged as important signaling molecules regulating fundamental cell responses such as cell death and differentiation, proliferation and aspects of inflammation. Especially ceramide has been a main focus of research since it possesses pro-apoptotic capacity in many cell types. A counterplayer of ceramide was found in sphingosine-1-phosphate (S1P), which is generated from ceramide by the consecutive actions of ceramidase and sphingosine kinase. S1P can potently induce cell ",Current pharmaceutical design,"Andrea Huwiler, Josef Pfeilschifter"," Pharmazentrum frankfurt, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.",2006 Jan;12(35):4625-35,10.2174/138161206779010422
17175216,20061201,article,"xref,mesh","Animals,Cytokines,Fingolimod Hydrochloride,Graft vs Host Disease,Immune Tolerance,Immunosuppressive Agents,Intestine, Small,Male,Propylene Glycols,Rats,Rats, Inbred ACI,Rats, Inbred WF,Sphingosine,T-Lymphocytes,Transplantation, Homologous,Transplantation, Isogeneic","analogs &amp; derivatives,biosynthesis,immunology,prevention &amp; control,therapeutic use,transplantation","D016207 Q000096 NN,D013110 Q000031 NY,D006086 Q000276 NY,D007421 Q000637 NY,D007166 Q000627 NY,D013601 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NY,D006086 Q000517 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation.,"AIMS: The potency of immunosuppression is a critical factor in small bowel transplantation (SBTx). FTY720 altered lymphocyte trafficking and prevented the donor T cells from migrating into target organs, resulting in the prolongation of recipient survival in acute graft-versus-host disease (GVHD) of SBTx. However, the effect of FTY720 on donor T cells in the chronic phase of GVHD following SBTx remains unclear. METHODS: Heterotopic SBTx was performed in a WF-to-F1 (WF x ACI) rat combination. Recipients were",Transplantation proceedings,"J Song, T Ito, C Matsuda, M Tanemura, T Nishida, M Nozawa, Y Sawa"," Department of Surgery (E1) Osaka University Graduate School of Medicine, Osaka, Japan.",2006 Dec;38(10):3181-3,10.1016/j.transproceed.2006.10.091
17175310,20061201,article,"xref,mesh","Drug Therapy, Combination,Everolimus,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Function Tests,Kidney Transplantation,Lymphocyte Count,Postoperative Complications,Propylene Glycols,Sirolimus,Sphingosine","analogs &amp; derivatives,epidemiology,immunology,pathology,pharmacokinetics,physiology,therapeutic use","D016030 Q000276 NN,D011183 Q000453 NN,D016030 Q000473 NN,D013110 Q000031 NY,D016030 Q000502 NY,D007166 Q000493 NN,D007166 Q000627 NY,D011409 Q000493 NN,D013110 Q000493 NN,D020123 Q000031 NY,D013110 Q000627 NN,D011409 Q000627 NY,D020123 Q000493 NN,D020123 Q000627 NN","8252,31270,107969,107970,5280335,5284616,6442177,90696889,91534498","128394615,129060975,129645792,242749350,248766214",Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.,"OBJECTIVE: We explored relationships between blood levels of fingolimod (FTY720) and everolimus versus treated biopsy-proven acute rejection (BPAR) in an open-label trial in de novo kidney transplant recipients. METHODS: Patients (n = 52) who fulfilled predefined criteria placing them at increased risk of delayed graft function received fingolimod 2.5 mg/d, everolimus 2 mg twice daily with trough blood levels (C0) adjusted to 4 to 8 ng/mL, and corticosteroids. Everolimus and fingolimod C0 were collected ove",Transplantation proceedings,"J M Kovarik, H Tedesco-Silva, M I Lorber, C Foster"," Department of Clinical Pharmacology, Novartis Pharma, Basel, Switzerland. john.kovarik@novartis.com",2006 Dec;38(10):3479-82,10.1016/j.transproceed.2006.10.084
17198261,20061227,article,"xref,mesh","Adult,Creatinine,Cyclosporine,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Middle Aged,Mycophenolic Acid,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,prevention &amp; control,therapeutic use,urine","D007166 Q000008 NN,D013110 Q000008 NN,D016572 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D003404 Q000652 NN,D007166 Q000627 NY,D009173 Q000008 NN,D009173 Q000031 NN,D009173 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NY,D006084 Q000517 NY","588,2909,4271,4272,8252,31270,62280,107969,107970,446541,5280335,5280754,5281078,5284373,5458585,6435893,6441022,9855081,23665584,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,128094727,128394615,129060975,129178479,129645792",Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.,"BACKGROUND: Phase II trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings. METHODS: This one-year, multicenter, randomized, phase III study in 696 de novo renal transplant patients compared FTY720 5 mg plus reduced-dose cyclosporine (RDC) or FTY720 2.5 mg plus full-dose cyclosporine (FDC) with mycophenolate mofetil (MMF) plus FDC. All patients received concomitant corticos",Transplantation,"Helio Tedesco-Silva, Mark D Pescovitz, Diane Cibrik, Michael A Rees, Shamkant Mulgaonkar, Barry D Kahan, Kristene K Gugliuzza, P R Rajagopalan, Ronaldo de M Esmeraldo, Hélène Lord, Maurizio Salvadori, Jennifer M Slade, FTY720 Study Group"," Setor de Transplante Renal, Hospital do Rim Hipertensão/ UNIFESP, Rua Borges, Lagoa, 960-11o andar, Sao Paulo, SP, Brazil. heliotedesco@hrim.com.br",2006 Dec;82(12):1689-97,10.1097/01.tp.0000251718.95622.b3
17200201,20070101,article,"xref,mesh","Animals,Cell Differentiation,Cells, Cultured,Extracellular Matrix Proteins,Fibroblasts,Fingolimod Hydrochloride,Immunologic Factors,Mice,Mice, Knockout,Muscle, Smooth,Phosphorylation,Propylene Glycols,Receptor Cross-Talk,Receptors, Lysosphingolipid,Signal Transduction,Smad3 Protein,Sphingosine,Transforming Growth Factor beta","analogs &amp; derivatives,biosynthesis,cytology,drug effects,metabolism,pharmacology,physiology","D016326 Q000096 NN,D049349 Q000378 NY,D005347 Q000166 NY,D020239 Q000187 NN,D002454 Q000187 YN,D005347 Q000378 NN,D007155 Q000494 NN,D016212 Q000494 NN,D013110 Q000031 NY,D011409 Q000494 NY,D009130 Q000166 NN,D002454 Q000502 YN,D009130 Q000378 NN,D013110 Q000494 NN,D015398 Q000187 NY,D051900 Q000378 NY","8252,31270,107969,107970,5280335,56842206","128394615,129060975,129645792",Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.,The novel immunomodulator FTY720 is an effective immunosuppressive agent in experimental models of transplantation and autoimmunity and is currently undergoing phase III clinical trials for multiple sclerosis. Phosphorylated FTY720 is a structural analogue of sphingosine 1-phosphate (S1P) and therefore acts as a high-affinity agonist at four of the five G protein-coupled S1P receptors. It has been well established that there exists a crosstalk between S1P and transforming growth factor (TGF)-beta signaling.,The American journal of pathology,"Christina D Keller, Pilar Rivera Gil, Markus Tölle, Markus van der Giet, Jerold Chun, Heinfried H Radeke, Monika Schäfer-Korting, Burkhard Kleuser"," Institute of Pharmacy, Pharmacology and Toxicology, Freie Universität Berlin, Königin-Luise-Str. 2+4, D-14195 Berlin, Germany.",2007 Jan;170(1):281-92,10.2353/ajpath.2007.060485
17203219,20070201,article,"xref,mesh","Animals,Antineoplastic Agents,Cell Line, Tumor,Cell Proliferation,Cell Survival,Disease Progression,Down-Regulation,Fingolimod Hydrochloride,Gene Expression Regulation, Neoplastic,Immunosuppressive Agents,Liver Neoplasms,Lymphocytes,Neoplasm Transplantation,Propylene Glycols,Proto-Oncogene Proteins c-akt,Rats,Sphingosine,Up-Regulation","analogs &amp; derivatives,drug therapy,immunology,metabolism,pharmacology,physiology","D008113 Q000276 NY,D051057 Q000502 NY,D000970 Q000494 NN,D008214 Q000378 NN,D008113 Q000378 NN,D008113 Q000188 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.,We aim to investigate the anticancer effect of a novel immunomodulator FTY720 on a rat orthotopic liver tumor model. A buffalo rat orthotopic liver tumor model was established by injection of a buffalo hepatoma cell line MH7777 into the right portal vein. FTY720 was administered by intraperitoneal injection starting at 10 days after tumor cell injection at a dosage of 5 mg/kg/day. FTY720 markedly suppressed tumor growth and inhibited tumor progression by selective induction of apoptosis of tumor cells via d,International journal of oncology,"Kevin T Ng, Kwan Man, Joanna W Ho, Chris K Sun, Terence K Lee, Yi Zhao, Chung Mau Lo, Ronnie T Poon, Sheung Tat Fan"," Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, PR China.",2007 Feb;30(2):375-80,NULL
17203465,20070501,article,"xref,mesh","Angiogenesis Inhibitors,Animals,Carcinoma, Lewis Lung,Cell Division,Cells, Cultured,Coculture Techniques,Collagen,Drug Combinations,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Laminin,Mice,Mice, Inbred C57BL,Muscle, Smooth,Neoplasm Transplantation,Neovascularization, Pathologic,Neutralization Tests,Oxadiazoles,Propylene Glycols,Proteoglycans,Receptors, CXCR4,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,Transcriptional Activation,Transplantation, Isogeneic,Umbilical V","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,blood,cytology,drug effects,drug therapy,pathology,pharmacology","D049349 Q000037 NY,D007166 Q000494 NY,D002455 Q000187 NN,D049349 Q000819 NN,D004730 Q000166 NN,D010069 Q000494 NN,D004730 Q000187 NN,D007797 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D003094 Q000187 NN,D014471 Q000166 NN,D042461 Q000494 NN,D009130 Q000166 NN,D018827 Q000473 NN,D020533 Q000494 NY,D009130 Q000187 NN,D013876 Q000494 NN,D019718 Q000097 NN,D013110 Q000494 NN,D009389 Q000188 NY,D011509 Q000187 NN","8252,31270,107969,107970,4077460,5280335,10523409","128394615,129060975,129645792",The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.,"FTY720, a sphingosine 1-phosphate (S1P) analog, acts as an immunosuppressant through trapping of T cells in secondary lymphoid tissues. FTY720 was also shown to prevent tumor growth and to inhibit vascular permeability. The MTT proliferation assay illustrated that endothelial cells are more susceptible to the anti-proliferative effect of FTY720 than Lewis lung carcinoma (LLC1) cells. In a spheroid angiogenesis model, FTY720 potently inhibited the sprouting activity of VEGF-A-stimulated endothelial cells eve",Journal of cellular biochemistry,"Gerald Schmid, Markus Guba, Ivan Ischenko, Armine Papyan, Mareile Joka, Sabine Schrepfer, Christiane J Bruns, Karl-Walter Jauch, Christopher Heeschen, Christian Graeb"," Department of Surgery, Ludwig-Maximilian University, Klinikum Grosshadern, Munich, Germany.",2007 May;101(1):259-70,10.1002/jcb.21181
17219691,20061220,article,"xref,mesh","Animals,Biomarkers,Blood Glucose,Creatinine,Diabetes Mellitus,Diuresis,Drug Synergism,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney,Lymphocyte Count,Lymphopenia,Male,Mice,Mice, Inbred C57BL,Potassium,Propylene Glycols,Sodium,Sphingosine,Tacrolimus","analogs &amp; derivatives,analysis,blood,chemically induced,drug effects,pharmacology,physiology,toxicity,urine","D003920 Q000139 NN,D015415 Q000652 NN,D007668 Q000187 NY,D008231 Q000139 NN,D004231 Q000187 NN,D003404 Q000097 NN,D013110 Q000633 NN,D013110 Q000031 NY,D011409 Q000494 NY,D015415 Q000097 NY,D007668 Q000502 NN,D003404 Q000652 NN,D007166 Q000633 NN,D016559 Q000633 NN,D011188 Q000097 NN,D012964 Q000652 NN,D016559 Q000494 NY,D013110 Q000494 NN,D011409 Q000633 NN,D007166 Q000494 NN,D012964 Q000097 NN,D001786 Q000032 NN","588,5372,5793,8252,31270,107969,107970,445643,5280335,5282315,5360545,5462222,6473866,6536850,71668407,90726579,134694629","127719861,128394615,129060975,129621433,129645792,242963342",Tacrolimus in combination with FTY720--an analysis of renal and blood parameters.,"Calcineurin inhibitors (CNIs) are routinely used in immunosuppressive therapy and both Cyclosporine (CsA) and Tacrolimus (FK506) show similar efficacies to prevent rejection and death within the first year after organ transplantation. However, their use is limited by side effects such as kidney damage, hypertension, onset of diabetes and hyperlipidemia. It is a consensus that compared with CsA, FK506 causes less changes in blood pressures, serum lipids and renal function. Nevertheless, FK506 use is associat",International immunopharmacology,"Ana Paula Gallo, Lea Bueno Lucas Silva, Marcello Franco, Emmanuel Almeida Burdmann, Valquiria Bueno"," FAMERP São José do Rio Preto Medical School, Av.Brig.Faria Lima, 5416, Rua Francisco Giglioti, 160 ap 71, São Jose do Rio Preto, SP 15090-000, Brazil.",2006 Dec;6(?):1919-24,10.1016/j.intimp.2006.07.012
17219813,20061001,article,"xref,mesh","Acute Disease,Administration, Intravaginal,Anti-Bacterial Agents,Chitosan,Female,Humans,Inflammation,Lactic Acid,Middle Aged,Streptococcal Infections,Streptococcus agalactiae,Treatment Outcome,Vaginal Discharge,Vaginosis, Bacterial","administration &amp; dosage,complications,diagnosis,drug therapy,etiology,isolation &amp; purification,microbiology","D007249 Q000188 NN,D013292 Q000302 NY,D016585 Q000382 NY,D000900 Q000008 NN,D019522 Q000188 NN,D016585 Q000188 NN,D007249 Q000382 NY,D048271 Q000008 NN,D019344 Q000008 NN,D007249 Q000175 NN,D013290 Q000150 NY,D016585 Q000175 NN,D019522 Q000209 NN","612,753,61503,62358,71853,91435,107689,21896651",128902940,"[Acute, hemorrhagic, overgrowing vaginal inflammation caused by Streptococcus agalacitae--case study].","The aim of this study was to discuss a case of an acute, hemorrhagic, overgrowing vaginal inflammation caused by Streptococcus agalacitae. Intravaginal globules based on methylcellulose and gelatin, containing a lactic acid and chitosan complex in mole relation 1:1 to 4:1 and, in succesion, an addition of hydrophilisating substances like: PEG-200, propylene-1,2 glycol or glycerol, were applied in the treatment process. The technology was invented in Fac. of pharmacy. Dep. of Pharmaceutical Technology, Wrocl",Ginekologia polska,"Lidia Hirnle, Katarzyna Małolepsza-Jarmołowska, Aleksander A Kubis, Piotr Hirnle"," Klinika Rozrodczości i Poloznictwa AM, we Wroclawiu. lidiahirnle@tlen.pl",2006 Oct;77(10):793-6,NULL
17226956,20070101,article,"xref,mesh","Animals,Antineoplastic Agents,Cell Line, Tumor,Drug Delivery Systems,Drug Design,Female,Humans,Mice,Molecular Structure,Neoplasms,Propylene Glycol,Receptors, Transferrin,Transferrin,Tumor Necrosis Factor-alpha","chemical synthesis,chemistry,drug therapy,metabolism,methods,pathology,pharmacology","D000970 Q000378 NN,D014409 Q000494 NY,D009369 Q000473 NN,D000970 Q000494 NN,D014409 Q000138 NN,D014168 Q000737 NY,D014409 Q000737 NN,D009369 Q000188 NN,D011990 Q000378 NY,D000970 Q000737 NN,D014168 Q000378 NY,D016503 Q000379 NY,D019946 Q000737 NY","1030,8252,10935","128903125,129060975","Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.","PEGylation is a procedure of growing interest for enhancing the therapeutic and biotechnological potential of peptides and proteins. Transferrin (Tf) has been proposed to be useful for targeting cancer cells. The aim of this study was to modify PEGylated recombinant human tumor necrosis factor alpha (PEG-TNF-alpha) with Tf to form Tf-PEG-TNF-alpha conjugates, which would maintain the advantages of PEGylation and also achieve the function of active targeting to tumor cells. In PEGylation reactions with 5-, 2",Bioconjugate chemistry,"Yan-Yan Jiang, Chen Liu, Ming-Huang Hong, Sai-Jie Zhu, Yuan-Ying Pei"," Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, China, 200032.",2007 Jan;18(1):41-9,10.1021/bc060135f
17230596,20070301,article,"xref,mesh","Administration, Oral,Adult,Area Under Curve,Biological Availability,Cross-Over Studies,Female,Fingolimod Hydrochloride,Heart,Heart Rate,Humans,Immunosuppressive Agents,Injections, Intravenous,Lymphocyte Count,Lymphocytes,Male,Middle Aged,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug effects,pharmacokinetics,pharmacology","D007166 Q000494 NY,D011409 Q000493 NY,D007166 Q000008 NN,D013110 Q000008 NN,D007166 Q000493 NY,D008214 Q000187 NY,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D006321 Q000187 NY,D013110 Q000493 NN,D006339 Q000187 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.","OBJECTIVE: The pharmacokinetics and lymphocyte responses to the immunomodulator fingolimod (FTY720) were characterized after oral and intravenous administration. METHODS: In this randomized, two-period crossover study 11 evaluable healthy subjects received single doses of fingolimod 1.25 mg orally and 1 mg intravenously infused over 2 h. The pharmacokinetics of fingolimod, blood lymphocyte counts and heart rate were characterized for 28 days after each dose. RESULTS: After oral administration, Cmax was 1.1+",Biopharmaceutics & drug disposition,"John M Kovarik, Stefan Hartmann, Michael Bartlett, Gilles-Jacques Riviere, Daniel Neddermann, Yibin Wang, Andreas Port, Robert L Schmouder"," Novartis Pharmaceuticals, Basel, Switzerland. john.kovarik@novartis.com",2007 Mar;28(2):97-104,10.1002/bdd.535
17234743,20070501,article,"xref,mesh","Animals,Antibodies, Antiphospholipid,Antibodies, Bacterial,B-Lymphocytes,Bacterial Vaccines,Cell Movement,Female,Fingolimod Hydrochloride,Immunoglobulin A,Immunoglobulin J-Chains,Immunosuppressive Agents,Intestine, Small,Lymphoid Tissue,Lysophospholipids,Mice,Mice, Inbred BALB C,Mice, Inbred ICR,Mice, SCID,Peritoneal Cavity,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Streptococcus pneumoniae,Vaccination","agonists,analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology,secretion","D007070 Q000276 NY,D007166 Q000494 NY,D007421 Q000276 NY,D008246 Q000494 NN,D049349 Q000819 NY,D013296 Q000276 NN,D002465 Q000187 NY,D000907 Q000096 NN,D000907 Q000276 NN,D001402 Q000276 NY,D007421 Q000557 NN,D049349 Q000276 NN,D049349 Q000096 NN,D001428 Q000494 NN,D001428 Q000276 NN,D017152 Q000096 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008221 Q000378 NN,D007070 Q000378 NN,D007144 Q000096 NN,D013110 Q000494 NN,D008221 Q000276 NN,D017152 Q000276 NN,D001402 Q000378 NN,D007144 Q000276 NN","8252,31270,107969,107970,5280335,5283560,10149006","128394615,129060975,129645792,135990222",Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production.,"Sphingosine 1-phosphate (S1P) is known to play a pivotal role in the regulation of lymphocyte emigration from organized lymphoid tissues such as the peripheral lymph nodes and thymus, but its immunologic role in unorganized and diffused tissues remains to be elucidated. Here we show that the trafficking of peritoneal B cells is principally regulated by S1P. All peritoneal B cells including B1a, B1b, and B2 B cells express comparable levels of the type 1 S1P receptor. Thus, treatment with FTY720, an S1P rece",Blood,"Jun Kunisawa, Yosuke Kurashima, Masashi Gohda, Morio Higuchi, Izumi Ishikawa, Fumi Miura, Ikuko Ogahara, Hiroshi Kiyono"," Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.",2007 May;109(9):3749-56,10.1182/blood-2006-08-041582
17237497,20070323,article,"xref,mesh","Angiogenesis Inhibitors,Cell Line,Enzyme Inhibitors,Fingolimod Hydrochloride,Green Fluorescent Proteins,Humans,Immunosuppressive Agents,Leupeptins,Ligands,Microscopy, Confocal,Propylene Glycols,Proteasome Endopeptidase Complex,Protein Binding,Receptors, Lysosphingolipid,Sphingosine,Ubiquitin","agonists,analogs &amp; derivatives,chemistry,metabolism,pharmacology","D007166 Q000494 NY,D025801 Q000737 NY,D007976 Q000494 NN,D049349 Q000819 NY,D013110 Q000031 NY,D011409 Q000494 NY,D046988 Q000378 NY,D020533 Q000494 NY,D049452 Q000378 NN,D004791 Q000494 NN,D013110 Q000494 NN","8252,31270,107969,107970,425562,462382,5280335,53863337","128022692,128394615,129060975,129645792",Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.,"Sphingosine 1-phosphate (S1P), a multifunctional lipid mediator, regulates lymphocyte trafficking, vascular permeability, and angiogenesis by activation of the S1P1 receptor. This receptor is activated by FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720. However, in contrast to the natural ligand S1P, FTY720-P appears to act as a functional antagonist, even though the mechanisms involved are poorly understood. In this study, we investigated the fate of endogenous",The Journal of biological chemistry,"Myat Lin Oo, Shobha Thangada, Ming-Tao Wu, Catherine H Liu, Timothy L Macdonald, Kevin R Lynch, Chen-Yong Lin, Timothy Hla"," Center for Vascular Biology, University of Connecticut Health Center, Farmington, Connecticut 06030-3501, USA.",2007 Mar;282(12):9082-9,10.1074/jbc.m610318200
17242282,20070130,article,"xref,mesh","Animals,Atherosclerosis,Cell Division,Cholesterol, HDL,Cytokines,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Count,Lymphocytes,Lysophospholipids,Macrophages,Mice,Mice, Inbred C57BL,Mice, Mutant Strains,Propylene Glycols,Receptors, LDL,Signal Transduction,Sphingosine,Triglycerides","analogs &amp; derivatives,blood,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D008264 Q000276 NN,D011973 Q000235 NY,D002455 Q000187 NN,D050197 Q000473 NN,D008214 Q000473 NN,D050197 Q000188 NY,D015398 Q000276 NN,D008076 Q000097 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008264 Q000473 NN,D013110 Q000378 NN,D050197 Q000276 NN,D008264 Q000187 NN,D014280 Q000097 NN,D008214 Q000276 NN,D016207 Q000097 NN,D008246 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D008214 Q000187 NN,D002455 Q000276 NN","5997,8252,31270,107969,107970,5280335,5283560","128121087,128394615,129060975,129645792","FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.","BACKGROUND: Numerous in vitro studies suggest that sphingosine 1-phosphate (S1P), a bioactive lysosphingolipid associated with high-density lipoproteins, accounts at least partly for the potent antiinflammatory properties of high-density lipoprotein and, thereby, contributes to the antiatherogenic potential attributed to high-density lipoproteins. The present study was undertaken to investigate whether modulation of S1P signaling would affect atherosclerosis in a murine model of disease. METHODS AND RESULTS",Circulation,"Jerzy-Roch Nofer, Martine Bot, Martin Brodde, Paul J Taylor, Paul Salm, Volker Brinkmann, Theo van Berkel, Gerd Assmann, Erik A L Biessen"," Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität Münster, Albert Schweizer Str 33, D-48129 Münster, Germany. nofer@uni-muenster.de",2007 Jan;115(4):501-8,10.1161/circulationaha.106.641407
17276731,20070301,review,"xref,mesh","Animals,Antigens, CD,Antigens, Differentiation, T-Lymphocyte,Cell Movement,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Lectins, C-Type,Lymphocytes,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,metabolism,pharmacology,physiology","D015703 Q000502 NN,D000945 Q000502 NN,D008214 Q000502 NN,D013110 Q000031 NY,D008246 Q000502 NY,D011409 Q000494 NN,D013110 Q000494 NN,D004730 Q000378 NY,D049349 Q000502 NN,D013110 Q000502 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Tipping the gatekeeper: S1P regulation of endothelial barrier function.,"The lysophospholipid sphingosine 1-phosphate (S1P) is a pleiotropic signaling lipid present constitutively in plasma, and secreted locally at elevated concentrations at sites of inflammation. S1P maintains essential variable homeostatic functions in addition to inducing pathophysiology through the activation of five specific high-affinity G-protein-coupled receptors. Therefore, S1P can function as an extracellular rheostat regulating tonic and acutely evoked functions. Although S1P receptors can regulate ly",Trends in immunology,"Hugh Rosen, M Germana Sanna, Stuart M Cahalan, Pedro J Gonzalez-Cabrera"," Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA. hrosen@scripps.edu",2007 Mar;28(3):102-7,10.1016/j.it.2007.01.007
17277153,20070215,article,"xref,mesh","Animals,Antigens, CD,Antigens, Differentiation,Aziridines,CTLA-4 Antigen,Cell Differentiation,Choline,Colitis,Cytokines,Disease Models, Animal,Down-Regulation,Fingolimod Hydrochloride,Forkhead Transcription Factors,Immunosuppressive Agents,Inflammation,Inflammatory Bowel Diseases,Intestinal Mucosa,Male,Mice,Mice, Inbred BALB C,Neuromuscular Blocking Agents,Propylene Glycols,Sphingosine,T-Lymphocytes, Regulatory,Th1 Cells","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pathology,pharmacology,toxicity","D007249 Q000188 NN,D007166 Q000494 NY,D003092 Q000139 NN,D016207 Q000276 NN,D003092 Q000188 NN,D002794 Q000031 NN,D015536 Q000187 NN,D015212 Q000473 NN,D018417 Q000276 NY,D002794 Q000633 NN,D050378 Q000276 NY,D001388 Q000633 NN,D007249 Q000139 NN,D015536 Q000276 NN,D013110 Q000031 NY,D007413 Q000473 NN,D011409 Q000494 NY,D050378 Q000473 NN,D003092 Q000276 NY,D015212 Q000276 NN,D000943 Q000276 NN,D018417 Q000473 NN,D015703 Q000276 NN,D007249 Q000276 NN,D009466 Q000633 NN,D015212 Q000188 NN,D007413 Q000276 NN","305,485,6209,6900,8252,31255,31270,45414,60232,80661,107969,107970,5280335,10198924,57206506,100914982","128394615,128799283,128933135,129060975,129645792,136128132",FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.,"Following the present concepts, the synthetic sphingosine analog of myriocin FTY720 alters migration and homing of lymphocytes via sphingosine 1-phosphate receptors. However, several studies indicate that the immunosuppressive properties of FTY720 may alternatively be due to tolerogenic activities via modulation of dendritic cell differentiation or based on direct effects on CD4(+)CD25(+) regulatory T cells (Treg). As Treg play an important role for the cure of inflammatory colitis, we used the Th1-mediated","Journal of immunology (Baltimore, Md. : 1950)","Carolin Daniel, Nico Sartory, Nadine Zahn, Gerd Geisslinger, Heinfried H Radeke, Juergen M Stein"," First Department of Internal Medicine, Entwicklung und Sicherheit-ZAFES, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.",2007 Feb;178(4):2458-68,10.4049/jimmunol.178.4.2458
17283580,20070101,article,"xref,mesh","Administration, Oral,Animals,Antibodies, Antinuclear,Apoptosis,Autoantigens,Cell Movement,Chromatin,Complement C3,Complement C3 Nephritic Factor,Cyclophosphamide,Disease Models, Animal,Dose-Response Relationship, Drug,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,Glomerular Mesangium,Immunoglobulin G,Immunosuppressive Agents,Injections, Intraperitoneal,Kidney Glomerulus,Lupus Nephritis,Lymphocytes,Mice,Mice, Inbred NZB,Nucleosomes,Propylene Glycols,Proteinuria,Receptors, Lysosphingolipid,Siro","administration &amp; dosage,analogs &amp; derivatives,analysis,blood,drug effects,drug therapy,etiology,genetics,immunology,pathology,pharmacology,therapeutic use","D002465 Q000187 NN,D007678 Q000473 NN,D001324 Q000276 NN,D000974 Q000097 NN,D003178 Q000032 NN,D008181 Q000473 NN,D009707 Q000276 NN,D013110 Q000008 NN,D002843 Q000276 NN,D020123 Q000008 NN,D013110 Q000031 NY,D007074 Q000032 NN,D007678 Q000276 NN,D011409 Q000008 NN,D020123 Q000494 NN,D011507 Q000209 NN,D005920 Q000473 NN,D007166 Q000627 NY,D049349 Q000187 NN,D008181 Q000276 NN,D003176 Q000032 NN,D017209 Q000276 NN,D008181 Q000188 NY,D011409 Q000494 NN,D020123 Q000627 NY,D003520 Q000627 NN,D008181 Q000235 NN","2907,8252,22420,31270,107969,107970,5280335,5284616,91534498","128394615,129060975,129645792,248766214",New immunosuppresor strategies in the treatment of murine lupus nephritis.,"Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Although treatment with corticosteroids and cytotoxic drugs may be useful in many cases, morbidity associated with these drugs and the relapsing nature of the disease make it necessary to develop new treatment strategies. Five-month old female NZB/W F1 mice were divided into the following groups: CYP group (n = 10), cyclophosphamide (CYP) 50 mg/kg intraperitoneally every 10 days; RA",Lupus,"G Alperovich, I Rama, N Lloberas, M Franquesa, R Poveda, M Gomà, I Herrero-Fresneda, J M Cruzado, N Bolaños, M Carrera, J M Grinyó, J Torras"," Laboratori de Nefrologia Experimental, Hospital de Bellvitge, Barcelona, Spain. galper75@hotmail.com",2007 Jan;16(1):18-24,10.1177/0961203306073136
17323348,20070401,article,"xref,mesh","Apoptosis,Caspases,Cytochrome c Group,DNA Fragmentation,Enzyme Inhibitors,Fingolimod Hydrochloride,Flow Cytometry,Humans,Jurkat Cells,Ligands,Membrane Potential, Mitochondrial,Membrane Proteins,Mitochondrial Proteins,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Sphingosine,Time Factors,Transfection","analogs &amp; derivatives,analysis,immunology,metabolism,pharmacology","D019253 Q000378 NN,D024101 Q000032 NN,D008565 Q000378 NY,D008565 Q000032 NN,D013110 Q000031 NN,D008565 Q000276 NN,D024101 Q000378 NY,D024101 Q000276 NN,D020169 Q000378 NY,D003574 Q000378 NN,D011409 Q000494 NN,D004791 Q000494 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Mechanism of mitochondrial 7A6 antigen exposure triggered by distinct apoptotic pathways: involvement of caspases.,"BACKGROUND: During the early stages of apoptosis, 7A6 antigen is exposed on mitochondria. 7A6 antigen is observed in various cells and is thought to be a specific marker of apoptosis determination. However, the exposure mechanism of 7A6 during apoptosis is poorly understood. METHODS: In this study, we used two major distinct (mitochondria-mediated and receptor-mediated) apoptotic pathways to elucidate the 7A6 exposure pathway. Jurkat cells were incubated with either a mitochondrial permeability transition p",Cytometry. Part A : the journal of the International Society for Analytical Cytology,"Yukitoshi Nagahara, Masato Tanaka, Takahisa Shinomiya"," Department of Biotechnology, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama 350-0394, Japan. yunagahara@b.dendai.ac.jp",2007 Apr;71(4):232-41,10.1002/cyto.a.20359
17323789,20070201,article,"xref,mesh","Area Under Curve,Asian Continental Ancestry Group,Dose-Response Relationship, Drug,Double-Blind Method,Drug Administration Schedule,European Continental Ancestry Group,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Inactivation, Metabolic,Lymphocyte Count,Lymphocytes,Male,Metabolic Clearance Rate,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,blood,cytology,drug effects,ethnology,pharmacokinetics,urine","D013110 Q000097 NN,D011409 Q000009 NN,D013110 Q000009 NN,D011409 Q000493 NY,D007166 Q000097 NN,D011409 Q000652 NN,D007166 Q000493 NY,D013110 Q000031 NY,D013110 Q000652 NN,D008658 Q000208 NN,D007166 Q000652 NN,D008214 Q000166 NN,D013110 Q000493 NN,D006339 Q000187 NN,D007166 Q000009 NN,D008214 Q000187 NN,D011409 Q000097 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Ethnic sensitivity study of fingolimod in white and Asian subjects.,"OBJECTIVE: The authors compared the pharmacokinetics and pharmacological effects of the immunomodulator fingolimod in healthy white and Asian subjects for potential ethnic differences. METHODS: White and Asian (Japanese) healthy subjects were demographically matched for sex, age and weight. Subjects received single 1.25 mg doses of fingolimod (6 ethnic pairs), 2.5 mg (7 pairs), 5 mg (6 pairs) or 5 mg/day for 7 days (6 pairs). The pharmacokinetics of fingolimod, major metabolites, peripheral blood lymphocyte",International journal of clinical pharmacology and therapeutics,"J M Kovarik, A Slade, B Voss, H Schmidli, G J Riviere, F Picard, Y Sugita, R Kawai, D Mee-Lee, R L Schmouder"," Novartis Pharmaceuticals, Basle, Switzerland. john.kovarik@Novartis.com",2007 Feb;45(2):98-109,NULL
17325654,20070401,article,"xref,mesh","Animals,Anti-Inflammatory Agents,Arachidonic Acid,Cells, Cultured,Fingolimod Hydrochloride,Group II Phospholipases A2,Histone Deacetylase Inhibitors,Hydroxamic Acids,Immunosuppressive Agents,Interleukin-1beta,Mesangial Cells,Phospholipases A,Phospholipases A2,Propylene Glycols,Protein Synthesis Inhibitors,RNA, Messenger,Rats,Sphingosine,Transcription, Genetic","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D006877 Q000494 NN,D000893 Q000494 NY,D010741 Q000235 NN,D013110 Q000031 NY,D011409 Q000494 NY,D010741 Q000378 NN,D011500 Q000494 NN,D053583 Q000494 NN,D016718 Q000378 NN,D012333 Q000378 NN,D010741 Q000037 NY,D050527 Q000378 NN,D014158 Q000187 NN,D013110 Q000494 NN,D050527 Q000187 NY","231,8252,31270,105065,107969,107970,444732,444899,5280335,23675453,91145047","128394615,129060975,129645792,129872283,136111139,245921350",FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism.,BACKGROUND AND PURPOSE: FTY720 is a potent immunomodulatory prodrug that is converted to its active phosphorylated form by a sphingosine kinase. Here we have studied whether FTY720 mimicked the action of sphingosine-1-phosphate (S1P) and exerted an anti-inflammatory potential in renal mesangial cells. EXPERIMENTAL APPROACH: Prostaglandin E(2) (PGE(2)) was quantified by an enzyme-linked immunosorbent-assay. Secretory phospholipase A(2) (sPLA(2)) protein was detected by Western blot analyses. mRNA expression ,British journal of pharmacology,"C Xin, S Ren, W Eberhardt, J Pfeilschifter, A Huwiler"," Institute of Pharmacology, University of Bern, Bern, Switzerland.",2007 Apr;150(7):943-50,10.1038/sj.bjp.0707171
17339438,20070315,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Cell Movement,Cells, Cultured,Dendritic Cells,Dose-Response Relationship, Drug,Down-Regulation,Endocytosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, Knockout,Oxadiazoles,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Thiophenes","agonists,analogs &amp; derivatives,cytology,deficiency,drug effects,genetics,immunology,metabolism,pharmacology","D015496 Q000378 NN,D002465 Q000187 NN,D004705 Q000187 NN,D049349 Q000819 NN,D015536 Q000235 NN,D004705 Q000276 NY,D015536 Q000187 NN,D002465 Q000235 NN,D010069 Q000494 NN,D002465 Q000276 NY,D003713 Q000166 NN,D015536 Q000276 NN,D013110 Q000031 NY,D015496 Q000276 NY,D013110 Q000276 NN,D015496 Q000166 NN,D003713 Q000276 NY,D013876 Q000494 NN,D004705 Q000235 NN,D011409 Q000494 NN,D008246 Q000276 NY,D003713 Q000378 NN,D049349 Q000276 NY,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000172 NN","8252,31270,107969,107970,4077460,5280335,5283560,10523409","128394615,129060975,129645792",Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.,"Dendritic cells (DCs) and lymphocytes are known to show a migratory response to the phospholipid mediator, sphingosine 1-phosphate (S1P). However, it is unclear whether the same S1P receptor subtype mediates the migration of lymphocytes and DCs toward S1P. In this study, we investigated the involvement of S1P receptor subtypes in S1P-induced migration of CD4 T cells and bone marrow-derived DCs in mice. A potent S1P receptor agonist, the (S)-enantiomer of FTY720-phosphate [(S)-FTY720-P], at 0.1 nM or higher ","Journal of immunology (Baltimore, Md. : 1950)","Yasuhiro Maeda, Hirofumi Matsuyuki, Kyoko Shimano, Hirotoshi Kataoka, Kunio Sugahara, Kenji Chiba"," Research Laboratory III (Immunology), Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Japan.",2007 Mar;178(6):3437-46,10.4049/jimmunol.178.6.3437
17344585,20070201,article,"xref,mesh","Animals,Antibodies, Monoclonal,Dose-Response Relationship, Drug,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunoglobulin M,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Interferon-gamma,Interleukin-2,Interleukin-4,Mice,Mice, Inbred BALB C,Propylene Glycols,Rats,Rats, Wistar,Sphingosine,Time Factors,Transplantation, Heterologous","adverse effects,analogs &amp; derivatives,blood,drug effects,etiology,immunology,methods,prevention &amp; control,therapeutic use","D006085 Q000187 NN,D018799 Q000276 NY,D015847 Q000097 NN,D016027 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D006084 Q000209 NN,D000911 Q000627 NY,D006084 Q000097 NN,D007075 Q000097 NN,D016027 Q000379 NY,D006084 Q000517 NN,D013110 Q000627 NN,D007371 Q000097 NN,D011409 Q000627 NY,D007376 Q000097 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[Effect of mono and combination therapy with FTY720 and ICAM-1 mAb for mouse-to-rat cardiac xenotransplantation].,"OBJECTIVE: To observe the effect of FTY720 and ICAM-1 mAb mono and combination therapy in mouse-to-rat cardiac xenotransplantation. METHODS: Cardiac xenotransplantation was performed in abdominal site with micro-surgical technique. Recipients with xenografts were treated with different doses of FTY720 and/or ICAM-1 mAb. Graft survival, histopathology, infiltration of CD4+, and CD8+ T cells and levels of serum IL-2, IFN-gamma, IL-4, and IgM were investigated. RESULTS: Survival time of xenografts was (2.75+/-",Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,"Hai-Bo Xiong, Zu-Fa Huang, Qi-Fa Ye, Sui-Sheng Xia"," Institute of Transplantation, Third Xiangya Hospital, Central South University, Changsha 410013, China. haiboxiong@sohu.com",2007 Feb;32(1):41-6,NULL
17352219,20070101,article,"xref,mesh","Animals,Antineoplastic Agents,Apoptosis,Carcinoma, Renal Cell,Caspase 3,Caspase 8,Cell Growth Processes,Cell Line, Tumor,Cisplatin,Dose-Response Relationship, Drug,Drug Resistance, Neoplasm,Drug Synergism,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Neoplasms,Kidney Tubules,Male,Mice,Mice, Inbred BALB C,Nephrectomy,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,Sphingosine,Xenograft Model Antitumor Assays,fas Receptor","analogs &amp; derivatives,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology,physiology,surgery,toxicity","D007680 Q000188 NY,D002292 Q000473 NN,D048708 Q000187 NN,D053181 Q000378 NN,D017209 Q000187 NN,D007684 Q000187 NN,D000970 Q000494 NN,D007684 Q000166 NN,D002292 Q000188 NY,D017209 Q000502 NN,D013110 Q000633 NN,D002945 Q000494 NN,D013110 Q000031 NY,D011409 Q000494 NY,D019014 Q000378 NY,D007680 Q000473 NN,D019253 Q000378 NY,D007166 Q000633 NN,D048049 Q000378 NN,D053148 Q000378 NN,D002292 Q000601 NN,D013110 Q000494 NN,D011409 Q000633 NN,D007166 Q000494 NN,D002292 Q000378 NN,D007680 Q000378 NN,D007680 Q000601 NN","8252,31270,84691,107969,107970,441203,5280335","128394615,129060975,129645792",FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.,"BACKGROUND: A unique immunosuppressant, FTY720, selectively induces apoptosis in activated lymphocytes, but not in other hematopoietic cells. The potential that this unique mechanism could provide anticancer potential by inducing apoptosis in the human renal cancer cell line, ACHN, which is resistant to cisplatin, and its molecular pathway was investigated. MATERIALS AND METHODS: The difference in drug susceptibility to FTY720 between cancer cells and non-cancer cells was examined by MTT assay and flow cyto",Anticancer research,"Takanobu Ubai, Haruhito Azuma, Yatsugu Kotake, Teruo Inamoto, Kiyoshi Takahara, Yuko Ito, Satoshi Kiyama, Takeshi Sakamoto, Shigeo Horie, Satoru Muto, Shiro Takahara, Yoshinori Otsuki, Yoji Katsuoka"," Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.",2007 Jan;27(1A):75-88,NULL
17353787,20070315,article,"xref,mesh","Adrenergic Antagonists,Adult,Female,Fingolimod Hydrochloride,Heart Conduction System,Heart Rate,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Middle Aged,Mycophenolic Acid,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D016030 Q000276 NN,D007166 Q000627 NN,D006329 Q000187 NN,D009173 Q000031 NY,D006329 Q000276 NY,D013110 Q000031 NY,D016030 Q000502 NY,D006339 Q000187 NN,D009173 Q000627 NN,D013110 Q000627 NN,D018674 Q000627 NN,D011409 Q000627 NY,D006339 Q000502 NY","4271,4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,23665584","128094727,128394615,129060975,129178479,129645792",Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.,"The novel immunomodulator FTY720 has been associated with a mild reduction in heart rate (HR) in clinical trials. A total of 421 patients (FTY720, n=94; mycophenolate mofetil [MMF], n=327) underwent 2-day electrocardiogram and 24-h Holter monitoring. Patients had been maintained on cyclosporine plus MMF or FTY720 (2.5 mg and 5.0 mg) for > or =12 months. No significant differences in mean hourly heart rate (HR) over 24 hrs were noted between groups. Bradycardia (HR 35-50 bpm) and sustained bradycardia (HR <5",Transplantation,"Federico Oppenheimer, Shamkant Mulgaonkar, Ronald Ferguson, Josep Grinyó, Federico Juarez, Marek Ostrowski, Marian Klinger, Rowan Walker, Armando Torres, Ralph Preiss, Malika Cremer, Alan Jardine, FTY720 2216 Clinical Study Group"," Hospital Clinico y Provincial de Barcelona, Barcelona, Spain. OPPEN@clinic.ub.es",2007 Mar;83(5):645-8,10.1097/01.tp.0000253421.18892.b8
17359484,20070301,review,"xref,mesh","Anti-Inflammatory Agents,Apoptosis,Atherosclerosis,Endothelial Cells,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,therapeutic use","D042783 Q000378 NN,D017209 Q000187 NN,D049349 Q000627 NY,D050197 Q000188 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D008246 Q000627 NY,D000893 Q000627 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.,"All stages of atherosclerosis have been identified as a chronic vascular inflammatory disease. In the last few years there is increasing evidence that endogenous lysophospholipids such as sphingosine-1-phosphate (S1P) have potent anti-inflammatory properties. The S1P analogue FTY720 that has been developed as a potent, orally active, immunosuppressant in the field of transplantation and autoimmune disease has interesting effects on inflammatory processes in the arterial vessel wall. S1P targets five specifi",European journal of clinical investigation,"M Tölle, B Levkau, B Kleuser, M van der Giet"," Charite - Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik mit Schwerpunkt Nephrologie, Berlin, Germany.",2007 Mar;37(3):171-9,10.1111/j.1365-2362.2007.01776.x
17362766,20070301,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver,Male,Mice,Mice, Inbred C57BL,Models, Animal,Propylene Glycols,Reperfusion Injury,Sphingosine,Survival Analysis,Time Factors","analogs &amp; derivatives,blood supply,drug effects,immunology,mortality,prevention &amp; control,therapeutic use","D015427 Q000401 NN,D008099 Q000276 NY,D008099 Q000098 NN,D013110 Q000031 NY,D015427 Q000517 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D008099 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model.,"BACKGROUND: Ischemia-reperfusion-Injury (I/RI) is a common complication in transplant-, liver-, and heart surgery. The I/RI is mediated and aggravated by different types of leukocytes such as lymphocytes, monocytes, and neutrophil granulocytes, with consecutive enlargement of the expression of adhesion molecules. This study shows an organ-protective effect of an intraoperative FTY720 administration following warm liver ischemia (Pringle's maneuver). METHODS: Male c57BL6/J mice (n = 46, body weight [BW] 25 t",Transplantation proceedings,"C P Kaudel, M Frink, M van Griensven, U Schmiddem, C Probst, S Bergmann, C Krettek, J Klempnauer, M Winkler"," Department of Transplant Surgery, Hannover Medical School, Hannover, Germany. kaudel.philipp@mh-hannover.de",2007 Mar;39(2):493-8,10.1016/j.transproceed.2007.01.021
17362767,20070301,article,"xref,mesh","Animals,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Renal Circulation,Reperfusion Injury,Sphingosine,Survival Analysis,T-Lymphocytes","analogs &amp; derivatives,drug effects,drug therapy,immunology,mortality,therapeutic use","D015427 Q000401 NN,D012079 Q000187 NY,D013110 Q000031 NY,D007166 Q000627 NY,D015427 Q000188 NY,D013601 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NY,D013601 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.,"BACKGROUND: Organ dysfunction due to ischemia-reperfusion (I/R) injury is a common problem in transplant, liver, trauma, and heart surgery. I/R injury is mediated by upregulated expression of endothelial cell surface adhesion molecules and subsequent adhesion and activation of circulating leukocytes. The purpose of this study was to evaluate the effect of an intraoperative administration of FTY720 in an animal model with controlled bilateral warm kidney ischemia compared to steroids or placebo application. ",Transplantation proceedings,"C P Kaudel, M Frink, U Schmiddem, C Probst, S Bergmann, C Krettek, J Klempnauer, M van Griensven, M Winkler"," Department of General-, Visceral- and Transplant Surgery, Hannover Medical School, Hannover, Germany. kaudel.philipp@mh-hannover.de",2007 Mar;39(2):499-502,10.1016/j.transproceed.2006.12.010
17371198,20070401,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D006084 Q000188 NN,D011409 Q000276 NN,D013110 Q000031 NY,D013110 Q000276 NN,D007166 Q000627 NY,D007166 Q000276 NN,D009103 Q000276 NN,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY,D009103 Q000188 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Current perspectives on FTY720.,"The search for effective immunosuppressants with fewer side effects continues not only for transplantation, but also for autoimmune diseases. With a novel mechanism of action (sphingosine-1 receptor modulation), oral FTY720 (fingolimod) has the potential to address this need. FTY720 has been preclinically tested with promising results in transplantation and autoimmune disease models. Phase I studies explored the pharmacokinetics and pharmacodynamics of this novel therapeutic concept. Recently, the surprisin",Expert opinion on investigational drugs,"Sebastian Martini, Harm Peters, Torsten Böhler, Klemens Budde"," Charité, Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany. Sebastian.Martini@charite.de",2007 Apr;16(4):505-18,10.1517/13543784.16.4.505
17400555,20070525,article,"xref,mesh,assay","Animals,Apoptosis,Autoimmune Diseases,Calcium Signaling,Caspases,Cell Membrane Permeability,Drug Resistance, Neoplasm,Endoplasmic Reticulum,Fingolimod Hydrochloride,HeLa Cells,Humans,Immunosuppressive Agents,Jurkat Cells,Lymphoproliferative Disorders,Mice,Mice, Knockout,Mitochondria,Mutagenesis,Organ Specificity,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Transport,Receptors, Lysosphingolipid,Sphingolipids,Sphingosine,Spleen,Thymus Gland,bcl-2-Associated X Protein","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,enzymology,genetics,metabolism,pharmacology","D007166 Q000494 NY,D008232 Q000188 NN,D009928 Q000187 NN,D017209 Q000187 NY,D001327 Q000201 NN,D017209 Q000235 NN,D021381 Q000187 NN,D020013 Q000187 NY,D002463 Q000235 NN,D013950 Q000201 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001327 Q000235 NN,D004721 Q000201 NN,D001327 Q000188 NN,D013107 Q000378 NN,D008232 Q000201 NY,D051028 Q000378 NN,D019008 Q000187 NN,D020169 Q000378 NN,D017853 Q000378 NY,D002463 Q000187 NN,D010766 Q000187 NN,D020013 Q000235 NN,D013110 Q000494 NN,D049349 Q000037 NN,D013107 Q000494 NN","8252,31270,36462,91486,107969,107970,122121,5280335,6857804,10493971,10904818","128394615,129060975,129645792",Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.,"The clinical immunosuppressant FTY720 is a sphingosine analogue that, once phosphorylated by sphingosine kinase 2 (Sphk2), is an agonist of multiple receptor subtypes for sphingosine 1-phosphate. Short exposures to FTY720 afford long term protection in lymphoproliferative and autoimmune disease models, presumably by inducing apoptosis in subsets of cells essential for pathogenesis. Sphingosine itself is pro-apoptotic, and apoptosis induced with FTY720 or sphingosine is thought to proceed independently of th",The Journal of biological chemistry,"Anthony S Don, Carolina Martinez-Lamenca, William R Webb, Richard L Proia, Ed Roberts, Hugh Rosen"," Departments of Immunology and Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA.",2007 May;282(21):15833-42,10.1074/jbc.m609124200
17431159,20070413,article,"xref,mesh","Animals,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Mice,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,isolation &amp; purification,metabolism,pharmacology,physiology","D017853 Q000378 NN,D004730 Q000502 NN,D008246 Q000302 NN,D013110 Q000031 NY,D008214 Q000502 NY,D008246 Q000502 NY,D011409 Q000494 NN,D013110 Q000302 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013110 Q000502 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Immunology. The sources of a lipid conundrum.,NULL,"Science (New York, N.Y.)",Jerold Chun," Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. jchun@scripps.edu",2007 Apr;316(5822):208-10,10.1126/science.1142239
17442922,20070501,article,"xref,mesh","Animals,CD4 Antigens,Cells, Cultured,Cytokines,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-23,Lymphocyte Activation,Lysophospholipids,Mice,Mice, Inbred C57BL,Phosphatidylinositol 3-Kinases,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Spleen,T-Lymphocyte Subsets,T-Lymphocytes, Helper-Inducer","agonists,analogs &amp; derivatives,analysis,antagonists &amp; inhibitors,cytology,drug effects,immunology,metabolism,pharmacology","D016176 Q000276 NY,D049349 Q000378 NY,D049349 Q000819 NN,D019869 Q000378 NN,D008246 Q000494 NN,D008213 Q000187 YN,D016207 Q000494 NN,D006377 Q000187 NN,D013154 Q000166 NN,D013110 Q000031 NY,D006377 Q000276 NY,D016176 Q000187 NN,D013110 Q000378 NN,D053759 Q000494 NN,D013154 Q000276 NN,D008246 Q000378 NY,D015704 Q000032 NN,D011409 Q000494 NN,D013110 Q000494 NN,D049349 Q000037 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.,"Sphingosine 1-phosphate (S1P) in blood and lymph controls T cell traffic and proliferation through type 1 S1P receptor (S1P(1)) signals, but suppression of IFN-gamma generation has been the only consistently observed effect on T cell cytokines. The fact that S1P enhances the development of Th17 cells from Ag-challenged transgenic S1P(1)-overexpressing CD4 T cells suggested that the S1P-S1P(1) axis may promote the expansion of Th17 cells in wild-type mice. In a model of Th17 cell development from CD4 T cells","Journal of immunology (Baltimore, Md. : 1950)","Jia-Jun Liao, Mei-Chuan Huang, Edward J Goetzl"," Department of Medicine and Department of Microbiology-Immunology, University of California, San Francisco, CA 94143, USA.",2007 May;178(9):5425-8,10.4049/jimmunol.178.9.5425
17444276,20070301,review,"xref,mesh","Angiotensin-Converting Enzyme Inhibitors,Animals,CCR5 Receptor Antagonists,Chemokines,Chemotaxis,Clinical Trials as Topic,Duffy Blood-Group System,Fingolimod Hydrochloride,Graft Rejection,Humans,Kidney Transplantation,Models, Animal,Propylene Glycols,Receptors, CCR1,Receptors, Cell Surface,Receptors, Chemokine,Sirolimus,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,deficiency,drug effects,drug therapy,immunology,physiology,physiopathology,secretion,therapeutic use","D006084 Q000188 NN,D002633 Q000187 NN,D019707 Q000037 NN,D011956 Q000172 NN,D006084 Q000503 NN,D016030 Q000502 NY,D002633 Q000502 NN,D018925 Q000502 NY,D013110 Q000031 NN,D019707 Q000502 NY,D018925 Q000557 NN,D018925 Q000037 NN,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NN,D000806 Q000627 NN,D020123 Q000627 NN","8252,31270,107969,107970,5280335,5284616,91534498","128394615,129060975,129645792,248766214",Chemokines and chemokine receptors in renal transplantation--from bench to bedside.,"Attraction of mononuclear cells to sites of inflammation requires a close interplay of the inflammatory signal presented via chemokines and specific receptors on effector cells. First studies on acute renal transplant rejection demonstrated the involvement of CC-chemokines, such as RANTES, MIP-1alpha, MIP-1beta and MCP-1, as well as CXC-chemokines such as IL-8 and IP-10, correlating with expression of the corresponding chemokine receptors, CCR1, CCR5 and CCR2 as well as CXCR3. Since then, the pathophysiolog",Acta physiologica Hungarica,M Fischereder," Medizinische Poliklinik Innenstadt, Klinikum der Ludwig-Maximilians Universität München, Pettenkoferstr. 8a, 80336 München, Germany. Michael.Fischereder@med.uni-muenchen.de",2007 Mar;94(?):67-81,10.1556/aphysiol.94.2007.1-2.7
17449719,20070901,article,"xref,mesh","Animals,Calcium,Calcium Signaling,Cells, Cultured,Female,Fingolimod Hydrochloride,Immunoblotting,Immunosuppressive Agents,Lysophospholipids,Muscle Contraction,Muscle Tonus,Muscle, Smooth,Propylene Glycols,Rabbits,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Type C Phospholipases","analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D009119 Q000187 NN,D009129 Q000187 NY,D009130 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D008246 Q000494 NY,D010738 Q000494 NN,D009130 Q000166 NN,D002118 Q000378 NN,D013110 Q000494 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560,5460341,6337033","128394615,129060975,129645792,136111139","Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone.","Overactive bladder syndrome (OBS) results from disturbances of bladder function. Bladder smooth muscle (detrusor) exhibits spontaneous rhythmic activity (tone) independent of neurogenic control, which is enhanced in patients with OBS. We have now uncovered a prominent role for the bioactive sphingolipid metabolite, sphingosine-1-phosphate (S1P), in regulating rabbit detrusor smooth muscle tone and contraction. S1P-induced contraction of detrusor muscle was dependent on stretch and intracellular calcium. Alt",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,"Kenneth R Watterson, Krystina M Berg, Dmitri Kapitonov, Shawn G Payne, Amy S Miner, Robert Bittman, Sheldon Milstien, Paul H Ratz, Sarah Spiegel"," Department of Biochemistry and Molecular Biology, VCU School of Medicine, 1101 E. Marshall St., Richmond, VA 23298, USA.",2007 Sep;21(11):2818-28,10.1096/fj.06-7326com
17462818,20070908,article,"xref,mesh","Adenocarcinoma,Apoptosis,Ascomycota,Cell Division,Cell Line, Tumor,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Pancreatic Neoplasms,Propylene Glycols,Sphingosine,Wound Healing","analogs &amp; derivatives,drug effects,isolation &amp; purification,pathology,pharmacology","D017209 Q000187 NY,D010190 Q000473 NY,D013110 Q000031 NY,D011409 Q000494 NY,D000230 Q000473 NN,D002455 Q000187 NY,D013110 Q000302 NN,D011409 Q000302 NN,D013110 Q000494 NN,D007166 Q000494 NN,D014945 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells.","FTY720, a synthetic compound produced by modification of a metabolite from Isaria sinclairii, is known as a unique immunosuppressive agent that exerts its activity by inducing apoptosis of lymphocytes [S. Suzuki, FTY720: Mechanisms of action and its effect on organ transplantation, Transplant. Proc. 31 (1999) 2779-2782]. Additionally, it has been found that FTY720 has inhibitory effects on various cancer growth and metastasis [J.D. Wang, S. Takahara, N. Nonomura, Early induction of apoptosis in androgen-ind",Cancer letters,"Yan Shen, Minxia Cai, Weiliang Xia, Junwei Liu, Qiyi Zhang, Haiyang Xie, Chen Wang, Xiaohui Wang, Shusen Zheng"," Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health and Department of Hepato-Biliary-Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China.",2007 Sep;254(2):288-97,10.1016/j.canlet.2007.03.013
17475330,20070701,article,"xref,mesh","Adjuvants, Immunologic,Animals,Cells, Cultured,Colitis, Ulcerative,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Mice,Mice, Inbred BALB C,Oxazolone,Propylene Glycols,Sphingosine,Th2 Cells","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pathology,pharmacology","D007166 Q000494 NY,D000276 Q000009 NN,D003093 Q000276 NY,D003093 Q000188 NY,D018418 Q000187 NY,D003093 Q000139 NN,D013110 Q000031 NY,D011409 Q000494 NY,D003093 Q000473 NN,D018418 Q000276 NY,D010081 Q000009 NN,D013110 Q000494 NN","8252,27435,31270,105065,107969,107970,1712093,1712094,5280335","128394615,129060975,129244491,129645792,136111139",FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.,"The sphingosine-1-phosphate analogue FTY720 is known to alter migration and homing of lymphocytes via sphingosine-1-phosphate receptors. However, several studies indicate that its mode of action is more complex and that FTY720 may also directly influence cytokine effector functions. Therefore, we studied the effect of FTY720 in T helper type (Th2)-mediated oxazolone-induced colitis in mice. Following rectal oxazolone instillation, Th2 cells producing IL-13 induce a progressive colitis resembling human ulcer",Molecular immunology,"Carolin Daniel, Nico A Sartory, Nadine Zahn, Ronald Schmidt, Gerd Geisslinger, Heinfried H Radeke, Jurgen M Stein"," First Department of Internal Medicine, JWG University of Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.",2007 Jul;44(13):3305-16,10.1016/j.molimm.2007.02.026
17475445,20070801,article,"xref,mesh","Adenoviridae,Capillary Permeability,Cells, Cultured,Cytoskeleton,Electric Impedance,Endothelial Cells,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lung,Models, Biological,Phosphorylation,Propylene Glycols,Pulmonary Artery,RNA, Small Interfering,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Threonine,rac1 GTP-Binding Protein","analogs &amp; derivatives,cytology,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D049349 Q000378 NY,D004730 Q000166 NN,D011651 Q000166 NN,D013110 Q000031 NY,D003599 Q000378 NN,D011409 Q000494 NY,D000256 Q000235 NN,D013912 Q000378 NN,D042783 Q000187 NY,D008168 Q000166 NN,D013110 Q000494 NN,D034741 Q000378 NN,D020830 Q000378 NN","6288,8252,31270,107969,107970,5280335","127476202,128394615,129060975,129645792",Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.,"Novel therapeutic strategies are needed to reverse the loss of endothelial cell (EC) barrier integrity that occurs during inflammatory disease states such as acute lung injury. We previously demonstrated potent EC barrier augmentation in vivo and in vitro by the platelet-derived phospholipid, sphingosine 1-phosphate (S1P) via ligation of the S1P1 receptor. The S1P analogue, FTY720, similarly exerts barrier-protective vascular effects via presumed S1P1 receptor ligation. We examined the role of the S1P1 rece",Cellular signalling,"S M Dudek, S M Camp, E T Chiang, P A Singleton, P V Usatyuk, Y Zhao, V Natarajan, J G N Garcia"," Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, 5841 South Maryland Ave. Chicago, IL 60637, United States. sdudek@medicine.bsd.uchicago.edu",2007 Aug;19(8):1754-64,10.1016/j.cellsig.2007.03.011
17477424,20070101,article,"xref,mesh","Animals,Blood Glucose,Cell Movement,Diabetes Mellitus, Experimental,Disease Models, Animal,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Islets of Langerhans Transplantation,Lymphocyte Count,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Random Allocation,Sphingosine,Time Factors","analogs &amp; derivatives,drug effects,pathology,pharmacology,surgery","D016381 Q000473 YN,D007166 Q000494 NY,D002465 Q000187 NN,D003921 Q000473 NY,D013110 Q000031 NY,D011409 Q000494 NY,D003921 Q000601 NN,D006085 Q000187 NY,D013110 Q000494 NN","5793,8252,31270,107969,107970,5280335","128394615,129060975,129621433,129645792",Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice.,"This study was performed to observe the long-term effect of FTY720 on lymphocyte count change and islet allograft survival. Diabetic C57BL/6 mice were given FTY720 (group 1, 0.5 mg/kg/day; group 2, 1.0 mg/kg/day) or its vehicle (group 3, controls) after transplantation. Median graft survival time was prolonged in a dose-dependent manner (group 1, 84.5 days; group 2, >100 days, and group 3, 10 days, P < 0.01). Peripheral blood lymphocytes in groups 1 and 2 decreased to 23.81% and 12.59% compared with control",Microsurgery,"Longshan Liu, Changxi Wang, Xiaoshun He, Wenjun Shang, Ying Bi, Dong Wang"," Organ Transplant Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.",2007 Jan;27(4):300-4,10.1002/micr.20360
17488279,20070801,article,"xref,mesh","2',3'-Cyclic-Nucleotide Phosphodiesterases,Animals,Astrocytes,Calcium Signaling,Cell Movement,Cell Proliferation,Cells, Cultured,Cerebral Cortex,Cyclic AMP,Dose-Response Relationship, Drug,Embryo, Mammalian,Fingolimod Hydrochloride,Glial Fibrillary Acidic Protein,Glutamic Acid,Hippocampus,Immunosuppressive Agents,Inositol Phosphates,Organ Culture Techniques,Oxadiazoles,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,beta-Alanine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,metabolism,pharmacology,physiology","D002540 Q000166 NN,D015091 Q000031 NN,D007166 Q000494 NY,D015087 Q000378 NN,D006624 Q000187 NN,D018698 Q000494 NN,D049349 Q000819 NN,D002465 Q000187 NY,D010069 Q000494 NN,D007295 Q000378 NN,D001253 Q000502 NN,D000242 Q000378 NN,D005904 Q000378 NN,D049109 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D006624 Q000166 NN,D001253 Q000187 NY,D015091 Q000494 NN,D013876 Q000494 NN,D049349 Q000502 NY,D020013 Q000187 NN,D013110 Q000494 NN,D049349 Q000037 NN,D002465 Q000502 NN","239,611,892,6076,8252,23327,31270,33032,104813,105065,107969,107970,161901,168185,4077460,4525487,5128032,5147171,5280335,5460299,5460544,7059571,10523409,11259583,11840951,12201475,14598502,23669634,23674880,23696295,129674751,129773928","127607297,128394615,129060975,129348709,129583715,129645792,136111139",Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors.,"Sphingosine-1-phosphate (S1P) receptors are widely expressed in the central nervous system where they are thought to regulate glia cell function. The phosphorylated version of fingolimod/FTY720 (FTY720P) is active on a broad spectrum of S1P receptors and the parent compound is currently in phase III clinical trials for the treatment of multiple sclerosis. Here, we aimed to identify which cell type(s) and S1P receptor(s) of the central nervous system are targeted by FTY720P. Using calcium imaging in mixed cu",Journal of neurochemistry,"Florian Mullershausen, Luis M Craveiro, Youngah Shin, Marta Cortes-Cros, Frederic Bassilana, Maribel Osinde, William L Wishart, Danilo Guerini, Michaela Thallmair, Martin E Schwab, Rajeev Sivasankaran, Klaus Seuwen, Kumlesh K Dev"," Department of G Protein-Coupled Receptors, Novartis Institutes for BioMedical Research, Novartis Pharma, Basel, Switzerland.",2007 Aug;102(4):1151-61,10.1111/j.1471-4159.2007.04629.x|10.1111/j.1471-4159.2007.4629.x
17488479,20070301,article,"xref,mesh","Animals,Brain Injuries,Cytokines,Fingolimod Hydrochloride,Histocompatibility Antigens Class II,Immunohistochemistry,Immunosuppressive Agents,Monocytes,Neoplasm Proteins,Propylene Glycols,RNA-Binding Proteins,Rats,Rats, Inbred Lew,Sphingosine,Time Factors","analogs &amp; derivatives,biosynthesis,etiology,metabolism,pathology,pharmacology,physiology","D007166 Q000494 NY,D009000 Q000502 NY,D001930 Q000473 NY,D016207 Q000096 NY,D009363 Q000096 NY,D013110 Q000031 NY,D001930 Q000209 NN,D011409 Q000494 NY,D000949 Q000378 NY,D013110 Q000494 NN,D016601 Q000096 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury.,"FTY720 (Fingolimod) is a novel type of immunosuppressive agent inhibiting lymphocyte egress from secondary lymphoid tissues thereby causing peripheral lymphopenia. FTY720 can inhibit macrophage infiltration into inflammatory lesions under pathological conditions. FTY720 has been clinically evaluated for prophylaxis of allograft rejection and treatment of multiple sclerosis, showing promising immunosuppressive effects. A robust inflammatory response after traumatic brain injury (TBI) plays an important role ",Journal of cellular and molecular medicine,"Zhiyuan Zhang, Zhiren Zhang, Uwe Fauser, Matthias Artelt, Michael Burnet, Hermann J Schluesener"," Institute of Brain Research, University of Tuebingen, Calwer Strasse 3, D-72076 Tuebingen, Germany.",2007 Mar;11(2):307-14,10.1111/j.1582-4934.2007.00019.x
17488588,20070501,review,"xref,mesh","Administration, Oral,Anti-Bacterial Agents,Anti-Inflammatory Agents, Non-Steroidal,Cladribine,Clinical Trials as Topic,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Immunosuppressive Agents,Interferon beta-1b,Interferon-beta,Isoxazoles,Minocycline,Multiple Sclerosis,Mycophenolic Acid,Propylene Glycols,Pyridones,Quinolones,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy,metabolism,therapeutic use","D019161 Q000627 NN,D015363 Q000627 NN,D016899 Q000627 NN,D007166 Q000008 YN,D007166 Q000627 YN,D005650 Q000627 NN,D008911 Q000627 NN,D000894 Q000627 NN,D013110 Q000031 NN,D000900 Q000627 NN,D007555 Q000378 NN,D009173 Q000031 NN,D017338 Q000627 NN,D009173 Q000627 NN,D011728 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007555 Q000627 NN,D009103 Q000188 NY","3899,4271,4272,8252,9254,12215,20279,31270,40632,107969,107970,446541,637568,3036108,5280335,5281078,6441022,23665584,54575046,54675783,54677946,54685925,54751657,126456762","127968532,128094727,128215666,128394615,128471922,128966217,129060975,129178479,129476173,129645792,129979483",Novel oral agents for multiple sclerosis.,"In 1993, interferon beta-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trial",Current neurology and neuroscience reports,"Jodie M Burton, Paul O'Connor"," Multiple Sclerosis Clinic, Division of Neurology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada. burtonj@smh.toronto.on.ca",2007 May;7(3):223-30,10.1007/s11910-007-0034-2
17493961,20070601,article,"xref,mesh","Animals,Basement Membrane,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cell Movement,Collagen,DNA-Binding Proteins,Endothelial Cells,Fibronectins,Fingolimod Hydrochloride,Hematopoietic Stem Cell Transplantation,Hematopoietic Stem Cells,Immunosuppressive Agents,Interleukin-7 Receptor alpha Subunit,Laminin,Mice,Mice, Inbred C57BL,Mice, Knockout,Pericytes,Propylene Glycols,Proto-Oncogene Proteins c-kit,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes,Thymus Gland","agonists,analogs &amp; derivatives,analysis,blood supply,chemistry,cytology,drug effects,genetics,immunology,metabolism,pharmacology","D020286 Q000166 NN,D013601 Q000378 NN,D042783 Q000166 NN,D004268 Q000235 NN,D053699 Q000032 NN,D002465 Q000187 NN,D049349 Q000819 NN,D003094 Q000032 NN,D002465 Q000276 NY,D006412 Q000166 NY,D042783 Q000737 NN,D020286 Q000737 NN,D005353 Q000032 NN,D006412 Q000737 NN,D004268 Q000378 NN,D019009 Q000032 NN,D018414 Q000737 NN,D013601 Q000166 NY,D013110 Q000031 NN,D013601 Q000737 NN,D018414 Q000166 NN,D007797 Q000032 NN,D013950 Q000166 NY,D006412 Q000276 NN,D015496 Q000166 NN,D001485 Q000166 NY,D013950 Q000098 NN","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792",The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma.,"It is known that selected populations of lymphoid cells migrate into and from the adult thymus through blood vessels at the cortico-medullary junction and in the medulla. Here, we show that in the perivascular spaces (PVS) of mice surrounding large blood vessels, CD117-positive hematopoietic progenitor cells, CD4 single-positive (SP) and CD8SP T cells are located. However, developing thymocytes, CD25-positive cells and CD4 and CD8 double-positive cells, are not detectable in the PVS. After intravenous (i.v.",International immunology,"Kazuya Mori, Manami Itoi, Noriyuki Tsukamoto, Hajime Kubo, Takashi Amagai"," Department of Immunology and Microbiology, Meiji University of Oriental Medicine, Hiyoshi-cho, Nantan, Kyoto 629-0392, Japan.",2007 Jun;19(6):745-53,10.1093/intimm/dxm041
17516874,20070601,review,"xref,mesh","Antibodies, Monoclonal,Cladribine,Cyclophosphamide,Drug Delivery Systems,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Isoxazoles,Ligands,Mitoxantrone,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,pharmacology,therapeutic use","D003520 Q000494 NN,D008942 Q000627 NY,D008942 Q000494 NN,D000911 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D008942 Q000009 NN,D000911 Q000494 NN,D011409 Q000494 NN,D017338 Q000627 NN,D003520 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D007166 Q000494 NN,D007555 Q000494 NN,D007555 Q000627 NN,D009103 Q000188 NY,D017338 Q000494 NN","2907,4212,8252,9254,20279,22420,31270,51082,51151,107969,107970,134019,5280335,5458171,54607525","127673746,128394615,128397534,128906544,128966217,129060975,129645792",Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.,"An important amount has been learnt about the mechanisms of action, efficacy and long-term toxicities of mitoxantrone. Importantly, recent observations strongly suggest that early administration of potent immunosuppressants (mitoxantrone and alemtuzumab) is definitely more effective than approved immunomodulators to delay or even reverse disability progression. Given the cardiotoxicity of mitoxantrone, restricting exposure to the drug to 2 or 3 years, the benefits and risks of immunosuppressants previously ",Expert opinion on pharmacotherapy,Richard E Gonsette," National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium. r.gonsette@skynet.be",2007 Jun;8(8):1103-16,10.1517/14656566.8.8.1103
17526535,20070801,article,"xref,mesh","Adult,Animals,Arteries,Cyclosporine,Elasticity,Endothelium, Vascular,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Mice,Middle Aged,Propylene Glycols,Sphingosine,Vasodilation","analogs &amp; derivatives,drug effects,metabolism,methods,pathology,pharmacology,therapeutic use","D001158 Q000187 NY,D004730 Q000187 NN,D016030 Q000379 NY,D014664 Q000187 NY,D013110 Q000031 NY,D004730 Q000378 NN,D007166 Q000627 NY,D016572 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NY,D001158 Q000473 NN","588,753,2909,4271,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,128394615,128902940,129060975,129178479,129645792",The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.,"BACKGROUND: FTY720 has recently demonstrated a similar efficacy in prevention of acute graft rejection compared with mycophenolate mofetil (MMF) in a large phase III trial of de novo renal transplant recipients. Creatinine clearance, however, was significantly lower in FTY720-treated patients. In the present study, we examined the impact of FTY720 on vascular function in a subgroup of patients of this trial. METHODS: Eighteen patients (12 FTY720, 6 MMF) agreed to be enrolled for an analysis of vascular func","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Timm H Westhoff, Sven Schmidt, Petra Glander, Lutz Liefeld, Sebastian Martini, Gerd Offermann, Hans H Neumayer, Walter Zidek, Markus van der Giet, Klemens Budde"," Centrum 10 - Nephrology, Charité - Campus Benjamin Franklin, 12200 Berlin, Germany. timm.westhoff@charite.de",2007 Aug;22(8):2354-8,10.1093/ndt/gfm313
17553484,20070730,article,"xref,mesh","Animals,Blood Platelets,Cell Line,Erythrocytes,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Male,Phosphorylation,Plasma,Prodrugs,Propylene Glycols,Rats,Rats, Wistar,Sphingosine","analogs &amp; derivatives,blood,drug effects,metabolism,pharmacology","D013110 Q000097 NN,D007166 Q000494 NY,D010949 Q000187 NN,D010949 Q000378 NN,D007166 Q000097 NN,D004912 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D001792 Q000378 NN,D008246 Q000378 NN,D013110 Q000494 NN,D001792 Q000187 NY,D011355 Q000494 NY,D011409 Q000097 NN,D004912 Q000187 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The immunomodulator FTY720 is phosphorylated and released from platelets.,"The novel immunomodulator FTY720 causes lymphocytes from peripheral blood to accumulate in lymphoid tissues. In vivo, FTY720 is phosphorylated to FTY720-P, which binds to the sphingosine 1-phosphate receptor S1P(1). So far, it has been unclear where FTY720-P is produced. We demonstrate that platelets efficiently convert FTY720 to FTY720-P and release it into the extracellular space. This release is mostly independent of platelet activation, but is slightly increased upon thrombin stimulation. These results ",European journal of pharmacology,"Yoshihiro Anada, Yasuyuki Igarashi, Akio Kihara"," Laboratory of Biomembrane and Biofunctional Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-choume, Kita-ku, Sapporo 060-0812, Japan.",2007 Jul;568(?):106-11,10.1016/j.ejphar.2007.04.053
17561264,20070701,review,"xref,mesh","Animals,Disease,Fingolimod Hydrochloride,Gene Deletion,Graft Rejection,Health,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,genetics,pharmacology,physiology,therapeutic use","D007166 Q000494 NY,D006084 Q000188 NN,D007166 Q000627 NN,D013110 Q000031 NY,D011409 Q000494 NY,D049349 Q000187 NN,D049349 Q000235 NY,D049349 Q000502 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.,"Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that is critically involved in the embryonic development of the cardiovascular and central nervous systems. In the adult, S1P can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system. S1P is contained in body fluids and tissues at different concentrations, and excessive production of the pleiotropic mediator at inflammatory sites may part",Pharmacology & therapeutics,Volker Brinkmann," Autoimmunity and Transplantation, Novartis Institutes for BioMedical Research, Lichtstrasse 35, CH-4002 Basel, Switzerland. volker.brinkmann@novartis.com",2007 Jul;115(1):84-105,10.1016/j.pharmthera.2007.04.006
17606761,20071101,article,"xref,mesh","Animals,Cells, Cultured,Chemotaxis, Leukocyte,Combined Modality Therapy,Fingolimod Hydrochloride,Graft vs Host Disease,Immunosuppressive Agents,Immunotherapy, Adoptive,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Sphingosine,Spleen,Survival Analysis,T-Lymphocytes, Regulatory,Transplantation Conditioning","analogs &amp; derivatives,cytology,drug effects,immunology,methods,mortality,pharmacology,therapeutic use,therapy,transplantation","D007166 Q000627 NN,D006086 Q000401 NN,D019172 Q000379 NN,D013154 Q000166 NN,D013110 Q000031 NY,D050378 Q000637 NY,D006086 Q000628 NY,D011409 Q000494 NY,D013154 Q000276 NN,D002634 Q000187 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).,"The immunomodulator FTY720 (FTY) has been shown to be beneficial in experimental models of organ transplantation and autoimmunity. We show that FTY significantly inhibited but did not prevent graft-versus-host disease (GVHD) in lethally irradiated or nonirradiated allogeneic recipients. Although most studies implicate prevention of lymphocyte egress from lymphoid organs as the primary mechanism of action, our data indicate that FTY effects on the host are more likely to be responsible for GVHD inhibition. F",Blood,"Patricia A Taylor, Michael J Ehrhardt, Christopher J Lees, Jakub Tolar, Brenda J Weigel, Angela Panoskaltsis-Mortari, Jonathan S Serody, Volker Brinkmann, Bruce R Blazar"," Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, 420 Delaware Street SE, Minneapolis, MN 55455, USA.",2007 Nov;110(9):3480-8,10.1182/blood-2007-05-087940
17617868,20070801,article,"xref,mesh","Animals,Apoptosis,Blood Glucose,C-Peptide,Cells, Cultured,Fingolimod Hydrochloride,Follow-Up Studies,Glucose Tolerance Test,Graft Rejection,Graft Survival,Humans,Immunosuppressive Agents,In Situ Nick-End Labeling,Insulin,Islets of Langerhans,Islets of Langerhans Transplantation,Mice,Mice, Inbred C57BL,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Tissue and Organ Procurement","analogs &amp; derivatives,blood,cytology,drug effects,metabolism,methods,pathology,prevention &amp; control,secretion,therapeutic use","D007328 Q000557 NN,D002096 Q000097 NN,D009927 Q000379 NY,D007515 Q000166 NN,D007166 Q000627 NN,D006084 Q000378 NN,D013110 Q000031 NY,D007515 Q000187 NY,D049349 Q000187 NY,D006084 Q000473 NN,D006085 Q000187 NY,D001786 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY,D006084 Q000517 NY,D049349 Q000378 NN","5793,8252,31270,105065,107969,107970,5280335,16132309,16157840,70678557,118984375","128394615,129060975,129621433,129645792,136111139",Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720.,"Clinical islet transplantation for type 1 diabetes mellitus currently requires potent immunosuppressive drugs, which limits the procedure to the most severe forms of the disease, and many of the drugs are directly beta-cell toxic. A class of compounds called sphingosine-1-phosphate receptor modulators has been explored in transplantation and shown to be highly effective in multiple sclerosis and other autoimmune conditions. While FTY720, the first drug in this class, may not move forward initially in transp",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,"W Truong, J A Emamaullee, S Merani, C C Anderson, A M James Shapiro"," The Surgical Medical Research Institute, Department of Surgery, Faculty of Medicine, The University of Alberta, Edmonton, Alberta, Canada.",2007 Aug;7(8):2031-8,10.1111/j.1600-6143.2007.01880.x
17641024,20070801,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Cell Migration Inhibition,Cells, Cultured,Chemotaxis, Leukocyte,Diarrhea,Epitopes, T-Lymphocyte,Female,Fingolimod Hydrochloride,Food Hypersensitivity,Immunosuppressive Agents,Intestine, Large,Lysophospholipids,Mast Cells,Mice,Mice, Inbred BALB C,Mice, Nude,Mice, SCID,Propylene Glycols,Sphingosine,Spleen,Th2 Cells","administration &amp; dosage,analogs &amp; derivatives,biosynthesis,cytology,drug effects,immunology,metabolism,pathology,physiology,prevention &amp; control","D005512 Q000517 NN,D007166 Q000008 NN,D015496 Q000276 NN,D018984 Q000276 NN,D007420 Q000473 NN,D013110 Q000008 NN,D013154 Q000166 NN,D013110 Q000031 NY,D011409 Q000008 NN,D018418 Q000473 NN,D005512 Q000473 NY,D003967 Q000517 NN,D005512 Q000276 NY,D008246 Q000096 NN,D013154 Q000276 NN,D015496 Q000473 NN,D008246 Q000502 NY,D007420 Q000276 NN,D018418 Q000378 NN,D013154 Q000473 NN,D002634 Q000187 NN,D018418 Q000276 NY,D003967 Q000473 NN,D003967 Q000276 NN,D008407 Q000473 NN,D013110 Q000096 NN,D008407 Q000276 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy.,"Sphingosine 1-phosphate (S1P) has been proposed as a regulator of lymphocyte trafficking, but its role in mucosa-associated diseases, such as in food allergies, remains to be elucidated. To examine the role of S1P in allergic diseases in the intestine, we used a Th2 cell-mediated Ag-specific allergic diarrhea model and demonstrated that type 1 S1P receptor (S1P(1)) expression was preferentially associated with pathogenic CD4(+) T cells for the development of allergic reactions. Consistent with this demonstr","Journal of immunology (Baltimore, Md. : 1950)","Yosuke Kurashima, Jun Kunisawa, Morio Higuchi, Masashi Gohda, Izumi Ishikawa, Naoko Takayama, Miki Shimizu, Hiroshi Kiyono"," Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.",2007 Aug;179(3):1577-85,10.4049/jimmunol.179.3.1577
17667810,20070727,article,"xref,mesh","Animals,Apoptosis,Cell Proliferation,Creatinine,Disease Models, Animal,Fingolimod Hydrochloride,Flow Cytometry,Follow-Up Studies,Immunohistochemistry,Immunosuppressive Agents,Kidney,Kidney Transplantation,Male,Proliferating Cell Nuclear Antigen,Propylene Glycols,Rats,Rats, Sprague-Dawley,Reperfusion Injury,Sphingosine,Treatment Outcome","analogs &amp; derivatives,blood,blood supply,chemical synthesis,drug effects,metabolism,pathology,prevention &amp; control,therapeutic use","D018809 Q000378 NN,D017209 Q000187 NN,D015427 Q000473 NN,D003404 Q000097 NN,D049109 Q000187 NN,D013110 Q000031 NY,D015427 Q000097 NN,D015427 Q000517 NY,D013110 Q000138 NN,D007166 Q000138 NN,D007166 Q000627 NY,D011409 Q000138 NN,D013110 Q000627 NN,D007668 Q000098 NY,D011409 Q000627 NY","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792","Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine.",BACKGROUND: The current shortage of organ donors has led many centers to use marginal and nonheart-beating donors (NHBDs). Recent research has implicated the infiltration of lymphocytes as an important mediator of ischemia-reperfusion injury (IRI). FTY720 is an immunosuppressant that promotes lymphocyte sequestration into lymph nodes. The purpose of this study was to examine the potential for FTY720 to abrogate IRI when subjected to increasing ischemic times. METHODS: Male Sprague-Dawley rats underwent bila,Transplantation,"Michael S Delbridge, Badri M Shrestha, Andrew T Raftery, A Meguid El Nahas, John L Haylor"," Department of Vascular Surgery, Northern General Hospital, Sheffield, UK.",2007 Jul;84(2):187-95,10.1097/01.tp.0000269794.74990.da
17668161,20071001,review,"xref,mesh","Administration, Oral,Animals,Clinical Trials, Phase III as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].,"All currently available therapeutic options for multiple sclerosis have to be administered parenterally. Several oral substances are currently in the late clinical development stage. One of them, FTY720 (also known as fingolimod) is highlighted in this review. The biological effects of FTY720 are presented as well as animal data and first clinical data from a phase II trial in multiple sclerosis patients. The effects of FTY720 are based on an innovative approach and apparently target several key elements in",Der Nervenarzt,"J Klatt, H-P Hartung, R Hohlfeld", Novartis Pharma GmbH Nürnberg.,2007 Oct;78(10):1200-8,10.1007/s00115-007-2298-9
17682127,20071101,article,"xref,mesh","Administration, Oral,Animals,Autoradiography,Brain,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocyte Count,Multiple Sclerosis,Phosphorylation,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology,metabolism,pharmacokinetics,therapeutic use","D011409 Q000493 NY,D004681 Q000276 NN,D004681 Q000378 NN,D013110 Q000008 NN,D007166 Q000493 NY,D013110 Q000031 NY,D011409 Q000008 NN,D013110 Q000493 NN,D001921 Q000378 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D004681 Q000188 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.,"FTY720 [2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol hydrochloride] is an oral sphingosine-1-phosphate receptor modulator under development for the treatment of multiple sclerosis (MS). The drug is phosphorylated in vivo by sphingosine kinase 2 to its bioactive form, FTY720-P. Although treatment with FTY720 is accompanied by a reduction of the peripheral lymphocyte count, its efficacy in MS and experimental autoimmune encephalomyelitis (EAE) may be due to additional, direct effects in the central ner",The Journal of pharmacology and experimental therapeutics,"Carolyn A Foster, Laurence M Howard, Alain Schweitzer, Elke Persohn, Peter C Hiestand, Balázs Balatoni, Roland Reuschel, Christian Beerli, Manuela Schwartz, Andreas Billich"," Novartis Institutes for BioMedical Research, Vienna, Austria.",2007 Nov;323(2):469-75,10.1124/jpet.107.127183
17692046,20070801,review,"xref,mesh","Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lymphocytes,Propylene Glycols,Sphingosine","analogs &amp; derivatives,cytology,drug effects,pharmacology,therapeutic use","D007166 Q000494 NY,D007166 Q000627 NN,D013110 Q000031 NY,D013110 Q000627 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007107 Q000166 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720: a most promising immunosuppressant modulating immune cell functions.,"FTY720, the pharmacological analog of S1P, acts as an agonist of sphingosine-1-phosphate receptors, resulting in the inhibition of lymphocyte egress from secondary lymphoid tissues and thymocytes from the thymus, peripheral lymphopenia and interfering with normal functions of several other cell types. FTY720 has been clinically tried for transplantation and multiple sclerosis, showing promising protective effects. This review will summarize potential applications and effects of FTY720. ",Mini reviews in medicinal chemistry,"Zhiren Zhang, Hermann J Schluesener"," Institute of Brain Research, University of Tuebingen, Calwer Str. 3, D-72076 Tuebingen, Germany. zhangzhiren@yahoo.com",2007 Aug;7(8):845-50,10.2174/138955707781387948
17693822,20070801,article,"xref,mesh","Analysis of Variance,Animals,Biomarkers,Cytokines,Disease Models, Animal,Fingolimod Hydrochloride,Hindlimb,Immunosuppressive Agents,Interleukin-1,Ischemia,Male,Mice,Mice, Inbred C57BL,Peroxidase,Probability,Propylene Glycols,Random Allocation,Reference Values,Reperfusion Injury,Reverse Transcriptase Polymerase Chain Reaction,Sensitivity and Specificity,Sphingosine,Survival Rate","analogs &amp; derivatives,analysis,blood supply,drug therapy,genetics,metabolism,mortality,pharmacology","D007511 Q000188 NY,D009195 Q000378 NN,D009195 Q000032 NN,D007375 Q000235 NN,D016207 Q000378 NN,D006614 Q000098 NN,D015427 Q000401 NY,D013110 Q000031 NY,D011409 Q000494 NY,D016207 Q000235 NN,D007375 Q000378 NN,D007511 Q000401 NY,D015415 Q000032 NN,D015427 Q000188 NY,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335,11973707","128394615,129060975,129645792",FTY720 improves survival after transient ischemia and reperfusion of the hind limbs.,"BACKGROUND: Ischemia and reperfusion (I/R) damage involves adhesion and transmigration of lymphocytes and neutrophils. FTY720 is an immunosuppressive agent that reduces the number of neutrophils and monocytes in peripheral blood as well as tissue lymphocyte infiltration. This study investigated the effect of FTY720 during hind limb I/R. METHODS: Male C57/BL6 mice underwent temporary ligation of the infrarenal aorta for 4 hours. After 48 hours of reperfusion, animals were killed by exsanguination. Tissue mye",The Journal of trauma,"Michael Frink, Christian P Kaudel, Frank Hildebrand, Hans-Christoph Pape, Jürgen Klempnauer, Michael Winkler, Christian Krettek, Martijn van Griensven"," Trauma Department, Hannover Medical School, Hannover, Germany. frink.michael@mh-hannover.de",2007 Aug;63(2):263-7,10.1097/ta.0b013e3180d0a6fc
17716652,20071114,article,"xref,mesh","Animals,Ankle Joint,Arthritis, Experimental,Bone Density,CD4 Antigens,CD4 Lymphocyte Count,CD4-Positive T-Lymphocytes,CD8 Antigens,CD8-Positive T-Lymphocytes,Chickens,Collagen Type II,Female,Fingolimod Hydrochloride,Flow Cytometry,Forelimb,Immunohistochemistry,Immunosuppressive Agents,Inflammation,Prednisone,Propylene Glycols,Rats,Rats, Wistar,Sphingosine,Time Factors,Tomography, X-Ray Computed,Treatment Outcome,Weight Loss","analogs &amp; derivatives,analysis,chemically induced,diagnostic imaging,drug effects,immunology,methods,pathology,pharmacology,prevention &amp; control,toxicity","D000843 Q000187 NN,D018414 Q000276 NN,D015496 Q000276 NN,D005552 Q000473 NN,D015431 Q000187 NN,D015496 Q000187 NY,D001169 Q000139 NN,D001169 Q000473 NN,D007249 Q000139 NN,D000843 Q000000981 NN,D007249 Q000517 NN,D013110 Q000031 NY,D018414 Q000473 NN,D011409 Q000494 NY,D005552 Q000000981 NN,D011241 Q000494 NN,D000843 Q000473 NN,D015496 Q000473 NN,D018791 Q000379 NN,D016827 Q000032 NN,D018414 Q000187 NN,D001169 Q000517 NY,D005552 Q000187 NN,D015704 Q000032 NN,D013110 Q000494 NN,D015519 Q000187 NN,D007166 Q000","5865,8252,31270,107969,107970,5280335","128394615,129060975,129645792,129717275",Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720.,"FTY720 belongs to a new class of immunosuppressants. Little is known about its influence on T cell subtypes and pathological changes in arthritis. Here we illustrated the effect of FTY720 on peripheral T cell subsets and joint damage of collagen-induced arthritis rats. Rats were administered FTY720 or prednisone daily from day 0 to day 28. Body weight, hind paw swelling and arthritis index were measured. Bone destruction was determined by micro-computed tomography and histopathology, and T cell subsets were",European journal of pharmacology,"Fang Wang, Wenfeng Tan, Dunming Guo, Shaoheng He"," The Clinical Experiment Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China. fangwang7608@263.net",2007 Nov;573(?):230-40,10.1016/j.ejphar.2007.07.029
17726159,20071101,article,"xref,mesh","Animals,Apoptosis,Cell Differentiation,Cells, Cultured,Cytoprotection,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,Immunosuppressive Agents,Microglia,Neurotrophin 3,Oligodendroglia,Phosphatidylinositol 3-Kinases,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Proto-Oncogene Proteins c-akt,Rats,Rats, Sprague-Dawley,Sphingosine,Stem Cells","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,metabolism,pharmacology,physiology","D007166 Q000494 NY,D019869 Q000037 NN,D017209 Q000187 NN,D009836 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D017853 Q000502 NN,D048049 Q000378 NN,D020933 Q000494 NN,D051057 Q000378 NN,D002454 Q000187 NN,D013110 Q000494 NN,D017628 Q000502 NN,D013234 Q000187 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors.,"The immunomodulator 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol (FTY720) has promising therapeutic effects in multiple sclerosis (MS), a degenerative disease in which demyelination of the central nervous system is accompanied by death of oligodendrocytes (OLGs), the myelin-producing cells. In vivo phosphorylation of FTY720 generates an agonist for G protein-coupled receptors for sphingosine-1-phosphate, a lipid mediator that plays a crucial role in the stimulation of OLG survival by neurotrophin-3 (N",The Journal of pharmacology and experimental therapeutics,"Rochelle P Coelho, Shawn G Payne, Robert Bittman, Sarah Spiegel, Carmen Sato-Bigbee"," Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.",2007 Nov;323(2):626-35,10.1124/jpet.107.123927
17761520,20080101,article,"xref,mesh","Animals,Apoptosis,B-Lymphocytes,Caspases,Cell Line,Cysteine Endopeptidases,Down-Regulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukemia, Lymphocytic, Chronic, B-Cell,Lysophospholipids,Mice,Mice, SCID,Myeloid Cell Leukemia Sequence 1 Protein,Neoplasm Proteins,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Propylene Glycols,Protein Phosphatase 2,Proto-Oncogene Proteins c-bcl-2,Signal Transduction,Sphingosine,Xenograft Model Antitumor Assays","analogs &amp; derivatives,cytology,drug effects,drug therapy,metabolism,toxicity","D019253 Q000378 NN,D017209 Q000187 NN,D003546 Q000378 NN,D009363 Q000378 NN,D011409 Q000633 NY,D015536 Q000187 NN,D001402 Q000166 NN,D001402 Q000187 NN,D054198 Q000188 NY,D013110 Q000633 NN,D013110 Q000031 NY,D015451 Q000188 NY,D054648 Q000378 NN,D013110 Q000378 NN,D020169 Q000378 NN,D008246 Q000378 NN,D015398 Q000187 NN,D007166 Q000633 NY","5862,8252,31270,107969,107970,5280335,5283560,57059112","128394615,129060975,129645792,129742316,135870608",FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.,"FTY720 is an immunosuppressant developed to prevent organ transplant rejection. Recent studies indicate an additional role for FTY720 in inducing cell apoptosis. We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chronic lymphocytic leukemia (CLL). In contrast to previous reports in T-cell lines, FTY720-induced toxicity in the Raji cell line and primary CLL B cells is independent of activation of caspases or ",Blood,"Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching-Shih Chen, James T Dalton, Natarajan Muthusamy, John C Byrd"," Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.",2008 Jan;111(1):275-84,10.1182/blood-2006-10-053884
17761943,20071101,article,"xref,mesh","Animals,Apolipoproteins E,Atherosclerosis,Fingolimod Hydrochloride,Hypercholesterolemia,Immunosuppressive Agents,Lipid Metabolism,Lymphocyte Subsets,Lymphocytes,Lymphopenia,Lysophospholipids,Male,Mice,Mice, Knockout,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,blood,chemically induced,deficiency,drug effects,immunology,pharmacology,physiology,physiopathology","D016131 Q000187 NN,D050197 Q000503 YN,D007166 Q000494 NY,D013154 Q000187 NN,D008231 Q000139 NN,D050356 Q000187 NN,D013110 Q000031 NY,D001057 Q000172 NN,D011409 Q000494 NY,D013154 Q000276 NN,D006937 Q000139 NY,D050197 Q000276 YN,D008246 Q000502 NY,D008214 Q000097 NN,D013110 Q000494 NN,D008214 Q000187 NN,D013110 Q000502 NN","5997,8252,31270,105065,107969,107970,5280335,5283560","128121087,128394615,129060975,129645792,136111139",Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.,"OBJECTIVE: Resident immune cells are a hallmark of atherosclerotic lesions. The sphingolipid analogue drug FTY720 mediates retrafficking of immune cells and inhibits their homing to inflammatory sites. We have evaluated the effect of FTY720 on atherogenesis and lipid metabolism. METHODS AND RESULTS: ApoE-/- mice on a normal laboratory diet received oral FTY720 for 12 weeks, which led to a 2.4-fold increase in serum cholesterol (largely VLDL fraction) and a 1.8-fold increase in hepatic HMGCoA reductase mRNA.","Arteriosclerosis, thrombosis, and vascular biology","Roland Klingenberg, Jerzy-Roch Nofer, Mats Rudling, Florian Bea, Erwin Blessing, Michael Preusch, Hermann J Grone, Hugo A Katus, Göran K Hansson, Thomas J Dengler"," Department of Cardiology, University Hospital Heidelberg, Germany. roland.klingenberg@ki.se",2007 Nov;27(11):2392-9,10.1161/atvbaha.107.149476
17785617,20071001,review,"xref,mesh","Animals,Drugs, Investigational,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D013110 Q000009 NN,D011409 Q000009 NN,D011409 Q000276 NN,D015507 Q000627 NY,D013110 Q000031 NY,D015507 Q000009 NN,D013110 Q000276 NN,D007166 Q000627 NY,D007166 Q000276 NN,D009103 Q000276 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Fingolimod: a novel immunosuppressant for multiple sclerosis.,"OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of fingolimod, a novel immune modulator. DATA SOURCES: Information was obtained through a MEDLINE search (1966-February 2007) and from published abstracts. Search terms included fingolimod, FTY720, FTY-720, and sphingosine-1-phosphate receptor agonist. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts pertaining to fingolimod were considered for inclusion. Preference was given to human data. DATA SYNT",The Annals of pharmacotherapy,"Brandon A Brown, Pranish P Kantesaria, Lisa M McDevitt"," Partners Multiple Sclerosis Center, Brookline, MA 02445, USA. bbrown8@partners.org",2007 Oct;41(10):1660-8,10.1345/aph.1g424
17845905,20071019,article,"xref,mesh","Analysis of Variance,Animals,Body Weight,Disease Models, Animal,Electric Stimulation,Encephalomyelitis, Autoimmune, Experimental,Evoked Potentials, Somatosensory,Evoked Potentials, Visual,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Longitudinal Studies,Myelin Proteins,Myelin-Associated Glycoprotein,Myelin-Oligodendrocyte Glycoprotein,Neural Conduction,Propylene Glycols,Rats,Reaction Time,Sphingosine,Spinal Cord,Time Factors","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pathology,physiopathology,therapeutic use","D009431 Q000187 NN,D004681 Q000473 NY,D001835 Q000187 NN,D013116 Q000187 NN,D005074 Q000187 NN,D013116 Q000473 NN,D005073 Q000187 NN,D004681 Q000139 NN,D013110 Q000031 NY,D001835 Q000276 NN,D007166 Q000627 NY,D011930 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NY,D004681 Q000503 NY,D004681 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.,"FTY720 (fingolimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator under development for the treatment of multiple sclerosis (MS). To elucidate its effects in the central nervous system (CNS), we compared functional parameters of nerve conductance in the DA rat model of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) after preventive and therapeutic treatment. We demonstrate that prophylactic therapy protected against the emergence of EAE sympto",Brain research bulletin,"Balázs Balatoni, Maria K Storch, Eva-M Swoboda, Vinzenz Schönborn, Agnieszka Koziel, George N Lambrou, Peter C Hiestand, Robert Weissert, Carolyn A Foster"," Novartis Institutes for BioMedical Research, Brunner Strasse 59, A-1235, Vienna, Austria. balazs.balatoni@novartis.com",2007 Oct;74(5):307-16,10.1016/j.brainresbull.2007.06.023
17854447,20071001,article,"xref,mesh","Animals,Disease Models, Animal,Female,Fingolimod Hydrochloride,Flow Cytometry,Graft Rejection,Graft Survival,Immunosuppressive Agents,Major Histocompatibility Complex,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Skin Transplantation,Sphingosine,Thymus Gland,Transplantation, Homologous,Treatment Outcome","analogs &amp; derivatives,immunology,pathology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D008285 Q000276 NY,D016038 Q000276 NY,D013110 Q000031 NY,D011409 Q000494 NY,D006084 Q000473 NN,D006085 Q000276 NN,D013950 Q000276 NY,D006084 Q000276 NN,D013110 Q000494 NN,D006084 Q000517 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers.,"The immunosuppressive effect of FTY720 is associated with the reversible sequestration of lymphocytes from the blood and the spleen into secondary lymphoid organs and reduced egress of mature thymocytes from the thymus. This work was designed to dissect the differential effect of FTY720 on CD4 and CD8 T cell-mediated mechanisms of skin graft rejection in the presence (euthymic) or absence (thymectomized) of thymic output. To that end, untreated and FTY720-treated euthymic (Euthy) and thymectomized (ATX) mic",Transplant international : official journal of the European Society for Organ Transplantation,"María L del Rio, Oliver Pabst, Pablo Ramirez, Giovanna Penuelas-Rivas, Reinhold Förster, Jose-Ignacio Rodriguez-Barbosa"," Institute of Immunology, Hannover Medical School, Hannover, Germany.",2007 Oct;20(10):895-903,10.1111/j.1432-2277.2007.00539.x
17914846,20071026,article,"xref,mesh","Boron Compounds,Cholesterol,Fingolimod Hydrochloride,Fluorescent Dyes,Molecular Structure,Porphobilinogen,Propylene Glycols,Spectrophotometry, Ultraviolet,Sphingosine,Stereoisomerism","analogs &amp; derivatives,chemical synthesis,chemistry,methods","D011409 Q000737 NY,D013056 Q000379 NN,D011162 Q000031 NY,D005456 Q000737 NN,D001896 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011162 Q000737 NN,D005456 Q000138 NY,D001896 Q000138 NY,D011162 Q000138 NN,D002784 Q000737 NY","304,1021,5997,8252,10821,31270,67516,107969,107970,581764,3083424,5280335,5283629,25058173","127412361,128121087,128394615,129060975,129068198,129083870,129645792,136001504,136245714,249365405",Synthesis and spectral properties of cholesterol- and FTY720-containing boron dipyrromethene dyes.,"Two analogues (1, 2) of free cholesterol and one analogue (3) of the immunosuppressive sphingolipid FTY720 containing a boron dipyrromethene chromophore (BODIPY) were synthesized. The synthetic routes involved preparation of boron dipyrromethene moieties (5, 11), bearing a phenylethynyl group at different positions of the chromophore, and lipids (13, 20) bearing an azido group. The dye was tethered to the lipid via a 1,2,3-triazole in the linker by the click reaction. Analogues derived from 11 [in which an ",The Journal of organic chemistry,"Zaiguo Li, Robert Bittman"," Department of Chemistry and Biochemistry, Queens College of City University of New York, Flushing, New York 11367-1597, USA.",2007 Oct;72(22):8376-82,10.1021/jo701475q
17918267,20080101,article,"xref,mesh","Cell Differentiation,Cell Line,Cell Movement,Cell Surface Extensions,Cell Survival,Cytoskeleton,Down-Regulation,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Oligodendroglia,Propylene Glycols,RNA, Messenger,Receptors, G-Protein-Coupled,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Stem Cells,Suramin,rho-Associated Kinases","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology,physiology,therapeutic use","D013498 Q000494 NN,D002465 Q000187 NN,D002470 Q000187 NN,D015536 Q000235 NN,D049349 Q000819 NY,D015536 Q000187 NN,D049349 Q000235 NN,D054460 Q000037 NN,D009836 Q000187 NY,D002454 Q000187 NY,D013110 Q000031 NY,D003599 Q000378 NN,D011409 Q000494 NY,D043562 Q000187 NN,D013110 Q000378 NN,D043562 Q000378 NN,D002454 Q000502 NN,D009836 Q000378 NN,D048049 Q000378 NN,D002470 Q000502 NN,D012333 Q000378 NN,D012333 Q000187 NN,D022081 Q000187 NY,D054460 Q000378 NN,D008246 Q000378 NN,D003599 Q000187 NN,D048049 Q000187 NN","5361,8252,8514,31270,105065,107969,107970,5280335,5283560","127850182,128394615,129060975,129645792,136111139",FTY720 modulates human oligodendrocyte progenitor process extension and survival.,"OBJECTIVE: FTY720, a sphingosine-1-phosphate (S1P) receptor agonist that crosses the blood-brain barrier, is a potential immuno-therapy for multiple sclerosis. Our objective was to assess the effect of FTY720 on process extension, differentiation, and survival of human oligodendrocyte progenitor cells (OPCs), and link the functional effects with S1P receptor expression and signaling. METHODS: Functional assays and receptor expression studies were conducted on A2B5+ OPCs derived from the human fetal central ",Annals of neurology,"Veronique E Miron, Cha Gyun Jung, Hye Jung Kim, Timothy E Kennedy, Betty Soliven, Jack P Antel"," Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.",2008 Jan;63(1):61-71,10.1002/ana.21227
17954194,20071001,article,"xref,mesh","Animals,Apoptosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Models, Animal,Muscle, Smooth, Vascular,Propylene Glycols,Rabbits,Sphingosine","analogs &amp; derivatives,cytology,drug effects,pharmacology,physiology","D007166 Q000494 NY,D017209 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D009131 Q000502 NY,D009131 Q000187 NN,D009131 Q000166 NY,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 on apoptosis of smooth muscle cells.,BACKGROUND: Hyperproliferation of smooth muscle cells (SMCs) plays a key role in allograft arteriosclerosis. This prompted us to investigate the effect of the novel immune modulator and synthetic sphingolipid FTY720 on apoptosis of SMCs. METHODS: Rabbit SMC cultures were treated with FTY720 and apoptosis and necrosis were detected by fluorescence microscopy. RESULTS: We investigated dose- and time-dependent effects of FTY720 and found that clinically relevant low doses of FTY720 (<1 micromol/L) did not indu,Transplantation proceedings,"T Böhler, J Guillebaud, L Etienne, C Canivet, N Kamar, L Rostaing, J C Thiers, S Galvani, N Augé, R Salvayre, A Nègre-Salvayre, M Thomsen"," INSERM U858, CHU Rangueil, 31403 Toulouse, France. boehlert@toulouse.inserm.fr",2007 Oct;39(8):2624-6,10.1016/j.transproceed.2007.08.012
17961662,20080101,review,"xref,mesh","Animals,Brain,Drug Delivery Systems,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,physiopathology,therapeutic use","D007166 Q000494 NY,D049349 Q000378 NY,D001921 Q000503 NN,D007166 Q000627 NN,D009103 Q000503 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001921 Q000378 NN,D049349 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.,"Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-ph",Pharmacology & therapeutics,"Kumlesh K Dev, Florian Mullershausen, Henri Mattes, Rainer R Kuhn, Graeme Bilbe, Daniel Hoyer, Anis Mir"," Department of Anatomy and Neuroscience, University College Cork, Windle Building, Cork, Ireland. k.dev@ucc.ie",2008 Jan;117(1):77-93,10.1016/j.pharmthera.2007.08.005
17983426,20080601,article,"xref,mesh","Animals,Anti-Inflammatory Agents,Brain Injuries,Dexamethasone,Fingolimod Hydrochloride,Functional Laterality,Immunohistochemistry,Interleukin-16,Macrophages,Propylene Glycols,Rats,Sphingosine,Up-Regulation","analogs &amp; derivatives,biosynthesis,metabolism,pathology,pharmacology,physiopathology","D000893 Q000494 NY,D008264 Q000378 NN,D001930 Q000503 NN,D019410 Q000096 NY,D003907 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D001930 Q000473 NN,D001930 Q000378 NY,D013110 Q000494 NN","5743,8252,31270,107969,107970,5280335","128394615,129060975,129645792",Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury.,"AIMS: Interleukin-16 (IL16) is an immunomodulatory cytokine, which induces lymphocyte migration, expression of proinflammatory IL1 beta, IL6 and tumour necrosis factor-alpha, and modulates apoptosis. IL16 expression has been observed in several central nervous system diseases and may play a role in promoting inflammatory responses. Inflammation contributes considerably to secondary injury following traumatic brain injury (TBI). The aim of this study was to investigate early IL16 expression following experim",Neuropathology and applied neurobiology,"Z Zhang, U Fauser, H J Schluesener"," Institute of Brain Research, University of Tuebingen, Tuebingen, Germany. zhangzhiren@yahoo.com",2008 Jun;34(3):330-9,10.1111/j.1365-2990.2007.00893.x
17984842,20071015,article,"xref,mesh","Adult,Biopsy,Bradycardia,Cohort Studies,Cyclosporine,Double-Blind Method,Female,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Mycophenolic Acid,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,metabolism,methods,therapeutic use","D016572 Q000627 NY,D009173 Q000031 NY,D016030 Q000379 NY,D013110 Q000031 NY,D001919 Q000378 NN,D007166 Q000627 NY,D009173 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NY,D049349 Q000378 NN","588,2909,4271,4272,8252,31270,62280,107969,107970,446541,5280335,5280754,5281078,5284373,5458585,6435893,6441022,9855081,23665584,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,128094727,128394615,129060975,129178479,129645792",FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.,"BACKGROUND: FTY720 is a novel immunomodulator that was developed to produce optimal graft protection with improved safety and tolerability. Phase II studies have demonstrated the efficacy of FTY720 up to the doses of 2.5 mg with full-dose cyclosporine (FDC). METHODS: This multicenter, double-blind, Phase IIb, randomized study evaluated the safety and efficacy of 5 mg FTY720 (n=87; Group 1) vs. 2.5 mg FTY720 (n=90; Group 2) vs. mycophenolate mofetil (MMF; n=94; Group 3) in de novo renal transplant patients r",Transplantation,"Helio Tedesco-Silva, Peter Szakaly, Ahmed Shoker, Claudia Sommerer, Norio Yoshimura, Francesco Paolo Schena, Malika Cremer, Abdel Hmissi, Hartmut Mayer, Philippe Lang, FTY720 2218 Clinical Study Group"," Setor de Transplante Renal, Hospital do Rim Hipertensão/ UNIFESP, Rua Borges Lagoa, Sao Paulo, Brazil. heliotedesco@hrim.com.br",2007 Oct;84(7):885-92,10.1097/01.tp.0000281385.26500.3b
18037890,20080101,article,"xref,mesh","Animals,Cell Movement,Endothelium, Lymphatic,Fingolimod Hydrochloride,Homeostasis,Inflammation,Integrin alpha4beta1,Intercellular Adhesion Molecule-1,Lymph Nodes,Lymphatic Vessels,Lymphocyte Function-Associated Antigen-1,Lysophospholipids,Mice,Mice, Inbred C57BL,Models, Immunological,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,T-Lymphocytes,Vascular Cell Adhesion Molecule-1","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,immunology,metabolism,pharmacology","D049349 Q000819 NN,D004729 Q000276 NN,D008198 Q000276 NN,D013110 Q000031 NY,D013110 Q000378 NN,D039041 Q000276 NN,D008246 Q000378 NY,D019010 Q000276 NN,D007249 Q000276 NN,D013601 Q000276 NY,D042601 Q000276 NY,D011409 Q000494 NN,D018799 Q000276 NN,D049349 Q000276 NY,D013110 Q000494 NN,D049349 Q000037 NN,D016169 Q000276 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics.,"Although much is known about the migration of T cells from blood to lymph nodes, less is known about the mechanisms regulating the migration of T cells from tissues into lymph nodes through afferent lymphatics. Here we investigated T cell egress from nonlymphoid tissues into afferent lymph in vivo and developed an experimental model to recapitulate this process in vitro. Agonism of sphingosine 1-phosphate receptor 1 inhibited the entry of tissue T cells into afferent lymphatics in homeostatic and inflammato",Nature immunology,"Levi G Ledgerwood, Girdhari Lal, Nan Zhang, Alexandre Garin, Steven J Esses, Florent Ginhoux, Miriam Merad, Helene Peche, Sergio A Lira, Yaozhong Ding, Yu Yang, Xingxuan He, Edward H Schuchman, Maria L Allende, Jordi C Ochando, Jonathan S Bromberg"," Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.",2008 Jan;9(1):42-53,10.1038/ni1534
18039015,20070101,review,"xref,mesh","Acne Vulgaris,Animals,Cell Transformation, Neoplastic,Connective Tissue,Epidermis,Fingolimod Hydrochloride,Humans,Immunity,Immunosuppressive Agents,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Skin,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pharmacology,physiology,therapeutic use","D008246 Q000494 NN,D007166 Q000627 NN,D003238 Q000276 NN,D003238 Q000378 NN,D000152 Q000188 NN,D002471 Q000378 NN,D004817 Q000276 NN,D013110 Q000031 NY,D012867 Q000378 NN,D004817 Q000378 NN,D008246 Q000502 NY,D007109 Q000502 NY,D013601 Q000502 NN,D008246 Q000627 NN,D012867 Q000276 NY,D015398 Q000502 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007109 Q000187 NN,D013110 Q000494 NN,D013110 Q000502 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,135820018,136111139",Sphingosine-1-phosphate signaling and the skin.,"Sphingolipids have long been viewed as rather passive structural components of cellular membranes. More recently, it has become evident that metabolism of sphingomyelin yields several lipid mediators that evoke diverse and specific responses in different cell types. One sphingomyelin derivate, sphingosine-1-phosphate (S1P), has attracted particular attention for its effect on epidermal cells, which differs from those on most other cell types. S1P inhibits keratinocyte proliferation and induces keratinocyte ",American journal of clinical dermatology,"Thomas Herzinger, Burkhard Kleuser, Monika Schäfer-Korting, Hans Christian Korting"," Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilian-University, Munich, Germany. Thomas.Herzinger@lrz.uni-muenchen.de",2007 Jan;8(6):329-36,10.2165/00128071-200708060-00002
18085360,20080101,article,"xref,mesh","Animals,Cell Adhesion Molecules,Disease Models, Animal,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Intestinal Mucosa,Intestine, Small,Organ Transplantation,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,biosynthesis,drug effects,drug therapy,metabolism,methods,radiation effects,radiotherapy,therapeutic use,transplantation","D006085 Q000187 NN,D016377 Q000379 NY,D007413 Q000187 NN,D007413 Q000528 NN,D007413 Q000378 NY,D007421 Q000528 NN,D006085 Q000528 NN,D007421 Q000378 NN,D013110 Q000031 NY,D006084 Q000378 YN,D006084 Q000532 YN,D007421 Q000637 NY,D007166 Q000627 NY,D015815 Q000096 NY,D013110 Q000627 NN,D011409 Q000627 NY,D006084 Q000188 YN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.,"PURPOSE: We performed a semiquantitative analysis of the expression of Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and gut-associated tissues (GALT) during small bowel graft rejection in the rat to confirm the effect of FTY720 and ex vivo graft irradiation. METHODS: Small bowel transplantations (SBT) were performed from BN rats to LEW rats. Four groups of SBT animals were studied on days 3, 5, and 7 after operations (untreated, FTY720, ex vivo graft irradiation, FTY720+ex vivo graft irradiation). ",Surgery today,"Kiminobu Sugito, Mikiya Inoue, Taro Ikeda, Noritsugu Hagiwara, Tsugumichi Koshinaga, Takeshi Kusafuka"," Division of Pediatric Surgery, Department of Surgery, Nihon University School of Medicine, 30-1 Ohyaguchi-Kamimachi, Itabashi-ku, Tokyo 173-8610, Japan.",2008 Jan;38(1):38-41,10.1007/s00595-007-3583-8
18089307,20071201,article,"xref,mesh","Animals,Creatinine,Cyclosporine,Disease Models, Animal,Extracellular Matrix,Fingolimod Hydrochloride,Immunosuppressive Agents,Kidney Transplantation,Male,Propylene Glycols,Rats,Rats, Sprague-Dawley,Reperfusion Injury,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,blood,drug effects,immunology,pathology,pharmacology,physiology,physiopathology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D007166 Q000494 NY,D016030 Q000276 NN,D005109 Q000187 NN,D003404 Q000097 NN,D013110 Q000031 NY,D016030 Q000473 NY,D011409 Q000494 NY,D015427 Q000517 NN,D013110 Q000494 NN,D005109 Q000502 NY,D015427 Q000503 NY","588,2909,3763,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,128394615,128922443,129060975,129645792",FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.,"BACKGROUND: Ischemia-reperfusion (IR) is one of the strongest nonimmune factors associated with the development of chronic allograft nephropathy (CAN). This effect is often exacerbated by immunosuppressive medications, most notably cyclosporine. Although traditionally the macrophage was thought to stimulate fibroblast activity in CAN, recent evidence supports a role for lymphocytes. FTY720 is a new immunosuppressant that promotes lymphocyte sequestration into lymph nodes and Peyer's patches. This study inve",Transplantation proceedings,"M S Delbridge, B M Shrestha, A T Raftery, A M El Nahas, J Haylor"," Sheffield Kidney Institute, Northern General Hospital, Herries Road, Sheffield, South Yorkshire, United Kingdom. mdelbridge@sth.nhs.uk",2007 Dec;39(10):2992-6,10.1016/j.transproceed.2007.04.027
18089399,20071201,article,"xref,mesh","Animals,Apoptosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Intestine, Small,Lymphocytes,Propylene Glycols,Rats,Rats, Inbred BN,Rats, Inbred Lew,Sphingosine,Survival Analysis,Transplantation, Homologous","analogs &amp; derivatives,cytology,drug effects,pathology,radiation effects,therapeutic use,transplantation","D017209 Q000187 NY,D007421 Q000187 NN,D007421 Q000528 NY,D008214 Q000166 NY,D013110 Q000031 NY,D007421 Q000637 NY,D007166 Q000627 NY,D007421 Q000473 NN,D008214 Q000528 NN,D013110 Q000627 NN,D008214 Q000187 NN,D011409 Q000627 NY,D017209 Q000528 NN,D014184 Q000473 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes.,"OBJECTIVE: We investigated the extent of apoptosis in crypt cells and Peyer's patches (PPs) during small bowel allograft rejection in rats to examine the effect of FTY720 and ex vivo graft irradiation during rejection. MATERIALS AND METHODS: Orthotopic small bowel transplantations (SBT) were performed from Brown Norway (BN) rats to Lewis (LEW) rats. Four groups of SBT animals were studied on days 3, 5, and 7 after operations: untreated allograft, allograft with FTY720, allograft with irradiation, and allogr",Transplantation proceedings,"K Sugito, M Inoue, T Ikeda, N Hagiwara, T Koshinaga, T Kusafuka"," Department of Pediatric Surgery, Nihon University, Tokyo, Japan. Ksugito@hotmail.com",2007 Dec;39(10):3432-5,10.1016/j.transproceed.2007.07.083
18155542,20080101,article,"xref,mesh","Antibodies,Cell Movement,Extracellular Fluid,Fingolimod Hydrochloride,Graft Rejection,HLA-B27 Antigen,HLA-DR Antigens,HLA-DR Serological Subtypes,HLA-DR4 Antigen,Humans,Immunosuppressive Agents,Kidney Transplantation,Macrophages,Male,Middle Aged,Monocytes,Propylene Glycols,Sphingosine,Transplantation, Homologous","adverse effects,analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,pathology,therapeutic use","D006084 Q000188 NY,D009000 Q000473 NY,D009000 Q000187 NN,D007166 Q000627 NN,D002465 Q000276 NY,D016030 Q000473 NN,D013110 Q000031 NY,D015796 Q000276 NN,D008264 Q000187 NN,D006084 Q000097 NN,D000906 Q000009 NY,D016030 Q000276 NY,D008264 Q000473 NY,D013110 Q000627 NN,D011409 Q000627 NY,D045604 Q000276 NN,D006084 Q000276 NY,D006684 Q000276 NN,D045604 Q000187 NN,D015804 Q000276 NN","588,5865,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792,129717275",Antibody-mediated rejection with a striking interstitial monocyte/macrophage infiltration in a renal allograft under FTY720 treatment.,"FTY720, a novel immunomodulator, causes rapid temporary depletion of peripheral-blood lymphocytes, inducing their sequestration in secondary lymphoid organs. FTY720 is effective in animal models of transplantation and is under evaluation for use in human transplantation. We report a 48-year-old renal transplant recipient who developed acute antibody-mediated rejection under a high-dose FTY720 (5 mg/d), low-dose cyclosporine A, and prednisone treatment protocol. A T-cell antihuman globulin and National Insti",American journal of kidney diseases : the official journal of the National Kidney Foundation,"Banu Sis, Richard Grynoch, Allan G Murray, Patricia Campbell, Kim Solez"," Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. bsis@ualberta.ca",2008 Jan;51(1):127-30,10.1053/j.ajkd.2007.08.023
18195237,20080101,article,"xref,mesh","Cyclosporine,Drug Therapy, Combination,Fingolimod Hydrochloride,Fluorescein Angiography,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Failure, Chronic,Kidney Transplantation,Macular Edema,Prednisone,Propylene Glycols,Sphingosine,Tomography, Optical Coherence,Transplantation, Homologous","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,physiopathology,prevention &amp; control,surgery,therapeutic use","D016572 Q000627 NN,D007676 Q000601 NN,D013110 Q000009 NN,D008269 Q000175 NN,D013110 Q000031 NY,D008269 Q000503 NY,D011241 Q000627 NN,D008269 Q000139 NY,D007166 Q000009 NY,D006084 Q000517 NN,D011409 Q000009 NY","2909,5865,8252,16850,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127977452,128394615,129060975,129645792,129717275",Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.,NULL,"Archives of ophthalmology (Chicago, Ill. : 1960)","Georges Saab, Arghavan Almony, Kevin J Blinder, Rebecca Schuessler, Daniel C Brennan",NULL,2008 Jan;126(1):140-1,10.1001/archophthalmol.2007.23
18196225,20080501,article,"xref,mesh","Adolescent,Adult,Antihypertensive Agents,Area Under Curve,Atenolol,Blood Pressure,Blood Pressure Monitoring, Ambulatory,Cross-Over Studies,Diltiazem,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Male,Middle Aged,Propylene Glycols,Receptors, Lysosphingolipid,Single-Blind Method,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacokinetics,pharmacology","D007166 Q000494 NY,D001262 Q000493 NN,D006339 Q000187 NY,D000959 Q000494 NY,D013110 Q000031 NY,D004110 Q000493 NN,D011409 Q000494 NY,D007166 Q000493 NN,D001262 Q000494 NY,D011409 Q000493 NN,D000959 Q000493 NN,D013110 Q000493 NN,D001794 Q000187 NN,D004110 Q000494 NY,D013110 Q000494 NN,D049349 Q000378 NN","2249,3076,8252,31270,39186,62920,105065,107969,107970,3037122,5280335","128108066,128394615,128585206,129060975,129645792,136111139",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.,"OBJECTIVE: The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) is known to elicit a negative chronotropic effect at treatment initiation that attenuates over time with continued dosing. The authors determined the effect of combining a single dose of fingolimod with steady-state atenolol or diltiazem on heart rate and mean arterial pressure. METHODS: In a partially randomized, single-blind, placebo-controlled, three-period, crossover study, 25 healthy subjects received (1) a single oral 5-mg d",European journal of clinical pharmacology,"John M Kovarik, Michael Lu, Gilles-Jacques Riviere, Irene Barbet, Steve Maton, D Ronald Goldwater, Robert L Schmouder"," Novartis Pharma, Building WSJ 210.423, 4002, Basel, Switzerland. john.kovarik@novartis.com",2008 May;64(5):457-63,10.1007/s00228-007-0448-4
18220956,20071201,review,"xref,mesh","Animals,Blood-Brain Barrier,Cell Movement,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Immunosuppressive Agents,Leukocytes,Propylene Glycols,Sphingosine","analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D002465 Q000187 NN,D007962 Q000187 NN,D001812 Q000187 NN,D019161 Q000494 NN,D004730 Q000187 NN,D013110 Q000031 NN,D004730 Q000276 NN,D002465 Q000276 NN,D001812 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007962 Q000276 NY,D007962 Q000166 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Therapeutic targeting of leukocyte trafficking across the blood-brain barrier.,"The central nervous system (CNS) has long been regarded as an immune privileged organ implying that the immune system avoids the CNS not to disturb its homeostasis, which is critical for proper function of neurons. Meanwhile, it is accepted that immune cells do in fact gain access to the CNS and that immune responses are mounted within this tissue. However, the unique CNS microenvironment strictly controls these immune reactions starting with tightly regulating immune cell entry into the tissue. The endothe",Inflammation & allergy drug targets,"Caroline Coisne, Ruth Lyck, Britta Engelhardt"," Theodor Kocher Institute, University of Bern, Freiestrasse 1, CH-3012 Bern, Switzerland. caroline.coisne@tki.unibe.ch",2007 Dec;6(4):210-22,10.2174/187152807783334328
18261728,20080401,article,"xref,mesh","Animals,Body Weight,CD3 Complex,Disease Models, Animal,Ectodysplasins,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Lymphocytes,Macrophages,Male,Neuritis, Autoimmune, Experimental,Propylene Glycols,Rats,Rats, Inbred Lew,Sciatic Nerve,Sphingosine,Sulfonamides","analogs &amp; derivatives,drug effects,drug therapy,metabolism,methods,pathology,pharmacology,physiopathology,therapeutic use","D012584 Q000187 NN,D013449 Q000378 NN,D007166 Q000494 NY,D017252 Q000378 NN,D007166 Q000627 NN,D008214 Q000378 NN,D008264 Q000378 NN,D053331 Q000378 NN,D008214 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D009444 Q000188 NN,D005434 Q000379 NN,D009444 Q000503 NN,D012584 Q000473 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D008264 Q000187 NY,D009444 Q000473 NY","4299,8252,31270,105065,107969,107970,5280335,16760706","128284729,128394615,129060975,129645792,136111139",FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.,"Experimental autoimmune neuritis (EAN) is a T cell-mediated autoimmune demyelinating inflammatory disease of the peripheral nervous system (PNS). T cells and macrophages are essential for the initiation and development of EAN. FTY720 acts as an agonist of sphingosine-1-phosphate receptors, resulting in inhibition of lymphocyte egress from secondary lymphoid tissues and thymocytes from thymus. This investigation describes the immunosuppressive effects of FTY720 in EAN, the animal model of autoimmune neuropat",Experimental neurology,"Zhiren Zhang, Zhi-Yuan Zhang, Uwe Fauser, Hermann J Schluesener"," Institute of Brain Research, University of Tuebingen, Calwer Street 3, D-72076 Tuebingen, Germany. zhangzhiren@yahoo.com",2008 Apr;210(2):681-90,10.1016/j.expneurol.2007.12.025
18339282,20071201,article,"xref,mesh","Animals,Cell Cycle Proteins,Disease Models, Animal,Fingolimod Hydrochloride,Glomerulosclerosis, Focal Segmental,Immunosuppressive Agents,Kidney,Male,Nephrectomy,Postoperative Period,Propylene Glycols,Rats,Rats, Sprague-Dawley,Sphingosine","adverse effects,analogs &amp; derivatives,biosynthesis,metabolism,pathology,pharmacology,surgery,therapeutic use,therapy","D007668 Q000601 NN,D005923 Q000628 NY,D007668 Q000473 NN,D013110 Q000031 NY,D009392 Q000009 NY,D005923 Q000378 NN,D007166 Q000627 NY,D011409 Q000494 NN,D018797 Q000096 NN,D013110 Q000627 NN,D013110 Q000494 NN,D005923 Q000473 NN,D011409 Q000627 NY,D007166 Q000494 NN","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792",[Effect of FTY720 on glomerulosclerosis and expression of cell cycle regulatory proteins in subtotally nephrectomized rats].,"OBJECTIVE: To study the effect of FTY720 on glomerulosclerosis and expression of cell cycle regulatory proteins in subtotal nephrectomized rats. METHODS: Twenty-four rats were divided into sham-operation group, glomerulosclerosis model group and FTY720 treated glomerulosclerosis group with 8 rats in each group. The rats in the latter two groups were subjected to subtotal nephrectomy. After operation, the FTY720 treated group was fed with FTY720 at a dose of 0.5 mg/(kg x d) for 12 weeks. Urine protein excret",Zhonghua er ke za zhi = Chinese journal of pediatrics,"Guo-qin Zhu, Jian-hua Zhou, Min Xie, Yan Hao"," Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.",2007 Dec;45(12):922-6,NULL
18343890,20080501,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cell Proliferation,Female,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Homeostasis,Immunologic Memory,Immunosuppressive Agents,Interferon-gamma,Lymph Nodes,Mice,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,biosynthesis,cytology,drug effects,immunology,metabolism,pharmacology","D007166 Q000494 NY,D015496 Q000378 NN,D018414 Q000378 NN,D018414 Q000276 NY,D007371 Q000276 NN,D015496 Q000187 NN,D008198 Q000276 NN,D049109 Q000187 NN,D013154 Q000166 NN,D013110 Q000031 NY,D011409 Q000494 NY,D015496 Q000276 NY,D013154 Q000276 NN,D007371 Q000096 NN,D018414 Q000187 NN,D006706 Q000187 NN,D008198 Q000378 NN,D013110 Q000494 NN,D016027 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.,"The immunomodulator FTY720 inhibits lymph node (LN) and thymic egress, thereby constraining T cell circulation and reducing peripheral T cell numbers. Here, we analyzed in mouse models the as yet scarcely characterized impact of long-term (up to 6 months) FTY720 exposure on T cell homeostasis and possible consequences for alloreactivity. In green fluorescent protein (GFP) hemopoietic chimeras, the turnover of (initially GFP(-)) peripheral T cell pools was markedly delayed under FTY720, while normal homeosta",International immunology,"Barbara Metzler, Patrick Gfeller, Grazyna Wieczorek, Jianping Li, Barbara Nuesslein-Hildesheim, Andreas Katopodis, Matthias Mueller, Volker Brinkmann"," Department of Autoimmunity and Transplantation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. barbara.metzler@novartis.com",2008 May;20(5):633-44,10.1093/intimm/dxn023
18365684,20080201,article,"xref,mesh","Aniline Compounds,Animals,Antibiotics, Antineoplastic,Cell Proliferation,Cyclosporine,Fingolimod Hydrochloride,Fungi,Hydroxybutyrates,Immunity, Cellular,Immunosuppressive Agents,Interleukin-2,Lipopolysaccharides,Macrophages,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Nitric Oxide,Propylene Glycols,Sphingosine,T-Lymphocytes,Tetrazolium Salts,Thiazoles,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,biosynthesis,chemistry,drug effects,immunology,isolation &amp; purification,metabolism,pharmacology,physiology","D005658 Q000737 NY,D008070 Q000494 NN,D013601 Q000276 NN,D008264 Q000378 NN,D005658 Q000378 NY,D000903 Q000302 NN,D007376 Q000502 NN,D049109 Q000187 NN,D009569 Q000096 NN,D013110 Q000031 NY,D011409 Q000494 NY,D014409 Q000096 NN,D006885 Q000494 NN,D008264 Q000187 NN,D000903 Q000494 NY,D016572 Q000494 NN,D007111 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013601 Q000187 NN,D000814 Q000494 NN","2909,6115,8252,9256,31270,62280,64965,64966,67519,105065,107969,107970,145068,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","128392536,128394615,128889888,129060975,129401397,129645792,136111139","Non-specific anti-proliferative effect of FTY720, a derivative of fungal metabolite from Iscaria sinclarii.","FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii, with agonistic effect for sphingosine-1-phosphate receptor. In this study, we examined the potential adverse effect of FTY720 in terms of cell cytotoxicity and the relevance to its pharmacological action, using cell proliferation assay and functional aspect of activated macrophages producing NO and TNF-alpha. FTY720 potently blocked the proliferation of allogeneic T cells. However, this compound did not st",Archives of pharmacal research,Jae Youl Cho," School of Bioscience and Biotechnology, Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon 200-701, Korea. jaecho@kangwon.ac.kr",2008 Feb;31(2):160-6,10.1007/s12272-001-1135-0
18383466,20080701,article,"xref,mesh","Catalysis,Fingolimod Hydrochloride,Immunosuppressive Agents,Models, Chemical,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemistry,metabolism,pharmacology","D007166 Q000494 NY,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D017853 Q000378 NY,D007166 Q000737 NN,D017853 Q000737 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues.,NULL,ChemMedChem,"Klemens Högenauer, Andreas Billich, Charles Pally, Markus Streiff, Trixie Wagner, Karl Welzenbach, Peter Nussbaumer"," Novartis Institutes for Biomedical Research, Brunner Strasse 59, 1235 Wien, Austria. klemens.hoegenauer@novartis.com",2008 Jul;3(7):1027-9,10.1002/cmdc.200800037
18390708,20080415,article,"xref,mesh","Animals,Antigen Presentation,Apoptosis,Apoptosis Regulatory Proteins,Autoantigens,CD8-Positive T-Lymphocytes,Clonal Deletion,Fingolimod Hydrochloride,Glucose,Immunosuppressive Agents,Insulin-Secreting Cells,Mice,Mice, Inbred BALB C,Mice, Transgenic,Propylene Glycols,Receptors, Tumor Necrosis Factor, Type I,Receptors, Tumor Necrosis Factor, Type II,Self Tolerance,Sphingosine,fas Receptor","analogs &amp; derivatives,analysis,cytology,immunology,metabolism,pharmacology","D050417 Q000276 NN,D001324 Q000276 NY,D051017 Q000378 NY,D019014 Q000378 NN,D018414 Q000378 NN,D047888 Q000378 NN,D047889 Q000378 NN,D018414 Q000276 NY,D051017 Q000276 NN,D013110 Q000031 NN,D018414 Q000166 NN,D005947 Q000032 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN","5793,5798,8252,24749,31270,107526,107969,107970,5280335,10954115,87517085","128133524,128394615,129060975,129621433,129645792",The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen.,"The maintenance of T cell tolerance in the periphery proceeds through several mechanisms, including anergy, immuno-regulation, and deletion via apoptosis. We examined the mechanism underlying the induction of CD8 T cell peripheral tolerance to a self-Ag expressed on pancreatic islet beta-cells. Following adoptive transfer, Ag-specific clone 4 T cells underwent deletion independently of extrinsic death receptors, including Fas, TNFR1, or TNFR2. Additional experiments revealed that the induction of clone 4 T ","Journal of immunology (Baltimore, Md. : 1950)","William L Redmond, Cheng-Hong Wei, Huub T C Kreuwel, Linda A Sherman"," Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.",2008 Apr;180(8):5275-82,10.4049/jimmunol.180.8.5275
18390715,20080415,article,"xref,mesh","Animals,B-Lymphocytes,Female,Fingolimod Hydrochloride,Immunoglobulin A,Immunosuppressive Agents,Intestines,Lysophospholipids,Mice,Mice, Inbred BALB C,Ovalbumin,Peyer's Patches,Plasma Cells,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,cytology,drug effects,immunology,metabolism,pharmacology","D010950 Q000187 NN,D007166 Q000008 NN,D010581 Q000187 NN,D001402 Q000276 NY,D013110 Q000008 NN,D001402 Q000166 NN,D007422 Q000187 NN,D001402 Q000187 NN,D007070 Q000276 NN,D013110 Q000031 NY,D011409 Q000008 NN,D008246 Q000276 NN,D013110 Q000378 NN,D013110 Q000276 NN,D008246 Q000378 NY,D010950 Q000276 NN,D010047 Q000276 NN,D010581 Q000276 NY,D007070 Q000378 NY,D007422 Q000276 NN,D011409 Q000494 NN,D010581 Q000166 NN,D010950 Q000166 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001402 Q000378 NN,D007422 Q000378 NY","8252,31270,107969,107970,5280335,5283560,5289086","128394615,129060975,129645792",Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses.,"It is well established that Peyer's patches (PPs) are sites for the differentiation of IgA plasma cell precursors, but molecular and cellular mechanisms in their trafficking remain to be elucidated. In this study, we show that alterations in type 1 sphingosine 1-phosphate (S1P) receptor expression during B cell differentiation in the PPs control the emigration of IgA plasma cell precursors. Type 1 S1P receptor expression decreased during the differentiation of IgM(+)B220(+) B cells to IgA(+)B220(+) B cells,","Journal of immunology (Baltimore, Md. : 1950)","Masashi Gohda, Jun Kunisawa, Fumi Miura, Yuki Kagiyama, Yosuke Kurashima, Morio Higuchi, Izumi Ishikawa, Ikuko Ogahara, Hiroshi Kiyono"," Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.",2008 Apr;180(8):5335-43,10.4049/jimmunol.180.8.5335
18402775,20080613,article,"xref,mesh","Actins,Cell Adhesion Molecules,Cell Membrane,Cell Movement,Cells, Cultured,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Neovascularization, Physiologic,Oxadiazoles,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,Wound Healing","analogs &amp; derivatives,analysis,antagonists &amp; inhibitors,chemistry,drug effects,injuries,metabolism,pharmacology","D007166 Q000494 NY,D049349 Q000378 NY,D002465 Q000187 NN,D002462 Q000737 NN,D008246 Q000494 NN,D015815 Q000032 NN,D004730 Q000187 NY,D010069 Q000494 NN,D049349 Q000032 NN,D004730 Q000293 NN,D014945 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000037 NN,D004730 Q000378 NN,D000199 Q000378 NN,D013876 Q000494 NN,D015815 Q000378 NN,D018919 Q000187 NN,D013110 Q000494 NN,D002462 Q000378 NN,D008246 Q000037 NY","8252,31270,107969,107970,4077460,5280335,5283560,10523409","128394615,129060975,129645792",FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.,"The phosphorylated derivative of the immunosuppressant FTY720 interacts with and modulates the function of sphingosine-1-phosphate (S1P)-receptors. We observed a significant reduction of endothelial surface binding of a S1P(1)-specific antibody after FTY720 treatment of 6h and longer, which was associated with a reduced healing after mechanic injury, impaired angiogenesis and enhanced adhesion molecule expression. FTY720 (5h) had no impact on the expression of S1P(1)- or S1P(3)-encoding transcripts. Notably",Biochemical and biophysical research communications,"Vera Krump-Konvalinkova, Ilona Chwalla, Wolfgang Siess"," Institute for Prevention of Cardiovascular Diseases, University of Munich, Pettenkoferstrasse 9, 80336 Munich, Germany. vkrump@med.uni-muenchen.de",2008 Jun;370(4):603-8,10.1016/j.bbrc.2008.03.144
18416311,20080101,review,"xref,mesh","Administration, Oral,Animals,Ascomycota,Biological Products,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Molecular Structure,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,chemistry,drug effects,drug therapy,isolation &amp; purification,pharmacology,therapeutic use","D001688 Q000627 NY,D007166 Q000008 NN,D001688 Q000494 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D049349 Q000187 NY,D007166 Q000627 NY,D001688 Q000302 NN,D001203 Q000737 NY,D011409 Q000494 NN,D013110 Q000302 NN,D007166 Q000302 NN,D013110 Q000627 NN,D011409 Q000302 NN,D001688 Q000008 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.,"Fingolimod (FTY720) represents the first in a new class of immune-modulators whose target is sphingosine-1-phosphate (S1P) receptors. It was first identified by researchers at Kyoto University and Yoshitomi Pharmaceutical as a chemical derivative of the ascomycete metabolite ISP-1 (myriocin). Unlike its natural product parent, FTY720 does not interfere with sphingolipid biosynthesis. Instead, its best characterized mechanism of action upon in vivo phosphorylation, leading to the active principle FTY720-P, i",Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,"Peter C Hiestand, Martin Rausch, Daniela Piani Meier, Carolyn A Foster"," Novartis Pharma AG, Lichtstrasse 35, 4002 Basel, Switzerland.","2008 Jan;66(?):361, 363-81",NULL
18421849,20080301,review,"xref,mesh","Animals,Autoimmune Diseases,Clinical Trials, Phase II as Topic,Disease Models, Animal,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,agonists,analogs &amp; derivatives,drug therapy,pharmacology,physiology,therapeutic use","D007166 Q000494 NY,D049349 Q000819 NY,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D007166 Q000627 NY,D049349 Q000502 NY,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D009103 Q000188 NN,D001327 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].,NULL,Nihon yakurigaku zasshi. Folia pharmacologica Japonica,"Kenji Chiba, Hirotoshi Kataoka",NULL,2008 Mar;131(3):24-5,NULL
18455036,20080401,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Flow Cytometry,Graft Survival,Immunosuppressive Agents,Kidney,Kidney Function Tests,Mice,Propylene Glycols,Skin Transplantation,Sphingosine,Tacrolimus,Transplantation, Homologous","analogs &amp; derivatives,drug effects,immunology,physiology,therapeutic use","D007668 Q000187 NN,D016038 Q000276 NN,D013110 Q000031 NY,D007166 Q000627 NY,D006085 Q000187 NY,D013110 Q000627 NN,D011409 Q000627 NY,D016559 Q000627 NY,D016038 Q000502 NY,D007668 Q000502 NY","5372,5793,8252,31270,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,90726579,134694629","128394615,129060975,129621433,129645792,242963342",Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice.,"Calcineurin inhibitors such as cyclosporine (CsA) and tacrolimus (FK506) show similar efficacy to prevent rejection within the first year after organ transplantation. However, their use is limited by side effects, such as kidney damage, hypertension, new-onset diabetes, and hyperlipidemia. The consensus opinion suggests that compared with CsA, FK506 has fewer negative effects on blood pressure, serum lipids, and renal function. Nevertheless, FK506 use is associated with a higher incidence of posttransplanta",Transplantation proceedings,"C T Lopes, A P Gallo, P V B Palma, P M Cury, V Bueno"," FAMERP São José do Rio Preto Medical School, São José do Rio Preto, São Paulo, Brazil.",2008 Apr;40(3):856-60,10.1016/j.transproceed.2008.02.051
18457527,20080501,review,"xref,mesh","Clinical Trials, Phase III as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Secondary Prevention,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,immunology,prevention &amp; control,therapeutic use,trends","D011409 Q000276 NN,D007166 Q000627 NN,D020529 Q000517 NY,D013110 Q000031 NY,D013110 Q000276 NN,D017326 Q000639 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D020529 Q000276 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,135650261,136111139",FTY720 (fingolimod) for relapsing multiple sclerosis.,"FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate. The immunomodulatory properties of this agent are mainly related to its ability to entrap lymphocytes in secondary lymphoid organs, reducing their availability for cell-mediated immune responses. Emerging evidence suggests that FTY720 also exerts direct actions on glial and precursor cells of the CNS which may be relevant fo",Expert review of neurotherapeutics,"Alejandro Horga, Xavier Montalban"," Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Barcelona, Spain. ahorga@comb.es",2008 May;8(5):699-714,10.1586/14737175.8.5.699
18466329,20080701,article,"xref,mesh","Actins,Animals,Antibodies,Cell Differentiation,Cell Movement,Cell Polarity,Cells, Cultured,Ceramides,Embryo, Mammalian,Fatty Acids, Monounsaturated,Immunosuppressive Agents,Mice,Neurons,Oleic Acids,Propylene Glycols,Protein Binding,Protein Kinase C,Protein Transport,Stem Cells,Tubulin,beta Catenin,cdc42 GTP-Binding Protein","drug effects,immunology,metabolism,pharmacology,physiology","D011493 Q000378 NN,D011485 Q000502 NN,D002518 Q000276 NN,D002465 Q000187 NY,D000906 Q000494 NN,D021381 Q000187 NN,D020764 Q000378 NN,D002518 Q000494 NY,D016764 Q000187 NN,D000199 Q000378 NN,D011485 Q000187 NN,D009829 Q000494 NN,D005229 Q000494 NN,D011409 Q000494 NN,D051176 Q000378 NN,D009474 Q000502 NY,D002454 Q000187 NN,D007166 Q000494 NN,D014404 Q000378 NN,D013234 Q000187 NY","8252,121989,6438394,44183838,57024517,71404344,91250800","129060975,129976789,135812730,135820018,135836815,246411077,246695817",Regulation of neural progenitor cell motility by ceramide and potential implications for mouse brain development.,"We provide evidence that the sphingolipid ceramide, in addition to its pro-apoptotic function, regulates neural progenitor (NP) motility in vitro and brain development in vivo. Ceramide (N-palmitoyl d-erythro sphingosine and N-oleoyl d-erythro sphingosine) and the ceramide analog N-oleoyl serinol (S18) stimulate migration of NPs in scratch (wounding) migration assays. Sphingolipid depletion by inhibition of de novo ceramide biosynthesis, or ceramide inactivation using an anti-ceramide antibody, obliterates ",Journal of neurochemistry,"Guanghu Wang, Kannan Krishnamurthy, Ying-Wei Chiang, Somsankar Dasgupta, Erhard Bieberich"," Program in Developmental Neurobiology, Institute of Molecular Medicine and Genetics, School of Medicine, Medical College of Georgia, Augusta, Georgia, USA.",2008 Jul;106(2):718-33,10.1111/j.1471-4159.2008.05451.x
18474015,20080101,review,"xref,mesh","Animals,Clinical Trials as Topic,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immune System Diseases,Immunosuppressive Agents,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemistry,drug therapy,pharmacology,therapeutic use","D007154 Q000188 NY,D007166 Q000494 NY,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D007166 Q000627 NY,D007166 Q000737 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine.,"Most of the conventional immunosuppressive drugs act by inhibiting the activation of enzymes, production of cytokines or proliferation of immune cells. Recently much attention is given to a new class of inhibitors that act by counteracting the functions of the lysophospholid sphingosine-1-phosphate (S1P). S1P is emerging as a potent stimulator of several immune cells and is critical for lymphocyte migration. The sphingosine analogue, FTY720 (fingolimod), a high affinity agonist of sphingosine-1-phosphate ty",Reviews on recent clinical trials,"Moizza Mansoor, Alirio J Melendez"," Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.",2008 Jan;3(1):62-9,10.2174/157488708783330486
18490766,20080601,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Female,Fingolimod Hydrochloride,Forkhead Transcription Factors,Herpesvirus 1, Human,Immunosuppressive Agents,Keratitis, Herpetic,Lymphocyte Count,Mice,Mice, Mutant Strains,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes, Regulatory,Transforming Growth Factor beta","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pathogenicity,pharmacology","D015496 Q000378 NN,D050378 Q000378 NN,D016849 Q000188 NN,D018259 Q000276 NY,D050378 Q000276 NY,D015496 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D051858 Q000378 NN,D016212 Q000378 NN,D015496 Q000276 NY,D018259 Q000472 NN,D016849 Q000276 NY,D016212 Q000276 NN,D016176 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335,56842206","128394615,129060975,129645792",Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators.,"FTY720 has been used to control inflammatory lesions, but the mechanisms by which the drug acts in vivo are poorly understood. Such mechanisms may result primarily from effects on lymphocyte and dendritic cell homing to lymphoid and inflammatory sites. We demonstrate that FTY720 may also act by causing the conversion of TCR-stimulated nonregulatory CD4(+) T cells to Foxp3(+)CD4(+) regulatory T cells and by enhancing their suppressive activity. In a model in which mice were ocularly infected with HSV, daily ","Journal of immunology (Baltimore, Md. : 1950)","Sharvan Sehrawat, Barry T Rouse"," Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996-0845, USA.",2008 Jun;180(11):7636-47,10.4049/jimmunol.180.11.7636
18494802,20080901,article,"xref,mesh","Animals,Blood Glucose,Diabetes Mellitus, Type 2,Fasting,Fingolimod Hydrochloride,Glucose Tolerance Test,Immunosuppressive Agents,Insulin,Insulin Resistance,Lymphopenia,Male,Mice,Mice, Inbred C57BL,Panniculitis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Weight Gain","analogs &amp; derivatives,analysis,blood,chemically induced,drug effects,drug therapy,pharmacology,physiology","D003924 Q000188 NY,D007166 Q000494 NY,D008231 Q000139 NN,D013110 Q000031 NY,D011409 Q000494 NY,D005215 Q000097 NN,D015434 Q000188 NY,D015430 Q000187 NY,D007328 Q000097 NN,D013110 Q000494 NN,D001786 Q000032 NN,D049349 Q000502 NN","5793,8252,31270,105065,107969,107970,5280335,70678557,118984375","128394615,129060975,129621433,129645792,136111139","FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice.",NULL,"Diabetes, obesity & metabolism","M R Kendall, C J Hupfeld",NULL,2008 Sep;10(9):802-5,10.1111/j.1463-1326.2008.00910.x
18494940,20080601,article,"xref,mesh","Amines,Analgesics,Animals,Cyclohexanecarboxylic Acids,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Injections, Intraperitoneal,Injections, Spinal,Pain,Pain Measurement,Propylene Glycols,Prostaglandins,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,gamma-Aminobutyric Acid","administration &amp; dosage,agonists,analogs &amp; derivatives,blood,drug therapy,pharmacology,physiopathology","D049349 Q000819 NY,D003509 Q000494 NN,D010146 Q000503 NN,D010146 Q000188 NY,D013110 Q000008 NN,D005680 Q000494 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D000588 Q000494 NN,D013110 Q000494 NN,D000700 Q000008 NN,D011453 Q000097 NN,D000700 Q000494 NY","119,3446,8252,31270,107969,107970,5280335","127564392,128394615,129060975,129364554,129645792",Antinociceptive activity of the S1P-receptor agonist FTY720.,"FTY720 is a novel immunosuppressive drug that inhibits the egress of lymphocytes from secondary lymphoid tissues and thymus. In its phosphorylated form FTY720 is a potent S1P receptor agonist. Recently it was also shown that FTY720 can reduce prostaglandin synthesis through the direct inhibition of the cytosolic phospholipase A2 (cPLA2). Since prostaglandins are important mediators of nociception, we studied the effects of FTY720 in different models of nociception. We found that intraperitoneal administrati",Journal of cellular and molecular medicine,"Ovidiu Coste, Sandra Pierre, Claudiu Marian, Christian Brenneis, Carlo Angioni, Helmut Schmidt, Laura Popp, Gerd Geisslinger, Klaus Scholich"," Pharmazentrum Frankfurt, ZAFES, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.",2008 Jun;12(3):995-1004,10.1111/j.1582-4934.2008.00160.x
18502570,20081101,review,"xref,mesh","Animals,Antineoplastic Agents,Central Nervous System,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Immunosuppressive Agents,Interferon Type I,Multiple Sclerosis,Peptides,Propylene Glycols,Recombinant Proteins,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,therapeutic use","D010455 Q000009 NN,D019161 Q000627 NN,D011409 Q000009 NN,D013110 Q000009 NN,D010455 Q000627 NN,D019161 Q000009 NN,D013110 Q000031 NN,D000970 Q000627 NN,D007166 Q000627 NY,D002490 Q000187 NY,D007370 Q000009 NN,D000970 Q000009 NN,D007370 Q000627 NN,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","6057,8252,31270,54454,65370,105065,107969,107970,3081884,5280335","128394615,128865459,129060975,129200050,129645792,136111139",Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.,"OBJECTIVE: To review the direct and indirect effects on the central nervous system (CNS) of systemically administered immuno-modulatory therapies in use or under evaluation for the relapsing forms of multiple sclerosis (MS). METHODS: We summarize data published by our own lab and by others that delineate the effects of such therapies on in vitro neural cell cultures and in animal model-based systems. RESULTS: The long-approved therapies, interferon beta (IFNbeta) and glatiramer acetate (GA), do not readily ",Clinical neurology and neurosurgery,"Jack P Antel, Veronique E Miron"," Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. jack.antel@mcgill.ca",2008 Nov;110(9):951-7,10.1016/j.clineuro.2008.03.021
18507656,20080801,article,"xref,mesh","Adult,Anti-Arrhythmia Agents,Area Under Curve,Atropine,Circadian Rhythm,Cross-Over Studies,Dose-Response Relationship, Drug,Drug Interactions,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Infusions, Intravenous,Male,Middle Aged,Propylene Glycols,Sphingosine,Telemetry,Time Factors,Treatment Outcome","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,methods,pharmacology","D013110 Q000009 NN,D006339 Q000187 NY,D000889 Q000494 NY,D013110 Q000031 NY,D001285 Q000008 NN,D002940 Q000187 NN,D007166 Q000009 NY,D013686 Q000379 NN,D001285 Q000494 NY,D000889 Q000008 NN,D011409 Q000009 NY","5927,8252,17184,31270,64663,107969,107970,174174,656678,5280335,57473071,60196398,67052243,131632429,134688695","128394615,129060975,129143706,129645792",The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.,"AIMS: The authors determined whether intravenous atropine can prevent or counteract the negative chronotropic effect of the immunomodulator fingolimod. METHODS: In this randomized, placebo-controlled, two-period, crossover study, 12 healthy subjects received 5 mg fingolimod orally concurrently with intravenous atropine (titrated to a heart rate of 110-120 beats min(-1)) or intravenous placebo. A second group of 12 subjects received atropine/placebo 4 h after the fingolimod dose. Continuous telemetry measure",British journal of clinical pharmacology,"John M Kovarik, Alan Slade, Gilles-Jacques Riviere, Daniel Neddermann, Steve Maton, Thomas L Hunt, Robert L Schmouder"," Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland. john.kovarik@novartis.com",2008 Aug;66(2):199-206,10.1111/j.1365-2125.2008.03199.x
18513330,20080701,article,"xref,mesh","Amino Acid Sequence,Animals,CHO Cells,Cell Movement,Cricetinae,Cricetulus,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Humans,Ligands,Lysophospholipids,Mice,Molecular Sequence Data,NIH 3T3 Cells,Phosphorylation,Propylene Glycols,RGS Proteins,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,deficiency,drug effects,genetics,metabolism,pharmacology,physiology","D002465 Q000502 NY,D049349 Q000378 NY,D020710 Q000172 NN,D002465 Q000235 NN,D002465 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D020710 Q000235 NN,D008246 Q000502 NY,D020710 Q000502 NN,D013110 Q000494 NN,D020710 Q000378 NY,D049349 Q000502 NN,D013110 Q000502 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.,"Sphingosine 1-phosphate (S1P) stimulation enhances cell motility via the G-protein coupled S1P receptor S1P1. This ligand-induced, receptor-mediated cell motility follows a typical bell-shaped dose-response curve, that is, stimulation with low concentrations of S1P enhances cell motility, whereas excess ligand stimulation does not enhance it. So far, the attenuation of the response at higher ligand concentrations has not been explained. We report here that S1P1 interacts with the regulator of G protein sign",Genes to cells : devoted to molecular & cellular mechanisms,"Takayuki Kohno, Yasuyuki Igarashi"," Laboratory of Biomembrane and Biofunctional Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan.",2008 Jul;13(7):747-57,10.1111/j.1365-2443.2008.01202.x
18520051,20080601,article,"xref,mesh","Antineoplastic Agents,Blotting, Western,Breast Neoplasms,Cell Line, Tumor,Cell Proliferation,Cell Survival,Colonic Neoplasms,Enzyme Inhibitors,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Indicators and Reagents,JNK Mitogen-Activated Protein Kinases,Mitogen-Activated Protein Kinases,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Spectrophotometry, Infrared,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,metabolism,pathology,pharmacology","D003110 Q000473 NN,D017853 Q000378 NN,D007166 Q000494 NY,D000970 Q000494 NY,D002470 Q000187 NN,D020928 Q000378 NN,D011409 Q000378 NY,D049109 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D000970 Q000378 NY,D013110 Q000378 NN,D003110 Q000188 NY,D048031 Q000378 NN,D007166 Q000378 NY,D004791 Q000494 NN,D017853 Q000037 NN,D001943 Q000473 NN,D013110 Q000494 NN,D001943 Q000188 NY","4285,8252,31270,107969,107970,5280335,5282309,6438166,54178976","128394615,128887832,129060975,129645792,129839329",Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.,"FTY720 (fingolimod), a novel immunosuppressant, was found to become biologically activated by phosphorylation into FTY720-1-phosphate (FTY720-P), which is a high-affinity agonist for sphingosine-1-phosphate (sphingosine-1-P)-receptors. FTY720 has also been reported to have a strong antitumor activity. The association between the phosphorylation of FTY720 and the growth inhibition of FTY720 against cancer cells are still not completely understood. In this study, we investigated the effects of FTY720, sphingo",Biological & pharmaceutical bulletin,"Yasuo Nagaoka, Kota Otsuki, Tetsuro Fujita, Shinichi Uesato"," Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka, Japan. ynagaoka@ipcku.kansai-u.ac.jp",2008 Jun;31(6):1177-81,10.1248/bpb.31.1177
18540945,20090401,article,"xref,mesh","Animals,Antigens,Blood-Brain Barrier,Blotting, Western,Brain,Capillary Permeability,Demyelinating Diseases,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immunization,Immunosuppressive Agents,Myelin Proteins,Phospholipases A2, Cytosolic,Polymerase Chain Reaction,Propylene Glycols,Random Allocation,Rats,Sphingosine,Spinal Cord","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,physiopathology,therapeutic use","D054510 Q000378 NN,D001812 Q000187 NN,D002199 Q000187 NN,D005786 Q000187 NY,D013116 Q000473 NN,D000941 Q000008 NN,D013110 Q000031 NY,D004681 Q000503 NN,D001921 Q000473 NN,D007166 Q000627 NY,D004681 Q000235 NN,D009185 Q000378 NN,D003711 Q000188 NN,D001812 Q000473 NY,D013116 Q000378 NY,D001921 Q000378 NY,D013110 Q000627 NN,D011409 Q000627 NY,D004681 Q000473 NN,D001812 Q000503 NN,D004681 Q000188 NY","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792",FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.,"FTY720 (fingolimod) is an oral sphingosine-1 phosphate (S1P) receptor modulator in phase III development for the treatment of multiple sclerosis. To further investigate its mode of action, we analyzed gene expression in the central nervous system (CNS) during experimental autoimmune encephalomyelitis (EAE). FTY720 downregulated inflammatory genes in addition to vascular adhesion molecules. It decreased the matrix metalloproteinase gene MMP-9 and increased its counterregulator--tissue inhibitor of metallopro","Brain pathology (Zurich, Switzerland)","Carolyn A Foster, Diana Mechtcheriakova, Maria K Storch, Balázs Balatoni, Laurence M Howard, Frédéric Bornancin, Alexander Wlachos, Jury Sobanov, Anu Kinnunen, Thomas Baumruker"," Novartis Institutes for BioMedical Research, Brunner Strasse 59, Vienna, Austria. carolyn.foster@novartis.com",2009 Apr;19(2):254-66,10.1111/j.1750-3639.2008.00182.x
18552276,20080601,review,"xref,mesh","Animals,Antibodies, Monoclonal,Antineoplastic Agents,Apoptosis,Enzyme Activation,Fingolimod Hydrochloride,Humans,Hypersensitivity,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis,Neoplasms,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Sulfhydryl Compounds","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,enzymology,immunology,metabolism,pharmacology,physiology,therapeutic use","D009103 Q000201 NN,D009369 Q000201 NN,D049349 Q000819 NN,D017209 Q000187 NN,D013438 Q000627 NN,D000970 Q000494 NN,D007166 Q000627 NN,D000911 Q000627 NN,D013110 Q000031 NY,D008246 Q000276 NN,D009369 Q000188 NN,D000970 Q000627 NN,D006967 Q000201 NN,D013110 Q000276 NN,D008246 Q000502 NY,D000911 Q000494 NN,D017853 Q000378 NY,D049349 Q000502 NY,D011409 Q000494 NN,D013438 Q000494 NY,D017853 Q000037 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NN,D013110 Q000502 NN","8252,31270,105065,107969,107970,5280335,5283560,11155873","128394615,129060975,129645792,135836815,136111139","""Inside-out"" signaling of sphingosine-1-phosphate: therapeutic targets.","Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in many critical cellular processes including proliferation, survival, and migration, as well as angiogenesis and allergic responses. S1P levels inside cells are tightly regulated by the balance between its synthesis by sphingosine kinases and degradation. S1P is interconvertible with ceramide, which is a critical mediator of apoptosis. It has been postulated that the ratio between S1P and ceramide determines cell fate. Activation",Pharmacological reviews,"Kazuaki Takabe, Steven W Paugh, Sheldon Milstien, Sarah Spiegel"," Department of Surgery, Division of Surgical Oncology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.",2008 Jun;60(2):181-95,10.1124/pr.107.07113
18555808,20080901,review,"xref,mesh","Animals,Biological Transport,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,biosynthesis,chemistry,drug effects,metabolism,pharmacology,secretion","D007166 Q000494 NY,D013110 Q000557 NN,D008246 Q000096 NY,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D008246 Q000557 NY,D010766 Q000187 NN,D008246 Q000737 NN,D013110 Q000096 NN,D013110 Q000494 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.,"The bioactive lipid molecule sphingosine 1-phosphate (S1P) binds to specific cell surface receptors and regulates several cellular processes. S1P is abundant in plasma, and physiologically its most important target cells are lymphocytes and vascular endothelial cells. S1P plays a pivotal role in the immune system by regulating lymphocyte egress from the thymus and secondary lymphoid organs. The immunomodulator FTY720 impairs this egress, causing lymphopenia. Platelets had long been considered to be the majo",Biochimica et biophysica acta,"Akio Kihara, Yasuyuki Igarashi"," Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-choume, Kita-ku, Sapporo 060-0812, Japan.",2008 Sep;1781(9):496-502,10.1016/j.bbalip.2008.05.003
18569090,20080101,article,"xref,mesh","Animals,Cell Cycle,Cyclin D,Cyclin-Dependent Kinase Inhibitor p16,Cyclins,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Gene Expression Regulation,Graft Survival,Immunosuppressive Agents,Lymphocytes,Mice,Mice, Inbred BALB C,Models, Biological,Propylene Glycols,Skin Transplantation,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,biosynthesis,drug effects,immunology,pharmacology","D008214 Q000276 NY,D019941 Q000276 NN,D007166 Q000494 NY,D016038 Q000276 NY,D002453 Q000187 NY,D013110 Q000031 NY,D005786 Q000276 NN,D011409 Q000494 NY,D019941 Q000096 NN,D006085 Q000187 NY,D016213 Q000096 NN,D006085 Q000276 NN,D005786 Q000187 NN,D002453 Q000276 NN,D013110 Q000494 NN,D016213 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models.,"To probe into the mechanism of immunosuppression of FTY720, the authors study the cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models and the expression of cell cycle-related factors in cell cycle regulation system in mouse skin allograft models using flow cytometry, Immunohistochemical staining, and reverse transcriptase-polymerase chain reaction (RT-PCR). FTY720 could prolong survival days of graft in mouse skin transplantation models obviously (p < 0.01). In",Immunopharmacology and immunotoxicology,"Q Y Li, Y Y Chi, S Q Liu"," Department of Urology and Transplantation, First Affiliated Hospital, Binzhou Medical University, Binzhou City, Shandong Province, China. Road, Binzhou City, Shandong Province 256603, China. lqy999496@yahoo.com.cn",2008 Jan;30(2):365-81,10.1080/08923970801949174
18589120,20080601,article,"xref,mesh","Cyclosporine,Fingolimod Hydrochloride,Gene Expression Regulation,Granulocyte-Macrophage Colony-Stimulating Factor,Humans,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Kidney Transplantation,Lymphocyte Activation,Lymphopenia,Methylprednisolone,NFATC Transcription Factors,Propylene Glycols,RNA, Messenger,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,chemically induced,drug effects,genetics,immunology,metabolism,therapeutic use","D012333 Q000235 NN,D016572 Q000627 NN,D050778 Q000378 NY,D007376 Q000235 NN,D008231 Q000139 NN,D013110 Q000031 NY,D007166 Q000627 NY,D016030 Q000276 NY,D016178 Q000235 NN,D013601 Q000276 NY,D007371 Q000235 NN,D008775 Q000627 NN,D005786 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NY,D008213 Q000187 NY,D013601 Q000187 NN","588,2909,4272,6741,8252,31270,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883465,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082","127719861,128094727,128394615,129060975,129645792,134409758",Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients.,"We studied the inhibition of nuclear factor of activated T-cell (NFAT)-regulated gene expression (interleukin-2 [IL-2], interferon-gamma [IFN-gamma], granulocyte-macrophage colony-stimulating factor [GMCSF]) in cyclosporine (CsA)-treated de novo patients with and without lymphopenia due to FTY720. MATERIALS AND METHODS: Sixteen CsA-treated de novo renal transplant recipients received either FTY720 (n = 8) or mycophenolic acid (MPA; n = 8) in combination with low-dose steroids. Expressions of IL-2, INF-gamma",Transplantation proceedings,"C Sommerer, C Morath, T Giese, S Meuer, M Zeier"," Department of Nephrology, University of Heidelberg, Heidelberg, Germany.",2008 Jun;40(5):1416-8,10.1016/j.transproceed.2008.01.067
18589181,20080601,article,"xref,mesh","Cell Division,Cell Line, Tumor,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Pancreatic Neoplasms,Propylene Glycols,Sirolimus,Sphingosine","analogs &amp; derivatives,drug effects,pathology,pharmacology","D010190 Q000473 NY,D013110 Q000031 NY,D011409 Q000494 NY,D020123 Q000494 NY,D002455 Q000187 NY,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335,5284616,91454826,91534498","128394615,129060975,129645792,248184126,248766214",Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.,"Rapamycin inhibits the growth of several tumors including pancreatic carcinoma both in vitro and in vivo. The antitumor effects of FTY720 were also shown recently. The present study was performed to investigate the in vitro antiproliferative capacity of combined treatment with rapamycin and FTY720 on pancreatic cacinoma cell lines. MATERIALS AND METHODS: The Panc-1 and AsPc-1 cell lines were employed as the pancreatic carcinoma model in vitro. For monotreatment experiments, rapamycin was added in increasing",Transplantation proceedings,"Y Shen, X Wang, W Xia, C Wang, M Cai, H Xie, L Zhou, S Zheng"," Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, PR China.",2008 Jun;40(5):1727-33,10.1016/j.transproceed.2008.03.150
18678377,20081115,review,"xref,mesh","Animals,Blood-Brain Barrier,Central Nervous System,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D007166 Q000494 NY,D007166 Q000627 NN,D001812 Q000187 NN,D002490 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D004681 Q000188 NN,D002490 Q000187 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Central nervous system-directed effects of FTY720 (fingolimod).,"FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue that is under investigation as a therapy for both relapsing-remitting (RR) and progressive forms of multiple sclerosis (MS). The demonstrated beneficial effect of FTY720 on disease activity in RR-MS patients and in the animal model experimental autoimmune encephalomyelitis (EAE) is largely attributed to effects on the systemic immune system. In addition, unlike other current systemic immuno-modulators used in ",Journal of the neurological sciences,"Veronique E Miron, Anna Schubart, Jack P Antel"," Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4. veronique.miron@mcgill.ca",2008 Nov;274(?):13-7,10.1016/j.jns.2008.06.031
18691149,20080801,review,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Azathioprine,Chemistry, Pharmaceutical,Cyclophosphamide,Drug Design,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Methotrexate,Methyltransferases,Mitoxantrone,Models, Chemical,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,metabolism,methods,pharmacology","D007166 Q000494 NY,D008727 Q000494 NN,D020529 Q000188 NN,D001379 Q000494 NY,D003520 Q000494 NN,D008942 Q000494 NN,D007155 Q000494 NN,D002626 Q000379 NY,D008780 Q000378 NN,D013110 Q000031 NN,D000911 Q000494 NN,D011409 Q000494 NN,D013110 Q000494 NN,D009103 Q000188 NY","2265,2907,4112,4212,8252,22420,31270,51082,51151,107969,107970,126941,165528,5280335,5458171,11329481,11529527,23678981,24906323,54607525","128394615,128397534,129060975,129645792",Azathioprine in multiple sclerosis.,"Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases. In multiple sclerosis, available evidence suggests that oral azathioprine reduces relapse rates, provides a slight benefit on disability, and reduces new inflammatory lesions. Here, we focus on molecular mechanisms of Azathioprine and on its usefulness in multiple sclerosis. ",Mini reviews in medicinal chemistry,"Paolo Invernizzi, Maria Donata Benedetti, Sarah Poli, Salvatore Monaco"," Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Piazzale L.A. Scuro 10, Verona, Italy. p_invernizzi@yahoo.it",2008 Aug;8(9):919-26,10.2174/138955708785132756
18694829,20081101,article,"xref,mesh","Animals,B7-2 Antigen,Cell Movement,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Histocompatibility Antigens Class II,Immunosuppressive Agents,Langerhans Cells,Lymph Nodes,Male,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Organophosphates,Propylene Glycols,Receptors, CCR7,Receptors, Lysosphingolipid,Skin Transplantation,Sphingosine,Transplantation, Homologous","agonists,analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D054400 Q000378 NN,D000949 Q000378 NN,D010755 Q000494 NN,D049349 Q000819 NY,D002465 Q000187 NY,D016038 Q000276 NY,D049349 Q000276 NN,D008198 Q000276 NN,D051940 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002465 Q000276 NN,D006085 Q000187 NY,D006085 Q000276 NN,D014184 Q000276 NN,D007801 Q000276 NN,D006084 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007801 Q000187 NY","8252,31270,105065,107969,107970,5280335,9908268,11452022,45268446","128394615,129060975,129645792,136111139",Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.,"The novel immunomodulator FTY720 is a prototypic sphingosine-1-phosphate (S1P) receptor agonist that regulates lymphocyte migration and prolongs allograft survival. Skin dendritic cells (DC) play important roles in cutaneous immunity. We investigated the migration and function of skin DC exposed to FTY720 in vivo, or to its metabolite FTY720 phosphate (P) in vitro. C57BL/10 (H2(b)) recipient (but not donor) FTY720 treatment prolonged median skin C3H (H2(k)) allograft survival significantly, from 12 to 34.5 ",Transplant immunology,"Yuk Yuen Lan, Daisuke Tokita, Zhiliang Wang, Hao Chen Wang, Jianghua Zhan, Volker Brinkmann, Angus W Thomson"," Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.",2008 Nov;20(?):88-94,10.1016/j.trim.2008.07.004
18704076,20080814,article,"xref,mesh","Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymph Nodes,Lymphocytes,Lymphocytic Choriomeningitis,Lymphocytic choriomeningitis virus,Mice,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,virology","D007166 Q000494 NY,D008216 Q000276 NY,D008214 Q000821 NN,D008198 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008216 Q000188 NN,D008217 Q000276 NN,D008198 Q000187 NY,D008214 Q000276 NN,D013110 Q000494 NN,D008214 Q000187 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Immunology: Surprising side effects.,NULL,Nature,"Michael J Bevan, Pamela J Fink",NULL,2008 Aug;454(7206):837-8,10.1038/454837a
18755152,20081031,article,"xref,mesh","Alternative Splicing,Animals,CHO Cells,Cricetinae,Cricetulus,Endothelial Cells,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Phosphatidate Phosphatase,Propylene Glycols,Protein Isoforms,Sphingosine","analogs &amp; derivatives,enzymology,genetics,metabolism","D042783 Q000201 NY,D020033 Q000235 NN,D011409 Q000378 NY,D013110 Q000031 NY,D013110 Q000378 NN,D010711 Q000378 NY,D007166 Q000378 NY,D020033 Q000378 NN,D010711 Q000235 NN","8252,31270,69676,107969,107970,5280335","128394615,129060975,129308074,129645792,136292196","A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate.","The sphingolipid metabolite sphingosine 1-phosphate (S1P) plays an essential function in the egress of T cells from the thymus and secondary lymphoid organs. The novel immunomodulating agent FTY720 is phosphorylated in vivo to the functional form FTY720 phosphate (FTY720-P), which is structurally similar to S1P. FTY720-P inhibits the S1P-mediated T cell egress as an agonist of S1P receptors. FTY720-P is not stable in plasma and is dephosphorylated to FTY720. In the present study, we investigated activities ",Biochemical and biophysical research communications,"Masao Yamanaka, Yoshihiro Anada, Yasuyuki Igarashi, Akio Kihara"," Laboratory of Biomembrane and Biofunctional Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-choume, Kita-ku, Sapporo 060-0812, Japan.",2008 Oct;375(4):675-9,10.1016/j.bbrc.2008.07.165
18764723,20080901,review,"xref,mesh","Administration, Oral,Cladribine,Crotonates,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Quinolones,Sphingosine,Toluidines","administration &amp; dosage,analogs &amp; derivatives,drug therapy,therapeutic use","D015363 Q000627 NN,D007166 Q000008 NN,D013110 Q000008 NN,D005650 Q000627 NN,D011409 Q000008 NN,D014052 Q000008 NN,D003437 Q000008 NN,D003437 Q000627 NN,D013110 Q000031 NN,D015363 Q000008 NN,D007166 Q000627 NY,D017338 Q000008 NN,D014052 Q000627 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D005650 Q000008 NN","8252,20279,31270,107969,107970,444972,3036108,5280335,6076814,6364607,6433510,6440849,9793847,10197734,23500906,54677946,87110070,101823788","127968532,128394615,128672523,128966217,129060975,129645792",Emerging oral drugs for multiple sclerosis.,"BACKGROUND: Therapy for multiple sclerosis (MS) has changed dramatically over the past decade, yielding significant progress in the treatment of relapsing/remitting and secondary progressive MS. Disease-modifying treatments are now widely available, and their beneficial effects on relapse rates, MRI outcomes and, in some cases, relapse-related disability have been shown in several clinical studies. However, as these treatments are only partially effective in halting the MS disease process and in clinical pr",Expert opinion on emerging drugs,"Claudio Gasperini, Luca Ausili Cefaro, Giovanna Borriello, Giuseppe Tosto, Luca Prosperini, Carlo Pozzilli"," S Camillo-Forlanini Hospital, Department of Neuroscience, Viale dell'Università 30, 00185 Rome, Italy.",2008 Sep;13(3):465-77,10.1517/14728214.13.3.465
18800788,20081020,article,xref,NULL,NULL,NULL,6335,128659454,Computational studies of the reactions of B10H13- with alkynes and olefins: pathways for dehydrogenative alkyne-insertion and olefin-hydroboration reactions.,"Quantum mechanical computational studies of possible mechanistic pathways for B10H13(-) dehydrogenative alkyne-insertion and olefin-hydroboration reactions demonstrate that, depending on the reactant and reaction conditions, B10H13(-) can function as either an electrophile or nucleophile. For reactions with nucleophilic alkynes, such as propyne, the calculations indicate that at the temperatures (approximately 110-120 degrees C) required for these reactions, the ground-state B10H13(-) (1) structure can rear",Inorganic chemistry,"Chang Won Yoon, Upal Kusari, Larry G Sneddon"," Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, USA.",2008 Oct;47(20):9216-27,10.1021/ic8010019
18852417,20081001,article,"xref,mesh","Administration, Oral,Animals,Autoimmune Diseases,Disease Models, Animal,Dose-Response Relationship, Drug,Drug Administration Schedule,Emergency Treatment,Female,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Propylene Glycols,Random Allocation,Reference Values,Retinitis,Sensitivity and Specificity,Sphingosine,Treatment Outcome,Uveitis","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug therapy,immunology,methods,pathology","D014605 Q000188 NY,D012173 Q000473 NN,D014605 Q000276 NN,D013110 Q000008 NN,D001327 Q000175 NN,D013110 Q000031 NY,D004638 Q000379 NN,D012173 Q000188 NY,D014605 Q000473 NN,D012173 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY,D001327 Q000188 NY","1070,8252,31270,107969,107970,5280335","128394615,128684338,129060975,129645792",Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease.,"OBJECTIVE: To examine the efficacy of the immunomodulatory drug fingolimod (FTY720) as a rescue therapy for noninfectious intraocular inflammation. METHODS: Experimental autoimmune uveoretinitis, the murine correlate of human uveitis, was induced in B10.RIII mice. The mice were treated with 2 oral doses of fingolimod daily, either during early ocular infiltration or following clinical onset of the disease. At subsequent times, retinal infiltrates were examined and enumerated using flow cytometry, and struct","Archives of ophthalmology (Chicago, Ill. : 1960)","Ben J E Raveney, David A Copland, Lindsay B Nicholson, Andrew D Dick"," Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. ben@raveney.co.uk",2008 Oct;126(10):1390-5,10.1001/archopht.126.10.1390
18852441,20081014,article,"xref,mesh","Animals,Antigens, CD,Cell Proliferation,Cytokines,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Lymphocyte Subsets,Multiple Sclerosis,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D007166 Q000494 NY,D016207 Q000276 NN,D013601 Q000276 NN,D007166 Q000627 NN,D007371 Q000276 NN,D049109 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D009103 Q000276 NY,D007376 Q000276 NN,D015703 Q000276 NN,D013601 Q000187 NY,D016131 Q000187 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN,D016131 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.,"BACKGROUND: The oral immunomodulator FTY720 has shown efficacy in patients with relapsing multiple sclerosis (MS). FTY720 functionally antagonizes sphingosine 1-phosphate receptor-1 (S1P1) on T cells and consequently inhibits S1P/S1P1-dependent lymphocyte egress from secondary lymphoid organs. Little is known about the phenotype and function of T cells remaining in peripheral blood during long-term FTY720 treatment. METHODS: T cells from FTY720-treated, interferon-beta (IFNbeta)-treated and untreated patien",Neurology,"M Mehling, V Brinkmann, J Antel, A Bar-Or, N Goebels, C Vedrine, C Kristofic, J Kuhle, R L P Lindberg, L Kappos"," Department of Biomedicine and Neurology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.",2008 Oct;71(16):1261-7,10.1212/01.wnl.0000327609.57688.ea
18854957,20090101,review,"xref,mesh","Animals,B-Lymphocytes,Cell Movement,Endothelium,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymph Nodes,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,T-Lymphocytes","agonists,analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D013601 Q000378 NN,D049349 Q000378 NY,D002465 Q000187 NN,D049349 Q000819 NN,D004727 Q000378 NN,D002465 Q000276 NY,D001402 Q000276 NY,D049349 Q000276 NN,D008198 Q000276 NN,D015398 Q000276 NY,D004727 Q000276 NN,D013110 Q000031 NN,D013601 Q000276 NY,D011409 Q000494 NN,D008198 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001402 Q000378 NN,D013601 Q000187 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an ""immature"" vascular maturation factor to a ""mature"" mediator of lymphocyte behavior and function.","Since the initial observations that highlighted the importance of lymphocyte trafficking for immune responses, the pathways utilized by B and T lymphocytes to recirculate and properly position themselves have been intensely studied. Most of the chemoattractants along with their cognate receptors that affect lymphocyte trafficking have been identified. Some of their functions are promotion of lymphocyte ingress into immune organs, localization of cells to specific regions within those organs, maintenance of ",Immunologic research,"Michael D Davis, John H Kehrl"," Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N214, 10 Center Drive MSC 1876, Bethesda, MD 20892, USA.",2009 Jan;43(?):187-97,10.1007/s12026-008-8066-5
18977458,20090101,article,"xref,mesh","Biological Availability,Cell Survival,Chromosome Aberrations,Comet Assay,Dose-Response Relationship, Drug,Free Radicals,Humans,Imidazoles,Jurkat Cells,Lymphocytes,Micronucleus Tests,Models, Chemical,Mutagens,Neonicotinoids,Nitro Compounds,Reactive Oxygen Species","drug effects,methods,toxicity","D009574 Q000633 NY,D015162 Q000379 NN,D007093 Q000633 NY,D008214 Q000187 NY,D009153 Q000633 NY,D002869 Q000187 NN","679,13387,86418,104913,18183689,86287518","128141778,129223097,129514013,129859355,129889442,347827978",Genotoxicity of imidacloprid in relation to metabolic activation and composition of the commercial product.,"Imidacloprid is a neonicotinoid insecticide combining excellent efficiency against parasites with low toxicity for mammals. Commercially, it is co-formulated with dimethyl sulfoxide, methylpyrrolidone, propylene carbonate and mineral oil, which can modify its bioavailability and toxicological profile for humans following occupational exposure. A combined in vitro approach employing the comet assay and the micronucleus test was used to assess the genotoxicity of imidacloprid in relation to formulation, metab",Mutation research,"C Costa, V Silvari, A Melchini, S Catania, J J Heffron, A Trovato, R De Pasquale"," Dip. Medicina Sociale del Territorio, Sez. Medicina del Lavoro, Policlinico Universitario Gaetano Martino, 98125 Messina, Italy. ccosta@unime.it",2009 Jan;672(1):40-4,10.1016/j.mrgentox.2008.09.018
18978068,20090401,article,"xref,mesh","Azathioprine,Calcineurin Inhibitors,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mycophenolic Acid,Neoplasms,Organ Transplantation,Propylene Glycols,Protein Kinases,Sphingosine,TOR Serine-Threonine Kinases","adverse effects,analogs &amp; derivatives,chemically induced,etiology,immunology,pharmacology,physiology","D011409 Q000009 NN,D013110 Q000009 NN,D011494 Q000502 NN,D009369 Q000276 NN,D001379 Q000009 NN,D009369 Q000139 NN,D009173 Q000494 NN,D013110 Q000031 NN,D007166 Q000009 NY,D011409 Q000494 NN,D001379 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D016377 Q000009 YN,D009369 Q000209 NY,D009173 Q000009 NN","2265,4272,8252,31270,107969,107970,446541,5280335,5281078,6441022,11529527,23665584,53903450","128094727,128132375,128394615,129060975,129645792",Immunosuppressive therapy and post-transplant malignancy.,NULL,"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Sophie Domhan, Martin Zeier, Amir Abdollahi"," Department of Medicine, Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University, 736 Cambridge Street, CBR1, Boston, MA 02135, USA. Sophie.Domhan@Tufts.edu",2009 Apr;24(4):1097-103,10.1093/ndt/gfn605
19074680,20090301,article,"xref,mesh","Animals,Calcium,Chemotaxis,Chromatography, Liquid,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Liver Neoplasms,Liver Neoplasms, Experimental,Lymphoid Tissue,Mass Spectrometry,Organophosphates,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine,Spleen","analogs &amp; derivatives,cytology,drug effects,immunology,isolation &amp; purification,metabolism,pharmacokinetics,pharmacology,physiology","D011409 Q000493 NY,D010755 Q000494 NN,D002633 Q000187 NN,D013154 Q000187 NN,D013154 Q000502 NN,D007166 Q000493 NY,D013154 Q000166 NN,D013110 Q000031 NY,D010755 Q000302 NN,D002633 Q000502 NN,D008221 Q000276 NY,D049349 Q000187 NN,D013110 Q000493 NN,D002118 Q000378 NN,D008221 Q000187 NN,D011409 Q000494 NN,D013110 Q000302 NN,D011409 Q000302 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5460341,6337033,9908268,11452022,45268446","128394615,129060975,129645792",Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.,"The immunomodulator fingolimod (FTY720) induces lymphopenia by inhibiting lymphocyte egress from thymus and secondary lymphoid organs (SLOs). It is phosphorylated mainly by sphingosine kinase (SK) 2 in vivo. FTY720-phosphate (FTY-P) activated and rapidly internalized S1P(1), which is the major sphingosine 1-phosphate (S1P) receptor for mediating lymphocyte egress. Although FTY-P is thought to be the active metabolite for triggering the onset of lymphopenia, nonphosphorylated FTY720 was much more potent in i",The Journal of pharmacology and experimental therapeutics,"Sven-Christian Sensken, Constantin Bode, Markus H Gräler"," Institute for Immunology, Hannover Medical School, 30625 Hanover, Germany.",2009 Mar;328(3):963-9,10.1124/jpet.108.148163
19076834,20090101,article,"xref,mesh","Adoptive Transfer,Allergens,Animals,Asthma,Bronchoalveolar Lavage Fluid,Cell Division,Cell Movement,Cytokines,Eosinophilia,Female,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Lung,Lymph Nodes,Mice,Mice, Inbred BALB C,Mice, Transgenic,Microscopy, Confocal,Models, Animal,Ovalbumin,Propylene Glycols,Receptors, Antigen, T-Cell,Sphingosine,Th2 Cells,Time Factors","administration &amp; dosage,analogs &amp; derivatives,drug effects,genetics,immunology,methods,pharmacology","D016207 Q000276 NN,D002465 Q000187 NN,D001992 Q000276 NN,D008198 Q000276 NY,D008168 Q000276 NY,D005434 Q000379 NN,D013110 Q000031 NN,D011948 Q000235 NN,D018418 Q000276 NY,D011948 Q000276 NN,D000485 Q000008 NY,D001249 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335,5289086","128394615,129060975,129645792",An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation.,"It is widely accepted that allergic asthma is orchestrated by T helper type 2 lymphocytes specific for inhaled allergen. However, it remains unclear where and when T cell activation and division occurs after allergen challenge, and whether these factors have a significant impact on airways inflammation. We therefore employed a CD4-T cell receptor transgenic adoptive transfer model in conjunction with laser scanning cytometry to characterize the location and timing of T cell division in asthma in vivo. Thus,",Clinical and experimental immunology,"S Hutchison, B S W Choo-Kang, V B Gibson, R V Bundick, A J Leishman, J M Brewer, I B McInnes, P Garside"," Centre for Biophotonics, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. s.hutchison@strath.ac.uk",2009 Jan;155(1):107-16,10.1111/j.1365-2249.2008.03800.x
19100477,20081201,article,"xref,mesh","Animals,Chronic Disease,Cyclosporine,Drug Therapy, Combination,Everolimus,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred Lew,Sirolimus,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,drug effects,drug therapy,immunology,therapeutic use","D006084 Q000188 NY,D016572 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D006085 Q000187 NY,D006085 Q000276 NN,D014184 Q000276 NN,D016030 Q000276 NY,D020123 Q000031 NY,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY,D020123 Q000627 NN","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,24883466,25246316,49867938,71306795,71463825,73896891,90696889,91534498,122172945,123134263,123134270,132274082","128394615,129060975,129645792,242749350,248766214",Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.,"OBJECTIVE: In this study, we used combined treatment with cyclosporine (CsA)/everolimus (EVR) or CsA/FTY720 to affect ongoing chronic allograft nephropathy (CAN) compared with monotherapy with EVR or FTY720. BACKGROUND: CAN is an important cause of renal allograft loss. Immunosuppressive therapy is based on calcineurin inhibitors, which are associated with nephrotoxicity and decreasing graft function. Thus, alternative treatment regimens, including new immunosuppressants, such as EVR or FTY720, are of inter",Transplantation proceedings,"M Roos, S Liu, M Strobl, C Schmaderer, M Baumann, U Heemann, J Lutz"," Department of Nephrology, Klinikum rechts der Isar, Munich, Germany.",2008 Dec;40(10):3731-6,10.1016/j.transproceed.2008.06.114
19100737,20090301,article,"xref,mesh","Animals,Cell Proliferation,Disease Models, Animal,Down-Regulation,Fingolimod Hydrochloride,Forkhead Transcription Factors,Immunity, Cellular,Immunosuppressive Agents,Lymph Nodes,Lymphocyte Activation,Lymphocyte Count,Lymphoid Tissue,Male,Neuritis, Autoimmune, Experimental,Polyradiculoneuropathy,Propylene Glycols,Rats,Rats, Inbred Lew,Sciatic Nerve,Sphingosine,Spleen,T-Lymphocytes, Regulatory","analogs &amp; derivatives,analysis,drug effects,immunology,metabolism,pharmacology,physiopathology","D011129 Q000378 NN,D008198 Q000503 NN,D011129 Q000276 NY,D050378 Q000378 NN,D008221 Q000503 NN,D015536 Q000187 NN,D050378 Q000276 NY,D008213 Q000276 NN,D050378 Q000187 NN,D012584 Q000276 NY,D009444 Q000378 NN,D015536 Q000276 NN,D008198 Q000276 NN,D049109 Q000187 NN,D008221 Q000378 NN,D013110 Q000031 NN,D008221 Q000276 NY,D009444 Q000503 NN,D013154 Q000276 NN,D008213 Q000187 NN,D012584 Q000378 NN,D009444 Q000276 NN,D013154 Q000503 NN,D011129 Q000503 NN,D013154 Q000378 NN,D011409 Q000494 NN,D007111 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats.,"T-regulatory cells expressing the forkhead box transcription factor 3 (Foxp3) play essential roles in immune homeostasis. Experimental autoimmune neuritis (EAN) is an autoantigen-specific T-cell-mediated disease model for human demyelinating inflammatory disease of the peripheral nervous system. We investigated the distribution of Foxp3(+) cells in sciatic nerves, spleen and lymph nodes of EAN rats, and the influence of FTY720 on the localization of Foxp3(+) cells in EAN rats. In sciatic nerves of EAN rats,",Experimental neurology,"Zhiren Zhang, Zhi-Yuan Zhang, Uwe Fauser, Hermann J Schluesener"," Institute of Brain Research, University of Tuebingen, Tuebingen, Germany. zhangzhiren@yahoo.com",2009 Mar;216(1):75-82,10.1016/j.expneurol.2008.11.014
19118083,20090201,article,"xref,mesh","Adult,Antifungal Agents,Area Under Curve,Cross-Over Studies,Cytochrome P-450 Enzyme Inhibitors,Cytochrome P-450 Enzyme System,Cytochrome P450 Family 4,Dose-Response Relationship, Drug,Drug Interactions,Drug Monitoring,Enzyme Inhibitors,Female,Fingolimod Hydrochloride,Half-Life,Humans,Immunosuppressive Agents,Ketoconazole,Male,Middle Aged,Propylene Glycols,Sphingosine,Young Adult","administration &amp; dosage,analogs &amp; derivatives,pharmacokinetics,pharmacology","D004791 Q000493 NN,D007654 Q000493 NN,D011409 Q000493 NY,D007166 Q000008 NN,D013110 Q000008 NN,D007166 Q000493 NY,D000935 Q000493 NN,D013110 Q000031 NY,D011409 Q000008 NN,D013110 Q000493 NN,D007654 Q000494 NY,D011409 Q000494 NN,D004791 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D000935 Q000494 NN","3823,8252,31270,47576,105065,107969,107970,456201,5280335,5702077,16757695","128394615,129060975,129645792,129708236,136111139",Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.,"The sphingosine-1-phosphate receptor modulator fingolimod is predominantly hydroxylated by cytochrome CYP4F2. In vitro experiments showed that ketoconazole significantly inhibited the oxidative metabolism of fingolimod by human liver microsomes and by recombinant CYP4F2. The authors used ketoconazole as a putative CYP4F2 inhibitor to quantify its influence on fingolimod pharmacokinetics in healthy subjects. In a 2-period, single-sequence, crossover study, 22 healthy subjects received a single 5-mg dose of f",Journal of clinical pharmacology,"John M Kovarik, Kiran Dole, Gilles-Jacques Riviere, Francoise Pommier, Steve Maton, Yi Jin, Kenneth C Lasseter, Robert L Schmouder"," Novartis Pharma, Building WSJ 210.427, 4002 Basel, Switzerland.",2009 Feb;49(2):212-8,10.1177/0091270008329553
19119142,20090227,article,"xref,mesh","Cells, Cultured,Ceramides,Chromatography, Liquid,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lung,Lysophospholipids,Oxidoreductases,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Pulmonary Artery,RNA, Messenger,RNA, Small Interfering,Reverse Transcriptase Polymerase Chain Reaction,Serine C-Palmitoyltransferase,Sphingosine,Tandem Mass Spectrometry,Up-Regulation","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,enzymology,genetics,metabolism,pharmacology","D012333 Q000235 NN,D017853 Q000378 NN,D010088 Q000235 NN,D007166 Q000494 NY,D010088 Q000378 NN,D004730 Q000166 NN,D011651 Q000166 NN,D004730 Q000187 NY,D004730 Q000201 NN,D008168 Q000201 NN,D011651 Q000201 NN,D013110 Q000031 NY,D034741 Q000494 NN,D011409 Q000494 NY,D013110 Q000378 NN,D012333 Q000378 NN,D010088 Q000037 NY,D011651 Q000187 NY,D008168 Q000166 NN,D008246 Q000378 NN,D002518 Q000378 NN,D013110 Q000494 NN,D051102 Q000378 NN,D008168 Q000187 NY,D051102 Q000235 NN","8252,31270,91486,107969,107970,644260,5280335,5283560,6610273,44317142,57024517","128394615,128859215,129060975,129645792,135812730,135836815,136104881",FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.,"Novel immunomodulatory molecule FTY720 is a synthetic analog of myriocin, but unlike myriocin FTY720 does not inhibit serine palmitoyltransferase. Although many of the effects of FTY720 are ascribed to its phosphorylation and subsequent sphingosine 1-phosphate (S1P)-like action through S1P(1,3-5) receptors, studies on modulation of intracellular balance of signaling sphingolipids by FTY720 are limited. In this study, we used stable isotope pulse labeling of human pulmonary artery endothelial cells with l-[U",The Journal of biological chemistry,"Evgeny V Berdyshev, Irina Gorshkova, Anastasia Skobeleva, Robert Bittman, Xuequan Lu, Steven M Dudek, Tamara Mirzapoiazova, Joe G N Garcia, Viswanathan Natarajan"," Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA. eberdysh@medicine.bsd.uchicago.edu",2009 Feb;284(9):5467-77,10.1074/jbc.m805186200
19122034,20090106,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Disability Evaluation,Double-Blind Method,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Incidence,Kaplan-Meier Estimate,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Respiratory Function Tests,Severity of Illness Index,Sphingosine,Time Factors,Young Adult","administration &amp; dosage,analogs &amp; derivatives,drug therapy,methods,mortality","D009103 Q000401 NN,D013110 Q000008 NN,D013110 Q000031 NY,D012129 Q000379 NN,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.,"OBJECTIVE: To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS). METHODS: In the randomized, double-blind, placebo-controlled core study, 281 patients received placebo or FTY720, 1.25 or 5.0 mg/day, for 6 months. During the subsequent dose-blinded extension, patients assigned to placebo were re-randomized to either dose of ",Neurology,"P O'Connor, G Comi, X Montalban, J Antel, E W Radue, A de Vera, H Pohlmann, L Kappos, FTY720 D2201 Study Group"," St. Michael's Hospital, Toronto, ON, Canada. oconnorp@smh.toronto.on.ca",2009 Jan;72(1):73-9,10.1212/01.wnl.0000338569.32367.3d
19146992,20090601,article,"xref,mesh","Adenoma,Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,Lung Neoplasms,Male,Mice,Mice, Inbred BALB C,Proliferating Cell Nuclear Antigen,Propylene Glycols,Sphingosine,Urethane,Vascular Endothelial Growth Factor A","administration &amp; dosage,analogs &amp; derivatives,chemically induced,immunology,metabolism,prevention &amp; control,toxicity","D018809 Q000378 NN,D008175 Q000517 NY,D008175 Q000139 NN,D042461 Q000276 NN,D013110 Q000008 NN,D014520 Q000633 NN,D042461 Q000378 NN,D013110 Q000031 NY,D000236 Q000517 NY,D000236 Q000139 NN,D011409 Q000008 NY,D007166 Q000008 NY,D018809 Q000276 NN","5641,8252,31270,107969,107970,5280335","128306526,129060975,129645792",FTY720 and lung tumor development.,FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in mice by urethane injection followed by different periods of FTY720 administration in order to evaluate lung tumor development. BALB/c mice received urethane intraperitoneally in two doses of 1.5 g/kg and were submitted to five daily doses of FTY720 (1 mg/kg/day) starting just after urethane i,International immunopharmacology,"Natália Regina Antunes Salinas, Celina Tizuko Fujiyama Oshima, Patrícia Maluf Cury, José Antonio Cordeiro, Valquiria Bueno"," Division of Immunology, UNIFESP-Federal University of São Paulo, R. Botucatu 862, São Paulo, Brazil.",2009 Jun;9(6):689-93,10.1016/j.intimp.2008.12.007
19152589,20090201,article,"xref,mesh","Administration, Oral,Animals,Cyclosporine,Drug Therapy, Combination,Immunosuppressive Agents,Lymphadenitis,Male,Rabbits,Triglycerides","administration &amp; dosage,drug therapy,pathology,therapeutic use,veterinary","D016572 Q000627 NY,D008199 Q000188 NN,D008199 Q000473 NN,D016572 Q000008 NN,D007166 Q000627 NY,D008199 Q000662 NY,D014280 Q000008 NN,D014280 Q000627 NY","2909,8252,62280,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,57123750,71306795,71463825,73896891,122172945,123134263,123134270,132274082","129060975,135979775",Successful treatment of sebaceous adenitis in a rabbit with ciclosporin and triglycerides.,"A 4-year-old rabbit was presented with a chronic exfoliative dermatitis and patchy alopecia. General physical examination revealed no abnormalities. Skin scrapings and fungal culture were negative. A blood sample was obtained for a complete blood cell count and biochemical profile, and yielded results that were within normal limits. Radiographic examination of the thorax excluded the presence of a thymoma. Histopathology of the skin showed orthokeratotic hyperkeratosis, absence of sebaceous glands and mural",Veterinary dermatology,"Annette Jassies-van der Lee, Yvonne van Zeeland, Marja Kik, Nico Schoemaker"," Department of Clinical Sciences of Companion Animals, Utrecht University, The Netherlands. A.Jassies-vanderLee@uu.nl",2009 Feb;20(1):67-71,10.1111/j.1365-3164.2008.00726.x
19154762,20090402,article,"xref,mesh","Apoptosis,Cell Survival,Drug Carriers,Fluorescein-5-isothiocyanate,HeLa Cells,Humans,Hydrogels,Microscopy, Confocal,Microscopy, Electron, Scanning,Microscopy, Electron, Transmission,Necrosis,Particle Size,Phase Transition,Polyesters,Polyethylene Glycols,Polyethyleneimine,Polylysine,Surface Properties,Temperature","analogs &amp; derivatives,chemical synthesis,chemistry,drug effects,pharmacology","D011094 Q000494 NN,D011094 Q000737 NY,D011092 Q000138 NN,D004337 Q000138 NN,D017209 Q000187 NY,D002470 Q000187 NN,D011092 Q000737 NY,D011107 Q000138 NN,D011091 Q000138 NN,D004337 Q000737 NY,D011094 Q000138 NN,D011091 Q000737 NN,D011092 Q000494 NN,D011107 Q000737 NN,D011107 Q000031 NN,D020100 Q000138 NN,D004337 Q000494 NN,D020100 Q000494 NN,D020100 Q000737 NY","18730,162282",128596404,Thermally triggered intracellular explosion of volume transition nanogels for necrotic cell death.,"Here we report a novel class of super-expandable smart nanogels that undergo nano- to micro-scale volume transition in response to temperature change, applicable for thermally triggered death of cancer cells. The nanogels fabricated by light cross-linking between oligo(L-lactic acid)-poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-oligo(L-lactic acid) and poly(ethylene glycol) grafted poly(L-lysine) exhibited a reversible volume transition from approximately 150 nm at 37 degrees C to approxi",Journal of controlled release : official journal of the Controlled Release Society,"Yuhan Lee, Sung Young Park, Chunsoo Kim, Tae Gwan Park"," Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.",2009 Apr;135(1):89-95,10.1016/j.jconrel.2008.12.008
19158148,20090701,article,"xref,mesh","Administration, Oral,Chronic Disease,Dexamethasone,Drug Administration Schedule,Excipients,Female,Gestational Age,Glucocorticoids,Humans,Infant, Newborn,Infant, Premature,Infant, Premature, Diseases,Lung Diseases,Male,Retrospective Studies,Sorbitol","administration &amp; dosage,drug therapy,toxicity","D007235 Q000188 NY,D008171 Q000188 NN,D005079 Q000633 NY,D013012 Q000008 NN,D005079 Q000008 NN,D005938 Q000008 NN,D003907 Q000008 NN","453,702,5743,5780,8252","127822831,128482492,129060975",Toxic additives in medication for preterm infants.,"BACKGROUND: Little is known about exposure of preterm infants to excipients during routine clinical care. OBJECTIVE: To document excipient exposure in vulnerable preterm babies in a single centre, taking into account chronic lung disease (CLD) as a marker of illness severity. DESIGN: Excipient exposure after treatment with eight oral liquid medications was determined by retrospectively analysing the drug charts of infants admitted to a neonatal unit. SETTING: The Leicester Neonatal Service. PARTICIPANTS: 38",Archives of disease in childhood. Fetal and neonatal edition,"A Whittaker, A E Currie, M A Turner, D J Field, H Mulla, H C Pandya"," Department of Infection, Immunity & Inflammation, University of Leicester Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK. hp28@le.ac.uk",2009 Jul;94(4):F236-40,10.1136/adc.2008.146035
19180099,20090201,article,"xref,mesh","Administration, Oral,Clinical Trials, Phase III as Topic,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Randomized Controlled Trials as Topic,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Trial watch: Phase III promise for oral multiple sclerosis therapy.,NULL,Nature reviews. Drug discovery,NULL,NULL,2009 Feb;8(2):98,10.1038/nrd2821
19194476,20090801,article,"xref,mesh","Administration, Topical,Animals,Cell Movement,Dendritic Cells,Dermatitis, Allergic Contact,Female,Fingolimod Hydrochloride,Histocompatibility Antigens Class II,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, Inbred BALB C,Oxadiazoles,Propylene Glycols,Receptors, Lysosphingolipid,Skin,Sphingosine,Thiophenes,Toluene 2,4-Diisocyanate","administration &amp; dosage,analogs &amp; derivatives,analysis,blood,cytology,drug effects,physiology,prevention &amp; control","D013110 Q000097 NN,D000949 Q000032 NN,D003713 Q000187 NY,D002465 Q000187 NN,D013110 Q000008 NN,D013876 Q000008 NN,D013110 Q000031 NY,D008246 Q000097 NN,D017449 Q000517 NY,D008246 Q000008 NY,D012867 Q000166 NN,D003713 Q000502 NN,D010069 Q000008 NN,D011409 Q000008 NY,D007166 Q000008 NY,D049349 Q000502 NN","1140,8252,11443,31270,105065,107969,107970,4077460,5280335,5283560,10523409","128394615,129060975,129645792,129861263,136111139",Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration.,"Migration of Langerhans cells (LCs) from the skin to the lymph node is an essential step in the pathogenesis of allergic contact dermatitis (ACD). Therefore, inhibition of LC-migration could be a promising strategy to improve this skin disease. Effects of sphingosine-1-phosphate (S1P) and the immunomodulator FTY720 on LC trafficking is not well defined, yet. Thus, we investigated the action of topically administered S1P and FTY720 in a murine model of ACD. Most interestingly, FTY720 as well as S1P inhibited",The Journal of investigative dermatology,"Ilka Reines, Manfred Kietzmann, Reinhard Mischke, Thomas Tschernig, Anja Lüth, Burkhard Kleuser, Wolfgang Bäumer"," Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany.",2009 Aug;129(8):1954-62,10.1038/jid.2008.454
19195223,20090101,review,"xref,mesh","Animals,Cell Physiological Phenomena,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Insulin,Lysophospholipids,Neurotransmitter Agents,Propylene Glycols,Receptors, G-Protein-Coupled,Sphingosine","analogs &amp; derivatives,etiology,metabolism,pharmacology,physiology,secretion","D007328 Q000557 NN,D018377 Q000557 NN,D013110 Q000378 NN,D013110 Q000031 NN,D008246 Q000502 NY,D007249 Q000209 NN,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000494 NN,D043562 Q000502 NN,D013110 Q000502 NN","3988,8252,31270,107969,107970,5280335,5283560,5289143,5311263,5497152,5885531,42607474,46936676,70678557,73755067,73755142,118984375","128394615,129060975,129622673,129645792,248976559",[Lysophospholipid mediators].,NULL,"Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme","Kumiko Makide, Kuniyuki Kano, Hajime Kitamura, Naoaki Arima, Junken Aoki", makide@mail.pharm.tohoku.ac.jp,2009 Jan;54(1):29-39,NULL
19207263,20091001,article,"xref,mesh","Animals,Chemotaxis, Leukocyte,Fingolimod Hydrochloride,Flow Cytometry,Immunohistochemistry,Immunosuppressive Agents,Interleukin-17,Lymph Nodes,Lysophospholipids,Male,Neuritis, Autoimmune, Experimental,Propylene Glycols,Rats,Rats, Inbred Lew,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Sciatic Nerve,Signal Transduction,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes","analogs &amp; derivatives,cytology,drug effects,immunology,metabolism,pathology,pharmacology,physiology","D012584 Q000473 NN,D012584 Q000276 NN,D016176 Q000276 NY,D007166 Q000494 NY,D002634 Q000502 NN,D049349 Q000276 NN,D015398 Q000276 NN,D009444 Q000378 NN,D008198 Q000276 NN,D013110 Q000031 NY,D008246 Q000276 NN,D020381 Q000378 NN,D011409 Q000494 NY,D016176 Q000187 NN,D013110 Q000378 NN,D009444 Q000276 NY,D013110 Q000276 NN,D008198 Q000166 NN,D013601 Q000276 NY,D009444 Q000473 NN,D008246 Q000378 NN,D013110 Q000494 NN,D013601 Q000187 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis.,"AIMS: Experimental autoimmune neuritis (EAN) is a well-known animal model of human demyelinating polyneuropathies. Here we have studied the spatiotemporal accumulation of interleukin (IL)-17(+) cells in sciatic nerves of EAN rats and effects of FTY720, an agonist of sphingosine-1-phosphate (S1P) receptors. METHODS: In this study, we examined the spatiotemporal expression of IL-17 using immunohistochemistry and RT-PCR, and analysed the IL-17(+) cell proportion in blood and lymph nodes using flow cytometry. R",Neuropathology and applied neurobiology,"Z-Y Zhang, Z Zhang, H J Schluesener"," Institute of Brain Research, University of Tuebingen, Tuebingen, Germany.",2009 Oct;35(5):487-95,10.1111/j.1365-2990.2009.01016.x
19230723,20090320,article,"xref,mesh","Animals,B-Lymphocytes,Cell Movement,Chemotaxis,Endothelium,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Lymph Nodes,Mice,Mice, Inbred C57BL,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology,physiology","D049349 Q000819 NN,D004727 Q000187 NN,D004727 Q000166 NN,D001402 Q000187 NN,D008198 Q000276 NY,D013110 Q000031 NN,D001402 Q000502 NY,D011409 Q000494 NN,D049349 Q000276 NY,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.,"Sphingosine-1-phosphate (S1P) helps mediate lymphocyte egress from lymph nodes, yet many mechanistic questions remain. Here, we show the presence of B lymphocyte egress sites located in the lymph node cortex close to lymph node follicles. B cells exited lymph nodes by squeezing through apparent portals in the lymphatic endothelium of these sinusoids. Treatment with the S1P receptor agonist FTY720 emptied the cortical sinusoids of lymphocytes, blocked lymphatic endothelial penetration, and displaced B lympho",Immunity,"Rajesh K Sinha, Chung Park, Il-Young Hwang, Michael D Davis, John H Kehrl"," B-Cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892-1876, USA.",2009 Mar;30(3):434-46,10.1016/j.immuni.2008.12.018
19230848,20090401,article,"xref,mesh","Allergens,Ambrosia,Animals,Conjunctivitis, Allergic,Disease Models, Animal,Eosinophils,Fingolimod Hydrochloride,Immunosuppressive Agents,Macrophages,Mice,Mice, Inbred BALB C,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug therapy,immunology,metabolism,pathology,therapeutic use","D013601 Q000378 NN,D008264 Q000276 NN,D004804 Q000276 NN,D003233 Q000188 NY,D013601 Q000276 NN,D008264 Q000378 NN,D013110 Q000031 NY,D000485 Q000276 NN,D003233 Q000473 NN,D007166 Q000627 NY,D003233 Q000276 NN,D031164 Q000276 NN,D004804 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.,"PURPOSE: To investigate whether experimental allergic conjunctivitis (EC) can be suppressed by treatment with the immunomodulatory drug FTY720, which reduces the recruitment of effector T cells into inflammatory sites. METHODS: BALB/c mice were actively immunized with ragweed (RW) and then injected intraperitoneally with FTY720 on days 0, 2, 4, 6 and 8 (induction phase treatment) followed by challenge on day 10 with RW-containing eye drops. Alternatively, naïve mice that received RW-primed splenocytes were ",Cell biology international,"Tamaki Sumi, Atsuki Fukushima, Koji Nishino, Ken Fukuda, Naoki Kumagai, Teruo Nishida, Hisayuki Ueno"," Department of Ophthalmology and Visual Science, Kochi Medical School, Kohasu, Oko-cho, Nankoku-city, Japan.",2009 Apr;33(4):534-41,10.1016/j.cellbi.2009.02.002
19252372,20090201,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Chronic Disease,Colitis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Mice, SCID,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug therapy,immunology,physiology,therapeutic use","D003092 Q000188 NN,D015496 Q000276 NN,D013601 Q000276 NN,D007166 Q000627 NN,D013110 Q000031 NY,D003092 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000502 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",[An additional role of FTY720 in chronic colitis].,"FTY720 is a sphingosine-1-phosphate receptor modulator, which inhibits T-cell egress from lymph nodes, thereby prevents pathogenic T cells from migrating towards disease sites. In inflammatory bowel diseases, it is thought that colitogenic memory CD4+ T cells are intermittently reactivated in regional lymphoid organs, and return to inflammatory tissues. Little is known about how FTY720 controls the migration property of memory T cells and whether FTY720 could control the trafficking of T cells without the p",Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,"Toshimitsu Fujii, Mamoru Watanabe"," Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University.",2009 Feb;32(1):7-14,10.2177/jsci.32.7
19269902,20090604,article,"xref,mesh","Adenosine Triphosphatases,Alkyl and Aryl Transferases,DNA Adducts,DNA Repair,DNA, Bacterial,DNA-Binding Proteins,Escherichia coli,Escherichia coli Proteins,Genes, Bacterial,Guanine,Mutagenesis,Mutation,Rifampin","analogs &amp; derivatives,enzymology,genetics,metabolism,pharmacology,physiology","D005798 Q000502 NY,D004268 Q000235 NN,D012293 Q000494 NN,D004269 Q000235 NY,D019883 Q000235 NY,D029968 Q000378 NN,D004268 Q000378 NN,D004926 Q000235 NN,D006147 Q000031 NY,D004926 Q000201 NY,D018736 Q000235 NY,D000251 Q000378 NN,D029968 Q000235 NY,D000251 Q000235 NN,D019883 Q000378 NN,D006147 Q000378 NN","764,1135,4578,5862,6378,5381226,5388984,5458213,5702112,6243627,6842115,6913622,16043998,24871024,25141428,45356263,56947149,57020413,57419136,66584054,87059079,98042559,101476308,118725302,122172997,131632417,131839595,134693938,135398634","127983601,129192465,129439837,129742316",The alkyltransferase-like ybaZ gene product enhances nucleotide excision repair of O(6)-alkylguanine adducts in E. coli.,O(6)-methylguanine adducts are potent pre-mutagenic lesions owing to their high capacity to direct mis-insertion of thymine when bypassed by replicative DNA polymerases. The strong mutagenic potential of these adducts is prevented by alkyltransferases such as Ada and Ogt in Escherichia coli that transfer the methyl group to one of their cysteine residues. Alkyl residues larger than methyl are generally weak substrates for reversion by alkyltransferases. In this paper we have investigated the genotoxic poten,DNA repair,"Gerard Mazon, Gaëlle Philippin, Jean Cadet, Didier Gasparutto, Robert P Fuchs"," CNRS, UPR 3081, Genome Instability and Carcinogenesis, Conventionné par l'Université d'Aix-Marseille 2, 31, Chemin Joseph Aiguier, 13402 Marseille cedex 20, France.",2009 Jun;8(6):697-703,10.1016/j.dnarep.2009.01.022
19289744,20090317,article,"xref,mesh","Adult,Brain,Cerebral Hemorrhage,Contrast Media,Encephalitis,Epilepsy, Complex Partial,Female,Fingolimod Hydrochloride,Gadolinium,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Necrosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug therapy,pathology,physiopathology","D013110 Q000009 NN,D020529 Q000188 NN,D017029 Q000503 NN,D020529 Q000150 NN,D013110 Q000031 NY,D002543 Q000473 NN,D001921 Q000473 NN,D002543 Q000139 NY,D004660 Q000139 NY,D004660 Q000473 NN,D007166 Q000009 NY,D017029 Q000139 NN,D011409 Q000009 NY","8252,23982,31270,107969,107970,5280335","128394615,129060975,129645792",Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.,NULL,Neurology,"F Leypoldt, A Münchau, F Moeller, M Bester, C Gerloff, C Heesen"," Department of Neurology, University Hospital Hamburg, Hamburg, Germany. F.Leypoldt@uke.uni-hamburg.de",2009 Mar;72(11):1022-4,10.1212/01.wnl.0000344567.51394.e3
19296586,20090417,article,"xref,mesh","Animals,Cells, Cultured,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intestinal Mucosa,Molecular Structure,Organophosphonates,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Stereoisomerism,Vinyl Compounds","analogs &amp; derivatives,chemical synthesis,chemistry,drug effects,pharmacology","D014753 Q000737 NN,D007413 Q000187 NN,D011409 Q000138 NY,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D013110 Q000138 NN,D063065 Q000138 NY,D049349 Q000187 NN,D063065 Q000737 NN,D007166 Q000138 NY,D011409 Q000494 NN,D014753 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D014753 Q000138 NY","8252,31270,107969,107970,168725,5280335","128394615,129060975,129645792,129954420",Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.,"The first enantioselective synthesis of chiral isosteric phosphonate analogues of FTY720 is described. One of these analogues, FTY720-(E)-vinylphosphonate (S)-5, but not its R enantiomer, elicited a potent antiapoptotic effect in intestinal epithelial cells, suggesting that it exerts its action via the enantioselective activation of a receptor. (S)-5 failed to activate the sphingosine 1-phosphate type 1 (S1P(1)) receptor. ",The Journal of organic chemistry,"Xuequan Lu, Chaode Sun, William J Valentine, E Shuyu, Jianxiong Liu, Gabor Tigyi, Robert Bittman"," Department of Chemistry and Biochemistry, Queens College of The City University of New York, Flushing, New York 11367-1597, USA.",2009 Apr;74(8):3192-5,10.1021/jo900023u
19328962,20090301,article,"xref,mesh","Cell Division,Cell Survival,Cells, Cultured,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Muscle, Smooth,Phosphorylation,Propylene Glycols,Signal Transduction,Sphingosine,Transplantation, Homologous,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,enzymology,immunology,pharmacology,physiology,prevention &amp; control,therapeutic use","D007166 Q000494 NY,D002455 Q000187 NN,D002470 Q000187 NN,D007166 Q000627 NN,D048049 Q000037 NY,D009130 Q000201 NN,D013110 Q000031 NY,D011409 Q000494 NY,D009130 Q000502 NY,D009130 Q000166 NN,D009130 Q000187 NN,D014184 Q000276 NN,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D014409 Q000037 NY,D013110 Q000494 NN,D006084 Q000517 NY,D015398 Q000502 NN,D014409 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells.,We investigated the effects of the sphingolipid FTY720 on tumor necrosis factor-alpha (TNF-alpha)-induced proliferation and signal transduction in human smooth muscle cells (SMC). We showed that clinically relevant concentrations of FTY720 inhibited TNF-alpha-induced SMC proliferation and extracellular signal-regulated kinase (ERK) phosphorylation. We concluded that FTY720 may be a useful drug to inhibit chronic vascular rejection. ,Transplantation proceedings,"T Böhler, N Kamar, L Etienne, S Galvani, C Canivet, M Thomsen, R Salvayre, A Nègre-Salvayre, L Rostaing, N Auge"," INSERM U858/I2MR EQ 10 Artériosclérose et Artériosclérose de Greffe, CHU Rangueil, Toulouse, France.",2009 Mar;41(2):705-6,10.1016/j.transproceed.2008.12.017
19357080,20090612,article,"xref,mesh","Acyl Coenzyme A,Binding, Competitive,Carcinoma, Hepatocellular,Cell Line, Tumor,Ceramides,Enzyme Inhibitors,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney,Liver Neoplasms,Mast Cells,Oxidoreductases,Propylene Glycols,Sphingosine,Tritium","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,chemistry,cytology,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D010088 Q000378 NN,D007668 Q000166 NN,D004791 Q000737 NN,D002518 Q000096 NY,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D008407 Q000166 NN,D010088 Q000037 NY,D001667 Q000187 NN,D007166 Q000737 NN,D004791 Q000494 NN,D013110 Q000494 NN,D000214 Q000378 NY","8252,24824,31270,91486,107969,107970,119434,5280335","128394615,128859215,129060975,129645792,135820018,135836815",Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.,"FTY720, a sphingosine analog, is in clinical trials as an immunomodulator. The biological effects of FTY720 are believed to occur after its metabolism to FTY720 phosphate. However, very little is known about whether FTY720 can interact with and modulate the activity of other enzymes of sphingolipid metabolism. We examined the ability of FTY720 to modulate de novo ceramide synthesis. In mammals, ceramide is synthesized by a family of six ceramide synthases, each of which utilizes a restricted subset of acyl-",The Journal of biological chemistry,"Sujoy Lahiri, Hyejung Park, Elad L Laviad, Xuequan Lu, Robert Bittman, Anthony H Futerman"," Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel.",2009 Jun;284(24):16090-8,10.1074/jbc.m807438200
19404007,20090401,review,"xref,mesh","Animals,Autoimmune Diseases,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,drug therapy,therapeutic use","D049349 Q000819 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D001327 Q000188 NY","8252,31270,107969,107970,5280335,57024517","128394615,129060975,129645792,135812730","[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].","Fingolimod (FTY720) is the first of a new immunomodulator class : sphingosine 1-phosphate (S1P) receptor modulator. We have found FTY720 by chemical modification of a natural product, myriocin derived from Isaria sinclairii, a kind of vegetative wasp. FTY720 has shown to be highly effective in experimental allograft models and autoimmune disease models. A most striking feature of FTY720 is the induction of a marked decrease in peripheral blood lymphocytes at doses that show immunomodulating effects in these",Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,Kenji Chiba," Pharmacology Laboratory, Research Division, Mitsubishi Tanabe Pharma Corporation.",2009 Apr;32(2):92-101,10.2177/jsci.32.92
19416991,20090715,article,"xref,mesh","Animals,Animals, Newborn,Cardiotonic Agents,Cell Death,Cells, Cultured,Fingolimod Hydrochloride,Humans,Lysophospholipids,Myocardial Reperfusion Injury,Myocytes, Cardiac,Oxadiazoles,Perfusion,Propylene Glycols,Proto-Oncogene Proteins c-akt,Rats,Receptor, Epidermal Growth Factor,Receptors, Lysosphingolipid,Recovery of Function,Signal Transduction,Sphingosine,Thiophenes,Time Factors,Ventricular Function, Left,Ventricular Pressure","agonists,analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology,physiopathology,prevention &amp; control","D010069 Q000494 NY,D011958 Q000378 NN,D049349 Q000819 NY,D032383 Q000187 NY,D002316 Q000494 NY,D013110 Q000031 NY,D032383 Q000473 NN,D011409 Q000494 NY,D015428 Q000517 NY,D013110 Q000378 NN,D032383 Q000378 NN,D013876 Q000494 NY,D008246 Q000378 NY,D015428 Q000473 NN,D016277 Q000187 NN,D017725 Q000187 NN,D051057 Q000378 NN,D015428 Q000503 NN,D011958 Q000819 NN,D015398 Q000187 NN,D013110 Q000494 NN,D015428 Q000378 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,4077460,5280335,5283560,10523409","128394615,129060975,129645792,136111139",Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion.,"AIMS: Several experimental studies have demonstrated protection against cardiac ischaemia-reperfusion injury achieved by pre-treatment with exogenous sphingosine-1-phosphate (S1P). We tested the hypothesis that pharmacological S1P receptor agonists improve recovery of function when applied with reperfusion. METHODS AND RESULTS: Isolated rat cardiomyocytes were stimulated with exogenous S1P, the selective S1P1 receptor agonist SEW2871, or the S1P1/3 receptor agonist FTY720. Western blot analysis was performe",Cardiovascular research,"Ulrich Hofmann, Natalie Burkard, Carolin Vogt, Annemarie Thoma, Stefan Frantz, Georg Ertl, Oliver Ritter, Andreas Bonz"," Department of Internal Medicine I, University of Würzburg, Medizinische Klinik und Poliklinik I, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany. hofmann_u2@klinik.uni-wuerzburg.de",2009 Jul;83(2):285-93,10.1093/cvr/cvp137
19439518,20090701,article,"xref,mesh","Animals,Blood Pressure,Cell Movement,Cell Proliferation,Disease Models, Animal,Extracellular Matrix,Fibrosis,Fingolimod Hydrochloride,Hypertension,Immunosuppressive Agents,Kidney,Kidney Diseases,Lymphocytes,Macrophages,Male,Nephrectomy,Propylene Glycols,Proteinuria,Rats,Rats, Wistar,Sphingosine,Transforming Growth Factor beta","analogs &amp; derivatives,complications,drug effects,drug therapy,etiology,metabolism,pathology,pharmacology,physiology,therapeutic use","D002465 Q000502 NY,D006973 Q000188 NY,D002465 Q000187 NN,D005109 Q000187 NN,D008214 Q000473 NY,D007668 Q000473 NN,D005109 Q000378 NN,D049109 Q000187 NN,D013110 Q000031 NY,D008264 Q000473 NN,D007674 Q000188 NY,D016212 Q000378 NN,D008264 Q000187 NN,D007166 Q000627 NY,D001794 Q000502 NN,D007674 Q000473 NY,D006973 Q000150 NN,D001794 Q000187 NN,D007674 Q000209 NN,D011409 Q000494 NN,D011507 Q000188 NN,D013110 Q000627 NN,D013110 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN","8252,31270,107969,107970,5280335,56842206","128394615,129060975,129645792",The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.,"The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Infiltration with lymphocytes is found in both immune and nonimmune chronic kidney diseases. In a rat model of immune-initiated progressive glomerulosclerosis, selective inhibition of lymphocyte infiltration by FTY720 showed significant beneficial effects on renal fibrosis. To test whether this translates into hypertensive nephropathy (HN), the lymphocyte migration inhibitor was administered to rats following nephrec",American journal of physiology. Renal physiology,"Stephanie Krämer, Eva Binder, Tanja Loof, Yingrui Wang-Rosenke, Sebastian Martini, Dmytro Khadzhynov, Klemens Budde, Hans-H Neumayer, Harm Peters"," Department of Nephrology and Center for Cardiovascular Research, Charité Universitätsmedizin Berlin, Charité Campus Mitte, Humboldt University Berlin, D-10117 Berlin, Germany.",2009 Jul;297(1):F218-27,10.1152/ajprenal.90617.2008
19483408,20090601,review,"xref,mesh","Animals,Autoimmune Diseases,Clinical Trials as Topic,Encephalomyelitis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D049349 Q000819 NN,D013110 Q000031 NY,D001327 Q000276 NN,D004679 Q000188 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NN,D001327 Q000188 NY","8252,31270,107969,107970,5280335,57024517","128394615,129060975,129645792,135812730","[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].","Fingolimod (FTY720) is the first substance in the new immunomodulator class called sphingosine 1-phosphate (S1P) receptor modulators. We isolated an immunosuppressive natural product, myrocin, from the culture broth of Isaria sinclairii, a kind of vegetative wasp. The chemical modification of myriocin yielded a new compound, FTY720, which has more potent immunosuppressive activity and less toxicity than myriocin. FTY720 has been shown to be highly effective in experimental allograft models and autoimmune di",Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,Kenji Chiba," Pharmacology Laboratory, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan. Chiba.Kenji@mk.mt-pharma.co.jp",2009 Jun;129(6):655-65,10.1248/yakushi.129.655
19487793,20090101,article,"xref,mesh","Animals,Cyclosporine,Everolimus,Fingolimod Hydrochloride,Gastrointestinal Motility,Immunosuppressive Agents,In Vitro Techniques,Intestinal Absorption,Jejunum,Male,Mycophenolic Acid,Propylene Glycols,Sirolimus,Sphingosine,Tacrolimus","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D007583 Q000187 NY,D016559 Q000494 NN,D007408 Q000187 NN,D009173 Q000494 NN,D013110 Q000031 NN,D020123 Q000494 NN,D016572 Q000494 NN,D011409 Q000494 NN,D005769 Q000187 NN,D009173 Q000031 NN,D013110 Q000494 NN,D020123 Q000031 NN","2153,2471,2909,4271,4272,5372,5793,8252,31270,62280,96241,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6442177,6473866,6536850,9855081,23665584,24883466,25246316,49867938,57123750,71306795,71463825,71668407,73896891,90696889,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,128566414,129060975,129178479,129214656,129621433,129645792,129896981,135979775,242749350,242963342,248766214",The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study.,"BACKGROUND: Gastrointestinal side effects of immunosuppressive drugs have got a high importance in clinical practice. The aim of this basic experimental study was to characterize the direct and immediate influence of seven commonly used immunosuppressive drugs on the small bowel functions. Therefore, the influence of ciclosporin A, tacrolimus, mycophenolate mofetil, enteric coated MPA, sirolimus, everolimus and FTY720 on-glucose absorption (I-GLU), chloride secretion (I-CHL), and barrier function (I-BAR) wa",Annals of transplantation,"Maciej Malinowski, Peter Martus, Peter Neuhaus, Martin Stockmann"," Department of General, Visceral, and Transplantation Surgery, University Hospital Charité, Berlin, Germany.",2009 Jan;14(2):38-44,NULL
19490468,20090601,article,"xref,mesh","Apoptosis,Arthritis, Rheumatoid,Blotting, Western,Cells, Cultured,Fibroblasts,Fingolimod Hydrochloride,Fluorescent Antibody Technique,Humans,Immunosuppressive Agents,In Situ Nick-End Labeling,Microscopy, Confocal,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Synovial Membrane","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology,physiology","D007166 Q000494 NY,D017209 Q000187 NN,D001172 Q000235 NN,D017853 Q000235 NN,D013110 Q000031 NY,D017209 Q000502 NY,D005347 Q000378 NY,D011409 Q000494 NY,D005347 Q000187 NN,D001172 Q000378 NY,D017853 Q000378 NY,D013583 Q000378 NN,D013110 Q000494 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720.","Gene expression profiles in synovial tissues from rheumatoid arthritis (RA) patients have yielded useful information on the pathogenetic process of the synovitis. In one group of them, sphingosine kinase 2 (SPHK2), a nuclear protein regulating cell proliferation, seemed to be highly expressed, undergoing a different pathogenetic process of synovitis. In the present study it was clarified that SPHK2 was expressed in the synovial fibroblasts of the synovial tissues obtained from the knee joints of the RA pati",Pathology international,"Kazuo Kamada, Norimasa Arita, Takahito Tsubaki, Nobuo Takubo, Takahiro Fujino, Yoshiko Soga, Tatsuhiko Miyazaki, Haruyasu Yamamoto, Masato Nose"," Department of Pathogenomics, Ehime University Graduate School of Medicine, Ehime, Japan.",2009 Jun;59(6):382-9,10.1111/j.1440-1827.2009.02381.x
19535570,20090901,article,"xref,mesh","Administration, Oral,Albuminuria,Animals,Blood Pressure,Body Weight,Chemokine CCL2,Chemokine CCL5,Chemokines,Creatinine,Disease Models, Animal,Disease Progression,Dose-Response Relationship, Drug,Fibronectins,Fibrosis,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Inflammation Mediators,Kidney,Kidney Failure, Chronic,Lymphocytes,Macrophages,Male,Nephrectomy,Nephritis,Phenotype,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, CCR1,Receptors, CCR2,Receptors, CCR5,Sphingosin","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology,prevention &amp; control","D003404 Q000378 NN,D007166 Q000494 NY,D007676 Q000276 NN,D018946 Q000378 NN,D008264 Q000276 NN,D007166 Q000008 NN,D007676 Q000473 NN,D001835 Q000187 NN,D007668 Q000473 NN,D018836 Q000378 NY,D013110 Q000008 NN,D007668 Q000187 NY,D009393 Q000517 NN,D000419 Q000276 NN,D019713 Q000378 NN,D008214 Q000187 NY,D054390 Q000378 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D018925 Q000235 NN,D018932 Q000378 NN,D000419 Q000517 NN,D054389 Q000378 NN,D007668 Q000276 NN,D005353 Q000378 NN,D008214 Q000276 NN","588,8252,31270,107969,107970,5280335","127719861,128394615,129060975,129645792","Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.",Renal injury is accompanied by the presence of infiltrating inflammatory cells in the glomerulus and tubulointerstitium. FTY720 modifies lymphocyte migration into injured tissues by lymphocyte sequestration to secondary lymphoid organs. The purpose of this study was to examine the potential of FTY720 to influence the inflammatory response in a nonimmunological model of renal failure. Sham-operated and 5/6 nephrectomized (SNX) Sprague-Dawley rats received two different doses of FTY720 or vehicle orally for 1,American journal of physiology. Renal physiology,"Matthias Schaier, Stefanie Vorwalder, Claudia Sommerer, Ralf Dikow, Friederike Hug, Marie-Luise Gross, Rüdiger Waldherr, Martin Zeier"," Dept. of Nephrology, Univ. of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. matthias_schaier@med.uni-heidelberg.de",2009 Sep;297(3):F769-80,10.1152/ajprenal.90530.2008
19549308,20090101,article,xref,NULL,NULL,NULL,"453,602,753,1030,1060,2332,5988,6251,6912,8252,67519,68152,54226752,57059112","127380029,127424782,127700385,127759455,127822827,127822831,128047544,128392536,128470468,128902940,128984259,129019136,129046631,129060975,135870608",Is inflammation a consequence of extracellular hyperosmolarity?,"BACKGROUND: There are several reports suggesting that hyperosmolarity induces inflammation. We recently showed that Dextran Sodium Sulfate causes inflammatory bowel disease due to hyperosmolarity. The aim of this study was to confirm the link between hyperosmolarity and inflammation by assessing osmolarity values in vivo during inflammation, compare the inflammatory potential of different osmotic agents and finally study the long-term consequences of hyperosmolarity on cell fate. METHODS: Osmotic pressures ","Journal of inflammation (London, England)","Laurent Schwartz, Adeline Guais, Mohammad Pooya, Mohammad Abolhassani"," Service de Radiothérapie Hôpital Pitié-Salpétrière, Paris, 75013 France. laurent.schwartz@polytechnique.edu.",2009 Jan;6(?):21,10.1186/1476-9255-6-21
19592667,20091001,article,"xref,mesh","Animals,Capillary Permeability,Cell Line,Fingolimod Hydrochloride,Humans,Inflammation Mediators,Lung,Mice,Mice, Inbred C57BL,Organophosphonates,Propylene Glycols,Pulmonary Artery,Sphingosine","analogs &amp; derivatives,blood supply,chemical synthesis,drug effects,pathology,pharmacology,physiology","D008168 Q000187 NN,D002199 Q000187 NY,D008168 Q000473 NN,D011409 Q000138 NY,D000068876 Q000138 NN,D063065 Q000494 NY,D018836 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D000068876 Q000031 NY,D013110 Q000138 NN,D063065 Q000138 NY,D018836 Q000138 NY,D002199 Q000502 NY,D011651 Q000473 NN,D011651 Q000187 NY,D008168 Q000098 NN,D000068876 Q000494 NN,D013110 Q000494 NN","6057,8252,31270,107969,107970,5280335","128394615,128865459,129060975,129645792","Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.","Novel therapies are needed to address the vascular endothelial cell (EC) barrier disruption that occurs in inflammatory diseases such as acute lung injury (ALI). We previously demonstrated the potent barrier-enhancing effects of both sphingosine 1-phosphate (S1P) and the structurally similar compound FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] in inflammatory lung injury. In this study, we examined the therapeutic potential of several novel FTY720 analogs to reduce vascular leak. Similar to ",The Journal of pharmacology and experimental therapeutics,"S M Camp, R Bittman, E T Chiang, L Moreno-Vinasco, T Mirzapoiazova, S Sammani, X Lu, C Sun, M Harbeck, M Roe, V Natarajan, J G N Garcia, S M Dudek"," Department of Medicine, University of Chicago, IL 60637, USA.",2009 Oct;331(1):54-64,10.1124/jpet.109.153544
19624262,20091201,article,"xref,mesh","Animals,Autoimmunity,Chemotaxis, Leukocyte,Demyelinating Autoimmune Diseases, CNS,Disease Models, Animal,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Lymphocyte Activation,Myelitis,Nerve Fibers, Myelinated,Nerve Regeneration,Paralysis,Propylene Glycols,Rats,Rats, Long-Evans,Recovery of Function,Sphingosine,Spinal Cord Injuries,T-Lymphocytes,Treatment Outcome,Urinary Bladder, Neurogenic,Wallerian Degeneration","analogs &amp; derivatives,drug effects,drug therapy,etiology,immunology,pathology,pharmacology,physiopathology,therapeutic use","D013119 Q000503 NN,D014855 Q000276 NN,D007166 Q000494 NY,D010243 Q000503 NN,D020278 Q000188 NN,D020127 Q000276 NN,D013601 Q000276 NN,D009416 Q000187 NY,D007166 Q000627 NN,D015551 Q000187 NN,D020127 Q000187 NY,D009413 Q000473 NN,D009416 Q000276 NN,D015551 Q000276 NN,D001750 Q000503 NN,D008213 Q000276 NN,D010243 Q000209 NN,D014855 Q000503 NN,D013110 Q000031 NY,D020278 Q000503 NN,D013119 Q000276 NN,D011409 Q000494 NY,D014855 Q000188 NN,D008213 Q000187 NN,D001750 Q000188 NN,D009187 Q000188 NY,D013119 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 reduces inflammation and promotes functional recovery after spinal cord injury.,"A robust and complex inflammatory cascade is known to be a prominent component of secondary injury following spinal cord injury (SCI). Specifically, the concept of trauma-induced autoimmunity has linked the lymphocyte population with neural tissue injury and neurologic deficit. FTY720, a sphingosine receptor modulator that sequesters lymphocytes in secondary lymphoid organs, has been shown to be effective in the treatment of a variety of experimental autoimmune disorders. Accordingly, by reducing lymphocyte",Journal of neurotrauma,"Kangmin D Lee, Woon N Chow, Carmen Sato-Bigbee, Martin R Graf, Robert S Graham, Raymond J Colello, Harold F Young, Bruce E Mathern"," Department of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA.",2009 Dec;26(12):2335-44,10.1089/neu.2008.0840
19632123,20090815,article,"xref,mesh,assay","Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphopenia,Mice,Prodrugs,Propanols,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Structure-Activity Relationship","agonists,analogs &amp; derivatives,chemical synthesis,chemically induced,chemistry,metabolism,pharmacology","D011409 Q000737 NY,D011355 Q000737 NN,D049349 Q000819 NY,D011355 Q000138 NY,D008231 Q000139 NN,D013110 Q000031 NY,D013110 Q000737 NN,D013110 Q000138 NN,D011409 Q000138 NN,D007166 Q000138 NY,D020005 Q000737 NN,D020005 Q000138 NY,D007166 Q000737 NN,D011409 Q000494 NN,D011355 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN","795,8252,9255,31270,105065,107969,107970,5280335,10197612,45268446,45270141,45270981,45271833,45272694,45273626,45273628,70689724,70691867","128394615,129060975,129103178,129562150,129645792,129883583,136111139",Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.,"In the search for bioactive sphingosine 1-phosphate (S1P) receptor ligands, a series of 2-amino-2-heterocyclic-propanols were synthesized. These molecules were discovered to be substrates of human-sphingosine kinases 1 and 2 (SPHK1 and SPHK2). When phosphorylated, the resultant phosphates showed varied activities at the five sphingosine-1-phosphate (S1P) receptors (S1P(1-5)). Agonism at S1P(1) was displayed in vivo by induction of lymphopenia. A stereochemical preference of the quaternary carbon was crucial",Bioorganic & medicinal chemistry,"Frank W Foss, Thomas P Mathews, Yugesh Kharel, Perry C Kennedy, Ashley H Snyder, Michael D Davis, Kevin R Lynch, Timothy L Macdonald"," Department of Chemistry, University of Virginia, Charlottesville, 22904, USA.",2009 Aug;17(16):6123-36,10.1016/j.bmc.2009.04.015
19644058,20091001,article,"xref,mesh","Animals,Arterioles,Brain Edema,Cerebral Arteries,Cerebrovascular Circulation,Disease Models, Animal,Fingolimod Hydrochloride,Hypoxia-Ischemia, Brain,Immunosuppressive Agents,Infarction, Middle Cerebral Artery,Ischemic Preconditioning,Lysophospholipids,Male,Mice,Microcirculation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,RNA, Messenger,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,etiology,genetics,metabolism,methods,pharmacology,physiology,physiopathology,therapy","D002536 Q000378 NY,D002560 Q000502 NN,D019194 Q000379 NY,D020925 Q000378 NY,D001160 Q000503 NN,D008833 Q000502 NY,D017853 Q000235 NN,D015427 Q000503 NN,D020244 Q000503 NN,D015427 Q000378 NN,D001160 Q000378 NN,D013110 Q000378 NN,D001929 Q000503 NN,D013110 Q000031 NN,D012333 Q000378 NN,D001929 Q000209 NN,D012333 Q000187 NN,D020925 Q000628 NY,D001929 Q000628 NN,D017853 Q000378 NY,D011409 Q000494 NN,D008246 Q000378 NN,D020244 Q000628 NN,D020244 Q000378 NN,D017853 Q000037 NN,D002536 Q000503 NN,D020925 Q000503 NN","8252,31270,69676,105065,107969,107970,5280335,5283560,54178976","128394615,128887832,129060975,129308074,129645792,136111139",Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2.,"BACKGROUND AND PURPOSE: The importance of bioactive lipid signaling under physiological and pathophysiological conditions is progressively becoming recognized. The disparate distribution of sphingosine kinase (SphK) isoform activity in normal and ischemic brain, particularly the large excess of SphK2 in cerebral microvascular endothelial cells, suggests potentially unique cell- and region-specific signaling by its product sphingosine-1-phosphate. The present study sought to test the isoform-specific role of",Stroke,"Bradley K Wacker, Tae Sung Park, Jeffrey M Gidday"," Department of Neurosurgery, Washington University School of Medicine, St Louis, MO 63110, USA.",2009 Oct;40(10):3342-8,10.1161/strokeaha.109.560714
19647880,20090929,article,"xref,mesh","Animals,Autoimmunity,Blood-Nerve Barrier,Blotting, Western,Cell Culture Techniques,Cell Proliferation,Cell Survival,Cytokines,Electrophysiology,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred NOD,Mice, Transgenic,Oxadiazoles,Polymerase Chain Reaction,Polyneuropathies,Propylene Glycols,Schwann Cells,Severity of Illness Index,Sphingosine,Spleen,Thiophenes","analogs &amp; derivatives,biosynthesis,cytology,drug therapy,immunology,metabolism,pharmacology","D007166 Q000494 NY,D010069 Q000494 NY,D016207 Q000096 NN,D011115 Q000188 NY,D013154 Q000166 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013876 Q000494 NY,D013154 Q000378 NN,D011115 Q000276 NY,D013110 Q000494 NN","8252,31270,105065,107969,107970,4077460,5280335,10523409","128394615,129060975,129645792,136111139",Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.,"We investigated potential therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators FTY720 (fingolimod) and selective S1P1 agonist SEW2871 on a spontaneous autoimmune polyneuropathy (SAP) when given orally at 7 mo (anticipated disease onset) for 4 weeks. Clinical severity, electrophysiologic and histological findings were ameliorated in mice treated with 1 mg/kg of FTY720. Subsequent studies showed that SEW2871 was also effective in halting the progression of SAP, which was accompanied by dec",Journal of neuroimmunology,"Hye-Jung Kim, Cha-Gyun Jung, Danuta Dukala, Hyun Bae, Rafael Kakazu, Robert Wollmann, Betty Soliven"," Department of Neurology, The University of Chicago, Chicago, IL 60637, United States.",2009 Sep;214(?):93-100,10.1016/j.jneuroim.2009.07.006
19657053,20091001,article,"xref,mesh","Actins,Adherens Junctions,Cadherins,Cell Adhesion Molecules,Cells, Cultured,Electric Impedance,Endothelial Cells,Endothelium, Vascular,Fingolimod Hydrochloride,Focal Adhesion Protein-Tyrosine Kinases,Humans,Hyperglycemia,Immunosuppressive Agents,Lysophospholipids,Microvessels,Monomeric GTP-Binding Proteins,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,rac GTP-Binding Proteins,rho GTP-Binding Proteins","analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology,physiology","D020741 Q000502 NN,D015820 Q000502 NY,D020559 Q000502 NY,D004730 Q000187 NN,D020744 Q000502 NN,D055806 Q000166 NN,D013110 Q000031 NY,D006943 Q000378 NY,D011409 Q000494 NY,D042783 Q000187 NN,D013110 Q000378 NN,D042783 Q000502 NN,D051416 Q000502 NY,D000199 Q000378 NN,D004730 Q000502 NY,D008246 Q000378 NN,D022005 Q000502 NY,D015815 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D022005 Q000187 NN,D049349 Q000502 NN","6057,8252,31270,107969,107970,5280335,5283560","128394615,128865459,129060975,129645792","Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.","Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincu",American journal of physiology. Cell physiology,"Kei Sarai, Kenichi Shikata, Yasushi Shikata, Kazuyoshi Omori, Naomi Watanabe, Motofumi Sasaki, Shingo Nishishita, Jun Wada, Noriko Goda, Noriyuki Kataoka, Hirofumi Makino"," Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. shikata@md.okayama-u.ac.jp",2009 Oct;297(4):C945-54,10.1152/ajpcell.00606.2008
19658199,20100201,article,"xref,mesh","Animals,Autoantibodies,Axons,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Gene Expression,Immunosuppressive Agents,Lymphocytes,Multiple Sclerosis,Myelin Proteins,Myelin-Associated Glycoprotein,Myelin-Oligodendrocyte Glycoprotein,Propylene Glycols,Rats,Rats, Inbred Strains,Recombinant Proteins,Severity of Illness Index,Sphingosine,Spinal Cord,Time Factors","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D013116 Q000276 NN,D001369 Q000187 NN,D015870 Q000187 NN,D013116 Q000187 NN,D001323 Q000378 NN,D013116 Q000473 NN,D001369 Q000276 NN,D004681 Q000139 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001369 Q000473 NN,D013110 Q000494 NN,D008214 Q000187 NN,D004681 Q000473 NN,D004681 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.,"FTY720, an oral sphingosine 1-phosphate (S1P) receptor modulator, has shown efficacy in phase II trials in patients with relapsing-remitting multiple sclerosis (MS). Although this molecule is thought to immunosuppress by inhibiting lymphocyte egress from the lymph nodes, the full spectrum of FTY720's actions has not yet been uncovered. In this study, we investigated the effects of FTY720 treatment on disease severity and histopathology of MOG-induced experimental autoimmune encephalomyelitis (EAE) in the da",Journal of neuroscience research,"Dimitrios Papadopoulos, Jon Rundle, Ryan Patel, Ian Marshall, Jennifer Stretton, Rachel Eaton, Jill C Richardson, Maria I Gonzalez, Karen L Philpott, Richard Reynolds"," Department of Cellular and Molecular Neuroscience, Division of Neuroscience, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom.",2010 Feb;88(2):346-59,10.1002/jnr.22196
19692647,20090915,article,"xref,mesh","Adoptive Transfer,Animals,Cell Proliferation,Fingolimod Hydrochloride,Immunosuppression,Immunosuppressive Agents,Interleukin-2,Mice,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,T-Lymphocytes, Regulatory","agonists,analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D049349 Q000819 NY,D049349 Q000276 NN,D049109 Q000187 NY,D013110 Q000031 NN,D050378 Q000166 NY,D011409 Q000494 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007376 Q000494 NN","5262,31270,107969,107970,5280335","127790758,128394615,129645792",The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.,"CD4(+)CD25(+) regulatory T cell (Treg) entry into secondary lymphoid organs and local expansion is critical for their immunosuppressive function. Long-term application of the sphingosine-1 phosphate receptor agonist FTY720 exerts pleiotropic anti-inflammatory effects, whereas short-term FTY720 boosts antiviral immunity. In this study, we provide evidence that FTY720 potently inhibits Treg proliferation in vitro and in vivo without affecting their viability, phenotype, or in vitro immunosuppression. In contr","Journal of immunology (Baltimore, Md. : 1950)","Anna Maria Wolf, Kathrin Eller, Robert Zeiser, Christoph Dürr, Ulrike V Gerlach, Michael Sixt, Lydia Markut, Guenther Gastl, Alexander R Rosenkranz, Dominik Wolf"," Tyrolean Cancer Research Institute, Innsbruck Medical University, Innsbruck, Austria. maria.wolf@i-med.ac.at",2009 Sep;183(6):3751-60,10.4049/jimmunol.0901011
19719728,20090101,article,"xref,mesh","Adult,Delayed Graft Function,Drug Therapy, Combination,Everolimus,Female,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Middle Aged,Prognosis,Propylene Glycols,Prospective Studies,Sirolimus,Sphingosine,Survival Rate,Treatment Outcome","analogs &amp; derivatives,etiology,prevention &amp; control,therapeutic use","D013110 Q000031 NY,D006084 Q000209 NN,D007166 Q000627 NY,D051799 Q000209 NN,D020123 Q000031 NY,D051799 Q000517 NY,D013110 Q000627 NN,D011409 Q000627 NY,D020123 Q000627 NN,D006084 Q000517 NY","588,8252,31270,107969,107970,5280335,5284616,6442177,90696889,91534498","127719861,128394615,129060975,129645792,242749350,248766214",FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.,"This exploratory, multicenter, open-label study evaluated the efficacy and safety of FTY720, as a part of an immunosuppressive regimen, in combination with everolimus and steroids in de novo renal transplant recipients at increased risk of delayed graft function (DGF). Patients received FTY720 (5 mg) and everolimus (4 mg) 2-12 h pre-transplantation, followed by 2.5 mg/d FTY720 and concentration-controlled everolimus (4-8 ng/mL) post-transplant for 12 months. Induction therapy was prohibited. After enrollmen",Clinical transplantation,"H Tedesco-Silva, M I Lorber, C E Foster, H W Sollinger, R Mendez, D B Carvalho, R Shapiro, P R Rajagopalan, H Mayer, J Slade, B D Kahan, FTY720A2202 clinical study group"," Hospital do Rim Hipertensão/UNIFESP, Setor de Transplante Renal, Sao Paulo, SP, Brazil. heliotedesco@hrim.com.br",2009 Jan;23(5):589-99,10.1111/j.1399-0012.2009.01070.x
19720050,20091113,article,"xref,mesh","Active Transport, Cell Nucleus,Animals,Apoptosis,Apoptosis Inducing Factor,Blood-Brain Barrier,Brain,Brain Ischemia,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Macrophages,Male,Mice,Mice, Inbred C57BL,Microglia,Neuroprotective Agents,Neutrophils,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pathology,therapeutic use","D008264 Q000276 NN,D017209 Q000187 NN,D009504 Q000187 NN,D001812 Q000187 NN,D002545 Q000188 NY,D017628 Q000276 NN,D002545 Q000276 NN,D017628 Q000187 NN,D001921 Q000187 NN,D013110 Q000031 NY,D001921 Q000473 NN,D051033 Q000378 NN,D008264 Q000187 NN,D009504 Q000276 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D008246 Q000627 NY,D018696 Q000627 NY,D002545 Q000473 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.,Cerebral ischemia is accompanied by fulminant cellular and humoral inflammatory changes in the brain which contribute to lesion development after stroke. A tight interplay between the brain and the peripheral immune system leads to a biphasic immune response to stroke consisting of an early activation of peripheral immune cells with massive production of proinflammatory cytokines followed by a systemic immunosuppression within days of cerebral ischemia that is characterized by massive immune cell loss in sp,Biochemical and biophysical research communications,"Bozena Czech, Waltraud Pfeilschifter, Niloufar Mazaheri-Omrani, Marc André Strobel, Timo Kahles, Tobias Neumann-Haefelin, Abdelhaq Rami, Andrea Huwiler, Josef Pfeilschifter"," Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.",2009 Nov;389(2):251-6,10.1016/j.bbrc.2009.08.142
19782082,20100101,article,"xref,mesh","Adoptive Transfer,Animals,Antibodies,CD3 Complex,Cells, Cultured,Chemokine CCL20,Cholera Toxin,Diarrhea,Female,Fingolimod Hydrochloride,Food Hypersensitivity,Immunoglobulin E,Immunosuppressive Agents,Jejunum,Lymph Nodes,Mast Cells,Mice,Mice, Inbred BALB C,Mice, Mutant Strains,Ovalbumin,Propylene Glycols,Receptors, CCR6,Sphingosine,Th2 Cells","analogs &amp; derivatives,chemically induced,cytology,genetics,immunology,pharmacology,toxicity","D008407 Q000276 NN,D054418 Q000276 NN,D054399 Q000235 NN,D002772 Q000633 NN,D000906 Q000494 NN,D007073 Q000276 NN,D003967 Q000139 NN,D003967 Q000276 NY,D017252 Q000276 NN,D008198 Q000276 NN,D013110 Q000031 NN,D005512 Q000276 NY,D010047 Q000276 NN,D008198 Q000166 NN,D018418 Q000276 NY,D007583 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D054399 Q000276 NY,D010047 Q000494 NN","8252,31270,107969,107970,5280335,5289086","128394615,129060975,129645792",A functional role for CCR6 on proallergic T cells in the gastrointestinal tract.,"BACKGROUND & AIMS: CCL20 is a chemokine that regulates the homeostatic and inflammatory trafficking of leukocytes to the small intestine and regulates the development of the gastrointestinal lymphoid architecture. T cells expressing T helper cell (Th) 2 cytokines are critical for experimental food allergy, and we hypothesized that CCL20 is involved in the localization of these cells to the gut. METHODS: We evaluated the role of CCR6 in allergic diarrhea induced by sensitization and oral challenge with ovalb",Gastroenterology,"Ana Belén Blázquez, Adina Kay Knight, Hoheteberhan Getachew, Jonathan S Bromberg, Sergio A Lira, Lloyd Mayer, M Cecilia Berin"," Jaffe Food Allergy Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.",2010 Jan;138(1):?,10.1053/j.gastro.2009.09.016
19785648,20091101,article,"xref,mesh","Administration, Intranasal,Allergens,Animals,Anti-Asthmatic Agents,Anti-Inflammatory Agents,Budesonide,Capillary Permeability,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Immunologic Factors,Lung,Magnetic Resonance Imaging,Mice,Mice, Inbred C57BL,Mice, Knockout,Pneumonia,Propylene Glycols,Pulmonary Edema,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,beta-Alanine","administration &amp; dosage,agonists,analogs &amp; derivatives,drug effects,genetics,immunology,metabolism,pharmacology,prevention &amp; control","D015091 Q000031 NN,D011654 Q000276 NN,D008168 Q000276 NN,D000893 Q000494 NY,D049349 Q000819 NY,D011014 Q000378 NN,D011654 Q000517 NN,D049349 Q000235 NN,D013110 Q000008 NN,D011014 Q000276 NN,D019819 Q000494 NN,D011654 Q000378 NN,D018927 Q000494 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D000893 Q000008 NN,D015091 Q000494 NN,D011014 Q000517 NN,D013876 Q000494 NN,D000485 Q000276 NY,D007155 Q000494 NY,D013110 Q000494 NN,D008168 Q000187 NY,D007155 Q000008 NN,D008168 Q000378 NN","239,2462,8252,31270,40000,63006,105065,107969,107970,161901,969510,3033890,5280335,5281004,5702148,11259583,12201475,16759566,18647121,23674880,24867460,46780910,73759663","128394615,129060975,129348709,129645792,136098781,136111139",Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice.,"BACKGROUND AND PURPOSE: It has been suggested that intratracheal administration of the immunomodulator, FTY720, could have anti-inflammatory effects without causing a decrease in blood lymphocyte counts. However, the receptor responsible for this effect has not been defined. EXPERIMENTAL APPROACH: We have described, in a mouse model of allergen-induced inflammation, the use of proton magnetic resonance imaging to non-invasively assess lung fluid accumulation and inflammation. Here, we used this model to inv",British journal of pharmacology,"F-X Blé, C Cannet, S Zurbruegg, C Gérard, N Frossard, N Beckmann, A Trifilieff"," Global Imaging Group, Novartis Institutes for BioMedical Research, Basel, Switzerland.",2009 Nov;158(5):1295-301,10.1111/j.1476-5381.2009.00391.x
19809964,20091001,review,"xref,mesh","Biological Availability,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Transplantation,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemistry,drug therapy,pharmacokinetics,prevention &amp; control,therapeutic use","D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D007166 Q000493 NN,D007166 Q000627 NY,D011409 Q000493 NN,D013110 Q000493 NN,D007166 Q000737 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D006084 Q000517 NY","8252,31270,107969,107970,5280335,57024517","128394615,129060975,129645792,135812730",[Fingolimod - a new immunomodulator].,"Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingo",Deutsche medizinische Wochenschrift (1946),"F W Friedrich, T Eschenhagen"," Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg.",2009 Oct;134(42):2127-31,10.1055/s-0029-1241903
19814729,20091101,review,"xref,mesh","Animals,Astrocytes,Brain,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Gap Junctions,Humans,Immune System,Inflammation,Lymph Nodes,Lysophospholipids,Multiple Sclerosis,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology,physiology,therapeutic use","D001253 Q000276 NN,D007107 Q000187 NY,D017853 Q000378 NN,D049349 Q000037 NY,D004681 Q000276 NN,D049349 Q000235 NN,D017853 Q000235 NN,D008198 Q000276 NN,D013110 Q000031 NY,D009103 Q000276 NY,D001921 Q000187 NY,D017629 Q000502 NN,D004681 Q000188 NN,D007249 Q000276 NN,D008246 Q000502 NN,D013601 Q000502 NN,D001253 Q000473 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D009103 Q000188 NY,D049349 Q000502 NN,D013110 Q000502 NN,D008198 Q000473 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.,FTY720 (fingolimod) is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was highly effective in Phase II clinical trials for Multiple Sclerosis (MS). FTY720 is phosphorylated in vivo by sphingosine kinase-2 to form the active moiety FTY720-phosphate that binds to four of the five G protein-coupled S1P receptor subtypes. Studies using conditional S1P1 receptor-deficient and sphingosine kinase-deficient mice showed that the egress of lymphocytes from lymph nodes requires signalling of ly,British journal of pharmacology,Volker Brinkmann," Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland. volker.brinkmann@novartis.com",2009 Nov;158(5):1173-82,10.1111/j.1476-5381.2009.00451.x
19823172,20100101,article,"xref,mesh","Animals,Antibodies,Antigens, CD1d,Arthritis, Experimental,Cell Movement,Cytokines,Fingolimod Hydrochloride,GATA3 Transcription Factor,Immunosuppressive Agents,In Vitro Techniques,Mice,Mice, Inbred C57BL,Mice, Inbred NOD,Mice, Knockout,Mice, Transgenic,Natural Killer T-Cells,Propylene Glycols,Receptors, Antigen, T-Cell,Receptors, GABA-A,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,drug effects,genetics,immunology,metabolism,pharmacology,physiology,prevention &amp; control","D055611 Q000502 NN,D055610 Q000276 NN,D007166 Q000494 NY,D049349 Q000378 NY,D002465 Q000187 NY,D050990 Q000378 NN,D016207 Q000096 NN,D000906 Q000276 NN,D055611 Q000276 NY,D016207 Q000037 NY,D013110 Q000031 NY,D011963 Q000378 NN,D011409 Q000494 NY,D001169 Q000276 NN,D011948 Q000378 NN,D055611 Q000378 NY,D049349 Q000187 NN,D011948 Q000235 NN,D013601 Q000502 NN,D055610 Q000235 NN,D055610 Q000378 NY,D013110 Q000494 NN,D001169 Q000517 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration.","FTY720, a sphingosine 1-phosphate (S1P) receptor modulator, suppresses immune responses by inhibiting T-cell migration into target tissues; however, it does not alter T-cell functions. In this study, we investigated the biological effects of FTY720 on NKT cells. Unlike T cells, FTY720 suppressed the production of IL-4, IFN-gamma, IL-10, and IL-13 by NKT cells through the S1P1 receptor (S1P(1)). Moreover, FTY720 also inhibited the expression of T-bet and GATA-3 of NKT cells in the presence of TCR engagement.",Laboratory investigation; a journal of technical methods and pathology,"Su Jin Hwang, Ji Hyung Kim, Hye Young Kim, Sanghee Kim, Doo Hyun Chung"," Department of Pathology, Seoul National University College of Medicine, Seoul 110-744, Korea.",2010 Jan;90(1):9-19,10.1038/labinvest.2009.109
19823820,20100401,article,"xref,mesh","Chemokines,Cytokines,Cytotoxicity, Immunologic,Dendritic Cells,Enzyme-Linked Immunosorbent Assay,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunoblotting,Immunosuppressive Agents,K562 Cells,Killer Cells, Natural,Lysophospholipids,Oxadiazoles,Propylene Glycols,Sphingosine,Thiophenes,Up-Regulation","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D003713 Q000187 NY,D007694 Q000187 NY,D010069 Q000494 NY,D007694 Q000378 NN,D003713 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008246 Q000494 NY,D013876 Q000494 NY,D016207 Q000378 NY,D018925 Q000378 NN,D003713 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007694 Q000276 NN","8252,31270,107969,107970,4077460,5280335,5283560,10523409","128394615,129060975,129645792",FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release.,"The aims of this study are to examine the effect of sphingosine 1-phosphate (S1P) on IL-2-activated natural killer (NK) cell lysis of K562 tumor cells and immature dendritic cells (iDCs), and to investigate the mechanisms involved in S1P activity. Our results show that S1P protected K562 cells or iDCs from NK cell lysis, which was reversed by FTY720 and SEW2871, the antagonists of S1P(1). S1P did not modulate the expression of NKG2D, NKp30, NKp44 or CD158 on the surface of NK cells, and neither affected the","Cancer immunology, immunotherapy : CII","Johannes Rolin, Kristin L Sand, Eirunn Knudsen, Azzam A Maghazachi"," Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway.",2010 Apr;59(4):575-86,10.1007/s00262-009-0775-7
19855243,20091027,article,"xref,mesh","Animals,Carcinoma, Hepatocellular,Cell Division,Cell Line, Tumor,Cell Movement,Culture Media,Down-Regulation,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver Neoplasms,Liver Transplantation,Propylene Glycols,Rats,Rats, Inbred BUF,Receptors, Lysosphingolipid,Recurrence,Sphingosine","analogs &amp; derivatives,drug effects,genetics,immunology,pathology,physiology,prevention &amp; control,surgery,therapeutic use","D016031 Q000473 NN,D006528 Q000473 NN,D015536 Q000187 NN,D008113 Q000601 NY,D016031 Q000502 NN,D049349 Q000235 NN,D006528 Q000276 NN,D049349 Q000276 NN,D013110 Q000031 NY,D008113 Q000517 NN,D008113 Q000276 NN,D007166 Q000627 NY,D006528 Q000517 NN,D006528 Q000601 NY,D008113 Q000473 NN,D013110 Q000627 NN,D011409 Q000627 NY,D002455 Q000276 NN,D016031 Q000276 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog.","BACKGROUND.: Although the outcome of liver transplant patients with hepatocellular carcinoma (HCC) has improved with the introduction of strict criteria, tumor recurrence still remains a significant problem. Sphingosine-1-phosphate (S1P) is a phospholipid mediator that can induce diverse cellular responses, such as proliferation, migration, adhesion, and cell-rounding, in cancer cells. We investigated whether FTY720, a S1P analog, suppresses tumor recurrence after experimental liver transplantation in a rat",Transplantation,"Yuichiro Ushitora, Hirotaka Tashiro, Takayuki Ogawa, Yoshisato Tanimoto, Shintaro Kuroda, Tsuyoshi Kobayashi, Yoshihiro Miyata, Toshiyuki Itamoto, Toshimasa Asahara, Hideki Ohdan"," Second Department of Surgery, Faculty of Medicine, Hiroshima University, Hiroshima, Japan.",2009 Oct;88(8):980-6,10.1097/tp.0b013e3181b9ca69
19882371,20091001,review,"xref,mesh","Cladribine,Clinical Trials, Phase III as Topic,Crotonates,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Quinolones,Sphingosine,Toluidines","analogs &amp; derivatives,drug therapy,therapeutic use","D015363 Q000627 NN,D007166 Q000627 NN,D005650 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D014052 Q000627 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","8252,20279,31270,107969,107970,444972,3036108,5280335,6076814,6364607,6433510,6440849,9793847,10197734,23500906,54677946,87110070,101823788","127968532,128394615,128672523,128966217,129060975,129645792",New oral drugs for multiple sclerosis.,"Disease-modifying treatments are now available in relapsing-remitting and secondary progressive multiple sclerosis (MS), and their beneficial effects have been shown in several clinical studies. However, as these treatments are only partially effective in halting the MS disease process and are frequently associated with side effects and suboptimal patient adherence, new oral therapeutic approaches are warranted. This review focuses on advances in current and novel oral treatment approaches for MS. Several p",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,"Claudio Gasperini, S Ruggieri"," Centro Sclerosi Multipla, Azienda Ospedaliera S. Camillo-Forlanini, Rome, Italy. c.gasperini@libero.it",2009 Oct;?(?):S179-83,10.1007/s10072-009-0146-3
19934952,20091201,article,"xref,mesh","Animals,Brain Infarction,Cytokines,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Infarction, Middle Cerebral Artery,Interleukin-17,Interleukin-23,Mice,Mice, Knockout,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,complications,deficiency,drug therapy,etiology,genetics,immunology,metabolism,therapeutic use,therapy","D020244 Q000150 NY,D020520 Q000209 NY,D053759 Q000172 NN,D020381 Q000172 NN,D007166 Q000627 NN,D020520 Q000276 NN,D020244 Q000276 NY,D020520 Q000188 NN,D016207 Q000378 NN,D013110 Q000031 NN,D016207 Q000235 NN,D020520 Q000628 NY,D013601 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion?,NULL,Neurosurgery,"Ning Lin, Robert M Friedlander",NULL,2009 Dec;65(6):N13,10.1227/01.neu.0000345343.04287.23
19940275,20100201,article,"xref,mesh","Animals,Apoptosis,Apoptosis Regulatory Proteins,Brain,Brain Ischemia,Disease Models, Animal,Drug Administration Schedule,Fingolimod Hydrochloride,Immunosuppressive Agents,In Situ Nick-End Labeling,Infarction, Middle Cerebral Artery,MAP Kinase Signaling System,Male,Nerve Degeneration,Neuroprotective Agents,Oxadiazoles,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,Stroke,Thiophenes,Treatment Outcome","agonists,analogs &amp; derivatives,blood supply,drug effects,drug therapy,etiology,metabolism,pharmacology,physiology,physiopathology,prevention &amp; control,therapeutic use","D013876 Q000627 NN,D001921 Q000503 NN,D002545 Q000378 NN,D017209 Q000187 NN,D051017 Q000187 NN,D020521 Q000378 NN,D049349 Q000819 NY,D007166 Q000627 NN,D002545 Q000188 NY,D010069 Q000494 NN,D009410 Q000517 NN,D001921 Q000098 NN,D002545 Q000503 NN,D017209 Q000502 NN,D051017 Q000378 NN,D001921 Q000187 NN,D010069 Q000627 NN,D020244 Q000503 NN,D013110 Q000031 NY,D011409 Q000494 NY,D020244 Q000188 NN,D018696 Q000494 NY,D018696 Q000627 NN,D009410 Q000188 NN,D020521 Q000503 NN,D013876 Q000494 NN,D009410 Q000209 NN","8252,31270,107969,107970,4077460,5280335,10523409","128394615,129060975,129645792",Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.,"BACKGROUND AND PURPOSE: FTY720 is a known sphingosine 1-phosphate receptor agonist. In the present study, we investigated the neuroprotective effect of postischemic administration of FTY720 in rats with 2 hours transient middle cerebral artery occlusion (MCAO). METHODS: One hundred eleven male rats were randomly assigned to sham-operated and MCAO treated with vehicle, 0.25 mg/kg and 1 mg/kg of FTY720, another selective sphingosine 1-phosphate receptor-1 agonist SEW2871 (5 mg/kg), or 0.25 mg/kg of FTY720 plu",Stroke,"Yu Hasegawa, Hidenori Suzuki, Takumi Sozen, William Rolland, John H Zhang"," Department of Physiology, Loma Linda University School of Medicine, Loma Linda, Calif 92354, USA.",2010 Feb;41(2):368-74,10.1161/strokeaha.109.568899
19966528,20091201,article,"xref,mesh","Animals,Axons,Evoked Potentials, Somatosensory,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Myelin Sheath,Propylene Glycols,Rats,Rats, Sprague-Dawley,Recovery of Function,Sphingosine,Spinal Cord Injuries,Tacrolimus","analogs &amp; derivatives,drug effects,drug therapy,pathology,pharmacology,physiology,physiopathology,surgery,therapeutic use,ultrastructure","D013119 Q000473 NN,D013119 Q000601 NN,D009186 Q000648 NN,D001369 Q000187 NN,D016559 Q000494 NN,D009186 Q000187 NN,D005073 Q000187 NN,D020127 Q000187 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013119 Q000503 NY,D013119 Q000188 NY,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D020127 Q000502 NY,D016559 Q000627 NY,D001369 Q000648 NN","5372,8252,31270,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,90726579,134694629","128394615,129060975,129645792,242963342",Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats.,Spinal cord injury (SCI) occurs frequently and is a leading cause of permanent disability in young adults. Many immune inhibitors including tacrolimus (FK506) are shown to be helpful in the regeneration of neural tissue following spinal cord injury. FTY720 belongs to a new class of immunosuppressants. The combination of FTY720 and tacrolimus has been reported to elicit synergistic immunosuppresive effects in rat allograft models without causing critical adverse effects. This study was to determine whether t,The Tohoku journal of experimental medicine,"Jie Zhang, Ailiang Zhang, Yu Sun, Xiaojian Cao, Ning Zhang"," Department of Orthopedics, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.",2009 Dec;219(4):295-302,10.1620/tjem.219.295
19968652,20100301,article,"xref,mesh","Animals,Asthma,Disease Models, Animal,Female,Fingolimod Hydrochloride,Inflammation,Mice,Mice, Inbred BALB C,Ovalbumin,Propylene Glycols,Rhinitis, Allergic, Perennial,Sphingosine,Th2 Cells","adverse effects,analogs &amp; derivatives,complications,drug therapy,immunology,pathology,physiopathology,therapeutic use","D012221 Q000503 NN,D012221 Q000276 NY,D007249 Q000150 NY,D001249 Q000188 NN,D012221 Q000150 NY,D010047 Q000009 NN,D001249 Q000503 NN,D013110 Q000031 NN,D001249 Q000150 NY,D018418 Q000276 NY,D012221 Q000188 NN,D001249 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007249 Q000473 NN","8252,31270,107969,107970,5280335,5289086","128394615,129060975,129645792",United airways: circulating Th2 effector cells in an allergic rhinitis model are responsible for promoting lower airways inflammation.,"BACKGROUND: Allergic rhinitis (AR) and asthma often coexist and are referred to as 'united airways' disease. However, the molecular and cellular pathways that are crucially involved in the interaction between upper and lower airways remain to be identified. OBJECTIVE: We sought to assess whether and how AR exacerbates lower airway inflammation upon allergen challenge in mice. METHODS: We previously developed an intranasal ovalbumin (OVA)-driven AR model, characterized by nasal eosinophilic inflammation, enh",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,"A KleinJan, M Willart, M van Nimwegen, K Leman, H C Hoogsteden, R W Hendriks, B N Lambrecht"," Department of Pulmonary Medicine, Erasmus MC Rotterdam, The Netherlands. a.kleinjan@erasmusmc.nl",2010 Mar;40(3):494-504,10.1111/j.1365-2222.2009.03417.x
20003043,20100501,article,"xref,mesh","Animals,Cyclosporine,Drug Interactions,Drug Therapy, Combination,Enzyme Inhibitors,Everolimus,Fingolimod Hydrochloride,Heart Transplantation,Immunosuppressive Agents,Male,Propylene Glycols,Protein Kinase C,Pyrroles,Quinazolines,Rats,Rats, Inbred Lew,Rats, Wistar,Sirolimus,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,methods,pharmacology","D011493 Q000037 NY,D011799 Q000494 NY,D013110 Q000008 NN,D020123 Q000008 NN,D013110 Q000031 NY,D011758 Q000494 NY,D004359 Q000379 NN,D004791 Q000494 NY,D016027 Q000379 NY,D020123 Q000031 NY,D016572 Q000008 NY,D011409 Q000008 NY,D007166 Q000008 NY","2909,8252,31270,62280,107969,107970,5280335,5280754,5284373,5284616,5458585,6435893,6442177,9855081,10296883,24883466,25246316,49867938,71306795,71463825,73896891,90696889,91534498,122172945,123134263,123134270,132274082","128394615,129060975,129645792,242749350,245514708,248766214","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.","NVP-AEB071 (AEB, sotrastaurin), an oral inhibitor of protein kinase C (PKC), effectively blocks T-cell activation. The immunosuppressive effects of oral AEB were demonstrated in a rat local graft versus host (GvH) reaction and rat cardiac transplantation models. T-cell activation was suppressed by 95% in blood from AEB-treated rats, with a positive correlation between T-cell inhibition and AEB blood concentration. In GvH studies, AEB inhibited lymph node swelling dose-dependently (3-30 mg/kg). BN and DA car",Transplant international : official journal of the European Society for Organ Transplantation,"Gisbert Weckbecker, Charles Pally, Christian Beerli, Christoph Burkhart, Grazyna Wieczorek, Barbara Metzler, Randall E Morris, Juergen Wagner, Christian Bruns"," Novartis Institutes for BioMedical Research, Autoimmunity and Transplantation Disease Area, Novartis Pharma AG, Basel, Switzerland. gisbert.weckbecker@novartis.com",2010 May;23(5):543-52,10.1111/j.1432-2277.2009.01015.x
20009947,20100101,article,xref,"Acanthamoeba,Acanthamoeba Keratitis,Animals,Contact Lens Solutions,Contact Lenses, Hydrophilic,Disinfectants,Humans","drug effects,growth &amp; development,isolation &amp; purification,microbiology,parasitology,pharmacology,prevention &amp; control","D015823 Q000517 NN,D000048 Q000187 NY,D004202 Q000494 NN,D015823 Q000469 NN,D003263 Q000382 NY,D018639 Q000494 NY,D000048 Q000302 NN,D000048 Q000254 NY",8252,129060975,Disinfection efficacy and encystment rate of soft contact lens multipurpose solutions against Acanthamoeba.,OBJECTIVES: To assess the ability of commercial and experimental soft contact lens multipurpose solutions (MPS) to promote Acanthamoeba trophozoite encystment and their biocidal efficacy against Acanthamoeba trophozoites and cysts. The effects on encystment and disinfection efficacy by the incorporation of propylene glycol (PG) in the formulation of MPS were also investigated. METHODS: Acanthamoeba trophozoites (Acanthamoeba castellanii ATCC 50730 and Acanthamoeba polyphaga CCAP 1501/3G) were inoculated int,Eye & contact lens,"James Lonnen, Wayne Heaselgrave, Miya Nomachi, Osamu Mori, Jacinto Santodomingo-Rubido"," Department of Infection, Immunity and Inflammation, University of Leicester, Medical Sciences Building, Leicester, United Kingdom.",2010 Jan;36(1):26-32,10.1097/icl.0b013e3181c6e184
20014532,20091101,article,"xref,mesh","Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,Causality,Cladribine,Disabled Persons,Fingolimod Hydrochloride,Forecasting,France,Humans,Immunologic Factors,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Research,Sphingosine,Vaccination,Vaccines, DNA","analogs &amp; derivatives,epidemiology,immunology,statistics &amp; numerical data,therapeutic use,therapy,trends","D012106 Q000639 NN,D009103 Q000453 NN,D019444 Q000276 NN,D005602 Q000453 NN,D007155 Q000627 NY,D000912 Q000627 NN,D013110 Q000031 NN,D014611 Q000639 NN,D009103 Q000628 NY,D007166 Q000627 NY,D000911 Q000627 NY,D017338 Q000627 NN,D009103 Q000276 NN,D013110 Q000627 NN,D006233 Q000706 NN,D011409 Q000627 NN","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792","[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].",NULL,Soins; la revue de reference infirmiere,Hélène Zéphir," Service de Neurologie, Pôle de Neurologie, Hôpital Roger-Salengro, Centre Hospitalier Régional Universitarie, Lille. h-zephir@chru-lille.fr",2009 Nov;?(740):39-41,NULL
20019358,20100501,article,"xref,mesh","Animals,Autoimmune Diseases,CD4 Lymphocyte Count,CD4-Positive T-Lymphocytes,Cell Movement,Cytokines,Disease Models, Animal,Enzyme-Linked Immunosorbent Assay,Eye Proteins,Fingolimod Hydrochloride,Flow Cytometry,Immunoglobulin G,Immunosuppressive Agents,Interleukin-2 Receptor alpha Subunit,Intubation, Gastrointestinal,Lymph Nodes,Mice,Peptide Fragments,Propylene Glycols,Retinol-Binding Proteins,Sphingosine,T-Lymphocytes, Regulatory,Uveitis, Posterior","administration &amp; dosage,analogs &amp; derivatives,blood,immunology,metabolism,pathology,prevention &amp; control","D005136 Q000276 NN,D010446 Q000276 NN,D016207 Q000378 NN,D013110 Q000008 NN,D012177 Q000276 NN,D008198 Q000276 NN,D013110 Q000031 NY,D001327 Q000276 NN,D002465 Q000276 NN,D015866 Q000276 NN,D050378 Q000276 NN,D015866 Q000473 NN,D015866 Q000517 NY,D007074 Q000097 NN,D011409 Q000008 NY,D001327 Q000473 NN,D053645 Q000276 NN,D007166 Q000008 NY,D001327 Q000517 NY","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792",Evaluation of experimental autoimmune uveitis in mice treated with FTY720.,"PURPOSE: FTY720 (fingolimod) is an immunomodulatory drug capable of preventing T-cell migration to inflammatory sites by binding to and subsequently downregulating the expression of sphingosine-1 phosphate receptor 1 (S1P(1)) leading in turn to T-cell retention in lymphoid organs. Additional effects of FTY720 by increasing functional activity of regulatory T cells have recently been demonstrated, raising the conversion of conventional T cells into regulatory T cells and affecting the sequestration of regula",Investigative ophthalmology & visual science,"Alessandra Gonçalves Commodaro, Jean Pierre S Peron, Camila Takao Lopes, Christina Arslanian, Rubens Belfort, Luiz Vicente Rizzo, Valquiria Bueno"," Vision Institute, Universidade Federal de São Paulo, São Paulo, Brazil.",2010 May;51(5):2568-74,10.1167/iovs.09-4769
20028707,20100201,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Disability Evaluation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kaplan-Meier Estimate,Magnetic Resonance Imaging,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Time Factors,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,diagnosis,drug therapy,pathology","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D020529 Q000473 NN,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.,"In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7-36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at t","Multiple sclerosis (Houndmills, Basingstoke, England)","G Comi, P O'Connor, X Montalban, J Antel, E-W Radue, G Karlsson, H Pohlmann, S Aradhye, L Kappos, FTY720D2201 Study Group"," Department of Neurology, Università Vita-Salute San Raffaele, Milan, Italy. g.comi@hsr.it",2010 Feb;16(2):197-207,10.1177/1352458509357065
20037283,20091201,review,"xref,mesh","CD4-Positive T-Lymphocytes,Colon,Fingolimod Hydrochloride,Humans,Immunologic Memory,Immunosuppressive Agents,Inflammatory Bowel Diseases,Leukapheresis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,cytology,drug effects,drug therapy,immunology,therapeutic use","D015496 Q000276 NN,D015496 Q000187 NY,D013110 Q000031 NY,D007156 Q000187 NN,D015212 Q000276 NY,D015212 Q000188 NY,D007166 Q000627 NY,D015496 Q000166 NN,D007156 Q000276 NN,D013110 Q000627 NN,D003106 Q000276 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Systemically circulating colitogenic memory CD4+T cells may be an ideal target for the treatment of inflammatory bowel diseases.,"Inflammatory bowel diseases (IBD) are thought to be caused by a complex interaction of genetic, immunological, and environmental factors. Why is it that once an IBD develops it lasts a long time? Considering this simple question, we propose that coliotogenic memory CD4+T cells that remember the prototype of the disease in each patient are formed in IBD at the onset, and, perceiving them as ""benign T-cell leukemia""-like lifelong memory CD4+T cells that hematogenously spread throughout the body, we thus propo",The Keio journal of medicine,"Takanori Kanai, Mamoru Watanabe, Toshifumi Hibi"," Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku, Tokyo, Japan. takagast@sc.itc.keio.ac.jp",2009 Dec;58(4):203-9,10.2302/kjm.58.203
20038198,20100601,article,"xref,mesh","Animals,Bone Diseases,Bone Regeneration,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Microvessels,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Skull,Sphingosine,Tissue Scaffolds,X-Ray Microtomography","agonists,analogs &amp; derivatives,chemistry,diagnostic imaging,drug effects,drug therapy,pathology,pharmacology,surgery,therapeutic use","D007166 Q000494 NY,D049349 Q000819 NN,D007166 Q000627 NN,D001861 Q000187 NY,D055806 Q000000981 NN,D055806 Q000187 NY,D012886 Q000000981 NN,D011409 Q000737 NN,D012886 Q000187 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D054457 Q000737 NY,D012886 Q000473 NN,D007166 Q000737 NN,D013110 Q000627 NN,D011409 Q000627 NN,D001847 Q000000981 NN,D001847 Q000188 NN,D012886 Q000601 NY,D013110 Q000494 NN,D001847 Q000601 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 promotes local microvascular network formation and regeneration of cranial bone defects.,"The calvarial bone microenvironment contains a unique progenitor niche that should be considered for therapeutic manipulation when designing regeneration strategies. Recently, our group demonstrated that cells isolated from the dura are multipotent and exhibit expansion potential and robust mineralization on biodegradable constructs in vitro. In this study, we evaluate the effectiveness of healing critical-sized cranial bone defects by enhancing microvascular network growth and host dura progenitor traffick",Tissue engineering. Part A,"Caren E Petrie Aronin, Lauren S Sefcik, Sunil S Tholpady, Ashok Tholpady, Karim W Sadik, Timothy L Macdonald, Shayn M Peirce, Brian R Wamhoff, Kevin R Lynch, Roy C Ogle, Edward A Botchwey"," Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia 22908, USA.",2010 Jun;16(6):1801-9,10.1089/ten.tea.2009.0539
20056921,20100305,article,"xref,mesh","ATP Binding Cassette Transporter 1,ATP-Binding Cassette Transporters,Apolipoprotein A-I,Atherosclerosis,Biological Transport,Carrier Proteins,Cell Culture Techniques,Cell Death,Cell Survival,Cells, Cultured,Cholesterol,Cholesterol Esters,Endoplasmic Reticulum,Endosomes,Fingolimod Hydrochloride,Humans,Hydroxycholesterols,Lipoproteins, LDL,Liver X Receptors,Macrophages,Membrane Glycoproteins,Orphan Nuclear Receptors,Propylene Glycols,Receptors, Scavenger,Signal Transduction,Sphingosine,Time Factors","agonists,analogs &amp; derivatives,drug effects,metabolism,pharmacology,prevention &amp; control","D011992 Q000378 NN,D008562 Q000378 NN,D008264 Q000378 NN,D011992 Q000187 NN,D018528 Q000378 NN,D002352 Q000378 NN,D057093 Q000378 NN,D002784 Q000378 NY,D050197 Q000378 NN,D013110 Q000031 NY,D008077 Q000378 NN,D011409 Q000494 NY,D051116 Q000187 NN,D050197 Q000517 NY,D002788 Q000378 NN,D051116 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D057093 Q000819 NN,D008264 Q000187 NY,D004721 Q000378 NN,D016632 Q000378 NN,D004721 Q000187 NN,D006888 Q000378 NY","304,5997,8252,31270,99470,107969,107970,123976,313019,447912,5280335,5283629,44566108,50990021,126963441,133562451","53787861,53790753,99300562,99300584,99300596,127917056,128121087,128394615,129060975,129645792,283537481",FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages.,"RATIONALE: The synthetic sphingosine analog FTY720 is undergoing clinical trials as an immunomodulatory compound, acting primarily via sphingosine 1-phosphate receptor activation. Sphingolipid and cholesterol homeostasis are closely connected but whether FTY720 affects atherogenesis in humans is not known. OBJECTIVE: We examined the effects of FTY720 on the processing of scavenged lipoprotein cholesterol in human primary monocyte-derived macrophages. METHODS AND RESULTS: FTY720 did not affect cholesterol up",Circulation research,"Tomas Blom, Nils Bäck, Aino-Liisa Mutka, Robert Bittman, Zaiguo Li, Angel de Lera, Petri T Kovanen, Ulf Diczfalusy, Elina Ikonen"," Institute of Biomedicine/Anatomy, Haartmaninkatu 8, University of Helsinki, Finland.",2010 Mar;106(4):720-9,10.1161/circresaha.109.204396
20061941,20100101,review,"xref,mesh","Administration, Oral,Animals,Central Nervous System,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lymphocytes,Models, Immunological,Multiple Sclerosis,Neuroglia,Neurons,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,adverse effects,agonists,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology","D007107 Q000187 NY,D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D049349 Q000819 NN,D004681 Q000378 NN,D013110 Q000008 NN,D009103 Q000378 NN,D009474 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002490 Q000187 NY,D013110 Q000494 NN,D007166 Q000009 NN,D008214 Q000187 NN,D009103 Q000188 NY,D011409 Q000008 NY,D009457 Q000187 NN,D049349 Q000378 NN,D004681 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.,"Fingolimod (FTY720) is a first-in-class orally bioavailable compound that has shown efficacy in advanced clinical trials for the treatment of multiple sclerosis (MS). In vivo, fingolimod is phosphorylated to form fingolimod-phosphate, which resembles naturally occurring sphingosine 1-phosphate (S1P), an extracellular lipid mediator whose major effects are mediated by cognate G protein-coupled receptors. There are at least 5 S1P receptor subtypes, known as S1P subtypes 1-5 (S1P1-5), 4 of which bind fingolimo",Clinical neuropharmacology,"Jerold Chun, Hans-Peter Hartung"," Department of Molecular Biology, Helen L. Dorris Child and Adolescent Neuropsychiatric Disorder Institute, The Scripps Research Institute, La Jolla, CA, USA. jchun@scripps.edu",2010 Jan;33(2):91-101,10.1097/wnf.0b013e3181cbf825
20089952,20100204,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Arrhythmias, Cardiac,Brain,Disability Evaluation,Disease Progression,Double-Blind Method,Female,Fingolimod Hydrochloride,Herpesviridae Infections,Humans,Immunosuppressive Agents,Kaplan-Meier Estimate,Liver Function Tests,Macular Edema,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,etiology,mortality,pathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D008269 Q000139 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D020529 Q000473 NN,D001921 Q000473 NN,D007166 Q000627 NY,D020529 Q000188 NY,D006566 Q000209 NN,D006566 Q000401 NN,D001145 Q000139 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.,"BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis. METHODS: In our 24-month, double-blind, randomized study, we enrolled patients who had relapsing-remitting multiple sclerosis, were 18 to 55 years of age, had a scor",The New England journal of medicine,"Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson, Pascale Burtin, FREEDOMS Study Group"," Department of Neurology, University Hospital, University of Basel, Switzerland. lkappos@uhbs.ch",2010 Feb;362(5):387-401,10.1056/nejmoa0909494
20089954,20100204,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Arrhythmias, Cardiac,Brain,Disability Evaluation,Disease Progression,Double-Blind Method,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Injections, Intramuscular,Intention to Treat Analysis,Interferon beta-1a,Interferon-beta,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Statistics, Nonparametric,Young Adult","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,pathology,therapeutic use","D016899 Q000627 NY,D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D020529 Q000473 NN,D001921 Q000473 NN,D016899 Q000009 NN,D007166 Q000627 NY,D020529 Q000188 NY,D001145 Q000139 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.,"BACKGROUND: Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis. METHODS: In this 12-month, double-blind, double-dummy study, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a recent history of at least one relapse to receive either oral fingolimod at a daily dose of either 1.25 or 0.5 mg or in",The New England journal of medicine,"Jeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo, Klaus Tiel-Wilck, Ana de Vera, James Jin, Tracy Stites, Stacy Wu, Shreeram Aradhye, Ludwig Kappos, TRANSFORMS Study Group"," Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA. cohenj@ccf.org",2010 Feb;362(5):402-15,10.1056/nejmoa0907839
20089958,20100204,article,"xref,mesh","Administration, Oral,Arrhythmias, Cardiac,Cladribine,Disease Progression,Female,Fingolimod Hydrochloride,Herpesviridae Infections,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,etiology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D017338 Q000627 NY,D016899 Q000627 NN,D017338 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D006566 Q000209 NN,D001145 Q000139 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Oral therapy for multiple sclerosis--sea change or incremental step?,NULL,The New England journal of medicine,William M Carroll,NULL,2010 Feb;362(5):456-8,10.1056/nejme0912019
20099165,20100101,article,"xref,mesh","Animals,Apoptosis,Fingolimod Hydrochloride,Graft vs Host Disease,Immunosuppressive Agents,Intestine, Small,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred WF,Sphingosine,Transplantation, Heterotopic","analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology,prevention &amp; control,transplantation","D007166 Q000494 NY,D017209 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D006086 Q000276 NY,D007421 Q000637 NY,D008214 Q000166 NN,D013110 Q000494 NN,D008214 Q000187 NN,D006086 Q000517 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[FTY720-induced lymphocyte apoptosis inhibits acute graft versus host disease in rat small bowel transplantation].,OBJECTIVE: To investigate the effect and mechanism of FTY720 on acute graft versus host disease (GVHD) in rat small bowel transplantation (SBTx). METHODS: Heterotopic SBTx was performed using a parent (WF)-into-F1 (WFxACI) rat combination. Recipient rats were divided into experimental group (n=6) and control group (n=6). Rats in the experimental group were administered with FTY720 at 0.5 mg/kg for 14 days. Lymphocyte apoptosis in the liver and the mucosa of intestine and graft was detected by TUNEL and flow,Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,"Jing-Hai Song, Toshinori Ito, Jun-Min Wei, Mei-Xiong Huang"," Department of Complementary and Alternative Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.",2010 Jan;13(1):60-3,NULL
20153186,20100301,article,"xref,mesh,assay","Administration, Oral,Amino Acids,Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,Isoleucine,Lymphocytes,Phosphates,Phosphorylation,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,chemical synthesis,chemistry,drug effects,immunology,metabolism,pharmacology","D011409 Q000737 NY,D010710 Q000737 NY,D007532 Q000737 NN,D049349 Q000819 NY,D007166 Q000737 NY,D013110 Q000031 NY,D013110 Q000737 NN,D007532 Q000138 NN,D007166 Q000138 NN,D000596 Q000737 NN,D007532 Q000031 NY,D008214 Q000276 NN,D007532 Q000494 NN,D011409 Q000494 NN,D013110 Q000494 NN,D008214 Q000187 NN,D007166 Q000494 NN,D049349 Q000378 NN","1061,6306,8252,31270,99288,107969,107970,5280335,10125714,10149595,11222939,46866185,46866186,46881847,46881848,46881875,46881876,46881877,46881912","127403921,128394615,129060975,129645792",S1P receptor mediated activity of FTY720 phosphate mimics.,"Various carboxylic acids, phosphonic acids, sulfonic acids, tetrazoles as well as sulfonylhydantoins were prepared as phosphate mimics of the chiral aminophosphate 1-P to act as agonists on the S1P(1) receptor. It was found that amino phosphonates and amino carboxylates are potent S1P(1) binders. beta-Amino acid 11 could be shown to reversibly reduce blood lymphocyte counts in rats after po administration. ",Bioorganic & medicinal chemistry letters,"Klemens Högenauer, Klaus Hinterding, Peter Nussbaumer"," Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland. klemens.hoegenauer@novartis.com",2010 Mar;20(5):1485-7,10.1016/j.bmcl.2010.01.118
20174580,20100101,article,"xref,mesh","Animals,B-Lymphocytes,Bone Marrow,Bromodeoxyuridine,Cell Movement,Chemotaxis, Leukocyte,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Male,Mice,Mice, Inbred C57BL,Mice, Inbred CBA,Mice, Knockout,Mice, Transgenic,Precursor Cells, B-Lymphoid,Propylene Glycols,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Signal Transduction,Sphingosine","analogs &amp; derivatives,cytology,deficiency,drug effects,genetics,metabolism,pharmacology,physiology","D002465 Q000187 NN,D001853 Q000378 NY,D049349 Q000235 NN,D001402 Q000166 NN,D054448 Q000166 NN,D054448 Q000502 NY,D013110 Q000031 NY,D013110 Q000378 NN,D054448 Q000378 NN,D001402 Q000502 NN,D001973 Q000378 NN,D008246 Q000502 NY,D002634 Q000187 NN,D049349 Q000502 NY,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001402 Q000378 NN,D015398 Q000502 NN,D013110 Q000502 NN,D049349 Q000172 NN","187,1541,6035,8252,31270,105065,107969,107970,5280335,5283560,6918942,44258291","128394615,128814285,129060975,129110214,129645792,136111139,136216744,243214637",A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow.,"B lymphocyte egress from secondary lymphoid organs requires sphingosine-1-phosphate (S1P) and S1P receptor-1 (S1P1). However, whether S1P contributes to immature-B cell egress from the bone marrow (BM) has not been fully assessed. Here we report that in S1P- and S1P1-conditionally deficient mice, the number of immature-B cells in the BM parenchyma increased, while it decreased in the blood. Moreover, a slower rate of bromodeoxyuridine incorporation suggested immature-B cells spent longer in the BM of mice i",PloS one,"João Pedro Pereira, Ying Xu, Jason G Cyster"," Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California, United States of America. Joao.Pereira@ucsf.edu",2010 Jan;5(2):e9277,10.1371/journal.pone.0009277
20177341,20100227,article,"xref,mesh","Adenosine,Allopurinol,Animals,Cell Culture Techniques,Cell Division,Cell Survival,Fingolimod Hydrochloride,Flow Cytometry,Glutathione,Immunohistochemistry,Immunosuppressive Agents,Inflammation,Insulin,Kidney Transplantation,Male,Organ Preservation Solutions,Propylene Glycols,Raffinose,Rats,Rats, Inbred Lew,Reperfusion Injury,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,immunology,pathology,prevention &amp; control,therapeutic use","D016030 Q000276 NN,D002455 Q000187 NN,D002470 Q000187 NN,D016030 Q000009 NY,D015427 Q000473 NN,D016030 Q000473 NN,D015427 Q000276 NN,D013110 Q000031 NY,D015427 Q000517 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D007249 Q000473 NN","2094,8252,31270,60961,107969,107970,124886,439242,2724100,5280335,70678557,118984375,135401907","128394615,128650051,128799971,128814610,129060975,129192846,129645792",Cytoprotective Actions of FTY720 Modulate Severe Preservation Reperfusion Injury in Rat Renal Transplants.,BACKGROUND: Fingolimod (FTY720) is a potent agonist of sphingosine 1 phosphate receptors and thereby interferes with lymphocyte trafficking. We previously showed that FTY720 protects from mild preservation reperfusion injury induced by 4 hr of cold ischemia. The purpose of this study was to explore the role of FTY720 in ischemic injury and regeneration using a clinically relevant rat renal transplant model with 24 hr of cold ischemia. METHODS: Donor kidneys were cold stored in the University of Wisconsin so,Transplantation,"T Florian Fuller, Uwe Hoff, Linghua Kong, Melanie Naether, Philine Wagner, Melina Nieminen-Kelhä, Jochen Nolting, Friedrich C Luft, Björn Hegner, Duska Dragun"," Department of Urology, Charité Universitaetsmedizin Berlin, Berlin, Germany.",2010 Feb;89(4):402-8,10.1097/tp.0b013e3181caa499
20185772,20100401,article,"xref,mesh","Animals,Blood-Brain Barrier,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Neuroprotective Agents,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Signal Transduction,Sphingolipids,Sphingosine,Stroke","analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,metabolism,pathology,physiology,physiopathology,therapeutic use","D001812 Q000378 NN,D013107 Q000378 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020521 Q000473 NN,D020521 Q000503 NN,D015398 Q000502 NY,D013110 Q000627 NN,D020521 Q000188 NY,D049349 Q000037 NN,D011409 Q000627 NY,D018696 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Targeting the sphingolipid signaling pathway in stroke.,NULL,Stroke,"Waltraud Pfeilschifter, Bozena Czech, Tobias Neumann-Haefelin",NULL,2010 Apr;41(4):?,10.1161/strokeaha.110.578278
20201753,20101201,article,"xref,mesh","Animals,Blood,Cell Cycle,Cell Division,Disease Models, Animal,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Interphase,Lymph Nodes,Lymphocyte Count,Lymphocytes,Lymphopenia,Male,Propylene Glycols,Rats,Rats, Sprague-Dawley,Rats, Wistar,Sphingosine,Thymus Gland","analogs &amp; derivatives,chemically induced,drug effects,pathology,pharmacology","D006085 Q000187 NN,D001769 Q000187 NN,D002455 Q000187 NN,D013950 Q000187 NN,D008214 Q000473 NN,D002453 Q000187 NY,D008231 Q000139 NN,D008198 Q000187 NN,D008214 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013950 Q000473 NN,D008231 Q000473 NN,D007399 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D008198 Q000473 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats.,"PURPOSES: To probe into immunosuppressive effect and cell cycle arrest effect of different dose of FTY720. METHOD: we study immunosuppressive effect and cell cycle arrest effect of different dose of FTY720 and time and dose dependence of FTY720 with control and random method in vivo, respectively. RESULTS: (i) survival time of graft in rat cardiac transplantation model is prolonged in group treated with FTY720. It is longer in group treated with FTY720 10 mg/kg than that in group treated with FTY720 2 mg/kg",Immunopharmacology and immunotoxicology,"Qingyuan Li, Feng Li"," Department of Urology and Transplantation, First Affiliated Hospital, Binzhou Medical University, Binzhou City, Shandong Province, China. lqy999496@yahoo.com.cn",2010 Dec;32(4):680-7,10.3109/08923971003674433
20208513,20100301,article,"xref,mesh","Cladribine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D017338 Q000627 NY,D017338 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792","New drugs may improve, complicate treatment for multiple sclerosis.",NULL,Nature medicine,"Hans Link, Roland Martin"," Karolinska Institute, Stockholm, Sweden.",2010 Mar;16(3):272,10.1038/nm0310-272
20214743,20100801,article,"xref,mesh","Animals,Combined Modality Therapy,Fingolimod Hydrochloride,Immunoglobulins,Immunosuppressive Agents,Intestine, Small,Mucoproteins,Propylene Glycols,Rats,Sphingosine,Tacrolimus,Transplants","analogs &amp; derivatives,biosynthesis,drug effects,metabolism,pharmacology,radiation effects,transplantation","D009088 Q000096 NY,D007166 Q000494 NY,D007421 Q000637 NN,D007136 Q000096 NY,D007421 Q000528 NY,D007421 Q000187 NY,D007421 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D016559 Q000494 NY,D013110 Q000494 NN","5372,8252,31270,107969,107970,445643,5280335,5282315,6473866,6536850,71668407,90726579,134694629","128394615,129060975,129645792,242963342","Effect of combined treatment with FK506, FTY720, and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.","We studied the effect of the combined treatment with FK506, FTY720, and ex vivo graft irradiation. Five groups of SBT animals were studied on days 3, 5, and 7 after operation (untreated, FK506, FTY720, FK506 + FTY720, FK506 + FTY720 + irradiation). Indirect immunoperoxidase staining was performed against CD4 and MAdCAM-1. The numbers of CD4 positive cells in allografts were also analyzed by flow cytometry. The graft survival was prolonged in all of the FK506- and FTY720-treated groups. SBT allografts treate",Pediatric transplantation,"Kiminobu Sugito, Shota Uekusa, Hiroyuki Kawashima, Takayuki Masuko, Takeshi Furuya, Noriyoshi Konuma, Kensuke Ohashi, Mikiya Inoue, Taro Ikeda, Tsugumichi Koshinaga"," Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan. ksugito@med.nihon-u.ac.jp",2010 Aug;14(5):614-7,10.1111/j.1399-3046.2010.01295.x
20233577,20100409,article,"xref,mesh","Animals,Antibodies, Antinuclear,Fingolimod Hydrochloride,Immunosuppressive Agents,Leukocyte Count,Lupus Erythematosus, Systemic,Lupus Nephritis,Lymphocytes,Mesangial Cells,Mice,Monocytes,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,mortality,pathology,prevention &amp; control,therapeutic use","D009000 Q000187 NN,D013154 Q000187 NN,D000974 Q000097 NN,D008181 Q000473 NN,D013110 Q000031 NY,D008181 Q000097 NN,D008180 Q000097 NN,D013154 Q000276 NN,D007166 Q000627 NY,D009000 Q000276 NN,D008214 Q000276 NN,D050527 Q000473 NN,D008180 Q000188 NY,D008181 Q000517 NY,D013110 Q000627 NN,D008214 Q000187 NN,D011409 Q000627 NY,D050527 Q000187 NY,D008180 Q000401 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.,"FTY720 is a novel investigational agent targeting the sphingosine 1-phosphate (S1P) receptors with an ability to cause immunosuppression by inducing lymphocyte sequestration in lymphoid organs. Systemic lupus erythematosus (SLE) is refractory autoimmune disease characterized by the production of a wide variety of autoantibodies and immune complex (IC)-mediated lupus nephritis. Among several SLE-prone strains of mice, BXSB is unique in terms of the disease-associated monocytosis in periphery and the reduced ",Biochemical and biophysical research communications,"Seiichiro Ando, Hirofumi Amano, Eri Amano, Kentaro Minowa, Takashi Watanabe, Soichiro Nakano, Yutaka Nakiri, Shinji Morimoto, Yoshiaki Tokano, Qingshun Lin, Rong Hou, Mareki Ohtsuji, Hiromichi Tsurui, Sachiko Hirose, Yoshinari Takasaki"," Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. andosei78102@biscuit.ocn.ne.jp",2010 Apr;394(3):804-10,10.1016/j.bbrc.2010.03.078
20298547,20100101,article,"xref,mesh","Adoptive Transfer,Animals,Antigen-Presenting Cells,Arthritis, Experimental,Arthritis, Rheumatoid,Autoantibodies,Cell Movement,Female,Fingolimod Hydrochloride,Gene Knock-In Techniques,Humans,Immunosuppressive Agents,Joints,Lymph Nodes,Male,Mice,Mice, Inbred BALB C,Mice, SCID,Propylene Glycols,Proteoglycans,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,chemically induced,drug effects,immunology,pathology,pharmacology","D000938 Q000276 NN,D001172 Q000473 NN,D001172 Q000139 NN,D001169 Q000139 NN,D001169 Q000276 NY,D001169 Q000473 NN,D008198 Q000276 NN,D007596 Q000473 NN,D013110 Q000031 NN,D011509 Q000276 NY,D001172 Q000276 NY,D011509 Q000494 NN,D007596 Q000276 NY,D013601 Q000276 NY,D013601 Q000473 NN,D011409 Q000494 NN,D000938 Q000473 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013601 Q000187 NN,D008198 Q000473 NN,D001323 Q000276 NY","180,702,3763,5707,7880,8252,31270,105065,107969,107970,122297,644025,5280335,14844438,44258291","127548708,127669892,128201052,128394615,128482492,128806316,128922443,129060975,129645792,129915696,136111139,136326756,243214637","Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.","INTRODUCTION: Inflammatory joint destruction in rheumatoid arthritis (RA) may be triggered by autoantibodies, the production of which is supported by autoreactive T cells. Studies on RA and animal models of the disease suggest that T cells recruited in the joints can locally initiate or propagate arthritis. Herein, we investigated the role of joint-homing versus lymphoid organ-homing T cells in the development of proteoglycan-induced arthritis (PGIA), an autoimmune model of RA. METHODS: To identify T cells ",Arthritis research & therapy,"Adrienn Angyal, Colt Egelston, Tamás Kobezda, Katalin Olasz, Anna László, Tibor T Glant, Katalin Mikecz"," Section of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA.",2010 Jan;12(2):R44,10.1186/ar2954
20299465,20100601,article,"xref,mesh","Adolescent,Animals,CD4-Positive T-Lymphocytes,Child,DNA-Binding Proteins,Diabetes Mellitus,Diabetes Mellitus, Type 1,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Islets of Langerhans,Lymphocytes,Mice,Mice, Inbred NOD,Mice, Knockout,Propylene Glycols,Sphingosine,T-Lymphocytes,Young Adult","analogs &amp; derivatives,deficiency,drug effects,immunology,physiology,prevention &amp; control,therapeutic use","D003922 Q000276 NN,D015496 Q000276 NN,D013601 Q000276 NN,D003920 Q000517 NY,D015496 Q000187 NN,D007515 Q000276 NY,D013110 Q000031 NY,D007166 Q000627 NY,D008214 Q000276 NN,D013110 Q000627 NN,D008214 Q000187 NN,D011409 Q000627 NY,D013601 Q000187 NN,D013110 Q000502 NN,D004268 Q000172 NN","180,5793,8252,31270,105065,107969,107970,5280335,53658517","127449181,127669892,128394615,129060975,129621433,129645792,136111139",Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.,"OBJECTIVE: The nonobese diabetic (NOD) mouse is a well-established mouse model of spontaneous type 1 diabetes, which is characterized by an autoimmune destruction of the insulin-secreting pancreatic beta-cells. In this study, we address the role of tertiary lymphoid organs (TLOs) that form in the pancreas of NOD mice during disease progression. METHODS: We developed a model designed to ""lock"" lymphocytes in the pancreatic lymph node (PLN) and pancreas by the use of FTY720, which blocks the exit of lymphocyt",Diabetes,"Cristina Penaranda, Qizhi Tang, Nancy H Ruddle, Jeffrey A Bluestone"," Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California, USA.",2010 Jun;59(6):1461-8,10.2337/db09-1129
20304195,20100301,article,"xref,mesh","Animals,Cell Count,Fingolimod Hydrochloride,Flow Cytometry,Graft Survival,Immunosuppressive Agents,Leukocyte Count,Leukocytes,Male,Mice,Mice, Inbred BALB C,Models, Animal,Phenotype,Propylene Glycols,Sirolimus,Skin,Skin Transplantation,Sphingosine,Transplantation, Homologous","analogs &amp; derivatives,cytology,immunology,physiology,therapeutic use","D016038 Q000276 NY,D013110 Q000031 NY,D012867 Q000166 NN,D007166 Q000627 NY,D006085 Q000276 NN,D020123 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D007962 Q000502 NN,D007962 Q000166 NN","8252,31270,107969,107970,5280335,5284616,91534498","128394615,129060975,129645792,248766214",Cell phenotype evaluation at various sites after skin transplantation and FTY720 plus sirolimus therapy.,"Cell phenotype evaluation enables better understanding of the rejection process in experimental transplantation. We studied allograft survival and the mechanisms associated with rejection in a murine model of skin transplantation in the absence of immunosuppression or after FTY720 or sirolimus (SRL) administration for 21 days. Leukocyte phenotype was evaluated in the peripheral blood, spleen, axillary lymph nodes, thymus gland, and skin graft using flow cytometry at 5 days posttransplantation. Treatment wit",Transplantation proceedings,"C T Lopes, F C P Rosin, J A Cordeiro, V Bueno"," Nephrology Division, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.",2010 Mar;42(2):573-7,10.1016/j.transproceed.2010.01.027
20304196,20100301,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Fingolimod Hydrochloride,Flow Cytometry,Hindlimb,Immunosuppressive Agents,Leishmania mexicana,Leishmaniasis, Cutaneous,Lymphocyte Count,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,drug effects,immunology,pathology,pharmacology","D007166 Q000494 NY,D013154 Q000187 NN,D006614 Q000187 NN,D015496 Q000187 NN,D006614 Q000473 NN,D013110 Q000031 NY,D011409 Q000494 NY,D015496 Q000276 NY,D013154 Q000473 NN,D013110 Q000494 NN,D016773 Q000473 NN,D016773 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Leishmania (Leishmania) amazonensis infection in mice treated with FTY720.,"In transplantation, parasite diseases are transmitted from the donor, or appear as de novo infections, or activate from a dormant insource as a consequence of immunosuppression. Clinical findings have shown that an intact immune system is crucial to prevent recurrence of Leishmania infection. We used BALB/c and C57BL/6 mice to evaluate the role of FTY720 in leishmaniasis. Mice inoculated with Leishmania (Leishmania) amazonensis were followed over 7 weeks for foot thickness measurements after initiation of F",Transplantation proceedings,"C T Lopes, D M B de Paula, P M Cury, V B Valero-Lapchik, V Bueno"," Nephrology Division, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.",2010 Mar;42(2):578-81,10.1016/j.transproceed.2010.01.026
20304197,20100301,article,"xref,mesh","Animals,Creatinine,Diuresis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney,Kidney Transplantation,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Proteinuria,Sirolimus,Sphingosine","adverse effects,analogs &amp; derivatives,blood,drug effects,immunology,pathology,pharmacology,therapeutic use,urine","D007166 Q000494 NY,D016030 Q000276 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007668 Q000187 NN,D007166 Q000627 NN,D007668 Q000473 NN,D004231 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D003404 Q000652 NN,D003404 Q000097 NY,D020123 Q000494 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D020123 Q000627 NN","588,1176,8252,31270,107969,107970,5280335,5284616,91534498","127719861,128394615,129060975,129645792,129735276,248766214",Sirolimus in combination with FTY720: analysis of urinary and serum parameters.,The goal in transplantation is to obtain immunosuppressant combinations that decrease the incidence of acute and chronic rejection but cause fewer side effects. FTY720 is a new immunomodulator that prevents experimental allograft rejection without inhibiting T-cell activation. It is currently under clinical investigation for multiple sclerosis. We investigated whether FTY720 in combination with sirolimus (SRL) could cause renal toxicity in C57BL/6 mice when administered for 21 days. Serum creatinine and 24-,Transplantation proceedings,"C T Lopes, T M F Pletiskaitz, M F de Franco, J A Cordeiro, V Bueno"," Nephrology Division, Department of Medicine, São Paulo, Brazil.",2010 Mar;42(2):582-4,10.1016/j.transproceed.2010.01.025
20367536,20100501,review,"xref,mesh","Administration, Oral,Animals,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Randomized Controlled Trials as Topic,Receptors, Lysosphingolipid,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D020529 Q000503 NN,D004681 Q000188 NN,D007166 Q000627 NY,D049349 Q000187 NN,D020529 Q000188 NY,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod for relapsing multiple sclerosis: an update.,"IMPORTANCE OF THE FIELD: Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the CNS. There is a large unmet need for new disease-modifying therapies with improved convenience, safety and efficacy. Fingolimod is an oral sphingosine-1-phosphase (S1P) receptor modulator under clinical investigation for the treatment of relapsing-remitting and primary progressive MS. AREAS COVERED IN THIS REVIEW: This review provides an update on the mechanism of action, pharmacological properties ",Expert opinion on pharmacotherapy,"Alejandro Horga, Joaquín Castilló, Xavier Montalban"," Multiple Sclerosis Centre of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain. ahorga@cem-cat.org",2010 May;11(7):1183-96,10.1517/14656561003769866
20395429,20100601,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunomodulation,Immunosuppressive Agents,Multiple Sclerosis,Neurons,Oligodendroglia,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,metabolism,pharmacology,therapeutic use","D007166 Q000494 YN,D007166 Q000627 YN,D013110 Q000031 NY,D009836 Q000378 NN,D011409 Q000494 YN,D009474 Q000378 NN,D009103 Q000276 NN,D011409 Q000627 YN,D013110 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NY,D049349 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.,This commentary discusses the non-immune effects of fingolimod on neuroimmunological diseases. ,The American journal of pathology,"Aiden Haghikia, Ralf Gold"," Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstrasse 56, D-44791 Bochum, Germany.",2010 Jun;176(6):2599-601,10.2353/ajpath.2010.100200
20403428,20100901,article,"xref,mesh","14-3-3 Proteins,Animals,Apoptosis,COS Cells,Caspases,Cell Survival,Cercopithecus aethiops,Fingolimod Hydrochloride,Humans,Jurkat Cells,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Isoforms,Protein Kinase C-delta,Sphingosine","analogs &amp; derivatives,metabolism,pharmacology","D017853 Q000378 NN,D013110 Q000378 NY,D051745 Q000378 NN,D013110 Q000031 NN,D048948 Q000378 NY,D020169 Q000378 NN,D020033 Q000378 NN,D011409 Q000494 NN,D013110 Q000494 NN,D011409 Q000378 NN","4285,8252,31270,107969,107970,5280335,5282309,6438166","128394615,129060975,129645792,129839329",Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function.,"The dimeric 14-3-3 protein family protects cells from apoptosis by regulating pro-apoptotic molecules. Conversely, the cationic lipid sphingosine is associated with physiological apoptosis and induces apoptosis in its own right by a largely undefined mechanism. We show here that sphingosine and 14-3-3 interact directly in the control of cell death. The binding of sphingosine to 14-3-3 proteins renders them phosphorylatable at the dimer interface, an event that abolishes the pro-survival signalling of 14-3-3",Cellular signalling,"Joanna M Woodcock, Yuefang Ma, Carl Coolen, Duyen Pham, Claire Jones, Angel F Lopez, Stuart M Pitson"," Division of Human Immunology, Centre for Cancer Biology, SA Pathology, Adelaide, SA 5000, Australia. Joanna.Woodcock@health.sa.gov.au",2010 Sep;22(9):1291-9,10.1016/j.cellsig.2010.04.004
20413685,20100601,article,"xref,mesh","Animals,Animals, Newborn,Astrocytes,Cerebellum,Demyelinating Diseases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophosphatidylcholines,Mice,Microglia,Multiple Sclerosis,Myelin Sheath,Oligodendroglia,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Stem Cells,Tissue Culture Techniques","analogs &amp; derivatives,chemically induced,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology,physiology,physiopathology,therapeutic use,toxicity","D007166 Q000494 NY,D007166 Q000627 NN,D009103 Q000503 NN,D017628 Q000187 NN,D003711 Q000139 NN,D002531 Q000473 NN,D013110 Q000031 NY,D008244 Q000633 NN,D001253 Q000187 NN,D002531 Q000187 NY,D013234 Q000187 NN,D002531 Q000166 NY,D009836 Q000378 NN,D001253 Q000166 NN,D011409 Q000494 YN,D017628 Q000166 NN,D009186 Q000502 NY,D009836 Q000166 NN,D002531 Q000502 NN,D011409 Q000627 YN,D013110 Q000627 NN,D013234 Q000378 NN,D013110 Q000494 NN,D009836 Q000187 NN,D009103 Q000188 NN,D003711 Q000188 NY,D013234 Q000166 NN","8252,31270,107969,107970,5280335,5311264","128394615,129060975,129645792",Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.,"Remyelination, which occurs subsequent to demyelination, contributes to functional recovery and is mediated by oligodendrocyte progenitor cells (OPCs) that have differentiated into myelinating cells. Therapeutics that impact remyelination in the CNS could be critical determinants of long-term functional outcome in multiple sclerosis (MS). Fingolimod is a S1P receptor modulator in MS clinical trials due to systemic anti-inflammatory properties, yet may impact cells within the CNS by crossing the blood-brain ",The American journal of pathology,"Veronique E Miron, Samuel K Ludwin, Peter J Darlington, Andrew A Jarjour, Betty Soliven, Timothy E Kennedy, Jack P Antel"," Neuroimmunology Unit, McGill University, Montreal Neurological Institute, 3801 University St., Montreal, QC, Canada, H3A 2B4.",2010 Jun;176(6):2682-94,10.2353/ajpath.2010.091234
20421177,20100801,article,"xref,mesh","Administration, Oral,Animals,Arthritis, Rheumatoid,CD4-Positive T-Lymphocytes,Cell Line,Cytokines,Dinoprostone,Disease Models, Animal,Female,Fingolimod Hydrochloride,Glucans,Humans,Immunosuppressive Agents,Interleukin-4,Mice,Mice, Inbred Strains,Polysaccharides,Propylene Glycols,Specific Pathogen-Free Organisms,Sphingosine,Spleen,Thymus Gland","administration &amp; dosage,analogs &amp; derivatives,biosynthesis,cytology,drug effects,drug therapy,immunology,metabolism,therapeutic use","D016207 Q000187 NN,D007166 Q000008 NN,D015496 Q000276 NN,D013950 Q000166 NN,D016207 Q000378 NN,D015847 Q000096 NN,D013110 Q000008 NN,D013154 Q000166 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D015232 Q000096 NN,D001172 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D015232 Q000378 NN","8252,9691,31270,107969,107970,439306,455149,5280335,5280360,46173707","128394615,129060975,129645792,129679141",Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model.,We investigated the effects and mechanisms by which FTY720 (FTY) inhibits arthritis development in the SKG mouse rheumatoid arthritis (RA) model. FTY (1mg/kg/day) administration suppressed the progression of laminarin-induced arthritis in SKG mice. FTY treatment decreased IL-6 and TNF-alpha expression in synovial fibroblast cells and the number of inflammatory cells overall. Bone destruction was also suppressed by treatment with FTY. The numbers of CD4(+) and CD8(+) T cells were significantly increased in t,"Clinical immunology (Orlando, Fla.)","Sachi Tsunemi, Tsuyoshi Iwasaki, Sachie Kitano, Takehito Imado, Keiji Miyazawa, Hajime Sano"," Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.",2010 Aug;136(2):197-204,10.1016/j.clim.2010.03.428
20429402,20100401,review,"xref,mesh","Cladribine,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,diagnosis,drug therapy,pathology,therapeutic use","D009103 Q000473 NN,D017338 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000175 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","1727,8252,20279,31270,107969,107970,5280335","128394615,128756319,128966217,129060975,129645792","[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].","Orally disposable drugs for the treatment of multiple sclerosis have been research topics for long-term. Actually there are several drugs in clinical trial. Their mode of action differs among themselves and from established therapeutic agents. While cladribine acts as an antimetabolite and reduces lymphocytopoiesis, fingolimod influences circulation of lymphocytes. Fampridine alleviates symptoms by blocking potassium-channels. These and other drugs which are currently examined for oral administration are pr",Medizinische Monatsschrift fur Pharmazeuten,Birgit Hecht, bhecht@wissenschaftliche-verlagsgesellschaft.de,2010 Apr;33(4):?,NULL
20432416,20100611,article,xref,NULL,NULL,NULL,"6378,90848851","127905148,127983601,243784536",The immobilization of glycidyl-group-containing ionic liquids and its application in CO2 cycloaddition reactions.,"Covalent immobilization of glycidyl-group-containing ionic liquids (ILs) on organic and inorganic supports with functional surfaces was achieved, based on the fact that the glycidyl group can actively react with almost all nucleophilic, electrophilic, neutral, and free-radical species. By using polymer spheres with amino- and carboxyl-group-functionalized surfaces as organic supports and silicas (including SBA15 and silica gel) with amino groups attached as inorganic supports, the ionic liquid 1-glycidyl-bu","Chemistry (Weinheim an der Bergstrasse, Germany)","Yun Xie, Kunlun Ding, Zhimin Liu, Jianjun Li, Guimin An, Ranting Tao, Zhenyu Sun, Zhenzhong Yang"," Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, No.2, Zhongguancun Beiyijie, Beijing 100190, China.",2010 Jun;16(22):6687-92,10.1002/chem.201000020
20439540,20100510,article,mesh,"Animals,Bone Marrow Transplantation,Cognition Disorders,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-4,Learning,Lymphocyte Depletion,Meninges,Mice,Mice, Inbred BALB C,Mice, Knockout,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,deficiency,drug effects,genetics,immunology,pharmacology,physiology","D003072 Q000235 NN,D015847 Q000502 NY,D013601 Q000276 NN,D008578 Q000187 NN,D007858 Q000187 NN,D013110 Q000031 NN,D007858 Q000502 NY,D015847 Q000172 NN,D015847 Q000235 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D008578 Q000276 NN","107969,107970,5280335",NULL,Regulation of learning and memory by meningeal immunity: a key role for IL-4.,"Proinflammatory cytokines have been shown to impair cognition; consequently, immune activity in the central nervous system was considered detrimental to cognitive function. Unexpectedly, however, T cells were recently shown to support learning and memory, though the underlying mechanism was unclear. We show that one of the steps in the cascade of T cell-based support of learning and memory takes place in the meningeal spaces. Performance of cognitive tasks led to accumulation of IL-4-producing T cells in th",The Journal of experimental medicine,"Noël C Derecki, Amber N Cardani, Chun Hui Yang, Kayla M Quinnies, Anastasia Crihfield, Kevin R Lynch, Jonathan Kipnis"," Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.",2010 May;207(5):1067-80,10.1084/jem.20091419
20445188,20100506,article,"xref,mesh","Cladribine,Ethics, Research,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Informed Consent,Multiple Sclerosis, Relapsing-Remitting,Placebos,Propylene Glycols,Research Design,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000627 NN,D013110 Q000031 NN,D020529 Q000188 NY,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D010919 Q000627 NN","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Oral cladribine and fingolimod for relapsing multiple sclerosis.,NULL,The New England journal of medicine,Howard Mann,NULL,2010 May;362(18):?,10.1056/nejmc1002550
20500147,20100901,review,"xref,mesh","Adjuvants, Immunologic,Administration, Oral,Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Neoplasm,Antineoplastic Agents,Cladribine,Disease Progression,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000008 NN,D000911 Q000008 NN,D000276 Q000627 NY,D013110 Q000008 NN,D000911 Q000627 NN,D011409 Q000008 NN,D000912 Q000627 NN,D013110 Q000031 NN,D000970 Q000627 NY,D007166 Q000627 NY,D017338 Q000008 NN,D000912 Q000008 NN,D000276 Q000008 NN,D020529 Q000188 NY,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D000970 Q000008 NN","723,4212,6057,8252,20279,31270,107969,107970,5280335,23500906,54677946","127968532,128394615,128397534,128672523,128865459,128966217,129060975,129547888,129645792",Emerging therapies in relapsing-remitting multiple sclerosis.,Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the moderately effective injectable agents interferon (IFN)-beta and glatiramer acetate (GA). The subsequent licensure of mitoxantrone (MX) and natalizumab (NZ) has allowed for better control of refractory disease at the expense of potentially life-threatening side effects in a minority of patients. This dichotomy between DMT potency and safety also characterizes,Reviews on recent clinical trials,"James J Marriott, Paul W O'Connor"," The MS Clinic, St. Michael's Hospital, Division of Neurology, University of Toronto, Toronto ON, Canada. marriottj@smh.toronto.on.ca",2010 Sep;5(3):179-88,10.2174/157488710792007275
20501676,20100801,article,"xref,mesh","Animals,CD8 Antigens,Cytokines,Diabetes Mellitus, Experimental,Diabetes Mellitus, Type 1,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immune System,Immunomodulation,Immunosuppressive Agents,Lymph Nodes,Lymphocyte Activation,Male,Pancreas,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,drug effects,genetics,immunology,metabolism,pathology,prevention &amp; control,therapeutic use","D003921 Q000517 NY,D007107 Q000187 NY,D007107 Q000276 NN,D003922 Q000473 NN,D003921 Q000473 NN,D007166 Q000627 NN,D016827 Q000378 NN,D003922 Q000378 NN,D016207 Q000378 NN,D003921 Q000276 NY,D008198 Q000276 NN,D013110 Q000031 NY,D010179 Q000187 NN,D016207 Q000235 NN,D010179 Q000473 NN,D003922 Q000517 NY,D008213 Q000187 NN,D003922 Q000276 NY,D003921 Q000378 NN,D008213 Q000235 NN,D005786 Q000187 NN,D008198 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY,D008198 Q000473 NN,D010179 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation.,"The prevention of diabetes by the immunomodulatory agent FTY720 (fingolimod) was studied in the LEW.1AR1-iddm (IDDM) rat, an animal model of human type 1 diabetes. Immune cell subtypes and cytokine profiles in pancreatic islets, secondary lymphoid tissue, and serum were analyzed for signs of immune cell activation. Animals were treated with FTY720 (1 mg/kg body weight) for 40 d starting on d 50 of life. Changes in gene and protein expression of cytokines, CD8 markers, monocyte chemoattractant protein-1, ind",Endocrinology,"Anne Jörns, Klaus Jan Rath, Taivankhuu Terbish, Tanja Arndt, Andreas Meyer Zu Vilsendorf, Dirk Wedekind, Hans-Jürgen Hedrich, Sigurd Lenzen"," Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany. joerns.anne@mh-hannover.de",2010 Aug;151(8):3555-65,10.1210/en.2010-0202
20502006,20100101,review,"xref,mesh","Apoptosis,Extracellular Signal-Regulated MAP Kinases,Fibroblasts,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intracellular Signaling Peptides and Proteins,Membrane Potential, Mitochondrial,Organophosphates,Phosphorylation,Propylene Glycols,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins c-akt,Proto-Oncogene Proteins c-bcl-2,Receptors, Lysosphingolipid,Sphingosine,TOR Serine-Threonine Kinases","analogs &amp; derivatives,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D049349 Q000378 NY,D017209 Q000187 NY,D013110 Q000031 NY,D005347 Q000378 NY,D011409 Q000494 NY,D019253 Q000378 NY,D048049 Q000378 NN,D017346 Q000378 NN,D047908 Q000378 NN,D010755 Q000494 NY,D053078 Q000187 NN,D051057 Q000378 NN,D013110 Q000494 NN","8252,31270,105065,107969,107970,5280335,9908268,11452022,45268446,53903450","128132375,128394615,129060975,129645792,136111139",Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.,"BACKGROUND: FTY720, a synthetic compound produced by modification of a metabolite from Isaria sinclairii, is known as a unique immunosuppressive agent that exerts its activity by inhibiting lymphocyte egress from secondary lymphoid tissues. FTY720 is phosphorylated in vivo by sphingosine kinase 2 to FTY720-phosphate (FTY720-P), which acts as a potent sphingosine-1-phosphate (S1P) receptor agonist. Despite its homology to S1P, which exerts antiapoptotic actions in different cells, FTY720 has also been report","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","Henrik Potteck, Barbara Nieuwenhuis, Anja Lüth, Markus van der Giet, Burkhard Kleuser"," Faculty of Mathematics and Natural Science, Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.",2010 Jan;26(1):67-78,10.1159/000315107
20502007,20100101,review,"xref,mesh","Autoimmune Diseases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,immunology,metabolism,therapeutic use,therapy","D049349 Q000378 NY,D049349 Q000819 NN,D007166 Q000627 NN,D008214 Q000378 NN,D007166 Q000378 NN,D013110 Q000031 NY,D013110 Q000378 NN,D001327 Q000628 NN,D008246 Q000378 NY,D008214 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D049349 Q000037 NN,D011409 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions.,"Sphingosine 1-phosphate (S1P) is an important regulator of many different immune functions including lymphocyte circulation, antigen presentation, and T cell development. It stimulates five G protein-coupled receptors designated S1P(1-5), which are also expressed by immune cells. S1P receptors couple to different heterotrimeric G proteins including G alpha i, q, and 12/13, and elicit cellular signalling events by activating the small GTPases Rac and Rho and protein kinases Akt, ERK, and JNK, and by inducing","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",Markus H Gräler," Institute for Immunology, Hannover Medical School, Hannover, Germany. graeler.markus@mh-hannover.de",2010 Jan;26(1):79-86,10.1159/000315108
20506484,20100901,article,"xref,mesh","Animals,Antineoplastic Agents,Apoptosis,Cell Cycle Proteins,Cell Line, Tumor,Cell Proliferation,Cisplatin,Fingolimod Hydrochloride,G1 Phase,Humans,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Nude,Neoplasm Transplantation,PTEN Phosphohydrolase,Phosphatidylinositol 3-Kinases,Propylene Glycols,Proto-Oncogene Proteins c-akt,Proto-Oncogene Proteins c-mdm2,RNA, Small Interfering,Signal Transduction,Sphingosine,Stomach Neoplasms,Tumor Suppressor Protein p53","analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,physiopathology,therapeutic use","D051059 Q000235 NN,D013274 Q000503 YN,D018797 Q000378 NN,D007166 Q000494 YN,D016159 Q000378 NY,D017209 Q000187 NY,D019869 Q000378 NN,D013274 Q000473 YN,D000970 Q000494 NN,D051736 Q000378 NN,D013274 Q000188 YN,D007166 Q000627 YN,D002945 Q000627 NN,D049109 Q000187 NN,D002945 Q000494 NN,D013110 Q000031 NY,D000970 Q000627 NN,D034741 Q000235 NN,D016159 Q000235 NN,D051059 Q000378 NY,D016193 Q000187 NY,D011409 Q000494 YN,D051057 Q000378 NN,D011409 Q000627 YN,D013110 Q000627 NN,D015398 Q000187 NN,D013110 Q000494 NN","8252,31270,84691,107969,107970,441203,5280335","128394615,129060975,129645792",PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.,"FTY720, a new immunosuppressant, derived from ISP-1, has been studied for its putative anti-cancer properties in the recent years. In this study, we have reported that FTY720 greatly inhibited gastric cancer cell proliferation for the first time, and found this effect was associated with G1 phase cell cycle arrest and apoptosis. Results from our Western blotting and Real-time PCR showed that FTY720 induced obvious PTEN expression in a p53-independent way, consistent with a substantial decrease in p-Akt and ",Journal of cellular biochemistry,"Tongsen Zheng, Xianzhi Meng, Jiabei Wang, Xi Chen, Dalong Yin, Yingjian Liang, Xuan Song, Shangha Pan, Hongchi Jiang, Lianxin Liu"," Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China. zhengtongsen@hotmail.com",2010 Sep;111(1):218-28,10.1002/jcb.22691
20517533,20100501,review,"xref,mesh","Administration, Oral,Animals,Clinical Trials as Topic,Drug Interactions,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Ketoconazole,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,physiopathology,therapeutic use","D013110 Q000009 NN,D011409 Q000009 NN,D013110 Q000031 NY,D020529 Q000503 NN,D049349 Q000187 NN,D007166 Q000627 NY,D007654 Q000494 NN,D020529 Q000188 NY,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D049349 Q000378 NN","3823,8252,31270,47576,105065,107969,107970,456201,5280335,5702077,16757695","128394615,129060975,129645792,129708236,136111139",Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.,"The sphingosine-1-phosphate receptor modulator fingolimod (FTY-720), which acts by preventing lymphocyte egress from lymph nodes thus reducing lymphocyte infiltration into the central nervous system (CNS), represents a novel therapeutic modality for the treatment of multiple sclerosis (MS). Results obtained from preclinical studies have also attributed a potential neuroprotective and reparative function to the agent within the CNS. Clinical evaluation in placebo-controlled trials in healthy individuals and ","Drugs of today (Barcelona, Spain : 1998)",S Vasiliou," Thomson Reuters, Barcelona, Spain. sylvia.vasiliou@thomsonreuters.com",2010 May;46(5):315-25,10.1358/dot.2010.46.5.1497556
20537703,20100801,article,"xref,mesh","Animals,Biocompatible Materials,Cell Death,Cell Line,Cross-Linking Reagents,DNA,Disulfides,Gene Transfer Techniques,Humans,Mice,Neoplasms,Organ Specificity,Particle Size,Peptides, Cyclic,Plasmids,Polyethylene Glycols,Polyethyleneimine,Transfection,Viruses","chemical synthesis,chemistry,drug effects,genetics,metabolism,pharmacology","D001672 Q000737 NY,D011094 Q000737 NY,D011092 Q000138 NN,D009928 Q000187 NN,D003432 Q000737 NN,D011092 Q000737 NY,D011094 Q000138 NN,D016923 Q000187 NN,D010456 Q000737 NY,D004220 Q000378 NY,D004247 Q000235 NN,D010957 Q000235 NN,D003432 Q000494 NN,D010456 Q000138 NN,D014780 Q000235 NN,D009369 Q000378 NY","9033,14072,44135672,53835817","127946759,128572009,128733350",Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier.,"The work demonstrated development of multifunctional gene carrier which has incorporated reducible moiety, tumor targeting ligands as well as PEG to achieve efficient release of pDNA, enhanced tumor-specificity and long circulation, respectively. In our successful one-pot synthesis of multifunctional polymer, low molecular weight branched polyethylenimine (BPEI) was thiolated with propylene sulfide, and mixed with alpha-Maleimide-omega-N-hydroxysuccinimide ester polyethylene glycol (MAL-PEG-NHS, MW: 5000), ",Biomaterials,"Sejin Son, Kaushik Singha, Won Jong Kim"," Department of Chemistry, BK21 program, Polymer Research Institute, Pohang University of Science and Technology (POSTECH), San 31, Hyoja-dong, Nam-Gu, Pohang 790-784, Republic of Korea.",2010 Aug;31(24):6344-54,10.1016/j.biomaterials.2010.04.047
20551946,20100701,review,"xref,mesh","Animals,Cell Movement,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Mice,Multiple Sclerosis,Nerve Regeneration,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,immunology,physiology,therapeutic use","D049349 Q000037 NY,D011409 Q000009 NN,D013110 Q000009 NN,D002465 Q000187 NN,D008214 Q000502 NN,D013110 Q000031 NY,D009416 Q000187 NN,D007166 Q000627 NY,D009103 Q000276 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY,D049349 Q000502 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Fingolimod is a potential novel therapy for multiple sclerosis.,"Fingolimod (also known as FTY720) is an orally available sphingosine-1-phosphate (S1P) receptor modulator that has unique and potent immunoregulatory properties. Mechanistic studies indicate that on phosphorylation fingolimod can bind with high affinity to S1P(1) receptors. Persistent modulation of lymphocyte S1P(1) receptors by fingolimod and the subsequent internalization of these receptors inhibits lymphocyte egress from the lymph nodes, and prevents these cells from infiltrating inflammatory lesions in ",Nature reviews. Neurology,"Orhan Aktas, Patrick Küry, Bernd Kieseier, Hans-Peter Hartung"," Department of Neurology, Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany.",2010 Jul;6(7):373-82,10.1038/nrneurol.2010.76
20572362,20100602,article,"xref,mesh","Cladribine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Prognosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D017338 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",[Emerging treatments for multiple sclerosis].,NULL,Revue medicale suisse,Jean-Yves Nau, jeanyves.nau@gmail.com,2010 Jun;6(251):1162-3,NULL
20592255,20100803,article,"xref,mesh","Adult,CD3 Complex,CD4 Antigens,Case-Control Studies,Clinical Trials, Phase II as Topic,Clinical Trials, Phase III as Topic,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunologic Memory,Immunosuppressive Agents,Interferon-beta,Interleukin-17,Male,Multiple Sclerosis,Propylene Glycols,Prospective Studies,Receptors, CCR4,Receptors, CCR6,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,metabolism,secretion,therapeutic use","D013601 Q000378 NN,D015704 Q000378 NN,D007166 Q000008 NN,D017252 Q000378 NN,D007155 Q000627 NN,D009103 Q000097 NN,D016899 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D020381 Q000378 NN,D009103 Q000276 NY,D007166 Q000627 NY,D013601 Q000187 NY,D007156 Q000187 NY,D013110 Q000627 NN,D054399 Q000378 NN,D011409 Q000627 NY,D009103 Q000188 NY,D054398 Q000378 NN,D020381 Q000557 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.,"OBJECTIVE: FTY720 is a sphingosine 1-phosphate (S1P) receptor modulator that showed efficacy in phase II and III clinical trials in patients with multiple sclerosis (MS). FTY720 inhibits lymphocyte egress from secondary lymphoid organs into the peripheral circulation, thereby reducing the number of circulating naïve and central memory T cells, but not effector memory T cells in blood. Little is known to which of these memory T-cell subsets interleukin 17 (IL-17)-producing T cells (Th17 cells) belong, which ",Neurology,"M Mehling, R Lindberg, F Raulf, J Kuhle, C Hess, L Kappos, V Brinkmann"," Department of Neurology, University Hospitals Basel, Petersgraben 4, CH-4031 Basel, Switzerland.",2010 Aug;75(5):403-10,10.1212/wnl.0b013e3181ebdd64
20599429,20101001,article,"xref,mesh","Adult,CD8-Positive T-Lymphocytes,Chemical and Drug Induced Liver Injury,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Lymph Nodes,Lymphocyte Count,Lymphocytes,Lymphopenia,Mediastinum,Middle Aged,Multiple Sclerosis,Patient Dropouts,Propylene Glycols,Receptors, CCR7,Sphingosine,Withholding Treatment","adverse effects,analogs &amp; derivatives,anatomy &amp; histology,blood,chemically induced,cytology,drug effects,drug therapy,immunology,metabolism,pharmacology,therapeutic use","D054400 Q000378 NN,D013110 Q000009 NN,D011409 Q000009 NN,D018414 Q000378 NN,D007166 Q000627 NN,D008214 Q000166 NY,D008231 Q000139 NN,D013110 Q000031 NY,D008482 Q000033 NN,D011409 Q000494 NY,D018414 Q000166 NN,D056486 Q000097 NN,D008198 Q000166 NN,D009103 Q000276 NN,D013110 Q000627 NN,D013110 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.,"FTY720 (Fingolimod) reduces multiple sclerosis disease activity by inducing lymphopenia and inhibiting lymphocyte re-entry from lymph nodes. Peripheral lymphocyte reconstitution following drug discontinuation has been considered relatively rapid (2-4 weeks), based on short-term studies. We investigated the kinetics of lymphocyte reconstitution in MS patients in open label extension phases of FTY720 clinical trials who discontinued therapy after prolonged use (>1-5 years), and examined histological features ","Clinical immunology (Orlando, Fla.)","Trina A Johnson, Igor Shames, Mark Keezer, Yves Lapierre, David G Haegert, Amit Bar-Or, Jack Antel"," Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.",2010 Oct;137(1):15-20,10.1016/j.clim.2010.06.005
20610831,20100803,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,immunology,physiopathology,therapeutic use","D007166 Q000008 NN,D013601 Q000276 NN,D009103 Q000503 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D016176 Q000187 NN,D007166 Q000627 NY,D013601 Q000187 NY,D009103 Q000276 NN,D013110 Q000627 NN,D016176 Q000276 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","FTY720 and central memory: out of sight, out of mind.",NULL,Neurology,"Anthony J Slavin, Scott S Zamvil",NULL,2010 Aug;75(5):388-9,10.1212/wnl.0b013e3181eee298
20621764,20100901,article,"xref,mesh","Animals,Bone Remodeling,Bone Transplantation,Bone and Bones,Coated Materials, Biocompatible,Compressive Strength,Elastic Modulus,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Neovascularization, Physiologic,Osseointegration,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,Tissue Engineering,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,chemistry,drug effects,metabolism,physiology,therapeutic use,ultrastructure","D001842 Q000648 NN,D049349 Q000378 NY,D016025 Q000502 NY,D007166 Q000627 NN,D013110 Q000008 NN,D020099 Q000737 NN,D013110 Q000031 NY,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000008 NY,D001842 Q000187 NN,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720.,"Poor vascularization coupled with mechanical instability is the leading cause of post-operative complications and poor functional prognosis of massive bone allografts. To address this limitation, we designed a novel continuous polymer coating system to provide sustained localized delivery of pharmacological agent, FTY720, a selective agonist for sphingosine 1-phosphate receptors, within massive tibial defects. In vitro drug release studies validated 64% loading efficiency with complete release of compound f",Biomaterials,"Caren E Petrie Aronin, Soo J Shin, Kimberly B Naden, Peter D Rios, Lauren S Sefcik, Sarah R Zawodny, Namory D Bagayoko, Quanjun Cui, Yusuf Khan, Edward A Botchwey"," Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.",2010 Sep;31(25):6417-24,10.1016/j.biomaterials.2010.04.061
20648639,20100901,article,"xref,mesh","Adult,Aged,Aged, 80 and over,Astrocytes,Brain,Cells, Cultured,Chemokines,Enzyme-Linked Immunosorbent Assay,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes,Up-Regulation","analogs &amp; derivatives,cytology,drug effects,genetics,metabolism,methods,pharmacology,physiology,physiopathology","D013601 Q000378 NN,D049349 Q000378 NY,D015854 Q000187 NN,D004797 Q000379 NN,D049349 Q000235 NN,D009103 Q000503 NY,D013110 Q000031 NN,D015854 Q000502 NY,D011409 Q000494 NN,D018925 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001253 Q000378 NN,D001921 Q000166 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.,"Sphingolipids are a class of biologically active lipids that have a role in multiple biological processes including inflammation. Sphingolipids exert their functions by direct signaling or through signaling by their specific receptors. Phosphorylated FTY720 (FTY720P) is a sphingosine 1-phosphate (S1P) analogue that is currently in trial for treatment of multiple sclerosis (MS), which targets all S1P receptors but S1P(2). To date, however, it remains unknown whether FTY720P may exert direct anti-inflammatory",Glia,"Ruben Van Doorn, Jack Van Horssen, Dennis Verzijl, Maarten Witte, Eric Ronken, Bert Van Het Hof, Kim Lakeman, Christine D Dijkstra, Paul Van Der Valk, Arie Reijerkerk, Astrid E Alewijnse, Stephan L M Peters, Helga E De Vries"," Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands.",2010 Sep;58(12):1465-76,10.1002/glia.21021
20660615,20100802,article,"xref,mesh","Adoptive Transfer,Animals,Antigen Presentation,Antigen-Presenting Cells,CD11a Antigen,CD8-Positive T-Lymphocytes,Carcinoma, Lewis Lung,Cell Differentiation,Cell Movement,Cell Proliferation,DNA-Binding Proteins,Fingolimod Hydrochloride,Granzymes,Hyaluronan Receptors,Immunosuppressive Agents,Integrin alpha4,Interferon-gamma,Lymph Nodes,Lymphocyte Activation,Lysosome-Associated Membrane Glycoproteins,Melanoma, Experimental,Mice,Mice, Inbred C57BL,Mice, Knockout,Mice, Transgenic,Monophenol Monooxygenase,Neoplas","analogs &amp; derivatives,cytology,drug effects,genetics,immunology,metabolism,pathology,pharmacology","D017951 Q000276 NN,D000938 Q000276 NN,D004268 Q000235 NN,D014442 Q000276 NN,D018414 Q000378 NN,D002465 Q000187 NN,D009369 Q000473 NN,D007371 Q000378 NN,D010446 Q000276 NN,D018414 Q000276 NY,D002465 Q000276 NY,D002454 Q000276 NY,D053804 Q000378 NN,D051907 Q000378 NN,D039441 Q000378 NN,D008198 Q000187 NN,D008546 Q000276 NN,D008198 Q000276 NN,D040881 Q000378 NN,D016176 Q000166 NN,D013110 Q000031 NN,D018827 Q000276 NN,D018414 Q000166 NN,D018827 Q000473 NN,D010047 Q000276 NN,D009369 Q000276 NY,D008198 Q000166 NN","8252,31270,107969,107970,5280335,5289086","128394615,129060975,129645792","Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.",Studies of T cell responses to tumors have focused on the draining lymph node (LN) as the site of activation. We examined the tumor mass as a potential site of activation after adoptive transfer of naive tumor-specific CD8 T cells. Activated CD8 T cells were present in tumors within 24 h of adoptive transfer and proliferation of these cells was also evident 4-5 d later in mice treated with FTY720 to prevent infiltration of cells activated in LNs. To confirm that activation of these T cells occurred in the t,The Journal of experimental medicine,"Elizabeth D Thompson, Hilda L Enriquez, Yang-Xin Fu, Victor H Engelhard"," Department of Microbiology and Carter Immunology Center, University of Virginia, Charlottesville, VA 22908, USA.",2010 Aug;207(8):1791-804,10.1084/jem.20092454
20662750,20100801,article,"xref,mesh","Cladribine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mesenchymal Stem Cell Transplantation,Mesenchymal Stromal Cells,Multiple Sclerosis,Neurology,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,methods,physiopathology,therapeutic use,therapy","D009462 Q000379 NY,D017338 Q000627 NY,D009103 Q000503 NN,D013110 Q000031 NY,D009103 Q000628 NY,D007166 Q000627 NY,D045164 Q000379 NN,D013110 Q000627 NN,D011409 Q000627 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Update on emerging therapies for multiple sclerosis.,"The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and treatment of Alzheimer's disease and dementia, cerebrovascular and neuromuscular disorders, as well as the rapidly changing areas of genetic testing and stem cell research. This meeting report f",Expert review of neurotherapeutics,"Eppie M Yiu, Brenda Banwell"," The Hospital for Sick Children, Toronto, Canada.",2010 Aug;10(8):1259-62,10.1586/ern.10.98
20688386,20101101,article,"xref,mesh","Acrylates,Adipogenesis,Adolescent,Adult,Cell Death,Cell Proliferation,Collagen Type I,Cross-Linking Reagents,Elastic Modulus,Elastomers,Humans,Microscopy, Electron, Scanning,Middle Aged,Multipotent Stem Cells,Osteogenesis,Polymers,Propylene Glycols,Stromal Cells,Surface Properties,Tissue Engineering,Tissue Scaffolds,Transcription Factors,Young Adult","chemistry,cytology,drug effects,metabolism,methods,pharmacology","D017154 Q000378 NN,D054457 Q000737 NN,D020724 Q000737 NN,D055119 Q000187 NY,D039902 Q000166 NN,D010012 Q000187 NN,D024042 Q000494 NN,D016923 Q000187 NN,D011409 Q000737 NN,D023822 Q000379 NY,D049109 Q000187 NN,D011409 Q000494 NY,D017154 Q000166 NN,D017154 Q000187 NN,D020724 Q000494 NY,D039902 Q000378 NN,D011108 Q000494 NY,D003432 Q000494 NN,D000179 Q000737 NN,D000179 Q000494 NY,D013499 Q000187 NN,D039902 Q000187 NN,D050156 Q000187 NN,D011108 Q000737 NN,D014157 Q000378 NN","8252,32881",129060975,A synthetic elastomer based on acrylated polypropylene glycol triol with tunable modulus for tissue engineering applications.,"As strategies for manipulating cellular behaviour in vitro and in vivo become more sophisticated, synthetic biomaterial substrates capable of reproducing critical biochemical and biophysical properties (or cues) of tissue micro-environments will be required. Cytoskeletal tension has been shown to be highly deterministic of cell fate decisions, yet few synthetic biomaterials are capable of modulating cytoskeletal tension of adhered cells through variations in stiffness, at least in the ranges applicable to t",Biomaterials,"James E Hudson, Jessica E Frith, Bogdan C Donose, Elisabeth Rondeau, Richard J Mills, Ernst J Wolvetang, Gary P Brooke, Justin J Cooper-White"," Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, St. Lucia, Queensland, Australia.",2010 Nov;31(31):7937-47,10.1016/j.biomaterials.2010.07.007
20689698,20100101,review,"xref,mesh","Administration, Oral,Animals,Cladribine,Clinical Trials as Topic,Drug Delivery Systems,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D017338 Q000009 NN,D020529 Q000503 NN,D013110 Q000031 NN,D007166 Q000627 NY,D020529 Q000188 NY,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN","176,723,1044,4212,6057,8252,13711,20279,31270,60961,107969,107970,5280335,23500906,44258291,54677946","46504588,127639621,127968532,128365023,128394615,128397534,128672523,128814610,128865459,128966217,129060975,129071275,129547888,129645792,243214637",Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.,"Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribi","Drug design, development and therapy","Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, Olaf Stüve, Bernd C Kieseier"," Department of Neurology, Heinrich-Heine University Düsseldorf, Germany.",2010 Jan;4(?):117-26,NULL
20695767,20110301,article,"xref,mesh","Adoptive Transfer,Animals,Diabetes Mellitus, Type 1,Disease Models, Animal,Fingolimod Hydrochloride,Immunomodulation,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, Inbred C57BL,Mice, Inbred NOD,Mice, SCID,Propylene Glycols,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,immunology,metabolism,prevention &amp; control,therapeutic use","D003922 Q000276 NN,D007166 Q000008 NN,D007166 Q000378 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D013110 Q000378 NN,D003922 Q000517 NY,D007166 Q000627 NY,D013601 Q000276 NY,D008246 Q000378 NN,D013110 Q000627 NN,D011409 Q000378 NN,D011409 Q000627 NY","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139","Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells.","FTY720 modulates lymphocyte trafficking through blood (peripheral blood lymphocyte, PBL) and peripheral lymph nodes (PLN). Treatment with FTY720 causes retention of most blood lymphocytes in PLN. Long-term treatment can slow and/or prevent Type 1 diabetes (T1D) in the nonobese diabetic (NOD) mouse model. B and T cells are both affected by FTY720 binding to sphingosine-1-phosphate receptor 1 (S1P₁). However, little has been done to elucidate which T-cell subsets are differentially affected by FTY720 under he",Autoimmunity,"Margaret A Morris, Marcia McDuffie, Jerry L Nadler, Klaus Ley"," Department of Biomedical Engineering and Cardiovascular Research Center, University of Virginia, P.O. Box 801394, Charlottesville, VA 22908, USA.",2011 Mar;44(2):115-28,10.3109/08916934.2010.499885
20702533,20110101,article,"xref,mesh","Acute Kidney Injury,Animals,CD4-Positive T-Lymphocytes,Dendritic Cells,Fingolimod Hydrochloride,Flow Cytometry,Forkhead Transcription Factors,Immunosuppressive Agents,Interleukin-2 Receptor alpha Subunit,Kidney,Lymphocyte Culture Test, Mixed,Lymphopenia,Lysophospholipids,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,RNA, Messenger,Reperfusion Injury,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Spleen,T-Lymphocytes, Regulatory","analogs &amp; derivatives,complications,cytology,etiology,genetics,immunology,metabolism,pathology,pharmacology","D058186 Q000209 NY,D053645 Q000378 NY,D012333 Q000235 NN,D003713 Q000473 NN,D007166 Q000494 NY,D007668 Q000166 NN,D007668 Q000378 NN,D050378 Q000276 NY,D058186 Q000378 NN,D013154 Q000166 NN,D003713 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D051858 Q000378 NN,D015496 Q000276 NY,D013154 Q000276 NN,D007668 Q000276 NN,D008231 Q000209 NN,D051858 Q000235 NN,D015427 Q000150 NY,D013154 Q000378 NN,D003713 Q000378 NN,D013110 Q000494 NN,D058186 Q000473 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139","CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury.","BACKGROUND: The synthetic sphingosine-1-phosphate (S1P) analogue, FTY720, attenuates ischaemia/reperfusion (I/R) injury by inducing peripheral lymphopaenia. Recent studies suggest that FTY720 may also exert protective effects by modulating dendritic cell (DC) function or directly affecting regulatory T cells (Tregs). The purpose of the present study was to examine whether the beneficial effect of FTY720 in I/R-induced acute kidney injury (AKI) involves modulation of DCs or Tregs. METHODS: Mice underwent bil","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Myung-Gyu Kim, So Young Lee, Yoon Sook Ko, Hee Young Lee, Sang-Kyung Jo, Won Yong Cho, Hyoung-Kyu Kim"," Division of Nephrology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.",2011 Jan;26(1):111-24,10.1093/ndt/gfq480
20802177,20101001,article,"xref,mesh","Animals,Blotting, Western,Bone Marrow,Cell Movement,Chemotaxis,Disease Models, Animal,Eosinophils,Female,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Inflammation,Interleukin-5,Lymph Nodes,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,RNA, Messenger,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Skin,Skin Diseases,Sphingosine","analogs &amp; derivatives,cytology,drug effects,etiology,genetics,immunology,metabolism,pathology,physiology,prevention &amp; control,therapeutic use","D012333 Q000235 NN,D004804 Q000187 NY,D012871 Q000517 NY,D012871 Q000209 NN,D049349 Q000235 NN,D012867 Q000187 NY,D012871 Q000473 NN,D007249 Q000517 NN,D008198 Q000187 NN,D008198 Q000276 NN,D004804 Q000166 NN,D013110 Q000031 NY,D001853 Q000378 NN,D007166 Q000627 NY,D007249 Q000209 NN,D004804 Q000378 NN,D012867 Q000276 NY,D015848 Q000502 NN,D013110 Q000627 NN,D011409 Q000627 NY,D007249 Q000473 NN,D001853 Q000187 NY,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice.,"Eosinophilia in the blood and skin is frequently observed in patients with certain inflammatory skin diseases, such as atopic dermatitis. However, the mechanism underlying eosinophil circulation and the role of eosinophils in cutaneous immune responses remain unclear. In repeated hapten application-induced cutaneous responses in BALB/c mice, the administration of FTY720 before the last challenge decreased the number of skin-infiltrating eosinophils and reduced the late-phase reaction. A similar reduction of",The American journal of pathology,"Kazunari Sugita, Kenji Kabashima, Jun-Ichi Sakabe, Ryutaro Yoshiki, Hideaki Tanizaki, Yoshiki Tokura"," Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan. k-sugita@med.uoeh-u.ac.jp",2010 Oct;177(4):1881-7,10.2353/ajpath.2010.100119
20820453,20100701,article,"xref,mesh","Activities of Daily Living,Administration, Oral,Disability Evaluation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Recovery of Function,Sphingosine,Treatment Outcome","administration &amp; dosage,adverse effects,analogs &amp; derivatives,diagnosis,drug effects,drug therapy,metabolism","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D049349 Q000187 NN,D020529 Q000188 NY,D020529 Q000378 NN,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY,D049349 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","[Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].","Fingolimod, a sphingosine 1-phosphate receptor modulator, is currently on registration as an oral treatment for relapsing-remitting multiple sclerosis in the European Union and United States of America. New and important information on the drug was presented during the annual meeting of the American Academy of Neurology held in Toronto in April 2010, including, notably, results from the TRANSFORMS and FREEDOMS studies that, besides confirming the therapeutic benefit of the drug as a first-line therapy for m","Drugs of today (Barcelona, Spain : 1998)",Xavier Rabasseda," Prous Science, Thomson Reuters, Barcelona, Spain.",2010 Jul;?(?):1-14,NULL
20822073,20100801,article,"xref,mesh","Adult,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Infusions, Parenteral,Managed Care Programs,Multiple Sclerosis,Propylene Glycols,Sphingosine,United States,United States Food and Drug Administration,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000008 NN,D007166 Q000627 NN,D013110 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D007263 Q000009 YN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Avoiding infusion therapy prime benefit of new MS drug.,NULL,"Managed care (Langhorne, Pa.)",Thomas Morrow," Genentech Inc, USA. TMorrow@ManagedCareMag.com",2010 Aug;19(8):49-50,NULL
20826007,20110101,article,"xref,mesh","Blotting, Western,Cytokines,Dendritic Cells,Enzyme-Linked Immunosorbent Assay,Fingolimod Hydrochloride,Gene Expression,Humans,Immunosuppressive Agents,Lysophospholipids,Macrophages,Microglia,Myeloid Cells,Propylene Glycols,RNA, Messenger,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine","analogs &amp; derivatives,analysis,biosynthesis,drug effects,immunology,metabolism,pharmacology","D012333 Q000032 NN,D007166 Q000494 NY,D008264 Q000276 NN,D003713 Q000187 NN,D008264 Q000378 NN,D022423 Q000378 NN,D017628 Q000276 NN,D016207 Q000096 NN,D017628 Q000378 NN,D049349 Q000276 NN,D003713 Q000276 NN,D013110 Q000031 NY,D008246 Q000276 NN,D011409 Q000494 NY,D013110 Q000378 NN,D008264 Q000187 NN,D013110 Q000276 NN,D049349 Q000187 NN,D022423 Q000276 NN,D022423 Q000187 NY,D017628 Q000187 NY,D008246 Q000378 NN,D003713 Q000378 NN,D013110 Q000494 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",Differential responses of human microglia and blood-derived myeloid cells to FTY720.,"Human microglia, monocyte-derived dendritic cells (DCs) and macrophages ex vivo express relatively higher levels of sphingosine-1-phosphate (S1P) receptor 1 (S1P1) mRNA as compared to other receptor subtypes. The S1P agonist FTY720 decreased ERK phosphorylation and induced myosin light chain (MLC) II phosphorylation only in macrophages and DCs. FTY720 inhibited IL-12p70 production (CD40L induced) by DCs and macrophages but not microglia (poly I:C induced). IL-10 production was increased in DCs and unaffecte",Journal of neuroimmunology,"Bryce A Durafourt, Caroline Lambert, Trina A Johnson, Manon Blain, Amit Bar-Or, Jack P Antel"," Neuroimmunology Unit, Montréal Neurological Institute, McGill University, Montréal, Québec, Canada.",2011 Jan;230(?):10-6,10.1016/j.jneuroim.2010.08.006
20838962,20100101,review,"xref,mesh","Alemtuzumab,Animals,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Monoclonal, Murine-Derived,Antibodies, Neoplasm,Cladribine,Crotonates,Dimethyl Fumarate,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Fumarates,Humans,Immunoglobulin G,Immunosuppressive Agents,Immunotherapy,Mice,Multiple Sclerosis,Myelin Basic Protein,Peptide Fragments,Propylene Glycols,Quinolones,Rituximab,Sphingosine,Toluidines,Vaccines, DNA","analogs &amp; derivatives,etiology,immunology,methods,therapeutic use,therapy,trends","D015363 Q000627 NN,D019444 Q000627 NN,D004681 Q000276 NN,D007166 Q000627 NN,D009103 Q000209 NN,D004681 Q000628 NN,D010446 Q000627 NN,D000911 Q000627 NN,D005650 Q000627 NN,D000912 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D007074 Q000627 NN,D009103 Q000628 NY,D007167 Q000639 NN,D004676 Q000627 NN,D007167 Q000379 NY,D014052 Q000627 NN,D017338 Q000627 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN","8252,12215,20279,31270,107969,107970,637568,3036108,4670741,5280335,23500906,44151255,54677946,70683017","127968532,128394615,128471922,128672523,128966217,129060975,129645792",Multiple sclerosis therapies: molecular mechanisms and future.,"The current treatments for multiple sclerosis (MS) are, by many measures, not satisfactory. The original interferon-β therapies were not necessarily based on an extensive knowledge of the pathophysiological mechanisms of the disease. As more and more insight has been acquired about the autoimmune mechanisms of MS and, in particular, the molecular targets involved, several treatment approaches have emerged. In this chapter, we highlight both promising preclinical approaches and therapies in late stage clinic",Results and problems in cell differentiation,"Paulo Fontoura, Hideki Garren"," Roche Pharmaceuticals, CNS Translational Medicine Group, Basel, Switzerland.",2010 Jan;51(?):259-85,10.1007/400_2010_36
20842337,20110201,review,"xref,mesh","Administration, Oral,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Prevalence,Propylene Glycols,Receptors, Lysosphingolipid,Risk Assessment,Risk Factors,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,epidemiology","D049349 Q000037 NY,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D009103 Q000453 NY,D009103 Q000188 NY,D011409 Q000008 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].,"In this article the recent clinical data on novel therapy of relapsing multiple sclerosis with oral fingolimod (FTY720), lead substance of the recently described class of sphingosine-1-phosphate (S1P) receptor modulators are reviewed. Results of the two phase III studies (FREEDOMS; TRANSFORMS) corroborating previous phase II trial observations suggest that fingolimod has a strong anti-inflammatory effect in relapsing multiple sclerosis (MS), most probably by suppression of lymphocyte re-circulation from lym",Der Nervenarzt,"O Aktas, J Ingwersen, B Kieseier, P Küry, R Hohlfeld, H-P Hartung"," Neurologische Universitätsklinik, Heinrich-Heine-Universität, Düsseldorf, Deutschland.",2011 Feb;82(2):215-25,10.1007/s00115-010-3075-8
20873946,20100901,review,"xref,mesh","4-Aminopyridine,Cladribine,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Quinolones,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D015363 Q000627 NN,D007166 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D009103 Q000188 NY,D015761 Q000627 NN","1727,8252,20279,31270,107969,107970,3036108,5280335,54677946","127968532,128394615,128756319,128966217,129060975,129645792",Emerging oral agents for multiple sclerosis.,"A variety of emerging therapies for the treatment of multiple sclerosis (MS) are currently in development or have recently been approved by the US Food and Drug Administration (FDA). These new agents offer novel mechanisms of action and potentially improved efficacy over existing first-line MS therapies. Much attention has been given to emerging therapies delivered orally which, at minimum, will likely improve long-term adherence over existing agents delivered via injection. This article reviews the mechani",The American journal of managed care,Edward J Fox," Central Texas Neurology Consultants, 16040 Park Valley Dr, Bldg B, Ste 100, Round Rock, TX 78681, USA. foxtexms@gmail.com",2010 Sep;16(?):S219-26,NULL
20920189,20100101,article,"xref,mesh","Animals,Cells, Cultured,Disease Progression,Gene Expression Regulation, Enzymologic,Lipopolysaccharides,Matrix Metalloproteinase Inhibitors,Matrix Metalloproteinases,Mice,Mice, Inbred C57BL,Pancreatic Elastase,Pulmonary Disease, Chronic Obstructive,Quercetin,Swine","biosynthesis,chemically induced,drug effects,enzymology,pharmacology,prevention &amp; control,therapeutic use,toxicity","D020782 Q000096 NY,D029424 Q000517 NY,D011794 Q000494 NN,D011794 Q000627 NY,D010196 Q000633 NY,D015971 Q000187 NN,D008070 Q000633 NY,D029424 Q000201 NY,D029424 Q000139 NN","679,738,996,2153,2889,5056,6049,6057,6503,8252,12035,44259,65124,124886,312145,1268265,5280343,5280445,5281672,44259136,53903450","127823549,128074998,128132375,128141778,128181033,128206177,128215673,128364298,128477989,128542940,128865459,128977994,129006930,129060975,129116523,129192846,129287822,129467351,129888769,129896981,135897353,136137642,248319850",Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression.,"BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis, emphysema and irreversible airflow limitation. These changes are thought to be due to oxidative stress and an imbalance of proteases and antiproteases. Quercetin, a plant flavonoid, is a potent antioxidant and anti-inflammatory agent. We hypothesized that quercetin reduces lung inflammation and improves lung function in elastase/lipopolysaccharide (LPS)-exposed mice which show typical features of COPD, including",Respiratory research,"Shyamala Ganesan, Andrea N Faris, Adam T Comstock, Sangbrita S Chattoraj, Asamanja Chattoraj, John R Burgess, Jeffrey L Curtis, Fernando J Martinez, Suzanna Zick, Marc B Hershenson, Uma S Sajjan"," Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48109, USA.",2010 Jan;11(1):131,10.1186/1465-9921-11-131
20921378,20101019,article,mesh,"Alkyl and Aryl Transferases,Base Pair Mismatch,Binding, Competitive,DNA Adducts,DNA Repair,Electrophoretic Mobility Shift Assay,Escherichia coli,Escherichia coli Proteins,MutS DNA Mismatch-Binding Protein,Mutagenesis,Plasmids","genetics,metabolism,physiology","D029968 Q000378 NN,D029968 Q000502 NY,D004926 Q000235 NY,D019883 Q000502 NY,D019883 Q000378 NN,D051719 Q000378 NN",NULL,NULL,Alkyltransferase-like protein (eATL) prevents mismatch repair-mediated toxicity induced by O6-alkylguanine adducts in Escherichia coli.,"O(6)-alkylG adducts are highly mutagenic due to their capacity to efficiently form O(6)-alkylG:T mispairs during replication, thus triggering G→A transitions. Mutagenesis is largely prevented by repair strategies such as reversal by alkyltransferases or excision by nucleotide excision repair (NER). Moreover, methyl-directed mismatch repair (MMR) is known to trigger sensitivity to methylating agents via a mechanism that involves recognition by MutS of the O(6)-mG:T replication intermediates. We wanted to inv",Proceedings of the National Academy of Sciences of the United States of America,"Gerard Mazon, Gaëlle Philippin, Jean Cadet, Didier Gasparutto, Mauro Modesti, Robert P Fuchs"," Centre National de la Recherche Scientifique, Unité Propre de Recherche 3081, Genome Instability and Carcinogenesis, Conventionné par l'Université d'Aix-Marseille 2, 13402 Marseille Cedex 20, France.",2010 Oct;107(42):18050-5,10.1073/pnas.1008635107
20935520,20101101,article,"xref,mesh","Apoptosis,Autophagy,Caspases,Cell Line, Tumor,Cisplatin,Cytoprotection,Drug Screening Assays, Antitumor,Female,Fingolimod Hydrochloride,Humans,Inhibitory Concentration 50,Lysophospholipids,Necrosis,Ovarian Neoplasms,Propylene Glycols,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,enzymology,metabolism,pathology,pharmacology,ultrastructure","D010051 Q000648 NN,D017209 Q000187 NN,D001343 Q000187 NY,D010051 Q000201 NN,D002945 Q000494 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D019610 Q000187 NY,D020169 Q000378 NN,D010051 Q000473 NY,D008246 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN","8252,31270,84691,107969,107970,441203,5280335,5283560","128394615,129060975,129645792",FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy.,"FTY720, a sphingosine analog, is a novel immunosuppressant currently undergoing multiple clinical trials for the prevention of organ transplant rejection and treatment of various autoimmune diseases. Recent studies indicate an additional cytotoxic effect of FTY720 and its preclinical efficacy in a variety of cancer models, yet the underlying mechanisms remain unclear. We demonstrate here for the first time that FTY720 exhibits a potent, dose- and time-dependent cytotoxic effect in human ovarian cancer cells",Autophagy,"Ning Zhang, Yanfei Qi, Carol Wadham, Lijun Wang, Alessandra Warren, Wen Di, Pu Xia"," Signal Transduction Program, Centenary Institute; Sydney Medical School, University of Sydney, Sydney, Australia.",2010 Nov;6(8):1157-67,10.4161/auto.6.8.13614
20947176,20110201,review,"xref,mesh","Administration, Oral,Animals,Clinical Trials as Topic,Drug Discovery,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology,methods,therapeutic use,trends","D007166 Q000627 NN,D013110 Q000008 NN,D011409 Q000008 NN,D055808 Q000639 NY,D002986 Q000379 NN,D013110 Q000031 NN,D002986 Q000639 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Emerging disease-modifying oral therapies for multiple sclerosis.,"Although therapy for multiple sclerosis (MS) has changed substantially over the past few decades, introducing immunomodulatory drugs into everyday clinical practice, it is still not satisfactory enough in halting the disease progression and increasing disability. Moreover, its injection-based administration leads to suboptimal adherence, even further reducing the potential treatment benefits. Emerging disease-modifying oral agents for MS are therefore warranted. In this paper advances in the novel oral ther",Journal of neuroimmunology,"Jacek Losy, Alicja Kalinowska-Łyszczarz"," Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, ul. Przybyszewskiego 49, 60-355 Poznań, Poland. jlosy@ump.edu.pl",2011 Feb;231(?):15-22,10.1016/j.jneuroim.2010.09.016
20955831,20110301,article,"xref,mesh","Animals,Dose-Response Relationship, Drug,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Mice,Mice, Inbred C57BL,Myelin Proteolipid Protein,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use,toxicity","D018991 Q000633 NN,D016899 Q000627 NY,D013110 Q000008 NN,D007155 Q000627 NY,D004681 Q000139 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D004681 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.","Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) receptor modulator, inhibits S1P-dependent lymphocyte egress from secondary lymphoid organs and is highly effective in experimental autoimmune encephalomyelitis (EAE) in mice. In this study, we directly compared the therapeutic effects of FTY720 and recombinant mouse interferon (rm-IFN)-β on relapse and progression of EAE in mice. When FTY720 at oral dose of 0.03 to 1 mg/kg was administered daily after establishment of EAE induced by myelin proteolipid pr",International immunopharmacology,"Kenji Chiba, Hirotoshi Kataoka, Noriyasu Seki, Kyoko Shimano, Mamoru Koyama, Atsushi Fukunari, Kunio Sugahara, Takahisa Sugita"," Pharmacology Research Laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation, Aoba-ku, Yokohama, 227-0033, Japan. Chiba.Kenji@mk.mt-pharma.co.jp",2011 Mar;11(3):366-72,10.1016/j.intimp.2010.10.005
20957081,20100101,article,"xref,mesh","Apoptosis,Apoptosis Regulatory Proteins,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Jurkat Cells,Propylene Glycols,RNA, Messenger,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology","D012333 Q000235 NN,D051017 Q000378 NY,D007166 Q000494 NY,D017209 Q000187 NY,D051017 Q000235 NN,D013110 Q000031 NY,D011409 Q000494 NY,D012333 Q000378 NN,D013110 Q000494 NN","668,679,702,738,4939,5962,6049,31270,77129,105065,107969,107970,5280335,54226752","127978224,128141778,128364298,128368395,128482492,129019136,129551052,129645792,129888650,129888769,136111139,136137642",Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis.,"FTY720, a novel immunosuppressant, has a marked activity in decreasing peripheral blood T lymphocytes upon oral administration. Recent investigations suggest that the action of FTY720 on lymphocytes may result from its ability to induce cell apoptosis. However, the cell signaling mechanism involved in the FTY720-induced cell apoptosis remains unclear. Here we examined the apoptotic signal pathways mediated by FTY720 in Jurkat cells using microarray analysis. The results showed that FTY720 can induce Jurkat ",International journal of molecular sciences,"Fang Wang, Wenfeng Tan, Dunming Guo, Xiaomin Zhu, Keqing Qian, Shaoheng He"," The Lab of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; E-Mail: fangwang7608@263.net.",2010 Jan;11(9):3087-105,10.3390/ijms11093087
20959149,20110201,review,"xref,mesh","Animals,Autoimmune Diseases,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunomodulation,Inflammation Mediators,Propylene Glycols,Sphingosine,Uveitis","analogs &amp; derivatives,drug effects,immunology,pharmacology","D001327 Q000276 NY,D056747 Q000276 YN,D007155 Q000494 NN,D018836 Q000276 YN,D013110 Q000031 NN,D056747 Q000187 YN,D014605 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation.,"Uveitis is an intraocular inflammatory disease causing a significant visual impairment. The disease can be idiopathic, associated with infectious and systemic disorders or arisen from an unknown cause. Over the last 20years the model of EAU in mice has contributed significantly for the establishment of parameters for diagnostic evaluations and therapies for posterior uveitis in human. Many studies using recently discovered molecules which present proinflammatory and anti-inflammatory effects have been descr",Autoimmunity reviews,"Alessandra Goncalves Commodaro, Valquiria Bueno, Rubens Belfort, Luiz Vicente Rizzo"," Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo, Brazil.",2011 Feb;10(4):205-9,10.1016/j.autrev.2010.10.002
20959468,20101101,article,"xref,mesh","Animals,Apoptosis,Blotting, Western,Cell Cycle,Cell Proliferation,Fingolimod Hydrochloride,Flow Cytometry,Gamma Rays,Humans,Immunosuppressive Agents,Male,Mice,Mice, Nude,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Prostatic Neoplasms,RNA, Messenger,RNA, Small Interfering,Radiation Tolerance,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Tumor Cells, Cultured,Xenograft Model Antitumor Assays","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,enzymology,genetics,metabolism,pharmacology,radiation effects,radiotherapy","D012333 Q000235 NN,D017853 Q000378 NN,D007166 Q000494 NY,D017209 Q000187 NN,D011471 Q000201 NY,D011471 Q000188 NN,D011836 Q000187 NY,D011471 Q000532 NY,D002453 Q000528 NN,D017853 Q000235 NN,D017853 Q000037 NY,D049109 Q000187 NN,D013110 Q000031 NY,D034741 Q000494 NN,D011409 Q000494 NY,D049109 Q000528 NN,D002453 Q000187 NN,D013110 Q000494 NN,D017209 Q000528 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.,"Radiotherapy is widely used as a radical treatment for prostate cancer, but curative treatments are elusive for poorly differentiated tumors where survival is just 15% at 15 years. Dose escalation improves local response rates but is limited by tolerance in normal tissues. A sphingosine analogue, FTY720 (fingolimod), a drug currently in phase III studies for treatment of multiple sclerosis, has been found to be a potent apoptosis inducer in prostate cancer cells. Using in vitro and in vivo approaches, we an",Cancer research,"Dmitri Pchejetski, Torsten Bohler, Leyre Brizuela, Lysann Sauer, Nicolas Doumerc, Muriel Golzio, Vishal Salunkhe, Justin Teissié, Bernard Malavaud, Jonathan Waxman, Olivier Cuvillier"," Department of Surgery and Cancer, Imperial College London, London, United Kingdom. d.pshezhetskiy@imperial.ac.uk",2010 Nov;70(21):8651-61,10.1158/0008-5472.can-10-1388
20979571,20110201,review,"xref,mesh","Animals,Central Nervous System,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Inflammation,Lymphocytes,Lysophospholipids,Multiple Sclerosis,Phosphorylation,Propylene Glycols,Receptors, Lysophospholipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pharmacology,physiology","D049312 Q000187 NY,D002490 Q000276 NN,D008214 Q000502 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D008246 Q000378 NY,D009103 Q000378 NY,D007249 Q000276 NN,D008214 Q000276 NN,D049312 Q000378 NY,D013110 Q000494 NN,D011409 Q000378 NN,D009103 Q000188 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Roles for lysophospholipid S1P receptors in multiple sclerosis.,"Sphingosine 1-phosphate (S1P) signaling in the treatment of multiple sclerosis (MS) has been highlighted by the efficacy of FTY720 (fingolimod), which upon phosphorylation can modulate S1P receptor activities. FTY720 has become the first oral treatment for relapsing MS that was approved by the FDA in September 2010. Phosphorylated FTY720 modulates four of the five known S1P receptors (S1P(1), S1P(3), S1P(4), and S1P(5)) at high affinity. Studies in human MS and its animal model, experimental autoimmune ence",Critical reviews in biochemistry and molecular biology,"Kyoko Noguchi, Jerold Chun"," Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA.",2011 Feb;46(1):2-10,10.3109/10409238.2010.522975
21031003,20101101,review,"xref,mesh","Administration, Oral,Animals,Drug Discovery,Fingolimod Hydrochloride,Humans,Inflammation Mediators,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Research,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy,pathology,trends","D018836 Q000008 NN,D009103 Q000473 NN,D020529 Q000188 NN,D013110 Q000008 NN,D013110 Q000031 NY,D055808 Q000639 NY,D020529 Q000473 NN,D012106 Q000639 NY,D009103 Q000188 NY,D011409 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.,"The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system. Elucidation of the effects of fingolimod--mediated by the modulation of sphingosine 1-phosphate (S1P) receptors--has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct eff",Nature reviews. Drug discovery,"Volker Brinkmann, Andreas Billich, Thomas Baumruker, Peter Heining, Robert Schmouder, Gordon Francis, Shreeram Aradhye, Pascale Burtin"," Department of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus Forum 1, WSJ-386, CH-4056 Basel, Switzerland. volker.brinkmann@novartis.com",2010 Nov;9(11):883-97,10.1038/nrd3248
21052934,20101001,review,"xref,mesh","Animals,Drugs, Investigational,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis, Relapsing-Remitting,Neuroglia,Phosphorylation,Prodrugs,Propylene Glycols,Protein Isoforms,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,therapeutic use","D009457 Q000378 NY,D020033 Q000819 NN,D049349 Q000819 NY,D007166 Q000627 NN,D015507 Q000627 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D011355 Q000627 NN,D015507 Q000494 NN,D008246 Q000378 NY,D020529 Q000188 NY,D020033 Q000378 NN,D020529 Q000378 NN,D013110 Q000627 NN,D011355 Q000494 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009457 Q000187 NN,D015398 Q000187 NY,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.,"FTY720 (fingolimod, Novartis) is a promising investigational drug for relapsing forms of multiple sclerosis (MS), an autoimmune and neurodegenerative disorder of the central nervous system. It is currently under FDA review in the United States, and could represent the first approved oral treatment for MS. Extensive, ongoing clinical trials in Phase II/III have supported both the efficacy and safety of FTY720. FTY720 itself is not bioactive, but when phosphorylated (FTY720-P) by sphingosine kinase 2, it beco",Archives of pharmacal research,"Chang Wook Lee, Ji Woong Choi, Jerold Chun"," Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA.",2010 Oct;33(10):1567-74,10.1007/s12272-010-1008-5
21071472,20110701,article,"xref,mesh","Adherens Junctions,Cells, Cultured,Endothelial Cells,Fingolimod Hydrochloride,Gene Expression Regulation,Humans,Inflammation,Lung,Lysophospholipids,Permeability,Phosphorylation,Propylene Glycols,Proto-Oncogene Proteins c-abl,Pulmonary Artery,RNA, Small Interfering,Signal Transduction,Sphingosine,Subcellular Fractions,Tight Junctions","analogs &amp; derivatives,cytology,drug effects,metabolism,pathology,pharmacology","D011651 Q000166 NN,D022005 Q000473 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D019108 Q000473 NN,D008246 Q000378 NN,D016315 Q000378 NY,D013110 Q000494 NN,D013347 Q000378 NN,D034741 Q000378 NN,D008168 Q000187 NY,D042783 Q000166 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl.,"Strategies to improve pulmonary endothelial barrier function are needed to reverse the devastating effects of vascular leak in acute respiratory distress syndrome. FTY720 is a pharmaceutical analogue of the potent barrier-enhancing phospholipid sphingosine 1-phosphate (S1P). FTY720 decreases vascular permeability by an incompletely characterised mechanism that differs from S1P. Here, we describe its barrier-promoting effects on intracellular signalling and junctional assembly formation in human pulmonary en",The European respiratory journal,"L Wang, E T Chiang, J T Simmons, J G N Garcia, S M Dudek"," Institute for Personalized Respiratory Medicine, Section of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.",2011 Jul;38(1):78-88,10.1183/09031936.00047810
21077438,20100101,article,xref,"Administration, Inhalation,Animals,Antineoplastic Agents,Inflammation,Ketones,Mice,Mice, Inbred BALB C,Molecular Structure,Neoplasms, Experimental,Neovascularization, Pathologic,Sarcoma,Vascular Endothelial Growth Factors","administration &amp; dosage,blood supply,chemistry,drug therapy,metabolism,pathology,pharmacology,prevention &amp; control","D012509 Q000098 NY,D000970 Q000494 NY,D012509 Q000473 NN,D007659 Q000008 NN,D012509 Q000378 NN,D007659 Q000494 NY,D000970 Q000737 NN,D007659 Q000737 NN,D009389 Q000517 NY,D042442 Q000378 NY,D012509 Q000188 NN,D007249 Q000473 NN,D000970 Q000008 NN","8163,75189,84467,91522586","128454588,128679281,129821266,248678701",The effect of undecanones and their derivatives on tumor angiogenesis and VEGF content.,"The in vivo effects of some derivatives of aliphatic ketones (2-undecanone, 3-undecanone, 4-undecanone and their derivatives) on L-1 sarcoma tumor angiogenesis and VEGF content were studied in Balb/c mice. Mice that inhaled 10% solution of 3-undecanone(3-on) or 1% solution of 2-undecanone propylene acetal (Acpr2) for 3 days after tumor cells implantation, presented lower neovascular response measured by tumor-induced cutaneous angiogenesis test (TIA) and lower tumor VEGF content in 5-days tumors, than non-i",Polish journal of veterinary sciences,"J Gibka, A Wasiutyński, E Skopińska-Rózewska, A K Siwicki, J Chorostowska-Wynimko, E Sommer, M Mazurkiewicz, M Gliński, H Skurzak, R Wójcik, L Jung"," Institute of General Food Chemistry, Technical University of Łódź, Stefanowskiego 4/10, 90-924 Łódź, Poland.",2010 Jan;13(1):105-15,NULL
21084291,20110121,article,"xref,mesh","Animals,Biological Transport,CHO Cells,Carrier Proteins,Cricetinae,Cricetulus,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Membrane Proteins,Mice,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacokinetics,pharmacology,physiology","D010766 Q000502 NN,D007166 Q000494 NY,D001692 Q000502 NN,D049349 Q000235 NN,D008565 Q000378 NY,D002352 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D007166 Q000493 NN,D013110 Q000378 NN,D008565 Q000235 NN,D011409 Q000493 NN,D013110 Q000493 NN,D013110 Q000235 NN,D002352 Q000235 NN,D008246 Q000378 NN,D001692 Q000187 NN,D010766 Q000187 NN,D013110 Q000494 NN,D008246 Q000235 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792","The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.","FTY720 is a novel immunomodulating drug that can be phosphorylated inside cells; its phosphorylated form, FTY720-P, binds to a sphingosine 1-phosphate (S1P) receptor, S1P(1), and inhibits lymphocyte egress into the circulating blood. Although the importance of its pharmacological action has been well recognized, little is known about how FTY720-P is released from cells after its phosphorylation inside cells. Previously, we showed that zebrafish Spns2 can act as an S1P exporter from cells and is essential fo",The Journal of biological chemistry,"Yu Hisano, Naoki Kobayashi, Atsuo Kawahara, Akihito Yamaguchi, Tsuyoshi Nishi"," Department of Cell Membrane Biology, Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka 567-0047, Japan.",2011 Jan;286(3):1758-66,10.1074/jbc.m110.171116
21091442,20110401,review,"xref,mesh","Animals,Anti-Asthmatic Agents,Asthma,Cytokines,Disease Models, Animal,Epithelial Cells,Fingolimod Hydrochloride,Humans,Inflammation,Lung,Lysophospholipids,Mast Cells,Mice,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingolipids,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug therapy,immunology,metabolism,therapeutic use","D016207 Q000276 NN,D001249 Q000378 NY,D016207 Q000378 NN,D013110 Q000031 NY,D001249 Q000188 NY,D013110 Q000378 NN,D001249 Q000276 NN,D018927 Q000627 NN,D008246 Q000378 NY,D013107 Q000378 NN,D017853 Q000378 NY,D008168 Q000166 NN,D017853 Q000037 NN,D013110 Q000627 NN,D011409 Q000627 NN,D004847 Q000378 NN,D008168 Q000378 NN,D008407 Q000378 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792,135836815",Sphingosine kinase and sphingosine 1-phosphate in asthma.,"Sphingolipids are amphiphatic molecules ubiquitously expressed in all eukaryotic cell membranes. Initially characterized as structural components of cell membranes, sphingolipids have emerged as sources of important signalling molecules over the past decade. Sphingolipid metabolites, such as ceramide and S1P (sphingosine 1-phosphate), have been demonstrated to have roles as potent bioactive messengers involved in cell differentiation, proliferation, apoptosis, migration and angiogenesis. The importance of S",Bioscience reports,"Wen-Qi Lai, W S Fred Wong, Bernard P Leung"," Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, 2 Medical Drive, Singapore 117597.",2011 Apr;31(2):145-50,10.1042/bsr20100087
21103024,20080505,article,NULL,NULL,NULL,NULL,NULL,NULL,Synthetic Utility of Epoxides for Chiral Functionalization of Isoxazoles.,"The lithio-anion of isoxazole 2 was found to ring open propylene oxide in good yields with complete regioselectivity. Vinylic and benzylic epoxides were utilized as key examples of electrophiles and found to produce a mixture of regioisomeric adducts. Additionally, the use of chiral epoxides was explored, and absolute configuration was determined by X-ray crystallography to prove that nucleophilic attack at the benzylic carbon of (R)-styrene oxide proceeds with 100% inversion at the benzylic carbon to affor",Tetrahedron letters,"Jared K Nelson, Christopher T Burns, Miles P Smith, Brendan Twamley, N R Natale"," Department of Chemistry, University of Idaho, Moscow, ID 83844-2343.",2008 May;49(19):3078-3082,10.1016/j.tetlet.2008.03.059
21113155,20101201,article,"xref,mesh","Animals,Cell Movement,Dendritic Cells,Fingolimod Hydrochloride,Flow Cytometry,Humans,Ileus,Immunologic Memory,Immunosuppressive Agents,Interferon-gamma,Interleukin-12,Macrophages,Mice,Mice, Inbred C57BL,Postoperative Complications,Propylene Glycols,Sphingosine,Statistics, Nonparametric,Th1 Cells","analogs &amp; derivatives,drug effects,etiology,immunology,metabolism,pharmacology,prevention &amp; control,secretion","D018664 Q000557 NY,D018417 Q000276 NN,D002465 Q000187 NN,D008264 Q000378 NN,D007371 Q000276 NN,D011183 Q000276 NY,D013110 Q000031 NN,D045823 Q000209 NN,D007156 Q000276 NN,D011409 Q000494 NN,D003713 Q000557 NY,D013110 Q000494 NN,D007166 Q000494 NN,D045823 Q000517 NY,D045823 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract.,"Localized abdominal surgery can lead to disruption of motility in the entire gastrointestinal tract (postoperative ileus). Intestinal macrophages produce mediators that paralyze myocytes, but it is unclear how the macrophages are activated, especially those in unmanipulated intestinal areas. Here we show that intestinal surgery activates intestinal CD103(+)CD11b(+) dendritic cells (DCs) to produce interleukin-12 (IL-12). This promotes interferon-γ (IFN-γ) secretion by CCR9(+) memory T helper type 1 (T(H)1) ",Nature medicine,"Daniel R Engel, Arne Koscielny, Sven Wehner, Juliane Maurer, Marzena Schiwon, Lars Franken, Beatrix Schumak, Andreas Limmer, Tim Sparwasser, Andreas Hirner, Percy A Knolle, Jörg C Kalff, Christian Kurts"," Institutes for Molecular Medicine and Experimental Immunology, University Clinic of Bonn, Bonn, Germany.",2010 Dec;16(12):1407-13,10.1038/nm.2255
21130737,20110107,article,"xref,mesh","Animals,Antidepressive Agents, Tricyclic,Cathepsins,Cell Line, Tumor,Cells, Cultured,Cysteine Proteinase Inhibitors,Desipramine,Enzyme Inhibitors,Fibroblasts,Fingolimod Hydrochloride,Humans,Hydrolases,Immunosuppressive Agents,Leupeptins,Mice,Neurons,Propylene Glycols,Sphingomyelin Phosphodiesterase,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,enzymology,pharmacology","D015853 Q000494 NN,D007976 Q000494 NN,D006867 Q000037 NN,D009474 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013108 Q000037 NY,D005347 Q000201 NN,D000929 Q000494 NY,D005347 Q000187 NN,D004791 Q000494 NY,D003891 Q000494 NY,D002403 Q000037 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009474 Q000201 NN","2995,4941,5862,8252,31270,65327,72429,105065,107969,107970,425562,2733491,5280335,7098622","128394615,129060975,129645792,129742316,135820018,136033793,136111139",Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.,"The immunomodulator drug Gilenya (FTY720), marketed as the first oral sphingosine-1-phosphate receptor (S1P-R) modulator for treatment of Multiple Sclerosis (MS) also inhibits lysosomal acid sphingomyelinase (ASMase). Treatment of cultured cells for 24 h with FTY720 (up to 10 μM) inhibited ASMase by >80% and this could be reversed by pre-treatment with the cathepsin protease inhibitor leupeptin (5 μM). In contrast, neutral sphingomyelinase activity was unaffected and sphingosine-1-phosphate treatment had no",Biochemical and biophysical research communications,"Glyn Dawson, Jingdong Qin"," Department of Pediatrics, University of Chicago, Chicago, IL 60637, USA. dawg@uchicago.edu",2011 Jan;404(1):321-3,10.1016/j.bbrc.2010.11.115
21136155,20110901,article,"xref,mesh","Animals,Cell Differentiation,Cell Lineage,Cells, Cultured,Ceramides,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Mice,Molecular Structure,Oligodendroglia,Propylene Glycols,Receptors, Lysosphingolipid,Sphingolipids,Sphingosine,Stem Cells","analogs &amp; derivatives,chemistry,cytology,drug effects,metabolism,pharmacology,physiology","D008246 Q000494 NN,D002454 Q000502 NY,D009836 Q000502 NY,D013107 Q000737 NN,D013107 Q000378 NY,D013110 Q000031 NN,D013234 Q000502 NY,D011409 Q000494 NN,D009836 Q000166 NN,D002518 Q000737 NN,D002518 Q000378 NN,D002454 Q000187 NN,D013110 Q000494 NN,D009836 Q000187 NN,D007166 Q000494 NN,D013234 Q000166 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560,91250800","128394615,129060975,129645792,135836815,136111139,246695817",There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells.,"Dr. Robert K. Yu's research showed for the first time that the composition of glycosphingolipids is tightly regulated during embryo development. Studies in our group showed that the glycosphingolipid precursor ceramide is also critical for stem cell differentiation and apoptosis. Our new studies suggest that ceramide and its derivative, sphingosine-1-phosphate (S1P), act synergistically on embryonic stem (ES) cell differentiation. When using neural precursor cells (NPCs) derived from ES cells for transplant",Neurochemical research,Erhard Bieberich," Program in Developmental Neurobiology, Institute of Molecular Medicine and Genetics, School of Medicine, Medical College of Georgia/Georgia Health Sciences University, 1120 15th Street Room CA4012, Augusta, GA 30912, USA. ebieberich@mcg.edu",2011 Sep;36(9):1601-11,10.1007/s11064-010-0338-5
21149807,20101201,article,"xref,mesh","Cell Movement,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukocytes,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D002465 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN,D007962 Q000187 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Understanding the effects of FTY720 on leukocyte trafficking.,NULL,Archives of neurology,Michael K Racke,NULL,2010 Dec;67(12):1433-4,10.1001/archneurol.2010.299
21149809,20101201,article,"xref,mesh","CD8-Positive T-Lymphocytes,Cell Count,Cell Movement,Chemokine CCL2,Chemokine CXCL12,Cytokines,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Interferon-gamma,Multiple Sclerosis,Propylene Glycols,Receptors, CCR2,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,classification,drug effects,drug therapy,immunology,metabolism,methods,pathology,pharmacology,therapeutic use","D007166 Q000494 NY,D007166 Q000627 NN,D007371 Q000378 NN,D002465 Q000187 NY,D014409 Q000378 NN,D016207 Q000378 NN,D009103 Q000473 NY,D018414 Q000145 NY,D054390 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D005434 Q000379 NN,D018932 Q000378 NN,D018414 Q000187 NN,D054377 Q000378 NN,D002452 Q000379 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.,OBJECTIVE: To define the capacity of peripheral blood CD8(+) T cells from patients with multiple sclerosis (MS) receiving fingolimod (FTY720) to migrate in response to chemokines that contribute to trafficking into the central nervous system. DESIGN: Peripheral blood T cells of FTY720-treated patients with MS (MS-FTY) are mainly CD8(+) CCR7⁻ effector memory cells as CCR7(+) T cells are inhibited from exiting from secondary lymph nodes. Migration of CD8(+) T cells from MS-FTY patients and untreated donors to,Archives of neurology,"Trina A Johnson, Yves Lapierre, Amit Bar-Or, Jack P Antel"," Montreal Neurological Institute, QC, Canada.",2010 Dec;67(12):1449-55,10.1001/archneurol.2010.312
21158700,20110201,review,"xref,mesh","Administration, Oral,Clinical Trials, Phase II as Topic,Clinical Trials, Phase III as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Lymphocytes,Lysophospholipids,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,adverse effects,agonists,analogs &amp; derivatives,drug therapy,immunology,metabolism,therapeutic use","D016899 Q000627 NY,D013110 Q000009 NN,D011409 Q000009 NN,D049349 Q000819 NY,D008214 Q000378 NN,D013110 Q000008 NN,D049349 Q000276 NN,D013110 Q000031 NY,D011409 Q000008 NN,D016899 Q000009 NN,D013110 Q000378 NN,D007166 Q000627 NY,D020529 Q000188 NY,D008246 Q000378 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D011409 Q000378 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Fingolimod for the treatment of relapsing multiple sclerosis.,"Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of lymphocytes in lymphoid tissue. Effector memory T cells are not sequestered so that immune surveillance may be minimally affected. Two large-scale Phase III clinical trials have demonstrated the",Expert review of neurotherapeutics,"Douglas R Jeffery, Clyde E Markowitz, Anthony T Reder, Bianca Weinstock-Guttman, Kathy Tobias"," The Multiple Sclerosis and Movement Disorders Center at Advance Neurology at Cornerstone Health Care, Winston-Salem, NC 27006, USA. douglas.jeffery@cornerstonehealthcare.com",2011 Feb;11(2):165-83,10.1586/ern.10.193
21164103,20110204,article,"xref,mesh","Animals,Apolipoproteins E,Atherosclerosis,Cell Movement,Cell Proliferation,Disease Models, Animal,Fingolimod Hydrochloride,Inflammation,Macrophages,Mice,Mice, Inbred C57BL,Mice, Knockout,Monocytes,Peritonitis,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Thioglycolates","adverse effects,analogs &amp; derivatives,chemically induced,deficiency,drug effects,genetics,metabolism,pathology,pharmacology,physiology","D017853 Q000378 NN,D049349 Q000378 NY,D009000 Q000473 NY,D009000 Q000187 NN,D001057 Q000378 NN,D010538 Q000139 NN,D049349 Q000235 NN,D050197 Q000378 NY,D007249 Q000473 NY,D013864 Q000009 NN,D007249 Q000378 NY,D010538 Q000378 NN,D013110 Q000031 NN,D008264 Q000187 NN,D001057 Q000235 NN,D010538 Q000473 NN,D008264 Q000473 NY,D011409 Q000494 NN,D013110 Q000494 NN,D050197 Q000473 NY,D049349 Q000172 NN,D002465 Q000502 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis.,"RATIONALE: The role of sphingosine-1-phosphate (S1P) and its receptors in the pathogenesis of atherosclerosis has not been investigated. OBJECTIVE: We hypothesized that the S1P receptor 3 (S1P(3)) plays a causal role in the pathogenesis of atherosclerosis. METHODS AND RESULTS: We examined atherosclerotic lesion development in mice deficient for S1P(3) and apolipoprotein (Apo)E. Although S1P(3) deficiency did not affect lesion size after 25 or 45 weeks of normal chow diet, it resulted in a dramatic reduction",Circulation research,"Petra Keul, Susann Lucke, Karin von Wnuck Lipinski, Constantin Bode, Markus Gräler, Gerd Heusch, Bodo Levkau"," Institute for Pathophysiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.",2011 Feb;108(3):314-23,10.1161/circresaha.110.235028
21166720,20110301,article,"xref,mesh","Animals,Cell Line, Transformed,Cell Survival,Dose-Response Relationship, Drug,Down-Regulation,Extracellular Signal-Regulated MAP Kinases,Fingolimod Hydrochloride,Gene Expression,Glycogen Synthase Kinase 3,Glycogen Synthase Kinase 3 beta,Indoles,Maleimides,Melanins,Melanocytes,Mice,Microphthalmia-Associated Transcription Factor,Monophenol Monooxygenase,Phosphorylation,Propylene Glycols,Protein Kinase Inhibitors,Proto-Oncogene Proteins c-akt,Signal Transduction,Sphingosine,beta Catenin","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,cytology,drug effects,genetics,metabolism,pharmacology,physiology","D015536 Q000502 NN,D047428 Q000494 NN,D002470 Q000187 NN,D015870 Q000187 NN,D008544 Q000166 NN,D008543 Q000096 NY,D051739 Q000378 NN,D014442 Q000235 NN,D013110 Q000031 NY,D011409 Q000494 NY,D007211 Q000494 NN,D051739 Q000235 NN,D051176 Q000235 NN,D048049 Q000378 NN,D008544 Q000378 NY,D008544 Q000187 NY,D008301 Q000494 NN,D038362 Q000378 NN,D014442 Q000378 NN,D051057 Q000378 NN,D015398 Q000502 NY,D010766 Q000187 NN,D038362 Q000037 NN,D015398 Q000187 NN,D051176 Q000378 NN,D013110 Q000494 NN,D015870 Q000235 NN","8252,31270,105065,107969,107970,176158,5280335,6325610","128394615,129060975,129645792,136111139","The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue.","We previously reported that sphingosine-1-phosphate (S1P) decreases melanin synthesis via extracellular signal-regulated protein kinase (ERK) activation and microphthalmia-associated transcription factor (MITF) degradation. Although FTY720 is an S1P structural analogue, the effects of FTY720 on melanogenesis are not completely understood. Thus, we investigated the influence of FTY720 on melanin synthesis in a spontaneously immortalized mouse melanocyte cell line (Mel-Ab). FTY720 inhibited melanin synthesis ",Experimental dermatology,"Ju Eun Lee, Su Yeon Kim, Yun-Mi Jeong, Hye-Young Yun, Kwang Jin Baek, Nyoun Soo Kwon, Kyoung-Chan Park, Dong-Seok Kim"," Department of Biochemistry, Chung-Ang University College of Medicine, Seoul, Korea.",2011 Mar;20(3):237-41,10.1111/j.1600-0625.2010.01148.x
21168606,20101201,article,"xref,mesh","Animals,Female,Fingolimod Hydrochloride,Hemodynamics,Immunosuppressive Agents,Propylene Glycols,Rats,Rats, Wistar,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,pharmacology","D007166 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Effect of FTY720 treatment on postischemic pancreatic microhemodynamics.,"CD4+ T cells contribute to disturbances of pancreatic microcirculation after cold and even after warm ischemia/reperfusion (I/R). The aim of this study was to investigate a possible protective role of FTY720 (fingolimod) in this setting. In an in vivo model (42 Wistar rats), ischemia of the pancreas was induced for 60 minutes under anesthesia with xylazin/ketanest. Sham-operated (SO) (I), untreated ischemic (II), and treatment group with FTY720 pre-treatment (1 mg/kg body weight i.v.) (III) were investigate",Transplantation proceedings,"A Prescher, C Mory, M Martin, M Fiedler, D Uhlmann"," University of Leipzig, 2(nd) Department of Surgery, Leipzig, Germany.",2010 Dec;42(10):3984-5,10.1016/j.transproceed.2010.09.046
21177320,20110501,article,"xref,mesh","Administration, Oral,Brain,Cladribine,Disability Evaluation,Disease Progression,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis,Predictive Value of Tests,Propylene Glycols,Recurrence,Regression Analysis,Reproducibility of Results,Sphingosine,Time Factors,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug effects,drug therapy,pathology","D009103 Q000473 NN,D013110 Q000008 NN,D013110 Q000031 NY,D017338 Q000008 NY,D001921 Q000473 NN,D001921 Q000187 NY,D009103 Q000175 NN,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.,"Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of previous results to novel therapies is not warranted. We tested here the validity of MRI surrogacy in MS studies on recently published trials of oral drugs. The 92% of observed effects of oral drugs on clinical outcom","Multiple sclerosis (Houndmills, Basingstoke, England)","M P Sormani, L Bonzano, L Roccatagliata, N De Stefano"," Biostatistics Unit, Department of Health Sciences, University of Genoa, Italy. mariapia.sormani@unige.it",2011 May;17(5):630-3,10.1177/1352458510393770
21177428,20110111,article,mesh,"Animals,Astrocytes,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Lymphocytes,Mice,Mice, Inbred C57BL,Mice, Knockout,Multiple Sclerosis,Propylene Glycols,Receptors, G-Protein-Coupled,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,cytology,drug therapy,metabolism,pharmacology","D049349 Q000378 NY,D008214 Q000378 NN,D004681 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D043562 Q000378 NN,D001253 Q000166 NY,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NY,D004681 Q000188 NY","107969,107970,5280335",NULL,FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.,"Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple sclerosis through the discovery of FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis. Its mechanism of action is thought to be immunological through an active phosphorylated metabolite, FTY720-P, that resembles S1P and alters lymphocyte trafficking through receptor subtype S1P(1). However, previously reported expression and in vitro studies of S1P receptors suggested that d",Proceedings of the National Academy of Sciences of the United States of America,"Ji Woong Choi, Shannon E Gardell, Deron R Herr, Richard Rivera, Chang-Wook Lee, Kyoko Noguchi, Siew Teng Teo, Yun C Yung, Melissa Lu, Grace Kennedy, Jerold Chun"," Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA.",2011 Jan;108(2):751-6,10.1073/pnas.1014154108
21184668,20110101,review,"xref,mesh","Administration, Oral,Cladribine,Crotonates,Diterpenes,Epoxy Compounds,Fingolimod Hydrochloride,Fumarates,Humans,Multiple Sclerosis,Patents as Topic,Phenanthrenes,Propylene Glycols,Quinolones,Sphingosine,Toluidines","analogs &amp; derivatives,drug therapy,therapeutic use","D015363 Q000627 NN,D010616 Q000627 NN,D005650 Q000627 NN,D004852 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D004224 Q000627 NN,D014052 Q000627 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","8252,20279,31270,107969,107970,107985,160438,444972,3036108,5280335,6076814,6364607,6433510,6440849,9793847,10197734,23500906,54677946,87110070,101823788","127523511,127968532,128394615,128672523,128966217,129060975,129645792",Therapeutic approach to multiple sclerosis by novel oral drug.,"Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system and the most common cause of neurological disability in young adults, along with a considerable clinical and pathological heterogeneity. Since, current therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive phase of this disease, thus novel promising therapeutic strategies might open a light horizon in approaching to an efficient treatment in MS. In this revi",Recent patents on inflammation & allergy drug discovery,"Farhad Jadidi-Niaragh, Abbas Mirshafiey"," Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran-14155, Box: 6446, Iran.",2011 Jan;5(1):66-80,10.2174/187221311794474900
21192322,20110227,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Diabetes Mellitus,Embryo, Mammalian,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Insulin,Mice,Mice, Inbred C57BL,Pancreas Transplantation,Propylene Glycols,Sirolimus,Sphingosine,Swine,T-Lymphocytes, Regulatory,Transplantation Tolerance,Transplantation, Heterologous","analogs &amp; derivatives,blood,embryology,immunology,surgery,therapeutic use","D014183 Q000276 NY,D018414 Q000276 NN,D015496 Q000276 NN,D003920 Q000601 NY,D007166 Q000627 NN,D050378 Q000276 NY,D013552 Q000196 NN,D013110 Q000031 NN,D013552 Q000276 NY,D016035 Q000276 NY,D006085 Q000276 NN,D004622 Q000276 NN,D007328 Q000097 NN,D013110 Q000627 NN,D011409 Q000627 NN,D020123 Q000627 NN","8252,31270,107969,107970,5280335,5284616,70678557,91454826,91534498,118984375","128394615,129060975,129645792,248184126,248766214","Embryonic pig pancreatic tissue for the treatment of diabetes: potential role of immune suppression with ""off-the-shelf"" third-party regulatory T cells.","BACKGROUND: Xenogeneic embryonic pancreatic tissue can provide an attractive alternative for organ replacement therapy. However, immunological rejection represents a major obstacle. This study examines the potential of regulatory T cells (Tregs) in the prevention of E42 pancreas rejection. METHODS: To develop new approaches to combat rejection, we evaluated engraftment, growth, and development of E42 pig pancreatic tissue in mice treated with ex vivo expanded Tregs in combination with T-cell debulking and t",Transplantation,"Dalit Tchorsh-Yutsis, Yael Zlotnikov Klionsky, Esther Bachar-Lustig, Anna Aronovich, Ilan Feine, Elias Shezen, Chava Rosen, Rivka Bitcover, Smadar Eventov-Friedman, Helena Katchman, Lior Zangi, Orna Tal, Sivan Cohen, Yair Reisner"," Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.",2011 Feb;91(4):398-405,10.1097/tp.0b013e318204be15
21208295,20110201,article,"xref,mesh","Animals,Biological Transport,Cyclosporine,Diarrhea,Everolimus,Fingolimod Hydrochloride,Glucose,Immunosuppressive Agents,Intestinal Absorption,Intestine, Large,Intestine, Small,Male,Mycophenolic Acid,Propylene Glycols,Rats,Rats, Wistar,Sirolimus,Sphingosine,Tacrolimus","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,metabolism,pharmacology,physiology","D007166 Q000494 NY,D001692 Q000187 NY,D016559 Q000494 NN,D007421 Q000187 NY,D003967 Q000139 NN,D007408 Q000187 NN,D007421 Q000502 NN,D009173 Q000494 NN,D013110 Q000031 NN,D020123 Q000494 NN,D016572 Q000494 NN,D005947 Q000378 NN,D011409 Q000494 NN,D009173 Q000031 NN,D007420 Q000502 NN,D013110 Q000494 NN,D007166 Q000009 NN,D020123 Q000031 NN,D007420 Q000187 NY","2909,4271,4272,5372,5793,8252,24749,31270,62280,107526,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5284616,5458585,6435893,6441022,6442177,6473866,6536850,9855081,10954115,23665584,24883466,25246316,49867938,71306795,71463825,71668407,73896891,87517085,90696889,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129621433,129645792,242749350,242963342,248766214",Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function.,"Immunosuppressive drug (ISD)-associated gastrointestinal disorders are a relevant risk factor for graft loss or patient death. The pathomechanisms and the incidence of post-transplantation diarrhea remain to be fully understood. The aim of this study was to characterize the impact of cyclosporine A, tacrolimus (TAC), mycophenolate mofetil (MMF), enteric coated mycophenolic acid (EC-MPA), sirolimus, everolimus (EVE) and fingolimod (FTY 720) on small and large bowel transport and barrier function. Functions o",Transplant international : official journal of the European Society for Organ Transplantation,"Maciej Malinowski, Peter Martus, Johan Friso Lock, Peter Neuhaus, Martin Stockmann"," Department of General, Visceral, and Transplantation Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.",2011 Feb;24(2):184-93,10.1111/j.1432-2277.2010.01167.x
21248243,20110501,article,"xref,mesh","Animals,Axons,Blotting, Western,Corpus Callosum,Cuprizone,Demyelinating Diseases,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Interleukin-1beta,Male,Mice,Mice, Inbred C57BL,Mice, Knockout,Microscopy, Electron,Myelin Sheath,Oligodendroglia,Propylene Glycols,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine","analogs &amp; derivatives,chemically induced,cytology,drug effects,drug therapy,genetics,metabolism,pharmacology,therapeutic use,toxicity","D009186 Q000378 NN,D049349 Q000378 NY,D001369 Q000187 NN,D003471 Q000633 NY,D003337 Q000187 NN,D049349 Q000235 NN,D003337 Q000166 NN,D009186 Q000187 NN,D003711 Q000139 NN,D053583 Q000378 NN,D003337 Q000378 NN,D013110 Q000031 NN,D009836 Q000378 NN,D001369 Q000378 NN,D003711 Q000188 NN,D011409 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009836 Q000187 NN,D007166 Q000494 NN","8252,9723,31270,107969,107970,5280335","128394615,129060975,129645792",Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.,"Fingolimod (FTY720) is a sphingosine 1-phosphate (S1P) receptor modulator that regulates lymphocyte trafficking and exerts pleiotropic actions on oligodendrocytes (OLGs) and other neural cells. The purpose of this study was to investigate the role of S1P receptors in a non-T-cell model of demyelination, the cuprizone (cupr) model in C57BL/6 mice. Treatment with FTY720 (1 mg/kg) led to attenuated injury to OLGs, myelin, and axons in the corpus callosum (percentage of myelinated fibers was 44.7% in cupr-water",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,"Hye Jung Kim, Veronique E Miron, Danuta Dukala, Richard L Proia, Samuel K Ludwin, Maria Traka, Jack P Antel, Betty Soliven"," Department of Neurology, University of Chicago, Chicago, Illinois 60637, USA.",2011 May;25(5):1509-18,10.1096/fj.10-173203
21268796,20101201,article,"xref,mesh","Administration, Oral,Central Nervous System,Drug Approval,Fingolimod Hydrochloride,Humans,Inflammation Mediators,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Secondary Prevention,Sphingosine,United States,United States Food and Drug Administration","analogs &amp; derivatives,drug effects,drug therapy,therapeutic use","D013110 Q000031 NY,D002490 Q000187 NY,D020529 Q000188 NY,D018836 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FDA approves the first oral drug for reducing multiple sclerosis relapses.,NULL,Harvard women's health watch,NULL,NULL,2010 Dec;18(4):5,NULL
21280082,20110101,article,"xref,mesh","Animals,Apoptosis,Brain Ischemia,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,In Vitro Techniques,Inflammation,Mice,Mice, Inbred C57BL,Neurons,Neuroprotective Agents,Neurotoxicity Syndromes,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine,Stroke","agonists,analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,prevention &amp; control,therapeutic use","D007249 Q000188 NN,D020258 Q000517 NN,D049349 Q000819 NN,D017209 Q000187 NN,D020521 Q000517 NN,D002545 Q000188 NY,D018696 Q000494 NN,D009474 Q000187 NN,D013110 Q000031 NY,D009474 Q000276 NN,D018696 Q000627 NN,D007166 Q000627 NY,D002545 Q000517 NY,D011409 Q000494 NN,D013110 Q000627 NN,D020521 Q000188 NY,D013110 Q000494 NN,D011409 Q000627 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Fingolimod provides long-term protection in rodent models of cerebral ischemia.,"OBJECTIVE: The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced multiple sclerosis clinical trials, decreases reperfusion injury in heart, liver, and kidney. We therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral ischemia. To assess the translational significance of these findings, we asked whether fingolimod improved long-term behavioral outcomes, whether delayed treatment was still effective, and whether n",Annals of neurology,"Ying Wei, Muge Yemisci, Hyung-Hwan Kim, Lai Ming Yung, Hwa Kyoung Shin, Seo-Kyoung Hwang, Shuzhen Guo, Tao Qin, Nafiseh Alsharif, Volker Brinkmann, James K Liao, Eng H Lo, Christian Waeber"," Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA.",2011 Jan;69(1):119-29,10.1002/ana.22186
21289599,20110501,article,"xref,mesh","Animals,Cells, Cultured,Diabetes Mellitus, Experimental,Diabetic Nephropathies,Fingolimod Hydrochloride,Kidney,Lymphocytes,Mice,Mice, Inbred C57BL,Oxadiazoles,Phosphotransferases (Alcohol Group Acceptor),Podocytes,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,Tumor Necrosis Factor-alpha","agonists,analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,physiology,physiopathology,prevention &amp; control,urine","D049349 Q000819 NN,D007668 Q000187 NN,D010069 Q000494 NN,D007668 Q000473 NN,D050199 Q000378 NN,D017853 Q000235 NN,D007668 Q000503 NN,D003921 Q000503 NN,D013110 Q000031 NN,D008214 Q000502 NY,D003921 Q000188 NN,D014409 Q000652 NN,D013876 Q000494 NN,D049349 Q000502 NY,D011409 Q000494 NN,D013110 Q000494 NN,D003928 Q000517 NY","5793,8252,29327,31270,107969,107970,4077460,5280335,10523409","128394615,129060975,129621433,129645792,135758261",Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.,"Sphingosine 1-phosphate (S1P), a pleiotropic lipid mediator, binds to five related G-protein-coupled receptors to exert its effects. As S1P1 receptor (S1P1R) activation blocks kidney inflammation in acute renal injury, we tested whether activation of S1P1Rs ameliorates renal injury in early-stage diabetic nephropathy (DN) in rats. Urinary albumin excretion increased in vehicle-treated diabetic rats (single injection of streptozotocin), compared with controls, and was associated with tubule injury and increa",Kidney international,"Alaa S Awad, Michael D Rouse, Konstantine Khutsishvili, Liping Huang, W Kline Bolton, Kevin R Lynch, Mark D Okusa"," Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.",2011 May;79(10):1090-8,10.1038/ki.2010.544
21297650,20110201,review,"xref,mesh","Biomarkers,Cladribine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis,Propylene Glycols,Randomized Controlled Trials as Topic,Sphingosine","analogs &amp; derivatives,analysis,diagnosis,drug therapy,therapeutic use","D009103 Q000175 NY,D007166 Q000627 NN,D013110 Q000031 NN,D015415 Q000032 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.,NULL,Nature reviews. Neurology,Massimo Filippi," Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, University Hospital San Raffaele, Milan, Italy. filippi.massimo@hsr.it",2011 Feb;7(2):74-5,10.1038/nrneurol.2010.215
21323692,20110601,article,"xref,mesh","Animals,Autoimmune Diseases,Disease Models, Animal,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Male,Propylene Glycols,Prostatitis,Rats,Rats, Inbred Lew,Receptors, Lysosphingolipid,Specific Pathogen-Free Organisms,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,immunology,pharmacology","D007166 Q000494 NY,D011472 Q000276 NN,D013110 Q000031 NY,D001327 Q000276 NN,D011409 Q000494 NY,D011472 Q000188 NY,D049349 Q000276 NY,D013110 Q000494 NN,D049349 Q000037 NN,D001327 Q000188 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis.,"Experimental autoimmune prostatitis (EAP) is an autoimmune inflammatory disease of male sex accessory glands and is characterized by a cellular and humoral prostate-specific autoimmune response associated with inflammatory mononuclear cell (MNC) infiltration. EAP shares important clinical and immunological features with human chronic prostatitis and chronic pelvic pain syndrome. Using immunohistochemistry, we determined the pattern of pathological changes during rat EAP development, regarding the cellular r",Scandinavian journal of immunology,"Z-Y Zhang, C Zug, H J Schluesener"," Institute of Brain Research, University of Tuebingen, Tuebingen, Germany. zhiyuan.zhang@medizin.uni-tuebingen.de",2011 Jun;73(6):546-53,10.1111/j.1365-3083.2011.02528.x
21339486,20110222,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Gene Expression Regulation,Humans,Immune System,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Virus Diseases","analogs &amp; derivatives,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology,physiology,therapeutic use","D009103 Q000473 NN,D008214 Q000378 NN,D007107 Q000187 NN,D005786 Q000502 NN,D014777 Q000188 NN,D013110 Q000031 NY,D013110 Q000378 NN,D014777 Q000276 NN,D008246 Q000378 NY,D049349 Q000187 NN,D005786 Q000187 NN,D013110 Q000235 NN,D011409 Q000494 NN,D009103 Q000276 NN,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007107 Q000502 NY,D013110 Q000494 NN,D008214 Q000187 NN,D007166 Q000494 NN,D009103 Q000188 NN,D014777 Q000473 NN,D008246 Q000235 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Impact of sphingosine 1-phosphate modulation on immune outcomes.,"Viral infections may have an important role in the precipitation or relapse of multiple sclerosis (MS) and its treatment. This review describes the normal immune response to viral infection, the possible associations between viral infections and MS therapy, and the impact of sphingosine 1-phosphate (S1P) receptor (S1PR) modulation with fingolimod (FTY720) on the immune responses to viral infection. The physiologic immune response to viral infection involves lymphocyte activation and control of the circulati",Neurology,"Daniel D Pinschewer, Volker Brinkmann, Doron Merkler"," Department of Pathology and Immunology, University of Geneva, Geneva.",2011 Feb;76(?):S15-9,10.1212/wnl.0b013e31820d9596
21339487,20110222,review,"xref,mesh","Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,cytology,drug effects,drug therapy,immunology,metabolism,pharmacology,physiology,therapeutic use","D049349 Q000378 NY,D007107 Q000187 NN,D049349 Q000276 NN,D013110 Q000031 NY,D009103 Q000276 NY,D013110 Q000378 NN,D007166 Q000627 NY,D008214 Q000276 NN,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000627 NN,D007107 Q000502 NY,D013110 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY,D007107 Q000166 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.,"The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)). After binding, the receptors are internalized, degraded, and thus functionally antagonized by fingolimod. Under physiologic conditions, S1P(1) mediates the egress of lymphocytes from secondary lymphoid organs to the peripheral circulation. Func",Neurology,"M Mehling, T A Johnson, J Antel, L Kappos, A Bar-Or"," Department of Neurology, University Hospital, Basel, Switzerland.",2011 Feb;76(?):S20-7,10.1212/wnl.0b013e31820db341
21339488,20110222,review,"xref,mesh","Animals,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,metabolism,pharmacology,therapeutic use,trends","D049349 Q000378 NY,D007166 Q000627 NN,D002986 Q000639 NY,D049349 Q000276 NN,D013110 Q000031 NN,D011409 Q000494 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.,"The limitations of established therapies for multiple sclerosis (MS) are well-known and include the need for injections, treatment adherence and convenience issues, partial efficacy, and, in some cases, a risk of potentially life-threatening adverse events, such as progressive multifocal leukoencephalopathy. Recently, attention has focused on developing more effective therapies that are administered orally and target neurodegeneration as well as inflammation. In this review, we provide an outlook on the fut",Neurology,"Reinhard Hohlfeld, Frederik Barkhof, Chris Polman"," Institute for Clinical Neuroimmunology, Munich, Germany. reinhard.hohlfeld@med.uni-muenchen.de",2011 Feb;76(?):S28-37,10.1212/wnl.0b013e31820db40f
21339489,20110222,review,"xref,mesh","Animals,Autoimmune Diseases,Cardiovascular System,Central Nervous System,Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lymph Nodes,Lysophospholipids,Models, Biological,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,cytology,drug effects,drug therapy,immunology,metabolism,pathology,pharmacology,therapeutic use","D002490 Q000378 NN,D049349 Q000378 NY,D007166 Q000627 NN,D007107 Q000187 NN,D002319 Q000187 NN,D008198 Q000187 NN,D013110 Q000031 NY,D001327 Q000276 NN,D013110 Q000378 NN,D001327 Q000188 NN,D008246 Q000378 NY,D049349 Q000187 NN,D002490 Q000187 NN,D002319 Q000378 NN,D011409 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN,D001327 Q000473 NN,D007107 Q000166 NN,D008198 Q000473 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.,"Sphingosine 1-phosphate (S1P) and 5 specific high-affinity S1P receptor (S1PR) subtypes, S1P(1-5), have important regulatory functions in normal physiology and disease processes, particularly involving the immune, central nervous, and cardiovascular systems. Within the immune system, downmodulation of S1P(1) prevents the egress of B and T cells from lymph nodes (LN) into the lymphatic circulation. This is especially relevant in certain autoimmune diseases, including multiple sclerosis (MS), in which demyeli",Neurology,"Timothy Hla, Volker Brinkmann"," Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Cornell University, New York, NY 10065, USA. tih2002@med.cornell.edu",2011 Feb;76(?):S3-8,10.1212/wnl.0b013e31820d5ec1
21339490,20110222,article,"xref,mesh","Animals,Blood-Brain Barrier,Central Nervous System,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Lymphocytes,Lysophospholipids,Neurobiology,Neuroglia,Neurons,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology,physiology,therapeutic use","D002490 Q000378 NN,D049349 Q000378 NY,D007166 Q000627 NN,D001812 Q000187 NN,D001812 Q000502 NN,D007155 Q000494 NN,D009474 Q000187 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000378 NY,D049349 Q000187 NN,D002490 Q000187 NN,D002490 Q000166 NN,D011409 Q000494 NN,D015398 Q000502 NY,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D008214 Q000187 NN,D007166 Q000494 NN,D009457 Q000187 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.,"Sphingosine 1-phosphate receptors (S1PRs) are G protein-coupled receptors expressed by many cell types, including immune and neural cells. These receptors are promising targets for immunomodulatory and possibly neuromodulatory therapies. Fingolimod (FTY720) is a sphingosine analog that, when phosphorylated, becomes a prototypical S1PR modulator. It has recently been approved as the first oral treatment for relapsing forms of multiple sclerosis in some countries. Fingolimod has documented effects on lymphocy",Neurology,"Betty Soliven, Veronique Miron, Jerold Chun"," Department of Neurology, University of Chicago, IL 60637, USA. bsoliven@neurology.bsd.uchicago.edu",2011 Feb;76(?):S9-14,10.1212/wnl.0b013e31820d9507
21344782,20101229,review,"xref,mesh","Administration, Oral,Animals,Fingolimod Hydrochloride,Headache,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Randomized Controlled Trials as Topic,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,methods,pharmacokinetics","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000008 NN,D013110 Q000031 NY,D007166 Q000493 NN,D011409 Q000493 NN,D013110 Q000493 NN,D016032 Q000379 NN,D007166 Q000009 NN,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY,D006261 Q000139 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Oral fingolimod (gilenya) for multiple sclerosis.,NULL,The Medical letter on drugs and therapeutics,NULL,NULL,2010 Dec;52(?):98-9,NULL
21360856,20110222,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Nervous System Diseases,Propylene Glycols,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,physiology,physiopathology,therapeutic use","D009422 Q000378 NY,D009422 Q000503 NN,D007166 Q000627 NN,D009422 Q000188 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000378 NY,D011409 Q000494 NN,D015398 Q000502 NY,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Modulation of sphingosine 1-phosphate signaling in neurologic disease.,NULL,Neurology,"Jack Antel, Reinhard Hohlfeld"," Montreal Neurological Institute, McGill University, Quebec, Canada. jack.antel@mcgill.ca",2011 Feb;76(?):S1-2,10.1212/wnl.0b013e31820d5e55
21370569,20110101,review,"xref,mesh","Antibodies,Antibodies, Monoclonal, Murine-Derived,Boronic Acids,Bortezomib,Cyclosporine,Everolimus,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Kidney Transplantation,Propylene Glycols,Pyrazines,Rituximab,Sirolimus,Sphingosine,T-Lymphocytes,TOR Serine-Threonine Kinases,Tacrolimus","administration &amp; dosage,adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,immunology,prevention &amp; control","D020123 Q000009 NN,D001897 Q000009 NN,D058570 Q000037 NN,D013601 Q000276 NN,D011719 Q000008 NN,D016559 Q000008 NN,D013110 Q000008 NN,D000906 Q000276 NN,D020123 Q000008 NN,D016572 Q000008 NN,D011409 Q000008 NN,D016572 Q000009 NN,D013110 Q000031 NN,D058846 Q000008 NN,D011719 Q000009 NN,D016559 Q000009 NN,D001897 Q000008 NN,D006084 Q000276 NN,D007166 Q000009 NN,D007166 Q000008 NY,D006084 Q000517 NY,D020123 Q000031 NN","2909,5372,8252,31270,62280,93860,107969,107970,387447,445643,5280335,5280754,5282315,5284373,5284616,5458585,6435893,6442177,6473866,6536850,9855081,24883466,25246316,49867938,53903450,71306795,71463825,71668407,73896891,90696889,90726579,91534498,122172945,123134263,123134270,132274082,134694629","128132375,128394615,129060975,129645792,242749350,242963342,243055978,248766214",[Immunosuppressive agents in kidney transplantation].,NULL,Nihon Jinzo Gakkai shi,Shinichi Nishi,NULL,2011 Jan;53(1):1-5,NULL
21387383,20110201,article,"xref,mesh","Adaptive Immunity,Adult,Enzyme-Linked Immunospot Assay,Female,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Influenza Vaccines,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Prospective Studies,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D013601 Q000276 NN,D007252 Q000276 NY,D013110 Q000031 NY,D009103 Q000276 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D056704 Q000276 NY","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792",Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.,"T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod-treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine-triggered T cells accumulated normally ",Annals of neurology,"Matthias Mehling, Patricia Hilbert, Stefanie Fritz, Bojana Durovic, Dominik Eichin, Olivier Gasser, Jens Kuhle, Thomas Klimkait, Raija L P Lindberg, Ludwig Kappos, Christoph Hess"," Department of Neurology, Clinical Neuroimmunology Laboratory, University Hospital Basel, Switzerland.",2011 Feb;69(2):408-13,10.1002/ana.22352
21391227,20110601,article,"xref,mesh","Animals,Antineoplastic Agents,Carcinoma, Hepatocellular,Caspase 3,Cell Line, Tumor,Cell Proliferation,Cells, Cultured,Fingolimod Hydrochloride,Hepatocytes,Humans,Liver Neoplasms,Mice,Mice, Nude,Propylene Glycols,Protein Kinase C-delta,Reactive Oxygen Species,Signal Transduction,Sphingosine,Xenograft Model Antitumor Assays","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology,physiology,physiopathology","D006528 Q000503 NN,D000970 Q000494 NY,D008113 Q000473 NY,D006528 Q000473 NY,D017382 Q000378 NN,D051745 Q000378 NN,D008113 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D049109 Q000187 NY,D008113 Q000503 NN,D053148 Q000378 NN,D006528 Q000378 NN,D022781 Q000473 NN,D022781 Q000187 NN,D015398 Q000187 NN,D013110 Q000494 NN,D015398 Q000502 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.","Accumulating evidence suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in hepatocellular carcinoma (HCC). Based on our previous finding that FTY720 mediates apoptosis in HCC cells by activating reactive oxygen species (ROS)-protein kinase Cδ (PKCδ) signaling independent of effects on sphingosine-1-phosphate (S1P) receptors, we embarked on the pharmacological exploitation of FTY720 to develop a nonimmunosuppressive analogue with antitumor activity. This effort led to the ","Hepatology (Baltimore, Md.)","Hany A Omar, Chih-Chien Chou, Lisa D Berman-Booty, Yihui Ma, Jui-Hsiang Hung, Dasheng Wang, Takayuki Kogure, Tushar Patel, Luigi Terracciano, Natarajan Muthusamy, John C Byrd, Samuel K Kulp, Ching-Shih Chen"," Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, OH 43210, USA. chen.844@osu.edu",2011 Jun;53(6):1943-58,10.1002/hep.24293
21394595,20110401,review,"xref,mesh","Activities of Daily Living,Administration, Oral,Bradycardia,Central Nervous System,Clinical Trials, Phase II as Topic,Clinical Trials, Phase III as Topic,Disease Progression,Female,Fingolimod Hydrochloride,Herpesviridae Infections,Humans,Immunosuppressive Agents,Macular Edema,Male,Multiple Sclerosis, Relapsing-Remitting,Neuroimmunomodulation,Neurologic Examination,Propylene Glycols,Receptors, Lysosphingolipid,Recurrence,Sphingosine,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug effects,drug therapy,metabolism,pathology,physiopathology","D011409 Q000008 YN,D049349 Q000378 NY,D013110 Q000009 NN,D007166 Q000008 NN,D008269 Q000139 NN,D002490 Q000473 NN,D001919 Q000139 NN,D011409 Q000009 YN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D020529 Q000503 NN,D015213 Q000187 NY,D020529 Q000378 NY,D006566 Q000139 NN,D020529 Q000188 NY,D007166 Q000009 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.,"This paper presents a summary of the current knowledge of the mechanism of action of fingolimod (FTY720; Gilenya®; Novartis Pharma Stein AG, Stein, Switzerland) and the phase 2 and 3 studies that have been performed on the drug. This study will discuss specific safety issues that should be considered when initiating this therapy. Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is considered to be a leading cause of neurologic disability in young adults, and predominantly affe",Advances in therapy,"E Ann Yeh, B Weinstock-Guttman"," Women and Children's Hospital of Buffalo, NY 14222, USA.",2011 Apr;28(4):270-8,10.1007/s12325-011-0004-6
21406175,20110401,article,"xref,mesh","Animals,Anti-Inflammatory Agents,Apoptosis,Cytokines,Disease Models, Animal,Electrophysiology,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Glycoproteins,Immunosuppressive Agents,Myelin Sheath,Neurons,Oligodendroglia,Optic Neuritis,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,cytology,immunology,metabolism,methods,pharmacology","D009186 Q000378 NN,D009902 Q000378 NY,D000893 Q000494 NY,D004681 Q000276 NN,D006023 Q000378 NN,D016207 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D004594 Q000379 NN,D009836 Q000378 NN,D009474 Q000166 NY,D013110 Q000494 NN,D007166 Q000494 NN","1070,8252,31270,107969,107970,439212,5280335","128394615,128684338,129060975,129645792",Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.,"In multiple sclerosis, long-term disability is caused by axonal and neuronal damage. Established therapies target primarily the inflammatory component of the disease, but fail to prevent neurodegeneration. Fingolimod (codenamed FTY720) is an oral sphingosine 1-phosphate (S1P) receptor modulator with promising results in phase II trials in multiple sclerosis patients and is under further development as a novel treatment for multiple sclerosis. To evaluate whether FTY720 has neuroprotective properties, we tes",The American journal of pathology,"Christian R Rau, Katharina Hein, Muriel B Sättler, Benedikt Kretzschmar, Carina Hillgruber, Bradford L McRae, Ricarda Diem, Mathias Bähr"," Department of Neurology, University Medicine Göttingen, Göttingen, Germany.",2011 Apr;178(4):1770-81,10.1016/j.ajpath.2011.01.003
21406406,20110315,article,"xref,mesh","Animals,Cell Line, Tumor,Cell Proliferation,Enzyme Activation,Fingolimod Hydrochloride,Gastrointestinal Stromal Tumors,Humans,Immunosuppressive Agents,Inhibitory Concentration 50,Mice,Mutation,Propylene Glycols,Protein Phosphatase 2,Proto-Oncogene Proteins c-kit,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology","D046152 Q000188 NN,D019009 Q000378 NN,D004789 Q000187 NN,D019009 Q000235 NN,D013110 Q000031 NY,D054648 Q000378 NN,D011409 Q000494 NY,D049109 Q000187 NY,D054648 Q000235 NN,D046152 Q000473 NN,D046152 Q000235 NN,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter.,NULL,Cancer research,"Amaury G Dumont, David G Reynoso, Jonathan C Trent",NULL,2011 Mar;71(6):?,10.1158/0008-5472.can-10-3383
21417621,20110801,article,"xref,mesh","Animals,Area Under Curve,Biological Availability,Drug Delivery Systems,Drug Stability,Emulsions,Immunosuppressive Agents,Male,Particle Size,Rats,Rats, Sprague-Dawley,Sirolimus,Solubility,Solvents","administration &amp; dosage,pharmacokinetics","D007166 Q000008 NN,D007166 Q000493 NY,D020123 Q000008 NN,D020123 Q000493 NY","753,8252,249377,5284616,91454826,91534498","128902940,129060975,129885148,248184126,248766214",The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems.,"OBJECTIVE: This work aims to investigate the influence of various types and different contents of co-solvent on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems (SMEDDS). METHODS: A series of SMEDDS of rapamycin were prepared with different co-solvents [including PEG 400/ethanol (F1), glycerol/ethanol (F2), propylene glycol (F3), glycerol formal (F4), transcutol P (F5)]. Drug stability in aqueous media at different pH values and in vitro dispersion of ",Drug development and industrial pharmacy,"Minghui Sun, Luqin Si, Xuezhen Zhai, Zhaoze Fan, Yiming Ma, Rui Zhang, Xiangliang Yang"," Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China.",2011 Aug;37(8):986-94,10.3109/03639045.2011.553618
21425262,20110101,review,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antineoplastic Agents,Clinical Trials as Topic,Disease Progression,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Mitoxantrone,Multiple Sclerosis,Natalizumab,Patient Selection,Peptides,Propylene Glycols,Secondary Prevention,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,physiopathology,therapy","D010455 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D000911 Q000008 NN,D016899 Q000008 NN,D000911 Q000009 NN,D013110 Q000008 NN,D011409 Q000008 NN,D016899 Q000009 NN,D013110 Q000031 NN,D009103 Q000628 YN,D009103 Q000503 YN,D008942 Q000009 NN,D008942 Q000008 NN,D000970 Q000009 NN,D010455 Q000008 NN,D007166 Q000009 NN,D000970 Q000008 NN","4212,6057,8252,31270,51082,51151,65370,107969,107970,3081884,5280335,5458171,54607525","128394615,128397534,128865459,129060975,129645792",Current disease-modifying treatment of multiple sclerosis.,"The treatment era for multiple sclerosis began in 1993 with the approval of the first disease-modifying therapy. This changed the management of multiple sclerosis from treating acute exacerbations to focusing on preventive therapeutic options that lessen the risk for exacerbations, changes on magnetic resonance imaging, and disability as measured by the Expanded Disability Status Scale. Currently, there are 8 therapies approved to treat multiple sclerosis: beta-interferons (Avonex, Betaseron, Extavia, and R","The Mount Sinai journal of medicine, New York",Joy Derwenskus," Department of Neurology, Northwestern University, Chicago, IL, USA. jderwenskus1@nmff.org",2011 Jan;78(2):161-75,10.1002/msj.20239
21425264,20110101,review,"xref,mesh","4-Aminopyridine,Administration, Oral,Antibodies, Monoclonal,Confusion,Disease Progression,Drug Monitoring,Drug Therapy, Combination,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Locomotion,Multiple Sclerosis,Patient Care Team,Patient Selection,Potassium Channel Blockers,Propylene Glycols,Severity of Illness Index,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,physiopathology","D007155 Q000009 YN,D011409 Q000009 NN,D013110 Q000009 NN,D000911 Q000009 YN,D015761 Q000008 YN,D026902 Q000008 NN,D013110 Q000008 NN,D007166 Q000009 YN,D015761 Q000009 YN,D007166 Q000008 YN,D008124 Q000187 NY,D000911 Q000008 YN,D011409 Q000008 NN,D007155 Q000008 YN,D013110 Q000031 NN,D009103 Q000503 YN,D003221 Q000139 NN,D009103 Q000188 YN,D026902 Q000009 NN","1727,8252,12215,20279,31270,107969,107970,5280335,23500906,54677946","127968532,128394615,128471922,128672523,128756319,128966217,129060975,129645792",Multiple sclerosis therapeutic pipeline: opportunities and challenges.,"The year 2010 marked the beginning of the era of oral medications for the treatment of multiple sclerosis, with the approval of dalfampridine to improve walking and fingolimod as the first oral disease-modifying agent. This review provides an overview of these and other emerging therapies, with an emphasis on the opportunities for new treatment paradigms they have the potential to offer, followed by a discussion of the challenges they will pose in the new era of multiple sclerosis management. Therapeutics i","The Mount Sinai journal of medicine, New York",Stephen Krieger," Mount Sinai School of Medicine, New York, NY, USA. stephen.krieger@exchange.mssm.edu",2011 Jan;78(2):192-206,10.1002/msj.20241
21437661,20110501,review,"xref,mesh","Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Cladribine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-beta,Mitoxantrone,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","analogs &amp; derivatives,therapeutic use,therapy","D016899 Q000627 NN,D000911 Q000627 NN,D013110 Q000031 NN,D009103 Q000628 NY,D007166 Q000627 NY,D008942 Q000627 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN","1044,4212,5262,6057,8252,20279,31270,51082,51151,107969,107970,5280335,5458171,54607525","127790758,128365023,128394615,128397534,128865459,128966217,129060975,129645792",Managing MS in a changing treatment landscape.,"Increasing options are dictating the development of new algorithms to provide guidance in the treatment of people with multiple sclerosis (MS). There is a wealth of evidence on the safety and efficacy of interferon-beta and glatiramer acetate, which have been used in Europe and in the United States for more than 10 years. The spectrum of approved indications for these conventional disease modifying therapies includes the treatment of relapsing-remitting MS, secondary progressive MS, and the clinically isola",Journal of neurology,"Martin Duddy, Aiden Haghikia, Eleonora Cocco, Christian Eggers, Jelena Drulovic, Olga Carmona, Helene Zéphir, Ralf Gold"," Department of Neurology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.",2011 May;258(5):728-39,10.1007/s00415-011-6009-x
21440955,20110501,article,"xref,mesh","Administration, Intravesical,Animals,Chemotaxis, Leukocyte,Cystitis, Interstitial,Disease Models, Animal,Edema,Female,Gels,Glutathione,Hyperemia,Instillation, Drug,Neutrophils,Nitric Oxide Donors,Nitro Compounds,Oxidative Stress,Pharmaceutical Vehicles,Polyethylene Glycols,Potassium Chloride,Propylene Glycols,Protamines,Rats,Rats, Wistar","administration &amp; dosage,analogs &amp; derivatives,chemically induced,drug effects,pathology,toxicity","D009574 Q000633 NY,D011189 Q000633 NN,D020030 Q000633 NY,D005978 Q000031 NY,D018856 Q000473 NN,D005978 Q000008 NN,D005978 Q000633 NN,D009504 Q000473 NN,D004487 Q000473 NN,D011479 Q000633 NN,D020030 Q000008 NN,D002634 Q000187 NN,D018856 Q000139 NY,D004487 Q000139 NN,D006940 Q000139 NN,D006940 Q000473 NN,D009574 Q000008 NN","4873,8252,124886,54501752,87354512","129060975,129192846,129777713",[A new experimental model for inducing interstitial cystitis by oxidative stress using bladder instillation of a nitric oxide donor gel].,"PURPOSE: The aim of this study is to develop a new experimental model of inducing interstitial cystitis (IC) through vesical instillation of a polymeric solution containing the NO donor S-nitrousglutathione (GSNO) and to compare it to the experimental interstitial cystitis induced by vesical instillation of protamine and potassium chloride. MATERIAL AND METHOD: For that purpose 40 female Wistar rats were used, divided in four groups: 1. saline solution + GSNO; 2. saline solution + polymeric solution (withou",Actas urologicas espanolas,"T F Palma, A Seabra, S C Souto, L Maciel, M Alvarenga, R Siniscalchi, M Ganzarolli, C Ricetto"," Hospital Clínico Universitario de la Universidad Estatal de Campinas, Brasil. thais.palma@gmail.com",2011 May;35(5):253-8,10.1016/j.acuro.2010.05.018
21456524,20110425,review,"xref,mesh,assay","Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Hypocreales,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Structure-Activity Relationship,United States,United States Food and Drug Administration","analogs &amp; derivatives,chemical synthesis,chemistry,drug therapy,pharmacology","D006999 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D013110 Q000138 NN,D011409 Q000737 YN,D005229 Q000737 NN,D011409 Q000494 YN,D011409 Q000138 YN,D005229 Q000138 NY,D005229 Q000494 NN,D007166 Q000138 NY,D007166 Q000737 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NY","8252,31270,107969,107970,121989,5280335,5284373,6438394,9860720,10712432,10834317,11452022,42611957,57024517","128394615,129060975,129645792,129976789,135812730",Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.,"Fingolimod (Gilenya; FTY720), a synthetic compound based on the fungal secondary metabolite myriocin (ISP-I), is a potent immunosuppressant that was approved (September 2010) by the U.S. FDA as a new treatment for multiple sclerosis (MS). Fingolimod was synthesized by the research group of Tetsuro Fujita at Kyoto University in 1992 while investigating structure-activity relationships of derivatives of the fungal metabolite ISP-I, isolated from Isaria sinclairii. Fingolimod becomes active in vivo following p",Journal of natural products,"Cherilyn R Strader, Cedric J Pearce, Nicholas H Oberlies"," Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, North Carolina 27402-6170, USA.",2011 Apr;74(4):900-7,10.1021/np2000528
21459808,20110801,article,"xref,mesh","Animals,Disease Progression,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Mice,Nerve Degeneration,Propylene Glycols,Recovery of Function,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,pathology,therapeutic use","D020127 Q000187 NN,D013110 Q000031 NY,D009410 Q000188 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D004681 Q000473 NN,D004681 Q000188 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.,"BACKGROUND: There has been poor translation for the use of immunosuppressive agents from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), into the treatment of MS. This may be due to the fact that most EAE studies examine prophylactic, pre-treatment regimes that prove to be therapeutically-ineffective in long-established, often progressive, MS. FTY720 (fingolimod/Gilenya) is a sphingosine-1-phosphate receptor modulator. This is a new oral agent that markedly reduc","Multiple sclerosis (Houndmills, Basingstoke, England)","Sarah Al-Izki, Gareth Pryce, Samuel J Jackson, Gavin Giovannoni, David Baker"," Centre of Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK. s.al-izki@qmul.ac.uk",2011 Aug;17(8):939-48,10.1177/1352458511400476
21460633,20110701,article,"xref,mesh","Adolescent,Aged,Autophagy,Caspases,Cell Death,Cell Line, Tumor,Cell Proliferation,Cell Survival,Child,Child, Preschool,Cytoprotection,Enzyme Activation,Female,Fingolimod Hydrochloride,Humans,Male,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Propylene Glycols,Protein Phosphatase 2,Reactive Oxygen Species,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Young Adult","analogs &amp; derivatives,drug effects,enzymology,metabolism,pathology,pharmacology","D054198 Q000201 NN,D002470 Q000187 NN,D017382 Q000378 NN,D016923 Q000187 NN,D004789 Q000187 NN,D049109 Q000187 NN,D001343 Q000187 NN,D013110 Q000031 NY,D054198 Q000473 NY,D054648 Q000378 NN,D011409 Q000494 NY,D020169 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D019610 Q000187 NN,D049349 Q000378 NN","8252,12035,31270,107969,107970,5280335,53903450,57059112","128132375,128394615,128977994,129060975,129645792,135870608",FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.,"Acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, usually responds to chemotherapy but patients who develop disease relapse have a poor prognosis. New agents to treat ALL are urgently required. FTY720 is an immunosuppressive drug that has promising in vitro activity in a number of malignancies, with the proposed mechanism being the reactivation of the protein serine/threonine phosphatase, PP2A. FTY720 reduced the proliferation and viability of Ph(+) and Ph(-) ALL cell lines and p",Autophagy,"Craig T Wallington-Beddoe, John Hewson, Kenneth F Bradstock, Linda J Bendall"," Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, Australia.",2011 Jul;7(7):707-15,10.4161/auto.7.7.15154
21464128,20110527,article,"xref,mesh","Actins,Allosteric Regulation,Breast Neoplasms,Catalytic Domain,Cell Line, Tumor,Enzyme Inhibitors,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Models, Chemical,Neoplasm Proteins,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Proteasome Endopeptidase Complex,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,chemistry,drug effects,drug therapy,enzymology,metabolism,pharmacology","D017853 Q000037 YN,D009363 Q000037 YN,D001943 Q000201 NY,D004791 Q000737 NN,D011409 Q000737 NN,D001943 Q000188 NN,D013110 Q000031 NY,D000199 Q000378 NY,D013110 Q000737 NN,D011409 Q000494 NY,D046988 Q000378 NY,D013110 Q000378 NN,D009363 Q000378 YN,D017853 Q000378 YN,D004791 Q000494 NY,D007166 Q000737 NN,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D000494 Q000187 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792","FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.","Sphingosine kinase 1 (SK1) catalyzes the conversion of sphingosine to the bioactive lipid sphingosine 1-phosphate. We have previously demonstrated that FTY720 and (S)-FTY720 vinylphosphonate are novel inhibitors of SK1 activity. Here, we show that (S)-FTY720 vinylphosphonate binds to a putative allosteric site in SK1 contingent on formation of the enzyme-sphingosine complex. We report that SK1 is an oligomeric protein (minimally a dimer) containing noncooperative catalytic sites and that the allosteric site",The Journal of biological chemistry,"Keng G Lim, Francesca Tonelli, Zaiguo Li, Xuequan Lu, Robert Bittman, Susan Pyne, Nigel J Pyne"," Cell Biology Group, Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, Scotland, United Kingdom.",2011 May;286(21):18633-40,10.1074/jbc.m111.220756
21464424,20110405,article,"xref,mesh","Adult,Aged,Aged, 80 and over,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Longitudinal Studies,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocytes,Young Adult","analogs &amp; derivatives,blood,cerebrospinal fluid,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D020529 Q000188 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013601 Q000276 NY,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D020529 Q000097 NY,D020529 Q000276 NN,D020529 Q000134 NY,D013601 Q000187 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.,"BACKGROUND: The oral immunomodulator fingolimod (FTY720) has recently been shown to be highly effective in relapsing-remitting multiple sclerosis (MS). Fingolimod is a functional antagonist of the sphingosine-1-phosphate receptor 1 and thereby inhibits sphingosine-1-phosphate-dependent lymphocyte egress from secondary lymphoid tissues, resulting in a pronounced lymphopenia in the peripheral blood. The effects of fingolimod treatment on the CSF of patients with MS have not been studied so far. METHODS: We an",Neurology,"M C Kowarik, H L Pellkofer, S Cepok, T Korn, T Kümpfel, D Buck, R Hohlfeld, A Berthele, B Hemmer"," Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.",2011 Apr;76(14):1214-21,10.1212/wnl.0b013e3182143564
21508896,20110715,article,"xref,mesh","Animals,Antibodies, Monoclonal,Diabetes Mellitus, Experimental,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Immunosuppressive Agents,Indoles,Islets of Langerhans Transplantation,Lymphangiogenesis,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Pyrroles,Sphingosine,T-Lymphocytes,Transplantation Tolerance,Transplantation, Homologous,Vascular Endothelial Growth Factor Receptor-3","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,immunology,pathology,pharmacology,prevention &amp; control,surgery","D006085 Q000187 NN,D000911 Q000008 NN,D042583 Q000187 NN,D013601 Q000276 NN,D016381 Q000473 NN,D006085 Q000276 NY,D023001 Q000187 NN,D007211 Q000494 NN,D013110 Q000031 NN,D003921 Q000601 NN,D016381 Q000276 NY,D023001 Q000276 NN,D042583 Q000276 NY,D040321 Q000037 NN,D013601 Q000473 NN,D011409 Q000494 NN,D006084 Q000517 NN,D006084 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN,D011758 Q000494 NN,D040321 Q000276 NN","5793,8252,29327,31270,107969,107970,3086686,5280335,5329102,6456015,44181971,91826462","128394615,129060975,129621433,129645792,135758261,247499656",Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.,"BACKGROUND: Lymphatics are important for their conduit functions of transporting antigen, immune cells, and inflammatory mediators to draining lymph nodes and to the general circulation. Lymphangiogenesis is involved in many pathologic processes; however, the roles for lymphatic responses in transplantation have not been thoroughly investigated. METHODS: Mice were made diabetic by a single high dose of streptozotocin and then received islet allografts. Animals were treated with three different lymphatic inh",Transplantation,"Na Yin, Nan Zhang, Jiangnan Xu, Qixin Shi, Yaozhong Ding, Jonathan S Bromberg"," Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, USA.",2011 Jul;92(1):25-30,10.1097/tp.0b013e31821d2661
21519925,20111001,article,"xref,mesh","Animals,Apoptosis,Caspase 3,Caspase 7,Caspase Inhibitors,Cell Line,Fingolimod Hydrochloride,Gene Expression Profiling,Gene Regulatory Networks,Humans,Immunosuppressive Agents,Microarray Analysis,Microglia,Multiple Sclerosis,Pertussis Toxin,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Sterol Regulatory Element Binding Protein 2","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug effects,drug therapy,genetics,immunology,metabolism,pathology,pharmacology,physiology,therapeutic use","D007166 Q000494 NY,D037342 Q000494 NN,D017209 Q000187 NY,D009103 Q000473 NN,D007166 Q000627 NN,D049349 Q000235 NN,D017628 Q000473 NY,D053179 Q000378 NN,D051782 Q000235 NN,D013110 Q000031 NY,D011409 Q000494 NY,D017628 Q000502 NY,D051782 Q000378 NY,D053148 Q000378 NN,D017628 Q000166 NN,D017628 Q000187 NY,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D049349 Q000037 NN,D009103 Q000188 NN,D049349 Q000378 NN","5361,8252,31270,54454,105065,107969,107970,5280335","127850182,128394615,129060975,129200050,129645792,136111139",Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.,"A synthetic analog of sphingosine named FTY720 (Fingolimod), phosphorylated by sphingosine kinase-2, interacts with sphingosine-1-phosphate (S1P) receptors expressed on various cells. FTY720 suppresses the disease activity of multiple sclerosis (MS) chiefly by inhibiting S1P-dependent egress of autoreactive T lymphocytes from secondary lymphoid organs, and possibly by exerting anti-inflammatory and neuroprotective effects directly on brain cells. However, at present, biological effects of FTY720 on human mi",Cellular and molecular neurobiology,"Takashi Yoshino, Hiroko Tabunoki, Shigeo Sugiyama, Keitaro Ishii, Seung U Kim, Jun-Ichi Satoh"," Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.",2011 Oct;31(7):1009-20,10.1007/s10571-011-9698-x
21520239,20110501,review,"xref,mesh","Animals,Central Nervous System,Chemical and Drug Induced Liver Injury,Clinical Trials as Topic,Disease Models, Animal,Fingolimod Hydrochloride,Heart Diseases,Humans,Immunosuppressive Agents,Infection,Liver Diseases,Lymphocytes,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Respiration Disorders,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,metabolism,pathology,pharmacology,physiology","D013110 Q000009 NN,D009103 Q000473 NN,D007239 Q000139 NN,D006331 Q000139 NN,D002490 Q000276 NN,D008214 Q000502 NN,D013110 Q000031 NY,D013110 Q000378 NN,D002490 Q000187 NN,D007166 Q000009 NY,D011409 Q000494 NN,D008246 Q000378 NN,D009103 Q000276 NN,D012120 Q000139 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NY,D049349 Q000378 NN,D011409 Q000009 NY","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792,135650261",Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.,"Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally. Oral fingolimod was approved in September 2010 by the US Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS. In the clinical trials that led to approval, fingolimod reduced not only acute relapses and magnetic resonance imaging lesion activity but also disability progression and brain volume loss, suggesting preservation of tissue. Fingolimod's mechanism of",Annals of neurology,"Jeffrey A Cohen, Jerold Chun"," Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA. cohenj@ccf.org",2011 May;69(5):759-77,10.1002/ana.22426
21552174,20110601,article,"xref,mesh","Benzimidazoles,Contraceptives, Postcoital,Dabigatran,Drug Therapy,Fibrinolytic Agents,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Norpregnadienes,Pharmaceutical Preparations,Propylene Glycols,Pyridines,Sphingosine","adverse effects,analogs &amp; derivatives,nursing,therapeutic use","D005343 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000627 NN,D001562 Q000627 NN,D011725 Q000009 NN,D011725 Q000627 NN,D009649 Q000009 NN,D003281 Q000627 NN,D013110 Q000031 NN,D001562 Q000009 NN,D005343 Q000627 NN,D004358 Q000451 NY,D003281 Q000009 NN,D009649 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN","8252,31270,107969,107970,130904,213023,216210,581866,5280335,6445226,9578572,10439877,11434065,13559282,72960092","128394615,129060975,129645792,243566365",New drugs 2011 part 2.,NULL,Nursing,Daniel A Hussar," Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.",2011 Jun;41(6):?,10.1097/01.nurse.0000397931.58044.99
21555855,20110601,article,"xref,mesh","Animals,Capillary Leak Syndrome,Dose-Response Relationship, Drug,Endocytosis,Fingolimod Hydrochloride,Gene Knock-In Techniques,Lymphopenia,Lysophospholipids,Mice,Organophosphates,Peptide Hydrolases,Phosphorylation,Propylene Glycols,Protein Processing, Post-Translational,Protein Structure, Tertiary,Pulmonary Edema,Receptors, G-Protein-Coupled,Receptors, Lysosphingolipid,Recombinant Fusion Proteins,Sphingosine,Ubiquitin-Protein Ligases,Ubiquitination","analogs &amp; derivatives,chemically induced,drug effects,genetics,metabolism,pharmacology,physiology,physiopathology,toxicity","D054875 Q000187 NN,D011654 Q000139 NN,D049349 Q000378 NY,D010755 Q000494 NN,D044767 Q000502 NN,D011499 Q000187 NN,D011409 Q000633 NY,D049349 Q000235 NN,D044767 Q000235 NN,D008231 Q000139 NN,D010447 Q000378 NN,D013110 Q000633 NN,D013110 Q000031 NY,D019559 Q000503 NY,D011993 Q000502 NN,D011654 Q000503 NN,D008246 Q000502 NN,D011409 Q000494 NN,D010766 Q000187 NN,D013110 Q000494 NN,D043562 Q000378 NY,D013110 Q000502 NN","8252,31270,105065,107969,107970,5280335,5283560,9908268,11452022,45268446","128394615,129060975,129645792,136111139",Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice.,"GPCR inhibitors are highly prevalent in modern therapeutics. However, interference with complex GPCR regulatory mechanisms leads to both therapeutic efficacy and adverse effects. Recently, the sphingosine-1-phosphate (S1P) receptor inhibitor FTY720 (also known as Fingolimod), which induces lymphopenia and prevents neuroinflammation, was adopted as a disease-modifying therapeutic in multiple sclerosis. Although highly efficacious, dose-dependent increases in adverse events have tempered its utility. We show ",The Journal of clinical investigation,"Myat Lin Oo, Sung-Hee Chang, Shobha Thangada, Ming-Tao Wu, Karim Rezaul, Victoria Blaho, Sun-Il Hwang, David K Han, Timothy Hla"," Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, New York 10065, USA.",2011 Jun;121(6):2290-300,10.1172/jci45403
21556483,20110101,article,"xref,mesh","Aldehyde-Lyases,Animals,Antimalarials,Artemisinins,Brain,Cell Adhesion Molecules,Child,Child, Preschool,Female,Fingolimod Hydrochloride,Humans,Imidazoles,Immunosuppressive Agents,Infant,Interferon-gamma,Lysophospholipids,Malaria, Cerebral,Mice,Mice, 129 Strain,Mice, Inbred C57BL,Mice, Knockout,Oximes,Plasmodium berghei,Propylene Glycols,Sphingosine,Survival Analysis,T-Lymphocytes,Treatment Outcome","analogs &amp; derivatives,antagonists &amp; inhibitors,blood,drug effects,drug therapy,genetics,growth &amp; development,metabolism,pharmacology","D013601 Q000378 NN,D013110 Q000097 NN,D000446 Q000037 NN,D000962 Q000494 NN,D016779 Q000378 NY,D007093 Q000494 NN,D037621 Q000494 NN,D016779 Q000188 NN,D010962 Q000254 NY,D001921 Q000187 NN,D013110 Q000031 NY,D010091 Q000494 NN,D001921 Q000378 NN,D013110 Q000378 NN,D000446 Q000235 NN,D008246 Q000097 NN,D015815 Q000097 NN,D010962 Q000187 NN,D008246 Q000378 NY,D000446 Q000378 NY,D011409 Q000494 NN,D007371 Q000097 NN,D013110 Q000494 NN,D007166 Q000494 NN,D016779 Q000235 NN,D013601 Q000187 NN","8252,31270,65664,105031,107969,107970,156252,180624,5280335,5283560,5464098,6917864,9821433,16394563,16731781,23697153,44410736,46926352,49769200,53486426,57253359,60196289,71300409,91617420,91746179,126963478,129317578","128394615,129060975,129645792,136206684,244111387",S1P is associated with protection in human and experimental cerebral malaria.,"Cerebral malaria (CM) is associated with excessive inflammatory responses and endothelial activation. Sphingosine 1-phosphate (S1P) is a signaling sphingolipid implicated in regulating vascular integrity, inflammation and T-cell migration. We hypothesized that altered S1P signaling during malaria contributes to endothelial activation and inflammation, and show that plasma S1P levels were decreased in Ugandan children with CM compared with children with uncomplicated malaria. Using the Plasmodium berghei ANK","Molecular medicine (Cambridge, Mass.)","Constance Am Finney, Cheryl A Hawkes, Dylan C Kain, Aggrey Dhabangi, Charles Musoke, Christine Cserti-Gazdewich, Tamas Oravecz, W Conrad Liles, Kevin C Kain"," SA Rotman Laboratories, McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, Canada Faculty of Medicine, University of Toronto, Canada.",2011 Jan;17(?):717-25,10.2119/molmed.2010.00214
21559342,20110101,article,"xref,mesh","Animals,Apoptosis,Cryopreservation,Female,Fingolimod Hydrochloride,Graft Survival,Humans,Immunohistochemistry,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, SCID,Neovascularization, Physiologic,Ovarian Follicle,Ovary,Oxadiazoles,Propylene Glycols,Sphingosine,Thiophenes,Transplantation, Heterologous","analogs &amp; derivatives,blood supply,metabolism,methods,pharmacology,physiology,transplantation","D010069 Q000494 NN,D006080 Q000502 NY,D013110 Q000378 NN,D013110 Q000031 NN,D013876 Q000494 NN,D010053 Q000637 NY,D010053 Q000098 NY,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007150 Q000379 NN","3988,5707,8252,31270,35864,105065,107969,107970,644025,644073,4077460,5280335,5283560,10523409","127548708,128394615,129060975,129622673,129645792,129696267,136111139,136178062,136326756",Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants.,Ovarian transplantation is one of the key approaches to restoring fertility in women who became menopausal as a result of cancer treatments. A major limitation of human ovarian transplants is massive follicular loss during revascularization. Here we investigated whether sphingosine-1-phosphate or its receptor agonists could enhance neoangiogenesis and follicle survival in ovarian transplants in a xenograft model. Human ovarian tissue xenografts in severe-combined-immunodeficient mice were treated with sphin,PloS one,"Reza Soleimani, Elke Heytens, Kutluk Oktay"," Laboratory of Molecular Reproduction, Institute for Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla, New York, United States of America.",2011 Jan;6(4):e19475,10.1371/journal.pone.0019475
21571592,20110601,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Multiple Sclerosis,Placebos,Propylene Glycols,Randomized Controlled Trials as Topic,Research Design,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D016899 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Transforming multiple sclerosis trials into practical reality.,NULL,The Lancet. Neurology,"Bernd C Kieseier, Heinz Wiendl"," Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. bernd.kieseier@uni-duesseldorf.de",2011 Jun;10(6):493-4,10.1016/s1474-4422(11)70100-4
21571593,20110601,article,"xref,mesh","Adjuvants, Immunologic,Adolescent,Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Injections, Intramuscular,Interferon beta-1a,Interferon-beta,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome,Young Adult","analogs &amp; derivatives,drug therapy,pathology,physiopathology,therapeutic use","D016899 Q000627 NY,D000276 Q000627 NY,D013110 Q000031 NY,D020529 Q000473 NN,D020529 Q000503 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.,"BACKGROUND: In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess the effect of delaying the start of treatment ",The Lancet. Neurology,"Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Xavier Montalban, Jean Pelletier, Tracy Stites, Stacy Wu, Fred Holdbrook, Lixin Zhang-Auberson, Gordon Francis, Jeffrey A Cohen, TRANSFORMS Study Group"," St Luke's Medical Center, Center for Neurological Disorders, Milwaukee, WI 53215, USA. bokhatri@aol.com",2011 Jun;10(6):520-9,10.1016/s1474-4422(11)70099-0
21585629,20110601,article,"xref,mesh","Administration, Oral,Adolescent,Adult,Age Factors,Area Under Curve,Dose-Response Relationship, Drug,Drug Administration Schedule,Electrocardiography,Electrocardiography, Ambulatory,Female,Fingolimod Hydrochloride,Follow-Up Studies,Graft Survival,Heart Rate,Humans,Immunosuppressive Agents,Kidney Transplantation,Male,Monitoring, Physiologic,Postoperative Care,Propylene Glycols,Prospective Studies,Risk Assessment,Sphingosine,T-Lymphocyte Subsets","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,methods,pharmacokinetics","D011409 Q000009 NN,D013110 Q000009 NN,D011409 Q000493 NY,D008991 Q000379 NN,D013110 Q000008 NN,D016030 Q000379 NY,D007166 Q000493 NY,D013110 Q000031 NY,D016176 Q000187 NN,D015716 Q000379 NN,D013110 Q000493 NN,D011182 Q000379 NN,D006339 Q000187 NN,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.",Oral fingolimod signals the sphingosine 1-phosphate receptor and this in turn mediates immunomodulatory activity. No data of fingolimod in any pediatric population existed before this study. We put our study results in perspective against data from adult renal transplant patients. We investigated pharmacokinetics and pharmacodynamics of single-dose fingolimod (0.07 mg/kg) and its effects on lymphocytes and heart rate in seven adolescents (14.1 ± 1.6 yr) with stable renal transplants. Blood samples for pharm,Pediatric transplantation,"R Ettenger, R Schmouder, J M Kovarik, M C Bastien, P F Hoyer"," Division of Pediatric Nephrology, Mattel Children's Hospital UCLA, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095-1752, USA. rettenger@mednet.ucla.edu",2011 Jun;15(4):406-13,10.1111/j.1399-3046.2011.01498.x
21622858,20110701,article,"xref,mesh","CD56 Antigen,Cells, Cultured,Chemotaxis, Leukocyte,Down-Regulation,Fingolimod Hydrochloride,Humans,Immunophenotyping,Immunosuppressive Agents,Killer Cells, Natural,Lymphocyte Count,Lymphopenia,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,biosynthesis,drug effects,drug therapy,immunology,metabolism,pathology,therapeutic use","D019002 Q000096 NN,D007694 Q000276 NY,D015536 Q000276 NN,D013110 Q000031 NY,D020529 Q000473 NN,D008231 Q000473 NN,D007166 Q000627 NY,D007694 Q000473 NN,D008231 Q000276 NY,D002634 Q000276 NN,D002634 Q000187 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D019002 Q000378 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.,"FTY720 (fingolimod) treatment of multiple sclerosis (MS) results in lymphopenia due to increased recruitment into and decreased egress from secondary lymphoid organs of CCR7(+) lymphocytes. Although absolute numbers of NK lymphocytes were reported as being unaltered in FTY720-treated MS patients (MS-FTY), such analyses did not detect a change in a minor subset. Because expression of CCR7 has been described on CD56(bright) NK cells, a minority population of NK cells, we investigated the effect of FTY720 trea","Journal of immunology (Baltimore, Md. : 1950)","Trina A Johnson, Barbara L Evans, Bryce A Durafourt, Manon Blain, Yves Lapierre, Amit Bar-Or, Jack P Antel"," Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada.",2011 Jul;187(1):570-9,10.4049/jimmunol.1003823
21623989,20111101,article,"xref,mesh","Animals,CD4-Positive T-Lymphocytes,Disease Models, Animal,Embryo Loss,Female,Fingolimod Hydrochloride,Forkhead Transcription Factors,Humans,Immunosuppressive Agents,Mice,Mice, Inbred BALB C,Mice, Inbred NOD,Mice, SCID,Pregnancy,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes, Regulatory","agonists,analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,prevention &amp; control,therapeutic use","D007166 Q000494 NY,D015496 Q000378 NN,D049349 Q000819 NN,D050378 Q000378 NN,D007166 Q000627 NN,D007166 Q000378 NN,D050378 Q000276 NY,D015496 Q000187 NN,D011409 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D015496 Q000276 NY,D020964 Q000517 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D051858 Q000378 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice.,"PROBLEM: FTY720 is known as an agonist of sphingosine-1-phosphate (S1P) receptor, but little is known about the possibility that FTY720 induces the conversion of conventional Foxp3(-) CD4(+) T cells to Foxp3(+) regulatory T cells in non-obese diabetic (NOD) mice. METHOD OF STUDY: FTY720 treatment was performed using Foxp3(-) CD4(+) T cells purified from NOD mice. RESULTS: FTY720 caused an increase in Foxp3(+) Treg cells in lymphoid organs in NOD mice. FTY720 effectively induced Foxp3 expression in Foxp3(-) ","American journal of reproductive immunology (New York, N.Y. : 1989)","Yun Sun, Wenjing Wang, Bin Shan, Jingfang Di, Linlin Chen, Lingling Ren, Weiping Li, Da-Jin Li, Yi Lin"," Department of Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.",2011 Nov;66(5):349-62,10.1111/j.1600-0897.2011.01010.x
21628899,20110101,article,"xref,mesh","Animals,Autoantigens,Cyclosporine,Demyelinating Diseases,Drug Therapy, Combination,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Glycoproteins,Immunosuppression,Immunosuppressive Agents,Lymphocyte Activation,Mice,Mice, Inbred C57BL,Multiple Sclerosis,Myelin-Oligodendrocyte Glycoprotein,Nerve Tissue Proteins,Peptide Fragments,Propylene Glycols,Remission Induction,Secondary Prevention,Specific Pathogen-Free Organisms,Sphingosine,Spinal Cord","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,drug therapy,etiology,immunology,pathology,physiopathology,prevention &amp; control,therapeutic use","D016572 Q000627 NN,D013116 Q000276 NN,D007166 Q000008 NN,D013116 Q000187 NN,D010446 Q000008 NN,D003711 Q000209 NN,D013116 Q000473 NN,D013110 Q000008 NN,D009419 Q000009 NN,D006023 Q000627 NY,D010446 Q000009 NN,D016572 Q000008 NN,D013110 Q000031 NY,D004681 Q000503 NN,D011409 Q000008 NN,D001324 Q000627 NY,D001324 Q000008 NN,D009419 Q000008 NN,D010446 Q000627 NY,D007166 Q000627 NY,D008213 Q000187 NN,D004681 Q000517 NN,D006023 Q000008 NN,D009419 Q000627 NY,D001324 Q000009 NN,D013110 Q000627 NN,D006023 Q000009 NN","2909,8252,31270,62280,107969,107970,439212,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,126963437,132274082","128394615,129060975,129645792,175443599","Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.","FTY720 (Fingolimod) is known to have a significant therapeutic effect on experimental autoimmune encephalomyelitis (EAE). Here, we used an EAE mouse model, which had been established by immunizing C57BL/6J mice with a partial peptide of myelin oligodendrocyte glycoprotein (MOG₃₅₋₅₅), to examine the relapse of EAE upon discontinuation of treatment with FTY720 alone or in combination with MOG₃₅₋₅₅. Relapse was confirmed to occur in all animals (n=6) within one week after discontinuation of FTY720, with increa",Biological & pharmaceutical bulletin,"Yuya Yoshida, Takumi Tsuji, Tetsuro Fujita, Takeyuki Kohno"," Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan.",2011 Jan;34(6):933-6,10.1248/bpb.34.933
21652609,20111101,article,"xref,mesh","Administration, Oral,Antipsychotic Agents,Bradycardia,Electrocardiography,Fingolimod Hydrochloride,Heart Arrest,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Risperidone,Sphingosine,Time Factors,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug therapy","D006323 Q000139 NY,D013110 Q000009 NN,D007166 Q000008 NN,D001919 Q000139 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D018967 Q000009 NN,D006323 Q000175 NN,D007166 Q000009 NY,D009103 Q000188 NY,D014150 Q000009 NN,D011409 Q000009 NY","5073,8252,31270,107969,107970,5280335","128394615,129060975,129101897,129645792",Delayed fingolimod-associated asystole.,Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod. ,"Multiple sclerosis (Houndmills, Basingstoke, England)","Patricio S Espinosa, Joseph R Berger"," North Oaks Neurology, Hammond, LA, USA. ps.espinosa@gmail.com",2011 Nov;17(11):1387-9,10.1177/1352458511410344
21653325,20110728,article,"xref,mesh","Animals,Antigens, Neoplasm,Cell Separation,Fingolimod Hydrochloride,Flow Cytometry,Graft vs Host Disease,Immunosuppressive Agents,Immunotherapy, Adoptive,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Neoplasms,Propylene Glycols,Sphingosine,T-Lymphocytes,Transplantation, Homologous","analogs &amp; derivatives,immunology,methods,pharmacology,prevention &amp; control,therapy,transplantation","D006086 Q000276 NN,D000951 Q000276 NN,D009369 Q000276 NN,D016219 Q000379 NY,D013110 Q000031 NN,D013601 Q000276 NY,D009369 Q000628 NY,D011409 Q000494 NN,D013601 Q000637 NY,D013110 Q000494 NN,D007166 Q000494 NN,D006086 Q000517 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",Redirected tumor-specific allogeneic T cells for universal treatment of cancer.,"Adoptive cell transfer of allogeneic tumor-specific T cells could potentially be used as a universal treatment for cancer. We present a novel approach for adoptive immunotherapy using fully MHC-mismatched allogeneic T cells redirected with tumor-specific, non-MHC-restricted antibody-based chimeric antigen receptor (T-bodies) in the absence of GVHD. Mice bearing systemic metastatic disease were lymphodepleted by irradiation and treated with Her2/neu re-directed T cells. Lymphodepletion created a 'therapeutic",Blood,"Assaf Marcus, Tova Waks, Zelig Eshhar"," Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.",2011 Jul;118(4):975-83,10.1182/blood-2011-02-334284
21669553,20120101,review,"xref,mesh","Animals,Clinical Trials as Topic,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Chronic Progressive,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,pharmacology","D007166 Q000494 NY,D011409 Q000276 NN,D020528 Q000276 NN,D020528 Q000188 NY,D013110 Q000031 NY,D011409 Q000494 NY,D004681 Q000188 NN,D013110 Q000276 NN,D007166 Q000276 NN,D013110 Q000494 NN","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792",Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.,"Fingolimod, also known as FTY720, has recently been approved by the regulatory authorities in the US, EU, Australia, Russia, among others, for the treatment of relapsing-remitting multiple sclerosis. Fingolimod therefore represents the first oral drug for the treatment of this autoimmune disease of the central nervous system. Fingolimod modulates sphingosine-1 phosphate receptors and has unique immunoregulatory properties. Mechanistic studies from animal models have shown that fingolimod prevents immune cel","Clinical immunology (Orlando, Fla.)","Jens Ingwersen, Orhan Aktas, Patrick Kuery, Bernd Kieseier, Alexey Boyko, Hans-Peter Hartung"," Multiple Sclerosis Center, Department of Neurology, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany.",2012 Jan;142(1):15-24,10.1016/j.clim.2011.05.005|10.1016/j.clim.2011.10.008
21679286,20110801,review,"xref,mesh","Administration, Oral,Adult,Clinical Trials, Phase III as Topic,Dose-Response Relationship, Drug,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Middle Aged,Multicenter Studies as Topic,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Randomized Controlled Trials as Topic,Receptors, Lysosphingolipid,Risk Factors,Secondary Prevention,Sphingosine,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,drug therapy,pharmacokinetics","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000008 NN,D013110 Q000031 NY,D007166 Q000493 NN,D049349 Q000187 NN,D011409 Q000493 NN,D013110 Q000493 NN,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.,"Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS). The aim of this review was to provide a concise, comprehensive overview of the clinically relevant mechanism of action, efficacy and safety information available for fingolimod. Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 an",International journal of clinical practice,"B Singer, A P Ross, K Tobias"," MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO 63131, USA. hg@schmerzklinik.de",2011 Aug;65(8):887-95,10.1111/j.1742-1241.2011.02721.x
21701599,20110101,article,"xref,mesh","Animals,Brain Edema,Brain Ischemia,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-6,Leukocytes,Lymphocytes,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,therapeutic use","D008214 Q000276 NY,D001929 Q000188 NN,D002545 Q000378 NN,D015850 Q000378 NN,D007962 Q000187 NN,D008214 Q000378 NN,D014409 Q000378 NN,D002545 Q000188 NY,D008214 Q000187 NY,D013110 Q000031 NY,D002545 Q000276 NY,D001929 Q000378 NN,D007962 Q000378 NN,D007166 Q000627 NY,D001929 Q000276 NN,D007962 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY","291,6556,8252,22880,31270,105065,107969,107970,5280335,21226166","127986152,128090012,128394615,129060975,129086167,129645792,135763149,136111139",FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia.,BACKGROUND: The contribution of neuroinflammation and specifically brain lymphocyte invasion is increasingly recognised as a substantial pathophysiological mechanism after stroke. FTY720 is a potent treatment for primary neuroinflammatory diseases by inhibiting lymphocyte circulation and brain immigration. Previous studies using transient focal ischemia models showed a protective effect of FTY720 but did only partially characterize the involved pathways. We tested the neuroprotective properties of FTY720 in,PloS one,"Arthur Liesz, Li Sun, Wei Zhou, Sönke Schwarting, Eva Mracsko, Markus Zorn, Henrike Bauer, Clemens Sommer, Roland Veltkamp"," Department of Neurology, University Heidelberg, Heidelberg, Germany. Arthur.Liesz@med.uni-heidelberg.de",2011 Jan;6(6):e21312,10.1371/journal.pone.0021312
21707492,20111101,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Hematologic Neoplasms,Humans,Immunosuppressive Agents,Lysophospholipids,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,enzymology,metabolism,pharmacology,therapeutic use","D019337 Q000188 NY,D013110 Q000031 NY,D013110 Q000378 NN,D019337 Q000201 NN,D008246 Q000378 NY,D007166 Q000627 NY,D019337 Q000378 NY,D017853 Q000378 NY,D011409 Q000494 NN,D017853 Q000037 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",Targeting sphingosine-1-phosphate in hematologic malignancies.,"Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that regulates several processes important for hematologic cancer progression. S1P is generated by two sphingosine kinases, SphK1 and SphK2, and is exported outside the cell, where it activates specific cell surface S1P G-protein coupled receptors in autocrine/paracrine manner, coined ""inside-out signaling"". In this review, we highlight the importance of SphK1 and inside-out signaling by S1P in hematologic malignancy. We also summarize ",Anti-cancer agents in medicinal chemistry,"Christina E Stevenson, Kazuaki Takabe, Masayuki Nagahashi, Sheldon Milstien, Sarah Spiegel"," Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, 23298-0614, USA.",2011 Nov;11(9):794-8,10.2174/187152011797655122
21710707,20110201,review,"xref,mesh","Administration, Oral,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Cladribine,Dimethyl Fumarate,Drug Administration Schedule,Fingolimod Hydrochloride,Fumarates,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Propylene Glycols,Quinolones,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D015363 Q000627 NN,D007166 Q000008 NN,D010455 Q000627 NN,D020529 Q000188 NN,D016899 Q000627 NN,D000911 Q000627 NN,D005650 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D017338 Q000627 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","6057,8252,12215,20279,31270,65370,107969,107970,637568,3036108,3081884,5280335,54677946","127968532,128394615,128471922,128865459,128966217,129060975,129645792",[Current treatment of multiple sclerosis].,"Multiple sclerosis (MS) is an autoimmune and degenerative disorder. In the past decades, the introduction of parenteral immunomodulatory therapies brought significant progress. These agents increase the number of relapses (shubs) by about 30%, and some of them has been shown to halter the accumulation of neurological symptoms and the development of disability. As first-line agents, interferon beta and glatiramer acetate (consisting of amino acids) can be used. Some new therapeutic strategies have been devel",Lege artis medicinae : uj magyar orvosi hirmondo,Tünde Csépány," Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Neurológiai Klinika/University of Debrecen, Medical and Health Science Center, Department of Neurology; H-4032 Debrecen, Móricz Zsigmond krt. 22. csepany@dote.hu",2011 Feb;21(2):97-104,NULL
21719706,20110902,article,"xref,mesh","Amino Acid Motifs,Animals,Carcinoma, Hepatocellular,Cell Line, Tumor,Fingolimod Hydrochloride,HEK293 Cells,Humans,Immunosuppressive Agents,Ligands,Lipids,Mutagenesis,Propylene Glycols,Protein Structure, Tertiary,Rats,Receptors, G-Protein-Coupled,Receptors, Lysosphingolipid,Recombinant Fusion Proteins,Sphingosine","analogs &amp; derivatives,chemistry,metabolism,pharmacology","D049349 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D008055 Q000737 NN,D006528 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D011993 Q000737 NN,D043562 Q000378 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.,"FTY720 phosphate (FTY720P) is a high potency agonist for all the endothelial differentiation gene family sphingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)). To map the distinguishing features of S1P(2) ligand recognition, we applied a computational modeling-guided mutagenesis strategy that was based on the high degree of sequence homology between S1P(1) and S1P(2). S1P(2) point mutants of the ligand-binding pocket were characterized. The head group-interacting residues Arg3.28, G",The Journal of biological chemistry,"William J Valentine, Virginia I Godwin, Daniel A Osborne, Jianxiong Liu, Yuko Fujiwara, James Van Brocklyn, Robert Bittman, Abby L Parrill, Gabor Tigyi"," Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.",2011 Sep;286(35):30513-25,10.1074/jbc.m111.263442
21725758,20110101,article,"xref,mesh","Analysis of Variance,Animals,Brain Edema,Cerebral Hemorrhage,Collagenases,Disease Models, Animal,Fingolimod Hydrochloride,Functional Laterality,Immunosuppressive Agents,Mice,Nervous System Diseases,Neurologic Examination,Propylene Glycols,Psychomotor Performance,Sphingosine,Time Factors","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,etiology,physiopathology,prevention &amp; control,radiation effects,therapeutic use","D002543 Q000139 NN,D011597 Q000528 NN,D009422 Q000517 NN,D013110 Q000031 NY,D009422 Q000209 NN,D007166 Q000627 NY,D001929 Q000209 NN,D002543 Q000503 NY,D002543 Q000188 NY,D017364 Q000009 NN,D013110 Q000627 NN,D001929 Q000517 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice.,"Intracerebral hemorrhage (ICH) accounts for 20% of all strokes and is the most devastating form across all stroke types. Lymphocytes have been shown to potentiate cerebral inflammation and brain injury after stroke. FTY720 (Fingolimod) is an immune-modulating drug that prevents the egress of peripheral lymphocytes from peripheral stores. We hypothesized that FTY720 would reduce peripheral circulating lymphocytes, resulting in reduced brain injury and improved functional outcomes. CD-1 mice were anesthetized",Acta neurochirurgica. Supplement,"William B Rolland, Anatol Manaenko, Tim Lekic, Yu Hasegawa, Robert Ostrowski, Jiping Tang, John H Zhang"," Department of Physiology, Loma Linda University, School of Medicine, Loma Linda, CA 92350, USA.",2011 Jan;111(?):213-7,10.1007/978-3-7091-0693-8_36
21726878,20110915,article,"xref,mesh","Animals,Cardiovirus Infections,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Injections, Intraperitoneal,Mice,Multiple Sclerosis,Propylene Glycols,Sphingosine,Theilovirus,Viral Load","analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,pharmacology,therapeutic use,virology","D018188 Q000276 NN,D017945 Q000187 NY,D009103 Q000821 NY,D018188 Q000473 NN,D009103 Q000473 NY,D018188 Q000188 NN,D013110 Q000031 NY,D019562 Q000187 NN,D007166 Q000627 NY,D017945 Q000276 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NN,D019562 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",The effect of FTY720 in the Theiler's virus model of multiple sclerosis.,"FTY720 (fingolimod) has demonstrated efficacy in multiple sclerosis (MS). We evaluated the effects of FTY720 on progressive disability, viral load, and antibody responses in mice infected with Theiler's murine encephalomyocarditis virus (TMEV). FTY720 and phosphorylated FTY720 (FTY720-P) were detected in the brain after intraperitoneal injection of the drug. Bioactivity of FTY720 was confirmed by reduced numbers of mononuclear cells in the spleen and blood after treatment. No significant differences were fo",Journal of the neurological sciences,"Libin Li, Makiko Matsumoto, Timothy J Seabrook, Celine Cojean, Volker Brinkman, Andrew R Pachner"," Department of Neurology and Neuroscience, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA. lili@umdnj.edu",2011 Sep;308(?):41-8,10.1016/j.jns.2011.06.029
21727148,20111101,article,"xref,mesh","Administration, Oral,Adult,Canada,Chi-Square Distribution,Depression,Double-Blind Method,Europe,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Chronic Progressive,Multiple Sclerosis, Relapsing-Remitting,Placebos,Propylene Glycols,Psychiatric Status Rating Scales,Quality of Life,Sphingosine,Surveys and Questionnaires,Time Factors,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug therapy,etiology,psychology","D020529 Q000523 NN,D003863 Q000188 NN,D013110 Q000008 NN,D020528 Q000188 NY,D020529 Q000175 NN,D020528 Q000523 NN,D013110 Q000031 NY,D020528 Q000175 NN,D020529 Q000188 NY,D003863 Q000209 NN,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.,"BACKGROUND: Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL. OBJECTIVES: To report exploratory analyses assessing the impact of fingolimod (FTY720) on HRQoL and depression in a phase II study of relapsing MS. METHODS: The Hamburg Quality of Life Questionnaire in MS (HAQUAMS) and Beck Depression Inventory second edition (BDI-II) scores were assessed during a 6-month, pla","Multiple sclerosis (Houndmills, Basingstoke, England)","X Montalban, G Comi, P O'Connor, Sm Gold, A de Vera, B Eckert, L Kappos"," Unitat de Neuroimmunologia Clinica, Vall d'Hebron University Hospital, Barcelona, Spain. xavier.montalban@unic-em.com",2011 Nov;17(11):1341-50,10.1177/1352458511411061
21729281,20110101,article,"xref,mesh","Animals,Biomarkers,Cell Culture Techniques,Cells, Cultured,Demyelinating Diseases,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophosphatidylcholines,Microglia,Multiple Sclerosis, Relapsing-Remitting,Myelin Basic Protein,Myelin Sheath,Nerve Degeneration,Pregnancy,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Spheroids, Cellular,Sphingosine","analogs &amp; derivatives,chemically induced,cytology,drug effects,drug therapy,immunology,metabolism,pathology,pharmacology,physiology,therapeutic use","D007166 Q000494 NY,D004676 Q000378 NN,D007166 Q000627 NN,D018874 Q000502 NN,D009410 Q000473 NN,D003711 Q000139 NN,D009186 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D017628 Q000502 NY,D020529 Q000473 NN,D018874 Q000187 NN,D017628 Q000166 NN,D009410 Q000188 NN,D017628 Q000187 NY,D003711 Q000473 NN,D013110 Q000627 NN,D008244 Q000494 NN,D011409 Q000627 NN,D018874 Q000166 NN,D013110 Q000494 NN,D020529 Q000276 NN,D015415 Q000378 NY,D049349 Q000378 NN","305,996,1070,4941,5988,8252,12035,31270,105065,107969,107970,4670741,5280335,5311264,5478883,53782692","127700385,127796644,127819769,128215673,128394615,128684338,128799283,128977994,129060975,129645792,136033793,136111139",Fingolimod modulates microglial activation to augment markers of remyelination.,"INTRODUCTION: Microglial activation in multiple sclerosis has been postulated to contribute to long-term neurodegeneration during disease. Fingolimod has been shown to impact on the relapsing remitting phase of disease by modulating autoreactive T-cell egress from lymph organs. In addition, it is brain penetrant and has been shown to exert multiple effects on nervous system cells. METHODS: In this study, the impact of fingolimod and other sphingosine-1-phosphate receptor active molecules following lysophosp",Journal of neuroinflammation,"Samuel J Jackson, Gavin Giovannoni, David Baker"," Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. s.j.jackson@qmul.ac.uk",2011 Jan;8(?):76,10.1186/1742-2094-8-76
21740406,20120201,article,"xref,mesh","Animals,Dendritic Spines,Encephalomyelitis, Autoimmune, Experimental,Excitatory Postsynaptic Potentials,Female,Fingolimod Hydrochloride,Glutamic Acid,Glycoproteins,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Multiple Sclerosis,Myelin-Oligodendrocyte Glycoprotein,Peptide Fragments,Propylene Glycols,Sphingosine,Synapses,Synaptic Transmission","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,pathology,pharmacology,physiology,physiopathology,therapeutic use","D049229 Q000187 NN,D007166 Q000494 NY,D009103 Q000473 NN,D007166 Q000627 NN,D009103 Q000503 NY,D013569 Q000187 NY,D004681 Q000139 NN,D013110 Q000031 NY,D011409 Q000494 NY,D004681 Q000188 NN,D013569 Q000502 NN,D018698 Q000502 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D049229 Q000473 NN,D009435 Q000187 NN,D009103 Q000188 NN,D004681 Q000473 NN,D004681 Q000503 NY,D019706 Q000187 NN","611,8252,23327,31270,33032,104813,107969,107970,168185,439212,4525487,5128032,5147171,5280335,5460299,5460544,11840951,14598502,23669634,23696295,126963437,129674751,129773928","128394615,129060975,129583715,129645792",Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.,"BACKGROUND AND PURPOSE Alterations of glutamate-mediated synaptic transmission occur early during neuroinflammatory insults, and lead to degenerative neuronal damage in multiple sclerosis (MS) and also in experimental autoimmune encephalomyelitis (EAE), which is a murine model of MS. Fingolimod is an effective orally active agent for the treatment of MS, affecting lymphocyte invasion of the brain. However, it is still unclear if fingolimod can be neuroprotective in this disorder. EXPERIMENTAL APPROACH Using",British journal of pharmacology,"S Rossi, T Lo Giudice, V De Chiara, A Musella, V Studer, C Motta, G Bernardi, G Martino, R Furlan, A Martorana, D Centonze"," Clinica Neurologica, Dipartimento di Neuroscienze, Università Tor Vergata, Rome, Italy.",2012 Feb;165(4):861-9,10.1111/j.1476-5381.2011.01579.x
21740973,20110901,article,"xref,mesh","Animals,Chelating Agents,Cuprizone,Demyelinating Diseases,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Myelin Sheath,Nerve Regeneration,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,therapeutic use","D007166 Q000494 NY,D049349 Q000378 NY,D009186 Q000187 NY,D009416 Q000187 NY,D007166 Q000627 NN,D002614 Q000494 NN,D009186 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D003471 Q000494 NN,D003711 Q000188 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN","8252,9723,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.,"The sphingosine 1-phosphate (S1P) receptor modulators have emerged as a new therapeutic opportunity paradigm for the treatment of immune-mediated demyelinating diseases such as multiple sclerosis (MS). The S1P analog fingolimod (FTY720) has been shown to alleviate disease burden in immune-mediated animal models of MS, and has been approved for treatment in clinical trials in patients with MS in the United States. While the immunological effects of FTY720 are well established, there is controversy in the lit",Molecular and cellular neurosciences,"Yinghui Hu, Xinhua Lee, Benxiu Ji, Kevin Guckian, Daniel Apicco, R Blake Pepinsky, Robert H Miller, Sha Mi"," Biogen Idec Inc, Neuro-Discovery Biology, 14 Cambridge Center, Cambridge, Massachusetts 02142, United States.",2011 Sep;48(1):72-81,10.1016/j.mcn.2011.06.007
21750524,20110712,article,"xref,mesh","Cladribine,Clinical Trials as Topic,Device Approval,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D020529 Q000188 NN,D017338 Q000627 NY,D013110 Q000031 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.,NULL,Nature reviews. Neurology,Reinhard Hohlfeld,NULL,2011 Jul;7(8):425-7,10.1038/nrneurol.2011.105
21750611,20110101,article,xref,NULL,NULL,NULL,"453,702,753,1031,6251,8252,688096,54091660,54575046,57317596","127822827,127822831,128482492,128648755,128902940,129054265,129060975,129979483,135919923,136314073",Systane lubricant eye drops in the management of ocular dryness.,"The understanding of dry eye disease has advanced recently through increasing recognition that the etiology of the condition involves both tear evaporation and insufficient tear production, and that tear film instability and inflammation play roles in the various stages of the disease. Of significance, it has been recognized that lipid layer thickness correlates with tear film stability. The management of dry eye involves various strategies and therapeutic approaches that address one or more etiopathologica","Clinical ophthalmology (Auckland, N.Z.)",Umberto Benelli," Department of Neurosciences, Section of Ophthalmology, University of Pisa, Pisa, Italy.",2011 Jan;5(?):783-90,10.2147/opth.s13773
21751747,20110101,article,"xref,mesh","Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-beta,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy","D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","8252,20279,31270,107969,107970,5280335","128394615,128966217,129060975,129645792",Fingolimod.,"In the absence of a better alternative, subcutaneous interferon beta is the standard first-line treatment for relapsing-remitting multiple sclerosis. Fingolimod, an oral immunosuppressant that reduces the circulating lymphocyte count, is in the process of receiving marketing authorisation for this use in the European Union. Initial clinical evaluation is based on 2 trials. In a 12-month, comparative, double-blind, randomised trial including 1292 patients daily treatment with oral fingolimod (0.5 mg or 1.25 ",Prescrire international,NULL,NULL,"2011 Jan;20(118):173-4, 176-7",NULL
21768294,20110908,article,"xref,mesh","Animals,Apoptosis,Blotting, Western,Cell Proliferation,Chronic Disease,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Killer Cells, Natural,Leukemia,Male,Myeloid Cell Leukemia Sequence 1 Protein,Propylene Glycols,Proto-Oncogene Proteins c-bcl-2,RNA, Small Interfering,Rats,Rats, Inbred F344,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,genetics,immunology,metabolism,pathology,therapeutic use","D019253 Q000235 NN,D019253 Q000378 NN,D007694 Q000187 NY,D007938 Q000276 NN,D017209 Q000187 NY,D007938 Q000473 NN,D019253 Q000037 NN,D049109 Q000187 NN,D013110 Q000031 NY,D034741 Q000235 NN,D007166 Q000627 NY,D007694 Q000473 NN,D007938 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D007694 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.,NK-cell leukemia is a clonal expansion of NK cells. The illness can occur in an aggressive or chronic form. We studied cell lines from human and rat NK-cell leukemias (aggressive NK-cell leukemia) as well as samples from patients with chronic NK-cell leukemia to investigate pathogenic mechanisms. Here we report that Mcl-1 was overexpressed in leukemic NK cells and that knockdown of Mcl-1 induced apoptosis in these leukemic cells. In vitro treatment of human and rat NK leukemia cells with FTY720 led to caspa,Blood,"Aijun Liao, Kathleen Broeg, Todd Fox, Su-Fern Tan, Rebecca Watters, Mithun Vinod Shah, Lucy Q Zhang, Yongping Li, Lindsay Ryland, Jun Yang, Cesar Aliaga, Alden Dewey, Andrew Rogers, Kelly Loughran, Leah Hirsch, Nancy Ruth Jarbadan, Kendall Thomas Baab, Jason Liao, Hong-Gang Wang, Mark Kester, Dhimant Desai, Shantu Amin, Thomas P Loughran, Xin Liu"," Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.",2011 Sep;118(10):2793-800,10.1182/blood-2011-01-331447
21777161,20110101,article,"xref,mesh","Antibodies, Monoclonal, Humanized,Cost-Benefit Analysis,Fingolimod Hydrochloride,Health Care Costs,Humans,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Propylene Glycols,Recurrence,Sphingosine,United States","analogs &amp; derivatives,drug therapy,economics,prevention &amp; control,therapeutic use,trends","D007166 Q000627 NN,D017048 Q000639 NY,D013110 Q000031 NY,D013110 Q000191 NN,D061067 Q000627 NN,D061067 Q000191 NY,D011409 Q000191 NY,D009103 Q000517 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D007166 Q000191 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.,"BACKGROUND: With the addition of new agents for the treatment of multiple sclerosis (MS) (e.g., fingolimod), there is a need to evaluate the relative value of newer therapies in terms of cost and effectiveness, given healthcare resource constraints in the United States. OBJECTIVE: To assess the cost-effectiveness of natalizumab vs fingolimod in patients with relapsing MS. METHODS: A decision analytic model was developed to estimate the incremental cost per relapse avoided of natalizumab and fingolimod from ",Journal of medical economics,"Ken O'Day, Kellie Meyer, Ross M Miller, Sonalee Agarwal, Meg Franklin"," Xcenda, Palm Harbor, FL, USA.",2011 Jan;14(5):617-27,10.3111/13696998.2011.602444
21788441,20110901,article,"xref,mesh","Animals,Cell Adhesion,Cell Separation,Chemotaxis, Leukocyte,Fingolimod Hydrochloride,Flow Cytometry,GTP-Binding Protein alpha Subunit, Gi2,Immunosuppressive Agents,Lymph Nodes,Mice,Mice, Knockout,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes","agonists,analogs &amp; derivatives,cytology,drug effects,genetics,immunology,metabolism,pharmacology","D013601 Q000378 NN,D007166 Q000494 NY,D002634 Q000187 NY,D049349 Q000819 NN,D013601 Q000276 NN,D051960 Q000235 NN,D002448 Q000187 NN,D002448 Q000276 NN,D008198 Q000187 NN,D008198 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013601 Q000187 NY,D008198 Q000166 NN,D002634 Q000276 NN,D051960 Q000378 NN,D051960 Q000276 NN,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus.,"Egress of lymphocytes from lymphoid tissues is a complex process in which Gαi-mediated signals play a decisive role. We show here that although FTY720, an agonist of the sphingosine 1-phosphate (S1P)(1) receptor, induces S1P(1) receptor internalization sufficiently in the presence or absence of Gαi2 or Gαi3, the drug blocks egress of wild-type (WT) and Gαi3-deficent T cells, but not Gαi2-deficient T cells, in both WT and Gαi2-deficient hosts. Intravital imaging of lymph nodes revealed that all three groups ","Journal of immunology (Baltimore, Md. : 1950)","Liang Zhi, Pilhan Kim, Brian D Thompson, Costas Pitsillides, Alexander J Bankovich, Seok-Hyun Yun, Charles P Lin, Jason G Cyster, Mei X Wu"," Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.",2011 Sep;187(5):2244-51,10.4049/jimmunol.1100670
21789537,20111001,review,"xref,mesh","Central Nervous System,Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,therapeutic use","D009103 Q000473 NN,D002490 Q000276 NN,D013110 Q000031 NY,D007166 Q000627 NY,D002490 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.","The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically ",Current neurology and neuroscience reports,"Matthias Mehling, Ludwig Kappos, Tobias Derfuss"," Department of Neurology and Department of Biomedicine, University Hospital Basel, Petersgraben, Switzerland.",2011 Oct;11(5):492-7,10.1007/s11910-011-0216-9
21790210,20110801,review,"xref,mesh","Administration, Oral,Adult,Animals,Drug Delivery Systems,Drug Interactions,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","adverse effects,agonists,analogs &amp; derivatives,drug therapy,pharmacology,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D049349 Q000819 NN,D013110 Q000031 NY,D020529 Q000503 NN,D007166 Q000627 NY,D020529 Q000188 NY,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN","6057,8252,31270,107969,107970,5280335","128394615,128865459,129060975,129645792",Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.,"Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a single-agent DMT in selected patients with highly-active, relapsing-remitting (RR) MS. This article reviews the pharmacological properties and clinical use of the drug in patients with RRMS. Fingo",CNS drugs,Lesley J Scott," Adis, a Wolters Kluwer Business, Auckland, New Zealand.",2011 Aug;25(8):673-98,10.2165/11207350-000000000-00000
21805322,20120101,review,"xref,mesh","Animals,Atherosclerosis,Blood Coagulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Lymph Nodes,Lymphocytes,Lysophospholipids,Multiple Sclerosis,Neoplasm Metastasis,Neoplasms,Neovascularization, Pathologic,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,antagonists &amp; inhibitors,blood,drug effects,drug therapy,immunology,metabolism,pathology,therapeutic use","D013110 Q000097 NN,D007249 Q000188 NN,D009389 Q000276 NN,D014409 Q000097 NN,D050197 Q000473 NN,D009369 Q000473 NN,D007249 Q000097 NN,D008214 Q000473 NN,D007166 Q000627 NN,D008214 Q000378 NN,D050197 Q000188 NN,D009103 Q000097 NN,D009369 Q000097 NN,D007249 Q000276 NY,D008198 Q000276 NN,D009369 Q000276 NN,D015398 Q000276 NY,D013110 Q000031 NY,D050197 Q000097 NN,D009369 Q000188 NN,D008246 Q000097 NN,D050197 Q000276 NN,D013110 Q000276 NN,D009389 Q000473 NN,D008214 Q000276 NN,D009389 Q000097 NN,D009389 Q000188 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792,135820018",Sphingosine 1-phosphate in coagulation and inflammation.,"Sphingosine 1-phosphate (S1P) is a lipid mediator produced from sphingomyelin by the sequential enzymatic actions of sphingomyelinase, ceramidase, and sphingosine kinase. Five subtypes of cell surface G-protein-coupled receptors, S1P(1-5), mediate the actions of S1P in various organs systems, most notably cardiovascular, immune, and central nervous systems. S1P is enriched in blood and lymph but is present at much lower concentrations in interstitial fluids of tissues. This vascular S1P gradient is importan",Seminars in immunopathology,"Hideru Obinata, Timothy Hla"," Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.",2012 Jan;34(1):73-91,10.1007/s00281-011-0287-3
21806598,20120201,article,"xref,mesh","Animals,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Multiple Sclerosis,Propylene Glycols,Sphingosine,Synapses","analogs &amp; derivatives,drug effects,drug therapy,pharmacology,physiology,physiopathology,therapeutic use","D007166 Q000494 NY,D007166 Q000627 NN,D009103 Q000503 NY,D013569 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D004681 Q000188 NN,D013569 Q000502 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN,D004681 Q000503 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?,"Multiple sclerosis (MS) is an inflammatory disorder affecting the brain and spinal cord. Major hallmarks of MS typically include inflammation, demyelination and axon degeneration, although recent studies have also implicated synaptic dysfunction and degeneration in disease pathogenesis. The discovery that treatment with the orally active immunomodulatory drug fingolimod (FTY720) confers benefits in animal models and human patients has opened up new avenues for the treatment of MS. In the present issue of th",British journal of pharmacology,Thomas H Gillingwater," School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK. t.gillingwater@ed.ac.uk",2012 Feb;165(4):858-60,10.1111/j.1476-5381.2011.01612.x
21826025,20110901,article,"xref,mesh","Blindness,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Middle Aged,Multiple Sclerosis,Propylene Glycols,Retinal Vein,Retinal Vein Occlusion,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug effects,drug therapy,pathology,physiopathology","D013110 Q000009 NN,D001766 Q000503 NN,D001766 Q000175 NN,D012169 Q000473 NN,D012170 Q000503 NN,D012170 Q000139 NY,D013110 Q000031 NY,D012170 Q000175 NN,D007166 Q000009 NY,D009103 Q000188 NY,D012169 Q000187 NN,D001766 Q000139 NY,D011409 Q000009 NY","1070,8252,31270,107969,107970,5280335","128394615,128684338,129060975,129645792",Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.,NULL,Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,"Roberto Gallego-Pinazo, Enrique España-Gregori, Bonaventura Casanova, Diamar Pardo-López, Manuel Díaz-Llopis",NULL,2011 Sep;31(3):292-3,10.1097/wno.0b013e31822bed20
21831936,20110810,article,"xref,mesh","Cost-Benefit Analysis,Fingolimod Hydrochloride,Health Care Costs,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,National Health Programs,Prescription Drugs,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,economics,legislation &amp; jurisprudence,therapeutic use","D007166 Q000191 NN,D055553 Q000191 NY,D013110 Q000031 NY,D013110 Q000191 NN,D009313 Q000331 NY,D007166 Q000627 NY,D011409 Q000191 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D055553 Q000627 NN","107969,107970,5280335",128394615,NICE rules out NHS prescription of fingolimod for multiple sclerosis.,NULL,BMJ (Clinical research ed.),Deborah Cohen,NULL,2011 Aug;343(?):d5117,10.1136/bmj.d5117
21833515,20120101,article,"xref,mesh","Analysis of Variance,Animals,Anti-Glomerular Basement Membrane Disease,Apoptosis,CD4-Positive T-Lymphocytes,Creatinine,DNA Primers,Fingolimod Hydrochloride,Freund's Adjuvant,Gene Expression Regulation,Immune Sera,Immunoglobulin G,Immunosuppressive Agents,Interleukin-4,Male,Mice,Mice, Inbred C57BL,Prednisone,Propylene Glycols,Proteinuria,Rabbits,Real-Time Polymerase Chain Reaction,Receptors, Lysosphingolipid,Sphingosine,Spleen","administration &amp; dosage,agonists,analogs &amp; derivatives,blood,cytology,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D007074 Q000008 NN,D017209 Q000187 NN,D049349 Q000819 NY,D019867 Q000517 NY,D015847 Q000378 NN,D005786 Q000187 NY,D015496 Q000187 NN,D003404 Q000097 NN,D013110 Q000031 NY,D011409 Q000494 NY,D007106 Q000008 NN,D011241 Q000494 NN,D017931 Q000235 NN,D015496 Q000166 NN,D013154 Q000378 NN,D007074 Q000097 NN,D011507 Q000188 NN,D019867 Q000473 NN,D013110 Q000494 NN,D049349 Q000378 NN","588,5865,8252,31270,105065,107969,107970,5280335","127719861,128394615,129060975,129645792,129717275,136111139",The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis.,"The sphingosine-1-phosphate (S1P) agonist FTY720 prolongs the survival of organ allograft and attenuates autoimmune-mediated injury in experimental models. Most cases of glomerulonephritis (GN) in human appear to be immunologically initiated. In this study, we evaluated the potential therapeutic role of FTY720 in GN via a mouse anti-glomerular basement membrane (GBM) model. Mice were immunized with rabbit IgG in complete Freund's adjuvant (CFA) followed by an intravenous injection of a rabbit anti-mouse GBM",Molecular biology reports,"Manshu Sui, Jin Zhou, Rujuan Xie, Xiaogang Liu, Suhong Mu, Xibei Jia, Jing Ma, Hongchi Wu"," Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150001, People's Republic of China.",2012 Jan;39(1):389-97,10.1007/s11033-011-0750-1
21840330,20111101,article,"xref,mesh","Animals,Apoptosis,Atropine,Blotting, Northern,Brain,Cell Death,Cell Survival,Chickens,Cholinesterase Inhibitors,Female,Isoflurophate,Neurotoxicity Syndromes,Organophosphorus Compounds,Physostigmine,Spinal Cord,Time Factors","drug effects,metabolism,pathology,pharmacology,physiology,toxicity","D016923 Q000187 NY,D007531 Q000633 NN,D002800 Q000633 NN,D017209 Q000187 NN,D013116 Q000187 NN,D013116 Q000473 NN,D020258 Q000378 NY,D001921 Q000187 NN,D001921 Q000473 NN,D016923 Q000502 NN,D001285 Q000494 NN,D002470 Q000502 NN,D010830 Q000494 NN,D020258 Q000473 NN,D002470 Q000187 NY,D009943 Q000633 NY","679,5927,5936,5983,8252,17184,64663,174174,656678,57473071,60196398,67052243,131632429,134688695","53790824,128141778,128648130,128920415,129060975,129143706","Early differential cell death and survival mechanisms initiate and contribute to the development of OPIDN: a study of molecular, cellular, and anatomical parameters.","Organophosphorus-ester induced delayed neurotoxicity (OPIDN) is a neurodegenerative disorder characterized by ataxia progressing to paralysis with a concomitant central and peripheral, distal axonapathy. Diisopropylphosphorofluoridate (DFP) produces OPIDN in the chicken that results in mild ataxia in 7-14 days and severe paralysis as the disease progresses with a single dose. White leghorn layer hens were treated with DFP (1.7 mg/kg, sc) after prophylactic treatment with atropine (1mg/kg, sc) in normal sali",Toxicology and applied pharmacology,"T V Damodaran, M K Attia, M B Abou-Donia"," Dept of Medicine, Duke University Medical Center, Durham, NC, USA. tdamodar@nccu.edu",2011 Nov;256(3):348-59,10.1016/j.taap.2011.07.017
21844470,20110801,article,"xref,mesh","Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Melanoma,Multiple Sclerosis,Propylene Glycols,Skin Neoplasms,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D012878 Q000139 NY,D013110 Q000009 NN,D013110 Q000031 NY,D008545 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.,NULL,Archives of dermatology,"Katrin Baumann Conzett, Isabel Kolm, Ilijas Jelcic, Jivko Kamarachev, Reinhard Dummer, Ralph Braun, Lars E French, Michael Linnebank, Günther F L Hofbauer",NULL,2011 Aug;147(8):991-2,10.1001/archdermatol.2011.212
21845450,20120201,article,"xref,mesh","Fingolimod Hydrochloride,Herpes Simplex,Humans,Immunization, Secondary,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,complications,diagnosis,drug therapy,methods,prevention &amp; control","D009103 Q000175 NY,D013110 Q000009 NN,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D006561 Q000175 NN,D007117 Q000379 NY,D009103 Q000150 NN,D006561 Q000517 NY,D007166 Q000009 NN,D009103 Q000188 NY,D006561 Q000139 NY,D011409 Q000008 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].,"Since April 2011 fingolimod (FTY 720, Gilenya®), a new oral treatment, is available for relapsing-remitting multiple sclerosis (MS) in Germany. Adverse effects in pre-marketing clinical controlled multicenter studies have led to specific precautions that have to be followed before initiating treatment. According to the European Union prescribing information fingolimod is not to be used as a first-line treatment, but is licensed as a second-line option or escalating therapy of MS. During treatment physical a",Der Nervenarzt,"A Winkelmann, M Löbermann, E C Reisinger, U K Zettl"," Klinik und Poliklinik für Neurologie, Universität Rostock, Gehlsheimer Str. 20, 18147, Rostock, Deutschland. alexander.winkelmann@med.uni-rostock.de",2012 Feb;83(2):236-42,10.1007/s00115-011-3360-1
21864270,20110101,review,"xref,mesh","Administration, Oral,Animals,Antibodies, Monoclonal,Drug Design,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,immunology,pharmacology,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D007166 Q000627 NN,D000911 Q000009 NN,D007155 Q000627 NN,D009103 Q000503 NN,D013110 Q000008 NN,D007155 Q000494 NN,D000911 Q000627 NN,D011409 Q000008 NN,D020529 Q000503 NN,D013110 Q000031 NN,D007155 Q000009 NN,D000911 Q000494 NN,D020529 Q000188 NY,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D009103 Q000188 NY,D020529 Q000276 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Novel therapeutic approaches to autoimmune demyelinating disorders.,"Multiple Sclerosis (MS) is the most common autoimmune demyelinating disorder in Western countries and can lead to permanent disability. Over the past decades remarkable progress has been made in providing new therapeutic strategies to tackle the burden of the disease. Oral drugs and monoclonal antibodies are the main innovative approaches that have been tested in advanced stage clinical trials. Several new drugs have been shown to be superior to traditional disease modifying treatments (DMTs), in terms of b",Current pharmaceutical design,"Lara Sanvito, Cris S Constantinescu, Bruno Gran"," Division of Clinical Neurology, University of Nottingham, United Kingdom.",2011 Jan;17(29):3191-201,10.2174/138161211798157630
21864593,20111210,article,"xref,mesh","Animals,Anti-Inflammatory Agents,Dendritic Cells,Drug Carriers,Immunosuppressive Agents,Lymph Nodes,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Micelles,Mometasone Furoate,Polyethylene Glycols,Pregnadienediols,Sirolimus,Skin Transplantation,Sulfides,Tacrolimus,Transplantation, Homologous","administration &amp; dosage,chemistry,cytology,drug effects,immunology,therapeutic use","D016038 Q000276 YN,D003713 Q000187 NN,D011092 Q000737 NY,D016559 Q000627 NN,D007166 Q000627 NN,D020123 Q000008 NY,D004337 Q000737 NY,D003713 Q000276 NN,D000893 Q000008 NN,D013440 Q000737 NY,D000893 Q000627 NN,D008198 Q000187 NY,D014184 Q000276 NN,D008198 Q000166 NN,D011244 Q000627 NN,D016559 Q000008 NY,D011244 Q000008 NN,D020123 Q000627 NN,D007166 Q000008 NY","5372,441335,441336,445643,5282315,5284616,6473866,6536850,71668407,90726579,91454826,91534498,134694629","135769229,135855390,242963342,248184126,248766214",Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival.,"By delivering immunomodulatory drugs in vivo directly to lymph nodes draining an injection site, an opportunity exists to increase drug bioavailability to local immune cells. Importantly, particles smaller than 100 nm are efficiently transported through lymphatic vessels to draining lymph nodes. To investigate whether this approach could be used for local delivery of immunomodulatory drugs, amphiphilic poly(ethylene glycol)-bl-poly(propylene sulfide) (PEG-bl-PPS) block copolymers forming 50 nm micelles were",Journal of controlled release : official journal of the Controlled Release Society,"Karen Y Dane, Chiara Nembrini, Alice A Tomei, Jackson K Eby, Conlin P O'Neil, Diana Velluto, Melody A Swartz, Luca Inverardi, Jeffrey A Hubbell"," Institute of Bioengineering, École Polytechnique Fédérale de Lausanne-EPFL, 1015 Lausanne, Switzerland.",2011 Dec;156(2):154-60,10.1016/j.jconrel.2011.08.009
21890131,20111001,article,"xref,mesh","Animals,Comet Assay,DNA Damage,Female,Horses,Mice,Mutagens,Oocytes,Propylene Glycol","drug effects,methods,physiology,toxicity","D004249 Q000502 NN,D019946 Q000633 NY,D009865 Q000187 NY,D004249 Q000187 NY,D009865 Q000502 NN,D009153 Q000633 NY,D020552 Q000379 NY","1030,8252,259994","127759454,129060975","Assessment of 1,2-propanediol (PrOH) genotoxicity on mouse oocytes by comet assay.","OBJECTIVE: To assess the genotoxicity of 1,2-propanediol (PrOH) on mouse oocytes by comet assay. DESIGN: In vitro assay using murine model. SETTING: Biogenotoxicology research laboratory. ANIMAL(S): CD1 female mice. INTERVENTION(S): Three 40-oocyte groups were exposed to different PrOH concentrations (5%, 7.5%, and 15%). Each concentration was tested during both long and short exposures (1-2 hours and 1-5 minutes) in comparison with control groups. DNA damage was evaluated by a single-cell gel electrophores",Fertility and sterility,"Anais Berthelot-Ricou, Jeanne Perrin, Carole di Giorgio, Michel de Meo, Alain Botta, Blandine Courbiere"," Laboratoire de Biogénotoxicologie et Mutagenèse Environnementale, Fédération de Recherche CNRS 3098 ECCOREV, Facultés de Médecine et Pharmacie, Université de Méditerranée, Marseille, France.",2011 Oct;96(4):1002-7,10.1016/j.fertnstert.2011.07.1106
21909447,20110901,article,"xref,mesh","Administration, Oral,Africa South of the Sahara,Animals,Antiprotozoal Agents,Blood-Brain Barrier,Brain,Cyclodextrins,Disease Models, Animal,Humans,Magnetic Resonance Imaging,Male,Melarsoprol,Mice,Models, Molecular,Molecular Structure,Parasite Load,Parasitic Sensitivity Tests,Radiography,Treatment Outcome,Trypanosoma brucei brucei,Trypanosomiasis, African","administration &amp; dosage,chemistry,diagnostic imaging,drug effects,drug therapy,parasitology,pathology,pharmacology,physiology","D000981 Q000737 NN,D014353 Q000188 NY,D001812 Q000502 NN,D000981 Q000494 NN,D014346 Q000187 NY,D003505 Q000737 NN,D001921 Q000469 NN,D001921 Q000473 NN,D008549 Q000737 NN,D003505 Q000494 NN,D003505 Q000008 NY,D001921 Q000000981 NN,D000981 Q000008 NY,D008549 Q000008 NY,D008549 Q000494 NN","2082,2354,5361,5793,8111,8252,10311,65220,68827,442514,459963,18379476","127384203,127534140,127850182,128126506,128436652,129060975,129163296,129621433,129716154,135985134,247966132",Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis.,"Human African trypanosomiasis (HAT), or sleeping sickness, results from infection with the protozoan parasites Trypanosoma brucei (T. b.) gambiense or T. b. rhodesiense and is invariably fatal if untreated. There are 60 million people at risk from the disease throughout sub-Saharan Africa. The infection progresses from the haemolymphatic stage where parasites invade the blood, lymphatics and peripheral organs, to the late encephalitic stage where they enter the central nervous system (CNS) to cause serious ",PLoS neglected tropical diseases,"Jean Rodgers, Amy Jones, Stéphane Gibaud, Barbara Bradley, Christopher McCabe, Michael P Barrett, George Gettinby, Peter G E Kennedy"," Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.",2011 Sep;5(9):e1308,10.1371/journal.pntd.0001308
21911597,20111101,article,"xref,mesh","Adolescent,Adult,Aged,Cyclosporine,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Follow-Up Studies,Glomerular Filtration Rate,Graft Rejection,Humans,Immunosuppressive Agents,Kidney Failure, Chronic,Kidney Function Tests,Kidney Transplantation,Male,Middle Aged,Mycophenolic Acid,Prognosis,Propylene Glycols,Sphingosine,Survival Rate,Tacrolimus,Young Adult","adverse effects,analogs &amp; derivatives,drug therapy,etiology,therapeutic use,therapy","D016572 Q000627 NN,D006084 Q000188 NY,D016030 Q000009 NY,D007676 Q000628 NY,D013110 Q000031 NY,D006084 Q000209 NN,D007166 Q000627 NY,D009173 Q000031 NN,D009173 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NY,D016559 Q000627 NY","2909,4271,4272,5372,8252,31270,62280,107969,107970,445643,446541,5280335,5280754,5281078,5282315,5284373,5458585,6435893,6441022,6473866,6536850,9855081,23665584,24883466,25246316,49867938,71306795,71463825,71668407,73896891,90726579,122172945,123134263,123134270,132274082,134694629","128094727,128394615,129060975,129178479,129645792,242963342","FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.","BACKGROUND: FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine. METHODS: This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation. RESULTS: Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increa","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Andries J Hoitsma, Ervin S Woodle, Daniel Abramowicz, Pieter Proot, Yves Vanrenterghem, FTY720 Phase II Transplant Study Group"," Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. a.hoitsma@nier.umcn.nl",2011 Nov;26(11):3802-5,10.1093/ndt/gfr503
21916166,20110101,article,"xref,mesh","Contraindications,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Risk Management,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,standards,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D012308 Q000592 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D007166 Q000008 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].,NULL,Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,N F Popova,NULL,2011 Jan;111(?):110-3,NULL
21921486,20101101,review,"xref,mesh","Animals,Antibodies, Neutralizing,Brain Ischemia,Corynebacterium,Cytokines,Disease Progression,Fingolimod Hydrochloride,Humans,Inflammation Mediators,Interleukin-17,Interleukin-23,Mice,Molecular Targeted Therapy,Propylene Glycols,Sphingosine,T-Lymphocytes,Time Factors","analogs &amp; derivatives,drug therapy,etiology,immunology,metabolism,pathology,pharmacology,physiology,therapeutic use","D013601 Q000378 NN,D002545 Q000378 NN,D002545 Q000188 NN,D020381 Q000502 NN,D002545 Q000209 NY,D003352 Q000276 NN,D053759 Q000502 NN,D057134 Q000627 NN,D013110 Q000031 NN,D018836 Q000378 NN,D057134 Q000494 NN,D013601 Q000276 NY,D011409 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D002545 Q000473 NN,D003352 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[Role of T lymphocytes in ischemic brain injury].,"Recently, inflammation has been implicated in the progression of cerebral ischemic injury. Especially, T lymphocytes have been shown to infiltrate into the ischemic brain 24 hours after the onset, however, the function and specific subpopulation of these infiltrated T lymphocytes have not been fully understood. By using cytokine-deficient mice with transient focal ischemia model, we have shown that IL-23 and IL-17 but not IL-6 or IFN-γ play pivotal roles in the ischemic brain injury. We found that IL-23, wh",Rinsho shinkeigaku = Clinical neurology,"Takashi Shichita, Fumie Konoeda, Akihiko Yoshimura"," Department of Microbiology and Immunology, School of Medicine, Keio University.",2010 Nov;50(11):878-80,10.5692/clinicalneurol.50.878
21946305,20111101,review,"xref,mesh","Administration, Oral,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug therapy,pharmacology","D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D011409 Q000494 NY,D020529 Q000188 NY,D013110 Q000494 NN,D007166 Q000009 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.",NULL,Current opinion in ophthalmology,"Alison Huggins, Robert C Sergott",NULL,2011 Nov;22(6):447-50,10.1097/icu.0b013e32834be03b
22001715,20121001,article,"xref,mesh","Animals,Calcium Channels,Cell Proliferation,Cell Survival,Eye Diseases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intermediate Filament Proteins,Lysophospholipids,Membrane Glycoproteins,Nerve Tissue Proteins,Opsins,Peripherins,Propylene Glycols,Receptors, Lysosphingolipid,Retinal Photoreceptor Cell Outer Segment,Rhodopsin,Sphingosine","agonists,analogs &amp; derivatives,drug therapy,metabolism,pharmacology,physiology","D005128 Q000188 NN,D008562 Q000378 NN,D012243 Q000378 NN,D007381 Q000378 NN,D005128 Q000378 NN,D055214 Q000378 NN,D009419 Q000378 NN,D013110 Q000031 NY,D008246 Q000819 NN,D055355 Q000378 NN,D008246 Q000502 NY,D011409 Q000494 NN,D015220 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013110 Q000819 NN,D013110 Q000502 NN,D049349 Q000378 NN","31270,107969,107970,5280335,5283560",129645792,Focus on molecules: Sphingosine 1 Phosphate (S1P).,NULL,Experimental eye research,"Vivek K Gupta, Yuyi You, Alexander Klistorner, Stuart L Graham"," Australian School of Advanced Medicine, Macquarie University, Sydney, NSW 2109, Australia. vivek.gupta@mq.edu.au",2012 Oct;103(?):119-20,10.1016/j.exer.2011.09.023
22014437,20111101,review,"xref,mesh","Administration, Oral,Cladribine,Clinical Trials as Topic,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Quinolones,Sphingosine,Toluidines","administration &amp; dosage,analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000008 NN,D015363 Q000627 NY,D017338 Q000627 NY,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D014052 Q000008 NN,D003437 Q000008 NN,D015363 Q000008 NN,D007166 Q000627 NY,D017338 Q000008 NN,D020529 Q000188 NY,D005650 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D014052 Q000627 NY,D005650 Q000008 NN,D003437 Q000627 NY","8252,12215,20279,31270,107969,107970,637568,3036108,5280335,23500906,54677946","127968532,128394615,128471922,128672523,128966217,129060975,129645792",Oral treatment for multiple sclerosis.,"BACKGROUND: The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have shown benefit and will generate much interest because of the convenience of such administration. However, availability of convenient oral drugs will not necessarily translate into clinical effectiveness and safety. Here, we provide an interim report about the mechanisms of action, and efficacy and safety results that have been reported since January, 2010, for ",The Lancet. Neurology,"Joep Killestein, Richard A Rudick, Chris H Polman"," Department of Neurology, Multiple Sclerosis Centre Amsterdam, Vrije University Medical Centre, Amsterdam, Netherlands. j.killestein@vumc.nl",2011 Nov;10(11):1026-34,10.1016/s1474-4422(11)70228-9
22019925,20111218,article,"xref,mesh","Cells, Cultured,Comet Assay,DNA Breaks,DNA Damage,Dose-Response Relationship, Drug,Flame Retardants,Humans,Oxidative Stress,Propylene Glycols,Reactive Oxygen Species,Time Factors,Urothelium","administration &amp; dosage,cytology,drug effects,metabolism,pathology,toxicity","D019459 Q000187 NY,D053960 Q000187 NN,D019459 Q000166 NN,D011409 Q000633 NY,D017382 Q000378 NN,D004249 Q000187 NY,D011409 Q000008 NN,D018384 Q000187 NY,D005411 Q000008 NN,D019459 Q000473 NN,D005411 Q000633 NY","5641,8252,12035,18692,65154,135420630","53789062,127627244,127641595,128306526,128977994,129060975","Induction of DNA damage in human urothelial cells by the brominated flame retardant 2,2-bis(bromomethyl)-1,3-propanediol: role of oxidative stress.","2,2-bis(bromomethyl)-1,3-propanediol (BMP) is an extensively used brominated flame retardant found in urethane foams and polyester resins. In a 2-year dietary study conducted by the National Toxicology Program, BMP caused neoplastic lesions at multiple sites including the urinary bladder in both rats and mice. The mechanism of its carcinogenic effect is unknown. In the present study, using SV-40 immortalized human urothelial cells (UROtsa), endpoints associated with BMP induced DNA damage and oxidative stre",Toxicology,"Weixi Kong, Robert K Kuester, Alfred Gallegos, I Glenn Sipes"," Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ 85724, USA.",2011 Dec;290(?):271-7,10.1016/j.tox.2011.10.006
22028236,20111001,article,"xref,mesh","Animals,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy","D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","8252,31270,107970,5280335","128394615,129060975,129645792",Fingolimod treatment for multiple sclerosis patients What do we do with varicella?,NULL,Annals of neurology,"Alexander Winkelmann, Micha Loebermann, Emil C Reisinger, Hans Peter Hartung, Uwe K Zettl",NULL,2011 Oct;70(4):?,10.1002/ana.22605
22031473,20120201,article,"xref,mesh","Animals,Central Nervous System,Cytokines,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Immunosuppressive Agents,Indans,Lymphopenia,Mice,Multiple Sclerosis,Oxadiazoles,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,drug effects,drug therapy,metabolism,therapeutic use","D002490 Q000378 NN,D016207 Q000187 NN,D049349 Q000819 NY,D013110 Q000031 NN,D004681 Q000188 NN,D008231 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,10523409,25110406","128394615,129060975,129645792,136111139,246038057",S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.,"Multiple sclerosis (MS) therapies modulate T-cell autoimmunity in the central nervous system (CNS) but may exacerbate latent infections. Fingolimod, a nonselective sphingosine-1-phosphate (S1P) receptor agonist that induces sustained lymphopenia and accumulates in the CNS, represents a new treatment modality for MS. We hypothesized that sustained lymphopenia would not be required for efficacy and that a selective, CNS-penetrant, peripherally short-acting, S1P(1) agonist would show full efficacy in a mouse M",Molecular pharmacology,"Pedro J Gonzalez-Cabrera, Stuart M Cahalan, Nhan Nguyen, Gor Sarkisyan, Nora B Leaf, Michael D Cameron, Tomoyuki Kago, Hugh Rosen"," Department of Chemical Physiology, Scripps Research Institute, La Jolla, CA 92037, USA.",2012 Feb;81(2):166-74,10.1124/mol.111.076109
22042694,20111222,article,"xref,mesh","Animals,Antibodies, Monoclonal, Humanized,Antigens, Differentiation, B-Lymphocyte,Antineoplastic Combined Chemotherapy Protocols,Autophagy,Cell Death,Cell Line, Tumor,Drug Synergism,Female,Fingolimod Hydrochloride,Gene Expression Regulation, Neoplastic,Histocompatibility Antigens Class II,Humans,Immunoblotting,Immunosuppressive Agents,Lymphoma, Mantle-Cell,Lysosomes,Mice,Mice, SCID,Microscopy, Confocal,Microtubule-Associated Proteins,Propylene Glycols,Protein Transport,Reverse Transcriptase Polymerase Chain","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,therapeutic use","D020522 Q000188 NY,D008869 Q000378 NN,D015972 Q000187 NN,D000944 Q000378 NY,D008247 Q000378 NN,D000944 Q000235 NN,D013110 Q000008 NN,D021381 Q000187 NN,D016923 Q000187 NN,D020522 Q000473 NN,D001343 Q000187 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D000971 Q000627 NN,D020522 Q000378 NN,D061067 Q000008 NN,D000949 Q000235 NN,D000949 Q000378 NY,D061067 Q000494 NY,D013110 Q000494 NN,D007166 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.,"Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a short median survival despite multimodal therapy. FTY720, an immunosuppressive drug approved for the treatment of multiple sclerosis, promotes MCL cell death concurrent with down-modulation of phospho-Akt and cyclin D1 and subsequent cell-cycle arrest. However, the mechanism of FTY720-mediated MCL cell death remains to be fully clarified. In the present study, we show features of autophagy blockage by FTY720 treatment, including accumulati",Blood,"Lapo Alinari, Emilia Mahoney, John Patton, Xiaoli Zhang, Lenguyen Huynh, Christian T Earl, Rajeswaran Mani, Yicheng Mao, Bo Yu, Carl Quinion, William H Towns, Ching-Shih Chen, David M Goldenberg, Kristie A Blum, John C Byrd, Natarajan Muthusamy, Mette Praetorius-Ibba, Robert A Baiocchi"," Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA.",2011 Dec;118(26):6893-903,10.1182/blood-2011-06-363879
22057838,20120401,article,"xref,mesh","Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D010455 Q000627 NN,D016899 Q000627 NN,D013110 Q000031 NY,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,65370,107969,107970,3081884,5280335","128394615,129060975,129645792",Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.,"OBJECTIVES: Oral drugs for relapsing-remitting multiple sclerosis (RRMS) have been recently investigated and, one of these, fingolimod, is already available in several countries. In this framework, an analysis of the data in terms of the comparative effectiveness for all treatments thus far approved for RRMS can be useful to reappraise their place in therapy. METHODS: After a MEDLINE search, we selected all randomised trials studying the effectiveness of drugs for RRMS and included in our analysis those ran",European journal of clinical pharmacology,"Fabiola Del Santo, Dario Maratea, Valeria Fadda, Sabrina Trippoli, Andrea Messori"," Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100, Prato, Italy.",2012 Apr;68(4):441-8,10.1007/s00228-011-1141-1
22071882,20120401,article,"xref,mesh","Adult,Cardiac Output,Double-Blind Method,Female,Fingolimod Hydrochloride,Heart,Heart Rate,Humans,Immunosuppressive Agents,Lymphocyte Count,Male,Middle Aged,Propylene Glycols,Respiratory Function Tests,Sphingosine,Stroke Volume,Vascular Resistance","analogs &amp; derivatives,drug effects,pharmacology,physiology","D007166 Q000494 NY,D002302 Q000187 NN,D006321 Q000187 NN,D006339 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D014655 Q000187 NN,D013318 Q000187 NN,D013110 Q000494 NN,D006321 Q000502 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.,"PURPOSE: Fingolimod (FTY720) is a sphingosine-1 phosphate-receptor (S1PR) modulator recently approved as a once-daily oral therapy for relapsing multiple sclerosis (MS) in many countries. As S1PRs are widely expressed, including in heart and lung tissues, this study investigated the possible effects of fingolimod on heart-rate circadian rhythm and pulmonary function. METHODS: Healthy volunteers (n = 39) were randomized to receive fingolimod 0.5 mg, 1.25 mg, or placebo for 14 days. Heart rate and measures of",European journal of clinical pharmacology,"Robert Schmouder, Sam Hariry, Olivier J David"," Novartis Institutes of Biomedical Research, Cambridge, MA, USA. robert.schmouder@novartis.com",2012 Apr;68(4):355-62,10.1007/s00228-011-1146-9
22099778,20111101,article,mesh,"Animals,Automation,Biocompatible Materials,Diabetes Mellitus, Experimental,Drug Delivery Systems,Extracellular Matrix,Fingolimod Hydrochloride,Hypoxia,Image Processing, Computer-Assisted,Immunosuppressive Agents,Lactic Acid,Male,Materials Testing,Mice,Mice, Inbred C57BL,Microvessels,Nanofibers,Polyglycolic Acid,Polymers,Propylene Glycols,Sphingosine,Streptozocin,Tissue Scaffolds","administration &amp; dosage,analogs &amp; derivatives,chemistry,metabolism,therapy","D019344 Q000737 NY,D011100 Q000737 NY,D013110 Q000008 NN,D013311 Q000737 NN,D005109 Q000378 NN,D001672 Q000737 NN,D013110 Q000031 NY,D003921 Q000628 NY,D011108 Q000737 NN,D011409 Q000008 NY,D007166 Q000008 NY,D057139 Q000737 NN","612,5300,29327,61503,62358,71391,91435,107689,107969,107970,2733335,5280335,6420074,6713972,23615975,45357367",NULL,FTY720-loaded poly(DL-lactide-co-glycolide) electrospun scaffold significantly increases microvessel density over 7 days in streptozotocin-induced diabetic C57b16/J mice: preliminary results.,BACKGROUND: Nanofiber scaffolds could improve islet transplant success by physically mimicking the shape of extracellular matrix and by acting as a drug-delivery vehicle. Scaffolds implanted in alternate transplant sites must be prevascularized or very quickly vascularized following transplantation to prevent hypoxia-induced islet necrosis. The local release of the S1P prodrug FTY720 induces diameter enlargement and increases in length density. The objective of this preliminary study was to evaluate length ,Transplantation proceedings,"D T Bowers, P Chhabra, L Langman, E A Botchwey, K L Brayman"," Biomedical Engineering, University of Virginia, Charlottesville, Virginia 22908, USA.",2011 Nov;43(9):3285-7,10.1016/j.transproceed.2011.09.008
22099787,20111101,article,"xref,mesh","Animals,Cadaver,Creatinine,Fingolimod Hydrochloride,Graft Survival,Hypertonic Solutions,Immunosuppressive Agents,Kidney Transplantation,Male,Propylene Glycols,Rats,Rats, Sprague-Dawley,Reperfusion Injury,Sirolimus,Sphingosine,Tissue Donors","analogs &amp; derivatives,blood,chemistry,pharmacology,prevention &amp; control,therapeutic use","D006982 Q000737 NN,D003404 Q000097 NN,D015427 Q000517 NY,D013110 Q000031 NN,D020123 Q000494 NN,D007166 Q000627 NY,D011409 Q000494 NN,D013110 Q000494 NN","588,107969,107970,5280335,5284616,91534498","127719861,248766214",Short-term immunossupressive treatment of the donor does not prevent ischemia-reperfusion kidney damage in the rat.,INTRODUCTION: Ischemia-reperfusion (IR) kidney damage is an important factor for allograft survival in kidney transplantation. Recently it has been shown that immune factors from donor-derived cells are important in IR injury. The aim of this article was to evaluate the impact of short-term immunosuppressive treatment of the donor over a time frame relevant to cadaveric transplantation on IR damage to the rat kidney. METHODS: Male Sprague-Dawley rats served as donors and recipients. Three experimental group,Transplantation proceedings,"J Domínguez, F Lira, A Giacaman, G Mendez"," Facultad de Medicina, Departamento de Urología, Pontificia Universidad Católica de Chile, Santiago, Chile. javierdomi@hotmail.com",2011 Nov;43(9):3315-8,10.1016/j.transproceed.2011.09.093
22108845,20120301,article,mesh,"Animals,Animals, Newborn,Astrocytes,Cell Movement,Cerebellum,Chemokine CCL20,Chemokine CCL3,Chemokines,Demyelinating Diseases,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Lysophosphatidylcholines,Myelin Basic Protein,Neurofilament Proteins,Organ Culture Techniques,Oxadiazoles,Propylene Glycols,Rats,Rats, Wistar,Receptors, Lysosphingolipid,Sphingosine,Thiophenes","analogs &amp; derivatives,antagonists &amp; inhibitors,chemically induced,cytology,drug effects,drug therapy,metabolism,toxicity","D054405 Q000378 NN,D049349 Q000378 NY,D004676 Q000378 NN,D002465 Q000187 NN,D003711 Q000378 NY,D003711 Q000139 NN,D013110 Q000633 NN,D002531 Q000166 NN,D016900 Q000378 NN,D008244 Q000633 NN,D001253 Q000187 NN,D002531 Q000187 NN,D013110 Q000031 NN,D007166 Q000633 NN,D013876 Q000633 NN,D054418 Q000378 NN,D010069 Q000633 NN,D018925 Q000378 NY,D003711 Q000188 NN,D005786 Q000187 NN,D049349 Q000037 NN,D011409 Q000633 NN,D001253 Q000378 NN","107969,107970,4077460,4670741,5280335,5311264,10523409",NULL,S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures.,"Sphingosine-1-phosphate receptors (S1PRs) are drug targets for the compound FTY720, which is the first oral therapy developed for treatment of relapsing-remitting multiple sclerosis. S1PRs play a variety of functional roles in the differentiation, proliferation, survival and/or migration of neurons and glia. In this study, rat organotypic cerebellar slice cultures were used to assess whether S1PRs play a role in demyelination induced by lysolecithin (LPC). The data demonstrated that FTY720 and SEW2871 (a S1",Glia,"Graham K Sheridan, Kumlesh K Dev"," Department of Physiology, Trinity College Institute of Neuroscience (TCIN), School of Medicine, Trinity College Dublin, Dublin 2, Ireland.",2012 Mar;60(3):382-92,10.1002/glia.22272
22110161,20120701,article,"xref,mesh","Administration, Oral,Adult,Biological Availability,Clinical Trials, Phase I as Topic,Clinical Trials, Phase III as Topic,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Models, Biological,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Time Factors,Tissue Distribution,Young Adult","administration &amp; dosage,analogs &amp; derivatives,drug effects,metabolism,pharmacokinetics","D011409 Q000493 NY,D007166 Q000008 NN,D013110 Q000008 NN,D007166 Q000493 NY,D013110 Q000031 NY,D011409 Q000008 NN,D049349 Q000187 NN,D013110 Q000493 NN,D049349 Q000378 NN","31270,107969,107970,5280335","128394615,129645792",Population pharmacokinetics of fingolimod phosphate in healthy participants.,"Fingolimod (FTY720) is a sphingosine 1-phosphate receptor (S1PR) modulator currently being evaluated for the treatment of multiple sclerosis. Fingolimod undergoes phosphorylation in vivo to yield fingolimod phosphate (fingolimod-P), which modulates S1PRs expressed on lymphocytes and cells in the central nervous system. The authors developed a population model, using pooled data from 7 phase 1 studies, to enable characterization of fingolimod-P pharmacokinetics following oral administration of fingolimod and",Journal of clinical pharmacology,"Kai Wu, Francois Mercier, Olivier J David, Robert L Schmouder, Michael Looby"," Daiichi Sankyo Pharma Development, Edison, NJ, USA.",2012 Jul;52(7):1054-68,10.1177/0091270011409229
22111333,20111101,review,"xref,mesh","Administration, Oral,Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Molecular Targeted Therapy,Multiple Sclerosis,Natalizumab,Peptides,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D010455 Q000627 NN,D007166 Q000627 NN,D016899 Q000627 NN,D013110 Q000031 NN,D061067 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","6057,8252,31270,65370,107969,107970,3081884,5280335","128394615,128865459,129060975,129645792",[Multiple sclerosis: current therapies and future perspectives].,"Multiple sclerosis is characterized by temporal and spatial dissemination of demyelination in the central nervous system. After a discovery of disease modifying effects of interferon beta and glatiramer acetate for multiple sclerosis, many drugs for disease modifying therapy have been developed. Recently, some multicenter studies have shown that early introduction of interferon beta or glatiramer acetate into patients with clinically isolated syndrome delayed the conversion to clinically definite multiple s",Nihon rinsho. Japanese journal of clinical medicine,Takuya Matsushita," Department of Clinical Neuroimmunology, Graduate School of Medicine, Kyushu University.",2011 Nov;69(11):2077-86,NULL
22115743,20120301,article,"xref,mesh","Animals,Comet Assay,DNA,DNA Damage,Furans,Liver,Propylene Glycols,Turkeys","drug effects,embryology,metabolism,pharmacology","D004247 Q000187 NY,D008099 Q000187 NY,D011409 Q000494 NY,D005663 Q000494 NY,D008099 Q000378 NN,D008099 Q000196 NN","8029,8252,10442,75389,44135672","128270327,129060975,129813428,129828206","Furan induction of DNA cross-linking and strand breaks in turkey fetal liver in comparison to 1,3-propanediol.","Furan, a food contaminant formed by heating, is hepatocarcinogenic to rats and mice. Conflicting genotoxicity data exist on furan and its metabolite, cis-2-butene-1,4-dial and there are few data for the target organ, the liver. We assessed the abilities of furan and, as a positive control, 1,3-propanediol (PDO), to cause DNA damage in the livers of turkey fetuses in ovo using the alkaline comet assay. Single injections of furan (2-20 μmoles) into turkey eggs, at 23 days of incubation, when the liver is well",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,"Alan M Jeffrey, Klaus D Brunnemann, Jian-Dong Duan, Josef Schlatter, Gary M Williams"," Department of Pathology, New York Medical College, Valhalla, NY 10595, United States.",2012 Mar;50(?):675-8,10.1016/j.fct.2011.11.011
22119341,20120101,article,"xref,mesh,assay","Amides,Amino Acids,Benzamides,Catalytic Domain,Chemistry, Pharmaceutical,Drug Design,Fingolimod Hydrochloride,Humans,Hydrogen Bonding,Immunologic Factors,Immunosuppressive Agents,Inhibitory Concentration 50,Models, Chemical,Models, Molecular,Molecular Conformation,Oxazolone,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,chemical synthesis,chemistry,methods,pharmacology","D049349 Q000819 NN,D001549 Q000494 NN,D000577 Q000138 NY,D002626 Q000379 NY,D001549 Q000138 NY,D013110 Q000031 NN,D000596 Q000737 NN,D010081 Q000031 NY,D010081 Q000138 NN,D011409 Q000494 NN,D007155 Q000494 NY,D013110 Q000494 NN,D007166 Q000494 NN,D010081 Q000494 NN,D000577 Q000494 NY","2331,8252,27435,31270,107969,107970,1712093,1712094,5280335,11452022,14524248,56835157,57393474,57393475,57398732,57402192,57403950","128394615,128447465,129060975,129244491,129645792,129854636",Novel immunomodulators based on an oxazolin-2-one-4-carboxamide scaffold.,"A series of oxazolidin-2-one-4-carboxylic amide compounds (1a-f) were designed and synthesized as the non-phosphate S1P(1) receptor agonists. The single crystal of 1e was prepared and solved to elucidate the structure of 1a-f. EC(50) of 1a-d were about 1.1-3.6 μM in S1P(1) Redistribution® assay, and their cytotoxicity was 8-40-fold lower than FTY720. Though its S1P(1) agonist activities in vitro were about 1000-folds weaker than (S)-FTY720-P, at a dose of 10mg/Kg, the immunosuppressive effects of 1a were co",Bioorganic & medicinal chemistry letters,"Xinhua He, Lili Wang, Zhibing Zheng, Junhai Xiao, Wu Zhong, Song Li"," Beijing Institute of Pharmacology & Toxicology, No.27 Taiping Road, Beijing 100850, PR China. hexinhua2007@gmail.com",2012 Jan;22(1):553-7,10.1016/j.bmcl.2011.10.088
22119714,20120201,article,"xref,mesh","Animals,Apoptosis,Autoimmune Diseases,Blood-Retinal Barrier,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Microvessels,Permeability,Propylene Glycols,Retinitis,Sphingosine,Uveitis","administration &amp; dosage,analogs &amp; derivatives,drug effects,pathology,pharmacology,prevention &amp; control","D007166 Q000494 NY,D012173 Q000473 NN,D007166 Q000008 NN,D014605 Q000517 NY,D013110 Q000008 NN,D001813 Q000187 NY,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D012173 Q000517 NY,D055806 Q000473 NN,D001813 Q000473 NN,D014605 Q000473 NN,D013110 Q000494 NN,D001327 Q000473 NN,D001327 Q000517 NY","5262,8252,31270,107969,107970,5280335","127790758,128394615,129060975,129645792","Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.","Fingolimod (FTY720) is an FDA-approved therapeutic drug with efficacy demonstrated in experimental models of multiple sclerosis and in phase III human multiple sclerosis trials. Fingolimod prevents T-cell migration to inflammatory sites by decreasing expression of the sphingosine-1 phosphate receptor normally required for egress from secondary lymphoid tissue. As a preclinical model of human uveitis, experimental autoimmune uveoretinitis permits assessment of immunotherapeutic efficacy. Murine experimental ",The American journal of pathology,"David A Copland, Jian Liu, Lauren P Schewitz-Bowers, Volker Brinkmann, Karen Anderson, Lindsay B Nicholson, Andrew D Dick"," Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.",2012 Feb;180(2):672-81,10.1016/j.ajpath.2011.10.008
22119782,20120301,article,"xref,mesh","Animals,Antioxidants,Baccharis,Chromatography, High Pressure Liquid,Glutathione,Lipids,Male,Mitochondria, Liver,Oxidation-Reduction,Oxidative Stress,Propolis,Rats,Rats, Wistar,Spectrophotometry, Ultraviolet","chemistry,drug effects,metabolism,pharmacology","D011429 Q000494 NY,D008930 Q000187 NY,D008930 Q000378 NN,D031175 Q000737 NY,D018384 Q000187 NY,D008055 Q000737 NN,D005978 Q000378 NN,D000975 Q000494 NY","8252,124886","129060975,129192846","Baccharis dracunculifolia, the main source of green propolis, exhibits potent antioxidant activity and prevents oxidative mitochondrial damage.","Baccharis dracunculifolia DC (Asteraceae) is the main botanical source used by honeybees to produce Brazilian green propolis whose hepatoprotective properties have been already described. In this work we investigated the protective effects of the glycolic extract of B. dracunculifolia (GEBd) against oxidative stress in isolated rat liver mitochondria (RLM). The GEBd was prepared by fractionated percolation using propylene glycol as solvent. The total phenols and flavonoids, which are substances with recogni",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,"Natalia S S Guimarães, Joyce C Mello, Juliana S Paiva, Paula C P Bueno, Andresa A Berretta, Ricardo J Torquato, Iseli L Nantes, Tiago Rodrigues"," Centro Interdisciplinar de Investigação Bioquímica (CIIB), Universidade de Mogi das Cruzes (UMC), Brazil.",2012 Mar;50(?):1091-7,10.1016/j.fct.2011.11.014
22146605,20120101,article,"xref,mesh","Adult,Brain,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Neuromyelitis Optica,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,pathology","D013110 Q000009 NN,D001921 Q000473 NY,D001921 Q000187 NN,D013110 Q000031 NY,D009471 Q000473 NY,D009471 Q000188 NY,D007166 Q000009 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.,"We report the case of a patient who developed extensive brain lesions during fingolimod (FTY720) treatment in the TRANSFORMS study. His initial diagnosis was multiple sclerosis, but after encephalopathy anti-aquaporin4 antibody (anti-AQP4 Ab) was detected, it was changed to neuromyelitis optica spectrum disorder. After treatment with fingolimod, he developed bilateral extensive brain lesions. The brain MRI showed lesions predominantly involving the right frontal and parietal lobes, with vasogenic edema and ","Multiple sclerosis (Houndmills, Basingstoke, England)","Ju-Hong Min, Byoung Joon Kim, Kwang Ho Lee"," Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",2012 Jan;18(1):113-5,10.1177/1352458511431973
22149256,20120101,review,"xref,mesh","Animals,Blood Proteins,Drug Interactions,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Diseases,Liver Diseases,Multiple Sclerosis,Propylene Glycols,Protein Binding,Sphingosine","analogs &amp; derivatives,drug therapy,metabolism,pharmacokinetics,therapeutic use","D011409 Q000493 NY,D007674 Q000378 NN,D001798 Q000378 NN,D007166 Q000627 NN,D009103 Q000378 NN,D007166 Q000493 NY,D013110 Q000031 NY,D013110 Q000493 NN,D013110 Q000627 NN,D011409 Q000627 NN,D008107 Q000378 NN,D009103 Q000188 NN","3823,8252,31270,107969,107970,5280335","127362988,128394615,129060975,129645792,129708236",Clinical pharmacokinetics of fingolimod.,"Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compounds and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod is a structural analogue of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety. Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central n",Clinical pharmacokinetics,"Olivier J David, John M Kovarik, Robert L Schmouder"," Novartis Institutes for Biomedical Research, Basel, Switzerland. olivier.david@novartis.com",2012 Jan;51(1):15-28,10.2165/11596550-000000000-00000
22149932,20120101,review,"xref,mesh","Animals,Bone Marrow,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymph Nodes,Lymphocytes,Lymphoid Tissue,Lysophospholipids,Models, Biological,Propylene Glycols,Sphingosine,Thymus Gland","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology","D008214 Q000276 NY,D001853 Q000276 NN,D013950 Q000187 NN,D008221 Q000378 NY,D008214 Q000378 NY,D008198 Q000187 NN,D008198 Q000276 NN,D013110 Q000031 NY,D008246 Q000276 NN,D013110 Q000378 NN,D001853 Q000378 NN,D013950 Q000276 NN,D008221 Q000276 NY,D013110 Q000276 NN,D008246 Q000378 NY,D008221 Q000187 NN,D011409 Q000494 NN,D008198 Q000378 NN,D013950 Q000378 NN,D013110 Q000494 NN,D008214 Q000187 NN,D007166 Q000494 NN,D001853 Q000187 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.,"Much has been learned about how cells enter lymphoid tissues. But how do they leave? Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress. In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus. We review what is known about additional requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow. Egress from lymphoid organs is limited during ",Annual review of immunology,"Jason G Cyster, Susan R Schwab"," Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, California 94143-0414, USA. Jason.Cyster@ucsf.edu",2012 Jan;30(?):69-94,10.1146/annurev-immunol-020711-075011
22151889,20110101,article,"xref,mesh","Animals,Cartilage, Articular,Cattle,Cells, Cultured,Chondrocytes,Fingolimod Hydrochloride,Glycosaminoglycans,Immunosuppressive Agents,Interleukin-1beta,Matrix Metalloproteinase 13,Matrix Metalloproteinase 3,Nitric Oxide Synthase Type II,Propylene Glycols,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,drug effects,enzymology,genetics,metabolism,pathology,physiology,toxicity","D052247 Q000378 NN,D053509 Q000096 NN,D002358 Q000187 NY,D011409 Q000633 NY,D019902 Q000187 NY,D019902 Q000473 NN,D019902 Q000378 NN,D013110 Q000633 NN,D013110 Q000031 NY,D002358 Q000201 NN,D006025 Q000378 NY,D002358 Q000378 NN,D053583 Q000502 NN,D052247 Q000235 NN,D019278 Q000096 NN,D006025 Q000037 NY,D014409 Q000502 NN,D007166 Q000633 NY","668,679,702,4271,5793,5865,5961,6049,8252,31270,67149,105065,107969,107970,3323161,5280335,57317596,90726579","127978224,128141778,128364298,128394615,128482492,129060975,129178479,129621433,129624995,129645792,129717275,129888770,135855964,136111139,136314073,242963342",The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage.,"BACKGROUND: FTY720 (Fingolimod) is a novel immunosuppressive drug investigated in clinical trials for organ transplantation and multiple sclerosis. It acts as a functional sphingosine-1-phosphate (S1P) receptor antagonist, thereby inhibiting the egress of lymphocytes from secondary lymphoid organs. As S1P is able to prevent IL-1beta induced cartilage degradation, we examined the direct impact of FTY720 on cytokine induced cartilage destruction. METHODS: Bovine chondrocytes were treated with the bioactive ph",BMC musculoskeletal disorders,"Martin H Stradner, Hannes Angerer, Thomas Ortner, Florentine C Fuerst, Daniela Setznagl, Marie-Luise Kremser, Josef Hermann, Winfried B Graninger"," Division of Rheumatology and Immunology, Medical University of Graz, Austria. martin.stradner@medunigraz.at",2011 Jan;12(?):279,10.1186/1471-2474-12-279
22170282,20120401,article,"xref,mesh","Adoptive Transfer,Animals,Chemotaxis, Leukocyte,Disease Models, Animal,Fingolimod Hydrochloride,Genes, T-Cell Receptor,Herpes Simplex,Herpesvirus 1, Human,Immunosuppressive Agents,Lymph Nodes,Lymphatic Vessels,Lymphocyte Activation,Mice,Mice, Inbred C57BL,Mice, Transgenic,Propylene Glycols,Skin,Sphingosine,T-Lymphocytes,Time Factors","analogs &amp; derivatives,drug effects,genetics,immunology,pathogenicity,pharmacology,transplantation,virology","D042601 Q000821 NN,D006561 Q000235 NN,D008213 Q000187 YN,D018259 Q000276 NN,D008198 Q000276 NY,D006561 Q000276 NY,D013601 Q000637 NN,D013110 Q000031 NN,D012867 Q000821 NN,D018259 Q000472 NN,D013601 Q000276 NY,D042601 Q000276 NY,D012867 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D013601 Q000821 NN,D007166 Q000494 NN,D013601 Q000187 NN,D006561 Q000821 NN,D008198 Q000821 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Reactive murine lymph nodes uniquely permit parenchymal access for T cells that enter via the afferent lymphatics.,"Whereas naïve T cells access the lymph nodes predominantly via the high endothelial venules, their effector counterparts can also enter via the afferent lymphatics. It is unclear if such cells are confined to the lymphatic spaces during their transit through the lymph node or whether they can access the lymphocyte- and dendritic cell-rich parenchyma with its potentially stimulatory environment. We used a flank HSV inoculation model that featured neuronal-mediated movement of virus to distinct areas of skin ",The Journal of pathology,"Liv Eidsmo, Angus T Stock, William R Heath, Sammy Bedoui, Francis R Carbone"," Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria 3010, Australia.",2012 Apr;226(5):806-13,10.1002/path.3975
22174429,20121201,article,mesh,"Administration, Oral,Adult,Antigens,Antigens, Fungal,Candida albicans,Double-Blind Method,Female,Fingolimod Hydrochloride,Hemocyanins,Humans,Hypersensitivity, Delayed,Immunoglobulin G,Immunoglobulin M,Immunosuppressive Agents,Male,Pneumococcal Vaccines,Propylene Glycols,Sphingosine,T-Lymphocytes,Tetanus Toxoid,Young Adult","administration &amp; dosage,analogs &amp; derivatives,blood,drug effects,etiology,immunology,pharmacokinetics","D013745 Q000008 NN,D013110 Q000097 NN,D013601 Q000276 NN,D007166 Q000097 NN,D006433 Q000008 NN,D013110 Q000008 NN,D000941 Q000008 NN,D013110 Q000031 NY,D007166 Q000493 NN,D006968 Q000209 NN,D007075 Q000097 NY,D007074 Q000097 NY,D011409 Q000493 NN,D013601 Q000187 NY,D002176 Q000276 NN,D013110 Q000493 NN,D000946 Q000008 NN,D006968 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY,D011409 Q000097 NN,D022242 Q000008 NN","107969,107970,5280335",NULL,"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.","Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in many countries for relapsing-remitting multiple sclerosis, at a once-daily 0.5-mg dose. A reduction in peripheral lymphocyte count is an expected consequence of the fingolimod mechanism of S1PR modulation. The authors investigated if this pharmacodynamic effect impacts humoral and cellular immunogenicity. In this double-blind, parallel-group, 4-week study, 72 healthy volunteers were randomized to steady state",Journal of clinical pharmacology,"Craig Boulton, Karin Meiser, Olivier J David, Robert Schmouder"," MPhil, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, UK. craig.boulton@novartis.com",2012 Dec;52(12):1879-90,10.1177/0091270011427908
22206763,20111201,article,mesh,"Administration, Oral,Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Mitoxantrone,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Pharmacovigilance,Propylene Glycols,Risk Assessment,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000009 NN,D011409 Q000009 NN,D010455 Q000627 NN,D061067 Q000009 NN,D008942 Q000627 NY,D061067 Q000627 NY,D016899 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D008942 Q000009 NN,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","4212,51082,51151,65370,107969,107970,3081884,5280335,5458171,54607525",NULL,Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.,"Balancing efficacy versus burden of therapy is essential for the choice of disease-modifying therapy in every MS patient. The first-line therapies, interferon-? and glatiramer acetate, have well-established efficacy and present no major safety concerns. Certain second-line therapies, such as natalizumab, offer potentially greater efficacy, but are associated with an increased level of risk. Over the last year, the first two oral treatments of relapsing-remitting multiple sclerosis, cladribine and fingolimod",Journal of the neurological sciences,Per Soelberg Sørensen," Danish Multiple Sclerosis Research Centre, Copenhagen University and Rigshospitalet, Copenhagen, Denmark.",2011 Dec;?(?):S29-34,10.1016/s0022-510x(11)70006-5
22210496,20120301,article,"xref,mesh","Animals,CHO Cells,Cricetinae,Cricetulus,Cytokines,Disease Models, Animal,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Humans,Immunosuppressive Agents,Intestine, Small,Propylene Glycols,Rats,Rats, Wistar,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes,Time Factors,Transplantation, Homologous","agonists,analogs &amp; derivatives,drug effects,immunology,pharmacology,prevention &amp; control,transplantation","D007166 Q000494 NY,D049349 Q000819 NY,D013110 Q000031 NN,D007421 Q000637 NY,D007421 Q000276 NN,D006085 Q000187 NY,D006085 Q000276 NN,D011409 Q000494 NN,D006084 Q000276 NN,D013110 Q000494 NN,D006084 Q000517 NY","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139","Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation.","BACKGROUND: In small bowel transplantation (SBTx), inhibition of both graft-versus-host disease (GVHD) and allograft rejection is necessary. METHODS: We investigated the potency of a new sphingosine-1-phosphate receptor agonist, W-061, for these two immune responses in SBTx. W-061 has a completely different molecular structure from FTY720. Heterotopic SBTx was performed from Wistar-Furth (WF) into (WF×ACI) F1 rats as a GVHD model or F1 to WF rats as a rejection model. Recipients were orally given 3 mg/kg/da",Transplant immunology,"Jinghai Song, Hiroshi Hagiya, Haruto Kurata, Hirotaka Mizuno, Toshinori Ito"," Department of Complementary and Alternative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.",2012 Mar;26(?):163-70,10.1016/j.trim.2011.12.005
22225501,20120701,article,"xref,mesh","Animals,Arrestin,Fingolimod Hydrochloride,GTP-Binding Proteins,Lymphocytes,Lysophospholipids,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Rats,Rats, Inbred Strains,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacokinetics,pharmacology,therapeutic use","D011409 Q000493 NY,D008246 Q000819 NY,D020529 Q000188 NN,D008214 Q000378 NN,D019393 Q000378 NN,D013110 Q000031 NY,D013110 Q000378 NN,D019204 Q000378 NN,D013110 Q000493 NN,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D008214 Q000187 NN,D013110 Q000819 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists.,"Sphingosine-1-phosphate (S1P(1)) receptor agonists such as Fingolimod (FTY-720) are a novel class of immunomodulators that have clinical utility in the treatment of remitting relapsing multiples sclerosis. This class of compound act by inducing peripheral lymphopenia. Using an integrated pharmacokinetic/pharmacodynamic (PK-PD) approach based on an in vivo rat model, novel S1P(1) agonists were identified with a predicted more rapid rate of reversibility of lymphocyte reduction in human compared to Fingolimod",Xenobiotica; the fate of foreign compounds in biological systems,"Simon Taylor, James R J Gray, Robert Willis, Nigel Deeks, Andrea Haynes, Colin Campbell, Pam Gaskin, Karen Leavens, Emmanuel Demont, Simon Dowell, Jenni Cryan, Mary Morse, Aarti Patel, Helen Garden, Jason Witherington"," Immuno-Inflammation Center of Excellence for Drug Discovery , GlaxoSmithKline, Stevenage, UK. Simon.5.taylor@gsk.com",2012 Jul;42(7):671-86,10.3109/00498254.2011.645908
22231867,20120201,article,"xref,mesh","Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macular Edema,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Tomography, Optical Coherence","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D013110 Q000031 NY,D020529 Q000188 NY,D008269 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","8252,16850,31270,107969,107970,5280335","127977452,128394615,129060975,129645792",Does fingolimod in multiple sclerosis patients cause macular edema?,"Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is the common cause of optic neuritis. Fingolimod, an immunosuppressive agent, is used in MS to prevent acute exacerbations. We report a case of relapsing-remitting MS treated with fingolimod. The patient presented with an acute decrease in vision in the left eye. Eye examination showed clinical macular edema (ME) in the left eye, which was confirmed on fluorescein angiogram and optical coherence tomography (OCT). After dis",Journal of neurology,"Kiran Turaka, Joseph Shepard Bryan"," Associated Retina Consultants Ltd, 7600 N 15th Street, Phoenix, AZ 85020, USA. keen_268@yahoo.com",2012 Feb;259(2):386-8,10.1007/s00415-011-6367-4
22251137,20120601,article,"xref,mesh","Animals,Blood Pressure,Carotid Arteries,Cyclooxygenase Inhibitors,Endothelium, Vascular,Enzyme Inhibitors,Fingolimod Hydrochloride,Hypertension,Immunosuppressive Agents,Isoenzymes,Male,Muscle, Smooth, Vascular,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Rats,Rats, Inbred SHR,Rats, Inbred WKY,Sphingosine,Thromboxane A2,Vascular Resistance,Vasoconstrictor Agents","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,chemically induced,chemistry,cytology,drug effects,metabolism,pathology,pharmacology,physiopathology","D002339 Q000378 NY,D002339 Q000473 NN,D011409 Q000009 NN,D013110 Q000009 NN,D006973 Q000473 NN,D009131 Q000473 NN,D004730 Q000166 NN,D013928 Q000037 NN,D014662 Q000009 NN,D004730 Q000187 NN,D007527 Q000378 NN,D004791 Q000737 NN,D014655 Q000187 YN,D007527 Q000037 NN,D011409 Q000737 NN,D016861 Q000494 NN,D013110 Q000737 NN,D014662 Q000494 NN,D006973 Q000378 NY,D013110 Q000031 NN,D004730 Q000473 NN,D002339 Q000187 NN,D006973 Q000139 NN,D001794 Q000187 NN,D009131 Q000166 NN,D009131 Q000187 NN,D017853 Q000378 NY","31270,107969,107970,114873,5280335,5280497,54178976","128887832,129205760,129645792",FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.,"BACKGROUND AND PURPOSE: FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensiv",British journal of pharmacology,"Léon J A Spijkers, Astrid E Alewijnse, Stephan L M Peters"," Department of Pharmacology & Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands.",2012 Jun;166(4):1411-8,10.1111/j.1476-5381.2012.01865.x
22262169,20120201,article,"xref,mesh","Animals,Benzopyrenes,Disease Models, Animal,Fingolimod Hydrochloride,Gene Knock-In Techniques,Humans,Immunosuppressive Agents,Lung Neoplasms,Mice,Mice, Knockout,Point Mutation,Propylene Glycols,Protein Phosphatase 2,Signal Transduction,Sphingosine,Tumor Suppressor Protein p53,ras Proteins","analogs &amp; derivatives,chemically induced,chemistry,drug effects,drug therapy,genetics,metabolism,pharmacology,therapeutic use,toxicity","D007166 Q000494 NY,D007166 Q000627 NN,D008175 Q000235 NN,D008175 Q000139 NN,D054648 Q000737 NN,D018631 Q000378 NN,D001580 Q000633 NN,D013110 Q000031 NN,D054648 Q000378 NY,D054648 Q000235 NN,D016159 Q000378 NN,D011409 Q000494 NN,D013110 Q000627 NN,D011409 Q000627 NN,D008175 Q000188 NN,D013110 Q000494 NN,D018631 Q000235 NN,D015398 Q000187 NY","2336,8252,31270,107969,107970,5280335","127868578,128394615,129060975,129645792",Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.,"Evidence that protein phosphatase 2A (PP2A) is a tumor suppressor in humans came from the discovery of mutations in the genes encoding the Aα and Aβ subunits of the PP2A trimeric holoenzymes, Aα-B-C and Aβ-B-C. One point mutation, Aα-E64D, was found in a human lung carcinoma. It renders Aα specifically defective in binding regulatory B' subunits. Recently, we reported a knock-in mouse expressing Aα-E64D and an Aα knockout mouse. The mutant mice showed a 50-60% increase in the incidence of lung cancer induce","Cell cycle (Georgetown, Tex.)","Gernot Walter, Ralf Ruediger"," Department of Pathology, University of California, San Diego, La Jolla, CA, USA. gwalter@ucsd.edu",2012 Feb;11(3):451-9,10.4161/cc.11.3.19057
22276823,20120126,review,"xref,mesh","Adult,Algorithms,Central Nervous System,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,pharmacology,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D009103 Q000503 NN,D013110 Q000031 NY,D007166 Q000627 NY,D002490 Q000187 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod for multiple sclerosis.,NULL,The New England journal of medicine,"Daniel Pelletier, David A Hafler"," Yale Multiple Sclerosis Center, Department of Neurology, Yale School of Medicine, New Haven, CT 06520-8018, USA. daniel.pelletier@yale.edu",2012 Jan;366(4):339-47,10.1056/nejmct1101691
22287614,20120415,article,"xref,mesh","Airway Remodeling,Allergens,Animals,Anti-Asthmatic Agents,Asthma,Bronchi,Bronchoalveolar Lavage Fluid,CD3 Complex,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Male,Muscle, Smooth,Propylene Glycols,Rats,Severity of Illness Index,Sphingosine,Treatment Outcome","adverse effects,agonists,analogs &amp; derivatives,analysis,blood supply,drug effects,drug therapy,pathology,therapeutic use","D008246 Q000819 NY,D056151 Q000187 NY,D001249 Q000188 NN,D001980 Q000473 NN,D013110 Q000031 NY,D001980 Q000187 NN,D017252 Q000032 NN,D000485 Q000009 NY,D018927 Q000627 NN,D007166 Q000627 NY,D009130 Q000187 NN,D001980 Q000098 NN,D013110 Q000627 NN,D011409 Q000627 NY,D008246 Q000627 NY,D013110 Q000819 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure.,"Sphingosine-1-phosphate (S1P) is an immunomodulatory lipid mediator that plays an important role in lymphocyte trafficking. Elevated levels of S1P are found in bronchoalveolar lavage (BAL) fluid of patients with asthma; however, its role in disease is not known. FTY720, a synthetic analog of S1P, has been shown to abrogate allergic inflammation and airway hyperresponsiveness following acute allergen challenge. However, its effects on asthmatic airway remodeling induced by repeated allergen exposure are unkn",American journal of physiology. Lung cellular and molecular physiology,"Harry Karmouty-Quintana, Sana Siddiqui, Muhannad Hassan, Kimitake Tsuchiya, Paul-Andre Risse, Laura Xicota-Vila, Maria Marti-Solano, James G Martin"," Meakins-Christie Laboratories, McGill University, Montreal, Canada. hkarquin@gmail.com",2012 Apr;302(8):L736-45,10.1152/ajplung.00050.2011
22300970,20121001,article,"xref,mesh","Arrhythmias, Cardiac,Death, Sudden, Cardiac,Female,Fingolimod Hydrochloride,Humans,Hypertension,Immunosuppressive Agents,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug therapy,etiology,pathology","D013110 Q000009 NN,D006973 Q000473 NN,D016757 Q000473 NN,D001145 Q000139 NY,D020529 Q000150 NN,D016757 Q000209 NY,D013110 Q000031 NY,D020529 Q000473 NN,D006973 Q000150 NN,D020529 Q000188 NY,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",128394615,Sudden unexpected death on fingolimod.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","J W Lindsey, K Haden-Pinneri, N B Memon, L M Buja",NULL,2012 Oct;18(10):1507-8,10.1177/1352458512438456
22303740,20120111,article,"xref,mesh","Antibodies, Monoclonal,Anticonvulsants,Atrial Fibrillation,Carbamates,Chronic Disease,Deep Brain Stimulation,Dopamine Agonists,Epilepsy,Fingolimod Hydrochloride,Genetic Therapy,Humans,Immunosuppressive Agents,Ischemic Attack, Transient,Multiple Sclerosis,Muscular Diseases,Neurology,Parkinson Disease,Phenylenediamines,Polyneuropathies,Propylene Glycols,Sphingosine,Stroke,Treatment Outcome,Valproic Acid","analogs &amp; derivatives,diagnosis,drug therapy,etiology,genetics,methods,prevention &amp; control,therapeutic use,therapy,trends","D010655 Q000627 NN,D004827 Q000188 YN,D014635 Q000627 NN,D002546 Q000209 YN,D007166 Q000627 NN,D002219 Q000627 NN,D010300 Q000175 YN,D001281 Q000175 YN,D009135 Q000235 YN,D000911 Q000627 NN,D000927 Q000627 NN,D011115 Q000175 YN,D002546 Q000188 YN,D013110 Q000031 NN,D015316 Q000379 NN,D010300 Q000188 YN,D020521 Q000188 NN,D002546 Q000517 YN,D004827 Q000175 YN,D009103 Q000175 YN,D009103 Q000188 YN,D011115 Q000188 YN,D013110 Q000627 NN,D009135 Q000628 YN,D011409 Q000627 NN,D001281 Q000188 YN,D009462 Q000639 NN","681,3121,8252,31270,86480,107969,107970,121892,147515,3549980,5280335,16760703,23663956","128394615,128706830,128896436,129060975,129544235,129645792",[Neurology].,"In 2011, new oral anticoagulants for atrial fibrillation are available and the ABCD3-I score predicting stroke after TIA updates the ABCD2 score. New McDonald criteria allow faster MS diagnosis and the first oral treatment (fingolimod) for MS can be prescribed. A new anti-antiepileptic drug (retigabine) is available and sodium valproate has long term neurological adverse effects after in utero exposure. Among Parkinson disease treatments, deep brain stimulation is extending applications and dopamine agonist",Revue medicale suisse,"J N Chabwine, A R Rossetti, L Hirt, T Kuntzer, M Schluep, P Michel, J F Démonet, R A du Pasquier, F G Vingerhoets"," Service de neurologie, Département de neurosciences cliniques, CHUV, Lausanne. jo.nsimy@gmail.com",2012 Jan;8(323):46-50,NULL
22322303,20120401,article,"xref,mesh","Animals,Cells, Cultured,Enzyme Inhibitors,Fingolimod Hydrochloride,Hemodynamics,Histamine,Human Umbilical Vein Endothelial Cells,Humans,Immunosuppressive Agents,Leukocyte Count,Leukocyte Rolling,MAP Kinase Signaling System,Mice,Mice, Knockout,Neutrophil Infiltration,P-Selectin,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Up-Regulation","analogs &amp; derivatives,antagonists &amp; inhibitors,deficiency,drug effects,enzymology,metabolism,pharmacology,physiology","D017853 Q000494 NN,D019007 Q000378 NN,D015854 Q000187 NN,D006632 Q000494 NY,D061307 Q000201 NN,D061307 Q000187 NN,D013110 Q000031 NN,D061307 Q000378 NN,D036904 Q000187 NN,D017853 Q000502 NY,D017853 Q000172 NN,D011409 Q000494 NN,D004791 Q000494 NN,D006439 Q000502 NN,D020935 Q000187 NN,D017853 Q000037 NN,D020935 Q000502 NN,D013110 Q000494 NN,D007166 Q000494 NN,D020556 Q000502 NN,D020556 Q000187 NY,D036904 Q000502 NN,D049349 Q000502 NN","774,5818,8252,31270,107969,107970,120160,5280335,25201573","128394615,128754351,129060975,129645792",Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent.,"Leukocyte recruitment to sites of inflammation is critical for the development of acute allergic responses. Rapid P-selectin up-regulation by endothelial cells is a key promoter of leukocyte infiltration in response to mediators such as histamine. However, the mechanisms underpinning this process are still incompletely understood. We examined the role of the sphingosine kinase/sphingosine-1-phosphate (SK/S1P) pathway and showed that in human umbilical vein endothelial cells, histamine rapidly activates SK i",The American journal of pathology,"Wai Y Sun, Latasha D Abeynaike, Samantha Escarbe, Charles D Smith, Stuart M Pitson, Michael J Hickey, Claudine S Bonder"," Division of Human Immunology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.",2012 Apr;180(4):1740-50,10.1016/j.ajpath.2011.12.024
22328075,20120210,article,"xref,mesh","Aniline Compounds,Animals,Anti-Inflammatory Agents, Non-Steroidal,Drug Design,Female,Male,Rats,Spectroscopy, Fourier Transform Infrared","chemical synthesis,chemistry,pharmacology","D000894 Q000494 NY,D000814 Q000737 NY,D000894 Q000138 NY,D000894 Q000737 NN","3033,3715,4044,6115,8252,79617,156391","127621112,127648365,127715174,128133330,128889888,129060975,129696552","Design, synthesis and preliminary pharmacological evaluation of new non-steroidal anti-inflammatory agents having a 4-(methylsulfonyl) aniline pharmacophore.",A series of 4-(methylsulfonyl)aniline derivatives were synthesized in order to obtain new compounds as a potential anti-inflammatory agents with expected selectivity against COX-2 enzyme. In vivo acute anti-inflammatory activity of the final compounds 11-14 was evaluated in rat using an egg-white induced edema model of inflammation in a dose equivalent to 3 mg/Kg of diclofenac sodium. All tested compounds produced significant reduction of paw edema with respect to the effect of propylene glycol 50% v/v (con,"Molecules (Basel, Switzerland)","Monther Faisel Mahdi, Mohamed Hassan Mohammed, Akeel Abdul Kadhum Jassim"," Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad 10047, Iraq. dmfalameri@yahoo.com",2012 Feb;17(2):1751-63,10.3390/molecules17021751
22329953,20120201,article,"xref,mesh","Administration, Oral,Drug Administration Schedule,Drug Approval,Drug Costs,Drug Information Services,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,economics","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000191 NN,D013110 Q000008 NN,D013110 Q000031 NY,D013110 Q000191 NN,D011409 Q000191 NN,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod for multiple sclerosis.,Fingolimod (Gilenya--Novartis) is a new treatment for patients with highly active relapsing-remitting multiple sclerosis. It is the first oral disease-modifying drug for the treatment of patients with multiple sclerosis. Here we assess the place of this drug. ,Drug and therapeutics bulletin,NULL,NULL,2012 Feb;50(2):18-20,10.1136/dtb.2012.02.0086
22339823,20111001,article,"xref,mesh","Apoptosis,Autophagy,Cell Line, Tumor,Fingolimod Hydrochloride,Humans,Multiple Myeloma,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,pathology,pharmacology","D017209 Q000187 NY,D001343 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN,D009101 Q000473 NY","8252,31270,72947,107969,107970,5280335","128394615,129060975,129645792,129672457",[The study of FTY720 on inducing apoptosis and autophagy in multiple myeloma cell line U266].,"OBJECTIVE: To investigate the effects of FTY720, a new immunosuppressive agent, on apoptosis and autophagy in multiple myeloma(MM) cell line U266 and to clarify its molecular mechanism. METHODS: U266 cells were treated with 0, 2.5, 5.0, 10.0 and 20.0 µmol/L FTY720 for 24 hours, and the cell viability was assayed by CCK-8 method. Then U266 cells were treated with 20.0 µmol/L FTY720 for 0, 2, 6 and 24 hours, the cell viability was tested. The apoptotic rates induced by different doses and time points of FTY72",Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,"Ai-jun Liao, Rong Hu, Ying-chun Li, Kun Yao, Hui-han Wang, Rong Zhang, Wei Yang, Zhuo-gang Liu"," Department of Hematology, China Medical University, Shenyang, China.",2011 Oct;32(10):664-7,NULL
22354739,20120901,article,"xref,mesh","Adolescent,Adult,Asian Continental Ancestry Group,Double-Blind Method,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Japan,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Odds Ratio,Propylene Glycols,Recurrence,Sphingosine,Time Factors,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,diagnosis,drug therapy,epidemiology,ethnology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D020529 Q000208 NN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007564 Q000453 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","107969,107970,5280335",128394615,"A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.","BACKGROUND: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). OBJECTIVES: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. METHODS: In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months. The primary and ","Multiple sclerosis (Houndmills, Basingstoke, England)","T Saida, S Kikuchi, Y Itoyama, Q Hao, T Kurosawa, K Nagato, D Tang, L Zhang-Auberson, J Kira"," Department of Neurology, Kyoto Min-Iren-Central Hospital, Kyoto, Japan. saida_takahiko@maia.eonet.ne.jp",2012 Sep;18(9):1269-77,10.1177/1352458511435984
22362460,20120223,article,"xref,mesh","Death, Sudden,Disclosure,Drug-Related Side Effects and Adverse Reactions,Europe,Fingolimod Hydrochloride,Government Agencies,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D009103 Q000188 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.,NULL,BMJ (Clinical research ed.),Jacqui Wise,NULL,2012 Feb;344(?):e1360,10.1136/bmj.e1360
22374347,20120801,article,mesh,"Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D011409 Q000627 NY",5280335,NULL,Indirect comparisons of treatment effects in multiple sclerosis.,NULL,European journal of clinical pharmacology,"Maria Pia Sormani, Alessio Signori",NULL,2012 Aug;68(8):?,10.1007/s00228-012-1246-1
22383793,20120301,article,"xref,mesh","Animals,Disease Models, Animal,Fingolimod Hydrochloride,Immunologic Surveillance,Immunosuppressive Agents,Lymphoma, B-Cell,Mice,Mice, SCID,Mice, Transgenic,Multiple Myeloma,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D007157 Q000187 NY,D009101 Q000276 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000494 NN,D016393 Q000276 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.,NULL,Blood,"Kristina Berg Lorvik, Bjarne Bogen, Alexandre Corthay",NULL,2012 Mar;119(9):2176-7,10.1182/blood-2011-10-388892
22384233,20120101,article,"xref,mesh","Animals,Carcinoma, Hepatocellular,Cell Line, Tumor,Fingolimod Hydrochloride,Gene Expression Regulation, Neoplastic,Humans,Immunosuppressive Agents,Liver,Liver Neoplasms,Neoplasm Metastasis,Neoplasm Transplantation,Neovascularization, Pathologic,Propylene Glycols,Rats,Reperfusion Injury,Sphingosine,Stem Cells,Time Factors","analogs &amp; derivatives,cytology,drug effects,drug therapy,pathology,pharmacology,physiology,surgery","D013234 Q000166 NY,D008099 Q000473 NN,D006528 Q000188 NN,D008113 Q000473 NY,D006528 Q000473 NY,D008113 Q000188 NN,D008099 Q000601 NN,D006528 Q000601 NN,D013110 Q000031 NY,D008113 Q000601 NN,D007166 Q000494 NN,D008099 Q000187 NN,D013110 Q000502 NN","702,7237,8252,31270,107969,107970,5280335,57024517","127676247,128394615,128482492,129060975,129645792,135812730",FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells.,"BACKGROUND: Surgical procedures such as liver resection and liver transplantation are the first-line treatments for hepatocellular carcinoma (HCC) patients. However, the high incidence of tumor recurrence and metastasis after liver surgery remains a major problem. Recent studies have shown that hepatic ischemia-reperfusion (I/R) injury and endothelial progenitor cells (EPCs) contribute to tumor growth and metastasis. We aim to investigate the mechanism of FTY720, which was originally applied as an immunomod",PloS one,"Chang Xian Li, Yan Shao, Kevin T P Ng, Xiao Bing Liu, Chang Chun Ling, Yuen Yuen Ma, Wei Geng, Sheung Tat Fan, Chung Mau Lo, Kwan Man"," Department of Surgery, Centre for Cancer Research and State Key Laboratory of Liver Research,The University of Hong Kong, Hong Kong, China.",2012 Jan;7(2):e32380,10.1371/journal.pone.0032380
22402856,20120320,article,"xref,mesh","Adult,Antibodies, Monoclonal, Humanized,Ataxia,Brain,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Plasma Exchange,Propylene Glycols,Recurrence,Sphingosine,Spine","adverse effects,analogs &amp; derivatives,complications,drug therapy,etiology,pathology,therapeutic use","D013110 Q000009 NN,D016899 Q000627 NN,D001259 Q000209 NN,D020529 Q000150 NY,D013110 Q000031 NY,D001921 Q000473 NN,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D013131 Q000473 NN,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NY,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?,NULL,Neurology,"F Castrop, M C Kowarik, H Albrecht, M Krause, B Haslinger, C Zimmer, A Berthele, B Hemmer"," Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany. florian@castrop.com",2012 Mar;78(12):928-30,10.1212/wnl.0b013e31824c46ad
22406106,20120601,article,"xref,mesh","Animals,Anti-Inflammatory Agents, Non-Steroidal,Cell Line,Dinoprostone,Enzyme Inhibitors,Gene Expression Regulation,Humans,Inflammation,Macrophages,Male,Mice,Mice, Inbred C57BL,Mice, Inbred ICR,Molecular Structure,Nitric Oxide,Phosphotransferases,Propylene Glycols,Rats","antagonists &amp; inhibitors,chemically induced,chemistry,drug effects,drug therapy,genetics,metabolism,pharmacology","D009569 Q000235 NN,D000894 Q000494 NY,D011409 Q000737 NN,D011409 Q000494 NY,D009569 Q000378 NN,D008264 Q000187 NN,D000894 Q000737 NN,D015232 Q000235 NN,D004791 Q000494 NY,D007249 Q000139 NY,D009569 Q000037 NN,D005786 Q000187 NN,D007249 Q000188 NY,D010770 Q000037 NY,D015232 Q000378 NN","8252,9691,145068,5280360,76283551","129060975,129679141,323388400","3-(4-(tert-Octyl)phenoxy)propane-1,2-diol suppresses inflammatory responses via inhibition of multiple kinases.","Novel anti-inflammatory compounds were synthesised by derivatization of militarin, a compound isolated from Cordyceps militaris that is an ethnopharmacologically well-known herbal medicine with multiple benefits such as anti-cancer, anti-inflammatory, anti-obesity, and anti-diabetic properties. In this study, we explored the in vitro and in vivo anti-inflammatory potencies of these compounds during inflammatory responses, their inhibitory mechanisms, and acute toxicity profiles. To do this, we studied infla",Biochemical pharmacology,"Tao Yu, Jaegal Shim, Yanyan Yang, Se Eun Byeon, Ji Hye Kim, Ho Sik Rho, Haeil Park, Gi-Ho Sung, Tae Woong Kim, Man Hee Rhee, Jae Youl Cho"," Department of Genetic Engineering, Sungkyunkwan University, Suwon, Republic of Korea.",2012 Jun;83(11):1540-51,10.1016/j.bcp.2012.02.018
22407397,20120601,article,"xref,mesh","Animals,Antigens, CD,Antigens, Differentiation, T-Lymphocyte,Cell Cycle Checkpoints,Cell Proliferation,Cell Survival,Concanavalin A,Down-Regulation,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-2 Receptor alpha Subunit,Lectins, C-Type,Lymphocyte Activation,Mice,Mice, Inbred BALB C,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,immunology,pharmacology","D007166 Q000494 NY,D003208 Q000276 NN,D002470 Q000187 NN,D013601 Q000276 NN,D000945 Q000276 NN,D049109 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D059447 Q000187 NN,D015703 Q000276 NN,D013601 Q000187 NY,D013110 Q000494 NN,D053645 Q000276 NN,D037181 Q000276 NN,D008213 Q000276 NY","774,8252,31270,107969,107970,5280335","128394615,128754351,129060975,129645792",FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.,"OBJECTIVE: FTY720 is a potent drug for multiple sclerosis treatment. To biologically address its possible applications to more generalized diseases with aberrant inflammation, we are testing whether FTY720 can function as a lymphocyte cell cycle blocker and activation suppressor via a concanavalin A (ConA)-mediated mouse lymphocyte pan-activation model. METHODS: Mouse lymphocytes were obtained from lymph nodes and subjected to ConA and/or FTY720 treatment. Cell viability was assayed by MTT and mitochondrial",Inflammation research : official journal of the European Histamine Research Society ... [et al.],"Xiangfeng Zeng, Tong Wang, Cairong Zhu, Yanxia Ye, Bing Song, Xinqiang Lai, Yaoying Zeng"," Institute for Tissue Transplantation and Immunology, Jinan University, Guangzhou, Guangdong, 510632, China.",2012 Jun;61(6):623-34,10.1007/s00011-012-0454-6
22409453,20120501,review,"xref,mesh","Administration, Topical,Alopecia,Animals,Antihypertensive Agents,Female,Hair,Humans,Male,Minoxidil,Patents as Topic,Potassium Channels,Vasodilator Agents","adverse effects,drug effects,drug therapy,metabolism,pharmacology,therapeutic use","D015221 Q000187 NN,D008914 Q000009 NN,D000505 Q000188 NY,D000959 Q000627 NN,D015221 Q000378 NN,D014665 Q000494 NN,D014665 Q000009 NN,D008914 Q000494 NN,D000959 Q000009 NN,D008914 Q000627 NY,D006197 Q000378 NN,D014665 Q000627 NY,D006197 Q000187 NN,D000959 Q000494 NN","4201,8252",129060975,"Minoxidil use in dermatology, side effects and recent patents.","Minoxidil, a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth, was first introduced, exclusively as an oral drug, to treat high blood pressure. It was however discovered to have the important side-effect of increasing growth or darkening of fine body hairs; this led to the development of a topical formulation as a 2% concentration solution for the treatment of female androgenic alopecia or 5% for treating male androgenic alopecia. Measurable changes disappear ",Recent patents on inflammation & allergy drug discovery,"Alfredo Rossi, Carmen Cantisani, Luca Melis, Alessandra Iorio, Elisabetta Scali, Stefano Calvieri"," Department of Dermatology and Plastic Surgery, University Sapienza of Rome, Azienda Policlinico Umberto I, Via di Boccea n. 10 int. 16, 00167 Rome, Italy.",2012 May;6(2):130-6,10.2174/187221312800166859
22417787,20120401,article,"xref,mesh","Animals,Astrocytes,Capillary Permeability,Cell Movement,Cytokines,Dose-Response Relationship, Drug,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Inflammation Mediators,Locomotion,Mice,Mice, Inbred C57BL,Mice, SCID,Microglia,Neutrophils,Propylene Glycols,Receptors, Lysosphingolipid,Recovery of Function,Sphingosine,Spinal Cord Injuries,T-Lymphocytes,Treatment Outcome","administration &amp; dosage,agonists,analogs &amp; derivatives,biosynthesis,complications,drug effects,drug therapy,etiology,immunology,metabolism,methods,physiopathology,therapeutic use","D013119 Q000503 NN,D007249 Q000188 NN,D002465 Q000187 NN,D007166 Q000008 NN,D049349 Q000819 NN,D009504 Q000187 NN,D007166 Q000627 NN,D002199 Q000187 NN,D013110 Q000008 NN,D016207 Q000096 NN,D004353 Q000379 NN,D017628 Q000187 NN,D020127 Q000187 NN,D013110 Q000031 NY,D011409 Q000008 NN,D013119 Q000276 NN,D001253 Q000187 NN,D018836 Q000378 NN,D008124 Q000187 NN,D013119 Q000188 NY,D007249 Q000209 NN,D013119 Q000150 NN,D013110 Q000627 NN,D011409 Q000627 NY,D013601 Q000187 NN","8252,31270,105065,107969,107970,5280335","128394615,129060975,129645792,136111139",FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms.,"Spinal cord injury (SCI) is an incapacitating injury that can result in limited functional recovery. We have previously shown increases in the lysophospholipid mediator, sphingosine-1-phosphate (S1P), in the spinal cord after contusion injury. To apply S1P receptor modulation to the treatment of SCI, we examined the therapeutic effects of FTY720, an S1P receptor agonist, on locomotor recovery after SCI in mice. Oral administration of FTY720 shortly after contusion SCI significantly improved motor function r",The American journal of pathology,"Yusuke Norimatsu, Tsukasa Ohmori, Atsushi Kimura, Seiji Madoiwa, Jun Mimuro, Atsushi Seichi, Yutaka Yatomi, Yuichi Hoshino, Yoichi Sakata"," Department of Orthopedics, Jichi Medical University School of Medicine, Tochigi, Japan.",2012 Apr;180(4):1625-35,10.1016/j.ajpath.2011.12.012
22455887,20120201,article,mesh,"Animals,Cell Proliferation,Connective Tissue Growth Factor,Down-Regulation,Extracellular Matrix Proteins,Fingolimod Hydrochloride,Gene Expression,Glomerular Mesangium,Glomerulonephritis, Membranoproliferative,Immunosuppressive Agents,Isoantibodies,Kidney Glomerulus,Male,Propylene Glycols,Proteinuria,Rats,Rats, Wistar,Signal Transduction,Sphingosine,Thy-1 Antigens,Transforming Growth Factor beta1","analogs &amp; derivatives,drug effects,genetics,immunology,metabolism,pathology,pharmacology,urine","D055513 Q000235 NN,D018800 Q000276 NN,D053773 Q000235 NN,D007518 Q000276 NN,D007678 Q000473 NN,D053773 Q000378 NY,D007678 Q000378 NN,D015432 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D005920 Q000473 NN,D015432 Q000473 NY,D005920 Q000378 NN,D015432 Q000276 NN,D016326 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D055513 Q000378 NY,D011507 Q000652 NN,D015398 Q000187 NY","107969,107970,5280335",NULL,[FTY720 attenuates rat anti-Thy-1 mesangial proliferative glomerulonephritis by inhibition of transforming growth factor β1-connective tissue growth factor pathway].,"OBJECTIVE: To investigate whether FTY720 inhibits rat mesangial proliferation and extracellular matrix expansion through suppression of transforming growth factor β1-connective tissue growth factor (TGFβ1-CTGF) pathway, and to explore experimental evidence for its effect on mesangial proliferative glomerulonephritis. METHODS: A rat model of anti-Thy-1 mesangial proliferative glomerulonephritis was established and FTY720 intervention was performed. Periphery blood lymphocyte count, urine protein excretion, g",Zhonghua bing li xue za zhi = Chinese journal of pathology,"Jing-yu Jiang, Xiao-dong Huang, Yi Wang, Ai-ping Deng, Jian-hua Zhou"," Department of Pharmacy, the Central Hospital of Wuhan, Wuhan 430014, China. jjy11170008@yahoo.cn",2012 Feb;41(2):107-11,NULL
22481287,20121001,article,"xref,mesh","Acute Disease,Amylases,Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Female,Fingolimod Hydrochloride,Hydrocortisone,Immunosuppressive Agents,Interleukin-10,Interleukin-6,Pancreas,Pancreatitis,Propylene Glycols,Rats,Rats, Wistar,Sirolimus,Sphingosine,T-Lymphocytes,Taurocholic Acid","administration &amp; dosage,analogs &amp; derivatives,blood,chemically induced,drug effects,drug therapy,immunology,pathology","D000681 Q000097 NN,D010195 Q000188 NY,D013601 Q000276 NN,D020123 Q000008 NY,D010195 Q000139 NN,D013110 Q000008 NN,D013110 Q000031 NY,D018414 Q000473 NN,D015850 Q000097 NN,D010179 Q000473 NN,D006854 Q000008 NN,D015496 Q000473 NN,D010195 Q000473 NN,D016753 Q000097 NN,D011409 Q000008 NY,D007166 Q000008 NY,D013601 Q000187 NN","5246,5754,6675,107969,107970,229860,5280335,5284616,11957443,23666345,23671686,23703313,91454826","128344927,248184126",Effects of FTY720 and rapamycin on inflammation in taurocholate-induced acute pancreatitis in the rat.,"OBJECTIVES: This study aimed at T-cell inhibition by immunosuppressants to reduce cell damage and improve the course of severe acute pancreatitis (SAP). METHODS: A taurocholate-induced SAP was used and 5 groups were compared: (1) rapamycin + FTY720, (2) rapamycin, (3) FTY720, (4) cortisol, and (5) control: sodium chloride. Drugs were applied intravenously at SAP induction; 6 hours later, rats were killed. Interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor α, platelet-activating factor, amylase, and lipa",Pancreas,"Christophe A Müller, Orlin Belyaev, Wenzel Burr, Johanna Munding, Nicholas McArthur, Uwe Bergmann, Jens Werner, Andrea Tannapfel, Waldemar Uhl"," Department of Surgery, St. Josef Hospital, Ruhr University of Bochum, Bochum, Germany. o.belyaev@klinikum-bochum.de",2012 Oct;41(7):1086-91,10.1097/mpa.0b013e3182496fd7
22490865,20120515,article,"xref,mesh","Animals,Cells, Cultured,Dendritic Cells,Fingolimod Hydrochloride,Humans,Immunologic Factors,Interferon Type I,Membrane Glycoproteins,Mice,Mice, Inbred C57BL,Mice, Knockout,Mice, Transgenic,Phosphorylation,Propylene Glycols,Signal Transduction,Sphingosine,Toll-Like Receptor 7,Up-Regulation,p38 Mitogen-Activated Protein Kinases","analogs &amp; derivatives,drug effects,immunology,metabolism,pharmacology,physiology","D010766 Q000276 NN,D003713 Q000187 NN,D015854 Q000187 NN,D048051 Q000502 NY,D015398 Q000276 NY,D013110 Q000031 NY,D011409 Q000494 NY,D007370 Q000502 NY,D051199 Q000502 NY,D015854 Q000276 NY,D003713 Q000276 NY,D048051 Q000378 NN,D008562 Q000502 NY,D010766 Q000187 NN,D015398 Q000187 NN,D003713 Q000378 NN,D007155 Q000494 NY,D013110 Q000494 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways.,"Sphingosine analogues display immunosuppressive activities and thus have therapeutic potential in the treatment of autoimmune diseases. In this study, we investigated the effects of the sphingosine analogue AAL-R (FTY720 derivative) on dendritic cell (DC) response upon TLR stimulation. Unlike its known immunosuppressive activity, AAL-R increased TLR7-mediated DC responses by elevating the levels of MHC class I and costimulatory molecules and type I IFN expression and by enhancing the capacity of DCs to indu","Journal of immunology (Baltimore, Md. : 1950)","Young-Jin Seo, Curtis J Pritzl, Madhuvanthi Vijayan, Celeste R Blake, Mariah E McClain, Bumsuk Hahm"," Department of Surgery, University of Missouri-Columbia, Columbia, MO 65212, USA.",2012 May;188(10):4759-68,10.4049/jimmunol.1102754
22492476,20120401,review,"xref,mesh","Administration, Oral,Antibodies, Monoclonal, Humanized,Brain,Combined Modality Therapy,Diagnosis, Differential,Dose-Response Relationship, Drug,Drug Administration Schedule,Fingolimod Hydrochloride,Glatiramer Acetate,Glucocorticoids,Humans,Immunosuppressive Agents,Infusions, Intravenous,Interferon-beta,Methylprednisolone,Mitoxantrone,Multiple Sclerosis, Chronic Progressive,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Plasmapheresis,Propylene Glycols,Pulse Therapy, Drug,Sphingosine,Spinal Cor","administration &amp; dosage,adverse effects,analogs &amp; derivatives,diagnosis,drug therapy,pathology","D010455 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D016899 Q000008 NN,D061067 Q000009 NN,D013116 Q000473 NN,D013110 Q000008 NN,D020528 Q000188 NY,D005938 Q000009 NN,D020529 Q000175 NN,D020528 Q000175 NY,D008775 Q000009 NN,D011409 Q000008 NN,D001921 Q000473 NN,D016899 Q000009 NN,D013110 Q000031 NN,D008942 Q000009 NN,D005938 Q000008 NN,D008942 Q000008 NN,D020529 Q000188 NY,D010455 Q000008 NN,D061067 Q000008 NN,D008775 Q000008 NN,D007166 Q000009 NN","4212,6741,8252,31270,51082,51151,65370,107969,107970,3081884,5280335,5458171,24883465,54607525","128394615,128397534,129060975,129645792,134409758",[2012: Update on diagnosis and treatment of multiple sclerosis].,NULL,Deutsche medizinische Wochenschrift (1946),"J Havla, T Kümpfel, R Hohlfeld"," Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München, München, Germany.",2012 Apr;137(17):894-9,10.1055/s-0032-1304927
22493799,20120101,review,"xref,mesh","Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Structure-Activity Relationship","agonists,analogs &amp; derivatives,classification,drug therapy,metabolism,pharmacology,physiology,therapeutic use","D049349 Q000819 NY,D013110 Q000031 NY,D007166 Q000627 NY,D008246 Q000502 NN,D049349 Q000502 NY,D011409 Q000494 NN,D049349 Q000145 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY,D013110 Q000502 NN,D049349 Q000378 NN","105065,107969,107970,5280335,5283560","128394615,136111139",[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].,"Sphingosine-1-phosphate (S1P) is a lysophospholipid signaling molecule that regulates important biological functions in both intracellular and extracellular compartments. It interacts with five G protein-coupled receptors subtypes (S1PR(1-5)) to generate multiple downstream signaling. Activation of S1PR1 has been validated to be involved in the process of immune modulation. Fingolimod (FTY720), the novel S1PR1 agonist, has been approved for the treatment of multiple sclerosis in clinical trials. The study t",Yao xue xue bao = Acta pharmaceutica Sinica,"Yu-Lin Tian, Jing Jin, Xiao-Jian Wang"," Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory ofActive Substance Discovery and Druggability Evaluation, Beijing 100050, China.",2012 Jan;47(1):7-17,NULL
22494954,20120501,article,"xref,mesh","Disability Evaluation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",MS clinical trials: what can subgroup analyses teach us?,NULL,The Lancet. Neurology,Richard A Rudick," Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. rudickr@ccf.org",2012 May;11(5):386-8,10.1016/s1474-4422(12)70066-2
22494956,20120501,article,"xref,mesh","Administration, Oral,Adult,Disability Evaluation,Disease Progression,Double-Blind Method,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-beta,Male,Multiple Sclerosis, Relapsing-Remitting,Proportional Hazards Models,Propylene Glycols,Secondary Prevention,Sex Factors,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D016899 Q000627 NN,D013110 Q000031 NY,D016899 Q000009 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.","BACKGROUND: Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline cha",The Lancet. Neurology,"Virginia Devonshire, Eva Havrdova, Ernst Wilhelm Radue, Paul O'Connor, Lixin Zhang-Auberson, Catherine Agoropoulou, Dieter Adrian Häring, Gordon Francis, Ludwig Kappos, FREEDOMS study group"," University of British Columbia Hospital Multiple Sclerosis Clinic, Vancouver, BC, Canada.",2012 May;11(5):420-8,10.1016/s1474-4422(12)70056-x
22509094,20120101,article,"xref,mesh","Administration, Ophthalmic,Animals,Cell Proliferation,Cornea,Corneal Transplantation,Cyclosporine,Cytokines,Fingolimod Hydrochloride,Forkhead Transcription Factors,Gels,Graft Survival,Immunosuppressive Agents,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Ophthalmic Solutions,Propylene Glycols,Sphingosine,T-Lymphocytes, Regulatory,Transplantation, Homologous","administration &amp; dosage,analogs &amp; derivatives,biosynthesis,cytology,drug effects,immunology,metabolism,therapeutic use","D016572 Q000627 NN,D016207 Q000276 NN,D003315 Q000187 NY,D007166 Q000627 NN,D013110 Q000008 NN,D016207 Q000096 NN,D051858 Q000096 NN,D050378 Q000187 NN,D003315 Q000276 NN,D049109 Q000187 NN,D013110 Q000031 NY,D050378 Q000166 NN,D003315 Q000378 NN,D006085 Q000187 NY,D006085 Q000276 NN,D016572 Q000008 NY,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000008 NY,D007166 Q000008 NY","679,2909,4271,8252,31270,62280,88983,105065,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,21226166,24883466,25246316,49867938,57024517,57123750,57317596,71306795,71463825,73896891,91534498,122172945,123134263,123134270,132274082","127986152,128141778,128394615,129060975,129178479,129645792,135812730,135979775,136068555,136111139,136314073,248766214",Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice.,"PURPOSE: To investigate the effects of topical FTY720 and cyclosporin A (CsA) on allogeneic corneal transplantation in mice. METHODS: A total of 75 BALB/c mice received corneal grafts from C57BL/6 donors. Recipients were treated with 0.1%, 0.3%, or 0.5% FTY720 ophthalmic gel or 1% CsA eye-drops after the graft (controls received no treatment). The number of cluster of differentiation (CD)4+ T cells and CD4+CD25+forkhead box P3 (Foxp3)+ regulatory (Treg) cell phenotypes were measured by flow cytometry. Cytok",Molecular vision,"Yong Liu, Jingjing Jiang, He Xiao, Xiaokui Wang, Yan Li, Yubo Gong, Dajiang Wang, Yifei Huang"," Departments of Ophthalmology, Chinese PLA General Hospital, Beijing, China.",2012 Jan;18(?):624-33,NULL
22509505,20120412,article,"xref,mesh","Alemtuzumab,Animals,Antibodies, Monoclonal, Humanized,Cladribine,Clinical Trials, Phase III as Topic,Crotonates,Dimethyl Fumarate,Disease Progression,Drug-Related Side Effects and Adverse Reactions,Fingolimod Hydrochloride,Fumarates,Humans,Inflammation,Multiple Sclerosis,Natalizumab,Propylene Glycols,Quinolones,Risk Assessment,Sphingosine,Toluidines,United States,United States Food and Drug Administration","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,immunology,pathology,pharmacology,therapeutic use","D007249 Q000188 NN,D011409 Q000009 NN,D015363 Q000627 NN,D013110 Q000009 NN,D014052 Q000009 NN,D061067 Q000009 NN,D009103 Q000473 NN,D013110 Q000008 NN,D017338 Q000009 NN,D005650 Q000627 NN,D011409 Q000008 NN,D061067 Q000494 NN,D003437 Q000627 NN,D013110 Q000031 NN,D015363 Q000008 NN,D003437 Q000009 NN,D007249 Q000276 NN,D061067 Q000627 NN,D014052 Q000627 NN,D017338 Q000627 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007249 Q000473 NN,D009103 Q000188 NY","8252,12215,20279,31270,107969,107970,637568,3036108,5280335,23500906,54677946","127968532,128394615,128471922,128672523,128966217,129060975,129645792",Drugs: An injection of hope.,NULL,Nature,Duncan Graham-Rowe,NULL,2012 Apr;484(7393):S4,10.1038/nature11109
22515137,20120401,article,"xref,mesh","Cardiovascular Diseases,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,etiology,mortality,therapeutic use","D002318 Q000209 NY,D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D007166 Q000009 NY,D002318 Q000401 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NN,D011409 Q000009 NY","8252,31270,107969,107970,5280335","128394615,129060975,129645792",Fingolimod: cardiovascular deaths.,NULL,Prescrire international,NULL,NULL,2012 Apr;21(126):99,NULL
22528220,20120401,article,mesh,"Animals,Cytokines,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Heart Transplantation,Immunosuppressive Agents,Longitudinal Studies,Male,Mice,Mice, Inbred C3H,Mice, Inbred C57BL,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,immunology,methods,physiology,prevention &amp; control","D016027 Q000379 NN,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D006085 Q000502 NY,D006085 Q000187 NY,D016027 Q000009 NY,D016207 Q000276 NY,D011409 Q000008 NY,D006084 Q000276 NY,D006084 Q000517 NY","107969,107970,5280335",NULL,Effects of long-term administration of low-dose FTY720 on survival of murine cardiac allograft.,This study examined the effect of long-term administration of low-dose FTY720 on survival of murine cardiac allograft and the possible mechanism. Murine models of abdominal heterotopic heart transplantation were established. Low-dose FTY720 (0.3 mg/kg) was administrated to the animals 4 days before the transplantation of cardiac allografts until the occurrence of rejection or the observation terminals. The animals without FTY720 treatment and those with syngeneic cardiac grafts transplanted served as contro,Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,"Qi Cheng, Dan Li, Huifang Liang, Hongqiang Yang, Dou Lei, Dan Gao, Xin Long, Yifa Chen, Peng Zhu, Xiaoping Chen"," Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China. Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China. Department of Surgery, Tianjin Nankai Hospital, Tianjin, 300100, China. Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China. Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China.",2012 Apr;32(2):199-204,10.1007/s11596-012-0035-5
22528818,20120901,article,"xref,mesh","Arthritis, Psoriatic,Atrial Fibrillation,Autoimmune Diseases,Celecoxib,Cyclooxygenase Inhibitors,Drug Therapy, Combination,Factor V,Fingolimod Hydrochloride,Heart,Heart Diseases,Heart Failure,Humans,Hypertension,Immunosuppressive Agents,Male,Middle Aged,Mitral Valve Insufficiency,Multiple Sclerosis,Mutation,Myocardium,Propylene Glycols,Pyrazoles,Sjogren's Syndrome,Sphingosine,Sulfonamides","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug effects,drug therapy,genetics,pathology,physiopathology","D011720 Q000009 NY,D001281 Q000139 NN,D006333 Q000139 NN,D013110 Q000009 NN,D009103 Q000235 NN,D015535 Q000235 NN,D006321 Q000187 NN,D012859 Q000235 NN,D006321 Q000503 NN,D013110 Q000031 NY,D015535 Q000150 NN,D012859 Q000188 NN,D001327 Q000235 NN,D016861 Q000009 NY,D015535 Q000188 NY,D006973 Q000235 NN,D009206 Q000473 NN,D006973 Q000150 NN,D008944 Q000139 NN,D005165 Q000235 NY,D007166 Q000009 NY,D009103 Q000150 NN,D001327 Q000150 NN,D013449 Q000009 NY,D006331 Q000503 NN,D009103 Q000188 NN,D006331 Q000139 NY","2662,107969,107970,5280335","128394615,129202881","A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?","The paper describes the case of a patient affected by a combination of genetic and autoimmune diseases (multiple sclerosis, psoriatic arthritis, Leiden V mutation, and sicca syndrome) and hypertension. The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod. The patient developed high fever and endocarditis, resulting in severe mitral regurgitation, atrial fibrillation, and congestive heart failure. Evidence is suggestive of adverse effects of potent immunosuppressive and a",Cardiovascular toxicology,G Cocco," Cardiology Office, Marktgasse 10A, 4310 Rheinfelden, Switzerland. praxis@cocco.ch",2012 Sep;12(3):266-72,10.1007/s12012-012-9166-y
22530640,20120401,review,"xref,mesh","Animals,Drug Discovery,Encephalomyelitis, Autoimmune, Experimental,Fatty Acids, Monounsaturated,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kidney Transplantation,Lymphocytes,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,chemistry,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D004681 Q000276 NN,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D005229 Q000737 NN,D004681 Q000188 NN,D007166 Q000627 NY,D008214 Q000276 NN,D007166 Q000737 NN,D011409 Q000494 NN,D009103 Q000276 NN,D013110 Q000627 NN,D049349 Q000276 NY,D013110 Q000494 NN,D008214 Q000187 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY","8252,31270,107969,107970,121989,5280335,6438394,57024517","128394615,129060975,129645792,129976789,135812730","Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.","Fingolimod (FTY720) is a first-in-class, orally active, sphingosine 1-phosphate (S1P)-receptor modulator with a structure closely related to sphingosine. The compound was discovered by chemical modification of a natural product, myriocin. Phosphorylated form of FTY720 acts as a functional antagonist at S1P receptor type 1 (S1P(1)), inhibits lymphocyte egress from secondary lymphoid organs and shows immunomodulating effects. Phase III studies in multiple sclerosis demonstrated that oral FTY720 had superior e",Future medicinal chemistry,"Kenji Chiba, Kunitomo Adachi"," Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, 227-0033, Japan. chiba.kenji@ mk.mt-pharma.co.jp",2012 Apr;4(6):771-81,10.4155/fmc.12.25
22550899,20120201,review,"xref,mesh","Adaptive Immunity,Animals,Endothelium, Vascular,Fingolimod Hydrochloride,Humans,Immunity, Innate,Immunosuppressive Agents,Lysophospholipids,Membrane Microdomains,Nervous System Physiological Phenomena,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Second Messenger Systems,Sphingolipids,Sphingosine","analogs &amp; derivatives,metabolism,pharmacology,physiology","D013110 Q000031 NY,D013110 Q000378 NN,D017853 Q000502 NN,D004730 Q000378 NN,D013107 Q000378 NN,D008246 Q000502 NY,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000502 NN,D013110 Q000502 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",[Role of S1P acting both inside and outside the cells].,NULL,Seikagaku. The Journal of Japanese Biochemical Society,"Taro Okada, Shun-ichi Nakamura"," Division of Biochemistry, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Kusunoki-Cho 7-5-1, Kobe 650-0017, Japan.",2012 Feb;84(2):92-101,NULL
22552898,20140301,article,mesh,"Alginates,Animals,Bone Cements,Bone Morphogenetic Protein 2,Calcium Phosphates,Dental Cementum,Dental Enamel Proteins,Fibroblast Growth Factor 2,Inflammation,Molecular Weight,Periodontitis,Periodontium,Propylene Glycol,Rats,Rats, Wistar,Regeneration","chemistry,metabolism,pathology,pharmacology","D010518 Q000378 NN,D010519 Q000378 NY,D010519 Q000473 NY,D016222 Q000494 NY,D000464 Q000737 NN,D001843 Q000737 NY,D019946 Q000737 NN,D003739 Q000737 NN,D055396 Q000494 NY,D003746 Q000737 NN","1030,57339413",NULL,Periodontal regeneration using an injectable bone cement combined with BMP-2 or FGF-2.,"Periodontitis is a frequently diagnosed oral disease characterized by bone resorption and soft tissue loss around teeth. Unfortunately, currently available therapies only slow or arrest progress of the disease. Ideally, treatment of periodontal defects should be focused on complete regeneration of the lost tissues [(bone and periodontal ligament (PDL)]. As a result, this study used intrabony defects to evaluate the regenerative potential of an injectable macroporous calcium phosphate cement (CaP) in combina",Journal of tissue engineering and regenerative medicine,"Daniël A W Oortgiesen, X Frank Walboomers, Antonius L J J Bronckers, Gert J Meijer, John A Jansen"," Department of Biomaterials, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands.",2014 Mar;8(3):202-9,10.1002/term.1514
22558085,20120101,article,"xref,mesh","Analysis of Variance,Animals,DNA Primers,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immunity, Innate,Immunohistochemistry,Immunosuppressive Agents,Liver,Lymph Nodes,Lymphocytes,Male,Neutrophils,Peroxidase,Propylene Glycols,Real-Time Polymerase Chain Reaction,Shock, Hemorrhagic,Sphingosine,Spleen,Swine,Swine Diseases","analogs &amp; derivatives,drug therapy,genetics,immunology,pathology,pharmacology,therapeutic use,veterinary","D008214 Q000276 NY,D007166 Q000494 NY,D007113 Q000276 NY,D007166 Q000627 NN,D013553 Q000188 NY,D012771 Q000473 NN,D008198 Q000276 NN,D013110 Q000031 NY,D005786 Q000276 NN,D011409 Q000494 NY,D013154 Q000276 NN,D009504 Q000276 NN,D017931 Q000235 NN,D012771 Q000662 NY,D008099 Q000473 NY,D012771 Q000188 NN,D013110 Q000494 NN,D013553 Q000276 NY,D012771 Q000276 NN","702,3763,5707,7237,8252,31270,105065,107969,107970,637577,644073,5280335,11973707,21226166","127548708,127676247,127986152,128394615,128482492,128922443,129060975,129645792,136111139,136178062,136326990",Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine.,The inflammatory response to severe traumatic injury results in significant morbidity and mortality. Lymphocytes have recently been identified as critical mediators of the early innate immune response to ischemia-reperfusion injury. Experimental manipulation of lymphocytes following hemorrhagic shock may prevent secondary immunologic injury in surgical and trauma patients. The objective of this study is to evaluate the lymphocyte sequestration agent FTY720 as an immunomodulator following experimental hemorr,PloS one,"Jason S Hawksworth, J Christopher Graybill, Trevor S Brown, Shannon M Wallace, Thomas A Davis, Doug K Tadaki, Eric A Elster"," Regenerative Medicine Department, Operational and Undersea Medicine Directorate, Naval Medical Research Center, Silver Spring, Maryland, United States of America.",2012 Jan;7(4):e34224,10.1371/journal.pone.0034224
22558878,20120419,review,"xref,mesh","4-Aminopyridine,Cannabinoids,Cooperative Behavior,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interdisciplinary Communication,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,diagnosis,drug therapy,therapeutic use","D002186 Q000627 NN,D002186 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000175 NN,D013110 Q000627 NN,D007166 Q000009 NN,D015761 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY,D015761 Q000627 NN","1727,8252,31270,107969,107970,5280335,9852188","128394615,128756319,129060975,129645792",[New disease-modifying and symptomatic therapies for multiple sclerosis].,NULL,MMW Fortschritte der Medizin,"Gesa Weise, Mathias Buttmann"," Klinische Forschungsgruppe für MS und Neuroimmunologie, Neurologische Universitätsklinik, Julius-Maximilians-Universität Würzburg.",2012 Apr;154(7):64-6,NULL
22562306,20120901,article,"xref,mesh","Alkenes,Animals,Benzothiazoles,Contrast Media,Gallbladder,Hydrazines,Hydroxyl Radical,Inflammation,Lipopolysaccharides,Liposomes,Male,Mice,Mice, Inbred C57BL,Microbubbles,Molecular Imaging,Nitrogen,Oxidation-Reduction,Oxidative Stress,Reactive Oxygen Species,Sulfonic Acids,Ultrasonography","administration &amp; dosage,chemically induced,chemistry,diagnostic imaging,metabolism","D005704 Q000000981 NY,D017382 Q000378 NN,D007249 Q000139 NN,D003287 Q000008 NY,D009584 Q000378 NN,D005704 Q000378 NN,D052160 Q000737 NN,D017665 Q000008 NY,D006834 Q000737 NN,D006834 Q000008 NY,D003287 Q000737 NN,D000475 Q000378 NN,D013451 Q000737 NN","947,8252,35687,35688,81921,171127,453626,5360881,5464076,6301202,6871216,9570474,16240279,53442174,76848883","129060975,129952183",Ultrasound imaging of oxidative stress in vivo with chemically-generated gas microbubbles.,"Ultrasound contrast agents (UCAs) have tremendous potential for in vivo molecular imaging because of their high sensitivity. However, the diagnostic potential of UCAs has been difficult to exploit because current UCAs are based on pre-formed microbubbles, which can only detect cell surface receptors. Here, we demonstrate that chemical reactions that generate gas forming molecules can be used to perform molecular imaging by ultrasound in vivo. This new approach was demonstrated by imaging reactive oxygen spe",Annals of biomedical engineering,"John Kangchun Perng, Seungjun Lee, Kousik Kundu, Charles F Caskey, Sarah F Knight, Sarp Satir, Katherine W Ferrara, W Robert Taylor, F Levent Degertekin, Daniel Sorescu, Niren Murthy"," The Wallace H. Coulter Department of Biomedical Engineering, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA.",2012 Sep;40(9):2059-68,10.1007/s10439-012-0573-9
22570713,20120101,article,"xref,mesh","Animals,Antineoplastic Agents,Disease Progression,Drug Administration Schedule,Fingolimod Hydrochloride,Humans,Mice,Mice, Inbred NOD,Mice, Knockout,Mice, SCID,Neoplasm Staging,Philadelphia Chromosome,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,Propylene Glycols,Protein Phosphatase 2,Sphingosine,Treatment Outcome,Xenograft Model Antitumor Assays","administration &amp; dosage,analogs &amp; derivatives,drug therapy,genetics,metabolism,pathology,therapeutic use","D015452 Q000188 NY,D013110 Q000008 NN,D015452 Q000473 NN,D013110 Q000031 NY,D011409 Q000008 NN,D054648 Q000378 NN,D015452 Q000235 NY,D000970 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D000970 Q000008 NN","702,753,2332,4939,4941,23831,31270,105065,107969,107970,5280335,53903450,57059112","128132375,128288165,128394615,128482492,128902940,128984259,129645792,129888650,135870608,136033793,136111139",Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.,"Most patients with acute lymphoblastic leukemia (ALL) respond well to standard chemotherapy-based treatments. However a significant proportion of patients, particularly adult patients, relapse with the majority dying of leukemia. FTY720 is an immunosuppressive drug that was recently approved for the treatment of multiple sclerosis and is currently under pre-clinical investigation as a therapy for a number of hematological malignancies. Using human ALL xenografts in NOD/SCIDγc(-/-) mice, we show for the firs",PloS one,"Craig T Wallington-Beddoe, Anthony S Don, John Hewson, Qiao Qiao, Rachael A Papa, Richard B Lock, Kenneth F Bradstock, Linda J Bendall"," Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, Australia.",2012 Jan;7(5):e36429,10.1371/journal.pone.0036429
22576630,20120701,article,"xref,mesh","Animals,Cell Proliferation,Fingolimod Hydrochloride,Forkhead Transcription Factors,Immunosuppressive Agents,Interleukin-10,Male,Mice,Mice, Inbred BALB C,Organophosphates,Propylene Glycols,RNA, Messenger,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes, Regulatory,Transforming Growth Factor beta","agonists,analogs &amp; derivatives,biosynthesis,drug effects,genetics,immunology,metabolism,pharmacology","D012333 Q000235 NN,D049349 Q000819 NY,D049349 Q000276 NN,D051858 Q000096 NN,D050378 Q000276 NY,D050378 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D016212 Q000096 NN,D012333 Q000378 NN,D051858 Q000235 NN,D010755 Q000494 NY,D016212 Q000235 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN,D016753 Q000096 NN","8252,31270,105065,107969,107970,5280335,9908268,11452022,45268446,56842206","129060975,129645792,136111139",The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro.,"The sphingosine-1-phosphate receptor agonist FTY720 and FTY720-P have a wide variety of fundamental functions. Many studies have demonstrated that CD4+CD25+ regulatory T (Treg) cells engage in the maintenance of immunological self-tolerance by actively suppressing self-reactive lymphocytes. Although FTY720 has also recently shown to possess an additional effect that increases the functional activity of Treg cells, the mechanism leading to the enhanced Treg activity after FTY720 treatment is still not clear.",International journal of molecular medicine,"Yong Liu, Jingjing Jiang, He Xiao, Xiaokui Wang, Yan Li, Yubo Gong, Yifei Huang"," Department of Ophthalmology, Chinese PLA General Hospital, Beijing,                     P.R. China.",2012 Jul;30(1):211-9,10.3892/ijmm.2012.973
22580711,20120801,article,mesh,"Animals,Apoptosis,Cell Cycle Checkpoints,Cell Cycle Proteins,Cell Line,Cell Proliferation,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Mesangial Cells,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D017209 Q000187 NY,D059447 Q000235 NN,D017209 Q000235 NN,D049109 Q000187 NN,D013110 Q000031 NY,D050527 Q000378 NY,D011409 Q000494 NY,D005786 Q000187 NN,D013110 Q000494 NN,D050527 Q000187 NY,D018797 Q000235 NN,D059447 Q000187 NY","107969,107970,5280335",NULL,FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells.,"The present study aimed to examine the effect of FTY720, a new immunosuppressive agent, on the proliferation and apoptosis of glomerular mesangial cells (GMC), and investigate the underlying mechanisms. Cultured rat GMC were treated by FTY720, and the cell viability, apoptosis and cell cycle progression were examined. Furthermore, cell cycle related gene expression profile was analyzed by cDNA microarray, and the protein expression of cell cycle related genes as well as Bax and Bcl-2 were examined by Wester",Molecular biology reports,"Jingyu Jiang, Xiaodong Huang, Yi Wang, Aiping Deng, Jianhua Zhou"," Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Shengli Street No. 26, Wuhan 430014, China. jjy1117@126.com",2012 Aug;39(8):8243-50,10.1007/s11033-012-1672-2
22583065,20120101,article,mesh,"Adult,Cost-Benefit Analysis,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Male,Markov Chains,Models, Econometric,Monte Carlo Method,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Quality-Adjusted Life Years,Sphingosine,United States","analogs &amp; derivatives,drug therapy,economics,therapeutic use","D020529 Q000191 NN,D007166 Q000627 NN,D016899 Q000627 NN,D016899 Q000191 NY,D013110 Q000031 NY,D013110 Q000191 NN,D020529 Q000188 NY,D011409 Q000191 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000191 NY","107969,107970,5280335",NULL,Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.,"OBJECTIVE: Fingolimod has been shown to be more efficacious than interferon (IFN) beta-1a, but at a higher drug acquisition cost. The aim of this study was to assess the cost-effectiveness of fingolimod compared to IFN beta-1a in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the US. METHODS: A Markov model comparing fingolimod to intramuscular IFN beta-1a using a US societal perspective and a 10-year time horizon was developed. A cohort of 37-year-old patients with RRMS and a Kurt",Journal of medical economics,"Soyon Lee, Daniel C Baxter, Brendan Limone, Matthew S Roberts, Craig I Coleman"," University of Connecticut School of Pharmacy, Storrs, CT, USA.",2012 Jan;15(6):1088-96,10.3111/13696998.2012.693553
22585671,20120701,article,mesh,"Animals,Cell Proliferation,Diabetes Mellitus, Type 1,Disease Progression,Fingolimod Hydrochloride,Flow Cytometry,Histocompatibility Antigens Class I,Immunohistochemistry,Immunosuppressive Agents,Islets of Langerhans,Mice,Mice, Inbred NOD,Mice, Transgenic,Propylene Glycols,Receptors, Antigen, T-Cell,Sphingosine,T-Lymphocytes, Cytotoxic","analogs &amp; derivatives,cytology,immunology,pathology,pharmacology","D003922 Q000473 NN,D007515 Q000166 NN,D007515 Q000276 NY,D015395 Q000276 NN,D013602 Q000166 NN,D013110 Q000031 NN,D003922 Q000276 NY,D011948 Q000276 NY,D013602 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D007515 Q000473 NN","107969,107970,5280335",NULL,Intra-islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression.,"Infiltration of pancreatic islets by immune cells, termed insulitis, increases progressively once it begins and leads to clinical type 1 diabetes. But even after diagnosis some islets remain unaffected and infiltration is patchy rather than uniform. Traffic of autoreactive T cells into the pancreas is likely to contribute to insulitis progression but it could also depend on T-cell proliferation within islets. This study utilizes transgenic NOD mice to assess the relative contributions of these two mechanism",European journal of immunology,"Kate L Graham, Balasubramanian Krishnamurthy, Stacey Fynch, Rochelle Ayala-Perez, Robyn M Slattery, Pere Santamaria, Helen E Thomas, Thomas W H Kay"," St. Vincent's Institute, Fitzroy, Victoria, Australia.",2012 Jul;42(7):1717-22,10.1002/eji.201242435
22613676,20120801,article,"xref,mesh","Adoptive Transfer,Animals,CD4-Positive T-Lymphocytes,Cell Count,Cyclophosphamide,Cyclosporine,Fingolimod Hydrochloride,Forkhead Transcription Factors,Immune Tolerance,Immunity,Immunosuppressive Agents,Interleukin-2 Receptor alpha Subunit,Isoxazoles,Lymph Nodes,Mice,Mice, Inbred BALB C,Mice, Nude,Mice, Transgenic,Mycophenolic Acid,Ovalbumin,Propylene Glycols,Sirolimus,Sphingosine,Spleen,T-Lymphocytes, Regulatory","analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology","D053645 Q000096 NN,D007166 Q000494 NY,D015496 Q000276 NN,D013154 Q000187 NN,D003520 Q000494 NN,D050378 Q000276 NY,D013154 Q000276 NY,D008198 Q000187 NN,D008198 Q000276 NY,D009173 Q000494 NN,D013110 Q000031 NN,D051858 Q000378 NN,D020123 Q000494 NN,D010047 Q000276 NN,D016572 Q000494 NN,D053645 Q000187 NN,D011409 Q000494 NN,D009173 Q000031 NN,D013110 Q000494 NN,D007555 Q000494 NN","2907,2909,3899,4271,9254,22420,62280,107969,107970,446541,5280335,5280754,5281078,5284373,5284616,5289086,5458585,6435893,6441022,9855081,23665584,24883466,25246316,49867938,57317596,71306795,71463825,73896891,91454826,122172945,123134263,123134270,132274082","128394615,129178479,129476173,136314073,248184126",Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.,"A variety of immunosuppressive drugs are currently used in patients with allo-grafts or autoimmune diseases. Though the effects of rapamycin (RPM) and other immunosuppressant on the CD4(+)CD25(+)Foxp3(+) T regulatory cells (Tregs) were studied, their impact on Ag-specific Tregs during immune response was not well defined. In our studies, we adoptively transferred TCR-transgenic CD4(+)KJ1-26(+) T cells, CD4(+)KJ1-26(+)CD25(-) naïve T cells or CD4(+)KJ1-26(+)CD25(+) Tregs into syngeneic BALB/c mice. 24h later",Transplant immunology,"Tingting Wu, Lianjun Zhang, Kerui Xu, Chenming Sun, Tong Lei, Jianxia Peng, Guangwei Liu, Ruoyu Wang, Yong Zhao"," State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.",2012 Aug;27(1):30-8,10.1016/j.trim.2012.05.001
22615252,20120801,article,mesh,"Animals,Citrobacter rodentium,Enterobacteriaceae Infections,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immunity, Mucosal,Immunosuppressive Agents,Lymphopenia,Mice,Mice, Inbred Strains,Propylene Glycols,RNA, Messenger,Specific Pathogen-Free Organisms,Sphingosine","analogs &amp; derivatives,chemically induced,drug effects,genetics,immunology,metabolism,microbiology,pharmacology","D012333 Q000235 NN,D004756 Q000382 NY,D007166 Q000494 NY,D008231 Q000139 NN,D018928 Q000187 NN,D013110 Q000031 NY,D005786 Q000276 NN,D011409 Q000494 NY,D012333 Q000378 NN,D004756 Q000276 NN,D044082 Q000276 NN,D044082 Q000187 NY,D013110 Q000494 NN","107969,107970,5280335",NULL,The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium.,"The sphingosine-1-phosphate (S1P) analogue FTY720 is therapeutically efficacious in multiple sclerosis and in the prevention of transplant rejection. It prevents the migration of lymphocytes to sites of pathology by trapping them within the peripheral lymph nodes, mesenteric lymph nodes (MLNs), and Peyer's patches. However, evidence suggests that its clinical use may increase the risk of mucosal infections. We investigated the impact of FTY720 treatment on susceptibility to gastrointestinal infection with t",Infection and immunity,"Carola T Murphy, Lindsay J Hall, Grainne Hurley, Aoife Quinlan, John MacSharry, Fergus Shanahan, Kenneth Nally, Silvia Melgar"," Alimentary Pharmabiotic Centre, University College Cork, National University of Ireland, Cork, Ireland.",2012 Aug;80(8):2712-23,10.1128/iai.06319-11
22642799,20120618,review,"xref,mesh","Adolescent,Child,Child, Preschool,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunologic Factors,Immunosuppressive Agents,Infant,Injections, Intramuscular,Injections, Subcutaneous,Interferon beta-1a,Interferon beta-1b,Interferon-beta,Multiple Sclerosis,Peptides,Propylene Glycols,Randomized Controlled Trials as Topic,Sphingosine,Time Factors","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D016899 Q000627 NY,D007166 Q000008 NN,D016899 Q000008 NN,D010455 Q000627 NN,D013110 Q000008 NN,D007155 Q000627 NY,D011409 Q000008 NN,D013110 Q000031 NN,D007166 Q000627 NY,D010455 Q000008 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D007155 Q000008 NN","6057,31270,65370,107969,107970,3081884,5280335","128394615,128865459,129645792",First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.,"Paediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18 years. Immunomodulatory disease-modifying therapies (i.e. the interferons [IFNs] and glatiramer acetate) are considered first-line treatments in adult patients with MS, but they are largely understudied in the paediatric population. IFNβ is a type 1 IFN produced by fibroblasts. The therapeutic effect achieved by IFNβ in MS is believed to be the result of a variety of mechanisms, including the inhibition of T-cell prolifera",Drugs,"Jessica Johnston, Tsz-Yin So"," University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC, USA.",2012 Jun;72(9):1195-211,10.2165/11634010-000000000-00000
22659743,20120622,article,"xref,mesh","Animals,Bone Morphogenetic Protein 2,Cell Differentiation,Cell Line,Core Binding Factor Alpha 1 Subunit,Fingolimod Hydrochloride,GTP-Binding Protein alpha Subunits, Gi-Go,Lysophospholipids,Mice,Osteoblasts,Osteocalcin,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Smad Proteins,Sphingosine","agonists,analogs &amp; derivatives,biosynthesis,cytology,drug effects,metabolism,pharmacology,physiology","D010006 Q000166 NY,D008246 Q000494 NN,D019206 Q000378 NN,D002454 Q000502 NY,D049349 Q000819 NY,D051785 Q000378 NN,D013110 Q000031 NN,D015675 Q000378 NN,D055396 Q000494 NY,D050659 Q000096 NN,D011409 Q000494 NN,D002454 Q000187 NN,D013110 Q000494 NN,D049349 Q000378 NN","8252,31270,107969,107970,5280335,5283560","128394615,129060975,129645792",Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation.,"We previously demonstrated that sphingosine 1-phosphate (S1P) receptor-mediated signaling induced proliferation and prostaglandin productions by synovial cells from rheumatoid arthritis (RA) patients. In the present study we investigated the role of S1P receptor-mediated signaling for osteoblast differentiation. We investigated osteoblast differentiation using C2C12 myoblasts, a cell line derived from murine satellite cells. Osteoblast differentiation was induced by the treatment of bone morphogenic protein",Biochemical and biophysical research communications,"Chieri Sato, Tsuyoshi Iwasaki, Sachie Kitano, Sachi Tsunemi, Hajime Sano"," Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.",2012 Jun;423(1):200-5,10.1016/j.bbrc.2012.05.130
22675826,20120502,review,"xref,mesh","Adjuvants, Immunologic,Antibodies, Monoclonal, Humanized,Choice Behavior,Combined Modality Therapy,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Immunotherapy,Multiple Sclerosis,Natalizumab,Patient Education as Topic,Propylene Glycols,Sphingosine,Therapies, Investigational","analogs &amp; derivatives,drug therapy,methods,therapeutic use,therapy,utilization","D007166 Q000627 NN,D013110 Q000031 NN,D009103 Q000628 NY,D035703 Q000379 NN,D000276 Q000627 NN,D061067 Q000627 NN,D035703 Q000656 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792",[Multiple sclerosis: beyong first line therapies].,"We are currently experiencing a key period in the management of patients with relapsing remitting multiple sclerosis. The application of new criteria allows early diagnosis, thus at a stage when the available immune treatments are the most likely to show a good efficacy. The therapeutic offer is expanding but its complexity too. It is thus important, for a given patient, to assess as precisely as possible the degree of severity of his/her disease, in order to give the drug with the optimal risk/benefit rati",Revue medicale suisse,"Myriam Schluep, Renaud Du Pasquier"," Service de neurologie, Département des neurosciences cliniques, CHUV, 1011 Lausanne. myriam.schluep@chuv.ch",2012 May;8(339):946-9,NULL
22677684,20120101,review,"xref,mesh","Animals,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immune System,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,immunology,metabolism,therapeutic use","D049349 Q000037 NY,D007107 Q000187 NN,D009103 Q000378 NN,D013110 Q000031 NY,D007107 Q000378 NN,D009103 Q000276 NY,D013110 Q000378 NN,D007166 Q000627 NY,D008246 Q000378 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D049349 Q000378 NN","8252,31270,105065,107969,107970,5280335,5283560","128394615,129060975,129645792,136111139",[Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].,"Over the last years, sphingosine-1-phosphate signaling function (S1P) is thought to play a key role in the development of immunological and neurological components of multiple sclerosis (MS). Modulators of the S1P-system are highly effective in MS treatment. Fingolimod, a structural analogue of endogenous sphingosine, is a first generation drug of a new class of medications known as ""modulators of sphingosine-1-phosphate receptors"". The inhibition of S1P receptors by fingolimod in MS reduces the recirculati",Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,"V I Shmyrev, S M Kryzhanovskiĭ, I V Danilycheva",NULL,2012 Jan;112(?):93-7,NULL
22693544,20120101,article,"xref,mesh","Animals,Antigen Presentation,Bone Marrow Cells,Cell Survival,Cytokines,Dendritic Cells,Female,Fingolimod Hydrochloride,Lipopolysaccharides,Mice,Mice, Inbred BALB C,Nitric Oxide,Phagocytosis,Phenotype,Propylene Glycols,Receptors, CCR7,Sphingosine","analogs &amp; derivatives,biosynthesis,cytology,drug effects,immunology,metabolism,pharmacology","D008070 Q000494 NN,D003713 Q000187 NY,D002470 Q000187 NN,D010587 Q000187 NN,D001854 Q000166 NY,D016207 Q000096 NN,D003713 Q000166 NN,D009569 Q000096 NN,D013110 Q000031 NY,D011409 Q000494 NY,D003713 Q000276 NY,D017951 Q000187 NN,D054400 Q000096 NN,D003713 Q000378 NN,D013110 Q000494 NN","679,702,3485,4939,5961,6057,8252,23831,31270,31276,105065,107969,107970,145068,5280335,54226752,57024517","128141778,128288165,128394615,128482492,128611894,128865459,129019136,129060975,129303766,129645792,129888650,129888770,135812730,136111139",Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro.,"Abnormal inflammations are central therapeutic targets in numerous infectious and autoimmune diseases. Dendritic cells (DCs) are involved in these inflammations, serving as both antigen presenters and proinflammatory cytokine providers. As an immuno-suppressor applied to the therapies of multiple sclerosis and allograft transplantation, fingolimod (FTY720) was shown to affect DC migration and its crosstalk with T cells. We posit FTY720 can induce an anergy-polarized phenotype switch on DCs in vitro, especia",PloS one,"Xiangfeng Zeng, Tong Wang, Cairong Zhu, Xiaobo Xing, Yanxia Ye, Xinqiang Lai, Bing Song, Yaoying Zeng"," Institute for Tissue Transplantation and Immunology, Jinan University, Guangzhou, China.",2012 Jan;7(5):e34830,10.1371/journal.pone.0034830
22697071,20120101,article,"xref,mesh","Administration, Oral,Animals,Aorta,Aortic Diseases,Apolipoproteins E,Atherosclerosis,Cell Proliferation,Cells, Cultured,Cholesterol, Dietary,Cytokines,Disease Models, Animal,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Forkhead Transcription Factors,Immune Tolerance,Immunosuppressive Agents,Lymphocyte Activation,Male,Mice,Mice, Knockout,Propylene Glycols,Protein Precursors,Sphingosine,T-Lymphocytes, Regulatory,Th1 Cells,Time Factors,Transforming Growth Factor beta","administration &amp; dosage,analogs &amp; derivatives,deficiency,drug effects,genetics,immunology,metabolism,pathology,prevention &amp; control","D018417 Q000276 NN,D001011 Q000187 NY,D050197 Q000473 NN,D001018 Q000276 NN,D001018 Q000378 NN,D011498 Q000378 NN,D001057 Q000172 NY,D016207 Q000378 NN,D001018 Q000473 NN,D013110 Q000008 NN,D001018 Q000517 NY,D050197 Q000235 NN,D050378 Q000187 NN,D050197 Q000378 NN,D049109 Q000187 NN,D001011 Q000276 NN,D013110 Q000031 NY,D018417 Q000187 NN,D051858 Q000378 NN,D016212 Q000378 NN,D050197 Q000276 NN,D007108 Q000187 NY,D001011 Q000473 NN,D050197 Q000517 NY,D008213 Q000187 NN,D001011 Q000378 NN,D001018 Q000235 NN","5997,8252,31270,107969,107970,5280335,56842206","128121087,128394615,129060975,129645792",Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice.,"Orally administered immunomodulatory drugs have recently demonstrated the ability to induce an oral tolerance via inhibition of effector T cells and induction of certain subsets of regulatory T cells (Tregs) which have the potential to prevent several autoimmune diseases. In the present study, we hypothesized that short-term, low-dose, oral FTY720 administration may induce latency-associated peptide (LAP) Tregs and CD4(+) Foxp3(+) Tregs in atherogenesis, potentially resulting in remission of early developme",International journal of immunopathology and pharmacology,"K Huang, S Q Li, W J Wang, L S Liu, Y G Jiang, P N Feng, Y Q Wang, S M Wang"," Department of Vascular and Thyroid Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.",2012 Jan;25(2):397-406,10.1177/039463201202500209
22701645,20120101,article,"xref,mesh","Adenosine Diphosphate,Analysis of Variance,Cardiac Surgical Procedures,Class I Phosphatidylinositol 3-Kinases,Enzyme-Linked Immunosorbent Assay,Extracorporeal Circulation,Flow Cytometry,Humans,Hypothermia, Induced,In Vitro Techniques,Leukocytes,Models, Biological,Morpholines,P-Selectin,Phosphatidylinositol 3-Kinases,Platelet Activation,Platelet Count,Purinergic P2 Receptor Antagonists,Pyrimidinones","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,metabolism,methods,pharmacology,physiology","D019007 Q000378 NN,D015539 Q000187 NN,D007036 Q000379 NN,D007962 Q000187 NN,D058919 Q000494 NY,D007036 Q000009 NY,D015539 Q000502 NY,D009025 Q000494 NN,D005112 Q000009 NY,D005112 Q000379 NN,D000244 Q000494 NN,D006348 Q000379 NY,D019869 Q000037 NY,D000244 Q000031 NN,D011744 Q000494 NN,D007962 Q000502 NY","5472,6022,6049,8252,30103,60606,69676,5311302,5311303,9854012,9907093,15764346,24867852,44258291,51371330","127968075,128364298,128756287,128918298,129060975,129308074,129740296,135897353,243214637,243850853,248489331",Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.,"Extracorporeal circulation (ECC) and hypothermia are used to maintain stable circulatory parameters and improve the ischemia tolerance of patients in cardiac surgery. However, ECC and hypothermia induce activation mechanisms in platelets and leukocytes, which are mediated by the platelet agonist ADP and the phosphoinositide-3-kinase (PI3K) p110β. Under clinical conditions these processes are associated with life-threatening complications including thromboembolism and inflammation. This study analyzes effect",PloS one,"Stefanie Krajewski, Julia Kurz, Tobias Geisler, Karlheinz Peter, Hans Peter Wendel, Andreas Straub"," Department of Anesthesiology and Intensive Care Medicine, University of Tübingen, Tübingen, Germany. krajewski@thg-lab.de",2012 Jan;7(6):e38455,10.1371/journal.pone.0038455
22703853,20120501,review,"xref,mesh","Adjuvants, Immunologic,Adrenal Cortex Hormones,Antibodies, Monoclonal, Humanized,Antibodies, Monoclonal, Murine-Derived,Azathioprine,Cyclophosphamide,Cyclosporine,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunoglobulins, Intravenous,Immunologic Factors,Immunosuppressive Agents,Interferon beta-1a,Interferon beta-1b,Interferon-beta,Mitoxantrone,Mycophenolic Acid,Natalizumab,Nervous System Diseases,Peptides,Plasma Exchange,Propylene Glycols,Rituximab,Sphingosine,Tacrolimus","analogs &amp; derivatives,immunology,therapeutic use,therapy","D016572 Q000627 NN,D010455 Q000627 NN,D016559 Q000627 NN,D007166 Q000627 NN,D007155 Q000627 NN,D009422 Q000628 NY,D009422 Q000276 NN,D016899 Q000627 NN,D016756 Q000627 NN,D013110 Q000031 NN,D001379 Q000627 NN,D058846 Q000627 NN,D000276 Q000627 NN,D008942 Q000627 NN,D061067 Q000627 NN,D009173 Q000031 NN,D009173 Q000627 NN,D003520 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D000305 Q000627 NN","2265,2907,2909,4212,4271,4272,5372,8252,22420,31270,51082,51151,62280,65370,107969,107970,445643,446541,3081884,5280335,5280754,5281078,5282315,5284373,5458171,5458585,6435893,6441022,6473866,6536850,9855081,11529527,23665584,24883466,25246316,49867938,54607525,71306795,71463825,71668407,73896891,90726579,122172945,123134263,123134270,132274082,134694629","128094727,128394615,128397534,129060975,129178479,129645792,242963342",Immunotherapies in neurologic disorders.,"Therapy for autoimmune demyelinating disorders has evolved rapidly over the past 10 years to include traditional immunosuppressants as well as novel biologicals. Antibody-mediated neuromuscular disorders are treated with therapies that acutely modulate pathogenic antibodies or chronically inhibit the humoral immune response. In other inflammatory autoimmune disorders of the peripheral and central nervous system, corticosteroids, often combined with conventional immunosuppression, and immunomodulatory treatm",The Medical clinics of North America,"Donna Graves, Steven Vernino"," Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9036, USA.","2012 May;96(3):497-523, x",10.1016/j.mcna.2012.05.001
22718407,20120701,article,"xref,mesh","Animals,Atrophy,B-Lymphocytes,Brain,Cell Movement,Drug Evaluation, Preclinical,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,L-Selectin,Lysophospholipids,Mice,Molecular Structure,Multiple Sclerosis,Neuroglia,Propylene Glycols,Rats,Receptors, CCR7,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocyte Subsets,Th17 Cells","agonists,analogs &amp; derivatives,analysis,chemistry,drug effects,drug therapy,immunology,pathology,pharmacology,physiology,therapeutic use","D007166 Q000494 NY,D058504 Q000276 NN,D049349 Q000819 NY,D007166 Q000627 NN,D054400 Q000032 NN,D011409 Q000737 NN,D001402 Q000187 NY,D013110 Q000031 NY,D013110 Q000737 NN,D019041 Q000032 NN,D011409 Q000494 NY,D001921 Q000473 NN,D004681 Q000188 NN,D058504 Q000187 NY,D001402 Q000276 NN,D008246 Q000502 NN,D007166 Q000737 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D016176 Q000276 NN,D013110 Q000494 NN,D009103 Q000188 NY,D009457 Q000187 NN,D001921 Q000276 NN,D009457 Q000276 NN,D013110 Q000502 NN","105065,107969,107970,5280335,5283560","128394615,136111139",[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].,"INTRODUCTION: Fingolimod has recently been approved for the therapy of relapsing multiple sclerosis. This drug binds to different sphingosine-1-phosphate receptors. AIM: To analyze basic mechanisms of action that can account for the efficacy of this drug in multiple sclerosis. DEVELOPMENT: Fingolimod acts as an inverse agonist on sphingosine-1-phosphate receptors, inducing degradation of receptors. On lymphoid circulation, this effect causes retention in lymph nodes of naive and central memory T cells, incl",Revista de neurologia,"J Antonio García-Merino, Antonio J Sánchez"," Unidad y Laboratorio de Neuroinmunología, Servicio de Neurología, Hospital Universitario Puerta de Hierro-Majadahonda, 28035 Majadahonda, Espana. jgarciam.hpth@salud.madrid.org",2012 Jul;55(1):31-7,NULL
22724290,20120530,article,"xref,mesh","Administration, Oral,Clinical Trials, Phase III as Topic,Congresses as Topic,Contrast Media,European Union,Fingolimod Hydrochloride,Gadolinium,Humans,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Posters as Topic,Propylene Glycols,Secondary Prevention,Sphingosine,Time Factors,Treatment Failure,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,epidemiology,immunology,methods,therapeutic use","D016899 Q000627 NY,D007166 Q000008 NN,D016899 Q000008 NN,D008279 Q000379 YN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D020529 Q000188 NY,D020529 Q000453 NN,D013110 Q000627 NN,D011409 Q000627 NY,D020529 Q000276 NN","8252,23982,31270,107969,107970,5280335","128394615,129060975,129645792",[Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].,NULL,Ideggyogyaszati szemle,Gábor Jakab," Uzsoki Utcai Kórház, Budapest.",2012 May;65(?):207-8,NULL
22728248,20120901,article,mesh,"Animals,Antibodies, Monoclonal,B-Lymphocytes,Bone Marrow Transplantation,CD40 Ligand,Cell Movement,Drug Synergism,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Graft Rejection,Graft vs Host Disease,Immunosuppressive Agents,Killer Cells, Natural,Mice,Propylene Glycols,Sphingosine,T-Lymphocytes,Thymocytes,Thymus Gland,Transplantation Chimera,Transplantation, Homologous,Whole-Body Irradiation","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,immunology,pathology,prevention &amp; control,therapeutic use","D006086 Q000276 NN,D023201 Q000037 NN,D060168 Q000276 NN,D002465 Q000187 NN,D006086 Q000473 NN,D013950 Q000187 NN,D023201 Q000276 NN,D013601 Q000276 NN,D001402 Q000187 NN,D013110 Q000031 NY,D002465 Q000276 NN,D060168 Q000187 NN,D013950 Q000276 NN,D001402 Q000473 NN,D006086 Q000517 NY,D007166 Q000627 NY,D007694 Q000473 NN,D000911 Q000627 NY,D001402 Q000276 NN,D006084 Q000473 NN,D060168 Q000473 NN,D013601 Q000473 NN,D007694 Q000187 NN,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY,D007694 Q000276 NN","107969,107970,5280335",NULL,FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.,"The immunomodulator FTY720 (FTY) is beneficial in models of graft-versus-host disease, solid organ transplantation, and autoimmunity and has been approved for use in patients with multiple sclerosis. FTY modifies the homing and migration of many cell types. We report that FTY has profound positive and negative effects on allogeneic bone marrow (BM) engraftment in sublethally irradiated recipients. FTY increased donor hematopoietic progenitors in the BM, resulting in high donor engraftment in the B cell, mye",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,"Patricia A Taylor, Ryan M Kelly, Nick D Bade, Michelle J Smith, Heather E Stefanski, Bruce R Blazar"," Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA.",2012 Sep;18(9):1341-52,10.1016/j.bbmt.2012.06.007
22729989,20130101,article,mesh,"Adult,Bradycardia,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D013110 Q000031 NY,D001919 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Prolonged and symptomatic bradycardia following a single dose of fingolimod.,"Fingolimod-related bradycardia is usually asymptomatic, reaches its nadir within 6 hours post-dose and recovers spontaneously. Here we report the case of a 30-year-old MS patient with vagotonia who developed symptomatic bradycardia with 33 beats per minute at nadir 39 hours after a single dose of fingolimod. Bradycardia was responsive to atropine, but returned within 2 hours. Overall, it took a week until the patient recovered. Extended monitoring is advised in patients with symptomatic bradycardia. ","Multiple sclerosis (Houndmills, Basingstoke, England)","Hans Faber, Hans-Jörg Fischer, Frank Weber"," Neurology, Max Planck Institute of Psychiatry, Munich, Germany. faber@mpipsykl.mpg.de",2013 Jan;19(1):126-8,10.1177/1352458512447596
22735460,20120801,article,"xref,mesh","Adolescent,Adult,Area Under Curve,Contraceptives, Oral, Combined,Drug Interactions,Ethinyl Estradiol,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Levonorgestrel,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,pharmacokinetics","D011409 Q000493 NY,D007166 Q000008 NN,D003277 Q000493 NY,D013110 Q000008 NN,D004997 Q000008 NN,D004997 Q000493 NY,D016912 Q000493 NY,D007166 Q000493 NY,D013110 Q000031 NY,D011409 Q000008 NN,D016912 Q000008 NN,D003277 Q000008 NN,D013110 Q000493 NN","5991,8252,13109,31270,62929,107969,107970,5280335","127508829,128394615,129060975,129645792,129646390",Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.,"BACKGROUND: Fingolimod has a novel mechanism of action in multiple sclerosis, being a first-in-class sphingosine 1-phosphate receptor modulator. Because of a potential risk of fetal toxicity based on animal studies, women of childbearing potential are advised to take effective contraceptive measures during and for 2 months after stopping fingolimod therapy. To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interacti",International journal of clinical pharmacology and therapeutics,"Olivier J David, Magdalena Ocwieja, Karin Meiser, Corinne Emotte, Annamaria Jakab, Johan Wemer, Izaak den Daas, Robert Schmouder"," Novartis Institute for Biomedical Research, Basel, Switzerland. olivier.david@novartis.com",2012 Aug;50(8):540-4,10.5414/cp201675
22737996,20120101,article,mesh,"Antibodies, Monoclonal, Humanized,Cost Savings,Costs and Cost Analysis,Fingolimod Hydrochloride,Health Services,Humans,Immunosuppressive Agents,Models, Econometric,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Netherlands,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,economics,therapeutic use,utilization","D020529 Q000191 NN,D006296 Q000191 NY,D007166 Q000627 NN,D013110 Q000031 NY,D013110 Q000191 NN,D006296 Q000656 NN,D061067 Q000627 NN,D061067 Q000191 NY,D020529 Q000188 NY,D011409 Q000191 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000191 NY","107969,107970,5280335",NULL,Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.,"OBJECTIVE: To assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri® (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) in The Netherlands. METHODS: A cost-minimization analysis was used to compare both treatments. The following cost categories were distinguished: drug acquisition costs, administration costs, and monitoring costs. Costs were discounted at 4%, and incremental model results were presented over a 1, 2, 5, and 10 year",Journal of medical economics,"M Heisen, M J Treur, W S van der Hel, S T F M Frequin, M T Groot, B G Verheggen"," Pharmerit Europe, Rotterdam, The Netherlands. mheisen@pharmerit.com",2012 Jan;15(6):1149-58,10.3111/13696998.2012.707631
22743277,20120922,article,mesh,"Abnormalities, Drug-Induced,Abortion, Spontaneous,Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunologic Factors,Immunosuppressive Agents,Infant, Newborn,Interferon-beta,Multiple Sclerosis,Natalizumab,Peptides,Pregnancy,Pregnancy Complications,Prenatal Exposure Delayed Effects,Propylene Glycols,Sphingosine,Stillbirth","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D010455 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007155 Q000009 NY,D010455 Q000627 NN,D061067 Q000009 NN,D007166 Q000627 NN,D000022 Q000139 NN,D007155 Q000627 NN,D016899 Q000627 NN,D016899 Q000009 NN,D013110 Q000031 NN,D061067 Q000627 NN,D011248 Q000188 NY,D007166 Q000009 NY,D011297 Q000139 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","65370,107969,107970,3081884,5280335",NULL,[Disease modifying drugs in multiple sclerosis and pregnancy].,NULL,Medicina clinica,"Carmen Tur, Mar Tintoré, Cristina Aguilera"," Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat), Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital Vall d'Hebron, Barcelona, España. ctur@cem-cat.org",2012 Sep;139(7):316-8,10.1016/j.medcli.2012.04.021
22749258,20120701,article,"xref,mesh","Adjuvants, Immunologic,Adolescent,Adult,Cost-Benefit Analysis,Dose-Response Relationship, Drug,Double-Blind Method,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Injections, Intramuscular,Interferon beta-1a,Interferon-beta,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Time Factors,Treatment Outcome,Young Adult","administration &amp; dosage,analogs &amp; derivatives,drug therapy,economics,therapeutic use","D020529 Q000191 NN,D016899 Q000627 NY,D016899 Q000191 NN,D000276 Q000191 NN,D007166 Q000627 NN,D007166 Q000191 NN,D013110 Q000008 NN,D013110 Q000031 NY,D013110 Q000191 NN,D000276 Q000627 NN,D011409 Q000191 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",128394615,Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.,"BACKGROUND: Fingolimod is a once-daily orally administered disease-modifying therapy (DMT) indicated for treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses and delay accumulation of physical disability. In the randomized, double-blind, phase 3 TRANSFORMS trial, 0.5 mg/d oral fingolimod substantially reduced relapse frequency when compared with IM interferon-β1a (IFN-β1a) at 12-months. In a 12-month, double-blind, extension phase of the TRANSFORMS study, pati",Clinical therapeutics,"Neetu Agashivala, Edward Kim"," Novartis Pharmaceuticals Corporation, Health Economics & Outcomes Research, One HealthPlaza, East Hanover, NJ 07936-1080, USA. neetu.agashivala@novartis.com",2012 Jul;34(7):1583-90,10.1016/j.clinthera.2012.06.012
22751847,20121001,article,mesh,"Administration, Oral,Adolescent,Adult,Brain,Disability Evaluation,Dose-Response Relationship, Drug,Double-Blind Method,Encephalitis,Female,Fingolimod Hydrochloride,Gadolinium,Humans,Immunosuppressive Agents,International Cooperation,Longitudinal Studies,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis,Outcome Assessment (Health Care),Propylene Glycols,Sphingosine,Time Factors,Young Adult","analogs &amp; derivatives,complications,drug effects,drug therapy,etiology,pathology,therapeutic use","D009103 Q000473 NY,D001921 Q000473 NY,D001921 Q000187 NN,D013110 Q000031 NY,D004660 Q000188 NN,D007166 Q000627 NY,D009103 Q000150 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D004660 Q000209 NN","23982,107969,107970,5280335",NULL,Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.,"OBJECTIVE: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study. DESIGN: Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume ",Archives of neurology,"Ernst-Wilhelm Radue, Paul O'Connor, Chris H Polman, Reinhard Hohlfeld, Peter Calabresi, Krystof Selmaj, Nicole Mueller-Lenke, Catherine Agoropoulou, Frederick Holdbrook, Ana de Vera, Lixin Zhang-Auberson, Gordon Francis, Pascale Burtin, Ludwig Kappos, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group"," Medical Image Analysis Center, University Hospital, Basel, Switzerland. eradue@uhbs.ch",2012 Oct;69(10):1259-69,10.1001/archneurol.2012.1051
22751954,20121001,article,mesh,"Animals,Apoptosis,Caspase 3,Caspase 7,Cell Proliferation,Cells, Cultured,Coculture Techniques,Dose-Response Relationship, Drug,Embryo, Mammalian,Fingolimod Hydrochloride,Ganglia, Spinal,Immunosuppressive Agents,In Situ Nick-End Labeling,Myelin Sheath,Neurons,Phosphorylation,Propylene Glycols,RNA, Messenger,Rats,Reactive Oxygen Species,Receptors, Lysosphingolipid,Schwann Cells,Sphingosine","analogs &amp; derivatives,cytology,drug effects,genetics,metabolism,pharmacology,physiology","D007166 Q000494 NY,D049349 Q000378 NY,D017209 Q000187 NN,D009474 Q000502 NN,D017382 Q000378 NN,D049349 Q000235 NN,D009474 Q000187 NN,D005727 Q000166 NN,D053179 Q000378 NN,D049109 Q000187 NN,D009186 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D012583 Q000378 NN,D012333 Q000378 NN,D053148 Q000378 NN,D012583 Q000187 NY,D010766 Q000187 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies?,"BACKGROUND: Fingolimod (FTY720), a first-in-class sphingosine-1-phosphate (S1P) receptor agonist, is a recently approved drug for treating relapsing multiple sclerosis. Experimental evidence suggests that FTY720 not only exhibits anti-inflammatory properties but also promotes myelination in the central nervous system by direct interaction with oligodendrocytes. OBJECTIVE: To assess the effects of FTY720 on Schwann cells (SCs) and peripheral nerve myelination. DESIGN: Receptor expression studies and myelinat",Archives of neurology,"Angelika Köhne, Mark Stettner, Parastoo Jangouk, Thomas Dehmel, Hans-Peter Hartung, Helmar C Lehmann, Bernd C Kieseier"," Department of Neurology Medical Faculty, Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany.",2012 Oct;69(10):1280-9,10.1001/archneurol.2012.394
22754354,20120101,article,"xref,mesh","Animals,Blood Glucose,Body Weight,Diabetes Mellitus, Type 1,Disease Models, Animal,Female,Fingolimod Hydrochloride,Glutamate Decarboxylase,Immunosuppressive Agents,Kidney,Liver,Mice,Mice, Inbred NOD,Propylene Glycols,Sphingosine,Spleen","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology","D003922 Q000276 NN,D001835 Q000187 NN,D007668 Q000187 NN,D013154 Q000187 NN,D013110 Q000008 NN,D005968 Q000276 NY,D001786 Q000187 NN,D013110 Q000031 NY,D003922 Q000473 NY,D003922 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY,D008099 Q000187 NN","5793,107969,107970,5280335",129621433,Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice.,"The studies were performed to investigate the physiological characteristics of non-obese diabetic (NOD) mice treated with FTY720. At the age of 12 weeks, each mouse was fed with FTY720 or physiological saline once a day for 10 weeks running, and their blood glucose, weight, anti-GAD antibody and organ indexes were determined. No mouse in group FTY720 (NOD mice treated with FTY720) showed diabetic symptoms. The average content of serum anti-GAD antibody in group FTY720 decreased 48.75% (P < 0.01). It was con",International journal of molecular sciences,"Xiaoqiang Chen, Sudan Ye, Shikang Zhang, Jianrong Li, Hongying Zhu, Gaoli Zheng, Yin Lu, Haitong Wan"," College of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou 310035, China; E-Mail:  lijianrong@mail.zjgsu.edu.cn.",2012 Jan;13(5):6129-37,10.3390/ijms13056129
22760478,20121001,article,"xref,mesh","Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,JC Virus,Leukoencephalopathy, Progressive Multifocal,Multiple Sclerosis,Natalizumab,Propylene Glycols,Risk,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,immunology,therapeutic use,virology","D011409 Q000009 NN,D013110 Q000009 NN,D061067 Q000009 NN,D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D007577 Q000276 NN,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY,D007968 Q000821 NN,D007968 Q000276 NN","6057,107969,107970,5280335","128394615,128865459",New disease-modifying therapies and new challenges for MS.,"The availability of the second-generation therapies for relapsing multiple sclerosis (MS), natalizumab and fingolimod, provides new treatment options for MS but also presents new challenges. Both natalizumab and fingolimod appear to be more effective than the interferon beta products and glatiramer acetate, but both have more safety problems than do the first-generation therapies. Treatment with natalizumab is associated with a significant risk of patients developing progressive multifocal leukoencephalopat",Current neurology and neuroscience reports,"Vijayshree Yadav, Dennis Bourdette"," Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L226, Portland, OR 97239, USA. yadavv@ohsu.edu",2012 Oct;12(5):489-91,10.1007/s11910-012-0295-2
22766059,20130119,review,mesh,"4-Aminopyridine,Administration, Oral,Adult,Alemtuzumab,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antibodies, Monoclonal, Murine-Derived,Cladribine,Clinical Trials as Topic,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Immunoglobulin G,Immunosuppressive Agents,Middle Aged,Multicenter Studies as Topic,Multiple Sclerosis,Propylene Glycols,Quinolones,Rituximab,Sphingosine,Toluidines,Young Adult","administration &amp; dosage,analogs &amp; derivatives,drug therapy,therapeutic use","D015363 Q000627 NN,D007166 Q000008 NN,D005650 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D007074 Q000627 NN,D058846 Q000627 NN,D007166 Q000627 NY,D000911 Q000627 NY,D061067 Q000627 NN,D014052 Q000627 NN,D017338 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D015761 Q000627 NN","1727,12215,20279,107969,107970,637568,3036108,5280335,54677946",NULL,[Emerging therapies for multiple sclerosis].,"Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system considered the second cause of disability in young adults. The prognosis of MS has improved significantly since the approval of the first interferon β in 1993 but, compared to other diseases, few new therapeutic products have been commercialized in the last years. However, currently, there are more than 600 ongoing clinical trials and new drugs that aim to improve efficacy and a more convenient schedule of admin",Medicina clinica,"Ana de Lorenzo-Pinto, Carmen Guadalupe Rodríguez-González, Arantza Ais-Larisgoitia"," Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, España. ana.lorenzo@salud.madrid.org",2013 Jan;140(2):76-82,10.1016/j.medcli.2012.05.008
22778861,20110316,review,mesh,"Animals,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Neurosciences,Propylene Glycols,Randomized Controlled Trials as Topic,Societies, Scientific,Sphingosine","analogs &amp; derivatives,chemistry,drug therapy,immunology,methods,therapeutic use,trends","D009488 Q000639 NN,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D007166 Q000627 NY,D007166 Q000737 NN,D009103 Q000276 NN,D016032 Q000379 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).,NULL,ACS chemical neuroscience,Corey R Hopkins," Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.",2011 Mar;2(3):116-7,10.1021/cn100113g
22797580,20120901,article,mesh,"Animals,Astrocytes,Blood-Brain Barrier,Ceramides,Demyelinating Diseases,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,NF-kappa B,Oligodendroglia,Propylene Glycols,Quinolones,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacology,physiopathology,prevention &amp; control","D007166 Q000494 NY,D003711 Q000517 NY,D002518 Q000378 NY,D009103 Q000503 NY,D009836 Q000187 NY,D013110 Q000031 NY,D016328 Q000378 NY,D011409 Q000494 NY,D001812 Q000187 NY,D015363 Q000494 NY,D001253 Q000187 NY,D013110 Q000494 NN","107969,107970,3036108,5280335,54677946",NULL,Targeting intracerebral inflammation in multiple sclerosis: is it feasible?,NULL,Acta neuropathologica,Hans Lassmann," Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Wien, Austria. hans.lassmann@meduniwien.ac.at",2012 Sep;124(3):395-6,10.1007/s00401-012-1015-3
22799042,20120401,article,mesh,"Animals,Cricetinae,Cricetulus,Female,Fingolimod Hydrochloride,Graft Survival,Heart Rate,Immunosuppressive Agents,Lymphocyte Count,Lymphocytes,Lymphopenia,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Microscopy, Confocal,Propylene Glycols,Protein Binding,Random Allocation,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Skin Transplantation,Sphingosine,Transplantation, Homologous","agonists,analogs &amp; derivatives,chemically induced,cytology,drug effects,metabolism,pharmacology","D006085 Q000187 NN,D007166 Q000494 NY,D049349 Q000819 NY,D008231 Q000139 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008214 Q000166 NN,D006339 Q000187 NN,D013110 Q000494 NN,D008214 Q000187 NN,D049349 Q000378 NN","107969,107970,5280335",NULL,[Immunosuppressive effect of S1P1 receptor agonist FTY720].,"FTY720 is a synthetic compound derived from the metabolites of Isaria sinclairii. Its unique chemical structure and mechanism appear to be distinctive from other known immunosuppressors. In the present study, the effect of FTY720 on immunosuppression and toxicity to heart was evaluated by detection of lymphocytes count, heart rate in rats, the survival time of the allografts of skin slice in mice and binding to S1P1 and S1P3 receptors by confocal. The results showed that FTY720 could induce lymphopenia, red",Yao xue xue bao = Acta pharmaceutica Sinica,"Wan-Qi Zhou, Hai-Jing Zhang, Jing Jin, Yan Li, Chao Li, Xiao-Guang Chen"," State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.",2012 Apr;47(4):546-50,NULL
22810490,20120901,article,"xref,mesh","Adult,Aged,Aged, 80 and over,Astrocytes,Blood-Brain Barrier,Cell Movement,Cells, Cultured,Ceramides,Endothelial Cells,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Monocytes,Multiple Sclerosis,Propylene Glycols,Sphingomyelins,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology,physiopathology","D001812 Q000473 NN,D042783 Q000473 NN,D007166 Q000494 NY,D042783 Q000378 NN,D009000 Q000187 NN,D002465 Q000187 NN,D009103 Q000473 NN,D002518 Q000378 NY,D009000 Q000473 NN,D009103 Q000378 NN,D009103 Q000503 NY,D009000 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001812 Q000187 NY,D042783 Q000187 NN,D001253 Q000187 NY,D013109 Q000378 NN,D001253 Q000473 NN,D013110 Q000494 NN,D001253 Q000378 NN,D001812 Q000503 NN","107969,107970,5280335,44176376","128394615,135820018,135836815",Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.,"Alterations in sphingolipid metabolism are described to contribute to various neurological disorders. We here determined the expression of enzymes involved in the sphingomyelin cycle and their products in postmortem brain tissue of multiple sclerosis (MS) patients. In parallel, we investigated the effect of the sphingosine-1 receptor agonist Fingolimod (Gilenya(®)) on sphingomyelin metabolism in reactive astrocytes and determined its functional consequences for the process of neuro-inflammation. Our results",Acta neuropathologica,"Ruben van Doorn, Philip G Nijland, Nick Dekker, Maarten E Witte, Melissa A Lopes-Pinheiro, Bert van het Hof, Gijs Kooij, Arie Reijerkerk, Christine Dijkstra, Paul van van der Valk, Jack van Horssen, Helga E de Vries"," Department of Molecular Cell Biology and Immunology, MS Center Amsterdam, VU University Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.",2012 Sep;124(3):397-410,10.1007/s00401-012-1014-4
22829086,20120816,review,"xref,mesh","Community-Acquired Infections,Contraindications,Disease Management,Disease Susceptibility,Drug Therapy, Combination,Fingolimod Hydrochloride,Graft Rejection,Humans,Immunocompromised Host,Immunologic Memory,Immunologic Surveillance,Immunosuppressive Agents,Kidney Transplantation,Leukoencephalopathy, Progressive Multifocal,Lymphopenia,Multiple Sclerosis, Relapsing-Remitting,Opportunistic Infections,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Vaccination","administration &amp; dosage,adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,chemically induced,complications,drug effects,drug therapy,etiology,pharmacology,prevention &amp; control,therapeutic use","D013110 Q000009 NN,D007166 Q000008 NN,D007157 Q000187 NY,D020529 Q000188 NN,D007166 Q000627 NN,D009894 Q000209 NY,D013110 Q000008 NN,D009894 Q000517 NN,D020529 Q000150 NN,D009894 Q000188 NN,D008231 Q000139 NY,D013110 Q000031 NY,D011409 Q000008 NN,D017714 Q000188 NN,D007156 Q000187 NN,D007968 Q000209 NN,D017714 Q000209 NN,D007166 Q000009 NY,D011409 Q000494 NN,D006084 Q000517 NN,D008231 Q000150 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D049349 Q000037 NN,D007166 Q000494 NN,D017714 Q000517 NN","31270,107969,107970,5280335","128394615,129645792",[Infections and fingolimod].,"INTRODUCTION: Fingolimod is the first approved drug with oral availability for the treatment of relapsing multiple sclerosis. AIMS: To review the mechanism of action of fingolimod and its relationship with the development of infections. To propose preventive measures for those patients who are receiving the drug or will initiate a new treatment. In addition, the role of fingolimod in the development of progressive multifocal leukoencephalopathy on the basis of recent knowledge of its pathophysiology will be",Revista de neurologia,Carlos Cervera," Hospital Clinic de Barcelona, 08036 Barcelona, Espana. ccervera@clinic.ub.es",2012 Aug;55(4):227-37,NULL
22834825,20121201,review,mesh,"Antineoplastic Agents,Apoptosis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphopenia,Lysophospholipids,Multiple Sclerosis,Neoplasms,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,metabolism,pharmacology","D009369 Q000188 NY,D013110 Q000009 NN,D017209 Q000187 NN,D000970 Q000494 NN,D011409 Q000009 YN,D008231 Q000139 NN,D013110 Q000031 NY,D011409 Q000378 YN,D013110 Q000378 NN,D011409 Q000494 YN,D017853 Q000378 NY,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D009103 Q000188 NY,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Molecular targets of FTY720 (fingolimod).,"FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable ",Current molecular medicine,"M R Pitman, J M Woodcock, A F Lopez, S M Pitson"," Centre for Cancer Biology, SA Pathology, Frome Road, Adelaide SA 5000, Australia.",2012 Dec;12(10):1207-19,10.2174/156652412803833599
22888087,20120101,article,"xref,mesh","Adolescent,Adult,Brain,Data Interpretation, Statistical,Dose-Response Relationship, Drug,Double-Blind Method,Endpoint Determination,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Models, Statistical,Multiple Sclerosis, Relapsing-Remitting,Poisson Distribution,Propylene Glycols,Regression Analysis,Sphingosine,Young Adult","administration &amp; dosage,analogs &amp; derivatives,drug therapy,methods,pathology,therapeutic use","D007166 Q000008 NN,D007166 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D020529 Q000473 NN,D001921 Q000473 NN,D008279 Q000379 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",128394615,Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis.,"Lesion count observed on brain magnetic resonance imaging scan is a common end point in phase 2 clinical trials evaluating therapeutic treatment in relapsing remitting multiple sclerosis (MS). This paper compares the performances of Poisson, zero-inflated poisson (ZIP), negative binomial (NB), and zero-inflated NB (ZINB) mixed-effects regression models in fitting lesion count data in a clinical trial evaluating the efficacy and safety of fingolimod in comparison with placebo, in MS. The NB and ZINB models p",Pharmaceutical statistics,"Mercier Francois, Chin Peter, Francis Gordon"," Pharsight - Consulting Services, Saint Louis, MO, USA. francois0mercier@gmail.com",2012 Jan;11(5):417-24,10.1002/pst.1529
22888218,20120101,review,"xref,mesh","Administration, Oral,Animals,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,physiopathology,therapeutic use","D007166 Q000008 NN,D009103 Q000503 NN,D016899 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D049349 Q000187 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY,D049349 Q000378 NN","8252,31270,107969,107970,5280335","128394615,129060975,129645792","Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.","Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs and two second-line treatments in MS. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different sid","Drug design, development and therapy","Claudio Gasperini, Serena Ruggieri"," Department of Neurosciences, S Camillo Forlanini Hospital, University of Rome Sapienza, Rome, Italy. c.gasperini@libero.it",2012 Jan;6(?):175-86,10.2147/dddt.s8927
22891354,20120828,article,mesh,"Animals,Astrocytes,Brain-Derived Neurotrophic Factor,Cell Death,Cells, Cultured,Disease Models, Animal,Excitatory Amino Acid Agonists,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,MAP Kinase Signaling System,Methyl-CpG-Binding Protein 2,Mice,Motor Activity,N-Methylaspartate,Neurons,Organ Culture Techniques,Pregnancy,Propylene Glycols,Receptors, Lysosphingolipid,Rett Syndrome,Sphingosine","agonists,analogs &amp; derivatives,cytology,deficiency,drug effects,drug therapy,genetics,metabolism,pharmacology,physiology,toxicity","D049349 Q000819 NY,D016202 Q000633 NN,D009474 Q000166 NN,D016923 Q000187 NN,D015518 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D016923 Q000502 NN,D015518 Q000188 NY,D051783 Q000235 NN,D009043 Q000502 NN,D019208 Q000172 NN,D009043 Q000187 NN,D001253 Q000166 NN,D019208 Q000378 NY,D009474 Q000378 NN,D020935 Q000187 NN,D020935 Q000502 NN,D013110 Q000494 NN,D007166 Q000494 NN,D015518 Q000235 NN,D001253 Q000378 NN,D018690 Q000633 NN","22880,107969,107970,5280335",NULL,"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.","The functional relevance of brain-derived neurotrophic factor (BDNF) is beginning to be well appreciated not only in mice, but also in humans. Because reduced levels typically correlate with impaired neuronal function, increasing BDNF levels with well-tolerated drugs diffusing into the central nervous system may help in ameliorating functional deficits. With this objective in mind, we used the sphingosine-1 phosphate receptor agonist fingolimod, a drug that crosses the blood-brain barrier. In addition, fing",Proceedings of the National Academy of Sciences of the United States of America,"Rubén Deogracias, Morteza Yazdani, Martijn P J Dekkers, Jacky Guy, Mihai Constantin S Ionescu, Kaspar E Vogt, Yves-Alain Barde"," Biozentrum,  University of Basel, 4056 Basel,  Switzerland.",2012 Aug;109(35):14230-5,10.1073/pnas.1206093109
22892927,20120701,article,mesh,"Animals,Cytokines,Female,Fingolimod Hydrochloride,Flow Cytometry,Graft Rejection,Graft Survival,Immunosuppressive Agents,Interleukins,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Real-Time Polymerase Chain Reaction,Skin Transplantation,Sphingosine,T-Lymphocytes, Regulatory,Th17 Cells","analogs &amp; derivatives,drug effects,immunology,metabolism,prevention &amp; control,therapeutic use","D007378 Q000378 NN,D058504 Q000276 NN,D016038 Q000276 NY,D016207 Q000378 NN,D013110 Q000031 NY,D007166 Q000627 NY,D058504 Q000187 NY,D050378 Q000187 NY,D006085 Q000187 NY,D006085 Q000276 NN,D050378 Q000276 NN,D013110 Q000627 NN,D006084 Q000276 NN,D011409 Q000627 NY,D006084 Q000517 NY","107969,107970,5280335",NULL,The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection.,"OBJECTIVES: FTY720 modulates CD4+T cells by the augmentation of regulatory T cell activity, secretion of suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft rejection/acceptance, we evaluated skin allograft survival and associated events after FTY720 treatment. METHODS: F1 mice (C57BL/6xBALB/c) and C57BL/6 mice were used as donors for and recipients of skin transplantation, respectively. The recipients were transplanted and either not treated or","Clinics (Sao Paulo, Brazil)","Alessandra Gonçalves Commodaro, Juliana Figueredo Pedregosa, Jean Pierre Peron, Wesley Brandão, Luiz Vicente Rizzo, Valquiria Bueno"," Vision Institute, Federal University of São Paulo, São Paulo/SP, Brazil.",2012 Jul;67(7):805-13,10.6061/clinics/2012(07)17
22895849,20120101,review,"xref,mesh","Administration, Oral,Algorithms,Clinical Trials as Topic,Dose-Response Relationship, Drug,Drug Therapy, Combination,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunologic Memory,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Lymphocyte Count,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocytes,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,immunology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007155 Q000627 NN,D016899 Q000627 NN,D013110 Q000031 NY,D007156 Q000187 NN,D016899 Q000009 NN,D007155 Q000009 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D020529 Q000276 NN,D013601 Q000187 NN","31270,107969,107970,5280335","128394615,129645792",Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.,Fingolimod is the first oral treatment of multiple sclerosis. It is the first-in-class sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phophate receptors on lymphocytes and via downregulation of the receptor prevents lymphocyte egress from lymphoid tissues into the circulation. This mechanism reduces the infiltration of potentially auto-aggressive lymphocytes into the central nervous system. Two large phase III studies with fingolimod have shown superior efficacy of the drug in two do,Wiener medizinische Wochenschrift (1946),"Franz Fazekas, Thomas Berger, Tanja Hojs Fabjan, Alenka Horvat Ledinek, Gábor Jakab, Samuel Komoly, Jörg Kraus, Egon Kurča, Theodoros Kyriakides, L'ubomír Lisý, Ivan Milanov, Panayiotis Panayiotou, Sasa Sega Jazbec, Radomír Taláb, Latchezar Traykov, Peter Turčáni, Karl Vass, Norbert Vella, Eva Havrdová"," Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria. franz.fazekas@medunigraz.at",2012 Jan;162(?):354-66,10.1007/s10354-012-0123-y
22898216,20120801,article,"xref,mesh","Aged,Cartilage, Articular,Cells, Cultured,Chondrocytes,Drug Interactions,Enzyme Inhibitors,Female,Fingolimod Hydrochloride,Flavonoids,Gene Expression,Humans,Imidazoles,Immunosuppressive Agents,Lysophospholipids,Male,Mitogen-Activated Protein Kinases,Osteoarthritis,Pertussis Toxin,Propylene Glycols,Pyridines,RNA, Messenger,Sphingosine,Vascular Endothelial Growth Factor A","analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,diagnosis,drug effects,genetics,metabolism,pathology,pharmacology","D037342 Q000494 NN,D020928 Q000037 NN,D007093 Q000494 NN,D010003 Q000378 NY,D019902 Q000187 NY,D010003 Q000235 NN,D019902 Q000473 NN,D019902 Q000378 NN,D011725 Q000494 NN,D013110 Q000031 NY,D002358 Q000166 NN,D008246 Q000494 NY,D015870 Q000187 NY,D010003 Q000175 NN,D012333 Q000378 NN,D011409 Q000494 NN,D004791 Q000494 NN,D005419 Q000494 NN,D042461 Q000235 NY,D042461 Q000378 NY,D013110 Q000494 NN,D007166 Q000494 NN","4713,105065,107969,107970,176155,581866,5280335,5283560",136111139,Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.,"AIM: Although sphingosine-1-phosphate (S1P) is suggested to have an important role in arthritis, its function in chondrocytes remains unknown. In contrast, vascular endothelial growth factor (VEGF) has been speculated to contribute to the pathogenesis of osteoarthritis (OA), most likely by regulating angiogenesis. We here investigated the in vitro effect of S1P on VEGF expression in human articular chondrocytes from OA patients. METHODS: Human articular cartilage samples were obtained from patients with OA ",International journal of rheumatic diseases,"Kayo Masuko, Minako Murata, Moroe Beppu, Hiroshi Nakamura, Tomohiro Kato, Kazuo Yudoh"," Department of Biochemistry, St. Marianna University School of Medicine, Kanagawa, Japan. k_msk@mac.com",2012 Aug;15(4):366-73,10.1111/j.1756-185x.2012.01756.x
22898729,20120901,article,"xref,mesh","Disability Evaluation,Female,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D011409 Q000627 NY","8252,31270,5280335","129060975,129645792",Reporting of subgroup analyses from clinical trials.,NULL,The Lancet. Neurology,"Maria Pia Sormani, Paolo Bruzzi",NULL,2012 Sep;11(9):?,10.1016/s1474-4422(12)70181-3
22936676,20130101,article,mesh,"Animals,Apoptosis,Blood Glucose,Body Weight,Cell Survival,Diabetes Mellitus, Type 2,Female,Fingolimod Hydrochloride,Glucose Tolerance Test,Immunosuppressive Agents,Insulin,Insulin Resistance,Insulin-Secreting Cells,Mice,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology","D050417 Q000187 NY,D007166 Q000494 NY,D017209 Q000187 NY,D001835 Q000187 NN,D001786 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D050417 Q000378 NN,D050417 Q000473 NN,D002470 Q000187 NY,D003924 Q000473 NY,D013110 Q000494 NN,D007328 Q000378 NN","107969,107970,5280335,70678557,118984375",NULL,FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice.,"BACKGROUND: FTY720, an analogue of sphingosine-1-phosphate, has shown potential in the treatment of several autoimmune diseases, such as multiple sclerosis, type 1 diabetes and systemic lupus erythematosus. It prevents development or cure of autoimmune diabetes in animal models. Recently, we reported that FTY720 also prevents development of diabetes in db/db mice by β-cell regeneration in vivo. This study investigated the effect of FTY720 on apoptosis in β-cells in db/db mice treated with FTY720 16 weeks. M",Diabetes/metabolism research and reviews,"Hosik Moon, Jinyoung Chon, Jindeok Joo, Daewoo Kim, Janghyeok In, Haejin Lee, Jaesik Park, Jinwoo Choi"," Anesthesiology and Pain Medicine, Catholic University of Saint Mary Hospital, Seoul, Korea.",2013 Jan;29(1):19-24,10.1002/dmrr.2341
22948694,20120905,article,"xref,mesh","Anticoagulants,Antineoplastic Agents,Benzimidazoles,Carcinoma, Neuroendocrine,Clinical Trials as Topic,Dabigatran,Drug Approval,Efficiency, Organizational,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Patient Safety,Piperidines,Propylene Glycols,Quinazolines,Risk,Sphingosine,Stroke,Thyroid Neoplasms,Time Factors,United States,United States Food and Drug Administration,beta-Alanine","adverse effects,analogs &amp; derivatives,drug therapy,prevention &amp; control,therapeutic use","D011799 Q000627 NN,D015091 Q000031 NN,D010880 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D020521 Q000517 NN,D007166 Q000627 NN,D001562 Q000627 NN,D010880 Q000627 NN,D015091 Q000009 NN,D000925 Q000009 NN,D013110 Q000031 NN,D000970 Q000627 NN,D001562 Q000009 NN,D000925 Q000627 NN,D000970 Q000009 NN,D013964 Q000188 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D009103 Q000188 NN,D011799 Q000009 NN,D015091 Q000627 NN","239,8252,31270,107969,107970,161901,213023,216210,3081361,5280335,6445226,9578572,10439877,11434065,12201475,23674880,72960092","128394615,129060975,129348709,129645792,129772675,247533733",The safety risks of innovation: the FDA's Expedited Drug Development Pathway.,NULL,JAMA,"Thomas J Moore, Curt D Furberg"," Institute for Safe Medication Practices, Alexandria, Virginia, USA.",2012 Sep;308(9):869-70,10.1001/jama.2012.9658
22949658,20120925,article,mesh,"ATP-Binding Cassette, Sub-Family B, Member 1,Animals,Biological Transport, Active,Blood-Brain Barrier,Calcium Channel Blockers,Capillaries,Drug Delivery Systems,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Nerve Tissue Proteins,Organophosphates,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Signal Transduction,Sphingolipids,Sphingosine,Tight Junctions,Tumor Necrosis Factor-alpha,Verapamil","analogs &amp; derivatives,cytology,drug effects,metabolism,pharmacology,physiology","D001693 Q000502 NN,D010755 Q000494 NN,D002196 Q000378 NN,D014409 Q000378 NN,D001693 Q000187 NN,D020168 Q000378 NY,D014700 Q000494 NN,D013107 Q000378 NY,D002196 Q000166 NN,D013110 Q000031 NY,D001812 Q000378 NY,D013110 Q000378 NN,D019108 Q000378 NN,D008246 Q000378 NY,D011409 Q000494 NN,D015398 Q000502 NY,D009419 Q000378 NY,D002121 Q000494 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN","2520,62969,65808,107969,107970,5280335,5283560,9908268,11452022,45268446",NULL,Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.,"P-glycoprotein, an ATP-driven drug efflux pump, is a major obstacle to the delivery of small-molecule drugs across the blood-brain barrier and into the CNS. Here we test a unique signaling-based strategy to overcome this obstacle. We used a confocal microscopy-based assay with isolated rat brain capillaries to map a signaling pathway that within minutes abolishes P-glycoprotein transport activity without altering transporter protein expression or tight junction permeability. This pathway encompasses element",Proceedings of the National Academy of Sciences of the United States of America,"Ronald E Cannon, John C Peart, Brian T Hawkins, Christopher R Campos, David S Miller"," Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA. cannon1@niehs.nih.gov",2012 Sep;109(39):15930-5,10.1073/pnas.1203534109
22960129,20121201,article,mesh,"Animals,Astrocytes,Disease Models, Animal,Encephalitis,Enzyme-Linked Immunosorbent Assay,Fingolimod Hydrochloride,Hippocampus,Immunohistochemistry,Interleukin-1beta,Lithium Compounds,Male,Pilocarpine,Propylene Glycols,Rats,Rats, Sprague-Dawley,Sphingosine,Status Epilepticus,Tumor Necrosis Factor-alpha","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,metabolism,pathology,pharmacology,physiopathology,prevention &amp; control","D006624 Q000378 NN,D006624 Q000187 NN,D018020 Q000009 NY,D014409 Q000378 NN,D013226 Q000517 NY,D053583 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D006624 Q000503 NN,D013226 Q000139 NY,D001253 Q000473 NN,D004660 Q000517 NY,D010862 Q000009 NY,D013110 Q000494 NN","5909,5910,91468,107969,107970,657349,5280335",NULL,Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.,"Accumulating evidence has shown that neuroinflammation plays a key role in epileptogenesis. However, the efficacy of anti-inflammatory agents for preventing epilepsy remains controversial. Fingolimod (FTY720), a sphingosine-1-phosphate (S1P) analog, has potent anti-inflammatory effects in multiple sclerosis (MS) patients and animal models. Here, we tested whether FTY720 could exert antiepileptogenic effects in an adult rat model of lithium-pilocarpine induced epilepsy. 24h after onset of status epilepticus ","Pharmacology, biochemistry, and behavior","Fei Gao, Yangfeng Liu, Xiaowei Li, Ying Wang, Dong Wei, Wen Jiang"," Department of Neurology, Xijing Hospital, Fourth Military Medical University, 17 Changle West Road, Xi'an 710032, China.",2012 Dec;103(2):187-96,10.1016/j.pbb.2012.08.025
23007332,20120701,article,"xref,mesh","Animals,Anti-Inflammatory Agents,Betamethasone,Dermatitis, Atopic,Drug Combinations,Female,Fingolimod Hydrochloride,Immunologic Factors,Immunosuppressive Agents,Mice,Mites,Ointments,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,immunology","D013110 Q000008 NN,D008925 Q000276 NY,D013110 Q000031 NY,D000893 Q000008 NN,D007155 Q000008 NY,D001623 Q000008 NY,D003876 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","9782,16533,107969,107970,5280335","135737929,136014646",[Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 (fingolimod) in combination with betamethasone ointment in NC/Nga mice].,"BACKGROUND: The increasing incidence and prevalence of atopic dermatitis (AD) have led to a requirement for new means to treat the disease. We investigated the therapeutic efficacy of the novel immunomodulator FTY720 (Fingolimod), alone and in combination with betamethasone valerate ointment, in the NC/Nga mouse model of mite-induced intractable dermatitis. METHODS: Female NC/Nga mice in which dermatitis had been induced with Dermatophagoides farinae were divided into six groups: 1) a betamethasone group (b",Arerugi = [Allergy],"Takumi Tsuji, Yuya Yoshida, Tetsuro Fujita, Takeyuki Kohno"," Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University.",2012 Jul;61(7):948-58,NULL
23035058,20121106,article,mesh,"Antibodies, Monoclonal, Humanized,Brain,Cerebrovascular Disorders,Encephalitis, Varicella Zoster,Female,Fingolimod Hydrochloride,Herpes Zoster,Humans,Immunosuppressive Agents,Leukoencephalopathy, Progressive Multifocal,Male,Multiple Sclerosis,Natalizumab,Nerve Fibers, Myelinated,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug therapy,pathology,therapeutic use","D061067 Q000009 NY,D013110 Q000009 NN,D007968 Q000188 NY,D009103 Q000473 NY,D001921 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009413 Q000473 NY,D007968 Q000139 NY,D006562 Q000150 NY,D007166 Q000009 NY,D002561 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D020804 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod and multiple sclerosis: four cautionary tales.,NULL,Neurology,"Dennis Bourdette, Don Gilden",NULL,2012 Nov;79(19):1942-3,10.1212/wnl.0b013e3182735edf
23035063,20121106,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,JC Virus,Leukoencephalopathy, Progressive Multifocal,Magnetic Resonance Imaging,Natalizumab,Propylene Glycols,Recurrence,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,immunology,pathogenicity,therapeutic use","D061067 Q000009 NY,D007968 Q000188 NY,D013110 Q000031 NY,D007166 Q000627 NY,D007577 Q000472 NN,D007968 Q000139 NY,D007577 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Severe relapses under fingolimod treatment prescribed after natalizumab.,NULL,Neurology,"Diego Centonze, Silvia Rossi, Francesca Rinaldi, Paolo Gallo"," Multiple Sclerosis Clinical and Research Center, Department of Neuroscience, Tor Vergata University, Rome, Italy. centonze@uniroma2.it",2012 Nov;79(19):2004-5,10.1212/wnl.0b013e3182735c7a
23035065,20121106,article,mesh,"Aspartic Acid,Brain,Choline,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inositol,Magnetic Resonance Imaging,Multiple Sclerosis,Nerve Fibers, Myelinated,Propylene Glycols,Sphingosine,Young Adult","analogs &amp; derivatives,drug therapy,metabolism,pathology,therapeutic use","D001224 Q000031 NN,D002794 Q000378 NN,D009103 Q000473 NY,D001921 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009413 Q000473 NY,D007294 Q000378 NN,D001224 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","305,424,485,5960,6209,6900,21806,26387,30465,31255,65065,87869,92912,107969,107970,2042020,5280335,5460294,5460541,6454950,10198924,12774278,16211203,16218492,23672344,23672742,23676147,23724958,56841975,60145874,60145875,71586907,86590683,86605460,88619861,90470772,100914982,134129865,134158187",NULL,Tumefactive multiple sclerosis lesions under fingolimod treatment.,NULL,Neurology,"Femke Visser, Mike P Wattjes, Petra J W Pouwels, Wim H J P Linssen, Bob W van Oosten"," Department of Neurology, Sint Lucas Andreas Hospital, Amsterdam, the Netherlands. f.visser@slaz.nl",2012 Nov;79(19):2000-3,10.1212/wnl.0b013e3182735cb3
23035072,20121106,article,mesh,"Brain,Cerebrovascular Disorders,Encephalitis, Varicella Zoster,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Propylene Glycols,Sphingosine","analogs &amp; derivatives,complications,drug therapy,pathology,therapeutic use,virology","D002561 Q000150 NN,D020804 Q000150 NN,D001921 Q000821 NN,D013110 Q000031 NY,D001921 Q000473 NN,D007166 Q000627 NY,D002561 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D020804 Q000188 NY,D002561 Q000821 NN","107969,107970,5280335",NULL,Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.,NULL,Neurology,"John N Ratchford, Kathleen Costello, Daniel S Reich, Peter A Calabresi"," Departments of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jratchf1@jhmi.edu",2012 Nov;79(19):2002-4,10.1212/wnl.0b013e3182735d00
23035074,20121106,article,mesh,"Adult,Anti-Inflammatory Agents,Brain,Fingolimod Hydrochloride,Herpes Zoster,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Methylprednisolone,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,complications,drug effects,drug therapy,etiology,pathology,therapeutic use,virology","D009103 Q000209 YN,D013110 Q000009 NN,D009103 Q000821 YN,D001921 Q000821 NN,D001921 Q000187 NN,D013110 Q000031 NY,D001921 Q000473 NN,D006562 Q000150 NY,D008775 Q000627 NN,D007166 Q000009 NY,D009103 Q000188 YN,D011409 Q000009 NY","6741,107969,107970,5280335,24883465",NULL,Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.,NULL,Neurology,"Claus Michael Gross, Annette Baumgartner, Sebastian Rauer, Oliver Stich"," Departments of Neurology, Albert Ludwigs University Freiburg, Germany.",2012 Nov;79(19):2006-7,10.1212/wnl.0b013e3182735d24
23042940,20130401,article,mesh,"Adult,Affective Disorders, Psychotic,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced","D013110 Q000009 NN,D013110 Q000031 NY,D000341 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod exacerbated affective psychosis?,NULL,The Australian and New Zealand journal of psychiatry,"Alyssa Fitzpatrick, Scott R Clark, Rowena Newcombe, Anthony Davis, Bernhard T Baune",NULL,2013 Apr;47(4):399-400,10.1177/0004867412463090
23047163,20121101,article,mesh,"Bradycardia,Drug Monitoring,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macular Edema,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D001919 Q000139 NY,D008269 Q000139 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Gilenya safety update: cardiac and macula.,NULL,Current opinion in ophthalmology,"Alison Huggins, Robert C Sergott",NULL,2012 Nov;23(6):457-9,10.1097/icu.0b013e3283590bda
23073075,20130101,article,mesh,"Animals,Astrocytes,Cell Death,Cells, Cultured,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Mice,Neurons,Neuroprotective Agents,Organophosphates,Propylene Glycols,Rats,Sphingosine","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D009474 Q000187 NY,D008246 Q000494 NN,D016923 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001253 Q000187 NN,D018696 Q000494 NY,D010755 Q000494 NY,D013110 Q000494 NN","107969,107970,5280335,5283560,9908268,11452022,45268446",NULL,Fingolimod protects cultured cortical neurons against excitotoxic death.,"Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes. Its primary mechanism of action is to reduce the egress of T lymphocytes from secondary lymphoid organs, thus restraining neuroinflammation and autoimmunity. However, recent evidence suggests that the action of FTY720 involves S1PRs expressed by cells resident in the CNS, including neurons. Here, we examined the effect of FTY720, its ac",Pharmacological research,"Luisa Di Menna, Gemma Molinaro, Luigi Di Nuzzo, Barbara Riozzi, Cristina Zappulla, Carlo Pozzilli, Renato Turrini, Filippo Caraci, Agata Copani, Giuseppe Battaglia, Ferdinando Nicoletti, Valeria Bruno"," I.R.C.C.S. Neuromed, 86077 Pozzilli (IS), Italy.",2013 Jan;67(1):1-9,10.1016/j.phrs.2012.10.004
23098525,20120101,article,"xref,mesh","4-Nitroquinoline-1-oxide,Animals,Bone Marrow,Carcinogens,Catalase,DNA Adducts,DNA Damage,Glutathione,Glutathione Peroxidase,Glutathione Reductase,Immunoenzyme Techniques,Lipid Peroxidation,Male,Malondialdehyde,Oxidative Stress,Polyphenols,Rats,Rats, Wistar,Superoxide Dismutase,Tea","chemistry,drug effects,metabolism,pathology,pharmacology,toxicity","D008315 Q000378 NN,D015112 Q000633 NY,D001853 Q000473 NN,D005979 Q000378 NN,D018736 Q000187 NN,D018384 Q000187 NN,D002273 Q000633 NY,D004249 Q000187 NY,D013662 Q000737 NY,D005980 Q000378 NN,D015227 Q000187 NY,D059808 Q000494 NY,D005978 Q000378 NN,D013482 Q000378 NN,D002374 Q000378 NN,D001853 Q000187 NY","5955,6830,8252,10964,75389,77341,124886,135398633","128270327,129060975,129192846,129701980,129937807",Green tea polyphenol protection against 4-nitroquinoline 1-oxide-induced bone marrow lipid peroxidation and genotoxicity in Wistar rats.,"4-Nitroquinoline 1-oxide (4-NQO) a potent oral carcinogen, widely used for induction of oral carcinogenesis, has been found to induce lipid peroxidation in vivo and in vitro. Green tea contains a high content of polyphenols, which are potent antioxidants. Thus green tea polyphenols (GTP) might be expected play a protective role against 4-NQO induced lipid peroxidation and bone marrow toxicity. In the present study, a dose of 200 mg of GTP/kg b.wt/day was given orally for a week, simultaneously animals recei",Asian Pacific journal of cancer prevention : APJCP,"Ashok Kumar Pandurangan, Srinivasan Periasamy, Suresh Kumar Anandasadagopan, Sudhandiran Ganapasam, Shyamala Devi Chennam Srinivasalu"," Cell Biology Laboratory, Department of Advanced Biochemistry, University of Madras, Chennai, India.",2012 Jan;13(8):4107-12,NULL
23113536,20130301,article,mesh,"Androgen Receptor Antagonists,Antineoplastic Agents,Cell Line, Tumor,Down-Regulation,Enzyme Inhibitors,Fingolimod Hydrochloride,Free Radical Scavengers,Humans,Isoenzymes,Male,Neoplasm Proteins,Oxidative Stress,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Prostate-Specific Antigen,Prostatic Neoplasms,Protein Processing, Post-Translational,Protein Stability,RNA, Messenger,Receptors, Androgen,Sphingosine,Thiazoles","analogs &amp; derivatives,antagonists &amp; inhibitors,chemistry,drug effects,drug therapy,genetics,metabolism,pharmacology","D017853 Q000378 NN,D015536 Q000187 NY,D011499 Q000187 NN,D009363 Q000378 NN,D011944 Q000378 NY,D000970 Q000494 NN,D007527 Q000378 NN,D059002 Q000494 NN,D017430 Q000378 NN,D004791 Q000737 NN,D007527 Q000037 NN,D055550 Q000187 NN,D017853 Q000037 NY,D013844 Q000494 NY,D059002 Q000737 NN,D009363 Q000037 NN,D013110 Q000031 NN,D018384 Q000187 NY,D000970 Q000037 NN,D012333 Q000378 NN,D016166 Q000494 NN,D004791 Q000494 NY,D011409 Q000494 NN,D011471 Q000188 NY,D011944 Q000235 NN,D013110 Q000494 NN,D013844 Q000037 NN","107969,107970,5280335",NULL,The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.,"BACKGROUND AND PURPOSE: Sphingosine kinase catalyses the formation of sphingosine 1-phosphate and is linked with androgen receptor signalling in prostate cancer cells. Therefore, we investigated the effect of sphingosine kinase inhibitors on androgen receptor expression. EXPERIMENTAL APPROACH: Androgen-sensitive LNCaP cells were treated with SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole), which inhibits sphingosine kinases 1 and 2 activity, and the effect on androgen receptor expression was measured.",British journal of pharmacology,"Francesca Tonelli, Manal Alossaimi, Leon Williamson, Rothwelle J Tate, David G Watson, Edmond Chan, Robert Bittman, Nigel J Pyne, Susan Pyne"," Cell Biology and Pharmaceutical Analysis and Metabolomics Groups, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.",2013 Mar;168(6):1497-505,10.1111/bph.12035
23124563,20120101,article,"xref,mesh","Alkynes,Benzene Derivatives,Catalysis,Fingolimod Hydrochloride,Immunosuppressive Agents,Palladium,Propylene Glycols,Sphingosine,Sulfhydryl Compounds","analogs &amp; derivatives,chemical synthesis,chemistry","D011409 Q000737 NY,D001555 Q000138 NN,D007166 Q000737 NY,D013438 Q000138 NN,D013110 Q000031 NY,D013110 Q000737 NN,D013110 Q000138 NN,D000480 Q000737 NN,D007166 Q000138 NN,D010165 Q000737 NN,D011409 Q000138 NN,D001555 Q000737 NN,D000480 Q000138 NN,D013438 Q000737 NN","23938,107969,107970,5280335,11155873",128394615,Synthesis of a key intermediate for the preparation of FTY720 analogs.,A concise synthesis of a useful intermediate 10 for the preparation of fingolimod (FTY-720) analogs was achieved by utilizing a chemoselective Sonogashira reaction of trihalobenzene 12 with alkyne 13. The reaction proceeded with high selectivity to give alkyne 11 containing the dihalobenzene moiety in good yield. Compound 11 was converted into intermediate 10 by hydrogenation without reduction of the halogen atoms. ,Chemical & pharmaceutical bulletin,"Maiko Hamada, Kunitomo Adachi, Hidemasa Hikawa, Yuusaku Yokoyama"," School of Pharmaceutical Science, Toho University, Funabashi, Chiba 274–8510, Japan. hamada.maiko@mc.mt-pharma.co.jp",2012 Jan;60(11):1395-8,10.1248/cpb.c12-00477
23136726,20120330,review,mesh,"Administration, Oral,Animals,Blood-Brain Barrier,Cardiovascular System,Central Nervous System,Dendritic Cells,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Count,Lysophospholipids,Multiple Sclerosis,Organophosphates,Propylene Glycols,Sphingosine,Th17 Cells,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,pharmacology,physiopathology,therapeutic use","D007166 Q000494 NY,D003713 Q000187 NN,D007166 Q000008 NN,D004681 Q000276 NN,D001812 Q000187 NN,D009103 Q000503 NN,D013110 Q000008 NN,D002319 Q000187 NN,D013110 Q000031 NY,D058504 Q000187 NN,D011409 Q000008 NN,D011409 Q000494 NY,D009103 Q000276 NY,D013110 Q000378 NN,D004681 Q000188 NN,D007166 Q000627 NY,D002490 Q000187 NN,D008246 Q000378 NN,D013110 Q000627 NN,D010755 Q000378 NN,D013110 Q000494 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335,5283560,9908268,11452022,45268446",NULL,[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].,Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system with neurodegenerative chararacteristics. The newly discovered per os administrable drug fingolimod (FTY720) has a different mechanism of action than the current disease-modifying therapies. In vivo the drug binds to four out of the five sphingosine-1-phosphate receptors after phosphorylation. Fingolimod-phosphate (FTY720-P) causes internalization and degradation of the sphingosine-1-phosphate receptors in the membrane of,Ideggyogyaszati szemle,"Lilla Tar, László Vécsei"," Szent-Györgyi Albert Klinikai Központ, Neurológiai Klinika, Altalános Orvostudományi Kar, Szegedi Tudományegyetem és MTA-SZTA Idegtudományi Kutatócsoport, Szeged.",2012 Mar;65(?):83-100,NULL
23145923,20130301,article,"xref,mesh","Animals,Cells, Cultured,Fingolimod Hydrochloride,HEK293 Cells,Humans,Immunosuppressive Agents,Membrane Potentials,Membrane Transport Modulators,Mice,Myocytes, Cardiac,Organophosphates,Phosphorylation,Propylene Glycols,Protein Kinase Inhibitors,Protein-Serine-Threonine Kinases,Recombinant Proteins,Sphingosine,TRPM Cation Channels","analogs &amp; derivatives,antagonists &amp; inhibitors,chemistry,cytology,drug effects,genetics,metabolism,pharmacology","D047428 Q000378 NN,D049990 Q000378 NN,D010755 Q000494 NN,D050053 Q000037 NY,D032383 Q000187 NY,D013110 Q000378 NY,D007166 Q000378 NN,D011994 Q000037 NN,D013110 Q000031 NY,D013110 Q000737 NN,D032383 Q000166 NN,D011409 Q000494 NY,D032383 Q000378 NN,D049990 Q000737 NN,D011994 Q000378 NN,D050053 Q000378 NN,D008564 Q000187 NY,D050053 Q000235 NN,D047428 Q000031 NN,D007166 Q000737 NN,D049990 Q000494 NY,D013110 Q000494 NN,D007166 Q000494 NN,D047428 Q000494 NY","107969,107970,5280335,5282309,6438166,9908268,11452022,45268446","53801018,135650261",Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.,"BACKGROUND AND PURPOSE: Transient receptor potential melastatin 7 (TRPM7) is a unique channel kinase which is crucial for various physiological functions. However, the mechanism by which TRPM7 is gated and modulated is not fully understood. To better understand how modulation of TRPM7 may impact biological processes, we investigated if TRPM7 can be regulated by the phospholipids sphingosine (SPH) and sphingosine-1-phosphate (S1P), two potent bioactive sphingolipids that mediate a variety of physiological fu",British journal of pharmacology,"Xin Qin, Zhichao Yue, Baonan Sun, Wenzhong Yang, Jia Xie, Eric Ni, Yi Feng, Rafat Mahmood, Yanhui Zhang, Lixia Yue"," Calhoun Cardiology Center, Department of Cell Biology, University of Connecticut Health Center, Farmington, CT 06030, USA.",2013 Mar;168(6):1294-312,10.1111/bph.12012
23161460,20130101,article,mesh,"Adult,Disability Evaluation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Middle Aged,Multiple Sclerosis,Propylene Glycols,Recurrence,Sphingosine,Substance Withdrawal Syndrome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,etiology","D013110 Q000008 NN,D013110 Q000031 NY,D013375 Q000209 NY,D013375 Q000188 NN,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.,NULL,Journal of neurology,"A Ghezzi, M A Rocca, D Baroncini, P Annovazzi, M Zaffaroni, G Minonzio, G Comi, M Filippi",NULL,2013 Jan;260(1):327-9,10.1007/s00415-012-6744-7
23168528,20130301,article,mesh,"ATP-Binding Cassette, Sub-Family B, Member 1,Animals,Biological Transport, Active,Blood-Brain Barrier,Capillaries,Endothelial Cells,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, Knockout,Multidrug Resistance-Associated Proteins,Nerve Tissue Proteins,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingolipids,Sphingosine,Spinal Cord,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology,physiology","D001693 Q000502 NN,D042783 Q000378 NN,D027425 Q000235 NN,D002196 Q000378 NN,D014409 Q000378 NN,D014409 Q000235 NN,D049349 Q000235 NN,D001693 Q000187 NN,D020168 Q000378 NY,D013107 Q000378 NY,D013110 Q000031 NY,D001812 Q000378 NY,D013110 Q000378 NN,D008246 Q000378 NY,D020168 Q000235 NN,D013110 Q000235 NN,D013116 Q000378 NY,D013107 Q000235 NN,D011409 Q000494 NN,D015398 Q000502 NY,D009419 Q000378 NY,D015398 Q000187 NN,D027425 Q000378 NY,D013110 Q000494 NN,D049349 Q000037 NN,D007166 Q000494 NN,D009419 Q000235 NN","107969,107970,5280335,5283560",NULL,Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.,"At the blood-brain and blood-spinal cord barriers, P-glycoprotein, an ATP-driven drug efflux pump, is a major obstacle to central nervous system (CNS) pharmacotherapy. Recently, we showed that signaling through tumor necrosis factor-α (TNF-α), sphingolipids, and sphingosine-1-phosphate receptor 1 (S1PR1) rapidly and reversibly reduced basal P-glycoprotein transport activity in the rat blood-brain barrier. The present study extends those findings to the mouse blood-brain and blood-spinal cord barriers and, i",Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,"Tara A Cartwright, Christopher R Campos, Ronald E Cannon, David S Miller"," Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.",2013 Mar;33(3):381-8,10.1038/jcbfm.2012.174
23198673,20121201,review,mesh,"Acetic Acid,Acute Disease,Anti-Bacterial Agents,Bacteria,Benzethonium,Drug Combinations,Humans,Hydrocortisone,Neomycin,Otitis Externa,Polymyxin B,Practice Guidelines as Topic,Propylene Glycols,Pseudomonas aeruginosa,Risk Factors,Staphylococcus aureus,Treatment Outcome","administration &amp; dosage,diagnosis,drug therapy,isolation &amp; purification,microbiology,prevention &amp; control","D010032 Q000175 NN,D010032 Q000382 NY,D000900 Q000008 NY,D019342 Q000008 NN,D011550 Q000302 NY,D009355 Q000008 NY,D001419 Q000302 NN,D001558 Q000008 NN,D011409 Q000008 NN,D010032 Q000188 NY,D006854 Q000008 NY,D013211 Q000302 NY,D010032 Q000517 NN,D011112 Q000008 NY","176,2335,4868,5754,8478,62403,65344,197162,229860,291576,5702091,5702092,5702105,6419968,9833652,24978553,44134844,45073487,45356929,49800004,56842110,71299257,71463900,118855445,123134032,124080932,134692135",NULL,Acute otitis externa: an update.,"Acute otitis externa is a common condition involving inflammation of the ear canal. The acute form is caused primarily by bacterial infection, with Pseudomonas aeruginosa and Staphylococcus aureus the most common pathogens. Acute otitis externa presents with the rapid onset of ear canal inflammation, resulting in otalgia, itching, canal edema, canal erythema, and otorrhea, and often occurs following swimming or minor trauma from inappropriate cleaning. Tenderness with movement of the tragus or pinna is a cl",American family physician,"Paul Schaefer, Reginald F Baugh"," University of Toledo Health Science Campus, MS 1179, 2240 Dowling Hall, 3000 Arlington Ave., Toledo, OH 43614, USA. paul.schaefer@utoledo.edu",2012 Dec;86(11):1055-61,NULL
23203160,20121201,article,mesh,"Adult,Case-Control Studies,Comorbidity,Compassionate Use Trials,Drug Approval,Drug-Related Side Effects and Adverse Reactions,Europe,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis,Prevalence,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,diagnosis,drug therapy,epidemiology,therapeutic use","D007166 Q000627 NN,D064420 Q000453 NY,D013110 Q000031 NY,D009103 Q000453 NY,D009103 Q000175 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D005060 Q000453 NN","107969,107970,5280335",NULL,[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].,"BACKGROUND: In order to meet the needs of therapy of multiple sclerosis (MS) new immune therapies with a user-friendly application and better effectiveness together with good tolerability are necessary. COMPASSIONATE USE: With respect to its potential to improve MS therapy, patients with a high medical need were given access to Fingolimod even before marketing approval. Therefore, a compassionate use program unique in the field of MS was initiated. In total 137 centers participated (75 % outpatient neurolog",Der Nervenarzt,"J Haas, R A Linker, H P Hartung, M Meergans, S Ortler, F Tracik"," Klinik für Neurologie, Jüdisches Krankenhaus, Heinz-Galinski-Str. 1, 13347 Berlin, Deutschland. Judith.Haas@jkb-online.de",2012 Dec;83(12):1575-81,10.1007/s00115-012-3612-8
23209069,20121201,review,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferons,Japan,Multiple Sclerosis,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007372 Q000627 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,[An update on the treatment options for multiple sclerosis].,"The treatment of multiple sclerosis (MS) has been remarkably progressed, especially in disease modifying therapies (DMTs). Recently, fingolimod, a novel oral DMT, was added to treatment options for relapsing-remitting MS (RRMS) in Japan. In Western countries, more kinds of DMTs are available for treatment for RRMS. Further, clinical trials on many drugs including DMTs are on-going, and the arrival of multiple options for MS is promising. This article reviews the recent progress in current therapeutic strate",Brain and nerve = Shinkei kenkyu no shinpo,Masaaki Niino," Department of Clinical Research, Hokkaido Medical Center, Sapporo, Japan.",2012 Dec;64(12):1421-6,NULL
23210668,20140201,article,mesh,"Animals,Chemistry, Pharmaceutical,Dermatitis,Drug Delivery Systems,Glycerides,Inflammation,Mice,Nanoparticles,Oleic Acid,Particle Size,Psoriasis,Skin,Skin Absorption,Tacrolimus","administration &amp; dosage,chemistry,drug therapy,metabolism","D007249 Q000378 NN,D053758 Q000737 NN,D003872 Q000378 NN,D011565 Q000378 NN,D012867 Q000378 NN,D005989 Q000008 NN,D016559 Q000737 NN,D011565 Q000188 NY,D053758 Q000008 NY,D016559 Q000008 NY,D019301 Q000008 NN","965,5372,33022,445639,445643,5282315,5283468,5364833,5460221,6473866,6536850,12178130,20056951,71668407,134694629",NULL,Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation.,"Psoriasis is a chronic relapsing inflammatory skin disorder affecting 2-3% of world population. In present context, a novel topical formulation that could effectively deliver tacrolimus for psoriasis treatment would be of great interest. Liquid crystalline nanoparticle (LCN) is one of the potential drug delivery systems for topical drug delivery. Herein, the effects of tacrolimus-loaded LCNs on in vitro skin permeation and retention as well as on in vivo psoriasis-like skin inflammation are studied. Charact",The Journal of dermatological treatment,"Raj Kumar Thapa, Bong Kyu Yoo"," Yeungnam University, College of Pharmacy , Kyungsan , South Korea.",2014 Feb;25(1):22-5,10.3109/09546634.2012.755250
23211038,20130101,article,mesh,"Antibodies, Monoclonal, Humanized,Cost of Illness,Costs and Cost Analysis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Medication Adherence,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine,Sweden","analogs &amp; derivatives,drug therapy,economics,epidemiology,methods,mortality,therapeutic use","D007166 Q000627 NN,D013548 Q000453 NN,D013110 Q000031 NY,D013110 Q000191 NN,D020529 Q000401 NN,D061067 Q000627 NN,D061067 Q000191 NY,D020529 Q000188 NY,D011409 Q000191 NY,D013110 Q000627 NN,D011409 Q000627 NN,D003365 Q000379 NN,D007166 Q000191 NY","107969,107970,5280335",NULL,Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.,"BACKGROUND: Fingolimod and natalizumab have the same European Union licence for the treatment of relapsing multiple sclerosis, and are considered by the Committee for Medicinal Products for Human Use (CHMP) to have broadly similar efficacy. OBJECTIVE: A cost-minimization analysis was performed to compare differences in treatment costs between fingolimod and natalizumab from a societal perspective in Sweden. METHODS: This analysis included costs associated with initiating and following treatment (physician v",Journal of medical economics,"Niklas Bergvall, Magnus Tambour, Freddie Henriksson, Sten Fredrikson"," Novartis Pharma AG, Basel, Switzerland. niklas.bergvall@novartis.com",2013 Jan;16(3):349-57,10.3111/13696998.2012.755537
23223537,20130108,article,mesh,"Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macula Lutea,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D008266 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?,"In the evaluation of patients with multiple sclerosis (MS), optical coherence tomography (OCT) is gaining traction as a tool to assess thinning of the retinal nerve fiber layer (RNFL) and, more recently, for looking at total macular volume (TMV) thickness, with both measures used as potential biomarkers for progression of disease. In medicine, it is not uncommon for structural changes to be presumed to reflect a certain physiologic process, when in fact, an alternative mechanism is at play. Fingolimod (FTY-",Neurology,"Marc Dinkin, Friedemann Paul",NULL,2013 Jan;80(2):128-9,10.1212/wnl.0b013e31827ccf4a
23223539,20130108,article,mesh,"Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Linear Models,Longitudinal Studies,Macula Lutea,Male,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Retinal Neurons,Sphingosine,Tomography, Optical Coherence","analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,pathology,therapeutic use","D009103 Q000473 NN,D055351 Q000473 NN,D008266 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D049349 Q000037 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Fingolimod treatment in multiple sclerosis leads to increased macular volume.,"OBJECTIVE: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume. METHODS: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingolimod and a matched reference cohort of patients with MS never exposed to the drug. The primary reference cohort wa",Neurology,"Rachel Nolan, Jeffrey M Gelfand, Ari J Green"," Multiple Sclerosis Center, UCSF Department of Neurology, San Francisco, CA, USA.",2013 Jan;80(2):139-44,10.1212/wnl.0b013e31827b9132
23227596,20121001,article,mesh,"Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000627 NN,D013110 Q000031 NN,D061067 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY","107969,107970,5280335",NULL,[New therapies in multiple sclerosis].,"Due to the autoimmune nature of multiple sclerosis (MS), the current disease modifying treatments aim at reducing the immune system activity or at interfering with it. Immune modulators from the interferon Beta and glatiramer acetate families are widely used as first line treatments. They often prove sufficient for moderately active forms of the disease. For more active forms, powerful immunosuppressants such as mitoxantrone or a monoclonal antibody (natalizumab), selective inhibitor of the T cell adhesion ",La Revue du praticien,"Stéphanie Roggerone, Florian Chenevier, Christian Confavreux, Sandra Vukusic"," Service de neurologie A et Fondation EDMUS pour la sclérose en plaques, hôpital neurologique Pierre-Wertheimer, 69677 Bron Cedex, France.",2012 Oct;62(8):1057-60,NULL
23238935,20130215,article,mesh,"Animals,Cytokines,Enteritis,Fingolimod Hydrochloride,Ileus,Inflammation Mediators,Lymphoid Tissue,Male,Mice,Muscle Contraction,Propylene Glycols,Sphingosine,Up-Regulation","analogs &amp; derivatives,etiology,immunology,metabolism,pharmacology,physiology,therapy","D016207 Q000378 NN,D004751 Q000209 NN,D009119 Q000502 NN,D018836 Q000494 NN,D008221 Q000502 NY,D013110 Q000031 NN,D045823 Q000209 NN,D018836 Q000378 NN,D045823 Q000628 NN,D011409 Q000494 NN,D013110 Q000494 NN,D045823 Q000276 NY","107969,107970,5280335",NULL,The role of lymphoid tissue in the attenuation of the postoperative ileus.,"Standardized intestinal manipulation (IM) leads to local bowel wall inflammation subsequently spreading over the entire gastrointestinal tract. Previously, we demonstrated that this so-called gastrointestinal field effect (FE) is immune-mediated. The aim of this study was to investigate the role of secondary lymphoid organs [mesenteric lymph nodes (MLN), gut-associated lymphoid tissue (GALT)] in IM-mediated FE by employing mice with deficient secondary lymphoid organs (aly/aly, MLN ex) or by administration ",American journal of physiology. Gastrointestinal and liver physiology,"A Koscielny, D Engel, J Maurer, S Wehner, C Kurts, J C Kalff"," Department of Surgery, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. Arne.Koscielny@ukb.uni-bonn.de",2013 Feb;304(4):G401-12,10.1152/ajpgi.00161.2012
23253209,20130201,article,mesh,"Administration, Topical,Animals,Apoptosis,Disease Models, Animal,Drug Delivery Systems,Eosinophils,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Mast Cells,Mice,Mice, Inbred Strains,Ovalbumin,Propylene Glycols,Random Allocation,Rhinitis, Allergic,Rhinitis, Allergic, Perennial,Sensitivity and Specificity,Sphingosine,Th2 Cells","analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,physiology,physiopathology","D018418 Q000502 NN,D008407 Q000276 NN,D007166 Q000494 NY,D004804 Q000276 NN,D017209 Q000187 NN,D012221 Q000503 NN,D012221 Q000276 NN,D012221 Q000188 NY,D013110 Q000031 NY,D011409 Q000494 NY,D008246 Q000494 NY,D004804 Q000187 NN,D008407 Q000187 NN,D013110 Q000494 NN,D018418 Q000187 NN,D010047 Q000494 NN","107969,107970,5280335,5283560,5289086",NULL,Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model.,BACKGROUND: Sphingosine-1-phosphate (S1P) plays a crucial role in homeostasis of the immune system by regulating lymphocyte recirculation and inflammatory cell recruitment. The levels of S1P are tightly controlled through regulated production and controlled breakdown by sphingosine-lyase (SL). The S1P analogue FTY720 has been developed as an immunosuppressant in transplantation and tested as a treatment for various inflammatory diseases. FTY720 exploits S1P biology by acting as a S1P1 and S1P 3 agonist and ,Allergy,"A Kleinjan, M van Nimwegen, K Leman, H C Hoogsteden, B N Lambrecht"," Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands. a.kleinjan@erasmusmc.nl",2013 Feb;68(2):204-12,10.1111/all.12082
23261767,20130301,article,mesh,"Analysis of Variance,Animals,Basal Ganglia,Behavior, Animal,Blood Transfusion, Autologous,Brain Edema,CD3 Complex,Cell Count,Cerebral Cortex,Cerebral Hemorrhage,Collagenases,Disease Models, Animal,Fingolimod Hydrochloride,Forelimb,Functional Laterality,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Interferon-gamma,Interleukin-17,Leukocytes,Lymphocytes,Male,Maze Learning,Mice,Nervous System Diseases,Propylene Glycols,Psychomotor Disorders,Rats,Rats, Sprague-Dawley,Space Perception,Sphingosine,Ti","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug effects,drug therapy,etiology,immunology,metabolism,pathology,pharmacology,physiology,physiopathology,prevention &amp; control,therapeutic use,toxicity","D002540 Q000473 NY,D002543 Q000139 NN,D017252 Q000378 NN,D007962 Q000187 NN,D007371 Q000378 NN,D007839 Q000187 NN,D008214 Q000378 NN,D011596 Q000209 NN,D017364 Q000633 NN,D011596 Q000188 NN,D009422 Q000517 NN,D002543 Q000150 NN,D001522 Q000502 NN,D008214 Q000187 NY,D013110 Q000031 NY,D020381 Q000378 NN,D009422 Q000209 NN,D001522 Q000187 NN,D002543 Q000209 NN,D007166 Q000627 NY,D002543 Q000473 NY,D001929 Q000209 NN,D001804 Q000009 NN,D011409 Q000494 NN,D002543 Q000276 NN,D002543 Q000188 NY,D013110 Q000627 NN","107969,107970,5280335",NULL,Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.,"T-lymphocytes promote cerebral inflammation, thus aggravating neuronal injury after stroke. Fingolimod, a sphingosine 1-phosphate receptor analog, prevents the egress of lymphocytes from primary and secondary lymphoid organs. Based on these findings, we hypothesized fingolimod treatment would reduce the number of T-lymphocytes migrating into the brain, thereby ameliorating cerebral inflammation following experimental intracerebral hemorrhage (ICH). We investigated the effects of fingolimod in two well-estab",Experimental neurology,"William B Rolland, Tim Lekic, Paul R Krafft, Yu Hasegawa, Orhan Altay, Richard Hartman, Robert Ostrowski, Anatol Manaenko, Jiping Tang, John H Zhang"," Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, USA.",2013 Mar;241(?):45-55,10.1016/j.expneurol.2012.12.009
23263181,20130131,article,mesh,"Animals,B-Lymphocytes,Cell Adhesion,Cell Movement,Dendritic Cells, Follicular,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Microscopy, Confocal,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,cytology,drug effects,immunology,pharmacology","D002465 Q000187 NN,D020566 Q000276 NN,D001402 Q000187 NN,D002448 Q000276 NN,D020566 Q000166 NN,D013154 Q000166 NY,D013110 Q000031 NN,D002465 Q000276 NN,D013154 Q000276 NN,D001402 Q000276 NN,D001402 Q000166 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335",NULL,Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress.,"The splenic marginal zone is a unique microenvironment where resident immune cells are exposed to the open blood circulation. Even though it has an important role in responses against blood-borne antigens, lymphocyte migration in the marginal zone has not been intravitally visualized due to challenges associated with achieving adequate imaging depth in this abdominal organ. Here we develop a two-photon microscopy procedure to study marginal zone and follicular B-cell movement in the live mouse spleen. We sh",Nature,"Tal I Arnon, Robert M Horton, Irina L Grigorova, Jason G Cyster"," Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, California 94143, USA.",2013 Jan;493(7434):684-8,10.1038/nature11738
23266894,20130501,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Disability Evaluation,Drug Substitution,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine,Time Factors,Young Adult","adverse effects,analogs &amp; derivatives,diagnosis,drug therapy,prevention &amp; control,therapeutic use","D061067 Q000009 NY,D020529 Q000517 NY,D020529 Q000175 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.,"After discontinuation of natalizumab (NAT), multiple sclerosis (MS) disease activity often recurs. We assessed the recurrence of clinical disease activity during the first year after switching from NAT to fingolimod (FTY) in patients with relapsing-remitting MS. The number of relapses and the annualized relapse rate (ARR) before, during and after NAT discontinuation were determined and compared between 26 MS patients who switched to FTY within 24 weeks, and 10 MS patients who remained without disease modify",Journal of neurology,"Joachim Havla, Björn Tackenberg, Kerstin Hellwig, Ingrid Meinl, Markus Krumbholz, Florian Seitz, Christian Eienbröker, Ralf Gold, Reinhard Hohlfeld, Ingo Kleiter, Tania Kümpfel"," Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistr. 15, 81377 Munich, Germany. joachim.havla@med.lmu.de",2013 May;260(5):1382-7,10.1007/s00415-012-6808-8
23273921,20130114,article,mesh,"Animals,Cell Transformation, Neoplastic,Colitis,Colon,Fingolimod Hydrochloride,Gene Deletion,Gene Expression Regulation, Neoplastic,Interleukin-6,Lysophospholipids,Mice,NF-kappa B,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,STAT3 Transcription Factor,Sphingosine,Tumor Microenvironment","analogs &amp; derivatives,complications,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,physiology,therapeutic use","D003092 Q000188 NN,D003092 Q000150 NN,D015850 Q000378 NN,D050796 Q000378 NN,D015972 Q000187 NN,D017853 Q000235 NY,D016328 Q000378 NN,D002471 Q000235 NN,D013110 Q000031 NY,D003106 Q000378 NN,D013110 Q000378 NN,D059016 Q000187 NN,D003106 Q000187 NN,D008246 Q000502 NY,D003106 Q000473 NN,D013110 Q000235 NN,D011409 Q000494 NN,D008246 Q000378 NN,D003092 Q000235 NY,D013110 Q000627 NN,D011409 Q000627 NN,D003092 Q000473 NN,D013110 Q000494 NN,D002471 Q000473 NN,D008246 Q000235 NN,D013110 Q000502 NN","107969,107970,5280335,5283560",NULL,"Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.","Inflammatory bowel disease is an important risk factor for colorectal cancer. We show that sphingosine-1-phosphate (S1P) produced by upregulation of sphingosine kinase 1 (SphK1) links chronic intestinal inflammation to colitis-associated cancer (CAC) and both are exacerbated by deletion of Sphk2. S1P is essential for production of the multifunctional NF-κB-regulated cytokine IL-6, persistent activation of the transcription factor STAT3, and consequent upregulation of the S1P receptor, S1PR1. The prodrug FTY",Cancer cell,"Jie Liang, Masayuki Nagahashi, Eugene Y Kim, Kuzhuvelil B Harikumar, Akimitsu Yamada, Wei-Ching Huang, Nitai C Hait, Jeremy C Allegood, Megan M Price, Dorit Avni, Kazuaki Takabe, Tomasz Kordula, Sheldon Milstien, Sarah Spiegel"," Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.",2013 Jan;23(1):107-20,10.1016/j.ccr.2012.11.013
23281423,20130201,article,mesh,"Age Factors,Antidepressive Agents,Benzofurans,Citalopram,Dose-Response Relationship, Drug,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Indoles,Models, Theoretical,Piperazines,Propylene Glycols,Risk Assessment,Sphingosine,Vilazodone Hydrochloride","administration &amp; dosage,adverse effects,analogs &amp; derivatives","D013110 Q000009 NN,D011409 Q000009 NN,D001572 Q000009 NN,D013110 Q000008 NN,D013110 Q000031 NY,D010879 Q000009 NN,D000928 Q000009 NN,D010879 Q000008 NY,D001572 Q000008 NY,D015283 Q000009 NN,D007211 Q000008 NY,D000928 Q000008 NY,D007166 Q000009 NN,D015283 Q000008 NY,D011409 Q000008 NY,D007211 Q000009 NN,D007166 Q000008 NY","2771,107969,107970,146570,146571,253613,5280335,6918313,6918314",NULL,Is this the dose for you?: the role of modeling.,"To make an informed benefit-risk evaluation of a drug, a range of doses needs to be evaluated and its dose-response and exposure-response relationships for safety and effectiveness assessed during drug development (International Conference on Harmonisation E4). Once a safe and effective population dose (or doses) has been determined for indicated use(s), the individual patient dose can then be adjusted based on patient-specific factors (e.g., age, race, genetics, organ functions, concomitant medications). ",Clinical pharmacology and therapeutics,"S-M Huang, A Bhattaram, N Mehrotra, Y Wang"," Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. shiewmei.huang@fda.hhs.gov",2013 Feb;93(2):159-62,10.1038/clpt.2012.228
23285242,20120101,article,"mesh,assay","Animals,Azetidines,Benzyl Compounds,Bradycardia,Cells, Cultured,Drug Evaluation, Preclinical,Fingolimod Hydrochloride,Humans,Hypertension,Immunosuppressive Agents,Male,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Sphingosine,Substrate Specificity","adverse effects,agonists,analogs &amp; derivatives,chemically induced,classification,pathology,pharmacology","D001384 Q000009 NY,D013110 Q000009 NN,D006973 Q000473 NN,D049349 Q000819 NY,D001384 Q000494 NN,D013110 Q000031 NY,D001919 Q000139 NY,D001593 Q000009 NY,D001919 Q000473 NN,D006973 Q000139 NY,D011409 Q000494 NN,D049349 Q000145 NN,D013110 Q000494 NN,D007166 Q000009 NN,D007166 Q000494 NN,D001593 Q000494 NN,D011409 Q000009 NY","107969,107970,5280335,44599207,46700777",NULL,"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.","Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial) as well as acute bradycardia independent of changes in blood pressure. However, the precise receptor subtypes responsible is controversial, likely dependent upon the cardiovascular response in question (e.g. bradycardia, hypertension), and perhaps even species-dependen",PloS one,"Ryan M Fryer, Akalushi Muthukumarana, Paul C Harrison, Suzanne Nodop Mazurek, Rong Rhonda Chen, Kyle E Harrington, Roger M Dinallo, Joshua C Horan, Lori Patnaude, Louise K Modis, Glenn A Reinhart"," Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America. ryan.fryer@boehringer-ingelheim.com",2012 Jan;7(12):e52985,10.1371/journal.pone.0052985
23289171,20121130,review,mesh,"Atrioventricular Block,Bradycardia,Cardiovascular System,Clinical Trials as Topic,Drug Administration Schedule,Fingolimod Hydrochloride,Heart Conduction System,Humans,Hypertension,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Secondary Prevention,Sphingosine,Treatment Outcome","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy,prevention &amp; control,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D054537 Q000139 NN,D006329 Q000187 NN,D001919 Q000139 NN,D016899 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D049349 Q000187 NN,D002319 Q000187 NY,D006973 Q000139 NN,D009103 Q000517 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].,"Fingolimod is a sphingosine-1 phosphate receptor modulator, which is effective in the treatment of severe relapsing-remitting form of multiple sclerosis. Once daily oral use of fingolimod decreased the annualized relapse rate, inflammatory brain lesion activity and the rate of brain atrophy compared both to placebo and intramuscular administered interferon beta-1a. The drug targets the cardiovascular system as well via sphingosine-1 phosphate receptors. After initiation of fingolimod therapy transient sinus",Ideggyogyaszati szemle,"Gábor Széplaki, Béla Merkely"," Semmelweis Egyetem, Altalános Orvosi Kar, Kardiológiai Központ--Kardiológia Tanszék, Budapest. szeplaki.gabor@kardio.sote.hu",2012 Nov;65(?):369-76,NULL
23289178,20121130,article,mesh,"Cardiovascular System,Clinical Trials, Phase III as Topic,Controlled Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,immunology,pharmacology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D007155 Q000627 NN,D002319 Q000187 NN,D013110 Q000031 NY,D007166 Q000627 NY,D007166 Q000009 NY,D011409 Q000494 NN,D009103 Q000276 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D007166 Q000494 NN,D009103 Q000188 NY","107969,107970,5280335",NULL,"[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].",NULL,Ideggyogyaszati szemle,Sámuel Komoly,NULL,2012 Nov;65(?):421-2,NULL
23307220,20130101,article,mesh,"Administration, Oral,Female,Fingolimod Hydrochloride,Fluorescein Angiography,Humans,Immunosuppressive Agents,Macular Edema,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Retrospective Studies,Sphingosine,Tomography, Optical Coherence,Visual Acuity","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug therapy,physiology,physiopathology","D013110 Q000009 NN,D008269 Q000503 NN,D008269 Q000175 NN,D013110 Q000031 NY,D008269 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NY,D014792 Q000502 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Cystoid macular edema associated with fingolimod use for multiple sclerosis.,NULL,JAMA ophthalmology,"Armin R Afshar, Joshua K Fernandes, Ravi D Patel, Susan M Ksiazek, Veeral S Sheth, Anthony T Reder, Seenu M Hariprasad"," Departments of Ophthalmology and Visual Science, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.",2013 Jan;131(1):103-7,10.1001/jamaophthalmol.2013.570
23311598,20130401,article,mesh,"Administration, Intravaginal,Administration, Intravenous,Animals,Anti-Infective Agents,Cervix Uteri,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,HIV Infections,Immunosuppressive Agents,Interleukin 1 Receptor Antagonist Protein,Interleukin-8,Lymphocyte Count,Macaca nemestrina,Mucous Membrane,Pilot Projects,Placebos,Propylene Glycols,Sphingosine,Vagina,Vaginal Creams, Foams, and Jellies","administration &amp; dosage,adverse effects,analogs &amp; derivatives,analysis,chemistry,drug effects,immunology,prevention &amp; control","D014621 Q000737 NN,D011409 Q000009 NN,D013110 Q000009 NN,D053590 Q000032 NN,D015658 Q000517 NN,D016209 Q000032 NN,D002584 Q000276 NN,D013110 Q000008 NN,D002584 Q000737 NN,D009092 Q000187 NN,D009092 Q000737 NN,D013110 Q000031 NY,D002584 Q000187 NN,D009092 Q000276 NN,D011409 Q000008 NY,D014621 Q000276 NY,D014621 Q000187 NY","107969,107970,5280335,44357137",NULL,Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues.,"BACKGROUND: FTY720 is an immunomodulatory agent that reduces lymphocytes in peripheral tissues and circulation. Such agents may be effective as vaginal microbicides for HIV prevention. Systemic or vaginal application of FTY720 may reduce lymphocyte concentrations in genital tissues, reducing HIV target cell numbers. METHODS: Five female pigtail macaques received topical vaginal gel FTY720 (n = 2), intravenous (i.v.) FTY720 (n = 2), or placebo gel (n = 1) in this pilot study. Circulating and mucosal lymphocy",Journal of medical primatology,"Ai Tsuiki, Wei Luo, Tara Henning, Sundaram Vishwanathan, Chuong Dinh, Debra Adams, Elizabeth Sweeney, James Mitchell, Shannon Bachman, Prachi Sharma, Nathaniel Powell, Michael Hendry, Janet McNicholl, Ellen Kersh"," Division of Scientific Resources, NCEZID, CDC, Atlanta, GA 30333, USA.",2013 Apr;42(2):89-100,10.1111/jmp.12033
23322501,20130801,article,mesh,"Adult,Aged,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphopenia,Multiple Sclerosis, Relapsing-Remitting,Neutropenia,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,blood,chemically induced,drug therapy","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000008 NN,D009503 Q000139 NY,D008231 Q000139 NY,D013110 Q000031 NY,D020529 Q000097 NN,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Masami Tanaka, Kwiyoung Park, Keiko Tanaka",NULL,2013 Aug;19(9):1244-5,10.1177/1352458512472750
23336398,20130801,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Drug Substitution,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon-beta,JC Virus,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Observation,Propylene Glycols,Sphingosine,Treatment Outcome,Young Adult","analogs &amp; derivatives,diagnosis,drug therapy,immunology,therapeutic use","D061067 Q000627 NY,D020529 Q000175 NN,D013110 Q000031 NY,D016899 Q000276 NN,D007166 Q000627 NY,D020529 Q000188 NY,D007577 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Switching from natalizumab to fingolimod: an observational study.,"BACKGROUND: Multiple sclerosis patients who discontinue using natalizumab are at risk of a rebound in disease activity. However, the optimal alternative therapy is not currently known. AIMS OF THE STUDY: We report on clinical and MRI data and patient safety in a group of relapsing-remitting multiple sclerosis patients who tested seropositive for the JC virus and who have switched from natalizumab to fingolimod because of concerns regarding PML risks. METHODS: The test for JC virus antibodies was performed i",Acta neurologica Scandinavica,"A P Sempere, P Martín-Medina, L Berenguer-Ruiz, N Pérez-Carmona, R Sanchez-Perez, J Polache-Vengud, E Feliu-Rey"," Neurology Department, Hospital General Universitario de Alicante, Alicante, Spain. aperezs@mac.com",2013 Aug;128(2):e6-e10,10.1111/ane.12082
23410536,20130301,article,mesh,"Adolescent,Adult,Clinical Trials, Phase III as Topic,Disease Progression,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Longitudinal Studies,Male,Middle Aged,Models, Statistical,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Young Adult","analogs &amp; derivatives,drug therapy,methods,pathology,therapeutic use","D020529 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D017326 Q000379 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D008137 Q000379 NY","107969,107970,5280335",NULL,Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.,"This article reports an analysis that aims to quantify the effect of fingolimod, an oral treatment for relapsing remitting multiple sclerosis (MS), on disability progression. The standard approach utilizes survival analysis methods, which may be problematic for MS studies that assess disability at only a few time points and include as a cardinal feature both relapses and remissions. Instead, a Markov transition model, originally developed in the framework of longitudinal data, is fit, and its special probab",Biometrics,"Micha Mandel, Francois Mercier, Benjamin Eckert, Peter Chin, Rebecca A Betensky"," Department of Statistics, The Hebrew University of Jerusalem, Jerusalem, Israel. msmic@huji.ac.il",2013 Mar;69(1):225-34,10.1111/biom.12002
23428909,20130701,article,mesh,"Animals,Bone Marrow Cells,Bone Marrow Transplantation,Busulfan,Cell Count,Fingolimod Hydrochloride,Graft Survival,Green Fluorescent Proteins,HLA-B27 Antigen,Heart Transplantation,Immunosuppressive Agents,Leukocytes,Myeloablative Agonists,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Transgenic,Skin Transplantation,Sphingosine,T-Lymphocytes, Regulatory,Transplantation Chimera,Transplantation Conditioning","administration &amp; dosage,analogs &amp; derivatives,cytology,genetics,immunology","D049452 Q000235 NN,D007166 Q000008 NN,D015796 Q000235 NN,D013110 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D019653 Q000008 NN,D002066 Q000008 NN,D050378 Q000276 NN,D001854 Q000166 NN,D007962 Q000166 NN","2478,107969,107970,5280335",NULL,Non-myeloablative conditioning is sufficient to induce mixed chimerism and subsequent acceptance of donor specific cardiac and skin grafts.,"Organ transplant recipients have elevated cancer and viral infection risks due to immunosuppression and long-term results of organ transplantation remain unsatisfactory, mainly because of chronic rejection. The purpose of the current study is to establish a nonmyeloablative perioperative regimen, able to induce mixed chimerism and tolerance of allografts. To establish a nonmyeloablative perioperative regimen, we used Busulfan, an important component of many bone marrow transplantation preparative regimens f",International immunopharmacology,"Chi Liu, Ping Zhu, Taro Saito, Yoshitaka Isaka, Yukitoshi Nagahara, Jian Zhuang, Xiao-Kang Li"," National Research Institute for Child Health and Development, Tokyo, Japan.",2013 Jul;16(3):392-8,10.1016/j.intimp.2013.02.003
23434284,20130501,article,mesh,"Case-Control Studies,Chemotaxis,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Depletion,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocyte Subsets","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,immunology,pathology,pharmacology","D016176 Q000276 NY,D049349 Q000037 NY,D002633 Q000187 NN,D020529 Q000188 NN,D002633 Q000276 NY,D020529 Q000473 NN,D016176 Q000187 NN,D013110 Q000031 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D020529 Q000276 NN","107969,107970,5280335",NULL,Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade.,NULL,The Journal of allergy and clinical immunology,"Matthias Mehling, Volker Brinkmann, Anne-Valerie Burgener, Patrick Gubser, Andrew D Luster, Ludwig Kappos, Christoph Hess",NULL,2013 May;131(5):?,10.1016/j.jaci.2012.12.1520
23436932,20130401,article,"xref,mesh","Animals,Bone Marrow,Cell Movement,Cytokines,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Killer Cells, Natural,Leukocyte Count,Mice,Monocytes,Neutrophils,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Sphingosine,Spleen","analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology","D049349 Q000378 NY,D004681 Q000276 NN,D013154 Q000187 NN,D004681 Q000378 NN,D007694 Q000378 NN,D016207 Q000096 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002465 Q000276 NN,D001853 Q000378 NN,D009000 Q000187 NY,D009000 Q000276 NN,D009504 Q000378 NN,D013154 Q000378 NN,D009000 Q000378 NY,D013110 Q000494 NN,D001853 Q000187 NN","107969,107970,5280335,11432307",318164808,Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.,"Sphingosine-1-phosphate (S1P) receptors are critical for lymphocyte egress from secondary lymphoid organs, and S1P receptor modulators suppress lymphocyte circulation. However, the role of S1P receptors on monocytes is less clear. To elucidate this, we systematically evaluated monocytes in rats and mice, both in naive and inflammatory conditions, with S1P receptor modulators FTY720 and BAF312. We demonstrate that S1P receptor modulators reduce circulating monocytes in a similar time course as lymphocytes. F","Journal of immunology (Baltimore, Md. : 1950)","Nuruddeen D Lewis, Sokol A Haxhinasto, Shawn M Anderson, Dimitria E Stefanopoulos, Steven E Fogal, Prathima Adusumalli, Sudha N Desai, Lori A Patnaude, Susan M Lukas, Kelli R Ryan, Anthony J Slavin, Maryanne L Brown, Louise K Modis"," Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877, USA.",2013 Apr;190(7):3533-40,10.4049/jimmunol.1201810
23468130,20130601,article,mesh,"Animals,Ceramides,Fingolimod Hydrochloride,Immunosuppressive Agents,Light,Neuroprotective Agents,Propylene Glycols,Rats,Rats, Sprague-Dawley,Retina,Retinal Degeneration,Sphingosine","adverse effects,analogs &amp; derivatives,biosynthesis,drug therapy,metabolism,pathology,pharmacology","D012162 Q000378 NN,D012162 Q000473 NN,D012160 Q000473 NN,D002518 Q000096 NY,D013110 Q000031 NY,D011409 Q000494 NY,D012160 Q000378 NY,D018696 Q000494 NY,D012162 Q000188 NY,D008027 Q000009 NY,D013110 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335",NULL,Inhibition of de novo ceramide biosynthesis by FTY720 protects rat retina from light-induced degeneration.,"Light-induced retinal degeneration (LIRD) in albino rats causes apoptotic photoreceptor cell death. Ceramide is a second messenger for apoptosis. We tested whether increases in ceramide mediate photoreceptor apoptosis in LIRD and if inhibition of ceramide synthesis protects the retina. Sprague-Dawley rats were exposed to 2,700 lux white light for 6 h, and the retinal levels of ceramide and its intermediary metabolites were measured by GC-MS or electrospray ionization tandem mass spectrometry. Enzymes of the",Journal of lipid research,"Hui Chen, Julie-Thu A Tran, Annette Eckerd, Tuan-Phat Huynh, Michael H Elliott, Richard S Brush, Nawajes A Mandal"," Department of Ophthalmology and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.",2013 Jun;54(6):1616-29,10.1194/jlr.m035048
23498820,20130301,article,mesh,"Acute Disease,Animals,Bronchiolitis Obliterans,Chronic Disease,Drug Administration Schedule,Fingolimod Hydrochloride,Graft Rejection,Immunosuppressive Agents,Lung,Lung Transplantation,Lymphocytes,Male,Propylene Glycols,Rats,Rats, Inbred F344,Rats, Inbred WKY,Sclerosis,Sphingosine,Time Factors,Vascular Diseases","administration &amp; dosage,adverse effects,analogs &amp; derivatives,blood supply,drug effects,immunology,pathology,prevention &amp; control","D014652 Q000276 NN,D001989 Q000473 NN,D008168 Q000276 NN,D008168 Q000473 NN,D014652 Q000473 NN,D013110 Q000008 NN,D016040 Q000009 NN,D013110 Q000031 NY,D001989 Q000517 NY,D006084 Q000473 NN,D008214 Q000276 NN,D008168 Q000098 NN,D014652 Q000517 NY,D006084 Q000276 NN,D001989 Q000276 NN,D008214 Q000187 NN,D011409 Q000008 NY,D007166 Q000008 NY,D006084 Q000517 NY,D008168 Q000187 NY,D016040 Q000276 NY","107969,107970,5280335",NULL,Early administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation.,"BACKGROUND: Chronic rejection (CR) in terms of bronchiolitis obliterans (BO) and vascular sclerosis (VS) still represents the major obstacle for pulmonary graft survival in the medium and long term course after lung transplantation (LTX). Aside from nonspecific stimuli, early acute rejection (AR) seems to be causative especially in cases of a late diagnosis or inadequate treatment. This study investigated the effects of FTY720, a new immunosuppressant that promotes lymphocyte sequestration into lymph nodes ",Transplantation proceedings,"S W Hirt, M von Suesskind-Schwendi, T Puehler, C Schmid, K Lehle"," Department of Cardiothoracic Surgery, University Medical Center, Regensburg, Germany.",2013 Mar;45(2):783-6,10.1016/j.transproceed.2012.03.066
23508350,20130601,article,mesh,"Animals,Bone Marrow Transplantation,Cytokines,Enzyme-Linked Immunosorbent Assay,Female,Fingolimod Hydrochloride,Flow Cytometry,Graft vs Host Disease,Immunohistochemistry,Immunosuppressive Agents,Male,Mice,PTEN Phosphohydrolase,Propylene Glycols,Reverse Transcriptase Polymerase Chain Reaction,Scleroderma, Localized,Skin,Sphingosine,Spleen","analogs &amp; derivatives,drug therapy,immunology,metabolism,pathology,therapeutic use","D006086 Q000276 NN,D016026 Q000276 NY,D006086 Q000473 NN,D006086 Q000188 NY,D013154 Q000276 NY,D013110 Q000031 NY,D051059 Q000378 NY,D012867 Q000473 NN,D007166 Q000627 NY,D016207 Q000378 NY,D012594 Q000276 NN,D012867 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NY,D012594 Q000188 NY,D012594 Q000473 NN","107969,107970,5280335",NULL,FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.,"OBJECTIVE: Sphingosine 1-phosphate (S1P) exerts a variety of activities in immune, inflammatory, and vascular systems. S1P plays an important role in systemic sclerosis (SSc) pathogenesis. Regulation of S1P in fibrotic diseases as well as in SSc was recently reported. FTY720, an oral S1P receptor modulator, has been shown to be a useful agent for the prevention of transplant rejection and autoimmune diseases. Murine sclerodermatous chronic graft-versus-host disease (GVHD) is a model for human sclerodermatou",Arthritis and rheumatism,"Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito Hamaguchi, Minoru Hasegawa, Kazuhiko Takehara, Manabu Fujimoto"," Kanazawa University, Kanazawa, Japan.",2013 Jun;65(6):1624-35,10.1002/art.37933
23509960,20130101,article,mesh,"Astrocytes,Cells, Cultured,Drug Administration Schedule,Fetus,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,MAP Kinase Signaling System,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug effects,immunology,metabolism,physiology,prevention &amp; control","D001253 Q000276 NN,D007249 Q000378 NN,D020935 Q000502 NY,D013110 Q000008 NN,D007249 Q000517 NN,D013110 Q000031 NY,D020935 Q000187 NY,D001253 Q000187 NY,D007249 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY,D001253 Q000378 NY","107969,107970,5280335",NULL,Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.,"BACKGROUND: FTY720 (fingolimod, Gilenya) is a daily oral therapy for multiple sclerosis that readily accesses the central nervous system (CNS). FTY720 is a structural analog to the sphingolipid sphingosine-1-phosphate (S1P) and is a cognate ligand for the S1P G-protein coupled receptors (S1PR). Studies in experimental autoimmune encephalomyelitis using mice with conditionally deleted S1P1R from astrocytes indicate that one beneficial effect of FTY720 in this model is via downregulating external receptors, w",Journal of neuroinflammation,"Celina Wu, Soo Y Leong, Craig S Moore, Qiao Ling Cui, Pavel Gris, Louis-Philippe Bernier, Trina A Johnson, Philippe Séguéla, Timothy E Kennedy, Amit Bar-Or, Jack P Antel"," Montreal Neurological Institute, McGill University, 3801 University St., Montreal QC H3A 2B4, Canada.",2013 Jan;10(?):41,10.1186/1742-2094-10-41
23514115,20130601,article,mesh,"Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon beta-1b,Interferon-beta,Middle East,Multiple Sclerosis,Myelitis,Natalizumab,Optic Nerve Diseases,Optic Neuritis,Propylene Glycols,Sphingosine,Spinal Cord Diseases","analogs &amp; derivatives,diagnosis,therapeutic use,therapy","D013118 Q000175 NN,D009103 Q000175 NY,D016899 Q000627 NN,D013110 Q000031 NN,D009901 Q000175 NN,D009103 Q000628 NY,D009187 Q000175 NN,D007166 Q000627 NY,D061067 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D009902 Q000175 NN","107969,107970,5280335",NULL,Consensus guidelines for the diagnosis and treatment of multiple sclerosis.,"The diagnosis of multiple sclerosis (MS) is dependent on the presence of clinical and paraclinical evidence demonstrating dissemination of central nervous system lesions in both space and time, as well as the exclusion of other disorders. Diagnostic criteria were originally promulgated in 1965 by the Schumacher committee and modified subsequently by the Poser committee to include paraclinical evidence. The most recent criteria are the 2010 modifications of the 2001 McDonald criteria, which are focused on ma",Current medical research and opinion,"B Yamout, R Alroughani, M Al-Jumah, S Khoury, N Abouzeid, M Dahdaleh, I Alsharoqi, J Inshasi, S Hashem, M Zakaria, K ElKallab, T Alsaadi, T Tawfeek, S Bohlega"," American University of Beirut Medical Center, Beirut, Lebanon. yamoutba@gmail.com",2013 Jun;29(6):611-21,10.1185/03007995.2013.787979
23518370,20130515,review,mesh,"Animals,Central Nervous System,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,metabolism,pharmacology,therapeutic use","D007166 Q000494 NY,D049349 Q000378 NY,D007166 Q000627 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002490 Q000187 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D009103 Q000188 NN,D002490 Q000378 NY","107969,107970,5280335",NULL,Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.,"Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod phosphate (fingolimod-P), acts as a sphingosine 1-phosphate (S1P) receptor modulator, binding with high affinity to four of the five known S1P receptors (S1P1, S1P3, S1P4 and S1P5). The mechanism of action of fingolimod in MS has primarily been considered as immunomodulatory, whereby fingolimod-P modulates S1P1 on lymphocytes, selecti",Journal of the neurological sciences,"Aran Groves, Yasuyuki Kihara, Jerold Chun"," The Scripps Research Institute, Molecular and Cellular Neuroscience Department, Dorris Neuroscience Center, 10550 N. Torrey Pines Rd, DNC-118, La Jolla, CA 92037, USA. agroves@scripps.edu",2013 May;328(?):9-18,10.1016/j.jns.2013.02.011
23519973,20130801,article,mesh,"Brain,CD4-Positive T-Lymphocytes,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, CCR7,Sphingosine,Young Adult","analogs &amp; derivatives,cerebrospinal fluid,drug therapy,immunology,pathology,therapeutic use","D020529 Q000188 NN,D013110 Q000031 NY,D001921 Q000473 NN,D015496 Q000276 NY,D007166 Q000627 NY,D054400 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D020529 Q000276 NN,D020529 Q000134 NY","107969,107970,5280335",NULL,Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.,"Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor, and it traps lymphocytes in secondary lymphoid organs and precludes their migration into the central nervous system. We report the case of a patient who suffered a relatively severe relapse of multiple sclerosis (MS) during the initial 3 months of fingolimod therapy, with retention of CCR7 expression on CD4(+) T cells in the cerebrospinal fluid (CSF) despite decreased numbers of lymphocytes and decreased expression of CCR7 o","Multiple sclerosis (Houndmills, Basingstoke, England)","Akiko Yokoseki, Etsuji Saji, Musashi Arakawa, Mariko Hokari, Takanobu Ishiguro, Fumihiro Yanagimura, Tomohiko Ishihara, Kouichirou Okamoto, Masatoyo Nishizawa, Izumi Kawachi"," Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.",2013 Aug;19(9):1230-3,10.1177/1352458513481395
23520898,20130101,review,mesh,"Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Practice Guidelines as Topic,Propylene Glycols,Sphingosine","analogs &amp; derivatives,diagnosis,drug therapy,therapeutic use","D010455 Q000627 NN,D016899 Q000627 NN,D020529 Q000175 NY,D007155 Q000627 NY,D013110 Q000031 NN,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NN","65370,107969,107970,3081884,5280335",NULL,[Update on current care guidelines: multiple sclerosis].,"Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. Patients with clinically isolated syndrome and at high-risk for RRMS are followed by magnetic resonance imaging to confirm the diagnosis of RRMS as early as possible. Interferon-beta and glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, fingolimod or na",Duodecim; laaketieteellinen aikakauskirja,NULL,NULL,2013 Jan;129(5):548-9,NULL
23528596,20130101,article,mesh,"Brain,Cytokines,Drug Therapy, Combination,Fingolimod Hydrochloride,Follow-Up Studies,Glatiramer Acetate,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Multiple Sclerosis,Peptides,Propylene Glycols,Secondary Prevention,Sphingosine,Time Factors,Treatment Outcome","analogs &amp; derivatives,blood,diagnosis,drug therapy,pathology,therapeutic use","D016899 Q000627 NY,D007166 Q000627 NN,D007155 Q000627 NN,D009103 Q000097 NN,D016207 Q000097 NY,D013110 Q000031 NY,D001921 Q000473 NN,D009103 Q000175 NN,D010455 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","65370,107969,107970,3081884,5280335",NULL,[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].,"The working experience of the Moscow oblast center for multiple sclerosis is analyzed. Along with standard methods of treatment efficacy evaluation, a cytokines (tumor necrosis factor alpha, gamma-interferon, interleukins 10 and 17) measurement, a morphological study of CD4 and CD8 lymphocytes with cell microelectrophoresis, a complex of morphometric and optic cell parameters using laser computed phase-interference microscopy and cell optic coherent tomography of the eye's retina are used. Preliminary resul",Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,"T I Iakushina, V Iu Lizhdvoĭ, I A Vasilenko, O M Andriukhina, S V Kotov",NULL,2013 Jan;113(?):61-5,NULL
23528598,20130101,article,mesh,"Administration, Oral,Adult,Blood Pressure,Electrocardiography,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Male,Monitoring, Physiologic,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Secondary Prevention,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,methods,physiopathology,therapeutic use","D007166 Q000008 NN,D007166 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D020529 Q000503 NN,D008991 Q000379 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].,"We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG and daily arterial pressure monitoring) during the treatment with the first dose of the drug are presented. No clinically significant disturbances of functions in patients without cardiovascular diseases were noted. In these cases, no progression of disease was identified. Relapses were not observed in 82% of patients. ",Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,"S V Kotov, S I Fedorova, T I Iakushina, V Iu Lizhdvoĭ",NULL,2013 Jan;113(?):74-8,NULL
23531349,20130701,article,mesh,"Adolescent,Adult,Double-Blind Method,Female,Fingolimod Hydrochloride,Fluorescein Angiography,Humans,Immunosuppressive Agents,Macular Edema,Male,Middle Aged,Multiple Sclerosis,Ophthalmoscopy,Propylene Glycols,Sphingosine,Tomography, Optical Coherence,Treatment Outcome,Uveitis,Visual Acuity,Young Adult","adverse effects,analogs &amp; derivatives,chemically induced,complications,diagnosis,drug therapy,physiology,physiopathology,therapeutic use","D014605 Q000150 NN,D013110 Q000009 NN,D007166 Q000627 NN,D008269 Q000503 NN,D008269 Q000175 NN,D013110 Q000031 NY,D008269 Q000139 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D014792 Q000502 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.,"PURPOSE: To report outcomes of ophthalmic evaluations in clinical studies of patients receiving fingolimod (Gilenya; Novartis Pharma AG, Basel, Switzerland) for multiple sclerosis (MS). DESIGN: Analysis done on pooled safety data (N = 2615, all studies group) from 3 double-masked, randomized, parallel-group clinical trials (phase 2 core and extension >5 years, and phase 3 FREEDOMS and TRANSFORMS core and extension studies). PARTICIPANTS: Patients aged 18 to 55 years (18-60 years in phase 2 study) diagnosed ",Ophthalmology,"Marco A Zarbin, Lee M Jampol, Rama D Jager, Anthony T Reder, Gordon Francis, William Collins, Dejun Tang, Xiaoli Zhang"," Institute of Ophthalmology & Visual Science, New Jersey Medical School, Newark, New Jersey 07103, USA. zarbin@earthlink.net",2013 Jul;120(7):1432-9,10.1016/j.ophtha.2012.12.040
23538612,20130501,article,mesh,"Administration, Topical,Aged,Anti-Inflammatory Agents, Non-Steroidal,Dexamethasone,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Fluorescein Angiography,Glucocorticoids,Humans,Immunosuppressive Agents,Intraocular Pressure,Ketorolac Tromethamine,Macular Edema,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Tomography, Optical Coherence,Treatment Outcome,Visual Acuity","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug therapy,therapeutic use","D013110 Q000009 NN,D020911 Q000627 NY,D005938 Q000627 NN,D008269 Q000188 NY,D008269 Q000175 NN,D013110 Q000031 NY,D000894 Q000627 NN,D003907 Q000627 NY,D020529 Q000188 NY,D008269 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","5743,84003,107969,107970,5280335",NULL,Management of fingolimod-associated macular edema.,NULL,JAMA ophthalmology,"Jeanie Chui, Geoffrey K Herkes, Andrew Chang",NULL,2013 May;131(5):694-6,10.1001/jamaophthalmol.2013.47
23541049,20130701,review,mesh,"Animals,Bradycardia,Cognition Disorders,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Patents as Topic,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","adverse effects,agonists,analogs &amp; derivatives,chemically induced,drug therapy,pharmacology,physiopathology","D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D020529 Q000188 NN,D049349 Q000819 NY,D001919 Q000139 NN,D003072 Q000188 NN,D020529 Q000503 NN,D013110 Q000031 NN,D003072 Q000503 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000009 NN","107969,107970,5280335",NULL,Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).,"INTRODUCTION: The sphingosine-1-phosphate (S1P)-driven signaling regulates fundamental biological functions, including cell proliferation, angiogenesis, endothelial cell chemotaxis, immune cell trafficking and mitogenesis. A large body of research has been focusing on the development of immunosuppressive S1P1 receptor (S1P1-R) agonist molecules. The S1P(1,3-5)-R pan-agonist fingolimod (FTY720) has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis. However, FTY720 is now co",Expert opinion on therapeutic patents,"Edward Roberts, Miguel Guerrero, Mariangela Urbano, Hugh Rosen"," The Scripps Research Institute, Department of Chemistry, 10550 N. Torrey Pines Rd, La Jolla, CA 92037, USA. eroberts@scripps.edu",2013 Jul;23(7):817-41,10.1517/13543776.2013.783022
23567658,20130101,article,mesh,"Adenosine,Algorithms,Animals,Fingolimod Hydrochloride,Immunosuppressive Agents,In Vitro Techniques,Ischemic Postconditioning,Lysophospholipids,Male,Mice,Mice, Inbred C57BL,Mice, Knockout,Perfusion,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Reperfusion Injury,Sphingosine","analogs &amp; derivatives,genetics,metabolism,methods,pharmacology","D007166 Q000494 NY,D017853 Q000235 NY,D057775 Q000379 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D008246 Q000378 NY,D017853 Q000378 NY,D013110 Q000494 NN,D000241 Q000378 NN","60961,107969,107970,5280335,5283560",NULL,FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.,BACKGROUND: We investigated the hypothesis that postconditioning by FTY720 (FTY) in isolated perfused mouse hearts is independent of the sphingosine 1-phosphate (S1P) pathway. MATERIAL AND METHODS: Ex vivo hearts were exposed to postconditioning (POST) by either ischemia or FTY720. Protection against ischemia/reperfusion (IR) injury was measured by recovery of left ventricular developed pressure (LVDP) and infarct size. RESULTS: FTY effectively postconditioned (POST) ex vivo hearts against ischemia/reperfus,Medical science monitor basic research,"Donald A Vessey, Luyi Li, Isabella Imhof, Norman Honbo, Joel S Karliner"," Liver Study Unit, Veterans Affairs Medical Center, San Francisco, CA, USA. donald.vessey@va.gov",2013 Jan;19(?):126-32,10.12659/msmbr.883877
23592281,20130601,article,mesh,"Adenine,Antineoplastic Agents,Autophagy,Cell Count,Cell Death,Cell Line, Tumor,Cisplatin,Drug Antagonism,Drug Resistance, Neoplasm,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Ovarian Neoplasms,Propylene Glycols,RNA, Small Interfering,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,genetics,pathology,pharmacology","D000970 Q000494 NN,D001343 Q000187 NY,D000225 Q000031 NN,D001343 Q000235 NN,D010051 Q000188 NY,D016923 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D010051 Q000473 NN,D002945 Q000494 NY,D019008 Q000187 NN,D016923 Q000235 NN,D013110 Q000494 NN,D000225 Q000494 NN,D007166 Q000494 NN,D045744 Q000187 NN","190,1673,84691,107969,107970,441203,5280335",NULL,Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.,"Combination therapy with different anticancer drugs has been proven to be an effective strategy for the treatment of various types of cancers, including ovarian cancer. We have previously reported that FTY720 exhibited potent cytotoxic effects in ovarian cancer cells through the necrotic pathway, which differs from the killing effect of cisplatin (CDDP). In the present study, we report that the combination of FTY720 with CDDP yields an unexpected antagonistic effect towards the cytotoxicity of CDDP in a var",International journal of oncology,"Ning Zhang, Lan Dai, Yanfei Qi, Wen Di, Pu Xia"," Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.",2013 Jun;42(6):2053-9,10.3892/ijo.2013.1906
23599188,20130601,article,mesh,"Administration, Oral,Female,Fingolimod Hydrochloride,Fluorescein Angiography,Glucocorticoids,Humans,Immunosuppressive Agents,Injections, Intraocular,Macular Edema,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Tomography, Optical Coherence,Treatment Outcome,Triamcinolone","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug therapy","D013110 Q000009 NN,D007166 Q000008 NN,D014221 Q000008 NY,D013110 Q000008 NN,D008269 Q000188 NY,D008269 Q000175 NN,D013110 Q000031 NY,D005938 Q000008 NY,D011409 Q000008 NN,D020529 Q000188 NY,D008269 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","31307,107969,107970,5280335",NULL,Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.,NULL,JAMA ophthalmology,"Ashley Minuk, Michel J Belliveau, David R P Almeida, Stephen J Dorrepaal, Jeffrey S Gale",NULL,2013 Jun;131(6):802-4,10.1001/jamaophthalmol.2013.2465
23609767,20130601,article,"xref,mesh","Animals,Disease Models, Animal,Female,Fingolimod Hydrochloride,Freund's Adjuvant,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Myelin-Oligodendrocyte Glycoprotein,Neuritis, Autoimmune, Experimental,Optic Nerve,Peptide Fragments,Pertussis Toxin,Propylene Glycols,Sphingosine,Statistics, Nonparametric,Visual Acuity","analogs &amp; derivatives,diagnosis,drug effects,drug therapy,etiology,immunology,pathology,therapeutic use,toxicity","D005620 Q000633 NN,D010446 Q000276 NN,D009444 Q000188 NY,D009900 Q000473 NN,D009444 Q000175 NN,D013110 Q000031 NY,D014792 Q000187 NN,D063308 Q000276 NN,D007166 Q000627 NY,D037342 Q000633 NN,D009444 Q000473 NN,D009444 Q000209 NN,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335,126963437",175427125,Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod.,"PURPOSE: Fingolimod is an immunomodulating agent that has been approved for the treatment of multiple sclerosis. Fingolimod-phosphate is an antagonist of sphingosine-1-phosphate receptor and known to act by preventing infiltration of autoreactive lymphocytes into the central nervous system. In this study, we investigated whether fingolimod prevents experimental autoimmune optic neuritis (EAON). METHODS: EAON was induced by immunizing C57BL/6 mice with myelin oligodendrocyte glycoprotein-derived peptide 35-5",Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,"Xiaoming An, Takeshi Kezuka, Yoshihiko Usui, Yoshimichi Matsunaga, Ryusaku Matsuda, Naoyuki Yamakawa, Hiroshi Goto"," Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.",2013 Jun;33(2):143-8,10.1097/wno.0b013e31828ea2fc
23629851,20131201,article,mesh,"Acrylates,Adipose Tissue,Biocompatible Materials,Bone and Bones,Cell Death,Compressive Strength,DNA,Humans,Materials Testing,Mesenchymal Stromal Cells,Microscopy, Electron, Scanning,Nanocomposites,Polymerization,Propylene Glycols,Tissue Scaffolds,Wound Healing,X-Ray Microtomography","chemistry,cytology,drug effects,metabolism,pathology,pharmacology,toxicity","D019245 Q000187 NN,D054457 Q000737 NN,D059630 Q000187 NN,D001672 Q000494 NY,D053761 Q000633 NN,D004247 Q000378 NN,D001672 Q000633 NN,D014945 Q000187 NY,D001672 Q000737 NN,D016923 Q000187 NN,D011409 Q000737 NN,D000273 Q000166 NN,D011409 Q000494 NY,D053761 Q000737 NY,D059630 Q000378 NN,D059630 Q000166 NN,D000179 Q000633 NN,D000179 Q000737 NN,D000179 Q000494 NY,D001842 Q000473 NY,D011409 Q000633 NN,D001842 Q000187 NN","19042,27423,25019176,44135672",NULL,Thiol-acrylate nanocomposite foams for critical size bone defect repair: A novel biomaterial.,"Bone tissue engineering approaches using polymer/ceramic composites show promise as effective biocompatible, absorbable, and osteoinductive materials. A novel class of in situ polymerizing thiol-acrylate based copolymers synthesized via an amine-catalyzed Michael addition was studied for its potential to be used in bone defect repair. Both pentaerythritol triacrylate-co-trimethylolpropane tris(3-mercaptopropionate) (PETA-co-TMPTMP) and PETA-co-TMPTMP with hydroxyapatite (HA) composites were fabricated in so",Journal of biomedical materials research. Part A,"Leah Garber, Cong Chen, Kameron V Kilchrist, Christopher Bounds, John A Pojman, Daniel Hayes"," Department of Chemistry, Louisiana State University, 232 Choppin Hall, Louisiana 70803.",2013 Dec;101(12):3531-41,10.1002/jbm.a.34651
23632946,20130801,article,mesh,"Adult,Aging,Analysis of Variance,Brain,Data Interpretation, Statistical,Female,Fingolimod Hydrochloride,Humans,Image Processing, Computer-Assisted,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Recurrence,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,pathology,physiology,physiopathology,therapeutic use","D016899 Q000627 NY,D007166 Q000008 NN,D016899 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D020529 Q000503 NN,D001921 Q000473 NN,D000375 Q000502 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.,"In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing-remitting multiple sclerosis (RRMS). This study analyzed fingolimod efficacy compared with IFNβ-1a in patient subgroups from TRANSFORMS. Patients were randomized to receive fingolimod or weekly IM IFNβ-1a for 12 months. Analyses of efficacy included annualized relapse rate (ARR), and magnetic resonance imaging (MRI) measures [gadolinium (Gd)-enhancing T1 lesion",Journal of neurology,"Jeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, Guillermo Izquierdo, Bhupendra Khatri, Xavier Montalban, Jean Pelletier, Benjamin Eckert, Dieter A Häring, Gordon Francis"," Mellen Center U-10, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. cohenj@ccf.org",2013 Aug;260(8):2023-32,10.1007/s00415-013-6932-0
23640687,20130601,review,mesh,"Adrenergic beta-Antagonists,Antineoplastic Agents,Fingolimod Hydrochloride,Humans,Hypolipidemic Agents,Immunosuppressive Agents,Interferons,Macular Edema,Niacin,Ophthalmic Solutions,Propylene Glycols,Sphingosine,Tamoxifen,Taxoids,Thiazolidinediones,Timolol","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis","D011409 Q000009 NN,D013110 Q000009 NN,D007372 Q000009 NY,D045162 Q000009 NY,D000960 Q000009 NN,D009525 Q000009 NN,D043823 Q000009 NN,D013629 Q000009 NN,D008269 Q000175 NN,D000319 Q000009 NY,D013110 Q000031 NN,D000970 Q000009 NY,D013999 Q000009 NN,D008269 Q000139 NY,D007166 Q000009 NN,D009883 Q000009 NY","937,938,33624,62932,62933,71558,107969,107970,2733525,2733526,5280335,5281056,23686395",NULL,Drug-induced macular edema.,"Macular edema constitutes a serious pathologic entity of ophthalmology resulting in vision loss with a remarkable impact on the quality of life of patients. It is the final common pathway of various systemic diseases and underlying intraocular conditions, with diabetes mellitus being the most frequent cause. Other causes include venous occlusive disease, intraocular surgery, and inflammatory conditions of the posterior segment of the eye. Macular edema is a recognized side effect of various systemic and loc",Drugs,"Olga E Makri, Ilias Georgalas, Constantine D Georgakopoulos"," Department of Ophthalmology, Medical School, University of Patras, Rio, 26504 Patras, Greece.",2013 Jun;73(8):789-802,10.1007/s40265-013-0055-x
23645219,20130601,article,mesh,"Age of Onset,Brain,Child,Cyclophosphamide,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Plasma Exchange,Propylene Glycols,Sphingosine,Young Adult","adverse effects,analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D013110 Q000009 NN,D013110 Q000031 NY,D001921 Q000473 NN,D020529 Q000188 NY,D007166 Q000009 NY,D003520 Q000627 NN,D011409 Q000009 NY","2907,22420,107969,107970,5280335",NULL,Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.,NULL,Journal of neurology,"E Piscolla, B Hakiki, L Pastò, L Razzolini, E Portaccio, M P Amato",NULL,2013 Jun;260(6):1675-7,10.1007/s00415-013-6933-z
23647445,20130701,article,mesh,"Canada,Drug Tolerance,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Patient-Centered Care,Propylene Glycols,Quality of Life,Sphingosine,Standard of Care,Treatment Outcome,United States","analogs &amp; derivatives,drug therapy,physiopathology,therapeutic use","D013110 Q000031 NY,D020529 Q000503 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,"Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.","OBJECTIVE: The study to Evaluate Patient OutComes, Safety, and Tolerability of Fingolimod (EPOC; NCT01216072) aimed to test the hypothesis that therapy change to oral Gilenya (Novartis AG, Stein, Switzerland) (fingolimod) improves patient-reported outcomes compared with standard-of-care disease-modifying therapy (DMT) in patients with relapsing multiple sclerosis; safety and tolerability were also assessed. This communication describes the study rationale and design. METHODS: EPOC is a phase 4, open-label, ",Journal of medical economics,"Mark Cascione, Daniel Wynn, Luigi M Barbato, Linda Pestreich, Lesley Schofield, Kevin McCague"," Tampa Neurology Associates, South Tampa Multiple Sclerosis Center, Tampa, FL 33609, USA. me@markcascione.com",2013 Jul;16(7):859-65,10.3111/13696998.2013.802239
23649711,20130101,article,mesh,"CD8-Positive T-Lymphocytes,Cytokines,Fingolimod Hydrochloride,Humans,Immunophenotyping,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes, Regulatory","analogs &amp; derivatives,biosynthesis,blood,drug effects,drug therapy,immunology,therapeutic use","D016176 Q000187 NY,D018414 Q000276 NN,D016207 Q000096 NN,D013110 Q000031 NY,D020529 Q000097 NN,D007166 Q000627 NY,D018414 Q000187 NY,D050378 Q000187 NY,D050378 Q000276 NN,D020529 Q000188 NY,D013110 Q000627 NN,D016176 Q000276 NN,D011409 Q000627 NY,D020529 Q000276 NN","107969,107970,5280335",NULL,Fingolimod modulates peripheral effector and regulatory T cells in MS patients.,"Multiple sclerosis (MS) is a complex neurological disease where, in genetically predisposed individuals, the unbalanced interplay between pathogenic and regulatory T cells will result in the progression of the autoimmune assault to neural antigens. Fingolimod (FTY720), an oral sphingosine 1-phosphate modulator recently approved for the treatment of MS, inhibits the egress of T cells from lymph nodes acting specifically on naïve and memory T cells and sparing effector T cells. Here we characterized IL-17 and",Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,"Laura D Serpero, Gilberto Filaci, Alessia Parodi, Florinda Battaglia, Francesca Kalli, Davide Brogi, Giovanni Luigi Mancardi, Antonio Uccelli, Daniela Fenoglio"," Center of Excellence for Biomedical Research, University of Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy.",2013 Jan;8(5):1106-13,10.1007/s11481-013-9465-5
23663713,20130501,article,mesh,"Adult,Betamethasone,Biopsy,Dermatomycoses,Desonide,Diagnostic Errors,Herpes Genitalis,Humans,Immunosuppressive Agents,Male,Penile Diseases,Propylene Glycol,Psoriasis,Recurrence","administration &amp; dosage,analogs &amp; derivatives,diagnosis,pathology,therapeutic use","D006558 Q000175 NN,D007166 Q000008 NN,D007166 Q000627 NN,D003881 Q000175 NN,D011565 Q000473 NN,D010409 Q000473 NN,D010409 Q000175 NY,D011565 Q000175 NY,D019946 Q000008 NN,D003898 Q000627 NN,D001623 Q000627 NN,D001623 Q000008 NN,D001623 Q000031 NN","1030,9782,21800,146364,546807,5311066,6708733,45356876,134460917",NULL,[Pustular psoriasis localized to the genital region].,NULL,Annales de dermatologie et de venereologie,"J-N Dauendorffer, M Bagot, H Bachelez, B Cavelier-Balloy",NULL,2013 May;140(5):386-7,10.1016/j.annder.2013.02.017
23668548,20140601,article,mesh,"Administration, Inhalation,Adult,Aerosols,Aged,Cyclosporine,Drug Administration Schedule,Drug Monitoring,Humans,Immunosuppressive Agents,Lung,Lung Transplantation,Middle Aged,Nebulizers and Vaporizers,Ohio,Pennsylvania,Radionuclide Imaging,Radiopharmaceuticals,Technetium Tc 99m Pentetate,Treatment Outcome","administration &amp; dosage,blood,diagnostic imaging,metabolism,pharmacokinetics,physiopathology,surgery","D007166 Q000097 NN,D008168 Q000000981 NN,D007166 Q000493 NY,D016572 Q000493 NY,D008168 Q000503 NN,D008168 Q000378 NY,D008168 Q000601 NY,D016572 Q000008 NY,D016572 Q000097 NN,D007166 Q000008 NY","2909,62280,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,56840886,71306795,71463825,73415750,73896891,122172945,123134263,123134270,132274082",NULL,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients.,BACKGROUND: Inhaled cyclosporine (CsA) is being investigated as a prophylaxis for lung transplant rejection. Lung deposition and systemic exposure of nebulized CsA in lung transplant patients was evaluated as part of the Phase 3 cyclosporine inhalation solution (CIS) trial (CYCLIST). METHODS: Ten patients received 300 mg of CIS (62.5 mg/mL CsA in propylene glycol) admixed with 148 MBq of Tc-DTPA (technetium-99m bound to diethylenetriaminepentaacetic acid) administered using a Sidestream(®) disposable jet ne,Journal of aerosol medicine and pulmonary drug delivery,"T E Corcoran, R Niven, W Verret, S Dilly, B A Johnson"," 1 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh , Pittsburgh, PA 15213.",2014 Jun;27(3):178-84,10.1089/jamp.2013.1042
23674616,20130801,article,mesh,"Alkaline Phosphatase,Amino Alcohols,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Isoenzymes,Kidney,Propylene Glycols,Proteomics,Pyrroles,Sphingosine","analogs &amp; derivatives,enzymology,isolation &amp; purification,metabolism,methods","D007166 Q000378 NN,D007527 Q000378 NN,D000469 Q000378 NN,D000469 Q000302 NY,D040901 Q000379 NY,D011758 Q000378 NN,D013110 Q000378 NN,D007527 Q000302 NN,D013110 Q000031 NN,D000605 Q000378 NN,D011409 Q000378 NN,D007668 Q000201 NY","107969,107970,5280335,11371290",NULL,Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling.,"Molecular identification of endogenous enzymes and biologically active substances from complex biological sources remains a challenging task, and although traditional biochemical purification is sometimes regarded as outdated, it remains one of the most powerful methodologies for this purpose. While biochemical purification usually requires large amounts of starting material and many separation steps, we developed an advanced method named ""proteomic correlation profiling"" in our previous study. In proteomic",Molecular & cellular proteomics : MCP,"Hidetaka Sakurai, Kazuishi Kubota, Shin-Ichi Inaba, Kaoru Takanaka, Akira Shinagawa"," Discovery Science and Technology Department, Daiichi Sankyo RD Novare Co., Ltd., 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan.",2013 Aug;12(8):2313-23,10.1074/mcp.m112.023853
23688261,20130611,article,mesh,"1-Propanol,Apurinic Acid,DNA Adducts,DNA Glycosylases,DNA Repair,Ethanol,Ethylene Glycol,Glycerol,Glycosides,Humans,Hydrolysis,Kinetics,Methanol,Propylene Glycols",chemistry,"D006027 Q000737 NN,D018736 Q000737 NY,D045647 Q000737 NY,D011409 Q000737 NN,D001080 Q000737 NY,D000433 Q000737 NN,D000432 Q000737 NN,D005990 Q000737 NN,D019855 Q000737 NN,D000431 Q000737 NN","174,702,753,887,1031,10942334",NULL,DNA-N-glycosylases process novel O-glycosidic sites in DNA.,"After the hydrolysis of the N-glycosyl bond between a damaged base and C1' of a deoxyribosyl moiety of DNA, human alkyladenine DNA glycosylase (AAG) and Escherichia coli 3-methyladenine DNA glycosylase II (AlkA) bind tightly to their abasic DNA products, potentially protecting these reactive species. Here we show that both AAG and AlkA catalyze reactions between bound abasic DNA and small, primary alcohols to form novel DNA-O-glycosides. The synthesis reactions are reversible, as the DNA-O-glycosides are co",Biochemistry,"Suzanne J Admiraal, Patrick J O'Brien"," Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109-0600, USA.",2013 Jun;52(23):4066-74,10.1021/bi400218j
23695445,20131001,article,mesh,"Brain,Humans,Immunosuppressive Agents,Male,Neuromyelitis Optica,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,pathology","D001921 Q000473 NY,D013110 Q000031 NY,D009471 Q000473 NY,D009471 Q000188 NY,D007166 Q000009 NY,D011409 Q000009 NY",5280335,NULL,Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","D Ferraro, L Federzoni, F Vitetta, Am Simone, A Cossarizza, Pf Nichelli, P Sola"," Department of Neurosciences, University of Modena and Reggio Emilia, Italy.",2013 Oct;19(11):1550,10.1177/1352458513490549
23700335,20130709,article,mesh,"Adult,Aged,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Herpes Zoster,Herpesvirus 3, Human,Herpesvirus 4, Human,Humans,Immunosuppressive Agents,Interferon-beta,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Saliva,Sphingosine,T-Lymphocytes,Virus Activation","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,pharmacology,therapeutic use,virology","D013110 Q000009 NN,D007166 Q000008 NN,D009103 Q000821 NY,D013601 Q000276 NN,D014775 Q000187 NN,D014645 Q000187 NN,D006562 Q000276 NN,D016899 Q000627 NN,D013110 Q000008 NN,D006562 Q000473 NY,D006562 Q000821 NN,D014775 Q000276 NN,D013110 Q000031 NY,D011409 Q000008 NN,D009103 Q000276 NY,D004854 Q000276 NN,D014645 Q000276 NY,D007166 Q000009 NY,D012463 Q000821 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013601 Q000821 NY,D007166 Q000494 NN,D009103 Q000188 NN,D013601 Q000187 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,T-cell response against varicella-zoster virus in fingolimod-treated MS patients.,"OBJECTIVE: To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy. METHODS: The VZV-specific immune response was studied using interferon (IFN)-γ enzyme-linked immunosorbent spot assay, proliferation assays, and upregulation of T-cell activation markers in patients before (n = 38) and after 3 months of fingolimod therapy (n = 34), in untreated (n = 33) and IFN-β-treated (n = 25) patients with multiple sclerosis, and in healt",Neurology,"Meret E Ricklin, Johannes Lorscheider, Anne Waschbisch, Cecile Paroz, Satish K Mehta, Duane L Pierson, Jens Kuhle, Bettina Fischer-Barnicol, Till Sprenger, Raija L P Lindberg, Ludwig Kappos, Tobias Derfuss"," Clinical Neuroimmunology, Department of Biomedicine, University of Basel, Switzerland.",2013 Jul;81(2):174-81,10.1212/wnl.0b013e31829a3311
23704073,20130901,article,mesh,"Animals,Cell Death,Child,Child, Preschool,Drug Synergism,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Infant,Male,Mice,Mice, Nude,Neuroblastoma,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Signal Transduction,Sphingolipids,Sphingosine,Topoisomerase I Inhibitors,Topotecan,Xenograft Model Antitumor Assays","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,metabolism,pharmacology","D017853 Q000378 NN,D007166 Q000494 YN,D009447 Q000378 NN,D007166 Q000819 YN,D013107 Q000378 NY,D009447 Q000188 NY,D013110 Q000031 NY,D059004 Q000494 YN,D059004 Q000819 YN,D011409 Q000819 YN,D019772 Q000819 YN,D011409 Q000494 YN,D019772 Q000494 YN,D017853 Q000037 NN,D013110 Q000494 NN,D013110 Q000819 NN,D015398 Q000187 NY","60699,60700,107969,107970,5280335,11972519",NULL,FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.,"BACKGROUND: Neuroblastoma (NB) is the most common extra-cranial solid tumor in childhood. Poor outcomes for children with advanced disease underscore the need for novel therapeutic strategies. FTY720, an immunomodulating drug approved for multiple sclerosis, has been investigated in oncology with promising preclinical activities. To date, its effect in NB has not been explored. Herein we describe our preclinical experience with FTY720, alone or in combination with topotecan, and its putative mechanism of ac",Pediatric blood & cancer,"Mei-Hong Li, Timothy Hla, Fernando Ferrer"," University of Connecticut Health Center, Center for Vascular Biology, Farmington, Connecticut, USA.",2013 Sep;60(9):1418-23,10.1002/pbc.24564
23709211,20130201,review,mesh,"Central Nervous System,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,metabolism,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D013110 Q000378 NN,D007166 Q000627 NY,D008246 Q000378 NY,D002490 Q000187 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335,5283560",NULL,Fingolimod therapy for multiple sclerosis.,"Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous system. The clinical trials that led to the approval of fingolimod demonstrated benefit on relapses, disability pro",Seminars in neurology,"Mary A Willis, Jeffrey A Cohen"," Neurological Institute, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA. cohenj@ccf.org",2013 Feb;33(1):37-44,10.1055/s-0033-1343794
23722322,20130801,article,mesh,"Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,drug therapy","D061067 Q000008 NY,D013110 Q000008 NN,D013110 Q000031 NY,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Reduction of the washout time between natalizumab and fingolimod.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Jérôme de Seze, Jean-Claude Ongagna, Nicolas Collongues, Christophe Zaenker, Sylvie Courtois, Marie Fleury, Aurélien Benoilid, Jean-Baptiste Chanson, Frédéric Blanc, Alsacep Network",NULL,2013 Aug;19(9):1248,10.1177/1352458513490551
23724710,20121108,article,mesh,"Antineoplastic Agents,Awards and Prizes,Drug Approval,Drug Discovery,Drug Industry,Fingolimod Hydrochloride,Germany,Humans,Immunosuppressive Agents,Indoles,Organizational Innovation,Propylene Glycols,Sphingosine,Sulfonamides",analogs &amp; derivatives,D013110 Q000031 NY,"107969,107970,5280335,42611257",NULL,[Galenus von Pergamon Prize 2012. Excellent research and innovation].,NULL,MMW Fortschritte der Medizin,Peter Leiner,NULL,2012 Nov;?(?):22,10.1007/s15006-012-1391-6
23725360,20130401,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Comparative Effectiveness Research,Cost-Benefit Analysis,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,JC Virus,Markov Chains,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Propylene Glycols,Quality-Adjusted Life Years,Recurrence,Sphingosine","analogs &amp; derivatives,drug therapy,isolation &amp; purification,prevention &amp; control,therapeutic use,virology","D010455 Q000627 NN,D061067 Q000627 NY,D020529 Q000517 NY,D007577 Q000302 NY,D013110 Q000031 NN,D007166 Q000627 NY,D020529 Q000188 NY,D020529 Q000821 NN,D013110 Q000627 NN,D011409 Q000627 NN","65370,107969,107970,3081884,5280335",NULL,Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.,"OBJECTIVES: To estimate the long-term comparative effectiveness of first-line treatment in patients negative for anti-JC virus (JCV) antibodies with glatiramer acetate (GA), fingolimod, or natalizumab for relapsing-remitting multiple sclerosis (RRMS). STUDY DESIGN: We developed a simulation model to estimate the average 20-year clinical risks and benefits of GA, fingolimod, and natalizumab for RRMS patients initially negative for anti-JCV antibodies. METHODS: Model inputs included published natural history ",The American journal of managed care,"Jonathan D Campbell, R Brett McQueen, Agusto Miravalle, John R Corboy, Timothy L Vollmer, Kavita Nair"," Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO 80045, USA. Jon.Campbell@ucdenver.edu",2013 Apr;19(4):278-85,NULL
23726226,20130801,article,mesh,"Antibodies, Monoclonal,Antigens, CD19,Antigens, CD20,Antigens, Neoplasm,Apoptosis,B-Lymphocytes,Cell Line, Tumor,Drug Delivery Systems,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukemia, Lymphocytic, Chronic, B-Cell,Liposomes,Propylene Glycols,Sphingosine,Tetraspanins","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,immunology,pathology,pharmacology","D018951 Q000276 NN,D017209 Q000187 NY,D008081 Q000276 NY,D013110 Q000008 NN,D059470 Q000276 NY,D001402 Q000187 NN,D013110 Q000031 NY,D015451 Q000188 NY,D000911 Q000276 NY,D000951 Q000276 NY,D015451 Q000473 NN,D001402 Q000473 NN,D015451 Q000276 NN,D001402 Q000276 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D018941 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,453626,5280335",NULL,Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.,"Despite advances in chemo and immunotherapeutic agents for B chronic lymphocytic leukemia (B-CLL), the undesirable adverse side effects due to non-specific cellular uptake remain to be addressed. We identified anti-CD37 monoclonal antibody immunoliposomes (ILs) as vehicles for targeted delivery to B chronic lymphocytic leukemia cells. To achieve maximal benefits for all patients, a new strategy of dual-ligand immunoliposomes (dILs) was developed. A combinatorial antibody microarray technology was adapted to",Biomaterials,"Bo Yu, Yicheng Mao, Yuan Yuan, Chaofang Yue, Xinmei Wang, Xiaokui Mo, David Jarjoura, Michael E Paulaitis, Robert J Lee, John C Byrd, L James Lee, Natarajan Muthusamy"," Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.",2013 Aug;34(26):6185-93,10.1016/j.biomaterials.2013.04.063
23738997,20130601,review,mesh,"Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod for the treatment of relapsing multiple sclerosis.,"Fingolimod 0.5 mg (Gilenya(™), Novartis Pharmaceuticals Corporation, FL, USA) is the first once-daily oral therapy approved for relapsing forms of multiple sclerosis (MS) in the USA and for rapidly evolving severe MS or highly active disease despite IFN-β treatment in Europe. An extensive clinical development program has established fingolimod as an effective therapy that reduces relapses by approximately half compared with placebo or intramuscular IFN-β1a. Over 2 years of postmarketing experience in >63,00",Expert review of neurotherapeutics,Barry A Singer," The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO 63131, USA. bnvsinger@earthlink.net",2013 Jun;13(6):589-602,10.1586/ern.13.52
23745720,20130101,article,mesh,"Animals,Delayed-Action Preparations,Dexamethasone,Drug Evaluation, Preclinical,Hot Temperature,Immunosuppressive Agents,Infusion Pumps, Implantable,Male,Polyethylene Glycols,Propylene Glycols,Rats,Rats, Sprague-Dawley,X-Ray Diffraction","administration &amp; dosage,chemical synthesis,methods","D007166 Q000008 NN,D011409 Q000138 NY,D004353 Q000379 NN,D003907 Q000138 NY,D011409 Q000008 NN,D011092 Q000138 NY,D003692 Q000138 NN,D007166 Q000138 NY,D003907 Q000008 NN,D003692 Q000008 NN,D011092 Q000008 NN",5743,NULL,"PLA/PEG-PPG-PEG/dexamethasone implant prepared by hot-melt extrusion for controlled release of immunosuppressive drug to implantable medical devices, Part 2: in vivo evaluation.","Hot-melt extrusion (HME) plays an important role in preparing implants as local drug delivery systems in pharmaceutical fields. Here, a new PLA/PEG-PPG-PEG/Dexamethasone (PLA/F68/Dex) implant prepared by HME has been developed. Importantly, the implant was successfully achieved to control release of immunosuppressive drug to an implanted device. In particular, this implant has not been reported previously in pharmaceutical fields. FTIR and XRD were adopted to investigate the properties of the samples. The i",Drug delivery,"DeXia Li, Gang Guo, Xin Deng, RangRang Fan, QingFa Guo, Min Fan, Jian Liang, Feng Luo, ZhiYong Qian"," State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.",2013 Jan;20(?):134-42,10.3109/10717544.2013.801049
23753531,20130701,article,mesh,"Animals,Animals, Newborn,Cardiomegaly,Cell Adhesion Molecules,Cells, Cultured,Fibroblasts,Fibrosis,Fingolimod Hydrochloride,Hemodynamics,Immunosuppressive Agents,Male,Mice,Mice, Inbred C57BL,Myocardium,NFATC Transcription Factors,Propylene Glycols,Rats,Rats, Sprague-Dawley,Sphingosine,Ventricular Pressure","analogs &amp; derivatives,cytology,drug effects,drug therapy,pathology,pharmacology,physiology","D015815 Q000502 NY,D007166 Q000494 NY,D009206 Q000473 NY,D006332 Q000188 NY,D013110 Q000031 NY,D011409 Q000494 NY,D005347 Q000166 NN,D006439 Q000187 NN,D050778 Q000187 NY,D015815 Q000187 NY,D013110 Q000494 NN,D050778 Q000502 NY","107969,107970,5280335",NULL,"A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin.","BACKGROUND: Hypertension or aortic stenosis causes pressure overload, which evokes hypertrophic myocardial growth. Sustained cardiac hypertrophy eventually progresses to heart failure. Growing evidence indicates that restraining hypertrophy could be beneficial; here, we discovered that FTY-720, an immunomodulator for treating multiple sclerosis, can reverse existing cardiac hypertrophy/fibrosis. METHODS AND RESULTS: Male C57/Bl6 mice underwent transverse aortic constriction (TAC) for 1 week followed by FTY-",Circulation. Heart failure,"Wei Liu, Min Zi, Hoyee Tsui, Sanjoy K Chowdhury, Leo Zeef, Qing-Jun Meng, Mark Travis, Sukhpal Prehar, Andrew Berry, Neil A Hanley, Ludwig Neyses, Rui-Ping Xiao, Delvac Oceandy, Yunbo Ke, R John Solaro, Elizabeth J Cartwright, Ming Lei, Xin Wang"," University of Manchester, Manchester, United Kingdom.",2013 Jul;6(4):833-44,10.1161/circheartfailure.112.000123
23789924,20140101,review,mesh,"Animals,Cell Proliferation,Disease Models, Animal,Fibrosis,Fingolimod Hydrochloride,Glomerulonephritis,Humans,Inflammation,Kidney Failure, Chronic,Lysophospholipids,Molecular Targeted Therapy,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology,therapy","D005921 Q000628 NN,D017853 Q000235 NN,D007249 Q000628 NY,D007676 Q000628 NY,D049109 Q000187 NN,D013110 Q000031 NY,D013110 Q000378 NN,D013110 Q000037 NN,D008246 Q000037 NN,D008246 Q000378 NY,D049349 Q000187 NN,D005355 Q000628 NN,D017853 Q000378 NY,D011409 Q000494 NN,D017853 Q000037 NN,D013110 Q000494 NN,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases.,"Chronic kidney diseases including glomerulonephritis are often accompanied by acute or chronic inflammation that leads to an increase in extracellular matrix (ECM) production and subsequent glomerulosclerosis. Glomerulonephritis is one of the leading causes for end-stage renal failure with high morbidity and mortality, and there are still only a limited number of drugs for treatment available. In this MiniReview, we discuss the possibility of targeting sphingolipids, specifically the sphingosine kinase 1 (S",Basic & clinical pharmacology & toxicology,"Stephanie Schwalm, Josef Pfeilschifter, Andrea Huwiler"," Pharmazentrum Frankfurt/ZAFES, Klinikum der Goethe-Universität, Frankfurt am Main, Germany; Institute of Pharmacology, University of Bern, Bern, Switzerland.",2014 Jan;114(1):44-9,10.1111/bcpt.12103
23810710,20130915,article,"xref,mesh","Acetaldehyde,Administration, Inhalation,Aldehyde Dehydrogenase,Aldehyde Dehydrogenase, Mitochondrial,Animals,Comet Assay,DNA Damage,Ethyl Ethers,Female,Male,Mice,Mice, Inbred C57BL,Mice, Knockout,Micronucleus Tests,Propylene Glycols,Sex Factors,Toxicity Tests, Subchronic,tert-Butyl Alcohol","blood,genetics,metabolism,pharmacokinetics,toxicity","D000444 Q000378 NY,D005019 Q000493 NN,D005019 Q000633 NY,D000444 Q000235 NN,D020002 Q000097 NN,D005019 Q000097 NN,D011409 Q000097 NN,D000079 Q000097 NN","177,6386,12512",57309686,Subchronic exposure to ethyl tertiary butyl ether resulting in genetic damage in Aldh2 knockout mice.,"Ethyl tertiary butyl ether (ETBE) is biofuel additive recently used in Japan and some other countries. Limited evidence shows that ETBE has low toxicity. Acetaldehyde (AA), however, as one primary metabolite of ETBE, is clearly genotoxic and has been considered to be a potential carcinogen. The aim of this study was to evaluate the effects of ALDH2 gene on ETBE-induced genotoxicity and metabolism of its metabolites after inhalation exposure to ETBE. A group of wild-type (WT) and Aldh2 knockout (KO) C57BL/6 ",Toxicology,"Zuquan Weng, Megumi Suda, Katsumi Ohtani, Nan Mei, Toshihiro Kawamoto, Tamie Nakajima, Rui-Sheng Wang"," Japan National Institute of Occupational Safety and Health, Kawasaki, Japan.",2013 Sep;311(3):107-14,10.1016/j.tox.2013.06.005
23815914,20130601,article,mesh,"1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt,Apoptosis,Autophagy,Cell Line, Tumor,Fingolimod Hydrochloride,Humans,Macrolides,Microtubule-Associated Proteins,Multiple Myeloma,Propylene Glycols,Reactive Oxygen Species,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology","D017209 Q000187 NY,D008869 Q000378 NN,D001343 Q000187 NY,D009101 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D017382 Q000378 NY,D013110 Q000494 NN,D009101 Q000473 NY","2287,9001,72947,107969,107970,5280335,5353429,5385089,5458921,5702538,6436223,21159502,53321987,71668406,90479784,90656913,129012189,131863036,131954761,133126837,133268469,134694634",NULL,[Mechanisms of ROS in U266 cell death induced by FTY720].,"This study was purpose to investigate the role of reactive oxygen species (ROS) in apoptosis and autophagy induced by FTY720 in multiple myeloma cell line U266. U266 cells were treated by different concentrations of FTY720 for 24 h, the apoptotic rates were detected by flow cytometry, and the expression of LC3B was detected by Western blot. The results indicated that apoptosis and autophagy were induced by FTY720 in U266 cells. Autophagy induced by FTY720 could lead to cell death. Bafilomycin A1, the inhibi",Zhongguo shi yan xue ye xue za zhi,"Ying-Chun Li, Zhuo-Gang Liu, Kun Yao, Hui-Han Wang, Rong Hu, Wei Yang, Ai-Jun Liao"," Department of Hematology, China Medical University, Shenyang, Liaoning Province, China.",2013 Jun;21(3):643-6,10.7534/j.issn.1009-2137.2013.03.021
23817558,20131001,article,mesh,"Anemia, Hemolytic, Autoimmune,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Young Adult","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D000744 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Andreas P Lysandropoulos, Fleur Benghiat"," Neurology Service, Erasmus Hospital, Université Libre de Bruxelles, Belgium.",2013 Oct;19(11):1551-2,10.1177/1352458513493035
23827570,20130401,article,mesh,"3-Mercaptopropionic Acid,Acetals,Animals,Biocompatible Materials,Biodegradation, Environmental,Cell Death,Cross-Linking Reagents,Cyclization,Fibroblasts,Gels,Hydrolysis,Light,Magnetic Resonance Spectroscopy,Mice,Microscopy, Fluorescence,Polymerization,Propylene Glycols,Spectroscopy, Fourier Transform Infrared,Temperature,Thermogravimetry","analogs &amp; derivatives,chemical synthesis,chemistry,cytology,drug effects,pharmacology,radiation effects","D000080 Q000494 NN,D001672 Q000737 NY,D003432 Q000737 NN,D006868 Q000187 NN,D001672 Q000138 NY,D015097 Q000031 NN,D058105 Q000528 NY,D005782 Q000737 NN,D011409 Q000737 NN,D005347 Q000166 NN,D015097 Q000737 NN,D000080 Q000737 NY,D005347 Q000187 NN,D000080 Q000138 NY,D005782 Q000138 NY,D001672 Q000494 NN,D003500 Q000528 NN",6514,NULL,Preparation and properties of cyclic acetal based biodegradable gel by thiol-ene photopolymerization.,"Synthetic, hydrolytically degradable biomaterials have been widely developed for biomedical use; however, most of them will form acidic products upon degradation of polymer backbone. In order to address this concern, we proposed to fabricate a biodegradable gel based on the crosslinking of a cyclic acetal monomer with reactable diallyl group and multifunctional thiols by thiol-ene photopolymerization. This gel produces diols and carbonyl end groups upon hydrolytic degradation and could be entirely devoid of","Materials science & engineering. C, Materials for biological applications","Kemin Wang, Jian Lu, Ruixue Yin, Lu Chen, Shuang Du, Yan Jiang, Qiang Yu"," School of Materials Science and Engineering, Changzhou University, Changzhou 213164, PR China. wangkm61@gmail.com",2013 Apr;33(3):1261-6,10.1016/j.msec.2012.12.024
23829238,20130801,article,mesh,"Adult,Anti-Inflammatory Agents,Disability Evaluation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Methylprednisolone,Multiple Sclerosis, Relapsing-Remitting,Pregnancy,Pregnancy Complications,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,complications,drug therapy,physiopathology,therapeutic use","D013110 Q000009 NN,D011248 Q000503 NY,D007166 Q000627 NN,D020529 Q000150 NY,D013110 Q000031 NY,D000893 Q000008 NN,D000893 Q000627 NN,D020529 Q000188 NY,D008775 Q000627 NN,D007166 Q000009 NY,D008775 Q000008 NN,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000009 NY","6741,107969,107970,5280335,24883465",NULL,Rebound of disease activity during pregnancy after withdrawal of fingolimod.,NULL,European journal of neurology,"A P Sempere, L Berenguer-Ruiz, E Feliu-Rey",NULL,2013 Aug;20(8):e109-10,10.1111/ene.12195
23845997,20131201,article,mesh,"Blindness,Female,Fingolimod Hydrochloride,Fluorescein Angiography,Hemorrhage,Humans,Immunosuppressive Agents,Macula Lutea,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Tomography, Optical Coherence","analogs &amp; derivatives,complications,drug therapy,etiology,pathology,therapeutic use","D008266 Q000473 NY,D020529 Q000150 NN,D006470 Q000188 NY,D013110 Q000031 NY,D001766 Q000209 NY,D007166 Q000627 NY,D006470 Q000473 NY,D013110 Q000627 NN,D011409 Q000627 NY,D006470 Q000209 NN","107969,107970,5280335",NULL,Fingolimod therapy and macular hemorrhage.,"A 54-year-old woman with relapsing-remitting multiple sclerosis (MS) developed visual loss in her left eye due to a macular hemorrhage 11 months after starting fingolimod. Visual acuity was 20/80 in the left eye, with a dense retinal hemorrhage involving the fovea with adjacent hard exudate and macular thickening confirmed by spectral domain optical coherence tomography. Three months after stopping fingolimod, vision in the left eye improved to 20/30 with resolution of the macular hemorrhage and exudates. F",Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,"M Tariq Bhatti, S Mitchell Freedman, Tamer H Mahmoud"," Departments of Ophthalmology (MTB, THM) and Medicine (Division of Neurology) (MTB), Duke Eye Center and Duke University Medical Center, Durham, North Carolina; and Raleigh Neurology Associates, PA (SMF), Raleigh, North Carolina.",2013 Dec;33(4):370-2,10.1097/wno.0b013e31829b42e1
23848241,20130801,article,mesh,"Animals,Cell Movement,Chemokine CCL2,Disease Models, Animal,Fibrosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-6,Kidney Tubules,Lymphocytes,Male,Nephrectomy,Nephritis, Interstitial,Propylene Glycols,Rats,Rats, Sprague-Dawley,Renal Insufficiency,Sphingosine,Transforming Growth Factor beta1,Treatment Outcome,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,complications,drug effects,drug therapy,etiology,immunology,metabolism,methods,pathology,pharmacokinetics,pharmacology,physiology","D009395 Q000276 YN,D009395 Q000188 YN,D011409 Q000493 NY,D002465 Q000187 NN,D015850 Q000378 NN,D007684 Q000187 NN,D014409 Q000378 NN,D051437 Q000473 YN,D007684 Q000473 NN,D005355 Q000473 YN,D009395 Q000150 YN,D007684 Q000276 NN,D008214 Q000502 NN,D013110 Q000031 NY,D009392 Q000379 NN,D005355 Q000276 YN,D018932 Q000378 NN,D051437 Q000209 YN,D013110 Q000493 NN,D053773 Q000378 NN,D008214 Q000187 NN,D007166 Q000494 NN,D005355 Q000209 YN,D051437 Q000276 YN","107969,107970,5280335",NULL,FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats.,"Tubulointerstitial fibrosis is a common pathway that leads to kidney failure, and persistent tubulointerstitial inflammation is a key event in the development of tubulointerstitial fibrosis. The new immunosuppressive drug FTY720 modifies lymphocyte migration into injured tissues by sequestering lymphocytes within secondary lymphoid organs. However, its therapeutic effect on tubulointerstitial inflammation and fibrosis had not been well understood. This study was designed to explore the effect of FTY720 on t",Renal failure,"Hai-Feng Ni, Jun-Feng Chen, Ming-Hui Zhang, Ming-Ming Pan, Jian-Dong Zhang, Hong Liu, Ri-Ning Tang, Kun-Ling Ma, Bi-Cheng Liu"," Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China.",2013 Aug;35(7):996-1004,10.3109/0886022x.2013.809006
23851982,20131101,article,mesh,"Antineoplastic Agents,Apoptosis,Apoptosis Regulatory Proteins,BH3 Interacting Domain Death Agonist Protein,Bcl-2-Like Protein 11,Cell Line, Tumor,Drug Resistance, Neoplasm,Fas-Associated Death Domain Protein,Fingolimod Hydrochloride,Gene Expression Regulation, Leukemic,Humans,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Membrane Proteins,Mutation,Primary Cell Culture,Propylene Glycols,Protein Kinase Inhibitors,Proto-Oncogene Proteins,RNA, Small Interfering,Signal Transduction,Sphingosine,bcl-Associated ","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pathology,pharmacology","D019008 Q000235 NN,D000970 Q000494 NY,D053200 Q000378 NN,D051017 Q000037 NN,D011518 Q000235 NY,D008565 Q000378 NN,D017209 Q000187 NN,D051023 Q000037 NN,D011518 Q000378 NN,D008565 Q000037 NN,D011518 Q000037 NN,D051017 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D053200 Q000235 NN,D034741 Q000235 NN,D008565 Q000235 NY,D015464 Q000235 NY,D019008 Q000187 NN,D051023 Q000235 NY,D015464 Q000378 NN,D051023 Q000378 NN,D051017 Q000235 NY,D051025 Q000378 NN,D013110 Q000494 NN,D034741 Q000378 NN,D051025 Q000235 NN","107969,107970,5280335",NULL,FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.,"PP2A activator FTY720 has been shown to possess the anti-leukemic activity for chronic myelogenous leukemia (CML), however, the cell killing mechanism underlying its anti-leukemic activity has remained to be verified. We investigated the precise mechanisms underlying the apoptosis induction by FTY720, especially focusing on the roles of BH3-only proteins, and the therapeutic potency of FTY720 for CML. Enforced expression of either BCL2 or the dominant-negative protein of FADD (FADD.DN) partly protected CML ",Apoptosis : an international journal on programmed cell death,"Miki Kiyota, Junya Kuroda, Mio Yamamoto-Sugitani, Yuji Shimura, Ryuko Nakayama, Hisao Nagoshi, Shinsuke Mizutani, Yoshiaki Chinen, Nana Sasaki, Natsumi Sakamoto, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Masafumi Taniwaki"," Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. junkuro@koto.kpu-m.ac.jp. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. Division of Hematology ",2013 Nov;18(11):1437-1446,10.1007/s10495-013-0882-y
23858414,20130716,article,mesh,"Cerebrovascular Disorders,Encephalitis, Varicella Zoster,Humans,Immunosuppressive Agents,Male,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D002561 Q000188 NY,D011409 Q000627 NY,D020804 Q000188 NY",5280335,NULL,Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.,NULL,Neurology,"Patricia H McNamara, Janice M T Redmond, Colin P Doherty",NULL,2013 Jul;81(3):306,10.1212/01.wnl.0000432547.27815.74
23877798,20130723,article,mesh,"Brain,Female,Humans,Immunosuppressive Agents,Multiple Sclerosis,Nerve Fibers, Myelinated,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D009103 Q000473 NY,D001921 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009413 Q000473 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Re: Tumefactive multiple sclerosis lesions under fingolimod treatment.,NULL,Neurology,"Michael O Kinney, Gavin McDonnell",NULL,2013 Jul;81(4):403,10.1212/wnl.0b013e31829deeb4
23892961,20130101,article,mesh,"Aquaporin 4,Brain,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Middle Aged,Neuromyelitis Optica,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,immunology,pathology","D013110 Q000009 NN,D051401 Q000276 NN,D013110 Q000031 NY,D001921 Q000473 NN,D009471 Q000473 NN,D009471 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment].,"A 49-year-old female neuromyelitis optica spectrum disorder (NMOSD) patient with positive anti-aquaporin 4 (AQP4) antibody was treated with fingolimod (FTY720). Ten days later, she developed acute disturbance of consciousness, aphasia, right hemi-spatial neglect, and right hemiparesis. Brain MRI showed multiple white-matter lesions with slight Gadolinium enhancement. She was diagnosed of acute exacerbation of NMOSD. Thus, fingolimod may be associated with the development of a fulminant course in NMOSD patie",Rinsho shinkeigaku = Clinical neurology,"Shoko Izaki, Shinya Narukawa, Akihiro Kubota, Takao Mitsui, Hikoaki Fukaura, Kyoichi Nomura"," Department of Neurology, Saitama Medical Center.",2013 Jan;53(7):513-7,10.5692/clinicalneurol.53.513
23897641,20140401,article,mesh,"Adult,Electrocardiography,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome,Wolff-Parkinson-White Syndrome","adverse effects,analogs &amp; derivatives,complications,diagnosis,drug effects,drug therapy,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D014927 Q000175 NY,D020529 Q000150 NN,D020529 Q000175 NN,D014927 Q000503 NN,D006339 Q000187 YN,D013110 Q000031 NY,D014927 Q000150 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod in a patient with Wolff-Parkinson-White syndrome.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Anne-Catherine Ml Huys, Patrice H Lalive, Lucka Sekoranja"," Department of Clinical Neurosciences, Division of Neurology, University Hospital of Geneva, Switzerland.",2014 Apr;20(5):636-7,10.1177/1352458513499422
23917669,20130701,article,mesh,"Animals,Antineoplastic Agents,Apoptosis,Blotting, Western,Caspase 3,Cell Line, Tumor,Cell Survival,Drug Screening Assays, Antitumor,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Lung Neoplasms,Male,Melanoma, Experimental,Mice,Mice, Inbred C57BL,Microscopy, Electron, Transmission,Propylene Glycols,Reactive Oxygen Species,Sphingosine,Time Factors","analogs &amp; derivatives,drug effects,drug therapy,methods,pathology,secondary,therapeutic use","D017209 Q000187 NY,D008546 Q000556 NN,D008175 Q000556 NN,D008546 Q000473 NN,D008546 Q000188 NY,D008175 Q000188 NY,D013110 Q000031 NY,D000970 Q000627 NY,D007166 Q000627 NY,D053148 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NY,D004354 Q000379 NN","107969,107970,5280335",NULL,"FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.",OBJECTIVE: Available chemotherapy presents poor control over the development of metastatic melanoma. FTY720 is a compound already approved by the Food and Drug Administration for the treatment of patients with multiple sclerosis. It has also been observed that FTY720 inhibits tumor growth in vivo (experimental models) and in vitro (animal and human tumor cells). The aim of this study was to evaluate the effects of FTY720 on a metastatic melanoma model and in tumor cell lines. METHODS: We analyzed FTY720 eff,"Clinics (Sao Paulo, Brazil)","Felipe V Pereira, Denise C Arruda, Carlos R Figueiredo, Mariana H Massaoka, Alisson L Matsuo, Valquiria Bueno, Elaine G Rodrigues"," Laboratório de Imunobiologia do Câncer, Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina (EPM-UNIFESP), Universidade Federal de São Paulo, São Paulo/SP, Brazil.",2013 Jul;68(7):1018-27,10.6061/clinics/2013(07)21
23926298,20130912,article,mesh,"Animals,Cell Line, Transformed,Cell Line, Tumor,Cells, Cultured,Class Ib Phosphatidylinositol 3-Kinase,Enzyme Activation,Fingolimod Hydrochloride,Humans,Immunoblotting,Immunosuppressive Agents,Janus Kinase 2,Kaplan-Meier Estimate,Leukemia,Mice,Mice, SCID,Mutation,Oncogene Proteins,Propylene Glycols,Protein Kinase C,Protein Phosphatase 2,RNA Interference,Reverse Transcriptase Polymerase Chain Reaction,Signal Transduction,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology","D011493 Q000378 NN,D053614 Q000235 NN,D011493 Q000235 NN,D007938 Q000235 NN,D007938 Q000473 NN,D004789 Q000187 NN,D053614 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D015513 Q000235 NN,D054648 Q000378 NY,D054648 Q000235 NN,D007938 Q000188 NY,D015513 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335",NULL,"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.","FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein phosphatase 2A (PP2A)-activating drug (PAD). PP2A is a tumor suppressor found inactivated in different types of cancer. We show here that PP2A is inactive in polycythemia vera (PV) and other myeloproliferative neoplasms characterized by the expression of the transforming Jak2(V617F) oncogene. PP2A inactivation occurs in a Jak2(V617F) dose/kinase-dependent manner t",Blood,"Joshua J Oaks, Ramasamy Santhanam, Christopher J Walker, Steve Roof, Jason G Harb, Greg Ferenchak, Ann-Kathrin Eisfeld, James R Van Brocklyn, Roger Briesewitz, Sahar A Saddoughi, Kyosuke Nagata, Robert Bittman, Michael A Caligiuri, Omar Abdel-Wahab, Ross Levine, Ralph B Arlinghaus, Alfonso Quintas-Cardama, John M Goldman, Jane Apperley, Alistair Reid, Dragana Milojkovic, Mark T Ziolo, Guido Marcucci, Besim Ogretmen, Paolo Neviani, Danilo Perrotti"," Human Cancer Genetics Program, Department of Molecular Virology Immunology and Medical Genetics.",2013 Sep;122(11):1923-34,10.1182/blood-2013-03-492181
23936150,20130101,article,mesh,"Aldehyde-Lyases,Animals,Astrocytes,Cerebral Cortex,Convalescence,Fingolimod Hydrochloride,Gene Expression,Gliosis,Immunosuppressive Agents,Intracranial Thrombosis,Male,Mice,Mice, Inbred C57BL,Post-Synaptic Density,Propylene Glycols,Recovery of Function,Reverse Transcriptase Polymerase Chain Reaction,Sphingosine,Stroke,Time Factors,Treatment Outcome,Vascular Endothelial Growth Factor A","analogs &amp; derivatives,complications,drug effects,etiology,genetics,metabolism,pathology,pharmacology,physiopathology,prevention &amp; control","D005911 Q000503 NN,D002540 Q000187 NN,D015870 Q000187 NN,D020521 Q000517 NY,D020521 Q000209 NN,D020767 Q000150 NN,D020127 Q000187 NY,D007166 Q000378 NN,D042461 Q000235 NN,D057907 Q000187 NN,D042461 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D000446 Q000235 NN,D002540 Q000378 NN,D005911 Q000517 NY,D001253 Q000473 NN,D020521 Q000503 NN,D000446 Q000378 NN,D013110 Q000494 NN,D011409 Q000378 NN,D007166 Q000494 NN,D002540 Q000503 NN","107969,107970,5280335",NULL,FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke.,"BACKGROUND: The Sphingosine-1-phosphate (S1P) signaling pathway is known to influence pathophysiological processes within the brain and the synthetic S1P analog FTY720 has been shown to provide neuroprotection in experimental models of acute stroke. However, the effects of a manipulation of S1P signaling at later time points after experimental stroke have not yet been investigated. We examined whether a relatively late initiation of a FTY720 treatment has a positive effect on long-term neurological outcome ",PloS one,"Robert Brunkhorst, Nathalie Kanaan, Alexander Koch, Nerea Ferreirós, Ana Mirceska, Pia Zeiner, Michel Mittelbronn, Amin Derouiche, Helmuth Steinmetz, Christian Foerch, Josef Pfeilschifter, Waltraud Pfeilschifter"," Department of Neurology, Goethe University Hospital, Frankfurt am Main, Germany. robert.brunkhorst@kgu.de",2013 Jan;8(7):e70124,10.1371/journal.pone.0070124
23945874,20131001,review,mesh,"Anilides,Antineoplastic Agents,Binding Sites,Crystallography, X-Ray,Databases, Chemical,Drug Design,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Ligands,Propylene Glycols,Protein Binding,Pyridines,Receptors, G-Protein-Coupled,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,chemical synthesis,chemistry,pharmacology","D043562 Q000819 NY,D011725 Q000737 NN,D000970 Q000494 NN,D011409 Q000737 NN,D000970 Q000138 NN,D013110 Q000737 NN,D013110 Q000138 NN,D013110 Q000031 NN,D007166 Q000138 NN,D000970 Q000737 NN,D000813 Q000737 NN,D000813 Q000138 NN,D011409 Q000138 NN,D007166 Q000737 NN,D011409 Q000494 NN,D013110 Q000494 NN,D043562 Q000737 NN,D007166 Q000494 NN,D043562 Q000037 NY,D011725 Q000138 NN","107969,107970,581866,5280335,24776445",NULL,Are GPCRs still a source of new targets?,"G-protein-coupled receptors (GPCRs) still offer enormous scope for new therapeutic targets. Currently marketed agents are dominated by those with activity at aminergic receptors and yet they account for only ~10% of the family. Progress up until now with other subfamilies, notably orphans, Family A/peptide, Family A/lipid, Family B, Family C, and Family F, has been, at best, patchy. This may be attributable to the heterogeneous nature of GPCRs, their endogenous ligands, and consequently their binding sites.",Journal of biomolecular screening,Stephen L Garland," 1NQuiX Ltd, Stevenage Bioscience Catalyst, Stevenage SG1 2FX, UK.",2013 Oct;18(9):947-66,10.1177/1087057113498418
23950550,20140401,article,mesh,"Adolescent,Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Infection,Lymphocyte Count,Lymphocytes,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine,Young Adult","analogs &amp; derivatives,drug effects,drug therapy,epidemiology,immunology,therapeutic use","D008214 Q000187 NY,D013110 Q000031 NY,D009103 Q000276 NY,D007166 Q000627 NY,D007239 Q000453 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.,BACKGROUND: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. OBJECTIVE: The objective of this article is to evaluate lymphocyte dynamics during and after fingolimod therapy and assess the relationship between lymphocyte counts and infections. METHODS: Lymphocyte counts and their relationship with infections were evaluated in three multiple sclerosis (MS) populations: (Group A) FREEDOMS phase 3 core study group (n = 1272); (Group B) All Studies group (on,"Multiple sclerosis (Houndmills, Basingstoke, England)","G Francis, L Kappos, P O'Connor, W Collins, D Tang, F Mercier, J A Cohen"," Novartis Pharmaceuticals Corporation-NJ, USA.",2014 Apr;20(4):471-80,10.1177/1352458513500551
23954263,20131009,article,mesh,"Animals,Carcinogens,Cell Line,Chromatography, High Pressure Liquid,Comet Assay,DNA Damage,Glutathione,Hepatocytes,Humans,Male,Oxidative Stress,Propylene Glycols,Rats,Rats, Sprague-Dawley,Urothelium","analysis,chemistry,cytology,drug effects,toxicity","D019459 Q000187 NY,D019459 Q000166 NN,D011409 Q000633 NY,D002273 Q000633 NY,D022781 Q000737 NN,D018384 Q000187 NY,D004249 Q000187 NN,D022781 Q000187 NY,D005978 Q000032 NN","18692,124886",NULL,"Comparison of 2,2-bis(bromomethyl)-1,3-propanediol induced genotoxicity in UROtsa cells and primary rat hepatocytes: relevance of metabolism and oxidative stress.","2,2-Bis(bromomethyl)-1,3-propanediol (BMP) is a brominated flame retardant used in urethane foams and polyester resins. In a two year dietary study, BMP caused neoplastic lesions at multiple sites including the urinary bladder of both rats and mice. However, liver was not a target tissue. We previously reported that BMP elicited oxidative DNA damage in a human uroepithelial cell line (UROtsa). The present in vitro study investigated the susceptibility of target (UROtsa cells) and non-target cells (primary r",Toxicology letters,"Weixi Kong, Pengfei Gu, Gabriel A Knudsen, I Glenn Sipes"," Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ 85724, United States. Electronic address: weixik@uci.edu.",2013 Oct;222(3):273-9,10.1016/j.toxlet.2013.07.026
23961604,20130101,review,mesh,"Female,Fetus,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Interferon-beta,Maternal-Fetal Exchange,Multiple Sclerosis,Peptides,Pregnancy,Propylene Glycols,Recurrence,Sphingosine","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,physiopathology,therapeutic use","D010455 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D010455 Q000627 NN,D016899 Q000627 NN,D009103 Q000503 NY,D005333 Q000187 NN,D016899 Q000009 NN,D013110 Q000031 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D009103 Q000188 NY","65370,107969,107970,3081884,5280335",NULL,[Multiple sclerosis and pregnancy].,"Multiple sclerosis will usually calm down during pregnancy, but the number of relapses again increases immediately after childbirth. Among the conventional immunomodulatory drugs, there is experience already for over 15 years of the use of interferon-beta and glatiramer. No indications of harmful effects on the fetus have been noted, and interferon-beta and glatiramer can very likely be safely used until the beginning of pregnancy. Fingolimod is suspected to be harmful for fetal development, and the use of ",Duodecim; laaketieteellinen aikakauskirja,"Jori Ruuskanen, Heli Malm, Laura Airas"," Turun yliopistollinen keskussairaala, neurotoimialue ja Medbase Oy, Turku",2013 Jan;129(14):1457-64,NULL
23995704,20130101,article,mesh,"Animals,Arthritis, Rheumatoid,Autoantibodies,Autoantigens,Disease Models, Animal,Drug Therapy, Combination,Fingolimod Hydrochloride,Glucose-6-Phosphate Isomerase,Immunoglobulin G,Immunosuppressive Agents,Joints,Male,Mice,Mice, Inbred DBA,Peptides,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,blood,chemistry,drug effects,drug therapy,immunology,pathology","D005956 Q000008 NN,D001172 Q000473 NN,D007596 Q000187 NN,D013110 Q000008 NN,D013110 Q000031 NY,D007596 Q000473 NN,D005956 Q000276 NY,D001323 Q000097 NN,D005956 Q000737 NN,D001172 Q000188 NY,D007074 Q000097 NN,D001324 Q000008 NY,D001172 Q000276 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI325-339)-induced arthritis mouse model.,"Fingolimod (FTY720) is known to have a significant therapeutic effect in various autoimmune disease models. Here, we examined FTY720 in a model of rheumatoid arthritis, induced by immunizing DBA/1 mice with a peptide consisting of residues 325 through 339 of glucose-6-phosphate isomerase (GPI325-339). The efficacy was evaluated in terms of macroscopic findings, inflammatory cell infiltration and autoantibody level. Prophylactic administration of FTY720 from the day of immunization significantly suppressed t",Biological & pharmaceutical bulletin,"Yuya Yoshida, Takumi Tsuji, Sayaka Watanabe, Ayane Matsushima, Yuki Matsushima, Rie Banno, Tetsuro Fujita, Takeyuki Kohno"," Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University.",2013 Jan;36(11):1739-46,10.1248/bpb.b13-00297
24008757,20130101,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Cohort Studies,Disease Progression,Female,Fingolimod Hydrochloride,Germany,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Outpatients,Propylene Glycols,Recurrence,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.,Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N). This observational cohort-study used health data routinely collected in outpatient neurology practices throughout Germany completing a treatment period of 12 months included 237 patients starting on N and 190 patients on FTY because of failure of the first-line treatment. Mean relapse rate drastically decrea,Journal of neurology,"Stefan Braune, M Lang, A Bergmann, NTC Study Group"," NeuroTrans Concept, Bahnhofstr. 103b, 86633, Neuburg, Germany, braune@neurozentrum-prien.de.",2013 Jan;260(12):2981-5,10.1007/s00415-013-7082-0
24024233,20130716,article,mesh,"Cerebrovascular Disorders,Encephalitis, Varicella Zoster,Humans,Immunosuppressive Agents,Male,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D002561 Q000188 NY,D011409 Q000627 NY,D020804 Q000188 NY",5280335,NULL,Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.,NULL,Neurology,"John N Ratchford, Kathleen Costello, Daniel S Reich, Peter A Calabresi",NULL,2013 Jul;81(3):306,10.1212/01.wnl.0000432547.27815.74
24024573,20130901,article,mesh,"Animals,Antibodies,Capillary Permeability,Cricetinae,Endothelial Cells,Fingolimod Hydrochloride,Hantavirus,Hantavirus Pulmonary Syndrome,Host-Pathogen Interactions,Humans,Immunosuppressive Agents,Mesocricetus,Propylene Glycols,Pulmonary Edema,Signal Transduction,Sirolimus,Sphingosine,Vascular Endothelial Growth Factor Receptor-2","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,immunology,metabolism,physiology,physiopathology,therapeutic use,virology","D000906 Q000627 NN,D042783 Q000378 NN,D002199 Q000187 NY,D042783 Q000502 NY,D007166 Q000627 NN,D018804 Q000188 NY,D006476 Q000502 NN,D040301 Q000276 NN,D000906 Q000276 NN,D011654 Q000378 NN,D013110 Q000031 NN,D040301 Q000378 NN,D011654 Q000503 NN,D018804 Q000503 NN,D011654 Q000188 NN,D040301 Q000037 NN,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D054884 Q000187 NN,D020123 Q000627 NN,D018804 Q000378 NN,D042783 Q000821 NN","107969,107970,5280335,5284616",NULL,Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.,"BACKGROUND: Hantaviruses in the Americas cause a highly lethal acute pulmonary edema termed hantavirus pulmonary syndrome (HPS). Hantaviruses nonlytically infect microvascular and lymphatic endothelial cells and cause dramatic changes in barrier functions without disrupting the endothelium. Hantaviruses cause changes in the function of infected endothelial cells that normally regulate fluid barrier functions. The endothelium of arteries, veins, and lymphatic vessels are unique and central to the function of",Lymphatic research and biology,"Erich R Mackow, Elena E Gorbunova, Nadine A Dalrymple, Irina N Gavrilovskaya"," Department of Molecular Genetics and Microbiology, Stony Brook University , Stony Brook, New York.",2013 Sep;11(3):128-35,10.1089/lrb.2013.0006
24029635,20131101,article,mesh,"Animals,Brain Ischemia,Enzyme Inhibitors,Fingolimod Hydrochloride,Homeodomain Proteins,Hypoxia,Immunosuppressive Agents,Inflammation,Lymphocytes,Lymphopenia,Male,Mice,Mice, Transgenic,Middle Cerebral Artery,Neurons,Neuroprotective Agents,Propylene Glycols,Sphingosine,Stroke,Thrombosis","analogs &amp; derivatives,drug effects,genetics,pathology,pharmacology,therapeutic use,therapy","D002545 Q000628 NY,D007166 Q000494 NY,D020768 Q000473 NN,D007249 Q000628 NY,D013927 Q000628 NY,D013110 Q000031 NY,D011409 Q000494 NY,D009474 Q000473 NN,D008231 Q000473 NN,D018696 Q000627 NN,D004791 Q000494 NN,D018398 Q000235 NN,D013110 Q000494 NN,D008214 Q000187 NN,D020521 Q000628 NY","107969,107970,5280335",NULL,FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection.,"BACKGROUND AND PURPOSE: Lymphocytes are important players in the pathophysiology of acute ischemic stroke. The interaction of lymphocytes with endothelial cells and platelets, termed thrombo-inflammation, fosters microvascular dysfunction and secondary infarct growth. FTY720, a sphingosine-1-phosphate receptor modulator, blocks the egress of lymphocytes from lymphoid organs and has been shown to reduce ischemic neurodegeneration; however, the underlying mechanisms are unclear. We investigated the mode of FT",Stroke,"Peter Kraft, Eva Göb, Michael K Schuhmann, Kerstin Göbel, Carsten Deppermann, Ina Thielmann, Alexander M Herrmann, Kristina Lorenz, Marc Brede, Guido Stoll, Sven G Meuth, Bernhard Nieswandt, Waltraud Pfeilschifter, Christoph Kleinschnitz"," From the University Clinic Würzburg, Departments of Neurology (P.K., E.G., M.K.S., G.S., C.K.) and Anesthesiology and Critical Care (M.B.), Rudolf Virchow Center, the Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine (C.D., I.T., B.N.), Institute of Pharmacology and Toxicology, University of Würzburg (K.L.), Würzburg, Germany; Department of Neurology (K.G., A.M.H., S.G.M.), Institute of Physiology and Neuropathophysiology (S.G.M.), University of Münster, Germany; and University C",2013 Nov;44(11):3202-10,10.1161/strokeaha.113.002880
24032536,20140301,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine,Time Factors","adverse effects,analogs &amp; derivatives,drug therapy,metabolism,pathology,therapeutic use","D061067 Q000009 NY,D007166 Q000627 NN,D020529 Q000473 NN,D013110 Q000031 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NN,D061067 Q000378 NY","107969,107970,5280335",NULL,Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?,BACKGROUND: More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity. AIM OF THE STUDY: The aim of this study was to evaluate the prognostic value of natalizumab saturation on T cells for the recurrence of clinical and radiological disease activity. METHODS: Cell surface-bound natalizumab saturat,Acta neurologica Scandinavica,"P Wipfler, A Harrer, G Pilz, K Oppermann, S Afazel, E Haschke-Becher, J Sellner, E Trinka, J Kraus"," Department of Neurology, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria.",2014 Mar;129(3):e12-5,10.1111/ane.12182
24044116,20130723,article,mesh,"Brain,Female,Humans,Immunosuppressive Agents,Multiple Sclerosis,Nerve Fibers, Myelinated,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D009103 Q000473 NY,D001921 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D009413 Q000473 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Author response.,NULL,Neurology,"Mike P Wattjes, Femke Visser, Bob W van Oosten",NULL,2013 Jul;81(4):403,10.1212/wnl.0b013e31829deeb4
24051419,20131201,article,mesh,"Adolescent,Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macula Lutea,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Nerve Fibers,North America,Propylene Glycols,Retina,Retrospective Studies,Sphingosine,Tomography, Optical Coherence,Young Adult","analogs &amp; derivatives,drug effects,drug therapy,pathology,therapeutic use","D020529 Q000473 NY,D012160 Q000473 NN,D009412 Q000473 NN,D008266 Q000187 NN,D008266 Q000473 NY,D013110 Q000031 NY,D009412 Q000187 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.,"BACKGROUND: Patients with multiple sclerosis (MS) demonstrate thinning of peripapillary retinal nerve fiber layer (RNFL) and decreased macular volume as measured by optical coherence tomography (OCT). To our knowledge, there are no previous reports from a large MS OCT database with strict quality control measures that quantitate RNFL and macula in patients with relapsing-remitting multiple sclerosis. METHODS: The University of California Davis OCT Reading Center gathered OCT data at baseline as part of the ",Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,"Kimberly M Winges, John S Werner, Danielle J Harvey, Kimberly E Cello, Mary K Durbin, Laura J Balcer, Peter A Calabresi, John L Keltner"," Department of Ophthalmology (KMW), Veterans Administration Medical Center, Portland, Oregon; Department of Ophthalmology and Vision Science (KMW, JSW, KEC, JLK), Division of Biostatistics (DJH), Department of Public Health Sciences, and Departments of Neurology and Neurosurgery (JLK), University of California Davis School of Medicine, Davis, California; Carl Zeiss Meditec, Inc (MKD), Dublin, California; Department of Neurology (LJB), New York University Langone Medical Center, New York, New York; and Depar",2013 Dec;33(4):322-9,10.1097/wno.0b013e31829c51f7
24059944,20131201,article,mesh,"Adult,Databases, Factual,Female,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,In Vitro Techniques,Insurance Claim Review,Interferons,Male,Middle Aged,Multiple Sclerosis,Peptides,Propylene Glycols,Recurrence,Retrospective Studies,Sphingosine,United States","administration &amp; dosage,analogs &amp; derivatives,drug therapy,epidemiology","D010455 Q000008 NY,D009103 Q000453 NN,D007372 Q000008 NY,D013110 Q000008 NN,D014481 Q000453 NN,D013110 Q000031 NY,D009103 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY","65370,107969,107970,3081884,5280335",NULL,Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.,"OBJECTIVE: Disease-modifying therapies, such as fingolimod, interferon (IFN) and glatiramer acetate (GA), have differing effects on relapse rates in patients with multiple sclerosis (MS), but little is known about the real-world differences in relapse rates with these treatments. This retrospective study assessed relapse rates in patients with active MS initiating fingolimod, IFN or GA therapy in a real-world setting. METHODS: Using administrative claims data from the US PharMetrics Plus database, we identi",Current medical research and opinion,"Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison Petrilla, Swapna U Karkare, Catherine Balderston McGuiness, Jonathan R Korn"," Novartis Pharma AG , Basel , Switzerland.",2013 Dec;29(12):1647-56,10.1185/03007995.2013.847411
24062194,20131001,article,mesh,"Adult,Animals,Apoptosis,Cell Survival,Female,Fibroblast Growth Factor 2,Fingolimod Hydrochloride,Graft Survival,Humans,Immunosuppressive Agents,Ki-67 Antigen,Neovascularization, Physiologic,Ovarian Follicle,Platelet Endothelial Cell Adhesion Molecule-1,Propylene Glycols,Rabbits,Sphingosine,Transplantation, Heterologous,Vascular Endothelial Growth Factor A","administration &amp; dosage,analogs &amp; derivatives,analysis,drug effects,pharmacology,transplantation","D019394 Q000032 NN,D007166 Q000008 NN,D017209 Q000187 NN,D002470 Q000187 NN,D016222 Q000494 NY,D013110 Q000008 NN,D011409 Q000008 NN,D013110 Q000031 NN,D042461 Q000494 NY,D019408 Q000032 NN,D006085 Q000187 NY,D018919 Q000187 NN,D006080 Q000637 NY","107969,107970,5280335,57339413",NULL,VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model.,PURPOSE: The aim of this study is to determine whether vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) could increase the survival of xenografted human ovarian tissue in an experimental rabbit model. METHODS: Fresh human ovarian tissue was xenotransplanted into the back muscle of 25 castrated female New Zealand rabbits for 6 weeks with the immunosuppression of FTY720 (2 mg/kg/d). Rabbits were randomly divided into five experimental groups: (A) graft and host treatment wit,Journal of assisted reproduction and genetics,"Lin Wang, Ying-fen Ying, Yin-luan Ouyang, Jing-fen Wang, Jian Xu"," Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China.",2013 Oct;30(10):1301-11,10.1007/s10815-013-0043-9
24085318,20131201,article,"xref,mesh","Animals,Antitussive Agents,Capsaicin,Codeine,Cough,Female,Flavanones,Guinea Pigs,Lung,Male,Neprilysin,Neurogenic Inflammation,Propylene Glycols,Receptors, Neurokinin-1,Smoke,Substance P,Thiazolidines,Tobacco","chemically induced,drug effects,metabolism,pharmacology","D020078 Q000139 NN,D008168 Q000187 NN,D003371 Q000378 NY,D018040 Q000378 NN,D000996 Q000494 NY,D003371 Q000139 NN,D044950 Q000494 NN,D013373 Q000378 NN,D015260 Q000378 NN,D053778 Q000494 NN,D020078 Q000378 NY,D011409 Q000494 NN,D003061 Q000494 NN,D008168 Q000378 NN","3169,36511,65859,65935,155557,442428,1548943,5284371,5324288,5359227,5362471,6321303,9894584,9953630,46783824","53786869,53788248,53788605,53790269,250230349,250230362",Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure.,"OBJECTIVE: The effects of four antitussives, including codeine phosphate (CP), moguisteine, levodropropizine (LVDP) and naringin, on airway neurogenic inflammation and enhanced cough were investigated in guinea pig model of chronic cough. METHODS: Guinea pigs were exposed to CS for 8 weeks. At the 7th and 8th week, the animals were treated with vehicle, CP (4.8 mg/kg), moguisteine (24 mg/kg), LVDP (14 mg/kg) and naringin (18.4 mg/kg) respectively. Then the cough and the time-enhanced pause area under the cu",Inflammation research : official journal of the European Histamine Research Society ... [et al.],"Yu-long Luo, Pei-bo Li, Chen-chen Zhang, Yan-fang Zheng, Sheng Wang, Yi-chu Nie, Ke-jian Zhang, Wei-wei Su"," Key Laboratory of Gene Engineering of the Ministry of Education, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, No.135, Xingangxi Street, Guangzhou, 510275, People's Republic of China, luo.yulong@aliyun.com.",2013 Dec;62(12):1053-61,10.1007/s00011-013-0664-6
24093542,20130101,article,mesh,"Adult,Aged,Cohort Studies,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Medication Adherence,Middle Aged,Multiple Sclerosis,Proportional Hazards Models,Propylene Glycols,Retrospective Studies,Sphingosine,Time Factors","analogs &amp; derivatives,drug therapy,psychology,therapeutic use","D009103 Q000523 NY,D055118 Q000523 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,"Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.","BACKGROUND: Adherence to disease-modifying therapies (DMTs) results in the reduction of the number and severity of relapses and delays the progression of multiple sclerosis (MS). Patients with lower adherence rates experience more inpatient visits and higher MS-related medical costs. Fingolimod, the first oral DMT approved by the US Food and Drug Administration, may improve the access and compliance to MS treatment when compared to injectable DMTs. METHODS: This retrospective cohort study used pharmacy clai",BMC neurology,"Neetu Agashivala, Ning Wu, Safiya Abouzaid, You Wu, Edward Kim, Luke Boulanger, David W Brandes"," Novartis Pharmaceuticals Corporation, One Health Plaza, 07936, East Hanover, NJ USA. neetu.agashivala@novartis.com.",2013 Jan;13(?):138,10.1186/1471-2377-13-138
24097812,20131105,article,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Immunotherapy,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,immunology,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.,"Our knowledge of the substantial complexities of the immune system and understanding of the immunopathogenesis of autoimmune diseases are increasing at such a rapid pace that it is impossible for the non-immunologist to stay abreast of the field. However, there are 2 general principles that are important for clinicians to keep in mind. One is that the immune system regulates itself. The effector arm of the adaptive immune system consists of subsets of lymphocytes that recognize and respond to non-self antig",Neurology,"Friedemann Paul, Dennis Bourdette"," From the NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité University Medicine Berlin, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the MS Center of Excellence-West (D.B.), Department of Veterans Affairs Medical Center, Portland, OR.",2013 Nov;81(19):1648-9,10.1212/01.wnl.0000435305.95271.84
24097813,20131105,review,mesh,"Adolescent,Brain,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis,Oligoclonal Bands,Plasma Exchange,Propylene Glycols,Sphingosine","analogs &amp; derivatives,cerebrospinal fluid,drug therapy,immunology,pathology,therapeutic use","D001921 Q000473 NY,D009103 Q000134 NN,D013110 Q000031 NY,D009103 Q000276 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D043025 Q000134 NN","107969,107970,5280335",NULL,Tumefactive MS lesions under fingolimod: a case report and literature review.,OBJECTIVE: To report about a possible association between fingolimod treatment and tumefactive demyelinating lesions (TDL) as seen in a patient developing repeated TDL on continued fingolimod therapy. METHODS: We performed serial clinical and radiologic assessments and immunophenotyping of blood and CSF immune cells. We also present a literature review about recent similar cases. RESULTS: Clinical course and radiologic findings were consistent with diagnosis of TDL. Immune cell phenotyping showed pronounced,Neurology,"Georg Pilz, Andrea Harrer, Peter Wipfler, Katrin Oppermann, Johann Sellner, Franz Fazekas, Eugen Trinka, Joerg Kraus"," From the Department of Neurology (G.P., A.H., P.W., K.O., J.S., E.T., J.K.), Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria; the Department of Neurology (J.S.), Klinikum rechts der Isar, Technische Universität München, Germany; and the Department of Neurology (F.F.), Medical University of Graz, Austria.",2013 Nov;81(19):1654-8,10.1212/01.wnl.0000435293.34351.11
24100923,20131201,review,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Neoplasms,Phosphorylation,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,United States,United States Food and Drug Administration","analogs &amp; derivatives,drug therapy,genetics,metabolism,pathology,therapeutic use","D009369 Q000188 NY,D049349 Q000378 NY,D009369 Q000473 NN,D009103 Q000473 NN,D049349 Q000235 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NN,D009369 Q000235 NN","107969,107970,5280335",NULL,FTY720 for cancer therapy (Review).,"2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. As an immunosuppressant, it displays its anti-multiple sclerosis, immunosuppressive effects by activating sphingosine-1-phosphate receptors (S1PRs). In addition to the immunosuppressive effects, FTY720 also shows preclinical antitumor efficacy in several cancer models. In most cases, phosphorylation of ",Oncology reports,"Li Zhang, Han-Dong Wang, Xiang-Jun Ji, Zi-Xiang Cong, Jian-Hong Zhu, Yuan Zhou"," Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China.",2013 Dec;30(6):2571-8,10.3892/or.2013.2765
24132373,20131112,article,mesh,"Adult,Cell Count,Cytokines,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Longitudinal Studies,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,classification,drug effects,drug therapy,metabolism,pathology,therapeutic use","D016207 Q000378 NN,D009103 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D013601 Q000145 NN,D009103 Q000188 NY,D013601 Q000473 NY,D013601 Q000187 NN","107969,107970,5280335",NULL,Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.,"OBJECTIVE: To determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4- to 7-year period in patients with MS receiving fingolimod (FTY720) and the relation between TLCs and T-cell subsets (CD4+, CD8+, CCR7+/-) that are differentially regulated in the lymph nodes by fingolimod. METHODS: TLCs were measured every 3 months in patients (n = 23) receiving fingolimod for 4 to 7 years. T-cell subset (CD4+, CD8+, and CCR7+/-) analyses were performed on whole-blood samples and",Neurology,"David Henault, Lorna Galleguillos, Craig Moore, Trina Johnson, Amit Bar-Or, Jack Antel"," From the Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Canada.",2013 Nov;81(20):1768-72,10.1212/01.wnl.0000435564.92609.2c
24142108,20131201,article,mesh,"Cell Death,Cell Line, Tumor,Enzyme Activation,Fingolimod Hydrochloride,Humans,JNK Mitogen-Activated Protein Kinases,MAP Kinase Signaling System,Mitochondria,Neurons,Neuroprotective Agents,Neurotoxins,Peptide Fragments,Phosphorylation,Prions,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology,toxicity","D008928 Q000187 NN,D009498 Q000633 NN,D016923 Q000187 NN,D009474 Q000187 NN,D004789 Q000187 NN,D011328 Q000633 NY,D013110 Q000031 NY,D011409 Q000494 NY,D020935 Q000187 NY,D018696 Q000494 NY,D048031 Q000378 NN,D008928 Q000378 NN,D009474 Q000378 NN,D010446 Q000633 NY,D010766 Q000187 NN,D013110 Q000494 NN,D009474 Q000473 NY","107969,107970,5280335",NULL,FTY720 protects neuronal cells from damage induced by human prion protein by inactivating the JNK pathway.,"Prion diseases affect the central nervous system (CNS) in humans and animals, and are associated with the conversion of the cellular prion protein (PrPC) to the misfolded isoform (PrPSc). FTY720, an immune modulator and synthetic analogue of sphingosine-1-phosphate (S1P), activates S1P receptors and has been shown to be effective in experimental models of transplantation and autoimmunity, including multiple sclerosis. Whereas the immune modulatory functions of FTY720 have been extensively investigated, the ",International journal of molecular medicine,"Myung-Hee Moon, Jae-Kyo Jeong, You-Jin Lee, Sang-Youel Park"," Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Jeonbuk 561-756, Republic of Korea.",2013 Dec;32(6):1387-93,10.3892/ijmm.2013.1528
24161412,20140501,article,mesh,"Antibodies, Monoclonal, Humanized,Cost Control,Drug Costs,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Spain,Sphingosine","analogs &amp; derivatives,drug therapy,economics,methods,therapeutic use","D003363 Q000379 NY,D061067 Q000627 NY,D013110 Q000031 NY,D013110 Q000191 NN,D007166 Q000627 NY,D061067 Q000191 NY,D020529 Q000188 NY,D011409 Q000191 NY,D020529 Q000191 NY,D013110 Q000627 NN,D011409 Q000627 NY,D007166 Q000191 NY","107969,107970,5280335",NULL,Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.,"INTRODUCTION: At present, there is a lack of economic assessments of second-line treatments for relapsing-recurring multiple sclerosis. The aim of this study was to compare the efficiency between fingolimod and natalizumab in Spain. METHODS: A cost minimisation analysis model was developed for a 2-year horizon. The same relapse rate was applied to both treatment arms and the cost of resources was calculated using Spain's stipulated rates for 2012 in euros. The analysis was conducted from the perspective of ","Neurologia (Barcelona, Spain)","C Crespo, G Izquierdo, A García-Ruiz, M Granell, M Brosa"," Departamento de Estadística, Universidad de Barcelona, Barcelona, España; Oblikue Consulting, Barcelona, España. Electronic address: carlos.crespo@oblikue.com. Unidad de Esclerosis Múltiple, Hospital Universitario Virgen de la Macarena, Sevilla, España. Departamento de Farmacología y Terapéutica Clínica, Facultad de Medicina, Universidad de Málaga, Málaga, España. Novartis Farmacéutica, Barcelona, España. Oblikue Consulting, Barcelona, España.",2014 May;29(4):210-7,10.1016/j.nrl.2013.04.003
24163092,20131201,article,mesh,"CD8-Positive T-Lymphocytes,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes, Regulatory","analogs &amp; derivatives,drug effects,drug therapy,therapeutic use","D016176 Q000187 NY,D013110 Q000031 NY,D007166 Q000627 NY,D018414 Q000187 NY,D050378 Q000187 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.,NULL,Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,"D Ferraro, S De Biasi, F Vitetta, A M Simone, L Federzoni, V Borghi, A Cossarizza, P F Nichelli, P Sola"," Neurology Unit, Department of Neurosciences, University of Modena and Reggio Emilia, Nuovo Ospedale Civile Sant'Agostino Estense, Via Pietro Giardini, 1355, 41126, Modena, Italy, perdiana@tin.it.",2013 Dec;8(5):1059-61,10.1007/s11481-013-9510-4
24178903,20140601,article,mesh,"Adult,Antidotes,Atropine,Bradycardia,Combined Modality Therapy,Drug Overdose,Female,Fingolimod Hydrochloride,Humans,Hypotension,Immunosuppressive Agents,Muscarinic Antagonists,Propylene Glycols,Sphingosine,Time Factors,Treatment Outcome","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,drug therapy,etiology,physiopathology,poisoning,therapeutic use,therapy","D001919 Q000188 NY,D003131 Q000009 NN,D007022 Q000209 NN,D011409 Q000506 NY,D001285 Q000627 NY,D000931 Q000627 NN,D013110 Q000031 NY,D018727 Q000627 NY,D013110 Q000037 NN,D007166 Q000037 NN,D062787 Q000628 NY,D013110 Q000506 NN,D011409 Q000037 NN,D007166 Q000506 NY,D007022 Q000188 NY,D001919 Q000209 NN,D062787 Q000503 NN","5927,17184,64663,107969,107970,174174,656678,5280335,57473071,60196398,67052243,131632429,134688695",NULL,Deliberate fingolimod overdose presenting with delayed hypotension and bradycardia responsive to atropine.,"INTRODUCTION: Fingolimod is an immunomodulating agent used in multiple sclerosis (MS). It is a sphingosine-1-phosphate (S1P) receptor agonist prescribed for relapsing forms of MS to delay onset of physical disability. As fingolimod is known to cause first-dose bradycardia, telemetry is recommended for the first 6 h post-dose. We present the first reported case of deliberate fingolimod overdose requiring atropine administration for bradycardia and hemodynamic instability. CASE REPORT: A 33-year-old woman ing",Journal of medical toxicology : official journal of the American College of Medical Toxicology,"M Stephenson, A Wong, J A Rotella, N Crump, F Kerr, S L Greene"," Department of Emergency Medicine, Austin Hospital, Heidelberg, Victoria, Australia.",2014 Jun;10(2):215-8,10.1007/s13181-013-0354-3
24187597,20131001,article,mesh,"Animals,Brain Ischemia,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Infarction, Middle Cerebral Artery,Male,Neurons,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Rats,Rats, Sprague-Dawley,Sphingosine","analogs &amp; derivatives,metabolism,pharmacology","D017853 Q000378 NN,D020244 Q000378 NY,D013110 Q000378 NY,D009474 Q000378 NY,D002545 Q000378 NY,D013110 Q000031 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335",NULL,Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats.,"Although there is evidence that sphingosine-1-phosphate receptor-1 (S1P1) activation occurs following experimental brain injury, there is little information about its metabolic pathway in cerebral ischemia. The purpose of this study was to evaluate the role of the sphingosine metabolic pathway including S1P1, sphingosine kinases 1 (SphK1), and 2 (SphK2) in transient middle cerebral artery occlusion (MCAO). Fifty-eight male Sprague-Dawley rats were used to asses temporal profiles of S1P1, SphK1 and 2 on neur",Translational stroke research,"Yu Hasegawa, Hidenori Suzuki, Orhan Altay, William Rolland, John H Zhang"," Department of Physiology, Loma Linda University School of Medicine, Loma Linda, California, USA.",2013 Oct;4(5):524-32,10.1007/s12975-013-0260-7
24195115,20131001,article,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukoencephalopathy, Progressive Multifocal,Multiple Sclerosis,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007968 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.,NULL,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NULL,NULL,2013 Oct;57(8):ii,NULL
24221641,20140101,article,mesh,"Adolescent,Adult,Age Factors,Aged,Bradycardia,Disability Evaluation,Electrocardiography,Endpoint Determination,Female,Fingolimod Hydrochloride,Heart Conduction System,Heart Diseases,Heart Rate,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Patient Safety,Propylene Glycols,Sphingosine,Treatment Outcome,Young Adult","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug effects,drug therapy,epidemiology,etiology,physiology,physiopathology,therapeutic use","D006331 Q000209 NN,D013110 Q000009 NN,D001919 Q000139 NN,D020529 Q000150 NN,D013110 Q000031 NY,D007166 Q000627 NY,D001919 Q000503 NN,D006331 Q000453 NY,D020529 Q000188 NY,D006329 Q000502 NN,D006339 Q000187 NN,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.","The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivotal studies with certain pre-existing cardiac conditions or baseline cardiac findings (PCCs), and those receiving beta blockers (BBs) and/or calcium channel blockers (CCBs), were eligible. Heart rate (HR) and ele",Journal of neurology,"Ralf Gold, Giancarlo Comi, Jacqueline Palace, Arno Siever, Rebecca Gottschalk, Mahendra Bijarnia, Philipp von Rosenstiel, Davorka Tomic, Ludwig Kappos, FIRST Study Investigators"," Department of Neurology, St Josef Hospital, Ruhr-University, Gudrunstr. 56, 44791, Bochum, Germany, Ralf.gold@ruhr-uni-bochum.de.",2014 Jan;261(2):267-76,10.1007/s00415-013-7115-8
24239768,20140501,review,mesh,"Biomedical Research,Clinical Medicine,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Propylene Glycols,Receptors, Lysosphingolipid,Research Design,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacology","D007166 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D008246 Q000378 NY,D013110 Q000494 NN,D015398 Q000187 NY,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Second generation S1P pathway modulators: research strategies and clinical developments.,"Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegeneration. Until recently, major therapeutic treatments have relied on agents requiring injection delivery. In September 2010, fingolimod/FTY720 (Gilenya, Novartis) was approved as the first oral treatment for relapsing forms of MS. Fingolimod causes down-modulation of S1P1 receptors on lymphocytes which prevents the invasion of autoaggressive T cells into the CNS. In astrocy",Biochimica et biophysica acta,"Marc Bigaud, Danilo Guerini, Andreas Billich, Frederic Bassilana, Volker Brinkmann"," Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Electronic address: marc.bigaud@novartis.com. Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Electronic address: volker.brinkmann@novartis.com.",2014 May;1841(5):745-58,10.1016/j.bbalip.2013.11.001
24266589,20150101,article,mesh,"Animals,Anti-Inflammatory Agents, Non-Steroidal,Chemistry, Pharmaceutical,Drug Delivery Systems,Drug Stability,Emulsions,Excipients,Gels,Hydrogen-Ion Concentration,Inflammation,Ketoprofen,Mice,Particle Size,Skin Absorption,Solubility,Surface-Active Agents,Viscosity","administration &amp; dosage,chemistry,drug therapy,pharmacokinetics","D007249 Q000188 NN,D013501 Q000737 NN,D000894 Q000493 NN,D000894 Q000737 NN,D007660 Q000493 NN,D007660 Q000737 NN,D005079 Q000737 NY,D000894 Q000008 NY,D007660 Q000008 NY",3825,NULL,"Formulation development, in vitro and in vivo evaluation of microemulsion-based gel loaded with ketoprofen.","BACKGROUND: Anti-inflammatory agents are widely used to relieve inflammation caused by various factors. AIM: This study was initiated with the intention to deliver low aqueous soluble ketoprofen to enhance its solubility by developing microemulsion system as a template and then incorporating it into gel phase. MATERIALS AND METHODS: Initially ketoprofen was solubilized into microemulsion preparation made up of clove oil, Tween 20 and propylene glycol as oil phase, surfactant and co-surfactant respectively, ",Drug delivery,"Kishor V Nikumbh, Shailesh G Sevankar, Moreshwar P Patil"," Department of Pharmaceutics, MET's Institute of Pharmacy, Bhujbal Knowledge City , Adgaon, Nashik , India.",2015 Jan;22(4):509-15,10.3109/10717544.2013.859186
24269406,20140301,article,mesh,"Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macular Edema,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D013110 Q000031 NY,D008269 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].,"CASE REPORT: A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and OCT examination now revealed cystoid macular oedema (CME). DISCUSSION: Attention to visual changes and periodic fun",Archivos de la Sociedad Espanola de Oftalmologia,"V M Asensio-Sánchez, L Trujillo-Guzmán, R Ramoa-Osorio"," Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España. Electronic address: victor_asensio@orangemail.es. Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España. Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España.",2014 Mar;89(3):104-6,10.1016/j.oftal.2012.07.020
24309839,20140301,article,mesh,"Administration, Oral,Atrioventricular Block,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Young Adult","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,physiopathology,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D020529 Q000188 NY,D007166 Q000009 NY,D054537 Q000139 NY,D054537 Q000503 NN,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.,NULL,European journal of clinical pharmacology,"Victor Voon, Lavanya Saiva, Sara O'Kelly, David Keane"," St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland, victor.voon@gmail.com.",2014 Mar;70(3):373-5,10.1007/s00228-013-1620-7
24314686,20131101,review,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Macular Edema,Multiple Sclerosis,Neuromyelitis Optica,Nystagmus, Pathologic,Ocular Motility Disorders,Optic Neuritis,Prognosis,Propylene Glycols,Sphingosine,Uveitis","adverse effects,analogs &amp; derivatives,chemically induced,complications,diagnosis,drug therapy,etiology","D009902 Q000188 NY,D011409 Q000009 NN,D013110 Q000009 NN,D015835 Q000209 NN,D008269 Q000139 NN,D014605 Q000209 NN,D009471 Q000209 NN,D009103 Q000150 NY,D009902 Q000209 NN,D013110 Q000031 NN,D009759 Q000209 NN,D007166 Q000009 NN,D009103 Q000188 NN,D009902 Q000175 NN","107969,107970,5280335",NULL,Visual issues in multiple sclerosis.,"Multiple sclerosis has several ophthalmic manifestations, including optic neuritis, internuclear ophthalmoplegia, and nystagmus. The presentation, treatment, and prognosis of visual complaints secondary to multiple sclerosis are discussed. Additionally, the use of optical coherence tomography and complications related to the use of fingolimod are considered. ",Physical medicine and rehabilitation clinics of North America,Courtney E Francis," Department of Ophthalmology, University of Washington, Box 359608, 325 9th Avenue, Seattle, WA 98104-2499, USA. Electronic address: francis3@uw.edu.",2013 Nov;24(4):687-702,10.1016/j.pmr.2013.06.002
24321158,20131201,review,mesh,"Administration, Oral,Disease Progression,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Secondary Prevention,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug therapy,therapeutic use","D007166 Q000008 NN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Management of fingolimod in clinical practice.,"The efficacy of the innovative oral drug fingolimod has been proven in the largest study program in multiple sclerosis (MS) demonstrating reduced relapse and reduced disability progression in relapsing-remitting MS patients. Based on the extensive safety data of all clinical trials and the natural distribution pattern of fingolimod interacting receptors in organism, careful clinical monitoring is recommend and reviewed in this paper. Safety and tolerability data from clinical studies as well as current post",Clinical neurology and neurosurgery,"Katja Thomas, Tjalf Ziemssen"," MS Center Dresden, Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany. Electronic address: Katja.Thomas@uniklinikum-dresden.de.",2013 Dec;?(?):S60-4,10.1016/j.clineuro.2013.09.023
24335183,20140301,article,mesh,"Apoptosis,Cell Line, Tumor,Drug Resistance, Neoplasm,Fingolimod Hydrochloride,Genetic Vectors,Humans,Immunosuppressive Agents,Lentivirus,Molecular Docking Simulation,Mutation,Nuclear Proteins,Oncogenes,Phosphoproteins,Propylene Glycols,Protein Structure, Tertiary,Repetitive Sequences, Amino Acid,Sphingosine,Transduction, Genetic","analogs &amp; derivatives,chemistry,drug effects,genetics,metabolism,pharmacology","D009687 Q000378 NN,D007166 Q000494 NY,D017209 Q000187 NN,D009687 Q000235 NY,D019008 Q000235 NY,D016086 Q000235 NN,D011409 Q000737 NN,D013110 Q000031 NY,D013110 Q000737 NN,D011409 Q000494 NY,D010750 Q000378 NN,D010750 Q000235 NY,D010750 Q000737 NN,D009687 Q000737 NN,D007166 Q000737 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).,"pp32r1 (ANP32C) is oncogenic and has been shown to be overexpressed in tumors of the breast, prostate, and pancreas. In this work we show that pp32 family proteins are able to bind to the sphingosine analog FTY720 (Finguimod). Molecular docking studies highlight that a conserved residue F136 is likely to be a key determinant of the FTY720 binding site on the pp32 leucine-rich repeat domain. Transduction of the renal carcinoma cell line ACHN or cervical cancer cell line HeLa with lentivirus expressing the on",Cancer biology & therapy,"Salma Buddaseth, Wiebke Göttmann, Rainer Blasczyk, Trevor Huyton"," Institute for Transfusion Medicine; Hannover Medical School; Hannover, Germany. Institute for Transfusion Medicine; Hannover Medical School; Hannover, Germany. Institute for Transfusion Medicine; Hannover Medical School; Hannover, Germany. Institute for Transfusion Medicine; Hannover Medical School; Hannover, Germany.",2014 Mar;15(3):289-96,10.4161/cbt.27307
24367037,20140401,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukoencephalopathy, Progressive Multifocal,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,pathology,therapeutic use","D061067 Q000009 NY,D013110 Q000031 NY,D020529 Q000473 NN,D007968 Q000139 NY,D020529 Q000188 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?,"We report two cases of multiple sclerosis (MS) patients with natalizumab-associated progressive multifocal leukoencephalopathy. Severe MS relapses occurred between four and five months after natalizumab discontinuation. After failure of immunomodulatory treatment, both patients were treated with fingolimod. The outcome was positive on clinical and MRI disease activity, without worsening of the progressive multifocal leukoencephalopathy. These observations suggest that using fingolimod for severe multiple sc","Multiple sclerosis (Houndmills, Basingstoke, England)","Elisabeth Maillart, Céline Louapre, Catherine Lubetzki, Caroline Papeix"," APHP, Hôpital Pitié Salpêtrière, France.",2014 Apr;20(4):505-9,10.1177/1352458513516530
24399624,20140116,article,mesh,"Brain,Confidentiality,Drug Prescriptions,Drug Utilization,Electronic Health Records,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Informed Consent,Magnetic Resonance Imaging,Multiple Sclerosis,Patient Dropouts,Practice Patterns, Physicians',Product Surveillance, Postmarketing,Propylene Glycols,Prospective Studies,Registries,Retrospective Studies,Risk Assessment,Severity of Illness Index,Socioeconomic Factors,Spain,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug effects,drug therapy,methods,pathology,statistics &amp; numerical data,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D011358 Q000379 NY,D009103 Q000473 NN,D001921 Q000187 NN,D013110 Q000031 NY,D001921 Q000473 NN,D007166 Q000627 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY,D011358 Q000706 NN,D011307 Q000706 NN","107969,107970,5280335",NULL,[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].,INTRODUCTION: This study outlines the design of an electronic register of patients with multiple sclerosis who began treatment with fingolimod in Spain. The system is intended to serve as a tool to monitor its utilisation in daily clinical practice and thus allow optimisation of the way it is used. AIMS: To establish the profile of patients with multiple sclerosis undergoing treatment with fingolimod and to determine the effectiveness and safety of this treatment in daily clinical practice. DEVELOPMENT: An ,Revista de neurologia,"Óscar Fernández, Alfredo Rodríguez-Antigüedad, Celia Oreja-Guevara, Margarida Garcia-Garcia, Xavier Montalban, investigadores del Registro Español de Gilenya"," Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana.",2014 Jan;58(2):77-83,NULL
24412675,20140401,article,mesh,"Animals,Blood-Brain Barrier,Brain,Capillary Permeability,Disease Models, Animal,Disease Progression,Fingolimod Hydrochloride,Immunosuppressive Agents,Lymphocytes,Macrophages,Male,Microglia,Multiple Sclerosis,Propylene Glycols,Rats,Rats, Inbred Lew,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,pathology,pharmacology,physiology,physiopathology","D001812 Q000473 NN,D007166 Q000494 NY,D008264 Q000502 NN,D008214 Q000473 NN,D009103 Q000473 NN,D001812 Q000187 NN,D002199 Q000187 NN,D002199 Q000502 NN,D009103 Q000503 NY,D017628 Q000187 NN,D008214 Q000502 NN,D013110 Q000031 NY,D011409 Q000494 NY,D008264 Q000473 NN,D001921 Q000473 NN,D017628 Q000473 NN,D001921 Q000187 NY,D008264 Q000187 NN,D013110 Q000494 NN,D008214 Q000187 NN,D009103 Q000188 NY,D001921 Q000503 NY,D017628 Q000502 NN,D001812 Q000503 NN","107969,107970,5280335",NULL,Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.,"We examined the effect of fingolimod (0.1 and 0.3 mg/kg/day orally) on blood-brain barrier (BBB) function, demyelination and leukocyte recruitment at different stages of the focal delayed-type hypersensitivity (DTH) multiple sclerosis model in Lewis rats using immunohistochemistry and gadolinium (Gd)-enhancing magnetic resonance imaging (MRI). During DTH lesion formation, fingolimod reduced BBB breakdown (52%; p = 0.05), and lymphocyte (53%; p = 0.016) and macrophage/activated microglia (49%; p = 0.002) rec",Neuropharmacology,"Daniel C Anthony, Nicola R Sibson, Patrick Losey, Daniela Piani Meier, David Leppert"," Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Electronic address: daniel.anthony@pharm.ox.ac.uk. Cancer Research UK (CR-UK), Gray Institute for Radiation Oncology and Biology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, OX3 7DQ Oxford, UK. Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Novartis Pharma AG, Kirschgartenstrasse 14, 4051 Basel, Switzerland. Department of Medicine, University Hospital Ba",2014 Apr;79(?):534-41,10.1016/j.neuropharm.2013.12.022
24432665,20131001,article,mesh,"Genetic Engineering,Hydroxybutyrates,Industrial Microbiology,Klebsiella pneumoniae,Polymers,Propylene Glycols","genetics,metabolism,methods","D007218 Q000379 NN,D007711 Q000378 NY,D011409 Q000378 NY,D005818 Q000379 NN,D006885 Q000378 NY,D011108 Q000378 NN,D007711 Q000235 NN",10442,NULL,[Construction of polyhydroxybutyrate pathway in Klebsiella pneumoniae].,"1,3-propanediol production with the byproduct of biodiesel production is important to increase the economic benefit of biodiesel industry. Accumulation of 3-hydroxypropionaldehyde is one of the key problems in the 1,3-propanediol fermentation process, leading to the cell death and the fermentation abnormal ceasing. Different from the traditional way of reducing the accumulation of the 3-hydroxypropionaldehyde, we introduced the polyhydroxybutyrate pathway into the Klebsiella pneumoniae for the first time to",Sheng wu gong cheng xue bao = Chinese journal of biotechnology,"Xiaochen Guo, Hongjuan Liu, Yanping Wang, Jian'an Zhang, Dehua Liu"," College of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China. Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing 100084, China. College of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China. Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing 100084, China. Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.",2013 Oct;29(10):1504-14,NULL
24463629,20140225,article,mesh,"Abnormalities, Drug-Induced,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Pregnancy,Pregnancy Complications,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D011248 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,The pill times 2: what every woman with multiple sclerosis should know.,NULL,Neurology,Annette M Langer-Gould," From the Department of Research & Evaluation and Southern California Permanente Medical Group, Kaiser Permanente Southern California, Pasadena; and the Neurology Department, Los Angeles Medical Center, CA.",2014 Feb;82(8):654-5,10.1212/wnl.0000000000000155
24463630,20140225,article,mesh,"Abnormalities, Drug-Induced,Abortion, Spontaneous,Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Middle Aged,Multiple Sclerosis,Pregnancy,Pregnancy Complications,Pregnancy Outcome,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D013110 Q000009 NN,D011248 Q000139 NY,D007166 Q000627 NN,D000022 Q000139 NN,D013110 Q000031 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.,"OBJECTIVE: To report outcomes of pregnancies that occurred during the fingolimod clinical development program. METHODS: Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined as fingolimod treatment at the time of conception or in the 6 weeks before conception. RESULTS: As of October 31, 2011, 89 pregnancies were reported in completed or ongoing clinical studies, with 74 in ",Neurology,"Goeril Karlsson, Gordon Francis, Gideon Koren, Peter Heining, Xiaoli Zhang, Jeffrey A Cohen, Ludwig Kappos, William Collins"," From Novartis Pharma AG (G. Karlsson, P.H., W.C.), Basel, Switzerland; Novartis Pharmaceuticals Corporation (G.F., X.Z.), East Hanover, NJ; Motherisk Program (G. Koren), Hospital for Sick Children, Toronto, Canada; Neurological Institute (J.A.C.), Cleveland Clinic, OH; and Neurology and Department of Biomedicine (L.K.), University Hospital, Basel, Switzerland.",2014 Feb;82(8):674-80,10.1212/wnl.0000000000000137
24468818,20140401,article,mesh,"Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukoencephalopathy, Progressive Multifocal,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D061067 Q000009 NY,D013110 Q000031 NY,D007968 Q000139 NY,D020529 Q000188 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Carmen Tur, Xavier Montalban"," Multiple Sclerosis Centre of Catalonia, Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain.",2014 Apr;20(4):510-1,10.1177/1352458513517281
24475777,20140101,article,mesh,"Adolescent,Adult,Asian Continental Ancestry Group,Double-Blind Method,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome,Young Adult","analogs &amp; derivatives,diagnosis,drug therapy,ethnology,therapeutic use","D020529 Q000208 NY,D044466 Q000208 NY,D020529 Q000175 NN,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.,"BACKGROUND: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod. METHODS: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to fingolimod 1.25 ",BMC neurology,"Jun-ichi Kira, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kazuo Nagato, Isao Tsumiyama, Philipp von Rosenstiel, Lixin Zhang-Auberson, Takahiko Saida"," Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. kira@neuro.med.kyushu-u.ac.jp.",2014 Jan;14(?):21,10.1186/1471-2377-14-21
24506481,20140401,article,mesh,"Acetylcysteine,Activating Transcription Factor 1,Calcium,Cell Proliferation,Fingolimod Hydrochloride,Free Radical Scavengers,Immunosuppressive Agents,Mitogen-Activated Protein Kinases,Oxidative Stress,Phosphoproteins,Propylene Glycols,Reactive Oxygen Species,Schizosaccharomyces,Schizosaccharomyces pombe Proteins,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology","D012568 Q000235 NN,D007166 Q000494 NY,D012568 Q000187 NY,D010750 Q000378 NY,D012568 Q000378 NN,D010750 Q000235 NN,D000111 Q000494 NN,D029702 Q000235 NN,D013110 Q000031 NY,D051697 Q000235 NN,D011409 Q000494 NY,D020928 Q000378 NY,D016166 Q000494 NN,D002118 Q000378 NN,D017382 Q000378 NY,D051697 Q000378 NY,D029702 Q000378 NY,D020928 Q000235 NN,D013110 Q000494 NN","12035,107969,107970,5280335,5460341,6337033,12114682,23678798",NULL,FTY720 stimulated ROS generation and the Sty1/Atf1 signaling pathway in the fission yeast Schizosaccharomyces pombe.,"Fingolimod hydrochloride (FTY720) is the first-in-class immune modulator known as sphingosine 1-phosphate (S1P) receptor agonists. FTY720 has also been reported to exert a variety of physiological functions such as antitumor effect, angiogenesis inhibition, and Ca2+ mobilization. Here, we show that FTY720 treatment induced reactive oxygen species (ROS) accumulation, and investigated the effect of FTY720 on the stress-activated MAP kinase Spc1/Sty1, a functional homologue of p38 MAPK, using a Renilla lucifer",Genes to cells : devoted to molecular & cellular mechanisms,"Kanako Hagihara, Aya Mizukura, Yuki Kitai, Mariko Yao, Kouki Ishida, Ayako Kita, Tatsuki Kunoh, Takashi Masuko, Sumio Matzno, Kenji Chiba, Reiko Sugiura"," Laboratory of Molecular Pharmacogenomics, School of Pharmaceutical Sciences, Kinki University, 3-4-1 Kowakae, Higashi-Osaka, 577-8502, Japan; Japan Society for the Promotion of Science, 1-8 Chiyoda-ku, Tokyo, 102-8472, Japan.",2014 Apr;19(4):325-37,10.1111/gtc.12134
24507619,20140315,article,mesh,"Cell Separation,Female,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocytes, Regulatory,Th17 Cells","analogs &amp; derivatives,blood,drug therapy,immunology,therapeutic use","D050378 Q000276 NY,D013110 Q000031 NY,D058504 Q000276 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY,D020529 Q000097 NY,D020529 Q000276 NN","107969,107970,5280335",NULL,Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.,"Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4+ T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequen",Journal of neuroimmunology,"Douglas Kazutoshi Sato, Ichiro Nakashima, Amit Bar-Or, Tatsuro Misu, Chihiro Suzuki, Shuhei Nishiyama, Hiroshi Kuroda, Kazuo Fujihara, Masashi Aoki"," Department of Neurology, Tohoku University School of Medicine, Sendai, Japan. Department of Neurology, Tohoku University School of Medicine, Sendai, Japan. Electronic address: nakashima@med.tohoku.ac.jp. Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Canada. Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan. Department of Neurology, Tohoku University School of Medicine, Sendai, Japan. Department of Neurology, Toh",2014 Mar;268(?):95-8,10.1016/j.jneuroim.2014.01.008
24508946,20140201,article,mesh,"Animals,Apolipoproteins E,Cardiotonic Agents,Coronary Artery Disease,Diet, High-Fat,Disease Models, Animal,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Male,Mice,Mice, Inbred C57BL,Mice, Knockout,Myocardial Infarction,Myocardial Reperfusion Injury,Propylene Glycols,Sphingosine,Survival Rate,T-Lymphocytes, Regulatory,Time Factors,Transforming Growth Factor beta,Ventricular Function, Left","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,drug therapy,etiology,genetics,metabolism,pharmacology,physiopathology","D002316 Q000008 NN,D059305 Q000009 NN,D009203 Q000188 NY,D007249 Q000188 NN,D007166 Q000008 NN,D009203 Q000503 NN,D050378 Q000378 NN,D002316 Q000494 NN,D001057 Q000235 NY,D013110 Q000008 NN,D003324 Q000503 NN,D007249 Q000503 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D016212 Q000378 NN,D015428 Q000188 NN,D016277 Q000187 NN,D007249 Q000209 NN,D015428 Q000503 NN,D013110 Q000494 NN,D007166 Q000494 NN,D003324 Q000188 NY","107969,107970,5280335,56842206",NULL,The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction.,"FTY720, an analogue of sphingosine-1-phosphate, is cardioprotective during acute injury. Whether long-term FTY720 affords cardioprotection is unknown. Here, we report the effects of oral FTY720 on ischemia/reperfusion injury and in hypomorphic apoE mice deficient in SR-BI receptor expression (ApoeR61(h/h)/SRB1(-/- mice), a model of diet-induced coronary atherosclerosis and heart failure. We added FTY720 (0.3 mg·kg(-1)·d(-1)) to the drinking water of C57BL/6J mice. After ex vivo cardiac ischemia/reperfusion ",Journal of cardiovascular pharmacology,"Guanying Wang, Roy Y Kim, Isabella Imhof, Norman Honbo, Fu Sang Luk, Kang Li, Nikit Kumar, Bo-Qing Zhu, Delphine Eberlé, Daniel Ching, Joel S Karliner, Robert L Raffai"," Cardiology Section, Medical Service, VA Medical Center, San Francisco and the University of California, San Francisco. Surgical Service, VA Medical Center, San Francisco and the Department of Surgery, University of California, San Francisco. Cardiology Section, Medical Service, VA Medical Center, San Francisco and the University of California, San Francisco. Cardiology Section, Medical Service, VA Medical Center, San Francisco and the University of California, San Francisco. Surgical Service, VA Medical Ce",2014 Feb;63(2):132-143,10.1097/fjc.0000000000000031
24514867,20140301,article,mesh,"Abnormalities, Drug-Induced,Female,Humans,Immunosuppressive Agents,Multiple Sclerosis,Pregnancy,Pregnancy Complications,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D011248 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY",5280335,NULL,Multiple sclerosis: Study reinforces need for contraception in women taking fingolimod.,NULL,Nature reviews. Neurology,Bryony Jones,NULL,2014 Mar;10(3):125,10.1038/nrneurol.2014.22
24515730,20141001,article,mesh,"Adult,Amenorrhea,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Time Factors,Treatment Outcome","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,diagnosis,drug therapy,therapeutic use","D000568 Q000175 NN,D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000008 NN,D000568 Q000139 NY,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod-associated amenorrhea: a report of three cases.,"Amenorrhea has not been reported as an adverse event in fingolimod phase III clinical trials in patients with multiple sclerosis (MS) with either 0.5 mg or 1.25 mg dosages. Here we report three cases of young women with MS who developed amenorrhea within 6 months of initiation of fingolimod. They experienced irregularities in their menstrual cycles in the first 3 months, which progressed to amenorrhea by 5(th) or 6(th) month. Gynecology evaluations showed no other etiologies. Menses returned to baseline aft","Multiple sclerosis (Houndmills, Basingstoke, England)",R Alroughani," Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait Neurology Clinic, Dasman Diabetes Institute, Kuwait alroughani@gmail.com.",2014 Oct;20(12):1662-4,10.1177/1352458514523497
24516904,20140101,article,mesh,"Cardiovascular Diseases,Death, Sudden,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,etiology","D013110 Q000009 NN,D003645 Q000209 NN,D013110 Q000031 NY,D002318 Q000139 NN,D006339 Q000187 NN,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod. Check cardiovascular status again on treatment resumption.,NULL,Prescrire international,NULL,NULL,2014 Jan;23(145):13,NULL
24523479,20140318,article,mesh,"Adult,Atrial Fibrillation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D001281 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.,NULL,Neurology,"Linda Rolf, Anne-Hilde Muris, Jan Damoiseaux, Marc van Daele, Raymond Hupperts"," From the School for Mental Health and Neuroscience (L.R., A.-H.M., R.H.) and the Central Diagnostic Laboratory (J.D.), Maastricht University Medical Center; and Academic MS Center Limburg (L.R., A.-H.M., R.H.) and the Department of Cardiology, Orbis Medical Center (M.v.D.), Sittard, the Netherlands.",2014 Mar;82(11):1008-9,10.1212/wnl.0000000000000218
24526661,20140901,article,mesh,"ADP-ribosyl Cyclase 1,Adult,B-Lymphocyte Subsets,Biomarkers,Case-Control Studies,Cell Proliferation,Drug Resistance,Female,Fingolimod Hydrochloride,Flow Cytometry,Humans,Immunologic Memory,Immunosuppressive Agents,Ki-67 Antigen,Lymphocyte Activation,Male,Membrane Glycoproteins,Middle Aged,Multiple Sclerosis,Phenotype,Propylene Glycols,RNA, Messenger,Receptors, Lysosphingolipid,Sphingosine,Syndecan-1,Time Factors,Treatment Outcome","analogs &amp; derivatives,blood,diagnosis,drug effects,drug therapy,genetics,immunology,metabolism,therapeutic use","D008562 Q000378 NN,D016175 Q000187 NY,D009103 Q000235 NN,D019394 Q000378 NN,D009103 Q000097 NN,D049349 Q000235 NN,D049109 Q000187 NN,D013110 Q000031 NY,D007166 Q000627 NY,D008213 Q000187 NN,D012333 Q000378 NN,D009103 Q000175 NN,D051997 Q000378 NN,D016175 Q000378 NN,D053668 Q000378 NN,D016175 Q000276 NN,D015415 Q000378 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D049349 Q000378 NN","107969,107970,5280335",NULL,Differential effects of fingolimod on B-cell populations in multiple sclerosis.,"BACKGROUND: Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells. OBJECTIVE: To clarify the effects of fingolimod on B-cell populations in patients with MS. METHODS: We analysed blood samples from 9 fingolimod-treated and 19 control patients with MS by flow cytometry, to determine the frequencies","Multiple sclerosis (Houndmills, Basingstoke, England)","Masakazu Nakamura, Takako Matsuoka, Norio Chihara, Sachiko Miyake, Wakiro Sato, Manabu Araki, Tomoko Okamoto, Youwei Lin, Masafumi Ogawa, Miho Murata, Toshimasa Aranami, Takashi Yamamura"," Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan. Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan. Department of Immunology, National Institu",2014 Sep;20(10):1371-80,10.1177/1352458514523496
24566807,20140401,article,mesh,"Adolescent,Adult,Aged,Antibodies, Monoclonal, Humanized,Cohort Studies,Drug Substitution,Female,Fingolimod Hydrochloride,France,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis,Natalizumab,Propylene Glycols,Prospective Studies,Risk Factors,Sphingosine,Tertiary Care Centers,Young Adult","analogs &amp; derivatives,diagnosis,drug therapy,epidemiology,methods,therapeutic use,trends","D009103 Q000453 NN,D005602 Q000453 NN,D061067 Q000627 NY,D057915 Q000639 NN,D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000175 NN,D057915 Q000379 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.,"IMPORTANCE: The safety and efficacy of switching from natalizumab to fingolimod have not yet been evaluated in a large cohort of patients with multiple sclerosis (MS) to our knowledge. OBJECTIVE: To collect data from patients with MS switching from natalizumab to fingolimod. DESIGN, SETTING, AND PARTICIPANTS: The Enquête Nationale sur l'Introduction du Fingolimod en Relais au Natalizumab (ENIGM) study, a survey-based, observational multicenter cohort study among MS tertiary referral centers. Participants we",JAMA neurology,"Mikael Cohen, Elisabeth Maillart, Ayman Tourbah, Jérôme De Sèze, Sandra Vukusic, David Brassat, Olivier Anne, Sandrine Wiertlewski, William Camu, Sylvie Courtois, Aurélie Ruet, Marc Debouverie, Emmanuelle Le Page, Olivier Casez, Olivier Heinzlef, Bruno Stankoff, Bertrand Bourre, Giovanni Castelnovo, Audrey Rico, Eric Berger, Jean-Philippe Camdessanche, Gilles Defer, Pierre Clavelou, Abdullatif Al Khedr, Hélène Zephir, Agnès Fromont, Caroline Papeix, Bruno Brochet, Jean Pelletier, Christine Lebrun, Club Fran"," Department of Neurology, University Hospital of Nice, Nice, France. Department of Neurology, Salpêtrière Hospital, Paris, France. Department of Neurology, University Hospital of Reims, Reims, France. Department of Neurology, University Hospital of Strasbourg, Strasbourg, France. Department of Neurology, University Hospital of Lyon, Lyon, France. Department of Neurology, University Hospital of Toulouse, Toulouse, France. Department of Neurology, University Hospital of La Rochelle, La Rochelle, France. Depar",2014 Apr;71(4):436-41,10.1001/jamaneurol.2013.6240
24567529,20140401,article,mesh,"Animals,CD11b Antigen,Cell Differentiation,Cells, Cultured,Chemical and Drug Induced Liver Injury,Female,Fingolimod Hydrochloride,Immunoblotting,Immunosuppressive Agents,Liver,Male,Mice,Mice, Inbred C57BL,Myeloid Cells,Nitric Oxide,Nitric Oxide Synthase Type II,Propylene Glycols,RNA Interference,Receptors, Chemokine,Receptors, Lysosphingolipid,Reverse Transcriptase Polymerase Chain Reaction,Sirolimus,Sphingosine,T-Lymphocytes, Regulatory,TOR Serine-Threonine Kinases,Th1 Cells,omega-N-Methylarginine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,immunology,metabolism,pathology,pharmacology,prevention &amp; control","D058570 Q000037 NN,D009569 Q000276 NN,D018417 Q000276 NN,D052247 Q000378 NN,D008099 Q000473 NN,D050378 Q000378 NN,D052247 Q000037 NN,D019323 Q000494 NN,D022423 Q000378 NN,D008099 Q000276 NY,D018417 Q000378 NN,D049349 Q000235 NN,D056486 Q000517 NN,D050378 Q000187 NN,D056486 Q000235 NN,D058570 Q000378 NN,D018417 Q000187 NN,D058570 Q000276 NN,D013110 Q000031 NN,D009569 Q000378 NN,D020123 Q000494 NN,D022423 Q000276 NY,D019707 Q000378 NN,D052247 Q000235 NN,D002454 Q000276 NN,D050378 Q000276 NN,D056486 Q000276 NY","107969,107970,132862,135242,145068,177980,2733509,5280335,5284616",NULL,Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells.,"Although FTY720 may alter migration and homing of lymphocytes via sphingosine-1-phosphate (S1P) receptors, our recent studies indicated that FTY720 directly controls the differentiation of Th1 cells to regulatory T cells (Tregs) by targeting S1P1. However, the pharmacological function of FTY720 in immunological hepatic injury remains unknown. In this study, the role and regulatory signaling pathway of S1P receptor were investigated using a pharmacological approach in immune-mediated hepatic injury (IMH). In","Journal of immunology (Baltimore, Md. : 1950)","Guangwei Liu, Yujing Bi, Ruoning Wang, Hui Yang, Yan Zhang, Xiao Wang, Huanrong Liu, Yun Lu, Zhengguo Zhang, Wanna Chen, Yiwei Chu, Ruifu Yang"," Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China;",2014 Apr;192(7):3068-79,10.4049/jimmunol.1301193
24573171,20140401,article,mesh,"Administration, Topical,Allografts,Animals,B7-2 Antigen,CTLA-4 Antigen,Cornea,Corneal Transplantation,Cyclosporine,Dendritic Cells,Fingolimod Hydrochloride,Graft Rejection,Graft Survival,Histocompatibility Antigens Class II,Immune Tolerance,Immunosuppressive Agents,Interferon-gamma,Interleukin-2,Male,Mice,Mice, Inbred BALB C,Mice, Inbred C57BL,Models, Animal,Ophthalmic Solutions,Propylene Glycols,RNA, Messenger,Real-Time Polymerase Chain Reaction,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology,prevention &amp; control","D006085 Q000187 NN,D000949 Q000378 NN,D007166 Q000494 NY,D003315 Q000187 NY,D049349 Q000819 NY,D007376 Q000235 NN,D006084 Q000235 NN,D006084 Q000378 NN,D051940 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D060908 Q000235 NN,D012333 Q000378 NN,D003315 Q000378 NN,D016572 Q000494 NN,D007371 Q000235 NN,D003713 Q000378 NN,D013110 Q000494 NN,D006084 Q000517 NY","2909,62280,107969,107970,5280335,5280754,5284373,5458585,6435893,9855081,24883466,25246316,49867938,71306795,71463825,73896891,122172945,123134263,123134270,132274082",NULL,Effects of topical sphingosine-1-phosphate 1 receptor agonist on corneal allograft in mice.,"PURPOSE: The aim of this study was to compare the antirejection effects of topical selective sphingosine-1-phosphate 1 receptor (S1P1) agonist and cyclosporine A (CsA) on the acceptance of a transplanted, allogeneic cornea graft in a murine animal model. METHODS: Fifty-six BALB/c mice were randomly divided into 4 groups. All the mice received corneal grafts from 28 C57BL/6 donors. Experimental recipients were treated with 0.25%, 0.5% S1P1 agonist suspension eye drops or 1% CsA eye drops 4 times a day after ",Cornea,"Liang Jia, Yong Liu, Liqiang Wang, Jing Zhu, Yifei Huang"," *Department of Ophthalmology, Chinese People's Liberation Army General Hospital, Beijing, China; †Department of Ophthalmology, Chinese People's Liberation Army Air Force General Hospital, Beijing, China; and ‡Department of Ophthalmology, First Affiliated Hospital of Chinese People's Liberation Army General Hospital, Beijing, China.",2014 Apr;33(4):398-404,10.1097/ico.0000000000000077
24579791,20140401,review,mesh,"Administration, Oral,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,pharmacokinetics,therapeutic use","D011409 Q000493 NY,D007166 Q000627 NN,D007166 Q000493 NY,D013110 Q000031 NY,D013110 Q000493 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NN","107969,107970,5280335",NULL,Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.,"INTRODUCTION: Fingolimod is a sphingosine 1-phosphate receptor modulator with a novel mechanism of action and the first oral drug approved for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod reduces relapses more effectively than intramuscular interferon β1a and delays disability progression. Associated safety risks are bradyarrhythmia and atrioventricular block following the initial dose, requiring monitoring. AREAS COVERED: This article examines the characteristics of fingolimod, i",Expert opinion on drug metabolism & toxicology,"Radu Tanasescu, Cris S Constantinescu"," University of Nottingham, Queen's Medical Centre, Academic Division of Clinical Neurology , C Floor, South Block, Nottingham, NG7 2UH , UK +44 115 8754597/98 ; +44 115 823 1443 ; cris.constantinescu@nottingham.ac.uk.",2014 Apr;10(4):621-30,10.1517/17425255.2014.894019
24599139,20140101,review,mesh,"Active Transport, Cell Nucleus,Animals,Arachidonic Acid,Cells, Cultured,Ceramides,Cyclooxygenase 2,Fingolimod Hydrochloride,Golgi Apparatus,Group IV Phospholipases A2,Humans,Inflammation,Lactosylceramides,Lysophospholipids,Propylene Glycols,Sphingolipids,Sphingomyelins,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,metabolism,pharmacology,physiology","D007790 Q000502 NN,D007249 Q000378 NN,D007790 Q000494 NN,D008246 Q000494 NN,D013109 Q000494 NN,D051546 Q000378 NN,D002518 Q000494 NN,D013110 Q000031 NN,D013109 Q000502 NN,D016718 Q000378 NY,D013107 Q000378 NN,D002518 Q000502 NN,D008246 Q000502 NN,D011409 Q000494 NN,D013110 Q000494 NN,D013107 Q000494 NN,D013107 Q000502 NY,D054513 Q000378 NN,D054513 Q000037 NN,D006056 Q000378 NN,D013110 Q000502 NN","107969,107970,444899,5280335,5283560,23675453,44176376",NULL,Role of sphingolipids in arachidonic acid metabolism.,"The arachidonic acid (AA) cascade is regulated mainly by the actions of two rate-limiting enzymes, phospholipase A₂ (PLA₂) and inducible cyclooxygenase-2 (COX-2). PLA₂ acts to generate AA, which serves as the precursor substrate for COX-2 in the metabolic pathway leading to prostaglandin production. Amongst more than 30 members of the PLA₂ family, cytosolic PLA₂α (cPLA₂α, group IVA) plays a major role in releasing AA from cellular membranes. Sphingolipids are a novel class of bioactive lipids that play key ",Journal of pharmacological sciences,"Hiroyuki Nakamura, Toshihiko Murayama"," Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Japan.",2014 Jan;124(3):307-12,10.1254/jphs.13r18cp
24599515,20140701,article,mesh,"Animals,Antibodies,Cell Proliferation,Cytokines,Diabetes Mellitus, Type 1,Disease Models, Animal,Drug Therapy, Combination,Fingolimod Hydrochloride,Hyperglycemia,Immunosuppressive Agents,Insulin-Secreting Cells,Lymph Nodes,Macrophages,Microscopy, Electron, Transmission,Propylene Glycols,Rats,Receptors, Antigen, T-Cell,Sphingosine,T-Lymphocytes","administration &amp; dosage,analogs &amp; derivatives,cytology,drug effects,drug therapy,immunology,ultrastructure","D050417 Q000648 NN,D016207 Q000276 NN,D008264 Q000276 NN,D003922 Q000276 NN,D013601 Q000276 NN,D013110 Q000008 NN,D008198 Q000187 NN,D008198 Q000276 NN,D049109 Q000187 NN,D050417 Q000187 NN,D013110 Q000031 NY,D006943 Q000188 NY,D008264 Q000187 NN,D006943 Q000276 NN,D050417 Q000166 NN,D011948 Q000276 NY,D003922 Q000188 NY,D000906 Q000008 NY,D011409 Q000008 NY,D007166 Q000008 NY,D013601 Q000187 NN","107969,107970,5280335",NULL,Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.,"The therapeutic capacity of an antibody directed against the T cell receptor (anti-TCR) of the TCR/CD3 complex alone or in combination with fingolimod (FTY720) to reverse the diabetic metabolic state through suppression of autoimmunity and stimulation of β cell regeneration was analyzed in the LEW.1AR1-iddm (IDDM) rat, an animal model of human type 1 diabetes. Animals were treated with anti-TCR (0.5 mg/kg body weight for 5 days) monotherapy or in combination with fingolimod (1 mg/kg body weight for 40 days)","Journal of molecular medicine (Berlin, Germany)","Anne Jörns, Muharrem Akin, Tanja Arndt, Taivankhuu Terbish, Andreas Meyer Zu Vilsendorf, Dirk Wedekind, Hans-Jürgen Hedrich, Sigurd Lenzen"," Institute of Clinical Biochemistry, Hannover Medical School, 30623, Hannover, Germany.",2014 Jul;92(7):743-55,10.1007/s00109-014-1137-2
24603883,20141001,article,mesh,"Adult,Angioedema,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Knee,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Skin,Sphingosine","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,chemically induced,diagnosis,drug therapy,metabolism,pathology","D013110 Q000009 NN,D013110 Q000031 NY,D007717 Q000473 NN,D000799 Q000473 NN,D000799 Q000175 NN,D012867 Q000473 NN,D020529 Q000188 NY,D020529 Q000378 NN,D007166 Q000009 NY,D000799 Q000139 NY,D049349 Q000037 NN,D049349 Q000378 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","S Masera, C Chiavazza, A Mattioda, G Superti, E Beggiato, P Crosasso, P Broganelli, L Pinessi, P Cavalla"," MS Center, & I Division of Neurology, Department of Neuroscience, University of Turin & City of Health and Science of Turin University Hospital, Italy. MS Center, & I Division of Neurology, Department of Neuroscience, University of Turin & City of Health and Science of Turin University Hospital, Italy. MS Center, & I Division of Neurology, Department of Neuroscience, University of Turin & City of Health and Science of Turin University Hospital, Italy. MS Center, & I Division of Neurology, Department of Neu",2014 Oct;20(12):1666-7,10.1177/1352458514525872
24607506,20140401,article,mesh,"Adult,B-Lymphocyte Subsets,B7-1 Antigen,Case-Control Studies,Chemotaxis, Leukocyte,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Interleukin-10,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Receptors, CCR7,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,blood,drug effects,drug therapy,immunology,metabolism,physiology,therapeutic use","D007249 Q000378 NN,D016175 Q000187 NY,D014409 Q000097 NN,D002634 Q000502 NN,D009103 Q000378 NN,D013110 Q000031 NY,D007166 Q000627 NY,D018122 Q000097 NN,D007249 Q000276 NN,D054400 Q000097 NN,D002634 Q000187 NN,D016175 Q000276 NN,D009103 Q000276 NN,D016175 Q000502 NN,D013110 Q000627 NN,D016753 Q000097 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,"Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.","The chief therapeutic mechanism of fingolimod in multiple sclerosis (MS) is considered to be sequestration of pathogenic lymphocytes into secondary lymphoid tissues. B cells have recently been recognized as important immune regulators in MS. In this study, the effects of fingolimod on B cells in MS patients were analyzed. MS patients treated with fingolimod (MS-F) had a significantly lower number of B cells in the circulation. The remaining B cells in the blood of MS-F had a reduced proportion of memory B c","Clinical immunology (Orlando, Fla.)","Yusei Miyazaki, Masaaki Niino, Toshiyuki Fukazawa, Eri Takahashi, Takayuki Nonaka, Itaru Amino, Jun Tashiro, Naoya Minami, Naoto Fujiki, Shizuki Doi, Seiji Kikuchi"," Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-choume, Nishi-ku, Sapporo 063-0005, Japan; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-choume, Nishi-ku, Sapporo 063-0005, Japan. Electronic address: yuseimiyazaki@hok-mc.hosp.go.jp. Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-choume, Nishi-ku, Sapporo 063-0005, Japan. Sapporo Neurology Clinic, 2-17 Kita-21-jo Higashi-21-choume, Higashi-ku, Sapporo 065-0021, Japan. Depar",2014 Apr;151(2):127-35,10.1016/j.clim.2014.02.001
24610329,20140408,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Risk Factors,Secondary Prevention,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,immunology,metabolism,prevention &amp; control,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007155 Q000276 NN,D007166 Q000627 NY,D020529 Q000517 NN,D016899 Q000378 NN,D020529 Q000188 NY,D013110 Q000627 NN,D007155 Q000378 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod after natalizumab and the risk of short-term relapse.,OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regr,Neurology,"Vilija G Jokubaitis, Vivien Li, Tomas Kalincik, Guillermo Izquierdo, Suzanne Hodgkinson, Raed Alroughani, Jeannette Lechner-Scott, Alessandra Lugaresi, Pierre Duquette, Marc Girard, Michael Barnett, Francois Grand'Maison, Maria Trojano, Mark Slee, Giorgio Giuliani, Cameron Shaw, Cavit Boz, Daniele L A Spitaleri, Freek Verheul, Jodi Haartsen, Danny Liew, Helmut Butzkueven, MSBase Study Group"," From the Department of Medicine (V.G.J., T.K., H.B.), Melbourne Brain Centre (RMH), The University of Melbourne; Department of Neurology (V.G.J., V.L., T.K., H.B.), Royal Melbourne Hospital, Australia; Hospital Universitario Virgen Macarena (G.I.), Seville, Spain; Liverpool Hospital (S.H.), New South Wales, Australia; Amiri Hospital (R.A.), Kuwait City, Kuwait; John Hunter Hospital (J.L.-S.), Newcastle, Australia; MS Center (A.L.), Department of Neuroscience and Imaging, University ""G. d'Annunzio,"" Chieti,",2014 Apr;82(14):1204-11,10.1212/wnl.0000000000000283
24610331,20140408,article,mesh,"Antibodies, Monoclonal, Humanized,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.,"With more choices for multiple sclerosis (MS) disease-modifying therapies, data are urgently required to support clinical decisions regarding safe transitioning and sequencing of therapies. With more than 7 years of clinical experience, natalizumab has been confirmed as highly effective in reducing MS disease activity. However, natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML),(1) with more than 400 cases of natalizumab-related PML to date.(2) Because 2 of the 3 initial natalizu",Neurology,"Gavin Giovannoni, Robert T Naismith"," From the Queen Mary University of London (G.G.), Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK; and the Department of Neurology (R.T.N.), Washington University School of Medicine, St. Louis, MO.",2014 Apr;82(14):1196-7,10.1212/wnl.0000000000000296
24626925,20140314,article,NULL,NULL,NULL,NULL,NULL,NULL,"Main-group compounds selectively oxidize mixtures of methane, ethane, and propane to alcohol esters.","Much of the recent research on homogeneous alkane oxidation has focused on the use of transition metal catalysts. Here, we report that the electrophilic main-group cations thallium(III) and lead(IV) stoichiometrically oxidize methane, ethane, and propane, separately or as a one-pot mixture, to corresponding alcohol esters in trifluoroacetic acid solvent. Esters of methanol, ethanol, ethylene glycol, isopropanol, and propylene glycol are obtained with greater than 95% selectivity in concentrations up to 1.48","Science (New York, N.Y.)","Brian G Hashiguchi, Michael M Konnick, Steven M Bischof, Samantha J Gustafson, Deepa Devarajan, Niles Gunsalus, Daniel H Ess, Roy A Periana"," The Scripps Energy and Materials Center, Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.",2014 Mar;343(6176):1232-7,10.1126/science.1249357
24634490,20140415,article,mesh,"Animals,Antigens, Protozoan,CD4-Positive T-Lymphocytes,Dendritic Cells,Epitopes, T-Lymphocyte,Female,Fingolimod Hydrochloride,Immunologic Memory,Immunosuppressive Agents,Leishmania donovani,Leishmaniasis, Visceral,Liver,Lymphocyte Activation,Lymphoid Tissue,Mice,Mice, Knockout,Propylene Glycols,Sphingosine,Spleen","analogs &amp; derivatives,drug effects,immunology,parasitology,pharmacology","D000953 Q000276 NN,D013154 Q000187 NN,D008099 Q000469 NN,D008221 Q000469 NN,D018984 Q000276 NN,D015496 Q000187 NN,D008213 Q000276 NN,D008099 Q000276 NN,D007893 Q000276 NY,D003713 Q000276 NN,D007898 Q000276 NY,D013110 Q000031 NN,D015496 Q000276 NY,D013154 Q000276 NN,D013154 Q000469 NN,D008221 Q000187 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D008221 Q000276 NN,D008099 Q000187 NN","107969,107970,5280335",NULL,Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.,"Organ-specific immunity is a feature of many infectious diseases, including visceral leishmaniasis caused by Leishmania donovani. Experimental visceral leishmaniasis in genetically susceptible mice is characterized by an acute, resolving infection in the liver and chronic infection in the spleen. CD4+ T cell responses are critical for the establishment and maintenance of hepatic immunity in this disease model, but their role in chronically infected spleens remains unclear. In this study, we show that dendri","Journal of immunology (Baltimore, Md. : 1950)","Patrick T Bunn, Amanda C Stanley, Fabian de Labastida Rivera, Alexander Mulherin, Meru Sheel, Clare E Alexander, Rebecca J Faleiro, Fiona H Amante, Marcela Montes De Oca, Shannon E Best, Kylie R James, Paul M Kaye, Ashraful Haque, Christian R Engwerda"," QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia;",2014 Apr;192(8):3709-18,10.4049/jimmunol.1300768
24635919,20140401,article,mesh,"Adult,Brain,Cohort Studies,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kuwait,Magnetic Resonance Imaging,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Retrospective Studies,Sphingosine,Treatment Outcome,Young Adult","analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D001921 Q000473 NY,D013110 Q000031 NY,D020529 Q000473 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.,"BACKGROUND: Post-marketing studies are important to confirm what was established in clinical trials, and to assess the intermediate and long-term efficacy and safety. OBJECTIVE: To assess efficacy and safety of fingolimod in multiple sclerosis (MS) in Kuwait. METHODS: We retrospectively evaluated MS patients using the MS registries in 3 MS clinics. Relapsing remitting MS patients according to revised 2010 McDonald criteria who had been treated with fingolimod for at least 12 months were included. Primary en",Clinical neurology and neurosurgery,"R Alroughani, S F Ahmed, R Behbehani, J Al-Hashel"," Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait; Neurology Clinic, Department of Medicine, Dasman Diabetes Institute, Dasman, Kuwait. Electronic address: alroughani@gmail.com. Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Neurology & Psychiatry, Al-Minia University Hospital, Minia, Egypt. Neurology Clinic, Department of Medicine, Dasman Diabetes Institute, Dasman, Kuwait. Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Departmen",2014 Apr;119(?):17-20,10.1016/j.clineuro.2014.01.007
24679864,20140501,article,mesh,"Animals,Blotting, Western,Disease Models, Animal,Female,Fibrosis,Fingolimod Hydrochloride,Immunohistochemistry,Immunosuppressive Agents,Inflammation,Kidney,Male,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine,Transforming Growth Factor beta1,Ureteral Obstruction","analogs &amp; derivatives,drug therapy,metabolism,pathology,prevention &amp; control,therapeutic use","D007668 Q000473 NY,D014517 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D007249 Q000517 NY,D053773 Q000378 NN,D014517 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction.,"PURPOSE: The S1P signaling pathway represents an important potential target for the modulation of tissue inflammation/injury. The immunomodulator FTY720, also known as fingolimod, is a potent agonist for multiple S1P receptors that was approved by the Food and Drug Administration to treat multiple sclerosis. We examined the therapeutic role of FTY720 for renal injury secondary to unilateral ureteral obstruction. MATERIALS AND METHODS: CB57BL/6 mice underwent a sham procedure or unilateral ureteral obstructi",The Journal of urology,"Shobha Thangada, Linda H Shapiro, Cynthia Silva, Harold Yamase, Timothy Hla, Fernando A Ferrer"," Center for Vascular Biology, University of Connecticut Health Center, Farmington, Connecticut; Department of Urology, Connecticut Children's Medical Center, Hartford, Connecticut. Center for Vascular Biology, University of Connecticut Health Center, Farmington, Connecticut; Department of Urology, Connecticut Children's Medical Center, Hartford, Connecticut. Department of Nephrology, Connecticut Children's Medical Center, Hartford, Connecticut. Department of Pathology, University of Connecticut Health Cente",2014 May;191(?):1508-16,10.1016/j.juro.2013.10.072
24680062,20140515,article,mesh,"Animals,CD8-Positive T-Lymphocytes,Chemotaxis, Leukocyte,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Flow Cytometry,Granzymes,Immunosuppressive Agents,Influenza A Virus, H1N1 Subtype,Interferon-gamma,Lysophospholipids,Mice,Mice, Inbred C57BL,Orthomyxoviridae Infections,Propylene Glycols,Signal Transduction,Sphingosine","analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology","D053804 Q000096 NN,D007166 Q000494 NY,D018414 Q000276 NN,D009976 Q000276 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013110 Q000378 NN,D018414 Q000187 NY,D007371 Q000096 NN,D002634 Q000187 NN,D008246 Q000378 NN,D004681 Q000276 NY,D015398 Q000187 NN,D013110 Q000494 NN","107969,107970,5280335,5283560",NULL,FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.,"Fingolimod (FTY720) is a multiple sclerosis (MS) therapeutic that upon phosphorylation causes the internalization of sphingosine-1-phosphate receptors (S1PR) and traps CCR7+ T-cells in lymph nodes but relatively spares CCR7-effector T-cells. Nonetheless, FTY720-treated patients are more susceptible to viral infections, indicating a CD8 T-cell defect. Thus, the effects of FTY720 on CD8 T-cells were investigated. To this end, we utilized experimental autoimmune encephalomyelitis (EAE) and a murine influenza m",Journal of neuroimmunology,"Achilles Ntranos, Olivia Hall, Dionne P Robinson, Inna V Grishkan, Jason T Schott, Dominique M Tosi, Sabra L Klein, Peter A Calabresi, Anne R Gocke"," Department of Neurology, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA. W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA. W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of",2014 May;270(?):13-21,10.1016/j.jneuroim.2014.03.007
24682874,20140801,article,mesh,"Animals,Bone Marrow Cells,Carbon Tetrachloride,Cell Movement,Disease Models, Animal,Fibrosis,Fingolimod Hydrochloride,Immunosuppressive Agents,Liver Cirrhosis,Mesenchymal Stromal Cells,Mice,Mice, Inbred ICR,Mice, SCID,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Wound Healing","analogs &amp; derivatives,chemically induced,chemistry,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology","D007166 Q000494 NY,D049349 Q000378 NY,D059630 Q000166 NY,D059630 Q000187 NN,D005355 Q000473 NN,D001854 Q000187 NN,D001854 Q000166 NY,D008103 Q000188 NY,D013110 Q000031 NY,D011409 Q000494 NY,D008103 Q000139 NN,D002251 Q000737 NN,D013110 Q000494 NN,D005355 Q000378 NN","5943,107969,107970,5280335",NULL,"FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.","FTY720 is a novel immunosuppressant that modulates sphingosine 1-phosphate (S1P) receptors for the treatment of several diseases. Several hallmarks of liver fibrosis are influenced by S1P, and the interference of S1P signaling by treatment with FTY720 results in beneficial effects in various animal models of fibrosis. However, whether these treatment strategies suppress liver fibrosis progression is incompletely understood. Here, we investigated the effects and mechanisms by which FTY720 improves liver fibr",Inflammation,"Yaxian Kong, Hong Wang, Shuling Wang, Na Tang"," Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China, kongyaxian@gmail.com.",2014 Aug;37(4):1326-36,10.1007/s10753-014-9877-2
24684973,20140501,article,mesh,"Adult,Disease Progression,Female,Fingolimod Hydrochloride,Gadolinium,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Kaplan-Meier Estimate,Magnetic Resonance Imaging,Male,Multiple Sclerosis,Propylene Glycols,Secondary Prevention,Sphingosine,Time Factors,Treatment Outcome","analogs &amp; derivatives,drug therapy,methods,pathology,therapeutic use","D009103 Q000473 NN,D008279 Q000379 NN,D007155 Q000627 NN,D016899 Q000627 NN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","23982,107969,107970,5280335",NULL,Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.,"AIMS: The phase 3 TRANSFORMS and FREEDOMS studies established the efficacy of fingolimod in reducing multiple sclerosis (MS) relapses and magnetic resonance imaging lesions compared with intramuscular (IM) interferon (IFN) β-1a and placebo over 12 and 24 months, respectively. METHODS: To investigate the efficacy of fingolimod at the approved 0.5 mg dose in patients early in the MS disease course, post hoc subgroup analyses of TRANSFORMS (n = 272) and FREEDOMS (n = 217) data were conducted in patients who ex",CNS neuroscience & therapeutics,"Mark Agius, Xiangyi Meng, Peter Chin, Augusto Grinspan, Ronny Hashmonay"," Department of Neurology, University of California Davis, Davis, CA, USA; Veteran's Affairs Northern California Health Care System, Mather, CA, USA.",2014 May;20(5):446-51,10.1111/cns.12235
24685276,20140601,article,mesh,"Adolescent,Adult,Disability Evaluation,Disease Progression,Double-Blind Method,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Placebos,Propylene Glycols,Secondary Prevention,Sphingosine,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,pharmacology","D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D020529 Q000188 NY,D013110 Q000494 NN,D007166 Q000009 NN","107969,107970,5280335",NULL,"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.","BACKGROUND: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. METHODS: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0·5 mg, fingolimo",The Lancet. Neurology,"Peter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, Douglas Jeffery, Kottil W Rammohan, Anthony T Reder, Timothy Vollmer, Mark A Agius, Ludwig Kappos, Tracy Stites, Bingbing Li, Linda Cappiello, Philipp von Rosenstiel, Fred D Lublin"," Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: pcalabr1@jhmi.edu. Medical Image Analysis Center, University Hospital, Basel, Switzerland. Department of Neurology, University of California, San Francisco, CA, USA. The Multiple Sclerosis and Movement Disorders Center, Cornerstone Health Care, Winston-Salem, NC, USA. Department of Neurology, University of Miami, Miami, FL, USA. Department of Neurology, University of Chicago Medical Center, Chicago",2014 Jun;13(6):545-56,10.1016/s1474-4422(14)70049-3
24685277,20140601,article,mesh,"Clinical Trials as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug therapy,methods,pharmacology,standards","D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002986 Q000009 NN,D002986 Q000379 NN,D002986 Q000592 NY,D020529 Q000188 NY,D013110 Q000494 NN,D007166 Q000009 NN","107969,107970,5280335",NULL,Effects of fingolimod in relapsing-remitting multiple sclerosis.,NULL,The Lancet. Neurology,Per Soelberg Sorensen," Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, DK2100 Copenhagen, Denmark. Electronic address: pss@rh.dk.",2014 Jun;13(6):526-7,10.1016/s1474-4422(14)70067-5
24690227,20140101,article,mesh,"Adolescent,Adult,Atrioventricular Block,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,epidemiology,therapeutic use","D013110 Q000009 NN,D007166 Q000008 NN,D054537 Q000139 NN,D007166 Q000627 NN,D054537 Q000453 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.,"BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After",BMC neurology,"Alice Laroni, Davide Brogi, Vincenzo Brescia Morra, Leonello Guidi, Carlo Pozzilli, Giancarlo Comi, Alessandra Lugaresi, Renato Turrini, Debora Raimondi, Antonio Uccelli, Giovanni Luigi Mancardi, EAP Investigators"," Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Largo Daneo 3, 16132 Genoa, Italy. glmancardi@neurologia.unige.it.",2014 Jan;14(?):65,10.1186/1471-2377-14-65
24733521,20140601,article,mesh,"Animals,Benzothiazoles,Biopsy, Needle,Disease Models, Animal,Foreign-Body Reaction,Immunohistochemistry,Inflammation,Inflammation Mediators,Mice,Mice, Inbred BALB C,Mice, Transgenic,Prosthesis Implantation,Random Allocation,Risk Assessment,Statistics, Nonparametric,Surgical Mesh,Wound Healing","adverse effects,blood,methods,pathology,physiology","D014945 Q000502 NN,D005549 Q000473 NY,D019919 Q000379 NN,D019919 Q000009 NY,D018836 Q000097 NN,D013526 Q000009 NY,D007249 Q000473 NN","5459882,5484207,5896494,6800291,7023066,28125558",NULL,In vivo characterisation of the inflammatory reaction following mesh implantation in transgenic mice models.,"INTRODUCTION: Hernia repair with prosthetic meshes represents one of the most common surgical procedures in the field of surgery. This intervention is always associated with an ensuing inflammatory response, angiogenesis and fibrotic encapsulation forming a foreign body granuloma (FBG) around the mesh fibres. Several studies have described this inflammatory reaction by characterising inflammatory cell infiltrate around the FBG after mesh explantation. However, very little is known about the real-time progre",Langenbeck's archives of surgery,"N Fet, P H Alizai, A Fragoulis, C Wruck, T Pufe, R H Tolba, U P Neumann, U Klinge"," Department of General, Visceral- and Transplantation Surgery, University Hospital of the RWTH, Pauwelsstr. 30, 52074, Aachen, Germany.",2014 Jun;399(5):579-88,10.1007/s00423-014-1192-8
24734428,20130101,review,mesh,"Animals,Antineoplastic Agents,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Phospholipids,Propylene Glycols,Signal Transduction,Sphingosine","analogs &amp; derivatives,drug effects,metabolism,pharmacokinetics,pharmacology","D007166 Q000494 YN,D000970 Q000494 YN,D011409 Q000493 YN,D007166 Q000493 YN,D013110 Q000031 NY,D010743 Q000378 NY,D000970 Q000493 YN,D011409 Q000494 YN,D013110 Q000493 NN,D013110 Q000494 NN,D015398 Q000187 NY","107969,107970,5280335",NULL,[Molecular and cellular mechanisms of fingolimod action].,"The data on the mechanism of action, efficacy and safety of the drug fingolimod are presented. Further study of the molecular, biochemical and cellular mechanisms of action of pharmacological regulators of phospholipid mediators' signal transduction is an important basis for developing new immunomodulators and antitumor agents. ",Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],A V Nikitin,NULL,2013 Jan;58(?):38-42,NULL
24754349,20140801,article,mesh,"Adolescent,Adrenal Cortex Hormones,Adult,Aged,Antibodies, Monoclonal, Humanized,Cohort Studies,Databases, Factual,Drug Therapy, Combination,Female,Fingolimod Hydrochloride,Health Services,Hospitalization,Humans,Immunosuppressive Agents,Kaplan-Meier Estimate,Male,Middle Aged,Multiple Sclerosis,Natalizumab,Propensity Score,Propylene Glycols,Recurrence,Retrospective Studies,Sphingosine,United States,Young Adult","analogs &amp; derivatives,drug therapy,statistics &amp; numerical data,therapeutic use,utilization","D006296 Q000656 NY,D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D006296 Q000706 NN,D013110 Q000627 NN,D000305 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D006760 Q000706 NN","107969,107970,5280335",NULL,Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.,"OBJECTIVE: Healthcare resource utilization in patients with multiple sclerosis (MS) is linked to relapses and disease progression. This retrospective cohort database analysis compared healthcare resource use and proxy measures of relapse outcomes in patients with active disease who switched to fingolimod or natalizumab. METHODS: Using administrative claims data from the US PharMetrics Plus database, we identified patients with an MS diagnosis and a claim for fingolimod or natalizumab between 1 October 2010 ",Current medical research and opinion,"Niklas Bergvall, Raquel Lahoz, Tracy Reynolds, Jonathan R Korn"," Novartis Pharma AG , Basel , Switzerland.",2014 Aug;30(8):1461-71,10.1185/03007995.2014.915802
24756193,20140901,article,mesh,"Adult,Female,Fingolimod Hydrochloride,Gadolinium,Humans,Immunosuppressive Agents,Lymphopenia,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,complications,drug therapy","D013110 Q000009 NN,D020529 Q000150 NN,D008231 Q000139 NY,D013110 Q000031 NY,D020529 Q000188 NY,D007166 Q000009 NY,D011409 Q000009 NY","23982,107969,107970,5280335",NULL,Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.,NULL,Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,"Loredana La Mantia, Valentina Prone, Maria Raffaella Marazzi, Cristina Erminio, Alessandra Protti"," Department of Clinical Neurology and Stroke Unit, Multiple Sclerosis Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, 20162, Milan, Italy, lamantialore@gmail.com.",2014 Sep;35(9):1485-6,10.1007/s10072-014-1800-y
24759080,20140601,review,mesh,"Alemtuzumab,Algorithms,Antibodies, Monoclonal, Humanized,Clinical Protocols,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Glatiramer Acetate,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Peptides,Propylene Glycols,Sphingosine,Toluidines","analogs &amp; derivatives,drug therapy,therapeutic use","D010455 Q000627 NN,D016899 Q000627 NN,D007155 Q000627 NY,D005650 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D014052 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN","12215,65370,107969,107970,637568,3081884,5280335",NULL,New management algorithms in multiple sclerosis.,"PURPOSE OF REVIEW: Our current treatment algorithms include only IFN-β and glatiramer as available first-line disease-modifying drugs and natalizumab and fingolimod as second-line therapies. Today, 10 drugs have been approved in Europe and nine in the United States making the choice of therapy more complex. The purpose of the review has been to work out new management algorithms for treatment of relapsing-remitting multiple sclerosis including new oral therapies and therapeutic monoclonal antibodies. RECENT",Current opinion in neurology,Per Soelberg Sorensen," Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.",2014 Jun;27(3):246-59,10.1097/wco.0000000000000096
24764670,20140421,article,mesh,"Adolescent,Biopsy,Celiac Disease,Child,Child, Preschool,Crystallization,Cytoplasm,Female,Hepatitis, Autoimmune,Hepatocytes,Humans,Inflammation,Lead,Liver Diseases,Male,Microscopy, Electron, Transmission,Mitochondria, Liver,Non-alcoholic Fatty Liver Disease,Organometallic Compounds","chemistry,cytology,metabolism,physiopathology,ultrastructure","D065626 Q000503 NY,D007854 Q000737 NN,D003593 Q000378 NN,D022781 Q000166 NN,D009942 Q000737 NN,D019693 Q000503 NN,D008930 Q000648 NY,D008107 Q000503 NN,D002446 Q000503 NN,D022781 Q000648 NY","10915,5352425",NULL,Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.,"AIM: To investigate the ultrastructure of abnormal hepatocyte mitochondria, including their cellular and hepatic zonal distribution, in bioptates in pediatric non-alcoholic steatohepatitis (NASH). METHODS: Ultrastructural investigations were conducted on biopsy liver specimens obtained from 10 children (6 boys and 4 girls) aged 2-14 years with previously clinicopathologically diagnosed NASH. The disease was diagnosed if liver biopsy revealed steatosis, inflammation, ballooned hepatocytes, Mallory hyaline, o",World journal of gastroenterology,"Joanna M Lotowska, Maria E Sobaniec-Lotowska, Sylwia B Bockowska, Dariusz M Lebensztejn"," Joanna M Lotowska, Department of General Pathomorphology, Medical University of Bialystok, 15269 Bialystok, Poland. Joanna M Lotowska, Department of General Pathomorphology, Medical University of Bialystok, 15269 Bialystok, Poland. Joanna M Lotowska, Department of General Pathomorphology, Medical University of Bialystok, 15269 Bialystok, Poland. Joanna M Lotowska, Department of General Pathomorphology, Medical University of Bialystok, 15269 Bialystok, Poland.",2014 Apr;20(15):4335-40,10.3748/wjg.v20.i15.4335
24810969,20140801,article,mesh,"Animals,Cell Count,Cell Survival,Cells, Cultured,Coculture Techniques,Embryonic Stem Cells,Fingolimod Hydrochloride,Ganglia, Spinal,Humans,Immunosuppressive Agents,MAP Kinase Signaling System,Myelin Sheath,Neural Stem Cells,Neurogenesis,Oligodendroglia,Propylene Glycols,Rats, Sprague-Dawley,Receptor, Platelet-Derived Growth Factor alpha,Receptors, Lysosphingolipid,Sphingosine,p38 Mitogen-Activated Protein Kinases","agonists,analogs &amp; derivatives,drug effects,metabolism,pharmacology,physiology","D055495 Q000187 NN,D007166 Q000494 NY,D049349 Q000378 NY,D049349 Q000819 NN,D002470 Q000187 NN,D009186 Q000502 NN,D009836 Q000502 NY,D020796 Q000378 NN,D009186 Q000187 NN,D053595 Q000187 NN,D053595 Q000502 NN,D058953 Q000502 NN,D055495 Q000502 NY,D005727 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D002470 Q000502 NN,D005727 Q000502 NN,D048051 Q000378 NY,D058953 Q000187 NN,D020935 Q000187 NN,D020935 Q000502 NN,D013110 Q000494 NN,D009836 Q000187 NN","107969,107970,5280335",NULL,Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors.,"FTY720 is a sphingosine 1-phosphate receptor (S1PR) modulator used as a daily therapy to reduce disease activity in the relapsing form of multiple sclerosis (MS). FTY720 readily accesses the CNS. Previous studies have shown that phosphorylated FTY720 (FTY720-p) enhances oligodendrocyte progenitor cell (OPC) survival, differentiation, and remyelination following experimentally induced demyelination in rodents. To elucidate the underlying mechanism, human fetal OPCs alone or in co-culture with rat dorsal root",Glia,"Qiao Ling Cui, Jun Fang, Timothy E Kennedy, Guillermina Almazan, Jack P Antel"," Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.",2014 Aug;62(8):1361-75,10.1002/glia.22688
24812043,20141101,article,mesh,"Adult,Brain,Double-Blind Method,Drug Combinations,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon-beta,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,drug therapy,pathology,therapeutic use","D016899 Q000627 NY,D020529 Q000473 NY,D001921 Q000473 NY,D001921 Q000187 NN,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,"The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.","BACKGROUND: Patients with multiple sclerosis (MS) lose brain volume (BV) faster than healthy individuals. OBJECTIVE: Our purpose, within the 12-month phase 3 TRANSFORMS study, was to examine the effect of treatment on BV loss in patient subgroups, establish correlations between baseline normalized BV (NBV) and baseline disease parameters, to identify variables predictive of baseline NBV and on-study percentage BV change (PBVC), and to establish correlations between on-study PBVC and on-study efficacy outcom","Multiple sclerosis (Houndmills, Basingstoke, England)","Frederik Barkhof, Remko de Jong, Nikolaos Sfikas, Ana de Vera, Gordon Francis, Jeffrey Cohen, TRANSFORMS study group"," Image Analysis Center, VU University Medical Center, The Netherlands f.barkhof@vumc.nl. Image Analysis Center, VU University Medical Center, The Netherlands. Novartis Pharma AG, Switzerland. Novartis Pharma AG, Switzerland. Novartis Pharmaceuticals Corporation, USA. Neurological Institute, Cleveland Clinic Foundation, USA.",2014 Nov;20(13):1704-13,10.1177/1352458514532317
24819611,20140101,article,mesh,"Animals,Blood Gas Analysis,Cardiopulmonary Bypass,Cell Count,Coronary Vessels,Fingolimod Hydrochloride,Follow-Up Studies,Interleukin-6,Lymphocytes,Male,Mesenteric Arteries,Oxadiazoles,Propylene Glycols,Rats,Rats, Wistar,Receptors, Lysosphingolipid,Sphingosine,Thiophenes,Vasoconstriction,Vasodilation","adverse effects,agonists,analogs &amp; derivatives,blood,cytology,drug effects,metabolism,pharmacology,physiology","D003331 Q000187 NN,D049349 Q000378 NY,D049349 Q000819 NN,D010069 Q000494 NN,D008638 Q000187 NN,D008214 Q000166 NY,D015850 Q000097 NN,D013110 Q000031 NN,D014664 Q000187 NN,D008638 Q000502 NY,D013876 Q000494 NN,D014661 Q000187 NN,D011409 Q000494 NN,D002315 Q000009 NY,D013110 Q000494 NN,D008214 Q000187 NN,D003331 Q000502 NY","107969,107970,4077460,5280335,10523409",NULL,S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes.,"BACKGROUND: Cardiopulmonary bypass (CPB) may induce systemic inflammation and vascular dysfunction. Sphingosine 1-phosphate (S1P) modulates various vascular and immune responses. Here we explored whether agonists of the S1P receptors, FTY720 and SEW2871 improve vascular reactivity after CPB in the rat. METHODS: Experiments were done in male Wistar rats (total n = 127). Anesthesia was induced by isoflurane (2.5-3%) and maintained by fentanyl and midazolam during CPB. After catheterization of the left femoral",PloS one,"Iryna V Samarska, Hjalmar R Bouma, Hendrik Buikema, Hubert E Mungroop, Martin C Houwertjes, Anthony R Absalom, Anne H Epema, Robert H Henning"," Department of Anesthesiology, University of Groningen, University Medical Center Groningen, The Netherlands. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands. Department of Anesthesiology, University of Groningen, University Medical Center Groningen, The Netherlands. Department of Anesthesiology, Unive",2014 Jan;9(5):e97196,10.1371/journal.pone.0097196
24831186,20140901,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Disability Evaluation,Disease Progression,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Recurrence,Sphingosine,Treatment Outcome","analogs &amp; derivatives,diagnosis,drug therapy,therapeutic use","D020529 Q000175 NN,D013110 Q000031 NY,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.,"OBJECTIVE: Fingolimod (FTY) is licensed as a disease-modifying treatment in highly active relapsing-remitting multiple sclerosis. The aim of the study was to evaluate the efficacy and safety of FTY in a real-life setting and to explore the possible role of clinical and MRI parameters, including previous treatment type, in predicting its efficacy. METHODS: Clinical and MRI data was collected on 127 patients assigned to treatment with FTY in six multiple sclerosis centers in Emilia-Romagna, Italy, between Aug",Current medical research and opinion,"Eleonora Baldi, Angelica Guareschi, Francesca Vitetta, Caterina Senesi, Erica Curti, Sara Montepietra, Anna Maria Simone, Paolo Immovilli, Luisa Caniatti, Maria Rosaria Tola, Ilaria Pesci, Enrico Montanari, Patrizia Sola, Franco Granella, Luisa Motti, Diana Ferraro"," Neurology Unit, Department of Neuroscience/Rehabilitation, Azienda Ospedaliera-Universitaria S. Anna , Ferrara , Italy.",2014 Sep;30(9):1849-55,10.1185/03007995.2014.921144
24836740,20140601,review,mesh,"Animals,Atrioventricular Block,Bradycardia,Electrocardiography,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,metabolism,pharmacology","D013110 Q000009 NN,D013110 Q000031 NY,D013110 Q000378 NN,D001919 Q000139 NY,D020529 Q000188 NY,D007166 Q000009 NY,D011409 Q000494 NN,D008246 Q000378 NN,D054537 Q000139 NY,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN,D011409 Q000009 NY","107969,107970,5280335,5283560",NULL,Vagomimetic effects of fingolimod: physiology and clinical implications.,"Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator approved to treat relapsing-remitting multiple sclerosis (MS). Initiation of treatment with fingolimod has been found to produce transient bradycardia and/or slowing of atrioventricular impulse conduction in a small proportion of patients. This effect is thought to be due to the interaction of fingolimod with S1P receptors on the surface membrane of atrial myocytes causing a vagomimetic effect, similar to the action of acetylcholine on muscari",CNS neuroscience & therapeutics,"Emilio Vanoli, Francesco Pentimalli, Gianluca Botto"," Cardiology Section, Department of Molecular Medicine, University of Pavia, Pavia, Italy; Cardiovascular Department, IRCCS Multimedica, Sesto San Giovanni, Italy.",2014 Jun;20(6):496-502,10.1111/cns.12283
24840971,20140601,article,mesh,"Antibodies, Monoclonal, Humanized,Drug Substitution,Female,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,methods,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D057915 Q000379 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.,NULL,Nature reviews. Neurology,"Martin Stangel, Olaf Stüve"," Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany. Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Centre, 4500 South Lancaster Road, Dallas, TX 75216, USA.",2014 Jun;10(6):311-3,10.1038/nrneurol.2014.82
24842961,20141101,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Drug Substitution,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Recurrence,Retrospective Studies,Risk Factors,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.,"BACKGROUND: Risks of natalizumab (NAT) therapy have to be weighed against disease recurrence after stopping NAT. OBJECTIVES: The objective of this paper is to identify risk factors for recurrence of relapses after switching from NAT to fingolimod (FTY) in relapsing-remitting multiple sclerosis (RRMS). METHODS: Patients (n = 33) were treated with NAT for ≥1 year, and then switched to FTY within 24 weeks (mean follow-up on FTY 81.1 (SD 26.5) weeks). Annual relapse rates (ARR) and Expanded Disability Status Sc","Multiple sclerosis (Houndmills, Basingstoke, England)","Robert Hoepner, Joachim Havla, Christian Eienbröker, Björn Tackenberg, Kerstin Hellwig, Ingrid Meinl, Reinhard Hohlfeld, Ralf Gold, Tania Kümpfel, Ingo Kleiter"," St Josef-Hospital, Ruhr-University, Germany. Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Germany. Clinical Neuroimmunology Group, Philipps-University, Germany. Clinical Neuroimmunology Group, Philipps-University, Germany. St Josef-Hospital, Ruhr-University, Germany. Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Germany. Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, GermanyMunich Cluster for Systems Neurology (SyNergy), Germany. St Jo",2014 Nov;20(13):1714-20,10.1177/1352458514533398
24846129,20140101,article,mesh,"Animals,Antibodies, Monoclonal,Antibodies, Neutralizing,Cell Differentiation,Disease Models, Animal,Female,Fingolimod Hydrochloride,Herpesvirus 1, Human,Immunosuppressive Agents,Interleukin-6,Keratitis, Herpetic,Mice,Mice, Knockout,Propylene Glycols,Receptors, Lysosphingolipid,Recurrence,Secondary Prevention,Sphingosine,T-Lymphocyte Subsets","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,cytology,drug therapy,immunology,metabolism,pathology,pharmacology,prevention &amp; control,virology","D016849 Q000473 NN,D007166 Q000008 NN,D000911 Q000008 NN,D016849 Q000821 NN,D016849 Q000188 NN,D013110 Q000008 NN,D018259 Q000276 NN,D011409 Q000008 NN,D016176 Q000166 NN,D013110 Q000031 NN,D057134 Q000008 NN,D016849 Q000276 NY,D000911 Q000494 NN,D057134 Q000494 NN,D015850 Q000276 NN,D016849 Q000517 NY,D015850 Q000037 NN,D011409 Q000494 NN,D016176 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN,D016176 Q000378 NN,D049349 Q000378 NN","107969,107970,5280335",NULL,An approach to control relapse of inflammatory lesions after discontinuation of primary therapy.,"Long-term treatment with the fungal metabolite drug FTY720 (Fingolimod) was shown to be highly effective in controlling viral immunopathological lesions. However, in this report we show that the anti-inflammatory effect of FTY720 in herpes simplex virus-1 (HSV-1) induced ocular inflammation is lost upon the discontinuation of treatment and lesions rapidly recurred. The lesions that developed after FTY720 treatment withdrawal involved mainly Th17 cells rather than Th1 cells explained in part by differential ",PloS one,"Pradeep B J Reddy, Sharvan Sehrawat, Amol Suryawanshi, Naveen K Rajasagi, Madhu Khatri, Barry T Rouse"," Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America. Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America. Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America. Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, Unite",2014 Jan;9(5):e98051,10.1371/journal.pone.0098051
24851861,20140101,article,mesh,"Animals,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Lysophospholipids,Mice,Mice, Inbred C57BL,Motor Activity,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Vocalization, Animal","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pathology,pharmacology,physiology,prevention &amp; control","D049349 Q000037 NY,D014828 Q000187 NN,D049349 Q000235 NN,D013110 Q000378 NN,D009043 Q000502 NY,D013110 Q000031 NN,D009043 Q000187 NN,D004681 Q000517 NN,D011409 Q000494 NN,D008246 Q000378 NN,D013110 Q000494 NN,D004681 Q000378 NY,D007166 Q000494 NN,D004681 Q000473 NN,D014828 Q000502 NY,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.,"Fingolimod (FTY720) is an oral therapy for relapsing remitting multiple sclerosis (MS) and targets sphingosine 1-phosphate receptors (S1PRs). FTY720 also rescues animals from experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The protective effects of FTY720 in EAE are primarily scored manually by examining weight loss and limb paralysis that begins around 10-12 days after immunisation. To our knowledge, pre-clinical effects of FTY720 on animal behaviour early in EAE have not been explo",Scientific reports,"Graham K Sheridan, Kumlesh K Dev"," 1] Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland [2]. Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland.",2014 Jan;4(?):5051,10.1038/srep05051
24852928,20140901,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Antibodies, Viral,Biomarkers,Contrast Media,Databases, Factual,Disease-Free Survival,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,JC Virus,Kaplan-Meier Estimate,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Predictive Value of Tests,Propylene Glycols,Retrospective Studies,Serologic Tests,Sphingosine,Time Factors,Treatment Outcome","analogs &amp; derivatives,blood,diagnosis,drug therapy,immunology,therapeutic use,virology","D000914 Q000097 NY,D061067 Q000627 NY,D020529 Q000175 NN,D013110 Q000031 NY,D020529 Q000097 NN,D007166 Q000627 NY,D020529 Q000188 NY,D020529 Q000821 NN,D013110 Q000627 NN,D011409 Q000627 NY,D020529 Q000276 NN,D015415 Q000097 NN,D007577 Q000276 NY","107969,107970,5280335",NULL,An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.,BACKGROUND: The lack of prospective trial data comparing certain multiple sclerosis (MS) therapies could be addressed with observational research. OBJECTIVE: The objective of this paper is to investigate outcomes of natalizumab versus fingolimod treatment in an MS cohort using a novel method of patient selection. METHODS: We reviewed entries from our clinic's database for all relapsing-remitting MS patients started on fingolimod and natalizumab where JCV serology was used to determine treatment. We analyzed,"Multiple sclerosis (Houndmills, Basingstoke, England)","Robert L Carruthers, Dalia L Rotstein, Brian C Healy, Tanuja Chitnis, Howard L Weiner, Guy J Buckle"," Harvard Medical School, USA/Partners Multiple Sclerosis Center, Brigham and Women's Hospital, USA. Harvard Medical School, USA/Partners Multiple Sclerosis Center, Brigham and Women's Hospital, USA. Harvard Medical School, USA/Partners Multiple Sclerosis Center, Brigham and Women's Hospital, USA/Biostatistics Center, Massachusetts General Hospital, USA. Harvard Medical School, USA/Partners Multiple Sclerosis Center, Brigham and Women's Hospital, USA. Harvard Medical School, USA/Partners Multiple Sclerosis C",2014 Sep;20(10):1381-90,10.1177/1352458514535282
24859201,20140701,article,"xref,mesh","Animals,Blotting, Western,Brain,Exploratory Behavior,Extinction, Psychological,Fear,Fingolimod Hydrochloride,Gene Expression,Hippocampus,Histone Deacetylase 1,Histone Deacetylase Inhibitors,Immunosuppressive Agents,Isoenzymes,Learning Disorders,Lysophospholipids,Maze Learning,Memory,Mice,Mice, Inbred C57BL,Mice, SCID,Models, Molecular,Phosphorylation,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Spectrometry, Mass, Electrospray Ionization,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology,physiology,psychology","D005106 Q000187 NN,D017853 Q000378 NN,D007166 Q000494 NY,D008246 Q000494 NN,D015870 Q000187 NN,D005108 Q000187 NY,D056284 Q000502 NN,D017853 Q000235 NN,D001921 Q000187 NN,D006624 Q000502 NN,D013110 Q000031 NY,D007859 Q000235 NN,D011409 Q000494 NY,D056284 Q000037 NN,D007859 Q000523 NN,D005106 Q000502 NN,D018782 Q000502 NN,D005239 Q000187 NY,D013110 Q000494 NN,D008568 Q000187 NY,D001921 Q000502 NN,D007527 Q000502 NN","5311,107969,107970,5280335,5283560","53788318,283537481,376229562","Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.","FTY720 (fingolimod), an FDA-approved drug for treatment of multiple sclerosis, has beneficial effects in the CNS that are not yet well understood, independent of its effects on immune cell trafficking. We show that FTY720 enters the nucleus, where it is phosphorylated by sphingosine kinase 2 (SphK2), and that nuclear FTY720-P binds and inhibits class I histone deacetylases (HDACs), enhancing specific histone acetylations. FTY720 is also phosphorylated in mice and accumulates in the brain, including the hipp",Nature neuroscience,"Nitai C Hait, Laura E Wise, Jeremy C Allegood, Megan O'Brien, Dorit Avni, Thomas M Reeves, Pamela E Knapp, Junyan Lu, Cheng Luo, Michael F Miles, Sheldon Milstien, Aron H Lichtman, Sarah Spiegel"," 1] Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. [2] Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. [3]. 1] Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. [2]. 1] Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. [2] Massey ",2014 Jul;17(7):971-80,10.1038/nn.3728
24863045,20141001,article,mesh,"Animals,CHO Cells,Cell Line,Cell Membrane Permeability,Cells, Cultured,Chemotaxis,Cricetulus,Encephalomyelitis, Autoimmune, Experimental,Endothelial Cells,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocytes,Mice,Mice, Inbred C57BL,Oxazoles,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,T-Lymphocytes,U937 Cells","analogs &amp; derivatives,chemistry,drug effects,drug therapy,metabolism,pharmacology,physiology,physiopathology","D007166 Q000494 NY,D042783 Q000378 NN,D010080 Q000494 NY,D002633 Q000187 NY,D010080 Q000737 NN,D011409 Q000737 NN,D008214 Q000502 NN,D004681 Q000503 NN,D013110 Q000737 NN,D013110 Q000031 NN,D013601 Q000502 NN,D042783 Q000187 NY,D007166 Q000737 NN,D011409 Q000494 NN,D002463 Q000187 NN,D013110 Q000494 NN,D008214 Q000187 NN,D013601 Q000187 NN,D049349 Q000378 NN,D004681 Q000188 NY","107969,107970,5280335",NULL,"Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.","The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P1 and S1P3, but not S1P2, receptor internalization ",Neuropharmacology,"Faik Imeri, Daniel Fallegger, Aleksandra Zivkovic, Stephanie Schwalm, Gaby Enzmann, Kira Blankenbach, Dagmar Meyer zu Heringdorf, Thomas Homann, Burkhard Kleuser, Josef Pfeilschifter, Britta Engelhardt, Holger Stark, Andrea Huwiler"," Institute of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland. Institute of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland. Institute of Pharmaceutical Chemistry, Goethe University Frankfurt am Main, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Universitätsstr. 1, D-40225 Düsseldorf, Germany. Pharmazentrum Frankfurt/ZAFES, University Hospit",2014 Oct;85(?):314-27,10.1016/j.neuropharm.2014.05.012
24866203,20141101,article,mesh,"Adult,Asthma,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D013110 Q000031 NY,D001249 Q000139 NY,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","J A van Rossum, E E Looysen, J M A Daniels, J Killestein"," VU University Medical Center, Amsterdam, The Netherlands j.vanrossum@vumc.nl. VU University Medical Center, Amsterdam, The Netherlands. VU University Medical Center, Amsterdam, The Netherlands. MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.",2014 Nov;20(13):1792-3,10.1177/1352458514531844
24868599,20140501,article,mesh,"ATP Binding Cassette Transporter, Sub-Family B,ATP-Binding Cassette, Sub-Family B, Member 1,Antibiotics, Antineoplastic,Antineoplastic Agents, Phytogenic,Apoptosis,Cell Line, Tumor,Cell Survival,Chemotherapy, Adjuvant,Colonic Neoplasms,Doxorubicin,Drug Resistance, Neoplasm,Etoposide,Fingolimod Hydrochloride,Gene Expression,Humans,Immunosuppressive Agents,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,genetics,metabolism,methods,pathology,pharmacology","D017209 Q000187 NN,D002470 Q000187 NN,D015870 Q000187 NN,D003110 Q000235 NN,D020168 Q000378 NY,D013110 Q000031 NY,D011409 Q000494 NY,D004317 Q000494 NY,D018435 Q000235 NN,D003110 Q000473 NY,D017024 Q000379 NN,D005047 Q000494 NY,D018435 Q000378 NN,D000972 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D003110 Q000378 NN,D000903 Q000494 NN","31703,36462,107969,107970,284997,439525,443939,5280335",NULL,FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.,OBJECTIVE: This study aimed to investigate the effects of FTY720 on inducing cell growth inhibition and enhancing the cytotoxicity of anti-cancer drugs in the human colon cancer cell line HCT-8 and its multidrug-resistant cell line HCT-8/5-fluorouracil (HCT-8/5-Fu). METHODS: Cell viability and apoptosis after being treated with FTY720 alone or in combination with doxorubicin (DOX) and etoposide (VP16) were tested in HCT-8 and HCT-8/5-Fu cells. The changes in P-glycoprotein (P-gp) and multidrug resistance pr,Journal of digestive diseases,"Ying Xing, Zhi Hong Wang, Dong Hong Ma, Ying Han",NULL,2014 May;15(5):246-59,10.1111/1751-2980.12131
24876379,20140725,article,mesh,"Anilides,Animals,Antineoplastic Agents, Phytogenic,Cytokines,Enzyme Activation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Indans,Lysophospholipids,Male,Neuralgia,Organophosphonates,Oxadiazoles,Paclitaxel,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Thiazoles,Thiophenes","adverse effects,analogs &amp; derivatives,antagonists &amp; inhibitors,chemically induced,drug effects,drug therapy,enzymology,metabolism,pharmacology","D013844 Q000494 NN,D049349 Q000378 NY,D007189 Q000494 NN,D000972 Q000009 NY,D010069 Q000494 NN,D016207 Q000378 NN,D000813 Q000494 NN,D017239 Q000009 NY,D004789 Q000187 NN,D013110 Q000378 NN,D013110 Q000031 NN,D009437 Q000139 NY,D009437 Q000188 NN,D017239 Q000494 NN,D013876 Q000494 NN,D011409 Q000494 NN,D008246 Q000378 NN,D000972 Q000494 NN,D013110 Q000494 NN,D049349 Q000037 NN,D009437 Q000201 NY,D007166 Q000494 NN,D063065 Q000494 NN,D015398 Q000187 NY","4666,36314,107969,107970,184492,4077460,5280335,5283560,10523409,11363176,25110406,53394627",NULL,The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.,"The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate. Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticancer effects. The ceramide-to-S1P pathway is also implicated in the development of pain, raising the intriguing possibility that these sphingolipids may contribute to chemotherapy- induced painful peripheral neuropathy, which can be a critical dose-limiting side effect of many widely used chemotherapeutic agents",The Journal of biological chemistry,"Kali Janes, Joshua W Little, Chao Li, Leesa Bryant, Collin Chen, Zhoumou Chen, Krzysztof Kamocki, Timothy Doyle, Ashley Snider, Emanuela Esposito, Salvatore Cuzzocrea, Erhard Bieberich, Lina Obeid, Irina Petrache, Grant Nicol, William L Neumann, Daniela Salvemini",NULL,2014 Jul;289(30):21082-97,10.1074/jbc.m114.569574
24906818,20140101,article,mesh,"Coronary Artery Disease,Female,Fingolimod Hydrochloride,Heart Failure,Humans,Hypertension, Pulmonary,Immunosuppressive Agents,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,complications,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D003324 Q000150 NY,D006976 Q000150 NY,D020529 Q000150 NY,D013110 Q000031 NY,D020529 Q000188 NY,D007166 Q000009 NY,D006333 Q000150 NY,D013110 Q000627 NN,D011409 Q000627 NN,D011409 Q000009 NY","107969,107970,5280335",NULL,Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.,"BACKGROUND: Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in patients with concomitant cardiological disease, especially wit",BMC neurology,"Katja Thomas, Hagen Schrötter, Michael Halank, Tjalf Ziemssen"," Center of Clinical Neuroscience, Department of Neurology, Neurological University Clinic Dresden, University Clinic Carl Gustav Carus Dresden, University of Technology Dresden, Fetscherstr, 74, 01307 Dresden, Germany. Tjalf.Ziemssen@uniklinikum-dresden.de.",2014 Jan;14(?):126,10.1186/1471-2377-14-126
24909140,20141001,article,mesh,"Adolescent,Demyelinating Diseases,Electric Stimulation,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Neural Conduction,Polyneuropathies,Propylene Glycols,Sphingosine","analogs &amp; derivatives,complications,drug effects,drug therapy,methods,physiology,therapeutic use","D009431 Q000187 NN,D003711 Q000150 NN,D009431 Q000502 NN,D011115 Q000188 NY,D013110 Q000031 NY,D007166 Q000627 NY,D004558 Q000379 NN,D013110 Q000627 NN,D011409 Q000627 NY,D011115 Q000150 NN,D003711 Q000188 NY","107969,107970,5280335",NULL,Remission with fingolimod in a case of demyelinating polyneuropathy.,NULL,Muscle & nerve,"Şefik E Erdener, Gülay Nurlu, Rahşan Göçmen, Sevim Erdem-Özdamar, Aslı Kurne"," Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey.",2014 Oct;50(4):615-7,10.1002/mus.24311
24911000,20140101,article,mesh,"Animals,Cerebellum,Coculture Techniques,Cytokines,Demyelinating Diseases,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation Mediators,Mice,Mice, Transgenic,Myelin-Oligodendrocyte Glycoprotein,Phenotype,Propylene Glycols,Sphingosine,Spleen,T-Lymphocytes,Tissue Culture Techniques","analogs &amp; derivatives,cytology,immunology,metabolism,pathology,pharmacology","D013601 Q000378 NN,D007166 Q000494 NY,D003711 Q000276 NY,D002531 Q000276 NY,D002531 Q000473 NY,D013601 Q000276 NN,D016207 Q000378 NN,D013154 Q000276 NY,D013110 Q000031 NY,D011409 Q000494 NY,D013154 Q000166 NY,D063308 Q000276 NN,D018836 Q000378 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.,"The family of sphingosine-1-phosphate receptors (S1PRs) is G-protein-coupled, comprised of subtypes S1PR1-S1PR5 and activated by the endogenous ligand S1P. The phosphorylated version of Fingolimod (pFTY720), an oral therapy for multiple sclerosis (MS), induces S1PR1 internalisation in T cells, subsequent insensitivity to S1P gradients and sequestering of these cells within lymphoid organs, thus limiting immune response. S1PRs are also expressed in neuronal and glial cells where pFTY720 is suggested to direc",PloS one,"Adam J Pritchard, Anis K Mir, Kumlesh K Dev"," Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland. Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland.",2014 Jan;9(6):e99444,10.1371/journal.pone.0099444
24927402,20140901,article,mesh,"Animals,Chromatography, Liquid,Female,Fingolimod Hydrochloride,Half-Life,Mice,Mice, Inbred ICR,Plasma,Propylene Glycols,Sphingosine,Tandem Mass Spectrometry","analogs &amp; derivatives,chemistry,methods","D011409 Q000737 NY,D002853 Q000379 NN,D013110 Q000031 NY,D013110 Q000737 NN,D010949 Q000737 NY","107969,107970,5280335",NULL,"Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.","OSU-2S is a novel anti-cancer and immune modulatory agent designed specifically to avert the immunosuppressive effects and related toxicities observed in clinical studies with its predecessor analog, FTY720. To characterize its preclinical pharmacokinetics, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of OSU-2S in mouse plasma. Ethyl acetate extraction of samples containing OSU-2S and the internal standard, Sph-17, was followed by sepa",Journal of pharmaceutical and biomedical analysis,"Yicheng Mao, Jiang Wang, Yuan Zhao, Ribai Yan, Hao Li, Ching-Shih Chen, Robert J Lee, John C Byrd, L James Lee, Natarajan Muthusamy, Mitch A Phelps"," College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices (CANPBD), The Ohio State University, Columbus, OH 43210, USA. College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. College of Pharmacy, The Ohio State University, Colum",2014 Sep;98(?):160-5,10.1016/j.jpba.2014.05.022
24933548,20140601,review,mesh,"Disease Progression,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Nurse Clinicians,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000008 NN,D020529 Q000188 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Fingolimod for multiple sclerosis: a review for the specialist nurse.,"The availability of treatments for multiple sclerosis (MS) has increased substantially over the past decade. Once-daily fingolimod 0.5 mg capsules (Gilenya, Novartis Pharma) were approved in the European Union in March 2011 as the first oral disease-modifying therapy for patients with relapsing MS. This review summarises the efficacy and safety of fingolimod, and discusses practical considerations for MS specialist nurses. Fingolimod has demonstrated efficacy in the treatment of relapsing-remitting MS, as a",British journal of nursing (Mark Allen Publishing),Kitty Harrison," Neurology Nursing Specialist, Department of Neurology, Tergooiziekenhuizen, Blaricum, Netherlands.",2014 Jun;23(11):582-9,10.12968/bjon.2014.23.11.582
24935336,20140601,article,mesh,"Animals,Blotting, Western,Calcitriol,Cell Proliferation,Cell Survival,Diabetes Mellitus, Experimental,Enzyme-Linked Immunosorbent Assay,Flow Cytometry,Graft Survival,Inflammation,Islets of Langerhans Transplantation,Macrophages,Rats,Rats, Sprague-Dawley","drug effects,pharmacology,prevention &amp; control,surgery","D002470 Q000187 NN,D049109 Q000187 NN,D008264 Q000187 NN,D002117 Q000494 NY,D003921 Q000601 NY,D006085 Q000187 NY,D007249 Q000517 NY","2524,5280453,5283740,5371993,6437079,9953732,13019066,73946427,129631814",NULL,"1,25(OH)2D3 prolongs islet graft survival by inflammatory inhibition.","OBJECTIVE: This study aimed to determine the protective effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) against islet graft loss. METHODS: Proliferation of tumor necrosis factor (TNF)-α-induced macrophages was determined in vitro after treatment with different concentrations of 1,25-(OH)2D3. Intraportal islet transplantation (IPIT) was performed with islets harvested from the Sprague-Dawley rats and transplanted to the diabetic rats. The transplanted rats were assigned to receive 1,25-(OH)2D3 or propylene ",Transplantation proceedings,"Z-Z Jiao, Y Li, P Fan, J Guo, W-J Xue, X-M Ding, X-H Tian, X-S Feng, J Zheng, P-X Tian, C-G Ding, X-H Fan"," Department of Renal Transplantation, Hospital of Nephrology, the First Affiliated Hospital, Medical College, Xi'an Jiaotong University, Xi'an City, Shannxi Province, People's Republic of China. Department of Renal Transplantation, Hospital of Nephrology, the First Affiliated Hospital, Medical College, Xi'an Jiaotong University, Xi'an City, Shannxi Province, People's Republic of China. Electronic address: jullian80915@126.com. Department of Rheumatism and Immunology, the First Affiliated Hospital, Medical C",2014 Jun;46(5):1615-20,10.1016/j.transproceed.2014.02.012
24935480,20140701,review,mesh,"Administration, Oral,Clinical Trials, Phase III as Topic,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.,"INTRODUCTION: Fingolimod (Gilenya®, FTY720) is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod's mechanism of action is primarily related to lymphocyte sequestration in primary and secondary lymphoid tissues. Phase III trials demonstrated a reduction in annualized relapse rate and MRI progression in fingolimod-treated subjects compared with both placebo and IFN-β-treated subjects. Frequent adverse effec",Expert opinion on drug safety,"Melanie D Ward, David E Jones, Myla D Goldman"," University of Virginia, Department of Neurology , PO Box 800394, Charlottesville, VA 22908 , USA.",2014 Jul;13(7):989-98,10.1517/14740338.2014.920820
24940647,20140701,article,mesh,"Atrioventricular Block,Child, Preschool,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced","D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000009 NY,D054537 Q000139 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,AV block II in a toddler after ingestion of a single tablet fingolimod.,NULL,"Clinical toxicology (Philadelphia, Pa.)","Jonas Höjer, Eva Olsson"," Karolinska Institute, Swedish Poisons Information Centre , Stockholm , Sweden.",2014 Jul;52(6):644,10.3109/15563650.2014.927478
24947019,20150201,article,mesh,"Animals,Apoptosis,B-Lymphocytes,Cell Line, Tumor,Cell Survival,Drug Delivery Systems,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leukemia, Lymphocytic, Chronic, B-Cell,Liposomes,Lymphoma, Mantle-Cell,Mice,Mice, Transgenic,Nanoparticles,Oligonucleotide Array Sequence Analysis,Phosphorylation,Propylene Glycols,Protein Kinase C,Receptor Tyrosine Kinase-like Orphan Receptors,Sphingosine,Treatment Outcome","analogs &amp; derivatives,chemistry,cytology,drug effects,metabolism,therapy","D011493 Q000378 NN,D015451 Q000628 NY,D015451 Q000378 NY,D001402 Q000187 NN,D011409 Q000737 NN,D053758 Q000737 NN,D013110 Q000737 NN,D057050 Q000378 NY,D020522 Q000378 NN,D013110 Q000031 NN,D008081 Q000737 NN,D001402 Q000166 NY,D007166 Q000737 NN","107969,107970,453626,5280335",NULL,Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.,"Selective cytotoxicity to cancer cells without compromising their normal counterparts pose a huge challenge for traditional drug design. Here we developed a tumor antigen-targeted delivery of immunonanoparticle carrying a novel non-immunosuppressive FTY720 derivative OSU-2S with potent cytotoxicity against leukemic B cells. OSU-2S induces activation of protein phosphatase 2A (PP2A), phosphorylation and nuclear translocation of SHP1(S591) and deregulation of multiple cellular processes in chronic lymphocytic",Leukemia,"R Mani, Y Mao, F W Frissora, C-L Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan, X Mo, L Yu, J Flynn, J Jones, L Andritsos, S Baskar, C Rader, M A Phelps, C-S Chen, R J Lee, J C Byrd, L J Lee, N Muthusamy"," 1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. 1] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA [3] Center fo",2015 Feb;29(2):346-55,10.1038/leu.2014.199
24964157,20140701,article,mesh,"Animals,Extinction, Psychological,Fear,Fingolimod Hydrochloride,Histone Deacetylase Inhibitors,Immunosuppressive Agents,Memory,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug effects,pharmacology","D007166 Q000494 NY,D005108 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D005239 Q000187 NY,D013110 Q000494 NN,D008568 Q000187 NY","107969,107970,5280335",NULL,Unlocking the constraints on memory formation.,NULL,Nature neuroscience,"Dina P Matheos, Marcelo A Wood"," Department of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, University of California Irvine, Irvine, California, USA. Department of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, University of California Irvine, Irvine, California, USA.",2014 Jul;17(7):895-6,10.1038/nn.3748
24977485,20140101,review,mesh,"Ceramides,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lysophospholipids,Multiple Sclerosis,Propylene Glycols,Sphingolipids,Sphingomyelin Phosphodiesterase,Sphingomyelins,Sphingosine","analogs &amp; derivatives,chemistry,drug therapy,metabolism,pathology,therapeutic use","D013108 Q000378 NN,D009103 Q000473 NN,D007166 Q000627 NN,D013107 Q000378 NY,D013110 Q000737 NN,D013110 Q000378 NN,D013110 Q000031 NN,D009103 Q000378 NY,D013109 Q000378 NN,D008246 Q000378 NN,D013110 Q000627 NN,D002518 Q000378 NN,D011409 Q000627 NN,D008246 Q000737 NN,D009103 Q000188 NN","107969,107970,5280335,5283560,44176376",NULL,Sphingolipids: important players in multiple sclerosis.,"Multiple Sclerosis (MS) is the most common cause for permanent disability in young adults. Current pathophysiological understanding has identified an autoaggressive immune reaction with infiltration of immune cells into the central nervous system and local inflammatory and demyelinating reactions. The current therapy focuses on a modulation or suppression of immune functions. Sphingolipids, main components of nervous tissue, have been linked to MS already 60 years ago with the description of an unusual myel","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","Ramona Halmer, Silke Walter, Klaus Faßbender"," Department of Neurology, University of the Saarland, Homburg, Germany.",2014 Jan;34(1):111-8,10.1159/000362988
24984268,20140901,article,mesh,"Animals,Cell Death,Cell Survival,Curcumin,Drug Delivery Systems,Endocytosis,Folic Acid,Hemolysis,Hep G2 Cells,Humans,Irritants,Lactic Acid,MCF-7 Cells,Male,Micelles,Microscopy, Fluorescence,Neoplasms,Particle Size,Polyesters,Polyethylene Glycols,Polymers,Rabbits,Rats,Static Electricity,Surface-Active Agents","administration &amp; dosage,chemical synthesis,chemistry,drug effects,drug therapy,pharmacokinetics,pharmacology,therapeutic use","D009369 Q000188 NY,D013501 Q000737 NN,D003474 Q000008 NN,D005492 Q000737 NY,D011092 Q000138 NN,D004705 Q000187 NN,D002470 Q000187 NN,D019344 Q000737 NN,D011092 Q000737 NN,D007509 Q000494 NN,D003474 Q000494 NN,D013501 Q000138 NN,D016923 Q000187 NN,D003474 Q000493 NN,D011108 Q000138 NN,D003474 Q000627 NY,D019344 Q000138 NN,D011108 Q000737 NN,D006461 Q000187 NN","612,6037,22986,61503,62358,91435,107689,969516,23678413",NULL,Development of a folate-modified curcumin loaded micelle delivery system for cancer targeting.,"Targeted drug delivery system for tumor cells is an appealing platform on enhancing the therapeutic effects and reducing the side effects of the drug. In this study, we developed folate-modified curcumin (Cur) loaded micelles (Cur-FPPs) for cancer chemotherapy. The targeting material, Folate-PEG3000-PLA2000, was synthesized by the amide bond formation reaction. And the Cur loaded micelles were prepared by thin-film hydration method with mPEG2000-PLA2000 (Cur-PPs) or mPEG2000-PLA2000 and Folate-PEG3000-PLA20","Colloids and surfaces. B, Biointerfaces","Chunfen Yang, Hao Chen, Jie Zhao, Xin Pang, Yanwei Xi, Guangxi Zhai"," Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, China. Department of Pharmacy, Qilu Hospital of Shandong University, Jinan 250012, China. Section of Cadre Health-Care, Affiliated Hospital of Shandong University of TCM, Jinan 250011, China. Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, China. Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, China. De",2014 Sep;121(?):206-13,10.1016/j.colsurfb.2014.05.005
24993468,20140915,article,mesh,"Brain Injuries,Encephalitis,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Occipital Lobe,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,pathology","D013110 Q000009 NN,D001930 Q000139 NY,D013110 Q000031 NY,D004660 Q000139 NY,D007166 Q000009 NY,D009778 Q000473 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Tumefactive multiple sclerosis and fingolimod.,NULL,Journal of the neurological sciences,"Jesus Lovera, Nicole Villemarette-Pittman"," Department of Neurology, Louisiana State University Health Sciences Center-New Orleans, 1542 Tulane Avenue, Rm 718A, New Orleans, LA 70112, United States. Electronic address: jlover@lsuhsc.edu. Department of Neurology, Louisiana State University Health Sciences Center-New Orleans, 1542 Tulane Avenue, Rm 718A, New Orleans, LA 70112, United States.",2014 Sep;344(?):1-2,10.1016/j.jns.2014.06.022
25001515,20140915,article,mesh,"Antigens, CD,Antigens, Differentiation, Myelomonocytic,Brain Injuries,Encephalitis,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Inflammation,Magnetic Resonance Imaging,Multiple Sclerosis,Occipital Lobe,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,metabolism,pathology","D013110 Q000009 NN,D007249 Q000139 NN,D001930 Q000139 NY,D013110 Q000031 NY,D015214 Q000378 NN,D004660 Q000139 NY,D007166 Q000009 NY,D015703 Q000378 NN,D009778 Q000473 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.,"Finglimod, a sphingosine 1-phosphate receptor modulator, is the first orally administered therapy approved for prophylaxis in multiple sclerosis (MS). Several reports in the last two years suggested that it might be associated with severe augmentation of disease activity upon initiation or discontinuation of therapy. We present an MS patient who developed a giant cavitating brain lesion under fingolimod and in whom cessation of therapy was associated with a very active course. Brain biopsy revealed the lesi",Journal of the neurological sciences,"M A Hellmann, N Lev, I Lotan, R Mosberg-Galili, E Inbar, J Luckman, S Fichman-Horn, M Yakimov, I Steiner"," Department of Neurology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Department of Neurology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Department of Neurology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Department of Neurology, Rabin Medical Center,",2014 Sep;344(?):193-7,10.1016/j.jns.2014.06.013
25003359,20140901,article,mesh,"Aged,Cerebral Hemorrhage,Female,Fingolimod Hydrochloride,Glasgow Coma Scale,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Propylene Glycols,Recovery of Function,Severity of Illness Index,Single-Blind Method,Sphingosine,Treatment Outcome","administration &amp; dosage,adverse effects,analogs &amp; derivatives,blood,drug effects,drug therapy,pathology,pharmacology,physiopathology","D007166 Q000494 NY,D011409 Q000009 NN,D013110 Q000009 NN,D002543 Q000097 NN,D007166 Q000008 NN,D013110 Q000008 NN,D020127 Q000187 NN,D013110 Q000031 NY,D011409 Q000008 NN,D002543 Q000473 NN,D011409 Q000494 NY,D002543 Q000503 NN,D002543 Q000188 NY,D013110 Q000494 NN,D007166 Q000009 NN","107969,107970,5280335",NULL,Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study.,"IMPORTANCE: Pronounced inflammatory reactions occurring shortly after intracerebral hemorrhage (ICH) contribute to the formation and progression of perihematomal edema (PHE) and secondary brain injury. We hypothesized that modulation of brain inflammation reduces edema, thus improving clinical outcomes in patients with ICH. OBJECTIVE: To investigate whether oral administration of fingolimod, a Food and Drug Administration-approved sphingosine 1-phosphate receptor modulator for multiple sclerosis, is safe an",JAMA neurology,"Ying Fu, Junwei Hao, Ningnannan Zhang, Li Ren, Na Sun, Yu-Jing Li, Yaping Yan, DeRen Huang, Chunshui Yu, Fu-Dong Shi"," Department of Neurology, Key Laboratory of Neurorepair and Regeneration, Tianjin and Ministry of Education, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Department of Neurology, Key Laboratory of Neurorepair and Regeneration, Tianjin and Ministry of Education, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Department of Radiology, Tianjin Medical University General Hospital, Tianjin, China. Department of Neurology",2014 Sep;71(9):1092-101,10.1001/jamaneurol.2014.1065
25004059,20141101,article,mesh,"Acute Lung Injury,Animals,Dose-Response Relationship, Drug,Drug Evaluation, Preclinical,Erythrocyte Deformability,Fingolimod Hydrochloride,Immunosuppressive Agents,Male,Multiple Organ Failure,Neutrophil Activation,Propylene Glycols,Rats, Sprague-Dawley,Respiratory Burst,Shock, Hemorrhagic,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,blood,complications,drug effects,drug therapy,etiology,methods,physiology,prevention &amp; control,therapeutic use","D055371 Q000517 NN,D007166 Q000008 NN,D009102 Q000209 NN,D013110 Q000008 NN,D004353 Q000379 NN,D013110 Q000031 NY,D009102 Q000097 NN,D012771 Q000097 NN,D011409 Q000008 NN,D012771 Q000188 NY,D055371 Q000209 NN,D012771 Q000150 NN,D007166 Q000627 NY,D009102 Q000517 NY,D004907 Q000502 NN,D016897 Q000187 NN,D018375 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NY,D004907 Q000187 NN","107969,107970,5280335",NULL,A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome.,"BACKGROUND: Trauma/hemorrhagic shock (T/HS) is one of the major consequences of battlefield injury as well as civilian trauma. FTY720 (sphingosine-1-phosphate agonist) has the capability to decrease the activity of the innate and adaptive immune systems and, at the same time, maintain endothelial cell barrier function and vascular homeostasis during stress. For this reason, we hypothesize that FTY720, as part of resuscitation therapy, would limit T/HS-induced multiple organ dysfunction syndrome in a rodent ","Shock (Augusta, Ga.)","Joyce A Bonitz, Julie Y Son, Benjamin Chandler, Jacquelyn N Tomaio, Yong Qin, Lauriston M Prescott, Eleonora Feketeova, Edwin A Deitch"," Department of Surgery, Rutgers New Jersey Medical School, Newark, New Jersey.",2014 Nov;42(5):448-55,10.1097/shk.0000000000000227
25004375,20140901,article,mesh,"Cerebral Hemorrhage,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pharmacology","D007166 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D002543 Q000188 NY,D013110 Q000494 NN","107969,107970,5280335",NULL,Targeting the immune system in intracerebral hemorrhage.,NULL,JAMA neurology,"Kevin N Sheth, Jonathan Rosand"," Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut. Division of Neurocritical Care and Emergency Neurology, Center for Human Genetic Research, Massachusetts General Hospital, Boston.",2014 Sep;71(9):1083-4,10.1001/jamaneurol.2014.1653
25011422,20140901,article,mesh,"Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Kuwait,Magnetic Resonance Imaging,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Registries,Retrospective Studies,Severity of Illness Index,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,drug therapy,pathology,physiopathology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D020529 Q000473 NN,D020529 Q000503 NN,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.,"BACKGROUND: Fingolimod is an oral sphingosine-1-phosphate-receptor modulator, which has demonstrated efficacy in clinical trials and has recently been approved for multiple sclerosis (MS) treatment in Kuwait. Post-marketing studies are important to demonstrate real-life efficacy and safety. OBJECTIVE: The objective of this study was to examine the efficacy and safety of fingolimod treatment in a clinical setting. METHODS: Using the national Kuwait MS registry, relapsing remitting MS patients who had been pr",CNS drugs,"Jasem Al-Hashel, Samar F Ahmed, Raed Behbehani, Raed Alroughani"," Department of Neurology, Ibn Sina Hospital, P.O. Box 25427, 13115, Safat, Kuwait.",2014 Sep;28(9):817-24,10.1007/s40263-014-0185-z
25015822,20140815,article,mesh,"Animals,Antigen-Antibody Complex,Antigens,B-Lymphocytes,Dendritic Cells, Follicular,Female,Fingolimod Hydrochloride,Germinal Center,Immunoglobulin E,Immunoglobulin G,Immunoglobulin M,Immunosuppressive Agents,Lymphocyte Activation,Mice,Mice, Inbred BALB C,Mice, Knockout,Ovalbumin,Propylene Glycols,Receptors, Complement 3d,Sphingosine,Spleen,Trinitrobenzenes","analogs &amp; derivatives,biosynthesis,cytology,genetics,immunology,pharmacology","D017464 Q000096 NN,D017464 Q000276 NN,D007075 Q000276 NN,D007073 Q000276 NN,D001402 Q000276 NY,D008213 Q000276 NN,D014301 Q000276 NN,D013154 Q000276 NY,D013154 Q000166 NN,D013110 Q000031 NN,D017464 Q000235 NN,D007074 Q000276 NY,D020566 Q000276 NY,D010047 Q000276 NN,D018858 Q000276 NN,D000936 Q000276 NY,D011409 Q000494 NN,D000941 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN","107969,107970,5280335,5289086",NULL,Marginal zone B cells transport IgG3-immune complexes to splenic follicles.,"Ag administered together with specific IgG3 induces a higher Ab response than Ag administered alone, an effect requiring the presence of complement receptors 1 and 2 (CR1/2). In this study, we have investigated the fate of Ag, the development of germinal centers (GCs), and the Ab response after i.v. administration of IgG3 anti-trinitrophenyl (TNP) in complex with OVA-TNP. After 2 h, OVA-TNP was detected on marginal zone (MZ) B cells, and a substantial amount of Ag was detected in splenic follicles and coloc","Journal of immunology (Baltimore, Md. : 1950)","Lu Zhang, Zhoujie Ding, Hui Xu, Birgitta Heyman"," Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123, Uppsala, Sweden. Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123, Uppsala, Sweden. Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123, Uppsala, Sweden. Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123, Uppsala, Sweden birgitta.heyman@imbim.uu.se.",2014 Aug;193(4):1681-9,10.4049/jimmunol.1400331
25015824,20140815,article,mesh,"Adoptive Transfer,Animals,Antigen-Antibody Complex,Cell Movement,Female,Fingolimod Hydrochloride,Immune System Diseases,Immunosuppressive Agents,Inflammation,L-Selectin,Leukocyte Disorders,Lymph Nodes,Lymphatic Vessels,Lymphocyte Function-Associated Antigen-1,Lysophospholipids,Macrophage-1 Antigen,Mice,Mice, Inbred BALB C,Neutrophils,P-Selectin,Propylene Glycols,Receptors, CXCR4,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,cytology,immunology,metabolism,pharmacology,transplantation","D019007 Q000276 NN,D007960 Q000276 NY,D019718 Q000276 NN,D008198 Q000276 NY,D042601 Q000276 NN,D013110 Q000031 NN,D009504 Q000637 NN,D002465 Q000276 NN,D016177 Q000276 NN,D009504 Q000276 NY,D019041 Q000276 NN,D008246 Q000819 NN,D007249 Q000276 NN,D008198 Q000166 NN,D000936 Q000276 NY,D007154 Q000276 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000494 NN,D016169 Q000276 NN,D013110 Q000819 NN,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Neutrophils exhibit differential requirements for homing molecules in their lymphatic and blood trafficking into draining lymph nodes.,"Although much is described about the molecules involved in neutrophil migration from circulation into tissues, less is known about the molecular mechanisms that regulate neutrophil entry into lymph nodes (LNs) draining a local inflammatory site. In this study, we investigated neutrophil migration toward LNs in a context of inflammation induced by immunization of BALB/c mice with OVA emulsified in CFA. We demonstrated that neutrophils can enter LNs of OVA/CFA-immunized mice not only via lymphatic vessels but","Journal of immunology (Baltimore, Md. : 1950)","Carolina V Gorlino, Romina P Ranocchia, María F Harman, Iris A García, María I Crespo, Gabriel Morón, Belkys A Maletto, María C Pistoresi-Palencia"," Centro de Investigación en Bioquímica Clínica e Inmunología, Consejo Nacional de Investigaciones Científica y Técnicas, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, X5000HUA, Argentina. Centro de Investigación en Bioquímica Clínica e Inmunología, Consejo Nacional de Investigaciones Científica y Técnicas, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, X5000HUA, Argentina. Centro de I",2014 Aug;193(4):1966-74,10.4049/jimmunol.1301791
25019581,20141001,article,mesh,"Adolescent,Adult,Aged,Antibodies, Monoclonal, Humanized,Drug Administration Routes,Female,Fingolimod Hydrochloride,Glatiramer Acetate,Humans,Immunosuppressive Agents,Insurance Claim Review,Interferon beta-1a,Interferon beta-1b,Interferon-beta,Male,Medication Adherence,Middle Aged,Multiple Sclerosis,Natalizumab,Peptides,Proportional Hazards Models,Propylene Glycols,Retrospective Studies,Sphingosine,United States,Young Adult","analogs &amp; derivatives,drug therapy,statistics &amp; numerical data,therapeutic use","D055118 Q000706 NY,D010455 Q000627 NN,D016899 Q000627 NN,D013110 Q000031 NY,D007166 Q000627 NY,D061067 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D007345 Q000706 NN","65370,107969,107970,3081884,5280335",NULL,Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.,"OBJECTIVE: Achieving therapeutic goals in multiple sclerosis (MS) requires strict adherence to treatment schedules. This retrospective study analyzed persistence with, and adherence to, fingolimod compared with injectable/infusible disease-modifying therapies (DMTs) in patients with MS. METHODS: Patients in the PharMetrics Plus™ US administrative claims database with at least one prescription for, or administration of, fingolimod, glatiramer acetate (GA), interferon (IFN), or natalizumab (index DMT) between",Journal of medical economics,"Niklas Bergvall, Allison A Petrilla, Swapna U Karkare, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Charles Makin, Catherine Balderston McGuiness, Jonathan R Korn"," Novartis Pharma AG , Basel , Switzerland.",2014 Oct;17(10):696-707,10.3111/13696998.2014.940422
25022794,20150101,article,mesh,"Administration, Oral,Adult,Animals,Evoked Potentials, Motor,Female,Fingolimod Hydrochloride,Glutamic Acid,Humans,Immunosuppressive Agents,Male,Middle Aged,Motor Cortex,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Prospective Studies,Sphingosine,Transcranial Magnetic Stimulation","administration &amp; dosage,analogs &amp; derivatives,drug effects,drug therapy,methods,physiology,physiopathology","D018698 Q000502 NY,D013110 Q000008 NN,D013110 Q000031 NY,D020529 Q000503 NN,D019054 Q000502 NN,D009044 Q000187 NY,D009044 Q000502 NN,D020529 Q000188 NY,D019054 Q000187 NN,D050781 Q000379 NN,D011409 Q000008 NY,D007166 Q000008 NY","611,23327,33032,104813,107969,107970,168185,4525487,5128032,5147171,5280335,5460299,5460544,11840951,14598502,23669634,23696295,129674751,129773928",NULL,Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis.,"OBJECTIVE: Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day. METHODS: Paired-pulse TMS was applied on the left primary motor cortex in 13 patients affected by relapsing-remitting MS, the day before the first dose of fi",Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,"D Landi, S Vollaro, G Pellegrino, D Mulas, A Ghazaryan, E Falato, P Pasqualetti, P M Rossini, M M Filippi"," Department of Neurology, Campus Bio-Medico University of Rome, via Alvaro del Portillo 200, Rome 00128, Italy. Electronic address: doriana.landi@gmail.com. Department of Neurology, Campus Bio-Medico University of Rome, via Alvaro del Portillo 200, Rome 00128, Italy. Department of Neurology, Campus Bio-Medico University of Rome, via Alvaro del Portillo 200, Rome 00128, Italy. Department of Neurology, Campus Bio-Medico University of Rome, via Alvaro del Portillo 200, Rome 00128, Italy. Department of Neurolog",2015 Jan;126(1):165-9,10.1016/j.clinph.2014.05.031
25023553,20140701,article,mesh,"Antibodies, Monoclonal, Humanized,Drug Substitution,Female,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,methods,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D057915 Q000379 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved.,NULL,JAMA neurology,"Assunta Bianco, Paolo Maria Rossini, Massimiliano Mirabella"," Institute of Neurology, Catholic University, Rome, Italy. Institute of Neurology, Catholic University, Rome, Italy. Institute of Neurology, Catholic University, Rome, Italy.",2014 Jul;71(7):924-5,10.1001/jamaneurol.2014.1135
25023556,20140701,article,mesh,"Antibodies, Monoclonal, Humanized,Drug Substitution,Female,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,methods,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D057915 Q000379 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Moving to fingolimod from natalizumab in multiple sclerosis-reply.,NULL,JAMA neurology,"Mikael Cohen, Christine Lebrun"," Department of Neurology, University Hospital of Nice, Nice, France. Department of Neurology, University Hospital of Nice, Nice, France.",2014 Jul;71(7):925,10.1001/jamaneurol.2014.1138
25034934,20141001,article,mesh,"Animals,Apoptosis,Apoptosis Regulatory Proteins,Cell Hypoxia,Cell Line,Fingolimod Hydrochloride,Immunosuppressive Agents,Interleukin-1beta,MAP Kinase Signaling System,Myocytes, Cardiac,Propylene Glycols,Rats,Sphingosine,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D053583 Q000235 NN,D032383 Q000187 NY,D014409 Q000378 NN,D014409 Q000235 NN,D051017 Q000378 NN,D051017 Q000235 NN,D053583 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D032383 Q000378 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes.,"FTY720, sphingosine 1 phosphate (S1P) receptor agonist, is a potent immunosuppressive agent. Numerous studies have documented a relationship between S1P and cardioprotection. We therefore hypothesized that a S1P analogue FTY720 would attenuate hypoxia/reoxygenation (H/R) induced cadiomyocyte apoptosis. H9C2 cardiomyocytes were employed to establish an in vitro model of H/R. Cells were treated or not with different doses of FTY720. Cell viability was measured by flow cytometry and TUNEL staining. Western blo",Experimental and molecular pathology,"Min Wang, Lin Lu, Yehong Liu, Gang Gu, Rong Tao"," Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China. Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China. Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China. Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: gugang@medmail.com.cn. Department of Cardiology, Rui Ji",2014 Oct;97(2):218-24,10.1016/j.yexmp.2014.07.008
25037058,20141201,article,"xref,mesh","Adiponectin,Angiotensin-Converting Enzyme Inhibitors,Animals,Apolipoproteins E,Blotting, Western,Coronary Artery Disease,Disease Models, Animal,Drug Therapy, Combination,Enalapril,Ergocalciferols,Female,Gene Expression Regulation,Mice,Mice, Inbred C57BL,Oxidative Stress,Polymerase Chain Reaction,RNA,Receptors, Calcitriol","biosynthesis,deficiency,drug effects,genetics,metabolism,pharmacology,prevention &amp; control","D004656 Q000494 NY,D052242 Q000096 NN,D004872 Q000494 NY,D003324 Q000235 NN,D052242 Q000235 NY,D018167 Q000378 NN,D000806 Q000494 NN,D003324 Q000378 NN,D012313 Q000235 NY,D001057 Q000172 NN,D018167 Q000187 NY,D003324 Q000517 NY","3249,5997,5280793,5281104,5315257,5353610,5362032,5388961,5388962,6372069,6432478,6435926,6536972,7067801,11963529,44630173,58855793,66577029,66577066,71308193,86280331,91746237,91884638,134694848,134715773","53787340,53787861,53788968,53789639",Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice.,"BACKGROUND: Coronary heart disease (CHD) is the number one cause of death in the US. The adipokine adiponectin has been studied intensively for presenting and inversed association with almost every stage of CHD. For instance, the evaluation of molecules capable of enhancing endogenous adiponectin expression is well justified. In this study, we investigated the effect of the vitamin D receptor activator (VDRA) paricalcitol and the angiotensin-converting enzyme inhibitor (ACEI) enalapril on adiponectin expres",Therapeutic advances in cardiovascular disease,"Edu Suarez-Martinez, Kazim Husain, Leon Ferder"," Department of Biology, University of Puerto Rico in Ponce, PO Box 7186, Ponce, PR 00732, USA esuarez@psm.edu. Department of Physiology, Pharmacology, and Toxicology, Ponce School of Medicine and Health Sciences, PO Box 7004, Ponce, PR 00732, USA. Department of Physiology, Pharmacology, and Toxicology, Ponce School of Medicine and Health Sciences, PO Box 7004, Ponce, PR 00732, USA.",2014 Dec;8(6):224-36,10.1177/1753944714542593
25038564,20141001,article,mesh,"Administration, Cutaneous,Administration, Topical,Animals,Antifungal Agents,Dose-Response Relationship, Drug,Female,Injections, Subcutaneous,Male,Mice,Mice, Inbred ICR,No-Observed-Adverse-Effect Level,Onychomycosis,Pharmaceutical Solutions,Rats,Rats, Sprague-Dawley,Skin,Swine,Swine, Miniature,Time Factors,Triazoles","administration &amp; dosage,drug effects,drug therapy,toxicity","D014230 Q000008 NN,D012867 Q000187 NY,D014230 Q000633 NY,D000935 Q000633 NY,D014009 Q000188 NY,D000935 Q000008 NN",489181,NULL,Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment.,"Efinaconazole is a triazole developed as a 10% solution for topical treatment of onychomycosis, a common fungal nail infection. Efinaconazole solution and topical formulation vehicle administered dermally to mice (13weeks), rats (6months) and minipigs (9months) produced transient erythema, minimal to modest hyperkeratosis, and mild microscopic skin inflammation. The liver was the target organ of systemic toxicity; reversible, minimal to moderate vacuolated changes were noted in the rat dermal study at 15 an",Regulatory toxicology and pharmacology : RTP,"William Jo, Marian Glynn, Hiroaki Nejishima, Hisakazu Sanada, Kenji Minowa, Barry Calvarese, Hisato Senda, Radhakrishnan Pillai, Linda Mutter"," Dow Pharmaceutical Sciences, A Division of Valeant Pharmaceuticals International, 1330 Redwood Way, Petaluma, CA 94954, USA. Electronic address: wjo@dowpharmsci.com. Dow Pharmaceutical Sciences, A Division of Valeant Pharmaceuticals International, 1330 Redwood Way, Petaluma, CA 94954, USA. Kaken Pharmaceutical Co., Ltd., 301, Gensuke, Fujieda, Shizuoka, Japan. Kaken Pharmaceutical Co., Ltd., 301, Gensuke, Fujieda, Shizuoka, Japan. Kaken Pharmaceutical Co., Ltd., 301, Gensuke, Fujieda, Shizuoka, Japan. Dow ",2014 Oct;70(1):242-53,10.1016/j.yrtph.2014.07.012
25042636,20141201,article,mesh,"Animals,Brain Neoplasms,Cell Proliferation,Cells, Cultured,Ceramides,Epidermal Growth Factor,Extracellular Fluid,Fibroblast Growth Factor 2,Fingolimod Hydrochloride,Glioblastoma,Humans,Immunosuppressive Agents,Ki-67 Antigen,Lysophospholipids,Mice,Mice, SCID,Middle Aged,Neoplastic Stem Cells,Propylene Glycols,Sphingolipids,Sphingosine,Tumor Cells, Cultured,Xenograft Model Antitumor Assays","analogs &amp; derivatives,drug effects,metabolism,pathology,pharmacology,physiology","D001932 Q000473 NY,D049109 Q000502 NY,D014411 Q000502 NY,D008246 Q000494 NN,D019394 Q000378 NN,D004815 Q000494 NN,D016222 Q000494 NN,D013110 Q000031 NY,D013110 Q000378 NN,D014411 Q000187 NN,D045604 Q000378 NN,D008246 Q000378 NY,D013107 Q000378 NN,D005909 Q000473 NY,D011409 Q000494 NN,D002518 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D045604 Q000187 NN","107969,107970,5280335,5283560,56841751,57339413",NULL,Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells.,"Accumulating reports suggest that human glioblastoma contains glioma stem-like cells (GSCs) which act as key determinants driving tumor growth, angiogenesis, and contributing to therapeutic resistance. The proliferative signals involved in GSC proliferation and progression remain unclear. Using GSC lines derived from human glioblastoma specimens with different proliferative index and stemness marker expression, we assessed the hypothesis that sphingosine-1-phosphate (S1P) affects the proliferative and stemn",Glia,"Giovanni Marfia, Rolando Campanella, Stefania Elena Navone, Clara Di Vito, Elena Riccitelli, Loubna Abdel Hadi, Andrea Bornati, Gisele de Rezende, Paola Giussani, Cristina Tringali, Paola Viani, Paolo Rampini, Giulio Alessandri, Eugenio Parati, Laura Riboni"," Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, University of Milan, Italy.",2014 Dec;62(12):1968-81,10.1002/glia.22718
25043204,20140901,article,mesh,"Aged,Animals,Astrocytes,Cells, Cultured,Cerebrum,Encephalomyelitis, Autoimmune, Experimental,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Middle Aged,Multiple Sclerosis,Neuroprotective Agents,Nitric Oxide,Propylene Glycols,Rats,Rats, Sprague-Dawley,Receptors, Interleukin-1 Type I,Receptors, Interleukin-17,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Spinal Cord","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,biosynthesis,drug effects,drug therapy,immunology,metabolism,pathology,pharmacology","D007166 Q000494 NY,D053573 Q000378 NN,D007166 Q000008 NN,D004681 Q000276 NN,D013116 Q000187 NN,D018696 Q000008 NN,D004681 Q000378 NN,D053722 Q000378 NN,D013116 Q000473 NN,D013110 Q000008 NN,D009103 Q000378 NN,D009569 Q000096 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D018696 Q000494 NY,D001253 Q000187 NY,D009569 Q000037 NY,D054022 Q000378 NN,D013116 Q000378 NN,D054022 Q000473 NN,D009103 Q000276 NN,D013110 Q000494 NN,D009103 Q000188 NY,D001253 Q000378 NN,D049349 Q000378 NN,D004681 Q000188 NY","107969,107970,145068,5280335",NULL,Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.,"OBJECTIVE: Although astrocytes participate in glial scar formation and tissue repair, dysregulation of the NFκB pathway and of nitric oxide (NO) production in these glia cells contributes to neuroinflammation and neurodegeneration. Here we investigated the role of the crosstalk between sphingosine-1-phosphate (S1P) and cytokine signaling cascades in astrocyte activation and inflammation-mediated neurodegeneration, and addressed the effects of fingolimod on astrocyte-neuron interaction and NO synthesis in vi",Annals of neurology,"Emanuela Colombo, Marco Di Dario, Eleonora Capitolo, Linda Chaabane, Jia Newcombe, Gianvito Martino, Cinthia Farina"," Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.",2014 Sep;76(3):325-37,10.1002/ana.24217
25070489,20141101,article,mesh,"Apoptosis,Blotting, Western,Cell Movement,Cell Proliferation,Fingolimod Hydrochloride,Glioblastoma,Humans,Immunosuppressive Agents,Neoplasm Invasiveness,Phosphatidylinositol 3-Kinases,Propylene Glycols,Proto-Oncogene Proteins c-akt,Ribosomal Protein S6 Kinases, 70-kDa,Signal Transduction,Sphingosine,TOR Serine-Threonine Kinases,Tumor Cells, Cultured,Wound Healing","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,metabolism,pathology,pharmacology","D005909 Q000188 NY,D058570 Q000037 NY,D017209 Q000187 NN,D019869 Q000378 NN,D038762 Q000378 NN,D002465 Q000187 NY,D038762 Q000037 NY,D051057 Q000037 NY,D005909 Q000378 NN,D058570 Q000378 NN,D049109 Q000187 NN,D005909 Q000473 NN,D013110 Q000031 NY,D011409 Q000494 NY,D019869 Q000037 NY,D051057 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D014945 Q000187 NN","107969,107970,5280335",NULL,FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway.,"2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720), a synthetic compound from Isaria sinclairii, has been proven to possess various biological benefits including anti-cancer activity. However, the effects and related mechanisms of FTY720 on the migration and invasion of glioblastoma cells are still unclear. In the present study, we utilized U251MG and U87MG human glioblastoma cell lines to assess the effects of FTY720. We found that FTY720 significantly inhibited migration and invasion of ",Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,"Li Zhang, Handong Wang, Jianhong Zhu, Ke Ding, Jianguo Xu"," Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, China.",2014 Nov;35(11):10707-14,10.1007/s13277-014-2386-y
25081505,20140915,article,mesh,"Animals,Blood-Brain Barrier,Brain Edema,Brain Injuries,Disease Models, Animal,Encephalitis,Fingolimod Hydrochloride,Flow Cytometry,Immunosuppressive Agents,Lymphopenia,Mice,Mice, Inbred C57BL,Propylene Glycols,Signal Transduction,Sphingosine,T-Lymphocytes,Treatment Outcome","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pharmacology","D001929 Q000188 NN,D011409 Q000276 NN,D013601 Q000276 NN,D001812 Q000187 NN,D004660 Q000188 NY,D008231 Q000276 NN,D008231 Q000139 NN,D001930 Q000188 NY,D015398 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001812 Q000276 NN,D001930 Q000276 NY,D013110 Q000276 NN,D007166 Q000276 NN,D004660 Q000276 NY,D001929 Q000276 NN,D015398 Q000187 NN,D013110 Q000494 NN,D007166 Q000494 NN,D013601 Q000187 NN","107969,107970,5280335",NULL,FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation.,"Inflammation is a pathological hallmark of traumatic brain injury (TBI). Recent evidence suggests that immune cells such as lymphocytes are of particular relevance for lesion development after TBI. FTY720, a sphingosine-1-phosphate (S1P) receptor modulator, sequesters T lymphocytes in lymphoid organs and has been shown to improve outcome in a variety of neurological disease models. We investigated the mode of FTY720 action in models of TBI. Focal cortical cryolesion was induced in C57BL/6 mice treated with ",Journal of neuroimmunology,"Stine Mencl, Nelli Hennig, Sarah Hopp, Michael K Schuhmann, Christiane Albert-Weissenberger, Anna-Leena Sirén, Christoph Kleinschnitz"," Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany. Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany. Department of Neurology, University Hospital Würzburg, Würzbu",2014 Sep;274(?):125-31,10.1016/j.jneuroim.2014.07.010
25098558,20141101,article,mesh,"Animals,Avoidance Learning,Brain,Caspase 3,Dark Adaptation,Disease Models, Animal,Drug Administration Routes,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Gene Expression Regulation,Immunosuppressive Agents,Interleukin-1beta,Lipopolysaccharides,Male,Memory Disorders,Nerve Tissue Proteins,Propylene Glycols,Rats,Rats, Wistar,Sphingosine,Transcriptome,Tumor Necrosis Factor-alpha","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology,physiopathology,toxicity","D008569 Q000503 NN,D008569 Q000139 NY,D053583 Q000235 NN,D014409 Q000378 NN,D005786 Q000187 NY,D014409 Q000235 NN,D009419 Q000378 NN,D008569 Q000188 NN,D001921 Q000187 NN,D008070 Q000633 NY,D053583 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D001921 Q000378 NN,D001921 Q000473 NN,D053148 Q000378 NN,D003623 Q000187 NN,D013110 Q000494 NN,D001362 Q000187 NN,D007166 Q000494 NN,D009419 Q000235 NN,D008569 Q000378 NN","107969,107970,5280335",NULL,Fingolimod affects gene expression profile associated with LPS-induced memory impairment.,"Lipopolysaccharide is an endotoxin to induce sickness behavior in several animal models to explore the link between immune activation and cognition. Neuroinflammation playing a pivotal role in disease progress is evidently influenced by sphingosine-1-phosphate. As one of the sphingosine analogs in clinical use for multiple sclerosis, fingolimod (FTY720) was shown to substantially affect gene expression profile in the context of AD in our previous experiments. The present study was designed to evaluate the d",Experimental brain research,"Rana Omidbakhsh, Banafshe Rajabli, Sanaz Nasoohi, Behzad Khallaghi, Zahurin Mohamed, Murali Naidu, Abolhassan Ahmadiani, Leila Dargahi"," Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.",2014 Nov;232(11):3687-96,10.1007/s00221-014-4052-4
25128750,20141101,article,mesh,"Animals,Fingolimod Hydrochloride,Inflammation,Kinetics,Lactic Acid,Ligands,Lymphocytes,Lysophospholipids,Male,Mice, Inbred C57BL,Microvessels,Polyglycolic Acid,Propylene Glycols,Prostheses and Implants,Receptors, Lysosphingolipid,Sphingolipids,Sphingosine,Tissue Engineering,Vascular Remodeling","agonists,analogs &amp; derivatives,chemistry,drug effects,metabolism,methods,pathology,physiopathology","D049349 Q000378 NY,D049349 Q000819 NN,D019344 Q000737 NN,D007249 Q000473 NY,D055806 Q000503 NY,D023822 Q000379 NY,D013110 Q000031 NN,D011100 Q000737 NN,D013107 Q000378 NN,D008214 Q000187 NN,D055806 Q000473 NY","612,61503,62358,71391,91435,107689,107969,107970,5280335,5283560",NULL,Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning.,"Biomaterial-mediated controlled release of soluble signaling molecules is a tissue engineering approach to spatially control processes of inflammation, microvascular remodeling and host cell recruitment, and to generate biochemical gradients in vivo. Lipid mediators, such as sphingosine 1-phosphate (S1P), are recognized for their essential roles in spatial guidance, signaling and highly regulated endogenous gradients. S1P and pharmacological analogs such as FTY720 are therapeutically attractive targets for ",Acta biomaterialia,"Molly E Ogle, Lauren S Sefcik, Anthony O Awojoodu, Nathan F Chiappa, Kevin Lynch, Shayn Peirce-Cottler, Edward A Botchwey"," Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 315 Ferst Drive, Atlanta, GA 30332, USA. Department of Chemical & Biomolecular Engineering, Lafayette College, 740 High Street, Easton, PA 18042, USA. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 315 Ferst Drive, Atlanta, GA 30332, USA. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emor",2014 Nov;10(11):4704-4714,10.1016/j.actbio.2014.08.007
25134927,20150201,article,mesh,"Animals,Drug Carriers,Drug Compounding,Drug Delivery Systems,Emulsions,Glycerides,Immunosuppressive Agents,Laurates,Male,Propylene Glycols,Rats, Sprague-Dawley,Solubility,Tacrolimus,Triglycerides","administration &amp; dosage,chemistry,methods,pharmacokinetics","D014280 Q000737 NN,D016559 Q000493 NN,D011409 Q000737 NN,D005989 Q000737 NN,D007166 Q000493 NN,D007848 Q000737 NN,D016503 Q000379 NY,D016559 Q000008 NY,D007166 Q000008 NY,D004337 Q000737 NN","5372,14870,445643,5282315,6473866,6536850,71668407,134694629",NULL,Preparation and pharmaceutical evaluation of new tacrolimus-loaded solid self-emulsifying drug delivery system.,"The purpose of this study was to develop a novel tacrolimus-loaded solid self-emulsifying drug delivery system (SEDDS) using Labrafac as an oil phase. The ternary phase diagram was plotted with Labrafac, Labrasol and Lauroglycol used as an oil, surfactant and co-surfactant, respectively. The liquid SEDDS formulated with Labrasol, Lauroglycol and Labrafac (70:15:15, volume ratio) furnished the smallest emulsion globule size. The solid SEDDS was obtained by spray-drying the liquid mixture containing the liqui",Archives of pharmacal research,"Youn Gee Seo, Dong-Wuk Kim, Kwan Hyung Cho, Abid Mehmood Yousaf, Dong Shik Kim, Jeong Hoon Kim, Jong Oh Kim, Chul Soon Yong, Han-Gon Choi"," College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan, 712-749, South Korea.",2015 Feb;38(2):223-8,10.1007/s12272-014-0459-5
25138356,20140101,article,mesh,"Animals,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cells, Cultured,Central Nervous System,Demyelinating Diseases,Disease Models, Animal,Encephalitis, Viral,Fingolimod Hydrochloride,Green Fluorescent Proteins,Immunosuppressive Agents,Lymph Nodes,Mice,Mice, Inbred C57BL,Mice, Transgenic,Murine hepatitis virus,Nerve Tissue Proteins,Propylene Glycols,Severity of Illness Index,Sphingosine,T-Lymphocytes, Cytotoxic,Virus Replication","analogs &amp; derivatives,drug effects,drug therapy,genetics,metabolism,pathogenicity,pathology,therapeutic use,virology","D049452 Q000235 NN,D006517 Q000472 NN,D002490 Q000473 NN,D014779 Q000187 NN,D018792 Q000188 NY,D015496 Q000187 NN,D018792 Q000235 NN,D013602 Q000187 NN,D013602 Q000473 NN,D013110 Q000031 NY,D007166 Q000627 NY,D003711 Q000821 NY,D049452 Q000378 NN,D018792 Q000473 NN,D003711 Q000473 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009419 Q000235 NN,D003711 Q000235 NN,D003711 Q000188 NY,D008198 Q000473 NN","107969,107970,5280335",NULL,FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.,BACKGROUND: FTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis. Evidence suggests that the therapeutic benefit of FTY720 occurs by preventing the egress of lymphocytes from lymph nodes thereby inhibiting the infiltration of disease-causing lymphocytes into the central nervous system (CNS). We hypothesized that FTY720 treatment would affect lymphocyte migratio,Journal of neuroinflammation,"Caroline A Blanc, Hugh Rosen, Thomas E Lane",NULL,2014 Jan;11(?):138,10.1186/s12974-014-0138-y
25138918,20140101,article,mesh,"Adult,Brain,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pathology,therapeutic use","D020529 Q000473 NY,D001921 Q000473 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.,"BACKGROUND: Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on MRI as compared to either interferon beta (IFNβ) or placebo. The effect of fingolimod on MRI outcomes compared to natalizumab treatment has not been investigated in (head to head) clinical trials. Clinical experience with natalizumab is much more extended and in general practice often prefe",BMC neurology,"Anne-Hilde Muris, Linda Rolf, Jan Damoiseaux, Ellen Koeman, Raymond Hupperts"," School for Mental Health and Neuroscience, Maastricht University Medical Center, Universiteitssingel 40, Maastricht, theNetherlands. a.muris@maastrichtuniversity.nl.",2014 Jan;14(?):164,10.1186/s12883-014-0164-5
25145931,20150401,article,mesh,"Acute Kidney Injury,Animals,Apoptosis,Cell Respiration,Cisplatin,Drug Evaluation, Preclinical,Epithelial Cells,Fingolimod Hydrochloride,Kidney Tubules, Proximal,Male,Mice, Inbred C57BL,Mitochondria,Mitochondrial Dynamics,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine","agonists,analogs &amp; derivatives,chemically induced,drug effects,metabolism,pharmacology,prevention &amp; control,therapeutic use","D017209 Q000187 NN,D008928 Q000187 NY,D049349 Q000819 NY,D004847 Q000187 NN,D007687 Q000187 NY,D013110 Q000031 NY,D058186 Q000139 NN,D011409 Q000494 NN,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000627 NY,D058186 Q000517 NY,D049349 Q000378 NN","84691,107969,107970,441203,5280335",NULL,Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.,"Sphingosine 1-phosphate (S1P), the natural sphingolipid ligand for a family of five G protein- coupled receptors (S1P1-S1P5Rs), regulates cell survival and lymphocyte circulation. We have shown that the pan-S1PR agonist, FTY720, attenuates kidney ischemia-reperfusion injury by directly activating S1P1 on proximal tubule (PT) cells, independent of the canonical lymphopenic effects of S1P1 activation on B and T cells. FTY720 also reduces cisplatin-induced AKI. Therefore, in this study, we used conditional PT-",Journal of the American Society of Nephrology : JASN,"Amandeep Bajwa, Diane L Rosin, Piotr Chroscicki, Sangju Lee, Krishna Dondeti, Hong Ye, Gilbert R Kinsey, Brian K Stevens, Katarzyna Jobin, Brandon M Kenwood, Kyle L Hoehn, Kevin R Lynch, Mark D Okusa"," Departments of Medicine and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia School of Medicine, Charlottesville, Virginia ab9nh@virginia.edu. Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia School of Medicine, Charlottesville, Virginia Pharmacology, and. Departments of Medicine and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia School of Medicine, Charlottesville, Virginia. Departments of Medicin",2015 Apr;26(4):908-25,10.1681/asn.2013121351
25151732,20140501,article,mesh,"Animals,Fingolimod Hydrochloride,Graft Survival,Immunosuppressive Agents,Lymphocytes,Mice,Propylene Glycols,Rats,Receptors, Lysosphingolipid,Skin Transplantation,Sphingosine,Transplantation, Homologous","agonists,analogs &amp; derivatives,drug effects,pharmacology","D006085 Q000187 NN,D007166 Q000494 NY,D049349 Q000819 NY,D013110 Q000031 NN,D011409 Q000494 NN,D013110 Q000494 NN,D008214 Q000187 NN","107969,107970,5280335",NULL,"[Effect of a novel selective S1P1 agonist, Syl948, on mouse skin transplantation].","Syl948 is a synthesized selective S1P1 agonist with novel structure. HTRF-IP1 test indicated that Syl948-P, the active form of Syl948 in vitro, has strong activity against S1P1 (EC50: 83 +/- 16 nmol x L(-1)), but its effect on S1P3 was very weak (EC50: 1 026 +/- 90 nmol x L(-1)). In SD rats, oral administration of Syl948 10 mg x kg(-1) significantly decreased the peripheral blood lymphocytes (PBL), with the maximal PBL inhibition rate of 63%, which was as similar as equal dose of fingolimod (FTY720). Oral a",Yao xue xue bao = Acta pharmaceutica Sinica,"Jing Jin, Hai-Jing Zhang, Xiao-Jian Wang, Wan-Qi Zhou, Da-Li Yin, Xiao-Guang Chen",NULL,2014 May;49(5):627-31,NULL
25160120,20140901,article,mesh,"Antibodies, Monoclonal, Humanized,Antibodies, Viral,Female,Humans,Immunosuppressive Agents,JC Virus,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Serologic Tests,Sphingosine","analogs &amp; derivatives,blood,drug therapy,immunology,therapeutic use","D000914 Q000097 NY,D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D011409 Q000627 NY,D007577 Q000276 NY",5280335,NULL,Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.,NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Devon S Conway, Jeffrey A Cohen"," Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, USA. Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, USA cohenj@ccf.org.",2014 Sep;20(10):1280-1,10.1177/1352458514535283
25163474,20140101,article,mesh,"Animals,Apoptosis,Chemical Warfare Agents,Cytokines,Enzymes,Inflammation,Male,Mustard Gas,Rats,Rats, Sprague-Dawley,Trachea","administration &amp; dosage,blood,chemically induced,drug effects,injuries,metabolism,pathology,toxicity","D007249 Q000378 NN,D017209 Q000187 NN,D009151 Q000633 NY,D004798 Q000097 NN,D007249 Q000139 NN,D009151 Q000008 NN,D002619 Q000633 NY,D016207 Q000097 NN,D014132 Q000293 NY,D007249 Q000473 NN,D014132 Q000473 NY",10461,NULL,Mechanistic insights of sulfur mustard-induced acute tracheal injury in rats.,"Sulfur mustard (SM) is believed to be a major threat to civilian populations because of the persistent asymmetric threat by nonstate actors, such as terrorist groups, the ease of synthesis and handling, and the risk of theft from stockpiles. The purpose of this study was to establish mechanisms of acute tracheal injury in rats induced by SM using histopathologic, immunohistochemical, and biochemical parameters. Male rats (Sprague-Dawley) were anesthetized, intratracheally intubated, and exposed to 2 mg/kg o",International journal of toxicology,"Xiao-Ji Zhu, Rui Xu, Xiao Meng, Hai-Bo Chu, Chao Zhao, Cheng-Jin Lian, Tao Wang, Wen-Jun Guo, Sheng-Ming Zhang"," Department of Respiration, the 89th Hospital of PLA, Weifang, China. Department of Pathology, Weifang Medical University, Weifang, China. Department of Pathology, Weifang Medical University, Weifang, China. Department of Respiration, the 89th Hospital of PLA, Weifang, China haibochuwf@163.com. Department of Respiration, the 89th Hospital of PLA, Weifang, China. Department of Respiration, the 89th Hospital of PLA, Weifang, China. Department of Respiration, the 89th Hospital of PLA, Weifang, China. Departmen",2014 Jan;33(5):382-92,10.1177/1091581814548730
25207757,20141201,article,mesh,"Animals,Calcium,Cell Line,Cytokines,Dendritic Cells,Epitopes, T-Lymphocyte,Fingolimod Hydrochloride,Homeostasis,Immunosuppressive Agents,Interleukin-1 Receptor-Like 1 Protein,Interleukin-33,Interleukins,Lymphocyte Activation,Mice,Propylene Glycols,Receptors, Interleukin,Signal Transduction,Sphingosine,T-Lymphocyte Subsets,Toll-Like Receptors","analogs &amp; derivatives,biosynthesis,drug effects,immunology,metabolism,pharmacology","D003713 Q000187 NN,D007378 Q000378 NY,D018123 Q000378 NY,D016207 Q000096 NN,D051193 Q000378 NY,D008213 Q000276 NN,D003713 Q000276 NN,D013110 Q000031 NY,D011409 Q000494 NY,D016176 Q000187 NN,D008213 Q000187 NN,D002118 Q000378 NN,D003713 Q000378 NN,D016176 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN,D016176 Q000378 NN,D015398 Q000187 NY","107969,107970,5280335,5460341,6337033",NULL,Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.,"For the immune modulatory drug fingolimod (FTY720), lymphocyte sequestration has been extensively studied and accepted as mode of action. Further, direct effects on immune cell signalling are incompletely understood. Herein, we used the parent drug and newly synthesized analogues to investigate their effects on dendritic cell (DC) calcium signalling and on Th1, Th2 and Th17 responses. DC calcium signalling was determined with a single cell-based confocal assay and IL-33/ST2-TIR Th2-like response with ST2-tr",Scandinavian journal of immunology,"K Rüger, F Ottenlinger, M Schröder, A Zivković, H Stark, J M Pfeilschifter, H H Radeke"," pharmazentrum frankfurt/ZAFES, Clinic of the J.W. Goethe University, Frankfurt am Main, Germany.",2014 Dec;80(6):398-407,10.1111/sji.12238
25216235,20140101,article,mesh,"Animals,Corneal Transplantation,Cytokines,Fingolimod Hydrochloride,Gene Expression Regulation,Graft Survival,Inflammation,Kidney,Male,Mice, Inbred BALB C,Mice, Inbred C57BL,Propylene Glycols,Receptors, Lysosphingolipid,Sphingosine,Time Factors","agonists,analogs &amp; derivatives,blood,drug effects,metabolism,pathology,pharmacology","D007668 Q000187 NN,D049349 Q000819 NY,D007668 Q000473 NN,D006085 Q000187 YN,D013110 Q000031 NN,D005786 Q000187 NN,D016207 Q000097 NN,D011409 Q000494 NN,D013110 Q000494 NN,D007249 Q000473 NN,D049349 Q000378 NN","107969,107970,5280335",NULL,Prolonging survival of corneal transplantation by selective sphingosine-1-phosphate receptor 1 agonist.,"Corneal transplantation is the most used therapy for eye disorders. Although the cornea is somewhat an immune privileged organ, immune rejection is still the major problem that reduces the success rate. Therefore, effective chemical drugs that regulate immunoreactions are needed to improve the outcome of corneal transplantations. Here, a sphingosine-1-phosphate receptor 1 (S1P1) selective agonist was systematically evaluated in mouse allogeneic corneal transplantation and compared with the commonly used imm",PloS one,"Min Gao, Yong Liu, Yang Xiao, Gencheng Han, Liang Jia, Liqiang Wang, Tian Lei, Yifei Huang"," Department of Ophthalmology, Chinese PLA General Hospital. Beijing, China; Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Department of Ophthalmology, Chinese PLA Air Force General Hospital, Beijing, China. Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Laboratory of Immunology, Institute of Basic Medical Sciences. Beijing, China. Department of Ophthalmology, Chinese PLA General Hospital. Beijing, Chin",2014 Jan;9(9):e105693,10.1371/journal.pone.0105693
25220288,20141201,article,mesh,"Animals,Antioxidants,Drug Delivery Systems,Epidermis,Histocytochemistry,In Vitro Techniques,Microscopy, Confocal,Microscopy, Electron, Scanning,Microscopy, Electron, Transmission,Nanoparticles,Palmitic Acid,Particle Size,Polysorbates,Quercetin,Rats,Skin Absorption","chemistry,metabolism,methods,pharmacology,physiology,standards,ultrastructure","D053758 Q000378 NY,D011136 Q000737 NN,D053758 Q000648 NN,D011794 Q000494 NY,D012869 Q000502 NY,D016503 Q000592 NN,D016503 Q000379 NY,D000975 Q000494 NY,D019308 Q000737 NN,D004817 Q000502 NY","985,443314,443315,2735111,5280343,5281955,6364656,9829021,12806382,86289060,86289077",NULL,Physical characterization and in vitro skin permeation of solid lipid nanoparticles for transdermal delivery of quercetin.,"OBJECTIVE: Quercetin, a phenolic compound isolated from plants, can act as an antioxidant to protect the skin from oxidative stress induced by ultraviolet rays. The aims of this work were (i) to compare the physical characterization of quercetin-loaded solid lipid nanoparticles (QSLNs) and (ii) to investigate the enhanced skin permeation of quercetin using QSLNs. METHODS: QSLNs were prepared with a certain amount lipid (palmitic acid) and the different ratio of surfactant (Tween(®) 80) by homogenization and",International journal of cosmetic science,"S B Han, S S Kwon, Y M Jeong, E R Yu, S N Park"," Department of Fine Chemistry, Nanobiocosmetic Laboratory, and Cosmetic R&D Center, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul, 139-743, Korea.",2014 Dec;36(6):588-97,10.1111/ics.12160
25227585,20141115,article,mesh,"Animals,Antigens, CD,Central Nervous System,Disease Models, Animal,Fingolimod Hydrochloride,Glatiramer Acetate,Immunologic Surveillance,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Peptides,Propylene Glycols,Sphingosine,Toxoplasmosis","analogs &amp; derivatives,drug effects,drug therapy,immunology,metabolism,mortality,therapeutic use","D007157 Q000187 NY,D014123 Q000401 NN,D013110 Q000031 NY,D007166 Q000627 NY,D002490 Q000276 NY,D014123 Q000188 NY,D010455 Q000627 NY,D015703 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY","65370,107969,107970,3081884,5280335",NULL,Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.,"Immune surveillance of the CNS is critical for preventing infections; however, there is no accepted experimental model to assess the risk of infection when utilizing disease-modifying agents. We tested two approved agents for patients with multiple sclerosis (MS), glatiramer acetate and fingolimod, in an experimental model of CNS immune surveillance. C57BL/6 mice were infected with the ME49 strain of the neuroinvasive parasite Toxoplasma gondii (T. gondii) and then treated with GA and fingolimod. Neither tr",Journal of neuroimmunology,"Cyd Castro-Rojas, Krystin Deason, Rehana Z Hussain, Liat Hayardeny, Petra C Cravens, Felix Yarovinsky, Todd N Eagar, Benjamine Arellano, Olaf Stüve"," Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA. Teva Pharmaceuticals, Petah Tikva, Israel. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA. Departme",2014 Nov;276(?):232-5,10.1016/j.jneuroim.2014.08.624
25230163,20141101,article,mesh,"Animals,Bacterial Adhesion,Biomarkers,Case-Control Studies,Colitis, Ulcerative,Crohn Disease,DNA, Bacterial,Dogs,Dysentery, Bacillary,Escherichia coli,Escherichia coli Infections,Fimbriae, Bacterial,Gene Expression Profiling,Genome, Bacterial,Humans,Ileitis,Inflammation,Intestinal Mucosa,Iron,Macrophages,Mice,Oligonucleotide Array Sequence Analysis,Phylogeny,Propylene Glycols,Shigella,Signal Transduction,Virulence Factors","etiology,genetics,isolation &amp; purification,metabolism,microbiology,pathogenicity,pathology,physiology","D007249 Q000378 NN,D003093 Q000378 NN,D008264 Q000382 NN,D003093 Q000382 NN,D003424 Q000378 NN,D007501 Q000378 NY,D004405 Q000473 NN,D004927 Q000209 NN,D007249 Q000382 NY,D007413 Q000382 NN,D001422 Q000502 NN,D007413 Q000378 NN,D004926 Q000235 NN,D011409 Q000378 NY,D007413 Q000473 NN,D003093 Q000473 NN,D008264 Q000473 NN,D008264 Q000378 NY,D007079 Q000378 NN,D037521 Q000378 NY,D003424 Q000473 NN,D004405 Q000378 NY,D007079 Q000473 NN,D004926 Q000472 NN,D004926 Q000302 NN,D007079 Q000382 NN,D012760 Q000472 NN","10442,10313045",NULL,Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.,"BACKGROUND: Perturbations of the intestinal microbiome, termed dysbiosis, are linked to intestinal inflammation. Isolation of adherent-invasive Escherichia coli (AIEC) from intestines of patients with Crohn's disease (CD), dogs with granulomatous colitis, and mice with acute ileitis suggests these bacteria share pathoadaptive virulence factors that promote inflammation. METHODS: To identify genes associated with AIEC, we sequenced the genomes of phylogenetically diverse AIEC strains isolated from people wit",Inflammatory bowel diseases,"Belgin Dogan, Haruo Suzuki, Deepali Herlekar, R Balfour Sartor, Barry J Campbell, Carol L Roberts, Katrina Stewart, Ellen J Scherl, Yasemin Araz, Paulina P Bitar, Tristan Lefébure, Brendan Chandler, Ynte H Schukken, Michael J Stanhope, Kenneth W Simpson"," Departments of *Clinical Sciences, and †Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York; ‡Department of Environmental Science and Engineering, Graduate School of Science and Engineering, Yamaguchi University, Yamaguchi, Japan; §Departments of Medicine, and ‖Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; ¶Department of Gastroenterology, Institute of Translational Medic",2014 Nov;20(11):1919-32,10.1097/mib.0000000000000183
25247669,20140101,review,mesh,"Alemtuzumab,Antibodies, Monoclonal, Humanized,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Immunoglobulin G,Immunosuppressive Agents,Interferon-beta,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine,Toluidines","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D007166 Q000008 NN,D016899 Q000627 NN,D005650 Q000627 NN,D003437 Q000627 NN,D013110 Q000031 NN,D007074 Q000627 NN,D007166 Q000627 NY,D061067 Q000627 NN,D020529 Q000188 NY,D014052 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN","12215,107969,107970,223382,637568,5280335",NULL,Update on multiple sclerosis treatments.,"Relapsing-remitting multiple sclerosis (RRMS) management has dramatically changed over the past decade. New drugs have arrived on the market, allowing for more individualised treatment selection. However, this diversity has increased the complexity of RRMS patient follow-up. In this review, we provide summarised information about treatment efficacy, potential side-effects, follow-up recommendations, vaccinations, and pregnancy safety issues for all currently available disease modifying therapies and those a",Swiss medical weekly,"Claire Bridel, Patrice H Lalive"," Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Switzerland. Department of Genetic and Laboratory Medicine, Division of Laboratory Medicine, Geneva University Hospital, Switzerland.",2014 Jan;144(?):w14012,10.4414/smw.2014.14012
25252227,20140901,article,mesh,"Cardiovascular Diseases,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000009 NN,D002318 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Oral fingolimod to treat multiple sclerosis: see your cardiologist first.,NULL,Arquivos de neuro-psiquiatria,"Douglas Kazutoshi Sato, Dagoberto Callegaro"," Department of Neurology, Tohoku University School of Medicine, Sendai, Japan. Department of Neurology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.",2014 Sep;72(9):651-2,10.1590/0004-282x20140171
25252236,20140901,article,mesh,"Adult,Aged,Bradycardia,Cardiovascular Diseases,Female,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine,Time Factors,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,drug effects,drug therapy","D013110 Q000009 NN,D007166 Q000008 NN,D001919 Q000139 NN,D013110 Q000008 NN,D002318 Q000139 NY,D013110 Q000031 NY,D011409 Q000008 NN,D006339 Q000187 NN,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.,"Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patie",Arquivos de neuro-psiquiatria,"Yara Dadalti Fragoso, Christian Cardoso Arruda, Walter Oleschko Arruda, Joseph Bruno Bidin Brooks, Alfredo Damasceno, Carlos Augusto de Albuquerque Damasceno, Alessandro Finkelsztejn, Juliana Finkelsztejn, Paulo Diniz da Gama, Maria Cristina Brandão Giacomo, Sidney Gomes, Marcus Vinicius Magno Goncalves, Andre Palma da Cunha Matta, Marilia Manprim de Morais, Enedina Maria Lobato de Oliveira, Yuna Ribeiro, Henry Koiti Sato, Carlos Bernardo Tauil"," Departamento de Neurologia, Universidade Metropolitana de Santos, Santos, SP, Brazil. Departamento de Neurologia, Universidade Positivo, Curitiba, PR, Brazil. Departamento de Neurologia, Universidade Federal do Paraná, Curitiba, PR, Brazil. Departamento de Neurologia, Universidade Metropolitana de Santos, Santos, SP, Brazil. Departamento de Neurologia, Universidade Estadual de Campinas, Campinas, SP, Brazil. Departamento de Neurologia, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil. Departa",2014 Sep;72(9):712-4,10.1590/0004-282x20140102
25293589,20141201,article,mesh,"Aged,Animals,Case-Control Studies,Cell Line,Cells, Cultured,Coronary Artery Disease,Cricetulus,Drug Resistance,Endocytosis,Female,Fingolimod Hydrochloride,Genetic Association Studies,Genetic Predisposition to Disease,Humans,Immunosuppressive Agents,Lysophospholipids,Male,Middle Aged,Mutant Proteins,Polymorphism, Single Nucleotide,Propylene Glycols,Receptors, Lysosphingolipid,Recombinant Fusion Proteins,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,genetics,metabolism,pharmacology","D007166 Q000494 NY,D003324 Q000235 NY,D049349 Q000819 NN,D050505 Q000378 NN,D015398 Q000187 YN,D004705 Q000187 NY,D003324 Q000378 NN,D013110 Q000031 NY,D013110 Q000378 NN,D008246 Q000378 NY,D049349 Q000235 NY,D011993 Q000378 NN,D011409 Q000494 NN,D013110 Q000494 NN,D049349 Q000037 NN,D049349 Q000378 NN","107969,107970,5280335,5283560",NULL,Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.,"Sphingosine 1-phosphate receptor 1 (S1P₁), an abundantly-expressed G protein-coupled receptor which regulates key vascular and immune responses, is a therapeutic target in autoimmune diseases. Fingolimod/Gilenya (FTY720), an oral medication for relapsing-remitting multiple sclerosis, targets S1P₁ receptors on immune and neural cells to suppress neuroinflammation. However, suppression of endothelial S1P₁ receptors is associated with cardiac and vascular adverse effects. Here we report the genetic variations ",Journal of lipid research,"Hideru Obinata, Sarah Gutkind, Jeremiah Stitham, Toshiaki Okuno, Takehiko Yokomizo, John Hwa, Timothy Hla"," Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065. Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065. Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510. Department of Biochemistry, Juntendo University Sc",2014 Dec;55(12):2665-75,10.1194/jlr.p054163
25302718,20141001,review,mesh,"Administration, Intravenous,Administration, Oral,Alemtuzumab,Antibodies, Monoclonal, Humanized,Crotonates,Dimethyl Fumarate,Disease Progression,Drug Administration Schedule,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Mitoxantrone,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Risk Assessment,Sphingosine,Toluidines","administration &amp; dosage,analogs &amp; derivatives,drug therapy,physiopathology","D007166 Q000008 YN,D020529 Q000503 NN,D013110 Q000031 NN,D020529 Q000188 NY","4212,12215,51082,51151,107969,107970,637568,5280335,5458171,54607525",NULL,Current management of relapsing-remitting multiple sclerosis.,"Multiple sclerosis was without effective disease-modifying therapy for many years. The introduction of the injectable therapies (interferon and glatiramer acetate) some 20 years ago was considered a major advance. Recent years have heralded a revolution in treatment options with the introduction of intravenous natalizumab and, even more recently, three oral agents. We are currently in a period of determining the best use of these therapies to ensure prevention of disease progression while maintaining patien",Internal medicine journal,"L Sedal, I B Wilson, E A McDonald"," Neuroimmunology Clinic, Clinical Neurosciences, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.",2014 Oct;44(10):950-7,10.1111/imj.12558
25308417,20141101,article,mesh,"Animals,Antibodies, Monoclonal, Humanized,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Glatiramer Acetate,History, 20th Century,History, 21st Century,Humans,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Peptides,Propylene Glycols,Sphingosine","analogs &amp; derivatives,diet therapy,drug therapy,history,immunology,pathology,therapeutic use","D004681 Q000266 YN,D004681 Q000276 YN,D011409 Q000266 YN,D009103 Q000178 YN,D009103 Q000473 YN,D007166 Q000627 YN,D007166 Q000266 YN,D004681 Q000188 YN,D013110 Q000031 NY,D061067 Q000627 YN,D004681 Q000473 YN,D013110 Q000266 NN,D011409 Q000627 YN,D013110 Q000627 NN,D009103 Q000276 YN,D010455 Q000627 YN,D009103 Q000266 YN,D061067 Q000266 YN,D010455 Q000266 YN","65370,107969,107970,3081884,5280335",NULL,From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.,"Ruth Arnon and Michael Sela profoundly influenced the development of a model system to test new therapies in multiple sclerosis (MS). Their application of the animal model, known as experimental autoimmune encephalomyelitis (EAE), for the discovery of Copaxone, opened a new path for testing of drug candidates in MS. By measuring clinical, pathologic, and immunologic outcomes, the biological implications of new drugs could be elucidated. Using EAE they established the efficacy of Copaxone as a therapy for pr",Journal of autoimmunity,"Lawrence Steinman, Yehuda Shoenfeld"," Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: steinman@stanford.edu. Sheba Medical Center, Tel-Hashomer 52621, Israel. Electronic address: shoenfel@post.tau.ac.il.",2014 Nov;54(?):1-7,10.1016/j.jaut.2014.08.001
25320259,20140101,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Drug Administration Schedule,Female,Fingolimod Hydrochloride,Humans,Immune Reconstitution Inflammatory Syndrome,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Propylene Glycols,Recurrence,Sphingosine","adverse effects,analogs &amp; derivatives,complications,drug therapy,immunology,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D061067 Q000009 NN,D061067 Q000627 NY,D013110 Q000031 NY,D009103 Q000276 NY,D007166 Q000627 NY,D054019 Q000150 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?,"Although few recent studies have reported efficacy and safety data among patients with multiple sclerosis (MS) switching between immunotherapies, data on the mechanism of rebound activity postwithdrawal of fingolimod in patients with MS is scarce. A 36-year-old woman developed severe reactivation of her disease within 7 weeks of fingolimod's withdrawal despite the absence of breakthrough disease during the 8-week natalizumab washout period previously. The clinical presentation and radiological features were",BMJ case reports,"R Alroughani, A Almulla, S Lamdhade, A Thussu"," Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait Neurology Clinic, Dasman Diabetes Institute, Kuwait City, Kuwait. Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait. Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait. Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait Neurology Clinic, Dasman Diabetes Institute, Kuwait City, Kuwait.",2014 Jan;2014(?):?,10.1136/bcr-2014-206314
25344106,20140715,article,mesh,"Animals,Butylhydroxybutylnitrosamine,Carcinogens,Comet Assay,DNA Damage,Dose-Response Relationship, Drug,Epoxy Compounds,Isothiocyanates,Male,Propanols,Propylene Glycols,Rats,Rats, Sprague-Dawley,Triazines,Uracil,Urinary Bladder","drug effects,methods,pathology,toxicity","D001743 Q000187 NY,D001743 Q000473 NY,D014227 Q000633 NN,D002273 Q000633 NY,D004249 Q000187 NY,D002085 Q000633 NN,D014498 Q000633 NN,D004852 Q000633 NN,D011409 Q000633 NN,D020552 Q000379 NY,D017879 Q000633 NN,D020005 Q000633 NN","1174,2346,7955,11164,18692,19665,92612",NULL,Effects of seven chemicals on DNA damage in the rat urinary bladder: a comet assay study.,"The in vivo comet assay has been used for the evaluation of DNA damage and repair in various tissues of rodents. However, it can give false-positive results due to non-specific DNA damage associated with cell death. In this study, we examined whether the in vivo comet assay can distinguish between genotoxic and non-genotoxic DNA damage in urinary bladder cells, by using the following seven chemicals related to urinary bladder carcinogenesis in rodents: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), glycidol, ",Mutation research. Genetic toxicology and environmental mutagenesis,"Kunio Wada, Toshinori Yoshida, Naofumi Takahashi, Kyomu Matsumoto"," Toxicology Division, The Institute of Environmental Toxicology, 4321, Uchimoriya-machi, Joso-shi, Ibaraki 303-0043, Japan. Electronic address: wada@iet.or.jp. Toxicology Division, The Institute of Environmental Toxicology, 4321, Uchimoriya-machi, Joso-shi, Ibaraki 303-0043, Japan. Toxicology Division, The Institute of Environmental Toxicology, 4321, Uchimoriya-machi, Joso-shi, Ibaraki 303-0043, Japan. Toxicology Division, The Institute of Environmental Toxicology, 4321, Uchimoriya-machi, Joso-shi, Ibaraki ",2014 Jul;769(?):1-6,10.1016/j.mrgentox.2014.04.015
25358761,20150301,article,mesh,"Adenosine Triphosphate,Autophagy,Cell Death,Cell Line, Tumor,Cell Membrane,Dimethyl Sulfoxide,Fingolimod Hydrochloride,Humans,Macrolides,Melanoma,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Phosphatase 2,Reactive Oxygen Species,Sphingosine,Vacuolar Proton-Translocating ATPases","analogs &amp; derivatives,drug effects,enzymology,metabolism,pathology,pharmacology","D000255 Q000378 NN,D017382 Q000378 NN,D004121 Q000494 NN,D016923 Q000187 NN,D025262 Q000378 NY,D001343 Q000187 NN,D013110 Q000031 NY,D054648 Q000378 NN,D011409 Q000494 NY,D008545 Q000473 NY,D002462 Q000187 NN,D018942 Q000494 NN,D017853 Q000378 NY,D008545 Q000201 NY,D013110 Q000494 NN,D002462 Q000378 NN","679,2287,5957,15126,72947,107969,107970,124341,5280335,5353429,5385089,5458921,5461108,5702538,6436223,18666496,21159502,53321987,71366967,71668406,90479784,90656913,129012189,129660564,131863036,131954761,133126837,133268469,134694634",NULL,Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.,"Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer. However, the effect of such an approach on survival of human melanoma cells remains less understood. Here, we show that the sphingosine analogue FTY720 that functionally antagonises S1PRs kills human melanoma cells through a mechanism involving the vacuolar H(+) -ATPase activity. Moreover, we demonstrate that FTY720-triggered cell death is characterized by features ",Pigment cell & melanoma research,"Kwang Hong Tay, Xiaoying Liu, Mengna Chi, Lei Jin, Chen Chen Jiang, Su Tang Guo, Nicole M Verrills, Hsin-Yi Tseng, Xu Dong Zhang"," School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.",2015 Mar;28(2):171-83,10.1111/pcmr.12326
25360562,20140101,article,mesh,"Adolescent,Adult,Aged,B-Lymphocyte Subsets,B7-1 Antigen,B7-2 Antigen,Female,Fingolimod Hydrochloride,Follow-Up Studies,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,T-Lymphocyte Subsets,T-Lymphocytes, Regulatory,Young Adult","analogs &amp; derivatives,blood,drug therapy,immunology,metabolism,pathology,therapeutic use","D016176 Q000276 NY,D050378 Q000378 NN,D016175 Q000276 NY,D051940 Q000378 NN,D013110 Q000031 NY,D050378 Q000473 NN,D020529 Q000097 NN,D018122 Q000378 NN,D007166 Q000627 NY,D050378 Q000276 NN,D020529 Q000188 NY,D016175 Q000378 NN,D013110 Q000627 NN,D011409 Q000627 NY,D016176 Q000473 NN,D016176 Q000378 NN,D016175 Q000473 NN,D020529 Q000276 NN","107969,107970,5280335",NULL,Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.,"BACKGROUND AND OBJECTIVE: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-",PloS one,"Nele Claes, Tessa Dhaeze, Judith Fraussen, Bieke Broux, Bart Van Wijmeersch, Piet Stinissen, Raymond Hupperts, Niels Hellings, Veerle Somers"," Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium. Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium. Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium. Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of",2014 Jan;9(10):e111115,10.1371/journal.pone.0111115
25361781,20141202,article,mesh,"Adult,Aged,Body Mass Index,Cohort Studies,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Count,Lymphopenia,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D008231 Q000139 NY,D013110 Q000031 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.,"OBJECTIVE: To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Data were obtained from a German multicenter, single-arm, open-label study of patients with RRMS treated with fingolimod, and findings were validated in an independent Swedish national pharmacovigilance study. RESULTS: Four hundred eighteen patients with RRMS fro",Neurology,"Clemens Warnke, Thomas Dehmel, Ryan Ramanujam, Carolina Holmen, Nina Nordin, Kathleen Wolfram, Verena I Leussink, Hans-Peter Hartung, Tomas Olsson, Bernd C Kieseier"," From the Department of Neurology (C.W., T.D., K.W., V.I.L., H.-P.H., B.C.K.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; and Department of Clinical Neuroscience (R.R., C.H., N.N., T.O.), Karolinska Institute, Stockholm, Sweden. From the Department of Neurology (C.W., T.D., K.W., V.I.L., H.-P.H., B.C.K.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; and Department of Clinical Neuroscience (R.R., C.H., N.N., T.O.), Karolinska Institute, Stockholm, Sweden. From the De",2014 Dec;83(23):2153-7,10.1212/wnl.0000000000001049
25373133,20141001,article,mesh,"Administration, Oral,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Toluidines","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,pharmacology","D005650 Q000008 NY,D005650 Q000009 NN,D013110 Q000009 NN,D011409 Q000009 NN,D003437 Q000008 NY,D014052 Q000009 NN,D014052 Q000494 NN,D013110 Q000008 NN,D003437 Q000494 NN,D013110 Q000031 NY,D003437 Q000009 NN,D014052 Q000008 NY,D011409 Q000494 NN,D013110 Q000494 NN,D007166 Q000009 NN,D007166 Q000494 NN,D009103 Q000188 NY,D005650 Q000494 NN,D011409 Q000008 NY,D007166 Q000008 NY","12215,107969,107970,637568,5280335",NULL,Recognizing and overcoming potential barriers to oral medications for MS.,"Three FDA-approved oral medications are available for the treatment of relapsing forms of multiple sclerosis: fingolimod, teriflunomide, and dimethyl fumarate. While injection and IV treatments have proven to be beneficial, these newer oral agents also offer positive outcomes for patients. Numerous barriers exist, though, for these oral agents, including the unknown long-term efficacy and safety and potential side effects. Despite possible side effects, oral agents provide convenience, ease of use, and the ",The Journal of clinical psychiatry,Harold Moses,NULL,2014 Oct;75(10):e28,10.4088/jcp.13037nr3c
25379595,20141001,article,mesh,"Administration, Intravaginal,Administration, Intravenous,Animals,Cervix Uteri,Drug Evaluation, Preclinical,Female,Fingolimod Hydrochloride,HIV Infections,Immunomodulation,Immunosuppressive Agents,Lymphocytes,Macaca nemestrina,Mucous Membrane,Pilot Projects,Propylene Glycols,Simian Acquired Immunodeficiency Syndrome,Simian Immunodeficiency Virus,Sphingosine,Vagina","analogs &amp; derivatives,chemistry,drug effects,immunology,pharmacology,prevention &amp; control","D014621 Q000737 NN,D007166 Q000494 NY,D015658 Q000517 NN,D002584 Q000737 NN,D009092 Q000737 NN,D013110 Q000031 NY,D016097 Q000517 NN,D011409 Q000494 NY,D015302 Q000187 NY,D002584 Q000276 NY,D009092 Q000276 NN,D013110 Q000494 NN,D008214 Q000187 NN,D014621 Q000276 NY","107969,107970,5280335",NULL,Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques.,FTY720 has been shown to reduce inflammatory cytokines and immune cells in the genital mucosa of macaques. This pilot study examined the ability of FTY720 to inhibit HIV acquisition. Systemic treatment with FTY720 failed to prevent or delay vaginal SHIV transmission. ,Journal of medical primatology,"Monica Morris, Rachael D Aubert, Katherine Butler, Tara Henning, James Mitchell, Leecresia Jenkins, David Garber, Janet McNicholl, Ellen N Kersh",NULL,2014 Oct;43(5):370-3,10.1111/jmp.12120
25399649,20141201,article,mesh,"Acetylglucosaminidase,Albuminuria,Animals,Anti-Inflammatory Agents,Disease Models, Animal,Down-Regulation,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation Mediators,Kidney Tubules,Lymphocytes,Lysophospholipids,Macrophages,Male,Nephritis, Interstitial,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Rats, Wistar,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine,Time Factors","analogs &amp; derivatives,drug effects,drug therapy,enzymology,metabolism,pathology,pharmacology,prevention &amp; control,urine","D008214 Q000201 NN,D008264 Q000201 NN,D007166 Q000494 NY,D000893 Q000494 NY,D009395 Q000652 NN,D000118 Q000652 NN,D009395 Q000517 NY,D000419 Q000652 NN,D007684 Q000473 NN,D013110 Q000031 NY,D009395 Q000201 NN,D011409 Q000494 NY,D007684 Q000201 NN,D013110 Q000378 NN,D000419 Q000201 NN,D007684 Q000187 NY,D008264 Q000187 NN,D049349 Q000187 NN,D018836 Q000378 NN,D009395 Q000473 NN,D017853 Q000378 NY,D000419 Q000473 NN,D008246 Q000378 NN,D015398 Q000187 NN,D013110 Q000494 NN,D008214 Q000187 NN,D000419 Q000188 NY","107969,107970,5280335,5283560",NULL,FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.,"AIM: FTY720, a new immunomodulatory drug with low cytotoxicity, is currently used to treat multiple sclerosis. In this study, we investigated the effects of FTY720 on inflammatory cell infiltration in albumin overload-induced nephropathy of rats. METHODS: Male Wistar rats were subjected to right-side nephrectomy and divided into 3 groups. One week after the surgery, albumin overload (AO) group was treated with BSA (5 g·kg(-1)·d(-1), ip) for 9 weeks; AO+FTY720 group was given BSA (5 g·kg(-1)·d(-1), ip) plus ",Acta pharmacologica Sinica,"Min Xu, Dan Liu, Li-hong Ding, Kun-ling Ma, Min Wu, Lin-li Lv, Yi Wen, Hong Liu, Ri-ning Tang, Bi-cheng Liu"," Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjin",2014 Dec;35(12):1537-45,10.1038/aps.2014.100
25416038,20150106,article,mesh,"Encephalitis, Varicella Zoster,Female,Fingolimod Hydrochloride,Herpes Zoster Vaccine,Humans,Immunocompromised Host,Immunosuppressive Agents,Middle Aged,Multiple Sclerosis, Chronic Progressive,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D053061 Q000627 NN,D013110 Q000009 NN,D020528 Q000188 NY,D013110 Q000031 NY,D020804 Q000139 NY,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,VZV encephalitis that developed in an immunized patient during fingolimod therapy.,NULL,Neurology,"Naoum P Issa, Afif Hentati"," From The University of Chicago (N.P.I.); and NorthShore Neurological Institute (A.H.), NorthShore University Health System, Evanston, IL. From The University of Chicago (N.P.I.); and NorthShore Neurological Institute (A.H.), NorthShore University Health System, Evanston, IL. ahentati@northshore.org.",2015 Jan;84(1):99-100,10.1212/wnl.0000000000001109
25419615,20150101,article,mesh,"Adolescent,Adrenal Cortex Hormones,Adult,Consensus,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Herpes Zoster,Herpesvirus 3, Human,Humans,Immunosuppressive Agents,Incidence,Male,Medication Reconciliation,Middle Aged,Product Surveillance, Postmarketing,Propylene Glycols,Risk Assessment,Risk Factors,Severity of Illness Index,Sphingosine,Young Adult","analogs &amp; derivatives,drug therapy,pathogenicity,standards,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D006562 Q000188 NY,D014645 Q000472 NY,D013110 Q000627 NN,D000305 Q000627 NN,D011409 Q000627 NY,D059065 Q000592 NY","107969,107970,5280335",NULL,Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.,"IMPORTANCE: Varicella-zoster virus (VZV) infections increasingly are reported in patients with multiple sclerosis (MS) and constitute an area of significant concern, especially with the advent of more disease-modifying treatments in MS that affect T-cell-mediated immunity. OBJECTIVE: To assess the incidence, risk factors, and clinical characteristics of VZV infections in fingolimod-treated patients and provide recommendations for prevention and management. DESIGN, SETTING, AND PARTICIPANTS: Rates of VZV inf",JAMA neurology,"Ann M Arvin, Jerry S Wolinsky, Ludwig Kappos, Michele I Morris, Anthony T Reder, Carlo Tornatore, Anne Gershon, Michael Gershon, Myron J Levin, Mauritz Bezuidenhoudt, Norman Putzki"," Department of Pediatrics, Stanford University School of Medicine, Stanford, California. Department of Neurology, The University of Texas Health Science Center at Houston. Department of Neurology, University Hospital Basel, Basel, Switzerland. Department of Infectious Diseases, University of Miami, Miami, Florida. Department of Neurology, University of Chicago Medical Center, Chicago, Illinois. Department of Neurology, MedStar Georgetown University Hospital, Washington, DC. Department of Pediatrics, Columbi",2015 Jan;72(1):31-9,10.1001/jamaneurol.2014.3065
25420159,20150101,article,mesh,"Female,Fingolimod Hydrochloride,Herpes Zoster,Herpesvirus 3, Human,Humans,Immunosuppressive Agents,Male,Medication Reconciliation,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pathogenicity,standards,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D006562 Q000188 NY,D014645 Q000472 NY,D013110 Q000627 NN,D011409 Q000627 NY,D059065 Q000592 NY","107969,107970,5280335",NULL,Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug.,NULL,JAMA neurology,Kenneth L Tyler," Department of Neurology, University of Colorado School of Medicine, Aurora.",2015 Jan;72(1):10-3,10.1001/jamaneurol.2014.3390
25429856,20150701,article,mesh,"Adenocarcinoma, Clear Cell,Animals,Cell Line, Tumor,Cell Proliferation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Mice,Mice, Nude,Neoplasm Transplantation,Neoplasms, Glandular and Epithelial,Ovarian Neoplasms,Phosphotransferases (Alcohol Group Acceptor),Propylene Glycols,Protein Kinase Inhibitors,RNA, Small Interfering,Sphingosine,Xenograft Model Antitumor Assays","administration &amp; dosage,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,metabolism,pathology,pharmacology","D009375 Q000473 NN,D017853 Q000378 NN,D047428 Q000494 NN,D047428 Q000008 NY,D013110 Q000008 NN,D010051 Q000188 NY,D017853 Q000037 NY,D049109 Q000187 NN,D013110 Q000031 NY,D010051 Q000473 NN,D018262 Q000378 NN,D010051 Q000378 NN,D009375 Q000378 NN,D018262 Q000473 NN,D011409 Q000494 NN,D009375 Q000188 NY,D018262 Q000188 NY,D013110 Q000494 NN,D007166 Q000494 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.,"Sphingosine kinase 1 (SK1) is over-expressed in multiple types of human cancer. SK1 has growth-promoting effects and has been proposed as a potential therapeutic target. We investigated the therapeutic effects of SK1 inhibition in epithelial ovarian carcinoma (EOC). SK1 siRNA or inhibitors were tested in EOC cell lines, including A2780, SKOV3ip1, A2780-CP20, SKOV3-TR, ES2 and RMG2. Cells were treated with SK inhibitor or FTY720, and cell proliferation, apoptosis, angiogenesis and invasion were examined by M",International journal of cancer,"Jeong-Won Lee, Ji-Yoon Ryu, Gun Yoon, Hye-Kyung Jeon, Young-Jae Cho, Jung-Joo Choi, Sang Yong Song, In-Gu Do, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Byoung-Gie Kim, Duk-Soo Bae"," Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",2015 Jul;137(1):221-9,10.1002/ijc.29362
25440790,20141101,review,mesh,"Atrioventricular Node,Cardiovascular System,Down-Regulation,Fingolimod Hydrochloride,Heart Rate,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Receptors, Lysosphingolipid,Signal Transduction,Sphingosine","agonists,analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,pharmacology,therapeutic use","D007166 Q000494 NY,D049349 Q000819 NN,D007166 Q000627 NN,D006339 Q000187 NY,D002319 Q000187 NN,D013110 Q000031 NY,D011409 Q000494 NY,D049349 Q000187 NY,D001283 Q000187 NY,D015398 Q000187 NN,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D049349 Q000037 NN,D009103 Q000188 NN","107969,107970,5280335",NULL,Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.,"Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis; it reduces autoreactive lymphocytes' egress from lymphoid tissues by down-regulating S1PRs. Sphingosine-1-phosphate signaling is implicated in a range of physiologic functions, and S1PRs are expressed differentially in various tissues, including the cardiovascular system. Modulation of S1PRs on cardiac cells provides an explanation for the transien",American heart journal,"John Camm, Timothy Hla, Rajesh Bakshi, Volker Brinkmann"," Cardiovascular Sciences Research Centre, Division of Clinical Sciences, St George's, University of London, London, United Kingdom. Electronic address: jcamm@sgul.ac.uk. Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY. Novartis Pharma AG, Basel, Switzerland. Novartis Pharma AG, Basel, Switzerland.",2014 Nov;168(5):632-44,10.1016/j.ahj.2014.06.028
25449461,20150115,article,mesh,"Animals,Anti-Inflammatory Agents,Antrodia,Complex Mixtures,Dermatologic Surgical Procedures,Disease Models, Animal,Ergosterol,Fruiting Bodies, Fungal,I-kappa B Proteins,Interleukin-6,Ischemia,Male,Mice,Mycelium,NF-kappa B,Nitric Oxide Synthase Type II,RNA, Messenger,Skin,Tumor Necrosis Factor-alpha,Vascular Endothelial Growth Factor A","analogs &amp; derivatives,blood supply,chemistry,drug therapy,genetics,isolation &amp; purification,metabolism,pathology,pharmacology,therapeutic use","D007511 Q000188 NY,D052247 Q000378 NN,D004875 Q000494 NN,D015850 Q000378 NN,D014409 Q000378 NN,D042461 Q000235 NN,D045424 Q000737 NN,D012867 Q000098 NN,D004875 Q000031 NY,D016328 Q000378 NN,D020672 Q000378 NN,D007511 Q000378 NN,D000893 Q000302 NN,D012867 Q000473 NN,D007511 Q000473 NN,D015850 Q000235 NN,D012333 Q000378 NN,D052247 Q000235 NN,D004875 Q000627 NN,D000893 Q000494 NN,D000893 Q000627 NY","444679,6436872,129737949",NULL,"Anti-inflammatory effects of Antrodia camphorata, a herbal medicine, in a mouse skin ischemia model.","ETHNOPHARMACOLOGICAL EVIDENCE: Antrodia camphorata, a highly valued polypore mushroom native only to Taiwan, has been traditionally used as a medicine for anti-inflammation. AIM OF THE STUDY: In this study, anti-inflammatory effects of Antrodia camphorata (AC) and its active compound, ergostatrien-3β-ol (ST1), were investigated in a mouse skin ischemia model induced by skin flap surgery on the dorsal skin. MATERIALS AND METHODS: A U-shaped flap was elevated on the dorsal skin of the nine-week-old male mice.",Journal of ethnopharmacology,"Tung-Chou Tsai, Yu-Tang Tung, Yueh-Hsiung Kuo, Jiunn-Wang Liao, Hsin-Chung Tsai, Kowit-Yu Chong, Hsiao-Ling Chen, Chuan-Mu Chen"," Department of Life Sciences, and Agricultural Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan. Department of Life Sciences, and Agricultural Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan. Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Graduate Institute of Veterinary Pathobiology, National Chung Hsing Uni",2015 Jan;159(?):113-21,10.1016/j.jep.2014.11.015
25471584,20141203,article,mesh,"Animals,Animals, Newborn,Atrophy,Blood-Brain Barrier,Brain,Cell Movement,Chorioamnionitis,Cytokines,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Humans,Hypoxia-Ischemia, Brain,Immunosuppressive Agents,Infant, Newborn,Inflammation,Lipopolysaccharides,Lymphocyte Activation,Lymphocytes,NF-kappa B,Pregnancy,Propylene Glycols,Rats,Receptors, Interleukin,Sphingosine,T-Lymphocytes,White Matter","analogs &amp; derivatives,cytology,drug effects,drug therapy,metabolism,pathology,pharmacology,prevention &amp; control,therapeutic use","D001284 Q000188 NN,D002821 Q000378 NN,D007166 Q000627 NN,D001812 Q000187 NN,D002465 Q000187 NY,D020925 Q000188 NN,D016207 Q000378 NN,D020925 Q000517 NY,D016328 Q000378 NN,D020925 Q000473 NY,D001921 Q000187 NN,D008214 Q000187 NY,D013110 Q000031 NY,D011409 Q000494 NY,D001921 Q000378 NN,D001921 Q000473 NN,D002821 Q000188 NN,D018123 Q000378 NN,D013601 Q000166 NN,D008214 Q000166 NN,D066127 Q000187 NN,D007249 Q000517 NY,D013110 Q000627 NN,D011409 Q000627 NN,D013110 Q000494 NN,D007166 Q000494 NN,D008213 Q000187 NY","107969,107970,5280335",NULL,Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns.,"Intrauterine infection (chorioamnionitis) aggravates neonatal hypoxic-ischemic (HI) brain injury, but the mechanisms linking systemic inflammation to the CNS damage remain uncertain. Here we report evidence for brain influx of T-helper 17 (TH17)-like lymphocytes to coordinate neuroinflammatory responses in lipopolysaccharide (LPS)-sensitized HI injury in neonates. We found that both infants with histological chorioamnionitis and rat pups challenged by LPS/HI have elevated expression of the interleukin-23 (I",The Journal of neuroscience : the official journal of the Society for Neuroscience,"Dianer Yang, Yu-Yo Sun, Siddhartha Kumar Bhaumik, Yikun Li, Jessica M Baumann, Xiaoyi Lin, Yujin Zhang, Shang-Hsuan Lin, R Scott Dunn, Chia-Yang Liu, Feng-Shiun Shie, Yi-Hsuan Lee, Marsha Wills-Karp, Claire A Chougnet, Suhas G Kallapur, Ian P Lewkowich, Diana M Lindquist, Kaja Murali-Krishna, Chia-Yi Kuan"," Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, Georgia 30303, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322. Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, Georgia 30303, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322. Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, Georgia 30303. Department of Pediatrics, Children's Healthcare of Atlanta, A",2014 Dec;34(49):16467-81,10.1523/jneurosci.2582-14.2014
25474413,20141201,article,mesh,"Animals,Blood-Brain Barrier,CD8-Positive T-Lymphocytes,Cerebral Cortex,Claudin-5,Disease Models, Animal,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intercellular Adhesion Molecule-1,Macrophages,Malaria, Cerebral,Mice,Neutrophils,Occludin,Plasmodium berghei,Plasmodium yoelii,Propylene Glycols,Sphingosine,Zonula Occludens-1 Protein","analogs &amp; derivatives,drug therapy,immunology,parasitology,pathology,pharmacology","D001812 Q000473 NN,D018414 Q000276 NN,D008264 Q000276 NN,D062793 Q000276 NN,D016779 Q000188 NN,D016779 Q000276 NY,D010962 Q000276 NY,D018414 Q000473 NN,D008264 Q000473 NN,D013110 Q000031 NN,D009504 Q000473 NN,D010967 Q000276 NY,D009504 Q000276 NN,D002540 Q000276 NY,D062826 Q000276 NN,D001812 Q000276 NY,D016779 Q000473 NN,D062507 Q000276 NN,D011409 Q000494 NN,D018799 Q000276 NN,D013110 Q000494 NN,D007166 Q000494 NN,D002540 Q000469 NN,D002540 Q000473 NN","107969,107970,5280335",NULL,Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.,"Cerebral malaria claims the lives of over 600,000 African children every year. To better understand the pathogenesis of this devastating disease, we compared the cellular dynamics in the cortical microvasculature between two infection models, Plasmodium berghei ANKA (PbA) infected CBA/CaJ mice, which develop experimental cerebral malaria (ECM), and P. yoelii 17XL (PyXL) infected mice, which succumb to malarial hyperparasitemia without neurological impairment. Using a combination of intravital imaging and fl",PLoS pathogens,"Adéla Nacer, Alexandru Movila, Fabien Sohet, Natasha M Girgis, Uma Mahesh Gundra, P'ng Loke, Richard Daneman, Ute Frevert"," Department of Microbiology, Division of Medical Parasitology, New York University School of Medicine, New York, New York, United States of America. Department of Microbiology, Division of Medical Parasitology, New York University School of Medicine, New York, New York, United States of America. Department of Anatomy, University of California San Francisco, San Francisco, California, United States of America. Department of Microbiology, Division of Medical Parasitology, New York University School of Medicin",2014 Dec;10(12):e1004528,10.1371/journal.ppat.1004528
25489101,20141223,article,mesh,"Adult,Aged,Brain Ischemia,Case-Control Studies,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Subsets,Male,Middle Aged,Propylene Glycols,Single-Blind Method,Sphingosine,Stroke","adverse effects,analogs &amp; derivatives,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D002545 Q000188 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D020521 Q000188 NY,D007166 Q000009 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Impact of an immune modulator fingolimod on acute ischemic stroke.,"Peripheral lymphocytes entering brain ischemic regions orchestrate inflammatory responses, catalyze tissue death, and worsen clinical outcomes of acute ischemic stroke (AIS) in preclinical studies. However, it is not known whether modulating brain inflammation can impact the outcome of patients with AIS. In this open-label, evaluator-blinded, parallel-group clinical pilot trial, we recruited 22 patients matched for clinical and MRI characteristics, with anterior cerebral circulation occlusion and onset of s",Proceedings of the National Academy of Sciences of the United States of America,"Ying Fu, Ningnannan Zhang, Li Ren, Yaping Yan, Na Sun, Yu-Jing Li, Wei Han, Rong Xue, Qiang Liu, Junwei Hao, Chunshui Yu, Fu-Dong Shi"," Departments of Neurology and Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013; and. Radiology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, 300070, China; Departments of Neurology and. Departments of Neurology and. Departments of Neurology and. Departments of Neurology and. Radiology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, 300070, China; Departments of N",2014 Dec;111(51):18315-20,10.1073/pnas.1416166111
25509362,20140730,review,mesh,"Adult,Antibodies, Monoclonal, Humanized,Disease Progression,Fingolimod Hydrochloride,Humans,Immunocompromised Host,Immunosuppressive Agents,JC Virus,Leukoencephalopathy, Progressive Multifocal,Magnetic Resonance Imaging,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,etiology,immunology,pathology,pharmacology,therapeutic use,virology","D007166 Q000008 NN,D061067 Q000009 NN,D009103 Q000473 NN,D061067 Q000627 NY,D061067 Q000494 NN,D013110 Q000031 NN,D007968 Q000209 NY,D007166 Q000627 NY,D061067 Q000008 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D007166 Q000494 NN,D009103 Q000188 NY,D007968 Q000821 NN,D007968 Q000276 NN","107969,107970,5280335",NULL,"[[Natalizumab therapy, 2013].","Multiple sclerosis (MS) is the most common chronic disease of the central nervous system in young adults. No curative therapy is known. Currently, six drugs are available that can reduce the activity of MS. The first-line drugs can completely reduce the activity of the disease in nearly two-thirds of the patients. In the remainder, who suffer from breakthrough disease, the condition of the patient worsens, and second-line therapies must be used. The second-line drug natalizumab exhibits almost double effica",Ideggyogyaszati szemle,"Mária Karácsony, Krisztina Bencsik, László Vécsei",NULL,2014 Jul;67(?):220-8,NULL
25511835,20150101,review,mesh,"Administration, Oral,Crotonates,Dimethyl Fumarate,Disease Progression,Drug Approval,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Toluidines,United States,United States Food and Drug Administration","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,physiopathology,therapeutic use","D005650 Q000009 NN,D011409 Q000009 NN,D013110 Q000009 NN,D007166 Q000008 NN,D014052 Q000009 NN,D013110 Q000008 NN,D005650 Q000627 NN,D011409 Q000008 NN,D014052 Q000008 NN,D003437 Q000008 NN,D020529 Q000503 NN,D003437 Q000627 NN,D013110 Q000031 NN,D007166 Q000627 NY,D003437 Q000009 NN,D020529 Q000188 NY,D014052 Q000627 NN,D013110 Q000627 NN,D011409 Q000627 NN,D007166 Q000009 NN,D005650 Q000008 NN","12215,107969,107970,637568,5280335",NULL,Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.,"PURPOSE: The efficacy and safety of the three oral agents approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS) are reviewed. SUMMARY: Limitations to parenteral disease-modifying therapies (DMTs) (interferon beta-1a, interferon beta-1b, and glatiramer acetate) for the treatment of RRMS have been addressed by the approval of three oral DMTs: fingolimod, teriflunomide, and dimethyl fumarate. In clinical trials, each of the oral DMTs was superior to pla",American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,"Rachel Hutchins Thomas, Richard A Wakefield"," Rachel Hutchins Thomas, Pharm.D., M.S., is Clinical Pharmacist, Shelby Baptist Medical Center, Alabaster, AL; at the time of writing she was Assistant Professor of Pharmacy Practice, McWhorter School of Pharmacy, Sanford University, Birmingham, AL. Richard A. Wakefield, Pharm.D., is Clinical Pharmacist, St. Dominic-Jackson Memorial Hospital, Jackson, MS; at the time of writing he was Resident, Drug Information Practice, McWhorter School of Pharmacy, Samford University. rahutchi@samford.edu. Rachel Hutchins",2015 Jan;72(1):25-38,10.2146/ajhp140023
25518257,20140930,review,mesh,"Adjuvants, Immunologic,Antibodies, Monoclonal, Humanized,Atrophy,Fingolimod Hydrochloride,Glatiramer Acetate,Gray Matter,Humans,Immunosuppressive Agents,Interferon beta-1a,Interferon beta-1b,Interferon-beta,Multiple Sclerosis,Muscle, Skeletal,Natalizumab,Peptides,Predictive Value of Tests,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug effects,drug therapy,immunology,pathology,physiopathology,therapeutic use","D016899 Q000008 NN,D000276 Q000627 NY,D009103 Q000503 NN,D013110 Q000008 NN,D009103 Q000473 NY,D066128 Q000187 NN,D011409 Q000008 NN,D013110 Q000031 NN,D066128 Q000473 NY,D018482 Q000276 NN,D007166 Q000627 NY,D066128 Q000503 NN,D061067 Q000008 NN,D009103 Q000276 NN,D001284 Q000175 NN,D009103 Q000188 NN","65370,107969,107970,3081884,5280335",NULL,Grey matter atrophy in patients suffering from multiple sclerosis.,"White matter lesions are defining characteristics of multiple sclerosis (MS), whereas grey matter involvement is a less recognised attribute. Recent investigations using dedicated imaging approaches have made it possible to depict cortical lesions. Additionally, grey matter atrophy may be estimated using various methods. Several studies have suggested that grey matter atrophy closely correlates to clinical disability. In this review we have collected information on grey matter atrophy in MS and the effect o",Ideggyogyaszati szemle,"Zsigmond Tamás Kincses, Eszter Tóth, Nóra Bankó, Dániel Veréb, Nikoletta Szabó, Gergő Csete, Péter Faragó, András Király, Krisztina Bencsik, László Vécsei",NULL,2014 Sep;67(?):293-300,NULL
25518386,20141101,article,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Lymphocyte Count,Lymphocytes,Multiple Sclerosis,Propylene Glycols,Sphingosine","adverse effects,analogs &amp; derivatives,diagnosis,drug effects,drug therapy,therapeutic use","D011409 Q000009 NN,D013110 Q000009 NN,D013110 Q000031 NY,D007166 Q000627 NY,D009103 Q000175 NN,D013110 Q000627 NN,D007166 Q000009 NN,D008214 Q000187 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,[Fingolimod treatment in multiple sclerosis].,"Multiple sclerosis (MS), an inflammatory disorder of the central nervous system, is characterized by relapsing-remitting (RR) clinical course. Fingolimod was the first oral therapy to prevent relapses in patients with RRMS, approved in Japan in 2011. In lymph node, fingolimod acts as functional antagonist, leading to internalization of sphingosine-1-phosphate 1(S1P1) receptors of lymphocytes. Lymphocytes in lymph nodes bearing S1P1 receptors cannot egress from lymph nodes. As a result, lymphocyte count in t",Nihon rinsho. Japanese journal of clinical medicine,Masami Tanaka,NULL,2014 Nov;72(11):2010-4,NULL
25537624,20160801,article,mesh,"Acute Lung Injury,Alkylating Agents,Alveolar Epithelial Cells,Animals,Apoptosis,Biomarkers,Bronchoalveolar Lavage Fluid,Chemical Warfare Agents,DNA Damage,Disease Models, Animal,Endoplasmic Reticulum, Rough,Lung,Lymphocyte Activation,Male,Microscopy, Electron, Transmission,Microvilli,Mitochondria,Mustard Gas,Oxidative Stress,Rats, Sprague-Dawley,Respiratory Mucosa,Specific Pathogen-Free Organisms","chemically induced,chemistry,drug effects,immunology,metabolism,pathology,toxicity,ultrastructure","D008928 Q000648 NN,D055371 Q000139 NY,D008928 Q000187 NN,D008168 Q000276 NN,D056809 Q000648 NN,D017209 Q000187 NN,D008871 Q000378 NN,D056809 Q000187 NN,D056809 Q000378 NN,D020545 Q000648 NN,D009151 Q000633 NY,D018384 Q000187 NN,D055371 Q000473 NN,D055371 Q000276 NN,D008871 Q000187 NN,D055371 Q000378 NN,D020545 Q000276 NN,D008928 Q000276 NN,D018870 Q000378 NN,D020545 Q000187 NY,D020545 Q000378 NN,D018870 Q000276 NN,D002619 Q000633 NY,D008213 Q000187 NN,D008871 Q000276 NN,D008168 Q000648 NN,D001992 Q000737 NN",10461,NULL,Mechanism underlying acute lung injury due to sulfur mustard exposure in rats.,"Sulfur mustard (SM), a bifunctional alkylating agent that causes severe lung damage, is a significant threat to both military and civilian populations. The mechanisms mediating the cytotoxic effects of SM are unknown and were investigated in this study. The purpose of this study was to establish a rat model of SM-induced lung injury to observe the resulting changes in the lungs. Male rats (Sprague Dawley) were anesthetized, intratracheally intubated, and exposed to 2 mg/kg of SM by intratracheal instillatio",Toxicology and industrial health,"Zhu Xiaoji, Meng Xiao, Xu Rui, Chu Haibo, Zhao Chao, Lian Chengjin, Wang Tao, Guo Wenjun, Zhang Shengming"," Department of Respiration, The 89th Hospital of PLA, Weifang, China. Department of Pathology, Weifang Medical University, Weifang, China. Department of Pathology, Weifang Medical University, Weifang, China. Department of Respiration, The 89th Hospital of PLA, Weifang, China haibochuwf@163.com. Department of Respiration, The 89th Hospital of PLA, Weifang, China. Department of Respiration, The 89th Hospital of PLA, Weifang, China. Department of Respiration, The 89th Hospital of PLA, Weifang, China. Departmen",2016 Aug;32(8):1345-1357,10.1177/0748233714560603
25546031,20150301,article,mesh,"Adult,Antibodies, Monoclonal, Humanized,Disability Evaluation,Disease Progression,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Recurrence,Registries,Severity of Illness Index,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,pharmacology","D007166 Q000494 NY,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D020529 Q000188 NY,D061067 Q000008 NN,D061067 Q000494 NY,D013110 Q000494 NN","107969,107970,5280335",NULL,Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.,"OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents. METHODS: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 m",Annals of neurology,"Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson, Celia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Ga"," Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.",2015 Mar;77(3):425-35,10.1002/ana.24339
25572093,20150201,article,mesh,"Animals,Autoradiography,BCG Vaccine,Carrier Proteins,Disease Models, Animal,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Freund's Adjuvant,Immunohistochemistry,Immunosuppressive Agents,Inflammation,Ligands,Male,Microglia,Multiple Sclerosis,Positron-Emission Tomography,Propylene Glycols,Rats,Rats, Inbred Lew,Receptors, GABA-A,Sphingosine,Time Factors","administration &amp; dosage,analogs &amp; derivatives,chemistry,diagnostic imaging","D007166 Q000008 NN,D004681 Q000000981 NN,D013110 Q000008 NN,D001500 Q000737 NN,D017628 Q000000981 NY,D011963 Q000737 NN,D013110 Q000031 NY,D002352 Q000737 NN,D011409 Q000008 NY,D009103 Q000000981 NY","107969,107970,5280335",NULL,In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.,"There is a great need for the monitoring of microglial activation surrounding multiple sclerosis lesions because the activation of microglia is thought to drive widespread neuronal damage. Recently, second-generation PET radioligands that can reveal the extent of microglial activation by quantifying the increased expression of the 18-kDa translocator protein have been developed. Here, we investigate whether PET imaging can be used to demonstrate the reduction in microglial activation surrounding a chronic f","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","Laura Airas, Alex M Dickens, Petri Elo, Päivi Marjamäki, Jarkko Johansson, Olli Eskola, Paul A Jones, William Trigg, Olof Solin, Merja Haaparanta-Solin, Daniel C Anthony, Juha Rinne"," Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland laura.airas@utu.fi. Medicity/Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland. Medicity/Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland. Medicity/Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland. Clinical Neurology, Turku PET Centre, University of Turku, Turku, Finland. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Tu",2015 Feb;56(2):305-10,10.2967/jnumed.114.149955
25582213,20150301,review,mesh,"Antibodies, Monoclonal, Humanized,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Natalizumab,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,pharmacology,therapeutic use","D007166 Q000627 NN,D013110 Q000031 NY,D011409 Q000494 NY,D061067 Q000494 NY,D013110 Q000494 NN,D009103 Q000188 NY","107969,107970,5280335",NULL,Therapeutic interference with leukocyte recirculation in multiple sclerosis.,"Multiple sclerosis (MS) is an immune-mediated disease where T cells are thought to initiate an inflammatory reaction in the brain and spinal cord, resulting in demyelination and axonal pathology. Interfering with the activation and recruitment of immune cells reduces disease activity in MS. We review the mechanism of action and treatment effects of natalizumab and fingolimod, which interfere with the recruitment of pathogenic immune cells in MS. Fingolimod blocks the egress of activated lymphocytes from lym",European journal of neurology,"F Sellebjerg, P S Sørensen"," Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.",2015 Mar;22(3):434-42,10.1111/ene.12668
25598630,20150101,article,NULL,NULL,NULL,NULL,NULL,NULL,Evaluation of anti-inflammatory activity of methanolic extract of leaves of Bougainvillea spectabilis in experimental animal models.,"BACKGROUND: Bougainvillea spectabilis (BS) (family Nyctaginaceae) is said to possess hypoglycemic and anti-inflammatory activities in experimental animals. We had set forward to examine the potential anti-inflammatory activities of BS in experimental models of inflammation. MATERIALS AND METHODS: Fresh dried leaves from the flowering plant of BS were collected from the local area during the flowering season and air dried (215.00 g). Methanol was extracted, and the solvent was removed on a rotary evaporator ",Pharmacognosy research,"Gautam Mandal, Chandan Chatterjee, Mitali Chatterjee"," Department of Pharmacology, IPGME and R and SSKM Hospital, Kolkata, West Bengal, India. Department of Pharmacology, ESIC PGIMSR Medical College and Model Hospital, Kolkata, West Bengal, India. Department of Pharmacology, IPGME&R and SSKM Hospital, Kolkata, West Bengal, India.",2015 Jan;7(1):18-22,10.4103/0974-8490.147194
25622658,20150201,article,mesh,"Adult,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sjogren's Syndrome,Sphingosine","analogs &amp; derivatives,complications,drug therapy,pathology,therapeutic use","D009103 Q000473 NN,D009103 Q000150 NY,D013110 Q000031 NY,D007166 Q000627 NY,D012859 Q000473 NN,D013110 Q000627 NN,D012859 Q000150 NY,D011409 Q000627 NY,D012859 Q000188 NY","107969,107970,5280335",NULL,Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.,"BACKGROUND: Sjogren syndrome (SS) is a common autoimmune disease characterized by lymphocytic infiltration of the exocrine glands with neurological involvement in about 20% of patients. The neurological manifestations in the central nervous system CNS may vary and include a multiple sclerosis (MS)-like disease, and the treatments with immunosuppressive drugs have been undertaken. CASE PRESENTATION: We describe a case of 40-year-old woman with clinical and instrumental evidence of an MS characterized by nume",Acta neurologica Scandinavica,"E Signoriello, A Sagliocchi, M Fratta, G Lus"," Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.",2015 Feb;131(2):140-3,10.1111/ane.12357
25627168,20150501,article,mesh,"Animals,Cell Death,Cell Line,Compressive Strength,Fibroblasts,Fumarates,Materials Testing,Mice,Polypropylenes,Porosity,Printing, Three-Dimensional,Tissue Scaffolds,X-Ray Microtomography","chemistry,cytology,drug effects,metabolism,toxicity","D019245 Q000187 NN,D005347 Q000166 NY,D005347 Q000378 NN,D011126 Q000737 NY,D016923 Q000187 NN,D054457 Q000737 NY,D005347 Q000187 NN,D011126 Q000633 NY,D005650 Q000633 NY,D005650 Q000737 NY",NULL,NULL,Evaluating changes in structure and cytotoxicity during in vitro degradation of three-dimensional printed scaffolds.,"This study evaluated the structural, mechanical, and cytocompatibility changes of three-dimensional (3D) printed porous polymer scaffolds during degradation. Three porous scaffold designs were fabricated from a poly(propylene fumarate) (PPF) resin. PPF is a hydrolytically degradable polymer that has been well characterized for applications in bone tissue engineering. Over a 224 day period, scaffolds were hydrolytically degraded and changes in scaffold parameters, such as porosity and pore size, were measure",Tissue engineering. Part A,"Martha O Wang, Charlotte M Piard, Anthony Melchiorri, Maureen L Dreher, John P Fisher"," 1 Fischell Department of Bioengineering, University of Maryland , College Park, Maryland.",2015 May;21(?):1642-53,10.1089/ten.tea.2014.0495
25630439,20160101,article,mesh,"Antineoplastic Agents,Apoptosis,Carcinoma, Hepatocellular,Cell Proliferation,Drug Screening Assays, Antitumor,Humans,Liver Neoplasms,Polyethylenes,Polypropylenes,Proto-Oncogene Proteins c-bcl-2,RNA, Messenger,Surface-Active Agents,Telomerase,Tumor Cells, Cultured,bcl-2-Associated X Protein","chemistry,drug effects,drug therapy,genetics,metabolism,pathology,pharmacology","D011095 Q000494 NY,D012333 Q000235 NN,D013501 Q000737 NN,D011095 Q000737 NN,D006528 Q000188 NN,D017209 Q000187 NY,D006528 Q000473 NY,D000970 Q000494 NN,D008113 Q000188 NN,D011126 Q000494 NY,D013501 Q000494 NY,D049109 Q000187 NN,D019098 Q000235 NY,D019253 Q000235 NY,D051028 Q000235 NY,D011126 Q000737 NN,D012333 Q000378 NN,D000970 Q000737 NN,D008113 Q000473 NN",NULL,NULL,"Effect of several PEO-PPO amphiphiles on bax, bcl-2, and hTERT mRNAs: An insight into apoptosis and cell immortalization induced in hepatoma cells by these polymeric excipients.","Recent data have shown that synthetic polymers and nanomaterials display phenotypic effects in cells and signal transduction mechanisms involved in inflammation, differentiation, proliferation, and apoptosis. AIM: This article aims to investigate the effect of poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) block copolymers with a wide range of biomedical and pharmaceutical applications on apoptosis and/or cell immortalization, by flow cytometry and multiplex RT-PCR for bax, bcl-2, and human telomerase",Biotechnology and applied biochemistry,"Cynthia Celeste Castronuovo, María Luján Cuestas, José Raúl Oubiña, Verónica Lidia Mathet"," Instituto de Investigaciones en Microbiología y Parasitología Médica, UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina. CONICET, Ciudad Autónoma de Buenos Aires, Argentina. Instituto de Investigaciones en Microbiología y Parasitología Médica, UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina. CONICET, Ciudad Autónoma de Buenos Aires, Argentina. Instituto de Investigaciones en Microbiología y P",2016 Jan;63(2):273-80,10.1002/bab.1352
25632085,20150224,article,mesh,"Brain,Double-Blind Method,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Longitudinal Studies,Magnetic Resonance Imaging,Male,Multiple Sclerosis,Organ Size,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,diagnosis,drug therapy,pathology,therapeutic use,trends","D009103 Q000175 NY,D001921 Q000473 NY,D008279 Q000639 YN,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.,"OBJECTIVE: We investigated the determinants and clinical correlations of MRI-detected brain volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase 3 trials of fingolimod: FREEDOMS, FREEDOMS II, and TRANSFORMS. METHODS: Post hoc analyses were conducted in the intent-to-treat populations from each trial and in a combined dataset of 3,635 patients from the trials and their extensions. The relationship between brain volume changes and demographic, clinical, and MRI parameter",Neurology,"Ernst-Wilhelm Radue, Frederik Barkhof, Ludwig Kappos, Till Sprenger, Dieter A Häring, Ana de Vera, Philipp von Rosenstiel, Jeremy R Bright, Gordon Francis, Jeffrey A Cohen"," From the Medical Image Analysis Centre (E.-W.R.), University Hospital, University of Basel, Switzerland; Image Analysis Center (F.B.), VU Medical Centre, Amsterdam, the Netherlands; Departments of Medicine and Clinical Research, Neurology (L.K., T.S.) and Radiology (T.S.), Division of Neuroradiology, University Hospital, Basel, Switzerland; Novartis Pharma AG (D.A.H., A.d.V., P.v.R.), Basel, Switzerland; Oxford PharmaGenesis Ltd. (J.R.B.), Tubney, Oxford, UK; Novartis Pharmaceuticals Corporation (G.F.), Ea",2015 Feb;84(8):784-93,10.1212/wnl.0000000000001281
25636714,20150303,article,mesh,"Adolescent,Adult,Double-Blind Method,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Influenza Vaccines,Male,Middle Aged,Multiple Sclerosis,Propylene Glycols,Sphingosine,Treatment Outcome,Vaccination,Young Adult","analogs &amp; derivatives,drug therapy,immunology,methods,therapeutic use","D011409 Q000276 NN,D007252 Q000627 NY,D014611 Q000379 YN,D013110 Q000031 NY,D007252 Q000276 NN,D013110 Q000276 NN,D007166 Q000627 NY,D007166 Q000276 NN,D009103 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.,"OBJECTIVE: To evaluate immune responses in fingolimod-treated patients with multiple sclerosis (MS) against influenza vaccine (to test for responses against anticipated novel antigens in seronegative patients) and recall (tetanus toxoid [TT] booster dose) antigens. METHODS: This was a blinded, randomized, multicenter, placebo-controlled study. Patients aged 18 to 55 years with relapsing MS were randomized (2:1) to fingolimod 0.5 mg or placebo for 12 weeks. At week 6, patients received seasonal influenza vac",Neurology,"Ludwig Kappos, Matthias Mehling, Rafael Arroyo, Guillermo Izquierdo, Krzysztof Selmaj, Valentina Curovic-Perisic, Astrid Keil, Mahendra Bijarnia, Arun Singh, Philipp von Rosenstiel"," From the University Hospital Basel (L.K., M.M.), Basel, Switzerland; Hospital Clínico San Carlos (R.A.), Madrid, Spain; Virgen Macarena Hospital (G.I.), Seville, Spain; Medical University of Lodz (K.S.), Lodz, Poland; Novartis Pharmaceuticals Corporation (V.C.-P.), Hanover, NJ; Novartis Pharma AG (A.K., P.v.R.), Basel, Switzerland; and Novartis Healthcare Pvt. Ltd. (M.B., A.S.), Hyderabad, India. ludwig.kappos@usb.ch. From the University Hospital Basel (L.K., M.M.), Basel, Switzerland; Hospital Clínico San",2015 Mar;84(9):872-9,10.1212/wnl.0000000000001302
25636716,20150303,article,mesh,"Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Influenza Vaccines,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine,Vaccination","analogs &amp; derivatives,drug therapy,therapeutic use","D007252 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY","107969,107970,5280335",NULL,"Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.",NULL,Neurology,"Myla D Goldman, Robert T Naismith"," From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO. mdg3n@virginia.edu. From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.",2015 Mar;84(9):864-5,10.1212/wnl.0000000000001319
25664937,20150401,article,mesh,"Female,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D016899 Q000627 NY,D007155 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Treatment decisions for patients with active multiple sclerosis.,NULL,JAMA neurology,"Olaf Stüve, Diego Centonze"," Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas3Department of Neurology, Klinikum rechts der Isar, Technische Universität. Department of Systems Medicine, Multiple Sclerosis Clinical and Research Center, Tor Vergata University and Hospital, Rome, Italy6Istituto Di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Centro Europeo di Ricerca sul Cervello, Rome, It",2015 Apr;72(4):387-9,10.1001/jamaneurol.2014.4494
25665031,20150401,article,mesh,"Adult,Cohort Studies,Female,Fingolimod Hydrochloride,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Magnetic Resonance Imaging,Male,Multiple Sclerosis,Propylene Glycols,Retrospective Studies,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,drug therapy,methods,therapeutic use","D016899 Q000627 NY,D007166 Q000008 NN,D016899 Q000008 NN,D008279 Q000379 NN,D013110 Q000008 NN,D007155 Q000627 NY,D013110 Q000031 NY,D011409 Q000008 NN,D007166 Q000627 NY,D013110 Q000627 NN,D011409 Q000627 NY,D009103 Q000188 NY,D007155 Q000008 NN","107969,107970,5280335",NULL,Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.,"IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with active MS. DESIGN, SETTING, AND PARTICIPANTS: Ma",JAMA neurology,"Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolaños, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella, Murat Terzi, Jeannette Lechner-Scott, Vincent Van Pesch, Raymond Hupperts, José Luis Sánchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Freek Verheul, Helmut Butzkueven"," Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. Department of Medicine, University of Melbourne, Melbourne, Australia. Department of Medicine, University of Melbourne, Melbourne, Australia. Department of Neurology and Center of Clinical Neuroscience, General University Hospital, Prague, Czech Republic4Department of Neurology and Center for Clinical Neuroscience, Charles University, Prague, Czech Republic. Department of Neurology and Center of Clinical Neuroscience, General Universi",2015 Apr;72(4):405-13,10.1001/jamaneurol.2014.4147
25669873,20150701,article,mesh,"Atrioventricular Block,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Middle Aged,Propylene Glycols,Sphingosine,Tachycardia, Ectopic Junctional,Time Factors","adverse effects,analogs &amp; derivatives,chemically induced,diagnosis","D013110 Q000009 NN,D054537 Q000175 NN,D013110 Q000031 NY,D013613 Q000175 NN,D013613 Q000139 NY,D007166 Q000009 NY,D054537 Q000139 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Delayed cardiac dysrhythmias after fingolimod administration.,"A 51-year-old woman with relapsing-remitting multiple sclerosis was initiated on fingolimod. She developed a Mobitz Type I (Wenckebach)second-degree atrioventricular (AV) heart block during the initial 6-hour monitoring. She was transferred to the emergency department for further monitoring, where she went into a junctional tachycardia then went back into a Mobitz Type I AV block. The patient was symptomatic with a heart rate nadir of 38 beats per minute and treated with atropine. Junctional tachycardia has",The American journal of emergency medicine,"Jamie M Rosini, Suraj Rajasimhan, Shawn E Fellows, Jason T Nomura"," Department of Pharmacy, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE, 19718 USA. Electronic address: jrosini@christianacare.org. Department of Pharmacy, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE, 19718 USA. Electronic address: suraj726@gmail.com. Department of Pharmacy, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE, 19718 USA. Electronic address: sfellows11@gmail.com. Department of Emergency Medicine, Christiana Care Health System",2015 Jul;33(7):?,10.1016/j.ajem.2014.12.037
25730065,20150213,article,mesh,"Animals,Calcium Channel Blockers,Free Radicals,Immunohistochemistry,Macrophages,Male,Malondialdehyde,Microscopy, Fluorescence,Motor Skills,Nimodipine,Oxidative Stress,Peroxidase,Propylene Glycol,Rats,Rats, Sprague-Dawley,Spinal Cord,Spinal Cord Injuries","chemistry,drug effects,drug therapy,pathology,physiopathology,therapeutic use","D008315 Q000737 NN,D009195 Q000737 NN,D013116 Q000187 NN,D013116 Q000473 NN,D019946 Q000737 NN,D008264 Q000187 NN,D013119 Q000503 NY,D013119 Q000188 NY,D009553 Q000627 NY,D002121 Q000627 NN","1030,4497,10964,11973707",NULL,Effect of nimodipine on rat spinal cord injury.,"We evaluated the potentially protective effect of nimodipine on rat spinal cord injury. Sprague-Dawley rats received spinal cord injury, and were separated into nimodipine (N = 12) and saline groups (N = 12). Within 1 h of the injury, rats were treated intraperitoneally with nimodipine (1.0 mg/kg) or an equal amount of saline. Treatment was performed 3 times a day for 1 week. Operation BBB score and track experiment were used to measure the physical function of the hind legs 1 and 2 weeks after injury. Two ",Genetics and molecular research : GMR,"Y-F Jia, H-L Gao, L-J Ma, J Li"," Department of Neurosurgery, Affiliated Hospital of Yanan University, Yanan, China jiayun_feng123@163.com. Department of Neurosurgery, Affiliated Hospital of Yanan University, Yanan, China. Department of Neurosurgery, Affiliated Hospital of Yanan University, Yanan, China. Department of Neurosurgery, Affiliated Hospital of Yanan University, Yanan, China.",2015 Feb;14(1):1269-76,10.4238/2015.february.13.5
25732946,20141201,review,mesh,"Administration, Oral,Crotonates,Dimethyl Fumarate,Fingolimod Hydrochloride,Fumarates,Humans,Immunosuppressive Agents,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Quinolones,Sphingosine,Toluidines","administration &amp; dosage,analogs &amp; derivatives,drug therapy","D007166 Q000008 NN,D020529 Q000188 NN,D013110 Q000008 NN,D011409 Q000008 NN,D014052 Q000008 NN,D003437 Q000008 NN,D013110 Q000031 NN,D015363 Q000008 NN,D009103 Q000188 NY,D005650 Q000008 NN","12215,107969,107970,637568,3036108,5280335,54677946",NULL,[Oral treatments in multiple sclerosis].,"The development of new disease-modifying drugs (DMD) in relapsing-remitting multiple sclerosis (RRMS), which share the common denominator of oral administration, considerably improves patient expectations in terms of effectiveness, tolerability and treatment adherence compared with currently available drugs. However, the common route of administration of these drugs does not mean that they are equivalent, since the heading of ""oral route"" encompasses drugs with distinct indications and mechanisms of action,",Medicina clinica,"José Eustasio Meca-Lallana, Rocío Hernández-Clares, Ester Carreón-Guarnizo"," Unidad de Esclerosis Múltiple, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio de Murcia, Murcia, España. Electronic address: pmecal@gmail.com. Unidad de Esclerosis Múltiple, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio de Murcia, Murcia, España. Unidad de Esclerosis ",2014 Dec;?(?):23-9,10.1016/s0025-7753(15)30006-3
25774462,20150315,article,mesh,"Animals,Antioxidants,Biphenyl Compounds,Cytokines,Down-Regulation,Female,Inflammation,Kruppel-Like Transcription Factors,Lignans,Neuroprotective Agents,Rats,Rats, Sprague-Dawley,Spinal Cord,Spinal Cord Injuries","analysis,drug effects,drug therapy,metabolism,pathology,pharmacology","D013119 Q000473 NN,D007249 Q000188 NN,D017705 Q000494 NY,D051741 Q000032 NN,D015536 Q000187 NN,D000975 Q000378 NN,D016207 Q000378 NN,D013116 Q000473 NN,D001713 Q000494 NY,D018696 Q000494 NY,D013116 Q000187 NY,D013119 Q000188 NY,D013119 Q000378 NY,D007249 Q000473 NN,D051741 Q000378 NY","72303,443013",NULL,"Honokiol downregulates Kruppel-like factor 4 expression, attenuates inflammation, and reduces histopathology after spinal cord injury in rats.",STUDY DESIGN: Randomized experimental study. OBJECTIVE: To investigate the neuroprotective effect of honokiol (HNK) on rats subjected to traumatic spinal cord injury (SCI) and the molecular mechanisms. SUMMARY OF BACKGROUND DATA: Inflammation contributes to the secondary injury to the spinal cord. Honokiol has been used as a neuroprotective agent because of its strong antioxidant and anti-inflammatory properties. Kruppel-like factor 4 (Klf4) is a newly identified critical target for the anti-inflammatory ef,Spine,"Jia Liu, Changmeng Zhang, Zhi Liu, Jianzheng Zhang, Zimin Xiang, Tiansheng Sun"," *Departmentof Institute of Orthopaedics, Chinese PLA (People's Liberation Army) Beijing Army General Hospital, Beijing, China; and †Department of Medical School of Chinese PLA, Beijing, China.",2015 Mar;40(6):363-8,10.1097/brs.0000000000000758
25774903,20150101,article,mesh,"Blood-Brain Barrier,Cell Line, Transformed,Claudin-5,Endothelial Cells,Fingolimod Hydrochloride,Gene Expression,Humans,Immune Sera,Immunosuppressive Agents,Multiple Sclerosis,NF-kappa B,Propylene Glycols,RNA, Messenger,Sphingosine,Vascular Cell Adhesion Molecule-1","adverse effects,analogs &amp; derivatives,drug effects,genetics,immunology,metabolism,pharmacology","D012333 Q000235 NN,D007166 Q000494 NY,D042783 Q000378 NN,D019010 Q000378 NN,D009103 Q000235 NN,D062507 Q000378 NN,D062507 Q000235 NN,D019010 Q000235 NN,D016328 Q000378 NN,D013110 Q000031 NY,D001812 Q000378 NY,D011409 Q000494 NY,D001812 Q000187 NY,D001812 Q000276 NN,D042783 Q000187 NN,D009103 Q000378 NY,D007106 Q000009 NY,D012333 Q000378 NN,D007106 Q000276 NN,D009103 Q000276 NN,D016328 Q000235 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.,"OBJECTIVE: Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the central nervous system across blood-brain barrier (BBB). However, brain microvascular endothelial cells (BMECs) represent a possible additional target for fingolimod in MS patients by directly repairing the function of BBB, as S1P receptors are also expressed by BMECs. In this study, we evaluated the effec",PloS one,"Hideaki Nishihara, Fumitaka Shimizu, Yasuteru Sano, Yukio Takeshita, Toshihiko Maeda, Masaaki Abe, Michiaki Koga, Takashi Kanda"," Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan. Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan. Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan. Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan. Department of Neurology and Clinical Neuroscience, Yamaguch",2015 Jan;10(3):e0121488,10.1371/journal.pone.0121488
25795646,20150414,article,mesh,"Adolescent,Adult,Brain,Disability Evaluation,Disease Progression,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Middle Aged,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Recurrence,Single-Blind Method,Sphingosine,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug therapy,pathology,pharmacology,physiopathology","D007166 Q000494 NY,D013110 Q000009 NN,D011409 Q000009 NN,D013110 Q000008 NN,D001921 Q000473 NY,D013110 Q000031 NY,D011409 Q000494 NY,D020529 Q000473 NN,D020529 Q000503 NN,D020529 Q000188 NY,D013110 Q000494 NN,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.,"OBJECTIVE: To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy variables included annualized relapse rate (ARR), brain volume loss (BVL), and confirmed disabi",Neurology,"Ludwig Kappos, Paul O'Connor, Ernst-Wilhelm Radue, Chris Polman, Reinhard Hohlfeld, Krzysztof Selmaj, Shannon Ritter, Rolf Schlosshauer, Philipp von Rosenstiel, Lixin Zhang-Auberson, Gordon Francis"," From the Department of Neurology (L.K.), University Hospital, Basel, Switzerland; St. Michael's Hospital (P.O.'C.), Toronto, Canada; Medical Image Analysis Centre (E.-W.R.), University Hospital, University of Basel, Switzerland; Department of Neurology (C.P.), VU University Medical Center, Amsterdam, Netherlands; Ludwig-Maximilians University of Munich and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Germany; Department of Neurology (K.S.), Medical University of Lodz, Poland; Novartis Pharmaceuti",2015 Apr;84(15):1582-91,10.1212/wnl.0000000000001462
25809304,20150421,article,mesh,"Adult,Axons,Biomarkers,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Intermediate Filaments,Male,Multiple Sclerosis, Relapsing-Remitting,Neurofibrils,Placebos,Propylene Glycols,Sphingosine,Treatment Outcome","administration &amp; dosage,analogs &amp; derivatives,cerebrospinal fluid,drug therapy,pathology,pharmacology","D007166 Q000494 NY,D007166 Q000008 NN,D013110 Q000008 NN,D013110 Q000031 NY,D011409 Q000008 NN,D011409 Q000494 NY,D001369 Q000473 NN,D020529 Q000188 NY,D013110 Q000494 NN,D020529 Q000134 NY","107969,107970,5280335",NULL,Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.,"OBJECTIVE: We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with relapsing-remitting multiple sclerosis (RRMS). Changes in NfL levels were also correlated with relapse and MRI outcomes. METHODS: CSF samples were available, at baseline and 12 months after treatment initiation, from a subset of 36 patients with RRMS (fingolimod 0.5 mg: n = 9; fingolimod 1.25 mg: n = 15; placebo: n = 12) participating in the 2-year, phase ",Neurology,"Jens Kuhle, Giulio Disanto, Johannes Lorscheider, Tracy Stites, Yu Chen, Frank Dahlke, Gordon Francis, Anupama Shrinivasan, Ernst-Wilhelm Radue, Gavin Giovannoni, Ludwig Kappos"," From the Neuroimmunology Unit (J.K., G.D., G.G.), Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK; Neurology, Departments of Medicine, Clinical Research and Biomedicine (J.K., J.L., L.K.), and the Medical Image Analysis Center (MIAC) (E.-W.R.), University Hospital, Basel, Switzerland; Novartis Pharmaceuticals Corporation (T.S., Y.C., G.F.), East Hanover, NJ; Novartis Pharma AG (F.D.), Basel, Switzerland; and Novartis Healthcare Pvt Ltd (A.S.), Hyderabad, India. jens.kuh",2015 Apr;84(16):1639-43,10.1212/wnl.0000000000001491
25809305,20150421,article,mesh,"Female,Humans,Immunosuppressive Agents,Intermediate Filaments,Male,Multiple Sclerosis, Relapsing-Remitting,Neurofibrils,Propylene Glycols,Sphingosine","analogs &amp; derivatives,cerebrospinal fluid,drug therapy,pharmacology","D007166 Q000494 NY,D013110 Q000031 NY,D011409 Q000494 NY,D020529 Q000188 NY,D020529 Q000134 NY",5280335,NULL,Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?,NULL,Neurology,"Bibiana Bielekova, Michael P McDermott"," From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY. bibi.bielekova@nih.gov. From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.",2015 Apr;84(16):1620-1,10.1212/wnl.0000000000001506
25829233,20150501,article,mesh,"Adaptor Proteins, Signal Transducing,Adoptive Transfer,Animals,Cell Movement,Encephalomyelitis, Autoimmune, Experimental,Fingolimod Hydrochloride,Homeodomain Proteins,Immunosuppressive Agents,Lymph Nodes,Lymphocyte Activation,Mice,Mice, Knockout,Multiple Sclerosis,Propylene Glycols,Proto-Oncogene Proteins c-cbl,Sphingosine,T-Lymphocytes","analogs &amp; derivatives,drug effects,drug therapy,genetics,immunology,metabolism,pharmacology,therapeutic use","D013601 Q000378 NY,D007166 Q000494 NY,D002465 Q000187 NN,D007166 Q000627 NN,D008198 Q000378 NY,D002465 Q000235 NY,D008198 Q000187 NN,D008198 Q000276 NN,D013110 Q000031 NY,D048868 Q000235 NY,D011409 Q000494 NY,D009103 Q000276 NY,D002465 Q000276 NN,D008213 Q000187 NN,D050721 Q000276 NN,D008213 Q000235 NN,D018398 Q000235 NN,D004681 Q000276 NY,D013110 Q000627 NN,D011409 Q000627 NN,D048868 Q000276 NN,D013110 Q000494 NN,D050721 Q000235 NY,D009103 Q000188 NN,D013601 Q000187 NN","107969,107970,5280335",NULL,"Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.",The variable response to therapy in multiple sclerosis (MS) suggests a need for personalized approaches based on individual genetic differences. GWAS have linked CBLB gene polymorphisms with MS and recent evidence demonstrated that these polymorphisms can be associated with abnormalities in T cell function and response to interferon-β therapy. Cbl-b is an E3 ubiquitin ligase that regulates T cell activation and Cbl-b-deficient (Cbl-b(-/-)) mice show T cell abnormalities described in MS patients. We now show,"Clinical immunology (Orlando, Fla.)","Mai Fujiwara, Emily J Anstadt, Kamal M Khanna, Robert B Clark"," Department of Immunology, University of Connecticut Health Center, Farmington, CT 06032, USA. Department of Immunology, University of Connecticut Health Center, Farmington, CT 06032, USA. Department of Immunology, University of Connecticut Health Center, Farmington, CT 06032, USA. Department of Immunology, University of Connecticut Health Center, Farmington, CT 06032, USA; Department of Medicine, University of Connecticut Health Center, Farmington, CT 06032, USA. Electronic address: rclark@nso2.uchc.edu.",2015 May;158(1):103-13,10.1016/j.clim.2015.03.018
25835036,20150801,article,mesh,"Adult,Electrocardiography, Ambulatory,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Tachycardia, Ventricular","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D013110 Q000031 NY,D017180 Q000139 NY,D007166 Q000009 NY,D013110 Q000627 NN,D011409 Q000627 NN,D009103 Q000188 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.,NULL,"Journal of neurology, neurosurgery, and psychiatry","Tamara Castillo-Trivino, Itziar Lopetegui, Jose Antonio Alarcón-Duque, Adolfo López de Munain, Javier Olascoaga"," Multiple Sclerosis Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Spain Department of Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain Department of Neurology, Zumarraga Hospital, Zumarraga, Spain. Multiple Sclerosis Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Spain. Department of Cardiology, Donostia University Hospital, San Sebastian, Spain. Department of Neuroscience Area, Biodonostia Research Institute, San Sebastian, S",2015 Aug;86(8):931-2,10.1136/jnnp-2014-310013
25855398,20150801,article,mesh,"Female,Humans,Immunosuppressive Agents,Multiple Sclerosis,Propylene Glycols,Sphingosine,Tachycardia, Ventricular","adverse effects,analogs &amp; derivatives,chemically induced,drug therapy","D013110 Q000031 NY,D017180 Q000139 NY,D007166 Q000009 NY,D009103 Q000188 NY,D011409 Q000009 NY",5280335,NULL,"Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?",NULL,"Journal of neurology, neurosurgery, and psychiatry",Masahiro Mori,NULL,2015 Aug;86(8):823,10.1136/jnnp-2015-310451
25862489,20150615,article,mesh,"Animals,Drug Evaluation, Preclinical,Edema,Fingolimod Hydrochloride,Immunosuppressive Agents,Inflammation,Lipid Metabolism,Male,Neutrophil Infiltration,Propylene Glycols,Random Allocation,Rats, Sprague-Dawley,Spermatic Cord Torsion,Sphingosine,Testis","analogs &amp; derivatives,drug effects,drug therapy,injuries,metabolism,pharmacology,therapeutic use","D007249 Q000188 NN,D013737 Q000378 NN,D007166 Q000378 NN,D013737 Q000187 NN,D050356 Q000187 NN,D004487 Q000188 NN,D013110 Q000031 NY,D020556 Q000187 NN,D013110 Q000378 NN,D007166 Q000627 NY,D013086 Q000188 NY,D011409 Q000494 NN,D013737 Q000293 NY,D013110 Q000627 NN,D013110 Q000494 NN,D011409 Q000378 NN,D011409 Q000627 NY,D007166 Q000494 NN","107969,107970,5280335",NULL,FTY720 mitigates torsion/detorsion-induced testicular injury in rats.,"BACKGROUND: FTY720, a sphingosine-1-phosphate (S1P) receptor agonist, possesses potent anti-inflammation capacity. We evaluated the therapeutic potentials of FTY720 against testicular injury induced by testicular torsion and/or detorsion (T/D). MATERIALS AND METHODS: Young adult male Sprague-Dawley rats were allocated to receive T/D (the T/D group) and T/D plus FTY720 (4 mg/kg, the T/D-FTY group, n = 6 in each group). To investigate the possible roles of the S1P receptors, another group of rats received T/D",The Journal of surgical research,"Hung-Jen Shih, Jiin-Cherng Yen, Allen W Chiu, Yung-Chiong Chow, Wynn H T Pan, Tao-Yeuan Wang, Chun-Jen Huang"," Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. School of Medicine, National Yang-Ming University, Taipei, Taiwan. Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan; Mackay Medical College, Taipei, Taiwan. Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. Department of Pathology, M",2015 Jun;196(2):325-31,10.1016/j.jss.2015.03.014
25878178,20150512,article,mesh,"Adult,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Leg,Male,Multiple Sclerosis,Propylene Glycols,Recurrence,Remission, Spontaneous,Sarcoma, Kaposi,Sphingosine,Treatment Outcome","adverse effects,analogs &amp; derivatives,chemically induced,complications,diagnosis,drug therapy,therapeutic use","D013110 Q000009 NN,D007166 Q000627 NN,D009103 Q000150 NY,D013110 Q000031 NY,D013110 Q000627 NN,D007166 Q000009 NN,D011409 Q000627 NY,D012514 Q000175 NY,D009103 Q000188 NY,D012514 Q000139 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.,NULL,Neurology,"Timothy Tully, Alastair Barkley, Eli Silber"," From Kings College Hospital London, UK. From Kings College Hospital London, UK. From Kings College Hospital London, UK. eli.silber@nhs.net.",2015 May;84(19):1999-2001,10.1212/wnl.0000000000001556
25893366,20151101,article,mesh,"3T3 Cells,Animals,Anti-Infective Agents,Boron Compounds,Burns,Cell Survival,Chemistry, Pharmaceutical,Gene Expression,Hydrogels,Male,Mice,Polyethylene Glycols,Polyethylenes,Polypropylenes,Propylene Glycols,Rats,Rats, Wistar,Skin,Wound Healing","administration &amp; dosage,drug effects,drug therapy,pathology,pharmacology,therapeutic use","D000890 Q000494 NN,D002470 Q000187 NN,D015870 Q000187 NN,D011092 Q000627 NY,D014945 Q000187 NY,D011095 Q000627 NY,D002056 Q000473 NN,D012867 Q000473 NN,D011126 Q000627 NY,D001896 Q000627 NY,D020100 Q000008 NN,D011409 Q000627 NY,D002056 Q000188 NY,D020100 Q000627 NN",16212863,NULL,Boron and Poloxamer (F68 and F127) Containing Hydrogel Formulation for Burn Wound Healing.,"Burn injuries, the most common and destructive forms of wounds, are generally accompanied with life-threatening infections, inflammation, reduced angiogenesis, inadequate extracellular matrix production, and lack of growth factor stimulation. In the current study, a new antimicrobial carbopol-based hydrogel formulated with boron and pluronic block copolymers was evaluated for its healing activity using in vitro cell culture techniques and an experimental burn model. Cell viability, gene expression, and woun",Biological trace element research,"Selami Demirci, Ayşegül Doğan, Emre Karakuş, Zekai Halıcı, Atila Topçu, Elif Demirci, Fikrettin Sahin"," Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Kayisdagi, Istanbul, Turkey. Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Kayisdagi, Istanbul, Turkey. Department of Pharmacology and Toxicology, Ataturk University School of Veterinary Medicine, Erzurum, Turkey. Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. Department of Pharmacology, Faculty of Medicine",2015 Nov;168(1):169-80,10.1007/s12011-015-0338-z
25896088,20150601,article,mesh,"Female,Humans,Immunologic Factors,Immunosuppressive Agents,Interferon-beta,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine","analogs &amp; derivatives,drug therapy,therapeutic use","D016899 Q000627 NY,D007155 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.,NULL,Nature reviews. Neurology,"Ian T Rossman, Jeffrey A Cohen"," Mellen Center for MS Treatment and Research, Neurological institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Mellen Center for MS Treatment and Research, Neurological institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.",2015 Jun;11(6):316-7,10.1038/nrneurol.2015.59
25903738,20150515,article,mesh,"Adult,Disability Evaluation,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Magnetic Resonance Imaging,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Young Adult","analogs &amp; derivatives,drug therapy,therapeutic use","D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.,"OBJECTIVES: Fingolimod is a well-established, highly effective immunomodulatory treatment for patients with relapsing-remitting multiple sclerosis (RRMS). However, little is known about disease course after its discontinuation. METHODS: This is a case series on four patients with RRMS who had a severe reactivation after fingolimod discontinuation. RESULTS: One patient had pretreatment with glatiramer acetate, interferon-β 1b and interferon-β 1a and another with interferon-β 1a, intravenous immunoglobulins a",Journal of neuroimmunology,"Benjamin Berger, Annette Baumgartner, Sebastian Rauer, Irina Mader, Niklas Luetzen, Ulrich Farenkopf, Oliver Stich"," University Hospital Freiburg, Department of Neurology and Neurophysiology, Breisacher Strasse 64, D-79106 Freiburg, Germany. Electronic address: benjamin.berger@uniklinik-freiburg.de. University Hospital Freiburg, Department of Neurology and Neurophysiology, Breisacher Strasse 64, D-79106 Freiburg, Germany. University Hospital Freiburg, Department of Neurology and Neurophysiology, Breisacher Strasse 64, D-79106 Freiburg, Germany. University Hospital Freiburg, Department of Neuroradiology, Breisacher Strass",2015 May;282(?):118-22,10.1016/j.jneuroim.2015.03.022
25910934,20150615,article,mesh,"Animals,Bronchoalveolar Lavage Fluid,Cyclopentanes,Cytokines,Fingolimod Hydrochloride,Flow Cytometry,Immunoenzyme Techniques,Immunosuppressive Agents,Lung Injury,Lysophospholipids,Mice,Mice, Inbred C57BL,Propylene Glycols,Receptors, Lysosphingolipid,Reperfusion Injury,Sphingosine","agonists,analogs &amp; derivatives,metabolism,pharmacology,prevention &amp; control","D055370 Q000517 NY,D049349 Q000819 NY,D016207 Q000378 NN,D013110 Q000031 NY,D011409 Q000494 NY,D015427 Q000517 NY,D013110 Q000378 NN,D003517 Q000494 NY,D008246 Q000378 NN,D013110 Q000494 NN,D007166 Q000494 NN,D049349 Q000378 NN","9253,107969,107970,5280335,5283560",NULL,Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.,"Outcomes for lung transplantation are the worst of any solid organ, and ischemia-reperfusion injury (IRI) limits both short- and long-term outcomes. Presently no therapeutic agents are available to prevent IRI. Sphingosine 1-phosphate (S1P) modulates immune function through binding to a set of G protein-coupled receptors (S1PR1-5). Although S1P has been shown to attenuate lung IRI, the S1P receptors responsible for protection have not been defined. The present study tests the hypothesis that protection from",American journal of physiology. Lung cellular and molecular physiology,"Matthew L Stone, Ashish K Sharma, Yunge Zhao, Eric J Charles, Mary E Huerter, William F Johnston, Irving L Kron, Kevin R Lynch, Victor E Laubach"," Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of Virginia, Charlottesville, Virginia; and. Department of Surgery, University of ",2015 Jun;308(12):L1245-52,10.1152/ajplung.00302.2014
25917844,20150801,article,mesh,"Acids,Animals,Cations,Cell Death,Cell Line,Endocytosis,Gene Expression,Humans,Mice,Nylons,Transfection,Transgenes","chemical synthesis,chemistry,drug effects,methods,toxicity","D009757 Q000633 NN,D004705 Q000187 NN,D015870 Q000187 NN,D016923 Q000187 NN,D002412 Q000737 NY,D014162 Q000379 NY,D009757 Q000138 NN,D009757 Q000737 NY,D000143 Q000737 NN",NULL,NULL,A family of cationic polyamides for in vitro and in vivo gene transfection.,"The purpose of this study is to develop biodegradable cationic polyamides for non-viral gene delivery and elucidate their structural effects on gene transfection activity. To this end, a group of novel cationic polyamides were synthesized by polycondensation reaction between different di-p-nitrophenyl esters and tertiary amine-containing primary diamines. These linear polyamides have flexible alkylene group (ethylene or propylene), protonable amino group and bioreducible disulfide linkage in the polyamide m",Acta biomaterialia,"Chengnan Zhang, Rong Jin, Peng Zhao, Chao Lin"," Shanghai East Hospital, The Institute for Biomedical Engineering and Nanoscience, Tongji University School of Medicine, Tongji University, Shanghai 200092, People's Republic of China. Institute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, People's Republic of China. Shanghai East Hospital, The Institute for Biomedical Engineering and Nanoscience, Tongji University School of Medicine, Tongji University, Shanghai 200092, People's Republic of China. Shanghai East Hospital, The Insti",2015 Aug;22(?):120-30,10.1016/j.actbio.2015.04.025
25931585,20150611,article,mesh,"Apoptosis,Fingolimod Hydrochloride,HSP90 Heat-Shock Proteins,Histone Chaperones,Humans,Immunosuppressive Agents,Leukemia, Lymphocytic, Chronic, B-Cell,Phosphorylation,Phosphotyrosine,Propylene Glycols,Protein Interaction Maps,Protein Phosphatase 2,Signal Transduction,Sphingosine,Transcription Factors,Tumor Cells, Cultured,src-Family Kinases","analogs &amp; derivatives,chemistry,drug effects,drug therapy,metabolism,pharmacology","D007166 Q000494 NY,D017209 Q000187 NN,D014157 Q000378 NY,D015451 Q000378 NY,D011409 Q000737 NN,D018841 Q000378 NN,D013110 Q000031 NY,D015451 Q000188 NY,D013110 Q000737 NN,D011409 Q000494 NY,D060066 Q000187 NN,D054648 Q000378 NY,D019000 Q000378 NN,D007166 Q000737 NN,D010766 Q000187 NN,D019061 Q000378 NY,D015398 Q000187 NN,D013110 Q000494 NN,D056488 Q000378 NY","30819,107969,107970,5280335",NULL,Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.,"Aberrant protein kinase activities, and the consequent dramatic increase of Ser/Thr and -Tyr phosphorylation, promote the deregulation of the survival pathways in chronic lymphocytic leukemia (CLL), which is crucial to the pathogenesis and progression of the disease. In this study, we show that the tumor suppressor protein phosphatase 2A (PP2A), one of the major Ser/Thr phosphatases, is in an inhibited form because of the synergistic contribution of 2 events, the interaction with its physiologic inhibitor S",Blood,"Francesca Zonta, Mario Angelo Pagano, Livio Trentin, Elena Tibaldi, Federica Frezzato, Valentina Trimarco, Monica Facco, Giuseppe Zagotto, Valeria Pavan, Giovanni Ribaudo, Luciana Bordin, Gianpietro Semenzato, Anna Maria Brunati"," Department of Molecular Medicine. Department of Pharmaceutical and Pharmacological Sciences, and. Department of Medicine, University of Padua, Padua, Italy; and Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica, Padua, Italy. Department of Molecular Medicine. Department of Medicine, University of Padua, Padua, Italy; and Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica, Padua, Italy. Department of Medicine, University of Padua, Pa",2015 Jun;125(24):3747-55,10.1182/blood-2014-12-619155
25935678,20150701,article,mesh,"Acetylcysteine,Chromatography, Liquid,High-Throughput Screening Assays,Humans,Limit of Detection,Smoking,Tandem Mass Spectrometry,Urinalysis","analysis,methods,urine","D012907 Q000652 NY,D057166 Q000379 NN,D002853 Q000379 NN,D000111 Q000652 NY,D000111 Q000032 NN,D053719 Q000379 NY,D016482 Q000379 NN","12035,12114682,23678798",NULL,Analysis of 18 urinary mercapturic acids by two high-throughput multiplex-LC-MS/MS methods.,"Mercapturic acids (MAs) are metabolic end products formed from conjugates between glutathione and electrophilic compounds. MAs are, therefore, suitable biomarkers of exposure to toxicants, which are either electrophiles by themselves or metabolized to electrophilic intermediates. We developed and validated two LC-MS/MS methods which allow the complementary, rapid, and sensitive determination of MAs derived from acrolein, acrylamide, acrylonitrile, benzene, 1,3-butadiene, crotonaldehyde, N,N-dimethylformamid",Analytical and bioanalytical chemistry,"Nikola Pluym, Gerhard Gilch, Gerhard Scherer, Max Scherer"," ABF, Analytisch-Biologisches Forschungslabor München, Goethestrasse 20, 80336, Munich, Germany.",2015 Jul;407(18):5463-76,10.1007/s00216-015-8719-x
25937048,20150901,article,mesh,"Animals,Antibodies, Monoclonal, Humanized,Antigens, Differentiation, B-Lymphocyte,Antigens, Neoplasm,Cytotoxins,Drug Delivery Systems,Fingolimod Hydrochloride,Histocompatibility Antigens Class II,Humans,Lymphoma, Mantle-Cell,Mice,Mice, Inbred NOD,Propylene Glycols,Receptor Tyrosine Kinase-like Orphan Receptors,Sphingosine,Xenograft Model Antitumor Assays","analogs &amp; derivatives,genetics,metabolism,pharmacology","D000949 Q000378 NN,D003603 Q000494 NY,D000944 Q000235 NN,D057050 Q000235 NN,D013110 Q000031 NY,D057050 Q000378 NY,D011409 Q000494 NY,D061067 Q000494 NN,D020522 Q000235 NN,D000951 Q000378 NN,D000944 Q000378 NN,D020522 Q000378 NY,D000949 Q000235 NN,D013110 Q000494 NN","107969,107970,5280335",NULL,"ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.","Mantle-cell lymphoma (MCL) remains incurable despite numerous therapeutic advances. OSU-2S, a novel nonimmunosuppressive FTY720 (Fingolimod) derivative, exhibits potent cytotoxicity in MCL cell lines and primary cells. OSU-2S increased the surface expression of CD74, a therapeutic antibody target in MCL cells. OSU-2S, in combination with anti-CD74 antibody milatuzumab, enhanced cytotoxicity in MCL. Moreover, MCL tumor antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeted immunonanoparticle",Experimental hematology,"Rajeswaran Mani, Chi-Ling Chiang, Frank W Frissora, Ribai Yan, Xiaokui Mo, Sivasubramanian Baskar, Christoph Rader, Rebecca Klisovic, Mitch A Phelps, Ching-Shih Chen, Robert J Lee, John C Byrd, Robert Baiocchi, L James Lee, Natarajan Muthusamy"," Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, US",2015 Sep;43(9):?,10.1016/j.exphem.2015.04.008
25957334,20150609,article,mesh,"Adult,Encephalitis, Herpes Simplex,Fingolimod Hydrochloride,Herpesvirus 1, Human,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Virus Activation","administration &amp; dosage,adverse effects,analogs &amp; derivatives,chemically induced,complications,drug effects,drug therapy,immunology,physiology","D013110 Q000009 NN,D007166 Q000008 NN,D020803 Q000139 NY,D020803 Q000276 NN,D013110 Q000008 NN,D014775 Q000187 NY,D013110 Q000031 NY,D011409 Q000008 NN,D020803 Q000150 NN,D018259 Q000502 NY,D020529 Q000188 NY,D007166 Q000009 NY,D011409 Q000009 NY","107969,107970,5280335",NULL,Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.,NULL,Neurology,"Nikolai Pfender, Ilijas Jelcic, Michael Linnebank, Urs Schwarz, Roland Martin"," From the University Hospital Zurich, Switzerland. From the University Hospital Zurich, Switzerland. From the University Hospital Zurich, Switzerland. From the University Hospital Zurich, Switzerland. From the University Hospital Zurich, Switzerland. roland.martin@usz.ch.",2015 Jun;84(23):2377-8,10.1212/wnl.0000000000001659
25973048,20150101,article,mesh,"Animals,Animals, Newborn,Blotting, Western,Cell Line,Disease Models, Animal,Enzyme-Linked Immunosorbent Assay,Female,Humans,Inflammation,Macrophages,Male,RNA, Small Interfering,Rats,Rats, Sprague-Dawley,Real-Time Polymerase Chain Reaction,S100 Proteins,Sepsis,Transfection","biosynthesis,metabolism,pathology","D007249 Q000378 NN,D008264 Q000378 NN,D009418 Q000096 NY,D018805 Q000378 NY,D018805 Q000473 NY,D007249 Q000473 NN",NULL,NULL,Expression of S100 family proteins in neonatal rats with sepsis and its significance.,OBJECTIVE: This study aims to study the expression changes of S100 family proteins in neonatal rats with sepsis and investigate the effect and significance of S100 family proteins in pathogenesis and development of sepsis. METHODS: The functions of S100 family proteins were analyzed with bioinformatics. The immune-associated proteins were chosen as the candidate proteins. Twenty neonatal SPF SD rats were randomly divided into two groups: sepsis model group and control group. The liver sample was stained wit,International journal of clinical and experimental pathology,"Haiying Huang, Luoyang Tu"," Department of Critical Care Medicine, Sir Run Run Shaw Hospital Affiliated School of Medicine, Zhejiang University 3 East Qingchun Rd. Jianggan District, Hangzhou, Zhejiang Province, People's Republic of China. Department of Critical Care Medicine, Sir Run Run Shaw Hospital Affiliated School of Medicine, Zhejiang University 3 East Qingchun Rd. Jianggan District, Hangzhou, Zhejiang Province, People's Republic of China.",2015 Jan;8(2):1631-9,NULL
25979079,20150715,article,mesh,"Animals,Capillary Permeability,Cell Proliferation,Cells, Cultured,Ceramides,Electric Impedance,Electronic Nicotine Delivery Systems,Endothelium, Vascular,Female,Gas Chromatography-Mass Spectrometry,Humans,Immunoblotting,Lysophospholipids,Mice,Mice, Inbred C57BL,Nicotine,Nicotinic Agonists,Oxidative Stress,Phosphorylation,Pneumonia,Rats,Signal Transduction,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization,Sphingosine","adverse effects,analogs &amp; derivatives,chemically induced,drug effects,metabolism,pathology","D002199 Q000187 NN,D004730 Q000187 NY,D011014 Q000378 NN,D011014 Q000139 NN,D011014 Q000473 NY,D049109 Q000187 NN,D018722 Q000009 NY,D013110 Q000378 NN,D013110 Q000031 NN,D018384 Q000187 NY,D004730 Q000378 NN,D004730 Q000473 NN,D009538 Q000009 NY,D066300 Q000009 NY,D008246 Q000378 NN,D010766 Q000187 NN,D015398 Q000187 NN,D002518 Q000378 NN","89594,2735102,5280335,5283560,57351368",NULL,Endothelial disruptive proinflammatory effects of nicotine and e-cigarette vapor exposures.,"The increased use of inhaled nicotine via e-cigarettes has unknown risks to lung health. Having previously shown that cigarette smoke (CS) extract disrupts the lung microvasculature barrier function by endothelial cell activation and cytoskeletal rearrangement, we investigated the contribution of nicotine in CS or e-cigarettes (e-Cig) to lung endothelial injury. Primary lung microvascular endothelial cells were exposed to nicotine, e-Cig solution, or condensed e-Cig vapor (1-20 mM nicotine) or to nicotine-f",American journal of physiology. Lung cellular and molecular physiology,"Kelly S Schweitzer, Steven X Chen, Sarah Law, Mary Van Demark, Christophe Poirier, Matthew J Justice, Walter C Hubbard, Elena S Kim, Xianyin Lai, Mu Wang, William D Kranz, Clinton J Carroll, Bruce D Ray, Robert Bittman, John Goodpaster, Irina Petrache"," Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indi",2015 Jul;309(2):L175-87,10.1152/ajplung.00411.2014
26024899,20150707,article,mesh,"Antibodies, Monoclonal, Humanized,Drug Substitution,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Randomized Controlled Trials as Topic,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug therapy,methods","D007166 Q000008 NN,D061067 Q000008 NY,D057915 Q000379 YN,D013110 Q000008 NN,D020529 Q000175 NN,D013110 Q000031 NY,D020529 Q000188 NY,D016032 Q000379 YN,D011409 Q000008 NY","107969,107970,5280335",NULL,"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.","OBJECTIVE: To investigate the effect of different natalizumab washout (WO) periods on recurrence of MRI and clinical disease activity in patients switching from natalizumab to fingolimod. METHODS: In this multicenter, double-blind, placebo-controlled trial (TOFINGO), patients with relapsing-remitting multiple sclerosis (RRMS) were randomized 1:1:1 to 8-, 12-, or 16-week WO followed by fingolimod treatment over 32 weeks from last natalizumab infusion (LNI). Brain MRI was performed at baseline and weeks 8, 12",Neurology,"Ludwig Kappos, Ernst-Wilhelm Radue, Giancarlo Comi, Xavier Montalban, Helmut Butzkueven, Heinz Wiendl, Gavin Giovannoni, Hans-Peter Hartung, Tobias Derfuss, Yvonne Naegelin, Till Sprenger, Nicole Mueller-Lenke, Sarah Griffiths, Philipp von Rosenstiel, Rebecca Gottschalk, Ying Zhang, Frank Dahlke, Davorka Tomic, TOFINGO study group"," From Neurology, the Departments of Medicine, Clinical Research and Biomedicine (L.K., T.D., Y.N., T.S.), the Medical Image Analysis Center (MIAC) (E.-W.R., T.S., N.M.-L.), and the Department of Radiology, Division of Neuroradiology (T.S.), University Hospital, University of Basel, Switzerland; the Department of Neuroscience (G.C.), Scientific Institute H. San Raffaele, University of Milan, Italy; Vall d'Hebron University Hospital (X.M.), Barcelona, Spain; Royal Melbourne Hospital (H.B.), Parkville, Austral",2015 Jul;85(1):29-39,10.1212/wnl.0000000000001706
26075785,20150616,article,mesh,"Female,Humans,Immunosuppressive Agents,Influenza Vaccines,Male,Multiple Sclerosis,Propylene Glycols,Sphingosine,Vaccination","analogs &amp; derivatives,drug therapy,therapeutic use","D007252 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D011409 Q000627 NY,D009103 Q000188 NY",5280335,NULL,"ACP Journal Club. In multiple sclerosis, use of fingolimod reduced immune responses to influenza and tetanus booster vaccines.",NULL,Annals of internal medicine,John R Absher,NULL,2015 Jun;162(12):JC8,10.7326/acpjc-2015-162-12-008
26084334,20150101,article,mesh,"Drug Industry,Female,Fingolimod Hydrochloride,Germany,Humans,Immunosuppressive Agents,Male,Multiple Sclerosis, Relapsing-Remitting,Patient Safety,Product Surveillance, Postmarketing,Propylene Glycols,Prospective Studies,Quality of Life,Research Design","drug therapy,economics,therapeutic use","D000068876 Q000627 NY,D007166 Q000191 NN,D007166 Q000627 NY,D000068876 Q000191 NN,D020529 Q000188 NY,D011409 Q000627 NN","107969,107970",NULL,"The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.","BACKGROUND: Fingolimod (Gilenya) is an oral medication for patients with highly active relapsing-remitting Multiple Sclerosis (RRMS). Clinical trials and post-marketing experience on more than 114,000 patients have established a detailed safety profile. Total patient exposure now exceeds 195,000 patient-years as stated in the last financial report (Dec 2014) of the Novartis Pharma AG, Basel, Switzerland. However, less is known about the safety of long-term fingolimod use in daily practice. Here, we describe",BMC neurology,"Tjalf Ziemssen, Raimar Kern, Christian Cornelissen"," Zentrum für klinische Neurowissenschaften, Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden, Fetscherstr. 43, D-01307, Dresden, Germany. tjalf.ziemssen@uniklinikum-dresden.de. Zentrum für klinische Neurowissenschaften, Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden, Fetscherstr. 43, D-01307, Dresden, Germany. Raimar.Kern@uniklinikum-dresden.de. Novartis Pharma GmbH, Roon",2015 Jan;15(?):93,10.1186/s12883-015-0342-0
26118259,20140330,article,mesh,"Antibodies, Monoclonal, Humanized,Disease-Free Survival,Fingolimod Hydrochloride,Germany,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Natalizumab,Propylene Glycols,Sphingosine,Treatment Outcome","analogs &amp; derivatives,drug therapy,therapeutic use","D061067 Q000627 NY,D013110 Q000031 NY,D007166 Q000627 NY,D020529 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY","107969,107970,5280335",NULL,[Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].,NULL,Ideggyogyaszati szemle,Lovas Gábor,NULL,2014 Mar;67(?):141,NULL
26148840,20160101,article,mesh,"Animals,Cell Death,Cell Survival,Cross-Linking Reagents,Electrons,Fibroblasts,Glass,Hydrogel, Polyethylene Glycol Dimethacrylate,Mice,NIH 3T3 Cells,Polyethylene Glycols,Porosity,Propylene Glycols,Spectroscopy, Fourier Transform Infrared,Temperature,Tensile Strength,Tissue Engineering,Tissue Scaffolds","chemistry,cytology,drug effects,methods,pharmacology","D002470 Q000187 NN,D011092 Q000494 NY,D016923 Q000187 NN,D023822 Q000379 NY,D011409 Q000494 NY,D005347 Q000166 NN,D054457 Q000737 NY,D005347 Q000187 NN,D005898 Q000737 NN,D003432 Q000737 NY,D020136 Q000494 NY",134715697,NULL,Hyperbranched poly(glycidol)/poly(ethylene oxide) crosslinked hydrogel for tissue engineering scaffold using e-beams.,"A microporous hydrogel scaffold was developed from hyperbranched poly(glycidol) (HPG) and poly(ethylene oxide) (PEO) using electron beam (e-beam) induced cross-linking for tissue engineering applications. In this study, HPG was synthesized from glycidol using trimethylol propane as a core initiator and cross-linked hydrogels were made using 0, 10, 20, and 30% HPG with respect to PEO. The effects of %-HPG on the swelling ratio, cross-linking density, mechanical properties, morphology, degradation, and cytoto",Journal of biomedical materials research. Part A," Haryanto, Deepti Singh, Pil Ho Huh, Seong Cheol Kim"," Department of Chemical Engineering, Muhammadiyah University of Purwokerto, Central Java, 53182, Indonesia. Department of Advanced Organic Materials Engineering, Yeungnam University, Gyongbuk, 712-749, Republic of Korea. Department of Nano, Medical and Polymer Materials, Yeungnam University, Gyongbuk, 712-749, Republic of Korea. Department of Polymer Science and Engineering, Pusan National University, Busan, 609-735, Republic of Korea. Department of Advanced Organic Materials Engineering, Yeungnam Universit",2016 Jan;104(1):48-56,10.1002/jbm.a.35539
26198913,20150815,article,mesh,"Administration, Oral,Adult,Dose-Response Relationship, Drug,Female,Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Liver Function Tests,Lymphocytes,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Treatment Outcome,Young Adult","administration &amp; dosage,adverse effects,analogs &amp; derivatives,diagnosis,drug effects,drug therapy,metabolism,trends","D013110 Q000009 NN,D011409 Q000009 NN,D008214 Q000378 NN,D013110 Q000008 NN,D020529 Q000175 NY,D008214 Q000187 NY,D008111 Q000639 NN,D013110 Q000031 NY,D020529 Q000188 NY,D007166 Q000009 NN,D011409 Q000008 NY,D007166 Q000008 NY","107969,107970,5280335",NULL,Safety and efficacy of reduced fingolimod dosage treatment.,"BACKGROUND: Oral fingolimod is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapse rate and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). Elevation of liver function tests (LFTs) and reduction in peripheral-blood lymphocyte counts were among the most common adverse events reported in phase II, phase III, and extension studies. OBJECTIVE: To describe eight patients in whom fingolimod dos",Journal of neuroimmunology,"Bassem I Yamout, Maya M Zeineddine, Raja A Sawaya, Samia J Khoury"," Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: sk88@aub.edu.lb.",2015 Aug;285(?):13-5,10.1016/j.jneuroim.2015.05.012
26198937,20150815,article,mesh,"Animals,Cerebellum,Cuprizone,Demyelinating Diseases,Disease Models, Animal,Female,Fingolimod Hydrochloride,Immunosuppressive Agents,Mice,Mice, Inbred C57BL,Propylene Glycols,Sphingosine","analogs &amp; derivatives,chemically induced,drug effects,drug therapy,immunology,pathology,therapeutic use,toxicity","D003471 Q000633 NY,D003711 Q000139 NN,D002531 Q000473 NN,D002531 Q000276 NN,D013110 Q000031 NY,D002531 Q000187 NY,D007166 Q000627 NY,D003711 Q000276 NN,D013110 Q000627 NN,D011409 Q000627 NY,D003711 Q000188 NY","9723,107969,107970,5280335",NULL,Fingolimod does not enhance cerebellar remyelination in the cuprizone model.,"Fingolimod (FTY720) is approved for treatment of relapsing-remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected any positive effect on cerebral remyelination. The discrepant findings could be a result of different mechanisms underlying cerebral and cerebellar remyelination. The cuprizone model for de- and remyelination was used to evaluate whether fingolimod had an impact on cerebellar remyelinat",Journal of neuroimmunology,"Maria Nordheim Alme, Agnes E Nystad, Lars Bø, Kjell-Morten Myhr, Christian A Vedeler, Stig Wergeland, Øivind Torkildsen"," Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: maria.alme@uib.no. Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: Agnes.elisabeth.nystad@helse-bergen.no. Department of Clinical Medicine, University of Bergen",2015 Aug;285(?):180-6,10.1016/j.jneuroim.2015.06.006
26359277,20160401,article,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine,Ventricular Function, Left","drug therapy,therapeutic use","D020529 Q000188 NN,D007166 Q000627 NN,D009103 Q000188 NY","107969,107970,5280335",NULL,"Comment on ""Fingolimod effects on left ventricular function in multiple sclerosis"" Mult Scler 2015.",NULL,"Multiple sclerosis (Houndmills, Basingstoke, England)","Rajesh Bakshi, Dieter A Häring"," Novartis Pharma AG, Switzerland rajesh.bakshi@novartis.com. Novartis Pharma AG, Switzerland.",2016 Apr;22(5):707-8,10.1177/1352458515600250
26403954,20151101,article,mesh,"Animals,Foot Diseases,Hoof and Claw,Horse Diseases,Horses,Inflammation,Liposomes,Male,Oligosaccharides,Polyethylene Glycols,Radiopharmaceuticals,Technetium Tc 99m Exametazime","chemically induced,chemistry,diagnostic imaging,metabolism,pathology,pharmacokinetics,toxicity,veterinary","D019275 Q000493 NN,D005534 Q000662 NY,D006734 Q000139 NY,D011092 Q000737 NY,D009844 Q000633 NY,D007249 Q000139 NN,D007249 Q000000981 NN,D007249 Q000662 NN,D006734 Q000000981 NN,D008081 Q000737 NY,D005534 Q000000981 NN,D005534 Q000378 NN,D019690 Q000493 NY,D006724 Q000473 NN","450484,453626,56841051,129626367",NULL,Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses.,"Liposomes are phospholipid nanoparticles used for targeted drug delivery. This study aimed to determine whether intravenous liposomes accumulate in lamellar tissue during laminitis development in horses so as to assess their potential for targeted lamellar drug delivery. Polyethylene-glycol (PEG) coated liposomes were prepared according to the film hydration method and labelled using (99m)Tc-hexamethyl-propylene-amine-oxime. Six horses received 10 g/kg oligofructose via nasogastric tube to induce laminitis,","Veterinary journal (London, England : 1997)","Claire Underwood, Christopher C Pollitt, Josbert M Metselaar, Peter Laverman, Louis van Bloois, Jolanda M van den Hoven, Gert Storm, Andrew W van Eps"," Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia. Electronic address: c.underwood1@uq.edu.au. Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia. Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany. Radboud University Medical Centre Nijmegen, The Nether",2015 Nov;206(2):218-25,10.1016/j.tvjl.2015.07.013
26456262,20151130,article,mesh,"Antineoplastic Agents,Cell Death,Cell Line, Tumor,Chloroquine,Drug Combinations,Drug Delivery Systems,Drug Liberation,Drug Resistance, Multiple,Drug Resistance, Neoplasm,Drug Synergism,Hemolysis,Humans,Micelles,Polyesters,Polyethylene Glycols,Taxoids,Vitamin E","administration &amp; dosage,adverse effects,analogs &amp; derivatives,drug effects,pharmacology","D019008 Q000187 NY,D002738 Q000494 NY,D000970 Q000494 NN,D043823 Q000009 NN,D043823 Q000008 NY,D016923 Q000187 NN,D018432 Q000187 NY,D002738 Q000009 NN,D043823 Q000494 NY,D002738 Q000008 NY,D014810 Q000031 NN,D000970 Q000009 NN,D000970 Q000008 NN,D006461 Q000187 NN","2719,14985,71406,91441,148123,148124,22600501,24721032,24820205,24883462,44408087,51051642,73440750,86280293,122130667,131632408,133121268,134694719",NULL,Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance.,The combination of two or more drug is a promising strategy to suppress the multidrug resistance (MDR) through different action mechanisms. Co-delivery drugs via polymeric micelle can minimize the amount of each drug and reduce toxic side effects. Here we co-encapsulate anticancer drug docetaxel (DTX) and autophagy inhibitor chloroquine (CQ) in complex micelles based on poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ϵ-caprolactone) (PEO-PPO-PCL) and D-α-tocopheryl poly(ethylene glycol) (TPGS) f,International journal of pharmaceutics,"Chunhuan Shi, Zhiqing Zhang, Jiaxing Shi, Fang Wang, Yuxia Luan"," School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, Jinan, Shandong 250012, PR China. College of Science, China University of Petroleum, 66 West Changjiang Road, Qingdao, Shandong 266580, PR China. School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, Jinan, Shandong 250012, PR China. College of Science, China University of Petroleum, 66 West Changjiang Road, Qingdao, Shandong 266580, PR China. School of Pharmaceutical Science, Shandong University, 44 West Wenh",2015 Nov;495(2):932-9,10.1016/j.ijpharm.2015.10.009
26521855,20150101,article,mesh,"Aza Compounds,Guanosine,Models, Molecular,Mutagens,Nitro Compounds,Nucleosides,Oxazines,Sulfhydryl Compounds,Thermodynamics,Water","analogs &amp; derivatives,analysis,chemistry","D006151 Q000032 NN,D010078 Q000737 NY,D009705 Q000737 NY,D001372 Q000737 NY,D009574 Q000032 NY,D006151 Q000031 NY,D014867 Q000737 NN,D009153 Q000032 NY,D013438 Q000737 NN","878,962,6802,519392,16727417,129829002",NULL,New NitroG-Grasp Molecules with Enhanced Capture Reactivity for 8-Nitroguanosine in the Aqueous Media.,"8-Nitroguanosine is formed by the nitration of guanosine, and has been conventionally classified as a genotoxic material. Recently, 8-nitroguanosine 3',5'-cyclic monophosphate (8-nitro-cGMP) has become of great interest due to its biological role as an intracellular signaling molecule. In an attempt to develop recognition molecules for 8-nitroguanosine, we have determined a 1,3-diazaphenoxazine nucleoside derivative (nitroG-grasp) bearing a thiol group with a urea linker, which efficiently displaces the nit",Chemical & pharmaceutical bulletin,"Yasufumi Fuchi, Shigeki Sasaki"," Graduate School of Pharmaceutical Sciences, Kyushu University.",2015 Jan;63(11):913-9,10.1248/cpb.c15-00550
26531696,20151115,article,mesh,"Female,Humans,Immunosuppressive Agents,Lymphocytes,Male,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols,Sphingosine","administration &amp; dosage,analogs &amp; derivatives,diagnosis,drug effects,drug therapy","D020529 Q000175 NY,D008214 Q000187 NY,D013110 Q000031 NY,D020529 Q000188 NY,D011409 Q000008 NY,D007166 Q000008 NY",5280335,NULL,Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.,"CD28/CTLA-4–CD80/CD86 molecules play an important role in the regulation of T cells activation. Defects in proteins involved in this pathway may lead to the development of autoimmune diseases in which T cells are involved. In this case–control study (336 multiple sclerosis (MS) patients and 322 controls) we investigated the possible association of eleven polymorphisms in CD28, CTLA-4, CD80 and CD86 genes with susceptibility to MS and/or its progression. We also took into account HLA-DRB1*15:01 status. Moreo",Journal of neuroimmunology,"Masami Tanaka, Masako Kinoshita"," Multiple sclerosis center, Utano National Hospital, 8 Ondoyama, Narutaki, Ukyo-ku, Kyoto 616-8255, Japan. Electronic address: nra17777@nifty.com. Department of Neurology, Utano National Hospital, 8 Ondoyama, Narutaki, Ukyo-ku, Kyoto 616-8255, Japan. Electronic address: machakok@unh.hosp.go.jp.",2015 Nov;288(?):69,10.1016/j.jneuroim.2015.09.002
26573170,20160101,article,mesh,"Biosensing Techniques,Cells,Dendrimers,Humans,Monoamine Oxidase,Nanoparticles,Oxidative Stress,Reactive Oxygen Species","analysis,chemistry,metabolism,methods","D008995 Q000737 NN,D017382 Q000032 NN,D017382 Q000378 NN,D015374 Q000379 NY,D002477 Q000378 NN,D053758 Q000737 NY,D002477 Q000737 NY,D050091 Q000737 NY",NULL,NULL,Acellular reactivity of polymeric dendrimer nanoparticles as an indicator of oxidative stress in vitro.,The need for rapid and cost-effective pre-screening protocols of the toxicological response of the vast array of emerging nanoparticle types is apparent and the emerging consensus on the paradigm of oxidative stress by generation of intracellular reactive oxygen species as a primary source of the toxic response suggests the development of acellular assays to screen for nanoparticle surface reactivity. This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dend,Analytical and bioanalytical chemistry,"Marcus A Maher, Humza Khalid, Hugh J Byrne"," FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. Hugh.Byrne@DIT.IE.",2016 Jan;408(3):695-703,10.1007/s00216-015-9171-7
26587577,20160101,review,mesh,"Fingolimod Hydrochloride,Humans,Immunosuppressive Agents,Multiple Sclerosis, Relapsing-Remitting,Propylene Glycols","drug therapy,standards,therapeutic use","D000068876 Q000627 NY,D007166 Q000627 NN,D000068876 Q000592 NN,D020529 Q000188 NY,D007166 Q000592 NN","107969,107970",NULL,Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.,"Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocyte",Expert review of neurotherapeutics,"Douglas R Jeffery, Kottil W Rammohan, Kathleen Hawker, Edward Fox"," a Multiple Sclerosis Center, Lake Norman Neurology , Piedmont HealthCare , Mooresville , NC , USA. b Department of Neurology , University of Miami , Miami , FL , USA. c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA. d Central Texas Neurology Consultants , Round Rock , TX , USA.",2016 Jan;16(1):31-44,10.1586/14737175.2016.1123094
26749811,20151101,article,mesh,"Alloxan,Animals,Blood Glucose,Blood Proteins,Diabetes Mellitus, Experimental,Humans,Hypoglycemic Agents,Liver Glycogen,Male,Phytotherapy,Plant Extracts,Pterocarpus,Rats,Rats, Wistar,Sulfhydryl Compounds","administration &amp; dosage,adverse effects,blood,chemistry,drug therapy,metabolism","D003921 Q000188 NY,D007004 Q000008 NN,D035721 Q000737 NY,D013438 Q000097 NN,D003921 Q000378 NN,D001786 Q000378 NN,D001798 Q000378 NY,D000496 Q000009 NN,D010936 Q000008 NY,D008112 Q000378 NY",5781,NULL,"Renoprotective Effects, Protein Thiols and Liver Glycogen Content of Alloxan-induced Diabetic Rats Treated with Different Fractions of Heartwood of Pterocarpus marsupium.","Oxidative stress is believed to be a pathogenic factor in the development of diabetic complications. In the present study, we aimed to evaluate the effects of different fractions of heart wood of Pterocarpus marsupium on antioxidant enzyme like protein thiols and also check the efficacy of the extract for the protection of the renal function in alloxan induced diabetic rats. The present study also investigates the levels of liver glycogen which are considered as the best biomarker for assaying the hypoglyce",Natural product communications,"Vinutha Bhata, B Shivananda Nayak",NULL,2015 Nov;10(11):1843-6,NULL
26826298,20160401,article,mesh,"2-Hydroxypropyl-beta-cyclodextrin,Animals,Cell Death,Cell Survival,Cyclodextrins,DNA,Flow Cytometry,Gene Knockdown Techniques,Genetic Vectors,Green Fluorescent Proteins,HeLa Cells,Humans,Mice,NIH 3T3 Cells,Plasmids,Poloxamer,Polyethylene Glycols,Propylene Glycols,RNA Interference,RNA, Small Interfering,Rotaxanes,Static Electricity,Structure-Activity Relationship,beta-Cyclodextrins","chemical synthesis,chemistry,metabolism","D011409 Q000737 NY,D011092 Q000138 NN,D043862 Q000737 NY,D011092 Q000737 NY,D034741 Q000378 NY,D004247 Q000378 NN,D010957 Q000378 NN,D047392 Q000138 NN,D003505 Q000737 NY,D047392 Q000737 NY,D020442 Q000737 NY,D005822 Q000378 NY,D049452 Q000378 NN,D011409 Q000138 NN","10154203,14049689,44135672",NULL,Structure-property relationship for in vitro siRNA delivery performance of cationic 2-hydroxypropyl-β-cyclodextrin: PEG-PPG-PEG polyrotaxane vectors.,"Nanoparticle-mediated siRNA delivery is a promising therapeutic approach, however, the processes required for transport of these materials across the numerous extracellular and intracellular barriers are poorly understood. Efficient delivery of siRNA-containing nanoparticles would ultimately benefit from an improved understanding of how parameters associated with these barriers relate to the physicochemical properties of the nanoparticle vectors. We report the synthesis of three Pluronic(®)-based, cholester",Biomaterials,"Vivek D Badwaik, Emilio Aicart, Yawo A Mondjinou, Merrell A Johnson, Valorie D Bowman, David H Thompson"," Department of Chemistry, Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, 1203 W. State Street, West Lafayette, IN 47907, USA. Department of Chemistry, Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, 1203 W. State Street, West Lafayette, IN 47907, USA. Department of Chemistry, Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, 1203 W. State Street, West Lafayette, IN 47907, USA. Department of Physics, Indiana University-Purdue University I",2016 Apr;84(?):86-98,10.1016/j.biomaterials.2015.11.032
27134519,20151101,article,NULL,NULL,NULL,NULL,NULL,NULL,Hydrolysable core crosslinked particle for receptor-mediated pH-sensitive anticancer drug delivery.,"Biodegradable micelle systems with both extracellular stabilities and specific targeting properties are highly desirable for anti-cancer drug delivery. Here, we report a biodegradable and crosslinkable poly(propylene fumarate)-co-poly(lactide-co-glycolide)-co-poly(ethylene glycol) (PPF-PLGA-PEG) copolymer conjugated with folate (FA) molecules for receptor-mediated delivery of doxorubicin. Micelles with folate ligands on surface and fumarate bonds within the core were self-assembled and crosslinked, which ex",New journal of chemistry = Nouveau journal de chimie,"Xifeng Liu, A Lee Miller, Brian E Waletzki, Tewodros K Mamo, Michael J Yaszemski, Lichun Lu"," Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA. Department of Or",2015 Nov;39(11):8840-8847,10.1039/c5nj01404b
27136276,20170901,article,mesh,"Animals,Antineoplastic Agents,Apoptosis,Cells, Cultured,Dog Diseases,Dogs,Lymphoma, B-Cell,Propylene Glycols,Reactive Oxygen Species,Sphingosine","analogs &amp; derivatives,antagonists &amp; inhibitors,drug effects,drug therapy,therapeutic use,veterinary","D017209 Q000187 NN,D016393 Q000662 NY,D016393 Q000188 NN,D017382 Q000037 NY,D013110 Q000031 NY,D000970 Q000627 NY,D004283 Q000188 NY,D013110 Q000627 NN,D011409 Q000627 NY",5280335,NULL,Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.,OSU-2S is a FTY720 (Fingolimod) derivative that lacks immunosuppressive properties but exhibits strong anti-tumour activity in several haematological and solid tumour models. We have recently shown OSU-2S to mediate potent cytotoxicity in human mantle cell lymphoma cell lines and primary cells. We report here the pre-clinical activity of OSU-2S in spontaneous B-cell lymphoma of dogs which shares many characteristics of human lymphoma. OSU-2S mediated apoptosis in canine B-cell lines and primary B-cell lymph,Veterinary and comparative oncology,"R Mani, R Yan, X Mo, C-S Chen, M A Phelps, R Klisovic, J C Byrd, W C Kisseberth, C A London, N Muthusamy"," Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA. Center for Biostatistics, The Ohio State University, Columbus, OH, USA. Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Department of Veterinary Biosciences, College of Veterinary Medicine, The",2017 Sep;15(3):1115-1118,10.1111/vco.12221
27165132,20161101,article,NULL,NULL,NULL,NULL,NULL,NULL,Intraocular silicone implant to treat chronic ocular hypotony-preliminary feasibility data.,"PURPOSE: Ocular hypotony secondary to proliferative vitreoretinopathy-related retinal detachment, trauma or inflammation is difficult to treat. Besides endotamponades such as silicone oil, vitreous implants such as iris diaphragms or balloons have been developed to stabilize the eye and to prevent phthisis of the globe. Vitreous implants tested thus far exhibit a seam at the attachment site of the hemispheres, or micropores. This manuscript reports the development of a seamless silicone balloon implant with",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,"Wesal Bayoudh, Markus Frentz, Dörthe Carstesen, Barbara Dittrich, Caroline Reismann, Norbert F Schrage, Peter Walter, Andreas W A Weinberger"," Department of Ophthalmology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. Klinikum Dortmund gGmbh, Dortmund, Germany. Department of Ophthalmology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. ACTO Aachen Center for Technology Transfer in Ophthalmology, Aachen, Germany. Department of Ophthalmology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Aachen, Germany. Department of Op",2016 Nov;254(11):2131-2139,10.1007/s00417-016-3364-4
27273457,20160808,article,NULL,NULL,NULL,NULL,NULL,NULL,Nickel-Catalyzed Cross-Electrophile Coupling with Organic Reductants in Non-Amide Solvents.,"Cross-electrophile coupling of aryl halides with alkyl halides has thus far been primarily conducted with stoichiometric metallic reductants in amide solvents. This report demonstrates that the use of tetrakis(dimethylamino)ethylene (TDAE) as an organic reductant enables the use of non-amide solvents, such as acetonitrile or propylene oxide, for the coupling of benzyl chlorides and alkyl iodides with aryl halides. Furthermore, these conditions work for several electron-poor heterocycles that are easily redu","Chemistry (Weinheim an der Bergstrasse, Germany)","Lukiana L Anka-Lufford, Kierra M M Huihui, Nicholas J Gower, Laura K G Ackerman, Daniel J Weix"," Department of Chemistry, University of Rochester, Rochester, NY, 14627-0216, USA. Department of Chemistry, University of Rochester, Rochester, NY, 14627-0216, USA. Department of Chemistry, University of Rochester, Rochester, NY, 14627-0216, USA. Department of Chemistry, University of Rochester, Rochester, NY, 14627-0216, USA. Department of Chemistry, University of Rochester, Rochester, NY, 14627-0216, USA. daniel.weix@rochester.edu.",2016 Aug;22(33):11564-7,10.1002/chem.201602668
27457305,20160101,article,mesh,"Acute-Phase Proteins,Animals,Cattle,Female,Food Preservatives,Hot Temperature,Milk,Potassium Dichromate,Propylene Glycols",chemistry,"D011409 Q000737 NY,D000209 Q000737 NY,D008892 Q000737 NY,D005520 Q000737 NN,D011192 Q000737 NY","2450,24502",NULL,Effect of pre-analytical treatments on bovine milk acute phase proteins.,BACKGROUND: Samples for diagnostic procedures often require some form of pre-analytical preparation for preservation or safe handling during transportation prior to analysis in the laboratory. This is particularly important for milk samples which frequently need preservatives to retain milk composition as close to that found in freshly collected samples as possible. METHODS: Milk samples were treated by heating at 56 °C for 30 min or preserved by addition of either potassium dichromate or bronopol respectiv,BMC veterinary research,"Funmilola C Thomas, Andre M Santana, Mary Waterston, Hayley Haining, Peter David Eckersall"," Institute of Biodiversity Animal Health and Comparative Medicine, University of Glasgow, Bearsden Road, Glasgow, UK. Present Address: Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Federal University of Agriculture, Abeokuta, Nigeria. Department of Veterinary Clinics and Surgery, FCAV, UNESP, Sao Paulo, Brazil. Institute of Infection, Immunity and Inflammation, GBRC University Place, University of Glasgow, Glasgow, UK. Veterinary Diagnostic Services, School of Veterin",2016 Jan;12(1):151,10.1186/s12917-016-0769-6
27497728,20160901,article,mesh,"Animals,Antioxidants,Biomarkers,Chemical and Drug Induced Liver Injury,Drug Synergism,Female,Isoniazid,Liver Function Tests,Male,Oxidative Stress,Rats, Wistar,Silymarin,Zidovudine","administration &amp; dosage,blood,drug effects,metabolism,pathology,prevention &amp; control,therapeutic use,toxicity","D056486 Q000378 NN,D000975 Q000008 NN,D007538 Q000008 NN,D007538 Q000633 NY,D056486 Q000473 NN,D015215 Q000008 NN,D018384 Q000187 NY,D012838 Q000627 NY,D012838 Q000008 NN,D000975 Q000627 NY,D015215 Q000633 NY,D056486 Q000517 NY,D015415 Q000097 NN","3767,5213,5726,31553,35370,451515,455007,1548994,5355297,5359363,5467200,5479610,6610285,7073228,10220987,24721673,44147684",NULL,Zidovudine and isoniazid induced liver toxicity and oxidative stress: Evaluation of mitigating properties of silibinin.,"HIV/AIDS patients are more prone for opportunistic TB infections and they are administered the combined regimen of anti-retroviral drug zidovudine (AZT) and isoniazid (INH) for therapy. However, AZT+INH treatment has been documented to induce injury and remedial measures to prevent this adversity are not clearly defined. Silibinin (SBN) is a natural hepatoprotective principle isolated from medicinal plant Silybum marianum and is currently used for therapy of various liver diseases. This study investigate th",Environmental toxicology and pharmacology,"Ramanathan Raghu, Sivanesan Karthikeyan"," Food and Hepatotoxicology Laboratory, Department of Pharmacology and Environmental Toxicology, Dr. ALM. Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamilnadu, India. Food and Hepatotoxicology Laboratory, Department of Pharmacology and Environmental Toxicology, Dr. ALM. Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamilnadu, India. Electronic address: hepatotoxicology.lab@gmail.com.",2016 Sep;46(?):217-226,10.1016/j.etap.2016.07.014
27770143,20170101,article,mesh,"Biomarkers,Cholecystitis,Formates,Glutamic Acid,Histidine,Humans,Lactic Acid,Lipoproteins,Metabolomics,Propylene Glycols,Proton Magnetic Resonance Spectroscopy",blood,"D006639 Q000097 NN,D018698 Q000097 NN,D002764 Q000097 NY,D019344 Q000097 NN,D005561 Q000097 NN,D011409 Q000097 NN,D015415 Q000097 NN,D008074 Q000097 NN","283,284,611,612,6274,10997,10998,10999,11195,23327,27506,33032,61216,61503,62358,62632,68404,68967,91435,104813,107689,117932,155559,168185,197815,2723810,2723923,2735122,4525487,5128032,5147171,5460299,5460544,10153989,11840951,14598502,17902988,19827577,23663999,23669634,23673641,23680280,23696295,44152240,53470841,54606124,57370201,71310765,73557423,86690051,90473727,129674751,129773928,131855144,131858412,131881670",NULL,(1)H nuclear magnetic resonance (NMR)-based serum metabolomics of human gallbladder inflammation.,"OBJECTIVE AND DESIGN: We present in this article (1)H nuclear magnetic resonance (NMR)-based metabolic approach to screen the serum metabolic alterations in human gallbladder inflammation with chronic cholecystitis (CC). MATERIAL/METHODS: Total of 71 human serum samples was divided into two groups, (n = 41, CC) and (n = 30 control). (1)H NMR metabolic profiling was carried out for investigation of metabolic alterations. Multivariate statistical analysis was applied for pattern recognition and identification",Inflammation research : official journal of the European Histamine Research Society ... [et al.],"Raj Kumar Sharma, Kumudesh Mishra, Alvina Farooqui, Anu Behari, Vinay Kumar Kapoor, Neeraj Sinha"," Centre of Biomedical Research, SGPGIMS Campus, Lucknow, 226014, India. Department of Biosciences, Integral University, Kursi Road, Lucknow, 226026, India. Department of Surgical Gastroenterology, SGPGIMS, Lucknow, 226014, India. Department of Biosciences, Integral University, Kursi Road, Lucknow, 226026, India. Department of Surgical Gastroenterology, SGPGIMS, Lucknow, 226014, India. Department of Surgical Gastroenterology, SGPGIMS, Lucknow, 226014, India. Centre of Biomedical Research, SGPGIMS Campus, Luc",2017 Jan;66(1):97-105,10.1007/s00011-016-0998-y
27935698,20161227,article,mesh,"Animals,Atherosclerosis,Dendritic Cells,Inflammation,Ligands,Mice,Micelles,Nanostructures,Polymers",therapy,D050197 Q000628 NY,NULL,NULL,Tailoring Nanostructure Morphology for Enhanced Targeting of Dendritic Cells in Atherosclerosis.,"Atherosclerosis, a leading cause of heart disease, results from chronic vascular inflammation that is driven by diverse immune cell populations. Nanomaterials may function as powerful platforms for diagnostic imaging and controlled delivery of therapeutics to inflammatory cells in atherosclerosis, but efficacy is limited by nonspecific uptake by cells of the mononuclear phagocytes system (MPS). MPS cells located in the liver, spleen, blood, lymph nodes, and kidney remove from circulation the vast majority o",ACS nano,"Sijia Yi, Sean David Allen, Yu-Gang Liu, Brian Zhou Ouyang, Xiaomo Li, Punn Augsornworawat, Edward Benjamin Thorp, Evan Alexander Scott"," Department of Biomedical Engineering, ‡Chemistry of Life Processes Institute, §Interdisciplinary Biological Sciences Program, and ∥Master of Biotechnology Program, Northwestern University , Evanston, Illinois 60208, United States. Department of Pathology and #Simpson Querrey Institute, Northwestern University Feinberg School of Medicine , Chicago, Illinois 60611, United States. Department of Biomedical Engineering, ‡Chemistry of Life Processes Institute, §Interdisciplinary Biological Sciences Program, and ",2016 Dec;10(12):11290-11303,10.1021/acsnano.6b06451
28012929,20170201,article,mesh,"Animals,Antineoplastic Agents,Apoptosis,Cell Line, Tumor,Cell Movement,Cell Proliferation,Humans,Male,Mice,Poloxalene,Poloxamer,Polyethylene Glycols,Prostatic Neoplasms,Schiff Bases","chemistry,drug effects,drug therapy,pharmacology","D000970 Q000494 NY,D002465 Q000187 NN,D012545 Q000737 NY,D017209 Q000187 NN,D011092 Q000737 NN,D000970 Q000737 NY,D049109 Q000187 NN,D020442 Q000737 NY,D011060 Q000737 NY,D011471 Q000188 NY","10154203,86573619",NULL,Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro.,Prostate cancer is a multistep and complicated cancer type that is regulated by androgens at the cellular level and remains the second commonest cause of death among men. Discovery and development of novel chemotherapeutic agents enabling rapid tumor cell death with minimal toxic effects to healthy tissues might greatly improve the safety of chemotherapy. The present study evaluates the anti-cancer activity of a novel heterodinuclear copper(II)Mn(II) complex (Schiff base) in combination with poly(ethylene o,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,"Selami Demirci, Ayşegül Doğan, Neşe Başak Türkmen, Dilek Telci, Albert A Rizvanov, Fikrettin Şahin"," Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey; National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, United States. Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey; National Cancer Institute (NCI), CDBL, NIH, Frederick, MD, United States. Electronic address: aguldgn@gmail.com. Department of Pharmaceutical Toxicology, University of Inonu, Malat",2017 Feb;86(?):492-501,10.1016/j.biopha.2016.11.101
28056091,20170101,article,mesh,"Animals,Cell Respiration,Colitis,Disease Models, Animal,Host-Pathogen Interactions,Mice,Mice, Inbred C57BL,Polymerase Chain Reaction,Propylene Glycol,Salmonella Infections, Animal,Salmonella typhimurium,Virulence Factors","growth &amp; development,metabolism,microbiology,pathogenicity,physiology","D012481 Q000378 NY,D037521 Q000378 NN,D019946 Q000378 NY,D019069 Q000502 NN,D012486 Q000254 NN,D012486 Q000472 NY,D054884 Q000502 NY,D003092 Q000382 NY",1030,NULL,"Respiration of Microbiota-Derived 1,2-propanediol Drives Salmonella Expansion during Colitis.","Intestinal inflammation caused by Salmonella enterica serovar Typhimurium increases the availability of electron acceptors that fuel a respiratory growth of the pathogen in the intestinal lumen. Here we show that one of the carbon sources driving this respiratory expansion in the mouse model is 1,2-propanediol, a microbial fermentation product. 1,2-propanediol utilization required intestinal inflammation induced by virulence factors of the pathogen. S. Typhimurium used both aerobic and anaerobic respiration",PLoS pathogens,"Franziska Faber, Parameth Thiennimitr, Luisella Spiga, Mariana X Byndloss, Yael Litvak, Sara Lawhon, Helene L Andrews-Polymenis, Sebastian E Winter, Andreas J Bäumler"," Department of Medial Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, United States of America. Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, United States of America. Department of Medial Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, United States of America. Department of Medial Mic",2017 Jan;13(1):e1006129,10.1371/journal.ppat.1006129
28352339,20170201,article,NULL,NULL,NULL,NULL,NULL,NULL,Determination of DNA damage and telomerase activity in stanozolol-treated rats.,"Anabolic androgenic steroids (AAS) are performance-enhancing drugs commonly abused by atheletes. Stanozolol is a synthetic testosterone-derived anabolic steroid. Although it is well known that AAS have several side-effects, there are only few toxicological studies available on the toxic effects and mechanisms of action of stanozolol. The aim of this study was to investigate the genotoxic effects of stanozolol and to determine its effects on telomerase activity in Sprague-Dawley male rats. For this purpose, ",Experimental and therapeutic medicine,"Mehtap Kara, Eren Ozcagli, Persefoni Fragkiadaki, Tugba Kotil, Polychronis D Stivaktakis, Demetrios A Spandidos, Aristides M Tsatsakis, Buket Alpertunga"," Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey. Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey. Center of Toxicology Science and Research, Medical School, University of Crete, Heraklion 71003, Greece. Department of Histology and Embryology, School of Medicine, Istanbul University, Istanbul 34116, Turkey. Center of Toxicology Science and Research, Medical School, University of Crete, Herakli",2017 Feb;13(2):614-618,10.3892/etm.2016.3974
28360111,20170701,article,mesh,"Aerosols,Airway Resistance,Animals,Body Weight,Elasticity,Electronic Nicotine Delivery Systems,Female,Functional Residual Capacity,Gas Chromatography-Mass Spectrometry,Inflammation,Inflammation Mediators,Lung,Methacholine Chloride,Mice, Inbred BALB C,Organ Size,Plethysmography,Respiratory Hypersensitivity,Smoking,Thorax","adverse effects,complications,drug effects,metabolism,pathology,pharmacology,physiopathology","D012907 Q000009 NN,D001835 Q000187 NN,D000403 Q000187 NN,D007249 Q000473 NY,D012130 Q000473 NN,D008168 Q000473 NY,D007249 Q000503 NY,D013909 Q000473 NN,D012130 Q000150 NN,D000336 Q000009 NY,D018836 Q000378 NN,D016210 Q000494 NN,D005652 Q000187 NN,D008168 Q000503 NY,D066300 Q000009 NY,D012130 Q000503 NN","1993,6114",NULL,The effects of electronic cigarette aerosol exposure on inflammation and lung function in mice.,"Electronic cigarette usage is increasing worldwide, yet there is a paucity of information on the respiratory health effects of electronic cigarette aerosol exposure. This study aimed to assess whether exposure to electronic cigarette (e-cigarette) aerosol would alter lung function and pulmonary inflammation in mice and to compare the severity of any alterations with mice exposed to mainstream tobacco smoke. Female BALB/c mice were exposed for 8 wk to tobacco smoke, medical air (control), or one of four diff",American journal of physiology. Lung cellular and molecular physiology,"Alexander N Larcombe, Maxine A Janka, Benjamin J Mullins, Luke J Berry, Arne Bredin, Peter J Franklin"," Telethon Kids Institute, University of Western Australia, Subiaco, Western Australia, Australia; alexander.larcombe@telethonkids.org.au. Health, Safety and Environment, School of Public Health, Curtin University, Perth, Western Australia, Australia. Telethon Kids Institute, University of Western Australia, Subiaco, Western Australia, Australia. Fluid Dynamics Research Group, Curtin University, Perth, Western Australia, Australia. Health, Safety and Environment, School of Public Health, Curtin University, P",2017 Jul;313(1):L67-L79,10.1152/ajplung.00203.2016
28394196,20171001,article,mesh,"Animals,Cell Adhesion,Cell Count,Cell Death,Cytoprotection,Humans,Hydrogels,Hydrogen Peroxide,Mesenchymal Stem Cell Transplantation,Mesenchymal Stromal Cells,Mice,Polymers,Reactive Oxygen Species,Rheology","chemical synthesis,chemistry,cytology,drug effects,pharmacology,toxicity","D059630 Q000166 NY,D017382 Q000633 NY,D059630 Q000187 NN,D020100 Q000737 NN,D006861 Q000633 NN,D002448 Q000187 NN,D016923 Q000187 NN,D011108 Q000138 NN,D020100 Q000138 NN,D011108 Q000737 NN,D020100 Q000494 NY,D019610 Q000187 NN",784,NULL,Reactive Oxygen Species Shielding Hydrogel for the Delivery of Adherent and Nonadherent Therapeutic Cell Types<sup/>.,"Cell therapies suffer from poor survival post-transplant due to placement into hostile implant sites characterized by host immune response and innate production of high levels of reactive oxygen species (ROS). We hypothesized that cellular encapsulation within an injectable, antioxidant hydrogel would improve viability of cells exposed to high oxidative stress. To test this hypothesis, we applied a dual thermo- and ROS-responsive hydrogel comprising the ABC triblock polymer poly[(propylene sulfide)-block-(N",Tissue engineering. Part A,"Bryan R Dollinger, Mukesh K Gupta, John R Martin, Craig L Duvall"," Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee. Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee. Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee. Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee.",2017 Oct;23(?):1120-1131,10.1089/ten.tea.2016.0495
28428175,20170701,article,mesh,"Aerosols,Cell Death,Cell Line,Cell Proliferation,Cell Survival,Cinnamomum aromaticum,Electronic Nicotine Delivery Systems,Epithelial Cells,Gas Chromatography-Mass Spectrometry,Humans,Inhibitory Concentration 50,Lung,Menthol,Nicotine","chemistry,cytology,drug effects,metabolism,pharmacology","D009538 Q000494 NN,D002470 Q000187 NN,D004847 Q000187 NN,D008610 Q000494 NN,D032904 Q000737 NN,D016923 Q000187 NN,D049109 Q000187 NN,D004847 Q000166 NY,D008168 Q000166 NY,D004847 Q000378 NN","1254,16666,89594,2735102,57351368",NULL,Flavored e-cigarette liquids reduce proliferation and viability in the CALU3 airway epithelial cell line.,"E-cigarettes are generally thought of as a safer smoking alternative to traditional cigarettes. However, little is known about the effects of e-cigarette liquids (e-liquids) on the lung. Since over 7,000 unique flavors have been identified for purchase in the United States, our goal was to conduct a screen that would test whether different flavored e-liquids exhibited different toxicant profiles. We tested the effects of 13 different flavored e-liquids [with nicotine and propylene glycol/vegetable glycerin ",American journal of physiology. Lung cellular and molecular physiology,"Temperance R Rowell, Steven L Reeber, Shernita L Lee, Rachel A Harris, Rachel C Nethery, Amy H Herring, Gary L Glish, Robert Tarran"," Marsico Lung Institute, The University of North Carolina, Chapel Hill, North Carolina. Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, North Carolina. Department of Chemistry, The University of North Carolina, Chapel Hill, North Carolina; and. Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, North Carolina. Department of Chemistry, The University of North Carolina, Chapel Hill, North Carolina; and. Department of Biostatistic",2017 Jul;313(1):L52-L66,10.1152/ajplung.00392.2016
28506203,20170101,article,mesh,"Administration, Cutaneous,Animals,Arthritis,Delayed-Action Preparations,Drug Liberation,Eczema,Emulsions,Gels,Glucocorticoids,Goats,Half-Life,Models, Chemical,Oils,Particle Size,Patents as Topic,Permeability,Psoriasis,Skin,Solubility,Surface-Active Agents,Triamcinolone,Vitelline Membrane","chemistry,drug effects,drug therapy,metabolism,pharmacology","D013501 Q000737 NN,D005938 Q000494 NY,D014221 Q000737 NN,D011565 Q000188 NN,D003692 Q000494 NY,D012867 Q000378 NN,D004485 Q000188 NN,D005938 Q000737 NN,D001168 Q000188 NN,D014817 Q000378 NN,D014817 Q000187 NN,D014221 Q000494 NY,D003692 Q000737 NN,D009821 Q000737 NN,D012867 Q000187 NN",31307,NULL,Optimization of Microemulsion Based Transdermal Gel of Triamcinolone.,"BACKGROUND: Triamcinolone is a long acting corticosteroid used in the treatment of arthritis, eczema, psoriasis and similar conditions which cause inflammation. Triamcinolone has half-life of 88min. Prolonged oral use is associated with gastrointestinal adverse effects as peptic ulcer, abdominal distention and ulcerative esophagitis as described in various patents. Microemulgel offers advantage of better stability, better loading capacity and controlled release especially for drug with short half life. OBJE",Recent patents on anti-infective drug discovery,"Swati Jagdale, Bhagyashree Chaudhari"," Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, MIT Campus, Pune, (MS), 411038. India. Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, MIT Campus, S. No. 124, Kothrud, Pune 411038, Savitribai Phule Pune University, Pune. India.",2017 Jan;12(1):61-78,10.2174/1574891x12666170426092911
28535038,20170612,article,mesh,"Absorbable Implants,Animals,Biocompatible Materials,Bone-Implant Interface,Carbon Dioxide,Cell Differentiation,Cell Line, Tumor,Ceramics,Female,Femur,Glycerol,Humans,Hydrolysis,Male,Mice,Mice, Inbred BALB C,Osteoblasts,Polypropylenes,Rats,Starch,Water,Wettability","anatomy &amp; histology,chemical synthesis,chemistry,cytology,diagnostic imaging,drug effects,metabolism,pharmacology,physiology,surgery","D005269 Q000601 NN,D002245 Q000378 NN,D001672 Q000378 NN,D000069343 Q000502 NY,D001672 Q000138 NY,D011126 Q000138 NY,D002516 Q000737 NN,D002516 Q000494 NY,D014867 Q000378 NN,D000069343 Q000033 NN,D010006 Q000187 NN,D010006 Q000166 NN,D013213 Q000737 NY,D013213 Q000378 NN,D011126 Q000494 NN,D005990 Q000737 NN,D011126 Q000378 NN,D005990 Q000378 NN,D001672 Q000494 NN,D002454 Q000187 NN,D000069343 Q000000981 NN","280,753,962",NULL,Fabrication of a Biodegradable Implant with Tunable Characteristics for Bone Implant Applications.,"Biodegradable polymers are appealing material for the manufacturing of surgical implants as such implants break down in vivo, negating the need for a subsequent operation for removal. Many biocompatible polymers produce acidic breakdown products that can lead to localized inflammation and osteolysis. This study assesses the feasibility of fabricating implants out of poly(propylene carbonate) (PPC)-starch that degrades into CO(2) and water. The basic compression modulus of PPC-starch (1:1 w/w) is 34 MPa; how",Biomacromolecules,"Iman Manavitehrani, Ali Fathi, Yiwei Wang, Peter K Maitz, Farid Mirmohseni, Tegan L Cheng, Lauren Peacock, David G Little, Aaron Schindeler, Fariba Dehghani"," The University of Sydney , School of Chemical and Biomolecular Engineering, Sydney, 2006, Australia. The University of Sydney , School of Chemical and Biomolecular Engineering, Sydney, 2006, Australia. Burns Research Group, ANZAC Research Institute, University of Sydney , Concord, New South Wales 2139, Australia. Burns Research Group, ANZAC Research Institute, University of Sydney , Concord, New South Wales 2139, Australia. Burns and Reconstructive Surgery Unit, Concord Repatriation General Hospital , Conc",2017 Jun;18(6):1736-1746,10.1021/acs.biomac.7b00078
28697472,20170801,article,mesh,"Animals,Chromatography, High Pressure Liquid,Collagen,Cyclooxygenase 2,Erythema,Gene Expression,Glutathione,Grape Seed Extract,Heme Oxygenase-1,Male,Malondialdehyde,Membrane Proteins,Mice,Mice, Inbred C57BL,Plant Extracts,Protective Agents,Skin,Skin Pigmentation,Ultraviolet Rays","analysis,chemistry,drug effects,genetics,metabolism,pathology,pharmacology,radiation effects","D012880 Q000187 NN,D010936 Q000737 NN,D008565 Q000378 NN,D015870 Q000187 NN,D004890 Q000473 NN,D051547 Q000378 NN,D003094 Q000378 NN,D051546 Q000378 NN,D010936 Q000032 NN,D012867 Q000187 NY,D003094 Q000235 NN,D020011 Q000494 NY,D008565 Q000235 NN,D015870 Q000528 NN,D051546 Q000235 NN,D051547 Q000235 NN,D056604 Q000494 NY,D012880 Q000528 NN,D005978 Q000032 NN,D008315 Q000032 NN,D012867 Q000528 NN","10964,124886,78577443",NULL,Protective effects of grape stem extract against UVB-induced damage in C57BL mice skin.,"Humans have become exposed to another form of a trait which is ultraviolet B (UVB) radiation reaching the earth's surface. This has become a major source of oxidative stress that ultimately leads to inflammation, DNA damage, photoaging and pigmentation disorders etc. Although several studies have shown the photo-protective role of different grape parts like the fruits and seeds, little or no data demonstrating the in vivo photo-protective role of grape stem, which is the most discarded part of the grape are","Journal of photochemistry and photobiology. B, Biology","Denis Nchang Che, Guang Hua Xie, Byoung Ok Cho, Jae Young Shin, Hyun Ju Kang, Seon Il Jang"," Department of Health Care & Science, Jeonju University, Jeonju 55069, Republic of Korea. Department of General Surgery, YanBian University Hospital, JiLin 133-000, China. Department of Health Care & Science, Jeonju University, Jeonju 55069, Republic of Korea; Research Institute, Ato Q&A Corporation, Jeonju 55069, Republic of Korea. Department of Health Care & Science, Jeonju University, Jeonju 55069, Republic of Korea. Research Institute, Ato Q&A Corporation, Jeonju 55069, Republic of Korea. Department of ",2017 Aug;173(?):551-559,10.1016/j.jphotobiol.2017.06.042
28736263,20170928,article,mesh,"Animals,Chemical Precipitation,Drug Delivery Systems,Immunosuppressive Agents,Male,Mice, Inbred C57BL,Nanoparticles,Polyethylene Glycols,Sirolimus,Sulfides,T-Lymphocytes,Theranostic Nanomedicine","administration &amp; dosage,chemistry,drug effects","D011092 Q000737 NN,D020123 Q000008 NY,D020123 Q000737 NN,D053758 Q000737 NN,D013440 Q000737 NN,D011092 Q000008 NY,D007166 Q000737 NN,D053758 Q000008 NY,D013440 Q000008 NY,D007166 Q000008 NY,D013601 Q000187 NN",5284616,NULL,Facile assembly and loading of theranostic polymersomes via multi-impingement flash nanoprecipitation.,"Flash nanoprecipitation (FNP) has proven to be a powerful tool for the rapid and scalable assembly of solid-core nanoparticles from block copolymers. The process can be performed using a simple confined impingement jets mixer and provides an efficient and reproducible method of loading micelles with hydrophobic drugs. To date, FNP has not been applied for the fabrication of complex or vesicular nanoarchitectures capable of encapsulating hydrophilic molecules or bioactive protein therapeutics. Here, we prese",Journal of controlled release : official journal of the Controlled Release Society,"Sean Allen, Omar Osorio, Yu-Gang Liu, Evan Scott"," Interdisciplinary Biological Sciences, Northwestern University, Evanston, IL, USA. Department of Biomedical Engineering and Northwestern University, Evanston, IL, USA. Department of Biomedical Engineering and Northwestern University, Evanston, IL, USA. Interdisciplinary Biological Sciences, Northwestern University, Evanston, IL, USA; Department of Biomedical Engineering and Northwestern University, Evanston, IL, USA; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA; Simpson",2017 Sep;262(?):91-103,10.1016/j.jconrel.2017.07.026
28867672,20170801,article,mesh,"Cell Line,Cytokines,Electronic Nicotine Delivery Systems,Flavoring Agents,Humans,Inflammation,Inflammation Mediators,Macrophages,Nicotine,Phagocytosis","administration &amp; dosage,chemically induced,drug effects,metabolism,physiology,secretion","D007249 Q000378 NN,D008264 Q000378 NN,D009538 Q000008 NN,D007249 Q000139 NY,D010587 Q000187 NY,D016207 Q000557 NN,D008264 Q000502 NY,D008264 Q000187 NY","89594,2735102,57351368",NULL,Phagocytosis and Inflammation: Exploring the effects of the components of E-cigarette vapor on macrophages.,"E-cigarettes are perceived as harmless; however, evidence of their safety is lacking. New data suggests E-cigarettes discharge a range of compounds capable of physiological damage to users. We previously established that cigarette smoke caused defective alveolar macrophage phagocytosis. The present study compared the effect E-cigarette of components; E-liquid flavors, nicotine, vegetable glycerine, and propylene glycol on phagocytosis, proinflammatory cytokine secretion, and phagocytic recognition molecule ",Physiological reports,"Miranda P Ween, Jonathan J Whittall, Rhys Hamon, Paul N Reynolds, Sandra J Hodge"," Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia Miranda.ween@adelaide.edu.au. School of Medicine, University of Adelaide, Adelaide, Australia. Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia. School of Medicine, University of Adelaide, Adelaide, Australia. Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia. School of Medicine, University of Adelaide, Adelaide, Australia. Department of Thoracic Medicine, Royal Adelaide Ho",2017 Aug;5(16):?,10.14814/phy2.13370
28890372,20180201,article,mesh,"Antioxidants,Cell Adhesion,Lignin,Oxidation-Reduction,Oxidative Stress,Phenols,Polymers,Polypropylenes,Propylene Glycols","chemistry,drug effects,pharmacology","D008031 Q000494 NN,D008031 Q000737 NY,D018384 Q000187 NN,D002448 Q000187 NN,D010636 Q000737 NN,D011126 Q000737 NY,D000975 Q000494 NN,D011409 Q000737 NN,D010084 Q000187 NY,D011108 Q000737 NN,D000975 Q000737 NY",32881,NULL,Thermal-oxidative effect of Kraft lignin antioxidant in polypropylene: Uncovering the key factor using correlation analysis model.,"Which factors are crucial to improving lignin antioxidant ability in polymers has been debated over years. Here, the structural effect of natural antioxidant from technical Kraft lignin (KL) on the oxidation induction time (OIT) of KL/polypropylene (PP) was quantitatively investigated using correlation analysis model instead of traditional linear fitting model. The correlation coefficient and significance value of their relationship clearly demonstrated the dominating role of non-condensed Phenolic OH (Ph-O",International journal of biological macromolecules,"Kai Chen, Dezhan Ye, Shaojin Gu, Yingshan Zhou"," School of Materials Science and Engineering, Wuhan Textile University, 430200, China. State Key Laboratory Cultivation Base for New Textile Materials & Advanced Processing Technology, Wuhan Textile University, Wuhan 430200, China; State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu 610065, China; School of Materials Science and Engineering, Wuhan Textile University, 430200, China. Electronic address: yedezhan@hotmail.com. School of Materials Science and Engineering, Wuhan Tex",2018 Feb;107(?):478-485,10.1016/j.ijbiomac.2017.09.016
28902008,20171101,article,mesh,"Acanthamoeba,Acanthamoeba Keratitis,Anti-Infective Agents,Contact Lens Solutions,Disinfection,Eye Infections, Parasitic,Humans,Hydrogen Peroxide","drug effects,isolation &amp; purification,methods,microbiology,parasitology,pharmacology,prevention &amp; control","D000890 Q000494 NY,D000048 Q000187 NN,D015823 Q000517 NY,D015823 Q000382 NN,D006861 Q000494 NY,D000048 Q000302 NY,D004203 Q000379 NY,D018639 Q000494 NY,D015822 Q000469 NN,D015822 Q000517 NY",784,NULL,Fibrous Catalyst-Enhanced Acanthamoeba Disinfection by Hydrogen Peroxide.,"Hydrogen peroxide (H2O2) disinfection systems are contact-lens-patient problem solvers. The current one-step, criterion-standard version has been widely used since the mid-1980s, without any significant improvement. This work identifies a potential next-generation, one-step H2O2, not based on the solution formulation but rather on a case-based peroxide catalyst. One-step H2O2 systems are widely used for contact lens disinfection. However, antimicrobial efficacy can be limited because of the rapid neutraliza",Optometry and vision science : official publication of the American Academy of Optometry,"Simon Kilvington, Lynn Winterton"," 1Department of Infection, Immunity & Inflammation, University of Leicester, Maurice Shock Building, Leicester, United Kingdom 2Better Vision Solutions, Keller, Texas *lynn@bvgsolutions.com.",2017 Nov;94(11):1022-1028,10.1097/opx.0000000000001126
28910554,20170914,article,NULL,NULL,NULL,NULL,NULL,NULL,Ocular Self-Microemulsifying Drug Delivery System of Prednisolone Improves Therapeutic Effectiveness in the Treatment of Experimental Uveitis.,"PURPOSE: The purpose of this study was to investigate the self-microemulsifying drug delivery systems (SMEDDS) for ophthalmic delivery of Prednisolone (PDN) to treat uveitis. MATERIALS AND METHODS: The pseudo-ternary phase diagrams were developed, and various SMEDDS were prepared using Linoleic acid as oil, Cremophore RH 40 as a surfactant, and propylene glycol as a co-surfactant. Physicochemical parameters (globule size, zeta potential, viscosity, and pH) and in vitro release of SMEDDS were studied. The in",Ocular immunology and inflammation,"Rahul Tiwari, Vibhuti Dubey, Karthikeyan Kesavan"," a Department of Pharmaceutics, Institute of Pharmaceutical Sciences , Guru Ghasidas Vishwavidyalaya, Koni , Bilaspur , Chhattisgarh , India. a Department of Pharmaceutics, Institute of Pharmaceutical Sciences , Guru Ghasidas Vishwavidyalaya, Koni , Bilaspur , Chhattisgarh , India. a Department of Pharmaceutics, Institute of Pharmaceutical Sciences , Guru Ghasidas Vishwavidyalaya, Koni , Bilaspur , Chhattisgarh , India.",2017 Sep;?(?):1-9,10.1080/09273948.2017.1333622
28962154,20170901,article,NULL,NULL,NULL,NULL,NULL,NULL,Interleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis.,The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL). Serum IL-6 levels were measured by ELISA. IL-6 gene expression levels in colonic mucosa specimens were assessed by reverse-transcription quantitative PCR and protein expression was evaluated by western blot analysis and immunohistochemistry. The expression of IL-6 was weak in mucosa,Experimental and therapeutic medicine,"Haifeng Zhang, Weichang Chen"," Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu 215006, P.R. China. Department of Infectious Diseases, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu 215006, P.R. China.",2017 Sep;14(3):2271-2276,10.3892/etm.2017.4778
29238164,20170101,article,mesh,"Adipose Tissue,Administration, Oral,Animals,Betahistine,Eating,Female,Gels,Inflammation,Nanostructures,Particle Size,Rats,Surface Properties,Weight Gain","administration &amp; dosage,chemistry,drug effects,drug therapy,pharmacology","D007249 Q000188 NN,D001621 Q000494 NY,D015430 Q000187 NN,D049329 Q000737 NY,D005782 Q000008 NN,D000273 Q000187 NN,D049329 Q000008 NN,D005782 Q000494 NN,D001621 Q000008 NN","2366,68643,198334,203875",NULL,A novel transdermal nanoethosomal gel of betahistine dihydrochloride for weight gain control: in-vitro and in-vivo characterization.,"BACKGROUND: Betahistine dihydrochloride (BDH) is a histamine analog used to control weight gain, with short elimination half-life and gastric irritation as side effects. OBJECTIVE: The aim of the current investigation is to formulate and optimize a topical BDH ethosomal gel for weight gain control. MATERIALS AND METHODS: Box-Behnken design was applied to study the effect of independent variables: phosphatidylcholine (PC), propylene glycol (PG), and ethanol on vesicle size; entrapment efficiency; % drug rele","Drug design, development and therapy","Shahira F El-Menshawe, Adel Ahmed Ali, Abdelkhalk Ali Halawa, Ahmed Sg Srag El-Din"," Department of Pharmaceutics and Industrial Pharmacy, Beni-Suef University, Beni-Suef. Department of Pharmaceutics and Industrial Pharmacy, Beni-Suef University, Beni-Suef. Department of Pharmaceutics and Clinical Pharmacy, Nahda University, Beni-Suef, Egypt. Department of Pharmaceutics and Clinical Pharmacy, Nahda University, Beni-Suef, Egypt.",2017 Jan;11(?):3377-3388,10.2147/dddt.s144652
29430254,20170101,article,NULL,NULL,NULL,NULL,NULL,NULL,Anti-Inflammatory Activity of Babassu Oil and Development of a Microemulsion System for Topical Delivery.,"Babassu oil extraction is the main income source in nut breakers communities in northeast of Brazil. Among these communities, babassu oil is used for cooking but also medically to treat skin wounds and inflammation, and vulvovaginitis. This study aimed to evaluate the anti-inflammatory activity of babassu oil and develop a microemulsion system with babassu oil for topical delivery. Topical anti-inflammatory activity was evaluated in mice ear edema using PMA, arachidonic acid, ethyl phenylpropiolate, phenol,",Evidence-based complementary and alternative medicine : eCAM,"Mysrayn Y F A Reis, Simone M Dos Santos, Danielle R Silva, Márcia V Silva, Maria Tereza S Correia, Daniela M A Ferraz Navarro, Geanne K N Santos, Fernando Hallwass, Otávio Bianchi, Alexandre G Silva, Janaína V Melo, Alessandra B Mattos, Rafael M Ximenes, Giovanna Machado, Karina L A Saraiva"," Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Estadual da Paraíba, Rua Juvêncio Arruda S/N, Bairro Universitário, 58429-600 Campina Grande, PB, Brazil. Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, No. 1235, Cidade Universitária, 50670-901 Recife, PE, Brazil. Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, No. 1235, Cidade Universitária, 50670-901 Recife, PE,",2017 Jan;2017(?):3647801,10.1155/2017/3647801
29452618,20180301,review,mesh,"Child,Humans,Infection,Inflammation,Positron Emission Tomography Computed Tomography,Radionuclide Imaging","diagnostic imaging,methods","D007239 Q000000981 NY,D011877 Q000379 NY,D007249 Q000000981 NY",NULL,NULL,Radionuclide Imaging of Infection and Inflammation in Children: a Review.,"With the exception of radiolabeled monoclonal antibodies, antibody fragments and radiolabeled peptides which have seen little application in the pediatric population, the nuclear medicine imaging procedures used in the evaluation of infection and inflammation are the same for both adults and children. These procedures include (1) either a two- or a three-phase bone scan using technetium-99m methylene diphosphonate; (2) Gallium 67-citrate; (3) in vitro radiolabeled white blood cell imaging (using (111)Indium",Seminars in nuclear medicine,"Marguerite T Parisi, Jeffrey P Otjen, A Luana Stanescu, Barry L Shulkin"," Department of Radiology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA.; Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA.. Electronic address: meg.parisi@seattlechildrens.org. Department of Radiology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA. Department of Radiology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle,",2018 Mar;48(2):148-165,10.1053/j.semnuclmed.2017.11.002
29468886,20180101,article,NULL,NULL,NULL,NULL,NULL,NULL,Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats.,"BACKGROUND: Cyclophosphamide (CP) is a nitrogen mustard alkylating drug used for the treatment of chronic and acute malignant lymphomas, myeloma, leukemia, neuroblastoma, adenocarcinoma, retinoblastoma, breast carcinoma, and immunosuppressive therapy. Despite its vast therapeutic uses, it is known to cause severe cardiac toxicity. Kolaviron (KV), a Garcinia kola seed extract containing a mixture of flavonoids, is reputed for its antioxidant and membrane stabilizing properties. OBJECTIVE: This study investig",Journal of evidence-based integrative medicine,"Joseph Gbenga Omole, Oladele Abiodun Ayoka, Quadri Kunle Alabi, Modinat Adebukola Adefisayo, Muritala Abiola Asafa, Babalola Olusegun Olubunmi, Benson Akinloye Fadeyi"," 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 2 Afe-Babalola University, Ado-Ekiti, Ekiti State, Nigeria. 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 3 University of Medical Sciences, Ondo City, Ondo State, Nigeria. 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 1 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 1 Obafemi Awolowo Univers",2018 Jan;23(?):2156587218757649,10.1177/2156587218757649
29477345,20180601,article,mesh,"Animals,Apoptosis,Biomarkers,Blood Vessels,Male,Myocardium,Oxidative Stress,Physical Conditioning, Animal,Rats,Rats, Sprague-Dawley,Stanozolol","cytology,drug effects,metabolism,pharmacology","D017209 Q000187 NY,D001808 Q000187 NN,D009206 Q000378 NY,D001808 Q000378 NN,D013197 Q000494 NY,D009206 Q000166 NY,D015415 Q000378 NN",25249,NULL,Effects of stanozolol on apoptosis mechanisms and oxidative stress in rat cardiac tissue.,"Stanozolol is a widely used 17α-alkylated anabolic androgenic steroid (AAS) derivative. Despite stanozolol's adverse effects, its effect on oxidative stress parameters and mitochondrial apoptosis pathway is not clearly defined. In our study, thirty four male Sprague-Dawley rats were divided into 5 groups as control (C), vehicle control (VC), steroid (ST), vehicle control-exercise (VCE), and steroid-exercise (STE). Animals were subcutaneously administered stanozolol 5 mg/kg in steroid groups and propylene gl",Steroids,"Mehtap Kara, Eren Ozcagli, Tuğba Kotil, Buket Alpertunga"," Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey. Electronic address: mehtap.kara@istanbul.edu.tr. Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey. Istanbul University, Istanbul Faculty of Medicine, Department of Histology and Embryology, Istanbul, Turkey. Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey.",2018 Jun;134(?):96-100,10.1016/j.steroids.2018.02.004
29491036,20180331,review,mesh,"Administration, Inhalation,Aerosols,Animals,Consumer Product Safety,Electronic Nicotine Delivery Systems,Humans,Immune System,Inflammation,Inflammation Mediators,Lung,Lung Diseases,Nicotine,Nicotinic Agonists,Risk Assessment,Vaping","administration &amp; dosage,adverse effects,chemically induced,drug effects,immunology,metabolism,physiopathology","D007249 Q000378 NN,D007107 Q000187 NY,D008168 Q000276 NN,D007107 Q000276 NN,D009538 Q000008 NN,D008171 Q000503 NN,D007249 Q000503 NN,D018722 Q000008 NN,D008171 Q000276 NN,D007107 Q000503 NN,D007107 Q000378 NN,D018722 Q000009 NY,D008168 Q000503 NN,D008171 Q000378 NN,D009538 Q000009 NY,D007249 Q000276 NN,D018836 Q000378 NN,D007249 Q000139 NY,D000072137 Q000009 NY,D008168 Q000187 NY,D008171 Q000139 NY,D008168 Q000378 NN","89594,2735102,57351368",NULL,Immunological and toxicological risk assessment of e-cigarettes.,"Knowledge of the long-term toxicological and immunological effects of e-cigarette (e-cig) aerosols remains elusive due to the relatively short existence of vaping. Therefore, we performed a systematic search of articles published in public databases and analysed the research evidence in order to provide critical information regarding e-cig safety. Electronic nicotine delivery systems (or e-cigs) are an alternative to traditional cigarettes for the delivery of nicotine and are typically filled with glycerol ",European respiratory review : an official journal of the European Respiratory Society,"Gagandeep Kaur, Rakeysha Pinkston, Benathel Mclemore, Waneene C Dorsey, Sanjay Batra"," Laboratory of Pulmonary Immuno-toxicology, Dept of Environmental Toxicology, Health Research Center, College of Sciences and Engineering, Southern University and A&M College, Baton Rouge, LA, USA. Both authors contributed equally. Laboratory of Pulmonary Immuno-toxicology, Dept of Environmental Toxicology, Health Research Center, College of Sciences and Engineering, Southern University and A&M College, Baton Rouge, LA, USA. Both authors contributed equally. Laboratory of Pulmonary Immuno-toxicology, Dept o",2018 Mar;27(147):?,10.1183/16000617.0119-2017
29521039,20180101,article,NULL,NULL,NULL,NULL,NULL,NULL,Comparison of polypropylene and silicone Ahmed® glaucoma valves in the treatment of neovascular glaucoma: A 2-year follow-up.,"BACKGROUND: Inflammation associated with biomaterials of Ahmed® glaucoma drainage devices may cause the formation of a capsule around the device and can thus have a significant influence on the level of intraocular pressure reduction. OBJECTIVES: The objective of this study was to compare the clinical outcomes after the implantation of a polypropylene or silicone Ahmed® glaucoma valve in patients with neovascular glaucoma. MATERIAL AND METHODS: In the study, 27 eyes with neovascular glaucoma (group 1) recei",Advances in clinical and experimental medicine : official organ Wroclaw Medical University,"Wojciech Lubiński, Karol Krzystolik, Wojciech Gosławski, Leszek Kuprjanowicz, Maciej Mularczyk"," Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland. Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland. Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland. Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland. Chair and Department of Human and Clinical Anatomy, Pomeranian Medical University, Szczecin, Poland.",2018 Jan;27(1):15-20,10.17219/acem/66806
29562272,20180319,article,NULL,NULL,NULL,NULL,NULL,NULL,A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients.,BACKGROUND: Crohn's disease (CD) patients who undergo ileocolonic resection frequently have disease recurrence. The aim of this preliminary study was to identify urinary metabolomic profiles associated with disease recurrence in order to identify underlying mechanisms of recurrence and possible disease biomarkers. METHODS: Biopsies from the neoterminal ileum were collected from CD patients (n = 38) after ileocolonic resection in order to assess mucosa-associated microbiota using 16S rRNA multitag pyrosequen,Inflammatory bowel diseases,"Ammar Hassanzadeh Keshteli, Robert Tso, Levinus A Dieleman, Heekuk Park, Karen I Kroeker, Juan Jovel, Patrick M Gillevet, Masoumeh Sikaroodi, Rupasri Mandal, Richard N Fedorak, Karen L Madsen"," Department of Medicine, University of Alberta, Edmonton, AB, Canada. Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), University of Alberta, Edmonton, AB, Canada. Department of Medicine, University of Alberta, Edmonton, AB, Canada. Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), University of Alberta, Edmonton, AB, Canada. Department of Medicine, University of Alberta, Edmonton, AB, Canada. Centre of Excellence for Gastrointestina",2018 Mar;24(4):861-870,10.1093/ibd/izx070
29571251,20180201,article,mesh,"Administration, Cutaneous,Anesthesia,Animals,Bupivacaine,Cell Death,Cell Line,Drug Carriers,Drug Liberation,Hyaluronic Acid,Linoleic Acid,Lipids,Mice,Nanostructures,Nociception,Polyethylene Glycols,Proton Magnetic Resonance Spectroscopy,Rats,Skin Absorption","administration &amp; dosage,chemistry,drug effects,pharmacology,ultrastructure","D059225 Q000187 NN,D019787 Q000737 NN,D002045 Q000494 NN,D011092 Q000737 NN,D002045 Q000737 NN,D049329 Q000737 NY,D004337 Q000737 NY,D016923 Q000187 NN,D008055 Q000737 NY,D006820 Q000737 NY,D012869 Q000187 NN,D049329 Q000648 NN,D002045 Q000008 NY","2474,3931,64737,3084049,5280450,5282457,5282797",NULL,Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation.,"For effective transdermal local anesthetic therapy, to reduce the barrier of stratum corneum and improve the antinociceptive effect, hyaluronic acid (HA) modified, bupivacaine (BPV) loaded nanostructured lipid carriers (NLCs) were designed. HA and linoleic acid (LOA) conjugated propylene glycol (PEG) was synthesized (HA-PEG-LOA). HA-PEG-LOA was added during the preparation process of NLCs, thus LOA was inserted into the NLCs, The physicochemical properties of NLCs, particle size, zeta potential, drug loadin",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,"Yaocun Yue, Dandan Zhao, Qiuwen Yin"," Department of Anesthesiology, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong, China. Department of Anesthesiology, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong, China. Department of Anesthesiology, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong, China. Electronic address: yinqiuwenjnph@126.com.",2018 Feb;98(?):813-820,10.1016/j.biopha.2017.12.103
29615068,20180101,article,mesh,"Adrenoleukodystrophy,Blood-Brain Barrier,Capillary Permeability,Cell Culture Techniques,Cell Differentiation,Cell Line,Electric Impedance,Endothelial Cells,Humans,Induced Pluripotent Stem Cells,Lipid Droplets,Microvessels,Models, Biological,Neuroprotective Agents,Polymers,Transcriptome","drug effects,drug therapy,metabolism,pathology,pharmacology","D001812 Q000473 NN,D042783 Q000473 NN,D057026 Q000187 NN,D057026 Q000473 NN,D000326 Q000188 NN,D001812 Q000187 NN,D018696 Q000494 NN,D000326 Q000473 NN,D066292 Q000187 NN,D001812 Q000378 NY,D011108 Q000494 NN,D042783 Q000187 NN,D066292 Q000473 NN,D000326 Q000378 NY,D055806 Q000473 NN,D057026 Q000378 NN,D066292 Q000378 NN,D055806 Q000187 NN,D055806 Q000378 NY,D042783 Q000378 NY",NULL,NULL,Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients.,BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene. 40% of X-ALD patients will convert to the deadly childhood cerebral form (ccALD) characterized by increased permeability of the brain endothelium that constitutes the blood-brain barrier (BBB). Mutation information and molecular markers investigated to date are not predictive of conversion. Prior reports have focused on toxic metabolic byproducts and reactive oxygen species as instigators of cerebral inflammation and,Fluids and barriers of the CNS,"Catherine A A Lee, Hannah S Seo, Anibal G Armien, Frank S Bates, Jakub Tolar, Samira M Azarin"," Department of Genetics and Cell Development, University of Minnesota, Minneapolis, MN, 55455, USA. Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, 55455, USA. Ultrastructural Pathology Unit, Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA. Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, 55455, USA. Department of Pediatrics, University of",2018 Jan;15(1):9,10.1186/s12987-018-0094-5
29667135,20180418,article,NULL,NULL,NULL,NULL,NULL,NULL,Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.,"The five-year survival rate for patients with head and neck squamous cell carcinoma (HNSCC) has remained at ~50% for the past 30 years despite advances in treatment. Tigilanol tiglate (TT, also known as EBC-46) is a novel diterpene ester that induces cell death in HNSCC in vitro and in mouse models, and has recently completed Phase I human clinical trials. The aim of this study was to optimise efficacy of TT treatment by altering different administration parameters. The tongue SCC cell line (SCC-15) was ide",Investigational new drugs,"Catherine M E Barnett, Natasa Broit, Pei-Yi Yap, Jason K Cullen, Peter G Parsons, Benedict J Panizza, Glen M Boyle"," Drug Discovery Group, QIMR Berghofer Medical Research Institute, Locked Bag 2000, Post Office Royal Brisbane Hospital, Brisbane, Queensland, 4029, Australia. Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia. Department of Otolaryngology, Head and Neck Surgery and Queensland Skull Base Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Drug Discovery Group, QIMR Berghofer Medical Research Institute, Locked Bag 2000, Post Office Royal Brisbane Hospital, Brisbane",2018 Apr;?(?):?,10.1007/s10637-018-0604-y
29733892,20180901,article,mesh,"Animals,Cell Cycle,Cell Proliferation,Cells, Cultured,Cytokines,Dinitrofluorobenzene,Esters,Female,Hypersensitivity, Delayed,Immunosuppressive Agents,Lymphocyte Activation,Mice, Inbred BALB C,Mitogen-Activated Protein Kinases,NF-kappa B,Palmitates,Propylene Glycols,Spleen,T-Lymphocytes","blood,cytology,drug effects,immunology,metabolism,toxicity","D013601 Q000378 NN,D011409 Q000633 NY,D006968 Q000097 NN,D016207 Q000378 NN,D016328 Q000378 NN,D020928 Q000378 NN,D049109 Q000187 NN,D013154 Q000166 NN,D010168 Q000633 NY,D008213 Q000187 NN,D013601 Q000187 NY,D002453 Q000187 NN,D016207 Q000097 NN,D006968 Q000276 NN,D007166 Q000633 NY",6264,NULL,"Suppression of T lymphocyte activation by 3-chloro-1,2-propanediol mono- and di-palmitate esters in vitro.","This study investigated whether and how 3-chloro-1,2-propanediol (3-MCPD) fatty acid esters, a group of food contaminants formed during processing, might inhibit the immune system through suppressing T lymphocyte activation for the first time. Three 3-MCPD esters including 1-palmitoyl-3-chloropropanediol (1-pal), 2-palmitoyl-3-chloropropanediol (2-pal), and1,2-dipalmitoyl-3-chloropropanediol (dipal) were selected as the probe compounds to test the possible effects of fatty acid structure on their potential ",Toxicology in vitro : an international journal published in association with BIBRA,"Guoren Huang, Jinli Xue, Xiangjun Sun, Jing Wang, Yilin Wang, Thomas T Y Wang, Lucy Yu Liangli"," Institute of Food and Nutraceutical Science, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai 200240, China. Institute of Food and Nutraceutical Science, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai 200240, China. Institute of Food and Nutraceutical Science, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address: xjsun@sjtu.edu.cn. Beijing Advanced Innovation Center for Food Nutrition and Human Health, B",2018 Sep;51(?):54-62,10.1016/j.tiv.2018.05.002
29847737,20180901,article,mesh,"Acute Kidney Injury,Animals,Diclofenac,Dinoprostone,Flavonoids,Garcinia kola,Kidney,Male,Oxidative Stress,Rats, Wistar,Seeds","chemically induced,chemistry,drug effects,drug therapy,pharmacology,physiology,physiopathology","D029763 Q000737 NN,D007668 Q000187 NN,D015232 Q000502 NN,D005419 Q000494 NY,D007668 Q000503 NN,D058186 Q000139 NN,D018384 Q000187 NY,D012639 Q000737 NN,D058186 Q000188 NY","3033,152165,155169,5018304,5280360,23667642",NULL,Kolaviron attenuates diclofenac-induced nephrotoxicity in male Wistar rats.,"The beneficial effects of kolaviron, a natural biflavonoid from the seeds of Garcinia kola, have been attributed to its antioxidant and anti-inflammatory activities. This study was designed to investigate the renoprotective effect of kolaviron in rat model of diclofenac (DFC)-induced acute renal failure. Thirty-five male Wistar rats were divided into 7 groups of 5 rats each as follows: a control group that received propylene glycol orally and treatment groups that received DFC, DFC recovery, DFC followed by","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme","Quadri K Alabi, Rufus O Akomolafe, Modinat A Adefisayo, Olaoluwa S Olukiran, Aliyat O Nafiu, Micheal K Fasanya, Ayowole A Oladele"," a Department of Physiological Sciences, Faculty of Basic Medical Sciences, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. b Department of Haematology and Blood Transfusion, Faculty of Basic Medical Sciences, College of Medicine, Afe Babalola University, Ado Ekiti, Ekiti, State, Nigeria. a Department of Physiological Sciences, Faculty of Basic Medical Sciences, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. a Department of Physiological Sciences, Faculty of Basic Medical Sciences, Obaf",2018 Sep;43(9):956-968,10.1139/apnm-2017-0788
29964220,20181001,article,NULL,NULL,NULL,NULL,NULL,NULL,Aortic plaque-targeted andrographolide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammation.,Inflammation and oxidative stress are two major factors that are involved in the pathogenesis of atherosclerosis. A smart drug delivery system that responds to the oxidative microenvironment of atherosclerotic plaques was constructed in the present study. Andrographolide-loaded micelle was assembled from the block copolymer of poly(ethylene glycol) and poly(propylene sulphide) (PEG-PPS) for the purpose of simultaneously decreasing inflammatory response and the level of reactive oxygen species (ROS) to treat,"Nanomedicine : nanotechnology, biology, and medicine","Teng Wu, Xiaoyan Chen, Yong Wang, Hong Xiao, Yuan Peng, Liteng Lin, Wenhao Xia, Ming Long, Jun Tao, Xintao Shuai"," PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou, 510275, China; Center of Biomedical Engineering, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou, 510275, China. PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou, 510275, China. PCFM Lab",2018 Oct;14(7):2215-2226,10.1016/j.nano.2018.06.010
30091379,20180809,article,NULL,NULL,NULL,NULL,NULL,NULL,Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice.,"Electronic cigarettes (e-cig) are advertised as a less harmful nicotine delivery system or as a new smoking cessation tool. We aimed to assess the in vivo effects of e-cigarette vapor in the lung and to compare them to those of cigarette smoke (CS). We exposed C57BL/6 mice for either 3 days or 4 weeks to ambient air, CS or e-cig vapor containing: i) propylene glycol/vegetable glycerol (1:1; PG:VG-Sol), ii) PG:VG with nicotine (G:VG-N), or iii) PG:VG with nicotine and flavor (PG:VG- N+F) and determined oxida",American journal of physiology. Lung cellular and molecular physiology,"Constantinos Glynos, Sofia-Iris Bibli, Paraskevi Katsaounou, Athanasia Pavlidou, Christina Magkou, Vassiliki Karavana, Stavros Topouzis, Ioannis Kalomenidis, Spyros G Zakynthinos, Andreas Papapetropoulos"," Dept. of Surgical Pathology, ""Evangelismos"" Hospital, Athens, Greece. Department of Critical Care and Pulmonary Services, Marianthi Simou Applied Biomedical Research Training Center, Evangelismos Hospital, University of Athens Medical School, Athens, Greece, Greece. University Of Athens. Critical Care and Pulmonary Services, Evangelismos Hospital, Medical School of Athens University, Greece. Department of Pharmacy, University of Athens, Greece.",2018 Aug;?(?):?,10.1152/ajplung.00389.2017
30291957,20181201,article,NULL,NULL,NULL,NULL,NULL,NULL,A Poloxamer-407 modified liposome encapsulating epigallocatechin-3-gallate in the presence of magnesium: Characterization and protective effect against oxidative damage.,"Epigallocatechin-3-gallate (EGCG) is a polyphenolic catechin from green tea, well known for being bioactive in age-associated pathologies where oxidative stress plays a preeminent role. The activity of this molecule is however contrasted by its high chemical and metabolic instability that determines a poor concentration of the antioxidant within the biological system after administration. In order to protect the molecule and increase its delivery efficiency, we have encapsulated EGCG inside anionic liposome",International journal of pharmaceutics,"Cristina Minnelli, Paolo Moretti, Gianluca Fulgenzi, Paolo Mariani, Emiliano Laudadio, Tatiana Armeni, Roberta Galeazzi, Giovanna Mobbili"," Dipartimento di Scienze della Vita e dell'Ambiente (DISVA), Università Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy. Dipartimento di Scienze della Vita e dell'Ambiente (DISVA), Università Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy. Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Via Conca, Torrette Polo scientifico didattico Murri, 60131 Ancona, Italy. Dipartimento di Scienze della Vita e dell'Ambiente (DISVA), Università Polit",2018 Dec;552(?):225-234,10.1016/j.ijpharm.2018.10.004
30346584,20181020,article,NULL,NULL,NULL,NULL,NULL,NULL,"Free Radical, Carbonyl, and Nicotine Levels Produced by Juul Electronic Cigarettes.","INTRODUCTION: Free radicals and carbonyls produced by electronic cigarettes (e-cigs) have the potential to inflict oxidative stress. Recently, Juul e-cigs have risen drastically in popularity; however, there is no data on nicotine and oxidant yields from this new e-cig design. METHODS: Aerosol generated from four different Juul flavors was analyzed for carbonyls, nicotine, and free radicals. The e-liquids were analyzed for propylene glycol (PG) and glycerol (GLY) concentrations. To determine the effects of ",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,"Samantha M Reilly, Zachary T Bitzer, Reema Goel, Neil Trushin, John P Richie"," Department of Food Science, Pennsylvania State University, College of Agricultural Sciences, University Park, PA. Department of Public Health Sciences, Pennsylvania State University Tobacco Center of Regulatory Science (TCORS), Pennsylvania State University College of Medicine, Hershey, PA. Department of Food Science, Pennsylvania State University, College of Agricultural Sciences, University Park, PA. Department of Food Science, Pennsylvania State University, College of Agricultural Sciences, University P",2018 Oct;?(?):?,10.1093/ntr/nty221
30359011,20181025,article,NULL,NULL,NULL,NULL,NULL,NULL,Oxidative Detoxification of Sulfur-Containing Chemical Warfare Agents by Electrophilic Iodine.,Mild oxidation of sulfur-containing chemical warfare agents was performed in organic medium by electrophilic iodine reagents. Kinetic experiments on sulfur mustard (HD) showed rapid ( t(1/2) < 3 min) and selective oxidation to the nonvesicant sulfoxide product (HD-SO) in acetonitrile or propylene carbonate solutions (9% water added) containing excess N-iodosuccinimide (NIS). Molecular iodine solutions in these solvents led to similar results as with NIS but at much slower rates ( t(1/2) ∼ 90 min). Higher do,The Journal of organic chemistry,"Boris Smolkin, Noam Levi, Naama Karton-Lifshin, Lea Yehezkel, Yossi Zafrani, Ishay Columbus"," Department of Organic Chemistry , Israel Institute for Biological Research , P.O. Box 19, Ness Ziona 74100 , Israel. Department of Organic Chemistry , Israel Institute for Biological Research , P.O. Box 19, Ness Ziona 74100 , Israel. Department of Organic Chemistry , Israel Institute for Biological Research , P.O. Box 19, Ness Ziona 74100 , Israel. Department of Organic Chemistry , Israel Institute for Biological Research , P.O. Box 19, Ness Ziona 74100 , Israel. Department of Organic Chemistry , Israel In",2018 Oct;?(?):?,10.1021/acs.joc.8b02306
30417290,20181112,article,NULL,NULL,NULL,NULL,NULL,NULL,DMSO-Free Cryopreservation of Human Umbilical Cord Tissue.,"Human umbilical cord represents a source of multipotent stromal cells of a supreme therapeutic potential. The cells can be isolated from either fresh or cryopreserved umbilical cord tissues. DMSO is a cryoprotectant most commonly used for preservation of umbilical cord tissues; however, cyto- and genotoxicity of this compound is evident and well documented. In the present study we performed successful cryopreservation of the umbilical cord tissue using other cryoprotectants: propylene glycol, ethylene glyco",Bulletin of experimental biology and medicine,"I V Arutyunyan, S О Strokova, А V Makarov, S М Mullabaeva, А V Elchaninov, А V Lokhonina, А А Abramov, Т Kh Fatkhudinov"," V. I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia. Peoples' Friendship University of Russia, Moscow, Russia. V. I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia. V. I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Mosc",2018 Nov;?(?):?,10.1007/s10517-018-4305-5
